From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Fri, 6 Mar 2020 03:49:45 +0000
To:	Haskins, Melinda (NIH/NIAID) [E]
Cc:	Selgrade, Sara (NIH/NIAID) [E];Crawford, Chase (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject:	RE: Please review: House Oversight Letter on Coronavirus Diagnostics

I do not understand why you are asking me to "review" this. Is this an FYI??

From: Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, March 5, 2020 9:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Selgrade, Sara (NIH/NIAID) [E] [redacted] (b) (6); Crawford, Chase (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Please review: House Oversight Letter on Coronavirus Diagnostics

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 03:00:23 +0000
To: Muniz, Maria de Los Angeles
Cc: 'Birx, Deborah L'
Subject: RE: National Blood Supply

Maria:
Thanks for the note. I will bring this us in our discussions
Best regards,
Tony

From: Muniz, Maria de Los Angeles <MMuniz@vitalant.org>
Sent: Thursday, March 5, 2020 9:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: National Blood Supply

Dear Dr. Fauci: I am an ex-alumni from the Department of Transfusion Medicine at the NIH. I am sorry to bother but I wanted to notify the Coronavirus Task force about potential blood shortages if blood centers get blood drive cancellations due to the fear in the public.

We are starting to see this locally and my concern is that other blood centers in the country are facing the same issue.

I tried to contact the office of the vice president, and all I could do was to send an email, which might get lost among thousands.

I am hoping you see this and perhaps bring this to the table. Blood centers use updated federal information when educating donors, staff and hospitals but the current fear is triggering blood drive cancellations. This might be experienced nationally and will impact the national blood inventory.

Thank you

Maria De Los Angeles Muñiz (Angie), MD
Medical Director
o 201.389.0439 | c [redacted] (b) (6) (please call cell phone first)
mmuniz@vitalant.org
Vitalant Montvale
102 Chestnut Ridge Road
Montvale, NJ 07645

Vitalant Cleveland
333 East Bridge Street
Elyria, OH 44035

Vitalant Cord Blood Bank
1 Pearl Court
Allendale, NJ 07401

Community Blood Services, Lifeshare & Blood Systems are now Vitalant.

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 21:27:53 +0000
To: NIAID OD AM
Subject: FW: 03 04 2020 Dr. Anthony Fauci RE Invite to join my head table at Global's AcceptAbility Gala on Wed 5/20
Attachments: 2020 03 GLOBAL AcceptAbility Gala Save the Date.pdf
Importance: High

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michelle Whitten - Global <mswhitten@globaldownsyndrome.org>
Sent: Wednesday, March 4, 2020 10:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Ashley Sparhawk <asparhawk@globaldownsyndrome.org>; Marisa Cucuzzella <mcucuzzella@ajsfoundation.com>; Rotrosen, Daniel (NIH/NIAID) [E] [redacted] (b) (6); Deckhut, Alison (NIH/NIAID) [E] [redacted] (b) (6)>; Rothermel, Annette (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: 03 04 2020 Dr. Anthony Fauci RE Invite to join my head table at Global's AcceptAbility Gala on Wed 5/20
Importance: High

Dear Dr. Fauci,

First let me say we are very grateful to everyone at NIH for working to contain the coronavirus, especially your team at the NIAID. Your interviews are articulate and informative - they give Americans some comfort and some concrete ways to think about protecting themselves and what to expect. It must be a stressful time and we want you to know that we have confidence in our NIH and CDC to contain it and to help stave it off globally as well.

On a happier note, I wanted to reach out and THANK YOU for all you do for our Down Syndrome research through the transformative trans-NIH INCLUDE program. It is making a HUGE difference!!

To this end, I am writing today in hopes you will be able to join us on Wednesday, May 20th for our AcceptAbility Gala at my head table. Attached is our save the date for the event. We are excited to have Caroline Cardenas as our 2020 Ambassador, Rep Pete Stauber as our keynote ([redacted] (b) (6)), and Reps Lucille Roybal-Allard and Jaime Herrera Beutler are Global's *Quincy Jones Exceptional Advocacy Awardees.* We believe the gala will be quite lovely and meaningful to so many.

We do understand that attendance cannot be considered if the coronavirus situation worsens. However, if things are looking much better (touch wood) we would be deeply honored if you and our friends from NIAID could attend. Looking forward to hearing from you soon.

All the Best, Michelle and family

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 11:00:39 +0000
To: [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers
([redacted] (b) (6);Marston, Hilary (NIH/NIAID) [E]
Subject: FW: New concerns for our randomized trial

What do you think? I see the FDA Commissioner every day in person.

From: Kalil, Andre C <[redacted] (b) (6)>
Sent: Wednesday, March 4, 2020 11:27 PM
To: Beigel, John (NIH) [E] [redacted] (b) (6)>; Davey, Richard (NIH/NIAID) [E]
<[redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Marston, Hilary (NIH/NIAID)
[E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: New concerns for our randomized trial

I want to share with you my concerns before the situation gets worse.

I have received many calls from physicians from all over the country about how to get "compassionate use" remdesivir. [redacted] (b) (4), (b) (5)

(b) (4), (b) (5)

[redacted]

I would appreciate hearing your thoughts on this critical issue.

Best,

Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM
Professor
Department of Internal Medicine
Division of Infectious Diseases
Director, Transplant ID Program
Associate Editor, CMI, Official Journal of ESCMID
Editorial Board, CCM, Official Journal of SCCM
UNMC
BREAKTHROUGHS FOR LIFE.
University of Nebraska Medical Center
985400 Nebraska Medical Center, Omaha, NE 68198-5400
(b) (6) | fax 402.559-5581
(b) (6)

UNMC | Facebook | Twitter | YouTube | Flickr

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."
Robert Ludlum - The Ambler Warning

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 03:29:00 +0000
To: Dave Doern
Subject: RE: Go Tony

Dave:
Many thanks for your kind note. I hope that all is well with you.
Best regards,
Tony

-----Original Message-----
From: Dave Doern (b) (6)
Sent: Wednesday, March 4, 2020 12:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Go Tony

Tony,
You always do the right thing......comforting for all your (b) (6) friends to see you up front in this serious coronavirus attack....
We'll do the praying and you go Keep doing the hard work.....
Thanks,
Dave

David Doern
Sent from my iPhone
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 03:19:47 +0000
To: [redacted] (b) (6)
Cc: Greg Folkers ([redacted] (b) (6))
Subject: RE: Conference Planning with respect to coronavirus.

There is no way of knowing for sure. I would wait until May and see what the dynamics of the outbreak are globally and make your decision then whether or not to cancel.

From: [redacted] (b) (6)
Sent: Wednesday, March 4, 2020 5:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Conference Planning with respect to coronavirus.

Dear Dr. Fauci

Dr. Miriam Kelty formerly of NIH referred me to you. I am on the board of directors and planning committee of the Applied Superconductivity Conference that is planned to be held in Tampa, Florida the last week of July. Over 50% of our expected 1500 attendees are from outside the continental US. Our planning committee appears to have three options:

1. Hold the conference on the original dates
2. Postpone the conference a few months
3. Cancel the conference

It would be most helpful to decision process if you can give us a prediction (anonymously of course) of how the effects of the virus will pan out.

I look forward to your reply.

Bruce Strauss
ScD, MBA, PE, F-IEEE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:59:22 +0000
To: Aliantha Angel
Subject: RE: A humble request for your wisdom

[redacted] (b) (6)

From: Aliantha Angel [redacted] (b) (6)
Sent: Wednesday, March 4, 2020 9:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Re: A humble request for your wisdom

Oh my God...

I honestly never expected you to reply and I thank you from the bottom of my heart for being so generous!

[redacted] (b) (6)

Is there anything I can do for you besides being grateful?

You and yours are in my prayers!

much love,
Aliantha

On Wed, Mar 4, 2020 at 9:45 PM Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:

> Dear Ms. Angel:
>
> The severe complication of coronavirus are heavily skewed towards the elderly and those with underlying conditions (Heart disease, Chronic lung disease, kidney disease, diabetes, etc.) Most of the pneumonias are pure viral pneumonia and so this vaccination will not help that. However, on the chance that you have a pure viral pneumonia that gets secondarily complicated by a bacterial pneumonia (pneumococcal) the vaccine would be beneficial. If you are 65 years of age or older, you should get the pneumonvax23 vaccine anyway regardless of the risk of coronavirus infection.
>
> Thanks,
> Tony
>
> **From:** Aliantha Angel [redacted] (b) (6)
> **Sent:** Wednesday, March 4, 2020 8:44 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: A humble request for your wisdom

Good evening!

I know you must be completely busy and inundated with people wanting your time. I apologize that I have nothing to offer in return and completely understand if you don't have time to answer. I called the CDC but they were totally unhelpful. I have a question that makes sense to me and I was hoping you could answer and the answer might help a lot of people.

I understand that over time I, and everyone else, will very likely get COVID-19 and that most people won't even realize it because it will be minor. I get that, so this is not a panicked question.

I also understand that while most cases will not be severe, the bad cases are complicated by pneumonia.

So my question is: If someone has been vaccinated against pneumonia, will that offer any protection in the event that they do contract COVID-19 and perhaps provide some barrier against the worst effects?

Thank you for your time if you have read this and I apologize if this is just another in a long line of ignorant questions, but it made sense in my brain so I thought I would at least ask.

Be well, be happy, and may life be kind and generous to you, those you love, and those who love you!

sincerely,

Aliantha Angel

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:50:29 +0000
To: Gordon, Joshua (NIH/NIMH) [E]
Subject: RE: Question re: [redacted] (b) (6) coronavirus case

Josh:
You should counsel the rabbi to cancel the services this [redacted] (b) (6) Are the local/city/state health departments [redacted] (b) (6) doing any contact tracing?
Tony

From: Gordon, Joshua (NIH/NIMH) [E] [redacted] (b) (6)>
Sent: Wednesday, March 4, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Subject: Question re: [redacted] (b) (6) coronavirus case

Dear Tony,

I know you are swamped but [redacted] (b) (6)

[redacted] (b) (6)

Is my reasoning sound? Should I counsel them to cancel services this Friday/Saturday? I'm hoping you can spare a bit of time for this advice, [redacted] (b) (6)

Best,

Josh

PS [redacted] (b) (6)

PPS great job today in the hearing

Joshua A Gordon, MD, PhD
Director
National Institute of Mental Health

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:47:27 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Dr. Fauci for ABC News 20/20, Friday 9pm Ashton / Muir

Do you think that we can do this? I like Jennifer Ashton.

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Wednesday, March 4, 2020 9:45 PM
To: Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Dr. Fauci for ABC News 20/20, Friday 9pm Ashton / Muir

Hello:

I wanted to make sure you are still considering our request for Dr. Ashton and David Muir to interview Dr. Fauci for our 2 hour program ABC News 20/20 **Friday from 9pm to 11pm.**

If a remote interview from a studio-on-the go mobile unit is preferable we can certainly arrange that.

Thank you for your consideration.

Keep up with our latest on the developing novel coronavirus outbreak:
https://abcnews.go.com/Health/coronavirus

Eric M. Strauss, ABC News
Managing Editor, Medical Unit
www.ericmstrauss.com
Phone: [redacted] (b) (6)
Connect on Social: T/I/F = @ericMstrauss

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:36:30 +0000
To: Rich Silverman
Subject: RE: Coronavirus Question

Richard:

Right!! Even if there was no coronavirus threat, [redacted] (b) (6)

Best regards,
Tony

From: Rich Silverman [redacted] (b) (6)
Sent: Wednesday, March 4, 2020 8:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Coronavirus Question

Dear Dr. Fauci,
I apologize in advance for this email. I am *sure* you are too busy these days to answer coronavirus questions from the general public. However, you are the only individual I know of who can be trusted to speak intelligently about the pandemic.

I know there is no preventive vaccine or cure, and there probably won't be for quite some time--despite what our ersatz President says. But there is something I don't understand. Since the coronavirus causes pneumonia, wouldn't it be a good idea to vaccinate more of the general population with Pneumovax 23 or Prevnar 13? That certainly wouldn't prevent people from catching coronavirus, but perhaps the resulting penumonia onsets might be a little weaker/short-lived? [redacted] (b) (6) I figured it couldn't hurt, right?

Bravo for your efforts to keep our population intelligently informed on this situation.

Sincerely
Richard E. Silverman
(b) (6) [redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 00:10:39 +0000
To: Basser, Peter (NIH/NICHD) [E]
Subject: RE: genetic screening

Peter:

Thanks for the note. This would not be feasible in an outbreak setting if you are talking about GWAS or any kind of sequencing. Things would be moving too quickly.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Basser, Peter (NIH/NICHD) [E] [redacted] (b) (6)
Sent: Wednesday, March 4, 2020 6:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: genetic screening

Dear Dr. Fauci,

I watched you and Dr. Collins (via videocast) with admiration and pride yesterday during President Trump's visit to the NIH.

This morning, [redacted] (b) (6) and I were discussing the spread of COVID-19. We were opining about why some people only have mild symptoms while others go on to develop ARDS. While we understand that age is a factor, we wondered [redacted] (b) (5)

(b) (5) [redacted]

[redacted] (b) (5)

Regards,

Peter J. Basser, Ph.D.
Senior Investigator, Intramural Research Program (IRP), NIH
Head, Section on Quantitative Imaging and Tissue Sciences (SQITS)
Associate Scientific Director (ASD), Division of Imaging, Behavior and Genomic Integrity (DIBGI)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institutes of Health (NIH)
13 South Drive, MSC 5772
Bldg. 13, Rm. 3W16
Bethesda, MD 20892-5772 USA

[redacted] (b) (6) (O)
(301) 480-0163 (office FAX)
[redacted] (b) (6)
https://science.nichd.nih.gov/confluence/display/sqits/Home

****
This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify me and the system manager immediately.

From: [redacted] (b) (6)
Sent: Wed, 4 Mar 2020 18:25:52 -0500
To: Marc Reinoso
Subject: Re: Coronavirus Covid 19 and smoking

Smoking is terrible under any circumstance

> On Mar 4, 2020, at 6:04 PM, Marc Reinoso [redacted] (b) (6)> wrote:
>
> Hello Dr. Fauci,
> In my review of data it appears there is a negative association with smoking . Should smoking cessation be mentioned during public announcements to help discourage smoking?
>
> Thank you,
>
> Marc Reinoso MD

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 21:27:42 +0000
To: NIAID OD AM
Subject: FW: Meeting to Assess Evaluation of COVID-19 vaccine candidates for risk of enhanced disease
Attachments: March 12th-Tentative list of questions to be discussed_JPC mg-sb[16212]-version4March-1239-CLEAN.docx, Draft agenda.Acc Assess ED.4Mar202011_with annexes.pdf

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Steve Black [redacted] (b) (6)
Sent: Wednesday, March 4, 2020 4:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Robert Chen <robert.chen@cepi.net>
Subject: Meeting to Assess Evaluation of COVID-19 vaccine candidates for risk of enhanced disease

Dear Doctor Fauci,

I am writing to you as a member of the SPEAC project which CEPI has funded to assist with the evaluation of the safety of vaccines in their portfolio. As part of this effort, we are assisting with developing preclinical and clinical testing criteria to evaluate the risk of enhanced disease following vaccination with COVID-19 vaccine candidates. As you know, this had been an issue with some prior SARS vaccine candidates.

We are convening a two day virtual meeting of experts via video conference next week on March 12 and 13 between 8 am and 1 pm Eastern time each day. Participants in the meeting are shown in the attached agenda but include Paul Henri Lambert from Geneva and Barney Graham from NIH. The meeting will actively involve the participants on the agenda the first day and on the second day the meeting will be open for several peer reviewers including Stanley Plotkin and Andy Pollard to review and comment on possible small and NHP animal models as well as appropriate immunologic testing to be done in early phase one trials.

I am wanted to make you aware of the meeting so that you could attend all or part as an observer if you wish but also to invite you to consider joining on day two as one of our formal peer reviewers. The goal of the meeting would be to share recommendations with CEPI COVID-19 developers as well as other interested parties.

Any comments you have on the agenda or draft questions for consideration would be greatly appreciated.

I look forward to hearing back from you.

ATTACHMENTS: DRAFT AGENDA; DRAFT QUESTIONS FOR CONSIDERATION

Steve

Steven Black MD
SPEAC Project work package lead for CEPI

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 21:16:44 +0000
To: NIAID OD AM
Subject: FW: TIME 100 Summit

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alice Park <alice.park@time.com>
Sent: Monday, March 2, 2020 6:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: TIME 100 Summit

Hi Dr. Fauci -- as we discussed, sending along an invitation for you to participate in our TIME 100 Summit, which will be held in New York on April 21-22. We would welcome your insights on a panel addressing COVID-19, likely moderated by me.

I certainly hope you will be able to join us; please let me know either way. Looking forward to hearing from you. Best, Alice

PLEASE NOTE NEW PHONE NUMBER
Alice Park
TIME
(b) (6)
alice.park@time.com
@aliceparkny

From: (b) (6)
Sent: Wed, 4 Mar 2020 09:46:55 -0500
To: Michael Gerson
Subject: Re: Coronavirus Live Updates: Fatality Rate of Covid-19 Is Higher Than the Flu - The New York Times

Talk later. Am in Hearing

> On Mar 4, 2020, at 8:10 AM, Michael Gerson (b) (6)> wrote:
>
> Can this be true?
> https://www.nytimes.com/2020/03/04/world/coronavirus-news.html

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 11:21:47 +0000
To: Emanuel, Ezekiel J
Subject: RE: RE:

No evidence in this regard, but you would assume that their would be substantial immunity post infection. It is an RNA virus and so you can expect mutations, but not sure how much is going on. Will have to check.

From: Emanuel, Ezekiel J [redacted] (b) (6)
Sent: Wednesday, March 4, 2020 5:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: RE:

Sorry the phone. Is a person likely to be immune once they caught the corocnavirus once? Do we know anything about likely drift?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (on Leave 2019-2020)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, March 3, 2020 10:57 PM

To: Emanuel, Ezekiel J [redacted] (b) (6)
Subject: RE:

Thanks for the note. I do not understand your question, See spelling below

-----Original Message-----
From: Emanuel, Ezekiel J [redacted] (b) (6)
Sent: Tuesday, March 3, 2020 9:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject:

Tony
Hope they are greatng you better about media appearances after my call with trump.
You were great at then press conference yesterday

Question:. Lilelynimmunitynince a person has the Coronavirus infection?.
Ari is pestering me

Ezekiel J. Emanuel, M.D. Ph.D.

[redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Wed, 4 Mar 2020 06:19:58 -0500
To: NIAID Public Inquiries
Subject: Fwd: [redacted] (b) (6)

Sent from my iPhone

Begin forwarded message:

> **From:** Patti Taylor [redacted] (b) (6)>
> **Date:** March 4, 2020 at 12:30:52 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject:** [redacted] (b) (6)
>
> Dr Fauci
> My name is Patti Taylor and I'm a nurse. Been one for 30 years. [redacted] (b) (6). Sounds too simple. Anyway I was thinking of the Coronavirus and maybe it has something like an autoimmune part to it that makes a person unable to fight back.....
> Just a thought. I think a lot.
> Sent from my iPhone

From: [redacted] (b) (6)
Sent: Wed, 4 Mar 2020 06:19:08 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: [redacted] (b) (4)
[redacted]
Attachments: PastedGraphic-1.tiff, ATT00001.htm, [redacted] (b) (4)Executive Summary.pdf, ATT00002.htm

Pls respond

Sent from my iPhone

Begin forwarded message:

> **From:** "Gupta, Sanchay" [redacted] (b) (6)>
> **Date:** March 4, 2020 at 1:40:30 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** Shaheer Piracha [redacted] (b) (6)
> **Subject: Meeting Request -** [redacted] (b) (4)
> [redacted]
>
> Hi Dr. Fauci,
> [redacted] (b) (4)
> Thank you in advance for your time.
> Very Best,
> Sanchay Gupta
> [redacted] (b) (4)

Cell: [redacted] (b) (6)

From: (b) (6)
Sent: Wed, 4 Mar 2020 06:17:35 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Press inquiry_Russia

Sent from my iPhone

Begin forwarded message:

> **From:** Валерия Попова (b) (6)
> **Date:** March 4, 2020 at 5:13:38 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
> **Subject: Press inquiry_Russia**
>
> Dear Dr Anthony S Fauci,
>
> My name is Valeria Popova, I am the senior editor of Channel One (Russia). We would like to invite you to take part in the popular international Russian-American project on Channel One. The big game is a television program, within the framework of which two points of view on international events are presented: American and Russian.
> One of the presenters of the program is Dmitry Simes, chairman of the Nixon Center, a US citizen. He was foreign policy adviser to former US President Richard Nixon.
> Only high-ranking officials participate in this discussion: presidents, diplomats, heads of ministries.
> This is an honest and reasonable discussion. It would be a great honor for us if you joined her and discass with our experts about situation with coronavirus. We work live and can use teleconference or skype for communication.
>
> Hope to cooperate!
>
> Channel One is the broadcasting leader in the Russian Federation. 250 million viewers in Russia and abroad. Today, Channel One programs have the opportunity to watch 98.8% of Russians and more than 250 million people in the world.
>
> Channel One is the recognized leader of the Russian television, the most popular and favorite Russian-language channel in the world. It started broadcasting in April 1995

and became the successor to the state television and radio company Ostankino, which was the main broadcaster in the USSR and covered 99.8% of the population of Russia. Channel One's daily programs: the best entertainment shows, unique documentaries, latest news and analytics, the most headline movies and TV premieres, exclusive sports broadcasts and popular Russian music. Channel One combines innovative television broadcasting concepts, the vastest national traditions and cutting-edge global trends in a unique format.

Hope to cooperate!

Sincerely,
Valeria Popova
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 03:09:35 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Routh, Jennifer (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: RE: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Let us discuss the feasibility, desirability and potential for clearance or not.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, March 3, 2020 8:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Is this what you are talking about? Seriously recommend from wdc but again – this is really late – 10 pm to midnight.

From: Johnson, Christie <Christie.Johnson@turner.com>
Sent: Tuesday, March 3, 2020 6:45 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Just making sure you received

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C: [redacted] (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Johnson, Christie
Sent: Tuesday, March 3, 2020 11:16:51 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

As promised, here is the big ticket item I wanted to flag for you. I was waiting to get through yesterday's hits to loop you in as to not overwhelm you. I have been speaking with the WH and VP's office to see if Dr. Fauci is available to join CNN this Thursday for our global town hall but wanted to make sure you have the info. Would you mind checking to see if he's avail?

Info:

We are reaching out to invite Dr. Fauci to join Anderson Cooper and Dr. Sanjay Gupta as our featured guest on the upcoming CNN special town hall - *Coronavirus: Facts and Fears.*

THE LATEST:

This Global Town Hall program will broadcast in front of a live audience from 10pm-Midnight EST on Thursday March 5 from the CNN studios in New York City. We would cover all expenses for someone from the task force to join us live in NY. If Dr. Fauci is unable to come to NY, we will take him remotely from DC.

Coronavirus: Facts and Fears will feature interviews with a wide range of front-line experts fighting to contain coronavirus, along with patients and others who have been directly impacted by it's spread. We're really hoping to include a voice from the administration in order to comfort and inform our worldwide audience.

Thoughts?

Thank you!

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C: (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 03:08:49 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

No. This is not what I was talking about. I received a text from Governor Cuomo of NY State and he wants me to come up to NYC for a Press Conference with his Health Commissioner, Howard Zuycker.

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Tuesday, March 3, 2020 8:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Is this what you are talking about? Seriously recommend from wdc but again – this is really late – 10 pm to midnight.

From: Johnson, Christie <Christie.Johnson@turner.com>
Sent: Tuesday, March 3, 2020 6:45 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Re: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Just making sure you received

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C: [redacted] (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Johnson, Christie
Sent: Tuesday, March 3, 2020 11:16:51 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

As promised, here is the big ticket item I wanted to flag for you. I was waiting to get through yesterday's hits to loop you in as to not overwhelm you. I have been speaking with the WH and VP's office to see if Dr. Fauci is available to join CNN this Thursday for our global town hall but wanted to make sure you have the info. Would you mind checking to see if he's avail?

Info:

We are reaching out to invite Dr. Fauci to join Anderson Cooper and Dr. Sanjay Gupta as our featured guest on the upcoming CNN special town hall - *Coronavirus: Facts and Fears.*

THE LATEST:

This Global Town Hall program will broadcast in front of a live audience from 10pm-Midnight EST on Thursday March 5 from the CNN studios in New York City. We would cover all expenses for someone from the task force to join us live in NY. If Dr. Fauci is unable to come to NY, we will take him remotely from DC.

Coronavirus: Facts and Fears will feature interviews with a wide range of front-line experts fighting to contain coronavirus, along with patients and others who have been directly impacted by it's spread. We're really hoping to include a voice from the administration in order to comfort and inform our worldwide audience.

Thoughts?

Thank you!

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C: (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 02:55:36 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Covid-19 Vaccine
Attachments: Press Release Preview - EIN Presswire - Press Release Distribution Service.pdf

Please take a look at this and act accordingly

From: KUMAR SHAH, MD [redacted] (b) (6)>
Sent: Tuesday, March 3, 2020 9:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Covid-19 Vaccine

To
Dr Anthony Fauci,
Director
NIAID/NIH
[redacted] (b) (6)
Dear Sir,
Humbly, Endocrine Technology, LLC is pleased to forward the enclosed press release for your comments and advice.

--
Best,

Kumar Shah, M.D.
Diplomate American Board of Internal Medicine
Endocrinology, Diabetes & Metabolism
326 Livingston St, Suite A
Brooklyn, N.Y 11217
Office:718-222-1065; c: [redacted] (b) (6)
Fx:718-222-1350
www.etdiabetes.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 02:27:43 +0000
To: Siegel, Marc
Subject: RE: Dr. Marc Siegel: Coronavirus public health response has been handled well; we have right leaders at helm | Fox News

Thanks, Marc

-----Original Message-----
From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Tuesday, March 3, 2020 9:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Dr. Marc Siegel: Coronavirus public health response has been handled well; we have right leaders at helm | Fox News

https://www.foxnews.com/opinion/dr-marc-siegel-coronavirus-public-health-response-has-been-handled-well-we-have-right-leaders-at-helm

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:52:20 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: COVID-19 Webinar

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Prosser <donna.prosser@patientsafetymovement.org>
Sent: Tuesday, March 3, 2020 5:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Mike Ramsay <michael.ramsay@bswhealth.org>; David B. Mayer <david.mayer@patientsafetymovement.org>
Subject: COVID-19 Webinar

Hello, Dr. Fauci,

My name is Donna Prosser, and I am the Chief Clinical Officer at the Patient Safety Movement Foundation. We are planning to host a webinar on Friday, March 6 at 8:00am PST to update our network on the coronavirus outbreak. Our network consists of 4,710 healthcare organizations across 46 countries, as well as patients, families, individual clinicians, and technology companies across the globe, who partner with us to achieve our goal of eliminating deaths from medical error.

During Friday's webinar, we plan to focus on how to keep patients safe from harm during this outbreak, and would love to have someone with your expertise join the call for a brief comment. Would you by any chance be available and willing to speak with our network sometime between 8-9am PST? We would be grateful for any amount of time that you could spare during that hour.

Thank you for your consideration!

Donna

Donna M. Prosser, DNP, RN, NE-BC, FACHE, BCPA
Chief Clinical Officer
Patient Safety Movement Foundation
p: 949.297.7066 **m:** [redacted] (b) (6)
a: 15776 Laguna Canyon Road, Irvine, CA 92618
w: patientsafetymovement.org **e:** donna.prosser@patientsafetymovement.org

Patient Safety
MOVEMENT
2020 World Patient Safety, Science & Technology Summit
March 5-7, 2020
REGISTER

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:51:35 +0000
To: Bob Isman
Subject: RE: How to put COVID-19 statistics in perspective

Thank you for your note.
AS Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bob Isman (b) (6)>
Sent: Tuesday, March 3, 2020 5:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Redfield, Robert R. (CDC/OD) (b) (6); briefing@nytimes.com
Subject: How to put COVID-19 statistics in perspective

Today (March 3), CNN featured a discussion with NY Gov. Cuomo regarding a new COVID-19 case in NY City. He happened to note that there are currently about 15,000 patients in NY hospitals with the flu. Although multiple government agencies, scientists and health experts keep reminding us that there are far more cases, hospitalizations and deaths each year from influenza than this coronavirus, it strikes me that a more effective, more visual and less fear-producing way of presenting this information would be to present the current number of cases, hospitalizations and deaths from EACH of these diseases side by side. If the number of flu cases, hospitalizations and/or deaths isn't available on a daily basis, we could use extrapolations based on known rates. I think this would certainly go a long way to putting the relative risks of these diseases in clearer focus.
Bob Isman, DDS, MPH

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:50:50 +0000
To: Jlevyusa
Subject: RE: Idea to help with Coronavirus infection

Thank you for your note.
AS Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jlevyusa [redacted] (b) (6)>
Sent: Tuesday, March 3, 2020 4:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Idea to help with Coronavirus infection

Dr. Fauci,
I first want to thank you for your service and efforts in combating this international health problem.

I'm neither a physician or a scientist so please accept my apology if my idea is simplistic or isn't feasible. But I was thinking about some of the information presented on why it seems to be less prevalent in children. One theory is that they are exposed to so many other coronavirus's that they experience cross-protection. So I was wondering if anyone had investigated the idea to flood adults with other, less lethal, coronavirus's as a way to develop some level of immunity? Ideally coronavirus's that are a match to what children would be exposed to is what I'm suggesting here. I wouldn't expect that this will totally protect an adult but it might reduce the severity of the illness if an adult becomes ill and help while a vaccine and treatments are launched.

Thank you for considering this idea.

Best,
Jeff

Jeffrey Levy

[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:50:07 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: my feeble attempt
Attachments: COVID-19.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tai Te Wu (b) (6)
Sent: Tuesday, March 3, 2020 2:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: my feeble attempt

Dear Dr. Fauci,

I have seen you on the television commenting about COVID-19.

Therefore, I have decided to squeeze some information out of their nucleotide and amino acid sequences as enclosed. Hope that you may soon find a cure with all the available data on this virus.

Best regards.

Tai Te Wu

From: [redacted] (b) (6)
Sent: Tue, 3 Mar 2020 13:36:59 -0500
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: Informal coronavirus teleconference: agenda + background documents
Attachments: image001.png, ATT00001.htm, 01 March_Chapeau_Critical preparedness readiness and response actions for COVID 19_DRAFT.pdf, ATT00002.htm, 01 March_COVID 2019 response scenarios_DRAFT.pdf, ATT00003.htm, 01 March_Preparing for Widespread Community Transmission_DRAFT.pdf, ATT00004.htm, 18624 Swisscom Call code.docx, ATT00005.htm

For the7 am folder pls

Sent from my iPhone

Begin forwarded message:

> **From:** "KABIR, Sophia" [redacted] (b) (6)
> **Date:** March 3, 2020 at 1:35:53 PM EST
> **To:** SHOC <shoc@who.int>, Office of the Director-General <DGOffice@who.int>, "Redfield, Robert R. (CDC/OD)" [redacted] (b) (6) David Heymann [redacted] (b) (6) "Felicity Harvey [redacted] (b) (6) "Chris.Elias" [redacted] (b) (6) [redacted], Jeremy Farrar [redacted] (b) (6)>, [redacted] (b) (6) "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6) [redacted], "GREIN, Thomas" [redacted] (b) (6)>, "COX, Paul Michael" [redacted] (b) (6), "SCHWARTLANDER, Bernhard F." [redacted] (b) (6)>, "MINHAS, Raman" [redacted] (b) (6) "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "MAHJOUR, Jaouad" [redacted] (b) (6)>, "FALL, Ibrahima Soce" [redacted] (b) (6), "Thomas R. Frieden" [redacted] (b) (6) Lynn Banks [redacted] (b) (6), President | Resolve to Save Lives <president@resolvetosavelives.org>, [redacted] (b) (6) "AL-SHORBAJI, Farah" [redacted] (b) (6) [redacted], Robynn Leidig [redacted] (b) (6) "DRURY, Patrick Anthony" [redacted] (b) (6), "Dr VAN KERKHOVE, Maria"

[redacted] (b) (6)
[redacted] "GRAAFF, Peter Jan"
(b) (6), "POOLE, Marcia" [redacted] (b) (6), Tarik Mohammed
[redacted] (b) (6)
"(SPmig) Carlos Navarro Colorado" < [redacted] (b) (6)
[redacted] Ryan Morhard
(b) (6), "BRIAND, Sylvie" [redacted] (b) (6)
"MORGAN, Oliver" [redacted] (b) (6) "Harries, Jenny"
[redacted] (b) (6)"Awwad, David (NIH/NIAID) [C]"
[redacted] (b) (6)>, "SIMONSON, Stewart" [redacted] (b) (6),
"SINGER, Peter Alexander" [redacted] (b) (6)>, "(SPmig) Carlos Navarro
Colorado" [redacted] (b) (6)>
Cc: "RYAN, Michael J." [redacted] (b) (6)>, "FARES, Christine Youssef"
[redacted] (b) (6), "BOKO, Ivana" [redacted] (b) (6)>
Subject: Informal coronavirus teleconference: agenda + background documents

Dear colleagues,

On behalf of Mike Ryan, allow me to share with you the following background documents ahead of the informal coronavirus teleconference tomorrow at 13.00 CET:

[redacted] (b) (4)

Please find below, the key questions for your consideration and input tomorrow. We do not expect you all to address/speak on all the questions but just as a guide to your thinking and the ones you have views/advice/ideas.

[redacted] (b) (4)

[redacted] (b) (4)

The dial-in number and passcode are attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: **+41 227 912 490**

Best,

Sophia

-----Original Appointment-----
From: RYAN, Michael J.
Sent: Tuesday, February 25, 2020 10:07 AM
To: RYAN, Michael J.; SHOC; Office of the Director-General; [redacted] (b) (6); Felicity Harvey [redacted] (b) (6); Chris Elias; [redacted] (b) (6) Jeremy Farrar; [redacted] (b) (6) GREIN, Thomas; COX, Paul Michael; SCHWARTLANDER, Bernhard F.; MINHAS, Raman; [redacted] (b) (6) MAHJOUR, Jaouad; FALL, Ibrahima Soce; Thomas R. Frieden; Elhadj SY; Lynn Banks; President | Resolve to Save Lives; [redacted] (b) (6) AL-SHORBAJI, Farah; [redacted] (b) (6); Robynn Leidig; DRURY, Patrick Anthony; Dr VAN KERKHOVE, Maria; [redacted] (b) (6) Cheryl Cohen; GRAAFF, Peter Jan; POOLE, Marcia; Tarik Mohammed; [redacted] (b) (6) Ryan Morhard; BRIAND, Sylvie; MORGAN, Oliver; Harries, Jenny; Awwad, David (NIH/NIAID) [C]; SIMONSON, Stewart
Cc: SINGER, Peter Alexander
Subject: Informal coronavirus teleconference
When: Wednesday, February 26, 2020 1:00 PM-2:00 PM (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna.
Where: Upper SHOC (For Call in: please see dial in details attached)

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted tomorrow Wednesday, 26 February at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email: (b) (6) mobile no. (b) (6)

Best,

Mike

Sophia Kabir
Executive Officer
Office of the Executive Director
WHO Health Emergencies Programme (WHE)
Tel. (b) (6)
Mobile (b) (6)

Website: WHO in emergencies | WHO Facebook | WHO Twitter

From: [redacted] (b) (6)
Sent: Tue, 3 Mar 2020 12:42:58 -0500
To: Oplinger, Anne (NIH/NIAID) [E]
Subject: Fwd: Interview request from the Jesuits

From Patty on Fauci email. Not for several weeks

Sent from my iPhone

Begin forwarded message:

> **From:** Mike Jordan Laskey <JCUcommunications@jesuits.org>
> **Date:** March 3, 2020 at 12:32:38 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Interview request from the Jesuits**
>
> Dear Dr. Fauci,
>
> I host the AMDG Jesuit Podcast, which reaches a faith-based audience connected to Jesuit institutions around the country. I would love to welcome you onto the show to discuss the coronavirus and how your Jesuit education has shaped your career. It would be great to have 15-20 minutes of your time. Thanks very much for your consideration.
>
> Best,
> Mike
>
> --
> Mike Jordan Laskey
> Senior Communications Manager
> Jesuit Conference of Canada and the United States
> 1016 16th Street NW 3rd Floor
> Washington, DC 20036
> 202.629.5933
> jcucommunications@jesuits.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:57:03 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona Virus and a possible path to a vaccine?
Attachments: Origin of Co-Vid 19 and possible path to vaccination.pdf, PastedGraphic-10.tiff

Pls respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: expand@omcasa.com <expand@omcasa.com>
Sent: Tuesday, March 3, 2020 5:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Corona Virus and a possible path to a vaccine?
Importance: High

Dear Dr. Fauci -

Thank you for helping millions of people with your research over the years.

The following information was culled from http://poleshift.ning.com.

Perhaps this article may help you and your colleagues develop a vaccine that may combat the Corona Virus. You were the first one I thought of who may be able to deem its worth and explore its research for practical purposes.
Some of the links have included nih.gov so maybe your colleagues have already read this.
With my limited medical knowledge, I have taken the liberty to highlight key points that seem important.

Wishing you and yours all the best for remaining healthy in Mind, Body & Spirit.

Warm Regards & Appreciation,

Liz Jan

LIZ JAN BAmst, CAPS
Vaastu Homes instill Harmony, Tranquility, Abundance & Love; featuring
Universal Design & Aging in Place for safety, comfort & accessibility.

Design & Consultations
540.300.0638
expand@OmCasa.com
www.OmCasa.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:55:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Covid-19 — Navigating the Uncharted

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: El Bcheraoui, Charbel [redacted] (b) (6)>
Sent: Tuesday, March 3, 2020 3:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Covid-19 — Navigating the Uncharted

Dear Dr. Fauci,

Thank you for your useful editorial published in NEJM last week, it helps confirming that the situation does not need to be as glim as the panic that most people are experiencing.
I am writing an editorial and hoping to submit it to The Lancet soon. Differently from NIH/US Government institutes, I have more room for reflection in my viewpoint.

For that reason, I was wondering if I can have a call with you to get your opinion/advice on the direction of my editorial. I know how busy you are and I can understand if you do not have the time, but if by chance you are willing to have this call, I'll be happy to share my editorial's draft first.
As a background, I am an EIS graduate (class of 2009), and trained by Robert T. Chen.

Thanks,
Charbel El Bcheraoui, PhD, MSc
Head of Evidence-Based Public Health,
Center for International Health Protection,
Robert Koch Institute,
Nordufer 20, 13353 Berlin,
Telephone: [redacted] (b) (6),
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:54:16 +0000
To: NIAID Public Inquiries
Subject: FW: Zinc gluconate by inhalation for early coronavirus in elderly?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Arthur (b) (6)
Sent: Tuesday, March 3, 2020 1:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Zinc gluconate by inhalation for early coronavirus in elderly?

Dr Fauci,

Since the elderly's response to pulmonary coronavirus infection may be impaired, especially in those with a chronic disorder, is there any information re: delivering by inhalation, low concentrations of a Zinc salt. Is there a potential rationale in early coronavirus infection to try to minimize serious pneumonia, were such inhalation shown to be reasonably safe?

Thank you,

Arthur Bobrove, MD
Stanford and Palo Alto VA

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:53:42 +0000
To: NIAID Public Inquiries
Subject: FW: Coronavirus: Six Eyed Sand Spider, Habanero, water, Qi

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Lily Carnie [redacted] (b) (6)
Sent: Tuesday, March 3, 2020 12:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Coronavirus: Six Eyed Sand Spider, Habanero, water, Qi

Dr. Fauci,

[redacted] (b) (6). I am an author on a Chinese form of healing called Qigong (a field I have studied for over 30 years), and am exploring Coronavirus from the perspective of a combination of the venom of the Vietnamese Six Eyed Sand Spider (entering the cells externally), Habanero capsaicin entering cells internally, the elevated water levels of infants and children and their higher levels of Qi in relation to them not getting the disease, and Qi from Traditional Chinese Medicine, Acupuncture, and Qigong.

I believe that the above combination can be beneficial in the study of Coronavirus. I am sure you are extremely busy and I am but a simple author but I just wanted to try to touch bases in case the above might help.

I live in [redacted] (b) (6).

I would be truly honored to hear from you.

Lily of the Valley Carnie

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:52:17 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Possible treatment of COVID-19 pneumonia

Pls respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paul Tone, MD (b) (6)>
Sent: Monday, March 2, 2020 11:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Possible treatment of COVID-19 pneumonia

Dear Dr. Fauci,

Nitric Oxide (NO) has been shown to contribute to the pathogenesis of influenza virus-induced pneumonia in mouse model (Zablockiene et al., 2012).

Zablockiene B, Ambrozaitis A, Kacergius T, Gravenstein S. Implication of nitric oxide in the pathogenesis of influenza virus infection. Biologija 2012; 58(1): 15-25.

NO overproduction in influenza virus pneumonia results from a sustained stimulation of inducible Nitric Oxide Synthase (iNOS) (Akaike et al., 1996).

Akaike T, Noguchi Y, Ijiri S, Setoguchi K, Suga M, Zheng YM, Dietzschold B, Maeda H. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc Natl Acad Sci U S A. 1996 Mar 19; 93(6):2448-53.

NO overproduction in influenza virus-induced pneumonia can generate highly reactive oxygen species, peroxynitrite, via radical coupling reaction of NO with superoxide [resulting from influenza virus-induced increased levels of xanthine oxidase (XO) (Maeda and Akaike, 1998).

Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc). 1998 Jul; 63(7):854-65

Peroxynitrite causes oxidative tissue injury through potent oxidation and nitration reactions of various biomolecules (Akaike and Maeda, 2000).

Akaike T, Maeda H. Nitric oxide and virus infection. Immunology. 2000 Nov; 101(3):300-8.

The crucial role of NO in influenza virus-induced pneumonia was demonstrated on iNOS gene knockout mice: at inocula sufficient to cause consolidating pneumonia and death in the wild-type control mice, iNOS gene deficient mice survived with little histopathologic evidence of pneumonia (Karupiah et al., 1998).

Karupiah G, Chen JH, Mahalingam S, Nathan CF, MacMicking JD. Rapid interferon gamma-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice. J Exp Med. 1998 Oct 19; 188(8):1541-6.

Both influenza and coronaviruses could have the same pathogenetic mechanism of inducing pneumonia, namely harmful overproduction NO.

I would like to present you my innovative idea: Suppressing NO overproduction in COVID-19 complicated to pneumonia with Methylene Blue (MB)

Arguments pro:

MB is known as a guanylate/guanylyl cyclase inhibitor but it is mainly a NOS inhibitor (nNOS and iNOS).

MB is an inhibitor of superoxide generation by xanthine oxidase and NADH/NADPH oxidases.

MB is a small molecule capable to penetrate in tissues and cells

MB was administered intravenously in patients with refractory septic shock and Hepatopulmonary Syndrome of advanced liver cirrhosis.

MB administered intravenously will definitively reach the cells where NOS is induced by COVID-19 complicated by pneumonia both in animals and humans:

-Airway epithelium (including alveolar epithelial cells);

-Alveolar macrophages;

-Capillary/vascular endothelium (endothelial cells).

MB is an inexpensive medication.

MB is non-toxic molecule in humans

There are only a few cases of MB toxicity published in the literature. These cases occurred in very peculiar situations:

Hemolytic anemia in patients with G6-PD deficiency

Severe neuropathology after intrathecal administration of MB

Eye injury after topical use of MB

Tissue necrosis due to the extravasation of injected MB

Jejunal atresia following intra-amniotic MB

Serotonin reuptake inhibitors (SRI's) interact with MB, causing a serious adverse reaction consistent with serotonin syndrome.

Very truly yours,

Paul Tone, MD, PhD

Internal Medicine and Gastroenterology

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:51:29 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Dr. Fauci. I have a possible reason children are immune to the coronavirus. Please read

Pls respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Rob Klein (b) (6)>
Sent: Monday, March 2, 2020 10:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Dr. Fauci. I have a possible reason children are immune to the coronavirus. Please read

Hello Dr. Fauci. I am a (b) (6) pharmacist from Ontario, Canada. I was just reading an article that stated covid-19 cases in children under nine y.o. are almost non-existant. I wondered why, and then an answer dawned on me. They have an immunity because one of the childhood vaccines all children get is giving them cross immunity to coronavirus as well. A study should be done immediately to see which one gives cross immunity, if indeed that is the reason for their seeming immunity to this virus. The immunity must wear off over time which is why adults and seniors seem to lack prior immunity and get sick. This hypothesis is certainly worth investigating. If this is what is happening, maybe millions of lives could be saved by a simple booster of an existing vaccine. Please let me know your thoughts on this matter. Thanks for your time. Rob

Sent from Mail for Windows 10

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Tue, 3 Mar 2020 13:21:11 +0000
To:	Conrad, Patricia (NIH/NIAID) [E]
Subject:	FW: Sky News

We should discuss

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Szweda, Jakub (Interviews producer) <jakub.szweda2@sky.uk>
Sent: Tuesday, March 3, 2020 6:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Sky News
Importance: High

Hello Dr Fauci,

Hope you're well. I'm a producer for Sky News, looking after our flagship evening programme Sky News Tonight 7-10pm UK time (2-5pm ET).

I was wondering if you might be available for an interview on the coronavirus outbreak? Either today or another day this week.

Happy to explain in more detail.

Any questions, please let me know.

Best,
Jakub

Jakub Szweda

Interviews Producer | Sky News

Phone: +44 (0)2070320436 | Mobile: (b) (6)
Address: 2nd Floor, 4 Millbank, Westminster, SW1P 3JA

Watched by 169m people in 138 countries

Information in this email including any attachments may be privileged, confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received it in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. SKY and the SKY marks are trademarks of Sky Limited and Sky International AG and are used under licence.

Sky UK Limited (Registration No. 2906991), Sky-In-Home Service Limited (Registration No. 2067075), Sky Subscribers Services Limited (Registration No. 2340150) and Sky CP Limited (Registration No. 9513259) are direct or indirect subsidiaries of Sky Limited (Registration No. 2247735). All of the companies mentioned in this paragraph are incorporated in England and Wales and share the same registered office at Grant Way, Isleworth, Middlesex TW7 5QD

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:10:22 +0000
To: George GAO
Cc: Mascola, John (NIH/VRC) [E];Conrad, Patricia (NIH/NIAID) [E];Graham, Barney (NIH/VRC) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Vaccine—confidential PPT
Attachments: 20200303 For Gao laoshi.pptx

George:

Thanks for the note. I will send this to Dr. John Mascola Director of the NIAID Vaccine Research Center and Dr. Barney Graham to follow-up with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: George GAO [redacted] (b) (6)
Sent: Tuesday, March 3, 2020 7:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Vaccine—confidential PPT

Dear Tony
Hope this email finds you well and the US will soon get the COVID-19 down.

[redacted] (b) (4)

All the best
George

发自我的iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 10:57:14 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Graham, Barney (NIH/VRC) [E]
Subject: Important - POYUS and VP visit slides
Attachments: VIP visit to VRC Coronavirus Short version - for 3-3-2020.pptx

John:

Yesterday when I spoke to your IT/audio visual guy I told him to pull out the single slide with the comparative time lines for various vaccines over the years and show it on the screen. I then asked him to have the full set of slides ready for me to show. I have now abridged that "full" set so that I can whip through them if it looks like the discuss slows down. I am attaching this abridged version here. Please ask him to substitute this shorter version for the full set from yesterday. Call me if you have any questions.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 03:40:19 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Can we get comment please?

I am not going to comment. [redacted] (b) (5).

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, March 2, 2020 3:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: Can we get comment please?

[redacted] (b) (5)

From: "Burton, Tom" <tom.burton@wsj.com>
Date: Monday, March 2, 2020 at 3:09:17 PM
To: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6), "Lane, Cliff (NIH/NIAID) [E]" [redacted] (b) (6), "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: Can we get comment please?

Folks, we're doing a story that focuses in part on the administration's conference call from last Thursday noon about a decision to send out more CDC coronavirus assays despite the fact that they had become contaminated and compromised. We understand that Dr. Fauci was one of four federal doctors (the others being Drs. Hahn, Shuren and Shah) who strongly recommended the assays not be sent out.
I want to give Dr. Fauci a chance, on or off the record, to comment on the story please.
Thank you,
Tom Burton

--
Thomas M. Burton, Staff Reporter
The Wall Street Journal
1025 Connecticut Ave. N.W., #800
Washington, D.C. 20036
W: 202 862-6611
Follow me @TomBurtonWSJ

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 03:11:52 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Alert: Questions from Sen. Alexander for tomorrow's hearing

Bob:
Please do me a favor and provide answers to the questions below from Sen. Alexander
Thanks,
Tony

From: Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, March 2, 2020 8:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Crawford, Chase (NIH/NIAID) [E] < [redacted] (b) (6); Selgrade, Sara (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] < [redacted] (b) (6)>
Subject: Alert: Questions from Sen. Alexander for tomorrow's hearing

Dr. Fauci,

We just received a number of questions from Senate HELP that Sen. Alexander plans to ask you at the hearing. Chase will pull together the epi info. Let us know if you want to discuss these.

Melinda

Sent from my iPhone

Begin forwarded message:

> **From:** "Hallett, Adrienne (NIH/OD) [E]" < [redacted] (b) (6)>
> **Date:** March 2, 2020 at 8:15:00 PM EST
> **To:** "Haskins, Melinda (NIH/NIAID) [E]" < [redacted] (b) (6)>, "Selgrade, Sara (NIH/NIAID) [E]" [redacted] (b) (6)>, "LaMontagne, Karen (NIH/OD) [E]" [redacted] (b) (6)>, "Berkson, Laura (NIH/OD) [E]" [redacted] (b) (6)
> **Subject: Fwd: Questions from Sen. Alexander**
>
> See anticipated questions below.
>
> Begin forwarded message:
>
> > **From:** "Coulter, Margaret (HELP Committee)"
> > [redacted] (b) (6)
> > **Date:** March 2, 2020 at 7:29:15 PM EST
> > **To:** "Pence, Laura (HHS/ASL)" [redacted] (b) (6), "Bradsher, Kris

(HHS/ASL)" (b) (6)>, "Berkson, Laura (NIH/OD) [E]"
(b) (6)>, "Hallett, Adrienne (NIH/OD) [E]"
(b) (6)>
Cc: "Bell, Kathryn (HELP Committee)" (b) (6)
"Pfaff, Melissa (HELP Committee)" (b) (6)>, "Vogt, Andrew (HELP Committee)" (b) (6)>, "Graham, Grace (HELP Committee)" (b) (6)>
Subject: Questions from Sen. Alexander

Hi Laura and team,

Thanks for all your work in advance of tomorrow's HELP hearing. Below are specific questions that Sen. Alexander plans to ask Dr. Fauci and would greatly appreciate concise answers to – he is happy to allow Dr. Fauci to elaborate if there is additional time. Additionally, he plans to ask Dr. Schuchat a few questions about CDC covering patient costs from quarantine.

Thank you very much and look forward to seeing you all or your colleagues tomorrow.

Best,
HELP team

Questions for Dr. Fauci:

1. How many cases are there in the world? In the U.S.?
2. How many deaths so far in the world? In the U.S.?
3. How many countries have cases of the coronavirus?
4. How do you know if you have the coronavirus?
5. What are the symptoms?
6. How do you protect yourself?
7. Should we all be wearing masks?
8. If not, why should health care workers have to wear masks?
9. What are the most effective ways to protect your families?
10. If someone has coronavirus symptoms, what should they do?

11. If a doctor has a patient with these symptoms, what should they do?

12. Who is most at risk?

13. What is the mortality rate?

14. Can you explain why there have been relatively few reports of cases in children?

15. This is the peak of the flu season –
    a. How many flu cases have we had this year so far?
    b. How many deaths have we had this year from the flu?
    c. How is the coronavirus different from the seasonal flu?
    d. Is it possible that we could reduce the infections or deaths from the seasonal flu because you need to do the same things to protect yourself for both types of viruses?

16. Can a person transmit the virus even if they are not showing symptoms?

17. Are your agencies doing any research to determine when exactly an individual may transmit the virus to others?

QUESTION FOR DR. SCHUCHAT:

- If a patient is under a federal government-required quarantine, who pays the bills?

- Does their insurance pay first, and then does the CDC cover the remaining bills as the payer of last resort?

- If CDC is the payer of last resort, does the agency pay the doctor or the hospital directly – or is the patient obligated to send their bills to the CDC?

- How and when is this information made available to the patients under a federal government-required quarantine?

From: (b) (6)
Sent: Mon, 2 Mar 2020 19:06:49 -0500
To: Johnson, Richard Allen,M.D.
Subject: Re: Telecast today

Thanks, Dick.

> On Mar 2, 2020, at 6:57 PM, Johnson, Richard Allen,M.D. (b) (6)>wrote:
>
> Tony,
> You were the star of the broadcast today! Your intelligence, confidence, warmth, and humor are what we all need with COVID-19. Please keep these coming. You appear to have a great working relationship with Dr. Burks.
> Very best,
> Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 17:56:05 +0000
To: Michael Gerson
Subject: RE: Q

See my edits in red for accuracy

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michael Gerson [redacted] (b) (6)>
Sent: Monday, March 2, 2020 11:41 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: Q

This is the descriptive portion of my column. I don't want to over or under-state:

America is entering a disturbing new stage in the coronavirus outbreak. There has been community spread in at least one and likely two locations in Washington State. And it appears the virus was being transmitted for at least a few weeks before current cases were recognized. So we can expect dozens or hundreds of cases in those locations unless contact tracing is especially efficient.

That means the disease is loose and easily transmitted.

The crucial issue now is the real mortality rate, which remains uncertain. The stated mortality is 2 percent. American experts are hoping the rate turns out to be considerably lower. But the math remains troubling in any case. If only 5 percent of the population eventually gets infected (which is on the low side of some estimates) and the mortality rate is 1 percent, there still would be a few hundred thousand deaths.

At this stage, the main tool that public health experts have is social distancing – the attempt to keep as many people as possible in affected areas out of sneezing distance from one another. This means measures such as closing schools, cancelling events in theaters and stadiums and encouraging employees to telework. States and localities ultimately make such decisions rather than the federal government. But according to some health experts I consulted, Washington State should be taking such measures right now. The effectiveness of social distancing is limited when action comes too late or ends too early.

The goal of such policies is to keep the R0 (reproduction ratio) as low as possible. When people are in close proximity, a single infected person can spread the disease to several others, boosting the R0 of the disease as high as 2 to 3 and causing an exponential increase in cases. If the R0 is less than one, the epidemic will gradually decline and stop on its own, with or without a vaccine.

A vaccine, however, would be tremendously helpful. There are at least ten vaccine development projects underway. But the one furthest along at the National Institutes of Health (NIH) is still about six weeks away from starting the process of **a** phase 1 **trial in human volunteers that will take 3 to 4 months to complete and to show that the vaccine safe and produces specific antibodies. A** phase 2 trial **will follow and will take at least 6 to 8 months to determine if the vaccine is efficacious in people at risk for infection**. Then production would need to be scaled up by a willing pharmaceutical company to deal with a global crisis. All this **in total will** take at least a year – assuming there are no unpredicted scientific obstacles in the way.

On Mar 2, 2020, at 7:54 AM, Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)> wrote:

Mike:

Social distancing is not really geared to wait for a vaccine. The major point is to prevent easy spread of infections in schools (closing them), crowded events such as theaters, stadiums (cancel events), work places (do teleworking where possible). States and localities make these decisions, not the Federal government. The goal of social distancing is to prevent a single person who is infected to readily spread to several others, which is facilitated by close contact in crowds. Close proximity of people will keep the R0 higher than 1 and even as high as 2 to 3. If we can get the R0 to less than 1, the epidemic will gradually decline and stop on its own without a vaccine.

[redacted] (b) (6)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Michael Gerson [redacted] (b) (6)>
Sent: Monday, March 2, 2020 7:22 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Q

Is the overall strategy for social distancing just to keep the percentage of Americans who get the disease low until a vaccine is available? This seems much harder to do in a free society. Does this mean closing schools? Public transport? Do states and localities make such decisions?

[redacted] (b) (6)

> On Mar 2, 2020, at 6:11 AM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:
>
> Mike:
>
> Thanks for the note. We are clearly getting "community spread" in at least one and likely two non-contiguous locations. It was likely spreading in Washington State for at least a few weeks before the current cases were recognized, which means we can expect dozens and dozens of cases (or more) in that location unless we are vey lucky and/or the contact tracing is highly efficient. The precise mortality rate is still uncertain. The stated

mortality is 2%; however, even if it is half that (1%) and only 5% of the population get infected, you are correct in that we can have a few hundred thousand deaths. The really critical issue is what the mortality rate actually turns out to be. I am hoping for a considerably lower mortality rate, but that might be wishful thinking. Whatever it turns out to be, the major tools that we have are public health measures, particularly social distancing, which we have to start doing right now in Washington State and thinking about in other locations. That is really the major weapon that we have. Even though we go into phase 1 with one candidate vaccien in about 6 weeks, vaccine is out of the question for at least a year or more if you want to make sure that you have an effective vaccine, i.e. some efficacy data before massive deployment. We are meeting with pharmaceutical executive today and I will bring up the issue of what the fastest possible timeline would be to have a deployable vaccine.

[redacted] (b) (6)

[redacted]. I hope that you are well.

Best regards,
Tony

-----Original Message-----
From: Michael Gerson [redacted] (b) (6)
Sent: Monday, March 2, 2020 5:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Q

Tony,

I was with Francis yesterday, and the news seemed pretty sobering. It seems like the virus is out in the general population in the Pacific Northwest and Silicon Valley. A pandemic now appears likely. Francis gave me a guesstimate that 5 to 20 percent of the US population may end up infected. Depending on the mortality rate, this could result in hundreds of thousands of deaths.

Not for attribution in any way, is this a fair summary? How and when will we know if the disease is on this track? Do we have any better info on mortality yet?

And is there any news on the vaccine front? As I understand it, we are not even to Phase 1 trials on anything. If a vaccine is promising, are well talking about late Fall as the earliest possibility? And are there any substantive measures that could be taken to make sure pharma steps up to produce a vaccine on a massive scale once we have It?

I'm not sure Americans have been adequately prepared for this possibility. That is partly a political problem (in my view). But what needs to happen soon to get people prepared?

Hope you are holding up well under all of this and taking care of yourself.

Mike

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 17:26:54 +0000
To: Reddy, Sumathi
Subject: RE: ?

For COVID-19 the mortality rate is approximately 2%. For seasonal influenza it is approximately 0.1%

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Reddy, Sumathi <sumathi.reddy@wsj.com>
Sent: Monday, March 2, 2020 10:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: ?

Hi there
Wanted to see what's the most up-to-date info you have on mortality rate for covid-19 versus influenza?

--

Sumathi Reddy
The Wall Street Journal
"Your Health" columnist

M: [redacted] (b) (6) O: +1 212 416 2945
E: sumathi.reddy@wsj.com
T: @rddysum
A: 1211 Avenue of the Americas, New York, NY 10036

From: [redacted] (b) (6)
Sent: Mon, 2 Mar 2020 09:24:45 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: 60 Minutes / COVID -19

Let us discuss

Begin forwarded message:

> **From:** Denise Cetta [redacted] (b) (6)>
> **Date:** March 2, 2020 at 9:20:42 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** Jon LaPook [redacted] (b) (6), "Stover, Kathy (NIH/NIAID) [E]" [redacted] (b) (6)>, "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6), Katie Brennan <BrennanK@cbsnews.com>
> **Subject: 60 Minutes / COVID -19**
>
> Dr. Fauci:
> Good morning.
> I know you are busy, so forgive me for reaching out directly, but time is of the essence.
> I know you spoke with Jon about doing a 60 Minutes story on COVID-19.
> We are interested in potentially crashing a story for this weekend.
> Is it possible for us to have a quick brainstorming phone call on what such a story might include if based at NIH with you?
> Some ideas…
>
> Following you closely as you engage in meetings, getting up to date info, giving your opinion, going to task force meeting at WH or elsewhere.
> Are you using the same "DNA platform" you showed us in the Zika story to build a potential vaccine for COVID-19? Or is it another approach?
> Will you be meeting with any patients who are currently infected? Bringing any patients to the NIH for care/evaluation?
>
> Let us know when you can talk.
> Denise
>
> Denise Schrier Cetta
> Producer, CBS News, 60 Minutes
> Cell: [redacted] (b) (6)

From: (b) (6)
Sent: Mon, 2 Mar 2020 09:20:56 -0500
To: Shlomchik, Mark Jay
Subject: Re: Is this true?

I have been very explicit in stating publicly that I am not being muzzled or censored. I say exactly what I want to say based on scientific evidence, I have stated this on multiple TV programs over the past few days including at a major press conference with many, many reporters present including several TV cameras. I could not possibly be more public about this. No censor. No muzzle. Free to speak out.

> On Mar 2, 2020, at 9:11 AM, Shlomchik, Mark Jay <MSHLOMCH@pitt.edu>wrote:
>
> OK, well that is good to know. It has been reported by many outlets including the NYT. So if not true I think it is critically important for you to say so publicly and show that it is not the case. It is critical, critical that we all have faith in the science and medical leadership. Your personal integrity is at stake here in the community and the world, and is a proxy for the integrity of science and medicine.
> According to one house member, the following:
>
> Garamendi told MSNBC's Hallie Jackson that Anthony Fauci was scheduled to do all five major Sunday talk shows, but says Fauci canceled the appearances after Vice President Pence took over the administration's response to the disease.
>
> Trump on Wednesday named Pence as the official overseeing the government's response.
>
> "I can repeat what he said, he said, 'I was not muzzled. However, I was to go on the Sunday talk shows five of them. The vice president's office then took over the control of this situation, and told me to stand down, not to do those shows,'" Garamendi said, quoting Fauci.
>
> We cannot mince words about this or have nuances. If you were told not to appear on Sunday talk shows, then a reasonable person would have to assume your speech indeed is being controlled. Whether you call it "muzzled" or censored is a matter of semantics. Is it factual that you were told/asked not to appear on these shows as had been scheduled?

I hope you understand my reason for and level of concern. I am certain it is shared by many of your colleagues and citizens.
Best,
Mark

Mark Shlomchik, MD, PhD
UPMC Endowed and Distinguished Professor of Immunology
Chair, Department of Immunology
University of Pittsburgh School of Medicine

W1052 Biomedical Science Tower
200 Lothrop St
Pittsburgh, PA 15261
Phone: [redacted] (b) (6)
Fax: 412-383-8098

[redacted] (b) (6)
https://www.immunology.pitt.edu
http://immunology.pitt.edu/person/mark-jay-shlomchik-md-phd

Check out our gene targeting and flow cores: http://immunology.pitt.edu/department-resources

> On Mar 2, 2020, at 9:03 AM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>wrote:
>
> The story is not true. I am not being muzzled or censored.
>
>> On Mar 2, 2020, at 8:51 AM, Shlomchik, Mark Jay <MSHLOMCH@pitt.edu>wrote:
>>
>> Dear Tony,
>> Is the information in this article true?
>> https://www.businessinsider.com/who-is-anthony-fauci-speech-controlled-by-trump-coronavirus-2020-2
>> If it is, I think that—in the interests of public health and the integrity of science in the US—you must not acquiesce but instead resign and speak out.
>> If it is not true, then please refute it and set the record straight.
>> Sincerely,
>>
>> Mark Shlomchik, MD, PhD
>> UPMC Endowed and Distinguished Professor of Immunology
>> Chair, Department of Immunology
>> University of Pittsburgh School of Medicine

W1052 Biomedical Science Tower
200 Lothrop St
Pittsburgh, PA 15261
Phone: 412-648-8771
Fax: 412-383-8098

mshlomch@pitt.edu
https://www.immunology.pitt.edu
http://immunology.pitt.edu/person/mark-jay-shlomchik-md-phd

Check out our gene targeting and flow cores: http://immunology.pitt.edu/department-resources

From: [redacted] (b) (6)
Sent: Mon, 2 Mar 2020 09:10:54 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: lay info for people who are at risk for COVID-19
Attachments: Wuhan Coronavirus for Mama.20020301.pdf, ATT00001.htm

Please take a look at this and respond.

Begin forwarded message:

> **From:** Cynthia Bristow <[redacted] (b) (6)
> **Date:** March 1, 2020 at 10:12:22 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: lay info for people who are at risk for COVID-19**
>
> Dear Tony,
>
> I would like to respectfully ask if someone in your Institute could kindly review the attached précis regarding the current COVID-19 situation and recommend any revisions prior to my disseminating this to my at risk family members including [redacted] (b) (6) and others in retirement communities who are concerned.
>
> I appreciate that this would not be an official endorsement by you. I am only asking if there is anything that you or others think I could add or subtract from this précis to give solace to those who are in need of knowledge and comfort.
>
> Thank you kindly for your attention to this matter.
>
> Best wishes,
>
> Cynthia L. Bristow, PhD
> Chief Executive Officer
> Alpha-1 Biologics
> 25 Health Sciences Drive, Suite 110
> Stony Brook, NY 11790-3383
> Office: [redacted] (b) (6)
> Cell phone: [redacted] (b) (6)
> [redacted] (b) (6)
> www.alpha1biologics.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 10:43:27 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: UPDATE: CONFIRMING 4 MARCH TELECONFERENCE
Attachments: Agenda Board telcon 4 Mar Fnl.pdf, Local_Access_en.pdf

FYI

From: Amelie RIOUX (b) (6)>
Sent: Monday, March 2, 2020 5:29 AM
To: Dzau, Victor J. <(b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6); Fore Henrietta (b) (6); Gao Fu (b) (6) Gashumba Diane <(b) (6); Ilona Kickbusch (b) (6)>; Suzuki Yasuhiro (b) (6) (b) (6) Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6); Skvortsova Veronika (b) (6)
Cc: Gro Brundtland (b) (6)>; As Sy <(b) (6)>; Elhadj SY (b) (6) Tore Godal (b) (6)>; Godal, Tore <(b) (6); (b) (6) SCHWARTLANDER, Bernhard F. (b) (6); RYAN, Michael J.([redacted] >; Pate Muhamed (b) (6); Kanarek, Morgan (b) (6) Conrad, Patricia (NIH/NIAID) [E] (b) (6); (b) (6); 'Sheila Austria' (b) (6) (b) (6) Teresa Miller de Vega (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6) Steven T. Smith (b) (6) [redacted] Zacharie Gahungu (b) (6) [redacted] [redacted] Toomas Palu (b) (6)
Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: UPDATE: CONFIRMING 4 MARCH TELECONFERENCE

Dear Board members,

We are confirming the Board teleconference on **Wednesday, 4 March at 14:00 Geneva time**.

Please find attached the agenda (also copied below) and the call-in numbers. The Access code is (b) (4)

Please let us know if you have any questions.

Thank you very much,

Amélie Rioux
On behalf of the Co-Chairs

Participant access

[redacted] (b) (4)

Optional dial-in numbers international
+41 58 262 07 22 (English) +41 58 262 07 44 (Italiano) +41 58 262 07 11 (Deutsch) +41 58 262 07 33 (Français)
Local Access

Access via Web

Global Preparedness Monitoring Board
Teleconference
4 March 2020, 14:00-15:00 CET
Agenda

1. Welcome and Roll call
2. Updates and stock taking on the COVID-19 outbreak
    - Update from George Fu Gao (TBC)
    - Update and Proposal from Jeremy Farrar
3. Discussion: Actions from the Board on the COVID-19 outbreak (30 minutes)
4. Adjourn

From: Amelie RIOUX
Sent: Tuesday, 25 February 2020 10:18
To: Dzau, Victor J. [redacted] (b) (6); Anthony Fauci [redacted] (b) (6); Fore Henrietta < [redacted] (b) (6)>; Gao Fu [redacted] (b) (6)>; Gashumba Diane [redacted] (b) (6); Ilona Kickbusch [redacted] (b) (6)>; Suzuki Yasuhiro [redacted] (b) (6); [redacted] (b) (6); Vega Morales Jeanette [redacted] (b) (6)>; VijayRaghavan Krishnaswamy [redacted] (b) (6)>; Skvortsova Veronika [redacted] (b) (6)
Cc: Gro Brundtland [redacted] (b) (6); As Sy < [redacted] (b) (6)>; Elhadj SY [redacted] (b) (6)>; Tore Godal < [redacted] (b) (6)>; Godal, Tore < [redacted] (b) (6)>; [redacted] (b) (6); SCHWARTLANDER, Bernhard F. < [redacted] (b) (6)>; RYAN, Michael J. [redacted] (b) (6)>; Pate Muhamed < [redacted] (b) (6)>; Kanarek, Morgan

[redacted] (b) (6)
[redacted] 'Sheila
Austria' <[redacted] (b) (6);
Teresa Miller de Vega <[redacted] (b) (6); 'Marston Hilary' [redacted] (b) (6)
[redacted]
[redacted] Zacharie Gahungu
[redacted] (b) (6)
[redacted]
[redacted]; Toomas Palu
<[redacted] (b) (6)
Subject: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: UPDATE

MESSAGE ON BEHALF OF THE GPMB CO-CHAIRS DR BRUNDTLAND AND MR SY

Dear Board members,

Thank you to those of you who joined the call on Thursday on short notice.

In light of our discussion, we would like to update you on a few matters:

[redacted] (b) (4)

- **Coronavirus outbreak.** We have asked Jeremy Farrar to act as the Board's focal point on the COVID-19 outbreak, to represent and advise the Board on the science of the outbreak and the financing of the response. We thank Jeremy for agreeing to take on this role.

- **Follow-up Board teleconference call.** Since many of you were unable to attend Thursday's call, we wish to propose to hold a follow-up Board teleconference call on **4 March at 14:00 Geneva time**. The purpose of the call will be to discuss the coronavirus outbreak, including Jeremy's proposal for Board action on financing. We would appreciate if you could confirm your participation to Amélie Rioux [redacted] (b) (6)). A more detailed agenda and call-in details will be shared shortly.

- **In-person Board meeting.** We wish to confirm that the next in-person Board meeting will take place **Tuesday-Wednesday, 5-6 May 2020, in Geneva**. The meeting will be an important opportunity to further discuss strategic issues as well as a draft of the annual report. We will communicate further on logistical details.

As always, thank you for your support and continued engagement.

With kind regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 23:25:39 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: event rundown for 3/2 webcast event

There is no attachment with this e-mail

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, March 1, 2020 6:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: event rundown for 3/2 webcast event

Sending this again as it is for tomorrow.

Sent from my iPhone

> On Feb 28, 2020, at 9:10 PM, Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6) wrote:
>
> Dear Dr. Fauci (and Hilary, if you end up doing this event as ASF's back-up),

I've attached an "event rundown" for the Harvard Forum Webcast, which is scheduled from 11:40-1pm on Monday 3/2—a moderated panel discussion. This is a document prepared by the event organizers outlining the run of show, noting what questions the moderator will pose, and some suggested points the organizers thought you might touch on in your answers.

Although the organizers prepared this document following a planning call, they have made it clear that the "talking points" in this document are of course not a script. I have taken their document and highlighted where you appear. I have also added some comments. Let me know what you think. There are no slides for this event.

Let me know if you would like to discuss further over the weekend or if you'd like anything for preparation.

Sincerely,

Andrea

Andrea Lerner, MD
Medical Officer
Office of the Director
NIAID/NIH
31 Center Drive, Room 7A10A
Bethesda, MD 20892
(b) (6) cell

<2020.3.2-Coronavirus-rundown_tony_AL highlights.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:53:00 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Proposal to Mitigate Spread of COVID-19
Attachments: Urgent Proposal to Mitigate Spread Fauci.pdf, HCQ, A Modest Proposal for Mitigating COVID-19 2.0.pdf

Please take a look and do what you feel is appropriate.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alexander Morden MD (b) (6)>
Sent: Sunday, March 1, 2020 2:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Proposal to Mitigate Spread of COVID-19

Enclosed is an article I have submitted which may offer an immediate strategy to help infection control in the general public (and possibly in Oregon & California).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:52:21 +0000
To: Tsang, John (NIH/NIAID) [E]
Cc: [redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: personal Immune baseline and its impact on infection and vaccine responses

John:

Thanks for your note. I am copying Cliff Lane here since he and his team is involved in a clinical protocol with COVID-19 patients. He may be able to point you in the right direction.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tsang, John (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, March 1, 2020 2:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: personal Immune baseline and its impact on infection and vaccine responses

Dear Dr. Fauci,

Hope you are doing well despite the rapidly evolving situation with COVID-19.

I wanted to send you a paper we just published last week that you might find relevant – please find attached and a NIAID piece below.

https://www.niaid.nih.gov/news-events/immune-system-status-predicts-future-responses

This paper asks the question of why do individuals mount variable immune responses to vaccines, infections, and diseases. This extends from our earlier work on baseline predictors of influenza vaccination responses that you highlighted as a NIAID Advance in 2014. A key message is that genetics is often unlikely the answer, but the status of the immune system before the perturbation may offer clues – here we identified such an immune cell circuit involving pDCs-Type I IFNs prior to perturbation in humans and found that its status can predict vaccination and lupus disease activities and is temporally stable within individuals for months.

[redacted] (b) (5)

Many thanks!

Best wishes,
John.

John Tsang, PhD, Senior Investigator | Chief, Multiscale Systems Biology Section, Laboratory of Immune System Biology | Co-Director, Center for Human Immunology (CHI) | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) | emai[redacted] (b) (6) | office: [redacted] (b) (6) | cell: [redacted] (b) (6) [redacted] (b) (6) | web: tsang lab | address: [redacted] (b) (6)4 Memorial Drive, Bethesda, MD, 20892 USA

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Wednesday, December 19, 2018 at 9:43 PM
To: "Tsang, John (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: Congratulations

John:

Congratulations on being granted tenure by the NIH Central Tenure Committee. Well-deserved! Keep up your terrific work.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:50:11 +0000
To: NIAID OD AM
Subject: FW: Outreach from STAT

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Berke, Rick <Rick.Berke@statnews.com>
Sent: Sunday, March 1, 2020 10:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Outreach from STAT

Tony,

I know you're swamped but I'm wondering if we could arrange for you this week to take questions from our readers about coronavirus. All of our coronavirus coverage is in front of STAT's paywall and we'd see your contribution as an enormous public service.

We would solicit questions for a "live chat" from readers -- and you could pick and choose which ones you want to answer -- and write most of them in advance.

Among other leading figures, we've done this format twice with Nobel winners and it's quite popular. https://www.statnews.com/events/stat-live-chat-chat-with-a-2019-nobel-winning-scientist/

With Helen Branswell, Sharon Begley, Matt Herper, and our whole team, we pride ourselves on covering the coronavirus in the most authoritative and fair-minded way. We've developed a tremendous audience for this coverage. https://www.statnews.com/tag/coronavirus/

Our readers are fairly sophisticated on health and medicine, and we're looking to focus on the health aspects, not the White House politics.

In addition, I'd be grateful if you'd consider writing another First Opinion for us, maybe on lessons you've learned regarding other outbreaks and how that might be relevant with coronavirus -- or whatever you'd like.

Your voice of course is very important and authoritative and we'd be grateful to have it again in STAT.

All best,

Rick

--

Rick BerkeCo-founder & Executive EditorO: (617) 929-7056M: (b) (6)@rickberke

STAT | **Reporting from the frontiers of health and medicine**@statnews | statnews.com | facebook.com/statnews

SUBSCRIBE TO STAT PLUS for an all-access pass to exclusive stories.**SIGN UP HERE** for free newsletters with the latest in health, biopharma, and science coverage.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:47:57 +0000
To: Jeffrey Sachs
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Might we speak briefly about the coronavirus vaccine development?

Jeff:

Thanks for the note. Happy to chat. Please give my office a call tomorrow AM [redacted] (b) (6) to set up a time when we can chat by phone.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeffrey Sachs [redacted] (b) (6)
Sent: Sunday, March 1, 2020 2:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Might we speak briefly about the coronavirus vaccine development?

Dear Tony,

Thanks as always for your leadership.

Déjà vu of our highly productive discussions 20 years ago!

Jeff

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:46:11 +0000
To: pascal goldschmidt
Cc: Sara Sigel;NIAID OD AM
Subject: RE: [redacted] (b) (6)

Thanks, Pascal. [redacted] (b) (6)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: pascal goldschmidt [redacted] (b) (6)>
Sent: Friday, February 28, 2020 9:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Sara Sigel [redacted] (b) (6)>
Subject: [redacted] (b) (6)

Greetings Tony,
I know how incredibly busy you are with the coronavirus challenge.
I admire so much your cool and effectiveness in the middle of a public health hurricane.
[redacted] (b) (6)
With warmest regards,
Pascal

Pascal J. Goldschmidt, M.D., Fellow A.C.C., Fellow A.H.A.
President and CEO, Alzady International, LLC.
President and CEO, American Healthcare System Ltd.
Dean Emeritus, Professor of Medicine Emeritus
University of Miami Miller School of Medicine USA

AHS
AMERICAN HEALTHCARE SYSTEM
European Care Global & Alzady International

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:44:16 +0000
To: Silverberg, Kristen
Subject: RE: question from BRT

Kristen:
Thanks for the note. Would your companies be able to effectively advocate for improved health care systems in low and middle income countries?
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Silverberg, Kristen <KSilverberg@brt.org>
Sent: Thursday, February 27, 2020 11:40 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: question from BRT

Dr. Fauci,

I hope you are well.

Last February, I moved to Business Roundtable, which represents CEOs of large U.S. companies. Josh is the BRT CEO, and it's been great to work with him again.

We wanted to check with you on something quickly. Traditionally, BRT has not weighed in on global health security policy, but COVID-19 has served as a reminder that global companies need to be strong advocates for global public health and security. If you had your choice, what would you want to see our companies advocating for, specifically?

No worries at all if you don't have time to respond. We fully appreciate how important your time is.

Best,

Kristen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:32:44 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: ARB therapy in Covid-19 infection

Please respond.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tom Leopold (b) (6)>
Sent: Sunday, March 1, 2020 8:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: ARB therapy in Covid-19 infection

Thank you for responding to my email yesterday about the possibility of ARB therapy in treatment of coronavirus infection. I realize that your research is ongoing. Would you anticipate, however, that the ARB with the most potential role in preventing virus attachment would be the one that has the greatest affinity for the AT2 receptor? Am i correct that losartan is the ARB with the lower receptor (AT1 vs AT2) selectivity and might logically be the most promising ARB to investigate? Thanks. Dr Thomas Leopold

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:31:42 +0000
To: JP Hanke
Subject: RE: Coronavirus

Thanks for the note. CDC is already preparing similar public service announcements, which I am sure will find its way to YouTube

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: JP Hanke (b) (6)>
Sent: Sunday, March 1, 2020 5:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus

Dear Dr Fauci,

I heard this idea on a radio interview with Laurie Garrett this morning – how about getting your committee (or one of the government health agencies) to produce a series of short YouTube videos on how to combat the coronavirus: such things as proper handwashing technique, when to wear a mask, how to ride the subway safely, etc, etc. I think this would be an excellent way to reach the public in the digital age (provided that Mike Pence doesn't try to turn them into campaign ads for Donald Trump), and I strongly urge you to give the strategy serious consideration. I know I would watch them and I'm sure millions of other people would too.

Sincerely,

Paul Hanke
[redacted] (b) (6) VT

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:29:32 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Report from 'HHS COVID-19 Situation Update' call today

Thanks. Very helpful.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, March 1, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Report from 'HHS COVID-19 Situation Update' call today

Passing on some main points from of an "HHS COVID-19 Situation Update" call that took place at 3pm today, FYI.

- The meat of the call was a situation update by Nancy Messonnier (with epi numbers below).
- She noted that the national strategy is still containment.
- However, since there are some US locales with evidence of community spread, there is consideration if some "community level action" may be appropriate, with a move towards a blend of mitigation/containment in certain areas.

Global epi update:
China lab/clinically confirmed cases: 79,824 (+573 in last 24h)
China deaths: 2,870

61 international locations with 7,102 cases so far (Armenia, Ecuador, Ireland, Luxembourg new in last 24h)

107 international deaths

Widespread community transmission occurring in:
China, Iran, Italy, Japan, S. Korea

US epi update:
63 confirmed US cases (16 diagnosed here, 3 in Hubei repatriates, 44 in Diamond princess repatriates)
11 presumptive cases (meaning they tested + at state public health labs, but confirmatory test at CDC is pending)
663 Persons Under Investigation

Andrea Lerner, MD
Medical Officer
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
31 Center Drive, Room 7A10A
Bethesda, MD 20892

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:22:15 +0000
To: Francis V. Chisari
Subject: RE: [redacted] (b) (6)

Given what is going on with coronavirus, I cannot guarantee that I will be able to attend the Section meeting. I will try my best.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Francis V. Chisari <fchisari@scripps.edu>
Sent: Sunday, March 1, 2020 5:19 PM
To: PAUL G AHLQUIST <ahlquist@wisc.edu>; Zhijian (James) Chen <zhijian.chen@utsouthwestern.edu>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Michael Oldstone <mbaobo@scripps.edu>; Eckard Wimmer <eckard.wimmer@stonybrook.edu>
Cc: Charles Rice <ricec@mail.rockefeller.edu>; Chisari, Francis <fchisari@scripps.edu>
Subject: [redacted] (b) (6)

Dear colleagues,

[redacted] (b) (6) . Please let me know if you will attend the Section meeting this year and if you're willing to say a few words of support.

Best regards,

Frank

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:32:36 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: SARS-CoV-19

Please respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Peter Panus (b) (6)>
Sent: Sunday, March 1, 2020 10:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: SARS-CoV-19

Although outside my main area of expertise I have been keeping up with CoVid-19 discussion. One item I have noted is that the disease appears to have a lower incidence in children. The other is that the virus appears to at least in part attach through cell membrane angiotensin II type 1 receptors. Is the lower incidence of the disease in children possibly due to this cohort having a higher proportion of angiotensin II type 2 receptors compared to the adult cohort?
Sincerely,
Peter C. Panus PhD, PT
Professor Emeritus
Pharmaceutical Sciences Dept.
Gatton on College of Pharmacy

Sent from Mail for Windows 10

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:23:14 +0000
To: NIAID OD AM
Subject: FW: Invitation to speak to the National Economists Club

Let us discuss. Unlikely I will have time depending on how things evolve.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Sanchez, Emily <Emily_Sanchez@americanchemistry.com>
Sent: Sunday, March 1, 2020 10:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E]
[redacted] (b) (6)
Subject: Invitation to speak to the National Economists Club

Dear Dr. Fauci,

My name is Emily Sanchez and I am an economist at the American Chemistry Council. I am reaching out to you in my capacity as President of the National Economists Club (NEC), which is an organization of over 1000 government and private sector economists based in DC. The NEC holds weekly luncheon events which feature notable experts and economists in Washington.

Increasingly, economists are being asked to assess the economic impacts around the incidence and spread of the corona virus as well as the impact of reduced economic activity due to behavioral changes (e.g. people not leaving their homes to work or shop, supply chain disruptions, etc.). As economists are tasked in assessments, scenario planning and communicating their estimates, accuracy around their assumptions and understanding of the corona virus and Covid-19 is imperative. We are incredibly appreciate of the important work and research that the National Institute of Allergy and Infectious Diseases provides and we are wondering if you would be willing to speak at one of our luncheons about Covid-19 and the latest developments.

Do you think you might have time in your schedule to speak to the National Economist Club this month? We would love to have you speak during the week of March 16-20.

Our luncheons typically take place at the Chinatown Garden Restaurant, 618 H St. NW, with lunch at noon and your presentation from 12:30 p.m. til 1:30 p.m. Talks are normally on the record and open to the press, unless you request otherwise.

Thank you for your consideration.

Best regards,

Emily

Emily Sanchez | American Chemistry Council
Director, Economics & Data Analytics
Economics & Statistics Department
emily_sanchez@americanchemistry.com
700 2nd Street, NE | Washington, DC | 20002
O: (202) 249-6183
www.americanchemistry.com

++++++++++++++++++++++++++++ This message may contain confidential information and is intended only for the individual named. If you are not the named addressee do not disseminate, distribute or copy this email. Please notify the sender immediately by email if you have received this email by mistake and delete this email from your system. E-mail transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this message which arise as a result of email transmission. American Chemistry Council, 700 – 2nd Street NE, Washington, DC 20002, www.americanchemistry.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:17:45 +0000
To: Thomas Murray
Subject: RE: Have you been muzzled?

Mr. Murray:

Thanks for the note. Please stay silent since I have not been muzzled. I will be on multiple TV shows tomorrow and was on FOX this AM. No one is censoring me.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Thomas Murray [redacted] (b) (6)
Sent: Sunday, March 1, 2020 11:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Have you been muzzled?

Reference: I'm the nuclear/aerospace engineer who subsequently obtained an MPH at the University of Washington since I was working disease transmission within commercial airlines when I was a Boeing employee. And, my undergraduate degree is in chemistry with a minor in microbiology. I've engaged you previously.

Hi Dr. Fauci,

You've kindly allowed me to engage you, and I'll take advantage of that kindness.

The news media is reporting that the White House has muzzled you. Is that true? Before entering the science/engineering world, I was a newspaper city editor in Southern CA (in the 1970s). Therefore, I get and understand the idea of coordinated messaging. (Plus, due to my media background, Boeing used me to help executives prepare for media engagements on challenging topics.) However, if it's true that you are muzzled, then I will initiate a "campaign" with my congressional representatives and the media to stop that action. ([redacted] (b) (6)

However, ***before I initiate such a campaign, will my actions possibly cause you harm?*** I recognize that you may have backchannels that I may disrupt by engaging.

As I related previously, I trust you since you focus on facts and data, you provide context for the information that you share, and you avoid emotion in your engagements. I think that residents of the US (and, frankly the world) need your insights regarding COVID-19. Plus, you're one of the world leaders with regard to infectious diseases. And, if you don't know, you know whom to ask.

Please let me know if I should stay silent or become noisy.

Thank you. And, thanks for your service to the US and the world during this very interesting time.

Thomas Murray

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:13:01 +0000
To: D.A. Sonneborn
Subject: RE: News about SARS-CoV-2 ad Covid-19

You can trust CDC.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: D.A. Sonneborn (b) (6)>
Sent: Sunday, March 1, 2020 3:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: News about SARS-CoV-2 ad Covid-19

Dear Dr. Fauci,

It would be good to know if you still believe Americans can trust CDC's public-facing authority or whether we'd best look to WHO for reliable information about the virus, the disease and any new mutations which might arise. Mike Pence does not have appropriate credentials.

Sincerely,

D.A. Sonneborn, Ph.D.
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:09:38 +0000
To: Corey MD, Larry
Subject: RE: Mike Pence ?

I am not going to CROI. I am sending in a taped short discussion of NIH research response to COVID-19

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Corey MD, Larry (b) (6)>
Sent: Sunday, March 1, 2020 3:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Mike Pence ?

Ah the great communicator of infectious disease epidemiology and pathogenesis.
On way back from (b) (6). News travels fast among the aficionados.

We need a POW wow with John and Carl on the path to (b) (4) I will schedule. You coming to CROI ? If not I could pop down to you.
Excuse the I phone typing. On the runway leaving (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:49:51 +0000
To: Jon LaPook
Subject: RE: My "CBS Sunday Morning" 5-minutes shpiel on coronavirus and COVID-19

Outstanding!!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Jon LaPook [redacted] (b) (6)
Sent: Sunday, March 1, 2020 11:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: My "CBS Sunday Morning" 5-minutes shpiel on coronavirus and COVID-19

Tony,
Here you go. You can enjoy it in al your spare time. Hope you managed to clear your desk last night.

https://vimeo.com/user10844306/review/394766243/cba5143d0d

Best,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:31:54 +0000
To: Jeffrey V. Ravetch
Cc: Stelios Bournazos
Subject: RE: Fc modifications for protective anti-COVID-19 antibodies

Jeff:

Thanks for the note and the slide. Very interesting. Please send me the preprint when it becomes available.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeffrey V. Ravetch [redacted] (b) (6)
Sent: Sunday, March 1, 2020 12:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Stelios Bournazos [redacted] (b) (6)
Subject: Fc modifications for protective anti-COVID-19 antibodies

Dear Tony,

I wanted to share a very recent and surprising result we've obtained on the mechanism of antibody protection for anti-viral antibodies. We've previously shown that bNAbs to flu and HIV require FcR engagement for their in vivo potency. Enhancing activating FcR engagement increases the potency of these antibodies by an order of magnitude, on average, and thus are significant contributors to anti-viral protection.

(b) (4)

[redacted]

We'll be writing up this story shortly and would be happy to share a pre-print with you.

Sincerely,

Jeff

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:30:12 +0000
To: Grandi, Paola
Subject: RE: [redacted] (b) (6)

Dr. Grandi:

[redacted] (b) (6)

Best regards,
A.S. Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Grandi, Paola [redacted] (b) (6)
Sent: Sunday, March 1, 2020 12:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [redacted] (b) (6)

Dear Dr. Fauci,

[redacted] (b) (6)

[redacted] (b) (6)

Please let me know if you would like to discuss this further. I was a former professor at the University of Pittsburgh and now [redacted] (b) (6) would also be available to discuss. My cell phone is [redacted] (b) (6).

Best Wishes,
Paola Grandi, PhD, M BA
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:22:37 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Novel Treatment for Reducing Symptoms Associated with Coronavirus (COVID-19) - "Non-Confidential"
Attachments: (0) The Science of Exulta for the Common Cold.pdf, 1) METHODS AND COMPOSITIONS TO INHIBIT SYMPTOMS ASSOCIATED WITH VIRAL UPPER RESPIRATORY TRACT INFECTIONS.pdf

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jim Iversen [redacted] (b) (6)
Sent: Sunday, March 1, 2020 1:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Jacqueline Iversen [redacted] (b) (6)>
Subject: Novel Treatment for Reducing Symptoms Associated with Coronavirus (COVID-19) - "Non-Confidential"

Dear Dr. Fauci,

Sen-Jam Pharmaceutical has a product under development to reduce the symptoms associated with Upper Respiratory Infection (URI). We believe it could provide relief to a large number of people during the COVID-19 pandemic. Our product SJP-002 is a combination of an NSAID and a non-sedating antihistamine and does not include a decongestant. Removing the decongestant makes our product ideal for treating the symptoms associated with COVID-19 in patients with cardiac conditions who cannot tolerate taking a decongestant.

What makes our product novel is that it can be administered early in the treatment phase, thereby reducing the excessive accumulation of inflammation, which typically results in head congestion, pulmonary congestion, coughing, & sneezing. Our experience has shown that at the 1st signs of experiencing symptoms of URI an individual's symptoms can be drastically reduced after taking our product twice a day for 3 days. The dramatic reduction in inflammation has the potential to reduce the spreading of the virus by means of cough, sneezing, and spreading of germs through contact. Currently, when individuals experience the start of a URI, there is little effective intervention available to change the course of the infection. Individuals delay administering pharmaceutical agents, until their congestion becomes intolerable and excessive.

Attached is a copy of our early research and a copy of our non-provisional patent. I share this information with the hope of providing some background for an immediately accessible, safe treatment, alternative to slow the pace and impact of the pandemic.

Let me now if we can be of any additional help?

Thanks and all the best,

Jim

sen-jam
PHARMACEUTICAL

Jim Iversen
CEO
Sen-Jam Pharmaceutical
223 Wall St., #130
Huntington, NY 11743
(b) (6)
(b) (6)
sen-jam.com
Linkedin: linkedin.com/in/jimiversen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:21:51 +0000
To: Lawrence O. Brown, Ph.D.
Subject: RE: Info re Covid-19

I can assure you that I am not being censored.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lawrence O. Brown, Ph.D. (b) (6)
Sent: Sunday, March 1, 2020 1:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Info re Covid-19

Dear Dr. Fauci,
Those of us who seek factual, scientifically-based information to the highest degree that it is possible to obtain it will remain hungry and on the alert for whatever complete, up-to-the-moment information that you may have as humanity proceeds deeper into the Covid-19 potential pandemic. We have trusted you through several previous epidemics to provide such information. Therefore, I know I'm not alone in being appalled and frightened by President Trump wanting you to issue information about the current crises only after it has been cleared by his administration. In his office as President, Donald Trump may be *de facto*, Commander-in Chief. There is nothing about his office that confers Expert-in-Chief on him, and what he chooses to say or not say about Covid-19 and its spread should not be treated by the media or anyone as information that is trustworthy for being factual and scientifically-based information to the highest degree that it is possible to obtain.

I hope that you will find it in yourself and in the mission of your office to publicly assure the American public in no uncertain terms that you will not be censored, and that you will honor the public's trust to continue to provide real, research-based information about the frightening health nightmare that all humans are facing in a way that distinguishes us from China's government in its disgraceful and destructive efforts to muzzle those experts who might be able to save lives by merely speaking truth to a population whose health depends on having fact-based, totally un-massaged knowledge as soon as it is available.

It is with our lives, the lives of our families, and the lives that make up our nation that we are counting on you.

Sincerely yours,
Lawrence O. Brown, Ph.D.
Clinical Psychologist/Psychoanalyst
[redacted] (b) (6)

[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 16:25:41 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Background briefer
Attachments: 20200229_VRCModerna mRNA candidate briefer - with Fauci edits.docx

Here it is.

From: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, March 1, 2020 10:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Background briefer

ASF:

Attached please find a proposed background briefer for the visit to the VRC (big thanks to John, Barney, Kizzmekia , the rest of their team and Andrea and Greg). We focused on the VRC itself and the mRNA candidate, figuring that the VPOTUS office would have a tick tock etc. VRC also prepared talking points for the round table should those be requested (I have those if you'd like to see them now, but so far the White House has not asked for this).

Available by cell. [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 15:48:15 +0000
To: Sharon Eblen
Subject: RE: Thank You

Sharon:
Many thanks for your kind words.
Best regards,
Tony

From: Sharon Eblen (b) (6)>
Sent: Sunday, March 1, 2020 10:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Thank You

Good Morning Dr. Fauci,
I just wanted to say a quick thank you for your recent words to the public. I am a high school physics teacher, and I recognize the importance and the challenges of conveying scientifically accurate information to the public. I watched you speak in the two recent press conferences held by the President, and I appreciated the way in which you communicated difficult information regarding the novel coronavirus. Please keep up the good work during what I'm sure is a very stressful time for you and everyone at the NIH.
Sincerely,
Sharon M. Eblen

From: [redacted] (b) (6)
Sent: Sun, 1 Mar 2020 10:34:15 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: NPR interview request: Dr. Fauci

Sent from my iPhone

Begin forwarded message:

> **From:** HJ Mai <HMai@npr.org>
> **Date:** March 1, 2020 at 10:29:41 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: NPR interview request: Dr. Fauci**
>
> Dear Dr. Fauci,
>
> I'm sorry to bother you on a Sunday, but with the first coronavirus death of a U.S. patient in Washington state, we are wondering if you would be available for a live interview tomorrow morning our show.
>
> We would like to talk to you about the significance of the death in Washington and what states can/must do to prevent a widespread outbreak.
>
> Kind regards,
> HJ
>
> ---
>
> **From:** HJ Mai <HMai@npr.org>
> **Sent:** Friday, February 28, 2020 6:54 AM
> **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
> **Cc:** Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
> **Subject:** Re: Confirmation of report
>
> Thank you for your reply Dr. Fauci.
>
> Sent from my iPhone
>
> > On Feb 27, 2020, at 10:57 PM, Fauci, Anthony (NIH/NIAID) [E]
> > [redacted] (b) (6)>wrote:

This is really not true. It was taken vey much out of context.

From: HJ Mai <HMai@npr.org>
Sent: Thursday, February 27, 2020 2:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Confirmation of report

Dear Dr. Fauci,

This is HJ from NPR again. I was wondering if you could confirm a NYT report that says the White House has instructed you not to say anything about the coronavirus outbreak without prior approval.

Kind regards,
HJ

<image001.jpg>
| HJ Mai | Editor, Morning Edition | hmai@npr.org | [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:39:59 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: VIP visit

I hope that someone in Building 1 is letting the Secretary's office know that the VP and POTUS are coming to NIH.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, March 1, 2020 6:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: VIP visit

See below. This is just a rough draft [redacted] (b) (5)

Sent from my iPhone

Begin forwarded message:

> **From:** "Blackburn, Amy (NIH/OD) [E]" [redacted] (b) (6)>
> **Date:** February 29, 2020 at 8:16:21 PM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "Burklow, John (NIH/OD) [E]" [redacted] (b) (6)>, "Folkers, Greg (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** "Daucher, Marybeth (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: RE: VIP visit**
>
> Hi Patty,
>
> This is just my really rough draft of an agenda. [redacted] (b) (5)
>
> Just let me know the timing of things.
>
> -----Original Message-----
> From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
> Sent: Saturday, February 29, 2020 7:53 PM
> To: Burklow, John (NIH/OD) [E] [redacted] (b) (6); Blackburn, Amy (NIH/OD) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
> Cc: Daucher, Marybeth (NIH/NIAID) [E] [redacted] (b) (6)
> Subject: VIP visit

Per Dr Fauci- for the round table - he is thinking that [redacted] (b) (5). This will get more fleshed out tomorrow.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:12:35 +0000
To: Bob Franken
Subject: RE: I'd like to talk

Bob:
Thanks for the note. I look forward to seeing you again soon.
Best regards,
Tony

-----Original Message-----
From: Bob Franken < (b) (6) >
Sent: Sunday, March 1, 2020 7:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Re: I'd like to talk

Tony,

First of all, thank you for getting back to me, in spite of the fact that you are so busy.
Secondly, it's nice to know they're not muzzled, since you are so incredibly good at making science speak so easy to understand for dummies like me.

Once the dust settles, I'd live to see you, to pay attention to our long friendship. Meanwhile, best of luck.

Bob

Bob Franken
www.bobfranken.tv

> On Mar 1, 2020, at 6:53 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> wrote:
>
> Bob:
> Thanks for the note. I hope that all is well with you. I have never been given orders to get approval from the VP's people to speak publicly about coronavirus. Ever since I have been doing this since the Reagan administration, whenever a member of the Executive Branch such as me gets invited and goes on National TV such as the Sunday Talk shows, there is always a routine process of clearing it with your department (in this case HHS) who then clears it with the White House. This is routine and has been true for the Reagan, Bush '41, Clinton, Bush'43, Obama, and now the Trump administration. It is merely a formality so that they know what is coming out from the executive branch. I have always gotten clearance with very few exceptions over the past 35 years (usually because they do not want you on TV at the same time that the President is making an important announcement). I have never been muzzled or told that I could not speak out publicly about anything during this administration.
> I hope that this is helpful.
> Best regards,
> Tony
>
> -----Original Message-----
> From: Bob Franken (b) (6)>
> Sent: Saturday, February 29, 2020 6:12 AM
> To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
> Subject: I'd like to talk
>
> Tony,
>
> I know you're busy, but I'd like to have a brief conversation with you.

> I'm now a syndicated political columnist, writing for King Features. You don't be surprised to hear that my column is described as "an extended middle finger pointed in all directions".
>
> Notwithstanding tgat, what I'd like to discuss with you is any orders you've received to get approval from the Vice President's people to speak publicly about the coronavirus.
>
> It can be on any basis you choose, on the record, or off. On background (knowledgeable sources), deep background (sources) , whatever.
>
> May I call you?
>
> Best,
>
> Bob
>
> Bob Franken
> www.bobfranken.tv

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:03:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Connecting you two

Let us discuss.

From: Collins, Francis (NIH/OD) [E] (b) (6)>
Sent: Wednesday, February 26, 2020 7:59 AM
To: Michael Milken (mmilken@knowledgeu.com) <mmilken@knowledgeu.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Connecting you two

Hi Mike,

Thanks for your call on Monday evening. I've reached out to Tony Fauci and he is interested in speaking with you about how your connections with philanthropy and industry might help as we face a major challenge from coronavirus. I'm ccing Tony on this e-mail and his cell phone is (b) (6). I've also given him your coordinates.

Best, Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:02:07 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: VIP visit

We can discuss.

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Sunday, March 1, 2020 6:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Fwd: VIP visit

See below. This is just a rough draft. [redacted] (b) (5).

Sent from my iPhone

Begin forwarded message:

> **From:** "Blackburn, Amy (NIH/OD) [E]" [redacted] (b) (6)>
> **Date:** February 29, 2020 at 8:16:21 PM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6), "Burklow, John (NIH/OD) [E]" <[redacted] (b) (6), "Folkers, Greg (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** "Daucher, Marybeth (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: RE: VIP visit**
>
> Hi Patty,
>
> This is just my really rough draft of an agenda. [redacted] (b) (5)
>
> Just let me know the timing of things.
>
> -----Original Message-----
> From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
> Sent: Saturday, February 29, 2020 7:53 PM
> To: Burklow, John (NIH/OD) [E] <[redacted] (b) (6)>; Blackburn, Amy (NIH/OD) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
> Cc: Daucher, Marybeth (NIH/NIAID) [E] [redacted] (b) (6)>
> Subject: VIP visit
>
> Per Dr Fauci- for the round table - [redacted] (b) (5),

[redacted] (b) (5)
[redacted]. This will get more fleshed out tomorrow.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:01:19 +0000
To: Geller, Robert D.
Subject: RE: COVID-19 Questions

Bob:

Thanks for the note. I hope that all is well with you. Use an N95 if you have them available. Transmission is similar to influenza: respiratory droplets and likely a bit more as aerosol than with influenza. People can transmit even when they are asymptomatic. No approved therapies; however, we are doing clinical trials on 're-purposed" drugs such as remdesivir (Gilead), Vaccine going into phase 1 trial in about 6 weeks, but will not be ready for at least 1.5 years.

Hope that this is helpful.
Best regards,
tony

From: Geller, Robert D. <RGeller@fhn.org>
Sent: Wednesday, February 26, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: COVID-19 Questions

Tony

Thanks for everything you are saying and doing. I'm writing to ask for the latest. Thanks Bob.

What about general care of a patient suspected or confirmed COVID-19. N95 or surgical mask? Any news on how this disease is being transmitted? Anything new on vaccine or treatment?

This e-mail message and any attached file(s) is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged and confidential. If the reader of this message is not the intended recipient or an agent or employee of the intended entity, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received the message in error, please notify the sender immediately for instructions. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 11:55:59 +0000
To: Anderson, Jennifer (NIH/NIAID) [E]
Subject: FW: Opportunity for a Research Position
Attachments: [redacted] (b) (6)

Please take a look and handle.

From: M. Burhan Majeed Rana <[redacted] (b) (6)
Sent: Thursday, February 27, 2020 9:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [redacted] (b) (6)

Dear Dr. Fauci,

[redacted] (b) (6)

Kindest regards,
Rana, Muhammad Burhan Majeed

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:14:20 +0000
To: Winnie Stachelberg
Subject: RE: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Winnie:
Thanks for your note.
Best regards,
Tony

From: Winnie Stachelberg <wstachelberg@americanprogress.org>
Sent: Thursday, February 27, 2020 8:02 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Tony – sending you an email to say thanks for your steady hand at the helm in this current challenge with Coronavirus. You are such an essential part of our government's response to this public health challenge.

Please let us know if there's anything we can do at CAP to assist. We plan on hosting an event next week and I'll send you details as they come together.

Again, thank you.

Winnie

From: Winnie Stachelberg
Sent: Monday, August 19, 2019 10:42 AM
To: (b) (6)
Subject: FW: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Tony –

Thank you so much for participating in CAP's podcast, Thinking CAP earlier this month. We think the interview turned out very well and hope you think so, too.

Have a good rest of the month and Labor Day and I hope our paths cross again soon – either in the neighborhood or at work.

Winnie

From: Steve Bonitatibus <sbonitatibus@americanprogress.org>
Sent: Thursday, August 15, 2019 11:21 AM
To: Posted Products <postedproducts@americanprogress.org>
Cc: Kyle Epstein <kepstein@americanprogress.org>; Chris Ford <cford@americanprogress.org>; Daniella

Leger <dleger@americanprogress.org>
Subject: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Daniella sits down with renowned immunologist Dr. Anthony Fauci to discuss how the United States has and can continue to combat the HIV/AIDS epidemic, both domestically and abroad.

https://www.americanprogress.org/issues/healthcare/news/2019/08/15/473666/dr-anthony-fauci-global-fight-hivaids/

For decades, the HIV/AIDS epidemic has been among the most challenging global health issues to contain. Enter Dr. Anthony Fauci, immunologist and director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. As one of the foremost experts and advocates against the HIV/AIDS epidemic, Dr. Fauci exuded optimism when talking about the progress being made in both global and domestic containment of the disease. He sat down with Daniella for an interview to discuss his work fighting HIV/AIDS and to share his thoughts on the growing, dangerous anti-vaccination movement.

Learn more about the podcast here.

Daniella Gibbs Léger is the executive vice president for Communications and Strategy at the Center for American Progress. Ed Chung is the vice president for Criminal Justice Reform at the Center. Kyle Epstein is the media relations manager at the Center. Chris Ford is the broadcast coordinator at the Center.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:13:25 +0000
To: Howard Schatz
Subject: RE: Commiserating

Howard:

Many thanks for your note. Much appreciated.

Best regards,
Tony

From: Howard Schatz [redacted] (b) (6)>
Sent: Thursday, February 27, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Commiserating

Tony,

Watching the spread of the Coronavirus worldwide(?), I can't help but feel for you, as well as the world's population.

It must be both challenging as well frustrating to be unable to control every important "leak" and then watching the consequences.

I would think it's also sort of exciting, while also being horrible, given this is what you've trained for most of your professional life.
And, I would think that most of your other important works need to be put on hold?

Wishing you (and all of us) the best of luck,

Howard

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:02:52 +0000
To: David Folkenflik
Subject: RE: Following up

I have never been inhibited from interacting with the press.

-----Original Message-----
From: David Folkenflik <DFolkenflik@npr.org>
Sent: Friday, February 28, 2020 7:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Following up

Dr Fauci - I cover media and flow of information to public for NPR and am also a host. (You and I once spoke years ago when I covered Johns Hopkins over a science research issue.)

You told a colleague the report you couldn't comment on Coronavirus was taken out of context. In what way?

Thank you -
D

David Folkenflik
Host and Editor, NPR's On Point
Media Correspondent, NPR News
11 W 42nd St
19th Floor
New York NY 10036
o) 212.880.3438
m) (b) (6)
e) dfolkenflik@npr.org

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:01:29 +0000
To: Andrew C von Eschenbach
Subject: RE: Question

Andy:
Thanks for the note. I am sure that the Chinese are looking at this, but I have not seen any data in this regard, I will try to find out if anyone is looking at this in the USA patients.
Best regards,
Tony

-----Original Message-----
From: Andrew C von Eschenbach (b) (6)
Sent: Friday, February 28, 2020 9:52 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Question

Tony
Does anyone know what the NK cell profile was like in patients who succumbed to Coronavirus? Is there a difference in immune profile between mild and severe cases?
Anyone looking at that?
Miss being there at your side in this battle Andy PS Thank you and your team for guiding the Celularity team to get it right. Also you have as always, my utmost respect for being the "good and faithful servant"

Andrew C. von Eschenbach MD
Samaritan Health Initiatives

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:57:44 +0000
To: Strauss, Eric M.
Subject: RE: 500k dead? (Background)

That number seems exceptionally high.

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Friday, February 28, 2020 10:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: 500k dead? (Background)

Hello Dr Fauci: Hope you're holding up well. Remember to rest and hydrate!

We had a DHS person tell us epidemiology models for US show worst case scenario 98m get COVID-19 and 500k dead.

I've seen models all over the board. And Dr Jen and I are keeping our coverage on point on what we know and what we don't know.

If that a possible number for our planning? Or is that outlandish?

Thx.
- EMS

Eric M. Strauss, ABC News
Managing Editor, Medical Unit
[redacted] (b) (6),
@ericMstrauss

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:49:57 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus

Please take a look and handle. Thanks.

From: William H. Sherman, MD [redacted] (b) (6)
Sent: Friday, February 28, 2020 11:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: coronavirus

William H. Sherman, M.D.
(b) (6) [redacted]

Anthony Fauci, M.D.
[redacted] (b) (6)

Dear Dr. Fauci:

I reviewed the publications about the last 2 coronavirus infections. Both MERS and SARS were severe, short lived problems that have not recurred. One would expect Covir-19 to follow a similar path: infect a wide group of susceptible people and then disappear, If that is so, anything that is more than six months away may not be of value—remdisivir or a vaccine. Even if remdisivir works, it will take months to produce sufficient amounts to treat this illness.

Has ribavirin been assessed for an ability to slow down the replication of this virus? We do not need to eradicate the virus. Just slowing down the rate of symptoms progression would allow time for the immune system to mount a curative response.

Ribivirin is the only approved anti-viral that may have shown some clinical benefit against similar coronavirus infections, but the reports are anecdotal and the benefit short term. It was only administered to a few patients who were already on respirator support, and most still died. If their lungs were already destroyed, eliminating the virus would not change the outcome. There were no studies of treating mild illnesses before they progressed to needing respirator support. If the 50 year old coronavirus patient described in the Lancet had been treated in first week of symptoms, before needing respiratory support, he may have survived. On autopsy, most of his lung had been destroyed.

If ribavirin has even marginal benefit, decreasing hospitalization by 10% yields an enormous savings. I do not have access to the data on this virus and the possible effects of the antivirals that have been evaluated. However, ribavirin has any effect on viral proliferation, we can write and a randomized trial of ribavirin, [redacted] (b) (4)

(b) (4) [redacted]

I look forward to hearing from you about the data on ribavirin against this virus and your thought on this clinical study.
Sincerely,
William H. Sherman, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:49:28 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: The Aspen Institute event today

Let us discuss.

From: Sabrina Malhi <smalhi@thehill.com>
Sent: Friday, February 28, 2020 11:14 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: The Aspen Institute event today

Hi Dr. Fauci,

The whole country is in a panic, could you write on behalf of the NIH regarding the coronavirus, please? Your voice is very important on this topic.

Thanks,
Sabrina

On Tue, Feb 11, 2020 at 7:12 PM Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:

> Sabrina:
>
> Many thanks. It was nice to meet you today. I certainly will keep your offer in mind.
>
> Best regards,
> Tony
>
> **Anthony S. Fauci, MD**
> **Director**
> **National Institute of Allergy and Infectious Diseases**
> **Building 31, Room 7A-03**
> **31 Center Drive, MSC 2520**
> **National Institutes of Health**
> **Bethesda, MD 20892-2520**
> **Phone:** [redacted] (b) (6)
> **FAX: (301) 496-4409**
> **E-mail:** [redacted] (b) (6)
>
> **The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.**
>
> **From:** Sabrina Malhi <smalhi@thehill.com>
> **Sent:** Tuesday, February 11, 2020 2:58 PM

To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: RE: The Aspen Institute event today

Hi Dr. Fauci,

It was nice meeting you at the event regarding the coronavirus today at The Aspen Institute. Your expert voice on the virus would be great to have in our publication.

As I mentioned, I am an opinion editor at The Hill and one of the areas that I focus on is health care. Please let me know if you'd like to discuss some ideas. I look forward to hearing from you!

Best,
Sabrina

--
Best,
Sabrina Malhi | Associate Editor | The Hill
*Please note that my email address is now smalhi@thehill.com.

--
Best,
Sabrina Malhi | Associate Editor | The Hill
*Please note that my email address is now smalhi@thehill.com.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:24:03 +0000
To: Gallin, John (OD) [E]
Cc: [redacted] (b) (6)
Subject: RE: Coronavirus vaccine center

[redacted] (b) (5)

From: Gallin, John (OD) [E] [redacted] (b) (6)>
Sent: Friday, February 28, 2020 1:52 PM
To: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Davey, Richard (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: Coronavirus vaccine center

Cliff and Rick (and Tony if you have time)

My friend Barry Coller is [redacted] (b) (4) (see below). Do you know if there is any need for this?

Thanks.

John

Sent from my iPhone

Begin forwarded message:

> **From:** Barry Coller [redacted] (b) (6)>
> **Date:** February 27, 2020 at 10:34:24 PM EST
> **To:** "Gallin, John (OD) [E]" [redacted] (b) (6)
> **Cc:** Barry Coller [redacted] (b) (6)
> **Subject: Coronavirus vaccine center**
>
> John,
> I suspect that this is an incredibly busy time for you and the Clinical Center.
> Tony was fantastic last night. Please let him know that he is my hero!
> [redacted] (b) (4)

[redacted] (b) (4)

If you know of any organizations or companies that are looking for sites to conduct vaccine studies, or if you would like us to collaborate with you to get studies completed more rapidly, please keep us in mind.

I am going crazy writing our [redacted] (b) (4) And it just gets harder.

Best regards to [redacted] (b) (6)

Barry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:17:42 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Brookings Invitation

Let us discuss.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, February 28, 2020 2:26 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Brookings Invitation

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Allen <JAllen@brookings.edu>
Sent: Friday, February 28, 2020 2:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Lucy Kim <LKim@brookings.edu>
Subject: Brookings Invitation

Dr. Fauci,

Greetings from the Brookings Institution. I'm writing to share the attached invitation for you to speak to our Board of Trustees at their annual dinner on Thursday, March 5 here in Washington, DC. The Brookings Board is a distinguished group of business and community leaders … I know they would be very eager to hear your thoughts, especially on the coronavirus crisis given its spread into the U.S. If this date does not work with your schedule, we'd be glad to welcome you to Brookings at a more convenient time.

I very much appreciate you considering our request, Dr. Fauci!

My very best,

John R. Allen
President
The Brookings Institution

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 02:58:01 +0000
To: Hodes, Richard (NIH/NIA) [E]
Cc: Cassetti, Cristina (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: SASP and Coronovirus 19

Richard:
Let me refer the e-mail to Cristina Cassetti who is in charge of the COVID-19 issues in our program. By this e-mail I will ask her to look into this and get back to Jim Kirkland.
Best regards,
Tony

Cristina:
See my note above to Dr. Hodes.
Thanks,
Tony

-----Original Message-----
From: Hodes, Richard (NIH/NIA) [E] [redacted] (b) (6)>
Sent: Saturday, February 29, 2020 9:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: SASP and Coronovirus 19

Hi Tony,
Please forgive me for intruding on your overwhelming priorities. If you have a moment to read the email below, [redacted] (b) (4) (b) (4) Thanks for any suggestions.
Best
Richard

-----Original Message-----
From: Kirkland, James L., M.D., Ph.D. [redacted] (b) (6)
Sent: Saturday, February 29, 2020 8:58 PM
To: Hodes, Richard (NIH/NIA) [E] [redacted] (b) (6)
Cc: Sierra, Felipe (NIH/NIA) [E] [redacted] (b) (6)>
Subject: SASP and Coronovirus 19

Dear Richard,

I am sorry to bother you late on a Saturday, but I wanted to let you know that we are finding in as yet unpublished [redacted] (b) (4)

(b) (4)

[redacted]

Jim

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 01:27:44 +0000
To: Barton Haynes, M.D.
Subject: RE:

Thanks, Bart.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Barton Haynes, M.D. < (b) (6)
Sent: Saturday, February 29, 2020 8:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE:

Great job in the press conference today.

Tough and high pressure situations it seems.

Thanks for being there and representing truth and science... best b

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)>
Sent: Saturday, February 29, 2020 7:14 PM
To: Barton Haynes, M.D. (b) (6)>; Marovich, Mary (NIH/NIAID) [E] (b) (6)>; Dieffenbach, Carl (NIH/NIAID) [E] <c (b) (6)>
Subject: RE:

Impressive!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Barton Haynes, M.D. <(b) (6)>
Sent: Saturday, February 29, 2020 2:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Marovich, Mary (NIH/NIAID) [E] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] (b) (6)
Subject: FW:

Hi Tony, Mary and Carl:

Every Saturday am, the DHVI team meets in my office to work on moving the HIV vaccine work forward, and now a new contingent is also working on coronavirus vaccine and new therapeutics.

This picture was from 9 am this Saturday morning. Great and dedicated crew listening to the presentation of data!

Best bart

-----Original Message-----
From: Barton Haynes, M.D.
Sent: Saturday, February 29, 2020 2:25 PM
To: (b) (6)
Subject:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 01:09:29 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: Clips

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Routh, Jennifer (NIH/NIAID) [E] < (b) (6)
Sent: Saturday, February 29, 2020 10:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] < (b) (6); Conrad, Patricia (NIH/NIAID) [E] < (b) (6)>
Subject: RE: Clips

Dr. Fauci - the clips I've been able to pull so far are listed below:

Hardball (MSNBC last night): https://www.msnbc.com/hardball/watch/dr-anthony-fauci-i-m-not-being-muzzled-79650373756?cid=sm_npd_ms_tw_hb

Lou Dobbs (Fox Business last night): https://twitter.com/LouDobbs/status/1233555383190507520

Today (NBC this morning): https://www.today.com/video/dr-fauci-on-coronavirus-fears-no-need-to-change-lifestyle-yet-79684677616

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, February 29, 2020 8:42 AM
To: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Clips

Jen:
This AM I did NBC Today and MSNBC. Please make sure that I get the clips.
Thanks
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 01:05:03 +0000
To: Holland, Steven (NIH/NIAID) [E]
Subject: RE: Human lung mice

Lease the decision up to HHS.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Holland, Steven (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Saturday, February 29, 2020 11:03 AM
To: [redacted] (b) (6) Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)
Subject: Re: Human lung mice

Thanks for the note, [redacted] (b) (5)

Steve

--
Director, Division of Intramural Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960
[redacted] (b) (6) voice
301-480-4507 fax
[redacted] (b) (6) email

Assistant lab: [redacted] (b) (6)
[redacted] (b) (6)

Assistant to SD: [redacted] (b) (6)
[redacted] (b) (6)

From: '[redacted] (b) (6)
Date: Saturday, February 29, 2020 at 10:55 AM
To: Anthony Fauci [redacted] (b) (6)>, Steven Holland [redacted] (b) (6)
Subject: Human lung mice

Hi Tony and Steve, I thought I'd better fill you in on some recent communications. Dr.
[redacted] (b) (5)

[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:55:28 +0000
To: [redacted] (b) (6)
Subject: RE: in case you need to hear it

Michael:

Thanks for the note. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michael Specter [redacted] (b) (6)
Sent: Saturday, February 29, 2020 12:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: in case you need to hear it

You are one of my very few heroes.
And in case you have not seen it, here is my personal love letter to the president (in which you feature semi prominently)

https://www.newyorker.com/news/daily-comment/donald-trumps-anti-globalist-response-to-a-global-coronavirus

Michael Specter
Staff Writer
The New Yorker
Adjunct Professor of Bioengineering
Stanford University
[redacted] (b) (6)
Phone: (Work, Cell, SMS) [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:53:55 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID-19

Please take a look and respond. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Fred Schaich <fred.schaich@ifaratv.org>
Sent: Saturday, February 29, 2020 12:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: COVID-19

Dear Dr. Fauci,

I'll not be at the CROI this year [redacted] (b) (6) So I hope I may be able to ask you a few questions as a concerned citizen.

Will we learn:
Why there are new cases in the US of unknown origin?
Could this virus infect carriers who do not present with symptoms or present in various levels of very mild infection and never get identified as infected?
Could individuals host the virus differently due to genetics or ethnicity?
Is this virus consistently similar after multiple generation or is it capable of mutating?
Is there an ability to develop an antibody immunity through infection? Can one be reinfected?
Could the level of infection be determined by the amount of inoculant?
Could we learn the level of infect ability of this virus by testing everyone in a given geographic area where there is a deep outbreak? We might also learn about the pathogenesis in a way that we cannot learn otherwise.
If this virus is so transmissible could we end up with almost everyone eventually being infected and present with various levels of serious acute infection and death to indistinguishable cases or just carriers?

With the clamp/filter on information from this administration, please tell us where we may find regular reports at various levels of current science on what we learn about this virus and vaccine progress, and where we may ask questions? I hope there is place for formal and informal community input into treatment, care and vaccine development.

Thank you for all your help over the years with your wise perspective through our interviews and leadership at the

NIH in such a reasonable and responsible way.

Warm regards,

Fred

Fred Schaich
(b) (6) OR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:27:04 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus - New Idea for treatment & clinical study
Attachments: The Nine Lives of Hydroxychloroquine.docx, Chloroquine & COVID-19 pneumonia.pdf, Remdesivir & Chloroquine Effective InVitro Against COVID-19.pdf, 6-27-19 (5).jpg

Please take a look and respond to them. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)>
Sent: Saturday, February 29, 2020 7:23 PM
To: vice.president@whitehouse.gov
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6) Secretary@HHS.gov
Subject: Coronavirus - New Idea for treatment & clinical study
Importance: High

Dear Vice President Pence,

We are thankful for your leadership of the White House Coronavirus Task Force in gathering the latest information about the outbreak, working with doctors and scientists to find solutions, and communicating with the general public regarding the situation. We were blessed to meet with you back in August, 2019, when [redacted] (b) (6) had expressed a desire to meet you. I have attached a picture from our meeting to help you remember. We pray for you often.

Since we are both physicians, we have been following the details of the COVID-19 outbreak closely. My husband was researching the anti-viral drug remdesivir this morning, and he came across some articles from Chinese studies that indicated a very well-known drug called hydroxychloroquine (already widely used for 70 years to treat malaria and rheumatological diseases) had very potent activity against COVID-19 infection and pneumonia. This was rather surprising to us, but as we read about the study and the characteristics of hydroxychloroquine, we realized that this could be a very good drug to use for the treatment of high-risk patients infected with COVID-19, who might deteriorate rapidly and progress to hospitalization and need for ICU care. Remdesivir also seems like an excellent anti-viral drug, but it is given intravenously, and is probably reserved for COVID-19 patients who are already entering into severe respiratory distress in the hospital.

Hydroxychloroquine, on the other hand, is given orally, and is cheap and readily available.
Low doses (6.5 mg / kg) have been effective in the management of Systemic Lupus Erythematosus and Rheumatoid Arthritis. 200 mg tablets are usually prescribed twice a day with meals; dosage can be increased up to the recommended 6.5 mg/kg if the patient tolerates the lower dose. **We wondered if the low dose hydroxychloroquine would be able to be studied quickly in various COVID-19 patients, especially those who are older and / or with medical conditions that put them at higher risk for pneumonia and complications (cardiovascular disease, chronic pulmonary disease, hypertension, diabetes, etc.). In addition, hydroxychloroquine may even be a useful drug to prevent the development of pneumonia in patients diagnosed with COVID-19.**

Because hydroxychloroquine in an older drug that is generic, current pharmaceutical companies have no incentive to do studies or research on its effectiveness for any new medical conditions. Therefore, the federal government would most likely have to construct and fund the studies. Perhaps Dr. Fauci has already considered this kind of study with hydroxychloroquine.

We understand that vaccines are already being studied, and Israel is working on an oral (pill) vaccine. Vaccines take time to go through testing and trials, which is why we are suggesting to you that studies be done on hydroxychloroquine, a readily-available oral drug that could “bridge the gap” to provide some potential treatment and mitigation of the COVID-19 infections while vaccines are being developed and mass produced.

We have attached several articles, which are electronic publications made available in advance (Feb. 4th & Feb 19th, 2020) of the printed journal publications. We will send a copy of this email to Dr. Fauci, Dr. Redfield, and Dr. Azar.

Sincerely yours,
Drs. Paul & Karyl Stanton

(b) (6)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:14:14 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: One solution in the armoury to protect Health Care Sector Workers against Covid-19

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Saturday, February 29, 2020 2:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: One solution in the armoury to protect Health Care Sector Workers against Covid-19

Dear Dr Fauci

A PPE device, tested and proven at **Public Health England Porton Down** (PHE), based on innovative technology could be ready to go into production within 20 weeks. It sterilises all airborne pathogens as air is inhaled by the wearer. See www.medi-immune.com and in particular the published report on the tests, by clicking on the report under "The Science" The device is due to undergo further tests, at PHE within the next week, specifically against Covid-19. For verification please contact Professor Nigel Silman at PHE Porton Down.

Health Services around the world are doing what they can to prepare for a significant increase in infections from this highly transmissible virus and if those people in the Health Care Sectors are infected the situation could become untenable.

The production of vaccines is under way but no one expects them to be available within the next 12 to 18 months. The Medi-Immune "ProtectivAir®", which has been under development for some years and could be available within a few months, will give a far greater level of protection than the current masks and respirators and more importantly can remain in use in the future for other emerging airborne pathogens – known, unknown or mutating.

Please take a little time to investigate this option, via the website, or pass it on to those who you believe need to be made aware of it. I will be happy to answer any questions, technical or otherwise, at my email address below or on my mobile number, also below.

Kind regards

James Love

James Love
Director
m: [redacted] (b) (6)
t:
www.medi-immune.com
www.revaxbiotech.com

MEDI-IMMUNE
Groundbreaking Protection & Immunity

Medi-Immune Limited, registered in England and Wales | Company registration No: 04554706 | Registered Office: 4 Lady Bank | Tamworth Staffordshire | B79 7NB | UK

DISCLAIMER: Privileged/Confidential information and/or Copyright Material may be contained in this email. The information and material is intended for the use of the addressee(s) only. If you are not the addressee or the person responsible for delivering it to the intended addressee(s), you may not copy or deliver it to anyone else or use it in any unauthorised manner. To do so is prohibited and may be unlawful. If you receive this email by mistake, advise the sender immediately by using the reply facility in your email software. Any views or opinions presented are solely those of the author and do not necessarily represent those of Medi-Immune Ltd. Although this email and attachments are believed to be free of any virus or other defects which might affect any computer or IT systems into which they are received, no responsibility is accepted by Medi-Immune Ltd for any loss of damage arising in any way from the receipt or use thereof.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:12:45 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: A sharing on COVID ARDS research
Attachments: Dexa_ARDS_COVID-19 for Dr. Tugwell.doc, Tsai 2020_Ann of Intensive Care_ARDS_corticosteroid.pdf

Please take a look at this and handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paul Elias Alexander (b) (6)>
Sent: Saturday, February 29, 2020 2:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: A sharing on COVID ARDS research

Hi Dr. Fauci, I am a trained epidemiologist and expert in evidence based medicine. Particularly in developing clinical practice guidelines and I teach EBM and GRADE methods.

You have no idea how much I have admired you across the years, your intelligence and poise.

May I ask how I may help you in this matter, this response, I am not talking about money, I wish to help, volunteer.

I draw your attention to 2 attachments...

1) one is a one page I wrote to summarize a meta analysis my team just completed and seeking to publish. It pertains to corticosteroids and ARDS. We are raising that this suggests indirect evidence that we may be able to extrapolate to the COVID patient with severe illness. This within the life threatening issue and emergency and no effective treatment. I share if this can

help you as I know you are leading this and listened to you today with the president. I support this president fully.

2) I share a paper published today, it on the other hand raises serious questions on the use of corticosteroids in influenza associated ARDS, and one may argue this patient set, is the closest to the COVID 19 patient.

My sense is that the accumulated evidence thus far is weak and argues against corticosteroids. For example, this recently published multicenter retrospective cohort study in medical center ICUs across Taiwan sought to assess the effectiveness of corticosteroids in patients presenting with influenza-associated ARDS (virology-proven ARDS and are on mechanical ventilation). Researchers examined the impact of early corticosteroid treatment (≥ 200 mg hydrocortisone equivalent dose within 3 days after ICU admission, determined by a sensitivity analysis) on subsequent hospital mortality. The study revealed that of the 241 patients with influenza-associated ARDS, those receiving early corticosteroid had a significantly higher hospital mortality rate than those who did not get early corticosteroid [43.5% (37/85) vs. 19.2% (30/156), p < 0.001]. Early corticosteroid treatment was independently associated with increased hospital mortality in overall patients [an adjusted OR of 5.02 (95% CI 2.39-10.54), *p* < 0.001] and in all examined subgroups. Researchers found that a higher dose and earlier treatment was linked to higher hospital mortality. Moreover, they found that earlier treatment was related to a significantly increased odds of subsequent bacteremia [an adjusted OR of 2.37 (95% CI 1.01-5.56)]. These results underscore the urgency for robust comparative randomized research given this study is based on weaker observational evidence that is confounded by selection bias and confounded. However this was a stronger study that used statistical adjustment and propensity score matching. Thus this study suggests caution with corticosteroid and thus the importance for caution by clinicians as to the potential harms of corticosteroids in this population. These results, while based on weaker methodology, have revealed large estimates of effect, is the strongest evidence to date on treatment for ARDS, and brings us closest to the COVID-19 ARDS patient.

Best,

Paul E. Alexander, MSc, MHSc, PhD
Assistant Professor
http://hei.mcmaster.ca/
McMaster University, 1280 Main Street W,
Hamilton, ON L8S 4K1
GUIDE Research Methods Group
http://guidecanada.org/

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:56:39 +0000
To: Les Gardonyi
Subject: RE: Suggestion

Leslie:

Thank you for your note. We are actually looking into the effect of ACE inhibitors on the coronavirus.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: ((b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Les Gardonyi (b) (6)>
Sent: Saturday, February 29, 2020 3:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Suggestion

Dear Mr. Fauci,

This may be way too presumptive of a note...
As an engineer I've always liked to understand the mechanics of how things work so I looked into educating myself about the coronavirus and it's mechanics. (b) (6) I've correlated a possible research route for your organization regarding the prevention aspect.

A quick overlook on this strategy is the following:

Coronaviruses are RNA viruses that typically enter human cells when their glycoproteins bind proteins on the cell surface. In the case of the virus that causes SARS, that human protein is **angiotensin-converting enzyme 2** (ACE2). At this time, scientists think the novel coronavirus is similar enough to SARS that its entry point is likely ACE2 as well.

source: https://cen.acs.org/biological-chemistry/infectious-disease/novel-coronavirus-hits-China/98/web/2020/01

Irbesartan is used to treat high blood pressure (hypertension) and to help protect the kidneys from damage due to diabetes. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Irbesartan belongs to a class of drugs called **angiotensin receptor blockers** (ARBs). It works by relaxing blood vessels so that blood can flow more easily.

source: https://www.webmd.com/drugs/2/drug-4720/irbesartan-oral/details

Idea:
Can Irbesartan, being an angiotensin receptor blocker, possibly help prevent Coronavirus infections... since the Coronavirus entry to humans is via ACE-2?

I share this suggestion with you in the hopes that it may help your department in the research to prevent the spread of the coronavirus... or to a presumptuous email slated for deletion.

Sincerely,
-Leslie Gardonyi

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:54:27 +0000
To: Ellen Butler
Subject: RE: [redacted] (b) (6)

Ellen:

Thank you for your kind note. Very nice family pictures! [redacted] (b) (6) [redacted], but in any event, thanks for the note.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ellen Butler [redacted] (b) (6)
Sent: Saturday, February 29, 2020 3:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [redacted] (b) (6)

I just watched you this afternoon at the press conference. Over the years I have seen you and wondered along with family members if [redacted] (b) (6)

Also I just wanted to say how professional you are and that I don't believe what #45 or his administration have to say regarding the coronavirus but have 100% confidence in what you say and do. Thank you for being the adult in the room.

[redacted] (b) (6) I am very proud of you.

Sincerely,

Ellen Butler

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:44:17 +0000
To: Margaret Liu
Subject: RE: kudos and comment about JAMA Coronavirus article

Margaret:

Thanks for the note. You make a valid point and I appreciate what you are saying. . On that issue, I have been vocal about making sure that we do not stigmatize Chinese people here in the USA or anywhere in relationship to the COVID-19 outbreak.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Margaret Liu <liu@protherimmune.com>
Sent: Saturday, February 29, 2020 3:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Alice Huang <stephen.lin@80-20ef.org>; president@80-20.us
Subject: kudos and comment about JAMA Coronavirus article

Dear Tony,

Wonderful articles in JAMA and NEJM. So glad you are still heading NIAID- it is comforting that there are experts of your caliber still in the room. And thrilled that the NIAID has done so much to develop rapid timelines for DNA vaccines and that you highlighted that progress in the article, since people call me the "Mother of DNA vaccines,".

As a former NIAID Council member, I felt I should write to raise an issue that I am sensitized to as a scientist who is ethnically Chinese while American:
Why in the JAMA article was it necessary to state that the first travel-related case to the US was a *Chinese* man (italics mine) who had visited Wuhan. Did his being Chinese either ethnically or by citizenship affect anything biologically?

I ask because not only have many Asian people now encountered increased racism in public places (due to fear that any Asian person is a source of COVID-19), but now that the President is turning this epidemic into additional fear-mongering about "borders" it seems all the more important that scientists do not inadvertently add to "xenophobia" (even though non-white skin does not mean a person is foreign) and do not seem to advance any political perspective.

Sincerely and with best personal regards,
Margaret

Margaret A. Liu, MD, DSc*hc*, MD*hc*, FISV
ProTherImmune &
Foreign Adjunct Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Full Professor, UCSF
San Francisco, CA USA
President Emeritus, International Society for Vaccines
Liu@ProTherImmune.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:40:04 +0000
To: Tom Leopold
Cc: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: ? ALTERNATIVE/SUPPLEMENTAL rx for COVID-19: Angiotensin Receptor Blockers

I have received this message and we are in fact looking into this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Tom Leopold (b) (6)>
Sent: Saturday, February 29, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: ? ALTERNATIVE/SUPPLEMENTAL rx for COVID-19: Angiotensin Receptor Blockers

Much appreciation for all of your work past and present. I am a cardiologist in New Jersey and when I read that the virus attaches to the AT2 receptors in the lungs I couldn't help but think that maybe the class of ARB's that we use so frequently for HTN and heart failure management could possibly block entry of virus into cells and prevent or mitigate the severity of infection. Has this approach ever been studied and is it worth looking into? Imagine if ARBs could lessen the severity of infection how readily available and relatively inexpensive this class of medication is! Would appreciate if someone could get back to inform me whether you received this message. Thanks. Dr Thomas Leopold Email: (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:34:59 +0000
To: Tom Leopold
Subject: RE: Angiotensin Receptor Blockers: a possible therapy for Covid-19

Thanks for the note. We are looking into this possibility.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Tom Leopold (b) (6)>
Sent: Saturday, February 29, 2020 5:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Angiotensin Receptor Blockers: a possible therapy for Covid-19

Much appreciation for all of your work past and present. I am a cardiologist in New Jersey and when I read that the virus attaches to the AT2 receptors in the lungs I couldn't help but think that maybe the class of ARB's that we use so frequently for HTN and heart failure management could possibly block entry of virus into cells and prevent or mitigate the severity of infection. Has this approach ever been studied and is it worth looking into? Imagine if ARBs could lessen the severity of infection how readily available and relatively inexpensive this class of medication is! Would appreciate if someone could get back to inform me whether you received this message. Thanks. Dr Thomas Leopold Email: (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:29:47 +0000
To: Richard Goodman
Subject: RE: Coronavirus question

Richard:

There are no CDC-issued travel restrictions within the USA. The CDC made this clear at the White House press conference this afternoon.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Goodman <goodmanr@ohsu.edu>
Sent: Saturday, February 29, 2020 5:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus question

We met many years ago, Tony,

...at an event marking Shelly Wolff's 10 year anniversary at New England Medical Center. (I had the distinction of being the first medical intern in that program who he reamed out.)

My question relates to travel restrictions. The current restrictions appear to be quite limited, but several organizations, including Google, Amazon, and the HHMI have restricted, or cancelled, even domestic meetings. As a result of the HHMI cancelation, my own program director indicated his intention to cancel our upcoming Scientific Advisory meeting and, in the non-academic world, (b) (6) [redacted] (which is ironic since there are more coronavirus infections in my town of (b) (6) Oregon than there are in all of New York).

In addition to announcing the new travel restrictions, could you also say something publicly about what doesn't need to be restricted? In particular, is domestic travel OK, or not? Does the HHMI know something the rest of us don't?

Sincerely,
Richard Goodman MD PhD

Vollum Institute
Oregon Health & Science University

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:06:38 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Rapid Collaboration for Hand & Nasal Decontamination Formulation
Attachments: NORS-viral review_V3.pdf, 1998 Reiss NO plays a role in viral infections.pdf, 2005 Akerstrom NO inhibits Corona Viral replication.pdf, 2010 Jung Nitric & SARS corona virus.pdf, 2013 Regev Nitric reduces viral infectivity.pdf, 2015Regev Nitric cattle vs antibiotics BRD.pdf

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gilly Regev (b) (6)
Sent: Saturday, February 29, 2020 5:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Chris Miller (b) (6)
Subject: Fwd: Rapid Collaboration for Hand & Nasal Decontamination Formulation

Dear Dr Fauci,

Dr Murad sits on our BOD and has suggested that we contact you to help expedite a rapid testing of our product on the COVID-19 virus. I know you are probably overwhelmed but hope you might pass this along or suggest a strategy that would be a win-win for us all.

We have developed a non-alcohol based formulation that utilizes the nanomolecule nitric oxide (NO). as you know, NO is produced in our body and is our first line of defense against microbes. We have harnessed this in a patented formulation called nitric oxide releasing solution/gel (NORGS). We are focused on the development of products for chronic sinusitis, diabetic foot wounds, warts and toenail fungus.
However, internally & personally, we have been using NORGS as an extremely effective natural hand sanitizer and nasal spray to protect ourselves from the common cold and flu for years.
There are strong independent published research that NO is antiviral against Corona viral species. We hae data showing definite virucidal characteristics and moderate antiviral effects in host cells.

With the recent concern with COVID-19, we felt we should try to rapidly test the hand rub and nasal spray against the COVID-19 but need to collaborate with a laboratory that could test this for us. Funding collaborators are welcome too, as this was not in our budget but we feel a social responsibility to move this forward.
I have included a short white paper of our data and a few articles to support our claims.
Feel free to contact me any time (b) (6)) or have one of your senior staff contact me.

Sincerely,
Chris Miller and Gilly Regev

--
Gilly Regev, Ph.D.

CEO / Co-founder
SaNOtize Research and Development Corp.

Phone: (b) (6)
email: (b) (6)
https://www.linkedin.com/in/gilly-regev-694b4a16/
https://www.sanotize.com

From: [redacted] (b) (6)
Sent: Sat, 29 Feb 2020 06:58:29 -0500
To: Heather DaVia
Subject: Re: Thank You

Joseph and Heather:
Many thanks for your kind words. Much appreciated.
Best regards,
Tony

> On Feb 28, 2020, at 8:45 PM, Heather DaVia [redacted] (b) (6)> wrote:
>
> Dear Dr. Fauci:
>
> Please accept my personal and heartfelt thanks for your continued efforts to keep the American public informed concerning the coronavirus. While listening to you on the radio or at press conferences, your calm, thoughtful, and measured words are very comforting and reassuring. Both your caring response and scientific/medical expertise are an example of the very best in the Federal Government.
>
> Again, thank you for your public service and your efforts to keep us as safe as possible.
>
> Sincerely,
>
> Joseph P. DaVia
> [redacted] (b) (6)
>
> P.S. [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 03:15:14 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E];Schwetz, Tara (NIH/OD) [E]
Subject: RE: OSTP call

Larry:
Thanks you very much.
Tony

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Sent: Friday, February 28, 2020 8:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)Schwetz, Tara (NIH/OD) [E]
[redacted] (b) (6)>
Subject: OSTP call

Tony,

Tara and I took the call with Kelvin Droegemeier, France Cordova (NSF), and Paul Dabbar (DOE).

[redacted] (b) (5)

Please let me know if you need anything else. (Tara -if I left anything out please add).
Larry

Sent from my iPhone

From: [redacted] (b) (6)
Sent: Fri, 28 Feb 2020 19:48:05 -0500
To: Harris, Kara (NIH/NIAID) [E];Haskins, Melinda (NIH/NIAID) [E]
Subject: Fwd: Coronavirus on surfaces

Public inq pls

Sent from my iPhone

Begin forwarded message:

> **From:** Deborah Greene [redacted] (b) (6)
> **Date:** February 28, 2020 at 7:38:44 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Subject: Coronavirus on surfaces**
>
> Hello Dr Fauci,
>
> I am trying to find out how long the coronavirus can remain infectious on the surface of an object handled by someone with the virus.
>
> My concern is with purchasing items for my jewelry shop that come from China , South Korea, and Turkey.
>
> I have not been able to find anything that addresses this question and hope you can clarify this for me. Thank you.
>
> Sincerely yours,
> Deborah Greene
>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 23:18:10 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona Virus
Attachments: US Biotest Letter re COVID-19 Fauci, A.pdf, Coronavirus-[redacted] (b) (4) Rationale.pptx, US Biotest Regulatory History of [redacted] (b) (4).pdf, US Biotest COVID-19 [redacted] (b) (4) References.pdf

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Samantha Mauro [redacted] (b) (6)>
Sent: Friday, February 28, 2020 6:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Gere diZerega [redacted] (b) (6)>
Subject: Corona Virus

Dear Dr. Fauci:

[redacted] (b) (4)

(b) (4)

[redacted]

Please contact us if we can be of any help in moving this potential life-support initiative forward.

Sincerely,

Gere diZerega MD
Professor
Keck School of Medicine
University of Southern California
And
President and CEO
US Biotest, LLC
San Luis Obispo, CA
(b) (6)

Kathleen Rodgers PhD
Professor, Department of Pharmacology
College of Medicine
Center for Innovation in Brain Sciences
Associate Director of Translational Neurosciences
University of Arizona
Tucson, AZ
(b) (6)

From: (b) (6)
Sent: Fri, 28 Feb 2020 16:54:13 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Urgent Email/Strategy to attack 2019-nCoV coronavirus
Attachments: Nucleotide_Analogues_as_Inhibitors of SARS-CoV Polymerase_2_28_2020.pdf, ATT00001.htm, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.pdf, ATT00002.htm

Pls handle

Sent from my iPhone

Begin forwarded message:

> **From:** Jingyue Ju (b) (6)>
> **Date:** February 28, 2020 at 4:46:04 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
> **Cc:** "Barasch, Kimberly (NIH/NIAID) [C]" (b) (6), "directorsincoming@cdc.gov" <directorsincoming@cdc.gov>, "Redfield, Robert R. (CDC/OD)" (b) (6), "Davis, Mindy (NIH/NIAID) [E]" (b) (6)>, "Eakin, Ann (NIH/NIAID) [E]" <(b) (6)>, "Stemmy, Erik (NIH/NIAID) [E]" (b) (6)>, "Sciotti, Rick (NIH/NIAID) [E]" (b) (6) "Schiltz, Helen (NIH/NIAID) [E]" (b) (6)>, "Krafft, Amy (NIH/NIAID) [E]" (b) (6)>
> **Subject: Re: Urgent Email/Strategy to attack 2019-nCoV coronavirus**
>
> Dear Dr. Fauci,
>
> Following my previous email regarding our work on developing strategies to attack the 2019-nCoV coronavirus, I am attaching in this email our experimental results demonstrating that 2 nucleotide analogues are inhibitors of the SARS-CoV polymerase. Since the SARS-CoV polymerase has over 96% similarity to the polymerase from SARS-CoV-2, we expect that the nucleotide analogues, 2'-F,Me-UTP and 3'-F-dTTP, will also inhibit the SARS-CoV-2 polymerase.
>
> At this point, it is imperative that the prodrug forms (one is Sofosbuvir that is FDA approved for HepC) of these molecules begin immediate in vitro testing with infected cells (similar to the studies carried out for Remdesivir and chloroquine in the Cell Research article at the link, https://www.nature.com/articles/s41422-020-0282-0; PDF file of the article also attached) followed by animal testing trials ASAP. Since we do not have access to the SARS-CoV-2 viral strains, we need your assistance to identify resources at the NIH laboratories to embark on this next step

investigation ASAP. We can provide the prodrugs to the labs at NIH that you identify for carrying out these studies. In view of the worldwide SARS-CoV-2 emergency, we'd like your assistance in getting this off the ground ASAP.

I can be reached any time at (b) (6)

All the best,

Jingyue Ju, Ph.D.
Samuel Ruben-Peter G. Viele Professor of Engineering
Professor of Chemical Engineering and Pharmacology
Director, Center for Genome Technology &Biomolecular Engineering
Columbia University
Northwest Corner Building, Room 1000M1
550 West 120th Street
New York, NY 10027
Phone:

(b) (6)>wrote:

> Dear Drs. Fauci and Redfield,
>
> Scientists in my laboratory at Columbia University are actively engaged in design strategies to cope with the new strain of coronavirus, 2019-nCoV, which has caused a global public health emergency. We have embarked on a project entitled "Nucleotide Analogues as Inhibitors of Viral Polymerases". We provide a summary of this work below.
>
> Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3'-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators.
>
> Please let me know if you would like to receive the full manuscript.
>
> Thank you very much for your consideration.

Sincerely,

Jingyue

Jingyue Ju, Ph.D.
Samuel Ruben-Peter G. Viele Professor of Engineering
Professor of Chemical Engineering and Pharmacology
Director, Center for Genome Technology &Biomolecular Engineering
Columbia University
Northwest Corner Building, Room 1000M1
Phone:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 21:27:35 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona Virus
Attachments: US Biotest Regulatory History of [redacted] (b) (4).pdf, US Biotest COVID-19 [redacted] (b) (4) References.pdf, US Biotest Letter re COVID-19 Fauci, A.pdf

Please take a look and handle if necessary.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gere diZerega < [redacted] (b) (6)
Sent: Friday, February 28, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Gere diZerega < [redacted] (b) (6)>
Subject: Corona Virus

Dear Dr. Fauci:

[redacted] (b) (4)

(b) (4)
[redacted]

Please contact us if we can be of any help in moving this potential life-support initiative forward.

Sincerely,
Gere

GERE DIZEREGA
PRESIDENT AND CEO
US BIOTEST, INC.

231 BONETTI DRIVE, SUITE 240
SAN LUIS OBISPO, CA 93401-7310
TEL: [redacted] (b) (6) ✧ FAX: 805.595.1350

The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer.

From: [redacted] (b) (6)
Sent: Fri, 28 Feb 2020 13:41:02 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: As bad as measles?

Please handle

Begin forwarded message:

> **From:** Ed Charlton <[redacted] (b) (6)>
> **Date:** February 28, 2020 at 1:07:32 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: As bad as measles?**
>
> Dr Fauci, you are the pre-eminent infectious disease physician in the world. I'm concerned the public has lost perspective on COVID-19. At this point, it would seem the r0 and CFR are more similar to rubeola than they are to Ebola. Can we remind the public of that? Communicating that influenza will kill more Americans than SARS-2 hasn't gained traction. Might someone like yourself or Dr Carson communicate more strongly to the public the risks compared to other viruses they are familiar with, like rubeola, rubella, varicella, etc?

From: [redacted] (b) (6)
Sent: Fri, 28 Feb 2020 13:39:34 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Experimental vaccine for Covid-19

Please respond. Mention risk of enhancement

Begin forwarded message:

> **From:** "William J. Buikema" [redacted] (b) (6)>
> **Date:** February 28, 2020 at 1:08:50 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Experimental vaccine for Covid-19**
>
> Dear Dr. Fauci,
> I understand the need for the various stages of testing a new experimental vaccine, but in listening to you give a timeline for any new vaccine for the corona virus, it struck me that perhaps a modified approach might be considered. Why not allow early use of a vaccine that has passed a phase 1 safety testing, similar to what was done for the Ebola vaccines. If a vaccine is shown to be reasonably safe, why not allow its use it in more at-risk people (elderly, smokers) before phase 2 trials are finished. It could also be helpful as with the Ebola vaccines to prevent transmission in hot spots of community acquired infections. There doesn't seem to be much downside compared to the potential for preventing many more deaths than was seen in the Ebola situation.
> Sincerely yours,
> Bill Buikema
> William J. Buikema, PhD, Research Associate
> Technical Director, DNA Sequencing & Genotyping Core
> University of Chicago, KCBD 1230H&I
> 900 E 57th Street, Chicago, IL 60637
> 773-702-1088, cancer-seqbase.uchicago.edu

From: [redacted] (b) (6)
Sent: Fri, 28 Feb 2020 11:21:22 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: coronavirus vaccine story?

Sent from my iPhone

Begin forwarded message:

> **From:** Olga Khazan <olga@theatlantic.com>
> **Date:** February 28, 2020 at 11:09:49 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Subject: coronavirus vaccine story?**
>
> Hi Tony -- It's Olga at the Atlantic ... I'm hearing that there's a coronavirus vaccine trial in the works at the VTEU sites. We'd love to tell the story, but everyone is directing me to you and NIAID. Would you be able to talk with me about this today for a story? My cell is [redacted] (b) (6), and my desk is 202-266-7387.
>
> Thanks,
> Olga
>
> --
> Olga Khazan
> Staff Writer
> The Atlantic
> olga@theatlantic.com
> cell: [redacted] (b) (6)

From: (b) (6)
Sent: Fri, 28 Feb 2020 08:59:04 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: MEDIA INQUIRY

Sent from my iPhone

Begin forwarded message:

> **From:** Lemonov Alexander <anlemonov@rttv.ru>
> **Date:** February 28, 2020 at 8:13:34 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
> **Subject: MEDIA INQUIRY**
>
> Dear Dr. Fauci,
>
> My name is Alexander Lemonov, I am a producer for RT International TV channel.
>
> I would like to invite you to appear on "Worlds Apart", RT's 26-minute uncensored one-on-one interview show.
> We would like to talk about the spread of the COVID-19 coronavirus, the response measures countries should take, the world's general preparedness for pandemics, COVID-19's possible consequences for other areas: healthcare, economy, security, etc.
>
> Would you be available?
>
> FYI: "Worlds Apart" is an uncensored interview show that is aired on RT International, RT America, RT UK, and RT Russia (in Russian).
> All episodes get featured on RT social media accounts, watched by their multimillion international crowd.
> Our guests endorse widely different views, and we are happy to broadcast different opinions.
> Here's the link to our show: https://www.rt.com/shows/worlds-apart-oksana-boyko/
>
> "Worlds Apart" has featured:
> businessman Richard Branson, lawyer Alan Dershowitz, former Israeli FM Tzipi Livni, UN Secretary General Antonio Guterres, UN Women Executive Director Phumzile Mlambo-Ngcuka, former Prime Minister of Italy Giuliano Amato, former U.S. State Department coordinator for JCPOA Jarrett Blanc, foreign minister of Iran Javad Zarif, adviser on international affairs to Supreme Leader of Iran Ali Akbar Velayati, former chief economist of the World Bank Anne Krueger, Secretary General of OSCE Thomas Greminger, special adviser to PM of Japan Tomohiko Taniguchi, senior fellow at the Brookings Institution Mike O'Hanlon, etc.
>
> I would appreciate a reply.

Kind regards,
Alexander Lemonov
Producer
"Worlds Apart", RT
Mobile: [redacted] (b) (6)
Office: +7 (499) 75-000-75, ext. 2492

Александр Лемонов
Продюсер
"Worlds Apart", RT
Моб.: [redacted] (b) (6)
Раб.: +7 (499) 75-000-75, доб. 2492

RT
rt.com

twitter.com/rt_com
facebook.com/RTnews
youtube.com/user/RussiaToday
plus.google.com/102728491539958529040/posts

CONFIDENTIALITY.
The information contained in this transmission is intended exclusively for the proper use by the intended addressees and may contain confidential and/or privileged material. Any views expressed in this transmission are those of the individual sender, except where the transmission states otherwise and the sender being authorised appropriately. Any review, dissemination and other use of this information, as well as any action in reliance upon this information by persons and/or entities other than the intended addressees is prohibited. If you received this information in error, please note that no confidentiality or privilege is waived or lost by any miss-transmission. Note that we monitor e-mails sent or received. Further communication will signify your consent to the above.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 11:50:04 +0000
To: Kaplan, Edward H
Subject: RE: Coronavirus

Ed:
Thanks for the note. Great to hear from you. I hope that all is well.
Best regards,
Tony

-----Original Message-----
From: Kaplan, Edward H <(b) (6)>
Sent: Thursday, February 27, 2020 10:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: RE: Coronavirus

Hi again Tony. Here's a link to a non-technical explanation of the paper I shared with you earlier:

https://insights.som.yale.edu/insights/new-outbreaks-of-coronavirus-can-be-halted-with-isolation-measures-according-to-study

I have seen predictions stating that upwards of 30% of the world's population will be infected, but I don't see this happening. What I do see are lots of local outbreaks from imported cases, some larger than others, but all heading towards containment. I find Israel to be an interesting test case. A group of infected Korean tourists who visited the country only tested positive for coronavirus after their return to Korea, joining the large outbreak that has been reported there. The itinerary of their travel group has been made public so that retrospectively, Israeli public health officials could ascertain who was exposed where and when (see https://www.health.gov.il/English/News_and_Events/Spokespersons_Messages/Pages/23022020_1.aspx). Already 1,600 Israelis have been quarantined on account of possible exposure. It has been twelve days since this group of tourists returned to Korea, and no new infections have been reported in Israel associated with this group (there are two Israelis who were infected on the Diamond Princess cruise ship, and one infected while in Italy). See https://www.ynetnews.com/article/H1nXPa7E8. It will be interesting (and important) to see how many new infections are detected in the days ahead, and if such new infections are found among those already under preventive watch.

Nonetheless I totally concur with preparing as if major transmission will occur. Much better to err by over- rather than under- preparing (a familiar perspective from those bygone smallpox debates).

Finally, a reporter asked me yesterday afternoon what I wanted the President to say last night. Here was my response:

In a sober way summarize the facts of the outbreak, state that the US has an excellent preparedness team between CDC and NIH, that at the advice of this team travel restrictions and quarantine measures have already been enacted, but as of now the public is at very low risk of infection. Still, citizens should go to cdc.gov now to learn from our experts how to prepare in the event that more extreme measures are needed, stay abreast of the situation here and abroad and follow the advice of our experts, get a flu shot (!), and know that the US has a very strong public health system that can withstand this challenge.

Anyway, just wanted to share all this with you. Keep up the good work and good luck with the vaccine research, Ed

-----Original Message-----
From: Kaplan, Edward H
Sent: Saturday, February 8, 2020 10:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Coronavirus containment modeling

Dear Dr. Fauci,

It has been many years since we corresponded regarding smallpox bioterrorism and vaccination control.

The attached paper on containing a community coronavirus outbreak from a few initial cases via isolation and quarantine might interest you. The news is mostly good - isolation and quarantine can get the transmission rate below epidemic threshold - but the key is rapid detection of infected persons. Also discussed are some ideas for alleviating congestion in the hospital. I hope that you find it helpful.

Best, Ed Kaplan

Edward H. Kaplan, Ph.D.
William N. and Marie A. Beach Professor of Operations Research Professor of Public Health Professor of Engineering Yale School of Management Box 208200 New Haven, Connecticut 06520-8200

Phone: (b) (6)
e-mail (b) (6)

https://nam05.safelinks.protection.outlook.com/?url=http%3A%2F%2Ffaculty.som.yale.edu%2FEdKaplan%2F&amp;data=02%7C01%7Cedward.kaplan%40yale.edu%7Cb00119dcdbe24bc635d208d7bb9b24c7%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637184147315834392&amp;sdata=I1LC4xAuAc%2BjdNuG%2BA2oGxcS9LS95PoQRi7yO0dLRd0%3D&amp;reserved=0

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 11:25:43 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Coronavirus update for your upcoming Keystone Symposia meeting

FYI

From: Allison Ogdon <AllisonO@keystonesymposia.org>
Sent: Friday, February 28, 2020 12:10 AM
To: Allison Ogdon <AllisonO@keystonesymposia.org>
Cc: Heidi Daetwyler <HeidiD@keystonesymposia.org>
Subject: Coronavirus update for your upcoming Keystone Symposia meeting
Importance: High

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

Greetings,

In light of the current coronavirus situation, we would like to provide an update on your upcoming Keystone Symposia conference.

The health and safety of our meeting attendees and speakers is our top priority, and we are carefully monitoring the coronavirus situation around the world to ensure we take the necessary precautions as recommended by healthcare providers and public health organizations.

Currently, ***your meeting will proceed as scheduled***, and we will contact you immediately if anything changes. Decisions will be made on a moment to moment basis, as new information becomes available. We assure you that the leadership team at Keystone Symposia is closely monitoring global developments and will take swift action to ensure the health and safety of all meeting participants.

As a speaker, you hold a very special role at the meeting as a field leader. We very much appreciate your contribution to both the scientific program, and the community of luminary scientists who will convene to direct the future of the field. Your presentation will be a highlight for many attendees, and your insights will inspire others to take on new and innovative directions in their own work. This is the essence of Keystone Symposia -- convening communities of leading scientists to inspire each other to advance biomedicine, and this would not be possible without your engagement.

We realize the current situation may add some inconveniences to travel at this time, but we also remind you that each and every one of our speakers is hand-selected by a committee of the world's leading experts to represent their field at the meeting. You are among a very select few to receive this honor.

The meeting organizers, and our team at Keystone Symposia, have put a great deal of time and effort over the last two years into designing the program, and your presentation is a key part of that. We hope you will take these thoughts into consideration as the meeting approaches.

While this is a time we must all be vigilant about public health measures, we are reminding conference attendees that this is also a time to remain calm, rational and scientific in addressing the situation. We encourage you to engage with your fellow colleagues at the meeting as you normally would, to forge new collaborations and novel ideas that will drive your research and the field in innovative and fruitful directions. At the meeting, we are providing the following suggestions based on recommendations from the National Foundation of Infectious Disease:

- ***The best way to protect yourself against COVID-19 is similar to how you would take precautions against the cold or flu.*** Wash your hands often using soap and water for at least 20 seconds. Cover your cough or sneeze with a tissue or the crook of your elbow rather than your hands.

- ***There is no need to wear a face mask if you are well and do not have symptoms***—masks protect the sick from spreading germs but will not prevent you from getting sick.

- ***Do not assume that anyone of Asian descent is more likely to have coronavirus***—do not forget about the importance of inclusivity and evidence-based information.

Again, we thank you for your contributions and commitment to Keystone Symposia and wish for a very successful and inspiring meeting.

Sincerely,

(b) (6)

Deborah L. Johnson, Ph.D.
President and Chief Executive Officer
Keystone Symposia on Molecular and Cellular Biology

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

INCLUDE
DIVERSITY IN THE SCIENTIFIC WORKFORCE

PO Box 1630 | Silverthorne | CO 80498 | USA (regular mail only)
160 US Highway 6, Ste. 200 | Silverthorne | CO 80498 | USA (courier only)
970.262.1230 | 800.253.0685 | www.keystonesymposia.org
Visit virtual.keystonesymposia.org to view our digital content.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:25:27 +0000
To: Kline, Lydia (NIH/OD) [E]
Subject: RE: thank you

Lydia:
  Thanks for your kind note.
Best regards,
Tony

From: Kline, Lydia (NIH/OD) [E] [redacted] (b) (6)>
Sent: Thursday, February 27, 2020 9:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: thank you

Tony,

I'm sure many people are telling you this, but I wanted to add my thanks to you for everything you do to keep the world safer and healthier! You are doing an incredible job (as always) out there with coronavirus.

Best,
Lydia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:23:12 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: invitation to speak on COVID 19 at the International ATS Conference in May
Attachments: image001.png, image003.png

Sorry no

From: Fennelly, Kevin (NIH/NHLBI) [E] (b) (6)>
Sent: Thursday, February 27, 2020 9:02 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: invitation to speak on COVID 19 at the International ATS Conference in May

Dear Dr. Fauci,

I don't believe that we've formally met, but I have seen you frequently on 5SE as I admit patients there and often participate in the ward rounds. I am an AI on several of Steve Hollands protocols, and I often help with the drug-resistant TB cases. I have been at the NIH now for over 4 years, although I still feel like the new guy on the block! Most of my career has been focused on quantifying the infectious aerosols generated by TB patients. I am very involved in the leadership of the American Thoracic Society (ATS) as the Past Chair of the Assembly on Pulmonary Infections and TB. I am writing to invite you to be a keynote speaker at a special Scientific Session being added to our International Conference May 16-20 due to the emerging pandemic of COVID-19. The exact time and data are not yet known, but the conference is relatively close in Philadelphia. This would be an opportunity to address and educate global academic leaders in pulmonary and critical medicine, infectious diseases, and public health. We usually have over 15,000 attendees at the ATS meeting. I am attaching the email string below to give you an idea of other speakers being considered.

I can only imagine how busy you must be now, so I apologize if this invitation is a distraction or a nuisance. And I would certainly understand if you are unable to join us given the demands on your time, but we would be absolutely delighted if you could speak.

Please feel to call or contact me at any time with questions or comments.

Sincerely,
Kevin Fennelly
Mobile (b) (6)

Kevin P Fennelly, MD, MPH, ATSF
Senior Research Clinician
Laboratory of Chronic Airway Infection
Pulmonary Branch
Division of Intramural Research
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)

Building 10, Room 5-1421
10 Center Drive
Bethesda, MD 20892

From: Saukkonen, Jussi J [redacted] (b) (6)>
Sent: Wednesday, February 26, 2020 7:15 PM
To: Dela Cruz, Charles [redacted] (b) (6)>
Cc: Kristina Crothers [redacted] (b) (6)>; Nahid, Payam [redacted] (b) (6); Saukkonen, Jussi < [redacted] (b) (6)>; Maria Novozhilova [redacted] (b) (6); Miriam Rodriguez [redacted] (b) (6); Fennelly, Kevin (NIH/NHLBI) [E] [redacted] (b) (6) Hicks, Lauri (CDC/DDID/NCEZID/DHQP) [redacted] (b) (6) Evans,Scott [redacted] (b) (6)>; Yeligar, Samantha [redacted] (b) (6) McGinniss, John E [redacted] (b) (6)>
Subject: Re: PI-TB Executive Committee Call

This looks like a great program. Hope you can get these speakers who will be in demand.

> On Feb 26, 2020, at 2:44 PM, Dela Cruz, Charles [redacted] (b) (6) wrote:
>
> Thank you all for your great suggestions...
>
> Here is a possible Agenda for the Special Session on Coronavirus.
> Ideally, we should have some ATS attendees to be speakers. If anyone knows possible candidate, please let us know. I also know that ATS would like to encourage some high profile speakers if possible. Someone from CDC, NIAID, etc.
>
> Please let us know additional suggestions.
> I highlighted bold are possible speakers.
> We will need to wait until the ATS BOD this week to get the go ahead to invite the speakers.
>
> ---
>
> [redacted] (b) (4)

(b) (4)

[redacted]

[redacted] (b) (4)

Charles S. Dela Cruz, MD, PhD
Associate Professor
Section of Pulmonary, Critical Care and Sleep Medicine
Department of Internal Medicine
Department of Microbial Pathogenesis
Director, Center of Pulmonary Infection Research and Treatment (CPIRT)
Yale University
300 Cedar Street TAC S441-D
New Haven, CT 06513
Phone: [redacted] (b) (6)
FAX: 203 785-5952

Email: [redacted] (b) (6)
Faculty profile: http://medicine.yale.edu/intmed/pulmonary/people/charles_delacruz.profile
Lab website: http://medicine.yale.edu/lab/delacruz/index.aspx
CPIRT website: cpirt.yale.edu

<image001.png>
<image003.png>

From: "Crothers, Kristina" <[redacted] (b) (6)
Date: Tuesday, February 25, 2020 at 8:52 PM
To: "Saukkonen, Jussi J" [redacted] (b) (6)>, "Nahid, Payam" [redacted] (b) (6)
Cc: "Dela Cruz, Charles' [redacted] (b) (6) "Saukkonen, Jussi" [redacted] (b) (6)>, Maria Novozhilova <[redacted] (b) (6), " [redacted] (b) (6) >, "Kevin P. Fennelly, MD" [redacted] (b) (6)>, [redacted] (b) (6) >, adam meyer <[redacted] (b) (6) >, Scott Evans [redacted] (b) (6)>, "Yeligar, Samantha M." <[redacted] (b) (6) [redacted], "McGinniss, John E"

[redacted] (b) (6)>
Subject: Re: PI-TB Executive Committee Call

Hi - these are great suggestions. [redacted] (b) (4)

(b) (4) [redacted]

Kristina

From: Saukkonen, Jussi J [redacted] (b) (6)
Sent: Tuesday, February 25, 2020 9:02:43 AM
To: Nahid, Payam
Cc: Dela Cruz, Charles; Saukkonen, Jussi; Crothers, Kristina; Maria Novozhilova; Miriam Rodriguez; [redacted] (b) (6); Kevin P. Fennelly, MD; [redacted] (b) (6) [redacted]; Evans,Scott; Yeligar, Samantha M.; [redacted] (b) (6); McGinniss, John E
Subject: Re: PI-TB Executive Committee Call

These would be excellent speakers to also try to get!

> On Feb 25, 2020, at 11:50 AM, Nahid, Payam [redacted] (b) (6) wrote:
>
> Agree, these are excellent suggestions. An FYI below on what CROI has assembled for ad hoc session on COVID-19:

(b) (4)

[redacted]

>
> --
> Payam Nahid, MD, MPH
> Professor of Medicine
> University of California, San Francisco
> Associate Director, Clinical Trials Operations, UCSF Office of Research
> Medical Director, UCSF CTSI Trials Innovation Network (TIN)
> Director, UCSF Center for Tuberculosis (http://tb.ucsf.edu)

UCSF Center for Tuberculosis | UCSF Center for TB

tb.ucsf.edu

>
> Zuckerberg San Francisco General Hospital
> Division of Pulmonary & Critical Care Medicine
> 1001 Potrero Avenue, Room 5K1
> San Francisco, CA 94110
> Email: [redacted] (b) (6)
> UCSF Profile: http://profiles.ucsf.edu/payam.nahid

Payam Nahid | UCSF Profiles

profiles.ucsf.edu

Payam Nahid's profile, publications, research topics, and co-authors

> Tel: [redacted] (b) (6)
> Pronouns: he, him, his

>
>
>
> On 2/25/20, 6:47 AM, "Dela Cruz, Charles" [redacted] (b) (6) wrote:
>
> Thanks Jussi for your great suggestions. We will try to incorporate these into the final session.
> Much appreciated
> Charles
>
>
>
> ---
> Charles S. Dela Cruz, MD, PhD
> Associate Professor
> Section of Pulmonary, Critical Care and Sleep Medicine
> Department of Internal Medicine
> Department of Microbial Pathogenesis
> Director, Center of Pulmonary Infection Research and Treatment (CPIRT)
> Yale University
> 300 Cedar Street TAC S441-D
> New Haven, CT 06513
> Phone: [redacted] (b) (6)
> FAX: 203 785-5952
>
> Email: [redacted] (b) (6)
> Faculty profile: https://urldefense.proofpoint.com/v2/url?u=http-3A__medicine.yale.edu_intmed_pulmonary_people_charles-5Fdelacruz.profile&d=DwIGaQ&c=iORugZls2LlYyCAZRB3XLg&r=XoHvlYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVInTNd--DXvFYATIjFpvUftbDe3o4&s=XbJr53zMi1g0yYn-iXh9t9_vBPfjcNC8h-jRJ2lihVk&e=

Charles Dela Cruz, MD, PhD < Pulmonary, Critical Care and Sleep Medicine

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine

and is currently an Associate
Professor at Yale University in the

> Lab website: https://urldefense.proofpoint.com/v2/url?u=http-3A__medicine.yale.edu_lab_delacruz_index.aspx&d=DwIGaQ&c=iORugZls2LlYyCAZRB3XLg&r=XoHvlYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVInTNd--DXvFYATIjFpvUftbDe3o4&s=F7cVzfOPw5tmgLz95Y984or0dPHCoEYBNsv_iP7GA2g&e=

Dela Cruz Lab

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Assistant Professor at Yale University in the

> CPIRT website: cpirt.yale.edu
>
>
>
>
> On 2/25/20, 9:34 AM, "Saukkonen, Jussi" [redacted] (b) (6) wrote:
>
> Great!

(b) (4)

[redacted]

(b) (4)

[redacted]

First US MERS-CoV Cases Underscore Need for Preparedness | Global Health | JAMA | JAMA Network

urldefense.proofpoint.com

Confirmation of the first 3 US cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection highlighted the importance of preparedness plans and infection control policies for hospitals and other facilities in dealing with a potentially dangerous infectious disease.

>

(b) (4)

[redacted]

2019 Novel Coronavirus—Important Information for Clinicians | Global Health | JAMA | JAMA Network

urldefense.proofpoint.com

This Viewpoint summarizes the epidemiology and clinical features of 2019-nCoV infection and reviews CDC criteria to guide evaluation and management of patients with possible infection.

(b) (4)

[redacted]

[redacted] (b) (4)

> -----Original Message-----
> From: Dela Cruz, Charles [redacted] (b) (6)
> Sent: Monday, February 24, 2020 9:49 PM
> To: Crothers, Kristina [redacted] (b) (6)>; Maria Novozhilova [redacted] (b) (6)>
> Cc: Miriam Rodriguez [redacted] (b) (6) Kevin P. Fennelly, MD [redacted] (b) (6)>; Nahid, Payam [redacted] (b) (6) [redacted]; Evans,Scott [redacted] (b) (6)>; Yeligar, Samantha M. [redacted] (b) (6) [redacted]; Saukkonen, Jussi [redacted] (b) (6) McGinniss, John E [redacted] (b) (6)
> Subject: [EXTERNAL] Re: PI-TB Executive Committee Call
>
> Dear colleagues
>
> Hope all is well.
>
> As part of ATS 2020 in May, PITB Programming has been requesting to see if there would be a venue for a coronavirus session.
>
> The ICC chair and ATS was able to seek out a possible forum for a Special Session on Coronavirus on the Monday Afternoon during ATS.
>
> Payam and I have been discussing a possible session title, content and speakers.
>
> The session title could be --
>

[redacted] (b) (4)

[redacted] (b) (4)

>
> Many thanks
> Charles
>
>
> --
> Charles S. Dela Cruz, MD, PhD
> Associate Professor
> Section of Pulmonary, Critical Care and Sleep Medicine Department of Internal Medicine Department of Microbial Pathogenesis Director, Center of Pulmonary Infection Research and Treatment (CPIRT) Yale University
> 300 Cedar Street TAC S441-D
> New Haven, CT 06513
> Phone: [redacted] (b) (6)
> FAX: 203 785-5952
>
> Email: [redacted] (b) (6)
> Faculty profile: https://urldefense.proofpoint.com/v2/url?u=https-3A__nam05.safelinks.protection.outlook.com_-3Furl-3Dhttp-253A-252F-252Fmedicine.yale.edu-252Fintmed-252Fpulmonary-252Fpeople-252Fcharles-5Fdelacruz.profile-26amp-3Bdata-3D02-257C01-257Ccharles.delacruz-2540yale.edu-257C07f45f4dbd774f4a3dcc08d7b9ffc1d2-257Cdd8cbebb21394df8b4114e3e87abeb5c-257C0-257C0-257C637182380425442155-26amp-3Bsdata-3DQWWL8cD0cYtHaxgilDZfU7dywmTyCbpP54blOO2RpHs-253D-26amp-3Breserved-3D0&d=DwIGaQ&c=iORugZls2LlYyCAZRB3XLg&r=XoHvlYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVInTNd--DXvFYATIjFpvUftbDe3o4&s=TVWeA9SztUxTEK8J5yHFcOkt3CyArZWDsYQDZPgeuEQ&e=

Charles Dela Cruz, MD, PhD < Pulmonary, Critical Care and Sleep Medicine

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Associate Professor at Yale University in the

> Lab website: https://urldefense.proofpoint.com/v2/url?u=https-3A__nam05.safelinks.protection.outlook.com_-3Furl-3Dhttp-253A-252F-252Fmedicine.yale.edu-252Flab-252Fdelacruz-252Findex.aspx-26amp-3Bdata-3D02-257C01-257Ccharles.delacruz-2540yale.edu-257C07f45f4dbd774f4a3dcc08d7b9ffc1d2-257Cdd8cbebb21394df8b4114e3e87abeb5c-257C0-257C0-257C637182380425442155-26amp-3Bsdata-3DaUEJSTgiaCXmTQiuAB0K0YrMiqFxdd2HiPhGuq8Psig-253D-26amp-3Breserved-3D0&d=DwIGaQ&c=iORugZls2LlYyCAZRB3XLg&r=XoHvlYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVInTNd--DXvFYATIjFpvUftbDe3o4&s=s6rnKnYIqiuUr8OlI_HRKyYFhvJwdc4_t9rmpZzqixY&e=

Dela Cruz Lab

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Assistant Professor at Yale University in the

> CPIRT website: cpirt.yale.edu
>
>
>

>
> On 2/22/20, 7:47 PM, "Crothers, Kristina" <[redacted] (b) (6)wrote:
>
> Hi all - we need to reschedule the call as both Rachel and I will be traveling to the ATS board meeting next Wednesday. Please let me and Maria know if you could join a call Wednesday March 4 at 4pm eastern instead.
> Kristina
>
> Sent from my iPhone
>
>> On Feb 21, 2020, at 12:20 PM, Maria Novozhilova [redacted] (b) (6)> wrote:
>>
>>
>> <PI-TB Executive Committee Call>
>
> ________________________________
>
> Privileged, confidential or patient identifiable information may be contained in this message. This information is meant only for the use of the intended recipients. If you are not the intended recipient, or if the message has been addressed to you in error, do not read, disclose, reproduce, distribute, disseminate or otherwise use this transmission. Instead, please notify the sender by reply e-mail, and then destroy all copies of the message and any attachments.
>
>
>
>
>
>

CPIRT

NIH-001207

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:21:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Invitation to Spanih meeting

RSVP sorry no.

From: Jose Alcami Pertejo <ppalcami@isciii.es>
Sent: Thursday, February 27, 2020 10:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Jose Alcami Pertejo <ppalcami@isciii.es>
Subject: Invitation to Spanih meeting

Dear Dr Fauci,

Hope this mail finds you well. We had the opportunity to meet in Madrid during the R4P meeting. I was the local chair of the Conference and had the privilege of introducing your talk to the plenary.

I would like to invite you as plenary speaker to the meeting of the Spanish AIDS Society (GESIDA) that will take place in Málaga, Spain next 30th November 2020. GESIDA Congress is the most important HIV national meetings in Spain that brings together the full "HIV Community" including clinicians, basic researchers, experts in epidemiology and public health and member from NGOs and patients' associations. Overall 700 attendees are expected to come to the meeting.

We would love to have you as a speaker in the Opening Plenary Session in evening the 30th November. Your challenging articles regarding the strategies to end the HIV epidemic in the United States, will be a great topic to be addressed in such session and an inspiration to Spanish researchers. If you prefer to talk about a different topic as the co-morbidities scenario in HIV infection it will be welcome too.

We would be more than happy if you could participate in this meeting.

If know your agenda is always full, even more these days with the current Coronavirus outbreak, but if you could accept this invitation I think this can represent a real boost in the fight against HIV epidemics in Spain, a field in which the Spanish AIDS Society is strongly committed.

It would we wonderful if we can have you as a speaker.

Best wishes

Jose Alcamí

************************* AVISO LEGAL ************************* Este mensaje electrónico está dirigido exclusivamente a sus destinatarios, pudiendo contener documentos anexos de carácter privado y confidencial. Si por error ha recibido este mensaje y no se encuentra entre los destinatarios, por favor no use, informe, distribuya, imprima o copie su contenido por ningún medio. Le rogamos lo comunique al remitente y borre completamente el mensaje y sus anexos. El Instituto de Salud Carlos III no asume ningún tipo de responsabilidad legal por el contenido de este mensaje cuando no responda a las funciones atribuidas al remitente del mismo por la normativa vigente.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:13:52 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: David Rubenstein's invitation to Dr. Fauci

I always like to do things with David Rubenstein

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Thursday, February 27, 2020 12:19 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: David Rubenstein's invitation to Dr. Fauci

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mary Brady <MBrady@economicclub.org>
Sent: Wednesday, February 26, 2020 6:07 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: [redacted] (b) (6); Judi Irastorza <Judi.Irastorza@economicclub.org>
Subject: David Rubenstein's invitation to Dr. Fauci

Patricia,

David Rubenstein asked that we reach out to you in an effort to schedule an Economic Club of Washington event that would feature Dr. Fauci in a conversation with David on COVID-19. It is my understanding that David had a similar interview with Dr. Fauci in the last week or so.

Below are several dates from David's calendar for your consideration.

Wednesday, April 22 – Breakfast

Tuesday, April 28 – Breakfast or lunch
Tuesday, May 5 – Breakfast or Lunch
Friday, May 15 – Lunch

Additionally, I have attached an invitation letter from Mr. Rubenstein to Dr. Fauci for your convenience. The Economic Club has the ability to turn around an event in a relatively short period of time. As you may recall, our events typically take place at breakfast, lunch or dinner, at downtown Washington, D.C. hotels. Events that feature a prominent world leader, such as Dr. Fauci, generally attract a select audience of over 500 members and guests from among Washington's business and government leaders, as well as the diplomatic corps.

We understand the complexities and constraints of Dr. Fauci's schedule and can be responsive to his needs. If none of the dates above work with Dr. Fauci's schedule, please suggest some that will and we will work with David to confirm a date and begin the process. I have copied Judi Irastorza, who I believe you have worked with in the past, and she will coordinate anything you need.

Sincerely,
Mary

Mary C. Brady
Executive Director
The Economic Club of Washington, D.C.

1601 K Street NW, Suite 210, Washington, DC 20006
Office: (202) 481-3260 | Mobile: [redacted] (b) (6)
mbrady@economicclub.org

Our Sponsors | www.EconomicClub.org
@TheEconomicClub | LinkedIn | YouTube

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:10:35 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Invitation to join Scientific Advisory Board

Please handle.

From: Ajay Gupta [redacted] (b) (6)>
Sent: Thursday, February 27, 2020 1:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Invitation to join Scientific Advisory Board

Hi Dr. Fauci,

just a quick question. [redacted] (b) (4)

thanks,

Ajay

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Monday, February 17, 2020 at 3:59 AM
To: Ajay Gupta [redacted] (b) (6)
Subject: RE: Invitation to join Scientific Advisory Board

Thanks for the note. My position in the US Government does not allow me to join such Boards.

From: Ajay Gupta <[redacted] (b) (6)>
Sent: Sunday, February 16, 2020 10:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Invitation to join Scientific Advisory Board

Dear Dr. Fauci,

By way of this email, I would like to introduce our new biotech company based in California, Celestial Therapeutics Inc.

[redacted] (b) (4)

[redacted] (b) (4)

We would like to extend an invitation to you to join our company's Scientific Advisory Board.

Please see attached herewith the executive summary and a slide deck of our company.

Thanks and looking forward to hearing from you shortly.

Best regards,

Ajay Gupta, Ph.D.
President, Chairman & CEO
Celestial Therapeutics Inc.
Tel: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:07:36 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Lack of preparedness for the coronavirus pandemic

FYI. Does this deserve a response.

From: Nejat Duzgunes [redacted] (b) (6)
Sent: Thursday, February 27, 2020 1:55 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)>
Cc: Nejat Duzgunes [redacted] (b) (6)
Subject: Lack of preparedness for the coronavirus pandemic
Importance: High

Dear Dr. Collins and Dr. Fauci,

I am sorry to say that our lack of preparedness for the coronavirus pandemic has its roots in the way biomedical research is funded in the United States, as well as in the lack of leadership and vision on the part of NIH and its institutes since the SARS coronavirus outbreak in 2003. I try to expand on these problems in the article below. I would welcome your response to my thesis.

Sincerely,

Nejat Düzgüneş, Ph.D.
Professor of Microbiology
Department of Biomedical Sciences
Arthur A. Dugoni School of Dentistry
University of the Pacific
155 Fifth Street, Room 412
San Francisco, CA 94103
[redacted] (b) (6)

UNIVERSITY OF THE
PACIFIC
Arthur A. Dugoni
School of Dentistry

The Wuhan Coronavirus (COVID-19): Why there is no cure or vaccine

In their *Medical Virology* text published in 1994, D.O. White and F.J. Fenner stated "No convincing evidence has yet been obtained to link human coronaviruses with serious disease ..., but they are an important cause of that trivial but annoying disease, the common cold." This generalization changed drastically with the emergence of the severe acute respiratory syndrome coronavirus in 2002-2003 (SARS-CoV), and the National Institutes of Health (NIH) immediately sought the expertise of these two scientists at the time. *Now, 17 years later, we still do not have an antiviral medicine or a vaccine against the novel coronavirus* that originated in China, now designated as COVID-19 by the World Health Organization (WHO). On February 21, there were 75,567 cases and 2,239 deaths in China; and 1,152 cases outside China, with 8 deaths, according to the Director-General of the WHO. The two viruses appear to use the same gate (or "receptor") on host cells to infect them. Despite such expected similarities between new and old strains of the virus, research on coronaviruses has not been a priority for the National Institute of Allergy and Infectious Diseases (NIAID). In the end, all that the Director of NIAID was able offer is "good healthcare" as a remedy for COVID-19 infections.

The major reason we do not have a cure for coronaviruses is that there has been no coordinated effort by the NIAID to establish long-term research programs focused on coronaviruses. Realizing the insufficient progress in this area, the NIAID announced on February 6 a "Notice of Special Interest to highlight the urgent need for research on the 2019 novel Coronavirus." Grants have indeed been awarded to some scientists since 2003, but such grants are highly competitive, with success rates of applications to NIAID between 14 and 18%, indicating that 82-86% of applicants are unable to obtain funding to carry out research. The *time* and *effort* spent on preparing grant applications to NIH are enormous, diverting these precious resources from actual research to what some scientists call "grantsmanship" (essentially, the ability to sell your idea to a review committee!). These "games scientist play" to procure funding are a hindrance to the progress of science. *The fact that we do not have a cure or a vaccine against coronaviruses over the past 17 years since the SARS epidemic, attests to this detrimental effect*.

Development of a vaccine against COVID-19t is also not straightforward. SARS was probably not considered by NIH to be an important pathogen on which to spend resources. Even if the biomedical research community had developed a vaccine against coronaviruses, pharmaceutical companies would probably not have considered it a profitable endeavor. *Therefore, it is essential for public funds to be used by NIH and the CDC to both discover an effective vaccine and to manufacture it.*

We need to ensure that long-term projects to develop antivirals and vaccines against coronaviruses and other infectious agents, including tuberculosis and influenza virus, are implemented and fully funded. *We need to have a funding system that does not depend on the often unfounded criticism or whims of grant reviewers*. Although the current peer review system is touted generally as the best way to allocate funding, *it has never been tested scientifically* against an alternative. While half of the NIH budget (currently $39 billion) may still be allocated for high-cost projects, including clinical trials, the other half should be awarded for periods of 10 years or longer to established scientists who have a track-record of scientific work, as well as to young scientists who are starting their first independent position. The budgets of these grants would be somewhat limited, but would provide uninterrupted funding and alleviate the stress of competing for renewals every 3–5 years. Scientists opting for these grants will not have to submit extensive grant applications. *More importantly, this system will more than double the number of independent investigators*. After a 10-12 year period, the scientific productivity (*per grant dollar*) of scientists on the classical grant system would be compared with that of scientists on long-term funding. *After all, the way we choose the mode of science funding should conform to the way science progresses, by experimentation and analysis*.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:05:11 +0000
To: Robert Durr
Subject: RE: Covid-19

We will be looking at this.

From: Robert Durr [redacted] (b) (6)
Sent: Thursday, February 27, 2020 2:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Covid-19

Dr. Fauci,
This may be terribly simplistic, but if Covid-19 binds to ACE2 receptors in host cells, has anyone looked at ACE2 receptor blockers as potentially ameliorating disease severity or infectivity?
Sincerely,
Robert Alan Durr, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:04:26 +0000
To: HMS-Faculty Affairs Senior Appointments
Subject: RE: Confidential Evaluation Request on behalf of Harvard Medical School Dean George Q. Daley, MD, PhD [redacted] (b) (6)

Dear Dr. Cotti:
I am very sorry, but I just do not have time to do this right now. I am inundated 24/7 with coronavirus issues. I hope thatyou understand.
Best regards,
Tony

From: HMS-Faculty Affairs Senior Appointments <FacultyAffairs_SeniorAppointments@hms.harvard.edu>
Sent: Thursday, February 27, 2020 1:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Cotti, Dagmara <Dagmara_Cotti@hms.harvard.edu>; Tekleab, Sarah <Sarah_Tekleab@hms.harvard.edu>
Subject: Confidential Evaluation Request on behalf of Harvard Medical School Dean George Q. Daley, MD, PhD – [redacted] (b) (6)

Dear Dr. Fauci,

Harvard Medical School is currently considering [redacted] (b) (6)

Attached is a letter from George Q. Daley, MD, PhD, Dean of the Faculty of Medicine at Harvard University and Caroline Shields Walker Professor of Medicine, requesting your evaluation of [redacted] (b) (6) academic accomplishments. The following materials are also attached: [redacted] (b) (6) curriculum vitae, an annotated bibliography of [redacted] (b) (6) self-selected 10 most significant scholarly works, and the criteria by which [redacted] (b) (6) qualifications are to be evaluated.

Please confirm receipt of this communication and let me know if you will be able to complete an evaluation. When composing your evaluation, please address the questions in Dean Daley's letter. We would greatly appreciate receiving letters of evaluation by **Thursday, March 26, 2020**. We are grateful for your time and expertise and we appreciate your consideration of this request.

Warm regards,
Dagmara

DAGMARA COTTI, PhD

Program Director for Academic Affairs

Harvard Medical School | **Office for Faculty Affairs**
Gordon Hall, 25 Shattuck Street, Suite 206 | Boston, MA 02115
office: 617.432.6889 | **fax:** 617.734.4382 | Hours: M-F 8:30am-4:00pm
fa.hms.harvard.edu
Executive Assistant: Sarah Tekleab
Sarah_Tekleab@hms.harvard.edu | **office:** 617.432.7438

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:57:45 +0000
To: HJ Mai
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Confirmation of report

This is really not true. It was taken vey much out of context.

From: HJ Mai <HMai@npr.org>
Sent: Thursday, February 27, 2020 2:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Confirmation of report

Dear Dr. Fauci,

This is HJ from NPR again. I was wondering if you could confirm a NYT report that says the White House has instructed you not to say anything about the coronavirus outbreak without prior approval.

Kind regards,
HJ

| HJ Mai | Editor, Morning Edition | hmai@npr.org | (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:54:23 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Idea for coronavirus contention

NIAID inquiries, Please

From: Blanco, Luz (NIH/NIAMS) [E] [redacted] (b) (6)>
Sent: Thursday, February 27, 2020 2:51 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Gottesman, Michael (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Idea for coronavirus contention
Importance: High

Dears Dr Collins, Dr Gottesman, and Dr. Fauci:
I am reaching to you with this idea that might sound weird but I think it might be helpful. I have this idea to reduce the coronavirus infection and spreading. It is very simple but can get more complex as well. [redacted] (b) (5)

[redacted] (b) (5). I do not have the capacity to work or promote these ideas but hopefully you have the power for doing so. Thanks, regards
Luz P. Blanco PhD.
Staff Scientist
SAB, NIAMS, NIH

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:54:22 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus : CONFIDENTIAL: [redacted] (b) (4) info
Attachments: image001.png, 2018_Book_UnderstandingTheHostImmuneResp.pdf, Advances in Clinical Chemistry 2018.pdf, BBASR-2016.pdf, Ch-22-francisandtaylor-2017.pdf, chapter-2012.pdf, GSH2005.pdf, HIVclinical trial2015.pdf, HIVclinical trial2017.pdf, macrophages2012.pdf, macrophages2013.pdf, NKCELLS2008.pdf, NKCELLS2012.pdf, RBC-HIV paper_2014.pdf

Please take a look at this.

-----Original Message-----
From: Parikh, Purvi [redacted] (b) (6)>
Sent: Thursday, February 27, 2020 10:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Coronavirus : CONFIDENTIAL: [redacted] (b) (4) info

Hi Dr Fauci
You must be swamped with coronavirus related correspondence but wanted to pass on some research that may prove helpful with coronavirus.

This pharmacist also plans to meet with Trump administration in upcoming weeks .

It may prove useful. I havent had a chance to dive deeply into the science of it so dont know efficacy but they are preparing a proof concept.

Main researcher is Nayan Patel and his email is [redacted] (b) (6)

Sincererely,

Purvi Parikh, M.D., FACP
Allergy/Immunology Attending Physician
Clinical Assistant Professor, Department of Medicine and Department of Pediatrics Division of Infectious Diseases and Immunology Division of Rheumatology Allergy and Asthma Associates of Murray Hill
212-685-4225 (office number)
212-696-5682 (fax)

From: Purvi Parikh [redacted] (b) (6)>
Sent: Thursday, February 27, 2020 9:43:18 PM
To: Parikh, Purvi
Subject: Fwd: CONFIDENTIAL: [redacted] (b) (4) info

[EXTERNAL]

Sent from my iPhone

Begin forwarded message:

From: Heather Pixton (b) (6)>
Date: February 3, 2020 at 12:43:59 PM EST
To: (b) (6)
Subject: FW: Fwd: CONFIDENTIAL: (b) (4) info

Hi Purvi,

Here is the email from Dr Patel with his research and other relevant PubMed links. The body of the email provides an idea of what he has been working on and how he hopes to contribute to the current outbreak.

I would be happy to connect Dr Patel with you (or someone you suggest) should you find the information provided warrants further inquiry.

Warm Regards,
Heather

Heather Pixton
CSO Pharmacology & Compliance I CABODI

[https://res.cloudinary.com/drasifo1s/image/upload/v1544910436/1130-cedrec/cell.jpg] <tel:+ (b) (6) (b) (6) I [https://res.cloudinary.com/drasifo1s/image/upload/v1544910437/1130-cedrec/mail.jpg] <mailto:Cedrec@SpectrumHP.com> Heather@CabodiCo.com<mailto:Heather@CabodiCo.com> I [https://res.cloudinary.com/drasifo1s/image/upload/v1544910436/1130-cedrec/web.jpg] http://www.bestefekt.com<https://urldefense.proofpoint.com/v2/url?u=http-3A__www.bestefekt.com_&d=DwMFaQ&c=j5oPpO0eBH1iio48DtsedeElZfc04rx3ExJHeIIZuCs&r=TxeKofMBvUAkTP9Z8swJDuMT3NwOKJuoZJ8jdtz5TG0&m=yoSwihtDq3ar56w9cqDSwhynOIH-OCP4NL4AZXwE63E&s=eCWhMiiUaJaCzK1mNZQpB21poltX9tSrIR2KsTm_RoI&e=>

[(b) (6)

From: Heather (b) (6)>
Sent: Monday, February 03, 2020 12:21 PM
To: Heather Pixton (b) (6)
Subject: FW: Fwd: CONFIDENTIAL: (b) (4) info

Sent from Mail<https://go.microsoft.com/fwlink/?LinkId=550986> for Windows 10

From: Cedrec Sumimoto<mailto: (b) (6)
Sent: Saturday, February 1, 2020 12:30 PM
To: Heather Pixton<mailto: (b) (6)>
Subject: Fwd: CONFIDENTIAL: (b) (4) info

(b) (6)

-------- Forwarded Message --------
Subject:

CONFIDENTIAL: (b) (4) info

Date:

Fri, 31 Jan 2020 15:25:40 -0800

From:

Nayan Patel [redacted] (b) (6)

To:

Cedrec Sumimoto < [redacted] (b) (6)

Hello Cedric,

[redacted] (b) (4)

[redacted] (b) (4)

Best Wishes,

[redacted] (b) (4)

CONFIDENTIALITY NOTICE: This e-mail message from Central Drugs (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review; use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message."

CABODI a'fekt A CABODI COMPANY

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:53:06 +0000
To: Leonard Schleifer
Cc: Erbelding, Emily (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Cassetti, Cristina (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Regeneron COVID-19 update

Len:
Thanks for the note. Of course, we would be interested in working with you as you develop these antibodies.
Best regards,
Tony

From: Leonard Schleifer [redacted] (b) (6)
Sent: Thursday, February 27, 2020 3:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Regeneron COVID-19 update

Tony,
Obviously you are swamped and the country is likely safer for it! I wanted to be sure you were up to date on our efforts re COVID-19. [redacted] (b) (4)
[redacted] (b) (4)
We have had discussions with our partners at BARDA and have had contact with the White House.
[redacted] (b) (4)
In the near future we will have a cocktail of antibodies ready for testing and we would be delighted to work with you and the NIH if that makes sense.
If you would like to discuss further, please call my cell [redacted] (b) (6) at anytime.

Len

** This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return electronic mail and permanently delete this email and any attachment hereto, any copy of this e-mail and of any such attachment, and any printout thereof. Finally, please note that only authorized representatives of Regeneron

Pharmaceuticals, Inc. have the power and authority to enter into business dealings with any third party.

****

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:42:11 +0000
To: Phillips, Kyra
Subject: RE: Confidential

Thanks, Kyra.

-----Original Message-----
From: Phillips, Kyra <Kyra.Phillips@abc.com>
Sent: Thursday, February 27, 2020 4:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Confidential

Dear Tony,
This note is between long time colleagues.
This entire Coronavirus story, and the handling of it, has really escalated into an unexpected journey. I want you to know how much I have respected you professionally and medically for nearly 20 years. I also want you to know that I have appreciated how we have communicated through the years about threats to our world's health and how honest and transparent you have always been. I know you are in a unique situation and I want you to know that I respect that and would never put you in a situation with my correspondence that would jeopardize you in anyway. With that said, I hope you can keep me informed, off the record if need be, so I can continue to cover this story honestly and fairly.
With utmost respect,
Kyra

@KyraPhillips
ABC News
Investigative Correspondent
KyraPhillips.Com
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:16:38 +0000
To: Alice Park
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Time follow up

Alice:
I am so sorry that I have not gotten back to you. I have been inundated 18 to 19 hours per day. By the time I get to e-mail it is late at night. I will try to connect with you tomorrow.
Best,
Tony

From: Alice Park <alice.park@time.com>
Sent: Thursday, February 27, 2020 5:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Time follow up

Hi -- do you have a few minutes to talk about the following? Happy to chat whenever you're free. Best, Alice

On Wed, Feb 26, 2020 at 11:50 AM Alice Park <alice.park@time.com> wrote:

> Hi Dr. Fauci -- have a couple of requests for you, one of which is to speak at our upcoming Time 100 Summit in April -- about COVID-19. I'll be sending a formal invite but wanted to explore your interest and availability.
>
> Also wanted to speak to you about a story I'm working on concerning the risk of community spread of COVID-19 in the US. Wanted to get your perspective on the CDC warning and where those cases might come from. Happy to chat whenever you're free; I'm relatively free today and this evening. Best, Alice
>
> **PLEASE NOTE NEW PHONE NUMBER**
> Alice Park
> TIME
> 212 522 9830
> alice.park@time.com
> @aliceparkny

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:49:34 +0000
To: Suzanne Bradley
Subject: RE: URGENT

There is much misinformation. I actually have not been muzzled at all by the Vice President. And BTW, it is safe to fly domestically (b) (6).

-----Original Message-----
From: Suzanne Bradley (b) (6)>
Sent: Thursday, February 27, 2020 5:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: URGENT

Dear Dr. Fauci,

I understand Vice President Pence has ordered you to not inform the public about Coronavirus without approval. This is quite terrifying, especially since Trump has already shown his desire to spread false or incomplete information about this public health crisis.

I'm planning to fly domestically TOMORROW (b) (6). Is it safe??

Thank you,

Suzanne Bradley

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:46:07 +0000
To: NIAID OD AM
Subject: FW: question

Let us discuss, but almost certainly no.

From: Fleisher, Thomas (NIH/CC/DLM) [V] (b) (6)>
Sent: Thursday, February 27, 2020 5:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Lang, David <LANGD@ccf.org>; Kay Whalen <KWhalen@aaaai.org>; Rebecca Brandt (AAAAI) <rbrandt@aaaai.org>
Subject: question

Tony,
As you are acutely aware, the COVID-19 situation is on everyone's mind and accordingly there have been questions raised by members of the AAAAI about what the organization can do to provide more guidance in this evolving situation. In light of this linked to the fact that our annual meeting begins March 13 in Philadelphia, we have made the decision to have a 45-60 minute session in the main hall on Saturday (March 14) morning from 7:00-8:00 prior to the scheduled plenary session slated to start at 8:15. My question is whether you would consider taking the Acela up Friday evening returning Saturday morning to host this session with a presentation followed by a Q&A session. If that is not possible, would you be willing to provide a 10-15 minute (shorter if you deem that appropriate) video generated as close to the 14th as possible that we would have projected in the main hall as noted above. If the latter, would you have a suggestion of an ID person in Philadelphia who would be knowledgeable and could field questions following your video. I recognize that even if you are willing to come to Philadelphia, that circumstances could arise that would preclude your traveling in which case we would ask for a video if at all possible. Finally, if neither option is possible, is there somebody in DC (including NIH), Baltimore or Philadelphia who could provide the short review and then sit for 30-45 minutes of Q&A. I am well aware that this is last minute and you have been incredibly busy with issues related to the pandemic, any help you could provide would be much appreciated by my colleagues and me.
Regards,
Tom

Thomas A. Fleisher, M.D.
Scientist Emeritus
Department of Laboratory Medicine
NIH Clinical Center
Bethesda, MD 20892
(b) (6) (tel)
301-402-1612 (fax)

The contents of this message, together with any attachments, are intended only for the use of the person(s) to which they are addressed and may contain confidential and/or privileged information. Further, any medical information herein is confidential and protected by law. It is unlawful for unauthorized persons to use, review, copy, disclose, or disseminate confidential medical information. If you are not the intended recipient, immediately advise the sender and delete this message and any attachments. Any distribution, or copying of this message, or any attachment, is prohibited.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:43:32 +0000
To: NIAID OD AM
Subject: FW: Invitation to speak at National Academies workshop
Attachments: FMT Vaccines SOT 12.20.pdf

Let us discuss.

From: Pavlin, Julie <JPavlin@nas.edu>
Sent: Thursday, February 27, 2020 6:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Invitation to speak at National Academies workshop

Dear Dr. Fauci,

It is my pleasure to invite you to present at the National Academies of Sciences, Engineering, and Medicine workshop on "The Critical Public Health Value of Vaccines – Tackling Issues of Access and Hesitancy." This workshop will be held on May 28-29, 2020 at the Pan American Health Organization (PAHO) headquarters in Washington, DC. The statement of task for the workshop is attached.

The 1.5-day workshop will provide a venue to examine the current state of vaccine preventable diseases and the impact of vaccine access and hesitancy on vaccine preventable diseases globally, as well as the multidimensional drivers and impacts of declining vaccine confidence. This workshop will explore health systems, research opportunities, communication strategies, and policies that could be considered to address access, perceptions, attitudes, and behaviors toward vaccination. The workshop will be broadcast live over the web to an international audience, and is being hosted by the National Academies' Forum on Microbial Threats.

Due to your in-depth expertise in this field, we would like to invite you to give a plenary presentation on **the development of new vaccines in the midst of an outbreak, specifically on the prospects of a coronavirus vaccine**. The primary audience for the event will be researchers, health practitioners, industry leaders, and policy makers in infectious diseases and global health, so we are looking to initiate this workshop with relevant discussions of barriers to accessing vaccines. Your responsibilities would be to prepare and deliver a 15-minute presentation. We would cover your travel expenses in accordance with U.S. federal government rules. We would be thankful to have your involvement in this workshop. Please let me know if you might be interested. I would be happy to answer any questions you may have.

Thank you in advance for your time and consideration. We understand that this is a very busy time and your calendar may be in flux.
Best wishes,
Julie
Julie A. Pavlin, MD, PhD, MPH
Director, Board on Global Health
Health and Medicine Division – Find us at nationalacademies.org/HMD
The National Academies of Sciences, Engineering, and Medicine

500 Fifth Street, NW
Washington, DC 20001
Phone: 202-334-2171

Follow Us

The National Academies of
SCIENCES · ENGINEERING · MEDICINE

==============

ORGANIZING COMMITTEE – THE CRITICAL PUBLIC HEALTH VALUE OF VACCINES – TACKLING ISSUES OF ACCESS AND HESITANCY
HEIDI LARSON (Co-Chair)**,** Professor of Anthropology, Risk and Decision Science, London School of Hygiene & Tropical Medicine
MATTHEW ZAHN (Co-Chair)**,** Medical Director, Division of Epidemiology and Assessment, Orange County Health Care Agency
KEVIN ANDERSON, Senior Program Manager, Chemical & Biological Defense Division, Science & Technology Directorate, Department of Homeland Security
ALISON BUTTENHEIM, Associate Professor, Family and Community Health, School of Nursing, University of Pennsylvania
ANDREW CLEMENTS, Deputy Director, Pandemic Influenza and Other Emerging Threats Unit, USAID
AMANDA COHN, Executive Secretariat, Advisory Committee on Immunization Practices, US Centers for Disease Control and Prevention
PETER DASZAK, President, EcoHealth Alliance
EVA HARRIS, Professor and Director, Division of Infectious Diseases and Vaccinology, Center for Global Public Health, University of California, Berkeley
ELIZABETH D. HERMSEN, Head, Global Antimicrobial Stewardship, Merck & Co., Inc.
NONI MACDONALD, Professor, Department of Pediatrics, Dalhousie University, Nova Scotia, Canada
WALT ORENSTEIN, Professor and Associate Director, Emory Vaccine Center

==============

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:42:42 +0000
To: Jon Cohen
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Interview request--typo fixed

Jon:
I am drowning right now. However, I am always happy to speak with you. Cannot do it until I dig out from under. Hopefully, soon.
Best,
Tony

-----Original Message-----
From: Jon Cohen <jcohen@aaas.org>
Sent: Thursday, February 27, 2020 5:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Interview request--typo fixed

Dr. Fauci,

I was most pleased to hear Sec. Azar's commitment to "radical transparency." In that vein, I would like to interview you about COVID-19 for a Science magazine article I am preparing.

Thanks in advance,

Jon Cohen
Science

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:32:50 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

That is not what I said. I said for SARS the virus went from bat to civet cat to human; for MERS it went from bat to camel to human. I said we did not know what the animal reservoir was for the jump from animal to human with the novel coronavirus. Please tell her that. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, February 27, 2020 7:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6) Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Q from Donna Young re comments In VP pool report:

> Do they now know the novel coronavirus jumped from a bat to a civet cat [skunk] served at feasts in China and then jumped to humans?
> Is that the source for certain? Or was he just giving an example? Is there something you can provide to show that information?

From: "Young, Donna" <Donna.Young@spglobal.com>
Date: Thursday, February 27, 2020 at 7:01:00 PM
To: "Billet, Courtney (NIH/NIAID) [E]" < [redacted] (b) (6)
Cc: "Stover, Kathy (NIH/NIAID) [E]" [redacted] (b) (6)>, "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>, "Myles, Renate (NIH/OD) [E]" [redacted] (b) (6)
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Thank you. Also, can you please clarify what was in the VP pool report today.

Do they now know the novel coronavirus jumped from a bat to a civet cat [skunk] served at feasts in China and then jumped to humans?
Is that the source for certain? Or was he just giving an example? Is there something you can provide to show that information?

Thank you again.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna.young@spglobal.com

301.216.2433 desk

[redacted] (b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

http://marketintelligence.spglobal.com/our-thinking/news.html

---

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, February 27, 2020 6:55 PM
To: Young, Donna <Donna.Young@spglobal.com>
Cc: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Myles, Renate (NIH/OD) [E] [redacted] (b) (6); Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Can you just attribute to NIAID spox? I ask because he's on meetings and calls..,,

---

From: "Young, Donna" <Donna.Young@spglobal.com>
Date: Thursday, February 27, 2020 at 6:52:48 PM
To: "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)>
Cc: "Stover, Kathy (NIH/NIAID) [E]" [redacted] (b) (6), "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>, "Myles, Renate (NIH/OD) [E]" [redacted] (b) (6)>
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Thank you. Is Dr. Fauci stating it is not true? Do I attribute to him or you stating the New York Times report is not true?

Thank you for your help.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna.young@spglobal.com

301.216.2433 desk

[redacted] (b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

http://marketintelligence.spglobal.com/our-thinking/news.html

---

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, February 27, 2020 6:39 PM
To: Young, Donna <Donna.Young@spglobal.com>
Cc: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Donna, so sorry, it's been a crazy day. We are not sure exactly where this came from. It's not true.

From: "Young, Donna" <Donna.Young@spglobal.com>
Date: Thursday, February 27, 2020 at 5:32:22 PM
To: "NIAID NEWS (NIH/NIAID)" [redacted] (b) (6)>, "Stover, Kathy (NIH/NIAID) [E]" [redacted] (b) (6)>, "Myles, Renate (NIH/OD) [E]" [redacted] (b) (6)>, "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Hi. I'm still waiting for a response on this. Could you at lest tell me me you are going to respond?

Thank you.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna.young@spglobal.com

301.216.2433 desk

[redacted] (b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

http://marketintelligence.spglobal.com/our-thinking/news.html

---

From: Young, Donna
Sent: Thursday, February 27, 2020 1:35 PM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Myles, Renate (NIH/OD) [E] [redacted] (b) (6); Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Good Day: Could you please comment on this report from the New York Times that Dr. Fauci has been told that he must clear anything he plans to say about the coronavirus outbreak with the White House before he speaks to any media?
https://www.nytimes.com/2020/02/27/us/politics/us-coronavirus-pence.html

"Dr. Anthony S. Fauci, one of the country's leading experts on viruses and the director of the National Institute of Allergy and Infections Diseases, told associates that the White House had instructed him not to say anything else without clearance."

Has Dr. Fauci or any other NIH official been told by the White House they cannot speak to the media unless cleared by the White House?

Please do let me know.

Thank you for your help.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna.young@spglobal.com

301.216.2433 desk

[redacted] (b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

http://marketintelligence.spglobal.com/our-thinking/news.html

---

The information contained in this message is intended only for the recipient, and may be a confidential attorney-client communication or may otherwise be privileged and confidential and protected from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, please be aware that any dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by replying to the message and deleting it from your computer. S&P Global Inc. reserves the right, subject to applicable local law, to monitor, review and process the content of any electronic message or information sent to or from S&P Global Inc. e-mail addresses without informing the sender or recipient of the message. By sending electronic message or information to S&P Global Inc. e-mail addresses you, as the sender, are consenting to S&P Global Inc. processing any of your personal data therein.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 00:47:19 +0000
To: Mark Zuckerberg
Subject: RE:

Mark:

Thanks for the note. If we start in April (~6-7 weeks from now) with a phase 1 trial of 45 subjects, it will take another 3-4 months to determine safety and some immunogenicity. The next step is phase 2 for efficacy. We may need help with resources for the phase 2 trial if we do not get our requested budget supplement. I believe that we will be OK. If this goes off track, I will contact you. Many thanks for the offer. Much appreciated.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mark Zuckerberg (b) (6)
Sent: Thursday, February 27, 2020 7:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject:

Tony:

I was glad to hear your statement that the covid-19 vaccine will be ready for human trials in six weeks. Are there any resources our foundation can help provide to potentially accelerate this or at least make sure it stays on track?

Mark

From: [redacted] (b) (6)
Sent: Thu, 27 Feb 2020 17:43:18 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Dr. Fauci--Coronavirus comment 3/2 Healthline MEDIA

Sent from my iPhone

Begin forwarded message:

> **From:** Kristen Fischer < [redacted] (b) (6)
> **Date:** February 27, 2020 at 5:20:21 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Dr. Fauci--Coronavirus comment 3/2 Healthline MEDIA**
>
> Hi there,
>
> I'm writing for Healthline about coronavirus and how the virus spread may be different in the Southern Hemisphere (they mention that in the story below). Care to weigh in?
>
> I'd love to know:
> 1. Will coronavirus be any less severe in the Southern Hemisphere due to the summer weather there at the moment?
> 2. Will the virus spread in North America slow down due to geography or warmer weather at all? What can we expect in 3 months--and in one year as far as coronavirus in the U.S.?
> 3. Will it differ in how it spreads/tapers off in Asia, due to proximity of the outbreak?
> 4. Will this eventually be gone or will it be something that is a new health threat that could return in a year or so?
> 5. Any insight into the outlook of coronavirus, how it will spread or how long it will be active?
>
> Looking for a brief email response by Monday morning at 10 a.m. Let me know if you can assist!
>
> Warmly,
> Kristen Fischer
>
> --
> Kristen Fischer
> www.kristenfischer.com
> (b) (6) [redacted]
>
> Find your family fun at the Jersey Shore--get yourfree weekly e-newsletter today!
> See your product or service Re-viewed by Kristen Fischer

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 16:29:44 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Covid-19--Conference Call Invitation

Let us discuss. Likely do not have time for this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Buono, Lucia <LBUONO@imf.org> **On Behalf Of** Gopinath, Gita
Sent: Wednesday, February 26, 2020 2:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Gopinath, Gita <GGopinath@imf.org>; Milesi-Ferretti, Gian Maria <GMILESIFERRETTI@imf.org>; Celasun, Oya <OCelasun@imf.org>; Nabar, Malhar Shyam <MNabar@imf.org>; Christiansen, Lone Engbo <LChristiansen@imf.org>; Buono, Lucia <LBUONO@imf.org>
Subject: Covid-19--Conference Call Invitation

On behalf of Ms. Gopinath:

Dear Professor Fauci:

We are contacting you in the context of the evolving spread of Covid-19, which is already impacting livelihoods and economic activity in several countries. As you may know, the IMF publishes forecasts of economic growth for member countries four times a year, as well as macroeconomic policy recommendations. In that context, it would be invaluable for us to hear public health experts' views on the likely trajectory of the virus—the number of people that are likely to get infected in different countries and the likely time path. We would also benefit from hearing experts' views on the optimal public health policy response in different types of countries (countries with stronger or weaker health systems, different development levels, etc.), and the implied resource needs.

We are planning to set up a conference call with several experts to discuss these issues and were wondering if you would be available to join us. If you would be interested in joining, would you be able to let my assistant Lucia Buono (lbuono@imf.org) know of some dates and times that would work for you this week or early next week?

We would be extremely grateful for any guidance you might be able to offer as we strive to do our part in helping member countries respond to the epidemic.

Best regards,

Gita Gopinath
Economic Counsellor and Director
Research Department
International Monetary Fund

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 13:31:19 +0000
To: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: The global health leaders call, Wednesday 4 March at 13:00 CET
Attachments: (b) (4) Swisscom Call code.pdf

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. (b) (6)>
Sent: Thursday, February 27, 2020 7:55 AM
To: Redfield, Robert R. (CDC/OD) (b) (6)
[redacted] Felicity Harvey
(b) (6) Chris.Elias
(b) (6); Jeremy Farrar
(b) (6); Fauci, Anthony
(NIH/NIAID) [E] (b) (6)
[redacted] Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>; Thomas R. Frieden (b) (6)
[redacted] Lynn Banks (b) (6); President | Resolve to Save Lives
<president@resolvetosavelives.org>; (b) (6)
[redacted]
Tarik Mohammed (b) (6)>
Cc: SHOC <shoc@who.int>; Office of the Director-General <DGOffice@who.int>; SCHWARTLANDER, Bernhard F. (b) (6)>; MAHJOUR, Jaouad (b) (6); FALL, Ibrahima Soce (b) (6)>; GREIN, Thomas (b) (6) MINHAS, Raman (b) (6); COX, Paul Michael (b) (6)>; AL-SHORBAJI, Farah (b) (6)>; POOLE, Marcia (b) (6); DRURY, Patrick Anthony (b) (6); GRAAFF, Peter Jan < (b) (6)>; Dr VAN KERKHOVE, Maria (b) (6); KABIR, Sophia

(b) (6)>; FARES, Christine Youssef (b) (6)
Subject: The global health leaders call, Wednesday 4 March at 13:00 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted on Wednesday, 4 March at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email: (b) (6) ; mobile no. (b) (6)

The agenda and background documents will be shared ahead of the call.

Best,

Mike

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:44:07 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: [EXTERNAL] RE: Hardball Tonight

FYI. (b) (6).

-----Original Message-----
From: Matthews, Chris (NBCUniversal, MSNBC) <kennedynixon@msnbc.com>
Sent: Wednesday, February 26, 2020 2:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: [EXTERNAL] RE: Hardball Tonight

When you can and are ready, I would love to have you on Hardball anytime in the 7pm hour tonight, tomorrow or Friday.

Sent from my iPhone

> On Feb 26, 2020, at 11:34 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> wrote:
>
> Chris:
> I am always happy to be on your show. I am hearing that they want us to hold on doing any interviews for the time being since the POTUS might do a press conference tonight. And so the decision is still in flux.
> Tony
>
> Anthony S. Fauci, MD
> Director
> National Institute of Allergy and Infectious Diseases Building 31,
> Room 7A-03
> 31 Center Drive, MSC 2520
> National Institutes of Health
> Bethesda, MD 20892-2520
> Phone (b) (6)
> FAX: (301) 496-4409
> E-mail: (b) (6)
> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
>
> -----Original Message-----
> From: Matthews, Chris (NBCUniversal, MSNBC) <kennedynixon@msnbc.com>
> Sent: Wednesday, February 26, 2020 9:04 AM
> To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)>
> Subject: Hardball Tonight
>
> Dear Tony -
>
> Could you come on tonight to address the coronavirus? We'd like to
> have you on anytime in the 7 hour. (b) (6)
>
> Best, Chris

>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:35:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Can you chat?

Please set this up. Thanks.

From: Fox, Lauren <Lauren.Fox@turner.com>
Sent: Wednesday, February 26, 2020 5:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Can you chat?

Hey Dr. Fauci,
I wanted to reach out because I am working on a big piece about the effort behind the scenes to contain the coronavirus and I was hoping you could talk on background about that,
Best,
Lauren Fox

Lauren Fox
Congressional Reporter
CNN Politics
Lauren.Fox@turner.com
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:34:46 +0000
To: Arturo Casadevall
Subject: RE: My OpEd on the WSJ coming out Friday on convalescent serum for Coronavirus

Arturo:
Thank you for your note and for sending the OpEd. Nice Job! I hope that all is well with you.
Best,
Tony

From: Arturo Casadevall [redacted] (b) (6) >
Sent: Wednesday, February 26, 2020 5:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: My OpEd on the WSJ coming out Friday on convalescent serum for Coronavirus

Dear Tony,

I just had an OpEd accepted in the WSJ proposing the use of convalescent sera to stem the coronavirus epidemic. The text of the OpEd is below in blue font (scroll down). I am sure the WSJ will shorten it and edit it but at least you have an advance copy of it. I just wanted you to have it since the WSJ is read widely in DC and I don't want anyone blindsiding you with questions about it.

As you know I have been long proponent of passive antibody therapies in infectious diseases and there is a huge body of historical data supporting this approach. Certainly, with modern blood banking techniques this option can be made quite safe and administration of a few cc's of serum could confer immediate immunity to those who will be exposed – like ER staff. I hope you agree with the message and like it.

Thank you for all you are doing for the country and humanity. If you need me for anything in this crisis rest assured that I am here.

Warm regards,
Arturo

From: Taranto, James <james.taranto@wsj.com>
Sent: Wednesday, February 26, 2020 4:27 PM
To: Arturo Casadevall [redacted] (b) (6) >
Subject: Re: Asking for a quick decision on the submitted OpEd on stemming coronavirus epidemic

OK, we'll take this and aim to get it out in Friday's paper, though it will likely need some trimming for space.

Dear Mr. Varadarajan,

I wonder if the WSJ is interested in my OpEd. I am trying to get a message out that convalescent serum (e.g. serum from people who recover) can be used to stem the coronavirus epidemic if administered to exposed people. This has been known for over a century, and is well accepted, but not widely known, even among experts today. There was one report that China was beginning to stockpile serum but there has been almost no discussion of this option among world public health authorities. Although I can get this published in a medical journal my hope is to publish it instead in a venue of high readership since this is something that can be done today to stem the epidemic. I am hoping that given the economic consequences of the outbreak that the WSJ is interested. I included a brief bio below. Thanks for looking at this.
Arturo

Proposed op-ed.
To Stem the Coronavirus Epidemic use Survivors Blood.

(b) (4)

[redacted]

(b) (4)

Arturo Casadevall MD, PhD

Author's brief bio

Arturo Casadevall, M.D., Ph.D., is a Bloomberg Distinguished Professor and Chair of the Molecular Microbiology and Immunology at Johns Hopkins School of Public Health. He received his M.D. and Ph.D. degrees from New York University. He completed his internship/residency in internal medicine at Bellevue Hospital and specialized in Infectious Diseases at the Albert Einstein College of Medicine. The author of over 800 papers, books and chapters, his major research interests are in fungal pathogenesis and the mechanisms of antibody action. He is also interested in the problems with scientific enterprise and with collaborators showed that misconduct accounts for the majority of retracted publications. He is editor-in-chief of mBio, Deputy Editor of the Journal of Clinical Investigation and serves on several editorial boards. He has served on several NIH committees including the NIAID Strategic Plan, the Blue Ribbon Panel on Biodefense Research, the NAS panel that reviewed the FBI investigation on anthrax attacks, the NAS Federal Regulations and Reporting committee and the National Science Advisory Board for Biosecurity. He was a Commissioner in the National Commission on Forensic Science and previously served as President of the Medical Mycology Society of the Americas. He is currently the Chair the Board of Governors of the American Academy of Microbiology. He has received numerous honors including election to the American Society for Clinical Investigation, American Academy of Physicians, American Academy of Microbiology, Fellow of the American Academy for the Advancement of Science, American Academy of Arts and Sciences and the National Academy of Medicine.

Arturo Casadevall MD, PhD
Chair, Molecular Microbiology & Immunology
Alfred & Jill Sommer Professor and Chair
Bloomberg Distinguished Professor
Johns Hopkins School of Public Health
615 N. Wolfe Street
Room E5132
Baltimore, Maryland 21205

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 03:48:12 +0000
To: Marston, Hilary (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: RE: For Review: [redacted] (b) (5)

Thanks.

From: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, March 5, 2020 10:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: For Review: [redacted] (b) (5)
Importance: High

[redacted] (b) (5)

From: "DLGDESK (HHS/ASPR/OPP)" <DLGDESK@hhs.gov>
Date: Thursday, March 5, 2020 at 6:19 PM
To: "Stannard, Paula (HHS/IOS)" [redacted] (b) (6) "Agnew, Ann (HHS/IOS)" [redacted] (b) (6)>, "Trueman, Laura (HHS/IEA)" [redacted] (b) (6)"Kadlec, Robert (OS/ASPR/IO)" [redacted] (b) (6)>, "Bird, Catherine (OS/OGC)" < [redacted] (b) (6)>, "Hittle, Taylor (HHS/ASFR)" < [redacted] (b) (6)>, "Arbes, Sarah (HHS/ASL)" [redacted] (b) (6)>, "Murphy, Ryan (OS/ASPA)" [redacted] (b) (6)>, "Destro, Brenda (HHS/ASPE)" [redacted] (b) (6)>, "Nevel, Amy (HHS/ASPE)" [redacted] (b) (6)>, "Tobias, Constance (HHS/DAB)" < [redacted] (b) (6)>, "Giroir, Brett (HHS/OASH)" [redacted] (b) (6)>, "Schwartz, Erica (HHS/OASH)" < [redacted] (b) (6), "Severino, Roger (HHS/OCR)" < [redacted] (b) (6)>, "Grigsby, Garrett (HHS/OS/OGA)" < [redacted] (b) (6)>, "Kerr, Lawrence (HHS/OS/OGA)" [redacted] (b) (6)>, "Chang, William (HHS/OGC)" [redacted] (b) (6)>, "Taitsman, Julie K (OIG/IO)" [redacted] (b) (6)>, "Griswold, Nancy (HHS/OMHA HQ)" [redacted] (b) (6)>, "Rucker, Donald (OS/ONC)" < [redacted] (b) (6)>, "Johnson, Lynn (ACF)" [redacted] (b) (6)>, "Meyers, David (AHRQ/IOD)" [redacted] (b) (6) "McNellis, Robert (AHRQ/CEPI)" [redacted] (b) (6)>, "Patel, Anita (CDC/DDID/NCIRD/OD)" [redacted] (b) (6), "Ethier, Kathleen (CDC/DDID/NCHHSTP/DASH)" < [redacted] (b) (6)>, "Brookes, Brady (CMS/OA)" [redacted] (b) (6) "Hinton, Denise (FDA/OC)" [redacted] (b) (6)>, "Cheever, Laura (HRSA)" [redacted] (b) (6),

"Espinosa, Diana (HRSA)" [redacted] (b) (6)>, "Macrae, Jim (HRSA)" [redacted] (b) (6)>, "Weahkee, Michael (IHS/HQ)" < [redacted] (b) (6)>, "McCollum, Jeffrey T (IHS/HQ)" [redacted] (b) (6)>, "Frazier, Francis (IHS/HQ)" < [redacted] (b) (6)>, "Collins, Francis (NIH/OD) [E]" [redacted] (b) (6)>, Anthony Fauci < [redacted] (b) (6)>, Hilary Marston [redacted] (b) (6)>, "McCance-Katz, Elinore (SAMHSA/OAS)" [redacted] (b) (6), "Shuy, Bryan (OS/ASPR/IO)" < [redacted] (b) (6)>, "Yeskey, Kevin (OS/ASPR/IO)" [redacted] (b) (6), Rick Bright [redacted] (b) (6)>, "Disbrow, Gary (OS/ASPR/BARDA)" [redacted] (b) (6)>, "Phillips, Sally (OS/ASPR/SPPR)" < [redacted] (b) (6)>, "Greene, Jonathan (OS/ASPR/EMMO)" [redacted] (b) (6), "DeBord, Kristin (OS/ASPR/SPPR)" [redacted] (b) (6)>, "Vineyard, Michael (OS/ASPR/IO)" [redacted] (b) (6)>, "Dodgen, Daniel (OS/ASPR/SPPR)" [redacted] (b) (6), "Imbriale, Samuel (OS/ASPR/SIIM)" < [redacted] (b) (6), "Donnelly, Kelsey (OS/ASPR/SPPR) (CTR)" [redacted] (b) (6)>, "Haris, Mariam (OS/ASPR/SPPR) (CTR)" [redacted] (b) (6)>, "Fucci, Michael (OS/ASPR/SPPR) (CTR)" [redacted] (b) (6)>, "Roman-Stolte, Claudia (OS/ASPR/SPPR) (CTR)" [redacted] (b) (6), "Austin, Meredith (uscg.mil)" [redacted] (b) (6)>, "Perdue, Christopher (OS/ASPR/SPPR)" [redacted] (b) (6)>, "Herrmann, Jack (OS/ASPR/OEA)" [redacted] (b) (6), Robert Johnson [redacted] (b) (6) "Wong, Diana (OS/ASPR/SIIM)" [redacted] (b) (6)>, "Robertson, Lance (ACL)" [redacted] (b) (6)>, "Nicholls, Richard (ACL)" < [redacted] (b) (6) "Phillips, Christine (ACL)" [redacted] (b) (6)>, "Blatner, Gretta (OS/ASPR/BARDA)" [redacted] (b) (6)>, "Feeney, Kathryn (OS/ASPR/IO) (CTR)" < [redacted] (b) (6)>, "Shirley, Mayo (FDA/OC)" [redacted] (b) (6)>, "Sheehy, Janice (FDA/ORA)" [redacted] (b) (6) "McDaniel, Eileen (HHS/OMHA)" < [redacted] (b) (6)>, Linda Lambert [redacted] (b) (6)>, "Gin, Julia (OS/ASPR/SPPR)" [redacted] (b) (6), "Adams, Steven A. (CDC/SNS/DSNS)" [redacted] (b) (6), "Wolf, Laura (OS/ASPR/SIIM)" [redacted] (b) (6)>, "Lee, Scott (OS/ASPR/EMMO)" [redacted] (b) (6)>, "Cooper, Kevin (OS/ASPR/ORM)" [redacted] (b) (6)>, "Moudy, Robin (OS/ASPR/SPPR)" [redacted] (b) (6)>, "Lawrence, Theresa (OS/ASPR/SPPR)" < [redacted] (b) (6), "Baker, Michael (OS/IEA)" < [redacted] (b) (6)>

Cc: "Holland, Tara (OS/ASPR/EMMO)" [redacted] (b) (6)>, "Delvecchio, Paolo (SAMHSA/OMTO)" [redacted] (b) (6), "Lobos, Elisa (SAMHSA/OFR/OD)" [redacted] (b) (6)>, "Bell, March (HHS/OCR)" [redacted] (b) (6), "Frohboese, Robinsue (HHS/OCR)" < [redacted] (b) (6), "Knutson, Donna (CDC/DDNID/NCEH/OD)' [redacted] (b) (6) "Mackay, Thomas (OS/ASPR/EEAA)" [redacted] (b) (6) Mango, Paul (HHS/IOS)" [redacted] (b) (6)>, "Blackford, Carol W. (CMS/CM)" [redacted] (b) (6)>, "Bradsher, Kris (HHS/ASL)" [redacted] (b) (6)>, "Payne, Skip (CMS/OA)" [redacted] (b) (6), "Gettinger, Andrew (OS/ONC)" [redacted] (b) (6)>, "Abbey, Rachel (OS/OSCP)" [redacted] (b) (6)>, "Cosgrove, Sandra (OS/ASPR/EEAA)" < [redacted] (b) (6)>, "Chaput, Daniel (OS/ONC)" [redacted] (b) (6)

Subject: For Review: [redacted] (b) (5)

Dear Disaster Leadership Group (DLG) Members,

Attached for review is a draft paper [redacted] (b) (5) We are asking that you review this draft and provide feedback to us by **8:00am** on **Friday, March 6.** Please note that we are looking for **substantive feedback only.**

If you have any questions or concerns, please reach out to me at [redacted] (b) (6) and kindly copy the DLGDESK@hhs.gov.

Thank you,

Daniel Dodgen, Ph.D.
Senior Advisor
Office of the Assistant Secretary for Preparedness and Response (ASPR)
Office of Strategy, Policy, Planning and Requirements (SPPR)

HEALTH AND HUMAN SERVICES (DHHS) | O'Neill House Office Building | 200 C Street SW | Washington, DC 20515
o. [redacted] (b) (6)
[redacted] (b) (6) | www.phe.gov

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 11:12:55 +0000
To: (b) (6) (OS/IOS)
Subject: RE: Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

Oh, I see what they are getting at. They examined at the single cell level the expression of RNA for ACH2, which is the receptor for the Coronavirus in the lung ,and found that when they looked at various demographic groups there was greater expression of this receptor in Asian males. They are thus hinting that this is the reason why there was such an explosion of infections in China. This is possible, but the lowest level was in Northern Italians and take a look at what is happening in Northern Italy. I do not mean to put the paper down since there may be some truth in it. However, this journal (bioRxiv) is not peer reviewed and the data are skimpy. Someone should do a more scholarly study.

-----Original Message-----
From: (b) (6) (OS/IOS) < (b) (6)
Sent: Tuesday, March 3, 2020 5:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)>
Subject: Re: Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

They asked if this proved certain ethnic groups more likely to get the disease and I said I had never anything like that suggested to me by our leading scientists.

> On Mar 2, 2020, at 10:44 PM, Fauci, Anthony (NIH/NIAID) [E] < (b) (6)> wrote:
>

I do not know what question they asked you about this paper, but any question about this gene expression paper to a non-scientist would be unfair and inappropriate.

-----Original Message-----
From: (b) (6) (OS/IOS) (b) (6)>
Sent: Monday, March 2, 2020 9:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)
Cc: Harrison, Brian (HHS/IOS) (b) (6)
Subject: Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

Was asked about this on tv tonight.

https://www.biorxiv.org/content/10.1101/2020.01.26.919985v1

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 03:26:29 +0000
To: Collins, Francis (NIH/OD) [E];Giroir, Brett (HHS/OASH)
Cc: Steele, Danielle (HHS/IOS);Tabak, Lawrence (NIH/OD) [E]
Subject: RE: SARS CoV-2 in humanized mice

Ditto.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Monday, March 2, 2020 9:32 PM
To: Giroir, Brett (HHS/OASH) [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>; Steele, Danielle (HHS/IOS) [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] < [redacted] (b) (6)
Subject: RE: SARS CoV-2 in humanized mice

Larry has it right. Tony may want to add.

Francis

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Sent: Monday, March 2, 2020 8:14 PM
To: Giroir, Brett (HHS/OASH) [redacted] (b) (6)>
Cc: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Steele, Danielle (HHS/IOS) [redacted] (b) (6)
Subject: Re: SARS CoV-2 in humanized mice

Brett,

Tony or Francis may offer additional insight, but the [redacted] (b) (5).

I hope this helps.
Larry

From: "Giroir, Brett (HHS/OASH)" < [redacted] (b) (6)>
Date: Monday, March 2, 2020 at 7:25 PM
To: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)>
Cc: Francis Collins [redacted] (b) (6)>, Anthony Fauci [redacted] (b) (6)>, "Steele, Danielle (HHS/IOS)" [redacted] (b) (6)>, "Giroir, Brett (HHS/OASH)" [redacted] (b) (6)
Subject: RE: SARS CoV-2 in humanized mice

Dear Larry,

Thank you for your patience. The question has been raised, [redacted] (b) (5)

I appreciate your willingness to continue to work on this and respond to the questions that I am receiving.

V/r
Brett

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: [redacted] (b) (6)

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Sent: Thursday, February 20, 2020 5:29 PM
To: Giroir, Brett (HHS/OASH) [redacted] (b) (6)>
Cc: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Steele, Danielle (HHS/IOS) [redacted] (b) (6)>
Subject: Re: SARS CoV-2 in humanized mice

Brett,
I have discussed with both Francis and Tony [redacted] (b) (5)

With regard to your questions:

[redacted] (b) (5)

[redacted] (b) (5)

Hope this is helpful. Please let me know if you require additional information.
Best wishes,
Larry

From: "Giroir, Brett (HHS/OASH)" [redacted] (b) (6)>
Date: Thursday, February 20, 2020 at 12:32 PM
To: "Tabak, Lawrence (NIH/OD) [E]" <[redacted] (b) (6)
Cc: "Steele, Danielle (HHS/IOS)" [redacted] (b) (6)
Subject: RE: SARS CoV-2 in humanized mice

Can you give me a quick call?

[redacted] (b) (5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: [redacted] (b) (6)

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Sent: Thursday, February 20, 2020 12:19 PM
To: Giroir, Brett (HHS/OASH) [redacted] (b) (6)>
Cc: Steele, Danielle (HHS/IOS) [redacted] (b) (6)>
Subject: Re: SARS CoV-2 in humanized mice

[redacted] (b) (5)

Thanks
Larry

From: "Giroir, Brett (HHS/OASH)" [redacted] (b) (6)>
Date: Thursday, February 20, 2020 at 12:17 PM
To: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)
Cc: "Steele, Danielle (HHS/IOS)" [redacted] (b) (6)
Subject: RE: SARS CoV-2 in humanized mice

Larry

[redacted] (b) (5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: [redacted] (b) (6)

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Sent: Wednesday, February 19, 2020 11:04 PM
To: Giroir, Brett (HHS/OASH) [redacted] (b) (6)
Cc: Steele, Danielle (HHS/IOS) [redacted] (b) (6)
Subject: FW: SARS CoV-2 in humanized mice

Brett,

[redacted] (b) (5)

Thanks for your consideration,
Larry

From: "Hasenkrug, Kim (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Wednesday, February 19, 2020 at 5:50 PM

To: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)
Subject: SARS CoV-2 in humanized mice

Hi Dr. Tabak, [redacted] (b) (5)

[redacted] (b) (5)

Best regards,

Kim

Kim J Hasenkrug, Ph.D.
Senior Investigator
Chief, Retroviral Immunology Section
Laboratory of Persistent Viral Diseases
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 S. 4th Street
Hamilton, MT 59840
[redacted] (b) (6)

Disclaimer:
The information in this e-mail and any of its attachments is confidential
and may contain sensitive information. It should not be used by anyone who
is not the original intended recipient. If you have received this e-mail in
error please inform the sender and delete it from your mailbox or any other
storage devices. National Institute of Allergy and Infectious Diseases
shall
not accept liability for any statements made that are sender's own and not
expressly made on behalf of the NIAID by one of its representatives

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 00:48:25 +0000
To: Cassetti, Cristina (NIH/NIAID) [E];Giroir, Brett (HHS/OASH)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: COVID and Chloroquine

Thanks, Cristina

From: Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, March 1, 2020 7:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Giroir, Brett (HHS/OASH)
[redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: COVID and Chloroquine

Hi,

Sorry for the late response, I just flew back from [redacted] (b) (6).

NIAD doesn't have ongoing trials with chloroquine and I heard that such trials are being conducted in China.

We are planning to evaluate chloroquine in animal models ASAP. If any therapeutic with a good clinical safety profile (like chloroquine) appears to be effective in vivo against COVID-19, we are planning to quickly add to them to the Remdesivir therapeutic trial as another arm.

Let me know if you have other questions.

Kind regards,

Cristina

Cristina Cassetti, Ph.D.
Deputy Director
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases, NIH
5601 Fishers Lane, Room 7G51
Rockville, MD 20852
Tel: [redacted] (b) (6)
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Saturday, February 29, 2020 8:20 PM

To: Giroir, Brett (HHS/OASH) (b) (6)>
Cc: Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: COVID and Chloroquine
Importance: High

Brett:

Thanks for the note. I will run this by the people in our Program and get back to you.

Best,
Tony

Cristina:

Are we or anyone else doing anything with clinical trials and chloroquine for COVID-19? Please respond directly to ADM Giroir.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Giroir, Brett (HHS/OASH) (b) (6)>
Sent: Saturday, February 29, 2020 9:31 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: COVID and Chloroquine

You know the old data and the new data. New in vitro look promising.
Do you have good visibility on the trials being conducted? Or is NIH running any of these?

Your time is precious, so 10 word response sufficient.

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:35:38 +0000
To: Kadlec, Robert (OS/ASPR/IO)
Subject: RE: Your thoughts

My thoughts – [redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>
Sent: Saturday, February 29, 2020 10:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Your thoughts
Importance: High

Tony I don't know if you saw this but wanted to ask your thought. [redacted] (b) (5) Your thoughts always appreciated
bob

<< File: CCDC Epi Report.pptx >> << File: The+Epidemiological+Characteristics+of+an+Outbreak+of+2019+Novel+Coronavirus+Diseases+(COVID-19)+—+China,+2020.pdf >>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:55:20 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

I would recommend Dr. Hilary Marston from my immediate office. Larry should go to the hearing with us

---

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Saturday, February 29, 2020 10:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Subject: FW: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Hi Tony,

Quick question – who would you suggest is the appropriate NIH representative for this ASPR-led trans-HHS effort to coordinate COVID-19 response? You and I will be testifying in front of the House Approps Subcommittee on Wednesday morning. Would it be best for Larry to represent NIH for the ASPR gathering (though he would normally attend the House hearing), or is there someone from NIAID that would be most appropriate?

Thanks, Francis

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)
Sent: Friday, February 28, 2020 10:23 AM
To: Trueman, Laura (HHS/IEA) [redacted] (b) (6)>; Rowell, Scott (OS/ASA) [redacted] (b) (6)>; Bird, Catherine (OS/OGC) [redacted] (b) (6)>; Moughalian, Jen (HHS/ASFR) [redacted] (b) (6)>; Arbes, Sarah (HHS/ASL) < [redacted] (b) (6)>; Murphy, Ryan (OS/ASPA) [redacted] (b) (6)>; Destro, Brenda (HHS/ASPE) [redacted] (b) (6)>; Giroir, Brett (HHS/OASH) [redacted] (b) (6)>; Severino, Roger (HHS/OCR) [redacted] (b) (6)>; Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)>; Kerr, Lawrence (HHS/OS/OGA) [redacted] (b) (6); Charrow, Robert (HHS/OGC) < [redacted] (b) (6); Grimm, Christi A (OIG/IO) [redacted] (b) (6)>; Griswold, Nancy (HHS/OMHA HQ) [redacted] (b) (6) Op Divs [redacted] (b) (6)>; Johnson, Lynn (ACF) [redacted] (b) (6) Robertson, Lance (ACL) [redacted] (b) (6)>; Khanna, Gopal (AHRQ/IOD) [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6) Verma, Seema (CMS/OA) [redacted] (b) (6)Saxon, Bobby (CMS/CCIIO) [redacted] (b) (6) Hinton, Denise (FDA/OC)

[redacted] (b) (6)>; Engels, Thomas (HRSA) [redacted] (b) (6); Weahkee, Michael (IHS/HQ) <[redacted] (b) (6)>; McCollum, Jeffrey T (IHS/HQ) [redacted] (b) (6)>; Frazier, Francis (IHS/HQ) <[redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; McCance-Katz, Elinore (SAMHSA/OAS) <[redacted] (b) (6); Krohmer, Jon (dot.gov) [redacted] (b) (6)
Cc: Ford-Barnes, Arwenthia (OS/ASPR/IO) [redacted] (b) (6); Waters, Cicely (OS/ASPR/OEA) <[redacted] (b) (6); Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)
Subject: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Dear ASPR Colleagues,

We are at a critical juncture in our nation's response to COVID-19. As we pivot from containment of the virus to mitigation of its impacts, it is imperative that HHS moves swiftly, transparently, and in a unified manner to protect lives and save Americans. The Secretary has charged my office to lead efforts across the Department to prepare and defend our health care system during the novel coronavirus outbreak through the Health Care System Resilience Task Force.

To date, this task force has engaged with public and private sector stakeholders to broadly identify efforts that can be taken to help ensure preparedness in response to a domestic COVID-19 outbreak, and more importantly their gaps, challenges, and potential areas of need from the federal government. Now, we must build on that knowledge to expedite and execute a whole of HHS response to support protection of the health care system that spans public health, health care, and human services.

Please join Dr. Kevin Yeskey, ASPR's Principal Deputy Assistant Secretary for Preparedness and Response, and Dr. Nancy Messonnier, CDC's Director of the National Center for Immunization and Respiratory Diseases, on **Wednesday, March 4 from 9:00 AM - 10:15 AM**, at the O'Neill House Office Building for a working session to align current activities and next steps to be executed as part of a coordinated HHS response to COVID-19.

Please provide the following information to ASPR.HCSRTF@hhs.gov no later than Monday, March 2 at 12:00 PM, and be prepared to share and discuss at Wednesday's session.

- Your Designee(s) name, title, and contact information
- OPDIV/STAFFDIV name
- OPDIV/STAFFDIV current and future top five priorities related to COVID-19 (priority leads, descriptions, timelines)

- OPDIV/STAFFDIV key activities and workgroups (current and under consideration) related to COVID-19 response (include activity/workgroup leads, key purpose, timelines)
- OPDIV/STAFFDIV key areas of concern or challenges identified to date
- OPDIV/STAFFDIV core competencies or other assets it can bring to COVID-19 response efforts

We look forward to working with you on this critical effort to defend the nation's health care system. Thank you in advance for your support and participation.

Respectfully,

Bob Kadlec
ASPR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:26:56 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Francis:

You are correct about the Israeli vaccine. I cannot imagine that they would have a safe and effective vaccine deployable in 90 days.

Tony

From: Collins, Francis (NIH/OD) [E] (b) (6)>
Sent: Friday, February 28, 2020 12:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)
Subject: FW: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Hi Tony and Larry,

See below for a new Health Care Resilience Task Force being convened by ASPR.

The initial meeting overlaps with our House approps hearing.

Tony, who shall we send to this one?

FC

P.S. to Tony – I'm getting a lot of buzz about the Israeli claim to have fast track vaccine: https://israelb.org/2020/02/israel-to-have-coronavirus-vaccine-within-3-weeks/ It looks to me that they are conflating having something ready to put into volunteers for a phase 1 trial, and having full scale production ready to go for the global needs. That still seems like it's a year away. Am I right?

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Friday, February 28, 2020 10:23 AM
To: Trueman, Laura (HHS/IEA) (b) (6)>; Rowell, Scott (OS/ASA) (b) (6); Bird, Catherine (OS/OGC) (b) (6)>; Moughalian, Jen (HHS/ASFR) (b) (6) Arbes, Sarah (HHS/ASL) (b) (6) Murphy, Ryan (OS/ASPA) < (b) (6)>; Destro, Brenda (HHS/ASPE) (b) (6); Giroir, Brett (HHS/OASH) < (b) (6)>; Severino, Roger (HHS/OCR) (b) (6)>; Grigsby, Garrett (HHS/OS/OGA)

<(b) (6)>; Kerr, Lawrence (HHS/OS/OGA) <(b) (6)>; Charrow, Robert (HHS/OGC) <(b) (6)>; Grimm, Christi A (OIG/IO) <(b) (6)>; Griswold, Nancy (HHS/OMHA HQ) (b) (6)>; Op Divs (b) (6)>; Johnson, Lynn (ACF) <(b) (6)>; Robertson, Lance (ACL) (b) (6)>; Khanna, Gopal (AHRQ/IOD) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)>; Verma, Seema (CMS/OA) <(b) (6)>; Saxon, Bobby (CMS/CCIIO) <(b) (6) Hinton, Denise (FDA/OC) (b) (6)>; Engels, Thomas (HRSA) <(b) (6)>; Weahkee, Michael (IHS/HQ) (b) (6)>; McCollum, Jeffrey T (IHS/HQ) (b) (6); Frazier, Francis (IHS/HQ) <(b) (6) Collins, Francis (NIH/OD) [E] <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6); McCance-Katz, Elinore (SAMHSA/OAS) (b) (6)>; Krohmer, Jon (dot.gov) (b) (6)>

Cc: Ford-Barnes, Arwenthia (OS/ASPR/IO) (b) (6)>; Waters, Cicely (OS/ASPR/OEA) (b) (6)>; Shuy, Bryan (OS/ASPR/IO) (b) (6)>

Subject: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Dear ASPR Colleagues,

We are at a critical juncture in our nation's response to COVID-19. As we pivot from containment of the virus to mitigation of its impacts, it is imperative that HHS moves swiftly, transparently, and in a unified manner to protect lives and save Americans. The Secretary has charged my office to lead efforts across the Department to prepare and defend our health care system during the novel coronavirus outbreak through the Health Care System Resilience Task Force.

To date, this task force has engaged with public and private sector stakeholders to broadly identify efforts that can be taken to help ensure preparedness in response to a domestic COVID-19 outbreak, and more importantly their gaps, challenges, and potential areas of need from the federal government. Now, we must build on that knowledge to expedite and execute a whole of HHS response to support protection of the health care system that spans public health, health care, and human services.

Please join Dr. Kevin Yeskey, ASPR's Principal Deputy Assistant Secretary for Preparedness and Response, and Dr. Nancy Messonnier, CDC's Director of the National Center for Immunization and Respiratory Diseases, on **Wednesday, March 4 from 9:00 AM - 10:15 AM**, at the O'Neill House Office Building for a working session to align current activities and next steps to be executed as part of a coordinated HHS response to COVID-19.

Please provide the following information to ASPR.HCSRTF@hhs.gov no later than Monday, March 2 at 12:00 PM, and be prepared to share and discuss at Wednesday's session.

- Your Designee(s) name, title, and contact information
- OPDIV/STAFFDIV name
- OPDIV/STAFFDIV current and future top five priorities related to COVID-19 (priority leads, descriptions, timelines)
- OPDIV/STAFFDIV key activities and workgroups (current and under consideration) related to COVID-19 response (include activity/workgroup leads, key purpose, timelines)
- OPDIV/STAFFDIV key areas of concern or challenges identified to date
- OPDIV/STAFFDIV core competencies or other assets it can bring to COVID-19 response efforts

We look forward to working with you on this critical effort to defend the nation's health care system. Thank you in advance for your support and participation.

Respectfully,

Bob Kadlec
ASPR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 15:45:23 +0000
To: Zebley, Kyle (HHS/OS/OGA)
Cc: Kerr, Lawrence (HHS/OS/OGA)
Subject: RE: Current TF Agenda Draft/Request for AMA High-level Talkers
Attachments: Task Force VP Briefing 2-13-20 - with Fauci TP.docx

Kyle:

Here is a talking point for the messaging section.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Zebley, Kyle (HHS/OS/OGA) (b) (6)
Sent: Thursday, February 27, 2020 9:11 AM
To: Hall, Bill (HHS/ASPA) (b) (6)>; Murphy, Ryan (OS/ASPA) < (b) (6); Trueman, Laura (HHS/IEA) (b) (6)>; Johnston, Darcie (HHS/IEA) (b) (6); Arbes, Sarah (HHS/ASL) < (b) (6); Morse, Sara (HHS/ASL) (b) (6)>; Twomey, John K. (HHS/ASL) (b) (6)>; Pence, Laura (HHS/ASL) (b) (6)>
Cc: Mango, Paul (HHS/IOS) (b) (6); Bird, Catherine (OS/OGC) < (b) (6) Grigsby, Garrett (HHS/OS/OGA) (b) (6)>; Kerr, Lawrence (HHS/OS/OGA) < (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) < (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6)>; Shuy, Bryan (OS/ASPR/IO) (b) (6)
Subject: Current TF Agenda Draft/Request for AMA High-level Talkers
Importance: High

Good morning,

Attached, please find a current draft of an agenda for a TF Briefing for VPOTUS this afternoon. Note that this is a draft and is not final. However, in order to prepare the Secretary, can ASPA, IEA, and ASL please help with 2-3 high-level talkers each the Secretary could highlight under the External Activity/Messaging section of the agenda? Could you please send to me and Dr. Larry Kerr by **11 AM this morning**? Apologies for the quick turnaround.

Dr. Redfield, Dr. Fauci, and Dr. Kadlec, please note your presence on the agenda and please be prepared to speak to the topics assigned.

Let me know if you have any questions. Thanks for your help.

Kyle Zebley
Chief of Staff
Office of Global Affairs (OGA)
Office of the Secretary
U.S. Department of Health and Human Services
Direct: (b) (6)/Mobile: (b) (6)

Confidential and pre-decisional communication

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:08:22 +0000
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: RE: mitigation in communities
Attachments: COVID-19 Targeted Layered Mitigation Strategy_Interim.022820.pdf

I assume that you are OK with the document that Garrett just sent around. See attached.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>
Sent: Sunday, March 1, 2020 2:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: mitigation in communities

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Sent: Sunday, March 1, 2020 2:59 PM
To: Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>
Cc: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) < [redacted] (b) (6) Schuchat, Anne MD (CDC/OD) [redacted] (b) (6)>
Subject: mitigation in communities

Here are the basic high level principles of a mitigation strategy. [redacted] (b) (5)
(b) (5)

(b) (5)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:02:24 +0000
To: Grigsby, Garrett (HHS/OS/OGA)
Subject: RE: [redacted] (b) (5)

It is a tough decision, [redacted] (b) (5).

From: Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)>
Sent: Thursday, February 27, 2020 5:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6); Adams, Jerome (HHS/OASH) [redacted] (b) (6)>
Cc: Harrison, Brian (HHS/IOS) [redacted] (b) (6) Zebley, Kyle (HHS/OS/OGA) <[redacted] (b) (6)>
Subject: FW: [redacted] (b) (5)
Importance: High

Gentlemen,

Any problem with this – see Marty's below. Need to know asap as I'd like to forward to NSC immediately. Many thanks!

From: Cetron, Marty (CDC/DDID/NCEZID/DGMQ) [redacted] (b) (6)
Sent: Thursday, February 27, 2020 5:08 PM
To: Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)>
Cc: Walker, Allison Taylor. (CDC/DDID/NCEZID/DGMQ) [redacted] (b) (6) McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6) Roohi, Shahrokh (CDC/DDID/NCEZID/DGMQ) [redacted] (b) (6) Elvander, Erika (OS/OGA) [redacted] (b) (6)>; Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6)>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [redacted] (b) (6)
Subject: [redacted] (b) (5)

Hi Garrett,

CDC intends [redacted] (b) (5) (b) (5)

Thanks,
Marty

[redacted] (b) (5)

(b) (5)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:31:21 +0000
To: Ms P
Subject: RE: A note from Sharon Perlman

Sharon:

Thanks for your note. It was great to hear from you. All is well with me and my family. I hope the same for you This whole coronavirus situation is rather exhausting since I am working 24/7 with no breaks at all. However, it needs to be done since this virus is a true threat to global heath.

Best regards,
Tony

From: Ms P [redacted] (b) (6)
Sent: Wednesday, February 26, 2020 6:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: A note from Sharon Perlman

Hi Dr. Fauci,

As I was watching my favorite CNN news show starring Chris Cuomo last night, to my delight, there you were! And again, this morning with John Berman and Alisyn Camerota on New Day.

I do hope all that all is well with you and your family. We are all doing fine. My

(b) (6)

[redacted]

I would love to hear from you, when you have time.

With best regards,
Sharon

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:27:18 +0000
To: Bennett Werner
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Clinical question, Sir....

Dear Drs. Werner and Uhl:
Thank you for your note. [redacted] (b) (6)

[redacted] (b) (6)

Best regards,
A.S. Fauci

-----Original Message-----
From: Bennett Werner [redacted] (b) (6)>
Sent: Wednesday, February 26, 2020 6:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Clinical question, Sir....

Dear Dr. Fauci,

[redacted] (b) (6)

By the way, we both feel you are an outstanding spokesperson and really appreciate both the work you do and your clear explanations on Public TV (and elsewhere).

Warm regards,

Bennett E. Werner, M.D. FACC FACP
Cleveland Clinic Cardiology - [redacted] (b) (6)

Michelle D. Uhl, M.D.
Cleveland Clinic - medical oncology [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:06:03 +0000
To: Morgan Fairchild
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Covid-19

Morgan:

Thanks for the note and the offer to help. It would be great if you could tweet to your many Twitter followers that although the current risk of coronavirus to the American public is low, the fact that there is community spread of virus in a number of countries besides China and including South Korea, Japan, Italy, Iran among others poses a risk that we may progress to a global pandemic of COVID-19. If that occurs we will surely have many more cases in the USA. And so for that reason, the American public should not be frightened, but should be prepared to mitigate an outbreak in this country by measures that include social distancing, teleworking, temporary closure of schools, etc. There is nothing to be done right now since there are so few cases in this country and these cases are being properly isolated, and so go about your daily business. However, be aware that behavioral adjustments may need to be made if a pandemic occurs.

Best regards,
Tony

From: Morgan Fairchild [redacted] (b) (6)
Sent: Wednesday, February 26, 2020 8:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Covid-19

Hi Dr. Fauci. I'm reaching out to see if I can help in any way to get good information out to the public, as I tried to do with AIDS. I have almost 100,000 Twitter followers and have been tweeting articles to them that I feel are helpful, but if you have any info I can help disseminate, please let me know.

Also, a great job today and this week!!

Hope you're well!

Thanks!

Best,

Morgan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 03:00:14 +0000
To: Laura Landerman-Garber
Subject: RE: Dr Sheldon Wolff Dr Fauci NIH [redacted] (b) (6)
Follow up 2/26/20

Laura:

Many thanks for your kind note. It was great to hear from you.
Warm regards,
Tony

From: Laura Landerman-Garber [redacted] (b) (6)>
Sent: Wednesday, February 26, 2020 9:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Re: Dr Sheldon Wolff Dr Fauci NIH [redacted] (b) (6) Follow up 2/26/20

Greetings from New Hampshire. Today I was watching the news and there you were, once again popping up in my life and making me not only smile by your kind and approachable style that I truly remember from the [redacted] (b) (6), but also taken care of by your expertise. Thank you for your medical leadership during these days as the Coronavirus spreads. Please know that your legacy of research and practice will live on for generations to come!
I hope that these complex days are soon quieted for us here in the US and around the Globe

Ps [redacted] (b) (6).
Amazing to think that so many of my questions were answered all those decades ago with you and Sheldon Wolff I remain forever grateful. Since I saw you last, [redacted] (b) (6) who you met, moved to DC and works at American Psychological Association. [redacted] (b) (6). Life marches on. I hope you and your family are well

Best,

Laura Landerman-Garber, Ph.D.

> On Apr 7, 2015, at 12:18 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:
>
> Laura:
>
> Thank you so much for your beautiful note. I do remember you and am so happy that you reached out to communicate with me. I am very pleased to hear that you are doing so well. You have "made my day" by your note. I wish you and your family all the best.

Warm regards,
Tony

From: Laura Landerman-Garber [redacted] (b) (6)
Sent: Tuesday, April 07, 2015 10:31 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Dr Sheldon Wolff Dr Fauci NIH [redacted] (b) (6) Follow up

See below please. Thank you!!

Sent from my iPhone

Begin forwarded message:

> **From:** Laura Landerman [redacted] (b) (6)
> **Date:** April 7, 2015 at 10:06:28 AM EDT
> **To:** "niaidnews@niaid.nih.gov" <niaidnews@niaid.nih.gov>
> **Subject: Dr Anthony Fauci/ NIH/ Dr SHeldon Wolff/** [redacted] (b) (6) **followup**
> **Reply-To:** Laura Landerman [redacted] (b) (6)>
>
> Greetings from NH. I am trying to contact Dr Fauci after many years. I have followed his career like so many others do... [redacted] (b) (6)
>
> (b) (6) [redacted]
>
> I am not sure if this can find its way to Dr Fauci but I would so appreciate it if it could. To let him know that all those years ago,

he left n outstanding impression on [redacted] (b) (6)
[redacted]. I want to thank him from the bottom of my heart.

Sincerely,

Laura M. Landerman-Garber, Ph.D.
[redacted] (b) (6)

[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 02:57:57 +0000
To: LOUIS FORTUNATO
Subject: RE: Dear Tony: Will you take the lead in the Coronavirus problem/ we always love you/Saw you on CNN/

Lou:
I do not believe that there is a chance to republish Harrison Practice.
Best regards,
Tony

From: LOUIS FORTUNATO [redacted] (b) (6)
Sent: Wednesday, February 26, 2020 9:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: Dear Tony: Will you take the lead in the Coronavirus problem/ we always love you/Saw you on CNN/

Begin forwarded message:

From: LOUIS FORTUNATO [redacted] (b) (6)>
Subject: Fwd: Any Chance of Harrison Practice being updated and replaced on the market? I loved it Tony/ Better than Harrison's Textbook
Date: February 17, 2020 at 9:41:40 PM EST
To: [redacted] (b) (6)

Dear Tony Fauci MD:
Any chance for Harrison Practice being republished again and
updated with the newest Pathophysiology and Treatments?
It was better than Harrisons Textbook/More Precise and Succinct

Please email me/
I would greatly appreciate your response
either wayYes or No//

Dr Lou Fortunato
[redacted] (b) (6)

Begin forwarded message:

From: LOUIS FORTUNATO (b) (6)>
Subject: HERE TONY IS ANOTHER CHAPTER OF MY FUTURE NUC MED BOOK
Date: November 3, 2019 at 5:11:19 AM EST
To: (b) (6)

HERE TONY IS MY NOTES IN BONE
IMAGING FOR MY FUTURE BOOK

LOU FORTUNATO

From: (b) (6)
Sent: Wed, 26 Feb 2020 20:24:59 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: [EXTERNAL] Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring/ Followup to our meeting at the ASPEN ideas festival -

Please handle.

Sent from my iPhone

Begin forwarded message:

> **From:** "Dr. Anita Goel , M.D., Ph.D." (b) (6)>
> **Date:** February 26, 2020 at 7:58:54 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
> **Subject: FW: [EXTERNAL] Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring/ Followup to our meeting at the ASPEN ideas festival -**
>
> Dear Dr. Anthony Fauci,
>
> It was a great pleasure meeting you all a couple of years ago when we were both speaking at the Aspen Ideas Festival. Some of my contacts at the CDC recently briefed me about the rapidly emerging threat of the coronavirus to the US and have been urging us to develop an app for detecting coronavirus with high sensitivity and specificity on our Gene-RADAR platform. Our platform has the ability to quantify viral loads in 'real-time' which would be a much more precise and accurate solution in deciding quarantine than the current thermometers or even the current CDC coronavirus test which has a very poor Limit of detection (ie low sensitivity).
>
> We have a strong track record of responding to previous pandemic threats and rapidly building Gene RADAR applications for Ebola and Zika and then getting them through clinical validation as per the the FDA EUA approval process. Our Gene-RADAR Zika test was FDA EUA certified right as the Zika crisis was coming to an end.
>
> I would love to work with you to see how we can help in your efforts to rapidly respond to this deadly threat to the US and the world. Here are some of the capabilities of our platform that we believe could be an enabler for helping to stop this out break from becoming a full-fledged global pandemic.

- Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring
    - Highly sensitive and specific – minimize false positives and false negatives
    - With very good LOD's we could potentially start to catch people presymptomatically and enable the early detection , early quarantine would limit the spread and early intervention could lead to better outcomes
    - More precise viral load monitoring could help determine when to release people from quarantine or ICU beds
    - Our platform's ability to quantify vial loads could change clinical trial endpoints for new drug candidates or (repurposed drug formulations), thereby accelerating FDA approvals for novel therapeutic regimen
    - We already have an ISO 13485 certified manufacturing facility (currently in Boston) that we are prepared to move as fast as possible to ramp up our production

      We would love to work with you to repurpose our FDA approved platform for the above coronavirus applications assay and help your noble efforts to stop this outbreak from becoming a full blown global pandemic that could costs thousands of lives and cause trillions of dollars of economic damage to the global economy.

We would love to speak with you to brief on our capabilities and discuss how we can qualify for some of the emergency funding being made available to help tackle this pandemic threat.

Happy to jump on a phone call to discuss further how we can help

How Nanobiophysics can Stop Ebola and Other Global Pandemics

- **Forbes**
- **Wired Magazine**

Best Wishes,

Dr. Anita Goel, MD, PhD
Chairman &CEO
Nanobiosym
==================================
www.nanobiosym.com
email: (b) (6)
Mobile: (b) (6)
http://www.people.fas.harvard.edu/~goel/
email: goel@physics.harvard.edu
================================

Selected Media Links:

Nanobiosym Gene-RADAR® X Prize Grand Prize Winner Video

Dr. Goel's Article in Scientific American Worldview
Nanobiosym Chairman &CEO Named 2018 Uber ELITE Award Winner
FDA Grants Emergency Use Authorization for Gene-RADAR® Zika Test
BBC Feature: The Genius Behind the "Tricorder that could revolutionize medicine"
Nanobiosym Selected As One Of The Top Growth Stage Ventures By The 'Unreasonable' Group
Dr. Anita Goel, MD, PhD awarded 2019 SEEMA Entrepreneur of the Year Award

How Nanobiophysics can Stop Ebola and Other Global Pandemics

- Forbes
- Wired Magazine

Nanobiosym Global Initiative Summit Website
Wall Street Journal
Washington Post
Boston Globe GameChangers
National Geographic
Forbes

Nanobiosym Space News
CBS News
Boston Business Journal
CNN
DailyMail
Space.com
Popular Mechanics
Forbes
US News and World Report
Wired
Daily Press
CBC Radio
Boston Globe STAT

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

From: [redacted] (b) (6)
Sent: Wed, 26 Feb 2020 19:24:48 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview request from WTOP [Please reply all]

Sent from my iPhone

Begin forwarded message:

> **From:** "Anderson, Liz" <landerson@wtop.com>
> **Date:** February 26, 2020 at 6:57:05 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** "Spitalniak, Laura" <lspitalniak@wtop.com>
> **Subject: Interview request from WTOP [Please reply all]**
>
> Good Evening Dr. Fauci,
>
> My name is Liz Anderson, and I'm working the editor's desk tonight at WTOP.
>
> Are you available for a brief live interview (about 2 minutes long) about what the latest COVID-19 developments? During this evening's press conference, President Trump said you two spoke about it.
>
> The Washington Post is also reporting that the CDC has been informed about the first coronavirus case of unknown origin confirmed in Northern California. We'd also like to talk about that and what that could mean about the spread of this virus in the states.
>
> We have the following time slots open tonight:
>
> 9:10p
> 9:40p

10:10p
10:40p

11:10p
11:40p

Many thanks for your time.

Sincerely,

Liz Anderson
AE/Editor/Reporter, WTOP News
202-895-5060 (newsroom)
landerson@wtop.com
Twitter: @planetnoun
http://wtop.com/author/landerson/
http://wtop.com/author/liz-anderson/

wtop | 103.5 FM
WTOP.COM

From: [redacted] (b) (6)
Sent: Wed, 26 Feb 2020 19:24:09 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview request from WTOP [Please reply all]

Sent from my iPhone

Begin forwarded message:

> **From:** "Anderson, Liz" <landerson@wtop.com>
> **Date:** February 26, 2020 at 7:01:22 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: RE: Interview request from WTOP [Please reply all]**
>
> Wait-- I see you're at the press conference, too. If you have availability at one of the times listed, we'd love to have you.
>
> Many thanks,
>
> Liz
>
> ---
>
> **From:** Anderson, Liz
> **Sent:** Wednesday, February 26, 2020 6:57 PM
> **To:** [redacted] (b) (6)>
> **Cc:** Spitalniak, Laura <lspitalniak@wtop.com>
> **Subject:** Interview request from WTOP [Please reply all]
>
> Good Evening Dr. Fauci,
>
> My name is Liz Anderson, and I'm working the editor's desk tonight at WTOP.
>
> Are you available for a brief live interview (about 2 minutes long) about what the latest COVID-19 developments? During this evening's press conference, President Trump said you two spoke about it.

The Washington Post is also reporting that the CDC has been informed about the first coronavirus case of unknown origin confirmed in Northern California. We'd also like to talk about that and what that could mean about the spread of this virus in the states.

We have the following time slots open tonight:

9:10p
9:40p

10:10p
10:40p

11:10p
11:40p

Many thanks for your time.

Sincerely,

Liz Anderson
AE/Editor/Reporter, WTOP News
202-895-5060 (newsroom)
landerson@wtop.com
Twitter: @planetnoun
http://wtop.com/author/landerson/
http://wtop.com/author/liz-anderson/

wtop | 103.5 FM
WTOP.COM

From: [redacted] (b) (6)
Sent: Wed, 26 Feb 2020 19:22:28 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: AM 970 the Answer Radio Request Re: Coronavirus Response from POTUS and NIH

Sent from my iPhone

Begin forwarded message:

> **From:** Alex Garrett <agarrett@nycradio.com>
> **Date:** February 26, 2020 at 7:13:41 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: AM 970 the Answer Radio Request Re: Coronavirus Response from POTUS and NIH**
>
> Hi Dr. Fauci,
> I hope you are well ! Would love to welcome you to Kevin McCullough Radio on AM 970 the Answer tomorrow to discuss the steps the White House and the NIH are taking to combat coronavirus. Kevin is our drive-time host at 5 PM and he is nationally syndicated as well with 300+ affiliates for his broadcast!
> Look forward to hearing from you. Thanks Dr. Fauci!
> Alex Garrett
>
> Producer: Kevin McCullough Radio
> AM 570 the Mission WMCA: 3-4 PM
> AM 970 the Answer: 5-6 PM

From: Folkers, Greg (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 21:50:05 +0000
To: Laurencot, Elizabeth;Fauci, Anthony (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: RE: NEJM content proof (Fauci)

Eli,

[redacted] (b) (5)

Thanks,
Tony

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 4:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6) Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Regarding the following information--

[redacted] (b) (5)

Please clarify --- thank you!

Best,
Eli

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)> **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, February 26, 2020 3:48 PM
To: Laurencot, Elizabeth <elaurencot@nejm.org>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Eli,

[redacted] (b) (5)

Thanks,
Tony

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.

The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.

Best,
Eli

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>
Cc: Folkers, Greg (NIH/NIAID) [E] <[redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Eli,
Here are my answers to your queries, and couple other minor changes:

[redacted] (b) (5)

(b) (5)

[redacted]

(b) (5)

[redacted]

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (http://www.adobe.com/products/acrobat/readermain.html).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.
This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.
This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended

recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: [redacted] (b) (6)
Sent: Wed, 26 Feb 2020 15:29:21 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: Seeking Dr. Fauci for coronavirus webinar

Let us discuss

> On Feb 26, 2020, at 11:59 AM, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6) wrote:
>
> Patricia L. Conrad
> Public Health Analyst and
> Special Assistant to the Director
> National Institute of Allergy and Infectious Diseases
> The National Institutes of Health
> 31 Center Drive, MSC 2520 - Room 7A03
> Bethesda, Maryland 20892
> [redacted] (b) (6)
> 301-496-4409 fax
>
> Disclaimer:
> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
>
> ---
>
> **From:** Chris Adams <cadams@nationalpress.org>
> **Sent:** Wednesday, February 26, 2020 11:01 AM
> **To:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
> **Subject:** Seeking Dr. Fauci for coronavirus webinar
>
> Patricia:
>
> I hope you are doing well. Dr. Fauci has been a wonderful speaker for us in the past, and I'm reaching out to him today for a discussion on coronavirus.
>
> When there are major news stories, we often will try to do a live webinar on the topic with a leading expert or two.

This is something we would do in our studio at our office near Dupont Circle. We normally do them for 45-60 minutes, and we take questions (visa Twitter) from our audience. The audience would be reporters who cover the topic, as well as others interested in the topic. It is a way to have an in-depth, thoughtful conversation about a pressing topic.

Here are a couple we've done (the first is on Zika a few years ago):

Zika panel discussion: https://nationalpress.org/topic/understanding-the-zika-threat/?st=0&t=&mm=Video
Ted Koppel: https://nationalpress.org/toolbox-topic/lights-out-risks-to-the-power-grid/?st=7042&mm=Video
Autonomous vehicles panel discussion: https://nationalpress.org/topic/whats-new-with-autonomous-vehicles/?st=8474&t=Automation&mm=Story

We'd like to do one of these on coronavirus. We'd love to have Dr. Fauci as our prime guest.

We can schedule it around his demands, but would of course love to do it as soon as possible.

We know he is in demand at this moment. But he is such a singular expert on the topic we'd love to have a discussion with him – one that would help get his message out to journalists (and others) who need to be informed to best cover the topic.

Is it possible to check with Dr. Fauci to see if this is possible?

Thanks,
Chris Adams
National Press Foundation

From: [redacted] (b) (6)
Sent: Wed, 26 Feb 2020 15:01:39 -0500
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E]
Subject: Re: ASF and CLIFF ------- DRAFT response to Eli at NEJM

Please send this to Eli. Thanks

> On Feb 26, 2020, at 12:49 PM, Folkers, Greg (NIH/NIAID) [E]
> [redacted] (b) (6)>wrote:
>
> Dear Eli,
>
> (b) (5)
> [redacted]

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 11:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] < [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

[redacted] (b) (5)

Thank you very much for your consideration!

Best,
Eli

From: Laurencot, Elizabeth
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.

The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.

Best,
Eli

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Eli,
Here are my answers to your queries, and couple other minor changes:

(b) (5)
[redacted]

(b) (5)

[redacted]

(b) (5)
[redacted]

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (http://www.adobe.com/products/acrobat/readermain.html).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.
This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.
<NEJMoa2002032_Guan_Content2_Author.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 17:33:08 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: RE: remarks for White House press conference
Attachments: Fauci remarks Feb 26 - with minor edit.docx

I have made a minor tweak.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, February 26, 2020 12:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Subject: remarks for White House press conference

Dr. Fauci,

Attached for review are proposed remarks (in bullet format) for the White House press conference.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C

Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:49:43 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: BBC Radio

What say you?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paul Coletti <paul.coletti@bbc.co.uk>
Sent: Wednesday, February 26, 2020 11:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: BBC Radio

Dear Dr. Fauci,

Newshour on the BBC World Service is today covering the US preparedness on the Coronavirus

Would you be available for interview on this topic?

We're on air at 3pm eastern and could speak to you live at around 3:10pm or alternatively we could record a few minutes between now and then. About 8 minutes duration and we've many ways to connect to get good audio (no video as we are radio).

If there is interest from your side then I'm on + [redacted] (b) (6)

Yours sincerely,

Paul Coletti
Tel: + [redacted] (b) (6)
Twitter: @bbcworldservice, @pcoletti
Newshour podcasts: www.bbc.co.uk/podcasts/series/newshour

BBC World Service listen live: www.bbc.co.uk/worldserviceradio/on-air

Newshour is the award-winning news and current affairs programme on BBC World Service English, the radio and online network which reaches 75 million listeners each week, including 12.5 million in the USA on National Public Radio.

Paul Coletti
Tel: (b) (6)
Twitter: @bbcworldservice, @pcoletti
Newshour podcasts: www.bbc.co.uk/podcasts/series/newshour
BBC World Service listen live: www.bbc.co.uk/worldserviceradio/on-air

Newshour is the award-winning news and current affairs programme on BBC World Service English, the radio and online network which reaches 75 million listeners each week, including 12.5 million in the USA on National Public Radio.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:37:50 +0000
To: Johnson, Martin S. (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E];Harper, Jill (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Appropriators going to have a call at 3:30 in Larry's office with HHS Op divs on the COVID-19 Supplemental Request

Martin:

You and Hugh should be on the call.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johnson, Martin S. (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, February 26, 2020 11:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>; Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Appropriators going to have a call at 3:30 in Larry's office with HHS Op divs on the COVID-19 Supplemental Request

Tony,

Appropriators going to have a call at 3:30 in Larry's office with HHS Op Divs concerning the 2020suplemental request.

Larry wants someone from NIAID to also be on the call. Please advise who you want to attend.

Thanks

Martin

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:36:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: SIBF inquiry

Please say no to this. Too busy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Shannon Williams <shannon.williams@sibf.org>
Sent: Wednesday, February 26, 2020 11:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: SIBF inquiry
Importance: High

Dear Dr. Fauci,

I am writing to inquire about your willingness to address the Society of International Business Fellows (SIBF) as part of our webinar series. SIBF is a distinguished organization of nearly 1600 global executives and senior leaders. Our C-level global membership would appreciate getting your perspectives on the coronavirus outbreak. We are open to topics which could include....What we know and don't know...As business and community leaders what SIBF members can do to prepare and educate their employees...Safety of travel, etc.

We were thinking the webinar could be approximately 30 minutes in length (15 minutes of remarks followed by 15 minutes of Q&A). SIBF's Communications Manager could work with someone on your team to set-up the webinar. SIBF is a non-profit, but we are able to provide a $2k honorarium to you or a charity of your choice.

Thank you for your gracious consideration and attention to our request. It is our sincere hope that you will be able to participate.

Best regards,

Mr. Shannon George Williams | Director of Programs
Society of International Business Fellows (SIBF)
715 Peachtree Street NE, Suite 200
Atlanta, GA 30308
P: (470) 378-1151 W: www.sibf.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:27:37 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: MSNBC Guest Request 2/26

FYI. Please handle as you see fit.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hirsch, Nancy (NBCUniversal) <Nancy.Hirsch@nbcuni.com>
Sent: Wednesday, February 26, 2020 10:59 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: MSNBC Guest Request 2/26

Hello Dr. Fauci
I hope this finds you well and I am sure receiving numerous requests
Would you be avail to join anchor Ari Melber tonight 6 pm EST to speak to Trumps presser and the latest on Coronavirus?
Thank you for letting me know if you can join soonest possible.
Nancy

Nancy Hirsch

The Beat with Ari Melber
Mavericks with Ari Melber
Booking Producer
30 Rockefeller Plaza|New York, NY 10112
(T) 212-664-4097
(C) (b) (6)
MSNBC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:22:01 +0000
To: Eisinger, Robert (NIH/NIAID) [E];Greg Folkers ((b) (6)
Subject: FW: NEJM content proof (Fauci)

See below. I will need your help on this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.

The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.

Best,
Eli

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>

Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] < [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: NEJM content proof (Fauci)

Dear Eli,
Here are my answers to your queries, and couple other minor changes:

(b) (5)

[redacted]

(b) (5)

[redacted]

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (http://www.adobe.com/products/acrobat/readermain.html).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:18:06 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: First in class, hemostatic drug - potential therapeutics for COVID-19
Attachments: NIAID EEEV - SP16_ Jan 28, 2020 - Read-Only - Read-Only.pdf, JACC manuscript Oct 2017 SP16 AMI (1).pdf, Serpin Pharma - Non-Confidential Partnering Deck v29.pdf

Please take a look at this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cohava Gelber [redacted] (b) (6)
Sent: Tuesday, February 25, 2020 8:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: First in class, hemostatic drug - potential therapeutics for COVID-19
Importance: High

Dear Dr. Fauci,

[redacted] (b) (4)

[redacted] (b) (4)

Please let us know how we can help.
I have attached a manuscript and company presentations for your review.
Sincerely,
Cohava

Cohava Gelber, PhD, MBA
Executive Chairperson & CEO
Serpin Pharma
www.serpinpharma.com
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:17:35 +0000
To: Mehta, Nehal N. (NIH/NHLBI) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers [redacted] (b) (6))
Subject: RE: Guidance for users of biologics in the age of Coronavirus.

I am sorry Nehal, but I am really swamped right now and cannot make this a priority. I hope that you understand.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mehta, Nehal N. (NIH/NHLBI) [E] [redacted] (b) (6)>
Sent: Tuesday, February 25, 2020 8:47 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: Guidance for users of biologics in the age of Coronavirus.

Dear Tony-
I wonder if you would be willing to participate in a short piece regarding use of biologics with looming Coronavirus for JAMA Dermatology or JAMA Internal Medicine?

Please see the email sent below to me by my colleague and collaborator Joel Gelfand from Penn.

I understand there are fierce demands on your time but we would be happy to draft for your approval.

Many thanks for your consideration!

All my best,
Nehal

Nehal N. Mehta, MD MSCE FAHA
Lasker Senior Investigator
Chief, Lab of Inflammation and Cardiometabolic Diseases
National Heart, Lung and Blood Institute
Bethesda MD 20892
Email [redacted] (b) (6)
Phone: [redacted] (b) (6)

Begin forwarded message:

From: "Gelfand, Joel" [redacted] (b) (6)
Date: February 25, 2020 at 8:12:48 PM EST
To: "Mehta, Nehal N. (NIH/NHLBI) [E]" [redacted] (b) (6)
Subject: Guidance for users of biologics in the age of Coronavirus.

Dear Nehal,

With the coronavirus bordering on a pandemic and the expectation that it will affect the US at some point, it seems to me we should be prepared to provide guidance to patients who are on immune modulators for inflammatory disease. Specifically, many will wonder if patients should stop their biologic if the virus becomes prevalent in their community. There will also be questions about stopping biologics in the setting of acute infection with coronavirus.

Any thoughts on this? My specific interests relates to patients with psoriasis or psoriatic arthritis on biologics but it's also relevant to patients with IBD, RA and other inflammatory diseases.

Joel

Joel M. Gelfand MD, MSCE
Professor of Dermatology
Professor of Epidemiology
Vice Chair for Clinical Research (Dermatology)
University of Pennsylvania, Perelman School of Medicine
https://www.med.upenn.edu/gelfand/

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:14:43 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft MA re: Fauci/Eisinger/Redfield COVID-19 paper

This looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, February 25, 2020 5:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FOR ASF REVIEW: Draft MA re: Fauci/Eisinger/Redfield COVID-19 paper

Hi Dr. Fauci,

Please find attached for your review a draft media availability about your imminent NEJM paper on COVID-19. We have named you as the spokesperson in the MA.

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A17F

Bethesda, MD 20892
(b) (6)
Media line: (301) 402-1663

From: [redacted] (b) (6)
Sent: Wed, 26 Feb 2020 09:23:22 -0500
To: Thomas R. Frieden
Subject: Re: FYI

Thanks, Tom.

> On Feb 25, 2020, at 3:41 PM, Thomas R. Frieden <[redacted] (b) (6)>wrote:
>
> Tony,
>
> Nothing you don't already know....
>
> Tom
>
> ---
>
> **From:** Tom Frieden [redacted] (b) (6)>
> **Date:** Tuesday, February 25, 2020 at 3:39 PM
> **To:** Tom Frieden [redacted] (b) (6)
> **Subject:** A COVID-19 Pandemic is Inevitable. Now what?
>
> Dear Colleague,
>
> It's now clear that COVID-19 will become a pandemic. We don't know if it will be mild, moderate or severe, or how many countries it will reach.
>
> As we shift from the initiation phase of the pandemic to the acceleration stage, I've highlighted 8 things we must do now in a new CNN OpEd: http://www.cnn.com/2020/02/25/health/coronavirus-pandemic-frieden/index.html
>
> Please share, and thank you for what you continue to do for public health.
>
> All the best,
>
> Tom
>
> If you'd like to retweet, here's a link.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 12:47:09 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: Milken outreach

Thanks, Francis. It might be better for you to make an e-mail introduction and I will take it from there.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Wednesday, February 26, 2020 7:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: RE: Milken outreach

He's at [redacted] (b) (6) and [redacted] (b) (6) Want to reach out directly or shall I make an e-mail introduction?

Francis

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, February 26, 2020 6:43 AM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Subject: Re: Milken outreach

Francis:
Thanks for the note. Milken can help in a number of ways including directly supporting the VRC. Also, as we start looking for Pharma to step up with us, his connections could be helpful.
Tony

On Feb 25, 2020, at 12:58 PM, Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> wrote:

Hi Tony,

I'm sure you know Michael Milken. I've worked with him over many years, and though he is a somewhat controversial figure he has certainly helped NIH in many ways. He reached out to me last night to ask if there is anything he could do to help with the coronavirus vaccine effort. He had seen press reports that finding a pharma partner had been challenging – and wanted to volunteer his help in that regard, since he has deep connections in the private sector. He also said that he'd be glad to help with any philanthropic needs, both through his own resources and his influence over members of the Giving Pledge.

Are there useful actions that I can suggest to him?

FC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 10:59:30 +0000
To: 辛恩波
Subject: RE: Questions about the coronavirus—Chinese Media Inquiry:

See answers below in **red**

From: 辛恩波 <xinenbo@thepaper.cn>
Sent: Wednesday, February 26, 2020 1:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Questions about the coronavirus—Chinese Media Inquiry:

Dear Dr Fauci,

My Name is Paul Xin, I'm a journalist from Pengpai News(ThePaper) of Shanghai, which is one of the most important new medai in China. I 'm Sorry to bother you as you must be very busy. I noticed your comment about coronavirus on American media, I deeply hope you could answer few of my questions.Your answers will be very helpful to me. The questions are below.

Thank you very much!

Sincerly,
Paul Xin

———————————————————————

1/You said on CNN that US have had pandemic preparedness plan that developed in preparation for pandemic influenza. Could you provide some details of this plan? **The plan outlines the differences between containment and mitigation. It speaks of the thing that should be done if an outbreak occurs in the USA. Thes inclue social distancing, use of telecommunication and telework, temporarily closing schools, avoiding crowed places such as indoor arenas and theaters.**

2/To prepare for potential communities spread of coronavirus in US, do you think that US need take the measures similar with China? **China was in the "reactive" mode of responding to an explosion of cases in Wuhan City and Hubei province with spread throughout China. China had to resort to very dramatic measures such as shutting down cities. The USA is now in a preparative mode and not a reactive mode and so our response is much different than that of China.**

澎湃
THE PAPER

辛恩波
澎湃新闻/时事新闻中心/国际新闻部
上海市延安中路839号

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 10:46:23 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Confirmation from CNN's New Day

Got it. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, February 26, 2020 5:40 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Fwd: Confirmation from CNN's New Day

Firm for 650 am hit today at med arts as per below.

Sent from my iPhone

Begin forwarded message:

> **From:** "Figliola, Mike" <Mike.Figliola@turner.com>
> **Date:** February 26, 2020 at 3:33:40 AM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" <[redacted] (b) (6)>, "Daniels, Ronnel (NIH/OD/ORS) [C]" [redacted] (b) (6)>, "Ryland, Ken (NIH/OD/ORS) [E]" [redacted] (b) (6)>, Jonathan Bennett [redacted] (b) (6), "Jackson Farrar, Joy (NIH/OD/ORS) [E]' [redacted] (b) (6)
> **Subject: RE: Confirmation from CNN's New Day**
>
> Hi everyone,
> This is Mike with CNN's New Day. Hope you are well.
> This is to confirm Dr. Fauci will be a guest today, **Wednesday 02.26.20** at around **6:50am EST to** discuss:
>
> **6E:**
>
> **Coronavirus latest – are we facing an outbreak?**
>
> You will be **solo at 6:45am EST** for the segments.
>
> **John Berman**, will both be conducting today's interview.
>
> Please arrive at the studio no later than **6:40am EST.**
>
> Here is your studio confirmation:

SHOW MANAGER: VENDOR STUDIO #2018562
NIH Events Management (Medical Arts) Studio Info
NIH Control Room numbers are 301-827-8478 and 8479
Encompass Booking and Circuit Number:
Booking: 1-800-243-1995
Circuit: 36TBGS104492
Our IFB: 301-496-1811 (we prefer to call into the station's IFB)
Video: 1080i (59.94) - the audio is embedded.
Please call the TOC with any technical questions at 301-827-8478

Please confirm you have received this and are all set to go!

Best,

M

Mike Figliola
Editorial Producer
CNN's New Day
212-275-8161
mike.figliola@turner.com

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 01:32:22 +0000
To: Jon LaPook
Subject: RE: CBS Sunday Morning

Jon:
The message would have to be that the situation continues to evolve and people need to follow the news and the reports from CDC. For example, a few weeks ago if you wanted to travel to Japan or South Korea, it was fine since there were few is any cases there. Now both countries have a travel alert that says "Avoid all but essential travel". You should tell people that travel to places with few or no reported cases is fine. Only when you have community spread (person to person to person) should you be concerned about a specific travel destination. Also, you could explain to people that pandemics evolve when a new infectious disease is spreading by sustained community spread in multiple countries in different regions of the globe. Once a pandemic erupts, it is virtually impossible for any country to be free of cases. People need to understand that. You can mitigate the effects, but you cannot avoid having infections since you cannot shut off the country from the rest of the world. Also, you need to speak of the real and present danger of seasonal influenza every year. Do not let the fear of the unknown (i.e. a pandemic of a new infectious agent) distort your evaluation of the risk of the pandemic to you relative to the risks that you face every day. The only thing that we can do is to prepare as best as possible and do not yield to unreasonable fear.
Best,
Tony

-----Original Message-----
From: Jon LaPook (b) (6)>
Sent: Tuesday, February 25, 2020 6:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)>
Subject: CBS Sunday Morning

Hi Tony,
I have an unusual opportunity: the executive producer of CBS Sunday Morning has asked me to do a straight to camera shpiel about COVID-19 for this Sunday. I did something similar when people are panicking about Ebola.

You and I have spoken enough about this so that I feel comfortable with the basics. But I would love you to give some thought to whether there are any misunderstandings that you would like cleared up or information you would like disseminated.

I would love to give some logical travel advice. I know there are so many unknowns, but I have had multiple people ask me whether they should cancel their upcoming to trip to ... you name it (Italy, Israel, San Francisco). I know it comes down to risk/benefit, and - as you told me during the Ebola outbreak - people have all sorts of varying levels of comfort with risk. But what do I actually SAY to the 6 million people who will be watching people? :)

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: (b) (6)
Sent: Tue, 25 Feb 2020 19:07:15 -0500
To: McNeil Jr, Donald G
Subject: Re: thought from a kibbitzer...

You make some very good points, Donald.

> On Feb 25, 2020, at 4:48 PM, McNeil Jr, Donald G <mcneil@nytimes.com>wrote:
>
> I was just watching the HHS briefing online, and thinking about an article I read this morning, and Bruce Aylward's description of what he saw in China, and a lot of videos I've watched on the South China Morning Post website (they're doing great coverage.).
>
> In China, we in the media tend to report the horrors and the lockdown and the government's early lies...
>
> But the truth is that a lot of average Chinese behaved incredibly heroically in the face of the virus: 25,000 doctors and nurses went into Wuhan to help, knowing they might die. Average people gave up their stockpiles of masks so they could be shipped to Wuhan. Neighborhood committees brought food to thousands of little old ladies and checked on them every day, even as they asked them to stay behind their doors for fear of infection.
>
> Meanwhile, in America, people tend to act like selfish pigs interested only in saving themselves. How can I hoard a mask? Where's my vaccine? This morning, I read this appalling article from Alabama. Here you have Americans coming back from a horrifying experience overseas, and the President -- who is popular in Alabama -- asks Alabamans to take some of those fellow Americans in. There is zero risk because they're going to be housed on a naval base.
>
> And yet, the answer is "No! Keep them out!" And their legislators encourage it....
>
> I dunno -- that's the kind of behavior I expect from my fellow New Yorkers, not from Alabama.
>
> If the virus arrives -- and we both know it will -- America is going to have to do better than that. Like the Chinese, Americans are going to have to look out for each other the way we haven't since 9/11. Or maybe since World War II.
>
> But that's not the tone of the HHS briefings. They're an aggressive, defensive, almost smart-alecky "we got this" tone. The only time the tone was right when you

were the third to take the mike and explain things to that kid shouting from the back without a mike about "What's the real message? What do we do?"

Maybe there could be some thought given to mentally preparing Americans to work together in the face of the crisis? Quarantines are a very aggressive approach -- but they require a lot of compassion or the people quarantined suffer.

I might get around to writing an article about this, but my editors keep grabbing me for minute by minute stuff and I'm way behind.

Donald

From: [redacted] (b) (6)
Sent: Tue, 25 Feb 2020 18:59:02 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Surfactant Protein-D against coronavirus

Please handle.

Begin forwarded message:

> **From:** Marc Salzberg < [redacted] (b) (6).
> **Date:** February 25, 2020 at 4:42:47 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Surfactant Protein-D against coronavirus**
>
> Dear Dr. Fauci,
>
> We are developing a recombinant human form of Surfactant Protein-D (AT-100), an endogenous collectin with strong immune-modulatory properties. AT-100 shows anti-inflammatory and anti-infectious properties. [redacted] (b) (4) There are data indicating that SP-D clears coronavirus (https://www.ncbi.nlm.nih.gov/pubmed/19439011). [redacted] (b) (4)
>
> While we are discussing this with a number of academic institutions, I was wondering, though, whether you and the NIH are interested to collaborate on evaluating AT-100 against coronavirus. Please let me know, if you are willing to schedule a phone call with our Chief Medical Officer Dr. Paul Kingma and I to discuss. There is obviously a sense of urgency behind this request.
>
> Best regards,
>
> Marc Salzberg
>
> ---
>
> **Airway Therapeutics, Inc.**
> **Marc Salzberg, MD**
> President &CEO
> 1200 Johnson Ferry Rd., Suite 300
> Marietta, GA 30068
>
> Ph
>
> [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Tue, 25 Feb 2020 18:33:00 -0500
To: David - Gmail
Subject: Re: David Pyrce Reconnecting - Coronavirus Task Force

David:

Thanks for your note and your keen interest in this important challenge of coronavirus. The White House Task Force is chosen by the President upon the advice of his senior staff. I am afraid that there will not be any additional members for now. Again, thank you for your interest.
Best regards,
Tony

> On Feb 25, 2020, at 5:29 PM, David - [redacted] (b) (6) wrote:
>
> Hello Dr. Fauci,
>
> I know you are extremely busy and will get right to the point. I would like to join the coronavirus taskforce.
>
> I worked on the Ebola task force about six years ago, which had a similar sense of urgency, and recognize that assembling a SWAT team overnight is critically important in order to monitor, contain and mitigate the spread of the coronavirus, not just for the United States, but on a worldwide basis.
>
> I've done a significant amount of work in infectious disease vaccine development at a number of biotech firms (Vical, Inovio and Intrexon) in partnership with the NIH, Vaccine Research Center, DOD and the CDC.
>
> I also [redacted] (b) (6) we discuss preparedness on a daily basis. Those conversations clearly indicate that the knowledge and expertise is severely lacking at both the academic medical center level, as well as the community health level.
>
> I believe my assistance can be deployed in several areas where my experience in virology, immunology, antivirals, Ebola, product development and strategic partnering could be of immediate value to research scientists, medical professionals and healthcare systems.
>
> 1. Identification of emerging therapeutics.
> 2. Fast track emerging therapeutics from pre-clinical to IND and fast-track clinical trials.
> 3. Identify opportunities to accelerate the production of commercial quantities of therapeutic material.
> 4. Identify unique genomic fingerprints of responders and patients undergoing treatment to guide therapeutic selection and optimize interventions.
> 5. Interface with public and/or institutional stakeholders on a worldwide basis (24/7) regarding safety procedures, diagnostics, therapeutic interventions, etc.
> 6. Other initiatives, representing areas where there is an immediate need to bring on board and deploy an individual with deep expertise, who can provide leadership, drop in and rapidly advance those initiatives.

With the urgently required, in order to provide a Navy SEAL like response, I would propose a consulting arrangement where I'm available 24/7, anywhere/anytime, for as long as needed. Please let me know your thoughts.

Here is a brief snapshot of my C.V.

1. SVP, Innovation and Chief Commercial Officer – NantKwest (gene/cell therapies, immunotherapeutics and molecular diagnostics)
2. SVP, Innovation and Chief Commercial Officer – NantHealth (AI/bioinformatics-based multi-omics based molecular diagnostics and neoantigen-based therapeutics)
3. Founder/CEO - Genomic Principles (neoantigen-based, individualized therapeutic vaccines)
4. Founder/CEO Canton Biotechnologies (DNA-based therapeutics and vaccines)
5. Chief Business Officer – Intrexon (gene/protein-based therapeutics and vaccines)
6. Chief Business Officer - Inovio (gene-based therapeutics and vaccines)
7. VP, Business Development – Vical (gene-based therapeutics and vaccines).

I know you are busy and you can feel free to forward this email to the appropriate individual. I can also be reached by cell phone (b)(6) to discuss further.

Best Wishes,

David

David Pyrce
Cel (b)(6)
[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 22:10:15 +0000
To: NIAID OD AM
Subject: FW: Hello from [redacted] (b) (6)

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Groslyn Burton <burton@theasiagroup.com>
Sent: Tuesday, February 25, 2020 10:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Hello from [redacted] (b) (6)

Dr. Fauci -

I hope this note finds you well. [redacted] (b) (6) I apologize for the direct out of the blue message, however, my company The Asia Group has a podcast called Tea Leaves and we would be interested in having you as a guest to speak about the Coronavirus. I mentioned to my CEO that you are the leading expert and that I had a connection with you. We would only take about 30-45 mins of your time and would be happy to work around your schedule if this is something that you would be willing to do. Below is a short description of the podcast and a link to our episodes. If able, I'd be happy to coordinate with your assistant.

Looking forward to hearing back soon.

Thanks,
Groslyn "Foster" Burton
Vice President, Culture and Values
Executive Assistant to the Chairman
Dr. Kurt M. Campbell, Chairman and CEO
The Asia Group, LLC

202-350-3285 – Office
(b) (6) – Mobile
202-750-2944 – Fax

he Asia Group announced the launch of Tea Leaves, a new podcast that will focus on the current affairs, foreign policy, business, and arts of Asia. The podcasts' hosts, Dr. Kurt M. Campbell and Ambassador Richard Verma, will lead a series of revealing interviews with policymakers, business leaders, journalists, and artists exploring the most dynamic and consequential region in the world.

In a joint statement, Campbell and Verma said, "We wanted to share our passion for Asia with listeners, both accomplished Asia hands and those with a budding interest in the dynamic region. Our aim is to provide listeners with a greater understanding of the individuals who focus on and live in the region, and how Asia affects our world."

The hosts bring significant experience and expertise to the podcast. Campbell is CEO and Chairman of The Asia Group, and served as Assistant Secretary of State for East Asian & Pacific Affairs from 2009 to 2013. Richard Verma is Vice Chairman and Partner at The Asia Group, and served as the United States Ambassador to India from 2015 to 2017.

The first episode of Tea Leaves is now live on major podcast platforms, including iTunes, Stitcher, and Overcast. Subsequent episodes will be animated by conversations with the movers, doers, and thinkers who are driving today's Indo-Pacific. "We hope that you will subscribe and give our first episode a listen," said Campbell and Verma.

The link to the podcast is available here: https://itunes.apple.com/us/podcast/the-tea-leaves-podcast/id1355207045

From: [redacted] (b) (6)
Sent: Tue, 25 Feb 2020 16:08:53 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: The Last Word with Lawrence O'Donnell

Let us discuss

Begin forwarded message:

> **From:** "Shuster, Amy (NBCUniversal, MSNBC)" <amy.shuster@msnbc.com>
> **Date:** February 25, 2020 at 3:40:25 PM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: The Last Word with Lawrence O'Donnell**
>
> Good afternoon,
>
> I wonder if Dr. Fauci could join our program this evening at 10 pm to discuss the best measures for the government and the American people to prepare for a coronavirus pandemic.
>
> Ali Velshi is hosting our show tonight on MSNBC.
>
> This would be a panel discussion this evening – we're still working through details of the panel.
>
> Interview would be from 10-10:20 pm EST.
>
> Please let me know if anything would be possible tonight.
>
> Many thanks,
> Amy
>
> Amy Shuster
> Senior Producer
> The Last Word
> o. 212-664-1657
> c. [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Tue, 25 Feb 2020 14:03:48 -0500
To: Ziady, Hanna (NE)
Subject: Re: Questions on coronavirus vaccine

45 people. It will take 3 to 4 months to complete.

> On Feb 25, 2020, at 11:12 AM, Ziady, Hanna (NE) <Hanna.Ziady@turner.com>wrote:
>
> Thanks very much for the quick response.
>
> Do you know at this stage when the phase 1 trial will be completed and how many people will participate in it?
>
> Many thanks,
> Hanna
>
> Hanna Ziady
> Writer | CNN Business
> O: +44 207 693 1884
> M: + [redacted] (b) (6)
> @hannaziady
>
> ---
>
> **From:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Date:** Tuesday, 25 February 2020 at 15:58
> **To:** "Ziady, Hanna (NE)" <Hanna.Ziady@turner.com>
> **Subject:** RE: Questions on coronavirus vaccine
>
> The phase 1 trial to determine safety for the mRNA vaccine platform that NIH is doing with Moderna is scheduled to start within 2 months (some time in April). However, this is just the first step in attempting to have a vaccine available for use. Even proceeding at an emergency speed, a vaccine would not be available for use for at least 1 to 1.5 years. It is characterized as a "vaccine".
>
> **Anthony S. Fauci, MD**
> **Director**
> **National Institute of Allergy and Infectious Diseases**
> **Building 31, Room 7A-03**
> **31 Center Drive, MSC 2520**
> **National Institutes of Health**

Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ziady, Hanna (NE) <Hanna.Ziady@turner.com>
Sent: Tuesday, February 25, 2020 5:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Questions on coronavirus vaccine

Dear Dr Fauci,

Trust this mail finds you well.

I have a few questions regarding the Moderna vaccine, which it would be great to get your input on.

Is it true that trials of the possible vaccine will start in April, but that, even if the first study is positive, the vaccine might not become widely available until next year because of the need for further studies and regulatory clearances?

The company is characterizing this as a vaccine. Strictly speaking, what should it be referred to as?

If you have time for a quick telephone call this morning as soon as you're able that would be great.

Many thanks,
Hanna

Hanna Ziady
Writer, CNN Business
Office: +44 207 693 1884
Mobile: (b) (6)
@hannaziady

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: [redacted] (b) (6)
Sent: Tue, 25 Feb 2020 13:56:38 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: cdc coronavirus

This does not change anything I said this AM. It is perfectly compatible with what I said. No conflict at all.

> On Feb 25, 2020, at 1:32 PM, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>wrote:
>
> Pls advise
>
> Patricia L. Conrad
> Public Health Analyst and
> Special Assistant to the Director
> National Institute of Allergy and Infectious Diseases
> The National Institutes of Health
> 31 Center Drive, MSC 2520 - Room 7A03
> Bethesda, Maryland 20892
> [redacted] (b) (6)
> 301-496-4409 fax
>
> Disclaimer:
> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
>
> ---
>
> **From:** Jakaitis, Mike <mjakaitis@wtop.com>
> **Sent:** Tuesday, February 25, 2020 1:26 PM
> **To:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
> **Subject:** cdc coronavirus
>
> The CDC today alerted Americans to begin to prepare for community spread of the coronavirus…..does this changes Dr. Fauci's view on the virus? If so can he join us. If this doesn't change anything. We can use what he said this morning….or if he wants to come on and talk about the new CDC warning…we would like to speak to him.

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:52:31 -0500
To: James Rae
Subject: Re: touch screens transmitting Coronavirus

Mr. Rae:
Thank you for your note.
Best regards,
A.S. Fauci

> On Feb 25, 2020, at 1:36 PM, James Rae (b) (6)> wrote:
>
> Dear Dr. Fauci-
>
> Thanks for your tv appearances to educate.
>
> Cell phone and other touch screens could be a major vector of transmission for Coronavirus.
>
> Please suggest frequent cleaning of devices with alcohol on your next tv appearance.
>
> Keep up the good work. I've watched you over the years. Your public education is much appreciated.
>
> Best regards,
>
> Jim Rae
> Boston area
> (b) (6) mobile

From: [redacted] (b) (6)
Sent: Tue, 25 Feb 2020 13:09:02 -0500
To: Emanuel, Ezekiel J
Cc: [redacted] (b) (6)
Subject: Re:

It may well diminish somewhat as weather gets warmer. However, there is no guarantee that this will occur. More likely that it will become seasonal and go down in our summer and resurge next winter

On Feb 25, 2020, at 12:48 PM, Emanuel, Ezekiel J [redacted] (b) (6)>wrote:

To get 1 million deaths of 1957 would require 200 million infections at a death rate of 0.5%. That seems high number of infections.

But what is the worldwide seasonal flu death numbers if the USA has 50,000 deaths in a bad year and the 1957 number of deaths was 116,000? The WHO says 650,000 deaths worldwide from seasonal flu. So this could be worse but by about 40% not an order of magnitude. Okay so I should be more concerned.

And do you think it will go down in late spring with warmer weather?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost for Global Initiatives
Diane v.S. Levy and Robert M. Levy University Professor
Chair, Department of Medical Ethics and Health Policy ([redacted] (b) (6) [redacted])
Co-Director, Healthcare Transformation Institute
University of Pennsylvania

Phone: [redacted] (b) (6)
Fax: 215-898-6567

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, February 25, 2020 12:32 PM
To: Emanuel, Ezekiel J <[redacted] (b) (6)>
Subject: RE:

Zeke:

Ari is also calling me frequently. The virus has adapted itself very well to humans with considerable community transmission (certainly in China) now in other countries such as South Korea, Japan, Iran, Italy, etc. If it continues to spread via multiple generations of human to human transmission, then we will not be able to avoid considerable amounts of infections and spread in the USA. Seasonal influenza has a mortality of 0.1%. The calculated mortality of COVID-19 to about 2.5 %. It is probably lower since the denominator is likely larger than we appreciate due to asymptomatic infections. Even if the mortality goes down to 0.5%, that is still equivalent to a pandemic influenza of 1957 or 1968. In other words, it could be worse than you think.
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J [redacted] (b) (6)
Sent: Tuesday, February 25, 2020 10:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject:

Tony,

Ari is pestering me endlessly. What is your latest update and assessment on coronavirus? I still am having a hard time seeing this as serious as everyone else. Am I blind? Yes very transmissible but low mortality like flu in many ways—the elderly, those with comorbidities, and total impact is likely to be less than flu. Also travel restrictions are delaying but not stopping virus.

Am I missing something big or small?

Thanks

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost for Global Initiatives
Diane v.S. Levy and Robert M. Levy University Professor
Chair, Department of Medical Ethics and Health Policy ([redacted] (b) (6)
)
Co-Director, Healthcare Transformation Institute
University of Pennsylvania

Phone: [redacted] (b) (6)
Fax: 215-898-6567

From: [redacted] (b) (6)
Sent: Tue, 25 Feb 2020 13:04:40 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: DDP4 Inhibitors and ACE2 Inhibitors :: Spike Protein Binding in MERS and SARS

Please handle. Thanks

Begin forwarded message:

> **From:** JoelMeyer [redacted] (b) (6)>
> **Date:** February 25, 2020 at 12:32:24 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" < [redacted] (b) (6)>
> **Subject: DDP4 Inhibitors and ACE2 Inhibitors :: Spike Protein Binding in MERS and SARS**
>
> Dear Dr. Fauci,
> Is it possible that DDP4 and ACE2 inhibitors would be effective in preventing coronavirus entry and thereby 'de-rail' the infectious cycle?
> Thank you for your work and guidance to NIAID!
> Sincerely,
> Joel R.L. Meyer
> [redacted] (b) (6)
> [redacted] (b) (6)
> ==
> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891363/
> **"Coronavirus entry is initiated by the binding of the spike protein (S) to cell receptors, specifically, dipeptidyl peptidase 4 (DDP4) and angiotensin converting enzyme 2 (ACE2) for MERS-CoV and SARS-CoV, respectively [1–5]"**
> ...
> References
> 1. Masters, PS., Perlman, S. Coronaviridae in Field's Virology. Knipe, DM., Howley, PM., editors. Vol. 1. Lippincott, Williams &Wilkins; Philadelphia: 2013. p. 825-858.
> 2. Coleman CM, Frieman MB. Coronaviruses: important emerging human pathogens. J Virol. 2014; 88:5209–5212. [PubMed: 24600003]
> 3. De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nature Rev Microbiol. 2016; 14:523–534. [PubMed: 27344959]

4. Greenberg SB. Update on human rhinovirus and coronavirus infections. Sem Respir Crit Care Med. 2016; 37:555–571.

5. Vijay R, Perlman S. Middle East respiratory syndrome and severe acute respiratory syndrome. Curr Opin Virol. 2016; 16:70–76. [PubMed: 26855039]

From: [redacted] (b) (6)
Sent: Tue, 25 Feb 2020 13:02:20 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Doctor Radio followup special

Please see if this is possible. Thanks

Begin forwarded message:

> **From:** "Siegel, Marc" <Marc.Siegel@nyulangone.org>
> **Date:** February 25, 2020 at 12:07:19 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, Beth Ameen <beth.ameen@siriusxm.com>
> **Subject: Doctor Radio followup special**
>
> Hi Tony
> Am wondering if you might have a few minutes to join us by phone again this Friday between
> 3 and 4 on coronavirus
> Would mean alot.
> Marc
>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:25:40 +0000
To: Gary Simon
Cc: Graham, Barney (NIH/VRC) [E];Ledgerwood, Julie (NIH/NIAID) [E];'Chen, Grace (NIH/NIAID) [E]';Conrad, Patricia (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E]
Subject: RE: Coronavirus vaccine

Thanks, Garry. I will pass your note on to the people who will be conducting the phase 1 vaccine trial here at NIH.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gary Simon [redacted] (b) (6) >
Sent: Tuesday, February 25, 2020 10:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Coronavirus vaccine

Dear Tony,

I'm not sure which email you use. [redacted] (b) (4) It would certainly expedite getting samples to NIH for immune assays.

gary

Gary L. Simon, MD, PhD, MACP
Walter G. Ross Professor of Medicine

Director, Division of Infectious Diseases
Vice-Chairman, Department of Medicine
T (b) (6)
F 202 741-2241

Confidentiality Note: This e-mail is intended only for the person or entity to which it is addressed and may contain information that is privileged, confidential or otherwise protected from disclosure. Dissemination, distribution or copying of this e-mail or the information herein by anyone other than the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, is prohibited. If you have received this e-mail in error, please call (202) 741-3636 and destroy the original message and all copies.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:15:43 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Collaboration proposal on [redacted] (b) (4) variants
Attachments: Macrogen (Dr. Jeong-sun Seo) letter to Dr. Anthony Fauci.pdf

Please handle and respond to this person. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ogan Gurel, MD [redacted] (b) (6)>
Sent: Tuesday, February 25, 2020 9:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Jeongsun Seo MD PhD [redacted] (b) (6); Changhoon Kim PhD [redacted] (b) (6); Moon-Young Shin [redacted] (b) (6)
Subject: Collaboration proposal on [redacted] (b) (4)

Dear Dr. Fauci,

Greetings and thank you for all your outstanding scientific and policy leadership regarding the evolving Covid-19 situation.

I am writing to you from South Korea where, as you well know, we are experiencing a very difficult phase of the epidemic. Among the several groups I have been engaged with to address this crisis, I am working with the genome sequencing company, Macrogen, which you may already be familiar with (https://dna.macrogen.com/eng/). Dr. Jeongsun Seo, the Chairman of Macrogen, along with other company leaders and myself have been discussing [redacted] (b) (4)

[redacted] (b) (4)

[redacted] (b) (4)

Barring the institution of any extreme travel restrictions, I am planning to visit the Bethesda area next week (Macrogen U.S. HQ is located in Rockville). I know you are extraordinarily busy but if you (or key colleagues) have time, I and other senior Macrogen colleagues would be happy to discuss the project, its necessary next steps, along with any other matters related to Korea as you wish. [Please note that I do not have any clinical symptoms or signs of Covid-19 nor any relevant contact history.]

Thank you very much for your attention to this matter and I hope that we may have a chance to advance this important project together.

Please take care and thanks again,

Ogan

[redacted] (b) (6)

in http://www.linkedin.com/in/ogangurel

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:08:19 +0000
To: Eisinger, Robert (NIH/NIAID) [E];Greg Folkers [redacted] (b) (6)
Subject: FW: NEJM content proof (Fauci)
Attachments: NEJMe2002387_Fauci_Content2_Author.pdf

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (http://www.adobe.com/products/acrobat/readermain.html).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Tue, 25 Feb 2020 17:07:30 +0000
To:	Eisinger, Robert (NIH/NIAID) [E];Greg Folkers [redacted] (b) (6)
Subject:	FW: NEJM content proof (Fauci)
Attachments:	NEJMe2002387_Fauci_Content2_Author.pdf

Please take a look at this for me and proof to the extent that you can. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (http://www.adobe.com/products/acrobat/readermain.html).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 15:55:19 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: The global health leaders call, Wednesday 26 February at 13:00 CET
Attachments: [redacted] (b) (4) Swisscom Call code.pdf

Please print out for tomorrow AM.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. [redacted] (b) (6)
Sent: Tuesday, February 25, 2020 4:10 AM
To: Redfield, Robert R. (CDC/OD) [redacted] (b) (6)
[redacted]
[redacted] David Heymann [redacted] (b) (6); Felicity Harvey
[redacted] (b) (6) Chris.Elias
[redacted] (b) (6); Jeremy Farrar
[redacted] (b) (6) Fauci, Anthony
(NIH/NIAID) [E] [redacted] (b) (6)
[redacted] Conrad, Patricia (NIH/NIAID) [E]
[redacted] (b) (6) Thomas R. Frieden [redacted] (b) (6)
[redacted] >; Lynn Banks [redacted] (b) (6); President | Resolve to Save Lives
<president@resolvetosavelives.org> [redacted] (b) (6)
[redacted]
Tarik Mohammed [redacted] (b) (6)
Cc: SHOC <shoc@who.int>; Office of the Director-General <DGOffice@who.int>; SCHWARTLANDER,
Bernhard F. [redacted] (b) (6)>; MAHJOUR, Jaouad [redacted] (b) (6)>; FALL, Ibrahima Soce
[redacted] (b) (6)>; GREIN, Thomas < [redacted] (b) (6); MINHAS, Raman [redacted] (b) (6)>; COX, Paul
Michael [redacted] (b) (6); AL-SHORBAJI, Farah [redacted] (b) (6)>; POOLE, Marcia
[redacted] (b) (6)>; DRURY, Patrick Anthony [redacted] (b) (6)>; GRAAFF, Peter Jan
[redacted] (b) (6); Dr VAN KERKHOVE, Maria [redacted] (b) (6)>; KABIR, Sophia

(b) (6)

Subject: The global health leaders call, Wednesday 26 February at 13:00 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted tomorrow Wednesday, 26 February at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email: (b) (6) ; mobile no. (b) (6)

Best,

Mike

From: [redacted] (b) (6)
Sent: Tue, 25 Feb 2020 07:30:31 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Bloomberg Radio 2/25

Let us discuss

Begin forwarded message:

> **From:** "Jameelah D Robinson (BLOOMBERG/ NEWSROOM:)" <jrobinson158@bloomberg.net>
> **Date:** February 25, 2020 at 7:25:43 AM EST
> **To:** "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>
> **Cc:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Bloomberg Radio 2/25**
> **Reply-To:** "Jameelah D Robinson" <jrobinson158@bloomberg.net>
>
> Hi Dr. Fauci!
>
> I Hope this email finds you well. I'm emailing to see if you can join Tom Keene, Bloomberg Suveillance Anchor/Editor-at-Large on his radio show tomorrow morning as a PHONER at 8:15am Et to discuss the Coronavirus. Please let me know if we can make this happen. Many thanks!
>
> -Jameelah

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 03:27:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: NIAF and coronavirus

Let us discuss.

From: Elvis Oxley <eoxley@bdo.com>
Sent: Monday, February 24, 2020 9:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Eric Jia-Sobota <esobota@bdo.com>
Subject: NIAF and coronavirus

Dr. Fauci, I trust this email finds you well. It has been a few years since we've seen one another on the Hill or at a NIAF event but hopefully we will rectify that soon.

I know you have a lot on your plate, especially with the coronavirus, but I am curious if you have five minutes for a call tomorrow so I can introduce you to my boss at BDO, Eric Jia-Soboda (https://www.linkedin.com/in/eric-jia-sobota-02156036/). Eric is an expert in cost accounting for Life Sciences companies and he wants to glean your perspective on the likely structure of the emergency coronavirus budget request so that NIH and others can maximize those research and implementation dollars at the most rapid pace. We would certainly appreciate your time.

My best, Elvis

Elvis Oxley
Managing Director
Industry Specialty Services
(b) (6) (Mobile)
703-245-8665 (Direct)
eoxley@bdo.com

BDO
Greater Washington D.C.
8401 Greensboro Drive, Suite 800
McLean, VA 22102
www.bdo.com

BDO USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

BDO is the brand name for the BDO network and for each of the BDO Member Firms.

IMPORTANT NOTICES

The contents of this email and any attachments to it may contain privileged and confidential information from

BDO USA, LLP. This information is only for the viewing or use of the intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of, or the taking of any action in reliance upon, the information contained in this e-mail, or any of the attachments to this e-mail, is strictly prohibited and that this e-mail and all of the attachments to this e-mail, if any, must be immediately returned to BDO USA, LLP or destroyed and, in either case, this e-mail and all attachments to this e-mail must be immediately deleted from your computer without making any copies hereof. If you have received this e-mail in error, please notify BDO USA, LLP by e-mail immediately.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 03:26:06 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: Close of Day Note for 2/24/2020 re: coronavirus preparedness

No, I did not see this. You should tell Jim Gillman to copy me on everything that relates to this issue since I am the one who will be dealing with the Congress, the President and the press about all of this.

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Sent: Monday, February 24, 2020 9:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: FW: Close of Day Note for 2/24/2020 re: coronavirus preparedness

Tony,
I assume you have already seen this, but just in case....
Larry

From: "Gilman, James (NIH/CC/OD) [E]" [redacted] (b) (6)>
Date: Monday, February 24, 2020 at 5:50 PM
To: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)>, Francis Collins [redacted] (b) (6), "Gottesman, Michael (NIH/OD) [E]" [redacted] (b) (6)>
Subject: Close of Day Note for 2/24/2020 re: coronavirus preparedness

Francis / Larry / Michael:

[redacted] (b) (5)

(b) (5)

[redacted]

Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 23:38:09 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: LA Magazine / Interview request

Let us discuss.

From: jmcgahan [redacted] (b) (6)
Sent: Monday, February 24, 2020 6:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: LA Magazine / Interview request

Dear Dr. Fauci,

You and I haven't met. I'm a long-time writer for Los Angeles Magazine. We're doing a cover story for the April issue on the threat of the new coronavirus poses to the 10 million inhabitants of metropolitan Los Angeles. Would you be available for an interview on Wednesday?

Thanks,
Jason

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 22:42:57 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Welcome packet & consent form | The Coronavirus Outbreak: Tracking COVID-19 | Forum
Attachments: 3.2.20 Consent form .pdf, 3.2.20 Forum welcome document.pdf, 3.2.20 Green room agenda .pdf

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dweck, Kristen <kdweck@hsph.harvard.edu>
Sent: Monday, February 24, 2020 5:34 PM
To: (b) (6) Lipsitch, Marc (b) (6) Yip, Winnie Chi-Man (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: (b) (6) Osborn, Elizabeth (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Subject: Welcome packet & consent form | The Coronavirus Outbreak: Tracking COVID-19 | Forum
Importance: High

Good evening,

Please find attached, The Forum welcome document, green room agenda and consent form.
The welcome packet includes information about our production along with what to wear while on camera. The Harvard T.H. Chan School of Public Health consent form is required for production of webcast series.

Please sign and scan a copy of the consent form back by **March 2, 2020.**

We look forward to an exciting event!

Best,
Kristen Dweck
--

Kristen A. Dweck
Digital Media and Engagement Manager, The Leadership Studio
Harvard T.H. Chan School of Public Health
677 Huntington Avenue, Kresge 329 | Boston, MA 02115
o: 617-432-1268 | f: 617-432-1780
kdweck@hsph.harvard.edu

HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH
Join the conversation:
The Forum | Twitter | YouTube | iPhone and iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 22:34:05 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Re:Following up on NIH visit

What is this?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Monday, February 24, 2020 4:04 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Hoffman, Hillary (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Segre, Julie (NIH/NHGRI) [E] [redacted] (b) (6)
Subject: RE: Re:Following up on NIH visit

Dear Hillary,
Thanks for your email.
I am indeed looking forward to my NIH visit on Friday, and am still hoping I might get some time with Dr. Fauci, though I can appreciate he might be busier than either of us expected to be back when we first scheduled my interview with him!
Warm regards,
Jason

Jason Gale, MHlthSec
Senior editor | Bloomberg News
Level 30, 120 Collins St., Melbourne VIC 3000

Tel. (landline) +61-3-9228-8783 | Mobile [redacted] (b) (6)
@jwgale | Linkedin: http://www.linkedin.com/pub/jason-gale/6/249/a56

From: [redacted] (b) (6) At: 02/25/20 06:47:17
To: Jason Gale (BLOOMBERG/ NEWSROOM:)
Subject: RE: Re:Following up on NIH visit

Hi Jason,

Hope you have/had safe travels to DC this week! I wanted to check in to confirm that you're still planning on coming to visit us at NIH this Friday?

Currently, Dr. Myles is holding 10am and Dr. Belkaid is holding 1:30pm to discuss their microbiome-related research with you. Dr. Fauci's schedule has been very fluid lately due to the coronavirus outbreak—we'll likely need to check in with his assistant Patty Conrad on Thursday to see how his Friday calendar looks (unless you hear otherwise from Patty directly).

Best,
Hillary

Hillary Hoffman, Ph.D., Writer/Editor
Office of Communications and Government Relations, NIAID, NIH
5601 Fishers Lane #6G38
Rockville, MD 20852
[redacted] (b) (6)
[redacted] (b) (6)

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Tuesday, January 28, 2020 4:39 PM
To: Hoffman, Hillary (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Re:Following up on NIH visit

Sounds good. Many thanks.

----- Original Message -----
From: Hillary Hoffman [redacted] (b) (6)>
To: JASON GALE
At: 29-Jan-2020 08:38:46

> Sounds good – I'll ask Dr. Myles to hold 10am, so you can chat with him before you meet Dr. Fauci at 11. We can re-confirm timing closer to the date. I'll tag along, and can make sure you get where you need to – you'll get to visit several different buildings, fortunately all close by!

From: Jason Gale (BLOOMBERG/ NEWSROOM:)
<j.gale@bloomberg.net>
Sent: Tuesday, January 28, 2020 4:32 PM
To: Hoffman, Hillary (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Re:Following up on NIH visit

Hi Hillary
Late night for me on 2019-nCoV...
Shall we say before DrFauci? Then I'll know better how to get to him. 😁
Thanks a lot. Jason

----- Original Message -----
From: Hillary Hoffman (b) (6)
To: JASON GALE
CC: (b) (6)
At: 29-Jan-2020 06:34:55

> Hi Jason,
>
> Great speaking with you last week. I wanted to follow up to let you know that Yasmine Belkaid and Ian Myles—whose work we discussed on host-microbe interactions and developing a bacteria-based treatment for eczema, respectively—are willing to meet with you on Feb. 28.
>
> Here are links to some background info:
>
> - Dr. Belkaid's lab page, and recent NIAID press release about a skin microbiome study from her lab
> - Dr. Myles' lab page, and NIAID press release about findings from a Ph 1/2 trial assessing the *R. mucosa* treatment for eczema
>
> Dr. Belkaid is available at 1:30pm (her building is next to the Clinical Center, where you'll be meeting with Julie Segre I believe from 12-1ish). Dr. Myles' schedule is a bit more flexible, and he's currently available to meet either in the morning before you speak with Dr. Fauci or later in the afternoon after Dr. Belkaid (Dr. Myles is in the Clinical Center, about a 5 min walk from Dr. Fauci's building) – let me know if you have a timing preference. We can firm up times a bit closer to the date, but wanted to give you an update.

Best,
Hillary

Hillary Hoffman, Ph.D., Writer/Editor
Office of Communications and Government Relations, NIAID, NIH
5601 Fishers Lane #6G38
Rockville, MD 20852
[redacted] (b) (6)
[redacted] (b) (6)

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Thursday, January 23, 2020 4:09 PM
To: Hoffman, Hillary (NIH/NIAID) [E] <hillary.hoffman@nih.gov>
Cc: Routh, Jennifer (NIH/NIAID) [E] <jennifer.routh@nih.gov>
Subject: RE: Re:Following up on NIH visit

Sorry!! Getting on now

From: [redacted] (b) (6) At: 01/24/20 08:07:48
To: Jason Gale (BLOOMBERG/ NEWSROOM:)
Cc: [redacted] (b) (6)
Subject: RE: Re:Following up on NIH visit

Hi Jason,

Wanted to check that you're still able to join us this afternoon/morning -- and that you aren't having issues calling into the conference line. Jen and I are both on.

Thanks, and hope to talk soon!
Hillary

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Friday, January 17, 2020 3:02 PM
To: Hoffman, Hillary (NIH/NIAID) [E]
[redacted] (b) (6)
Cc: Routh, Jennifer (NIH/NIAID) [E]

[redacted] (b) (6)>
Subject: RE: Re:Following up on NIH visit

Awesome. Thanks a lot.

----- Original Message -----
From: Hillary Hoffman
[redacted] (b) (6)
To: JASON GALE
CC: [redacted] (b) (6)
At: 18-Jan-2020 01:31:40

Hi Jason,

Yes, 4pm next Thursday (8am Friday for you) works for us. I will send out a calendar invitation with call-in information later today.

Enjoy your time off, and looking forward to speaking with you next week!

Best,
Hillary

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Thursday, January 16, 2020 6:24 PM
To: Hoffman, Hillary (NIH/NIAID) [E]
<[redacted] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E]
[redacted] (b) (6)>
Subject: RE: Re:Following up on NIH visit

Dear Hillary,
Thanks for your email.
I am on vacation Mon-

Thursday next week. Would a 4 pm call on Thursday Jan. 23 (8 am Friday for me) work?
I just saw happened to see this report, FYI:
https://medicalxpress.com/news/2020-01-gut-bacteria-parkinson.html?fbclid=IwAR2OXNzDroX9zaHhP73A22pK2zOP_2_cRQ6_YJjdQo-icbKrNKrjoPrQ9Z0
It's a good example of the growing awareness that the Human Microbiome Project is helping to provide of the complex interactions with various biological processes that underpin health and disease.
Have a great weekend,
jason

From:
[redacted] (b) (6)
At: 01/17/20 03:22:49
To: Jason Gale (BLOOMBERG/ NEWSROOM:)
Cc:
[redacted] (b) (6)
Subject: RE: Re:Following up on NIH visit

Hi Jason,

Great to hear of your interest in microbiome and flu research. Jen and I would be happy to chat about what NIAID may be able to offer in terms of subject matter experts and storylines in those areas.

Might you be available for a short call next week between 4-5pm EST on either Tues., Wed., or Thurs. afternoon – corresponding to 8-9am Melbourne time on Wed., Thurs., or Fri. morning (assuming I've got my time zones correct)? If we can't find a mutually convenient time, happy to continue discussions over email.

Best,
Hillary

Hillary Hoffman, Ph.D.,
Writer/Editor
Office of Communications and Government Relations,
NIAID, NIH
(b) (6)

Media line: 301-402-1663

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Wednesday,

January 15, 2020
11:56 PM
To: Rancourt, Anne (NIH/NIAID) [E]
(b) (6) [redacted]

Cc: Leifman, Laura (NIH/NIAID) [E]
(b) (6) [redacted] Hoffman, Hillary (NIH/NIAID) [E]
(b) (6) [redacted]; Routh, Jennifer (NIH/NIAID) [E]
(b) (6) [redacted] Lavelle, Judith (NIH/NIAID) [E]
(b) (6) [redacted] Segre, Julie (NIH/NHGRI) [E]
(b) (6) [redacted]

Subject: RE: Re:Following up on NIH visit

Hi Anne,
Thanks a lot for your email and your suggestions! After my last visit to NIH (and meeting with Lisa Proctor and Julie Segre years ago), we did the attached story on the gut microbiome. We're very keen to look

at doing a podcast series on the microbiome (skin, gut, other anatomical bits) and how it's informing our views on health, disease and the way we prevent and treat diseases.
It would be cool to workshop this theme with you and your colleagues before my visit, if you have some time?
I cut my teeth in medical science writing on (bird) flu and would be interested in the research Jeffrey Taubenberger's lab is doing, but my understanding (and I could be wrong) is that there's still a lot of work to be done in producing a universal flu

shot. If such vaccine candidates are still years from entering clinical trials, we probably would push that lower down the list.
Hope that helps, and thanks again!
Jason

Hi Jason,

Ahead of your visit, here are a few labs that are doing innovative work and may present interesting backgrounds to become future stories, or inform your reporting. For antimicrobial resistance specifically, Dr. Fauci is your best source. But the below are exciting areas of research at NIAID, and may be a fit for Prognosis. Let me know if any of the below pique your interest and we can share more detail and/or arrange time.

- **Skin microbiome:** NIAID researchers developed a topical therapy for eczema that involves treating skin with "good" bacteria. If proven effective, this strategy could offer an inexpensive treatment that requires less frequent application than many current eczema medications. A Phase 1/2 trial at NIH indicated that this novel therapy is safe, and most participants experienced improvements in their eczema. NIH has exclusively licensed the technology to Forte Biosciences to advance this potential new therapy through further clinical development.

- **Gene therapy**: NIAID is developing and applying gene correction techniques to treat a variety of genetic immune disorders. For example, NIAID scientists co-developed a lentiviral gene therapy to treat infants with X-SCID, a rare and fatal genetic immune deficiency. In clinical trials, the gene therapy successfully restored the immune systems of infants newly diagnosed with X-SCID, as well as older children and young adults with the condition who experienced complex medical problems after receiving standard therapy. Mustang Bio is handling commercial development of the lentiviral gene therapy for X-SCID.

- **Flu:** Dr. Jeffrey Taubenberger is a 1918 influenza expert who sequenced the 1918 pandemic viral genome using archival autopsy specimens from the Armed Forces Institute of

Pathology and frozen lung biopsies from 1918 flu victims interred in permafrost. Learning about 1918 pandemic flu can help us better prepare for and target future pandemic strains. Dr. Taubenberger's lab is developing a so-called universal flu vaccine that includes 4 inactivated influenza viruses and is expected to undergo clinical testing soon. Also, Dr. Matthew Memoli leads NIAID’s influenza challenge studies in which healthy volunteers are purposely exposed to influenza in a carefully controlled environment. Challenge studies offer a unique opportunity to ask focused questions regarding influenza virus pathogenesis and vaccine efficacy in a controlled manner.

- **Mosquitoes:** NIAID’s

Laboratory of Malaria and Vector Research investigates disease-transmitting insects and broad areas of malaria biology and pathogenesis. Dr. Tovi Lehman studies mosquito ecology, covering broad population biology questions relevant to patterns of malaria transmission and vector control. Recently, Dr. Lehman and colleagues in Mali found that a single mosquito can travel up to 200 miles in a single night with the right prevailing wind speed. The research involved collecting flying insects using sticky nets on helium-filled balloons suspended at varying heights.

- **Eating for the immune system**: Dr. Yasmin Belkaid is researching connections between the microbiome, nutrition

, fat, and immunity. This work is early stage, but potentially paradigm-shifting as she uncovers connections between diet and immunity, with implications for using nutrition to boost immune interventions, including vaccines.

- **RSV:** Multiple researchers are working to develop vaccines against respiratory syncytial virus (RSV)—something most parents have heard of, but is not covered by media. RSV usually causes mild cold-like symptoms in healthy adults; however, RSV can be serious, particularly for infants and the elderly. It is the most common cause of bronchiolitis and pneumonia in children younger than 1 in the US. Scientists have spent decades trying to develop an urgently needed safe and

> effective vaccine. One candidate known as DS-Cav1 developed by Dr. Barney Graham's team at NIAID's Vaccine Research Center has shown early promise in a Phase 1 clinical trial.

I'm CCing my public affairs colleagues who liaise with these topics in case there is follow up. Looking forward to hopefully meeting you when you visit.

Thanks,
Anne

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>

Sent: Thursday, December 19, 2019 4:24 PM
To: Rancourt, Anne (NIH/NIAID) [E] [redacted] (b) (6) >
Subject: Re:Following up on NIH visit

Hi Anne,

Thanks for your email and offer to assist with other interviews.

I'm "old school," and see merit in building relationships with researchers and hearing about their work without the expectation of necessarily getting a story.

My interests are pretty eclectic -- from antimicrobial resistance to anesthesia. If there's some interesting stuff happening that hasn't been reported on in much detail that speaks to the future of health care (that could would for our [Prognosis](#) platform), I'd be keen to hear about it.

Many thanks again and happy holidays,

Jason

Jason Gale, MHlthSec
Senior editor | Bloomberg News
Level 30, 120 Collins St., Melbourne VIC 3000
Tel. (landline)
(b) (6)
@jwgale | Linkedin: http://www.linkedin.com/pub/jason-gale/6/249/a56

From: [redacted] (b) (6) At: 12/20/19 02:54:30
To: Jason Gale (BLOOMBERG/ NEWSROOM:)
Subject: Following up on NIH visit

Hi Jason,

I heard you'll be visiting us at NIH on Feb. 28 for an interview with Dr. Fauci. Please let me know if I can help connect you with other experts while you are here. I'd be happy to arrange for you to see any labs or hear from experts on HIV or other diseases – just let me know what you're interested in hearing and seeing. Thanks! Looking forward to it.

Anne

Anne Rancourt, MPS Section

Chief, Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Pronouns: She/Her
(b) (6)
office
(b) (6)
mobile
(b) (6)

Madonna's Secret for Longevity Seen Aiding Bacteria Boom: Health

2012-05-08
21:34:07.963 GMT

By Kanoko Matsuyama and Jason Gale

May 9 (Bloomberg) -- The secret to Madonna's staying power may be surprisingly simple: gardening.

What the pop star does involves no trowel or soil. Thanks to dishes of fermented soy beans, millet and brown rice prepared by her personal chef, Mayumi Nishimura, Madonna practices a form of inner horticulture -- cultivating her intestinal flora in a burgeoning alternative approach to health.

Studies of the trillions of bacteria living on and in the body suggest the Material Girl, 53, may be onto something. By eating foods rich in fiber and laced with so-called good bacteria, she may be encouraging helpful microbes to flourish in her bowel, aiding in food digestion and vitamin extraction and possibly staving off diseases from asthma to colon cancer.

"This diet that Madonna is following is very sensible," says David Topping, chief food-nutrition researcher at Australia's Commonwealth Scientific and Industrial Research Organization in Adelaide, who studied gut biology for 25 years.

"The bacteria that live inside you are fulfilling very important functions."

While scientists try to understand the ecology of the bacteria and their interactions with diet and disease, companies are looking for ways to profit.

The health benefits of gut germs have spawned a global market for products that contain friendly bacteria, called probiotics, in the form of tablets or supplements added to foods by companies including Danone, Nestle SA, and Yakult Honsha Co. The market for supplemented dairy products such as Danone's Activia yoghurts and Yakult's fermented drinks, worth $14.7 billion six years ago, will probably expand 32 percent to $33.5 billion by 2016, Euromonitor International estimated last month.

Quinoa, Not Coffee

Studies published in the past year have linked certain bowel-dwelling bacteria to a stronger immune system, while others have been associated with autism and obesity. In one paper published in the journal Nature, scientists showed that a type of white blood cell that produces antibodies only acquired its infection-fighting ability after spending time in the gut.

Nishimura, who has cooked for cancer patients before being hired by Madonna, serves quinoa and other whole grains as staples, along with vegetables and soy sauce, she said in a telephone interview from New York. She also tries to offer seaweed every second day -- usually sautéed or boiled.

“We eat food processed as little as possible,” Nishimura, 55, says of her dietary approach, known as macrobiotic. She doesn’t recommend meat, dairy and coffee. An agent for Madonna didn’t respond to a request for comment.

Whole grains and fiber act as both food and fertilizer to the bacteria in the bowel, according to Mark Morrison, a microbiologist with Australia's CSIRO in Brisbane studying ways to improve gut function and health.

'Terrific Interest'

There are 10 times as many bacteria in the human intestinal tract as there are cells in the body. As coordinator of the Human Microbiome Project, Lita Proctor is helping to organize collaboration from hundreds of scientists around the world trying to map and study microbial communities living on the skin, in the mouth and bowel, and in other parts of the body.

"It's extremely heartening and healthy to have so much attention now paid to the diet," says Proctor, who works at the National Human Genome Institute in Bethesda, Maryland.

Even so, Proctor says the research is still in its infancy, and products based on partial understanding may not deliver what they promise. "That's not holding up the industry," she says. "It's a very fluid, ill-defined area, but with a lot of terrific interest."

Flowers and Weeds

The term probiotic is vague and there's no accepted definition for it. Measuring results may be even more of a grey area and some supplements are destroyed by stomach acid before entering the gut, according to Proctor. Nishimura relies on fermented foods such as miso, soy sauce and tempeh to play the role of probiotics and says the benefits of her diet can be quickly noticed. "I feel better than I did 20 years ago," Madonna wrote in a preface to the cookbook her chef had published in 2010. "I am very grateful to you for this."

The garden analogy is helpful when it comes to describing the complex ecology of the bacteria living on humans, says Julie Segre, the lead investigator working on the skin microbiome at the National Human Genome Research Institute.

"There are some flowers that make it easier for other flowers to grow in the same soil," Segre says. The most important thing is to keep out the invasive weeds, she says.

'Transpoosions'

When the weeds take over, Australian gastroenterologist Thomas Borody has a radical approach to reestablishing the balance of intestinal flora in his patients: he transplants fecal germs from disease-free individuals directly into the upper reach of the colon, in a pouch known as the cecum.

His Sydney clinic has done 1,800 of the procedures, which he jokingly dubs “transpoosions,” over 25 years.

Borody, 62, says the treatment has helped patients with ailments ranging from autism to pseudomembranous colitis, a resilient infection that causes abdominal pain, loose bowel movements and fever.

“The next day their diarrhea stops,” the doctor says.

After the procedure, he asks patients to avoid treatments that may damage their gut flora. Three studies presented at the American College of Gastroenterology’s meeting in October indicate fecal transplants can help with bouts of diarrhea associated with the bacterium Clostridium difficile.

When Weeds Take Over

Keeping inner bugs healthy is crucial because otherwise they risk taking over more than the garden. If intestinal bacteria aren't able to survive on the food their host consumes, the germs will try to feed on what they can find -- "mucus as well as anything else," according to CSIRO's Topping. That may lead to inflammatory bowel disease, a painful condition that can evolve into colon cancer, he says. Staving off disease is one reason people have turned to Nishimura's cooking in the past. The chef, who prepared meals for cancer patients in Boston, says the diet helps with constipation, menstrual pain and body odor. When she first changed the way she ate, Nishimura says she also found that her allergic skin rash improved.

'So Fresh'

Typically, Nishimura tailors her meals each day to suit the way her employer feels, she says, adding that Madonna prefers the chef herself to shop for ingredients. Popular dishes include seaweed in miso soup; hijiki -- a type of brown seaweed -- served with carrots and onions and seasoned with soy sauce; and cooked oats for breakfast, Nishimura says. Whole grains demand harder work for bowel bacteria, which help the body extract vitamins and nutrients from food, because the insoluble fiber they contain is only broken down in the lower reaches of the digestive tract in a fermentation process that delivers different quantities and varieties of inflammation-fighting short-chain fatty acids to the body’s cells.

There is “solid evidence” that microbes play a role in tuning the immune system, says Ian Lipkin, director of the Center for Infection and Immunity at Columbia University’s Mailman School of Public Health, where scientists showed in January that children with autism and gastrointestinal disturbances have a bacterial species not found in non-autistic children with tummy upsets.

Madonna and others making similar diet choices may not know they’re pushing the science frontier. They may just feel better.

“When you cut out animal products, white sugar and coffee for 10 days you start to feel the difference,” Nishimura said.

“When I first began

this diet, I remember how my head became clearer, I woke up earlier and felt so fresh in the morning that I didn't want to stay in bed."

Madonna herself isn't lacking in stamina. Her world tour, which starts in Tel Aviv this month and ends next March, includes 75 concerts in Europe and North America. Her previous world tour was in 2008 and 2009, when she also published six children's books and directed or produced two movies.

For Related News and Information:
Most-read health-care stories: MNI HEA <GO>
Bloomberg's top health stories: HTOP <GO>
Bloomberg's top stories on Japan: TOPY <GO>
Bloomberg drug database: BDRG <GO>

--Editors: Marthe Fourcade, Rick

Schine.

To contact the reporters responsible for this story:
Kanoko Matsuyama in Tokyo at +81-3-3201-3490 or kmatsuyama2@bloomberg.net;
Jason Gale in Melbourne at (b) (6) or j.gale@bloomberg.net

To contact the editor responsible for this story:
Jason Gale at +65-6212-1579 or j.gale@bloomberg.net.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 22:33:02 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Virus Transmission

NIAID inquiries, please

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: DANIEL GAGNON [redacted] (b) (6)
Sent: Monday, February 24, 2020 3:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Virus Transmission

Hi Dr. Fauci:

I have been a long time admirer of you in the field of modern medicine. This question I have relates to the current Coronavirus circulating around the world. For many years I have informed people that the ways a virus can be passed from person to person isn't always by a sneeze, cough or by touching someones face with their hands. Has anyone in your medical community thought that if someone were smoking and was an infected person that once they expel the smoke particles into the air that those micro smoke particles may contain viruses that were in the respiratory system of an infected person. Everyone I mention this to don't believe that this is possible. What are your thoughts on this matter? If so why hasn't the medical community warned the public about this possibility as I stay away from all establishments that allow smoking on their premises.

Thank you,

Daniel Gagnon
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 19:55:21 +0000
To: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: interview with Dr Fauci

Here is the reason for the confusion.,

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RABIN, RONI <roni.rabin@nytimes.com>
Sent: Monday, February 24, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: interview with Dr Fauci

I 'm sorry -- I thought you had canceled this time this morning when you said you needed to reschedule. I'm so sorry. I'm in the middle of a meeting with editors at the Times about coronavirus coverage.

On Mon, Feb 24, 2020 at 2:42 PM Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)> wrote:

> Hi Roni,
> We just tried calling you at [redacted] (b) (6) for our 2:30pm ET interview with Dr. Fauci. Please give us a call as soon as possible at [redacted] (b) (6).
>
> Thank you,
> Kim
>
> Kim Barasch [C]
> Office of the Director
> National Institute of Allergy & Infectious Diseases
> [redacted] (b) (6)
> [redacted] (b) (6)

From: Conrad, Patricia (NIH/NIAID) [E]
Sent: Friday, February 21, 2020 4:30 PM
To: [redacted] (b) (6)
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] <[redacted] (b) (6); Robinson, Whitney (NIH/NIAID) [C] [redacted] (b) (6)>
Subject: interview with Dr Fauci

Dr Fauci can be available for your interview as per below on Monday Feb 24th at 2:30 pm ET – 3:00 pm ET. Please let us know asap if that time works. The number to call for the interview will be [redacted] (b) (6)

Thank you,
-patty

Roni Rabin
New York Times
[redacted] (b) (6)
Roni.rabin@nytimes.com
Seeking: Phone interview
Subject: asymptomatic transmission of coronavirus

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

--
Roni Caryn Rabin
New York Times Staff Writer
(212) 556-8314

Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 18:07:33 +0000
To: Doepel, Laurie (NIH/NIAID) [E]
Subject: FW: ASF ---- measles - aerosol / contact / droplet
Attachments: 1-s2.0-S1879625717301773-main.pdf

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, September 4, 2018 3:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6); Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6) Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Subject: ASF ---- measles - aerosol / contact / droplet

And per CDC -- rrequires airbornes precautions
https://www.cdc.gov/infectioncontrol/basics/transmission-based-precautions.html



Table 2

Overview of the evidence on transmission routes of respiratory viruses based on experimental data and the transmission route according to infection prevention guidelines

Virus	Virus family[a]	Transmission route	
		Experimental and observational data	Guidelines[b]
Measles virus	*Paramyxoviridae*	Aerosol [75–77,78*,79*].	Contact [3,110], droplet [3,109–111], aerosol [3,109–111].
Parainfluenza virus	*Paramyxoviridae*	Limited data, contact (by fomite) [83,84] [e].	Contact [3,109–111], droplet [3,109–111], aerosol [3,109].
HMPV	*Pneumoviridae*	Limited data, contact (by fomite)[e] [30]	Contact [3,110,111], droplet [3,110,111].
RSV	*Pneumoviridae*	Contact [89,88], droplet [88], aerosol [90,91**].	Contact [3,109–111], droplet [3,109,110], aerosol [109,111].
HCoV	*Coronaviridae*	Limited data, contact (by fomite) [65–67] [e].	Contact [3,110,111], droplet [3,110,111].
MERS-CoV	*Coronaviridae*	Contact [84] [e] [89] [c] [91**], droplet [89] [c], aerosol [91**].	Contact [111], droplet [3,111]
SARS-CoV	*Coronaviridae*	Contact [70] [e] [73,79,101], droplet [73,78*,79*,117], aerosol [76,118] [c] [82] [c,d].	Contact [3,110,111], droplet [3,110,111], aerosol [3,110,111].
Rhinovirus	*Picornaviridae*	Contact [35,36,42], aerosol [37,40,119].	Contact [109–111], droplet [109,111], aerosol [109–111].
Adenovirus	*Adenoviridae*	Contact [100] [e] [100,101], droplet [103*], aerosol [102,103*].	Contact [3,109–111], droplet [3,109,110], aerosol [110,111].
Influenza virus	*Orthomyxoviridae*	Droplet/aerosol [55,56,57*,59]	Contact [109–111], droplet [3,109–111], aerosol [3,109–111].

[a] Taxonomy was based on [62], airborne transmission is seemingly linked to:
[b] WIP [108], 'Blue Book' [109], 'Red Book' [110], CDC [3] and Up-To-Date [111]. The conclusions on experimental data as presented in this table reflect the conclusions from the authors.
[c] Superspreader events.
[d] Aerosol-generating procedures (in a nosocomial situation).
[e] Conclusions were drawn based on stability experiments.

Disclaimer: Any third-party material in this email has been shared under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 17:21:34 +0000
To: Van Hoof, Johan [JRDBE];Erbelding, Emily (NIH/NIAID) [E]
Cc: Stoffels, Paul [JJCUS]
Subject: RE: as26 based COVID-19 vaccine candidate

Johan:

Thanks for the note. I enjoyed and learned from your presentation this morning. The best way to keep in touch with NIAID would be through Emily and Barney.

Best regards,.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Van Hoof, Johan [JRDBE] [redacted] (b) (6)
Sent: Monday, February 24, 2020 11:58 AM
To: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Stoffels, Paul [JJCUS] [redacted] (b) (6)
Subject: as26 based COVID-19 vaccine candidate

Dear Emily,

Dear Dr. Fauci,

First of all, I want to thank NIAID and its team for spending time with us going through the Janssen plans for Ad 26 COVID-19 vaccine development.

In follow up of our call earlier today, please find herewith the key action points I noted from our discussion. I would welcome your perspectives/comments, as well as the best way to keep in touch with NIAID.

Looking forward to your feedback,

Best regards,

Johan

Johan Van Hoof, M.D.

Managing Director, Janssen Vaccines and Prevention B.V.
Global Therapeutic Area Head IDV, Vaccines, Janssen Pharmaceuticals R&D

Phone : [redacted] (b) (6) : [redacted] (b) (6) Fax : +32 14 60 2841
E-mail : [redacted] (b) (6)

Assistant [redacted] (b) (6)
Phone :

****
****

-

-

Follow Up to Ad26 COVID-19 call with NIAID; February 24th 2020

(b) (4)
[redacted]

(b) (4)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 16:53:04 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: ASF ------- NEJM commentary -- change title?

You are correct.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, February 24, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: ASF ------- NEJM commentary -- change title?

[redacted] (b) (5)

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 16:51:09 +0000
To: Faye Li
Cc: Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Interview Request from China

Faye:

Thank you for your note. Please send me your questions by e-mail and I will try to answer them by e-mail.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Faye Li (b) (6)>
Sent: Monday, February 24, 2020 11:41 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Interview Request from China

Dear Dr. Fauci,

I'm Faye Li, journalist from the Portrait, a national magazine in China. My beat is science and technology. Since the outbreak of the 2019 novel coronavirus (COVID-19) in China, I'm covering feature stories about the outbreak, hoping to explain to readers what it is, especially since the virus is evolving daily at an unexpected high speed, and in so many confusing ways.

Now in China we are getting conflicting information about the new virus and thus become confused about it. For example, we are seeing more and more cases that a patient with negative test results for 2 non-continuous days, still infected with the virus and tested positive afterwards. It makes the treatment really difficult because it seems hard to determine whether the patient is fully cured or not. Since you are an experienced immunologist, I'm wondering if you could share your insights with the Chinese readers and take an interview. The Interview could be via phone or email, whichever works fine for you.

If possible, I'd love to send you the questions before we talk. Since we have time difference, I might not be available during the early afternoon (your time) but I could make it in the morning, noon and maybe late in the afternoon and evening (your time).

I’m sorry for bothering you on this subject, but we face severe difficulty in understanding this new virus and taking measures properly. We have quite limited sources and perspectives for understanding this new virus. However, as a science reporter, I believe in a crisis of public health, the information is the key for the public. They should have the opportunity to hear more perspectives from different specialists. Since you are experienced in fighting against so many viruses, especially SARS, I believe your opinions will be inspiring to the readers.

It would be of great help and great honor for us to invite you for an interview. A phone call interview would be preferred but if time doesn’t work for you, is it possible for you to reply via email? I'll list all the questions in detail.

I could be reached by [redacted] (b) (6) or [redacted] (b) (6) I’m looking forward to your reply.

Best wishes,

Faye

The Portrait
Beijing, China

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 16:01:59 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Call for Dr. Fauci

Cristina, please.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, February 24, 2020 10:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] < [redacted] (b) (6)>; Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: Call for Dr. Fauci

Is this a friend or do u just want to pass to Cristina. Pls advise

Sent from my iPhone

Begin forwarded message:

> **From:** "Haskins, Melinda (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Date:** February 24, 2020 at 10:40:37 AM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** "Harris, Kara (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: FW: Call for Dr. Fauci**
>
> ---
>
> **From:** Harris, Kara (NIH/NIAID) [E] [redacted] (b) (6)>
> **Sent:** Monday, February 24, 2020 10:39 AM

To: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>
Cc: Correa, Meylin (NIH/NIAID) [C] (b) (6)>; Forde, Michael (NIH/NIAID) [C] (b) (6)>; McCullough, Claire (NIH/NIAID) [E] (b) (6)>; Haskins, Melinda (NIH/NIAID) [E] (b) (6)
Subject: RE: Call for Dr. Fauci

Hi, Kim –
I spoke to Dr. Jacobs directly. He said that Dr. Michael Lockshin is a good friend/fellow Cornell graduate (Dr. Jacobs also noted he went to Cornell) and gave him Dr. Fauci's number.
Dr. Jacobs and Dr. Alexander Tarakhovsky, a virologist at The Rockefeller Institute, would like to speak to Dr. Fauci about the coronavirus. They have a theory that there may be yeast involved because it is sticky and perhaps it came from the Chinese government. They want to share their ideas and perhaps start a U.S. government effort "similar to The Manhattan Project." They do not want funding.
I thanked Dr. Jacobs for sharing his ideas and stated that I would pass along the message. Should Dr. Fauci wish to speak to them, Dr. Jacobs can be reached at the number below and Dr. Tarakhovsky can be reached at (b) (6)
Please let me know if you have any questions.
Thanks,
Kara

From: McCullough, Claire (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 24, 2020 10:07 AM
To: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>
Cc: Harris, Kara (NIH/NIAID) [E] (b) (6)>; Correa, Meylin (NIH/NIAID) [C] (b) (6)>; Forde, Michael (NIH/NIAID) [C] (b) (6)>
Subject: Call for Dr. Fauci

Hi, Kim--I got some additional information from Dr. Michael Jacobs office. He is a dermatologist in New York City and said that Dr. Fauci is expecting his call. The secretary provided no further information.

Dr. Michael Jacobs
(b) (6)

Thank you.

Claire A. McCullough
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Rm. 6F27 – MSC 9806
Bethesda, MD 20892
Tel: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 15:14:10 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: New England Journal of Medicine 20-02387
Attachments: Fauci-20-02387-Text.docx, Embargo-Guidelines-5.13.pdf, Production-and-proof.pdf

fyi

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: New England Journal of Medicine <onbehalfof@manuscriptcentral.com>
Sent: Monday, February 24, 2020 10:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)
Subject: New England Journal of Medicine 20-02387

Dear Dr. Fauci,

Thank you for the article, "COVID-19 : Navigating the Unchartered," which the Journal is pleased to accept for publication.

This acceptance is made with the understanding that neither the article itself nor any part of its essential substance, tables or figures has been published or will be submitted for publication elsewhere before it appears in the Journal. The acceptance is also made with the understanding that all the authors, the data, and its presentation meet the requirements as described in the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (www.icmje.org).

Please note that the acceptance of your commentary should be considered confidential information to be shared only with your coauthors until its final publication. To ensure that no news reports about the article appear prematurely in any form, do not speak to the media, hold press conferences, or issue news releases about your paper before the week of publication. You must receive an explicit commitment to withhold release of the information until the embargo is lifted at 5:00 p.m. (Eastern Time in the United States) on the day before the date of publication. If there are any questions about this policy, you should discuss them with the Editor.

We assume that financial relationships creating possible conflicts of interest for all authors have been fully disclosed to the Editor, including (but not limited to) any relevant relationships listed in the Open Payments database at https://openpaymentsdata.cms.gov/search/physicians/by-name-and-location for physicians practicing in the United States. For information on what would qualify as a 'relevant' disclosure, please review the instructions on page 1 of your disclosure form.

Authors are reminded that all material published in the Journal is copyrighted by the Massachusetts Medical Society, that by agreeing to have their manuscript published in the Journal they grant to the Society full right and authority to secure copyright for the full term and any renewals or extensions thereof, and that permission for reprinting must be obtained in writing from the Journal.

The Journal will edit your manuscript in accordance with its established style. You will receive a proof of the edited manuscript by e-mail; the proof stage will be your next opportunity to make changes. For important information about production and proofs, see the attached document. In the meantime, please do not make any changes or send any new material to us. Thank you for your contribution to the Journal.

Sincerely yours,

Eric J. Rubin, MD, PhD
Editor-in-Chief

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
http://www.nejm.org

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Mon, 24 Feb 2020 14:22:21 +0000
To:	[redacted] (b) (6)
Cc:	Barasch, Kimberly (NIH/NIAID) [C];Conrad, Patricia (NIH/NIAID) [E]
Subject:	RE: COVID-19 Quarantine

Ming:
Thank you for your note and offer to help. I will ask my Staff Assistant, Kim Barasch, to set up a brief call for you to relate your impressions to me.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: [redacted] (b) (6)>
Sent: Sunday, February 23, 2020 7:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: [redacted] (b) (6)
Subject: COVID-19 Quarantine

Dear Dr. Fauci,

My name is Ming Lei, a Division Director at the NIGMS. I am writing to you as a private citizen, to thank you for your leadership in yet another public health emergency, and to make myself available to you if you have the time for my in-person observations of the COVID-19 caused quarantine in Hubei Province, China; the evacuation of Americans; and the quarantine in the US.

[redacted] (b) (6) As the virus still roams around, and a possibility of causing a pandemic, I want to let you know that I am willing to share with you my direct observations in case such information is of value in the developing of our responses going forward, which you will undoubtedly playing a critical role.

I will send you a reminder through my NIH email account, in case this message is put into the junk mail folder.

Sincerely,

Ming

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 14:03:36 +0000
To: Billet, Courtney (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Looks fine to me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Monday, February 24, 2020 8:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] <(b) (6)
Subject: FW: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Renate is asking that I confirm that Dr. Collins' changes (tracked in attachments) sync with what we've been saying. They look ok to me. What say you?

From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Monday, February 24, 2020 6:45:07 AM
To: Myles, Renate (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] <(b) (6)>; Gilman, James (NIH/CC/OD) [E] (b) (6)>

Cc: Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Davey, Richard (NIH/NIAID) [E] [redacted] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] [redacted] (b) (6)>; Cohen, Justin (NIH/CC/OD) [E] [redacted] (b) (6)>
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Hi all,

Nicely done, Renate. I made a few edits in two of the documents, see attached.

[redacted] (b) (5)

FC

From: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)
Sent: Sunday, February 23, 2020 8:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Gilman, James (NIH/CC/OD) [E] [redacted] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] < [redacted] (b) (6); Davey, Richard (NIH/NIAID) [E] [redacted] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] [redacted] (b) (6)>; Cohen, Justin (NIH/CC/OD) [E] [redacted] (b) (6)>
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Thanks, all. [redacted] (b) (5) (b) (5) Latest rollout, all staff and statement are attached.

Best,
Renate

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, February 23, 2020 8:15 PM
To: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6) Tabak, Lawrence (NIH/OD) [E] < [redacted] (b) (6)>; Gilman, James (NIH/CC/OD) [E] [redacted] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E]

[redacted] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] [redacted] (b) (6) Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Davey, Richard (NIH/NIAID) [E] [redacted] (b) (6); Palmore, Tara (NIH/CC/OD) [E] < [redacted] (b) (6); Cohen, Justin (NIH/CC/OD) [E] [redacted] (b) (6)>
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Renate:

The rollout plan looks fine except that I would include [redacted] (b) (5) [redacted].

Thanks,
Tony

From: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>
Sent: Sunday, February 23, 2020 7:23 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Gilman, James (NIH/CC/OD) [E] [redacted] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] [redacted] (b) (6); Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Davey, Richard (NIH/NIAID) [E] [redacted] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] [redacted] (b) (6) Cohen, Justin (NIH/CC/OD) [E] [redacted] (b) (6)
Subject: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19
Importance: High

Good evening:

Attached for your review are draft materials to communicate NIH's preparation for potential receipt of patients with COVID-19 to the NIH Clinical Center (timing TBD), including:

1. Rollout plan
2. All staff email
3. Statement

These materials were reviewed by Rick Davey, Tara Palmore, and Courtney Billet. I am developing a list of potential Qs and will work with CC and NIAID folks to develop responses, but I wanted to get these products into review in the interest of time.

Best,
Renate

Renate Myles, MBA
DeputyDirectorfor Public Affairs
Office of Communications and Public Liaison
National Institutes of Health

Tel: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 12:59:47 +0000
To: Leggio, Lorenzo (NIH/NIDA) [E]
Subject: RE: Question from the Italian Embassy in DC re: coronavirus

Lorenzo
Thanks for the note. Unfortunately, I cannot be of any help to you since I myself have no access to this equipment. The best person to contact would be Dr. Robert Kadlec of ASPR at HHS.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Leggio, Lorenzo (NIH/NIDA) [E] [redacted] (b) (6)
Sent: Monday, February 24, 2020 5:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: [redacted] (b) (6)
Subject: Question from the Italian Embassy in DC re: coronavirus

Dear Dr. Fauci,

I apologize in advance if I write you directly to ask this question. I know you are super busy but I thought you could provide some guidance on someone I could contact about this matter.

[redacted] (b) (5)

[redacted] (b) (5)

I know this seems a very technical question and I appreciate you have many other things on your plate, so I hope you don't mind if I decided to reach you out. I do know that Filippo and his team will be very grateful for any guidance that they could receive.

Thanks in advance-
Lorenzo

Lorenzo Leggio, M.D., Ph.D.
Senior Investigator (Clinical), NIDA IRP and NIAAA DICBR
Chief, Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, NIDA IRP and NAAA DICBR
Associate Director for Clinical Research, Medication Development Program, NIDA IRP
Senior Medical Advisor to the Director, NIAAA
National Institutes of Health

10 Center Drive (10CRC/15330) Room 1-5429
Bethesda, MD 20892-1108

251 Bayview Blvd, Room 01A844
Baltimore, MD 21224

Office Phone: [redacted] (b) (6) (Bethesda); [redacted] (b) (6) (Baltimore)
Cell: [redacted] (b) (6)
E-mail: [redacted] (b) (6)

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 12:42:02 +0000
To: STEWART SIMONSON
Cc: [redacted] (b) (6) (NIH/CC/BEP) [E]
Subject: RE: Our story today

Thanks, Stewart. We will do it again after Cliff returns from China and finishes his 14 day self-quarantine

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: STEWART SIMONSON [redacted] (b) (6) >
Sent: Monday, February 24, 2020 7:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) >
Subject: Re: Our story today

Thank you—he is grateful for your help, Tony. He is in a unwindable situation but he is doing what is right and with integrity. [redacted] (b) (6). As do I– [redacted] (b) (6). I really appreciate it.

S

> On Feb 24, 2020, at 7:23 AM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:
>
> Stewart:
>
> Here is another article in which I strongly support Tedros.
>
> Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 24, 2020 7:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Our story today

Hi Dr. Fauci: here's our story on Tedros today, in case you haven't seen it.

https://www.bloomberg.com/news/features/2020-02-23/coronavirus-news-who-director-general-races-against-time

Thanks again for all your help with this one. Hope we get a chance to talk again soon.
Regards, JL

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell [redacted] (b) (6)
http://www.bloomberg.com
http://www.bloomberg.com/prognosis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 12:24:01 +0000
To: John Lauerman
Subject: RE: Our story today

Thanks, John.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 24, 2020 7:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Our story today

Hi Dr. Fauci: here's our story on Tedros today, in case you haven't seen it.

https://www.bloomberg.com/news/features/2020-02-23/coronavirus-news-who-director-general-races-against-time

Thanks again for all your help with this one. Hope we get a chance to talk again soon.
Regards, JL

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell (b) (6)
http://www.bloomberg.com
http://www.bloomberg.com/prognosis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 11:07:01 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Erbelding, Emily (NIH/NIAID) [E]
Subject: FW: ACT Additional reading material and developments
Attachments: About ACT.Global and its Premium Purity.pdf, ATT00001.htm, ACT CleanCoat February 2020.pdf, ATT00002.htm, ACT ECA System Februar 2020.pdf, ATT00003.htm, Dr.Brill and Dr.Steinmann - ACT CleanCoat Viruzidie englisch EN 14476 08.01.2015 Logo Brill.pdf, ATT00004.htm

Cristina:
Please se if we can engage this person (Richard Tubb) and see what he has to offer. He used to be the White House physician
Thanks,
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, February 24, 2020 10:42 PM
To: Biegun, Stephen E <[redacted] (b) (6)>
Cc: Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6); Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: ACT Additional reading material and developments

Steve:
Thanks for the note. I do indeed know Dr. Tubb. He sent me similar material and I am going to connect him with our program people here at NIAID to see if we can help in any way.
Best regards,
Tony

From: Biegun, Stephen E <[redacted] (b) (6)
Sent: Monday, February 24, 2020 10:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: ACT Additional reading material and developments

Tony,

I expect you know Dr. Richard Tubb. He and I worked closely together in the White House 18 years ago. I have a lot of confidence in his judgment, and therefore am forwarding the materials he sent me for your consideration.

I know nothing about the technologies involved, but I know this is a time to write off no good options.

Warm regards,

Steve

Sent from my iPhone

Begin forwarded message:

> **From:** Richard Tubb [redacted] (b) (6)>
> **Date:** February 24, 2020 at 8:47:23 PM EST
> **To:** "Biegun, Stephen E" [redacted] (b) (6), Robert Kadkec < [redacted] (b) (6), [redacted] (b) (6)
> **Subject: ACT Additional reading material and developments**

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 20:22:42 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: chloroquine in COVID-19
Attachments: chloroquine.pdf

Let us discuss

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip <(b) (6)>
Sent: Monday, February 24, 2020 2:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: chloroquine in COVID-19

Dear Dr. Fauci,
Is there any indication/data to substantiate this claim from China (attached publication) that chloroquine/hydroxychloroquine can decrease COVID-19 infections and lung disease?
Thank you,
Philip Gatti, Ph.D.
Pharmacologist
FDA
CDER
OND
Silver Spring, MD
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 20:21:35 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: chloroquine in COVID-19
Attachments: Chloroquine and SARS.pdf

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip <[redacted] (b) (6)
Sent: Monday, February 24, 2020 3:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: chloroquine in COVID-19

Tony,
Thanks for the quick response. There are data from 2005 showing inhibition of SARS infection and spread from 2005. Please see attached.
Regards,
Phil

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, February 24, 2020 3:00 PM
To: Gatti, Philip [redacted] (b) (6)>
Cc: Lane, Henry C (NIH) [redacted] (b) (6)>; Cassetti, Cristina G (NIH) [redacted] (b) (6);
Erbelding, Emily J (NIH) [redacted] (b) (6)>
Subject: RE: chloroquine in COVID-19

Phil:

There are no data in this brief report and so I have no way of evaluating their claim. There are a lot of these types of claims going around. I would love to see their data.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip < [redacted] (b) (6)
Sent: Monday, February 24, 2020 2:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: chloroquine in COVID-19

Dear Dr. Fauci,
Is there any indication/data to substantiate this claim from China (attached publication) that chloroquine/hydroxychloroquine can decrease COVID-19 infections and lung disease?
Thank you,
Philip Gatti, Ph.D.
Pharmacologist
FDA
CDER
OND
Silver Spring, MD
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 19:07:38 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: URGENT- Need your input

[redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Sent: Wednesday, February 26, 2020 2:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: URGENT- Need your input

Yes- that was the main thing- but any other issues that you can think of in our space?
Thanks

Get Outlook for iOS

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, February 26, 2020 2:04:38 PM
To: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: URGENT- Need your input

[redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Sent: Wednesday, February 26, 2020 1:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Fwd: URGENT- Need your input

I will join call- anything you want brought up?
Larry

Get Outlook for iOS

From: Pollard, Ashton (OS/IOS) [redacted] (b) (6)>
Sent: Wednesday, February 26, 2020 1:44:56 PM
To: Mango, Paul (HHS/IOS) [redacted] (b) (6)>; Lenihan, Keagan (FDA/OC) [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6); Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6)>; Charrow, Robert (HHS/OGC) <[redacted] (b) (6)>
Subject: RE: URGENT- Need your input

Hi All,

I am about to send this invite. Please confirm your attendance via email or by accepting the calendar invite.

Thank you,
Ashton

-----Original Message-----
From: Mango, Paul (HHS/IOS) [redacted] (b) (6)
Sent: Wednesday, February 26, 2020 1:43 PM
To: Lenihan, Keagan (FDA/OC) [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>; Shuy, Bryan

(OS/ASPR/IO) <[redacted] (b) (6); Zebley, Kyle (HHS/OS/OGA) <[redacted] (b) (6);
Charrow, Robert (HHS/OGC) [redacted] (b) (6)>
Cc: Pollard, Ashton (OS/IOS) <[redacted] (b) (6)>
Subject: URGENT- Need your input

Team- Urgent, how priority request: '[redacted] (b) (5) '

Ashton will invite you to a 230pm call to discuss. Please organize your responses into bullet points to discuss with the group.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 18:25:04 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Sec. Azar press briefing remarks
Attachments: 2 26 20 press briefing remarks - with Fauci edits.docx

Here are my edits.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, February 26, 2020 1:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] <(b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Subject: ASF: Sec. Azar press briefing remarks

These are Sec Azar's remarks for press tonight. (Plan still evolving.)
They are asking for our comments back by 2:45 pm. New content is highlighted to make it easier on reviewers.
We're sending your talking points down there momentarily.

From: Brennan, Patrick (OS/ASPA) (b) (6)
Sent: Wednesday, February 26, 2020 1:07 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) (b) (6)>; Galatas, Kate (CDC/OD/OADC) (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Michael, Gretchen (OS/ASPR/OEA) <(b) (6)>; Janik, Heather (FDA/OC) (b) (6)>; Caliguiri, Laura (FDA/OC)

[redacted] (b) (6)>; Lepore, Loretta (CDC/OD/OCS) <[redacted] (b) (6)>; Stimson, Brian (HHS/OGC) [redacted] (b) (6)>; Arbes, Sarah (HHS/ASL) [redacted] (b) (6)>; Morse, Sara (HHS/ASL) <[redacted] (b) (6)>; Pence, Laura (HHS/ASL) <[redacted] (b) (6)>; Moughalian, Jen (HHS/ASFR) [redacted] (b) (6); Shuy, Caitrin (HHS/ASFR) [redacted] (b) (6); Trueman, Laura (HHS/IEA) [redacted] (b) (6)v>; Mango, Paul (HHS/IOS) [redacted] (b) (6)>; Johnston, Darcie (HHS/IEA) [redacted] (b) (6)>; Kane, Elleen (OS/ASPR/OEA) [redacted] (b) (6); Shuy, Caitrin (HHS/ASFR) [redacted] (b) (6)>; Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6) Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)
Cc: ASPA-Deputies [redacted] (b) (6)>; Foster, Timothy (OS/ASPA) <[redacted] (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>
Subject: For review by 2:45 PM: Sec. Azar press briefing remarks

Hi all,

Attached is a draft of the Secretary's remarks for this evening's potential press briefing. Some of this is rote/repeated from yesterday or this morning's testimony; I have put the new content in yellow to accelerate review.

Please let me know if you have edits to this by 2:45 PM.

Thank you!

Best,
Patrick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:18:25 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed

I do not have time for this. Sorry.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 25, 2020 10:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: Fwd: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed

This is an oped for Peter Navarro. We are asked for comments by 10am Weds.

(Complicating things a little, he was apparently just on with Tucker Carlson stating parts of it verbatim. So, hopefully this is accurate!)

From: "Brennan, Patrick (OS/ASPA)" <(b) (6)>
Date: Tuesday, February 25, 2020 at 8:27:03 PM
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, "Bonds, Michelle E. (CDC/OD/OADC)" (b) (6)>, "Galatas, Kate (CDC/OD/OADC)" <(b) (6)>, "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>, "Michael, Gretchen (OS/ASPR/OEA)" (b) (6), "Janik, Heather (FDA/OC)" (b) (6)>, "Caliguiri, Laura (FDA/OC)" (b) (6)>, "Lepore, Loretta (CDC/OD/OCS)" (b) (6), "Stimson, Brian (HHS/OGC)" (b) (6), "Arbes, Sarah (HHS/ASL)" (b) (6)>, "Morse, Sara

(HHS/ASL)" <(b) (6)>, "Pence, Laura (HHS/ASL)" <(b) (6)>, "Moughalian, Jen (HHS/ASFR)" (b) (6)>, "Shuy, Caitrin (HHS/ASFR)" (b) (6)>, "Trueman, Laura (HHS/IEA)" (b) (6)v>, "Mango, Paul (HHS/IOS)" (b) (6), "Johnston, Darcie (HHS/IEA)" (b) (6), "Kane, Elleen (OS/ASPR/OEA)" (b) (6)>, "Shuy, Caitrin (HHS/ASFR)" (b) (6)>, "Zebley, Kyle (HHS/OS/OGA)" (b) (6)>, "Grigsby, Garrett (HHS/OS/OGA)" (b) (6)
Cc: "ASPA-Deputies" <ASPA-Deputies@hhs.gov>, "Foster, Timothy (OS/ASPA)" (b) (6), "McGowan, Robert (Kyle) (CDC/OD/OCS)" (b) (6)
Subject: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed

Hi all,

Attached is a draft op-ed from the WH's Peter Navarro regarding the administration's coronavirus response – covering PPE, vaccines, therapeutics, and diagnostics.

There is a lot going on here so **we'd like to have edits/recommendations/affirmative clearance from FDA, CDC, NIAID, ASFR, and ASPR.**

Please send edits to me and Tim Foster by 10:00 AM tomorrow (Wednesday). Thank you!

Best,
Patrick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 02:19:38 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: LHHS appropriators coronavirus supplemental brief 3:30p Wednesday

Thanks, Larry!

-----Original Message-----
From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Sent: Tuesday, February 25, 2020 9:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: LHHS appropriators coronavirus supplemental brief 3:30p Wednesday

Tony,
I will be able to do this. hopefully we can move this back in the correct direction.
Larry

On 2/25/20, 9:00 PM, "Cochran, Norris (HHS/ASFR)" [redacted] (b) (6) wrote:

> Correction, [redacted] (b) (5). Thank you in advance.
>
> Norris
>
> > On Feb 25, 2020, at 8:55 PM, Cochran, Norris (HHS/ASFR) [redacted] (b) (6)> wrote:
> >
> > Dr. Tabak, Neil - would you be available to brief [redacted] (b) (5) (b) (5) We would have CDC on the line as well. ASPR by phone or in person. We will be in person. Please let me know either way. Thank you in advance.
> >
> > Norris

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 03:46:47 +0000
To: Davey, Richard (NIH/NIAID) [E];Palmore, Tara (NIH/CC/OD) [E]
Cc: [redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Rick/Tara:
Please give me a call [redacted] (b) (5). If during business hours, please call my office at [redacted] (b) (6) If in the evening/night call my cell phone at [redacted] (b) (6). My home phone is [redacted] (b) (6).
Thanks,
Tony

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Sent: Monday, February 24, 2020 10:40 PM
To: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>; Stecker, Judy (OS/IOS) <[redacted] (b) (6)>
Cc: Harrison, Brian (HHS/IOS) [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] [redacted] (b) (6)>; Yeskey, Kevin (OS/ASPR/IO) [redacted] (b) (6); Greene, Jonathan (OS/ASPR/EMMO) [redacted] (b) (6); Lee, Scott (OS/ASPR/EMMO) [redacted] (b) (6)>
Subject: Re: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

thanks

From: "Kadlec, Robert (OS/ASPR/IO)" [redacted] (b) (6)>
Date: Monday, February 24, 2020 at 10:37 PM
To: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)>, "Stecker, Judy (OS/IOS)" [redacted] (b) (6)>
Cc: "Harrison, Brian (HHS/IOS)" <[redacted] (b) (6) Anthony Fauci [redacted] (b) (6)"Palmore, Tara (NIH/CC/OD) [E]" [redacted] (b) (6)>, "Yeskey, Kevin (OS/ASPR/IO)" <Kevin.Yeskey@hhs.gov>, "Greene, Jonathan (OS/ASPR/EMMO)" [redacted] (b) (6)>, "Lee, Scott (OS/ASPR/EMMO)" [redacted] (b) (6)
Subject: RE: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Larry would be [redacted] (b) (5). Best Bob

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Sent: Monday, February 24, 2020 10:28 PM
To: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>; Stecker, Judy (OS/IOS) [redacted] (b) (6)>
Cc: Harrison, Brian (HHS/IOS) [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Palmore, Tara (NIH/CC/OD) [E] [redacted] (b) (6); Yeskey, Kevin

(OS/ASPR/IO) <[redacted] (b) (6)>; Greene, Jonathan (OS/ASPR/EMMO)
[redacted] (b) (6)>; Lee, Scott (OS/ASPR/EMMO) [redacted] (b) (6)>
Subject: Re: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Any idea on timing? – please let me know [redacted] (b) (5)

Thanks
Larry

From: "Kadlec, Robert (OS/ASPR/IO)" <[redacted] (b) (6)
Date: Monday, February 24, 2020 at 10:26 PM
To: "Stecker, Judy (OS/IOS)" [redacted] (b) (6)>
Cc: "Harrison, Brian (HHS/IOS)" [redacted] (b) (6)>, Anthony Fauci
[redacted] (b) (6)>, "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6) "Palmore, Tara (NIH/CC/OD) [E]" [redacted] (b) (6)>, "Yeskey, Kevin (OS/ASPR/IO)"
[redacted] (b) (6)>, "Greene, Jonathan (OS/ASPR/EMMO)" [redacted] (b) (6)>,
"Lee, Scott (OS/ASPR/EMMO)" [redacted] (b) (6)>
Subject: FW: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Judy for action [redacted] (b) (5)

From: Kadlec, Robert (OS/ASPR/IO)
Sent: Monday, February 24, 2020 10:19 PM
To: Harrison, Brian (HHS/IOS) [redacted] (b) (6)>; Stecker, Judy (OS/IOS)
[redacted] (b) (6)>; Mango, Paul (HHS/IOS) [redacted] (b) (6)>; Murphy, Ryan (OS/ASPA)
[redacted] (b) (6); Arbes, Sarah (HHS/ASL) [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>;
Redfield, Robert R. (CDC/OD) [redacted] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS)
[redacted] (b) (6)>; Trueman, Laura (HHS/IEA) [redacted] (b) (6); Moughalian, Jen (HHS/ASFR)
[redacted] (b) (6)>; Johnston, Darcie (HHS/IEA) [redacted] (b) (6)>
Cc: Lee, Scott (OS/ASPR/EMMO) [redacted] (b) (6)>; Yeskey, Kevin (OS/ASPR/IO)
[redacted] (b) (6)>; Waters, Cicely (OS/ASPR/OEA) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)>; Greene, Jonathan (OS/ASPR/EMMO)
[redacted] (b) (6)>; Imbriale, Samuel (OS/ASPR/SIIM) [redacted] (b) (6)>; Austin, Meredith (uscg.mil) [redacted] (b) (6)>; Herrmann, Jack (HHS/ASPR/OPP)
[redacted] (b) (6) Ferro, Phil J. EOP/NSC
[redacted] (b) (6)>; Ruggiero, Anthony J. EOP/NSC <[redacted] (b) (6)>;
Cavanaugh, Brian J. EOP/NSC <[redacted] (b) (6)>
Subject: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB
Importance: High

This evening, we were advised by the State of California that 4 passengers from the Diamond Princess tested positive by the CDC for COVID-19.

One individual who tested positive by the CDC had been tested positive in Japan and is already in hospital in CA.

We are developing the following possible Courses of Action as the State of CA cannot absorb these 3 additional asymptomatic individuals:

(b) (5)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 18:46:26 +0000
To: Moughalian, Jen (HHS/ASFR)
Subject: RE: Close Hold Review - Send comments by 1:40 pm

Jen:

I had changed the [redacted] (b) (5)

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Moughalian, Jen (HHS/ASFR) [redacted] (b) (6)>
Sent: Monday, February 24, 2020 1:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6); Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>; Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6); Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6) Lenihan, Keagan (FDA/OC) [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>
Cc: Cochran, Norris (HHS/ASFR) [redacted] (b) (6)>; Cabezas, Miriam (HHS/ASFR) [redacted] (b) (6)>; Hittle, Taylor (HHS/ASFR) [redacted] (b) (6)
Subject: RE: Close Hold Review - Send comments by 1:40 pm

Thanks for the quick response!

From: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Monday, February 24, 2020 1:42 PM
To: Moughalian, Jen (HHS/ASFR) [redacted] (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)>; Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>; Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6) Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6); Lenihan, Keagan (FDA/OC) [redacted] (b) (6)>;

Redfield, Robert R. (CDC/OD) [redacted] (b) (6)
Cc: Cochran, Norris (HHS/ASFR) [redacted] (b) (6)>; Cabezas, Miriam (HHS/ASFR) [redacted] (b) (6)>; Hittle, Taylor (HHS/ASFR) [redacted] (b) (6)>
Subject: RE: Close Hold Review - Send comments by 1:40 pm

Jen:

See my suggested edits in **red.**

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Moughalian, Jen (HHS/ASFR) < [redacted] (b) (6)
Sent: Monday, February 24, 2020 1:18 PM
To: McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)>; Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6) Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)>; Zebley, Kyle (HHS/OS/OGA) < [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Lenihan, Keagan (FDA/OC) [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6)
Cc: Cochran, Norris (HHS/ASFR) [redacted] (b) (6); Cabezas, Miriam (HHS/ASFR) [redacted] (b) (6)>; Hittle, Taylor (HHS/ASFR) [redacted] (b) (6)>
Subject: Close Hold Review - Send comments by 1:40 pm
Importance: High

Close hold. Please see below draft OMB language for a possible emergency supplemental request. Due to the fast moving nature of this process, please send comments by 1:40 PM. Numbers are still under discussion, and we will share more info in the daily update.

(b) (5)

[redacted]

Jen Moughalian

Assistant Secretary for Financial Resources (ASFR)

US Department of Health and Human Services

[redacted] (b) (6) (Office)

[redacted] (b) (6) (Cell)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 02:00:10 +0000
To: Myles, Renate (NIH/OD) [E]
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

[redacted] (b) (5) Thanks.

From: Myles, Renate (NIH/OD) [E] <[redacted] (b) (6)
Sent: Sunday, February 23, 2020 8:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Gilman, James (NIH/CC/OD) [E] [redacted] (b) (6)
Cc: Burklow, John (NIH/OD) [E] [redacted] (b) (6); Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Davey, Richard (NIH/NIAID) [E] [redacted] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] [redacted] (b) (6)>; Cohen, Justin (NIH/CC/OD) [E] [redacted] (b) (6)>
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Thanks, all. [redacted] (b) (5) Latest rollout, all staff and statement are attached.

Best,
Renate

From: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Sent: Sunday, February 23, 2020 8:15 PM
To: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>; Tabak, Lawrence (NIH/OD) [E] <lawrence.tabak@nih.gov>; Gilman, James (NIH/CC/OD) [E] <james.gilman@nih.gov>
Cc: Burklow, John (NIH/OD) [E] <burklowj@od.nih.gov>; Hallett, Adrienne (NIH/OD) [E] <adrienne.hallett@nih.gov>; Allen-Gifford, Patrice (NIH/OD) [E] <patrice.allen-gifford@nih.gov>; Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>; Davey, Richard (NIH/NIAID) [E] <rdavey@niaid.nih.gov>; Palmore, Tara (NIH/CC/OD) [E] <tpalmore@cc.nih.gov>; Cohen, Justin (NIH/CC/OD) [E] <justin.cohen@nih.gov>
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Renate:

The rollout plan looks fine except that I would include [redacted] (b) (6)

Thanks,

Tony

From: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>
Sent: Sunday, February 23, 2020 7:23 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Gilman, James (NIH/CC/OD) [E] [redacted] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] < [redacted] (b) (6); Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] [redacted] (b) (6); Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Davey, Richard (NIH/NIAID) [E] [redacted] (b) (6); Palmore, Tara (NIH/CC/OD) [E] [redacted] (b) (6)>; Cohen, Justin (NIH/CC/OD) [E] [redacted] (b) (6)>
Subject: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19
Importance: High

Good evening:

Attached for your review are draft materials to communicate NIH's preparation for potential receipt of patients with COVID-19 to the NIH Clinical Center (timing TBD), including:

1. Rollout plan
2. All staff email
3. Statement

These materials were reviewed by Rick Davey, Tara Palmore, and Courtney Billet. I am developing a list of potential Qs and will work with CC and NIAID folks to develop responses, but I wanted to get these products into review in the interest of time.

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Office of Communications and Public Liaison
National Institutes of Health
Tel: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 23:14:18 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Important regarding CoronaVirus

Please handle.

From: [redacted] (b) (6)>
Sent: Sunday, February 23, 2020 6:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)
Subject: Important regarding CoronaVirus

Respected Dr. Anthony

It was great to know about you and your institution, for efforts in combating any emerging infectious disease.

I am writing this email regarding our preliminary observation about the coronavirus genome.

I wish to share with you we have found 12 mirror DNA sequence within the genome of Coronavirus. We have named it (MR1 to MR12). We are highly interested in MR2 as this mirror DNA sequence is absent in the human genome. [redacted] (b) (4)

I wish to add here there are few studies which state that mirror DNA has the potentiality to form H-DNA and later has a potentiality to induce mutations. We strongly believe a future study on mirror DNA can answer " Why some virus mutates faster ?" "Can we stop them from mutating? [redacted] (b) (4)

[redacted] (b) (4) I will be thankful to you, If you can give me your valuable time to discuss telephonically or through skype our ideas. I can be reached at [redacted] (b) (6).

I look forward to hearing from you.

with regards and Best wishes

Dr Vikash Bhardwaj (PhD JNU India)
Asst Professor Biotechnology
Starex University Gurugram India.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 23:11:59 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: COVID-19 clinical care team

I am totally aware of all of this and have been directly involved in setting it up. You have my OK to participate to the extent that you desire.

-----Original Message-----
From: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, February 23, 2020 5:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>
Subject: COVID-19 clinical care team

Dear Dr. Fauci,

I got a call a few minutes ago from Veronique Nussenblatt, Chief of the Clinical Center ID Consult Service, regarding me being a part of the clinical care team of COVID-19 patients if they come to the NIH.

She did not have any definitive information but said there was a chance patients could be coming from California this week— this is the first I had heard of that, and I'm guessing you may know more about it than I do.

The work would include either day or night shifts, likely a couple a week. People on the clinical care team are not instructed to separate themselves from others and will be pcr tested for the virus daily when working clinically.

I wanted to ask for your OK to do this clinical work— of course I will maintain my responsibilities in the office while doing so. Please let me know and happy to discuss further if you'd like.

Sincerely,
Andrea

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 21:35:02 +0000
To: Haskins, Melinda (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E];Crawford, Chase (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: Flip Cards

I have gone over the Flip cards. I note that we have only 2 cards for Coronavirus. I want to have a separate flip folder for coronavirus with a full set of cards for the specific coronavirus hearings that are coming up. You should sit down with me and also work with Hilary to prepare this set of cards. They should contain all the current epi as well as the dollar numbers for the proposed supplemental budget that we are putting together – I will get asked about that and I have clearance from the department to talk about it. Also, I want a set of cards for what we are doing in the area of research, i.e. basic research (eg animal models, etc.), diagnostics, therapeutics (remdesivir trials in China, Japan, and Nebraska), and the whole menu of vaccines. In other words, I want an entire set of cards for coronavirus. That is what I am going to get asked in both the coronavirus hearings as well as in the NIH Appropriations hearings.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 21:22:40 +0000
To: Jon LaPook
Subject: RE: Coronavirus reality check

How about a pastrami sandwich on rye and a potato knish?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Jon LaPook (b) (6)
Sent: Sunday, February 23, 2020 4:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Re: Coronavirus reality check

Thanks, Tony.
I would love you to consider my request to "tag along" with you some day - not to join you for meetings (I would wait outside unless invited in) or listen in on conference calls but to chat with you in between to give people an inside look at how seriously the government is taking the outbreak. And I could bring down a shmear from Barney Greengrass for lunch. How could you pass that up???

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Feb 23, 2020, at 4:05 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> wrote:

Jon:

The current appearance of community transmissions in Japan, South Korea, Italy and Iran is troublesome. As I have repeatedly said over the past couple of weeks, if and when (looks more like when now) a number of other countries besides China have sustained human to human transmissions, then we will be on the brink of a pandemic, if not already there. The reason to say this is that when several countries have widespread transmissions, then spill-over to other countries is inevitable since one cannot shut out the rest of the world and so you can expect increasing world-wide transmissions among progressively more countries. In essence, you will be experiencing a pandemic. We are not quite there yet, but we are getting disturbingly close. It will soon be a matter of semantics regarding who would be willing to call it since it is not a mathematically precise definition. I am not so sure that WHO will have the will to declare this a "pandemic" before a number of respected epidemiologists around the world start referring publicly to it as a pandemic regardless of what WHO does or does not declare. WHO will likely be behind the curve here and will wait until it is patently obvious what we are dealing with.

Hope that this is helpful.

Best,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Jon LaPook (b) (6)
Sent: Sunday, February 23, 2020 3:47 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: Coronavirus reality check

Hi Tony,

Why do I not think that this is a relaxing Sunday for you?

This definitely feels like an inflection point in the coronavirus outbreak - both in the unsurprising way it's spreading and the equally unsurprising misinformation and public alarm/panic we are seeing. Unsurprising but here we are. Can you give me a quick brain dump on where you think we are and how I can best inform the public?

Thanks,

Jon

P.S. please let me know whenever I can report that the outbreak is officially being called a pandemic.

Jonathan LaPook, M.D.

Chief Medical Correspondent, CBS News

Professor of Medicine

NYU Langone Health

Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 20:01:51 +0000
To: Richard Allen Johnson
Subject: RE: 2020.02.23 Sunday

Dick:

Transmission is definitely by respiratory droplet. Still unclear about aerosol transmission although there are anecdotal reports that this occurs similar to what we saw in individual episodes with SARS back in 2002-2003. Almost certainly contact transmission occurs with hand to mucosa (mouth, eyes, nasal mucosa). Unclear about fomites, doorknobs, etc. Virus can live for a couple of hours on certain inanimate objects. Virus definitely isolated from stool and urine, but not sure of role in transmission. No information about Transmission to fetus. Children have very low rate of infection. No good serologic test at this point although they are rapidly being developed.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Allen Johnson [redacted] (b) (6)>
Sent: Sunday, February 23, 2020 2:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Richard Allen Johnson [redacted] (b) (6)>
Subject: Re: 2020.02.23 Sunday

Thanks, Tony. Please continue communication with me by email. But rest your voice for a short whlle.

I am having trouble understanding the exact mode of transmission of COVID-19.

-Sneeze or cough produces respiratory droplet or aerosolized respiratory secretion which make contract with upper or lower respiratory mucosa, which results in infection of human cells. Seems most likely.
- What about contact transmission, contaminated hand to conjunctivae, nasal mucosa, or mouth
- Fecal/oral
- transmission to fetus
-What are the diagnostic tests to confirm diagnosis of novel coronavirus? PCR of secretions? Who in the world has these test kit; who manufactures kit.
-Are follow up serologies begin done?

Interesting questions to us and to Shelly Wolf if he were with us.

Thanks, Tony. My voice is also a little raspy.

Best,
Dick

On Sun, Feb 23, 2020 at 10:46 AM Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6) wrote:

> Dick:
> My voice is hoarse since I have been giving so many Congressional and White House briefings and TV and radio interviews. I just need to shut up for a while.
> Best,
> Tony
>
> **From:** Richard Allen Johnson [redacted] (b) (6)
> **Sent:** Sunday, February 23, 2020 5:25 AM
> **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> **Subject:** 2020.02.23 Sunday
>
> Hi, Tony
>
> I continue to follow the Cobid-19 epidemic.
>
> What is the problem with your voice. It crackles like mine. I attribute mine to 'postnasal drip.'
>
> WHO and Dr. Tedros are looking much better on TV. He has the WHO logo in the background. His tie show be tighter. His slouch is better. He still puts his elbows on the table in front of him.
>
> Looking forward to lunch with you.
>
> Best,
> Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 15:56:48 +0000
To: Margolis, Leonid (NIH/NICHD) [E]
Cc: Cassetti, Cristina (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Coronavirus tissue test system: a suggestion

Thanks, Leonid. I will pass this on to appropriate associates.
Best regards,
Tony

From: Margolis, Leonid (NIH/NICHD) [E] [redacted] (b) (6) >
Sent: Sunday, February 23, 2020 5:50 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Coronavirus tissue test system: a suggestion
Importance: High

Dear Tony,

As you may know, for many years we study HIV pathogenesis in human tissues *ex vivo.* (Among my many papers, there is one, may be not the best, but that I am most proud of. This is where my co-author is Dr. Fauci ☺)

[redacted] (b) (5)

Regards,
Leonid

Leonid Margolis, Ph.D.
Head,
Section of Intercellular Interactions
Eunice Kennedy-Shriver National Institute of Child Health and Human Development
Building 29B, Room 1H16D
29 Lincoln Drive
Bethesda, MD 20892
Phone: [redacted] (b) (6)
Fax: 301-480-0857
e-mail: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 15:53:48 +0000
To: john won
Subject: RE: KAMA

John:
Thank you very much for your kind note. I hope that all is well with you.
Best regards,
Tony

From: john won [redacted] (b) (6) >
Sent: Sunday, February 23, 2020 9:06 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) >
Subject: Re: KAMA

Dear Dr. Fauci,

I hope you are doing well. Your participation during our Washington DC 2017 convention was one of the most memorable events of our organization's history.

United States and the world now turns to you for your help as Coronavirus crisis is becoming pandemic. All of us here at KAMA are thinking about you and all those affected. Thank you very much for all your contributions.

Warm regards,

John Won

> On Oct 24, 2017, at 10:42 AM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:
>
> John:
> Thank you for your kind note. It was a pleasure to be with you.
> Best regards,
> Tony
>
> **From:** john won [redacted] (b) (6)
> **Sent:** Tuesday, October 24, 2017 10:12 AM
> **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) >
> **Subject:** KAMA

Dear Dr. Fauci,

Thank you very much for speaking to us at the 43rd Annual KAMA Convention. It was a tremendous privilege for all of us. You were also so kind to stay afterwards to take pictures with all those who asked.

To be honest, having you there was very surreal. You symbolize the best of American medicine. I grew up idolizing your accomplishments as college and medical student. You saved and touched the lives of so many around the world. It is still hard to believe that I had this special opportunity to welcome you.

We will continue to do our best to serve the public and mentor medical students. I hope you can speak to us again in the near future. Thank you very much. I hope you continue in your position for another 40 years.

Warmest regards,

John H. Won

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 15:52:06 +0000
To: Julia Belluz
Subject: RE: Comment?

Julia:

The appearance of community transmissions in Japan, South Korea, Italy and Iran is troublesome. As I have repeatedly said over the past couple of weeks, if and when (looks more like when now) a number of other countries besides China have sustained human to human transmissions, then we are on the brink of a pandemic, if not already there. The reason to say this is that when several countries have widespread transmission, then spill-over to other countries is inevitable since one cannot shut out the rest of the world and so you can expect increasing world-wide transmissions. Hence, you will be experiencing a pandemic. We are not quite there yet, but we are getting disturbingly close.

I hope that this is helpful.

Best,
Tony

From: Julia Belluz <julia.belluz@vox.com>
Sent: Sunday, February 23, 2020 4:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: julia.belluz@voxmedia.com; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
Subject: Comment?

Dear Dr. Fauci,

Just over a week ago we talked for this story about how the outbreak is likely larger than we know now:

https://www.google.com/amp/s/www.vox.com/platform/amp/2020/2/14/21134473/coronavirus-outbreak-singapore-us-symptoms-pandemic

Given the developments in Singapore, Iran, Italy, and on the Diamond Princess cruise ship, I'm just wondering how your opinion about the possibility of containment and how fast we are approaching a pandemic has changed. Do these developments suggest we've entered a new phase in the outbreak?

If you have a few minutes to chat or email today, let me know. We'll be aiming to run a story on this today.

Thank you for considering.

Julia

On Feb 15, 2020, at 12:10 AM, Julia Belluz <julia.belluz@vox.com> wrote:

Thank you so much for making the time to comment at what I know is a crushingly busy time. As usual don't hesitate to ping if you have any further comments or questions! Julia

https://www.vox.com/2020/2/14/21134473/coronavirus-outbreak-singapore-us-symptoms-pandemic

Sent from my iPhone

> On Feb 14, 2020, at 1:21 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:
>
> Julia:
>
> I just called you now (7:20 AM Washington, DC time) and got mvoice mail in German that I could not understand. You can call me at [redacted] (b) (6).
>
> Thanks,
>
> Tony
>
> **Anthony S. Fauci, MD**
> **Director**
> **National Institute of Allergy and Infectious Diseases**
> **Building 31, Room 7A-03**
> **31 Center Drive, MSC 2520**
> **National Institutes of Health**
> **Bethesda, MD 20892-2520**
> **Phone:** [redacted] (b) (6)
> **FAX: (301) 496-4409**
> **E-mail:** [redacted] (b) (6)
>
> **The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.**

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 14:26:22 +0000
To: Theodore Li
Subject: RE: Covid-19 question

Ted:

Thanks for the note. Since she is 22 days out of Singapore she would be well beyond the 14 day quarantine used for people who are coming out of risk zones. And so although her risk is never zero, it is really very low. If she were coming from Japan or South Korea, which are experiencing an emerging outbreak, I might feel a little different, but Singapore has good infection control despite the number of cases in that country Given her history of recent Shingrix vaccination, I would wait another day to see if her fever breaks. I agree that I would keep her at home for now. I do not think it would come to that, but if you want to get testing done, it still would have to go to the CDC via the Virginia department of health. Bottom line is that I would sit tight for now and see how she does over the next day or so. If things change, do not hesitate to call or e-mail me.

Best,
Tony

From: Theodore Li (b) (6)>
Sent: Sunday, February 23, 2020 9:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Covid-19 question

Hi Tony,

The wife of one of my patients received the Shingrix vaccine on Thursday 2/20 and developed fever to 101.4 the following day with malaise, headache, mild nausea (no respiratory symptoms). She's taken ibuprofen with transient temperature reduction; the fever and symptoms are the same today.

BUT . . . she and her daughter were in Singapore (b) (6) where they stayed at the (b) (6), visited (b) (6) and the (b) (6). They then flew to Colombo, Sri Lanka before returning via Europe last (b) (6) to (b) (6).. So her fever began 3 weeks plus 1 day after being in Singapore.

I've told her to keep treating the fever and symptoms but to stay at home for now. The fever after Shingrix usually resolves after 2-3 days so I'd expect it to abate today or tomorrow. My question is whether there's enough of a concern, viz. the time in Singapore, for her to be tested for covid-19. If so, what's the best way to conduct the testing? Or is it okay to see if her fever breaks by tomorrow?

(You must be getting lots of these questions).

Best,
Ted

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 04:27:10 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E] ([redacted] (b) (6));Conrad, Patricia (NIH/NIAID) [E]
Subject: Heads Up

Larry:

I need to speak with you tomorrow (Sunday) about a request that we (NIH) will get from ASPR (Kadlec) regarding the housing of asymptomatic coronavirus positive individuals. I am copying Francis since the discussion will ultimately get to him.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 21:06:45 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: OB Roberts [redacted] (b) (6)>
Sent: Saturday, February 22, 2020 4:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Coronavirus

To: Dr. Fauci

FM: Oliver B Roberts

[redacted] (b) (6)

Dr. Fauci; I attended a small water seminar, put on by local (Seventh Day Adventist) medical professionals, in the mid 1970's at Elms Haven, California.

This seminar taught the participants how to eliminate the flu with the use of water treatments, ie (steam baths, etc).

I have now for these past 40 some-odd years, been taking two treatment's; one in the evening and another in the middle of the night, whenever I have contacted the flu: AND have had the facilities to do so; and each time I was well the next morning. No temperature, no symptoms whatsoever.

With the high rate that this Coronavirus is spreading, one can see what a great tool these treatments can be for medical professionals. To have those who are sick with the flu, completely free of all symptoms after two treatments would greatly ease the burden on Dr's and other medical professionals AND each facility.

Dr. I am asking for a few minutes of your time to explain this. I would like to share this with you and others. I just want to help by sharing what I learned and have been doing all these years. I feel so guilty, knowing this and not having a way to get this information to those needing it, when there so many out there sick and dying.

Note: I have been trying to reach out, hoping someone will hear me. Alas I do not have the education, pedigree nor the contacts: But you Dr. have all three! I ask not that you believe in me, but that you believe in these treatments.

Thank You for your time, please feel free to contact me via email or by phone or text or even have someone up here talk with me.

Sincerely;

OB Roberts
(Ben)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 21:04:58 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Congratulations and time to speak: Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help? - The New York Times

Please set up a call with Hannah

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Valantine, Hannah (NIH/OD) [E] [redacted] (b) (6)
Sent: Tuesday, February 18, 2020 10:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Congratulations and time to speak: Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help? - The New York Times
Importance: High

Hi Tony,
I have been following this terrific work by NIAID scientists in the VRC – congratulations!

https://www.nytimes.com/2020/01/28/health/coronavirus-vaccine.html

As you can imagine I am delighted see Dr. Kizzmekia Corbett playing a leading role in these activities. Most importantly she is delighted with the mentorship, sponsorship and opportunity she has received at NIH, particularly from Barney Graham. [redacted] (b) (6), (b) (5)

Please let me know when you might be available to speak with me.

Best,
Hannah

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 20:53:35 +0000
To: NIAID OD AM
Subject: FW: CUGH Annual Meeting

Let bus discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Thomas Quinn (b) (6)
Sent: Thursday, February 20, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Judith Wasserheit (b) (6)>
Subject: CUGH Annual Meeting

Hi Tony,

I know how busy you are but I wanted to give you a brief update on the Annual Conference of the Consortium of Universities for Global Health (CUGH) based in Washington, DC. Here is the link to the overall CUGH meeting which provides an overview of the whole conference https://www.cugh2020.org/program. As we discussed months ago you agreed to be in the opening day plenary session on April 18th, entitled "Emerging Infectious Diseases and their Impact on Global Health Security". **The details and other speakers are listed below**. I may try to organize a call of all speakers in a month to coordinate talks/topics as the session is 90 minutes with 5 speakers, and a lot of ground to cover, especially with the COVID19 outbreak.

Judy Wasserheit, copied here, would also like to invite you to a special session she is organizing on the coronavirus epidemic at the same CUGH conference in a late-breaker session on Sunday, April 19 (the second day of the conference) from 8:45am-10:15am at the Washington Hilton Hotel (Monroe Room). This talk would be slightly different from the plenary session and you could expand on **COVID19 research priorities and update on progress**. We realize your schedule is very busy but your insights and knowledge on both of these topics is unparalleled. If you cannot speak at the second session we would appreciate your recommendation as to an alternative who could address this latter topic.

Thanks and all the best,
Tom

Plenary Session Details:

Session Day: Saturday, April 18, 2020
Session Time: 11:30am-1:00pm
Location: Washington Hilton Hotel, International Ballroom
Panel Title: ”Emerging Infectious Diseases and their Impact on Global Health Security”

Short Panel Description: This Plenary Panel will highlight the continual threats of emerging and re-emerging infectious diseases, and their impact on global security for surveillance, detection, treatment and prevention of these diseases. Over recent decades, multiple epidemic events have underscored how highly vulnerable we are to viral threats. Our world is globally connected—and an "emerging threat" in one part of the world can pose a threat everywhere and to everyone. About 75 percent of new human diseases are caused by microbes that originate in animals. These include HIV, influenza (including pandemic H1N1, H5N1, and H7N9), Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome-Coronavirus (MERS-CoV), Ebola, Marburg, and Nipah. The recent emergence of COVID from China clearly illustrates the magnitude, rapidity and impact that a new infectious agent can have on global health security. This panel of leading experts will discuss the emergence of these microbial threats, and our ability to detect, respond and prevent future epidemics of these pathogens.

Moderator(s) Info: Tom Quinn, Chief, NIAID, International HIV/STD Section and Man Charurat, Director, Division of Epidemiology and Prevention, Institute of Human Virology (IHV)

Speaker(s) Info:

1. Anthony Fauci, Director, NIAID
2. Chikwe Ihekweazu, Director General, Nigeria CDC
3. Peter Hotez, Dean, National School of Tropical Medicine, Baylor College of Medicine
4. Jonna Mazet, Executive Director, One Health Institute, and PI, PREDICT project, UC Davis
5. Jennifer Nuzzo, Senior Scholar, Center for Health Security, Johns Hopkins University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 20:51:00 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: launch of remdesivir COVID-19 trial
Attachments: NIAID press release COVID-19 treatment trial FOG - with fauci tracked edits.docx

See my minor tracked edits. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, February 21, 2020 3:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FOR ASF REVIEW: Draft PR re: launch of remdesivir COVID-19 trial

Hi Dr. Fauci,

Please find attached for your review a draft press release to announce the launch of the remdesivir COVID-19 treatment trial, which enrolled its first patient today. It's been reviewed by the following individuals/groups:

- FOG
- OCGR (Kathy Stover, Courtney Billet)
- DMID: Emily Erbelding, John Beigel
- DCR: Cliff Lane, Libby Higgs
- U Nebraska (Christopher Kratochvil, Andre Kalil, comms dept)
- Awaiting comments from Gilead and WHO.

For ease of reference, the following is the quote we have drafted for your use:

(b) (5)

[redacted]

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A17F
Bethesda, MD 20892
[redacted] (b) (6)
Media line: (301) 402-1663

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Sat, 22 Feb 2020 20:38:12 +0000
To:	Conrad, Patricia (NIH/NIAID) [E]
Cc:	Routh, Jennifer (NIH/NIAID) [E]
Subject:	RE: interview request: draft responses for Greek newspaper

Good job! See my minor edits in **red.** Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, February 21, 2020 4:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: interview request: draft responses for Greek newspaper

Do you want to edit these..greek paper/pring?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, February 21, 2020 4:52 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID FOG <fog@niaid.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: interview request: draft responses for Greek newspaper

Reporter: Theodora Tsoli
Organization: Greek newspaper To VIMA (www.tovima.gr)
Phone #(s): [redacted] (b) (6), thtsoli@tovima.gr
Subject: COVID-19
Deadline: Monday 2/24

The reporter emailed questions for ASF. I have drafted proposed responses for his review, also attached.

1. **Do you believe that SARS-COV2 is capable of causing a pandemic? Are you expecting many secondary transmissions of the virus outside China?**
   A pandemic is generally defined as sustained transmission of a new pathogen in multiple regions of the world. COVID-19 does not yet meet that definition, and I hope that China and other countries in Asia with some transmission are able to contain the outbreak. However, it is possible that COVID-19 could become a pandemic. It would not be surprising to see additional secondary transmissions of the virus outside of China.

2. **Chinese authorities are reporting a decline of new cases. Could we say that the virus has peaked and maybe it will slow down? When are you expecting to have a clearer picture about the evolution of this epidemic?**
   Although the number of **daily** cases in China appears to have gone down, it is too early to tell if this is really a decline in the outbreak.

3. **Could the virus become endemic and give seasonal outbreaks?**
   If China is not able to contain the outbreak, it is possible COVID-19 could become endemic and lead to seasonal outbreaks. However, it is too early to know the likelihood of this scenario.

4. **What about its transmissibility? Some experts say that WHO is underestimating it's transmissibility. Could the reality be different maybe because, among other things, many cases stay undetected?**
   Because of the many unknowns about SARS-CoV-2, it is difficult to make any firm conclusions regarding overall transmissibility and severity. However, it appears to be much more transmissible than SARS. Also, there are likely asymptomatic COVID-19 infections that are not getting counted because people do not go to the doctor for testing or treatment if they are not sick.

5. **Do you believe that the measures taken by China and countries around the world are adequate to stop SARS-COV2 spread? There is a lot of discussion about thermal cameras and travel restrictions for example.**
   China has taken extreme measures to control the outbreak. Restricting the movement of 50 million people is unprecedented. However, it might ultimately have an effect on slowing transmission. Precautions implemented in the U.S. are not intended to detect every person with COVID-19 entering the country. However, our approach has allowed us time to better plan and prepare our health system.

6. **What is the key to stop the worldwide spread of the virus?**
   Though we have mobilized a rapid research response to quickly develop effective countermeasures, right now, the outbreak response remains focused on the proven public health practices of identifying cases, isolating patients and tracing contacts.

7. **In the northern hemisphere we have a flu outbreak - in Greece as well. Some experts say that this is the real danger and not the coronavirus. What is your view?**
   I am always concerned about influenza. Every flu season, millions of people are at risk of getting very sick or dying. Currently people in the U.S. and most countries in the northern hemisphere are at a much higher risk of being exposed to influenza than SARS-CoV-2. However, the COVID-19 outbreak is an evolving situation and we are treating it as a very serious public health threat.

8. **Many efforts are being in process for the development of a vaccine for the new coronavirus. Are you coordinating any of them and which ones? Are there any efforts more promising than others? Which platforms of vaccine development are more promising? When do you believe that we could have a vaccine available for clinical trials and then for human use?**
   NIAID is exploring multiple candidates and is on track to test an experimental messenger RNA (mRNA) vaccine in a Phase 1 clinical trial this spring. This first phase of clinical testing will involve giving the vaccine to healthy adults in the United States to see if it is safe and if it can induce an immune response in recipients. It is important to realize that the development of investigational vaccines and the clinical testing to establish their safety and effectiveness takes time. A vaccine against the novel coronavirus will likely not be widely available for **more than** a year.

9. **What about therapies? Dozens are being tried - from plasma to herbal medicines in China. Which are the most promising?**
   NIAID is pursuing the development of antivirals and monoclonal antibodies for potential use against COVID-19. NIAID is preparing protocols for *in vitro* and *in vivo* studies of the antiviral remdesivir, which has shown promise against other coronaviruses in animal models. NIAID also plans to evaluate Kaletra (lopinavir/ritonavir) and interferon-beta for their activity against SARS-CoV-2. In addition, NIAID scientists are working to identify monoclonal antibodies with

therapeutic potential from stored SARS patient samples as well as COVID-19 patient samples.

10. **Are the things we know about this new virus more than the ones we don't know? Which are the main questions about it that remain to be answered?**
    New data **are** published about SARS-CoV-2 every day. However, we still have a lot to learn. For example, we do not know why there are **so few cases among** children, which is uncommon for a respiratory virus.

11. **How worried should people outside China be about SARS-COV2? What is the biggest danger from this virus?**
    . The risk to the general American public remains low at this time**; however, this could change and that is why we are treating the emergence of a novel coronavirus as a very serious public health threat**. We understand that people may be worried. We ask that people not let fear or panic guide their actions.

12. **Which are the protective measures anyone should take against the new virus? Do masks work?**
    The vast majority of people outside of China do not need to wear a mask. A mask is more appropriate for someone who is infected than for people trying to protect against infection.

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:41:48 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, February 22, 2020 2:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts

Cristina

Begin forwarded message:

> **From:** "Folkers, Greg (NIH/NIAID) [E]" [redacted] (b) (6)
> **Date:** February 18, 2020 at 3:07:21 PM EST
> **Subject: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine**
>
> **FOR IMMEDIATE RELEASE**
> **February 18, 2020**
> **Contact: ASPR Press Office**
> **202-205-8117**
> asprmedia@hhs.gov

HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi.

The Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will provide expertise and reallocated funds to support the vaccine's development. Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019 novel coronavirus vaccine candidate.

The technology produces an exact genetic match to proteins of the virus. The protein's DNA will be combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. The antigens will be separated and collected from these cells and purified to create working stocks of vaccine for advanced development.

"Flexibility and scalability are cornerstones of rapid response to an emerging infectious disease," said BARDA Director Rick A. Bright, Ph.D. "Using this proven technology, we can pivot immediately to address this new global health threat. Our goal is a licensed vaccine to provide long-term health security against this latest virus and prevent future coronavirus outbreaks."

BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein Sciences of Meridian, Connecticut, now owned by Sanofi, to develop a recombinant technology with the flexibility to make millions of doses of vaccine quickly in an influenza pandemic. In 2016, BARDA added this vaccine to the U.S. National Pre-pandemic Influenza Vaccine Stockpile. When Sanofi purchased the company and its technology in 2017, BARDA continued working with Sanofi on pandemic vaccine development, and in December 2019 the partners began focusing on increasing manufacturing capacity for recombinant influenza vaccine in the United States, in accordance with a presidential executive order to enhance national security and the public health by modernizing influenza vaccines and technologies.

This expanded collaboration with Sanofi is BARDA's second program to focus on developing a novel coronavirus vaccine candidate in the past few weeks. There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.

BARDA also is working with counterparts across the government, including within HHS and with the Department of Defense. The team is reviewing potential vaccines, treatments and diagnostics from across the public and private sectors, particularly products in development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS), to identify promising candidates for development and licensure to detect, protect against or treat novel coronavirus infections.

To obtain information about any potential products in development in the private sector that could be used in responding to the novel coronavirus outbreak, the U.S. government launched a single point-of-entry website for innovators and product developers to submit brief descriptions of their diagnostics, therapeutics, vaccines, and other products or technologies relevant to this new virus.

Federal agencies are particularly interested in identifying products and technologies that have progressed into or beyond non-clinical studies, have established large-scale commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have utilized a platform already approved by the U.S. Food and Drug Administration (FDA).

BARDA also opened an easy broad agency announcement, an EZ-BAA, specific to diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.

About HHS, ASPR, and BARDA

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 54 BARDA-supported products have achieved regulatory approval, licensure or clearance. BARDA DRIVe brings together the best ideas from the medical and scientific communities, together with government and venture capital investment, to drive innovation that will strengthen our nation's health security. To learn more about preparing for and responding to public health emergencies, from new infectious diseases to natural disasters and bioterrorism, by visiting the HHS public health emergency website, www.phe.gov. For more information on partnering with BARDA on developing medical countermeasures, visit www.medicalcountermeasures.gov, and for more on DRIVe, visit drive.hhs.gov.

###

Note: All HHS press releases, fact sheets and other news materials are available at https://www.hhs.gov/news.

Like HHS on Facebook, follow HHS on Twitter @HHSgov, and sign up for HHS Email Updates.

Last revised: February 18, 2020

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:41:42 +0000
To: David Willman
Subject: FW: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

David:

See press release below regarding BARDA and Sanofi.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Saturday, February 22, 2020 2:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts

Cristina

Begin forwarded message:

> **From:** "Folkers, Greg (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Date:** February 18, 2020 at 3:07:21 PM EST
> **Subject: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine**

FOR IMMEDIATE RELEASE
February 18, 2020
Contact: ASPR Press Office
202-205-8117
asprmedia@hhs.gov

HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi.

The Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will provide expertise and reallocated funds to support the vaccine's development. Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019 novel coronavirus vaccine candidate.

The technology produces an exact genetic match to proteins of the virus. The protein's DNA will be combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. The antigens will be separated and collected from these cells and purified to create working stocks of vaccine for advanced development.

"Flexibility and scalability are cornerstones of rapid response to an emerging infectious disease," said BARDA Director Rick A. Bright, Ph.D. "Using this proven technology, we can pivot immediately to address this new global health threat. Our goal is a licensed vaccine to provide long-term health security against this latest virus and prevent future coronavirus outbreaks."

BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein Sciences of Meridian, Connecticut, now owned by Sanofi, to develop a recombinant technology with the flexibility to make millions of doses of vaccine quickly in an influenza pandemic. In 2016, BARDA added this vaccine to the U.S. National Pre-pandemic Influenza Vaccine Stockpile. When Sanofi purchased the company and its technology in 2017, BARDA continued working with Sanofi on pandemic vaccine development, and in December 2019 the partners began focusing on increasing manufacturing capacity for recombinant influenza vaccine in the United States, in accordance with a presidential executive order to enhance national security and the public health by modernizing influenza vaccines and technologies.

This expanded collaboration with Sanofi is BARDA's second program to focus on developing a novel coronavirus vaccine candidate in the past few weeks. There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.

BARDA also is working with counterparts across the government, including within HHS and with the Department of Defense. The team is reviewing potential vaccines, treatments and diagnostics from across the public and private sectors, particularly products in development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS), to identify promising candidates for development and licensure to detect, protect against or treat novel coronavirus infections.

To obtain information about any potential products in development in the private sector that could be used in responding to the novel coronavirus outbreak, the U.S. government launched a single point-of-entry website for innovators and product developers to submit brief descriptions of their diagnostics, therapeutics, vaccines, and other products or technologies relevant to this new virus.

Federal agencies are particularly interested in identifying products and technologies that have progressed into or beyond non-clinical studies, have established large-scale commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have utilized a platform already approved by the U.S. Food and Drug Administration (FDA). BARDA also opened an easy broad agency announcement, an EZ-BAA, specific to diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.

About HHS, ASPR, and BARDA

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 54 BARDA-supported products have achieved regulatory approval, licensure or clearance. BARDA DRIVe brings together the best ideas from the medical and scientific communities, together with government and venture capital investment, to drive innovation that will strengthen our nation's health security. To learn more about preparing for and responding to public health emergencies, from new infectious diseases to natural disasters and bioterrorism, by visiting the HHS public health emergency website, www.phe.gov. For more information on partnering with BARDA on developing medical countermeasures, visit www.medicalcountermeasures.gov, and for more on DRIVe, visit drive.hhs.gov.

###

Note: All HHS press releases, fact sheets and other news materials are available at https://www.hhs.gov/news.

Like HHS on Facebook, follow HHS on Twitter @HHSgov, and sign up for HHS Email Updates.

Last revised: February 18, 2020

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:39:17 +0000
To: Kevin Thurm
Subject: RE: Thanks

Kevin:

Many thanks for your kind note. Much appreciated. I hope that all is well with you.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kevin Thurm (b) (6)>
Sent: Saturday, February 22, 2020 12:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Thanks

Tony

Good afternoon.

Just wanted to write and say how much I deeply appreciate your on-going public service; you've made extraordinary contributions over the course of your career and, as I've watched you on TV in the context of the current public health threat of the coronavirus, I know you're continuing to do so...

No need to respond; you have a lot going on.

From one citizen and a former colleague, extending my thanks and deep appreciation.

Best wishes.

Kevin Thurm

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:36:40 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: For review: ASM presentation for 26Feb2020
Attachments: ASM Public and Scientific Affairs Committee Meeting 2nd FINAL for 26Feb2020.pptx

I mistakenly put it into my Documents. Here it is, and I will put it into the OD now

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, February 22, 2020 2:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: For review: ASM presentation for 26Feb2020

I don't see it in OD

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, February 22, 2020 1:49 PM
To: Schneider, Johanna (NIH/NIAID) [E] < [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] < [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: For review: ASM presentation for 26Feb2020

This is now "2nd FINAL" in the OD folder. You just need to remove the instruction slides and do the required updates on several of the slides and then it is ready to go. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schneider, Johanna (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, February 21, 2020 4:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: For review: ASM presentation for 26Feb2020

Dr. Fauci,
Attached is the presentation to the American Society for Microbiology (ASM) Public and Scientific Affairs Committee on Wednesday Feb 26th.

The topics they have expressed interest in are:

- NIAID Budget Request FY2021
- Novel Coronavirus
- Progress on a Universal Flu Vaccine

The talk is 30 minutes plus 15-20 for discussion.

I've scheduled 30 minutes Monday morning at 10AM to review the slides with you as well.

The presentation has been uploaded to the shared drive. As indicated we will update the necessary slides on Monday afternoon before sending them to ASM on Tuesday.

Thanks,
Johanna

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:33:57 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: Question

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, February 22, 2020 2:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Erbelding, Emily (NIH/NIAID) [E] (b) (6)>
Subject: Re: Question

Hi Dr. Fauci,

This effort is completely driven by BARDA. DMID is not involved.

Cristina

> On Feb 22, 2020, at 2:18 PM, Fauci, Anthony (NIH/NIAID) [E] < (b) (6)> wrote:
>
> Cristina:
>
> What is the relationship that we (DMID/NIAID) has with Sanofi in the development of a coronavirus vaccine? Are we funding them? Do we

have any agreement with them to develop a coronavirus vaccine, or is it BARDA who is dealing with them?

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 18:32:37 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: Nabel NAS nomination
Attachments: (b) (6) 2020 NAS Nomination - Section 44 - 02-22-2020.docx

Bob:

Here is (b) (6) NAS nomination. Let us touch bases on Monday to get it uploaded to the website.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 14:08:16 +0000
To: Marlene Colucci
Cc: David Rubenstein;Ginni Rometty;Donahoe, John
Subject: RE: Business Council - Dr. Anthony Fauci "fireside chat" with David Rubenstein - Thank you!

Marlene: Thanks for the note. It was my pleasure, and I never miss an opportunity to interact with David. He is an incomparable interviewer.
Best,
Tony

From: Marlene Colucci <mcolucci@businesscouncil.com>
Sent: Friday, February 21, 2020 2:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: David Rubenstein [redacted] (b) (6); Ginni Rometty [redacted] (b) (6)>; Donahoe, John [redacted] (b) (6)>
Subject: Business Council - Dr. Anthony Fauci "fireside chat" with David Rubenstein - Thank you!

Dr. Fauci,

We wanted to send a quick note to thank you for joining us today. Your discussion with David was so interesting and well received.

The coronavirus alone was on the minds of so many CEOs as it impacts their supply chain.

David, it goes without saying that you are the best interviewer! You make everything substantive and entertaining.

Wishing everyone an enjoyable weekend!

Warmest regards,

Marlene

Marlene Colucci

EXECUTIVE
DIRECTOR

THE BUSINESS COUNCIL
T: 202-298-7650
C: [redacted] (b) (6)
F: 202-785-0296

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 14:06:21 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: CoVid-19 In Infants

Please hsandle.

-----Original Message-----
From: JF K[redacted] (b) (6)>
Sent: Friday, February 21, 2020 2:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: CoVid-19 In Infants

Dr. Fauci,

Infants and children infected with CoVid-19 seem to be an anomaly. Could it be as simple as childhood vaccinations? Are Chinese children vaccinated with anti malarial drugs such as Chloroquine phosphate, which is proving effective in older patients for CoVid-19?

If infants and children are not getting severe infections, why?

Jonathan F. King

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 14:00:30 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers (GFOLKERS@niaid.nih.gov)
Subject: FW: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time

fyi

From: Kevin Bowen <kbowen@iasusa.org>
Sent: Friday, February 21, 2020 6:31 PM
To: Donna Jacobsen <djacobsen@iasusa.org>; Zunyou Wu [redacted] (b) (6); Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) [redacted] (b) (6)>; Baric, Ralph [redacted] (b) (6) Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Sharon Hillier PhD [redacted] (b) (6) [redacted] El-Sadr, Wafaa M. [redacted] (b) (6)>; Schooley, Robert [redacted] (b) (6); Schooley, Chip [redacted] (b) (6)>; Eron, Joseph J Jr [redacted] (b) (6)>; Genesis Regalado [redacted] (b) (6)>; Baric, Toni C [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time

Dear CROI Speakers and Moderators:

We would like to schedule a planning call for next week to COVID-19 session at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI). Please submit your availability using the poll at http://whenisgood.net/ksy42az. The poll should automatically adjust to your local time zone, but you can adjust the setting using the "Select your location" dropdown if needed.

We will confirm the call as soon as possible.

Regards,

Kevin Bowen
Program Director
CROI Scientific Program and IAS-USA Production

From: Donna Jacobsen
Sent: Friday, February 21, 2020 1:37 PM
To: Zunyou Wu [redacted] (b) (6)>; John T. Brooks MD [redacted] (b) (6)>; Baric, Ralph S [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Sharon Hillier PhD [redacted] (b) (6) [redacted] El-Sadr, Wafaa M. [redacted] (b) (6)>; Kevin Bowen <kbowen@iasusa.org>; Schooley, Robert [redacted] (b) (6) 'Robert T. Schooley, MD [redacted] (b) (6)>; Eron, Joseph J Jr [redacted] (b) (6)>; Kevin Bowen <kbowen@iasusa.org>; Genesis Regalado <gregalado@iasusa.org>; Baric, Toni C

[redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time
Importance: High

Dear Drs Wu, Brooks, Baric, and Fauci:

It is more than incredibly impressive at how all of you, in just the past few days, have rearranged your schedules and agreed to participate in this special session in only about 2 weeks. We are all very grateful, and know this will be tremendously impactful for the CROI audience.

Below is the final list of presentations, although the order and titles may well change. We are hoping to have a conference call with the session liaisons and speakers next week if possible, to go over each of the talks to address the overall plan and discuss any overlap. Shortly we will send out a poll for availability for early morning in China, early-mid afternoon in the US West Coast, and late afternoon-evening in the US East Coast. If you can respond to the poll by Monday we would greatly appreciate it; things are moving quickly.

Many thanks again,

All of us at CROI!



SPECIAL LUNCHTIME SESSION ON COVID 19
Tue. 3/10: 12:10 PM - 1:20 PM EASTERN DAYLIGHT TIME
Auditorium

Preliminary Session Agenda (Order and talk titles to be confirmed)

1. FOCUS ON THE EPIDEMIOLOGY OF COVID-19 AND EFFORTS IN CHINA
   a. Zunyou Wu, Chinese Center for Disease Control, China
   15-minute live video (Skype or Zoom)update from China
2. FOCUS ON THE GLOBAL EPIDEMIOLOGY OF COVID-19 AND EFFORTS TO CONTROL THE OUTBREAK
   a. John Brooks, US Centers for Disease Control, USA
   15-minute update
3. FOCUS ON THE VIROLOGY OF CORONOVIRUSES OVERALL, MOLECULAR ASPECTS OF TRANSMISSION TO HUMANS, PATHOGENESIS IN MICE MODELS AND PARALLELS IN HUMANS, ETC
   a. Ralph Baric, University of North Carolina, USA
   25-minute lecture
4. FOCUS ON NIAID/HIH EFFORTS TO STUDY NOVEL CORONOVIRUSES AND DEVELOP DIAGNOSTICS. THERAPEUTICS, AND VACCINES
   a. Anthony Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
   15-minute recorded update

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 12:13:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Triple E letter

Let us discuss. Likely no.

-----Original Message-----
From: Bridbord, Ken (NIH/FIC) [V] [redacted] (b) (6)>
Sent: Friday, February 21, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Marietta Ethier [redacted] (b) (6); Emily Lane <ELane@[redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Triple E letter

Tony, my condominium community has established a program in which prominent members of the Washington area are invited to make presentations on subjects of great public interest. Shown in the email below is a description of this program. In this regard I have been asked to contact you to see, recognizing your incredibly busy schedule, if you would be interested and able to provide an update on the Coronavirus situation to our residents. Most likely you [redacted] (b) (6) If you have a potential interest in sharing your great expertise on this subject with our residents could you please have your staff contact Emily Lane who is copied on this email to explore possible dates and times that would work for you. Thank you so much for your consideration of this request. Ken

On 2/21/20, 3:36 PM, "Emily Lane" <ELane@[redacted] (b) (6) wrote:

Dear Ken,

The [redacted] (b) (6) Committee greatly appreciates your willingness to approach Dr. Anthony Fauci on our behalf, asking him to address the residents of the [redacted] (b) (6) on the Coronavirus. It would perhaps be helpful to Dr.Fauci, to explain who we are and what we do. [redacted] (b) (6), (b) (6)

The [redacted] (b) (6) Committee was formed recently to create and organize events to educate, enlighten and entertain members of the Somerset community. A few weeks ago [redacted] (b) (6) spoke to a sold out crowd on impeachment. We've featured authors on a variety of topics; invited doctors with specialties of interest to our community organized trips to the Kennedy Center and theaters for attendance at ballets and plays and sponsored visits, led by experts, to various museums and the Library of Congress to view special exhibitions. An example of the latter is a tour of the Folger Library [redacted] (b) (6). A presentation by Dr. Fauci on the coronavirus would be of great interest to our constituency who keep informed by reading both national and international journals. We are flexible on the date for such an appearance needing only a few days' notice to inform our residents.

I need not tell you that it would our great honor to welcome Dr. Fauci to the [redacted] (b) (6).

Sincerely

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 12:08:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time

I totally agree. I do not want to be on a "session planning" call. Please have Hilary do this as suggested by Patty since she is preparing the talk. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, February 21, 2020 4:44 PM
To: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time
Importance: High

Since this is a taping for his remarks – can hilary do this call since she is doing the slides? hate to waste ASF time on this with all our other moving parts....just a thought.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>
Sent: Friday, February 21, 2020 4:37 PM
To: Zunyou Wu [redacted] (b) (6)>; Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) [redacted] (b) (6)>; Baric, Ralph [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Sharon Hillier PhD [redacted] (b) (6);

[redacted] (b) (6)El-Sadr, Wafaa M. [redacted] (b) (6)>; Kevin Bowen
[redacted] (b) (6); Schooley, Robert [redacted] (b) (6); Schooley, Chip
[redacted] >; Eron, Joseph J Jr [redacted] ; Kevin Bowen
[redacted] ; Genesis Regalado [redacted] (b) (6)>; Baric, Toni C
[redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time
Importance: High

Dear Drs Wu, Brooks, Baric, and Fauci:

It is more than incredibly impressive at how all of you, in just the past few days, have rearranged your schedules and agreed to participate in this special session in only about 2 weeks. We are all very grateful, and know this will be tremendously impactful for the CROI audience.

Below is the final list of presentations, although the order and titles may well change. We are hoping to have a conference call with the session liaisons and speakers next week if possible, to go over each of the talks to address the overall plan and discuss any overlap. Shortly we will send out a poll for availability for early morning in China, early-mid afternoon in the US West Coast, and late afternoon-evening in the US East Coast. If you can respond to the poll by Monday we would greatly appreciate it; things are moving quickly.

Many thanks again,

All of us at CROI!



SPECIAL LUNCHTIME SESSION ON COVID 19
Tue, 3/10: 12:10 PM - 1:20 PM EASTERN DAYLIGHT TIME
Auditorium

Preliminary Session Agenda (Order and talk titles to be confirmed)

1. FOCUS ON THE EPIDEMIOLOGY OF COVID-19 AND EFFORTS IN CHINA
    a. Zunyou Wu, Chinese Center for Disease Control, China
    15-minute live video (Skype or Zoom)update from China
2. FOCUS ON THE GLOBAL EPIDEMIOLOGY OF COVID-19 AND EFFORTS TO CONTROL THE OUTBREAK
    a. John Brooks, US Centers for Disease Control, USA
    15-minute update
3. FOCUS ON THE VIROLOGY OF CORONOVIRUSES OVERALL, MOLECULAR ASPECTS OF TRANSMISSION TO HUMANS, PATHOGENESIS IN MICE MODELS AND PARALLELS IN HUMANS, ETC
    a. Ralph Baric, University of North Carolina, USA
    25-minute lecture
4. FOCUS ON NIAID/HIH EFFORTS TO STUDY NOVEL CORONOVIRUSES AND DEVELOP DIAGNOSTICS. THERAPEUTICS, AND VACCINES
    a. Anthony Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
    15-minute recorded update

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 12:06:10 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: DEAR TONY: CORONAVIRUS

Please handle.

From: Dr. Michael Jacobs [redacted] (b) (6)>
Sent: Friday, February 21, 2020 6:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Alexander Tarakhovsky [redacted] (b) (6); Lockshin, Michael MD [redacted] (b) (6); Dr. Michael Jacobs [redacted] (b) (6)>
Subject: DEAR TONY: CORONAVIRUS

dear tony:

i am a cornell medical school cumc [redacted] (b) (6) graduate. i am associate professor of dermatology at weill-cornell in private practice. [redacted] (b) (6) alexander tarakhovsky is [redacted] (b) (6) and a professor at rockefeller university. he is a virologist.

we have been following the corona virus pandemic closely, and a few days ago became alarmed at the news that the chinese government is sterilizing their paper money from hubei province.

we think that there is a possibility that the virus was released from a lab in wuhan, the biotech area of china. we also think that the virus might be complexed with another organism, such as a yeast or fungus, to make it more sticky.

we would like to discuss this with you further. we feel that immediate action must be taken by united states scientists to try to neutralize this threat.

please contact alexander and me at your earliest convenience at above emails or my mobile [redacted] (b) (6) or office [redacted] (b) (6) michael lockshin gave me your email.

with kind regards

michael jacobs

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 11:49:36 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus
Attachments: Cai & Garen 1995.pdf, Cai & Garen 1996 .pdf, Cai & Garen 1997.pdf

Please handle. Thanks.

From: Garen, Alan (b) (6)>
Sent: Friday, February 21, 2020 7:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Garen, Alan (b) (6)>
Subject: coronavirus

Dear D. Fauci,
I want to suggest that NIAID arrange to collect serum samples from Coronavirus patients who have survived a major infection and probably have generated antiviral antibodies. My laboratory showed in the attached papers that such antibodies could be cloned from sera using a powerful technology called Phage Display. The project could be initiated in this country with as few as 2 patients.
Sincerely, Alan Garen, Yale University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 11:39:57 +0000
To: Antoniak, Cynthia (NBCUniversal, MSNBC)
Cc: Goldner, Shannah (NBCUniversal);Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: MSNBC Reconfirming

No problem. See you then.

From: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Sent: Saturday, February 22, 2020 6:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: MSNBC Reconfirming

If you could get there by 7:30am...that would be great!

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, February 22, 2020 6:38 AM
To: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Cc: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: [EXTERNAL] RE: MSNBC Reconfirming

I have received this e-mail and confirm 7:45 AM hit. What time do you want me at the studio?

From: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Sent: Saturday, February 22, 2020 5:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: MSNBC Reconfirming

Good Morning Dr. Fauci,

I am just reconfirming you for your segment on MSNBC this morning with Kendis Gibson and Cori Coffin.
You are hitting at 7:45am from the NBC News Bureau at 4001 Nebraska Avenue.
Topics:
-Coronavirus-infected Americans flown home against CDC advice
https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html
-Decision to quarantine cruise ship—was that a misstep?
-Long term effects of decision to bring U.S. passengers back

Please reply that you got this.
Thank you!
Cyndi

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 3:09 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: contact at the studio tomorrow/MSNBC intv

We absolutely will do. Thank you so much and thank you for your patience. We will be in touch first thing in the morning.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, February 21, 2020 3:04 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Ok – I am adding Dr Fauci to this email - please confirm to both of us in the morning. Thank you

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 2:55 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: RE: contact at the studio tomorrow/MSNBC intv

We won't have an exact hit time until the morning BUT as of now, it's 7:30am. It might be 7:35am but that is the hit time.
Cyndi will send it to you by 5am tomorrow.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, February 21, 2020 2:48 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Will you or Cyndi send exact hit time tonight? What is the approx. time we will get that?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 10:42 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Robinson, Whitney (NIH/NIAID) [C] [redacted] (b) (6) Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6); Lavelle, Judith (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: contact at the studio tomorrow/MSNBC intv

Thank you so much

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, February 21, 2020 10:35 AM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Robinson, Whitney (NIH/NIAID) [C] [redacted] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6); Lavelle, Judith (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Great – thanks.

Please just let us know the exact him time and we will have him arrive 20 mins prior.

His cell is [redacted] (b) (6) and mine is [redacted] (b) (6)

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 10:29 AM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Robinson, Whitney (NIH/NIAID) [C] [redacted] (b) (6) Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6)>; Lavelle, Judith (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: contact at the studio tomorrow/MSNBC intv
Importance: High

Patricia, hi,
The contact at the studio in the morning is Natalia Abrams. The number at the office is 202-885-4800. Also, Cyndi Antoniak will be in touch with you in the morning and send you an email about the segment and just to touch base. If you need to reach Cyndi before she reaches you, her number is 212-664- 1450 and her email is Cynthia.antoniak@nbcuni.com .
Thank you so much for making the interview work out, we appreciate it.
Shannah

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Friday, February 21, 2020 9:06 AM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Robinson, Whitney (NIH/NIAID) [C] [redacted] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C]

(b) (6)>; Lavelle, Judith (NIH/NIAID) [E] (b) (6)>
Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

Hi Shannah

Saturday Morning between 7:30 am ET – 8 am ET is best for Dr Fauci and will need to be from the NBC Studio at 4001 Nebraska Ave NW studio. He has a hard stop no later than 8:15 am. Please send us the onsite contact name and number and firm hit time when you can.

Thanks,
-patty

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Thursday, February 20, 2020 4:17 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)
Subject: RE: hi and request for Dr. Fauci this weekend on MSNBC

That's terrific and yes, that studio is best if he can join us. Thank you so much. Shannah

---

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 20, 2020 4:16 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)
Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

I am sure we can make one of these work – will let you know tomorrow.
We would do from the NBC Nebraska Ave NW Studio.

thx

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Thursday, February 20, 2020 4:12 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6) Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)
Subject: hi and request for Dr. Fauci this weekend on MSNBC
Importance: High

Patricia, hi, I hope all is well with you.
Is Dr. Fauci available this weekend to be on MSNBC to discuss the latest re Corona virus - https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html

We'd like him on either on Saturday, in the 7:30am to 8am half hour, with Kendis Gibson/Cori Coffin, or on Sunday in the 12pm or 1pm hour with Alex Witt. Whatever day/hour that is good for him, we'll make work.

Thank you so much for your help in this matter.

All the best,

Shannah

Shannah Goldner
MSNBC
W: 212-664-1289
C: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 11:39:06 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: MSNBC Reconfirming

I just did reconfirm with a copy to you. Did you not get it?

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, February 22, 2020 6:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>
Subject: Fwd: MSNBC Reconfirming

You need to respond to this. It's in your on box

Sent from my iPhone

Begin forwarded message:

> **From:** "Antoniak, Cynthia (NBCUniversal, MSNBC)" <Cynthia.Antoniak@MSNBC.COM>
> **Date:** February 22, 2020 at 5:49:00 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** "Goldner, Shannah (NBCUniversal)" <shannah.goldner@nbcuni.com>, "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: MSNBC Reconfirming**
>
> Good Morning Dr. Fauci,
>
> I am just reconfirming you for your segment on MSNBC this morning with Kendis Gibson and Cori Coffin.
> You are hitting at 7:45am from the NBC News Bureau at 4001 Nebraska Avenue.
> Topics:
> -Coronavirus-infected Americans flown home against CDC advice
> https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html
> -Decision to quarantine cruise ship—was that a misstep?
> -Long term effects of decision to bring U.S. passengers back
>
> Please reply that you got this.
> Thank you!
> Cyndi
>
> ---
>
> **From:** Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
> **Sent:** Friday, February 21, 2020 3:09 PM
> **To:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)

Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: RE: contact at the studio tomorrow/MSNBC intv

We absolutely will do. Thank you so much and thank you for your patience. We will be in touch first thing in the morning.

From: Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6)
Sent: Friday, February 21, 2020 3:04 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Ok – I am adding Dr Fauci to this email - please confirm to both of us in the morning. Thank you

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 2:55 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: RE: contact at the studio tomorrow/MSNBC intv

We won't have an exact hit time until the morning BUT as of now, it's 7:30am. It might be 7:35am but that is the hit time.
Cyndi will send it to you by 5am tomorrow.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, February 21, 2020 2:48 PM

To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Will you or Cyndi send exact hit time tonight? What is the approx. time we will get that?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 10:42 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Robinson, Whitney (NIH/NIAID) [C] [redacted] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] <[redacted] (b) (6); Lavelle, Judith (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: contact at the studio tomorrow/MSNBC intv

Thank you so much

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, February 21, 2020 10:35 AM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Robinson, Whitney (NIH/NIAID) [C] [redacted] (b) (6) Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6) Lavelle, Judith (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Great – thanks.

Please just let us know the exact him time and we will have him arrive 20 mins prior.

His cell is [redacted] (b) (6) and mine is [redacted] (b) (6)

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 10:29 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Robinson, Whitney (NIH/NIAID) [C] [redacted] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6); Lavelle, Judith (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: contact at the studio tomorrow/MSNBC intv
Importance: High

Patricia, hi,
The contact at the studio in the morning is Natalia Abrams. The number at the office is 202-885-4800.
Also, Cyndi Antoniak will be in touch with you in the morning and send you an email about the segment and just to touch base. If you need to reach Cyndi before she reaches you, her number is 212-664- 1450 and her email is Cynthia.antoniak@nbcuni.com .
Thank you so much for making the interview work out, we appreciate it.
Shannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, February 21, 2020 9:06 AM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Robinson, Whitney (NIH/NIAID) [C] < [redacted] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] < [redacted] (b) (6)>; Lavelle, Judith (NIH/NIAID) [E]

(b) (6)
Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

Hi Shannah

Saturday Morning between 7:30 am ET – 8 am ET is best for Dr Fauci and will need to be from the NBC Studio at 4001 Nebraska Ave NW studio. He has a hard stop no later than 8:15 am. Please send us the onsite contact name and number and firm hit time when you can.

Thanks,
-patty

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Thursday, February 20, 2020 4:17 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)
Subject: RE: hi and request for Dr. Fauci this weekend on MSNBC

That's terrific and yes, that studio is best if he can join us. Thank you so much. Shannah

---

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 20, 2020 4:16 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Deatrick, Elizabeth

(NIH/NIAID) [C] < (b) (6)
Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

I am sure we can make one of these work – will let you know tomorrow.
We would do from the NBC Nebraska Ave NW Studio.

thx

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Thursday, February 20, 2020 4:12 PM
To: Conrad, Patricia (NIH/NIAID) [E] < (b) (6)
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] < (b) (6)>
Subject: hi and request for Dr. Fauci this weekend on MSNBC
Importance: High

Patricia, hi, I hope all is well with you.
Is Dr. Fauci available this weekend to be on MSNBC to discuss the latest re Corona virus - https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html

We'd like him on either on Saturday, in the 7:30am to 8am half hour, with Kendis Gibson/Cori Coffin, or on Sunday in the 12pm or 1pm hour with Alex Witt. Whatever day/hour that is good for him, we'll make work.

Thank you so much for your help in this matter.

All the best,

Shannah

Shannah Goldner
MSNBC
W: 212-664-1289
C: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 02:39:22 +0000
To: Morens, David (NIH/NIAID) [E]
Subject: FW: So what do you guys think ? (I no it's not influenza, but a lot of your 2007 conclusions seem very valid now...)

David:
Please respond to this person.
Thanks,
Tony

-----Original Message-----
From: [redacted] (b) (6)
Sent: Friday, February 21, 2020 9:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: So what do you guys think ? (I no it's not influenza, but a lot of your 2007 conclusions seem very valid now...)

Dear David Morens, dear Anthony Fauci,

I realise it is not an influenza virus, but the outlook of your 2007 paper ("The 1918 Influenza Pandemic: Insights for the 21st Century") seems to me to be very valid for the current coronavirus outbreak. Or put differently - your statements and concerns from then mostly coincide with my thinking and worries now... :(.

So a question - what is your thinking now? Are the hospitals you're affiliated with hiring additional staff (yet)? Any personal preparations?

Good luck to you and all the best for those close to you, kind regards, Sean Scherer

P.S. I guess part of the the reason I'm asking is, because I (a non-institutionally affiliated biologist), am in touch with the university-hospital here ([redacted] (b) (6) Germany), but my concerns are so far falling on deaf ears... But also just reading the paper and seeing others come to the same conclusions - albeit on more theoretical grounds and multiple years ago - made me want to reach out. Plus I guess I'm simply curious about what you think !

From: [redacted] (b) (6)
Sent: Fri, 21 Feb 2020 14:38:56 -0500
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: Re: Work related question

You are correct. No chance that I would accept. Thanks

> On Feb 21, 2020, at 2:23 PM, Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>wrote:
>
> In the interest of full disclosure: Stephanie [redacted] (b) (6) used to work here at HHS and is now a VP with the American College of Preventive Medicine. For the life of me I couldn't see you saying yes to a weekend trip to Denver in May, and I would hate to have them waste their time sending an invite when they could be pursuing someone more likely to accept. Hope this is OK.
>
> ---
>
> **From:** Billet, Courtney (NIH/NIAID) [E]
> **Sent:** Friday, February 21, 2020 2:18 PM
> **To:** Stephanie Marshall [redacted] (b) (6)>
> **Subject:** RE: Work related question
>
> Hi – good to hear from you! I hesitate to speak definitively for him and his scheduler, but to be perfectly honest I think it's really unlikely that'd he'd be able to accept a speaking invite for Denver. The schedule is insane for the foreseeable future and isn't letting up on the weekends. He's turning invitations down left and right, unfortunately – especially those involving travel!
>
> ---
>
> **From:** Stephanie Marshall [redacted] (b) (6)
> **Sent:** Friday, February 21, 2020 1:51 PM
> **To:** Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
> **Subject:** Work related question
>
> Hi Courtney,
>
> I hope you're doing well despite the ongoing craziness whether it's coronavirus or politics. Yikes, these are unsettled times.
>
> I have a quick question for you. Our annual meeting is May 14 - 17 in Denver. Many of the sessions are in place but there's talk about doing a session around

coronavirus and inviting Dr. Fauci as the speaker. The meeting is a Thursday through Sunday and they're looking at inviting him to speak potentially on Sunday morning. Is this something he would even consider and would he commit this far out given everything that's going on? Any quick thoughts you might have would be helpful.

Thank you, thank you! Have a great weekend.

Stephanie

From: [redacted] (b) (6)
Sent: Fri, 21 Feb 2020 10:40:17 -0500
To: Collins, Francis (NIH/OD) [E]
Cc: Hallett, Adrienne (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E]
Subject: Re: FYI on Senate staff visit

Thanks, Francis.

> On Feb 21, 2020, at 10:30 AM, Collins, Francis (NIH/OD) [E]
> <[redacted] (b) (6)
>
> Hi Tony,
>
> I got asked by Alex Keenan what the NIH needs for the coronavirus response. I said that this had been looked at with great care by you and your staff. If you are asking me for technical assistance, I said, we need about [redacted] (b) (5) for FY20-21, and more in the long run.
>
> ASFR was in the room but did not have a visible seizure.
>
> Just thought you'd want to know before you meet with the staffers later today.
>
> FC

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Fri, 21 Feb 2020 14:31:08 +0000
To:	Donna Jacobsen
Cc:	Conrad, Patricia (NIH/NIAID) [E];Greg Folkers
([redacted] (b) (6));	Marston, Hilary (NIH/NIAID) [E]
Subject:	RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:

Thanks for the note. I will be able to provide a 15 minute video with slides that discusses the NIH/NIAID efforts to study the novel coronavirus and to develop countermeasures in the form of diagnostics, therapeutics, and vaccines. Your team can work with Patty Conrad, Hilary Marston and Greg Folkers on the logistics. In the meantime, we will prepare the video.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>
Sent: Thursday, February 20, 2020 8:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch
Importance: High

Dear Dr Fauci:

We've had a lot of discussion around our COVID-19 session today. An idea that came up was possibly having you do something remotely. Either a live feed in from your office at approximately 1:05 PM to 1:20 PM EDT on Tuesday, March 10 if you have that time available, or have you send in a video recorded presentation a day or 2 before that we can show at the session. Having some way to communicate the high priority NIH/NIAID has on developing a vaccine and treatment would help bring the content together.

We know this is likely not possible, with the very short notice and your even more tremendously busy schedule around all of this. But it's worth the ask.

Please let me know if you think either of these is possible. And Patty, sorry for butchering your email address earlier.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
Executice Manager, CROI
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

https://www.iasusa.org

About IAS–USA: Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, February 20, 2020 7:12 AM

To: Donna Jacobsen <djacobsen@iasusa.org>
Cc: [redacted] (b) (6) 'Elaine J. Abrams, MD ([redacted] (b) (6) >; Sharon Hillier PhD [redacted] (b) (6) Hoxie, James [redacted] (b) (6); Benson, Connie [redacted] (b) (6); Kevin Bowen <kbowen@iasusa.org>
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:
Thanks for the note. Unfortunately, I need to be in Washington, DC on March 10, and so I will regrettably have to decline your kind invitation. Thank you for thinking of me.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>
Sent: Tuesday, February 18, 2020 8:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: [redacted] (b) (6); 'Elaine J. Abrams, MD [redacted] (b) (6) Sharon Hillier PhD [redacted] (b) (6) >; Hoxie, James [redacted] (b) (6); Benson, Connie [redacted] (b) (6) >; Kevin Bowen <kbowen@iasusa.org>
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Dear Dr Fauci:

As I mentioned on the phone, we just today decided that we will have a special session on COVID 19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being one of the first large medical conferences in infectious diseases this year, that we address COVID 19 at CROI

We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

https://www.iasusa.org

ACCME ACCREDITED **About IAS–USA**: Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 13:33:20 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: FDA Request
Attachments: FDA Clearance Letter.pdf, Nepal Corona Virus Paper.pdf

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeff Fischer [redacted] (b) (6)
Sent: Friday, February 21, 2020 8:30 AM
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>; Khabbaz, Rima (CDC/DDID/NCEZID/OD) [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Chris Helm [redacted] (b) (6) >
Subject: FDA Request

Drs Messonnier, Khabbaz, and Fauci,

The Center for Devices and Radiological Health at the FDA suggested that we reach out to COVID-19 EUA developers to [redacted] (b) (4)

(b) (4) [redacted]

[redacted]
(b) (4)

Respectfully,

Jeff

Jeff Fischer
President
Longhorn Vaccines and Diagnostics LLC
2 Bethesda Metro Center Suite 910
Bethesda, MD 20814
[redacted]
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 10:47:53 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Fwd:
Attachments: Notes for NIH.docx

Please handle.

From: RICK SAWAYA [redacted] (b) (6) >
Sent: Friday, February 21, 2020 1:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) >; Cassetti, Cristina (NIH/NIAID) [E]
[redacted] (b) (6)
Subject: Fwd:

2202020
Dr. Fauci:

This is Dr. Rick Sawaya :

Dr. Tom Betz is [redacted] (b) (6) and his training is more in line with yours than mine.
He submitted this mini-endorsement to you for me and my work. He has seen most of my works
and the NIH data protocol from 2016-2017.
I think his background gives credibility to my ideas and lends a public health opinion which I did not have until
calling him.

Hope you enjoy this.
I have treated cancers, herpes, acne easily with this stuff and honestly and confidentially
it will do anything but your income tax.

Thanks, Rick Sawaya M.D.

[redacted] (b) (6)
call between 10am and 10pm EST,

---------- Forwarded message ---------
From: **Tom Betz** [redacted] (b) (6)
Date: Thu, Feb 20, 2020 at 10:32 PM
Subject: Re:
To: RICK SAWAYA [redacted] (b) (6)

Rick,

I am attaching suggested notes for NIH. They may think we're both crazy but I imagine you have already been down that road and I'm interested to see what happens. Hang in there,

Tom

On Tue, Feb 18, 2020 at 2:01 PM RICK SAWAYA [redacted] (b) (6)> wrote:

> THIS HAS THE CELL WITH LEARS SIGNATURE ABOVE IT
> AND A CYSTEINE RANDOM DIAGRAM

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 02:42:07 +0000
To: NIAID OD AM
Subject: FW: CROI COVID 19 Session; Tuesday March 10 lunch
Importance: High

Let us discuss.

From: Donna Jacobsen <djacobsen@iasusa.org>
Sent: Thursday, February 20, 2020 8:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch
Importance: High

Dear Dr Fauci:

We've had a lot of discussion around our COVID-19 session today. An idea that came up was possibly having you do something remotely. Either a live feed in from your office at approximately 1:05 PM to 1:20 PM EDT on Tuesday, March 10 if you have that time available, or have you send in a video recorded presentation a day or 2 before that we can show at the session. Having some way to communicate the high priority NIH/NIAID has on developing a vaccine and treatment would help bring the content together.

We know this is likely not possible, with the very short notice and your even more tremendously busy schedule around all of this. But it's worth the ask.

Please let me know if you think either of these is possible. And Patty, sorry for butchering your email address earlier.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
Executice Manager, CROI
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

https://www.iasusa.org

ACCME ACCREDITED **About IAS–USA:** Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)]
Sent: Thursday, February 20, 2020 7:12 AM
To: Donna Jacobsen <djacobsen@iasusa.org>
Cc: [redacted] (b) (6) 'Elaine J. Abrams, MD [redacted] (b) (6) Sharon Hillier PhD [redacted] (b) (6) >; Hoxie, James < [redacted] (b) (6); Benson, Connie [redacted] (b) (6) >; Kevin Bowen <kbowen@iasusa.org>
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:

Thanks for the note. Unfortunately, I need to be in Washington, DC on March 10, and so I will regrettably have to decline your kind invitation. Thank you for thinking of me.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)

FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>
Sent: Tuesday, February 18, 2020 8:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: [redacted] (b) (6)'Elaine J. Abrams, MD [redacted] (b) (6) Sharon Hillier PhD [redacted] (b) (6)>; Hoxie, James [redacted] (b) (6); Benson, Connie [redacted] (b) (6); Kevin Bowen <kbowen@iasusa.org>
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Dear Dr Fauci:

As I mentioned on the phone, we just today decided that we will have a special session on COVID 19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being one of the first large medical conferences in infectious diseases this year, that we address COVID 19 at CROI

We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

https://www.iasusa.org

ACCME
ACCREDITED

About IAS–USA: Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 01:47:03 +0000
To: McNeil Jr, Donald G
Subject: RE: question re the WashPost story

Donald:

You know that I always answer your calls and e-mails, but this one I want to stay away from. Sorry.

Best,
Tony

From: McNeil Jr, Donald G <mcneil@nytimes.com>
Sent: Thursday, February 20, 2020 4:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: question re the WashPost story

Now that I've had a chance to read the whole story -- after editors finished whirling -- I see it also contains these grafs:

Are they accurate?

Thanks

During one call, the CDC's principal deputy director, **Anne Schuchat**, argued against taking the infected Americans on the plane, according to two participants. She noted the U.S. government had already told passengers they would not be evacuated with anyone who was infected or showed symptoms. She was also concerned about infection control. **Anthony Fauci**, head of the National Institute of Allergy and Infectious Diseases, who was also on the calls, **recalled** saying her points were valid and should be considered. But **Robert Kadlec**, assistant secretary for preparedness and response for the Department of Health and Human Services and a member of the coronavirus task force, pushed back: Officials had already prepared the plane to handle passengers who might develop symptoms on the long flight, he argued. The two Boeing 747s had 18 seats cordoned off with 10-foot-high plastic on all four sides. Infectious disease doctors would also be onboard.

On Thu, Feb 20, 2020 at 4:24 PM McNeil Jr, Donald G <mcneil@nytimes.com> wrote:

> Hi, Tony:
>
> The Washington Post has just put up a story saying that the 14 infected passengers on the buses containing 238 American passengers from the Diamond Princess were flown home AGAINST the CDC's advice. And that the States Department overruled the CDC on this.
>
> Can you confirm whether that's true?

Thanks...
Donald

Story contains these crucial grafs:

In Washington, where it was still Sunday afternoon, a fierce debate broke out: The State Department and a top Trump administration health official wanted to forge ahead. The infected passengers had no symptoms and could be segregated on the plane in a plastic-lined enclosure. But officials at the Centers for Disease Control and Prevention disagreed, contending they could still spread the virus. The CDC believed the 14 should not be flown back with uninfected passengers.

"It was like the worst nightmare," said a senior U.S. official involved in the decision, speaking on the condition of anonymity to describe private conversations. "Quite frankly, the alternative could have been pulling grandma out in the pouring rain, and that would have been bad, too."

--
Donald G. McNeil Jr.
Science Correspondent
The New York Times

Tel: +1 212 556 1142
mcneil@nytimes.com

Articles: https://www.nytimes.com/by/donald-g-mcneil-jr

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 00:13:55 +0000
To: Richard Allen Johnson
Subject: RE: 02.20.2020 Thursday

Dick:

Thanks for the note. Always good to hear from you.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Allen Johnson (b) (6)
Sent: Thursday, February 20, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Sandra Goldstein (b) (6)
Subject: 02.20.2020 Thursday

Hi, Tony,

(b) (6) this week.

We watched a life size ASF as you discussed and reassured us about Covid-19. You are simply the best. Were you running for president, I am sure that you would win the vote.

Don't forget our lunch in Boston.

Best,
Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 23:48:29 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Urgent- Phone Interview Request on Coronavirus

Done!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Qi Zhang <qizhang@caixin.com>
Sent: Thursday, February 20, 2020 3:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Urgent- Phone Interview Request on Coronavirus

Dear Dr. Fauci,

Good afternoon. I am Olivia Zhang with Caixin Media, which is the front-liner of the Coronavirus reporting in China. We spoke at the very beginning of the virus and I wanted to talk to you regarding the latest situation, especially from test, treatment point of view. I also left you a voice message. Feel free to call me via (b) (6) whenever you're free.

I look forward to hearing from you.

Best,
Olivia

Qi ZHANG (Olivia)
U.S. Correspondent
Caixin Media Company Limited

Email: qizhang@caixin.com
Mobile:+ (b) (6)
Twitter: @zhang_qiii
www.caixin.com | caixinglobal.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 23:28:04 +0000
To: Achenbach, Joel
Subject: RE: quick question: when does an epidemic become a "pandemic" officially?

It is impossible to predict at this point if the current outbreak will progress to a true pandemic. The future of this outbreak and whether it will progress to a pandemic will be determined by two factors: 1) the degree to which China controls infections in China, which will ultimately impact how many infections leak out to other countries in the world. 2) The success or not of other countries that have received travel-related cases from China in preventing the development of sustained transmission of infections in their own country. If these other countries are successful in containing the transmissions, then a pandemic will be avoided. If a large number of countries are unsuccessful in preventing sustained multi-generation transmissions, then we could witness the next pandemic.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Achenbach, Joel <Joel.Achenbach@washpost.com>
Sent: Thursday, February 20, 2020 6:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: RE: quick question: when does an epidemic become a "pandemic" officially?

Oh....and...the big question: How likely is it that covid-19 will become a pandemic? Would love an on-the-record assessment. Thanks...joel

---

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, February 20, 2020 6:06 PM
To: Achenbach, Joel <Joel.Achenbach@washpost.com>
Subject: RE: quick question: when does an epidemic become a "pandemic" officially?

CAUTION: EXTERNAL SENDER

Joel:

There are many iterations of the definition of a "pandemic". However, one that I use that is simple and understandable is as follows: An outbreak of a serious infectious disease with substantial global health consequences (usually one that has never before been experienced by the human population) that is transmitted readily from person to person and where there is sustained transmission (i.e. multiple generations of person to person to person) in multiple countries and regions of the world. In this regard, the coronavirus outbreak in China is an "epidemic" in China, but it is not yet a pandemic since there is not "sustained" person to person transmission throughout the world. There are infections in other countries (more than 25 countries), but these started as travel related cases from China and although there are several human to human infections in these other countries, these infections have not yet been "sustained". If we start seeing sustained, multiple generations of transmissions in many countries throughout the world, then the outbreak will have progressed to fill the criteria of a true pandemic.

Hope that this is helpful.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Achenbach, Joel <Joel.Achenbach@washpost.com>
Sent: Thursday, February 20, 2020 5:51 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: quick question: when does an epidemic become a "pandemic" officially?

Dear Tony Fauci:
Hi! Busy times. Hope you are well. Can you explain to me how we will know if and when covid-19 has become pandemic, versus whatever you'd call the current situation? Just in general, what's the definition of a pandemic?
Thank you...best, Joel

(and thanks for calling me back last weekend, sorry I missed you)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 16:45:39 +0000
To: Michael Gerson
Subject: RE: Tony, I'm still working on this, but need your reaction
Attachments: Gerson with minor Fauci edits.docx

Mike:

Thanks for sending this. It looks good. I have copied it to a WORD document and have made some minor suggested edits for your consideration.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michael Gerson [redacted] (b) (6)>
Sent: Thursday, February 20, 2020 11:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Tony, I'm still working on this, but need your reaction

Meanwhile, on the other side of the earth, there have been 73,000 cases of coronavirus and more than 2000 deaths. This leaves American health experts hoping that the number of infections has been dramatically underreported.

That is not a typo. If the current numbers are close to accurate, it indicates a coronavirus mortality rate upwards of 2 percent. The morality rate for the seasonable flu is generally .1 percent. The mortality rate for pandemic flu is .3 percent. The particularly deadly flu pandemic of 1918 –

which took the lives of more than 100 million people around the world – had a mortality rate of 1.8 to 2 percent.

So, if 2000 deaths is the numerator, scientists hope that the denominator is actually much larger. And that is probable, given the likelihood that there are many more people who have the infection but don't know it, or are not showing symptoms.

The good news? The outbreak started in a single location and seems largely contained there. There have been several hundred cases in more than 25 countries outside of China. But the overwhelming majority have been travel related. The containment measures of Singapore, Hong Kong and Japan – which have the most cases – seem to have been successful. Of the 15 American cases (before the arrival of the cruise ship passengers), 13 are travel related. The two others are spouses of people in that group. We still have not seen widespread, sustained transmission from person to person outside of China.

The Chinese reaction to the virus has shown the weaknesses and advantages of authoritarianism. The immediate response of a system built on fear is to a problem like this one is denial and deception. No one wants to carry bad news. So local Chinese officials spent the first week of the outbreak – as the disease was spreading under the radar – insisting that the transmission of the virus was all animal to human.

But only in a society like China could you have the effective lockdown of 50 million people, including the entire city of Wuhan, to slow the spread of the disease. Public health officials in most places – who are required to balance health needs with civil liberties – would not even consider such a measure. Yet it appears to be working.

The danger? "All that is needed is for a few countries in the developing world that can't contain the coronavirus," Tony Fauci told me. "This could be the second wave of the pandemic."

Pandemic diseases tend to attack the weakest links – the most vulnerable health systems – in the global chain. If there is sustained transmission in those places, says Fauci, "even countries with best practices will suffer." Countries in Africa are of particular concern. There are millions of Chinese in Africa, and many Africans study in China. Countries such as Ethiopia, Senegal and South Africa seem to be doing a good job at testing random samples for coronavirus in key cities. But Liberia? Guinea? Sierra Leone?

Seldom has there been a stronger argument for American global engagement to strengthen African health systems, which constitute part of own immune system against pandemics. Seldom has there been a better argument to abandon “America First” posturing and to recognize that our own fate is closely tied to the fate of other nations.

Much about the future course of the disease depends on the answer to a scientific question: Is someone who has the virus but lacks symptoms – or has symptoms so mild they hardly notice – capable of transmitting the virus to others? “It looks like the answer is yes,” says Fauci. Which would make the virus far harder to control.

“We may find that the virus is highly transmissible, but less lethal than we thought in the beginning,” Fauci told me. In this case, the danger would be similar to a particularly bad influenza. And the outbreaks could be seasonal, like the flu as well. “I would not be surprised if that happened,” Fauci concluded.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 15:15:05 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: inquiry/suggestion re Corona virus->

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alan DiCara [redacted] (b) (6)
Sent: Wednesday, February 19, 2020 8:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>
Subject: inquiry/suggestion re Corona virus->

2.19.2020

Dear Dr Fauci,

Thanks so much for being who you are and for dedicating your life to protecting all of us. I write because I saw your interview on PBS tonight and had a question pertaining to denominators and numerators. Please know that I profess absolutely no expertise in areas pertaining to biology nor medicine nor disease and while I understood and agree with your estimation that the fatality rate of the Corona virus to date may be somewhat inflated of the number of cases is understated, I have a related question for you regarding info I was able to find at this site https://www.worldometers.info/coronavirus/

Regarding data this site reports, among many things, and as one scrolls down, that the 'number of active cases' reported today is 57,228 and the number of these that are 'serious or critical' is 12,064. In a worst case scenario, and taking the 12,064 as the numerator and dividing it by a denominator of 57,228, we get 21.08, or about 21%, much higher that the 1% based on total deaths over total cases so far. Of course this is not fair but my question is this: can we know **better** how many of the patients (cases) who are 'serious or critical' and still being treated will recover?

Thanks much for any reply-
Alan DiCara, Winsted, CT

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 12:39:25 +0000
To: David Katz
Subject: RE: CoronaVirus Epidemic -- a Thought

David:

Thanks for the note. I hope that all is well with you. Although allogeneic/semi-allogeneic blood transfusions could be an interesting approach to serious COVID-19 disease, there are a number of existing drugs such as remdesivir (nucleotide analogue) and Kaletra (protease inhibitor) that have some pre-clinical activity against the virus and these are now being tested in randomized clinical trials.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: David Katz (b) (6)
Sent: Wednesday, February 19, 2020 6:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: CoronaVirus Epidemic -- a Thought

Dear Tony,

It has been some time since we last spoke, but this current catastrophe has provoked my thinking about possible therapeutic interventions that could be immediately employed -- in advance of therapies/vaccines that will take many months to create. And I need to share those thoughts with you.

My suggestion is to treat actively-infected, and acutely ill, patients (under carefully controlled procedures) with allogeneic/ semi-allogeneic blood transfusions. The resulting GVHD response should theoretically combat, and eradicate the viral infection.
I look forward to your thoughts on this suggestion.

With best wishes to you and your family,

David

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 10:51:23 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE TODAY

FYI

From: Amelie RIOUX [redacted] (b) (6)>
Sent: Thursday, February 20, 2020 2:00 AM
To: As Sy [redacted] (b) (6)>; Gro Harlem Brundtland <[redacted] (b) (6); 'Dzau Victor' [redacted] (b) (6); Chris Elias [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Fore Henrietta [redacted] (b) (6)>; Gao Fu [redacted] (b) (6); Gashumba Diane [redacted] (b) (6); Ilona Kickbusch [redacted] (b) (6); Suzuki Yasuhiro [redacted] (b) (6) [redacted] (b) (6); Vega Morales Jeanette [redacted] (b) (6); VijayRaghavan Krishnaswamy [redacted] (b) (6)>; Skvortsova Veronika [redacted] (b) (6)
Cc: [redacted] (b) (6)Tore Godal [redacted] (b) (6); Godal, Tore [redacted] (b) (6)
Subject: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE TODAY
Importance: High

MESSAGE ON BEHALF OF THE GPMB CO-CHAIRS DR BRUNDTLAND AND MR SY

Dear Board Members,

We would like to hold a teleconference of the Board **today, 20 February at 13:00 Geneva time**.

The agenda for the call would be as follows:

- Short update and stock taking on the coronavirus outbreak;
- Functioning of the Secretariat and improving effectiveness of the Board;
- Way forward

Please note that this call would be a **closed discussion, for Board members only**.

We would appreciate if you could confirm your participation to Amélie Rioux (at [redacted] (b) (6)

We will share with you shortly the call-in details.

Thank you for your support and continued engagement. We look forward to the call.

With kind regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 03:43:40 +0000
To: Sharon Rockefeller
Subject: RE: This evening's broadcast

Thanks, Sharon. It is always a pleasure to be on the PBS NewsHour. They are high on honesty and integrity.
Best regards,
Tony

From: Sharon Rockefeller <srockefeller@weta.org>
Sent: Wednesday, February 19, 2020 8:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: This evening's broadcast

Dear Dr. Fauci,

Thank you, once again, for appearing on the PBS NewsHour and for treating so many Coronavirus patients. Your gift of calm and clear explanations to normal people is unparalleled. Please do not exhaust yourself as you help so many others. [redacted] (b) (6).

Very sincerely,
Sharon

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 00:54:10 +0000
To: Crawford, Chase (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Haskins, Melinda (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E]
Subject: RE: Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus Hearings
Attachments: Draft NIAID insert for COVID-19 hearings_to ASF - with Fauci tracked edits.docx

Here it is. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Crawford, Chase (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, February 19, 2020 6:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)>; Selgrade, Sara (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus Hearings

Dr. Fauci:

In preparation for the upcoming COVID-19 hearings of the House Committee on Energy and Commerce Health Subcommittee and the Senate Committee on Health, Education, Labor and Pensions, we have drafted the attached NIAID insert for inclusion in the combined HHS statement for the record. The Department plans to use the same combined statement for both the House and Senate hearings.

The attached draft has been reviewed by the Divisions and Drs. Harper, Eisinger, Lerner, and Marston, as well as Courtney Billet, Martin Johnson, Greg Folkers, and Laurie Doepel.

The Department has asked to receive your statement by COB tomorrow, Feb. 20th.

Thank you for your help.

Chase

Chase Crawford, D.V.M., M.S.
Public Health Analyst
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
NIAID/NIH/DHHS
Bldg. 31, Room 7A17, MSC 2520
Bethesda, MD 20892-2520
(b) (6)

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 23:03:23 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: BioCentury coverage of mAbs to treat COVID-19

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Karen Tkach Tuzman <ktkach@biocentury.com>
Sent: Wednesday, February 19, 2020 5:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: BioCentury coverage of mAbs to treat COVID-19
Importance: High

Dear Dr. Fauci,

I hope all is well. BioCentury is doing a roundup of companies and institutions developing antibodies against the SARS-CoV-2 virus to treat patients with COVID-19. Since you told my colleague Steve Usdin NIAID is developing its own mAbs against the virus, we'd like to include information about that program in our roundup.

Would you or one of your colleagues be able to answer the following questions? Any information you could share by 5 PM Pacific Time on Thursday, Feb. 20 would be greatly appreciated.

1. Are your mAb candidates being developed against specific targets on SARS-CoV-2? If so, what are those targets?

2. What platforms or processes are you using to identify mAb candidates?

3. Do you have multiple mAb programs against SARS-CoV-2 proceeding in parallel, and if so, how are they distinguished?

4. What is that status of each of your mAb programs? For example, have you nominated any lead candidates, are you awaiting patient samples, etc.?

5. Do you have any metrics on lead candidates available yet, such as neutralization titers? If so, what are they?

All the best,
Karen

Karen Tkach Tuzman, Ph.D.
Head, Discovery & Preclinical Development
Associate Editor, BioCentury Inc.
650-595-5333 x 144 (office)
www.biocentury.com

Notice: This communication (including any attachments) constitutes an electronic communication within the meaning of the Electronic Communications Privacy Act, 18 USC 2510, and its disclosure is strictly limited to the recipient(s) intended by the sender of this message. This communication (including any attachments) contains proprietary information, is protected under U.S. and foreign copyright and other intellectual property law, and may contain confidential material for the sole use of the intended recipient. Any unauthorized review, use, disclosure, dissemination, copying or distribution of this communication (including any attachments), or any of their respective contents, is strictly prohibited. If you are not the intended recipient, please contact the sender by return email and destroy all copies of the original message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 20:27:04 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers ([redacted] (b) (6)
Subject: FW: Invitation to Speak
Attachments: Invitation_Dr. Anthony Fauci.pdf

Patty/Greg:
Let us discuss.
ASF

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Crow, Hilary <HCrow@USChamber.com>
Sent: Wednesday, February 19, 2020 12:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Invitation to Speak

Dear Dr. Fauci,

I'm writing to share the attached invitation with you to speak at the U.S. Chamber Foundation's program on March 10 on the future of medicine.

Our audience of CEOs, market leaders, and opinion leaders would be thrilled to learn more about your perspective on the future of medicine, current issues like the Coronavirus, and future challenges in health and medicine.

Please let me know if you have any questions. I'm happy to schedule a quick call to provide more detail over the phone with you or someone on your team.

I hope you will be able to join us.

Best,
Hilary

Hilary Crow
Executive Director, Programs
U.S. Chamber of Commerce Foundation
1615 H Street, NW | Washington, DC | 20062-2000
Office: 202.463.5710
Mobile: (b) (6)

U.S. Chamber of Commerce Foundation

www.uschamberfoundation.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 16:51:27 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Handley, Gray (NIH/NIAID) [E]
Subject: RE: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

If they accept two people, you should go with Gray. Obviously, you should make no commitments and when asked about policy issues, say that you will convey to me and we will get back to them.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, February 19, 2020 10:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Handley, Gray (NIH/NIAID) [E] (b) (6)
Subject: Re: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Have you had a chance to discuss this world bank conference? You, Cliff and Libby received invites. As Gray has mentioned, this is a pledging conference, so we will need to be prepared to address funding (the person that attends would need to be in sync with you on that).
Obviously Cliff is on travel. Who would you like to have at the conference, if anyone?

-hilary

From: Anthony Fauci <[redacted] (b) (6)>
Date: Friday, February 14, 2020 at 9:25 PM
To: NIAID AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Let us discuss.

From: Feng Zhao <fzhao@worldbank.org>
Sent: Friday, February 14, 2020 5:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: [redacted] (b) (6); Mukesh Chawla <mchawla@worldbank.org>; Rocio Schmunis <rschmunis@worldbank.org>; Adrienne Kate Mcmanus <amcmanus@worldbank.org>; Gabrielle Lynn Williams <gwilliams1@worldbank.org>; WB Health Events <wbhealthevents@worldbank.org>; Muhammad Ali Pate <mpate@worldbank.org>
Subject: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Dear Dr. Fauci,

On behalf of the World Bank health team, in coordination with the Coalition for Epidemic Preparedness Innovations (CEPI), it is our pleasure to invite you to a half-day consultation on ***Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development***. The meeting is set to take place on **Thursday, February 20, 2020** from **9:30am to 1:30pm** at the **World Bank Offices in Washington DC** (located at 1818 H St NW) on **floor C2, conference room MC C2-125.**

As you know, the novel Coronavirus outbreak, which started in Wuhan, China, is evolving rapidly. As of today, the number of confirmed cases has increased significantly to over 60,000 and the virus has reached 25 countries. The outbreak, a Public Health Emergency of International Concern (PHEIC), poses a threat to countries worldwide, especially those with weak health systems and low levels of pandemic preparedness.

It is of urgent importance that we move quickly to finance the development of the appropriate countermeasures for a disease that risks becoming endemic across the globe. Two critical issues are necessary to address: i) immediate financing for the development and scale-up of a diversified portfolio of vaccines, and ii) financing the manufacturing and procurement of vaccine for global distribution.

To enhance our discussions we are working on a background paper which we will share along with an agenda at the earliest. Recognizing the short notice, we will provide remote connection details for those unable to travel for the meeting. A working lunch will also be provided.

We hope that you will be able to participate in this important meeting. Kindly confirm your participation to Ms. Gabrielle Williams, Health, Nutrition and Population Global Practice, World Bank (wbhealthevents@worldbank.org). Please do not hesitate to reach out with any questions.

Looking forward to your positive response.

Best regards,
Feng Zhao

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 16:16:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Potential Speaking Engagement: Winter 2021

Please RSVP sorry no. Too busy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Andrew Turley [redacted] (b) (6)
Sent: Wednesday, February 19, 2020 10:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Andrew Turley [redacted] (b) (6)>
Subject: Potential Speaking Engagement: Winter 2021

Dear Dr Fauci

I know things must be impossibly busy right now with the current coronavirus issues but wanted to touch base to see whether you may be interested in a speaking engagement next Spring as part of our [redacted] (b) (6)

A bit about me: I am a [redacted] (b) (6) Air Force Major General and retired SES from the Department of Defense. [redacted] (b) (6) is an associate professor emeritus from the School of Medicine and Health Sciences at the George Washington University. We are both longtime admirers.

[redacted] (b) (6) consists of people drawn from a wide variety of backgrounds, including doctors, lawyers and many from the senior tiers of the finance and corporate worlds up to and including former CEOs and other executives (and even a few retired senior government folks like me). It is an active, well-read and learned community with a keen interest in current events. As an example, we have a very active Foreign Policy Association chapter that always draws folks from across the spectrum of political and policy perspectives for interesting and well-informed discussions.

Our [redacted] (b) (6) speaker series consists of presentations on a vast array of subjects, from literature and art to current events and public policy issues. Typically held on Tuesdays nights from December through April, these sessions consist of a presentation of an hour or so followed by Q&A and general discussion. We always draw standing room only crowds.

Recent and upcoming speakers have included:

(b) (6)

[redacted]

The recent coronavirus outbreak has captured the interest of the nation and the world. Our folks would be extremely interested in how organizations such as NIH respond and address these incredible challenges. A presentation by you about your work on these issues, from your groundbreaking work on AIDS onward or any other topic of your choosing, would be absolutely the height of our season.

We pay transportation, lodging, an honorarium, and could even arrange for a round of golf at one of our outstanding golf courses! (Of equal importance is that we can offer you a brief respite from the cold of winter.). There are direct flights from Washington DC to West Palm Beach. We have openings in January, February and March 2021.

We would be deeply appreciative of your favorable consideration. Please feel free to contact me if I can answer any questions

F. ANDREW TURLEY

(b) (6)

CELL: [redacted]
HOME:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 14:42:50 +0000
To: Greg Folkers ([redacted] (b)(6)
Subject: FW: Clip of Dr. Fauci on NPR

Good interview on NPR. Possible for Director's Page.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b)(6)
FAX: (301) 496-4409
E-mail: [redacted] (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lindsey Beall <lbeall@scgcorp.com>
Sent: Wednesday, February 19, 2020 8:22 AM
To: Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b)(6)>; Pekoc, Ken (NIH/NIAID) [E] [redacted] (b)(6)Conrad, Patricia (NIH/NIAID) [E] [redacted] (b)(6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b)(6)>; Doepel, Laurie (NIH/NIAID) [E] [redacted] (b)(6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b)(6); Hoffman, Hillary (NIH/NIAID) [E] [redacted] (b)(6); Oplinger, Anne (NIH/NIAID) [E] [redacted] (b)(6); Rancourt, Anne (NIH/NIAID) [E] [redacted] (b)(6); Lavelle, Judith (NIH/NIAID) [E] [redacted] (b)(6); Leifman, Laura (NIH/NIAID) [E] [redacted] (b)(6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b)(6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b)(6)>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>; Awwad, David (NIH/NIAID) [C] [redacted] (b)(6)
Cc: Osvald, Maria <mosvald@scgcorp.com>; Fabry, Cynthia (NIH/NIAID) [E] [redacted] (b)(6); Meylin Correa <mcorrea@scgcorp.com>; Marcia Bache <mbache@scgcorp.com>; Megan Schartner <MSchartner@scgcorp.com>
Subject: Clip of Dr. Fauci on NPR

Good morning,

Below is a clip of Dr. Fauci discussing coronavirus on NPR's Morning Edition. This clip aired earlier this morning.

https://app.criticalmention.com/app/#/clip/public/1b0da123-0cd7-4012-90a6-b82d27c73191?show_sentiment=false

Thanks,

Lindsey

From: Critical Mention <do-not-reply@criticalmention.com>
Sent: Wednesday, February 19, 2020 8:18 AM
To: Lindsey Beall
Subject: Critical Mention: Megan Schartner has shared a Radio Mention with you

critical mention

You're always on it with Critical Mention.

Megan Schartner has shared a Radio Mention with you!

From Megan Schartner (mschartner@scgcorp.com)

View Mention

No Program Name Available

Radio

Program Name No Program Name Available
Source WLRNFM
Market DMA: 16 Miami, FL
Time Feb 19, 2020 8:07 AM EST
Clip Length 07:16.852

it's morning edition from n. p. r. news on david green in culver city california and a militant in washington d. c. good morning in china the death toll from the corona virus has hit two thousand world leaders in public health officials are trying to contain it but new infections keep showing up carl golden for example he was a passenger on the diamond princess that's the cruise ship where hundreds of people got the virus we took an aquatic clues to also alone what went wrong who knew we were going and the crew and beautiful omar here's how he ended up in omaha carl his wife jerry were quarantined on that ship for twelve days in a felt fine the whole time but then the gun on a flight back to the u. s. and carl started feeling sick or wind burke from japan to this day about two hours into the flight they woke up with a high fever after napping a little bit and the doctors on board confirmed the and then on the flight landed he tested positive for the coronavirus he's recovering now in a bio contain mean unit at the university of nebraska's medical center he's going to have to spend fourteen days there and isolation well you know working %hesitation %hesitation catering we've heard on a but one of the two days of the different doctors each day i



didn't have a clue but got a little cough still you can you might want to debate left me and i'm a little to keep but maybe also because of the jet lag in the travels and everything else on top of it no it doesn't feel any different than you know recuperating from a regular coal carl's wave jerry hasn't been diagnosed with the virus is she's being monitored in a different part of the hospital but their case is a good example of some things we know and some things we don't know about how this virus is spreading so we have called doctor anthony **fauci** he's director of the national institute of allergy and infectious diseases good morning sir good morning so carl coleman was fine all those days on the ship then he gets on a plane and he gets a fever what does that tell us about how this virus is spreading well the virus has the ability to bind it to certain cells in your body particularly in your long so you can get anything from miles a symptomatic illness to a cough and a fever to some people about oh about twenty percent of the people come to the attention of medical than physicians in health care providers can get serious pneumonias requiring intensive care it sounds like this individual is on the %hesitation mild side of the illness because as he said it doesn't feel much more than just a common cold and as a matter of fact corona viruses in general prior to this all one of the causes of the common cold okay so what does that tell us i mean bleary often looking at the cases we're looking at a rising death toll which is tragic we look much less at the people like carly say you know my voice is raspy a had a fever had a cough the years a wide range of stuff symptoms with this virus did do do we know why some people seem to be doing okay and other people are getting hit really hard well whether a couple things about that for the first thing is that any any kind of viral infection or any pathogen infection there's always a wide range of responses in the sense almost like a bill shaped curve some people get no sim is at all and we do have a symptomatic corona virus infection with this particular episode and then there's the bulk of people who get some sort of symptoms and then a small percentage of people do really really very poorly now that relates to the ability of the body to handle the virus and the one thing we know when it's not unique to this virus is that the elderly those with underlying conditions like chronic heart disease lung disease diabetes obesity they tend to get more complications much more than for example and otherwise healthy individual and that's the reason why if you look at the death rate which is around two percent for this disease at this time it is disproportionately high are among the elderly and particularly those who have underlying conditions this is interesting question carlin is wave terry presumably they work together the entire time they were quarantined right and if he gets the virus she does not did she just get lucky do some people have some sort of immune undefended don't it's a combination that's a good question it's a combination of both there is no virus that has one hundred percent attack rate even the most of infectious of all viruses like measles doesn't get a hundred percent of of %hesitation vulnerable people but respiratory viruses particularly things like influenza or the corona virus the attack rate is burying percentage and it was if he was really likely that his wife i don't think she necessarily had any on the line immune protection though that's possible the maybe some cross reaction of immune protection with other %hesitation microbes that she came into contact with but in most likely is as you suggest the luck of the draw okay interesting and they got to patching wondered if you could clear something up because we've been hearing reports about so called super spread ours these you who spread the virus to a very high a number of other people and it sounds like a scary thing but and i just under is this a real phenomenon there that there are people who give the virus to more people than most and why is that happening well it is certainly the phenomenon of the super spreading israel we story with sars back in two thousand two and two thousand in three and they're episodes already with this particular new corona virus and it's a combination of two things it's an individual whose either at a particular moment in time shedding a very large amount of virus which makes it much easier to infect a group of people who are around him but you also see it sometimes in the hospital setting when you have a number of health care providers taking care of someone and that person is shedding a lot of virus so the short answer to your question is there are super spread is and it's a real phenomenon okay okay what we would you say at this moment is the most important or the most pressing question about this virus that we don't have answers to yet well what we don't know for sure we know that there are people who are infected will without symptoms or very minimal symptoms they hardly notice they're infected well we don't know is the extent to which people who have no symptoms are spreading it so we do know that this can occur because we have anecdotal documented cases of people who do not have symptoms who actually have infected someone usually a family member but we don't know the extent to which this cars in the broad component of this outbreak doctor anthony **fauci** the director of the national institute of allergy and infectious diseases sir thanks for joining us it was a pleasure to be with you

Critical Mention allows users to search global TV, Radio, Online News & Social from the United States, Canada, and Europe, watch video, edit and share coverage, receive real-time email alerts, build reports, and analyze coverage through word clouds and graphs.

Want to learn more about Critical Mention? Sign up for a demo here.

Copyright © 2020 Critical Mention, All rights reserved.

Our mailing address is:
Critical Mention
521 5th Avenue
16th Fl
New York, NY 10175

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 13:03:08 +0000
To: bdoherty@mms.org
Cc: lbaden@nejm.org;Fauci, Anthony (NIH/NIAID) [E];Redfield, Robert R. (CDC/OD);Lane, Cliff (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E]
Subject: RE: New England Journal of Medicine Editorial
Attachments: H. Clifford Lane's ICMJE-2013 - For Coronavirus Editorial Fauci et al -.pdf

Briana:

Cliff Lane has separately sent his signed CTA. I am attaching his ICMJE Form. And so you should have all the forms for all 3 authors: Fauci, Lane, and Redfield. Please let me know if you have any questions.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Briana Doherty <onbehalfof@manuscriptcentral.com>
Sent: Monday, February 10, 2020 11:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: lbaden@nejm.org
Subject: New England Journal of Medicine Editorial

Dear Dr. Fauci,

I am delighted that you have agreed to write a signed editorial to accompany the article on the initial estimates of key transmission parameters associated with nCoV-2019 virus by Li et al.

The general purpose of the Journal's editorials is to provide the reader with an authoritative interpretation or elaboration based on the substance of the article. Since this substance is usually not within the average reader's special competence, such readers will particularly benefit if the editorial avoids technical jargon, explains the article's contribution to a field of knowledge, and emphasizes, whenever possible, its clinical implications. The editorial commentary should not be concerned exclusively with the article in question but rather should use the article as a starting point for a more general discussion.

Because editorials involve interpretation and opinion, you and your potential coauthor must be free of significant relevant financial associations (including equity interest, regular consultancies, or major research support) with a company, or with a competing company, that stands to gain from the use of a product discussed in the editorial. Please contact me immediately if you are considering a coauthor, so I can ensure that your candidate meets our criteria. Additional information about disclosure of financial and other associations appears below this letter.

Please bear in mind that your editorial represents your (and any coauthor's) personal opinion. The Journal does not include statements of grant or other support or acknowledgments with editorials.

Journal policy dictates that we must have on file a signed Copyright Transfer and Authorship Agreement from each author before a manuscript can be accepted. Therefore, the enclosed form should be signed by all authors and faxed to (781) 207-6529.

Your editorial is due at the Journal on Monday, February 17, at the very latest if the deadline imposed by our printing schedule is to be met. If the editorial is to include a figure, please submit the figure at least one week before the due date for the editorial itself.

*** Additional information about preparing and submitting your editorial is given below; please read it carefully. ***

The editors must reserve the right to edit (or even reject) your editorial, but whether we use it or not, the Journal currently offers a modest stipend of $300.

Thanks again for agreeing to write this editorial for the Journal. I look forward to receiving it.

Sincerely yours,

Lindsey R. Baden, M.D.
Deputy Editor

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
http://www.nejm.org

LENGTH OF YOUR EDITORIAL
NEJM editorials should not exceed two printed pages. This means that your word count before editing should not exceed 750 words (approximately 4500 characters). Note that we spell out trial names and most other abbreviations for our readers, and we include trial registration numbers for any clinical trials mentioned; these will lengthen your editorial if you have not included them. Please provide a title not exceeding 45 characters and a word count for the text; the entire manuscript, including references, should be double-spaced.

REFERENCES
Cite no more than 10 references, including the article you are writing about. The average collection of 10 references requires about a quarter of a printed page.

TABLE OR FIGURE
A table or a figure in your editorial will require a reduction in the number of words; because figures and tables vary in size, you may be asked to shorten the text of your editorial during the production process. A quarter-page table roughly equals 250 words, and a half-page table roughly equals 500 words.

DISCLOSURES
When completing your disclosure form, please indicate, in the "Comments" field next to the type of relationship being disclosed, the amount (in U.S. dollars) of any support you have received. Please also indicate how much of this support has been received over the past 2 years. Please e-mail your completed disclosure form to editorial@nejm.org.

In the event of publication, each author's submitted disclosure form will be posted on the Web (with any dollar amounts redacted).

COPYRIGHT TRANSFER
Each author must complete a copyright transfer agreement form. Please sign it and fax it back to 781-207-6529 as soon as possible.

TO SUBMIT YOUR EDITORIAL
*** It is important that you follow the instructions below to ensure that your article enters the correct queue. ***

When you are ready to submit your manuscript, please log in to the New England Journal of Medicine - Manuscript Central site (http://mc05.manuscriptcentral.com/nejm). Your case-sensitive USER ID is afauci@niaid.nih.gov. For security purposes, your password is not listed in this message. If you are unsure of your password, please visit https://mc05.manuscriptcentral.com/nejm and enter your e-mail address in the "Forgot Your Password?" field.

Once you are logged in, the Main Menu will be displayed. Please click on the Author Center, where you will find the manuscript listed under "Invited Manuscripts." You can click on the "Continue Submission" button to begin submitting your article.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 12:37:58 +0000
To: Jon LaPook
Subject: RE: Coronavirus

It means that you are an outstanding and committed journalist. ☺

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Jon LaPook [redacted] (b) (6)
Sent: Wednesday, February 19, 2020 7:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Coronavirus

Got it. What does it mean that I'm waking up thinking about coronavirus?
:)

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine

NYU Langone Health
Twitter @DrLaPook

On Feb 19, 2020, at 7:33 AM, Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)> wrote:

Jon:

Your hypothesis is certainly possible, but I think unlikely. In a NEJM paper for which I have just written an editorial, there were 400+ patients and none younger than 15 years old. I am certain that children from birth to 15 years were exposed to and primed by coronaviruses multiple times and so if 2nd infection enhancement were an important issue, we should have seen it in children and adolescents 15 years old and younger. Just a thought, but anything is possible.
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Jon LaPook [redacted] (b) (6)
Sent: Wednesday, February 19, 2020 7:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)

Subject: Coronavirus

Good morning, Tony,
I woke up thinking this: given the relative sparing of young people during the COVID-19 outbreak, could something similar to what happens with dengue be going on? Could a second coronavirus infection - albeit with a genetically different variant than the first - bring about worse disease than the first? And, since up to a third of the common cold is caused by a variant of coronavirus, could older people somehow have been primed by an earlier coronavirus infection?

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 03:41:52 +0000
To: Grigsby, Garrett (HHS/OS/OGA);Redfield, Robert R. (CDC/OD);Cetron, Marty (CDC/DDID/NCEZID/DGMQ)
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Todays report from Dr Iwata From Kobe univ on Diamond Princess SHIP COVID-19

Folks:
You should take a look at this video (see link). The person, who is a Japanese infectious diseases specialist, is a bit inarticulate in the beginning of the video, but he provides a vivid and disturbing description of the conditions on the Diamond Princess.
Tony

From: Larry Washburn <[redacted] (b) (6)>
Sent: Tuesday, February 18, 2020 9:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Hodes, Richard (NIH/NIA) [E] [redacted] (b) (6)
Subject: Todays report from Dr Iwata From Kobe univ on Diamond Princess SHIP COVID-19

Dr. Fauci,

I am living in Japan [redacted] (b) (6) and this morning I saw this video released by Dr. Kentaro Iwata a infectious disease control.specialist

Please have somebody on your staff review this **ASAP** short description of Dr Iwata's 1 day visit on the ship. He has experience with Ebola, Sars etc. He describes an alarming condition that you and CDC must be aware of. Japan has no CDC and they tend to be very bureaucratic.

https://www.youtube.com/watch?v=vtHYZkLuKcI&feature=youtu.be

I apologize if you already have this information.

Respectfully
Larry Washburn [redacted] (b) (6) Living in Japan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 01:32:37 +0000
To: Conrad, Patricia (NIH/NIAID) [E];NIAID OD AM
Subject: RE: CROI COVID-19 Session; Tuesday March 10 lunch

I am not that excited about doing this. They have CDC doing the Epi, which is fun. They have Ralph Baric doing the virology, which I easily can do, and they have me talking about what NIAID is doing, which is important, but boring from a lecture standpoint.

Greg:
What say you?

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, February 18, 2020 8:22 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Fwd: CROI COVID-19 Session; Tuesday March 10 lunch

Sent from my iPhone

Begin forwarded message:

> **From:** Donna Jacobsen <djacobsen@iasusa.org>
> **Date:** February 18, 2020 at 8:18:06 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6), "Elaine J. Abrams, MD [redacted] (b) (6) "Sharon Hillier PhD [redacted] (b) (6)>, "Hoxie, James" [redacted] (b) (6), "Benson, Connie" [redacted] (b) (6)>, Kevin Bowen <kbowen@iasusa.org>
> **Subject: RE: CROI COVID-19 Session; Tuesday March 10 lunch**
>
> (resending with Patty's correct email address)
>
> Dear Dr Fauci:
>
> As I mentioned on the phone, we just today decided that we will have a special session on COVID-19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview of the epidemic (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being one of the first large medical conferences in infectious diseases this year, that it is important that we address COVID 19 at CROI.

We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

https://www.iasusa.org

About IAS–USA: Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 00:28:47 +0000
To: Retzlaff, Jon
Subject: RE: ACTION: Invitation to Provide Opening Remarks at the NIH-AACR Cancer, Autoimmunity, and Immunology Conference on March 23rd (on the NIH campus)

Not interested right now. Too busy. Have Hugh or someone else do this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Retzlaff, Jon <jon.retzlaff@aacr.org>
Sent: Sunday, February 16, 2020 6:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: ACTION: Invitation to Provide Opening Remarks at the NIH-AACR Cancer, Autoimmunity, and Immunology Conference on March 23rd (on the NIH campus)

Dear Dr. Fauci,

It's pretty clear that you have been ridiculously busy over the past month+ serving as our nation's top infectious disease doctor! Thanks so much for your leadership and dedication, Dr. Fauci!

I'm actually reaching out to you on a topic other than the coronavirus, as I am writing on behalf of the co-chairs for an important NIH-American Association for Cancer Research (AACR) conference (**the NIH-AACR Cancer, Autoimmunity, and Immunology Conference) that will be taking place on March 23-24, 2020, on the NIH campus (in the Masur Auditorium in the NIH Clinical Center).**

The co-chairs would like to invite you to be the opening speaker on Monday, March 23rd. Dr. Sharpless will be the opening speaker on Tuesday, March 24th. Please see the attached draft agenda.

Now in its third year, the Cancer, Autoimmunity, and Immunology Conference focuses on: 1) understanding the biology of immune-related adverse events which have occurred in cancer patients treated with immunotherapies and how that might inform the study of autoimmune disease, and 2) defining the potential for the study of autoimmune disease to lead to greater understanding of the treatment and management of immune-related adverse events during and following cancer therapies. The goal of this interdisciplinary conference is to bring together people who might not typically interact to promote cross-fertilization for the betterment of both research and clinical care, which is why there are four NIH ICs very much involved in the Conference, including: NCI, NIAID, NIAMS, and NIDDK.

Chairing this effort on behalf of the AACR is Julie R. Brahmer, MD, Johns Hopkins University. From the NIH, we have Elad Sharon, MD, MPH, NCI; Ravi Madan, MD, NCI; Connie Sommers, PhD, NCI; Howard Young, PhD, NCI; Katarzyna Bourcier, PhD, NCI; Marie Mancini, PhD, NIAMS; Annette Rothermel, PhD, NIAID; and Lisa Spain, PhD, NIDDK.

I know the diverse audience, including patients, researchers, clinicians, industry, regulators, and others, would be thrilled by your presence. Of course, we also know that you have participated in the previous two conference on this topic, which underscores why they would love to have you participate again!

Please let us know at your earliest convenience if you are interested and able to participate in the conference on Monday, March 23rd. If you have additional questions or concerns, you can contact me at jon.retzlaff@aacr.org or (b) (6)

Thanks again, Dr. Fauci, and I look forward to hearing from you!

Jon

Jon Retzlaff, MBA, MPA
CHIEF POLICY OFFICER
VICE PRESIDENT, SCIENCE POLICY AND GOVERNMENT AFFAIRS
Office of Science Policy and Government Affairs

AACR American Association for Cancer Research
FINDING CURES TOGETHER®

American Association for Cancer Research
1401 H Street, NW, Suite 740 | Washington, DC 20005

202-898-6499 Direct | 267-765-1087 Fax | (b) (6) Cell

jon.retzlaff@aacr.org | www.AACR.org

DONATE

Please note that this e-mail and any files transmitted with it may be privileged, confidential, and protected from disclosure under applicable law. This information is intended only for the person or entity to which it is addressed and may contain confidential or privileged material. Any review,

---

retransmission, dissemination, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 00:23:40 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: New England Journal of Medicine - 20-02387

FYI. Just to keep an eye on this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: New England Journal of Medicine <onbehalfof@manuscriptcentral.com>
Sent: Tuesday, February 18, 2020 10:41 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)>
Subject: New England Journal of Medicine - 20-02387

Dear Dr. Fauci,

Thank you for submitting your manuscript, "COVID-19 : Navigating the Unchartered" to the New England Journal of Medicine.

Your manuscript has been forwarded to members of our editorial staff, who will make an initial evaluation and decide whether it merits further consideration. You will be notified of the decision as soon as possible.

Your manuscript ID is 20-02387.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at https://mc05.manuscriptcentral.com/nejm and edit your user information as appropriate. You may also view the status of your manuscript at any time by checking For Authors section of the site.

We are undertaking evaluation of your manuscript with the understanding that neither the substance of the article nor the figures or tables have been published or will be submitted for publication elsewhere during the period of review.

Please provide the editors with copies of other manuscripts by you or your coauthors addressing similar or related research questions that are in preparation or under consideration at other journals. This does not apply to abstracts published in connection with scientific meetings or to news reports based on presentations at such meetings.

The Journal's policy is explained more fully at http://www.nejm.org/page/author-center/editorial-policies.

Please call us at 617-734-9800 if you have any questions.

Sincerely,

Eric J. Rubin, MD, PhD
Editor-in-Chief

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
http://www.nejm.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 23:57:32 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: draft response for NBC online

See my minor tweek

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, February 18, 2020 2:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: draft response for NBC online

Ok any edits? Pls advise

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, February 18, 2020 2:47 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; OCPLPressTeam <OCPLPressTeam@od.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: draft response for NBC online

Reporter: Jacqueline Stenson
Organization: NBC online
Phone #(s): [redacted] (b) (6)
Subject: COVID-19

NBC online asked, "What is NIAID's position on whether the SARS-CoV-2 is transmissible in asymptomatic people?"

I would propose that we send a response to Jacqueline attributed to ASF:

Early case reports indicate in certain circumstances **SARS-CoV-2 is transmissible in asymptomatic people. We do not know the extent to which asymptomatic transmission is impacting the outbreak. However, we know that people with symptoms are usually the main driver of outbreaks of other respiratory diseases.**

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: ([redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 23:32:19 +0000
To: Dennis Golden
Cc: Monica A Golden
Subject: RE: Coronavirus

Denny and Monica:
Many thanks for your kind note. I hope that all is well with you.
Warm regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Dennis Golden <[redacted] (b) (6)>
Sent: Tuesday, February 18, 2020 4:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Monica A Golden [redacted] (b) (6)
Subject: Coronavirus

Tony,

Our thoughts and prayers are with you as you professionally address the horrid coronavirus transmission.

We salute you for not "sugarcoating" or trying to be "diplomatic" about the Diamond Princess Cruises ship quarantine process.

As always, you proved yourself to be a courageous, honest and ethical man. A man who has always done the right things.

We stand with you !

In Hoc Signo Vinces,

Denny and Monica Golden

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 22:06:38 +0000
To: Selgrade, Sara (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];NIAID OCGR Leg
Subject: RE: Requesting your assistance: Draft NIAID Statement for Upcoming Appropriations Hearings
Attachments: Draft_NIAID FY2021 Statement for the Record_to ASF - with Fauci tracked edits.docx

Here it is. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Selgrade, Sara (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, February 18, 2020 4:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] < (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>
Subject: Requesting your assistance: Draft NIAID Statement for Upcoming Appropriations Hearings

Dr. Fauci:

In preparation for the upcoming NIH budget hearings of the House and Senate Appropriations Subcommittees on Labor, HHS, Education, and Related Agencies, we have drafted the attached NIAID statement for the record, highlighting the topics that you previously selected.

We have a firm 3-page limit for the statement. It has been reviewed by the Divisions and Drs. Harper, Eisinger, Lerner, and Marston, as well as Courtney Billet, Martin Johnson, Greg Folkers, and Laurie Doepel.

NIH OLPA has asked to receive your statement by this Wednesday, Feb. 19th. Please let us know if you would like us to request additional time for your review, given competing priorities.

Thank you for your help.

Sara

Sara Selgrade, Ph.D.
Section Chief for Legislative Activities
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
NIAID/NIH/DHHS
Bldg. 31, Room 7A17, MSC 2520
Bethesda, MD 20892-2520
Phone: (b) (6)
(b) (6)

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 14:37:35 +0000
To: Venigalla B Rao
Cc: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: Wuhan coronavirus vaccine candidates

Rao:

Best to contact Cristina Cassetti in DMID. I have copied her here.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Venigalla B Rao [redacted] (b) (6)
Sent: Tuesday, February 18, 2020 9:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Wuhan coronavirus vaccine candidates

Dear Tony,

Good morning!

Sorry for taking your time at this very super busy time. Greatly appreciate your service and leadership!!

[redacted] (b) (4)

[redacted] (b) (4)

With best regards,
Rao

On Tue, May 23, 2017 at 11:03 AM Venigalla B Rao <[redacted] (b) (6) wrote:

> Dear Tony,
> Just a quick update.
>
> [redacted] (b) (4)
>
> [redacted] (b) (4). He has accepted both the papers and the

papers should come out back-to-back in Virology soon. I am attaching both the pdfs for your interest.

From scientific perspective, it is very satisfying to see that both the papers using completely different approaches arrived at the same virion capture model. That was not anticipated when we initiated the work 5-years ago because the reasons to develop these assays were very different. I have mentioned to Emerman to consider highlighting the papers in the journal issue, and that you and Jim might be willing tom write a short piece but I have not heard about this.

With best regards,
Rao

On Mon, May 1, 2017 at 11:33 PM, Venigalla B Rao [redacted] (b) (6)> wrote:

> Dear Tony,
>
> [redacted] (b) (4)
>
> With best regards,
> Rao
>
> On Mon, May 1, 2017 at 9:40 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:
>
>> Rao:
>> Thanks for the note and for [redacted] (b) (4)
>>
>> [redacted] (b) (4)
>>
>> Best regards,
>> Tony
>>
>> **From:** Venigalla B Rao [mailto: [redacted] (b) (6)]
>> **Sent:** Thursday, April 27, 2017 8:24 PM
>> **To:** Fauci, Anthony (NIH/NIAID) [E]
>> **Cc:** Arthos, James (NIH/NIAID) [E]; [redacted] (b) (6)
>> **Subject:** Request

Dear Dr. Fauci,

This is Venigalla Rao from The Catholic University of America, Washington, DC. I have communicated with you a couple of times in the past years for different reasons. Having been involved in administrative duties (miniscule compared to yours), I can only imagine the demands on your time. I make this request despite this trepidation and I hope that you understand.

[redacted] (b) (4)

Thank you for consideration.

With best regards,

Rao

Dr. Venigalla B. Rao
Professor and Chairman
Department of Biology
The Catholic University of America
620 Michigan Ave., NE
Washington, DC, 20064

http://faculty.cua.edu/rao/
Phone: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 14:12:48 +0000
To: Suzanne Peskin
Subject: RE: Visiting !

Suzanne:
Thanks for the note. I am very, very sorry, but I do not think that we will be able to connect on Sunday. The White House and HHS have me going 24/7 including Saturday and Sunday with the coronavirus crisis. I have seen my wife (b) (6) for a total of about 45 minutes over the past 10 days. Hopefully, we can do this at some other opportunity, but this is a very bad time. I hope that you understand.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Suzanne Peskin (b) (6)
Sent: Monday, February 17, 2020 9:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Visiting !

Hi Tony, I hope all is well with you and your family. I know you are busy these days with the Coronovirus, but was wondering if you're in town this weekend ! (b) (6) lives in DC and works for Maryland CASA as a legal fellow. I'm coming in Friday evening and was planning on taking her down memory lane. She has heard so much about (b) (6) that I would love to introduce you two. (b) (6) We are free most of Sunday if you're in town. It's been way too long. Would love to see you.

Let me know if that is at all possible.

Love,

Suzanne
Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 13:17:03 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: [redacted] (b) (4) for coronavirus
Attachments: [redacted] (b) (4)

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Li,Qiuhong [redacted] (b) (6)
Sent: Tuesday, February 18, 2020 8:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: [redacted] (b) (4) for coronavirus

Dear Dr. Fauci,
I'm writing to you to seek advice on potential collaborations with NIAID-funded facilities or other private sectors to [redacted] (b) (4)
[redacted].

[redacted] (b) (4)

[redacted] (b) (4)

Please feel free to contact me if you have any questions.
Best regards,
Qiuhong

Qiuhong Li, Ph.D,
Dept. of Ophthalmology
University of Florida
Gainesville FL
32610-0284
Phone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Tue, 18 Feb 2020 07:00:32 -0500
To: Collins, Francis (NIH/OD) [E]
Subject: Re: Funds for CoV

Francis:

[redacted] (b) (5)

Tony

> On Feb 18, 2020, at 6:22 AM, Collins, Francis (NIH/OD) [E] [redacted] (b) (6) >wrote:
>
> Hi Tony,
>
> Larry and I will have our regular meeting with the Secretary today. [redacted] (b) (5) (b) (5) [redacted]
>
> I will see you this afternoon for our regular catch up, unless other events in our intensely busy lives intervene.
>
> Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 11:15:14 +0000
To: Bernice Mika Huang
Subject: RE: Singapore Coronavirus Updates

Bernice:

Thank you for this important update of information.

Best regards,
Tony

From: Bernice Mika Huang [redacted] (b) (6)
Sent: Tuesday, February 18, 2020 4:40 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Singapore Coronavirus Updates

Dear Dr. Anthony Fauci,

I'm Bernice [redacted] (b) (6).

I had read your online discussion details on USA Today which says:
" Another thing that we don't know is why, with a respiratory-borne illness, are there virtually no children getting infected. I mean, there are no cases of kids less than 15 years old. Does that mean for some strange reason they're not getting infected, or the illness is so mild in children that we're not noticing it? It's very clear the median age is 56 or 59."

I thought it would be crucial to share updates on Singapore's coronavirus situation for your reference, because you are the expert who could help analyze the current situation. Till date, in Singapore [redacted] (b) (6) have two young children who are infected:

ONE YEAR OLD
"Case 76 is a one-year-old Singaporean who was among the group evacuated from Wuhan on Feb 9. The toddler was without symptoms when he boarded the flight back to Singapore. He was put under quarantine upon landing in Singapore, and was confirmed to be infected with COVID-19 on Sunday afternoon. Advertisement He is currently warded in an isolation room at KK Women's and Children's Hospital, said MOH." Quoted from https://www.channelnewsasia.com/news/singapore/covid19-coronavirus-singapore-update-feb-17-12441176

SIX-MONTH OLD
" COUPLE, BABY AND MAID INFECTED The 28-year-old mother - whose infection was announced on Tuesday - works at Yong Thai Hang, a health product shop that primarily serves Chinese tourists. Her husband, a 45-year-old Singaporean tested positive on Wednesday at about 2pm, and is currently warded in an isolation room at the National Centre for Infectious Diseases (NCID). Both have no recent travel history to China. The couple's child, a six-month-old boy, tested positive at the same time and is currently warded in an isolation room at KK Women's and Children's Hospital. The family's domestic helper was one of the confirmed cases on Tuesday. MOH said in an update on Thursday that the child

was not in any infant care facility and was cared for at home, prior to being admitted to the hospital." - Quoted from https://www.channelnewsasia.com/news/singapore/wuhan-virus-coronavirus-singapore-number-cases-12395928

Thanks, Best Regards & God Bless,
Bernice Huang

[redacted] (b) (6)

--
Best Regards, Bernice

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 11:12:55 +0000
To: Sheeley, Colin (NBCUniversal)
Subject: RE: NBC News Inquiry

I know that it is frustrating for you, but they still have not changed the official number, even though we know that it is certainly more than 44. Sorry.

From: Sheeley, Colin (NBCUniversal) <Colin.Sheeley@nbcuni.com>
Sent: Tuesday, February 18, 2020 12:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chirbas@nbcuni.com>; Varela, Jay (NBCUniversal) <jay.varela@nbcuni.com>; Santana, Cristian (NBCUniversal) <Cristian.Santana@nbcuni.com>; Mitchell, Alexander (NBCUniversal) <Alexander.Mitchell@nbcuni.com>; DiCasimirro, Gemma (NBCUniversal) <Gemma.DiCasimirro@nbcuni.com>; Studley, Joe (NBCUniversal) <Joe.Studley@nbcuni.com>; Metsch, Abigail (NBCUniversal) <Abigail.Metsch@nbcuni.com>
Subject: RE: NBC News Inquiry

Thank you Tony,

We heard this evening that there were 169 new confirmed cases aboard the cruise ship. Do you know if this changes the "official public" number at all?

Thanks,
Colin

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, February 17, 2020 8:19 AM
To: Sheeley, Colin (NBCUniversal) <Colin.Sheeley@nbcuni.com>
Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chirbas@nbcuni.com>; Varela, Jay (NBCUniversal) <jay.varela@nbcuni.com>; Santana, Cristian (NBCUniversal) <Cristian.Santana@nbcuni.com>; Mitchell, Alexander (NBCUniversal) <Alexander.Mitchell@nbcuni.com>; DiCasimirro, Gemma (NBCUniversal) <Gemma.DiCasimirro@nbcuni.com>; Studley, Joe (NBCUniversal) <Joe.Studley@nbcuni.com>; Metsch, Abigail (NBCUniversal) <Abigail.Metsch@nbcuni.com>
Subject: [EXTERNAL] RE: NBC News Inquiry

Colin:

Thanks for the note. The number 44 is in flux. When I checked a couple of days ago, the "official public" number was 44. However, it was clear that there was likely more than that since the results of the tests were still coming back on some individuals. And so, it is a minimum of 44 infected from the cruise ship, but it is uncertain how many more than 44 are infected. I do not know where the Americans are staying
Best,
Tony

From: Sheeley, Colin (NBCUniversal) <Colin.Sheeley@nbcuni.com>
Sent: Monday, February 17, 2020 3:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chirbas@nbcuni.com>; Varela, Jay (NBCUniversal) <jay.varela@nbcuni.com>; Santana, Cristian (NBCUniversal) <Cristian.Santana@nbcuni.com>; Mitchell, Alexander (NBCUniversal) <Alexander.Mitchell@nbcuni.com>; DiCasimirro, Gemma (NBCUniversal) <Gemma.DiCasimirro@nbcuni.com>; Studley, Joe (NBCUniversal) <Joe.Studley@nbcuni.com>; Metsch, Abigail (NBCUniversal) <Abigail.Metsch@nbcuni.com>
Subject: NBC News Inquiry

Hi there,

I'm reaching out on behalf of NBC National News – would you be able to confirm that 44 Americans aboard the Diamond Princess cruises ship have tested positive for coronavirus?

Also, would you be able to say where the Americans are staying as they are being treated for the virus?

Please **REPLY ALL** with your response, or give us a call at (212) 664-5222.

Thank you,
Colin

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 11:08:19 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: CNNi Interview Request: Anthony Fauci

Let us discuss.

From: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Sent: Tuesday, February 18, 2020 5:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Roobeek, Rosanne <Rosanne.Roobeek@turner.com>; Avramova, Nina (NE) <Nina.Avramova@turner.com>
Subject: CNNi Interview Request: Anthony Fauci

Dear Mr Fauci,

I hope this finds you well.

I'm writing to you from CNN International to see if you are available to join Becky Anderson on her prime time flagship show 'Connect the World' for a live interview on today to discuss the coronavirus.

The show airs live between **10amET** – **12pmET** – do you have any availability during these hours to come to a convenient bureau?

We really loved having you on the show last Sunday! As the director of the National institute of Allergy and Infectious Diseases your insight is always great for our global audience.

Might it be possible to arrange something?

Background on CNN

- CNN International reaches more than 250 million households worldwide including in the US via DIRECTV.
- CNN International is the number one international TV news channel according to all major media surveys across Europe, the Middle East and Africa, the Asia Pacific region and Latin America.
- In September 2019 **CNN.com** had 162 million unique readers globally per month and 114 million mobile readers a month, leading the BBC, Yahoo and New York Times.

Best,

Joanna Hynds

Planning Desk
CNN International
+ 44 207 693 1640 (office)
+ [redacted] (b) (6) (cell)
joanna.hynds@turner.com

CNN go there

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 10:44:58 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Confirmation from CNN's New Day

OK. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, February 18, 2020 5:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: Confirmation from CNN's New Day

Firm hit for this morning in med arts studio at 715 am

Be in studio at 7 am

Sent from my iPhone

Begin forwarded message:

> **From:** "Steinfeld, Alix" <Alix.Steinfeld@turner.com>
> **Date:** February 18, 2020 at 5:13:08 AM EST
> **To:** "Figliola, Mike" <Mike.Figliola@turner.com>, Jonathan Bennett [redacted] (b) (6) >
> **Cc:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "Daniels, Ronnel (NIH/OD/ORS) [C]" [redacted] (b) (6) "Ryland, Ken (NIH/OD/ORS) [E]" [redacted] (b) (6)>, "Jackson Farrar, Joy (NIH/OD/ORS) [E]" [redacted] (b) (6)
> **Subject: RE: Confirmation from CNN's New Day**
>
> Good Morning
> We have DR. ANTHONY FAUCI on New Day
> Hit Time; 715aEST
> IFB: 212.275.9225
> PL: 212.275.9325
> CONTROL: 212-275-9053
> PO: 660980
> Thanks
> Alix
>
> ---
>
> **From:** Figliola, Mike <Mike.Figliola@turner.com>
> **Sent:** Tuesday, February 18, 2020 5:12 AM
> **To:** Jonathan Bennett [redacted] (b) (6) Steinfeld, Alix

<Alix.Steinfeld@turner.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6); Daniels, Ronnel (NIH/OD/ORS) [C] [redacted] (b) (6)>; Ryland, Ken (NIH/OD/ORS) [E] [redacted] (b) (6)>; Jackson Farrar, Joy (NIH/OD/ORS) [E] [redacted] (b) (6)
Subject: RE: Confirmation from CNN's New Day
Importance: High

Adding Alix who has that info

Mike Figliola
Editorial Producer
CNN's New Day
[redacted] (b) (6)
mike.figliola@turner.com

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Jonathan Bennett [redacted] (b) (6)
Sent: Tuesday, February 18, 2020 5:05 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Daniels, Ronnel (NIH/OD/ORS) [C] [redacted] (b) (6); Ryland, Ken (NIH/OD/ORS) [E] <[redacted] (b) (6); Jackson Farrar, Joy (NIH/OD/ORS) [E] <[redacted] (b) (6)>
Subject: Re: Confirmation from CNN's New Day

Mike,

Received and noted. What are the control room and and IFB numbers?

Jonathan

On Tue, Feb 18, 2020, 3:14 AM Figliola, Mike <Mike.Figliola@turner.com> wrote:

> Hi everyone,

This is Mike with CNN's New Day. Hope you are well.

This is to confirm Dr. Fauci will be a guest today, **Tuesday 02.18.20** at around **7am EST to** discuss:

7A:

Latest on Americans who tested positive after evacuation from cruise ship; What we know about how coronavirus spreads https://www.cbsnews.com/news/transcript-dr-anthony-fauci-on-face-the-nation-february-16-2020/

You will be **solo at 7am EST** for the segments.

Alisyn Camerota and Jim Sciutto, in for John Berman, will both be conducting today's interview.

Please arrive at the studio no later than **6:50am EST.**

Here is your studio confirmation:

STUDIO INFO 2013424
THIS INTERVIEW WILL B E FROM their NIH MED ARTS STUDIO with a direct IFB connection
Control Room numbers are 301-827-8478 and 8479
Encompass Booking and Circuit Number:

Booking:	**1-800-243-1995**
Circuit:	**36TBGS104492**

Our IFB: 301-496-1811 (we prefer to call into the station's IFB)

Video: 1080i - the audio is embedded.

Please confirm you have received this and are all set to go!

Best,

M

Mike Figliola
Editorial Producer
CNN's New Day

(b) (6)
mike.figliola@turner.com

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 03:08:59 +0000
To: Holland, Steven (NIH/NIAID) [E]
Subject: RE: New Coronavirus Draft Messaging

Short and sweet. Looks fine. Thanks.

From: Holland, Steven (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, February 17, 2020 10:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: New Coronavirus Draft Messaging

Tony,

When you get a moment could I get your take on this most recent iteration. Apologies for the intrusions.

Thanks

Steve

--
Director, Division of Intramural Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960
301-402-7684 voice
[redacted] (b) (6) fax
[redacted] (b) (6) email

Assistant lab: Eva Portillo
[redacted] (b) (6) email
[redacted] (b) (6) voice

Assistant to SD: Beth Schmidt
[redacted] (b) (6)
[redacted] (b) (6)

From: "Bailin, Heike (NIH/OD/ORS) [E]" [redacted] (b) (6)>
Date: Monday, February 17, 2020 at 10:01 PM
To: "Moss, Bradley (NIH/OD/ORS) [E]" [redacted] (b) (6)
Cc: "Gottesman, Michael (NIH/OD) [E]" [redacted] (b) (6), Steven Holland [redacted] (b) (6), "Schmitt, James (NIH/OD/ORS) [E]" [redacted] (b) (6) "Johnson, Alfred (NIH/OD) [E]" [redacted] (b) (6), "Palmore, Tara (NIH/CC/OD) [E]" [redacted] (b) (6)>, "McGowan, Colleen

(NIH/OD/ORS) [E]" [redacted] (b) (6), "Cullen, William (NIH/OD/ORS) [E]" [redacted] (b) (6)>, "Newcomer, Derek (NIH/OD/ORS) [E]" [redacted] (b) (6)>, "Tosten, Timothy (NIH/OD/ORS) [E]" [redacted] (b) (6)

Subject: Re: New Coronavirus Draft Messaging

Brad- thank you. I liked much of what you did. And thanks to all who've commented and edited. Your points are well taken.

For the sake of clarity and effectively steering folks to OMS for the proposed ICP measures I favor focusing the message even more. Pease find attached OMS edits:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 03:05:47 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID 19 Diamond Princess Patients Possible Transmission by Fomites
Attachments: SARS Transmission Fomites Temperature and Humidity Variables.pdf

Please have someone respond

From: Angela Moore <(b) (6)>
Sent: Monday, February 17, 2020 10:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: COVID 19 Diamond Princess Patients Possible Transmission by Fomites

I am a dermatologist but also a clinical researcher and scientist.
I was reading all of the news regarding concerns and questions on how the fellow patients are being infected.

A few questions arose, based on the NIH data on SARS Coronavirus, that has been much more studied, and most likely less virulent than the current COVID 19, which supposedly has HIV traits as well as traits to increase transmission.

I have wondered if COVID-19 is like Legionella, and possibly transmitted in the airborne water droplets in the air conditioning units of the Diamond Princess ship.

Even with the SARS Coronavirus, it was shown to be infective on fomites for up to 28 days unless 40 degrees Celsius and 80% humidity, when it was then inactivated in a few hours (see the attached article). I am wondering if the trays of food, after being passed to passengers on the ships, were then washed in suboptimal conditions (NOT at 40 degrees Celsium for several hours at 80% humidity)

I AM concerned, that based on the reinfection of those in Wuhan, China, after they returned home, on whether 14 days of quarantine is enough, based on the modeling and studies on the SARS Coronavirus, and whether 28 days of quarantine may actually be needed.

With the HIV virus component of COVID 19, one must also wonder if the T cells are being infected and passing the infection along within an infected patient. In the U.S., we may need to beware of blood transfusions from anyone infected, even asymptomatically, with COVID 19.

I am sure that you have teams of clinicians and scientists working on this, and I don't know if any of the original scientists working on the SARS models are still around at Chapel Hill to perform these related studies and modeling.

Angela Moore

Angela Yen Moore, MD
Arlington Center for Dermatology
Arlington Research Center

711 East Lamar Blvd., Suite 200
Arlington, Texas 76011
phone 817-795-7546
fax 817-226-7546

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:48:13 +0000
To: bdoherty@mms.org
Cc: lbaden@nejm.org;Redfield, Robert R. (CDC/OD); [redacted] (b) (6);Eisinger, Robert (NIH/NIAID) [E];Greg Folkers ([redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: New England Journal of Medicine Editorial
Attachments: NEJM Editorial - Fauci et al - FINAL - 02-18-2020.docx

Briana and Lindsey:

As promised, I am attaching the invited Editorial related to the COVID-19 manuscript that we had discussed. Should I also submit it through the NEJM online website or will you take care of this? We will send in the COI and authorship forms in the next day or 2. Please let me know if you have any questions. Thank you.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Briana Doherty <onbehalfof@manuscriptcentral.com>
Sent: Monday, February 10, 2020 11:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: lbaden@nejm.org
Subject: New England Journal of Medicine Editorial

Dear Dr. Fauci,

I am delighted that you have agreed to write a signed editorial to accompany the article on the initial estimates of key transmission parameters associated with nCoV-2019 virus by Li et al.

The general purpose of the Journal's editorials is to provide the reader with an authoritative interpretation or elaboration based on the substance of the article. Since this substance is usually not within the average reader's special competence, such readers will particularly benefit if the editorial avoids technical jargon, explains the article's contribution to a field of knowledge, and emphasizes, whenever possible, its clinical implications. The editorial commentary should not be concerned exclusively with the article in question but rather should use the article as a starting point for a more general discussion.

Because editorials involve interpretation and opinion, you and your potential coauthor must be free of significant relevant financial associations (including equity interest, regular consultancies, or major research support) with a company, or with a competing company, that stands to gain from the use of a product discussed in the editorial. Please contact me immediately if you are considering a coauthor, so I can ensure that your candidate meets our criteria. Additional information about disclosure of financial and other associations appears below this letter.

Please bear in mind that your editorial represents your (and any coauthor's) personal opinion. The Journal does not include statements of grant or other support or acknowledgments with editorials.

Journal policy dictates that we must have on file a signed Copyright Transfer and Authorship Agreement from each author before a manuscript can be accepted. Therefore, the enclosed form should be signed by all authors and faxed to (781) 207-6529.

Your editorial is due at the Journal on Monday, February 17, at the very latest if the deadline imposed by our printing schedule is to be met. If the editorial is to include a figure, please submit the figure at least one week before the due date for the editorial itself.

*** Additional information about preparing and submitting your editorial is given below; please read it carefully. ***

The editors must reserve the right to edit (or even reject) your editorial, but whether we use it or not, the Journal currently offers a modest stipend of $300.

Thanks again for agreeing to write this editorial for the Journal. I look forward to receiving it.

Sincerely yours,

Lindsey R. Baden, M.D.
Deputy Editor

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
http://www.nejm.org

LENGTH OF YOUR EDITORIAL
NEJM editorials should not exceed two printed pages. This means that your word count before editing should not exceed 750 words (approximately 4500 characters). Note that we spell out trial names and most other abbreviations for our readers, and we include trial registration numbers for any clinical trials mentioned; these will lengthen your editorial if you have not included them. Please provide a title not exceeding 45 characters and a word count for the text; the entire manuscript, including references, should be double-spaced.

REFERENCES
Cite no more than 10 references, including the article you are writing about. The average collection of 10 references requires about a quarter of a printed page.

TABLE OR FIGURE
A table or a figure in your editorial will require a reduction in the number of words; because figures and tables vary in size, you may be asked to shorten the text of your editorial during the production process. A quarter-page table roughly equals 250 words, and a half-page table roughly equals 500 words.

DISCLOSURES
When completing your disclosure form, please indicate, in the "Comments" field next to the type of relationship being disclosed, the amount (in U.S. dollars) of any support you have received. Please also indicate how much of

this support has been received over the past 2 years. Please e-mail your completed disclosure form to editorial@nejm.org.

In the event of publication, each author's submitted disclosure form will be posted on the Web (with any dollar amounts redacted).

COPYRIGHT TRANSFER
Each author must complete a copyright transfer agreement form. Please sign it and fax it back to 781-207-6529 as soon as possible.

TO SUBMIT YOUR EDITORIAL
*** It is important that you follow the instructions below to ensure that your article enters the correct queue. ***

When you are ready to submit your manuscript, please log in to the New England Journal of Medicine - Manuscript Central site (http://mc05.manuscriptcentral.com/nejm). Your case-sensitive USER ID is afauci@niaid.nih.gov. For security purposes, your password is not listed in this message. If you are unsure of your password, please visit https://mc05.manuscriptcentral.com/nejm and enter your e-mail address in the "Forgot Your Password?" field.

Once you are logged in, the Main Menu will be displayed. Please click on the Author Center, where you will find the manuscript listed under "Invited Manuscripts." You can click on the "Continue Submission" button to begin submitting your article.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:09:48 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Comments on Tedros

FYI

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 17, 2020 10:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Comments on Tedros

BTW, I just saw that you tried me earlier and I didn't respond. I was in Geneva and evidently didn't have service. Hope we can connect this time. Best number is my desk, +44 2035 251028. Thanks again, JL

From: John Lauerman (BLOOMBERG/ NEWSROOM:) At: 02/17/20 14:37:11
To: AFAUCI@NIAID.NIH.GOV
Subject: Comments on Tedros

Hi Dr. Fauci: I'm working on a story about WHO DG Tedros and the work that he's doing to contain the coronavirus epidemic. I'm planning on discussing a number of themes, including that responding to outbreaks has become the most visible job of the DG in the past couple of decades. I'd also like to explore the issue of how important it is that countries be as open as possible about disease outbreaks, and that it's the DG's job to encourage that and move countries toward greater transparency and participation in battling outbreaks. Would you care to comment on the job that Tedros is doing in these areas? Please give me a call at +44 2035 251028 or let me know when and at what number to call you. Thanks and regards, John Lauerman, Bloomberg News

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell [redacted] (b) (6)
http://www.bloomberg.com
http://www.bloomberg.com/prognosis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:09:18 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Comments on Tedros

Please try to set up a call with John Lauerman

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 17, 2020 9:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Comments on Tedros

Hi Dr. Fauci: I'm working on a story about WHO DG Tedros and the work that he's doing to contain the coronavirus epidemic. I'm planning on discussing a number of themes, including that responding to outbreaks has become the most visible job of the DG in the past couple of decades. I'd also like to explore the issue of how important it is that countries be as open as possible about disease outbreaks, and that it's the DG's job to encourage that and move countries toward greater transparency and participation in battling outbreaks. Would you care to comment on the job that Tedros is doing in these areas? Please give me a call at +44 2035 251028 or let me know when and at what number to call you. Thanks and regards, John Lauerman, Bloomberg News

---

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell [redacted] (b) (6)
http://www.bloomberg.com
http://www.bloomberg.com/prognosis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:02:35 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: [redacted] (b) (5)

Cristina:

[redacted] (b) (5)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Mon, 17 Feb 2020 20:56:50 -0500
To: Collins, Francis (NIH/OD) [E]
Subject: Re: [redacted] (b) (5) for SARS-CoV-2

[redacted] (b) (5)

On Feb 17, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E] [redacted] (b) (6) >wrote:

Hi Tony,

[redacted] (b) (5)

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 00:20:01 +0000
To: Townsend, Frances
Subject: RE: This ongoing 2019 novel coronavirus, or COVID-19, outbreak has a number...

Fran:
Thanks for the note. You certainly have covered a lot of ground with your questions. I look forward to seeing you tomorrow.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Townsend, Frances <FTownsend@MAFGRP.COM>
Sent: Monday, February 17, 2020 6:55 PM
To: (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6)
Fauci, Anthony (NIH/NIAID) [E] (b) (6) Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>
Cc: Hanson, Elizabeth <ehanson@MAFGRP.COM>
Subject: This ongoing 2019 novel coronavirus, or COVID-19, outbreak has a number…

All: Below is an outline of questions for tomorrow at CFR. Sorry to get this to you late but it seems the news changes everyday. As you will see I focus mostly on coronavirus as I suspect that's where the interest will be but get to bio weapons toward the end.

I am happy to take additional questions or suggestions. These sessions go quickly and we have time for Q and A so I doubt I will get through it all but wanted you all to have something to look at.

Thanks again for doing this tomorrow.

Best
Fran

This ongoing 2019 novel coronavirus, or COVID-19, outbreak has a number of historic firsts. It's the largest quarantine in world history with China locking down over 60 million people. It's the first mass repatriation of American citizens into a quarantine, climbing over 1,000.

Let's start with some quick basics: what is coronavirus? How contagious? What is the morbidity rate?

How does it compare to SARs and MERs? More/less infectious? Lethal?

Just to put this in perspective every year here in the US we deal with the flu. How many Americans on average die each year from the flu?

But as I mentioned coronavirus has resulted in a number of historic firsts, talk about what you expect could be our scientific firsts and what roadblocks do those scientific firsts confront?

Over the years, global economic interdependence has grown in nearly every industrial sector, including health care. But that means our health care is also globally interdependent on other systems less equipped, less transparent and perhaps less responsible global actors.

China closed the wet market where the coronavirus outbreak began on 1/1, gene sequenced the virus on 1/9 so they could develop a diagnostic test but did not share the gene sequence with the global health community until 1/12.

How transparent and quick was the Chinese response? What should the have done that they failed to do? What were the consequences?

China now claims more than 70K infected and almost 1800 deaths from the virus. But It has been widely reported that the Chinese have underreported both numbers. what are Countries international obligations to report accurately? To whom? How do you know the numbers are accurate?

How does the current outbreak impact the domestic medical supply chain? What steps could or should we consider to enhance supply chain resilience?

What do the numbers suggest to you about what to expect regionally and worldwide? Have numbers peaked? Will they continue to rise? With the cruise ship there re now a total of 15 Americans infected. Do you expect additional cases? What scale? How prepared are we nationally? Locally?

Looking back over the roughly past decade, emerging infectious diseases played a recurring ominous theme. Be it from H1N1, to ebola, then Zika, and now the 2019 novel coronavirus, the threat is clearly not dissipating. When it comes to non-disease natural disasters, the Stafford Act provides a Disaster Relief Fund to enable immediate response. By comparison, there is a small Infectious Diseases Rapid Response Reserve Fund. Do we need a more Stafford Act-like mechanism to enable quicker response and research to these new threats? What other actions can we take to better prepare?

While often we see folks painting emerging infectious diseases and biodefense into separate categories, the truth is that there is significant crossover in terms of preparedness and research. Understanding that this is a sensitive topic, could you talk about how we should approach these risks in a comprehensive manner that can achieve public health and national security objectives concurrently?

I'd like to use this to transition to the topic of bio weapons which is what we originally planned to talk about. The landscape here has also transformed. When BioShield was written and the Strategic National Stockpile established we worried about State actors deploying banned weapons like small pox; plague and hemorrhagic fever. And you still must prepare against those things as well as new and emerging threats like the toxins we have seen deployed by Russia and North Korea in more targeted assassinations.

How do you stay ahead of these threats? Do we have the resources and surveillance that we need to stay ahead of the threat? And ensure the necessary vaccines and therapeutics?

The ebola outbreak may be an instructive example, it seems to be coming under some control despite the precarious security situation in the Democratic Republic of Congo. But the ongoing 2018 outbreak was the second largest in history following the 2013-2016 West African outbreak. As a result of these outbreaks, the United States government has pioneered new FDA-approved diagnostics and vaccines, with promising therapeutics seemingly around the approval corner too. What lessons can we draw from the ebola outbreaks? How do you work with and incentivize industry to develop what you need in the event of a catastrophic bio attack? And How do you make the best possible decisions about the stockpile?

I always worried that because we are global leaders if there was a bio attack or outbreak anywhere in the world, others would look to us and to our stockpile for the answer. Are our global allies doing enough to prepare against these threats--whether they be manmade or natural? Are they maintaining adequate stockpiles of medical countermeasures and research bases--and should they be?

Lastly (if we have time)....the FBI recently arrested a Harvard scientist for accepting undisclosed grant money from China for scientific research. It has now been reported that there are similar investigations at a number of US universities including Yale and MIT to name two and that the grant monies are in the billions. What are foreign governments looking for? Why in the US? Clearly a national security risk, is it a bio weapons concern?

==
DISCLAIMER: This e-mail message and any attachments are intended solely for the use of the person(s) named in the message header to whom the email is addressed and may contain information that is confidential or legally privileged. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, copying, or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately and permanently delete this e-mail message and any attachments (and any copies or printouts of the same).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 20:29:27 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: COVID-1
Attachments: letter to NIAID-ICIS.pdf

Please respond to them. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fitzgerald, Kate <Kate.Fitzgerald@umassmed.edu>
Sent: Monday, February 17, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Eleanor Fish <en.fish@utoronto.ca>
Subject: COVID-1

Dear Dr. Fauci,

On behalf of the International Cytokine and Interferon Society, please find attached a letter from us as clinicians and scientists committed to developing and implementing therapeutic interventions targeted against global viral infection outbreaks. We propose that high priority be given to evaluating the therapeutic antiviral activities of IFN-as/bc(clinically approved formulations) against COVID-19 which poses a potential threat to global health. Further information is detailed in the attached. The ICIS would be happy to provide the scientific and clinical expertise for this program and welcome further discussion. In particular Dr. Eleanor Fish copied above has the track record and expertise in this area.

Sincerely,

Kate A. Fitzgerald | Professor of Medicine
President | International Cytokine and Interferon Society (ICIS)

www.cytokinesociety.org

Join us @ Cytokines 2020

Cytokines 2020
International Cytokine & Interferon Society ICIS
Structure Function & Systems Biology of Cytokines
8th Annual Meeting of the International Cytokine & Interferon Society
1 - 4 November
Hyatt Regency Seattle, USA
iCIS

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 20:22:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Happenings Radio Q+A...

Let us discuss. She called me up today and I told her to send me an e-mail since I was on a call. [redacted] (b) (5) For discussion.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: cassidy@happeningsmag.com <cassidy@happeningsmag.com>
Sent: Monday, February 17, 2020 3:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Happenings Radio Q+A...

Hi there,
This is Cassidy G-D from Happenings Magazine & Radio in Kenosha, WI- we ever so briefly spoke on the phone earlier today.

I was reaching out with the hope of getting you on our radio program for a 20-30 minute Q+A in which we would talk about the Coronavirus and more specifically the impact it is having on the Diamond Princess Cruise ship along with anything you would like to talk about regarding infectious diseases and or your position as director of the National Institute of Allergy and Infectious Diseases.

Please let me know if you have any interest in being on the air with us and I would be happy to provide further details. You can also get ahold of me by our office phone at 262-564-8800.

Hope you are well and I look forward to hearing back from you, Cassidy G-D

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 19:50:25 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Erbelding, Emily (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: BMGF

Cristina:

I just spoke with Chris Carp and Trevor Mundel of the BMGF and they want to try and coordinate some of the things that they and we are doing regarding COVID-19. I told them to give you a call to set up a teleconference to discuss respective R & D agendas of NIAID and BMGF.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 18:58:46 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Info from China

Please have someone respond to this person.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Jodie Dillman <(b) (6)>
Sent: Monday, February 17, 2020 12:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Info from China

Dear Dr. Fauci,
It is with trepidation that I reach out to you with information that has been shared with me regarding the real status of the Coronavirus in China. My information comes to me from a (b) (6) who has correspondence from a nurse in Harbin, China.

(b) (6) is here on an H1V visa, employed for the past several years at (b) (6) in the international student program. (b) (6) I have no reason to doubt the authenticity of the correspondence that she shared with me.

This correspondence shows a lung X-ray, a glass container of bloody fluid removed from an infected lung, and a map of Harbin, China depicting many areas of the coronavirus outbreaks. The written correspondence reveals that the numbers being released of confirmed deaths is drastically low due to the spread being too fast to test. Deaths in hospital hallways and of medical staff is not being shared in order to prevent panic.

Protective gear is unavailable and the nurse writing the correspondence is fearful for her life. She states that there are five levels of screenings (tests?) before a person is reported as testing positive or of being infected with the virus. If someone dies before being confirmed, these suspected deaths are covered up and not reported. Reported numbers, even of confirmed cases are grossly undercounted.

I figure you and our government realize the information and numbers coming out of China are highly inaccurate, but this correspondence on (b) (6) confirms it. I felt it was only ethical and moral to report this, despite (b) (6) plea that the two people involved in the correspondence fear governmental retribution if it was discovered that they discussed or passed on this confidential information.

I report this and swear it to be true and confidential. I am trusting it will help in some way and not just stir panic.

Jolonda Dillman

(b) (6)

[redacted]

.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 18:51:17 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: AI supplementation of influenza surveillance system for COVID-19 outbreak.

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ed Peshko <esp@hedviginc.com>
Sent: Monday, February 17, 2020 1:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: AI supplementation of influenza surveillance system for COVID-19 outbreak.

ps - feel free to contact me at this address, or my personal email address, that is (b) (6).

again, I have no dog in this fight aside from wanting to avoid a large scale pandemic worldwide.

And I'm sincerely hoping that we throw the rulebook out - and develop a new one - to deal with this the same way we did when we dealt with the 1918-1919 pandemic.

On Mon, Feb 17, 2020 at 10:09 AM Ed Peshko <esp@hedviginc.com> wrote:

> Dr. Fauci,
>
> Like you, I've been watching the COVID-19 outbreak with great alarm. Given the current data, I'm almost positive at this point that it will hit the US hard at some point and as a student of history that terrifies me.

So I'm hoping that your department has contacted the Bill and Melinda Gates foundation and see if you could make the following idea national or international. It is a supplemental health system based on AI and mobile technology and consists of two planks:

First:

- train an AI to be able to detect COVID-19 by measurements that can be done by cell phone (for example pictures of patients, recordings of patient's respiratory system)

Second:

- develop and release a smart-phone application that does the following:
    - turns on location tracking so health authorities can see where the cell phone owner is.
    - allows for people to upload health measurements from their cell phone.
    - keeps TRACK of where the cell phone owner is. If that person then tests positive for COVID later on, it can then automatically figure out all the contacts of that person for the last 14 days.
    - notifies those contacts that they have been in contact with someone with COVID-19, to isolate themselves and regularly test themselves.

The goal would be to prevent hundreds of thousands of people from descending on hospitals and overwhelming them, and to allow for the CDC or other medical personnel to go OUT and get them - or isolate them for treatment in their own homes - rather than having them come in and infect everybody.

Now this all hinges on the idea that AI could detect COVID-19 based on an audio recording or a simple picture and do it reliably, but I'm fairly sure that it can based of the peer-reviewed literature. It is not a difficult AI problem assuming that the microphone can pick up sounds well enough - if not, there are already integrated stethoscopes for cell phones that could be mass produced - and once developed to enough precision it could be deployed nationally or internationally fairly easily.

For all I know something like this is already in the works but I haven't heard of anything like it - apart from the chinese app which AFAICT does not use any AI but DOES allow for automatic contact tracing.

I sincerely hope this is already in the works. Ultimately it could be used both for detection and treatment - assuming the current antivirals work out they could be distributed to the same coordinates that positive diagnoses come in, perhaps by cheap drone so that nobody actually needs to be exposed to the virus to effect treatment.

Anyways, thanks for your time and efforts. Personally I'm a software developer but I'm hoping that perspective his helpful - for I view the fight against this virus as an INFORMATIONAL fight. It's like a fire-suppression system or food safety measures. Again, I have no clue whether or not this is already being done, and I apologize in advance if I'm missing something and this all seems obvious.

I just think that in this case it is prudent for us to be safe rather than sorry.

Thanks much,

Ed

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 18:47:09 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: AI supplementation of influenza surveillance system for COVID-19 outbreak.

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ed Peshko <esp@hedviginc.com>
Sent: Monday, February 17, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: AI supplementation of influenza surveillance system for COVID-19 outbreak.

Dr. Fauci,

Like you, I've been watching the COVID-19 outbreak with great alarm. Given the current data, I'm almost positive at this point that it will hit the US hard at some point and as a student of history that terrifies me.

So I'm hoping that your department has contacted the Bill and Melinda Gates foundation and see if you could make the following idea national or international. It is a supplemental health system based on AI and mobile technology and consists of two planks:

First:

- train an AI to be able to detect COVID-19 by measurements that can be done by cell phone (for example pictures of patients, recordings of patient's respiratory system)

Second:

- develop and release a smart-phone application that does the following:

- turns on location tracking so health authorities can see where the cell phone owner is.
- allows for people to upload health measurements from their cell phone.
- keeps TRACK of where the cell phone owner is. If that person then tests positive for COVID later on, it can then automatically figure out all the contacts of that person for the last 14 days.
- notifies those contacts that they have been in contact with someone with COVID-19, to isolate themselves and regularly test themselves.

The goal would be to prevent hundreds of thousands of people from descending on hospitals and overwhelming them, and to allow for the CDC or other medical personnel to go OUT and get them - or isolate them for treatment in their own homes - rather than having them come in and infect everybody.

Now this all hinges on the idea that AI could detect COVID-19 based on an audio recording or a simple picture and do it reliably, but I'm fairly sure that it can based of the peer-reviewed literature. It is not a difficult AI problem assuming that the microphone can pick up sounds well enough - if not, there are already integrated stethoscopes for cell phones that could be mass produced - and once developed to enough precision it could be deployed nationally or internationally fairly easily.

For all I know something like this is already in the works but I haven't heard of anything like it - apart from the chinese app which AFAICT does not use any AI but DOES allow for automatic contact tracing.

I sincerely hope this is already in the works. Ultimately it could be used both for detection and treatment - assuming the current antivirals work out they could be distributed to the same coordinates that positive diagnoses come in, perhaps by cheap drone so that nobody actually needs to be exposed to the virus to effect treatment.

Anyways, thanks for your time and efforts. Personally I'm a software developer but I'm hoping that perspective his helpful - for I view the fight against this virus as an INFORMATIONAL fight. It's like a fire-suppression system or food safety measures. Again, I have no clue whether or not this is already being done, and I apologize in advance if I'm missing something and this all seems obvious.

I just think that in this case it is prudent for us to be safe rather than sorry.

Thanks much,

Ed

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 17:42:47 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: PBS NewsHour inquiry for today

FYI
Let us discuss after I get off the AMA call, which is going long

---

From: David Coles <dcoles@newshour.org>
Sent: Monday, February 17, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: PBS NewsHour inquiry for today

Dr. Fauci,
Might you be available to update our viewers on the latest developments in the coronavirus story today/tonight? We are particularly interested in getting your evaluation of the passengers who have been released from two cruise ships. The first, in Yokohama, Japan, where over 300 Americans released from the ship have now arrived back in the US, to go into 14 days of quarantine. 14 of those people tested positive at some point after leaving the ship, but before they boarded the plane. The second ship we want to focus on is in Cambodia. Something in the neighborhood of 1,000 passengers released from that ship have been reported to be in some state of travel to their homes, presumably around the globe. One woman who made it as far as Malaysia tested positive there and is hospitalized in Kuala Lumpur. We do know that the CDC is working with WHO and the cruise ship line to track down those traveling people.

We would very much like to hear from you what level of concern we should have over those many hundreds of people traveling right now, how well quarantine works, how important it is to maintain it, etc. We would also like to touch on the methods of containment and treatment being done inside China and how well those methods have worked.

I realize it is a holiday, and that could complicate things. But please let me know whether you could consider this, Doctor, and we will begin to work out the logistics.

Thank you.

Very best regards,
Dave

David Coles
Deputy Senior Producer, National Affairs
PBS NEWSHOUR
703 998 2104

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 16:35:20 +0000
To: Smith, Steven
Subject: Re: i've been thinking about you
Attachments: image003.png

Steven:
Thanks for the note. Much appreciated. It has been 24/7 for me for the past 4 weeks. Hope that all is well with you.
Best,
Tony

> On Feb 17, 2020, at 10:39 AM, Smith, Steven <Steven.Smith@[redacted] (b) (6) wrote:
>
> Having just come back from Australia where coronavirus is hands down a national emergency, I've been thinking about you again and all the good work you do to keep us safe.
>
> I was with someone who's a diplomat with the Australian government who said "it's much, much worse than the Chinese would have you believe. Much worse." Melbourne and Sydney were deserted almost immediately of Chinese tourists and students. I luckily flew through DOHA.
>
> Hang in there. It's always something.
>
> Steven
>
> Steven W. Smith [redacted] (b) (6) (b) (6)
>
> <image003.png>
>
> This message, including attachments, is confidential and may be privileged. If you received this in error, please notify me by reply email and delete this message.

[redacted] (b) (6)

(b) (6

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 14:14:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: Request from CNN's New Day
Attachments: image001.jpg

Thanks

> On Feb 17, 2020, at 9:11 AM, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
>
> Working on this from med arts for tomorrow as well. Just FYI
>
> Sent from my iPhone
>
> Begin forwarded message:
>
> > **From:** "Figliola, Mike" <Mike.Figliola@turner.com>
> > **Date:** February 17, 2020 at 8:42:38 AM EST
> > **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>
> > **Subject: RE: Request from CNN's New Day**
> >
> > Copy will be back soonest
> >
> > M
> >
> > **Mike Figliola**
> > Editorial Producer
> > *CNN's New Day*
> > [redacted] (b) (6)
> > mike.figliola@turner.com
> >
> > <image001.jpg>
> >
> > CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please

immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, February 17, 2020 8:42 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: RE: Request from CNN's New Day

Between 7 am – 7:50 am ET

From: Figliola, Mike <Mike.Figliola@turner.com>
Sent: Monday, February 17, 2020 8:40 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Request from CNN's New Day

Working on timing – is there a preferred time?

Mike Figliola
Editorial Producer
CNN's New Day
[redacted] (b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Monday, February 17, 2020 8:40 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: Re: Request from CNN's New Day

Would hit time be I. The 7 am hour? Do I have exact time?

Sent from my iPhone

On Feb 17, 2020, at 4:16 AM, Figliola, Mike
<Mike.Figliola@turner.com> wrote:

Hi Patty,

Mike with cnn and new day here

Hope all is well

We are interested in checking Dr Fauci's availability for Tuesday's show.

May you let me know if he is avail and what time frame works best?

Topic is Coronavirus

Thanks!

M

Sent from my iPhone

> On Jan 30, 2020, at 10:05 AM, Figliola, Mike
> <Mike.Figliola@turner.com> wrote:
>
> Hi Patty!
>
> Morning
>
> If we want Fauci for tomorrow, is he avail?
>
> Barring maj breaking news we are not planning to cancel
>
> Thoughts?
>
> M
>
> **Mike Figliola**
> Editorial Producer
> *CNN's New Day*
> (b) (6)
> mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Figliola, Mike
Sent: Thursday, January 23, 2020 10:22 AM
To: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)
Subject: RE: Request from CNN's New Day

Copy thank you!

Mike Figliola
Editorial Producer
CNN's New Day
(b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>
Sent: Thursday, January 23, 2020 10:16 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: RE: Request from CNN's New Day

Per our chat just now – can have him avail between 6 am – 8:15. Hard stop at 815 am ET

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Figliola, Mike <Mike.Figliola@turner.com>
Sent: Thursday, January 23, 2020 10:02 AM
To: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)
Subject: RE: Request from CNN's New Day

Ok – we wont know until 1030a meeting – is it ok to hold 6 and 7a until then?

Mike Figliola

Editorial Producer
CNN's New Day
(b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)
Sent: Thursday, January 23, 2020 10:00 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: RE: Request from CNN's New Day

Sorry to be a pain-if you think it will be in the 6 am hour – we might need to use a different studio…if its in the 7 am hour we can use our remote studio…

Any thoughts as to which hour again, sorry

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03

Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Figliola, Mike <Mike.Figliola@turner.com>
Sent: Thursday, January 23, 2020 9:23 AM
To: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>
Subject: RE: Request from CNN's New Day

Copy thank you

Mike Figliola
Editorial Producer
CNN's New Day
(b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]
[redacted] (b) (6)>
Sent: Thursday, January 23, 2020 9:18 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: RE: Request from CNN's New Day

Checking now for all times between 6-9 will let you know soonest

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Figliola, Mike <Mike.Figliola@turner.com>
Sent: Thursday, January 23, 2020 9:10 AM
To: Conrad, Patricia (NIH/NIAID) [E]
[redacted] (b) (6)
Subject: RE: Request from CNN's New Day

Hi again

Could be back half of 7am but if this gets much worse we may play it higher in the hour – is there any time that doesn't work?

Mike Figliola
Editorial Producer
CNN's New Day
[redacted] (b) (6)

mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)
Sent: Thursday, January 23, 2020 8:57 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: FW: Request from CNN's New Day

Hi Mike – we can make this happen. The 7 am hour is best for us but will get back to you. do you have an idea of the hit time? need to make sure our nih studio is available.

thx

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Begin forwarded message:

> **From:** "Figliola, Mike" <Mike.Figliola@turner.com>
> **Date:** January 23, 2020 at 8:36:15 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
> **Subject: RE: Request from CNN's New Day**
>
> Hi everyone,
>
> This is Mike with CNN's New Day
>
> Hope you are well
>
> We would like to invite Dr, Fauci back to the program to discuss coronavirus
>
> Might he be available tomorrow
>
> We air 6-9am and happy to provide car service to and from the studio wherever you are located. John Berman and Alisyn Camerota anchor from NY.
>
> Thoughts?
>
> best,
>
> M

Mike Figliola
Editorial Producer
CNN's New Day
(b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 13:50:10 +0000
To: Natalie Rahhal
Cc: Kadlec, Robert (OS/ASPR/IO)
Subject: FW: Comments re: 14 US passengers with coronavirus and updates

Natalie:
I sent the incorrect e-mail address for Dr. Kadlec. Here is the correct one.
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, February 17, 2020 8:47 AM
To: Natalie Rahhal (b) (6)>
Cc: (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: Comments re: 14 US passengers with coronavirus and updates

Natalie:
Thank you for your note. Dr. Robert Kadlec, the Assistant Secretary for Preparedness and Response (ASPR) at HHS could either answer this question or point you in the direction of someone who could. I am copying him on this e-mail.
Best regards,
Tony

From: Natalie Rahhal (b) (6)
Sent: Monday, February 17, 2020 8:28 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: Comments re: 14 US passengers with coronavirus and updates

Hi Dr Fauci,

I hope this note finds you well and that you've gotten a little rest over the weekend, during what I'm sure is an inordinately busy time. Would you be able to elaborate on the measures taken to keep the 14 US evacuees who have coronavirus from infecting others on board the plane? I know that remdesivir, under compassionate use, was given to at least the first American coronavirus patient, and last week NIH researchers published results early that it had preventive effects for macaques exposed to MERS. Has the US considered using this drug to protect those exposed to but not yet infected with coronavirus?

Thank you,

Natalie A Rahhal
Acting US Health Editor

DailyMail.com

Daily Mail Online | **51 Astor Place**, 9th floor, New York NY 10003

Tel: +1 212 402 9086
Mobile: (b) (6)
Twitter: https://twitter.com/natalier78?lang=en
Email: Natalie.rahhal@mailonline.com

Disclaimer

This e-mail and any attached files are intended for the named addressee only. It contains information, which may be confidential and legally privileged and also protected by copyright. Unless you are the named addressee (or authorised to receive for the addressee) you may not copy or use it, or disclose it to anyone else. If you received it in error please notify the sender immediately and then delete it from your system. Associated Newspapers Ltd. Registered Office: Northcliffe House, 2 Derry St, Kensington, London, W8 5TT. Registered No 84121 England.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 13:24:34 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Doepel, Laurie (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: RE: ASF ------ attached for your review is draft abstract for Florence vaccine meeting
Attachments: Keystone abstract --transforming vaccinology -- 3-16-2020 - with minor Fauci edits.docx

Greg:

This looks great. I have made some minor edits that are tracked in the document. Please accept these and then it is ready to go. Thanks.

Best,
Tony

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 12, 2020 1:47 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Subject: ASF ------ attached for your review is draft abstract for Florence vaccine meeting

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 22:28:19 +0000
To: Jon LaPook
Subject: RE: Coronavirus

Jon:
I have no idea what this guy is talking about. I have never said the R0 was close to 5 or 6. The R0 is about 2.0 to 2.2. Also, the situation is as we have discussed on several occasions. In the USA, the travel restrictions seem to be working with only 15 cases in the USA (13 travel and 2 spouses). But, as I have said, this could change. If we get substantial sustained transmission in a number of countries throughout the world, including the developing world, then sooner or later there will be significant leakage of infected individuals into the USA since you cannot restrict incoming travel from the whole world. The way we might be able to avoid a real global pandemic is if the non-China countries can contain the infections in their respective countries before there is widely distributed sustained transmissions. Once widely distributed sustained transmissions happen, a global pandemic is inevitable. What would a global pandemic mean? It depends on the true rates of morbidity and mortality. The currently reported mortality of COVID-19 is about 2%. However, there are several folds more cases than are coming to the official attention of health authorities, i.e. asymptomatic or minimally symptomatic infections. If you count these, the denominator gets much larger and the case fatality rate could drop to 1% of even 0.5 % or less. If that is the case, then this could be a very severe seasonal flu (0.2% to 0.4%; regular seasonal flu is 0.1%) or a typical pandemic like 1957 or 1968 (0.5% -0.9 %). We are not sure where it is going to land.
Hope this is helpful.
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Jon LaPook (b) (6)>
Sent: Sunday, February 16, 2020 4:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus

Hi Tony,
I thought you would be interested to see a text (below my email) I just got from a very smart Wall Street guy who has been filling me in on reaction there. I've been doing my best on air to put the current situation in perspective - communicating that the risk in the U.S. is still relatively low while letting viewers know the situation is fluid and could change. How would you sum up where we are now?
Thanks,
Jon

TEXT I JUST RECEIVED:

"Doc, total panic mode setting in . Tony Fauci talking R nought at closer to 5 or 6. Good biotech guys saying it might not die down in April. People talking about 60% of us will get it ; unstoppable in Africa. I can't scare people but this is really bad. I hate bothering you on this but I know I need to take my cue from what you will say on CBS"

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 21:16:02 +0000
To: Lucassen, Elisabeth B
Subject: RE: Coronavirus patient--secure

Elisabeth:

Do you have time for a quick phone call?

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lucassen, Elisabeth B <Elisabeth.Lucassen@providence.org>
Sent: Friday, February 14, 2020 1:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Coronavirus patient--secure
Importance: High

Dear Dr. Fauci,

[redacted] (b) (6)

[redacted] (b) (6)

[redacted] (b) (6). Any input would be most appreciated. Many thanks in advance!

Sincerely,
Elisabeth Lucassen

This message is intended for the sole use of the addressee, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the addressee you are hereby notified that you may not use, copy, disclose, or distribute to anyone the message or any information contained in the message. If you have received this message in error, please immediately advise the sender by reply email and delete this message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 20:40:58 +0000
To: Redfield, Robert R. (CDC/OD)
Cc: Greg Folkers [redacted] (b) (6))
Attachments: nejmoa2001316.pdf, NEJM Editorial - Fauci et al - clean with Fauci edits accepted.docx

Bob:

As per our discussion, I am attaching the Editorial together with the NEJM paper upon which the editorial is based. Please take a look and give your approval. Of course if you have any comments or edits, they are most welcome. As mentioned, the NEJM wants the manuscript by COB tomorrow (Monday).
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 20:20:29 +0000
To: Arthos, James (NIH/NIAID) [E]
Subject: RE: one on one

No problem. I am drowning in coronavirus and our meeting likely would have wound up being cancelled anyway. Hopefully, we will soon get back to some sort of normality in our meetings. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Arthos, James (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, February 16, 2020 2:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: one on one

Hi Tony,

I'm very sorry to bother you when you are so busy. Regarding this Tuesday, we are on your schedule for a one on one and unit head meeting. something came up last minute andl am going to be away from Tuesday through Friday, so I won't be able to make either. Sorry for the late notice.

Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 20:17:53 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Cc: Greg Folkers [redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E]
Subject: NEJM manuscript
Attachments: NEJM Editorial - Fauci et al - clean wuth additional Fauci edits - 02-15-2020.docx, NEJM Editorial - Fauci et al - clean with Fauci edits accepted.docx

Cliff;

I am attaching 2 documents: 1) The revised manuscript that Greg worked on in which I have added a number of tracked changes including deleting a substantial amount to get it between 800 and 900 words; and 2) A clean version where I have accepted all the tracked changes (Greg's and mine). Right now I like it the way it is and would not change it much if at all. What it needs now is references. Greg will take a shot at adding the references. If you have references, please send them to Greg and me. In the meantime, I will send it without references to Bob Redfield for his review/approval. Let us discuss by phone if you wish.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 19:19:00 +0000
To: Greg Folkers [redacted] (b) (6))
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: NEJM manuscript
Attachments: NEJM Editorial - Fauci et al - clean wuth additional Fauci edits - 02-15-2020.docx, NEJM Editorial - Fauci et al - clean with Fauci edits accepted.docx

Greg;

I am attaching 2 documents: 1) The revised manuscript that you sent to me in which I have added a number of tracked changes including deleting a substantial amount to get it between 800 and 900 words; and 2) A clean version where I have accepted all the tracked changes (yours and mine. Right now I like it the way it is and would not change it much if at all. What it needs now is references. Can you add up to 10 references? It might be easier for you to do that rather than Cliff. If not, I will send to Cliff and see if he can do it. In the meantime, I will send it without references to Bob Redfield for his review/approval. Let us discuss by phone if you wish.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 12:12:58 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID-19 therapy

Please handle.

-----Original Message-----
From: Cesare Cocchi (b) (6)>
Sent: Sunday, February 16, 2020 5:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: COVID-19 therapy

Dear Doctor Fauci,
I am a pediatrician from (b) (6) (IT).
I was wondering if high doses of vitamin A have been tried in the therapy of COVID-19.
Do you remember the cases of viral pneumonia due to measles that take place in African infants in the late seventies.
It seemed to work.
Many sorry to bother you.
Have a good job!
Best regards
Cesare Cocchi MD

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 15 Feb 2020 22:21:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: To VIMA newspaper-Greece-interview request-coronavirus

FYI

-----Original Message-----
From: Θεοδώρα Τσώλη <thtsoli@tovima.gr>
Sent: Saturday, February 15, 2020 4:22 PM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: To VIMA newspaper-Greece-interview request-coronavirus

Hallo
My name is Theodora Tsoli and I am a science editor for the greek newspaper To VIMA (www.tovima.gr)one of the biggest Sunday papers in my country.I would like to have,if possible,a telephone interview with dr Fauci on the coronavirus outbreak for next Sunday's paper.If he won't be able to speak,could I send questions to which he could answer?
Looking forward to your reply
Thank you in advance
Theodora Tsoli

Στάλθηκε από το iPhone μου

Σημαντικό: Παρακαλώ δείτε την δήλωση αποποίησης ευθυνών<www.alteregomedia.org/disclaimer.html>
Important: Please read our disclaimer<www.alteregomedia.org/disclaimer.html>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:26:27 +0000
To: Folkers, Greg (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Cc: NIAID OD AM
Subject: RE: ASF RE: Dr. Fauci video request: Public Service Recognition Week
Attachments: ASF public service recognition - with tracked edits -05-05-2020.docx

See minor tracked changes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, May 5, 2020 6:16 PM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] <[redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF RE: Dr. Fauci video request: Public Service Recognition Week

ASF –
Here is a short script for Public Service Recognition Week. We agreed to do a short video
ASF – can u tweak as needed?
David, could u record in some format that is easy? Cell phone or other I just learned they want by COB tomorrow

<< File: ASF public service recognition.docx >>

From: Seigfreid, Kim (NIH/OD) [E] [redacted] (b) (6)>
Sent: Monday, April 27, 2020 4:30 PM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>; Polimeni, Lydia (NIH/OD) [E] [redacted] (b) (6)
Subject: Dr. Fauci video request: Public Service Recognition Week

Hi there,

Please see below. HHS is taking over the Partnership for Public Service IG account next week for Public Service Recognition Week. They asked if Dr. Fauci would be willing to do a short 30-second or less pre-recorded video thanking public servants for their work. It would be featured during the takeover, and also on NIH's other sm handles next week. It can be taken on a cell phone as sm does not require higher resolution. Let me know if you would like to accept or decline the request.

Many thanks,
Kim

Kim Seigfreid
Social Media Lead
NIH Office of Communications and Public Liaison
ph: [redacted] (b) (6)
[redacted] (b) (6)

From: Muhammad, Janell (HHS/ASPA) <[redacted] (b) (6)>
Sent: Monday, April 27, 2020 4:10 PM
To: Seigfreid, Kim (NIH/OD) [E] [redacted] (b) (6)>; Channer, Amber (OS/OASH) [redacted] (b) (6)>; Foster, Timothy (OS/ASPA) [redacted] (b) (6)>
Cc: Palczewski, Andrew (HHS/ASPA) <[redacted] (b) (6)>; Pratt, Michael (OS/ASPA) <[redacted] (b) (6)>; Sherman, Jennifer (HHS/OASH) [redacted] (b) (6) Wilker, Michael (HHS/ASPA) [redacted] (b) (6); Dine, Brooke (HHS/ASPA) [redacted] (b) (6)
Subject: Public Service Recognition Week

Hello All,

Hope everyone is holding up well!

OHR is taking over the Partnership for Public Service (PPS) Instagram account during Public Service Recognition Week (May 3-9, 2020). The OHR team has reached out about wanting to develop a senior leader "mashup" video —perhaps including the DepSec. T

They asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci and the SG doing a pre-recorded video thanking public servants for their work.

I wanted to gather the troops so we can identify what all is being planned for this week of recognition and provide a POC for OHR if the request is feasible.

Happy to set up a call, if that is needed to discuss further.

Thanks,
Janell

Janell Muhammad
ASPA Digital Engagement (Team Lead)
U.S. Department of Health and Human Services
Email: (b) (6)
Office: (b) (6)
iPhone: (b) (6)
HHS on Facebook | **HHS on Twitter** | **HHSLatino**

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:05:41 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: launch of ACTT 2 COVID treatment study

See my minor change of my comment in red.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, May 5, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FOR ASF REVIEW: Draft PR re: launch of ACTT 2 COVID treatment study

Hi Dr. Fauci,

Please find attached for your review a draft press release to announce the launch of the ACTT 2 COVID-19 treatment trial (remdesivir and baricitinib). Below is your draft quote:

"We now have solid data showing that remdesivir diminishes **to a modest degree** the time to recovery for people hospitalized with COVID-19," said NIAID Director Anthony S. Fauci, M.D. "ACTT 2 will examine if adding an anti-inflammatory agent to the remdesivir regimen can provide additional benefit for patients, including improving mortality outcomes."

The trial may start enrollment tomorrow.

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b) (6)
E-mail: (b) (6)
NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:00:53 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID-19, [redacted] (b) (4)
Attachments: Birman_Fauci_Azar_Adams_Hahn_letter_May_05_2020.docx

Please take a look at this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: [redacted] (b) (4)
Sent: Tuesday, May 5, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Azar, Alex M. [redacted] (b) (6)>; Adams, Jerome M <[redacted] (b) (6); Hahn, Stephen (FDA) [redacted] (b) (6)
Subject: RE: COVID-19, [redacted] (b) (4)

Dr. Anthony S. Fauci, M.D.
Director, NIAID
Mr. Alex M. Azar II
Secretary, HHS
Dr. Jerome M. Adams, M.D.
Surgeon General, HHS
Dr. Stephen M. Hahn, M.D.
Commissioner of FDA, HHS

Dear Dr. Fauci,
Dear Mr. Azar,
Dear Dr. Adams,
Dear Dr. Hahn,

[redacted] (b) (4)

(b) (4)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 21:17:33 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Dieffenbach, Carl (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Graham, Barney (NIH/VRC) [E];Marovich, Mary (NIH/NIAID) [E]
Subject: RE: D614G mutation paper

Thanks, John. [redacted] (b) (5) [redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Sent: Tuesday, May 5, 2020 5:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Graham, Barney (NIH/VRC) [E] [redacted] (b) (6)>; Marovich, Mary (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: D614G mutation paper

Tony,

David Montefiori will be on CNN tonight related to this paper – and story in in major newspapers. I spoke with David to get some advance info. The paper is out in BioRxiV.
Few key points

[redacted] (b) (5)

John

Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2

Korber B[1], Fischer WM[1], Gnanakaran S[1], Yoon H[1], Theiler J[1], Abfalterer W[1], Foley B[1], Giorgi EE[1], Bhattacharya T[1], Parker MD[3], Partridge DG[4], Evans CM[4], de Silva TI[4,5], on behalf of the Sheffield COVID-19 Genomics Group[#], LaBranche CC[2], and Montefiori DC[2]

Summary

We have developed an analysis pipeline to facilitate real-time mutation tracking in SARS-CoV-2, focusing initially on the Spike (S) protein because it mediates infection of human cells and is the target of most vaccine strategies and antibody-based therapeutics. To date we have identified fourteen mutations in Spike that are accumulating. Mutations are considered in a broader phylogenetic context, geographically, and over time, to provide an early warning system to reveal mutations that may confer selective advantages in transmission or resistance to interventions. Each one is evaluated for evidence of positive selection, and the implications of the mutation are explored through structural modeling. The mutation Spike D614G is of urgent concern; it began spreading in Europe in early February, and when introduced to new regions it rapidly becomes the dominant form. Also, we present evidence of recombination between locally circulating strains, indicative of multiple strain infections. These finding have important implications for SARS-CoV-2 transmission, pathogenesis and immune interventions.

From: David Montefiori, Ph.D. [redacted] (b) (6)
Sent: Tuesday, May 5, 2020 1:23 PM
To: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)
Subject: RE: D614G

John,

I thought you should know that the D614G story is getting a lot of press attention today. I story came out in the LA Times this morning that probably started it all. It will likely be on CNN tonight, and maybe other networks.

Just a heads-up.

David

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 20:43:39 +0000
To: Billet, Courtney (NIH/NIAID) [E];NIAID OD AM
Subject: RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards
Attachments: Script to honor Avi Schiffmann - 05-05-2020.docx

Here is my tracked version of the Schiffmann script.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, May 5, 2020 3:06 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

OK – so this is the ask from the Webby awards: a short recorded video message. They have sent a proposed script below -- just an example – obviously we're free to change it. Avi is a pretty extraordinary kid. 17 years old!

Here is the site he created, back in early January. He's aggregating data from WHO, CDC, and other sources: https://ncov2019.live/

NBC Today story: https://www.today.com/parents/17-year-old-built-website-track-coronavirus-t175245
New Yorker article about him: https://www.newyorker.com/magazine/2020/03/30/the-high-schooler-who-became-a-covid-19-watchdog

---

From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Sent: Tuesday, May 5, 2020 2:32 PM

To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

HI Courtney,

This would be a pre-recorded message with Dr Fauci solo. He would set up Avi's award and help to celebrate his Webby moment for him. Avi will be sending us his 5 word Webby speech which will then follow Dr. Fauci's intro. Below is a draft of the introduction for him, let us know if he would like to make any edits/changes. I've also attached the format for taping on his phone/computer. Please let me know if you need any additional information and hoping we can make it work.

Thank you so much

Best

Lesley

DR. FAUCI:

I'm Dr. Anthony Fauci. Unfortunately, you've seen a lot of me lately. But thankfully, I'm here to present some good news and I'm excited for the opportunity to shine some light on one of the many young people who have stepped up and helped us throughout a difficult time.

The 24th Annual Webby Awards would like to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world.

As we collectively navigate the severe impact of COVID-19, including the difficult, but critical calls for nationwide social distancing, the Internet has become the lifeblood of people looking for accurate information about the novel coronavirus and the necessary steps to combat it.

Since launching the site on December 29th, Schiffmann's tracking tool has been an invaluable resource that sounded the alarm on the virus and its spread, notably calling attention to its severity long before many global officials.

At a time when the spread of misinformation can be so detrimental to our efforts, the site has provided over 600 million visitors with accurate real-time data. Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and the importance of measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating an essential website to provide real-time data about the virus to people everywhere, it is my great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year.

WEBBY FROM HOME
PRESENTER GUIDE

1.
RECORD YOUR VIDEO IN LANDSCAPE

2.
LIGHT FROM THE FRONT

3.
EVERYONE, QUIET ON THE SET

4.
LIGHTS, CAMERA, ACTION!

5.
HAVE FUN AND BE YOURSELF

WFH
WEBBYS FROM HOME

On May 5, 2020, at 10:31 AM, Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6) wrote:

Lesley – we've been discussing this. Can you tell us exactly what would be involved in this? How many minutes would you be looking for Dr. Fauci to speak? Would this be pre-recorded, with Dr. Fauci solo? Or would it be done as a Zoom or something like that, with an interaction between Dr. Fauci and Avi?

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Monday, May 4, 2020 5:31 PM
To: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

HI Lesley – thanks so much for reaching out. Avi is so impressive! I am connecting you with Dr. Fauci's assistant and scheduler, Patty Conrad, for follow-up.

From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Sent: Monday, May 4, 2020 5:10 PM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

Hi Courtney,

Hope you are staying well during these uncertain times. I am a Talent Producer for The Webby Awards and had reached out to Dr. Fauci regarding being involved in our "virtual" internet celebration which will showcase the artists, organizations, and creators using their platforms to imagine a better tomorrow through information, education, movement, comedy, all while inspiring audiences to take action to enact positive change.

Avi Schiffman is being celebrated as our Person of the Year and we would be honored if Dr Fauci would "virtually" present him his honor. The official letter is below and would love to discuss in more detail when you have a chance to review.

Thank you

Best

Lesley

> Begin forwarded message:
>
> **From:** Lesley Cahill Roy <lesley@lesleycahillroy.com>
> **Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards**
> **Date:** May 1, 2020 at 12:13:10 PM EDT
> **To:** [redacted] (b) (6)
>
> HI Dr Fauci
>
> I just wanted to follow up on below regarding Avi and The Webby Awards. Would be wonderful if you could be a part of this moment for him.
>
> Thanks so much
>
> Lesley
>
> > On Apr 20, 2020, at 1:57 PM,
> > lesley lesleycahillroy.com<lesley@lesleycahillroy.com> wrote:
> >
> > <6EDD370A-6106-4603-B557-7AAEE9A9EF79.png>
> >
> > Dear Dr. Fauci,
> >
> > I hope you and the family are all safe and healthy during these challenging times. Hailed by The New York Times as "the Internet's highest honor," The Webby Awards has been the premiere award for online excellence for over two decades, honoring the companies and people who have critically shaped digital technology and culture.
> >
> > This year, due to the impact of the coronavirus The Webby Awards are moving their renowned award show to an online experience. On May 19th, 2020, the 24th Annual Webby Awards will bring together Webby Winners from around the world in an Internet Celebration which will showcase the artists,

organizations, and creators using their platforms to imagine a better tomorrow through information, education, movement, comedy, all while inspiring audiences to take action to enact positive change.

The 24th Annual Webby Awards are proud to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world. We would be honored if Dr. Fauci would "virtually" present Avi with his award.

As we collectively navigate the severe impact of COVID-19 on the world and late calls for nation-wide social distancing, the Internet has become the lifeblood for people looking for accurate information about the novel coronavirus. Since launching the site on December 29th, Avi Schiffmann's tracking site was a necessary tool that sounded the alarm on the novel coronavirus and its spread, notably calling attention to its severity long before many global officials. By providing over 100 million visitors with real-time data on the virus' spread, Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating a website to provide real-time data about the virus to people everywhere, it is our great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year. The celebration will highlight the important work Avi and his fellow winners are doing, and will mark his hallmark Webby 5-Word acceptance speech in Internet history. Dr. Fauci's presenter speech could be recorded on his phone and we can send you through a script for him to review, edit and details for format and deadline.

This year's Webby Awards will also take action, the impact of COVID-19 and government responses around the world, has brought the importance of voting into sharp focus. The Webby Awards has partnered with Vote.or and aim to check the voter registration status of 1 million voters in the United States, promoting the importance of voting to help ensure voter turnout this November is the highest it has ever been. This partnership will integrate into all elements of this year's online celebration.

Our thoughts are with all of you in this difficult time.

Best

Lesley Cahill Roy
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 19:49:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW:

unlikely

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Konstantin Vulkov <kv@egoist.bg>
Sent: Tuesday, May 5, 2020 3:42 PM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Cc: NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6)>
Subject:

Dear Sir/Madam,

My name is Konstantin Vulkov and I am Program director of the biggest Bulgarian private radio station, Darik radio (www.darikradio.bg). This is a news/talk radio station. I am a regular contributor to Bulgarian National TV as well as several online and print publications, editor-in-chief of egoist.bg as well as editor-in-chief of the biannual Darik-owned publication called Dolce Far Niente.

I am a document photographer as well, focusing mainly on portraits.

I am covering the coronavirus pandemic extensively - visiting COVID-19 units across the country, making my daily radio programme "Mind games", writing stories for our websites www.darikradio.bg. www.dnews.bg and egoist.bg.

It would be an honour if I can make a short telephone interview with Mr. Anthony S. Fauci, M.D.

Please let me know if I can call and make the interview. I promise I won't take more than 10 minutes of Mr. Fauci's time.

Your help is much appreciated.

Best,

Konstantin

***

Konstantin Vulkov
Program Director
Darik Radio
82, Dondukov blvd.
Sofia 1504
Bulgaria

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 19:48:10 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: AUSTRIA - Try to support - COVID 19 - Strategy

Looks fine.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, May 5, 2020 3:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: AUSTRIA - Try to support - COVID 19 - Strategy

Dr. Fauci,

I will respond. Here is what I propose to say (in addition to thanking him). Let me know if you'd change anything:

[redacted] (b) (5)

Sincerely,

Andrea

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, May 5, 2020 at 10:40 AM
To: "Lerner, Andrea (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: Fwd: AUSTRIA - Try to support - COVID 19 - Strategy

Not a crazy note. Please respond on my behalf. Thanks

Begin forwarded message:

> **From:** [redacted] (b) (6)
> **Date:** May 5, 2020 at 8:19:48 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: AUSTRIA - Try to support - COVID 19 - Strategy**
>
> **Dear – highly respected – Dr. Fauci**
>
> **Why do I try to childishly support a respected expert and personally highly honored Gentleman like you – Dr. Fauxi ?**
>
> **Because for me – it is heartbreaking and unbelievably disturbing, what was and is going on in the course of the last 4 months in the USA.**
>
> **I talk about the USA, that relieved my country - AUSTRIA - 75 years ago from the hell of the NAZI-Regime – with American Lifes and Blood.**
>
> **With all my respect, my hopes, my passion, my tears, my mourning – May Grace and Blessing be with You and the USA.**
>
> After running the numbers available on COVID 19 pandemic data – my experiences as an Economist led to following analysis and proposed strategy:

COVID 19 is a true threat for humans >65 years of age with pre-existing illnesses,
but nearly influenza-like for humans < 65 years of age and humans > 65 years of age without pre-existing illnesses

AUSTRIA: Deaths by age



Die dem Diagramm zugrundeliegenden Zahlen beziehen sich auf die bestätigten Todesfälle.

Deaths as of 100.000 inhabitants by age



Die dem Diagramm zugrundeliegenden Zahlen beziehen sich auf die bestätigten Todesfälle.



Germany – Death by age – men and women – mortality rate in %

Comparison – Italy and China



Coronavirus Mehr Männer unter den Toten

Die Auswertung des Robert-Koch-Instituts (RKI) basiert auf mehr als 149 000 Coronavirus-Fällen in Deutschland. Unter den mehr als 5000 erfassten **Covid-19-Todesfällen** finden sich über fast alle Altersgruppen hinweg auffallend mehr Männer als Frauen.

(Anzahl verstorbener Covid-19-Patienten nach Alter und Geschlecht, Altersgruppen-Einteilung laut RKI, Stand: 23. April 2020)

Grafik: ntv.de / Martin Morcinek • Quelle: RKI



Italien: mehr Covid-19-Tote als in China

Mortalitätsrate in Prozent der Erkrankten

Altersgruppen	ITALIEN	CHINA
0-9	0	0
10-19	0	0,2
20-29	0	0,2
30-39	0,3	0,2
40-49	0,4	0,4
50-59	1,0	1,3
60-69	3,5	3,6
70-79	12,8	8,0
≥ 80	20,2	14,8

Anteil der Verstorbenen über 80 Jahre

Proposed Strategy

1. **Keep the virus 100% (totally) away from people older than 60 with pre-existing illnesses**

Identify, Testing, Shelter, Preserve from contact with virus, Preserve from Hospitalization and ICU

2. **Minimize possible contact with virus for people older than 60 without pre-existing illnesses**
   Identify, Testing, Partial Stay at Home, Social Distancing, , Preserve from Hospitalization and ICU

Once 1 and 2 are warranted:

3. **Handle the rest of the population with care, but keep them going and working – as you would do in an influenza-season**
   The critical factor for further intervention is the capacity of the regionally available ICU-capacity
   Interventions: Social Distancing, Masks, Testing, Tracing, Stay at home when ill, Quarantine at home when ill

Respectfully Yours
Gerald Glockenstein

Mag. Gerald Glockenstein
(b) (6)
[redacted]

From: [redacted] (b) (6)
Sent: Tue, 5 May 2020 10:47:11 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: request of interview by Giuseppe Sarcina, corriere della Sera

Please try to get clearance. This is the top newspaper in Italy

Begin forwarded message:

> **From:** Sarcina Giuseppe <gsarcina@rcs.it>
> **Date:** May 5, 2020 at 8:03:29 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Re: request of interview by Giuseppe Sarcina, corriere della Sera**
>
> Inviato da iPhone
>
>> Dear Doc. Fauci,
>> this is Giuseppe Sarcina, the us correspondent of Corriere della Sera, the main italian newspaper.
>> I understood that you are looking at the italian case with great attention.
>> I wonder if you can grant me a short interview.
>> I have sent an email march 21. But then I saw that you spoke with an other italian newspaper. So I would like to have a chance to have your voice for our Readers as well. Corriere della Sera is a newspaper based in Milano, Lombardy, The region most affected by the coronavirus.
>> Thank you
>> Warm Regards
>> Giuseppe Sarcina
>> Washington dc

(b) (6)

Oggetto: request of interview by Giuseppe Sarcina, corriere della Sera

Dear Doc. Fauci,
this is Giuseppe Sarcina, the us correspondent of Corriere della Sera, the main italian newspaper.
I understood that you are looking at the italian case with great attention.
I wonder if you can grant me a short interview.
That would be really helpful for our readers
Thank you
Warm Regards
Giuseppe Sarcina
Washington dc

From: [redacted] (b) (6)
Sent: Tue, 5 May 2020 10:43:37 -0400
To: NIAID OD AM
Subject: Fwd: Invitation to Participate in Book Project on COVID-19

Let us discuss. [redacted] (b) (5)

Begin forwarded message:

> **From:** Dawinder Sidhu <dss@umbc.edu>
> **Date:** May 5, 2020 at 8:14:12 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Invitation to Participate in Book Project on COVID-19**
>
> Dr. Fauci,
>
> I hope this email finds you well. I am a professor at the University of Maryland, an elected term member in the Council on Foreign Relations, and a former fellow at the Supreme Court of the United States.
>
> I am writing because I am preparing a book, tentatively entitled "Rebuilding America: A Blueprint for Post-COVID-19 America," consisting of essays by leading figures on (1) how COVID-19 has impacted their particular field, and (2) how that field should be reimagined in light of the crisis. The essays will reconsider all sectors of society, including law, education, healthcare, fashion, music, etc., and collectively will be the first comprehensive guide for post-coronavirus reconstruction efforts.
>
> I am very hopeful that you may be willing to contribute a short essay on how the current coronavirus has impacted public health policy, and how such policies can and should evolve moving forward.
>
> Only 50 industry leaders are being asked to contribute. Commitments have been secured from an impressive group, including a retired four-star general and a preeminent constitutional scholar. I very much hope you will take part in this innovative project given your historic and unparalleled contributions to the public's understanding of the current crisis.
>
> With respect to logistics, I am hoping to receive commitments from all authors this month, with essays due within one month, and with the

essays available through Amazon's expedited publishing platform roughly one month after that. Each essay should be no more than 1,000 words, and I may offer light edits for the author's final approval. A final note: all proceeds from the sale of the book will be donated.

I am very hopeful that you will give every serious consideration to this invitation, and will lend your voice towards reimagining and revitalizing a new America.

Best,
Dave

Dawinder S. Sidhu
University of Maryland
(b) (6) [redacted]
dss@umbc.edu

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 13:00:29 +0000
To: Lipkin, Ian W.
Subject: RE: SARS-CoV-2

Thanks, Ian. I hope that you are well.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lipkin, Ian W. [redacted] (b) (6)
Sent: Tuesday, May 5, 2020 8:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: SARS-CoV-2

Tony,

[redacted] (b) (4) This prompted the letter I sent to him last evening to which he responded this morning. I dont expect a response but wanted to keep you updated. We deeply appreciate your efforts in steering and messaging.

All my best,
Ian

Ps. Skoll just invested $5M in piloting the GIDEoN international capacity building and surveillance network that includes Cliff and others in your intramural team.

Begin forwarded message:

From: ZhuChen [redacted] (b) (6)>
Subject: Re:SARS-CoV-2
Date: May 5, 2020 at 8:16:23 AM EDT
To: Lipkin, Ian W. [redacted] (b) (6)>

Dear Ian,
Thank you for your email detailing the [redacted] (b) (4) (b) (4) [redacted] (b) (4). I shall keep you informed of any progress in the coming weeks.
Best,
Zhu

------------------ Original ------------------
From: "Lipkin, Ian W.[redacted] (b) (6);
Date: Tue, May 5, 2020 06:06 AM
To: "ZhuChen"[redacted] (b) (6)>;
Subject: SARS-CoV-2

Dear Zhu,
The COVID-19 pandemic poses an unprecedented threat not only to global public health but also to economic and political stability. Uncertainty about the origin of COVID-19 pandemic is causing friction worldwide, particularly between China and the United States. There is agreement that the causative agent, SARS-CoV-2 originated in a bat. There is also a high level of confidence that the virus was not deliberately modified in any laboratory. What we do not know is the answers to two questions: (1) whether a precursor virus circulated in the human population before it evolved to become a pandemic virus and (2) whether a precursor virus adapted to humans by first passing through another animal. [redacted] (b) (4)

(b) (4) [redacted]

With great affection,
Ian

W. Ian Lipkin, MD
John Snow Professor of Epidemiology and Director
Center for Infection and Immunity
Mailman School of Public Health

Professor of Pathology and Neurology
College of Physicians & Surgeons
Columbia University
722 West 168th Street, 17th Floor
New York, NY 10032
Voice: [redacted] (b) (6)
Fax: (212) 342-9044
Email: [redacted] (b) (6)

Administrative Coordinator
[redacted] (b) (6)

www.cii.columbia.edu
Follow CII on Twitter: CII_Columbia | Facebook: CII.Columbia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 12:40:52 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: VP slides
Attachments: VP brief VRC 5may2020v2.pptx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] (b) (6)
Sent: Monday, May 4, 2020 7:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: VP slides

Tony, here are slides, including changes we discussed. Patty and all have them.
John

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 12:06:24 +0000
To: Harris, Mary (NIH/NIAID) [E]
Subject: RE: Thank you , Dr. Fauci, Thank you so very much!

Mary:
Many thanks for your kind note. It is much appreciated. Stay well.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harris, Mary (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, May 5, 2020 8:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Thank you , Dr. Fauci, Thank you so very much!

Dr. Fauci,

I wanted to personally thank you for being the voice of reason, security, comfort and insight. (b) (6) As much as I miss being in the office, I am grateful to say my Director is Dr. Anthony Fauci and share with my family, friends, and church that if you said it, it's gospel. They can bank on it! You have given comfort to my family and myself. You will never know how much! I want you and those who in researchers who are hard at work without much rest but tons of sacrifice including that of your families to find a vaccine, give the Nation a sense of safety and security in this unprecedented time are greatly appreciated. My family, friend and myself are send our prayers for your continued strength. Thank you doesn't seem like enough. I couldn't be prouder to work at NIAID and specifically on the 7th floor of Building 31.

Simply Grateful,

Mary Harris
NIAID Travel Policy Specialist
NIAID Travel Card Coordinator
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 00:37:21 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: CORONA and BACTERIAL SUPERINFECTION
Attachments: 1918 influenza insight- fauci.pdf, ESP el arroz epidemol.pdf, Infection and Immunity-2015-Rynda-Apple-3764.full.pdf, JClinsightco-infection.pdf, lancet.png, Mail Esp.pdf, mail germany 1.pdf, piramide.png, PLEASE FORWARD THIS MESSAGE TO error.pdf, portugal.pdf, Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza - Dr Fauci.pdf, press usa.pdf, Recuperados.pdf, spanish flu 1918 - eng original.pdf, tyska pres mail.pdf, US error message.pdf, Us mail 0408.pdf, WHO-2019-nCoV-clinical-2020.4-eng.pdf, virus piramdie eng.png

Please take a look and decide. Thanks.

From: Ola Melhus [redacted] (b) (6)
Sent: Monday, May 4, 2020 12:25 PM
To: [redacted] (b) (6) Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
[redacted]
Subject: CORONA and BACTERIAL SUPERINFECTION

Dear Doctors,

I don't know if you have got this infomation.

A truly deadly virus

cannot spread very far. Why? Because people quickly get sick and die. In other words, they cannot spread the virus further, which is a prerequisite for a large spread like corona. Covid-19 has spread throughout the world.

The premise is that it is not very dangerous, it causes mild symptoms for most people, many do not even notice that they were sick. But the virus has different phases in the body, after a while it goes into a resting phase, you feel better, but the virus is still present and can pass on. Covid-19 is an optimally developed virus that spreads rapidly around the world. But if it were really deadly, almost everyone would die.

So far in our 4 billion long history, there have been **no airborne** viruses or bacteria. Yes, in the hollywood movie "outbreak" there was, but it was a movie. Why hasn't it?

If it had existed, this planet would have been a dead planet without life. It would have killed all living. It is possible that there is somewhere else in the universe, but not here on planet Earth. Not now. Remember, this is not the first time a new virus is spreading in the world. What is happening now has happened earlier in our long history.

But people are die you say. Yes, but the virus don't kill them. The virus open a "door" in the cell wall thats allows for bacterias, how always are present, to invade the body and create an aggressiv bacterial superinfection. That's what kills them. See,

1. Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of Disease.


Reduced susceptibility
(day 2–3 post-IAV)
Increased susceptibility
(day 6–7 post-IAV)
Influenza infection
Bacteria
Alveolar macrophage
Macrophage
Bronchiole lumen
IFNα/β
IL-13
IFN-γ
Phagocyte
IL-1β
IL-13
IL-23
TNF-α
IFNα/β
AMPs
Chemokines
Growth factors
IL-10
IFN-γ
NETs
CD4⁺
γδ
IL-17A
IL-22
Phagocyte

FIG 1 Common pathways of susceptibility to postinfluenza bacterial superinfections. Early after influenza virus infection, mice show reduced susceptibility to superinfection that is at least in part due to increased production of IL-13. This IL-13-rich environment does not permit IFN-γ production, allowing unaltered phagocytosis and clearance of bacteria. The role for either neutrophils or macrophages (phagocytes) in bacterial clearance early during influenza virus infection has not been fully investigated. Progression of influenza virus infection results in increased susceptibility to secondary infection. Type I IFN (or IL-27) signaling initiated in response to influenza virus infection results in downregulated production of IL-1β and Il-23 and impaired type 17 immune responses. Inhibition of IL-17 and IL-22 reduces production of antimicrobial peptides. Type I IFN signaling also reduces levels of neutrophil chemoattractants Cxcl1 and Cxcl2 and can induce formation of NETs. IL-27 induced during influenza virus infection further suppresses IL-17 production but stimulates production of regulatory cytokine IL-10, which contributes to increased susceptibility to superinfection, presumably by alteration of the anti-influenza inflammatory response. IAV, influenza A virus infection.

and this reports:

2. Deaths from Bacterial Pneumonia during 1918–19 Influenza Pandemic

3. The 1918 Influenza Pandemic: Insights for the 21st Century

4. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness

5. Survival during influenza-associated bacterial superinfection improves following viral- and bacterial-specific monoclonal antibody treatment

6. Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness

How can this happen? How can the doctors be so blind. I have a theory about this and here it comes:

My (b)(6) was a psychologist. May she rest in peace in heaven.

It seems that the corona virus has affected the brain more in a certain group in society, namely politicians, doctors, journalists and other with power and positions in the society. The virus is not dangerous for this group, but it's opens a door in the brain's cell wall that allows it to enter the fear center of the brain.

This door has been closed for many years. We haven't had any major wars and nothing has threatened them. They have felt invulnerable. Convinced of their own superior ability and greatness. Not only can they control the people, they can now control the climate by turning the carbon dioxide tap. If they close it, the temperature drops, if they open it the temperature goes up. They don't know that the sun is 109 times as big as our planet. 109 times. It seams so small when we look up in the sky. They thought they could control everything.

Then came the VIRUS, they receive an abrupt awakening. They get scared. Politicans get sick and die. Doctors die. The brain is attacked by fear virus. They can no longer think clearly and logically. The panic is near, they are reminded of their own mortality. Just like a virus in a computer. It's slows it down and it becomes unusable. Thats whats happen when a fear virus attacks the brain.

Here where I live, there are panic over 1600 confirmed cases. The televison is talking "infected persons" when there is "confirmed laboratory cases". It's two different things. Misleading the people. Why panic over 1 600 infected? Closing all not nessecary buissness, all schools, all except for supermarket, gas station, banks. You can't go out after 5.00 pm. If you do, you get arrested.

Why? They are scared. Because the ruling class is afraid. Everyone with this masks. Doctors crying on television. The President with mask. They are scared. Doctors. Journalists. Polices.

2020. The year when the world got completely crazy.

You have an medical obligation to inform the world about the truth.

Kind regards,

Ola Melhus

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 00:36:13 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Therapeutics and vax
Attachments: NIAID SARS-CoV-2 Tx and Vax overview.docx

Please print out and put in folder labelled "COVID-19 Therapeutics and Vaccines"

From: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, May 4, 2020 12:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] <[redacted] (b) (6)>
Subject: Therapeutics and vax

For your Therapeutics discussion later today

From: [redacted] (b) (6)
Sent: Mon, 4 May 2020 19:52:45 -0400
To: Troye, Olivia EOP/NSC
Cc: Hurst, Natalie R. EOP/OVP;Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E];Francis Collins
Subject: Re: Email connecting us

Here they are. Thanks

> On May 4, 2020, at 7:46 PM, Troye, Olivia EOP/NSC
> [redacted] (b) (6)
>
> Hi Dr. Fauci,
> Per our conversation, sending you a note. I'm copying Natalie who will help get them cleared in.
> Thank you!
> Olivia
>
> Olivia Troye
> Special Advisor to the Vice President for
> Homeland Security, Counterterrorism, and North America
> Office of the Vice President, National Security Affairs
> White House Coronavirus Task Force
> O: [redacted] (b) (6) | M: [redacted] (b) (6) (Does not receive texts)
> [redacted] (b) (6)

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 21:05:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Invitation to join (virtually) the ACTIV Leadership Meeting 5/6

Please see me about this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6)>
Sent: Monday, May 4, 2020 11:18 AM
To: ICDDIR-L@LIST.NIH.GOV
Cc: Parker, Ashley (NIH/OD) [E] (b) (6); Wholley, David (FNIH) [T] (b) (6)>; Melencio, Cheryl (FNIH) [T] (b) (6)>
Subject: Invitation to join (virtually) the ACTIV Leadership Meeting 5/6

Dear Colleagues,

As you may be aware, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership has been moving forward rapidly to address the global pandemic. We held our initial ACTIV leadership meeting on April 3rd including, NIH, FDA, BARDA, EMA, and industry heads of research and development. Four working groups were formed out of this meeting to focus on preclinical therapeutics, clinical therapeutics, clinical trial capacity, and vaccines.

Although some ICs have representatives participating in the working groups, we recognize there is a need to keep everyone looped in to the various activities and progress of the partnership, particularly in view of all of the concurrent IC projects about COVID-19. The ACTIV working groups will be delivering their second report to the **ACTIV Leadership Group on Wednesday, May 6, from 3:30-5:00pm**. I am writing to invite the ICDs to listen-in on this meeting. There will be a lot to cover during the meeting and the members of the Leadership Group will be asking the questions. But to give a chance for us NIHers to discuss what has been presented, I am scheduling a separate ICD call for 5:05-5:30pm, immediately following the ACTIV leadership meeting.

If you are available to take part, please send your responses to David Wholley and Cheryl Melencio of FNIH (cc'd here) by noon tomorrow, May 5th. Once you confirm your attendance, Cheryl will send you a calendar invite for both the ACTIV leadership meeting and the ICD follow-up call.

Best regards,
Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 15:28:08 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Need your help Covid-19 CAS-10685

I do not know this person. We should refer him to Brett Giroir.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, May 4, 2020 10:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>
Subject: FW: Need your help Covid-19 CAS-10685

Do you know this person?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harris, Kara (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, May 1, 2020 8:38 AM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Need your help Covid-19 CAS-10685

Hi, Patty –

This individual states that he previously worked with Dr. Fauci and that he knows him. Please let me know if you would like Public Inquiries to handle.

Thanks,
Kara

From: Ray Rosa [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 5:58 PM
To: NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>
Subject: Need your help Covid-19

I am working with a group of physicians whom need your guidance on Serum Covid-19 tests. I need someone to call me so I can ask specific questions. I worked with Dr Fauci back in 1998 when I was in the Air Force. So he does know me. Ray Rosa is the name. Can you please call me.

[redacted] (b) (6) cell

Sent from AOL Mobile Mail
Get the new AOL app: mail.mobile.aol.com

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 14:00:23 +0000
To: NIAID OD AM
Subject: FW: inquiry

Another one that he will probably want to do.

From: Augustine M. K. Choi (b) (6)
Sent: Monday, May 4, 2020 9:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: inquiry

Hi Tony,

I can only imagine your schedule. Thank you for all you are doing for the country in our fight against this virus.

Weill Cornell would like to invite you for a 3 min remarks to the Class of 2020 at their upcoming graduation if your schedule allows. The virtual graduation is on May 28th. We can tape your remarks at any time which fits your schedule, from now or up to right before May 28.

If you able to accept this invitation, please let me know. If not, totally understandable and we would love to have you back again after covid subsides.

Thanks again!

Augustine M.K. Choi, M.D.
Stephen and Suzanne Weiss Dean, Weill Cornell Medicine
Provost for Medical Affairs, Cornell University

Weill Cornell Medicine
1300 York Avenue, Suite F-113 Box 83 | New York, NY 10065
Telephone: 212-746-6005
Fax: 212-746-8424
Email: amc2056@med.cornell.edu

From: Anthony Fauci < (b) (6)
Date: Monday, March 30, 2020 at 12:19 PM
To: Augustine Choi (b) (6)
Subject: [EXTERNAL] RE: all wearing masks

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 12:28:04 +0000
To: Corey, Larry
Subject: FW: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

As an FYI for the 9:00 AM meeting.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dolsten, Mikael [redacted] (b) (6)>
Sent: Monday, May 4, 2020 8:15 AM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>; Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Lowy, Douglas (NIH/NCI) [E] [redacted] (b) (6); Jansen, Kathrin [redacted] (b) (6)>
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Francis
Thanks for the response

We appreciate the federal initiative and opportunity to influence it's design . I know Kathrin Jansen (ccd here) from PFE is working w the team on this.

[redacted] (b) (4) (b) (4) It's great to be collaborating w NIH-FDA for the best of our nation and global health .

In the master protocol , I hope the working committee is discussing [redacted] (b) (5) (b) (5)

(b) (5)

[redacted]

These are just two examples we can discuss on Wednesday in the leadership meeting of times permits .

(b) (5)

[redacted]

I look forward to the meeting

Best
Mikael
Sent from my iPhone

> On May 4, 2020, at 04:26, Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> wrote:
>
> Hi Mikael,
>
> Wow, sounds like you are making fantastic progress with the vaccine program, and we would certainly not want to do anything to slow you down! I understand that you are evaluating several mRNA formats with BioNTech. If one of those turned out to be ready for phase II/III in late June, we would be most interested in the possibility of including that in the master protocol. Please keep Tony and me in touch with Pfizer's progress, including which mRNA format you choose to move into advanced development.
>
> Hope to hear your voice at the ACTIV Leadership Group meeting on Wednesday. There will be a lot to talk about!
>
> Best, Francis

From: Dolsten, Mikael [redacted] (b) (6)>
Sent: Sunday, May 3, 2020 6:26 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

We certainly enjoy taking part in ACTIV

I will check if we did get our drugs on the lists below

[redacted] (b) (4)

I will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats that is less advanced or a refined format of our most advanced in the master protocol etc

If we can agree about shared key endpoints , we can include that cross all studies Whether master protocol or more advanced sponsor trials which helps comparison

Happy to discuss w you and welcome your advice
Mikael

Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President,
Worldwide Research, Development and Medical
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

> On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> wrote:
>
> Mats

Hi Mikael,

Thanks for your note and this update on exciting progress on several fronts. ACTIV is moving forward with gratifying speed and commitment. With regard to vaccines, tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase II/III trial with adaptive design, multiple arms, and a shared placebo arm, aiming to launch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, and JnJ vaccines are likely to be included – might Pfizer also join?

(b) (4) – I trust that compound is on the list of therapeutic candidates that the Clinical Therapeutics WG of ACTIV is reviewing? They are supposed to put forward a tentative list for the Wednesday Leadership Group meeting. Ditto with the (b) (4) option!

Looking forward to catching up soon!

Best, Francis

From: Dolsten, Mikael (b) (6)>
Sent: Sunday, May 3, 2020 12:06 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

I trust you are well but likely working too many hours as we all experience in the difficult Covid times.

In the vaccine space we have progressed rapidly and are already in phase 1/2 studies dose escalation phase testing multiple format of mRNA vaccine . Key for us is (b) (4) .

In the anti-viral areas we are (b) (4)

We also want to start (b) (4)

[redacted] (b) (4)

How are things going w ACTIV.
Any issues to discuss ?

I hope our PFE representatives in ACTIV are helping out well

Pls let me know if there is anything particular to discuss or I can help you with

Best personal regards
Mikael

Sent from my iPhone

> On May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> wrote:
>
> Hi Morten,
>
> Thanks for your note. It would be great to have this connection – but let me suggest that you start with David Wholley (cc'd here), as he oversees all four of the ACTIV working groups. Joe is the program lead for the group on preclinical therapeutics/repurposing.
>
> Best, Francis
>
> ---
>
> **From:** Sogaard, Morten [redacted] (b) (6)
> **Sent:** Sunday, May 3, 2020 10:46 AM
> **To:** Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
> **Cc:** Dolsten, Mikael [redacted] (b) (6); Prof Trevor M Jones CBE FMedSci [redacted] (b) (6)>; Sogaard, Morten [redacted] (b) (6)>
> **Subject:** OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?
>
> Francis,

I hope you are having a good weekend.

Quick question: Would you be OK if I/we reached out to Joe Menetski, who I understand leads many of the ACTIV efforts. We have come to know Joe very well as a great collaborator on the AMP gene therapy initiative and It would be very easy I think working informally with Joe to look a bit more under the hood and identify/ map opportunities for alignment with the other initiatives.

All the Best,
Morten

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 10:53:14 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Subject: RE: EOP/OMB Alert: May Hearing Guidance

What does this mean for the May 12 Senate Hearing?

From: Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, May 4, 2020 6:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: EOP/OMB Alert: May Hearing Guidance

I have highlighted in yellow the fundaments of the OMB guidance below.

Melinda

From: Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)>
Sent: Sunday, May 3, 2020 9:54 PM
To: OD-OLPA-Leg Contacts <OD-OLPA-LegContacts@OD.NIH.GOV>
Subject: Fwd: May Hearing Guidance

FYI. New OMB hearing guidance.

From: Yaworske, Jason A. EOP/OMB [redacted] (b) (6)>
Sent: Sunday, May 3, 2020 9:06 PM
Cc: Ueland, Eric M. EOP/WHO <[redacted] (b) (6)>; Hodgson, Christopher (ovp.eop.gov) <[redacted] (b) (6)
Subject: May Hearing Guidance
Importance: High

Agency legislative affairs teams,

[redacted] (b)(5) - PCP

(b)(5) - PCP

[redacted]

Thank you, and please let us know if you have any questions.

Jason

Jason Yaworske
Associate Director for Legislative Affairs
Office of Management and Budget
[redacted] (b) (6) (o)
[redacted] (b) (6) (c)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 00:50:18 +0000
To: Collins, Francis (NIH/OD) [E];Mascola, John (NIH/VRC) [E];Lane, Cliff (NIH/NIAID) [E]
Cc: Tabak, Lawrence (NIH/OD) [E];Parker, Ashley (NIH/OD) [E]
Subject: RE: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

We need to find out precisely what he is talking about when he says "vaccine formats" and "refined formats". I really do not know what he is talking about. [redacted] (b) (4), (b) (5)

John/Cliff:
Let us discuss this at our morning meeting.

Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Sunday, May 3, 2020 8:03 PM
To: Mascola, John (NIH/VRC) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Parker, Ashley (NIH/OD) [E] [redacted] (b) (6)
Subject: FW: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi John, Cliff, and Tony,

See note below, where Mikael Dolsten indicates Pfizer is planning to [redacted] (b) (4). He intends to discuss our master protocol possibility with Kathrin Jensen. I am not quite sure what he means by "several vaccine formats".

Does this timetable sound realistic?

Any suggestion about a response?

Francis

From: Dolsten, Mikael [redacted] (b) (6)
Sent: Sunday, May 3, 2020 6:26 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)

Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

We certainly enjoy taking part in ACTIV

I will check if we did get our drugs on the lists below

[redacted] (b) (4)

I will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats that is less advanced or a refined format of our most advanced in the master protocol etc

If we can agree about shared key endpoints , we can include that cross all studies Whether master protocol or more advanced sponsor trials which helps comparison

Happy to discuss w you and welcome your advice
Mikael

Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President,
Worldwide Research, Development and Medical
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

> On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E] <[redacted] (b) (6) wrote:
> Mats
>
> Hi Mikael,
>
> Thanks for your note and this update on exciting progress on several fronts. ACTIV is moving forward with gratifying speed and commitment. With regard to vaccines, tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase II/III trial with adaptive design, multiple arms, and a shared placebo arm, aiming to launch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, and JnJ vaccines are likely to be included – might Pfizer also join?

[redacted] (b) (4)– I trust that compound is on the list of therapeutic candidates that the Clinical Therapeutics WG of ACTIV is reviewing? They are supposed to put forward a tentative list for the Wednesday Leadership Group meeting. Ditto with the [redacted] (b) (4) option!

Looking forward to catching up soon!

Best, Francis

From: Dolsten, Mikael [redacted] (b) (6)
Sent: Sunday, May 3, 2020 12:06 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

I trust you are well but likely working too many hours as we all experience in the difficult Covid times.

In the vaccine space we [redacted] (b) (4)

In the anti-viral areas we are [redacted] (b) (4)

[redacted] (b) (4)

.

How are things going w ACTIV.
Any issues to discuss ?

I hope our PFE representatives in ACTIV are helping out well

Pls let me know if there is anything particular to discuss or I can help you with

Best personal regards
Mikael

Sent from my iPhone

On May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E] [redacted] (b) (6) wrote:

Hi Morten,

Thanks for your note. It would be great to have this connection – but let me suggest that you start with David Wholley (cc'd here), as he oversees all four of the ACTIV working groups. Joe is the program lead for the group on preclinical therapeutics/repurposing.

Best, Francis

From: Sogaard, Morten [redacted] (b) (6)>
Sent: Sunday, May 3, 2020 10:46 AM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Dolsten, Mikael [redacted] (b) (6); Prof Trevor M Jones CBE FMedSci [redacted] (b) (6); Sogaard, Morten [redacted] (b) (6)
Subject: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Francis,

I hope you are having a good weekend.

Quick question: Would you be OK if I/we reached out to Joe Menetski, who I understand leads many of the ACTIV efforts. We have come to know Joe very well as a great collaborator on the AMP gene therapy initiative and It would be very easy I think working informally with Joe to look a bit more under the hood and identify/ map opportunities for alignment with the other initiatives.

All the Best,
Morten

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:45:43 +0000
To: Greg Folkers ([redacted] (b) (6));Doepel, Laurie (NIH/NIAID) [E]
Subject: Pitt and INC
Attachments: Commencement Remarks, generic 30-sec for UPitt and UNC SOM, - FINAL - for 5-08-2020 (videos).docx

See attachment with remarks for UPitt and UNC . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:28:33 +0000
To: Greg Folkers [redacted] (b) (6));Doepel, Laurie (NIH/NIAID) [E]
Subject: USUHS
Attachments: Commencement Remarks, USUHS 2-min -FINAL - for 5-16-2020 (Video).docx

See attachment with USUHS remarks . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:21:04 +0000
To: Greg Folkers [redacted] (b) (6));Doepel, Laurie (NIH/NIAID) [E]
Subject: AMA
Attachments: Commencement Remarks, AMA 3-min - FINAL - for May 2020 (Video).docx

See attachment with AMA remarks . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 20:58:32 +0000
To: Doepel, Laurie (NIH/NIAID) [E];Greg Folkers (b) (6))
Subject: UCSF
Attachments: Commencement Remarks, UCSF SOM - FINAL - for May 2020 (Video).docx

Greg/Laurie:

I am attaching the UCSF 3 minute talk. I labeled it as "FINAL" and it is in the OD folder. However, I have left in the tracked changes for you to see what I did. Please accept the changes and then go over it one last time. I like it the way it is and so please no trivial corrections.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 20:11:08 +0000
To: Doepel, Laurie (NIH/NIAID) [E];Greg Folkers ([redacted] (b) (6))
Subject: Holy Cross
Attachments: Commencement Remarks, Holy Cross - FINAL - for 05-22-2020 (video).docx

The Holy Cross video script is in the OD File marked as "FINAL". I have left the tracked changes showing so that you will know what I have done. Please accept the changes and take a final look. I am also attaching for your look.
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 18:34:28 +0000
To: Tromberg, Bruce (NIH/NIBIB) [E];'Sharpless, Ned [redacted] (b) (6))'
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: 2 quick points

Thanks, Bruce.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tromberg, Bruce (NIH/NIBIB) [E] [redacted] (b) (6)>
Sent: Sunday, May 3, 2020 2:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); 'Sharpless, Ned [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: 2 quick points

Hi Tony,
Thanks! Hope you are doing well.
This is basically exactly what we are working to facilitate with our RADx and digital health (app) platform initiatives...greatly expanding testing and creating a digital backbone to provide people with ways to access tests and interpret results. For expanding testing platforms, see https://www.nibib.nih.gov/news-events/newsroom/nih-mobilizes-national-innovation-initiative-covid-19-diagnostics We have >700 applications that have been started in just a few days. For the digital health (e.g. app) platform we've put a lot of thought into the design and are hoping a contractor will be able to launch a pilot study of healthcare workers soon. Ned and I plan on issuing additional calls in this area with multiple institutes as stakeholders in the coming weeks.
Best,
Bruce

Bruce J. Tromberg, Ph.D.

Director
National Institute of Biomedical Imaging and Bioengineering
National Institutes of Health
Building 31, Room 1C14
Bethesda, MD 20892-2281
[redacted] (b) (6)
301-480-0679 - FAX
[redacted] (b) (6)
http://www.nibib.nih.gov

From: "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)
Date: Sunday, May 3, 2020 at 1:55 PM
To: "'Sharpless, Ned [redacted] (b) (6)
"Tromberg, Bruce (NIH/NIBIB) [E]" [redacted] (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: FW: 2 quick points

Ned/Bruce:

I thought that I would pass this on to you in case you have interest. Thanks.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen [redacted] (b) (6)>
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview [redacted] (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but.....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland ([redacted] (b) (6) As his email says, [redacted] (b) (6) with Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 [redacted] (b) (4) It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out [redacted] (b) (6), and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto [redacted] (b) (6)]
Sent: Thursday, April 30, 2020 6:52 PM
To: [redacted] (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up [redacted] (b) (6) but I'm writing because it might yet bring at least the two of us together.

[redacted] (b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don’t worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:56:39 +0000
To: NIAID OD AM
Subject: RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

????? Who is this person?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)> **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Sunday, May 3, 2020 1:55 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

---

From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Sent: Friday, May 1, 2020 12:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

HI Dr Fauci

I just wanted to follow up on below regarding Avi and The Webby Awards. Would be wonderful if you could be a part of this moment for him.

Thanks so much

Lesley

On Apr 20, 2020, at 1:57 PM, lesley lesleycahillroy.com <lesley@lesleycahillroy.com> wrote:

<6EDD370A-6106-4603-B557-7AAEE9A9EF79.png>

Dear Dr. Fauci,

I hope you and the family are all safe and healthy during these challenging times. Hailed by The New York Times as "the Internet's highest honor," The Webby Awards has been the premiere award for online excellence for over two decades, honoring the companies and people who have critically shaped digital technology and culture.

This year, due to the impact of the coronavirus The Webby Awards are moving their renowned award show to an online experience. On May 19th, 2020, the 24th Annual Webby Awards will bring together Webby Winners from around the world in an Internet Celebration which will showcase the artists, organizations, and creators using their platforms to imagine a better tomorrow through information, education, movement, comedy, all while inspiring audiences to take action to enact positive change.

The 24th Annual Webby Awards are proud to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world. We would be honored if Dr. Fauci would "virtually" present Avi with his award.

As we collectively navigate the severe impact of COVID-19 on the world and late calls for nation-wide social distancing, the Internet has become the lifeblood for people looking for accurate information about the novel coronavirus. Since launching the site on December 29th, Avi Schiffmann's tracking site was a necessary tool that sounded the alarm on the novel coronavirus and its spread, notably calling attention to its severity long before many global officials. By providing over 100 million visitors with real-time data on the virus' spread, Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating a website to provide real-time data about the virus to people everywhere, it is our great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year. The celebration will highlight the important work Avi and his fellow winners are doing, and will mark his hallmark Webby 5-Word acceptance speech in Internet history. Dr. Fauci's presenter speech could be recorded on his phone and we can send you through a script for him to review, edit and details for format and deadline.

This year's Webby Awards will also take action, the impact of COVID-19 and government responses around the world, has brought the importance of voting into sharp focus. The

Webby Awards has partnered with Vote.or and aim to check the voter registration status of 1 million voters in the United States, promoting the importance of voting to help ensure voter turnout this November is the highest it has ever been. This partnership will integrate into all elements of this year's online celebration.

Our thoughts are with all of you in this difficult time.

Best

Lesley Cahill Roy
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:55:14 +0000
To: 'Sharpless, Ned [redacted] (b) (6)';Tromberg, Bruce (NIH/NIBIB) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 2 quick points
Attachments: covid contact tracing.pdf

Ned/Bruce:

I thought that I would pass this on to you in case you have interest. Thanks.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen [redacted] (b) (6)
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview [redacted] (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but.....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland [redacted] (b) (6) As his email says, [redacted] (b) (6) Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 [redacted] (b) (4). It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time

to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out [redacted] (b) (6) and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto [redacted] (b) (6)
Sent: Thursday, April 30, 2020 6:52 PM
To: [redacted] (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up [redacted] (b) (6) but I'm writing because it might yet bring at least the two of us together.

[redacted] (b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:53:55 +0000
To: Eric Ottesen
Subject: RE: 2 quick points

Eric:

Thanks for your note. No problem. I will forward this to people here at NIH who are pursuing such approaches. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen (b) (6)>
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but.....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland (b) (6) [redacted] As his email says, (b) (6) Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 (b) (4) [redacted]. It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) (6), and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto(b) (6)]
Sent: Thursday, April 30, 2020 6:52 PM
To: (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up (b) (6) but I'm writing because it might yet bring at least the two of us together.

(b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201
(b) (6)

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:52:37 +0000
To: NIAID OD AM
Subject: FW: INVITE- American College of Cardiology
Importance: High

From: Kim, Jonathan Ho-Youn [redacted] (b) (6)
Sent: Friday, May 1, 2020 3:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Ryan Meyer [redacted] (b) (6) Robyn Snyder [redacted] (b) (6)
Subject: Re: INVITE- American College of Cardiology
Importance: High

Dr. Fauci- Of course, I appreciate how busy you are, so just reaching out again on behalf of the American College of Cardiology as noted below. We were hopeful we could steal just an hour of your time in June for an important discussion on COVID-19 and exercise training. This is part of a virtual agenda for one of our national conferences (Care of the Athletic Heart) with outreach around the world given this is a part of the ACC educational platform.

We hope this is something you have the bandwidth for, and simply appreciate your consideration. I hope to hear from you and thank you for all your service once again.

My best, Jonathan Kim

Jonathan H. Kim MD, MSc, FACC
Chief of Sports Cardiology
Department of Medicine, Division of Cardiology
Department of Orthopedics
Emory University
Adjunct Assistant Professor
Division of Applied Physiology
Georgia Institute of Technology
Team Cardiologist for Emory Athletics, Georgia Tech Athletics, Atlanta Falcons, Atlanta Hawks, Atlanta Braves, and Atlanta Dream
Office Phone: [redacted] (b) (6)
Research Profile: http://medicine.emory.edu/cardiology/emory-first-faculty-directory/profile.html?f=JKIM10
Email: [redacted] (b) (6)

From: Kim, Jonathan Ho-Youn
Sent: Thursday, April 16, 2020 3:46 PM

To: [redacted] (b) (6)
Cc: Ryan Meyer [redacted] (b) (6)>; Robyn Snyder [redacted] (b) (6)>
Subject: INVITE- American College of Cardiology

Dr. Fauci-

On behalf of the American College of Cardiology (ACC), first I would like to thank you for your tremendous service throughout your incredible career and certainly during these present and challenging times. We are indebted to your service and thankful everyday we have you to help guide public health measures through the COVID-19 pandemic.

I am a member of the Sports and Exercise Council for the ACC and the Course Chair for our annual ACC Care of the Athletic Heart Conference. Originally scheduled June 18-20, 2020 at ACC Heart House in Washington DC. I am also faculty at Emory University and direct our sports cardiology program in Atlanta.

Of course, we have made the difficult decision to cancel our live meeting in June, but myself along with the staff at ACC are working very hard transitioning the course to a virtual course and agenda. This course will be a much shorter version and the agenda will all be pre-recorded and distributed as a 'live simulated version' on June 20, 2020.

With the impact of COVID-19 on all aspects of life and society, in our academic world of sports cardiology, we are dealing with how COVID has impacted exercise and athletes. As you can imagine, there are a multitude of different issues and questions that colleagues are raising.

One new session for our virtual agenda that we think will generate a lot of interest and is of high importance will be a panel discussion on sports, exercise, and COVID-19. We would like to get additional expertise on the panel from the ID/public health and Sports Medicine arenas, in addition to sports cardiology. Of course, there is no one that carries the expertise you do from the ID and public health perspective and we would be extremely honored if you could be a part of this one session and join our faculty for the course.

Before getting into more details and a formal invite from the ACC, I wanted to first see if you had the bandwidth for this. Understanding you are as busy, if not busier, than anyone in the world right now. This session would be pre-recorded and we would certainly work to be flexible with anytime you had for this in early June to record.

I hope this is something that could work- again we would be honored to host you virtually.

Many thanks for considering, and hope to hear from you soon. Best, Jonathan Kim

Jonathan H. Kim MD, MSc, FACC
Chief of Sports Cardiology

Department of Medicine, Division of Cardiology
Department of Orthopedics
Emory University
Adjunct Assistant Professor
Division of Applied Physiology
Georgia Institute of Technology
Team Cardiologist for Emory Athletics, Georgia Tech Athletics, Atlanta Falcons, Atlanta Hawks, Atlanta Braves, and Atlanta Dream
Office Phone: [redacted] (b) (6)
Research Profile: http://medicine.emory.edu/cardiology/emory-first-faculty-directory/profile.html?f=JKIM10
Email: [redacted] (b) (6)

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:50:45 +0000
To: Jon LaPook
Subject: RE: Today's segment on CBS Sunday Morning

Jon:
Terrific piece on ":No time to abandon science"! Keep up this great work. We need to stay on course.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Jon LaPook (b) (6)
Sent: Sunday, May 3, 2020 1:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Today's segment on CBS Sunday Morning

Dear Tony,

I hope (though would not bet my life that) you are getting at least a modicum of down time today.

Here's a link to the segment I told you about. No commercial!

https://www.youtube.com/watch?v=0jCohlBICg0

[http://img.youtube.com/vi/0jCohlBICg0/0.jpg]<https://www.youtube.com/watch?v=0jCohlBICg0>

Dr. Jon LaPook: No time to abandon science - YouTube<https://www.youtube.com/watch?v=0jCohlBICg0>
www.youtube.com
As we reach a point in the COVID-19 pandemic when some states are tempted to open sooner than health experts say they should, Dr. Jon LaPook notes that this ...

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS Evening News Professor of Medicine NYU Langone Health

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:23:12 +0000
To: Paola Dama
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: White House Coronavirus Task Force

Dr. Dama:

Thank you for your note. I am attaching a slide of the members of the USA Task Force and as you can see, Dr. Antonio Giordano is not a member.

Best regards,
A.S. Fauci



White House Coronavirus Task Force – Announced Jan. 29, 2020

Chair: VP Mike Pence
Response Coordinator: Deborah Birx

- Jerome Adams
- Alex Azar
- Stephen Biegun
- Robert Blair
- Ben Carson
- Ken Cuccinelli
- Kelvin Droegemeier
- Anthony Fauci
- Joe Grogan
- Stephen Hahn
- Derek Kan
- Larry Kudlow
- Chris Liddell
- Steven Mnuchin
- Robert O'Brien
- Matthew Pottinger
- Robert Redfield
- Joel Szabat
- Seema Verma
- Robert Wilkie

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paola Dama (b) (6)>
Sent: Sunday, May 3, 2020 10:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: White House Coronavirus Task Force

Dear Dr. Fauci,

I hope to find you well with this email.
I take the liberty to write you because I have some concern about the misinformation
that can discredit your task and honors.
On many occasions in tv and press, Antonio Giordano, Director of Sbarro Institute in Philadelphia,
Keeps saying that he is a member of the USA Task Force.
I'm wondering if it's true.

I work in UK, but I'm originally from Naples (Italy).
I held my PhD in Carlo Croce's lab at OSU and I specialized in immunotherapy at University of Chicago.
Currently I'm a research fellow at University of Sussex.

I apologize if you find this email inopportune, the time is unfortunate, I grant you.
I don't like the idea that some people might take advantage of this very unpleasant moment for all the world.
So I wish that I made a mistake this time.

I'm also wondering if you are willing to release a brief interview.
I stand with you and USA that I miss very much

I really appreciate your time
Thank you
Kind Regards
Ciao ☺

Paola Dama, Ph D
Molecular Oncology and Pharmacology

University of Sussex
School of Life Sciences
John Maynard Smith (JMS) Building
Room 4B13
Falmer, Brighton BN1 9QG

cell. (b) (6) (Italia) / (b) (6) (USA)
(b) (6)

Email: (b) (6)
Skype: (b) (6)
website www.taskforcepandora.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 15:44:23 +0000
To: [redacted] (b) (6)
[redacted]
Subject: Great photo of Mommy and me in this article

https://www.usatoday.com/story/news/nation/2020/05/03/coronavirus-white-house-expert-dr-anthony-fauci-americans-trust/3042991001/

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Sun, 3 May 2020 10:30:04 -0400
To: Collins, Francis (NIH/OD) [E]
Cc: Mascola, John (NIH/VRC) [E];Lane, Cliff (NIH/NIAID) [E];Wholley, David (FNIH) [T];Tabak, Lawrence (NIH/OD) [E];Denny, Joshua (NIH/OD) [E];Gebo, Kelly (NIH/OD) [G];Lowy, Douglas (NIH/NCI) [E];Devaney, Stephanie (NIH/OD) [E];Adam, Stacey (FNIH) [T];Santos, Michael (FNIH) [T];Freire, Maria (FNIH) [T]
Subject: Re: crazy idea

[redacted] (b) (5)

> On May 3, 2020, at 9:47 AM, Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>wrote:
>
> Hi John, Cliff, and Tony,
>
> As we contemplate ways to stand up a master protocol that could enroll 50 – 100K participants in a multi-arm COVID-19 trial this summer, I wondered if [redacted] (b) (5)
>
> See below - [redacted] (b) (5). What do you think?
>
> Francis
>
> ---
>
> **From:** Denny, Joshua (NIH/OD) [E] [redacted] (b) (6)>
> **Sent:** Saturday, May 2, 2020 11:22 PM
> **To:** Collins, Francis (NIH/OD) [E] < [redacted] (b) (6)
> **Cc:** Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
> **Subject:** Re: crazy idea
>
> Hi Francis,
>
> This is exciting to hear! Fabulous to hear we may be approaching such a trial. [redacted] (b) (5)

[redacted] (b) (5)

Best,
Josh

Sent from my iPhone

On May 2, 2020, at 8:34 PM, Collins, Francis (NIH/OD) [E]
[redacted] (b) (6)>wrote:

Hi Josh,

Developments over the last week [redacted] (b) (5)

[redacted] (b) (5)

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 12:31:13 +0000
To: Handley, Gray (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: form Jorge Perez IPK Cuba

Thanks.

From: Handley, Gray (NIH/NIAID) [E] (b) (6)
Sent: Saturday, May 2, 2020 11:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: form Jorge Perez IPK Cuba

Will send a reply tomorrow morning.

I have spoken to State Department and have approved response. Someone will listen in.

Will copy you.

Gray

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, May 2, 2020 3:18 PM
To: Handley, Gray (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FW: form Jorge Perez IPK Cuba

Gray:
Would you please handle this.
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any

other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Pérez Avila, Jorge <[redacted] (b) (6)
Sent: Friday, May 1, 2020 12:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: form Jorge Perez IPK Cuba

Dear Dr. Fauci

Hello from Cuba.

Have been a long time we haven't been in touch.

Now the whole world is facing a new epidemic and in Cuba we are working in order to controling. We will like to re-new our contact regarding this disease Covid 19, we prepare a telephone conference in order to exchange ideas to have a better understanding to control the epidemic. This conference will be held from Cuba next tuerday 05/05/2020 at 4:30pm Cuban time. In clouse I am sending the topics. We will like to have you and Dr. Handley in this activity if it is possible to attend this conference. If you are in agreement we will like to know by answering this email and them we will you any other detail.

If you have any other person to contact in order to participate will be helpfull for us.

Waiting for your answer.

Dr. Jorge Perez
IPK
Cuba

Preliminary program

Objectives:

- Updating COVID-19 situation at global, regional and mainly in Cuba and USA
- To sharing data of how our two countries are facing this emergency including research studies, etc

Topics for the discussion:

- The main strategies that both countries are developing to face COVID-19.
- Diagnostic strategy
- Clinical management in adults and children
- Innovative Cuban biotechnology products incorporated into the treatment models used in the different stages of treatment
- Some other research studies
- Discussion

Events and courses at the following address:
http://instituciones.sld.cu/ipk/

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 20:17:31 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE:

Thanks

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, May 2, 2020 4:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: RE:

Hi,

I already reached out to Dr. Bolognesi and some of us in Program have a call scheduled with him to discuss this proposal.
I will let you know the outcome.
Kind regards,
Cristina

From: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>
Sent: Saturday, May 2, 2020 3:39 PM
To: Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] < [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E]
[redacted] (b) (6)
Subject: RE:
Importance: High

Cristina:

It would be a good idea for you to show this to a couple of other NIAID people for their opinion, and then out of courtesy to get back to Dr. Bolognesi one way or another.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Thursday, April 30, 2020 11:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE:

Dear Dr. Fauci,

I reviewed this proposal [redacted] (b) (5)

[redacted] (b) (5), (b) (4)

[redacted] (b) (5), (b) (4)

[redacted] (b) (5) informative to discuss the project directly with them. Would you like for me to put together a small group at NIAID (with reps from DMID and DAIDS) to talk with Dr. Bolognesi and his colleagues?

Kind regards,

Cristina

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, April 30, 2020 7:58 PM
To: Cassetti, Cristina (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Erbelding, Emily (NIH/NIAID) [E] < [redacted] (b) (6)>
Subject: FW:
Importance: High

Cristina:

Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.
Thanks,
Tony

From: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)> **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Dani Bolognesi, Ph.D. [redacted] (b) (6)
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C]
< [redacted] (b) (6)
Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:

(b) (4), (b) (5)

[redacted]

We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani
[redacted] (b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." [redacted] (b) (6)
Date: Monday, April 27, 2020 at 2:53 PM
To: "Matthias Gromeier, M.D." [redacted] (b) (6)>
Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:

(b) (4), (b) (5)
[redacted]

(b) (4), (b) (5)

[redacted]

We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 19:08:58 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2 viral load

Please take a look at this and respond if appropriate.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Idonae Lovetrue [redacted] (b) (6)>
Sent: Friday, May 1, 2020 2:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Beigel, John (NIH) [E] [redacted] (b) (6); Booth, Mason (NIH/NIAID) [C] [redacted] (b) (6) Kim, Sonnie (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2 viral load

Dear Dr. Fauci,

I'd like to share with you that the recent clinical trial results on remdesivir have validated our prediction of the remdesivir-specific post-treatment viral rebound in human COVID-19 patients. More details can be found in our official announcement https://bit.ly/RRemdesivir.

This prediction of remdesivir's clinical efficacy on viral load made on Feb. 23 2020 [redacted] (b) (4)

[redacted] (b) (4)

(b) (4)

[redacted]

We appreciate and respect all the efforts your have made towards the COVID-19 pandemic.

Best regards,
Idonae

Idonae Lovetrue | CEO, Demiurge Technologies AG, Switzerland

www.demiurge.technology

--

This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto. This email is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. While some information used on this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge Technologies AG neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use.Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 19:00:06 +0000
To: Fetalvo, Ninio J. EOP/OVP
Subject: RE: Back to CMS

Ninio:

Thanks for all your good work in the White House. Stay safe and well.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fetalvo, Ninio J. EOP/OVP (b) (6)
Sent: Friday, May 1, 2020 3:12 PM
To: (b) (6); Fetalvo, Ninio (CMS/OC) (b) (6)
Subject: Back to CMS

All,

Today is my last day on detail to the Office of the Vice President. I am heading back to CMS to continue supporting the Trump Administration's response to the coronavirus. It has been an incredible honor serving the Vice President and the Coronavirus Task Force, and a pleasure working alongside all of you. I look forward to our ongoing work together.

Best,
Ninio

—

Ninio J.H. Fetalvo
Personal: (b) (6) | (b) (6)
CMS: (b) (6) | (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:27:23 +0000
To: Johnson, Martin S. (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E];NIAID OCGR Leg;McGowan, John J. (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E];Rotrosen, Daniel (NIH/NIAID) [E];Crum, Wayne (NIH/NIAID) [E];Harper, Jill (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Doepel, Laurie (NIH/NIAID) [E];Gilles, Sharon (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Law, Kim (NIH/NIAID) [E];Lee, Kun-Lin (NIH/NIAID) [E];Bushar, Nicholas (NIH/NIAID) [E];Schneider, Johanna (NIH/NIAID) [E]
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Thanks, Martin.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johnson, Martin S. (NIH/NIAID) [E] (b) (6)
Sent: Friday, May 1, 2020 7:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] < (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] <wcrum@niaid.nih.gov>; Harper, Jill (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6) Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6)>; Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6)v>;

Schneider, Johanna (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Tony,

YTD spending is $110.8M, increasing $24.1M from last week.

Spending driven by implementation of 3 epidemiological studies, ramp up of resources necessary for vaccine candidate testing and vaccine candidate development.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, April 24, 2020 7:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Rotrosen, Daniel (NIH/NIAID) [E] <[redacted] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] [redacted] (b) (6); Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Law, Kim (NIH/NIAID) [E] [redacted] (b) (6)>; Lee, Kun-Lin (NIH/NIAID) [E] <[redacted] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] [redacted] (b) (6)>; Schneider, Johanna (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Tony,

YTD spending is $86.7M, an increase of $8.3M from last week.

Spending driven by foundational research including the characterization of factors associated with severe disease, transmission dynamics, structural analysis of SARS-CoV-2 proteins. Small awards to support vaccine and therapeutic discovery.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, April 17, 2020 6:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] <[redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Rotrosen, Daniel

(NIH/NIAID) [E] [redacted] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] [redacted] (b) (6)>;
Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E]
< [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Marston,
Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E]
[redacted] (b) (6); Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6); Gilles, Sharon
(NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6); Law, Kim (NIH/NIAID) [E] [redacted] (b) (6)>;
Lee, Kun-Lin (NIH/NIAID) [E] < [redacted] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E]
[redacted] (b) (6)>; Schneider, Johanna (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/17/20

Tony,

YTD spending is $78.4M, an increase of $10.9M from last week including costs to evaluate therapeutics in humans and NHPs, manufacture of a protype virus-like vaccine candidate developed by Taubenberger/Memoli, and spending to accelerate discovery of new therapeutics , vaccines and diagnostics.

[redacted] (b) (5)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, April 10, 2020 8:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] [redacted] (b) (6); Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Rotrosen, Daniel (NIH/NIAID) [E] <[redacted] (b) (6); Crum, Wayne (NIH/NIAID) [E] [redacted] (b) (6); Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] [redacted] (b) (6); Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6) Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Law, Kim (NIH/NIAID) [E] [redacted] (b) (6)>; Lee, Kun-Lin (NIH/NIAID) [E] [redacted] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] [redacted] (b) (6); Schneider, Johanna (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/10/20

Tony,

YTD spending is $67.5M, unchanged* from last week. A summary is attached.

I have also attached an updated budget plan reflecting our projected spending by research category by fiscal year. We are updating this weekly as we receive updates from the divisions on the timing of clinical trials, observational studies, natural history studies and research resource needs.

We will report mid-week on our YTD spending which will be in sync with the data the Dept. extracts.

Martin

- The reason that we have reported no weekly increase is to match our reported spending with the financial information that the Department is now extracting from our accounting system. We have always included spending from our regular appropriation, as directed by the Department. Now the guidance from the Dept. has been updated to report **only** spending from the supplemental COVID-19 appropriations.

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, April 3, 2020 8:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E]

[redacted] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <[redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Rotrosen, Daniel (NIH/NIAID) [E] <[redacted] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] [redacted] (b) (6) Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Law, Kim (NIH/NIAID) [E] [redacted] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] [redacted] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] [redacted] (b) (6); Schneider, Johanna (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/3/20

Tony,

YTD spending is $67.5M , a weekly increase of $45.9M mostly for initial funding for set-up of clinical trials for evaluation of remdesivir in patients with early disease stage and a placebo-controlled clinical trial of intravenous hyperimmune immunoglobulin (IVIG) in patients with COVID-19.

I've provided a summary spending plan the team worked on and a table for the $1.532B that we have received in supplemental appropriations

- $826M NIAID received 3/5/20 - the Coronavirus Preparedness and Response Supplemental Appropriations Act
- $706M NIAID received 3/25/20 - the Coronavirus Aid, Relief, and. Economic Security (CARES) Act

In the last document I've also included narrative summarizing activities funded by the $249M Other NIH Institutes received in the CARES Act

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 27, 2020 7:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] [redacted] (b) (6)>; Harper, Jill (NIH/NIAID) [E] <[redacted] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] <[redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Rotrosen, Daniel (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Marston,

Hilary (NIH/NIAID) [E] <(b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>; Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/26/20

Tony,

YTD spending is $21.6M , a weekly increase of $4.0M for clinical trial site set-up for therapeutics, further vaccine development, small animal development, and therapeutic development (mAbs) and basic research.

Most of the $50M-$60M we listed last week we expect to be awarded before March 31. In many cases contractors have begun work without the award so as to not stall work.

Early next week I'll provide a summary spending plan for the additional $706M that NIAID received in the supplemental appropriation signed by the President today.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 20, 2020 4:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] <(b) (6); Doepel, Laurie (NIH/NIAID) [E] <(b) (6); Gilles, Sharon (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>; Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6) Schneider, Johanna (NIH/NIAID) [E] (b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/19/20

Tony,

YTD spending is $17.6M , a weekly increase of $3.5M for clinical trial site set-up, therapeutic development (mAbs) and basic research.

[redacted] (b) (5)

We greatly appreciate all your hard work.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 13, 2020 6:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <[redacted] (b) (6)>; Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6); Crum, Wayne (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] <[redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Law, Kim (NIH/NIAID) [E] [redacted] (b) (6)>; Lee, Kun-Lin (NIH/NIAID) [E] [redacted] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] [redacted] (b) (6)>; Schneider, Johanna (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/12/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by $1.5M for a total YTD spending of $14.1M.

The $1.5M increase is for the following:

> $1.0M awarded to set-up clinical sites at Emory and U. Washington Seattle for adaptable RCT of remdesivir.

$0.4M supported data analysis of rhesus animal model and grant to gain understanding of the host pathways that regulate viral gene expression and viral subversion of the host immune system.
$0.1M funded vaccine development at VRC and DIR

[redacted] (b) (5)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 6, 2020 5:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] [redacted] (b) (6)>; Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6)v>; Crum, Wayne (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6); Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6) Gilles, Sharon (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6); Law, Kim (NIH/NIAID) [E] [redacted] (b) (6)>; Lee, Kun-Lin (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/5/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by $0.2M for a total YTD spending of $12.6M.

The $0.2M increase is for vaccine candidate development at NIAID Intramural Labs including RML. Costs are mostly for staffing and overhead and include a preclinical immunogenicity study designed to test the mRNA-1273 nCoV vaccine two-dose schedule in mice. The study will measure the immune response to this vaccine in an animal model in anticipation of clinical test in humans.

[redacted] (b) (5)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, February 28, 2020 11:57 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <[redacted] (b) (6)>; Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6); Crum, Wayne (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Law, Kim (NIH/NIAID) [E] [redacted] (b) (6)>; Lee, Kun-Lin (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 2/27/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by $2.3M for a total YTD spending of $12.4M.

A recap of the $2.3 million spent in the last week is as follows:

- $1.9M to set-up a Phase I trial (45 subjects) of the VRC/Moderna mRNA platform candidate at Kaiser Permanente Washington Health Research Institute (One of the VTEUs)

- $0.3M that supported University of Hong Kong researchers in the development of a RT-PCR test to detect SARSCoV2 from human samples. The group has now shared the tests and relevant reagents with over 30 labs globally to enable diagnosis of COVID-19.
- $0.1M vaccine candidate development at NIAID Intramural Labs

[redacted] (b) (5)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, February 14, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] [redacted] (b) (6)>; Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] <[redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending as of 2/13/20

Dr. Fauci,

Attached is a narrative we are updating weekly for NIAID's COVID-19 response.

The accompanying spreadsheet summarizes the figures and includes a summary of our supplemental request.

We'll provide an update by Thursday of next week.

Martin

Resource Planning and Mission Integration Branch (RPMIB) - NIAID
NIH Bldg. 31 Room 7A47
Tel: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:22:37 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: [redacted] (b) (6)
Subject: RE: RE:

Zeke:

Thanks for your note. [redacted] (b) (6) and I would love to get together with you all for dinner. Let us try to do so within a reasonably soon time frame.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)> **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Saturday, May 2, 2020 7:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: RE:

Email from Zeke Emanuel.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Emanuel, Ezekiel J [redacted] (b) (6)>
Sent: Friday, May 1, 2020 8:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: [redacted] (b) (6)>
Subject: Re: RE:

Tony

You are national--international --treasure. And we are depending upon your sanity and smarts.

We can have you and [redacted] (b) (6) over for dinner on the porch and order in from [redacted] (b) (6) or something. Anytime you are ready.

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy [redacted] (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, May 1, 2020 6:55 PM
To: Emanuel, Ezekiel J < [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: RE: RE:

Zeke:

Thanks for the note. Indeed, we do agree. [redacted] (b) (6)
[redacted] I look forweard tochatting with you some time soon.
Best,
Tony

From: Emanuel, Ezekiel J <[redacted] (b) (6)>
Sent: Thursday, April 30, 2020 6:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: RE:

Sorry for misreading what you said--I think maybe I overintepreted--lots of finance people called and seemed like I was a downer compared to you. But I think we agree.

Are you and [redacted] (b) (6) doing okay?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy [redacted] (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 5:33 PM
To: Emanuel, Ezekiel J [redacted] (b) (6)>
Subject: RE:

Zeke:

I did not "strongly" endorse it. I specifically said that it was not a knockout drug and was only a baby step in the direction of developing more and better drugs. I said that it was important because it proved in a well-powered, randomized, placebo-controlled clinical trial that one can suppress the virus enough to see a clinical effect, as modest as the effect was. I do not think I forced anything.

Happy to chat with you about it.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J (b) (6)>
Sent: Thursday, April 30, 2020 2:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject:

Tony,

I hope you and (b) (6) are doing well. You are doing an amazing job under difficult circumstances. And just know we prefer the "real" Tony to the Brad Pitt version!!!

I am a bit perplexed by your seeming strong endorsement of remdesivir. Was it just a bit forced?

My reading was the data were weak and in normal times for normal disease it is not enough to to approve. And very unlikely to really impact COVID-19 disease pattern--regardless of supply issues.

Stay safe

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy [redacted] (b) (6))

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:00:31 +0000
To: Hurst, Natalie R. EOP/OVP
Subject: RE: Update - White House Coronavirus Task Force Meeting

Thanks, Natalie!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 17:57:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Greetings from India

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Prof. Chirantan Chatterjee <(b) (6)>
Sent: Saturday, May 2, 2020 11:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Deepak Bhatt Manager - Communications (b) (6)
Subject: Greetings from India

Dear Dr Fauci,

My greetings from India. I am a health economist and management professor at the Indian Institute of Management, Ahmedabad, India's premier management school. Also, i am a avid fan of your work even from pre-covid19 days.

I write to you requesting some time if possible to do a podcast of 45 minutes with you over zoom. The science and policy ecosystem in India i think would immensely benefit if you can offer your thoughts on what should be India's 12-month strategy going forward for COVID-19.

We have done some recent podcasts relatedly and they are listed her (https://m.soundcloud.com/healthcastbycmhs/).

If you agree, and we are flexible all of May, my communication head Mr. Deepak marked in the email will arrange the zoom logistics and make it as seamless as possible for you.

We will also go per your time zone conveniences and do this over webex/hangout/skype or phone call if that helps.

It would be a delight Dr. Fauci if you can join us in the conversation, looking forward to hearing from you. Our respectful namaste 🙏 from India for all the brave work you are doing.

My best, Chirantan

--

Chirantan Chatterjee (PhD, Carnegie Mellon) || Associate Professor (Economics & Business Policy) & ICICI Bank Chair in Strategic Management || Chairperson, Center for Management of Health Services at IIMA || 2019-2020 Visiting Fellow, 2018-2019 Campbell & Edward Teller National Fellow, Hoover Institution, Stanford University || Office Address: Wing 15F, Indian Institute of Management || Ahmedabad, 380 015 Gujarat, India || Skype: (b) (6) || Email: (b) (6) or (b) (6) || Hoover Institution Website | IIMA Official Website

----

What is laid down, ordered, factual is never enough to embrace the whole truth: life always spills over the rim of every cup. - Boris Pasternak in Bridges to Infinity : The Human Side of Mathematics (1983) by Michael Guillen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 12:08:00 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Haskins, Melinda (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Congresswoman Sheila Jackson Lee invites your participation in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT
Attachments: Dr. Anthony Fauci - Town Hall Invite.pdf

Please take a look at this. We obviously will have to get clearance through HHS and White House Leg. This is for Thursday and so we would need to submit soon.

From: Coney, Lillie [redacted] (b) (6)>
Sent: Friday, May 1, 2020 11:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Rushing, Glenn [redacted] (b) (6); Coney, Lillie [redacted] (b) (6)
Subject: Congresswoman Sheila Jackson Lee invites your participation in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT

May 1, 2020

Dr. Anthony Fauci, M.D.
Director of the National Institute of Allergy and Infectious Diseases
Department of Health and Human Services
5601 Fishers Lane
Bethesda, MD 20892-9806

Dear Dr. Fauci:

Thank you for your tremendous steadfast leadership during this pandemic and health crisis. Our nation has not faced a crisis of this magnitude since the 1918 Spanish Flu, but we will travel this journey together and defeat this virus. In the end, the nation will become stronger and more prepared.

Your participation is requested in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT. This town hall meeting will focus on testing and guidelines for re-opening our nation. It is scheduled to last an hour with 2 or 3 guests including yourself. Houston is the fourth largest city in the country and your knowledge and expertise would be most helpful in our fight to keep our infection and fatality rates low for this entire region and the State of Texas.

My office has been pushing testing and setting up testing sites since the first notification of the coronavirus. We currently have seven active testing sites and expanding each week to get to the mass testing necessary to flatten the infection rate.

Thank you for your consideration of this request and I look forward to participating with you in the Virtual Town Hall meeting. Again, thank you for your leadership. Please RSVP or if you have questions regarding this request with Glenn Rushing, my Chief of Staff at [redacted] (b) (6) and Lillie Coney, my Chief Policy Advisor at [redacted] (b) (6).

Very truly yours,

J

Sheila Jackson Lee
Member of Congress

Regards,
Lillie Coney
Policy Director
Congresswoman Sheila Jackson Lee (TX-18)
2079 Rayburn HOB
Washington, DC 20515
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 12:01:04 +0000
To: (b) (6)
Subject: FW: RE:

Let us try to do this next weekend.

From: Eisinger, Robert (NIH/NIAID) [E] [redacted] **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Saturday, May 2, 2020 7:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: RE:

Email from Zeke Emanuel.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Emanuel, Ezekiel J (b) (6)>
Sent: Friday, May 1, 2020 8:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: (b) (6)>
Subject: Re: RE:

Tony

You are national--international --treasure. And we are depending upon your sanity and smarts.

We can have you and (b) (6) over for dinner on the porch and order in from (b) (6) or something. Anytime you are ready.

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy [redacted] (b) (6))

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)v>
Sent: Friday, May 1, 2020 6:55 PM
To: Emanuel, Ezekiel J [redacted] (b) (6)>
Cc: [redacted] (b) (6)>
Subject: RE: RE:

Zeke:

Thanks for the note. Indeed, we do agree. [redacted] (b) (6) [redacted]. I look forweard tochatting with you some time soon.

Best,
Tony

From: Emanuel, Ezekiel J [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 6:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>
Subject: Re: RE:

Sorry for misreading what you said--I think maybe I overintepreted--lots of finance people called and seemed like I was a downer compared to you. But I think we agree.

Are you and [redacted] (b) (6) doing okay?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy [redacted] (b) (6))

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 5:33 PM
To: Emanuel, Ezekiel J [redacted] (b) (6)>
Subject: RE:

Zeke:

I did not "strongly" endorse it. I specifically said that it was not a knockout drug and was only a baby step in the direction of developing more and better drugs. I said that it was important because it proved in a well-powered, randomized, placebo-controlled clinical trial that one can suppress the virus enough to see a clinical effect, as modest as the effect was. I do not think I forced anything.

Happy to chat with you about it.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)

FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J [redacted] (b) (6)
Sent: Thursday, April 30, 2020 2:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject:

Tony,

I hope you and [redacted] (b) (6) are doing well. You are doing an amazing job under difficult circumstances. And just know we prefer the "real" Tony to the Brad Pitt version!!!

I am a bit perplexed by your seeming strong endorsement of remdesivir. Was it just a bit forced?

My reading was the data were weak and in normal times for normal disease it is not enough to to approve. And very unlikely to really impact COVID-19 disease pattern--regardless of supply issues.

Stay safe

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy [redacted] (b) (6))

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 02:04:00 +0000
To: Selgrade, Sara (NIH/NIAID) [E]
Cc: NIAID OCGR Leg;Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Requesting your assistance: Draft NIAID Statement for May 12 Senate HELP Hearing
Attachments: 2020.05.12 NIAID Senate HELP testimony COVID 19 - with Fauci tracked changes.docx

I am attaching the document with minor tracked edits. Nice job! Thanks.

From: Selgrade, Sara (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 5:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Requesting your assistance: Draft NIAID Statement for May 12 Senate HELP Hearing

Dr. Fauci:

In preparation for the upcoming May 12th COVID-19 hearing of the Senate Health, Education, Labor, and Pensions Committee (Chair: Sen. Lamar Alexander, R-TN), we have drafted the attached NIAID testimony, building on your prior testimony on COVID-19. Drs. Giroir, Hahn, and Redfield also have been invited to the hearing.

We expect that your testimony will be included as an insert to an HHS-wide testimony. At the request of NIH OD, we have incorporated into the draft COVID-19 activities across NIH.

The testimony has been reviewed by the Divisions and Drs. Lane, Harper, Marston, and Lerner, as well as Courtney Billet, Greg Folkers, Martin Johnson, and Laurie Doepel.

NIH OLPA has asked to receive your testimony for clearance by tomorrow, if possible.

Thank you for your help.

Sara

Sara Selgrade, Ph.D.
Section Chief for Legislative Activities
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
NIAID/NIH/DHHS
Bldg. 31, Room 7A17, MSC 2520
Bethesda, MD 20892-2520
Phone: (b) (6)
(b) (6)

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 15:28:23 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: clips

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Sent: Friday, May 1, 2020 8:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: RE: clips

Dr. Fauci –

I have requested the full clips from our clipping service. I found the following online in the meantime:

Today Show:
https://www.today.com/video/dr-anthony-fauci-remdesivir-is-a-very-important-first-step-in-fighting-coronavirus-82800197863

CNN Town Hall (clip discussing federal "reopening" guidelines):
https://twitter.com/CNN/status/1256023483638669313

CNN Town Hall (clip discussing vaccines):
https://twitter.com/CNN/status/1256044817093558272

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, May 1, 2020 7:44 AM
To: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: clips

Jen:

Can we please make sure that I get the lips from yesterday from NBC Today Show and CNN Town Hall with Sanjay and Anderson.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:26:55 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: [redacted] (b) (4)

Another email from Andre Kalil.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Kalil, Andre C [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 8:12 PM
To: Beigel, John (NIH) [E] [redacted] (b) (6); Dodd, Lori (NIH/NIAID) [E] [redacted] (b) (6); Davey, Richard (NIH/NIAID) [E] < [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Proschan, Michael (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: [redacted] (b) (4)

[redacted] (b) (4)

Thanks,

Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM
Professor
Department of Internal Medicine
Division of Infectious Diseases
Director, Transplant ID Program
Associate Editor, CMI, Official Journal of ESCMID
Editorial Board, CCM, Official Journal of SCCM
BREAKTHROUGHS FOR LIFE
University of Nebraska Medical Center
985400 Nebraska Medical Center, Omaha, NE 68198-5400
[redacted] (b) (6) | fax 402.559-5581
[redacted] (b) (6)

UNMC | Facebook | Twitter | YouTube | Flickr

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."
Robert Ludlum - The Ambler Warning

From: Beigel, John (NIH) [E] [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 5:25 AM
To: Dodd, Lori (NIH/NIAID) [E] [redacted] (b) (6)>; Kalil, Andre C [redacted] (b) (6)>; Davey, Richard (NIH/NIAID) [E] < [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] < [redacted] (b) (6)>; Proschan, Michael (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: [redacted] (b) (4)

Non-UNMC email

[redacted] (b) (4)

--
John Beigel, M.D.
Associate Director for Clinical Research
Division of Microbiology and Infectious Diseases

National Institute of Allergy and Infectious Diseases (NIAID)
Phone: [redacted] (b) (6)
email: [redacted] (b) (6)

From: Lori Dodd [redacted] (b) (6)>
Date: Thursday, April 30, 2020 at 6:05 AM
To: John Beigel [redacted] (b) (6)>, Andre Kalil [redacted] (b) (6)>, Richard Davey [redacted] (b) (6)>, Cliff Lane < [redacted] (b) (6), Michael Proschan [redacted] (b) (6)>, Hilary Marston [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: RE: [redacted] (b) (4)

Andre-
I like what you wrote, and particularly like the first two sentences.

From: Beigel, John (NIH) [E] [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 5:53 AM
To: Kalil, Andre C [redacted] (b) (6)>; Davey, Richard (NIH/NIAID) [E] < [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Dodd, Lori (NIH/NIAID) [E] < [redacted] (b) (6)>; Proschan, Michael (NIH/NIAID) [E] [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>
Subject: Re: [redacted] (b) (4)

Andre,

[redacted] (b) (4)

We too are open for further edits
John

--
John Beigel, M.D.
Associate Director for Clinical Research
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases (NIAID)
Phone: [redacted] (b) (6)
email: [redacted] (b) (6)

From: Andre Kalil [redacted] (b) (6)>
Date: Thursday, April 30, 2020 at 3:19 AM
To: John Beigel [redacted] (b) (6)>, Richard Davey [redacted] (b) (6)>, Cliff Lane [redacted] (b) (6), Lori Dodd [redacted] (b) (6)>, Michael Proschan [redacted] (b) (6)>, Hilary Marston <[redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: [redacted] (b) (4)

[redacted] (b) (4)

Please let me know your thoughts and suggestions.

Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM

Professor

Department of Internal Medicine

Division of Infectious Diseases

Director, Transplant ID Program

Associate Editor, CMI, Official Journal of ESCMID

Editorial Board, CCM, Official Journal of SCCM

UNMC
BREAKTHROUGHS FOR LIFE.

University of Nebraska Medical Center

985400 Nebraska Medical Center, Omaha, NE 68198-5400

[redacted] (b) (6) | fax 402.559-5581

(b) (6)

UNMC | Facebook [facebook.com] | Twitter [twitter.com] | YouTube [youtube.com] | Flickr [flickr.com]

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."
Robert Ludlum - The Ambler Warning

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:25:50 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Dani Bolognesi, Ph.D. [redacted] (b) (6)
Sent: Thursday, April 30, 2020 8:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE:

TX Tony. Nice touch reminding folks of how AZT propelled the pharmas and great to see things moving with this beast!

Sei un campione!

Dani

From: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Thursday, April 30, 2020 7:58 PM
To: Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW:

Cristina:

Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.
Thanks,
Tony

From: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)> **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM

To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)v>
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Dani Bolognesi, Ph.D. [redacted] (b) (6)>
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>
Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:

[redacted] (b) (4), (b) (5)

[redacted] (b) (4), (b) (5)

We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani
[redacted] (b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." <[redacted] (b) (6)>
Date: Monday, April 27, 2020 at 2:53 PM
To: "Matthias Gromeier, M.D." [redacted] (b) (6)
Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:

(b) (4), (b) (5)

[redacted]

We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:10:09 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: ACTT publication
Importance: High

Another email from Andre Kalil.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Kalil, Andre C (b) (6)>
Sent: Friday, May 1, 2020 2:59 AM
To: Beigel, John (NIH) [E] (b) (6)>; Davey, Richard (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6); Dodd, Lori (NIH/NIAID) [E] (b) (6)>; Proschan, Michael (NIH/NIAID) [E] (b) (6) Marston, Hilary (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: ACTT publication
Importance: High

Not my first choice, but I want to share the invitation email below with you.
Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM
Professor
Department of Internal Medicine
Division of Infectious Diseases
Director, Transplant ID Program
Associate Editor, CMI, Official Journal of ESCMID
Editorial Board, CCM, Official Journal of SCCM
UNMC
BREAKTHROUGHS FOR LIFE.
University of Nebraska Medical Center
985400 Nebraska Medical Center, Omaha, NE 68198-5400
(b) (6) | fax 402.559-5581
(b) (6)

UNMC | Facebook | Twitter | YouTube | Flickr

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."
Robert Ludlum - The Ambler Warning

From: [redacted] (b) (4)
Sent: Thursday, April 30, 2020 1:03 PM
To: Kalil, Andre C [redacted] (b) (6)
Subject: ACTT publication
Importance: High

Non-UNMC email

Dear Dr. Kalil,

[redacted] (b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 11:38:53 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: interview request by Greek newspaper Ethnos

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Γιώργος Σκαφιδάς <gskafidas@ethnos.gr>
Sent: Friday, May 1, 2020 6:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: interview request by Greek newspaper Ethnos

Dear Dr. Fauci,

my name is George Skafidas and I'm a journalist working for the Greek national weekly ETHNOS (www.ethnos.gr).

We would be very much interested in doing an interview with you, to be published in the Sunday edition of the paper, regarding the developments surrounding the COVID-19 pandemic.

Best regards

ΕΘΝΟΣ

George Skafidas

Senior editor, World Affairs

tel: +30 210 6510550

mob: [redacted] (b) (6)

Οι πληροφορίες που περιέχονται σε αυτό το μηνυμα ηλεκτρονικού ταχυδρομείου (e-mail) καθώς και σε τυχόν συνημμένα είναι εμπιστευτικές και προορίζονται για χρήση αποκλειστικά από το συγκεκριμένο παραλήπτη (-ες). Οι πληροφορίες αυτές μπορεί να καλύπτονται από επιχειρησιακό ή άλλο απόρρητο ή άλλους νόμους και δεν επιτρέπεται να ανακοινωθούν σε οποιονδήποτε τρίτο. Σε περίπτωση που δεν είστε ο παραλήπτης του μηνύματος ή το πρόσωπο που είναι αρμόδιο για την παράδοσή του στον παραλήπτη, απαγορεύεται να το ανακοινώσετε, αντιγράψετε, διανείμετε ή διατηρήσετε εν όλων ή εν μέρει.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 11:38:08 +0000
To: [redacted] (b) (6)
Subject: RE: Coronavirus: Covid 19

Ato:

Thank you for you note. We will know soon whether hydroxychloroquine has any beneficial effects as the results of randomized, controlled trials become available. The pathogenesis of COVID-19 is still an open question. You are correct in that there is a more recent tendency to use ventilators only as a very last resort since oxygenation rather than ventilation appears to be key to recovery.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: gabriel stephens [redacted] (b) (6)
Sent: Friday, May 1, 2020 4:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Coronavirus: Covid 19

Hi Dr Fauci,

Please find an audio attached of a doctor describing the experience with regards to covid 19 in the hospital. She seems to suggest covid 19 is a virus that rather attacks the blood cell, leading to respiratory and other organ complications, hence they need to loom at treatment in a different light. In the UK some hospitals have moved away from using ventilators due to the high death rate of those on ventilators, and are rather using ventilators for sleep apnea, as they are less invasive, and the results are much much better compared to invasive ventilators

There are some anecdotal observations I have also made. The infection rate in most African countries seem to be comparatively low, which could possibly due to the rate of testing being conducted. However the death rates are also comparatively very low. From initial information with regards to

hydroxychloroquine and some antimalaria drugs usage, it was suggested that those who were alleged to have had some benefits had mild symptoms of covid 19. I know some clinical trials have shown hydroxychloroquine not to be effective in the treatment of covid 19 in very ill patients. However, my hypothesis is, are the low death rates in Africa linked to the fact that malaria is very prevelant in Africa, and lots of Africans take antimalarial drugs, making them less susceptible to covid 19, hence the low death rate. Is there a similar trend in other countries where malaria is prevalent? Is there an unintended benefit of taking antimalarial drug (or other medication) before covid infection, or at the onset, making people less susceptible to covid19.
As I said, this is based on anecdotal observations.

Yours sincerely
Ato Stephens

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 23:58:07 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Erbelding, Emily (NIH/NIAID) [E]
Bcc: Dani Bolognesi, Ph.D.
Subject: FW:
Attachments: Brown et al submitted.pdf, NIH Presentation final.pptx, preprints202002.0147.v2 (1).pdf, Mosaheb et al 2020.pdf

Cristina:
Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.
Thanks,
Tony

From: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)> **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone [redacted] (b) (6) 9
Email: [redacted] (b) (6)

From: Dani Bolognesi, Ph.D. [redacted] (b) (6)>
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>
Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:

[redacted] (b) (4), (b) (5)

We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

[redacted] (b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." [redacted] (b) (6)>
Date: Monday, April 27, 2020 at 2:53 PM
To: "Matthias Gromeier, M.D." [redacted] (b) (6)>
Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:

(b) (4), (b) (5)

[redacted]

We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:35:34 +0000
To: Jeremy Farrar;Dzau, Victor J.;George GAO
Cc: Richard
(b) (6);Hannon, Emma;Conrad, Patricia (NIH/NIAID) [E];Teresa Miller de Vega; (b) (6);Rebeka Yasmin - CEPI;ben.tinker@cnn.com;Amanda.Sealy@cnn.com;Neel.Khairzada@turner.com;Tia.Miller@turner.com (b) (6) McGinnis, J. Michael;Balatbat, Celynne;Mun, Jenny; (b) (6);Redfield, Robert R. (CDC/OD)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Many thanks for the update. Please continue to keep me informed.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)
Sent: Tuesday, April 28, 2020 10:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Dzau, Victor J. <VDzau@nas.edu>; George GAO (b) (6)>
Cc: Richard Hatchett (b) (6)
(b) (6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Teresa Miller de Vega (b) (6)
(b) (6); Rebeka Yasmin - CEPI (b) (6); ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6)
McGinnis, J. Michael (b) (6)>; (b) (6)>; Mun, Jenny <JMun@nas.edu>; (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Quick update

Update in confidence

European network from this morning:

16 Paris, 2 Geneva, few Madrid last 10 days - nothing like this usually seen even with seasonal KD or TSS
Barcelona have slightly different experience of 6 'Kawasaki' in last 2 weeks - couple now who have large coronary aneurysms, as have one child South London and one in Bristol.
Most UK PICU have 1-2 of these type of cases
Phenotype seems Diarrhoea and abdominal pain, refractory shock then various degrees of heart involvement and inflammation ++ - several have had their normal appendix whipped out
Most negative respiratory and stool PCR for anything, some positive resp PCR COVID - GOSH early case has seroconverted, but had immunoglobulin
We are establishing database UK and Europe and trying to define what the clinician features are and agree investigations.
Notably, none in US reported (just D/W Boston childrens who have been running shared international COVID experience web calls) and none in Rome, unsure about rest of Italy yet
Does seem BAME preponderance -?? immune related or social phenomenon, in terms of deprivation prevalence and ability to isolate

---

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Monday, 27 April 2020 at 12:36
To: Jeremy Farrar <(b) (6)>, Victor Dzau <VDzau@nas.edu>, George Gao (b) (6)>
Cc: Richard Hatchett (b) (6) "Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6), Teresa de Vega <(b) (6) Rebeka Yasmin - CEPI <(b) (6), "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>, (b) (6) "McGinnis, J. Michael" <MMcGinnis@nas.edu>, (b) (6)>, "Mun, Jenny" <JMun@nas.edu>, (b) (6)>, "Redfield, Robert R. (CDC/OD)" (b) (6)>
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Thanks for the heads up. Is there any more detailed description of the precise clinical manifestations? They describe a "multisystem inflammatory state". It is vasculitis or anything more specific? Could be an infectious agent that has nothing to do with SARS-CoV-2 infection even though some children are circumstantially infected with SARS-CoV-2or it could be a post-SARS-CoV-2 inflammatory syndrome, perhaps a Kawasaki syndrome-like disease. Please keep me informed if you hear any further information.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)>
Sent: Monday, April 27, 2020 7:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Dzau, Victor J. <VDzau@nas.edu>; George GAO (b) (6)>
Cc: Richard Hatchett (b) (6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Teresa Miller de Vega <(b) (6); (b) (6); Rebeka Yasmin - CEPI (b) (6)t>; ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6) McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6)>; Mun, Jenny <JMun@nas.edu>; (b) (6)
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

To be aware of – news over night so a huge amount of uncertainty – important for COVID19 now, and a potential concern for how we view immunity, protection, post-infectious immunopathology.

https://www.hsj.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-emerging-in-children/7027496.article

https://t.co/Bj6YHLJ8zi

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
Date: Sunday, 26 April 2020 at 19:52
To: Victor Dzau <VDzau@nas.edu>, George Gao < [redacted] (b) (6)
Cc: Jeremy Farrar < [redacted] (b) (6)>, Richard Hatchett [redacted] (b) (6) [redacted] (b) (6) [redacted] "Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, Teresa de Vega [redacted] (b) (6)>, Rebeka Yasmin - CEPI [redacted] (b) (6) "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>, [redacted] (b) (6) "McGinnis, J. Michael" <MMcGinnis@nas.edu>, [redacted] (b) (6) "Mun, Jenny" <JMun@nas.edu>, [redacted] (b) (6)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

It was a real pleasure to join all of you on this important session. Many thanks for inviting me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Saturday, April 25, 2020 3:59 PM

To: George GAO (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) [redacted] Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6) (b) (6); rebeka.yasmin@cepi.net; ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6) McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6)>; Mun, Jenny (b) (6)>; haja.bally@cepi.net
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan and Richard,
Thank you so much for your superb contributions. It was a spectacular session- a truly inspiring one. I am grateful to all of you.
Hope to see you soon.
Warmest regards,
Victor

> On Apr 25, 2020, at 1:22 PM, George GAO (b) (6) wrote:
>
> I am waiting for being connected and will use slides which were sent to your office
> George
>
> 发自我的iPhone
>
>> 在 2020年4月24日，01:49，Dzau, Victor J. <VDzau@nas.edu> 写道：
>>
>> Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,
>>
>> I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.
>>
>> I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.
>>
>> I would greatly appreciate it if you would respond to this email.

Best,
Victor

PS, [redacted] (b) (6)t, my special assistant, will be sending you additional information about the session logistics shortly.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Thursday, April 9, 2020 11:01 AM
To: Mun, Jenny <JMun@nas.edu>; [redacted] (b) (6)
(b) (6)
Cc: [redacted] (b) (6) Hannon, Emma <EHannon@nas.edu>; [redacted] (b) (6)
; 'ben.tinker@cnn.com' <ben.tinker@cnn.com>; 'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>; 'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>; 'Tia.Miller@turner.com' <Tia.Miller@turner.com>; '[redacted] (b) (6)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny
Sent: Wednesday, April 8, 2020 10:56 AM
To: (b) (6)
Cc: Dzau, Victor J. ; (b) (6) ; Mun, Jenny ; Hannon, Emma ;
(b) (6)
ben.tinker@cnn.com' ; 'Amanda.Sealy@cnn.com' ; 'Neel.Khairzada@turner.com' ; 'Tia.Miller@turner.com'
Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (https://www.youtube.com/user/theNASciences) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13**.

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT)** to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases
Jeremy Farrar, Director, Wellcome Trust
George F. Gao, Director-General, Chinese Center for Disease Control & Prevention
Sanjay Gupta, Chief Medical Correspondent, CNN
Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations
Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as "sharing your screen" (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

****

Jenny Mun
Membership Director
National Academy of Sciences
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:19:19 +0000
To: Alexander Patterson
Subject: RE: [redacted] (b) (6) made a Video Game of Yo: "Fauci's Revenge"

Thanks, Alex! Much appreciated.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alexander Patterson <alex.patterson@beatthebomb.com>
Sent: Thursday, April 30, 2020 11:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Daniel Lahart <dlahart@regis.org>
Subject: [redacted] (b) (6) made a Video Game of Yo: "Fauci's Revenge"

Dear Dr. Fauci -

My name is Alex Patterson and I'm [redacted] (b) (6) I made a video game about you called **Fauci's Revenge**. Link to play: **https://beatthebomb.com/beatthevirus**

We are streaming the Finals of a tournament live tonight at 8 PM EST on Twitch, FB, and YouTube.
Twitch Stream Link (free to watch): https://www.twitch.tv/beatthebomb1000

Also available on:
Facebook: https://www.facebook.com/BeatTheBomb/
YouTube: https://www.youtube.com/channel/UC0yh7vo1knuKuaaCKUssAzA

Please watch the Twitch Stream if you can! Otherwise I will follow up tomorrow with a video!

Media coverage of the Fauci's Revenge in the News:

- NBC New York
  Spectrum NY1 News
  Timeout New York
  News 12 New York
  Bushwick Daily
  Fox 5 Good Day New York

To date we've raised over $6,150 for New York City's Public Health System (NYC Health + Hospitals). We've created limited edition t-shirts (including a Fauci's Revenge one). We've donated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields to Maimonides Medical Center. Men for others!

Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!

Best,
Alex Patterson (b) (6)

--
Alex Patterson
CEO BEAT THE BOMB
www.beatthebomb.com
Follow us on instagram: @beatthebomb
247 Water Street, Suite 106, Brooklyn, 11201
work: 718-643-0200 // cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:18:45 +0000
To: [redacted] (b) (6)
Subject: FW: [redacted] (b) (6) Grad made a Video Game of Yo: "Fauci's Revenge"
Attachments: Fauci's Revenge Game Logo.png

Yikes!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alexander Patterson <alex.patterson@beatthebomb.com>
Sent: Thursday, April 30, 2020 11:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Daniel Lahart <dlahart@regis.org>
Subject: [redacted] (b) (6) made a Video Game of Yo: "Fauci's Revenge"

Dear Dr. Fauci -

My name is Alex Patterson and I'm [redacted] (b) (6) I made a video game about you called **Fauci's Revenge**. Link to play: **https://beatthebomb.com/beatthevirus**

We are streaming the Finals of a tournament live tonight at 8 PM EST on Twitch, FB, and YouTube. Twitch Stream Link (free to watch): https://www.twitch.tv/beatthebomb1000

Also available on:
Facebook: https://www.facebook.com/BeatTheBomb/
YouTube: https://www.youtube.com/channel/UC0yh7vo1knuKuaaCKUssAzA

Please watch the Twitch Stream if you can! Otherwise I will follow up tomorrow with a video!

Media coverage of the Fauci's Revenge in the News:

- NBC New York
  Spectrum NY1 News
  Timeout New York
  News 12 New York
  Bushwick Daily
  Fox 5 Good Day New York

To date we've raised over $6,150 for New York City's Public Health System (NYC Health + Hospitals). We've created limited edition t-shirts (including a Fauci's Revenge one). We've donated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields to Maimonides Medical Center. Men for others!

Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!

Best,
Alex Patterson (b) (6)

--
Alex Patterson
CEO BEAT THE BOMB
www.beatthebomb.com
Follow us on instagram: @beatthebomb
247 Water Street, Suite 106, Brooklyn, 11201
work: 718-643-0200 // cell: (b) (6)


BEAT THE BOMB
PRESENTS
FAUCI'S
REVENGE


BEAT THE BOMB
PRESENTS
FAUCI'S
REVENGE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:14:57 +0000
To: [redacted] (b) (6)
Cc: Tromberg, Bruce (NIH/NIBIB) [E];Sharpless, Norman (NIH/NCI) [E];Birx, Deborah L. EOP/NSC;Redfield, Robert R. (CDC/OD);Collins, Francis (NIH/OD) [E] ([redacted] (b) (6));Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Stanford National Daily Health Survey for COVID - "Open Up America Again"
Attachments: 4.28.20 NDHS Overview Slides-Rusty-Fauci _ 1.pptx

Rod:

Great to hear from you. Thanks very much for sending this. Very impressive! I will forward this to Bruce Tromberg and Ned Sharpless who have been working on COVID-related apts. In addition, I have cc'd Deb Birx (Coordinator of the White House COVID-19 Task Force) as well as CDC Director Bob Redfield and Francis Collins. I hope that all is well with you. Stay well and safe.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Pettigrew, Roderic I
Sent: Thursday, April 30, 2020 4:20 AM
To: Anthony S. Fauci (NIH/NIAID) [redacted] (b) (6)
Subject: Stanford National Daily Health Survey for COVID - "Open Up America Again"

Hi Tony,

Greetings from Houston, where the number of cases peaked ~2 weeks ago , dropped 35 -40% and seemed to have plateaued since. Great to see you on TV and see the nation (including Brad

Pitt☺) get to know the rigorously informed, keenly rationale and consistently clear Tony your colleagues have long known.

[redacted] (b) (4), (b) (5)

Thank you, Tony. Very proud to know you. Kind regards to [redacted] (b) (6).

Rod

Roderic I Pettigrew, PhD, MD
CEO EnHealth | Health Science Center and College of Engineering
Robert A Welch Professor and Executive Dean EnMed | Colleges of Medicine, Engineering and Houston Methodist Hospital
Texas A&M University ALKEK Building|Suite 1103
2121 W Holcombe Blvd | Houston, TX 77030

www.enmed.tamu.edu

Ph: [redacted] (b) (6) | [redacted] (b) (6)
- -
MAKING WHAT IF POSSIBLE | whatif.tamu.edu

From: Hofmann, Lawrence, M.D. < [redacted] (b) (6)
Sent: Tuesday, April 28, 2020 11:19 AM
To: Pettigrew, Roderic I [redacted] (b) (6)
Cc: Pelc, Norbert J [redacted] (b) (6)
Subject: [EXTERNAL]National Daily Health Survey for COVID - "Open Up America Again"

[redacted] (b) (4), (b) (5)

Best,
R
Lawrence "Rusty" Hofmann, MD
Professor and Chief, Interventional Radiology
Medical Director, Digital Health Integration
Medical Director, Cardiac and Interventional Services
@rustyhofmannMD
(m) [redacted] (b) (6)
Assistant: [redacted] (b) (6)
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:05:19 +0000
To: Barillas, Carolina (NIH/NIAID) [E]
Cc: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: [redacted] (b) (5)

Carolina:

Thanks for sending this. [redacted] (b) (5)

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barillas, Carolina (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, April 30, 2020 11:25 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [redacted] (b) (5)

Dear Tony,

[redacted] (b) (5)

All the best,
Carolina

(b) (5)

[redacted]

(b) (5)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 21:47:05 +0000
To: [redacted] (b) (6)
Subject: FW: Autopsy data supporting Remdesivir trial
Attachments: [redacted] (b) (4)

Take a look at the Figures in the manuscript. [redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Timothy Schacker [redacted] (b) (6)
Sent: Thursday, April 30, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Autopsy data supporting Remdesivir trial

Tony,

[redacted] (b) (4)

Stay well (please) and thank you for all you are doing!
Tim

Timothy Schacker, M.D.
Vice Dean for Research, Medical School
Director, Program in HIV Medicine
University of Minnesota

Mail:
MMC 250
420 Delaware Street SE
Minneapolis, MN 55455

FedEx/UPS:
Mayo C688
420 Delaware Street SE
Minneapolis, MN 55455

Phone: [redacted] (b) (6)
Fax: 612-626-5599
email: [redacted] (b) (6)

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 14:17:43 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: May the Official Nobel documentary program at Swedish Television get an interview with you Dr Fauci about Covid-19 before May 7th please?

Please get clearance and set it up if possible.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johan Bergendorff <johan.bergendorff@svt.se>
Sent: Thursday, April 30, 2020 9:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: May the Official Nobel documentary program at Swedish Television get an interview with you Dr Fauci about Covid-19 before May 7th please?

Dear Dr. Fauci,

I had the honor to interview you in april 2016 about the zika epidemic at your office for a program for national Swedish radio as their global health correspondent. I hope I may have the honor again now Sir?

I am now working as science correspondent for the national Swedish Television (non commercial public service, half the population as daily viewers) in our official Nobel prize laureaute documentary program "Vetenskapens Värld" (the World of Science) and wonder if you have any chance to give us a 10 minute interview by web video before May 7th please?

I would like to ask you two questions: What is most crucial now to suceed with an covid-19 pandemic exit in the US? How do you find the Swedish strategy against Covid-19 so far (Dr. Mike Ryan praised it yeasterday at the WHO press conference as a model for an exit strategy, what is your view)?

In this one hour program aired on May 11th we will have other prominent scientists as well talking about exit strategies, among others Nobel prize winner prof. Paul Krugman, prof. Bengt Holmström MIT, prof. Angus Deaton Princeton, as well as Prof Gabriel Leung Dean University Hongkong etc.

Here you can see the reports I did from my earlier interview with you about the zika epidemic in 2016 (in Swedish). News report: https://sverigesradio.se/artikel/6420891 20 min documentary: https://sverigesradio.se/avsnitt/712016

One option is that I send you a link for a web video Conference call. Another option is that I call you on the phone and your media department may have the oportunity to record a video of your anseers with HD quality that is better to air.

Please let me know if you are available and when.

Best regards,

Johan Bergendorff
Science correspondent, Swedish Television
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 13:31:50 +0000
To: Julie.Steenhuysen@thomsonreuters.com
Cc: Greg Folkers [redacted] (b) (6)
Subject: FW: Fauci says leak concerns fueled his White House revelation of Gilead drug results

Julie:

You did a good job in reporting our conversation last night. Thanks.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 8:59 AM
To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Fauci says leak concerns fueled his White House revelation of Gilead drug results

Health News
April 30, 2020 / 1:07 AM / Updated 4 hours ago

Fauci says leak concerns fueled his White House revelation of Gilead drug results

Julie Steenhuysen
5 Min Read

CHICAGO (Reuters) - Concerns over leaks compelled the top U.S. infectious disease official to reveal data on Gilead Sciences Inc's experimental drug remdesivir, the first in a scientifically rigorous clinical trial to show benefit in treating COVID-19.

National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci attends a coronavirus response meeting between U.S. President Donald Trump and Louisiana Governor John Bel Edwards in the Oval Office at the White House in Washington, U.S., April 29, 2020. REUTERS/Carlos Barria

The dramatic announcement by Dr Anthony Fauci in the Oval Office on Wednesday prompted concerns among scientists that the Trump administration was raising hopes about a coronavirus treatment before sharing the full data with researchers.

As a cautionary example of inflating the potential value of a therapy, some pointed to President Donald Trump's repeated endorsements of malaria drug hydroxychloroquine as a treatment, with no evidence that it works.

Newer data suggests the malaria treatments may carry significant risks for some sufferers of the respiratory disease caused by the virus.

Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which is running the trial, said he took the first opportunity to get the word out that patients taking a dummy treatment or placebo should be switched to remdesivir in hopes of benefiting from it.

He expressed concern that leaks of partial information would lead to confusion. Since the White House was not planning a daily virus briefing, Fauci said he was invited to release the news at a news conference with Louisiana Gov. John Bel Edwards(D). "It was purely driven by ethical concerns," Fauci told Reuters in a telephone interview.

"I would love to wait to present it at a scientific meeting, but it's just not in the cards when you have a situation where the ethical concern about getting the drug to people on placebo dominates the conversation."

An independent data safety and monitoring board, which had looked at the preliminary results of the NIAID trial, determined it had met its primary goal of reducing hospital stays.

On Tuesday evening, that information was conveyed in a conference call to scientists studying the drug globally.

"There are literally dozens and dozens of investigators around the world," Fauci said. "People were starting to leak it." But he did not give details of where the unreported data was being shared.

Several scientists interviewed by Reuters felt the White House setting seemed inappropriate for the release of highly anticipated government-funded trial data on the Gilead therapy.

They had expected it to be presented simultaneously in a detailed news release, a briefing at a medical meeting or in a scientific journal, allowing researchers to review the data.

Information from various trials of remdesivir has been leaked to media in recent weeks. In a statement on Wednesday, Gilead said the NIAID's much anticipated trial had met its primary goal, but gave no details.

Data in a separate NIAID statement after Fauci spoke detailed preliminary results showing that patients who got the drug had a 31 percent faster time to recovery than those who got a placebo, cutting hospital stays by four days.

The trial also came close to showing the drug helped people survive the disease, but the data fell just short of statistical significance.

"I want to see the full data. I want to understand the statistics. I want to understand the benefit and risk. I want to understand the structure of the study, and all of it," said Dr. Steven Nissen, the chief academic officer at the Cleveland Clinic.

"Am I encouraged from what I've heard? Yes, I'm encouraged. But I want to get a full understanding of what happened here, and not get it via a photo opportunity from the Oval Office."

Data Gilead released on its own trial of remdesivir drew less attention, as it did not compare outcomes between those receiving therapy and those who did not.

Results from a third study in China suggesting remdesivir failed to help COVID-19 patients were released in the British medical journal the Lancet after review by a peer group of scientists.

"That's the only thing I'll hang my hat on, and that was negative," said Dr. Eric Topol, director and founder of the Scripps Research Translational Institute in La Jolla, California.

He was unimpressed by remdesivir's modest benefit.

"It was expected to be a whopping effect," Topol added. "It clearly does not have that."

At the Oval Office news conference, Fauci compared the study findings to AZT, the first drug to show any benefit against HIV, decades ago.

"We know that was an imperfect drug. It was the first step," Fauci said in the interview.

"Similar to AZT, it's (remdesivir) the first baby step towards what hopefully will be a number of better drugs that will come in and be able to treat people with COVID-19."

(This story has been refiled to correct spelling of "clinical" in paragraph one)

Reporting by Julie Steenhuysen; Editing by Michele Gershberg and Clarence Fernandez

Our Standards:The Thomson Reuters Trust Principles.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 10:20:32 +0000
To: STEWART SIMONSON [redacted] (b) (6)
Cc: Masur, Henry (NIH/CC/CCMD) [E];STEWART SIMONSON
Subject: RE: COVID-19 and Haiti

Bill:
[redacted] (b) (6) Work with him. As per our prior conversation and as you know better than anyone, Haiti is struggling and I know that Stewart will do whatever he can to assist you.
Warm regards,'
Tony

From: STEWART SIMONSON [redacted] (b) (6)
Sent: Thursday, April 30, 2020 5:44 AM
To: [redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Masur, Henry (NIH/CC/CCMD) [E] [redacted] (b) (6)>; STEWART SIMONSON [redacted] (b) (6)
Subject: COVID-19 and Haiti

Dear Dr. Pape:

I lead the World Health Organization (WHO) delegation to the United Nations and know of you through Tony Fauci and Henry Masur, [redacted] (b) (6). For nearly 5 years immediately preceding my appointment at WHO,, I was an technical advisor at Hôpital Sacré-Cœur in Milot and remain in close contact with institution. Because of this, PAHO leadership asked me to join their COVID-19 planning discussions related to Haiti. I understand from Henry that you have been appointed by MSPP to coordinate COVID-19 preparedness and response activities. If you have some time available on Friday, it would be good to talk via Zoom or Webex. I can arrange this and would plan to have the PAHO deputy director as well as other PAHO officials on the line. Would you be available Friday afternoon for such a discussion? If not Friday, anytime over the weekend would also likely work on our end.

Thanks so much for considering this.

With best regards,

Stewart Simonson

STEWART SIMONSON
Washington, DC/New York
[redacted] (b) (6) **or**
[redacted] (b) (6)
[redacted] (b) (6)**IS)**
IS)
(Switzerland)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 01:24:46 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Has anyone tried palivizumab (Synagis)

Please respond.

From: Rich May (b) (6)
Sent: Wednesday, April 29, 2020 10:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Has anyone tried palivizumab (Synagis)

Good morning Dr. Fauci,

Has anyone tried palivizumab (Synagis) on any new COVID-19 patients?

Thank you for your time,
Richard May, MD, PhD, D.H.Sc (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 22:42:24 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: NAD repletion for Covid-19

Please take a look and respond if appropriate

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mel Cohen (b) (6)
Sent: Wednesday, April 29, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: NAD repletion for Covid-19
Importance: High

Dear Dr. Fauci,

Recent research has shown that SARS-CoV-2 plays havoc with NAD function within cells.

Coronavirus Infection and PARP Expression Dysregulate the NAD Metabolome: A Potentially Actionable Component of Innate Immunity:
https://www.biorxiv.org/content/10.1101/2020.04.17.047480v3

The Molecular Story of COVID-19; NAD+ Depletion Addresses All Questions in this Infection:
https://www.preprints.org/manuscript/202003.0346/v1

Other research has shown that NAD+ levels decline from aging and obesity, both significant factors in Covid-19 severity. But it has also been demonstrated that NAD levels can be replenished through oral administration of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). NR in particular has had several human studies demonstrating its safety and efficacy, and roughly 50 human studies listed on clinicaltrials.gov for all manner of disorders.

There is at least one anecdotal report of dramatic improvement in a Covid-19 patient after administration of NMN.

NMN shows great promise in case studies of humans with COVID-19:
https://alivebynature.com/nmn-shows-promise-for-treatment-of-covid-19-in-case-studies/?utm_campaign=NMN%20for%20covid%20%28TqFTyz%29&utm_medium=email&utm_source=Main%20List&_ke=eyJrbF9lbWFpbCI6ICJtZWxAZGlzdHJpYnV0ZWwuY2EiLCAia2xfY29tcGFueV9pZCI6ICJSbWROWFoifQ%3D%3D

That article begins with the disclaimer, "*There are no human trials that prove effectiveness of any NAD+ boosting supplements for preventing or curing COVID-19.*"

That is a problem. When I see the resources that have been wasted pursuing hydroxychloroquine, I am saddened to learn that there are no clinical trials of nicotinamide riboside as part of a treatment regimen for Covid-19. Can you do anything about getting such a study done?

Regards,
Mel Cohen

Disclaimer: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 22:01:22 +0000
To: Folkers, Greg (NIH/NIAID) [E];NIAID OD AM
Subject: RE: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEW IN OD

Now FINAL in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Wednesday, April 29, 2020 5:03 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEW IN OD

- **This is a zoom call.**
- **I think you will be able to use slides.**
- **I have put in OD a draft "curtain-raiser" set that you could show to kick things off – or use them as TPs if you prefer.**
- **I will update any epi or other numbers tomorrow night**
- **The "ask" is below**

From: Silverberg, Kristen <KSilverberg@brt.org>
Sent: Tuesday, April 14, 2020 4:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>
Subject: invitation from BRT

Dr. Fauci,

First, thank you for everything you are doing. I have always been grateful for your public service, but feel particularly indebted to you these days.

To add to the debt…Josh and I wanted to see if you would be willing to join a call with Business Roundtable CEOs. We have been doing COVID-19 calls with them every Friday at 1:30pm. Typically, about 100-125 CEOS of large, U.S.-based firms will join. They are all managing and planning for difficult issues around employee and customer safety. They would love to hear from you directly and to ask a few questions. It might also be a good place to deliver any messages you want them to hear.

We completely understand if it isn't doable, of course. If you are able, we would love to host you sometime between 1:30pm-2:30pm this Friday (or any Friday on which your schedule would allow it).

Best,

Kristen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 15:09:44 +0000
To: Anthony Fauci
Subject: FW: Potential slides for Remdesivir presentation
Attachments: Remdesivir bullet slides - FAUCI - FINAL.pptx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, April 29, 2020 11:02 AM
To: Short, Marc T. EOP/OVP [redacted] (b) (6); 'Miller, Katie R. EOP/OVP' [redacted] (b) (6)>
Subject: Potential slides for Remdesivir presentation

Marc/Katie:

Here are 3 slides that I might use in the press briefing. If necessary, I could make the presentation without them, but it might be clearer to have them just in case.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)

FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 14:18:44 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: two things

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, April 29, 2020 9:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Subject: ASF: two things

Talked to FDA. They have written (and cleared with Gilead) a new sentence in place of what we had in there about an EUA. Our release has been updated (attached) with the sentence highlighted below.

ALSO: Bill Hall called me to ask if you had alerted the Secretary to this (so the press release clearance process isn't the way he first learns of it). I told him I wasn't sure. If you haven't done so, perhaps you wish to now?

As part of the U.S. Food and Drug Administration's commitment to expediting the development and availability of potential COVID-19 treatments, the agency has been engaged in sustained and ongoing discussions with Gilead Sciences regarding making remdesivir available to patients as quickly as possible, as appropriate.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 10:45:24 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E]
Subject: RE: please read, Gilead statement

Looks fine. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>
Sent: Wednesday, April 29, 2020 6:43 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Folkers, Greg (NIH/NIAID) [E] <gfolkers@niaid.nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Marston, Hilary (NIH/NIAID) [E] <hilary.marston@nih.gov>; Routh, Jennifer (NIH/NIAID) [E] <jennifer.routh@nih.gov>; Stover, Kathy (NIH/NIAID) [E] <kathy.stover@nih.gov>; Lane, Cliff (NIH/NIAID) [E] <clane@niaid.nih.gov>; Erbelding, Emily (NIH/NIAID) [E] <emily.erbelding@nih.gov>
Subject: ASF: please read, Gilead statement

FYI – this will go out before markets open this morning:

GILEAD SCIENCES STATEMENT ON POSITIVE DATA EMERGING FROM NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES' STUDY OF REMDESIVIR

Foster City, Calif., April 29, 2020 – Gilead Sciences. Inc. (Nasdaq: GILD) is aware of the positive data emerging from the National Institute of Allergy and Infectious Diseases' (NIAID) study of remdesivir. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing.

In addition to the NIAID trial, Gilead expects to share additional remdesivir data from the company's open-label Phase 3 SIMPLE trial in patients with severe COVID-19 disease shortly. This study will provide information on whether a shorter, 5-day duration of therapy may have similar efficacy and safety as the 10-day treatment course evaluated in the NIAID trial and other ongoing trials. Gilead expects data at the end of May from the second SIMPLE study evaluating the 5- and 10-day dosing durations of remdesivir in patients with moderate COVID-19 disease.

Gilead will continue to discuss with regulatory authorities the growing data set regarding remdesivir as a potential treatment for COVID-19.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 03:09:03 +0000
To: Berkowitz, Avrahm J. EOP/WHO
Subject: RE: Jared Kushner Defends Dr. Fauci After Fox News Host Criticises Top Coronavirus Task Force Expert

Thanks, Avi.

-----Original Message-----
From: Berkowitz, Avrahm J. EOP/WHO [redacted] (b) (6)
Sent: Tuesday, April 28, 2020 10:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Jared Kushner Defends Dr. Fauci After Fox News Host Criticises Top Coronavirus Task Force Expert

Just wanted to share an article- all the best!
Avi

https://www.newsweek.com/jared-kushner-defends-dr-fauci-fox-news-host-little-tough-1500339

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 03:08:36 +0000
To: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: SHORTENED NIAID statement NEW NEW - with Fauci edits.docx

See my minor edits. [redacted] (b) (5)

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 28, 2020 10:40 PM
To: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

OK – here's a re-do. [redacted] (b) (5)

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 28, 2020 10:02 PM
To: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)v>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)v>
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

(not sure what happened with spacing). Cliff – I got your suggestion too. I'll blend yours, mine, and Gregs and send a clean new one shortly.

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 28, 2020 10:01 PM
To: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] < [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

I took a crack at a revision as well. We can blend these.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 28, 2020 9:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6); Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] < [redacted] (b) (6); Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] < [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

Here is my suggested edit to the short version.

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 28, 2020 9:21 PM
To: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] < [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2
Importance: High

Thanks for all your work. [redacted] (b) (5) (b) (5) (b) (5). Please change this.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 28, 2020 7:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] < [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2
Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:53:28 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Bullets
Attachments: Rendesivir bullet slides - FAUCI.pptx

I added another bullet.

From: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 28, 2020 9:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Bullets

Graph inserted.

From: Anthony Fauci [redacted] (b) (6)>
Date: Tuesday, April 28, 2020 at 9:47 PM
To: "Lane, Cliff (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: RE: Bullets

I made some minor changes

From: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 28, 2020 9:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Bullets

For comment

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:50:16 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: ACTT 2 NIAID statement CB KS EE HM HCL1 - with minor edits.docx

[redacted] (b) (5) I made some minor edits.

From: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 28, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: DRAFT NIAID statement on remdesivir, ACTT 2

Attached for consideration.

From: Anthony Fauci [redacted] (b) (6)>
Date: Tuesday, April 28, 2020 at 9:21 PM
To: "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)>, "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)>, "Folkers, Greg (NIH/NIAID) [E]" [redacted] (b) (6), "Erbelding, Emily (NIH/NIAID) [E]" [redacted] (b) (6), "Lane, Cliff (NIH/NIAID) [E]" [redacted] (b) (6)>, Hilary Marston [redacted] (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2

Thanks for all your work. [redacted] (b) (5) (b) (5) (b) (5). Please change this.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 28, 2020 7:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2
Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:21:27 +0000
To: Routh, Jennifer (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Greg Folkers (GFOLKERS@niaid.nih.gov);Erbelding, Emily (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: ACTT 2 NIAID statement CB KS EE HM.docx, SHORTENED NIAID statement.docx

Thanks for all your work. However, [redacted] (b) (5) (b) (5) (b) (5). Please change this.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 28, 2020 7:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2
Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 00:56:02 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus info about a program that can help.
Attachments: BCA_id_V1 (wecompress.com).pdf

Please take a look and respond if appropriate

-----Original Message-----
From: Alex Holbus [redacted] (b) (6)
Sent: Tuesday, April 28, 2020 6:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Coronavirus info about a program that can help.

Dear Dr Fauci

It's a pleasure to send you this email my name is Alex Holbus I am from the UK I currently live in Serbia or ex Yugoslavia.
I am a Economist and Humanitarian. I can talk about my Biography but at this time the subject I want to share with you I much more important.

In January 2016 I sent a letter to Mr Trump [redacted] (b) (6) telling him that I was happy that he will bring change to America and the world and that if he needed my expertise that I would help your country and the world. As I have not got any responses from him nor his people I can see that he might not be interested. But as I have been following you over the media and be reading about your carrier as a Doctor I believe you know what your doing and would like to take this opportunity to help you and your country at this time when it's the worst then ever before in the modern world. I have a program that can help with the coronavirus in the way of identifying people and following there movement that can help you collect data faster and more sufficient. The program is based on an app so every one can use it. Countries in Europe are starting to use it by the end of May the Europe Union has made it mandatory that all member states need to use it and the future members like Serbia. So you will see attached a presentation about the program and if you or your country is interested please let me know and I will put you in contact with the company making this program. I did not send this email to you so we make money on people it's to help I just wanted to help. I will be contacting my contacts in the USA from Thursday morning but first I wanted to talk with you and give you the opportunity to see if Mr Trump would interested in this program for your country. If nothing comes back from you anyway my friend and contact in the USA will talk with the white house but I wanted to do it the proper way by talking to you as you are the main medical person in the USA for the coronavirus.

Anyway wish you and your country all the best and that the world will become a better place after this epidemic is over.

It's one life one world one human we are all one on this planet no one is bigger or better the all of us as humanity as one.

Kind regards

Alex Holbus

Director at Real Five Company.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 17:41:52 +0000
To: [redacted] (b) (6)
Subject: RE: worrisome

Yes. Please call to their attention. [redacted] (b) (6) It is merely a nasal swab

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Tuesday, April 28, 2020 10:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: worrisome

From today's Medscape.
https://www.medscape.com/viewarticle/929407?nlid=135287_5653&src=wnl_newsalrt_daily_200427_MSCPEDIT&uac=71367AK&impID=2361940&faf=1

Older adults with COVID-19, the illness caused by the coronavirus, have several "atypical" symptoms, complicating efforts to ensure they get timely and appropriate treatment, according to physicians. COVID-19 is typically signaled by three symptoms: a fever, an insistent cough and shortness of breath. But older adults — the age group most at risk of severe complications or death from this condition — may have none of these characteristics.
Instead, seniors may seem "off" — not acting like themselves — early on after being infected by the coronavirus. They may sleep more than usual or stop eating. They may seem unusually apathetic or confused, losing orientation to their surroundings. They may become dizzy and fall. Sometimes, seniors stop speaking or simply collapse.

[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 17:39:34 +0000
To: Janet Tobias;Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Riding along tomorrow am

OK

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Janet Tobias <janet@ikanamedia.com>
Sent: Tuesday, April 28, 2020 12:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E]
(b) (6)
Subject: Riding along tomorrow am

Hi Tony and Patty:

Would it be ok to do the 6:45 am ride to NIH tomorrow? We would also get there early to do one more paper throw. And last night was great!

Janet

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, April 26, 2020 at 4:30 PM
To: Janet Tobias <janet@ikanamedia.com>
Subject: RE: Quick question

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 15:50:24 +0000
To: NIAID OD AM
Subject: FW: Invitation from the Investment Community
Attachments: Letter of invitation_Dr. Anthony Fauci from UBS Investment Bank (1).pdf

I don't think so.

From: Elizabeth Haenle [redacted] (b) (6)>
Sent: Tuesday, April 28, 2020 11:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Invitation from the Investment Community

Dear Dr. Fauci,

I am the co-founder of SAGE Worldwide, a global speaker and consulting company. I am reaching out on behalf of one of my partners, Robert Karofsky, Co-President of UBS Investment Bank, with an invitation to join the UBS Global response to Covid-19 in a live streaming moderated discussion on May 18. Alternatively your conversation could be pre-recorded to accommodate your busy schedule. At this critically important time in our nation's history, the investment community wants to help our nation fight Covid-19 and use our country's economic engine to find a cure and solutions for Covid-19. They also are thinking through how to help our nation's businesses going forward. Your expertise is important to this conversation.

By way of background, I served in the White House for eight years in the Bush Administration as the Social Secretary to Vice President Cheney. In that capacity, I had the privilege of curating a range of discussions with global thinkers and thought leaders on the world's most pressing topics. At SAGE, we bring that level of excellence to our business partners as we help curate discussions that have an impact on public awareness and investor sentiment, which is particularly important as the U.S. responds to Covid-19.

Additionally, [redacted] (b) (6)

Participants at the UBS Global Healthcare Conference provide critical funding to pharmaceuticals and healthcare research and are the businesses on the frontline of the Covid-19 healthcare response.

Attached please find an invitation from UBS with further details of the event. I welcome the opportunity to hear from you at your earliest convenience, and thank you for your important work and dedication to our country's well being over the course of your distinguished career and service at NIAID.

Warmest regards,
Elizabeth Haenle
Co-Founder, SAGE Worldwide
Phone: [redacted] (b) (6)
Attachment 1

--

Elizabeth Haenle 戴丽翠

Co-founder and President

M: (b) (6)

E: (b) (6)

W: SAGEworldwide.com

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager. This message contains confidential information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this e-mail by mistake and delete this e-mail from your system. If you are not the intended recipient you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 14:46:56 +0000
To: NIAID OD AM
Subject: FW: HIGH SCHOOL MUN CONFERENCE

For discussion

From: Dane Cohn [redacted] (b) (6)>
Sent: Tuesday, April 28, 2020 10:44 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: HIGH SCHOOL MUN CONFERENCE

Dear Dr. Anthony Fauci,

My name is Dane Cohn, and I am an [redacted] (b) (6). I have often listened to your inspiring words on the news and followed your assiduous work to help us through this pandemic. Our school participates in Model UN, an event in which high school students represent various countries in debates on international issues from the past and present. Colorado's final Model UN conference was canceled, so our school ([redacted] (b) (6)) decided to host an online conference for the whole state of Colorado and beyond. Our team would like to formally invite you to give a short address (be it pre-recorded or live online) to the students during our opening ceremony.

We hope that our conference will inspire the youth of our nation and the world to stand up and fight for our future rather than resign their aspirations to lockdown. We host this conference because we see the importance of keeping our academic passions going while staying safe within the confines of our homes. We host this conference because we want to contribute to the fight against COVID-19 — money raised from our conference will go towards buying masks, food, and other resources for those who need it most.

This is why we ask you, a hero during this troubling time, to speak to the students of our conference, who not only include the youth of Colorado, but also the youth of our country and world. Any type of address would be greatly and wholeheartedly appreciated. If your address is pre-recorded, we would appreciate it if we could receive it by May 1st, as our conference is the morning of May 2nd. We believe you can bring true inspiration into our hearts and minds. We know you are very busy, but if it were at all possible to share with us even a short 2-3 minute pre-recorded greeting and message to the students participating in this Model UN conference, it would be truly inspirational. Thank you so much for your time, we hope to hear from you soon.

Most Respectfully,
Dane Cohn and the entire [redacted] (b) (6) Model UN Team

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Tue, 28 Apr 2020 11:25:09 +0000
To:	Haskins, Melinda (NIH/NIAID) [E]
Cc:	Conrad, Patricia (NIH/NIAID) [E]
Subject:	RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

8:30 AM would be good. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 28, 2020 7:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

Let me know when you'd like me to call please.

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 28, 2020 7:04 AM
To: Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

Let us chat by phone this morning

> On Apr 28, 2020, at 5:51 AM, Haskins, Melinda (NIH/NIAID) [E] <[redacted] (b) (6)> wrote:
>
> We do not know if the DeLauro hearing would be remote. The Senate HELP one would be in person with some form of social distancing.

Sent from my iPhone

> On Apr 27, 2020, at 10:36 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
>
> E should make sure that we schedule it at a time of day that does not conflict with the COS visit.
>
> ---
>
> **From:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
> **Sent:** Monday, April 27, 2020 8:20 PM
> **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
> **Subject:** Fwd: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6
>
> This is the day of the VIP visit—whoever it is. VP or COS. Pls advise. And not sure if these are I person or not. I suspect remote right??
>
> Sent from my iPhone
>
> Begin forwarded message:
>
>> **From:** "Haskins, Melinda (NIH/NIAID) [E]"
>> [redacted] (b) (6)
>> **Date**: April 27, 2020 at 8:10:52 PM EDT
>> **To:** "Conrad, Patricia (NIH/NIAID) [E]"
>> [redacted] (b) (6)>
>> **Cc:** NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>, "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)>, "Harper, Jill (NIH/NIAID) [E]" [redacted] (b) (6)
>> **Subject: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6**
>>
>> Patty,
>>
>> See below. Another hearing.
>>
>> Thank you,
>> Melinda
>>
>> Sent from my iPhone
>>
>> Begin forwarded message:
>>
>>> **From:** "Hallett, Adrienne (NIH/OD) [E]"
>>> [redacted] (b) (6)
>>> **Date:** April 27, 2020 at 7:57:36 PM EDT
>>> **To:** "Haskins, Melinda (NIH/NIAID) [E]"

[redacted] (b) (6)>, "Selgrade, Sara (NIH/NIAID) [E]" <[redacted] (b) (6)>, "LaMontagne, Karen (NIH/OD) [E]" [redacted] (b) (6)>, "Higgins, Lauren (NIH/OD) [E]" [redacted] (b) (6)>
Subject: Fwd: LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

Guess they really are coming back.

Begin forwarded message:

> **From:** "Steigleder, Stephen" [redacted] (b) (6) >
> **Date**: April 27, 2020 at 7:41:56 PM EDT
> **To:** "Hallett, Adrienne (NIH/OD) [E]" [redacted] (b) (6)>
> **Subject: LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6**
>
> Hi Adrienne,
>
> I hope you're doing well.
>
> I'm reaching out because Chair DeLauro would like to invite Dr. Fauci to a hearing next Wednesday, May 6, with the House LHHS appropriations subcommittee. The focus of the hearing, not surprisingly, would be COVID-19. Members of the subcommittee would very much like to hear from Dr. Fauci on anything related to COVID-19, but I think the main topics would be:
>
> - Mitigation and Testing; and
> - Progress on vaccines, therapeutics, and diagnostics, as well as necessary preparations to manufacture and disseminate a vaccine once it is ready.

Chair DeLauro is flexible about a starting time for the hearing on Wednesday, so she would be happy to accommodate a time that works for Dr. Fauci's schedule.

Please let me know as soon as possible, so we can plan accordingly.

Thanks so much,

Stephen

……

Stephen Steigleder
House Appropriations Committee
Labor/HHS/Education Subcommittee

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 00:22:50 +0000
To: [redacted] (b) (6)
Subject: FW: Remdesivir--good news
Attachments: 20-0006_DSMB_primary_analysis_report_for_DMID.pdf

---

From: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, April 27, 2020 8:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Remdesivir--good news

Tony,

[redacted] (b) (5)

Emily

Emily Erbelding, M.D., M.P.H.
Director, Division of Microbiology and Infectious Diseases
NIAID/NIH
5601 Fishers Lane
Rockville, MD 20852
Tel: [redacted] (b) (6)

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:56:59 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW:
Attachments: Brown et al submitted.pdf, NIH Presentation final.pptx, preprints202002.0147.v2 (1).pdf, Mosaheb et al 2020.pdf

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Dani Bolognesi, Ph.D. [redacted] (b) (6)>
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:

[redacted] (b) (4), (b) (5)

[redacted] (b) (4), (b) (5)

We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani
[redacted] (b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." [redacted] (b) (6)>
Date: Monday, April 27, 2020 at 2:53 PM
To: "Matthias Gromeier, M.D." [redacted] (b) (6)
Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:

(b) (4), (b) (5)

[redacted]

We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:17:19 +0000
To: Folkers, Greg (NIH/NIAID) [E];NIAID OD AM
Subject: RE: COVID/Transportation Impacts

Ok. Let us discuss forwarding to CDC>

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 6:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: RE: COVID/Transportation Impacts

this seems like CDC issue

They address some of the issues here:

What Rideshare, Taxi, Limo, and other Passenger Drivers-for-Hire Need to Know about COVID-19
https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/rideshare-drivers-for-hire.html

Communication Toolkit for Transportation Partners to Inform Road Travelers Monday, April 27, 2020
https://www.cdc.gov/coronavirus/2019-ncov/travelers/transportation-toolkit.html

Cleaning and Disinfection for Non-emergency Transport Vehicles Tuesday, April 14, 2020
https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/disinfecting-transport-vehicles.html

-----Original Message-----
From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)> On Behalf Of Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:05 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: COVID/Transportation Impacts

-----Original Message-----

From: Anthony Foxx (b) (6)>
Sent: Monday, April 27, 2020 4:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: COVID/Transportation Impacts

Dr. Fauci:

This is Anthony Foxx, immediate former US Transportation Secretary, and I greatly enjoyed our interactions (brief thoughts they were) during my time in the last Administration.

I write to request your help in advising the transportation community about how to manage through the present crisis, particularly as some areas are easing restrictions. I would welcome an opportunity to join you in a Q/A, which could be valuable for rideshare companies (b) (6)), transit agencies, airlines etc. I would think that a 10-15 minute chat would do wonders. That said, I know you are terribly busy and have so many things to do but would appreciate any opportunity to help you get important information out.

This could be pulled together rapidly and done within the next week or so.

Thanks for your attention to this matter. All my best,

Anthony.
Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:00:13 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Update - White House Coronavirus Task Force Meeting - 4.28.20

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

[redacted] (b)(5) - PCP

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:57:57 +0000
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: RE: Covid thrombi

Thanks, Paolo.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lusso, Paolo (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 12:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Kovacs, Joseph (NIH/CC/CCMD) [E] (b) (6) Masur, Henry (NIH/CC/CCMD) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Subject: Re: Covid thrombi

Dear Tony,

I talked with Dr. Viecca this morning who shared additional information about his protocol. They started from the pathological observation that all patients dying of Covid-19 pneumonia had diffuse pulmonary microthrombosis. Since they detected almost exclusively white thrombi, they reasoned that they had to block platelet activation/aggregation, while heparin would be ineffective at that stage. Thus, they treated a first group of five critical patients with potent anti-aggregant therapy (Tirofiban/Aggrastat) and apparently in all of them the pO2 started to rise within less than 2 hours, they got off the ventilators and went on to full recovery. Viecca is an interventional cardiologist (b) (4). I sent copy of his protocol and contact information to Joe.

Let me know if I can be of any further help. All the best,

Paolo

Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of Immunoregulation
Bldg. 10, Rm. 6A11
NIAID, NIH
Bethesda, MD 20892

Phone: (b) (6) (personal)
(b) (6) (lab)
Fax: (301) 480-5291
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

****

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:57:23 +0000
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Cc: Mascola, John (NIH/VRC) [E]
Subject: FW: Revised Slides
Attachments: Vaccine Development Slides Revised Draft 042720.pptx

Pleas respond for both of us. I already cc'd you on an email that I sent to John with a minor comment about slide #2.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marks, Peter [redacted] (b) (6)
Sent: Monday, April 27, 2020 1:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Cc: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Subject: Revised Slides

Dear Francis and Tony,

Apologize that the prior slides were too busy. John conveyed that message. Please see these versions that may be more along the lines that you are looking for. [redacted] (b) (5)

Best Regards,
Peter

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:54:37 +0000
To: Schwetz, Tara (NIH/OD) [E]
Subject: RE: Flagging NIH Media Product for Release Tomorrow

You could play the role in the movie of my medical school girl friend, which would give you the possibility of working with Brad Pitt ☺

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schwetz, Tara (NIH/OD) [E] (b) (6)
Sent: Monday, April 27, 2020 5:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Flagging NIH Media Product for Release Tomorrow

Now, you also have the answer to who would play you in a movie! ☺

Tara A. Schwetz, PhD
Acting Director, NINR
Associate Deputy Director, NIH
A: Building 1, Room 138
P: (b) (6) | **M:** (b) (6)

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Monday, April 27, 2020 at 5:46 PM
To: Tara Schwetz (b) (6)
Subject: RE: Flagging NIH Media Product for Release Tomorrow

Thanks, Tara. Pitt was amazing. One reviewer of the SNL show said that Pitt looked “exactly like me”. That statement made my year. ☺

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schwetz, Tara (NIH/OD) [E] [redacted] (b) (6)>
Sent: Monday, April 27, 2020 5:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6) Myles, Renate (NIH/OD) [E] [redacted] (b) (6); Walsh, Elizabeth (NIH/OD) [E] [redacted] (b) (6)
Subject: Flagging NIH Media Product for Release Tomorrow

Tony,

Please see below and attached a time-sensitive COVID-19 item for your awareness and sharing with the remainder of the Task Force, as appropriate. The plan is to release this tomorrow.

Item 1: Title: Rapid Acceleration of Diagnostics (RADx) Initiative

Activity Type: Funding of new research program
Summary: With a [redacted] (b) (5) investment from federal stimulus funding, RADx initiative will infuse funding into early innovation technologies to speed development of rapid and widely accessible COVID-19 testing. At the same time, NIH will seek opportunities to move more advanced diagnostic technologies swiftly through the development pipeline toward commercialization and broad availability. As part of the initiative, NIH is urging scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to $500 million over all phases for further development. The goal is to add tens of millions per month of accurate and easy-to-use tests to all Americans by Fall 2020.
Impact on COVID-19 Pandemic Response: RADx will accelerate the development, validation, and commercialization of innovative new testing methods that can be deployed in point-of-care and home settings. These technologies are urgently needed to guide and inform safe return to work, school, and life activities.

Office: National Institute of Biomedical Imaging and Bioengineering
Action Date: Solicitation announcement April 28, 2020
Type of Action: Research Program Award
Potential for Press Coverage: Mainstream Press
Press Release in Development?: Yes

Do let me know if you have any questions.

(Also, Brad Pitt?! Wow, that was a really nice shout out/thank you.)

Best,

Tara A. Schwetz, PhD
Acting Director, NINR
Associate Deputy Director, NIH
A: Building 1, Room 138
P: (b) (6) | **M:** (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:48:46 +0000
To: Birx, Deborah L. EOP/NSC
Cc: Redd, Stephen (CDC/DDPHSIS/OD);Hahn, Stephen
Subject: Flagging NIH Media Product for Release Tomorrow
Attachments: 2020-04-27_COVID-19WeeklyReport_NIBIB OD_tas.docx

Deb:

As an FYI. This is an initiative from NBIB/NIH on development of POC diagnostics for SARS-CoV-2.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:39:57 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in children

Looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Sent: Monday, April 27, 2020 4:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in children

Hi Dr. Fauci,

Please find attached for your review a draft release about the launch of the Human Epidemiology and Response to SARS-CoV-2 (HEROS) study, which is intended to help determine the percentage of children infected with SARS-CoV-2 and the percentage of infected children who develop COVID. In addition, the study will examine whether rates of SARS-CoV-2 infection differ between children who have asthma or other allergic conditions and children who do not. Your draft quote is as follows:

"One interesting feature of this novel coronavirus pandemic is that very few children have become sick with COVID-19 compared to adults," said NIAID Director Anthony S. Fauci, M.D. "Is this because children are resistant to infection with SARS-CoV-2, or because they are infected but do not develop symptoms? The HEROS study will help us begin to answer these and other key questions."

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: [redacted] (b) (6)
E-mail: [redacted] (b) (6)
NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:04:24 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E];Jean W Pape
Subject: [redacted] (b) (4)
Attachments:

Hugh:

[redacted] (b) (6), (b) (4)

[redacted] Please take care of it.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Monday, April 27, 2020 3:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [redacted] (b) (4)

Tony,

[redacted] (b) (4), (b) (6)

Best,

Bill

JEAN WILLIAM PAPE, MD

Howard and Carol Holtzmann Professor of Clinical Medicine,
Center for Global Health, Division of Infectious Diseases, Department of Medicine,
Weill Cornell Medical College, New York, New York, USA
402 East 67th Street, New York, NY 10065
Tel (Office) [redacted] (b) (6)

Director,
Les Centres GHESKIO,
33, Blvd. Harry Truman, Port-au-Prince, Haïti.
Tel (Office): [redacted] (b) (6)
Voip: [redacted] (b) (6)

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 16:09:04 +0000
To: NIAID OD AM
Subject: FW: The National Organization of Italian Americans in Film & Television (NOIAFT) - Interview Request

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor Taglianetti <taylor@noiaft.org>
Sent: Monday, April 27, 2020 12:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: The National Organization of Italian Americans in Film & Television (NOIAFT) - Interview Request

Dear Dr. Fauci,

I hope this email finds you well. My name is Taylor Taglianetti and I am the founder of the National Organization of Italian Americans in Film & Television (NOIAFT).

Our organization is so very proud of the work you are doing for our country and sends tremendous thanks for the hope and reassurance you have instilled during these trying times.

It would be an honor to conduct a short interview with you. Our organization includes many young Italian Americans breaking into the entertainment industry and with the coronavirus dramatically impacting our field, I'd love to ask you a few questions about what the future of the entertainment business looks like. We'd be happy to send the questions in advance for your approval. If you don't have time for a phone call, the questions can be answered via email at your leisure.

Thank you for your time and consideration.

Sincerely,

Taylor Taglianetti
Founder, *The National Organization of Italian Americans in Film & Television (NOIAFT)*
(347) 686-4968
www.noiaft.org
taylor@noiaft.org

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:19:38 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Media query: CNN, re: ASF's NAS web briefing on Saturday

I was referring only to animal (macaque) models. I never said that it looked good in humans. Human clinical trials are ongoing to answer that question. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, April 27, 2020 9:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: Media query: CNN, re: ASF's NAS web briefing on Saturday

Pls advise

Sent from my iPhone

Begin forwarded message:

> **From:** "Leifman, Laura (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Date:** April 27, 2020 at 9:27:13 AM EDT
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, NIAID FOG <fog@niaid.nih.gov>
> **Cc:** NIAID COGCORE <COGCORE@mail.nih.gov>, NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
> **Subject: Media query: CNN, re: ASF's NAS web briefing on Saturday**
>
> Elizabeth Cohen

CNN
Elizabeth.Cohen@turner.com
Topic: Statement by ASF during Saturday NAS web briefing
Deadline: urgent

Hi Patty,

Elizabeth would like to clarify something that Dr. Fauci apparently said about remdesivir during his NAS web briefing on Saturday. The transcribed segment of the talk that she is focused on says:

"Remdesivir is the one that's gotten the most publicity. It is interesting that if you look at it in a prophylactic therapeutic model in MERS coronavirus infection, it looked pretty good. There was clinical benefits just reported a couple of weeks ago of SARS coronavirus 2 in rhesus macaques."

She wants to clarify what Dr. Fauci meant by looking at remdesivir "in a prophylactic therapeutic model in MERS"—whether this means in an animal model or something else. It sounds like that phrase is referring to the RML study in which remdesivir successfully prevented disease in MERS-infected rhesus macaques, as reported in the Feb. 13 NIAID media availability pasted below. Is that correct?

Best,
Laura

Remdesivir Prevents MERS Coronavirus Disease in Monkeys

Results Support Testing Antiviral Against 2019 Novel Coronavirus

February 13, 2020

The experimental antiviral remdesivir successfully prevented disease in rhesus macaques infected with Middle East respiratory syndrome coronavirus (MERS-CoV), according to a new study from National Institutes of Health scientists. Remdesivir prevented disease when administered before infection and improved the condition of macaques when given after the animals already were infected.

The new report from NIH's National Institute of Allergy and Infectious Diseases (NIAID) appears in the *Proceedings of the National Academy of Sciences*.

MERS-CoV is closely related to the 2019 novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV) that has grown to be a global public health emergency since cases were first detected in Wuhan, China, in December.

Remdesivir has previously protected animals against a variety of viruses in lab experiments. The drug has been shown experimentally to effectively treat monkeys infected with Ebola and Nipah viruses. Remdesivir also has been investigated as a treatment for Ebola virus disease in people.

The current study was conducted at NIAID's Rocky Mountain Laboratories in Hamilton, Montana. The work involved three groups of animals: those treated with remdesivir 24 hours before infection with MERS-CoV; those treated 12 hours after infection (close to the peak time for MERS-CoV replication in these animals); and untreated control animals.

The scientists observed the animals for six days. All control animals showed signs of respiratory disease. Animals treated before infection fared well: no signs of respiratory disease, significantly lower levels of virus replication in the lungs compared to control animals, and no lung damage. Animals treated after infection fared significantly better than the control animals: disease was less severe than in control animals, their lungs had lower levels of virus than the control animals, and the damage to the lungs was less severe.

The scientists indicate that the promising study results support additional clinical trials of remdesivir for MERS-CoV and COVID-19, the disease that SARS-CoV-2 causes. Several clinical trials of remdesivir for COVID-19 are under way in China, and other patients with COVID-19 have received the drug under a compassionate use protocol.

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, also provided support for this study. Gilead Sciences, Inc., developed remdesivir, also known as GS-5734, and collaborated in the research.

MERS-CoV emerged in Saudi Arabia in 2012. Through December 2019, the World Health Organization had confirmed 2,499 MERS-CoV cases and 861 deaths (or about 1 in 3). Because about one-third of MERS-CoV cases spread from infected people being treated in healthcare settings, the scientists suggest that remdesivir could effectively prevent disease in other patients, contacts of patients, and healthcare workers. They also note the drug might help patients who are diagnosed with MERS or COVID-19 if given soon after symptoms start.

ARTICLE:

E de Wit *et al*. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *PNAS* DOI: 10.1073/pnas.1922083117.

WHO:

NIAID Director Anthony S. Fauci, M.D., and Emmie de Wit, Ph.D., a principal investigator in NIAID's Laboratory of Virology, are available to comment on this study.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:11:59 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus Antigen Microarray

Please take a look and handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Anderson, Cassandra (NIH/NIDDK) [E] [redacted] (b) (6)>
Sent: Monday, April 27, 2020 8:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Coronavirus Antigen Microarray

Good morning Dr. Fauci,

I work in NIDDK in bldg. 50 in the Laboratory Endocrinology and Receptor Biology.

Thank you for all the information you have provided to our nation. I also want to say you are doing a terrific job in handling the COVID-19 virus, without you and your staff I don't know where our country would be.

I received the email below this morning from Jiang Yufei from Sino Biological. Not sure why I was sent this email, but I thought of you and your staff. Please see the email below.

Thank you again for all that you are doing to help keep us safe!

Stay safe!

Cassandra Anderson
Administrative Professional
Bldg. 50 Room 4133
301-402-7845

From: Yufei Jiang <yufei.jiang@sinobiological.info>
Sent: Monday, April 27, 2020 8:04 AM
To: Anderson, Cassandra (NIH/NIDDK) [E] (b) (6)>
Subject: Coronavirus Antigen Microarray

Hi Cassandra,

Happy Day! I am excited to let you know that Sino Biological just released Coronavirus antigen Microarray (CoVAM) which belongs to our Sinommune™ Multiplex Antigen Microarray product line. You may get more details from the following link:

https://www.sinobiological.com/research/virus/coronavirus-array

Currently the standard pre-printed CoVAM array is sold in the unit of slide, 16 arrays/slide. In each array there are 65 antigens related to the viruses that can cause upper respiratory tract infections including the most recent SARS-CoV-2. The list price is $3,200/slide. Please contact me for how to place the order if you are interested or need more information.

So far, this array has mainly been used for two purposes: 1) Sero-surveillance studies of COVID-19 infection, and 2) Evaluating antibody reactivity in animals (monkeys and mice) after vaccination. Please be advised that our array is for research use only (RUO), not for the diagnostic purpose which needs the FDA approval.

After you run the samples on the slide, you may read the slide on the following compatible machines:

https://www.innopsys.com/en/lifesciences-products/microarrays/innoscan

https://www.moleculardevices.com/products/additional-products/genepix-microarray-systems-scanners#gref

https://www.agilent.com/en/product/cgh-cgh-snp-microarray-platform/cgh-cgh-snp-microarray-scanners-equipment/surescan-microarray-scanner-228493

Thanks.

-Yufei

Yufei Jiang, PhD
Manager, NY, MD, DC, VA
Sales & Business Development
Sino Biological US Inc.
1400 Liberty Ridge Dr., Suite 101
Wayne, PA 19087
Cell: (b) (6)
Email: yufei_jiang@sinobiological.com
www.sinobiological.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:11:06 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Otto e Mezzo - Italian Show

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Torchia Patrizia <Patrizia.Torchia@la7.it>
Sent: Monday, April 27, 2020 8:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Otto e Mezzo - Italian Show

Dear Mr. Fauci,

I'm Patrizia Torchia, I'm a journalist and I am a member of the team on the Italian show *Otto e Mezzo*, hosted daily by journalist Lilli Gruber on La7 channel.

I'm reaching out to invite you in our show. Mrs. Gruber would be honored to have you, Dr. Fauci explore in more depth the challenges Coronavirus has forced the world to face. Can make this happen?

Below is Lilli Gruber's bio and a brief description of the show.

WHO:

Lilli Gruber is the editor-in-chief and host of Italy's most influential political daily talk show, "Otto e mezzo", airing on prime-time on La7 TV. She's received Italy's most prestigious journalism awards for her work and was the first woman to ever conduct the prime-time News broadcast in Italy (RAI TV, 1987). As a foreign correspondent she covered most of last 30 years' major world events, from the fall of the Berlin wall to 9/11 to the Iraq war. Beside her television work, Ms. Gruber wrote eleven bestseller books including "Eredità", which was top seller for 20 weeks and ran 14 reprints. In 2004, Ms. Gruber won a head-to-head campaign against Silvio Berlusconi by a large margin of votes and was elected to the European Parliament. There, among other appointments, she was the Head of the EU Delegation to the Gulf States and Yemen and a member of the EU Delegation to Iran.

"Otto e mezzo"

Italy's most influential political daily talk show shown on prime-time on La7 TV. Through interviews with elected political figures and candidates for office, commentators, and journalists, the show focuses on international political news and economy with a special focus on Italy and Europe. Beginning in 2008 "*Otto e Mezzo*" became Lilli Gruber's way to keep her commitment to holding those in power accountable by asking questions and touching on topics citizens are curious about. ***Otto e Mezzo*** airs Monday to Saturday from 8:35pm to 9:10pm. Within this time-frame Paolo Pagliaro's news column "Il Punto" stands out for accuracy and thoughtfulness by pulling the thread on the highest rated issues in an agenda. During the current season Otto e Mezzo has become Italy's most watched political talk show reaching an average of 7.3% of share with 2.5 million viewers per day.

Production location(s): La7 studios, via Umberto Novaro 32, Rome, Italy
Presented by: Lilli Gruber
Original network: La7
Executive producers: Stefania Bucciarelli
Directed by: Lorenzo Fontana
www.live.la7.it
www.ottoemezzo.la7.it
Twitter: @OttoemezzoTW)
Facebook: OttoemezzoLa7)

Thank you in advance for the considering. Looking forward to hearing from you.

Patty Torchia
Otto e Mezzo
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:08:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Fauci and PayPal

Not really.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, April 27, 2020 9:54 AM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Fauci and PayPal

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fetalvo, Ninio J. EOP/OVP [redacted] (b) (6)
Sent: Monday, April 27, 2020 9:51 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Fauci and PayPal

FYI—Defer to you on this.

From: Miller, Amanda <amanmiller@paypal.com>
Sent: Monday, April 27, 2020 9:18 AM
To: Fetalvo, Ninio J. EOP/OVP [redacted] (b) (6)
Cc: Walters, Lindsay <Lindsay.Walters@edelman.com>
Subject: [EXTERNAL] Re: Fauci and PayPal

Hi Ninio,

We are wondering if Dr. Fauci would like to have a taped Skype conversation with PayPal CEO and President Dan Schulman to talk about safety measures, health and science tied to COVID-19. We would air the conversation during a global employee all hands to our 23,000 employees and then we could syndicate parts of it externally on our social channels.

Thanks for any help in reaching Fauci's team.

Thanks,
Amanda

Amanda Christine Miller
Senior Director, Corporate Communications
408.219.0563
@PayPalNews
PayPal

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:07:40 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: [redacted] (b) (4)

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, April 27, 2020 10:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: [redacted] (b) (4)

I will make sure they get a response!

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
Date: Sunday, April 26, 2020 at 8:43 PM
To: "Lerner, Andrea (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: FW: Update: [redacted] (b) (4)

Please respond to this person. Thanks.

From: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Sent: Wednesday, April 22, 2020 9:41 AM
To: Coomes, Stephanie (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: [redacted] (b) (6); Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Subject: Update: [redacted] (b) (4)
Importance: High

Dear Dr. Fauci,
dear Dr. Coomes,

thank you for your reply from 13. April with the notice that the information has been shared with NIAID's COVID-19 research team.

Has the project already been initially evaluated by the team?

Are there any questions or need for additional information?

(b) (4)

[redacted]

Looking forward to hearing from you.

Kind regards,

Ralf

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis
Director R&D
Research & Development

Mail: RKircheis@syntacoll.de
Phone: +49 9441 686048

syntacoll

Syntacoll GmbH, Donaustrasse 24, D-93342 Saal a. d. Donau
Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 1612
USt-IdNr. DE 128580796

Geschäftsführerin: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter
www.syntacoll.de/datenschutz

Von: Coomes, Stephanie (NIH/NIAID) [E] [redacted] (b) (6)]
Gesendet: Montag, 13. April 2020 02:37
An: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Betreff: RE: [redacted] (b) (4), (b) (5)

Dear Dr. Kircheis,

Thank you for your recent email to Dr. Anthony Fauci. Your message was forwarded to the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID). As a member of DMID's Office of Scientific Coordination and Program Operations, I am pleased to respond.

I want to thank you for reaching out to share this information and let you know that your message has been shared with NIAID's COVID-19 research team.

Sincerely,
Stephanie

Stephanie M. Coomes, Ph.D.
Health Scientist Administrator
Office of Scientific Coordination and Program Operations
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Room 7G68
Rockville, MD 20892
[redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this email and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the originally intended recipient. If you have received this email in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Kircheis Dr. Ralf <[redacted] (b) (6)>
Sent: Wednesday, April 8, 2020 2:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>
Cc: Fischer, Elizabeth (NIH/NIAID) [E] [redacted] (b) (6)>; Foster, Erin (NIH/NIAID) [E] [redacted] (b) (6) Foster, Sarah (NIH/NIAID) [E] [redacted] (b) (6)>; Vasilenko, Olga (NIH/NIAID) [E] [redacted] (b) (6)>; Vasquez, Aurelio (NIH/NIAID) [E] [redacted] (b) (6)>; Vostal, Alexander (NIH/VRC) [F] [redacted] (b) (6)>; Vazquez-Maldonado, Nancy (NIH/NIAID) [E] [redacted] (b) (6)>; Austin, James (NIH/NIAID) [E] [redacted] (b) (6)>; Agulto, Liane (NIH/NIAID) [E] [redacted] (b) (6); Deckhut, Alison (NIH/NIAID) [E] [redacted] (b) (6) Kircheis Dr. Ralf <RKircheis@syntacoll.de>

Subject: WG: [redacted] (b) (4), (b) (5)
Importance: High

[redacted] (b) (4), (b) (5)

Dear Dr. Fauci,
dear Madams/Sirs,
I want to bring to your attension some potentially important experimental data and a new proposal for treatment of COVID-19 patients with acute respiratory distress syndrome and organ failure. Sorry for the broad distribution but I wanted to make sure that my message reaches you.

[redacted] (b) (4), (b) (5)

[redacted] (b) (4), (b) (5)

Please forward this mail to the colleages you consider relevant for evaluation, discussion and consideration for your clinical strategy for COVID-19.

Please let me know if additional informations are necessary.

To my person: I have MD PhD degree and have many years experience in pharmaceutical development (Boehringer Ingelheim), Biotech (Igeneon, Aphton, Virologik GmbH) (for reference see also PubMed Kircheis r) currently leading R&D activities at Syntacoll (part of Innocoll). I am providing this information personally in order to help to find a treatment for COVID-19 patients.

Looking forward to getting feedback from you,

With kind regards,

Ralf Kircheis (MD PhD)

[redacted] (b) (6)

rkircheis@syntacoll.de

[redacted] (b) (6)

(b) (4), (b) (5)

(b) (4), (b) (5)

[redacted]

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis
Director R&D
Research & Development

Mail: RKircheis@syntacoll.de
Phone: +49 9441 686048

syntacoll

Syntacoll GmbH, Donaustrasse 24, D-93342 Saal a. d. Donau
Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 1612
USt-IdNr. DE 128580796

Geschäftsführerin: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter

www.syntacoll.de/datenschutz

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 12:33:44 +0000
To: Jeremy Farrar
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Thanks, Jeremy. I saw the report in the Post from Saturday. These children had mostly respiratory disease and diarrhea. I will check with the docs at DC Children's Hospital about the presence of "multisystem inflammatory state". This could just be the advanced stage of their disease compatible with advanced SARS-COV-2
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar [redacted] (b) (6)
Sent: Monday, April 27, 2020 7:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Dzau, Victor J. <VDzau@nas.edu>; George GAO [redacted] (b) (6)>
Cc: Richard Hatchett [redacted] (b) (6) [redacted]; Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Teresa Miller de Vega [redacted] (b) (6)>; [redacted] (b) (6); Rebeka Yasmin - CEPI [redacted] (b) (6); ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; [redacted] (b) (6) McGinnis, J. Michael <MMcGinnis@nas.edu>; [redacted] (b) (6) Mun, Jenny <JMun@nas.edu>; [redacted] (b) (6) Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Thanks Tony – have asked for that and will share as soon as I can.

I believe there have been reports in the Washington Post.

https://www.washingtonpost.com/local/new-dc-hospital-numbers-suggest-kids-do-face-some-risk-of-coronavirus-hospitalization/2020/04/25/5e78c268-86fe-11ea-878a-86477a724bdb_story.html

---

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Monday, 27 April 2020 at 12:36
To: Jeremy Farrar (b) (6)>, Victor Dzau <VDzau@nas.edu>, George Gao (b) (6)
Cc: Richard Hatchett (b) (6) "Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, Teresa de Vega (b) (6)>, Rebeka Yasmin - CEPI (b) (6) "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>, (b) (6) "McGinnis, J. Michael" <MMcGinnis@nas.edu>, (b) (6) "Mun, Jenny" <JMun@nas.edu>, (b) (6) "Redfield, Robert R. (CDC/OD)" (b) (6).
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Thanks for the heads up. Is there any more detailed description of the precise clinical manifestations? They describe a "multisystem inflammatory state". It is vasculitis or anything more specific? Could be an infectious agent that has nothing to do with SARS-CoV-2 infection even though some children are circumstantially infected with SARS-CoV-2or it could be a post-SARS-CoV-2 inflammatory syndrome, perhaps a Kawasaki syndrome-like disease. Please keep me informed if you hear any further information.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar [redacted] (b) (6)>
Sent: Monday, April 27, 2020 7:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Dzau, Victor J. <VDzau@nas.edu>; George GAO [redacted] (b) (6)>
Cc: Richard Hatchett [redacted] (b) (6) [redacted] Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6) Teresa Miller de Vega [redacted] (b) (6); [redacted] (b) (6); Rebeka Yasmin - CEPI [redacted] (b) (6)>; ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; [redacted] (b) (6); McGinnis, J. Michael <MMcGinnis@nas.edu>; [redacted] (b) (6)>; Mun, Jenny <JMun@nas.edu>; [redacted] (b) (6)
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

To be aware of – news over night so a huge amount of uncertainty – important for COVID19 now, and a potential concern for how we view immunity, protection, post-infectious immunopathology.

https://www.hsj.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-emerging-in-children/7027496.article

https://t.co/Bj6YHLJ8zi

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
Date: Sunday, 26 April 2020 at 19:52
To: Victor Dzau <VDzau@nas.edu>, George Gao [redacted] (b) (6)>
Cc: Jeremy Farrar [redacted] (b) (6)>, Richard Hatchett [redacted] (b) (6) [redacted] "Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, Teresa de Vega [redacted] (b) (6)>, Rebeka Yasmin - CEPI [redacted] (b) (6)>, "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>, [redacted] (b) (6) "McGinnis, J. Michael" <MMcGinnis@nas.edu>,

[redacted] (b) (6)>, "Mun, Jenny" <JMun@nas.edu>,
(b) (6)>

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

It was a real pleasure to join all of you on this important session. Many thanks for inviting me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Saturday, April 25, 2020 3:59 PM
To: George GAO [redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) [redacted]; Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6) [redacted] (b) (6) ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; [redacted] (b) (6) McGinnis, J. Michael <MMcGinnis@nas.edu>; [redacted] (b) (6)>; Mun, Jenny [redacted] (b) (6); haja.bally@cepi.net
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan and Richard,
Thank you so much for your superb contributions. It was a spectacular session- a truly inspiring one. I am grateful to all of you.
Hope to see you soon.
Warmest regards,
Victor

On Apr 25, 2020, at 1:22 PM, George GAO [redacted] (b) (6)> wrote:

I am waiting for being connected and will use slides which were sent to your office
George

发自我的iPhone

> 在 2020年4月24日，01:49，Dzau, Victor J. <VDzau@nas.edu> 写道：
>
> Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,
>
> I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.
>
> I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.
>
> I would greatly appreciate it if you would respond to this email.
>
> Best,
> Victor
>
> PS, [redacted] (b) (6) my special assistant, will be sending you additional information about the session logistics shortly.
>
> ---
>
> **From:** Dzau, Victor J. <VDzau@nas.edu>
> **Sent:** Thursday, April 9, 2020 11:01 AM
> **To:** Mun, Jenny <JMun@nas.edu>; [redacted] (b) (6)
> [redacted]
> **Cc:** [redacted] (b) (6) Hannon, Emma <EHannon@nas.edu>; [redacted] (b) (6)
> [redacted]

(b) (6); 'ben.tinker@cnn.com' <ben.tinker@cnn.com>;
'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>;
'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>;
'Tia.Miller@turner.com' <Tia.Miller@turner.com>; 'hujr@chinacdc.cn'
(b) (6)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny
Sent: Wednesday, April 8, 2020 10:56 AM
To: [redacted] (b) (6)
Cc: Dzau, Victor J. ; [redacted] (b) (6) ; Mun, Jenny ; Hannon, Emma ; [redacted] (b) (6) 'ben.tinker@cnn.com' ; 'Amanda.Sealy@cnn.com' ; 'Neel.Khairzada@turner.com' ; 'Tia.Miller@turner.com'
Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (https://www.youtube.com/user/theNASciences) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13**.

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT)** to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases
Jeremy Farrar, Director, Wellcome Trust
George F. Gao, Director-General, Chinese Center for Disease Control & Prevention
Sanjay Gupta, Chief Medical Correspondent, CNN
Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations
Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as "sharing your screen" (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

****

Jenny Mun
Membership Director
National Academy of Sciences
jmun@nas.edu
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 18:45:27 +0000
To: [redacted] (b) (6)
[redacted]
Subject: SNL review

OKAY, so here is something even better than having Brad Pitt portray me on SNL. It is a recent review of Pitt's performance in which the TV reviewer said :

"Kicking things off, the Oscar winner dropped jaws during the cold open with his monologue about President **Donald Trump**'s recent (and concerning) comments about COVID-19.

"Good evening, I'm Dr. Anthony Fauci," Pitt began his monologue and looked nearly identical to the director of the National Institute of Allergy and Infectious Diseases."

Someone said Pitt looked "nearly identical" to me. Yikes!! ☺

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 18:37:57 +0000
To: Barnes, Freddie
Subject: RE: Appreciation

Freddie:

Many thanks for your kind note. It is much appreciated.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barnes, Freddie <freddie.barnes@ncdps.gov>
Sent: Sunday, April 26, 2020 10:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Appreciation

Dr. Fauci I just wanted to express my profound appreciation to you for your work during this COVID-19 pandemic. I especially appreciate how you have spent considerable time and capital reaching out to the Black and brown communities. I saw exerts of your snapchat with Will Smith and saw nearly all of your interview on the Breakfast Club. I regret I have to send an email to you re this matter. But this is the day we live in. Minority communities continue to be over-looked in crises and the impact of such crises on their respective communities. For you to be intentional about keeping the minority communities in the loop is commendable, especially since these communities will be absorbing the disproportionate share of the sicknesses and deaths coming from COVID-19.

Thanks for all of what your are doing in keeping the nation informed. Thanks for informing based on the facts, data, and truth.

Take care and "Cover your six."

Email correspondence to and from this address may be subject to the North Carolina Public Records Law and may be disclosed to third parties by an authorized state official.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 13:29:53 +0000
To: Adams, Jerome (HHS/OASH);[redacted] (b) (6);Giroir, Brett (HHS/OASH)
Cc: [redacted] (b) (6)
Subject: RE: High touch points

[redacted] (b) (5).

From: Adams, Jerome (HHS/OASH) [redacted] (b) (6)>
Sent: Sunday, May 3, 2020 7:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; [redacted] (b) (6); Giroir, Brett (HHS/OASH) [redacted] (b) (6)>
Cc: [redacted] (b) (6)
Subject: Fwd: High touch points

Please see short thread below. Senator Young reached out to me about this and I forwarded to CDC. As I mention [redacted] (b) (5) Thoughts?
Jerome

VADM Jerome Adams
20th US Surgeon General

Begin forwarded message:

> **From:** "Adams, Jerome (HHS/OASH)" [redacted] (b) (6)>
> **Date:** May 3, 2020 at 7:32:46 AM EDT
> **To:** "Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)" [redacted] (b) (6)>
> **Cc:** "Schuchat, Anne MD (CDC/OD)" [redacted] (b) (6)
> **Subject: Re: High touch points**
>
> Thank you. [redacted] (b) (5) (b) (5)
>
> Please keep me posted. And should I refer the senator to you or someone at CDC to close the loop?
> Thanks!
> J

VADM Jerome Adams
20th US Surgeon General

On May 2, 2020, at 7:08 PM, Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [redacted] (b) (6)> wrote:

ADM Adams:
Thanks for sending this. There has been a lot of guidance on disinfection and cleaning, notably some very recent collaborative work we have done with EPA (https://www.cdc.gov/coronavirus/2019-ncov/community/reopen-guidance.html). Attached are two documents focused on re-opening America with emphasis on cleaning and disinfection, including high-touch surfaces. Also below are a number of websites that address cleaning and disinfection which point out the importance of disinfecting high-touch locations like doorknobs. They give guidance how to clean them, but they don't address methods for using a paper towel or Kleenex to first turn the knob and then discard the towel. [redacted] (b) (5) .
Thanks
Dan.

Daniel B. Jernigan, MD MPH
Director, Influenza Division; HHS CDC Lead, FEMA-HHS COVID-19 Response
Captain, USPHS (RET)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
1600 Clifton Rd NE, Atlanta, GA 30329
Phone [redacted] (b) (6), Cell [redacted] (b) (6)
[redacted] (b) (6) www.cdc.gov/flu

https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-building-facility.html
https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/disinfecting-your-home.html
https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-building-facility-H.pdf

---

From: Adams, Jerome (HHS/OASH) [redacted] (b) (6)>
Sent: Friday, May 1, 2020 5:35 PM
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [redacted] (b) (6)>
Cc: Schuchat, Anne MD (CDC/OD) < [redacted] (b) (6)>
Subject: High touch points

Dr. Jernigan,
I got a message from a Senator asking why we didn't have specific reopening recommendations for "high touch" points like door knobs/ handles/ elevator buttons. The Senator stated that [redacted] (b) (5) I told him I'd follow up with CDC, (b)(5) [redacted] Would appreciate your feedback on this.

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

<Reopening_America_Guidance.pdf>
<ReOpening_America_Cleaning_Disinfection_Decision_Tool.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:37:05 +0000
To: Hahn, Stephen;Debi Birx;Redfield, Robert R. (CDC/OD);Verma, Seema (CMS/OA)
Subject: RE: Serology Studies in Germany

Thanks, Steve!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 6:34 PM
To: Debi Birx [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6), Seema (CMS/OA) < [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: Serology Studies in Germany

Interesting information from Germany

From: Shuren, Jeff < [redacted] (b) (6)>
Date: April 30, 2020 at 5:46:27 PM EDT
To: Hahn, Stephen < [redacted] (b) (6)>, Shah, Anand [redacted] (b) (6)>, Lenihan, Keagan [redacted] (b) (6)>, Guram, Jeet < [redacted] (b) (6)>, Rom, Colin [redacted] (b) (6)>
Subject: Serology Studies in Germany

FYSA regarding serology studies being conducted in Germany, including status of tests to be used for those studies. This is the follow up to what I sent you last week. [redacted] (b) (5)

From: Hoshi, Ryan <[redacted] (b) (6)
Sent: Thursday, April 30, 2020 3:17 PM
To: Shuren, Jeff [redacted] (b) (6)
Cc: Nalubola, Ritu [redacted] (b) (6); Louati, Claudia (FSN)* [redacted] (b) (6)>; O'Leary, Brendan [redacted] (b) (6)>; Torres, Melissa A [redacted] (b) (6); Stenzel, Timothy [redacted] (b) (6)>
Subject: FW: PLEASE REVIEW >> Meeting Notes - Call with [redacted] (b) (5)

(b) (5)

[redacted]

(b) (5)

[redacted]

(b) (5)

[redacted]

Thank you,
Ryan

Ryan A. Hoshi, Ph.D.
International Policy Analyst | Center for Devices and Radiological Health | [redacted] (b) (6) | phone [redacted] (b) (6) | mobile [redacted] (b) (6)

FDA U.S. FOOD & DRUG ADMINISTRATION

Excellent customer service is important to us.

Please take a moment to provide feedback regarding the customer service you have received:

click here for survey

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:14:36 +0000
To: Halkovich, Townshend Connie
Subject: RE: Appreciation to my hero--Dr. Fauci--our country's voice of reason in these unsettling, uncertain times--We NEED YOU!!!! Please don't leave us now when we need you most!!!

Connie:
Many thanks for your kind note. Much appreciated.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Halkovich, Townshend Connie [redacted] (b) (6)
Sent: Monday, April 27, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Halkovich, Townshend Connie (FDA/OC) [redacted] (b) (6)
Subject: RE: Appreciation to my hero--Dr. Fauci--our country's voice of reason in these unsettling, uncertain times--We NEED YOU!!!! Please don't leave us now when we need you most!!!

Where is Dr. Fauci?
I know where Dr. Fauci is—I saw him on SNL—remarkably he looked like Brad Pitt—except [to many of us] Dr. Fauci is better looking. Smile, wink *Why? We look with our hearts*
I remember someone asked Dr. Fauci [in jest] who would he like to represent him in a movie...Dr. F. said Brad Pitt. Well—Dr. F. Your dream suggestion came true. But, in many of our hearts—NO ONE can take the place of our beloved, well respected, honored Dr. Anthony Fauci!!!!

God Bless America, God Bless Dr. Fauci !!!

From: Halkovich, Townshend Connie <[redacted] (b) (6)>
Sent: Friday, March 13, 2020 11:06 AM

To: 'anthony.fauci@nih.gov' [redacted] (b) (6)
Cc: Halkovich, Townshend Connie <Constance.Halkovich@fda.hhs.gov>
Subject: Appreciation

Dear Dr. Fauci:

1st & foremost—please keep yourself healthy....get more rest than 3 hrs/night. ☺ Why? We need you!
THANK YOU for all your very informative updates. YOU are voice of reason...in time of coronavirus fear...you give us hope...saying that action is what is needed...not fear!
You are someone we can be proud of...you provide service we can count on!!!!
God bless You & Your Family!!!

Warmest Regards from:

Connie Leigh Townshend Halkovich, Management Analyst, 410-867-0878,

#FDA/OIMT/DIO Proud: People & Service you can count on! ☺

[redacted] (b) (6)

My Wish 4 U: Peace, Love, Laugher —*blessed 2 work with U ALL!* *Abe Lincoln: "folks are as happy as they choose 2be"-B happy all circumstances—Hope all well with you, yours--if not, pretend it is.*

***FDA Mission**: Responsible for protecting public health by ensuring safety, efficacy/security of human & vet. drugs, biol. products, med. devices, our nation's food supply, cosmetics, & products that emit radiation.*

***DIO Mission:**-Provide excellent implementation, operation, maintenance of IT [equipment, services] to promote FDA's Public Health Mission.*

***DIO Vision:** Provide state-of-the-art IT services-inclusive of surrounding policy, planning, customer service, integration, & oversight necessary to make the mission successful & sustainable.*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:26:27 +0000
To: Folkers, Greg (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Cc: NIAID OD AM
Subject: RE: ASF RE: Dr. Fauci video request: Public Service Recognition Week
Attachments: ASF public service recognition - with tracked edits -05-05-2020.docx

See minor tracked changes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, May 5, 2020 6:16 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Awwad, David (NIH/NIAID) [C] (b) (6)>
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF RE: Dr. Fauci video request: Public Service Recognition Week

ASF –
Here is a short script for Public Service Recognition Week. We agreed to do a short video
ASF – can u tweak as needed?
David, could u record in some format that is easy? Cell phone or other I just learned they want by COB tomorrow

<< File: ASF public service recognition.docx >>

From: Seigfreid, Kim (NIH/OD) [E] [redacted] (b) (6)>
Sent: Monday, April 27, 2020 4:30 PM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>; Polimeni, Lydia (NIH/OD) [E] [redacted] (b) (6)
Subject: Dr. Fauci video request: Public Service Recognition Week

Hi there,

Please see below. HHS is taking over the Partnership for Public Service IG account next week for Public Service Recognition Week. They asked if Dr. Fauci would be willing to do a short 30-second or less pre-recorded video thanking public servants for their work. It would be featured during the takeover, and also on NIH's other sm handles next week. It can be taken on a cell phone as sm does not require higher resolution. Let me know if you would like to accept or decline the request.

Many thanks,
Kim

Kim Seigfreid
Social Media Lead
NIH Office of Communications and Public Liaison
ph: [redacted] (b) (6)
[redacted] (b) (6)

From: Muhammad, Janell (HHS/ASPA) < [redacted] (b) (6)>
Sent: Monday, April 27, 2020 4:10 PM
To: Seigfreid, Kim (NIH/OD) [E] [redacted] (b) (6)>; Channer, Amber (OS/OASH) [redacted] (b) (6)>; Foster, Timothy (OS/ASPA) [redacted] (b) (6)>
Cc: Palczewski, Andrew (HHS/ASPA) < [redacted] (b) (6)>; Pratt, Michael (OS/ASPA) < [redacted] (b) (6)>; Sherman, Jennifer (HHS/OASH) [redacted] (b) (6) Wilker, Michael (HHS/ASPA) [redacted] (b) (6); Dine, Brooke (HHS/ASPA) [redacted] (b) (6)
Subject: Public Service Recognition Week

Hello All,

Hope everyone is holding up well!

OHR is taking over the Partnership for Public Service (PPS) Instagram account during Public Service Recognition Week (May 3-9, 2020). The OHR team has reached out about wanting to develop a senior leader "mashup" video —perhaps including the DepSec. T

They asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci and the SG doing a pre-recorded video thanking public servants for their work.

I wanted to gather the troops so we can identify what all is being planned for this week of recognition and provide a POC for OHR if the request is feasible.

Happy to set up a call, if that is needed to discuss further.

Thanks,
Janell

Janell Muhammad
ASPA Digital Engagement (Team Lead)
U.S. Department of Health and Human Services
Email: (b) (6)
Office: (b) (6)
iPhone: (b) (6)
HHS on Facebook | **HHS on Twitter** | **HHSLatino**

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 21:58:55 +0000
To: Adams, Jerome (HHS/OASH)
Subject: RE: Update on Sara Alert

What do you mean by [redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Adams, Jerome (HHS/OASH) [redacted] (b) (6)>
Sent: Tuesday, May 5, 2020 2:49 PM
To: Birx, Deborah L. EOP/NSC <[redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Update on Sara Alert
Importance: High

[redacted] (b) (5)

Jerome
VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

From: Jarris, Paul [redacted] (b) (6)>
Sent: Friday, May 1, 2020 7:29 PM
To: Adams, Jerome (HHS/OASH) [redacted] (b) (6)>
Cc: Wright, Janet (HHS/OASH) [redacted] (b) (6)

Subject: Update on Sara Alert
Importance: High

Dear Jerome,

I hope you are well. Thank you for all you are doing to represent public health and our nation. It is very comforting knowing you are informing the nations COVID-19 response.

I wanted to give you an update on called Sara Alert, the software program I am leading at MITRE. Sara Alert is being provided free of any costs and deployed in state, tribal, and local health departments to support public health in contact tracing and active monitoring of individuals in isolation and quarantine. We are engaged with ASTHO, NACCHO, CSTE, and the application is hosted live on APHL's AIMS platform. Sara Alert officially launched on April 3 and is currently supporting multiple jurisdictions including Commonwealth of the Northern Mariana Islands, Danbury, CT, and the State of Arkansas. It is also being rolled out in Washington, Arizona, Pennsylvania, Virginia, Maine and Vermont. We are getting ready to launch in additional jurisdictions over the next couple of weeks.

We have recently responded to questions we were told came from the White House so I wanted to make sure you have background materials. I imagine you are the person that the President and Vice President would turn to for information. I am happy to arrange any briefing materials or demo that would be helpful for you to respond.

As I mentioned previously, **Sara Alert** is a standards-based, open source tool that automates the process of monitoring individuals exposed to or infected with COVID-19 (or any disease, it's configurable) – and will serve as an enduring national resource to contain disease. Sara Alert is free for use by public health organizations.

Best wishes to you. Stay healthy for all of us.

Paul

ABOUT SARA ALERT

In response to the COVID-19 pandemic, the MITRE Corporation, a not-for-profit that works in the public interest, developed **Sara Alert**, a standards-based, open source tool in partnership with national public health organizations. Sara Alert **automates the process of monitoring** individuals exposed to or infected with COVID-19 (or any disease, it's configurable) – and will serve as an **enduring national resource** to contain disease. **Sara Alert is free for use by public health organizations**.

- Sara Alert allows public health officials to import and enroll individuals (or households) at risk of developing or infected with COVID-19.
- Individuals enter their symptoms daily via web, text, email or phone, allowing public health officials to focus on high risk and non-reporting individuals.
- The web-based tool enables increased efficiency in tracking cases, leading to earlier containment of the virus and reduction of burden on public health resources.
- Sara Alert is a national system and allows transferal of monitorees across jurisdictions for tighter contact tracing.

Sara Alert launched on April 3 and **is now supporting multiple jurisdictions**.
Sara Alert YouTube Video: https://youtu.be/lQxAuNsg-RA

Paul E. Jarris, MD, MBA
Chief Medical Advisor
Health Transformation Center
MITRE Corporation
(b) (6)
(b) (6) Office
(b) (6) Mobile

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:45:26 +0000
To: Lane, Cliff (NIH/NIAID) [E];Collins, Francis (NIH/OD) [E]
Cc: Lowy, Douglas (NIH/NCI) [E];Mascola, John (NIH/VRC) [E]
Subject: RE: Gallo and OPV

[redacted] (b) (5).

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, May 3, 2020 1:22 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Lowy, Douglas (NIH/NCI) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Subject: Re: Gallo and OPV

Francis,

[redacted] (b) (5)

Cliff

> On May 3, 2020, at 12:55 PM, Collins, Francis (NIH/OD) [E] [redacted] (b) (6) wrote:
>
> Hi all,

I'm a bit at a loss to know how to respond to Bob Gallo. [redacted] (b) (5)

Francis

From: Gallo, Robert [redacted] (b) (6)>
Sent: Sunday, May 3, 2020 12:07 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Subject: RE: Your query to Dr. Kadlec

Dear Francis,

It was a pleasure to hear from you, and yes, it has been a long time since we met or even spoke. Moons ago I was set to write to you after reading your wonderful book, but I ended up instead speaking with others about it. I should add at this point that I did not quickly respond to your email of a few days ago because I simply missed it.

It is true that I strongly suggest that OPV be quickly (already it is not quickly) brought forward for induction of a strong innate immune response to prevent or markedly reduce SARS-CoV-2 infection and/or severity until the field obtains a proven safe and efficacious vaccine producing a long lasting, adaptive immunity. OPV is very safe (notably for OPV 1 and 3 as bOPV which we will use and completely safe in a vaccinated population), simple, cheap, rather obvious, yet unique among the massive number of vaccines many (maybe most) of which are the same or at least if not exactly the same aiming at the same mechanism (targeting the spike and searching for the putative correlate of neutralizing Abs.).

OPV should work for a few months and possibly longer. Also it should be working multiple times so I think could cover more than a few months, giving us time for a proven vaccine of adaptive immunity, which might be very long lasting as is hoped.

In the main the WHO comments are correct. Of course we sought and have letters of support from them as well as from many others. Though they are again supportive in their notes to you, there is one item that surprises me. They add that there was no clinical efficacy results as yet. They know or certainly should know that there is plenty of clinical data for this concept with BCG, OPV, and live Measles vaccine. Needless to say this is what turned me on during our regular Global Virus Network (GVN)conference calls. (Incidentally GVN is an organization I have thought of bringing to your attention. I think you would find it impressive and useful). I would be happy to share with you the clinical observations with OPV if you wish.

I would like to take a small diversion, but I suspect you are aware of these things. My colleagues and I respect the WHO because of its representation and because we have colleagues/friends there as well. However, sometimes bureaucracy of a massive degree leads to inaction or even much worse-- political expediency. I won't bother you with details of these unless you ask, but I had such experiences with HTLV-1 which we discovered in 1980 as the 1st human retrovirus and which cause not only the highest incidence of cancer (% of infections) of any virus and other fatal diseases as well but mainly in less developed countries (plus Japan) and again with HIV in 1984. Behavior was not beneficial. Perhaps it will be of relevance in the future because a few at WHO took a position to remove OPV (Sabin) in favor of IPV (Salk) in their polio eradication scheme. It was a huge failure. As my FDA collaborator, Konstantin Chumakov, says "Blessed be Bill Gates" because he saved OPV and saved the day and in so doing has produced a still better OPV.

There is indeed data also for BCG as well as live Measles though I know less of the latter. BCG is less available, requires injection, harder to make, not as safe, and we think unlikely to be as effective as OPV. Nonetheless, we favor its use too. The mechanisms will be similar.

You asked whether monkey trials are planned. For several reasons definitely not -- though we are planning some monkey experiments, but not large enough for "clinical" conclusions. The main reasons are: 1) cost; 2) that billions not thousands or millions have received OPV safely and in our collective view (and we know the studies pretty well) protection has been clinically shown; 3) In a pandemic we wished to move quickly (so far we must say that has not been achieved). A typical monkey vaccine study will take time, but 4) in this case it would be a huge amount of lost time as monkeys require great doses of polio for infection and monkeys have to be trained to drink their orange juice. It would be hard to imagine that such studies would even give us useful information.

On a final digression Francis I have had 36 years of on/off experiences with glycosylated spike proteins—their analyses immunologically and especially regarding use in vaccines and developing neutralizing Abs. I believe it will be a mistake to put most eggs in that basket. The risks: shortened antibody half life; 2) protection NOT correlating with neutralizing Abs; 3) sometimes hazards from them. Admittedly, they might work, but I trust and hope that not everything is going in this bag. If you wish to discuss this again I will be available.

Finally, I hd no idea you were into vaccines or SARS-2 nor any part of CoVID-19 disease, but I am very happy to learn this.

Thanks.

Bob Gallo

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 5:00 PM
To: Gallo, Robert [redacted] (b) (6)>
Cc: Disbrow, Gary (OS/ASPR/BARDA) < [redacted] (b) (6)>; Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] < [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)v>; Johnson, Robert (OS/ASPR/BARDA) [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Your query to Dr. Kadlec

CAUTION: This message originated from a non UMB, UMSOM, FPI, or UMMS email system. Whether the sender is known or not known, hover over any links before clicking and use caution opening attachments.

Dear Bob,

It's been quite a while since we've chatted. Bob Kadlec asked me to respond to your query about the possible use of OPV to activate innate immunity and provide COVID-19 protection. Has this been tested in a non-human primate model? I note the recommendation below that says a clinical trial is planned – can you tell me more about that?

As you can imagine, we are all flat out on the vaccine development pathway!

Francis

The use of oral polio vaccine (OPV) to prevent SARS-CoV2 (Polio Eradication Campaign)

There is no evidence that oral poliovirus vaccine (OPV) protects people against infection with COVID-19 virus.

A clinical trial addressing this question is planned in the USA, and WHO will evaluate the evidence when it is available.

In the absence of evidence, WHO does not recommend OPV vaccination for the prevention of COVID-19. WHO continues to recommend OPV as part of essential immunization services to prevent poliomyelitis and as part of global polio eradication efforts.

There are experimental signals from various studies over the years that OPV has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown. Such non-specific effects may not be limited to OPV, as other live vaccines have also been associated with non-specific protective effects (such as BCG vaccine against tuberculosis). Nonlive vaccines in contrast do not seem to have the same effects.

The exact mechanism of non-specific protection induced by live vaccines needs to be elucidated further. Clinical studies could begin immediately because the vaccines in question are licensed and have an excellent safety record. Clinical trials involving off-label use of various drugs licensed for other indications are currently underway. The existing scientific rationale suggests that the same should be done for OPV and other live vaccines. A study is currently being discussed with various partners and vaccine manufacturers, including the US FDA, the outcomes of which will be carefully assessed to determine potential use in the context of the spread of SARS-CoV2 until the time when specific vaccines and antiviral therapies are ready.

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)
Sent: Thursday, April 30, 2020 10:28 AM
To: Gallo, Robert [redacted] (b) (6); Collins, Francis (NIH/OD) [E] <[redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)>
Subject: Re: Respone

Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins and Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to consider scientific base approaches That you have described. Dr Collins has organized a vaccine group and I assess could be the best and fastest place to discuss your concept. I am sure they will connect with you soonest

Best

Bob Kadlec.

Sent from my iPhone

> On Apr 30, 2020, at 10:02 AM, Gallo, Robert [redacted] (b) (6)> wrote:
>
> Dear Dr. Kaldec,
>
> I have not heard from you in over a week. You mentioned getting back to me in a day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a bivalent, completely safe vaccine with powerful stimulation of innate immunity lasting several weeks , which can be given a second or third time, and with a historical track record of

preventing other infections from entirely different RNA viruses (such as protecting against influenza). Therefore, it should be really helpful for some months, and I think get us past a second wave of SARS-CoV-2, and help people return to work safely. I don't understand delays or apparent lack of interest. Who can possibly be against this? If you hear of hypothetical problems we can show you that these are false. Just ask the questions, and we can give you the evidence.

However, no answer from you suggests no interest and must quickly make alternative pathways. I am though quite surprised and fear you are receiving "fake news" if you will pardon the expression. Some have been against this who defend their old and failed position on polio eradication with their promotion of the use of the inactivated polio virus vaccine. Please note that in the US between 1962 and 1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already there has not been a single case of a complication and BILLIONS have received it. No it will not last long as innate immunity is short lived, but we strongly believe that we can break the back of the SARS-CoVID-2 spread. Also note that this is what Bill Gates is doing now in India and much of the Eastern hemisphere.

There are countries outside the US wanting to move fast on this. We are waiting for your reply.

Robert Gallo
Director, Institute of Human Virology,
Professor of Medicine and Professor of Microbiology,
UMB, School of Medicine, Baltimore,

And
Co-founder and International Science Advisor of the Global Virus Network (GVN)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 15:17:01 +0000
To: Collins, Francis (NIH/OD) [E];Mascola, John (NIH/VRC) [E];Lane, Cliff (NIH/NIAID) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: Respone

Francis:

Thanks for the note. I will let Cliff speak for himself, [redacted] (b) (5)

[redacted] (b) (5)

[redacted] (b) (5) but I will let him speak for himself. We can discuss further if you wish.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Thursday, April 30, 2020 10:58 AM
To: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Subject: FW: Respone

Hi John, Cliff, and Tony,

Ignore the silly part of the message below, where [redacted] (b) (5) [redacted]. But let me ask you guys whether [redacted] (b) (5) [redacted]

Francis

From: Collins, Francis (NIH/OD) [E]
Sent: Thursday, April 30, 2020 10:55 AM
To: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6); Disbrow, Gary (OS/ASPR/BARDA) [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6)
Subject: RE: Respone

Bob,

Dropping Bob Gallo from the thread, but adding Gary and Robert. [redacted] (b) (5) [redacted] Please advise.

Francis

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)
Sent: Thursday, April 30, 2020 10:28 AM
To: Gallo, Robert [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)
Subject: Re: Respone

Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins and Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to consider scientific base approaches That you have described. Dr Collins has organized a vaccine group and I assess could be the best and fastest place to discuss your concept. I am sure they will connect with you soonest

Best

Bob Kadlec.

Sent from my iPhone

> On Apr 30, 2020, at 10:02 AM, Gallo, Robert [redacted] (b) (6)> wrote:
>
> Dear Dr. Kaldec,
>
> I have not heard from you in over a week. You mentioned getting back to me in a day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a bivalent, completely safe vaccine with powerful stimulation of innate immunity lasting several weeks , which can be given a second or third time, and with a historical track record of preventing other infections from entirely different RNA viruses (such as protecting against influenza). Therefore, it should be really helpful for some months, and I think get us past a second wave of SARS-CoV-2, and help people return to work safely. I don't understand delays or apparent lack of interest. Who can possibly be against this? If you hear of hypothetical problems we can show you that these are false. Just ask the questions, and we can give you the evidence.
>
> However, no answer from you suggests no interest and must quickly make alternative pathways. I am though quite surprised and fear you are receiving "fake news" if you will pardon the expression. Some have been against this who defend their old and failed position on polio eradication with their promotion of the use of the inactivated polio virus vaccine. Please note that in the US between 1962 and 1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already there has not been a single case of a complication and BILLIONS have received it. No it will not last long as innate immunity is short lived, but we strongly believe that we can break the back of the SARS-CoVID-2 spread. Also note that this is what Bill Gates is doing now in India and much of the Eastern hemisphere.
>
> There are countries outside the US wanting to move fast on this. We are waiting for your reply.
>
> Robert Gallo
> Director, Institute of Human Virology,
> Professor of Medicine and Professor of Microbiology,
> UMB, School of Medicine, Baltimore,

And
Co-founder and International Science Advisor of the Global Virus Network (GVN)

From: [redacted] (b) (6)
Sent: Wed, 29 Apr 2020 13:39:44 -0400
To: Billet, Courtney (NIH/NIAID) [E]
Subject: Fwd: ASF: For review ASAP: draft Sec. Azar Remdesivir statement
Attachments: 4 29 20 remedesivir.docx, ATT00001.htm

Cannot do right now. Go without me

Begin forwarded message:

> **From:** "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)
> **Date:** April 29, 2020 at 1:11:19 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** "Routh, Jennifer (NIH/NIAID) [E]" <[redacted] (b) (6)>, "Stover, Kathy (NIH/NIAID) [E]" [redacted] (b) (6) "Lane, Cliff (NIH/NIAID) [E]" [redacted] (b) (6)>, "Marston, Hilary (NIH/NIAID) [E]" (b) (6)>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, "Folkers, Greg (NIH/NIAID) [E]" (b) (6)>
> **Subject: ASF: For review ASAP: draft Sec. Azar Remdesivir statement**
>
> ---
>
> **From:** Fritz, Craig (NIH/OD) [E] [redacted] (b) (6)
> **Sent:** Wednesday, April 29, 2020 10:38 AM
> **To:** Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6) Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
> **Cc:** Burklow, John (NIH/OD) [E] [redacted] (b) (6); Myles, Renate (NIH/OD) [E] [redacted] (b) (6); Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>; Wojtowicz, Emma (NIH/OD) [E] [redacted] (b) (6)>; NIH News Clearance (NIH/OD) <NIHNewsClearance@mail.nih.gov>
> **Subject:** FW: For review ASAP: draft Sec. Azar Remdesivir statement
> **Importance:** High
>
> Hi all – please let us know if you have any comments to the attached.
>
> Thanks!
> Craig

From: Brennan, Patrick (OS/ASPA) [redacted] (b) (6)>
Sent: Wednesday, April 29, 2020 10:33 AM
To: Fritz, Craig (NIH/OD) [E] [redacted] (b) (6)>; Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Myles, Renate (NIH/OD) [E] [redacted] (b) (6); Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>; Wojtowicz, Emma (NIH/OD) [E] [redacted] (b) (6)>; Charrow, Robert (HHS/OGC) [redacted] (b) (6)
Cc: Pence, Laura (HHS/ASL) [redacted] (b) (6)>; Hall, Bill (HHS/ASPA) [redacted] (b) (6)>; Pratt, Michael (OS/ASPA) [redacted] (b) (6)>; Blakeman, Scott (OS/ASPA) < [redacted] (b) (6)>
Subject: For review ASAP: draft Sec. Azar Remdesivir statement

NIH and Mr. Charrow,

Below and in the attached is a draft statement from the Secretary regarding the Remdesivir trial – please let me know as soon as you can if this looks OK. (I pulled the frontmatter from the NIH press release.) Thank you!

- Patrick

[redacted] (b) (5)

Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office: [redacted] (b) (6) | Cell [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:56:42 +0000
To: [redacted] (b) (6)v
Subject: FW: DRAFT document for WH Briefing Tomorrow
Attachments: Development-Medical-Countermeasures-WH-Briefing 29 April.pptx

Here it is.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Tuesday, April 28, 2020 8:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: DRAFT document for WH Briefing Tomorrow

Hi Tony,

I called Paul to [redacted] (b) (5).

Francis

From: Mango, Paul (HHS/IOS) < [redacted] (b) (6)>
Sent: Tuesday, April 28, 2020 7:26 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Marks, Peter (FDA/CBER) [redacted] (b) (6); Woodcock, Janet (FDA/CDER) [redacted] (b) (6)>; Tromberg, Bruce (NIH/NIBIB) [E] [redacted] (b) (6)
Subject: DRAFT document for WH Briefing Tomorrow

Thank you all for your timely responses for contributions to this today. Please give this a look and let us know if there is anything glaringly out of place. We will have time to address edits during and after our 930am check in tomorrow. The Secretary may or may not use page 1 during his introductory remarks.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 18:14:04 +0000
To: Gibbons, Gary (NIH/NHLBI) [E]
Cc: Koroshetz, Walter (NIH/NINDS) [E]; [redacted] (b) (6);Auchincloss, Hugh (NIH/NIAID) [C] [redacted] (b) (6);Collins, Francis (NIH/OD) [E] [redacted] (b) (6);Tabak, Lawrence (NIH/OD) [E];Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: Thrombotic phenomena in COVID-19

Gary:

In follow-up of our recent conversation regarding the growing evidence that the extremely catastrophic course of many patients with COVID-19 seems to me pathogenically associated with the findings of microthrombi in the lungs and often a multisystem process resembling DIC. In addition, there have been growing numbers of cases of individuals (some young and otherwise healthy) who have had unexplained strokes, only to find out that they actually have COVID-19. [redacted] (b) (5)

[redacted] (b) (5)

[redacted] (b) (5) Thanks.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 17:42:12 +0000
To: NIAID OD AM
Subject: FW: Invitation to Webinar as keynote speaker.

I wouldn't think so.

From: Secretary ARP (b) (6)>
Sent: Saturday, April 25, 2020 2:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Invitation to Webinar as keynote speaker.

To,
Anthony S. Fauci,
Office of the Director,
National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 9000 Rockville Pike, Bldg 31, Room 7A03,
Bethesda MD 20892

Subject: Invitation to Webinar as keynote speaker.

Dear Sir,

On behalf of ASSOCIATION OF REGISTERED PHARMACIST (An association working for Pharmacy Profession and having more than 2000 members) in collaboration with Divine International, Gwalior (A Pioneer Pharmacy Institute) I am pleased to invite you to our Webinar having THEME "CHALLENGES AND OPPORTUNITIES FOR PHARMACIST IN THE PRESENT EPIDEMIC COVID-19" that will be held from 2nd May 2020 to 3rd May 2020. This Webinar is the get together of Pharma professionals through the web. The vision of this Webinar is to Aware, Prepare and strengthen our Pharmacy professionals in our country to this epidemic COVID-19 for present and future aspect and exports more realistic ideas and present scenario of this epidemic COVID-19.

You are one of the legends of Pharma Expert of our country, it is a great privilege for us to see if you share your experience with us, we really expect and want that you join our Webinar and share with us the great experience of your life, we want to learn something from you so that we can create a great ideas, opportunity, and roll of Pharma professional for our country in the present scenario.

We would be pleased to have you present at this point at this webinar to listen to what the role and importance in the Pharmacist advancement and their impact on our society and daily life we would also love to hear your thoughts and opinion about the Pharma professional that is a dream of our pharmacy fraternity.

Therefore you are requested to send your recorded Lecture/presentation of 30-40 min

Sincerely,

--
Thanks

Rajesh Singh Jadon
Secretary (National)
Association of Registered Pharmacists
Gwalior MP
Mob: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 15:43:25 +0000
To: [redacted] (b) (6)
Subject: RE [redacted] (b) (6), (b) (4)
Attachments: [redacted] (b) (6), (b) (4)

From: [redacted] (b) (6)>
Sent: Sunday, April 26, 2020 11:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: [redacted] (b) (6), (b) (4)

To work on at home

From: Ulrich, Connie M [redacted] (b) (6)
Sent: Saturday, April 25, 2020 2:35 PM
To: Cynda Rushton [redacted] (b) (6)>; [redacted] (b) (6)
Subject: [redacted] (b) (6), (b) (4)

Hi Christine and Cynda,

I finished my section and unfortunately have to keep changing the COVID numbers! I will add some thoughts to the last section. Not sure how much we can add there but maybe some reflections would be helpful. Enjoy the sunshine today!!

Best.
Connie

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 02:57:31 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]
Bcc: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)
Subject: RE: agenda for Kadlec et al., Sun noon meeting

Francis:
Sorry that I took so long to respond. [redacted] (b) (5) (b) (5) (b) (5) Let us connect by phone first thing in the AM>
Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)>
Sent: Saturday, April 25, 2020 2:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Subject: RE: agenda for Kadlec et al., Sun noon meeting

[redacted] (b) (5)

From: Collins, Francis (NIH/OD) [E]
Sent: Saturday, April 25, 2020 2:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Subject: agenda for Kadlec et al., Sun noon meeting

Hi Tony and Larry,

For the meeting tomorrow at noon (currently invitees are Kadlec, Disbrow, Johnson, Woodcock, Marks, and us three), I would propose the following framework:

[redacted] (b) (5)

[redacted] (b) (5)

Thoughts? Tony, should [redacted] (b) (5)

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 01:22:21 +0000
To: Corey MD, Larry
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [redacted] (b) (6)

Let us talk tomorrow (Sunday). I am sorry that I did not get back to you today.

From: Corey MD, Larry [redacted] (b) (6)
Sent: Saturday, April 25, 2020 5:36 PM
To: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Subject: Re: [redacted] (b) (6)

Agree. [redacted] (b) (6)

Sent from my iPhone

> On Apr 25, 2020, at 1:59 PM, Mascola, John (NIH/VRC) [E] <[redacted] (b) (6)> wrote:
>
> [redacted] (b) (6) seem reasonable
>
> Sent from my iPhone
>
>> On Apr 25, 2020, at 15:54, Corey MD, Larry [redacted] (b) (6) wrote:
>>
>> A do have to say I am surprised . but ok
>>
>> ---
>>
>> **From:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
>> **Sent:** Saturday, April 25, 2020 12:53 PM
>> **To:** Corey MD, Larry [redacted] (b) (6); Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
>> **Cc:** Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
>> **Subject:** Fwd: New England Journal of Medicine 20-13479
>>
>> Let us discuss next steps

Begin forwarded message:

(b) (6)

[redacted]

From: [redacted] (b) (6)
Sent: Sat, 25 Apr 2020 13:05:04 -0400
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]
Subject: Re: White House Task Force Briefing Monday

[redacted] (b) (5).

On Apr 25, 2020, at 11:42 AM, Collins, Francis (NIH/OD) [E]
<[redacted] (b) (6)>:

Judy Stecker called. Said there's a separate [redacted] (b)(5) - PCP [redacted] [redacted] (b) (5) [redacted].

FC

From: Collins, Francis (NIH/OD) [E]
Sent: Saturday, April 25, 2020 10:36 AM
To: [redacted] (b) (6)(OS/IOS) [redacted] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>; Pence, Laura (HHS/ASL) <[redacted] (b) (6); Harrison, Brian (HHS/IOS) [redacted] (b) (6)>; Wood, Gretchen (NIH/OD) [E] [redacted] (b) (6) McManus, Ayanna (NIH/OD) [E] [redacted] (b) (6)
Subject: FW: White House Task Force Briefing Monday

Hi Mr. Secretary,

Please see below for a [redacted] (b)(5) - PCP [redacted] Glad to speak with you about how best to handle, if you have advice. [redacted] (b) (6)

Francis

[redacted] (b)(5) - PCP

(b)(5) - PCP

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 14:25:16 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Italy Covid-19

La Stampa is one of the two most important newspapers in Italy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mastrolilli Paolo <Paolo.MASTROLILLI@lastampa.it>
Sent: Friday, April 24, 2020 10:08 AM
To: Fauci, Anthony (NIH/NIAID) [E][redacted]
Subject: Italy Covid-19

Dear Doctor Fauci,
My name is Paolo Mastrolilli, I am the US Bureau Chief for the Italian daily La Stampa.
I am writing because we would appreciate very much the opportunity to have a phone or written Q&As interview with you to discuss the Covid 19 pandemic. Considering the difficult situation Italy is experiencing, the help President Trump is sending to Italy, and the plan to open America again, it would be very helpful for Italy to hear from your experience and competence to address the Covid 19. We think that your advices would be very helpful to help our country and our citizens in dealing with the pandemic.
We understand that you are very busy and this request has no deadline.
La Stampa is a leading Italian daily, it is owned by the Agnelli Elkann family, owner of Fiat Chrysler as well.
I am also a contributor for the Vatican Radio and the official news portal of the Holy See, I would share the interview with them as well, if you like.
My cellphone number is (b) (6)
Please let me know if you need any further information.
Best regards
Paolo Mastrolilli

Il presente messaggio (inclusi gli allegati) contiene informazioni riservate esclusivamente al destinatario/ai destinatari indicato/i nel messaggio, ed è protetto dalla legge. La diffusione, distribuzione e/o la copia del contenuto del presente messaggio da parte di qualsiasi soggetto diverso dal destinatario è severamente vietata ai sensi dell'art. 616 c.p. e delle vigenti normative in materia di protezione dei dati personali. Se non siete i destinatari del presente messaggio, vi preghiamo di distruggerlo e di darcene immediata comunicazione inviando un messaggio di ritorno all'indirizzo e-mail del mittente.

This message (including any attachments) contains confidential information intended only for the recipient(s) named above, and is protected by law. Any disclosure, distribution and/or copying of this message by any subject different from the named recipient(s) is strictly prohibited according to art. 616 c.p. and to the applicable data protection laws. If you are not the intended recipient, please delete this message and inform us immediately about the deletion by sending a message to the sender's e-mail address.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 10:33:49 +0000
To: Holland, Steven (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Successful Submission of a Manuscript to Science (abc4208)

Thanks, Steve.

-----Original Message-----
From: Holland, Steven (NIH/NIAID) [E] (b) (6)
Sent: Thursday, April 23, 2020 11:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Subject: FW: Successful Submission of a Manuscript to Science (abc4208)

This is the acalabrutinib paper today submitted to Science. NEJM was interested but wanted a month delay to be sure about the results but some of the authors (Not the NIAID one) balked and have gone elsewhere. Just keeping you in the loop.

Steve

--
Director, Division of Intramural Research National Institute of Allergy and Infectious Diseases National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960
(b) (6) voice
301-480-4507 fax
(b) (6)

Assistant lab: Eva Portillo
(b) (6)
(b) (6) voice

Assistant to SD: Beth Schmidt
(b) (6)
(b) (6) voice

On 4/23/20, 1:59 PM, "Lionakis, Michail (NIH/NIAID) [E]" (b) (6)> wrote:

> Attached the submitted paper, which will be deposited to MedRxiv.org today I think.
> Mihalis
>
> On 4/23/20, 1:34 PM, "science_editors@aaas.org" <science_editors@aaas.org> wrote:
>
> > Manuscript Title: Inhibition of Bruton Tyrosine Kinase in Patients with Severe Covid-19
> > Author: Lionakis
> > Manuscript Number: abc4208
> >
> > Dear Dr. Lionakis:
> >
> > You are listed as a coauthor on the above manuscript, which has recently been submitted to Science.

According to Science policy, all authors must have seen and approved the submission of their manuscript. If you have seen the manuscript and approved its submission, no action is necessary.

If you have not read this paper or do not approve its submission to Science, please let us know as soon as possible. Please refer to the manuscript number listed above in any correspondence (you can just reply to this message).

You can see the status of your manuscript at any time by logging into your account at the Science Journals Submission and Information Portal at https://cts.sciencemag.org.

If you do not yet have an account, please go to https://cts.sciencemag.org/scc/#/forgot-password and use the email at which you received this correspondence because that is linked to your manuscript. Then, follow the prompts to set your password and login. After login, you can access your manuscript and monitor its status.

Once you are registered, we encourage you to link your account to your ORCID ID, an identifier that facilitates the correct attribution of your publications to you. To learn more about ORCID or to obtain an ORCID ID, visit their site at: http://orcid.org.

Your manuscript is now undergoing an initial screening to determine whether it will be sent for in-depth review. If the manuscript is sent to review, its status will change to "To Review".

Sincerely,
The Editors
Science

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 01:58:36 +0000
To: Greg Folkers [redacted] (b) (6)
Subject: FW: HIVR4P postponed to 17-21 January 2021

FYI. See yellow highlighted request.

From: HIVR4P - Secretariat <secretariat@hivr4p.org>
Sent: Thursday, April 23, 2020 11:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: HIVR4P postponed to 17-21 January 2021

HIV R4P HIV RESEARCH FOR PREVENTION
CAPE TOWN, SOUTH AFRICA - 17-21 JANUARY 2021

Dear Dr. Fauci,

As the research community responds to the global challenges of the COVID-19 pandemic, HIV prevention science matters as much as ever. Our priority as organizers of the HIV Research for Prevention (HIVR4P) conference remains the safety and wellbeing of all participants.

After careful consideration, we have decided to postpone the HIVR4P conference to **17-21 January 2021**. Updated details for the session(s) are listed below:

Session title:	HIV prevention 2020 – Where are we now and where are we going?
Session type:	Opening plenary
Suggested presentation title/topic:	Much accomplished; Much to do – An overview on HIV prevention research
Session description:	Today's plenary sets the stage for the conference week ahead, outlining the big-picture challenges we face in research, product development and access to prevention. Speakers will provide diverse perspectives on the state of the field today, the opportunities and obstacles ahead and priorities for action moving forward.
Session date and time:	**Monday, 18 January 2021 - 16:00-18:00**

Meet the Experts lunches
We invite you to host an informal table discussion at a Meet the Experts lunch on **20 January 2021, 12:00-13:00**. Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges and HIV-affected communities.

Please reply to this email by Wednesday, 6 May if you are still available to deliver this important presentation and, if so, please also include a photo and a brief biography.

We are acutely aware many researchers and research organizations with critical studies and submissions to HIVR4P are now also heavily engaged in the COVID-19 response. Our hope is that postponing the conference, rather than presenting it virtually in October, will allow for the broadest participation to foster knowledge-exchange, debate and direction-setting in the field of HIV prevention research that HIVR4P is known for.

Thank you for your consideration.

Sincerely,

HIVR4P - Secretariat
HIV Research for Prevention

W: (b) (6)
Avenue de France 23 | CH-1202 Geneva | Switzerland

HIVR4P Conference | 17-21 January 2021 | Cape Town, South Africa

HIVR4P.org @HIVR4Px /HIVR4P

From: HIVR4P - Secretariat
Sent: 21 February 2020 16:57
To: (b) (6)
Cc: Bargavi Thyagarajan (b) (6)
Subject: HIVR4P 2020 - Invitation to present

HIV RESEARCH FOR PREVENTION
CAPE TOWN, SOUTH AFRICA - 11-15 OCTOBER 2020

Dear Dr. Fauci,

We are writing with great pleasure to invite you to present at the 4th HIV Research for Prevention Conference (HIVR4P 2020) in Cape Town, South Africa, from 11-15 October 2020. HIV Research for Prevention is the only global scientific conference focused exclusively on the challenging and fast-growing field of HIV prevention research. HIVR4P fosters interdisciplinary knowledge-exchange on HIV vaccines, microbicides, PrEP, treatment as prevention and biomedical interventions as well as their related social and behavioural implications.

Details for the session(s) are listed below:

Session title:	HIV prevention 2020 – Where are we now and where are we going?
Session type:	Opening plenary
Suggested presentation title/topic:	Much accomplished; Much to do – An overview on HIV prevention research
Session description:	Today's plenary sets the stage for the conference week ahead, outlining the big-picture challenges we face in research, product development and access to prevention. Speakers will provide diverse perspectives on the state of the field today, the opportunities and obstacles ahead and priorities for action moving forward.
Session date and time:	Monday, 12 October 2020 - 16:00-18:00

Meet the Experts lunches

We invite you to host an informal table discussion at a Meet the Experts lunch on **14 October 2020, 12:00-13:00**. Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges and HIV-affected communities.

As an invited-speaker, you would be eligible to receive:

- Complimentary conference registration;
- Roundtrip economy airfare arranged through the HIVR4P travel agency; and
- Accommodation at one of the hotels pre-blocked by the conference secretariat.

To accept this invitation, please reply to this email by **Thursday, 27 February** and include a photo and a brief biography. Please find also attached for your record the official invitation signed by the HIVR4P 2020 Co-Chairs.

We ask that you please send any questions to the HIVR4P Secretariat at secretariat@hivr4p.org.

Thank you for your consideration. We look forward to you joining us in Cape Town!

Sincerely,

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 01:30:49 +0000
To: blonda quirico
Subject: RE: estimation of dynamics of COVID-19 in USA new simulations at 23 April 2020

Thanks.

From: blonda quirico <[redacted] (b) (6)>
Sent: Thursday, April 23, 2020 5:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; COPPIETERS'T WALLANT Yves [redacted] (b) (6)>
Subject: estimation of dynamics of COVID-19 in USA new simulations at 23 April 2020

Tony,

We send you our simulations.

Best regards.

Quirico

Le mercredi 22 avril 2020 à 00:09:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> a écrit :

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: blonda quirico [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 11:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); COPPIETERS'T WALLANT Yves [redacted] (b) (6)>
Subject: Re: estimation of dynamics of COVID-19 in USA new simulations at 21 April 2020

Tony,

Professor COPPIETERS and I, we send you our new simulations :

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = more than 850610 people infected and detected;

- date of epidemic peak = +/- 7 April 2020 with theorical new cases - in one day during this peak - about +/- 35520;

- end of epidemic = +/- 19-28 June 2020 (we use two methods);

- mortality at the end of epidemic :

** if death rate 5% = +/- 42.530 deceased people (for the moment the death rate = 5%)

** if death rate 10% = +/- 85.060 deceased people

You reached 91,1 % of the theorical logistic curve.

Best regards.

Quirico

00 32 475 48 68 42

Le dimanche 19 avril 2020 à 15:57:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> a écrit :

Quirico:

Thanks again! Please keep this information coming to me.

Best regards,

Tony

From: blonda quirico [redacted] (b) (6)>
Sent: Sunday, April 19, 2020 5:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; COPPIETERS'T WALLANT Yves
[redacted] (b) (6)
Subject: Re: estimation of dynamics of COVID-19 in USA new simulations at 18 April 2020

Tony,

We send you our new simulations.

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = more than 779000 people infected and detected;

- date of epidemic peak = +/- 7 April 2020 with theorical new cases - in one day during this peak - about +/- 35063;

- end of epidemic = +/- 4-13 June 2020 (we use two methods);

- mortality at the end of epidemic :

** if dead rate 5% = +/- 40000 deceased people

** if dead rate 10% = +/- 80.000 deceased people

You reached 87.5 % of the theorical logistic curve.

Best regards.

Quirico

00 32 475 48 68 42

Le lundi 6 avril 2020 à 03:32:35 UTC+2, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> a écrit :

Dr. Blonda:

Thank you for sending me this information. I appreciate it.

Best regards,

Tony

From: blonda quirico [redacted] (b) (6)
Sent: Sunday, April 5, 2020 9:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; COPPIETERS'T WALLANT Yves [redacted] (b) (6)>
Subject: estimation of dynamics of COVID-19 in USA

Professor Anthony FAUCY,

Sorry to disturb during the COVID-19 in USA.

But I would you inform about the COVID-19 in USA.

I'm medical doctor in Belgium.

With my teacher Professor Yves COPPIETERS (Ecole de santé publique - ULB - Brussels), we make simulations about the COVID-19 for many countries.

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = +/- 462760 people infected and detected;

- date of epidemic peak = +/- 1- 2 April 2020 with theorical new cases - in one day during this peak - about +/- 28390;

- end of epidemic = +/- 15 May 2020;

- mortality :

** if dead rate 5% = +/- 23140 deceased people

** if dead rate 10% = +/- 46275 deceased people

If you are interrested by our simulations, you can contact us.

Best regards.

Dr Quirico BLONDA

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 00:50:12 +0000
To: [redacted] (b) (6)
[redacted]
Subject: FW: The Tablet I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.

You have got to read this!!!

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, April 23, 2020 7:21 PM
To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: The Tablet I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.

https://thetablet.org/only-in-print-dr-faucis-roots-in-dyker-heights/


ADVERTISE | CLASSIFIEDS | CONTACT US
THE TABLET
Search ...
GO
NEWS
OPINION
PARISHES
SCHOOLS
SPORTS
AROUND THE DIOCESE
SUBSCRIBE
Fauci PHARMAC
LSTERING

CORONAVIRUS

Only in Print: Dr. Fauci's Roots in Dyker Heights

April 8, 2020

Dr. Anthony Fauci meets with Regis High School students and the school's president, Father Daniel Lahart S.J., in 2019. Fauci (whose family owned a neighborhood pharmacy in Dyker Heights) is a 1958 graduate of the Jesuit school. (Photo: courtesy of Fauci family)

CATHOLIC NEWS SERVICE

Religious education continues in different format during pandemic

Bishops in Amazon urge Peru to guard indigenous needs during pandemic

April 15, 2020
Volume 15

From the Neighborhood
by Frank Derosa

Frank DeRosa retired as Associate Publisher of The Tablet and director of the Diocesan Public Information Office in 2008

When I see Dr. Anthony Fauci on the TV screen explaining expertly everything we need to know about the coronavirus pandemic, I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.

Steve Fauci was the neighborhood pharmacist.

The Fauci Pharmacy stood on the southwest corner of 13 th Ave. and 83 rd St., in the Dyker Heights section of Brooklyn, diagonally across from the Shrine Church of St. Bernadette. We lived two blocks away on 85 th .

Long ago parishioners like me remember what the store looked like, the soda fountain that ran along the right wall, the telephone booths at the left close to the entrance and the counter straight ahead down the center.

Whenever my mother sent me there, Mr. Fauci would be behind the counter, but it was a family enterprise. They lived in an apartment above the store, and if the patriarch wasn't serving you, his wife, Eugenia, or daughter, Denise, was there. Young Anthony, I've since learned, pitched in too, his father sending him out on his bike to deliver items to customers.

I've never met the man who has become the most important medical voice in the country. Nor have former parishioners that I've spoken to about him in recent days, like boyhood pals Anthony LoFrisco, from 80th St., now in Connecticut, and Bob Orlando, who lived on 84th, now a New Jersey resident, as well as Bishop Gerald Barbarito of the Palm Beach Diocese, from 11th Ave. But each remembers the pharmacy as a Dyker Heights institution.

While we don't know him personally, in a sense he's become everyone's friend. With his steady television presence, he's imparted his vast knowledge and straightforward advice in a trademark, sometimes gravelly or raspy, Brooklyn accent that has endeared him to people far and wide. You can't be anything but proud of someone of his prominence who came from the parish.

Anthony became known as Tony, as he tells it, when Father Flanagan, principal of Regis High School, decided to call him that on his first day as a freshman. The name stuck.

Tony took buses and trains to the Jesuit school in Manhattan, including the old Sea Beach Express. He traveled 70 minutes each way, did three hours of homework, captained the basketball team and excelled in the classroom.

I remember hearing that when Tony was a high schooler, he had a part-time job working in St. Bernadette's rectory, answering the phone and doing whatever else parishioners wanted him to do to put them in touch with one of the parish priests. In those days, the rectory had a priestly bonanza. There were four of them.

Because St. Bernadette's School had not yet been established, Tony went to Our Lady of Guadalupe School, where he was taught by Dominican Sisters. It was, and is, St. Bernadette's neighboring parish.

Like most kids, he loved sports. He played CYO baseball and basketball. At Dyker Park on 86th St., he and his friends developed skills in imitation of their heroes. A Yankee follower living in the midst of Brooklyn Dodgers fans who adored The Boys of Summer, he's said his favorite players were Joe DiMaggio and Mickey Mantle.

Tony's father and mother married at 18, after they graduated from New Utrecht High School. Steve went on to Columbia to study pharmacy.
Sometime after he opened his pharmacy, he became friends with Father Al Varriale, one of St. Bernadette's beloved parish priests. At one point, Steve, as a parent, and the priest known as Father V, who directed the parish's robust CYO sports program for youths, shared a concern. It was the easy availability of indecent

and immoral publications that they knew was a threat to the moral development of young people.
So, with the approval and support of the Diocese of Brooklyn, together they formed a diocesan commission against pornography. Both men are now long gone, and so is the commission, but it was a good idea, though it did not survive them.

Remarkably, just a few houses up the block from where Steve established his pharmacy, lived the Pellegrinos, another family of St. Bernadette's parishioners that produced a renowned medical professional. The eldest son, Edmund, became a bioethicist, a "preeminent" one, as one newspaper described him after he died. But he was more. He helped develop medical programs at Kentucky, Stony Brook and Tennessee Universities. Later, he took on the presidency of The Catholic University of America. Then, after completing his tenure there, he became, as physician and philosopher, the director of the Kennedy Institute of Ethics at Georgetown University.

Though years apart in age, both Dr. Fauci and Dr. Pellegrino became
Hippocratic stars, nurtured on the same block.

Only in Brooklyn, I say, not without bias.

Steve Fauci was known by members of his extended family and friends for his personality, kindness, sense of humor and wit, and for telling good stories. So they said in comments after he died in 2008.

Tony appears to have inherited Steve's gene for lightheartedness. His
daughter once told the Washington Post that her dad could be a "goofball. . .he works hard and does his thing, but he comes home and he's singing opera in the kitchen and dancing around."

That kind of calm can help a man maintain his balance as he deals with the pressure of talking to millions of people every day about the complexity of a global pandemic.

As one newsman said, "When Fauci appears on the screen, you turn up the volume."

He once said the Jesuits at Regis and Holy Cross College taught him the
importance of "precision of thought and economy of expression."

That's what he delivers every day: accurate information given concisely.

That's Tony Fauci, now a national treasure. And to think, he came from the neighborhood.

Dr. Anthony Fauci

THE PRESIDENT'S CORONAVIRUS GUIDELINES FOR AMERICA
30 DAYS TO SLOW THE SPREAD

He graduated from Regis High School and the College of Holy Cross.
He graduated number one in his class at Cornell Medical School in 1966.
He completed his medical residency at New York Hospital
In 1984, he became director of National Institute of Allergy and Infectious Diseases, a position he holds today.

Front row, kneeling

REGIS
14
34
22
32
24
4



Stephen A. Fauci

New Utrecht High Schoo

Dante Circle
Vox Populi

Steve was once known as the champ city sprinter, now he excells as the class great jester. A regular fellow with a ready smile and full of spirit. You could always count on Steve being present at every class and school affair.

Fauci PHARMAC
LSTERING

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 00:35:33 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Another Possible Tool in The Fight Against SARS-CoV-2 ?

Pleas take a look and figure out where to send it.

From: Gary Radin <GRadin@dhs.lacounty.gov>
Sent: Thursday, April 23, 2020 8:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Another Possible Tool in The Fight Against SARS-CoV-2 ?

Dr. Fauci---Forgive the crude and unsolicited manner in which I am attempting to reach out to you but I don't really KNOW any other way !
I am not a medical doctor nor am I a principle investigator. I am just a Cytologist employed in the Anatomic Pathology department at LA County-USC Medical Center here in Southern California.
But I have been reading a lot--- and in my own exploration I have come across several articles which suggest the possibility of using a class of agents called
SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS in combination with antivirals like oseltamivir (or perhaps Remdesivir?) to treat both the viral pathogen responsible for the current pandemic as well as the runaway immune response of the host leading to the oft fatal cytokine storms.

Apparently these compounds have been approved for flare-ups of multiple sclerosis, and have even been tried on Alzheimer's patients. The commonly known drug is FINGOLIMOD. But these papers that I have cited for you below seem to indicate that structural analogs of this compound could be important in damping down the dysregulated pro-inflammatory cascades which seem to be leading to DIC, alveolar exudates and diffuse alveolar damage, capillary leak syndrome and ultimately the multiple organ failure that is killing an unacceptably high number of people.

The fly in the ointment Dr. Fauci here is that these S-1-PR agonists have only been demonstrated to be effective in non-human primates and other mammals. And much of these studies on these compounds has been done not on coronaviruses but on influenza viruses.
So it would be a gamble. But is that not how we have learned much about human health and disease is by the gracious sacrifice of our animal cousins ? And might it not be a general effect that these sphingosine derivatives have on viral sepsis so that maybe what works for influenza might work for the coronavirus?
In the dire situation that many of the most critically ill COVID 19 patients find themselves, it seems they are on the precipice of a rapid demise once they begin to show certain key laboratory results---(spikes in D-DIMER, C-Reactive Protein, Serum Ferritin, prolongation of

prothrombin and APTT, increased cardiac troponin 1, surges in IL-6, IL-7, monocytic and macrophage chemo-attractant cytokines etc).

With patients isolated by these aberrant lab values, the window may be narrow but it may be a time where application of antiviral compounds in combination with these inflammatory modulators could have a striking impact on mortality? Indeed maybe even TWO different antivirals with differing mechanisms of action in combination with these S1-PR Agonists would even be better. And the possibilities of other combinations of course would be there for further exploration.

Fully cognizant of the Hippocratic Oath to 'first do no harm' I still believe that at least the medical rationale is sound for the inclusion of these agents into the possible arsenal of therapeutics for the more severe COVID 19 patients.

Please refer below to the studies I found particularly helpful or promising. Perhaps you can put together some 'teams' to further explore investigate these options ??

We all appreciate everything you have done, and continue to do !

Gary Radin

https://www.sciencedirect.com/science/article/pii/S0140673620303056

https://www.pnas.org/content/108/29/12018

https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0042682214000063?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0042682214000063%3Fshowall%3Dtrue&referrer=

PNAS
Tunicamycin transporter

Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus | PNAS

Human pandemic H1N1 2009 influenza virus rapidly infected millions worldwide and was associated with significant mortality. Antiviral drugs that inhibit influenza virus replication are the primary therapy used to diminish disease; however, there are two significant limitations to their effective use: (i) antiviral drugs exert selective pressure on the virus, resulting in the generation of ...

www.pnas.org

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study - The Lancet

The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.

www.thelancet.com

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176439/

Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection - PubMed Central (PMC)

Cytokine storm during viral infection is a prospective predictor of morbidity and mortality, yet the cellular sources remain undefined. Here, using genetic and chemical tools to probe functions of the S1P 1 receptor, we elucidate cellular and signaling mechanisms important in initiating cytokine storm. While S1P 1 receptor is expressed on endothelial cells and lymphocytes within lung tissue ...

www.ncbi.nlm.nih.gov

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 22:47:07 +0000
To: Billet, Courtney (NIH/NIAID) [E];Greg Folkers [redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Sammies recognition this year – congratulations
Attachments: AFauci, NIH.pdf

Please take a look at this and let us discuss. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Max Stier <mstier@ourpublicservice.org>
Sent: Thursday, April 23, 2020 2:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6); Sammies <Sammies@ourpublicservice.org>
Subject: Sammies recognition this year – congratulations

Dr. Fauci:

I hope you are healthy and well. The Partnership for Public Service is honored to inform you that we have selected you as a finalist for the 2020 Samuel J. Heyman Service to America Medals, otherwise known as the Oscars of government service.

You were nominated by Francis Collins for your outstanding career at NIAID and the work you are currently doing on behalf of the American people to prepare, inform and protect lives in our country and around the world during this uncertain time. Your work truly embodies the best of government that we strive to recognize through the Sammies program.

Attached, I've included the profile we have drafted to summarize your work and accomplishments – both for recognizing you as a finalist and for having the selection committee vote for the award recipients. Should you have any edits or wish to add a personal quote, please send those to us at your convenience. We will be releasing your profile publicly with the rest of the finalists on Sunday, May 3.

Again, thank you for the work you do on behalf of the NIH and our country.

Best,

Max Stier
President and CEO
Partnership for Public Service

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 22:37:35 +0000
To: Greg Folkers [redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Thursday, April 23, 2020 1:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
[redacted]
Cc: Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6);
[redacted] (b) (6)
[redacted] 'ben.tinker@cnn.com' <ben.tinker@cnn.com>; 'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>; 'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>; 'Tia.Miller@turner.com' <Tia.Miller@turner.com>; [redacted] (b) (6)
[redacted] >; McGinnis, J. Michael <MMcGinnis@nas.edu>; [redacted] (b) (6)
[redacted] (b) (6); Mun, Jenny <JMun@nas.edu>; [redacted] (b) (6)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,

I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.

I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.

I would greatly appreciate it if you would respond to this email.

Best,
Victor

PS, [redacted] (b) (6), my special assistant, will be sending you additional information about the session logistics shortly.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Thursday, April 9, 2020 11:01 AM
To: Mun, Jenny <JMun@nas.edu>; [redacted] (b) (6)
Cc: [redacted] (b) (6)>; Hannon, Emma <EHannon@nas.edu>; 'conradpa@niaid.nih.gov' [redacted] (b) (6)>; 'T.MillerdeVega@wellcome.ac.uk' [redacted] (b) (6)>; 'jsi@cepi.net' [redacted] (b) (6) 'rebeka.yasmin@cepi.net' [redacted] (b) (6)>; 'ben.tinker@cnn.com' <ben.tinker@cnn.com>; 'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>; 'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>; 'Tia.Miller@turner.com' <Tia.Miller@turner.com>; [redacted] (b) (6)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny
Sent: Wednesday, April 8, 2020 10:56 AM
To: (b) (6)
[redacted]
Cc: Dzau, Victor J. ; (b) (6) ; Mun, Jenny ; Hannon, Emma ; (b) (6) ;
(b) (6) 'ben.tinker@cnn.com' ; 'Amanda.Sealy@cnn.com' ; 'Neel.Khairzada@turner.com' ; 'Tia.Miller@turner.com'
Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (https://www.youtube.com/user/theNASciences) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13.**

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT)** to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases
Jeremy Farrar, Director, Wellcome Trust
George F. Gao, Director-General, Chinese Center for Disease Control & Prevention
Sanjay Gupta, Chief Medical Correspondent, CNN
Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations
Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as "sharing your screen" (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

****

Jenny Mun
Membership Director
National Academy of Sciences
jmun@nas.edu
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 22:36:33 +0000
To: Cassetti, Cristina (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];[redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: FW: New sheet
Attachments: COVID.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dani Bolognesi, Ph.D. <[redacted] (b) (6)
Sent: Thursday, April 23, 2020 1:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: FW: New sheet

Hi Tony:

I hesitate to bother you with this as I am sure that you are inundated with requests of this sort over and above everything else you are doing which is truly magnificent. I believe that there is something of potential importance in what is communicated below but you are in the best position to tell me whether it could fit in the toolbox you are assembling for COVID 19 in both the short and longer term. I have to acknowledge our friend Bob Gallo for triggering this

[redacted] (b) (4)

(b) (4)

[redacted]

Reaching out to you to see if you think this approach has merit. Since your time is so precious, I do not expect you to review this but perhaps you can forward to one of your trusted colleagues.

PPS. Loved the interview with Coach K!

Con un forte abbraccio!

Dani

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 22:25:14 +0000
To: [redacted] (b) (6)
Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC https://bit.ly/2yynEPf

I may have already sent this to you, but I do not think so. It is short (6 minutes) but it has a segment that shows me 37 years ago. Yikes!!! You will get a chuckle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
Sent: Thursday, April 23, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC https://bit.ly/2yynEPf

Kim Barasch [C]
Office of the Director
National Institute of Allergy & Infectious Diseases
[redacted] (b) (6)
[redacted] (b) (6)

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 11:06 PM
Subject: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC https://bit.ly/2yynEPf


NIH - 1984
PANDEMIC RESPONSE
DR. FAUCI TIRELESSLY CANVASSING MEDIA WITH FACTS
MSNBC
1:43 / 6:22

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 22:14:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: A proposal to stop COVID-19 and reopen our schools and businesses
Attachments: Scientists_to_Stop_COVID19_2020_04_23_FINAL.pdf

Email below from David Liu.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone (b) (6)
Email: (b) (6)

From: David Liu (b) (6)
Sent: Thursday, April 23, 2020 6:01 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Austin, Christopher (NIH/NCATS) [E] (b) (6)>; Wholley, David (FNIH) [T] (b) (6)>; Freire, Maria (FNIH) [T] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>
Cc: Michael Rosbash (b) (6)>; Ramnik Xavier (b) (6)>; EDWARD SCOLNICK (b) (6); Stuart Schreiber (b) (6)>; Michael Z Lin (b) (6)>; Ben Cravatt (b) (6)>; Thomas Cahill (b) (6) R. Scott Kemp (b) (6)
Subject: Re: A proposal to stop COVID-19 and reopen our schools and businesses

Dear Francis, Anthony, Cliff, Christopher, David, Maria, and Lawrence,

I hope you are all well. Attached is the updated set of four proposals on:

1) Rapid repurposing of antiviral drugs to treat COVID-19;
2) Expedited development of neutralizing monoclonal antibodies to treat COVID-19;
3) Rapid COVID-19 vaccine development;
4) Risk-reduced ways to reopen schools and businesses, and the healthcare system changes that are needed to enable them.

We hope you find these updated proposals useful, and would be happy to engage in any way that could be helpful.

Sincerely yours,

Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin (Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brandeis), Stuart Schreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier (MGH/Broad)

David R. Liu
Richard Merkin Professor and Director of the Merkin Institute
of Transformative Technologies in Healthcare
Director of the Chemical Biology and Therapeutic Sciences Program
Core Institute Member and Vice-Chair of the Faculty, Broad Institute
Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of the Natural Sciences
and Professor of Chemistry & Chemical Biology, Harvard University
75 Ames Street
Cambridge, MA 02142

On Apr 19, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> wrote:

Dear David et al.,

Thanks for forwarding this very thoughtful document, which presents a series of important recommendations – most of which I agree with. I don't know if you saw Friday's announcement (attached) of the new public private partnership called ACTIV (for Accelerating COVID-19 Therapeutic Interventions and Vaccines), but it has taken on most of the points you raise in sections 1 – 3 of your letter. I share your hopes that remdesivir will show benefit, and the current large NIH-sponsored RCT has completed enrollment and should reveal results in about a month. But of course we want to test multiple other interventions – both small molecules and antibody-based therapies, so we need our trial system to be optimized like never before. I will share your letter with the leaders of ACTIV, who are working with unprecedented speed to prioritize the next set of therapeutic candidates as well as pushing vaccine development programs to adopt exceptionally creative trial designs to test safety and efficacy (with full engagement by FDA).

Best regards, Francis

From: David Liu [redacted] (b) (6)
Sent: Sunday, April 19, 2020 5:20 PM
To: OD Labc (NIH/OD) [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Cc: Michael Rosbash [redacted] (b) (6)>; Ramnik Xavier [redacted] (b) (6); EDWARD SCOLNICK [redacted] (b) (6); Stuart Schreiber < [redacted] (b) (6)>; Michael Z Lin [redacted] (b) (6); Ben Cravatt [redacted] (b) (6)
Subject: A proposal to stop COVID-19 and reopen our schools and businesses

Dear Francis,

I hope you are well.

I write on behalf of a group of citizen-scientists, most or all of whom you know. Motivated solely by our desire to help defeat the serious threat our nation and the world now faces, we wrote a set of four actionable, non-partisan proposals (attached) to produce safe and effective COVID-19 therapeutics and vaccines in the shortest possible timeframe, and to reopen our society in a manner that reduces the risk of future COVID-19 outbreaks.

We hope you find these ideas interesting, and might be willing to share this set of proposals with Dr. Tony Fauci, along with our willingness to discuss any part of the proposals with him if we can be helpful. We understand from our efforts to contact Dr. Fauci through email routes that his standard inbox may be too overwhelmed for our proposal to reach him.

The four proposals attached describe: (1) How to rapidly repurpose an antiviral drug to treat COVID-19 patients; (2) How to expedite the development of human antibody drugs to treat patients and to provide short-term protection for healthy individuals; (3) How to develop COVID-19 vaccines on an expedited time scale; and (4) How to reopen our businesses and schools in a manner that reduces the risk of future outbreaks and deaths.

Thank you for any help or thoughts you might be able to provide.

Sincerely yours,
Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin (Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brandeis), Stuart Schreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier (MGH/Broad)

____
David R. Liu
Richard Merkin Professor and Director of the Merkin Institute
of Transformative Technologies in Healthcare
Director of the Chemical Biology and Therapeutic Sciences Program
Core Institute Member and Vice-Chair of the Faculty, Broad Institute
Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of the Natural Sciences
and Professor of Chemistry & Chemical Biology, Harvard University
75 Ames Street
Cambridge, MA 02142

<NIH_ACTIV_Release_041720.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 21:47:13 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: White House Coronavirus Task Force Meeting - 4.24.20

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

[redacted] (b)(5) - PCP

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 21:40:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Update: White House Coronavirus Task Force Meeting

Heads-up! Change in schedule for tomorrow.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP
[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 21:29:50 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC https://bit.ly/2yynEPf

https://bit.ly/2yynEPf

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
Sent: Thursday, April 23, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC https://bit.ly/2yynEPf

Kim Barasch [C]
Office of the Director
National Institute of Allergy & Infectious Diseases
[redacted] (b) (6)
[redacted] (b) (6)

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 11:06 PM
Subject: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC https://bit.ly/2yynEPf

NIH - 1984
PANDEMIC RESPONSE
DR. FAUCI TIRELESSLY CANVASSING MEDIA WITH FACTS
MSNBC
1:43 / 6:22

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: [redacted] (b) (6)
Sent: Thu, 23 Apr 2020 14:34:36 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Thank you, and...
Attachments: image002.png, ATT00001.htm, PasstheMic Expert Outreach.pdf, ATT00002.htm

Let us discuss

Begin forwarded message:

> **From:** Gayle Smith <gayle.smith@one.org>
> **Date:** April 23, 2020 at 1:49:04 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** Tom Hart <tom.hart@one.org>
> **Subject: Thank you, and...**
>
> Dear Tony,
>
> I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. As an American, a former colleague, a long-time admirer and student of your wisdom – thank you. We are all safer because of you, and the world will be a better place because of you. Again.
>
> As you know, I am now leading the ONE Campaign. We've been quite active with the ONEWorld Campaign, dedicated to the fight against this newest virus, and focused on Africa. We've made some progress on debt, and next up is a focus on ensuring that a vaccine, when it comes, is available to everyone.
>
> One of the things we want to do is educate people, in all of the places we work. It won't surprise you that of particular urgency amongst our partners in Africa is that facts and information get to people across the continent, but we also know that more facts are needed everywhere. So next month we are going to launch #PassTheMic, where every day for 19 days we will ask a celebrity to turn his or her social media channels over to an expert on COVID-19 for one day. So Julia Roberts might turn her Twitter account to you to talk about the critical elements needed to flatten the curve and slow the spread. Or Idris Elba could give up his Instagram to the head of the African CDC so that he can illustrate the impact COVID-19 will have across Africa and what that means for the rest of the world.
>
> We know artists want to be helpful right now, but that it is hard to know what to do. And we know there are experts like you out there who have the answers. We've thought about this a lot at ONE and wanted to do something we felt would truly have an impact. As we look ahead we know COVID-19 does not know borders and until it is beaten everywhere

we are not in the clear. We need a global response plan and we need it now. By turning over their platforms for the day, celebrity influencers will be donating one of their biggest assets – their followers – to YOU, giving you the platform you need (and we all need) to tell the world why a global response is critical. Because none of us are safe until all of us are safe.

We will work with each expert/celebrity pair to personalize the content to our and our celebrity partners' audiences – in North America, Europe and Africa, and help create content that both parties are happy with. We are now confirming our talent partners, and so far are getting a terrific response.

We know you're a busy man, so we've planned it so that the amount of time on your end would be minimal. But the impact would be maximal.

I'm attaching more information about the campaign. Please let me know what you think and if you have questions. Ideally we would like to get this off the ground in early May, so are hoping to confirm folks by April 28th at the latest. Our team will be in touch with your office to follow up.

Thanks as always for everything you do. All my best to you, Gayle

ONE

Gayle Smith | President & Chief Executive Officer | [redacted] (b) (6)

ONE.ORG | Twitter | Facebook | Instagram

ONE is a global movement campaigning to **end extreme poverty and preventable disease by 2030** so that everyone, everywhere can lead a life of dignity and opportunity.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 18:25:56 +0000
To: Simmons-Butler, Kirk (NIH/NIAID) [C]
Subject: Re: Thank you Dr. Fauci!
Attachments: image001.png, image002.gif

Kirk:
Thank you for your kind note. Much appreciated.
Best regards,
Tony

> On Apr 23, 2020, at 2:16 PM, Simmons-Butler, Kirk (NIH/NIAID) [C] [redacted] (b) (6) wrote:
>
> Greetings Dr. Fauci,
> I just wanted to take a moment to personally thank you for all of your support and leadership during these unprecedented times. I am proud to be a part of the NIAD family and you represent us and the country well! God continue to bless and keep you and your family! Thank you again sir!
>
> **Regards,**
> **Kirk**
>
> **Kirk D. Simmons-Butler, M.S.**
> **Assistant Facility Manager 14DNR, Charles River Laboratories Inc.**
> **NIH/NIAID**
> **(Office)** [redacted] (b) (6)
> **(Fax) (301) 761-6013**
> **Charles River website -** www.criver.com
>
> <image001.png>
>
> <image002.gif>
>
> **The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it**

from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Disease (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Friday, March 27, 2020 11:55 AM
To: NIAID Announcements <NIAID-announce@niaid.nih.gov>
Subject: Platelet Donations Down are Down Amid Coronavirus Outbreak -- Please Donate

Dear Colleagues:

The NIH Platelet Donor Center has an urgent need for healthy individuals to give lifesaving platelets to patients. The need for platelet donations is especially acute now with the coronavirus pandemic. While social distancing and increased telework are necessary to contain and slow the spread of coronavirus, we have seen a marked decline in platelet and blood donations for our patients.

To alleviate this shortage, NIAID and the Department of Transfusion Medicine (DTM) are co-sponsoring a two-week Platelet Drive from March 30 – April 10. Platelet collections, as well as whole blood and Double Red Cell donations, can only be made at the NIH Blood Bank on campus in Building 10, Room 1C713 Monday through Friday from 8:00 am to 5:00 pm. The Platelet Center at Fishers Lane is temporarily closed and platelet collections are now on the main campus through at least the next 30 days. This move helps to ensure that blood donors are protected by visitor screening, minimizing possible exposure to individuals at risk.

What is a double red cell donation? A double red cell donation enables donors to donate two units of red blood cells in one visit. During a procedure called apheresis, whole blood is separated through a cell separator and red blood cells are collected. The remainder of the blood components are returned to the donor along with saline to replace the lost volume.

I encourage participation of all employees who are eligible to provide a donation to benefit our NIH patients. I understand employees may be hesitant to participate under the current conditions, but I would like to reassure you that blood donation is a safe process. Additional precautions have been put in place at our Blood Bank to help prevent the spread of infection and protect the health of donors and staff.

Thank you to all who support our quarterly platelet drives. Your efforts provide a lifeline for our patients. Those who participated in the last drive are now eligible to help once again. In appreciation of your dedication to helping others, NIAID grants administrative leave to any NIAID federal employee who donates platelets at the NIH Blood Bank. Specifically, you will be granted 4 hours of administrative leave to be used immediately following your platelet donation appointment. As always with such activities, please notify your supervisor for approval prior to donating at the NIH Platelet Center.. Contractor employees should speak directly to their contract companies to determine what leave options are available. Please contact the Donor Center at 301-496-4321 to schedule your appointment. Let the Donor Center staff know you are with the NIAID Platelet/Double Red Cell Drive. They will answer eligibility questions and provide information about the donation process.

Thank you for considering donating during this stressful time. Best regards.

Sincerely,
A.S. Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: **(301) 496-4409**
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

NATIONAL INSTITUTES OF HEALTH

CHARLES RIVER
LABORATORIES

NATIONAL INSTITUTES OF HEALTH

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 17:39:48 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] [redacted] (b) (6)
Subject: FW: Wellness Initiative Proposal
Attachments: Wellness Initiative_POC_Sundar.zip, Wellness Initiative Proposal_Sundar.pdf, Managing Anxiety Around COVID-19 March 27 (007).pdf

Please take a look at this and handle.

From: Sundar, Sachin (NIH/NIAAA) [F] [redacted] (b) (6)>
Sent: Thursday, April 23, 2020 1:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Wellness Initiative Proposal

Dear Dr. Fauci,

I have an idea regarding science communication and wellness. Here's a rough proposal and proof of concept. At full effect, I think it could have noteworthy potential. [redacted] (b) (5)

Thank you for your time.

Respectfully,
Sachin Sundar

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 13:25:22 +0000
To: Stephen L. Hoffman
Subject: RE: Follow Up Thanks

Thanks, Steve. I appreciate your note.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stephen L. Hoffman <slhoffman@sanaria.com>
Sent: Wednesday, April 22, 2020 9:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Follow Up Thanks

Dear Tony,

I hear continuously from people from all walks of life how grateful they are for your presence on the COVID-19 team. You are performing an incredible service to our country and the world.

Thanks again,

Steve

Stephen L. Hoffman, M.D.
Chief Executive and Scientific Officer
Sanaria Inc.
9800 Medical Center Dr. ste 209a
Rockville MD 20850
tel: (b) (6) (work)

tel: (b) (6) (mobile)
fax: 301-770-5554
E-Mail: slhoffman@sanaria.com
www.sanaria.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 13:00:55 +0000
To: Redfield, Robert R. (CDC/OD)
Cc: Allison Arwady;David Barr;Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Dr. Fauci asked me to send Chicago question
Attachments: Workforce_Proposal_Chicago_April2020.pdf

Bob:

Please take a look at this. This question evolved from a teleconference that I had 2 nights ago with people "in the trenches" including Alison Arwady (Chicago). The question is what will be the relationship between the public health workforces at the federal and local levels. Youi had spoken of the CDC people that will be assigned locally and that will help build up a local workforce. How will CDD interact and relate to the locals. Is there any possibility of Federal funding of their proposal (see attachment). If not, do you have any suggestions for them? I can discuss this with you today at the Task Force meeting. Thanks.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6)
Sent: Wednesday, April 22, 2020 3:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Dr. Fauci asked me to send Chicago question

Pls advise.

From: Allison Arwady < (b) (6)
Sent: Wednesday, April 22, 2020 3:42 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: Dr. Fauci asked me to send Chicago question

Dear Patty,

Last night on his call with public health leaders from cities across the country, Dr. Fauci asked me to send him/you my follow-up question from Chicago:

How **will the necessary public health workforce expansion (e.g. for wide-scale case investigation, contact tracing, linkage to care, community testing, and vaccination) be supported at the federal level?**

Our understanding is that state or local jurisdictions will be able to develop their own workforces rather than supporting a single workforce at the federal level, and we agree with this approach, but it would be very helpful to understand next steps and potential timelines, particularly as the reopening drumbeat gets louder.

For example, Chicago has developed a local plan/proposal (attached) that would meet our local needs, help address some of our underlying race and economic equity concerns, and build on our existing community and clinical partnerships. We have shared it with some partners, but it is not at all clear how/whether/when/how much funding might be available. Given the need to quickly expand our workforce and plan ahead, it would be very helpful to get a sense of:

a. How much funding/support might be available, and how that will be determined
b. Whether funding might come through HHS/CDC (our preferred mechanism), FEMA, or another mechanism
c. Will support be available in weeks or months...and for how long—we are strongly advocating for 5 years, similar to what was done for Ebola
d. Any other information about how our local or state plans need to be adapted to fit into federal thinking on this approach

Thank you so much; I deeply appreciate Dr. Fauci taking the time to meet with us directly and hear our concerns.

Allison

Allison Arwady, MD, MPH
Commissioner
Chicago Department of Public Health
(b) (6)

HEALTHY
CHICAGO
CHICAGO DEPARTMENT OF PUBLIC HEALTH

From: David Barr (b) (6)
Sent: Wednesday, April 22, 2020 8:47 AM
To: Allison Arwady (b) (6); Percak, Jeffrey M (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Demetre Daskalakis (b) (6)>; Mushatt, David M (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] <(b) (6)>; Iyengar, Preetha (DOH) (b) (6) Duchin, Jeff (b) (6)
Subject: Notes from call with Dr. Fauci

Hello - Thanks for all for a very informative and sobering discussion last night. I've provided bullets below to capture the main points. Please add or change as needed. I've kept this relatively short but can supply a full recording of the call if you want it.

We will have another call next Tuesday.

David

PPE supplies:
- while hospitals are in better shape than a few weeks ago, significant shortages remain at long-term care facilitates, skilled nursing facilitates, outpatient settings like doctors' offices and urgent care clinics, shelters, prisons. Gowns are the biggest problem, but gloves, masks and shields are also short. Doctors offices are closing for lack of PPE.
- each city is trying to solve these shortages in a short-term, piecemeal way. They need a longer-term solution to stabilize availability. Outpatient settings are looking to health departments to provide supplies, something HDs are not set up to do.
- testing in most places still requires PPE use (e.g. no availability of anterior nasal swabs) and the PPE shortages are severely limiting testing scale up.
- even at hospitals, supply limitations make re-opening elective surgeries and other procedures impossible at this stage.
- If considering re-opening businesses, this will drastically increase PPE needs to a whole new sector.

TESTING challenges:
- Each city reported that, despite improvements, a very limited number of tests are being performed compared to need.
- Supply shortages are the biggest challenge: swabs, PPE, sample kits, reagents are the biggest obstacles. Not clear where this is going to come from or who is responsible for addressing problems.
- Private labs limit number of sample kits distributed each week. In places where public labs are available, there is a push to get providers to use the public labs. But many places don't have public labs.
- There is no clear guidance on how to prioritize who gets tested first. So, in some places, that means that people at lower-risk are being testing but people at greater risk (due to symptoms,

exposure, high-risk living/work environment, etc) are not being testing. Guidelines are needed to help prioritize where testing resources are used first.
- Public testing produces skewed results. Testing becomes available only to those who can make an appointment and who can drive to the site. This means many lower-priority people get tested but high-priority people do not. This skews understanding of positivity rates.
- Some labs are underutilized - but the reason is that there are breakdowns in the supply chain that make it difficult to test people and get tests to the labs. (e.g.) [redacted] (b) (4)
- Reimbursement is an obstacle. CMS offering to cover test costs ($100 per test) would help get labs to do more testing. It would not solve the problem, but it would help.
- Proliferation of unvalidated antibody tests is causing confusion. High rates of false results, misinterpretation of what results mean (e.g. telling people who test antibody positive that they must quarantine for two weeks). Chicago spends a lot time shutting down these testing sites as they make things harder and use up supplies.
- there is increasing pressure to reach a target number of tests performed each day in order to get to 're-opening'. But the number needed is contextual based on the environment, population - there isn't one 'right' number for everywhere.
- Need better public messaging on difference between virology and serologic tests.
- Current testing capacity is no where near what is needed to make informed decisions about re-opening.

TESTING: reporting challenges
- Current PoC tests have no link to provide results to health departments. Many outpatient facilities and SNFs have no system for reporting test results to HDs. Need electronic link for reporting PoC test results.
- While aggregate positive tests may be reported, negative results are not.
- Impossible to really understand population levels of infection because (1) number of tests performed is too low and (2) not testing the 'right' people
- Every one is pushing for rapid scale up of antibody tests, but we still don't know what the results of these tests mean and how to apply them to policy development.
- CDC and NIH will each coordinate sero-surveys. No details on CDC approach yet. NIH study is up. Still not clear how to use the results of these studies, but useful to collect data now and apply it as knowledge grows. Locally-coordinate aero-surveys can be helpful but only if tests are highly validated.

The Future:
- How many tests should we being doing? How much PPE/testings/beds/staff will be needed in the coming year? Next winter, we will face dual flu and COVID outbreaks, without stable testing capacity, how will we differentiate between the two?
- What are the plans for contact tracing? Who will recruit and train? Is there a federal plan or guidelines for this? How will it be paid for? What do we do to effectively isolate those infected?

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail (or the person responsible for delivering this document to the intended recipient), you are hereby notified that any dissemination, distribution, printing or copying of this e-mail, and any attachment thereto, is strictly prohibited. If you have received this e-mail in error, please respond to the individual sending the message, and permanently delete the original and any copy of any e-mail and printout thereof.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 12:53:24 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: launch of hydroxychloroquine/azithromycin study

Looks fine.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, April 22, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: FOR ASF REVIEW: Draft PR re: launch of hydroxychloroquine/azithromycin study

Hi Dr. Fauci,

Please find attached for your review a draft press release describing the launch of the ACTG hydroxychloroquine/azithromycin study for COVID-19. NIAID will issue the release after the first participant(s) has enrolled, which is currently anticipated around May 1.

The following is the quote we have drafted for you:

"We urgently need a safe and effective treatment for COVID-19. Repurposing existing drugs is an attractive option because these medications have undergone extensive testing, allowing them to move quickly into clinical trials and accelerating their potential approval for COVID-19 treatment," said NIAID Director Anthony S. Fauci, M.D. "Although there is anecdotal evidence that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes."

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b) (6)
E-mai (b) (6)
NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 11:54:41 +0000
To: Corey MD, Larry [redacted] (b) (6);Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Fauci, Anthony (NIH/NIAID) [E]
Subject: NEJM manuscript
Attachments: COVID vaccine editorial_prefinal April21_7pm fsc - with minor Fauci edits.docx

Larry/John:

I have gone over the changes that Francis has inserted and I have edited some of them. Please accept his changes and my edits of them (or any additional edits that you have) and then it is OK to send in. Please let me know if you have any questions.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 11:13:29 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: seeking your advice on a COVID-19 question

Email from Pardis Sabeti.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Pardis Sabeti [redacted] (b) (6)
Sent: Wednesday, April 22, 2020 9:47 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Subject: Re: seeking your advice on a COVID-19 question

Awe, thank you, here for you two any time, and grateful for the enormous positive impact you have on the world, Pardis

On Wed, Apr 22, 2020 at 9:43 PM Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)> wrote:

> Thanks, Pardis. It was great to spend time with you and your colleagues. We learned a lot.
> Warm regards,
> Tony
>
> ---
>
> **From:** Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
> **Sent:** Wednesday, April 22, 2020 8:44 PM
> **To:** Pardis Sabeti <[redacted] (b) (6)>
> **Cc:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> **Subject:** RE: seeking your advice on a COVID-19 question
>
> Hey there Pardis,
>
> You are much too kind – but we are grateful for YOU and your team!
>
> It was fun to talk science for a little while. ☺

Best, Francis

From: Pardis Sabeti [redacted] (b) (6)>
Sent: Wednesday, April 22, 2020 8:38 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: seeking your advice on a COVID-19 question

Dear Francis and Tony,

Thank you for a great conversation. Jacob, Bronwyn, and I stayed on a moment after you left and talked about how inspired we are by each of you and by the camaraderie between you two. Jacob added those two are national treasures, and Bronwyn and I wholeheartedly agreed.

Grateful for you both,

Pardis

On Wed, Apr 22, 2020 at 8:21 AM Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> wrote:

> Hi Pardis,
>
> See attached paper that argues there may be a significant difference in virulence of the COVID-19 clade that predominates on the west coast compared to the east coast. Tony Fauci and I would like to know [redacted] (b) (5)
>
> Also attached is a MedRxiv preprint that describes major differences in pathogenicity of different viral strains. I just got this [redacted] (b) (5)
>
> Can I talk with you later today after you have a chance to review this?
>
> Thanks, Francis

--
Pardis Sabeti, MD, DPhil
Professor, Harvard University & Harvard T.H. Chan School of Public Health
Broad Institute of MIT and Harvard
Howard Hughes Medical Institute

Assistant: [redacted] (b) (6)
Phone: [redacted] (b) (6)
Website: www.sabetilab.org

--
Pardis Sabeti, MD, DPhil
Professor, Harvard University & Harvard T.H. Chan School of Public Health
Broad Institute of MIT and Harvard
Howard Hughes Medical Institute

Assistant [redacted] (b) (6)>
Phone: [redacted] (b) (6)
Website: www.sabetilab.org

From: [redacted] (b) (6)
Sent: Thu, 23 Apr 2020 07:09:44 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: invitation to New Zealand conversation

Sent from my iPhone

Begin forwarded message:

> **From:** Pat Brittenden <info@blindfish.media>
> **Date:** April 23, 2020 at 12:02:13 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: invitation to New Zealand conversation**
>
> Good afternoon Dr Fauci,
>
> We are interested in seeing if you would be available for a chat via Zoom to New Zealand about COVID-19
>
> The US is an essential part of the NZ economy contributing between $1.5 and $2 billion dollars annually from tourism alone and we would love to have a conversation about where the US is at, how COVID-19 is being dealt with, and the future of things that could lead up to opening our borders again.
>
> We're happy to have you for any length of time, but if you have 10-20 minutes that would be amazing.
>
> Thank you for what you are doing in this global event, I hope we can connect sometime soon
>
> Sincerely,
> --
> Pat Brittenden
> www.theDOC.nz
> www.patbrittenden.com/about
> [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Thu, 23 Apr 2020 07:08:26 -0400
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: Global Health Leaders Call, Thursday, 23 April, 14:30 CET

Sent from my iPhone

Begin forwarded message:

> **From:** "KABIR, Sophia" [redacted] (b) (6)>
> **Date:** April 23, 2020 at 6:54:46 AM EDT
> **To:** SHOC <shoc@who.int>, Office of the Director-General <DGOffice@who.int>,
> "Redfield, Robert R. (CDC/OD)" [redacted] (b) (6)
> [redacted]
> David Heymann [redacted]
> (b) (6), "Felicity Harvey [redacted] (b) (6)
> [redacted], "Chris.Elias" [redacted] (b) (6),
> (b) (6)
> [redacted]
> "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> [redacted]
> "GREIN, Thomas"
> [redacted] (b) (6), "COX, Paul Michael" [redacted] (b) (6),
> "SCHWARTLANDER, Bernhard F." [redacted] (b) (6), "MINHAS,
> Raman" [redacted] (b) (6)
> "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "MAHJOUR,
> Jaouad" [redacted] (b) (6), "FALL, Ibrahima Soce" [redacted] (b) (6), "Thomas
> R. Frieden" [redacted] (b) (6)
> Lynn Banks [redacted] (b) (6), President | Resolve to Save Lives
> [redacted] (b) (6), "Amadou.SALL"
> [redacted] (b) (6) "AL-
> SHORBAJI, Farah" [redacted] (b) (6)
> [redacted] Robynn Leidig [redacted] (b) (6),
> "DRURY, Patrick Anthony" [redacted] (b) (6)>, "Dr VAN KERKHOVE, Maria"
> [redacted] (b) (6)
> [redacted] "GRAAFF, Peter Jan"

[redacted] (b) (6)>, "POOLE, Marcia" <[redacted] (b) (6), Tarik Mohammed
[redacted] (b) (6) Carlos
Navarro Colorado [redacted] (b) (6)
[redacted], Ryan Morhard [redacted] (b) (6)>,
"BRIAND, Sylvie" [redacted] (b) (6), "MORGAN, Oliver" [redacted] (b) (6)
"Harries, Jenny" [redacted] (b) (6)>, "Awwad, David (NIH/NIAID)
[C]" [redacted] (b) (6)>, "SIMONSON, Stewart" [redacted] (b) (6)
"SINGER, Peter Alexander" <[redacted] (b) (6), "Jayatunga, Wikum"
[redacted] (b) (6)
[redacted] "Julie.HALL" [redacted] (b) (6) Amelie
RIOUX [redacted] (b) (6)
[redacted], "SHIN, Young-Soo" [redacted] (b) (6)
" [redacted] (b) (6), Feng Ding
[redacted] (b) (6)
[redacted] "SMITH, Ian Michael" [redacted] (b) (6), "AYLWARD,
Raymond Bruce J." [redacted] (b) (6)
[redacted]

Cc: SHOC <shoc@who.int>, Office of the Director-General <DGOffice@who.int>,
"SCHWARTLANDER, Bernhard F." <[redacted] (b) (6) "MAHJOUR,
Jaouad" [redacted] (b) (6), "FALL, Ibrahima Soce" [redacted] (b) (6), "GREIN,
Thomas" [redacted] (b) (6)>, "MINHAS, Raman" [redacted] (b) (6), "COX, Paul
Michael" [redacted] (b) (6)>, "AL-SHORBAJI, Farah" [redacted] (b) (6)>,
"POOLE, Marcia" [redacted] (b) (6)>, "DRURY, Patrick Anthony"
[redacted] (b) (6)>, "GRAAFF, Peter Jan" [redacted] (b) (6)>, "Dr VAN
KERKHOVE, Maria" [redacted] (b) (6), "FARES, Christine Youssef"
[redacted] (b) (6)>

Subject: RE: Global Health Leaders Call, Thursday, 23 April, 14:30 CET

Dear colleagues,

Apologies for the mistake in the below subject line.

The meeting starts at **14.30 CET**, as mentioned in the email.

Kind regards,

Sophia

From: KABIR, Sophia
Sent: Thursday, April 23, 2020 10:51 AM
To: SHOC <shoc@who.int>; Office of the Director-General <DGOffice@who.int>;
[redacted] (b) (6)
[redacted] Felicity Harvey [redacted] (b) (6)
[redacted] (b) (6); Chris Elias [redacted] (b) (6)
[redacted] Jeremy Farrar
[redacted] (b) (6)
[redacted] GREIN, Thomas [redacted] (b) (6)>; COX, Paul Michael
[redacted] (b) (6)>; SCHWARTLANDER, Bernhard F. [redacted] (b) (6); MINHAS,
Raman [redacted] (b) (6)
[redacted] MAHJOUR, Jaouad [redacted] (b) (6); FALL, Ibrahima Soce
[redacted] (b) (6); 'Thomas R. Frieden' [redacted] (b) (6); 'Elhadj SY'
[redacted] (b) (6); 'Lynn Banks' [redacted] (b) (6); 'President |
Resolve to Save Lives' [redacted] (b) (6)
[redacted] AL-
SHORBAJI, Farah [redacted] (b) (6)
[redacted] 'Robynn Leidig' [redacted] (b) (6); DRURY,
Patrick Anthony [redacted] (b) (6) Dr VAN KERKHOVE, Maria [redacted] (b) (6)
[redacted] (b) (6)
[redacted] 'Cheryl Cohen' [redacted] (b) (6)>; GRAAFF, Peter
Jan [redacted] (b) (6); POOLE, Marcia [redacted] (b) (6) 'Tarik Mohammed'
[redacted] (b) (6)
[redacted] 'Ryan Morhard' < [redacted] (b) (6)>; BRIAND,
Sylvie [redacted] (b) (6); MORGAN, Oliver [redacted] (b) (6); 'Harries, Jenny'
[redacted] (b) (6)'Awwad, David (NIH/NIAID) [C]' [redacted] (b) (6);
SIMONSON, Stewart [redacted] (b) (6); SINGER, Peter Alexander [redacted] (b) (6)>;
'Jayatunga, Wikum' [redacted] (b) (6)
[redacted] ; SHIN, Young-Soo [redacted] (b) (6)
' [redacted] (b) (6) 'Feng Ding'
[redacted] (b) (6)
[redacted]

[redacted] (b) (6) SMITH, Ian Michael [redacted] (b) (6); AYLWARD, Raymond Bruce J. [redacted] (b) (6)
[redacted]

Cc: SHOC <shoc@who.int>; Office of the Director-General <DGOffice@who.int>; SCHWARTLANDER, Bernhard F. [redacted] (b) (6); MAHJOUR, Jaouad [redacted] (b) (6)>; FALL, Ibrahima Soce [redacted] (b) (6); GREIN, Thomas [redacted] (b) (6)>; MINHAS, Raman [redacted] (b) (6); COX, Paul Michael [redacted] (b) (6); AL-SHORBAJI, Farah [redacted] (b) (6); POOLE, Marcia [redacted] (b) (6)>; DRURY, Patrick Anthony [redacted] (b) (6)>; GRAAFF, Peter Jan [redacted] (b) (6); Dr VAN KERKHOVE, Maria <[redacted] (b) (6)>; FARES, Christine Youssef [redacted] (b) (6)
Subject: Global Health Leaders Call, Thursday, 23 April, 14:00 CET

Dear colleagues,

Ahead of the Global Health Leaders Call at 14.30 CET today, please find an epidemiological update and analysis attached, in addition to **the "Considerations in adjusting public health and social measures in the context of COVID-19"** interim guidance document, which was published on the WHO website on 16 April.

Please find below, the key questions for your consideration and input.

1. What is your view on the latest epidemiology, virus transmission and severity in affected countries ?
2. What are the emerging issues/challenges that you see as important ?
3. What should be the priorities for the 1-2 weeks?
4. Any other issues you see as important?

You will be able to connect via the Webex connection below. If you experience any technical difficulties, please contact the WHO HQ EOC operator at: +41 22 79 15 533 or via email: shoc@who.int.

Best,

Sophia

Meeting number (access code): [redacted] (b) (6), (b) (4)

Meeting password [redacted] (b) (6), (b) (4)

Thursday, April 23, 2020
2:00 pm | (UTC+02:00) Brussels, Copenhagen, Madrid, Paris |

Join meeting

Join by phone

Tap to call in from a mobile device (attendees only)

[redacted] (b) (6) TZERLAND Toll
US Toll

Global call-in numbers

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 02:16:12 +0000
To: Alice Park
Subject: FW: Time follow up
Attachments: MedRxiv_Mutations impact pathogenicity SARS-CoV-2_ Lanjuan Li et al. 2020.04.14..pdf

Alice:
Here is another manuscript.
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 02:11:27 +0000
To: Lou Ignarro
Subject: RE: Greetings- NOT urgent

Lou:
Thank you for your kind note. It is much appreciated. I hope that you are well.
Best regards,
Tony

From: Lou Ignarro (b) (6)
Sent: Tuesday, April 21, 2020 5:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Greetings- NOT urgent

Hi Tony,

This is Lou Ignarro from UCLA. You and I shared the stage in the "Shoe" at the Ohio State University a few years ago, where you gave the Graduation Address to the undergraduate seniors. I was on stage with you, to receive an award for my basic biomedical research which resulted in my being awarded the Nobel Prize in Medicine in 1998. I recall the nice conversations we were enjoying with Sanjay Gupta while robing for the event.

Thanks for the truly spectacular job you are doing, regarding the coronavirus pandemic. We Nobel Laureates especially regard your work as the most important during our lifetime. Thank you and God bless.

My best wishes,

Lou Ignarro

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 01:50:03 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: letter from the Governor of Puerto Rico
Attachments: Dr. Anthony S. Fauci, MD[2].pdf

Heads up for a call from the Puerto Rican Health Minister.

From: Pablo L. Peña Antonmarchi <ppena@fortaleza.pr.gov>
Sent: Wednesday, April 22, 2020 5:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>; Jennifer M. Storipan <jstoripan@prfaa.pr.gov>; Juan L. Negrón <jnegron@prfaa.pr.gov>; Maria del C Reyes Crespo <mreyes@fortaleza.pr.gov>; Antonio L. Pabon Batlle <apabon@fortaleza.pr.gov>
Subject: letter from the Governor of Puerto Rico
Importance: High

Dear Dr. Anthony Fauci:

I am sending you for your attention a letter from the Governor of Puerto Rico Hon. Wanda Vázquez Garced.

Cordially,

Pablo L. Peña Antonmarchi
Executive Assistant
Lcdo. Antonio Pabón Batlle
Chief of Staff Office
La Fortaleza
San Juan, Puerto Rico

NOTA DE CONFIDENCIALIDAD: Esta transmisión electrónica contiene información perteneciente a la Oficina del Gobernador, que es confidencial, privilegiada y/o privada bajo las leyes aplicables. Solamente podrá ser utilizada por la persona o entidad a la cual se dirige. Si usted no es el destinatario intencional, se le notifica que se prohíbe cualquier uso, diseminación o copia de esta comunicación. Si usted recibe esta comunicación por error, favor de notificar al remitente y eliminar este correo electrónico de su sistema.

CONFIDENTIALITY NOTE: This electronic transmission contains information belonging to the Governor's Office, which is confidential, privileged and exempt from disclosure under the applicable law. It is intended solely for the use of the individual or entity to which it is addressed. If you are not the intended recipient, you are hereby notified that any use, dissemination, or copying of the communication is strictly prohibited. If you have received this communication by error, please notify the sender and delete this e-mail from your system.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 01:40:52 +0000
To: Alice Park;Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Time follow up
Attachments: Viral Clades Brufsky 42020 Accepted Final.pdf

Alice:

It was great working with you today. Here is the reference. I believe that it will be in the Journal of Medical Virology. It has been accepted, but is no yet in print.

Best regards,
Tony

From: Alice Park <alice.park@time.com>
Sent: Wednesday, April 22, 2020 6:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>
Subject: Time follow up

Dear Dr. Fauci -- many thanks for your time today; we are thrilled to have you as part of the TIME 100 Talks, which will go live tomorrow.

In the meantime, I wanted to double check the reference to the study you mentioned about the east and west coast strains and their potential difference in virulence. Realize it's preliminary, so just wanted to confirm any references we make to it. I checked the biorxiv and medrxiv but didn't find the citation. Would appreciate the journal if it was published. Many thanks! Alice

PLEASE NOTE NEW PHONE NUMBER
Alice Park
TIME
(b) (6)
alice.park@time.com
@aliceparkny

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 16:29:19 +0000
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Cc: Corey MD, Larry [redacted] (b) (6);Mascola, John (NIH/VRC) [E]
Subject: FW: "final draft"
Attachments: COVID vaccine editorial_prefinal April21_7pm.docx

Francis:

Here is the paper that I mentioned to you and that we are planning to submit to the *NEJM*. I have put your name on it as the senior author. If you are comfortable with that, we will go with it. Please take a look at the manuscript and make any comments or edits that you see fit.

Thanks,

Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 14:41:09 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6);Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

I was thinking the very same thing.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 21, 2020 8:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)
Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Ps – what do you want to bet you get invited to throw a first pitch next year?

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 21, 2020 8:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: FW: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

We're a "go" on this. I'll circle back with his rep tomorrow.

(b)(5) - PCP

[redacted]

On Apr 21, 2020, at 6:50 PM, Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)> wrote:

Hi guys – as a huge Nats fan, Dr. Fauci very much wants to do this chat with Ryan Zimmerman. Can I get a green light to work on this with them? I'll get the q's but it will be the same general theme as with Steph Curry, YES Network, etc.

From: Judee Ann Williams <judeeann.williams@caa.com>
Sent: Tuesday, April 21, 2020 5:54 PM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Christine Lancman <christine.lancman@caa.com>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Absolutely! We would 100% be able to work around that and avoid any association of fundraising.
We would set this up however he will be most comfortable, seed questions in advance, etc. and shed a light on what is most helpful.
Will wait to hear and if you need anything else just let us know. Thank you so much!

From: "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, April 21, 2020 at 4:41 PM
To: Judee Williams <judeeann.williams@caa.com>
Cc: Christine Lancman <christine.lancman@caa.com>, "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

External Sender

Hi – thanks for your message – we will check and someone will get back to you in the next few days. One caveat is that as a Federal official, Dr. Fauci cannot be associated with fundraising in any way. Please confirm that is something you would be able to work around?

From: Judee Ann Williams <judeeann.williams@caa.com>
Sent: Monday, April 20, 2020 5:21 PM
To: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Christine Lancman <christine.lancman@caa.com>
Subject: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Jennifer & Courtney-

Hello! Our friends from Steph Curry's team passed along your contact information to us and we work at CAA where we represent World Series Champion, Ryan Zimmerman.

Ryan wanted to express his gratitude first & foremost to Dr. Fauci, the entire team and all those behind the scenes working around the clock.

Ryan recently launched the Pros for Heroes Covid-19 Fund last week, with more than 30 professional athletes supporting and over $300,000 raised across 1,400 separate donations. (>www.prosforheroes.org<). Since its launch last Tuesday, contributions from the Pros For Heroes Fund have gone directly towards PPE needs throughout the Inova hospital network throughout the mid-Atlantic and have helped provide meals to those critical care front-line workers - keeping these front-line heroes covered at work and comfortable at home.

If Dr. Fauci was up to it, Ryan would love to host either a short 15 minute Q&A on his Facebook to continue raising awareness for how we need to be responding to the ongoing crisis. Or even simply thank Dr. Fauci for the tireless work he is doing and shine a light on how folks can support these critical frontline workers.

We are also open to what you think would work best! Would there any openings that would work best?

We know Dr. Fauci is big baseball fan, and of course we are all huge fans of his! If we can ever be supportive or help navigate anything in the world of pop culture, please do not hesitate to ask.

Warmest wishes,

Judee Ann

Judee Ann Williams | Co-Head, CAA Social Impact
T: 212-277-5294| M: [redacted] (b) (6) | Washington, DC

NEW YORK - LONDON -NASHVILLE- MUNICH - LOS ANGELES -BEIJING - SHANGHAI
>https://www.caa.com/<

Pros For Heroes
"Teamwork is the ability to come together towards a common goal. We are looking forward to attracting as many supporters to help join this cause and give back as much as we can to those who have given us so much," said Washington National All-Star, Ryan Zimmerman, the fund's founder.

Social Links:
>https://www.instagram.com/prosforheroes/<
>https://twitter.com/prosforheroes<

Today Show:
>https://www.today.com/video/ryan-zimmerman-talks-pros-for-heroes-fund-for-feeding-health-care-workers-82202693577<

Washington Post Launch Article:
>https://www.washingtonpost.com/sports/2020/04/14/nationals-ryan-zimmerman-starts-fund-health-care-workers-with-100k-gift/<

This e-mail and any files transmitted with it are intended solely for the use of the individual or entity to whom they are addressed. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any use dissemination, forwarding, printing or copying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients are free to do their best work without experiencing harassment and want to ensure they have the relevant resources they need. Clients can go to >https://www.caa.com/legal/sexual-harassment-guidelines-caa-clients< to learn more about their rights, and how to report violations.

This e-mail and any files transmitted with it are intended solely for the use of the individual or entity to whom they are addressed. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any use dissemination, forwarding, printing or copying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients are free to do their best work without experiencing harassment and want to ensure they have the relevant resources they need. Clients can go to >https://www.caa.com/legal/sexual-harassment-guidelines-caa-clients< to learn more about their rights, and how to report violations.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 00:29:33 +0000
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

More on mutations

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tuesday, April 21, 2020 1:58 PM
To: Graham, Barney (NIH/VRC) [E] (b) (6)
Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

Not peer reviewed, but what do you think?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>
Sent: Monday, April 20, 2020 1:53 PM
Subject: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

China / Science

Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

- The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as the least potent type
- New York may have a deadlier strain imported from Europe, compared to less deadly viruses elsewhere in the United States

Stephen Chen in Beijing
Published: 10:41pm, 20 Apr, 2020
Updated: 1:33am, 21 Apr, 2020

A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possible implications for the pandemic. Photo: EPA-EFE

A new study by one of China's top scientists has found the ability of the new coronavirus to mutate has been vastly underestimated and different strains may account for different impacts of the disease in various parts of the world.

Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patients many mutations not previously reported. These mutations included changes so rare that scientists had never considered they might occur.

They also confirmed for the first time with laboratory evidence that certain mutations could create strains deadlier than others.

"Sars-CoV-2 has acquired mutations capable of substantially changing its pathogenicity," Li and her collaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday.

Li's study provided the first hard evidence that mutation could affect how severely the virus caused disease or damage in its host.

Li took an unusual approach to investigate the virus mutation. She analysed the viral strains isolated from 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, and then tested how efficiently they could infect and kill cells.

The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe, while the milder strains were the predominant varieties found in parts of the United States, such as Washington state, according to their paper.

A separate study had found that New York strains had been imported from Europe. The death rate in New York was similar to that in many European countries, if not worse.

But the weaker mutation did not mean a lower risk for everybody, according to Li's study. In Zhejiang, two patients in their 30s and 50s who contracted the weaker strain became severely ill. Although both survived in the end, the elder patient needed treatment in an intensive care unit.

This finding could shed light on differences in regional mortality. The pandemic's infection and death rates vary from one country to another, and many explanations have been proposed.

Genetic scientists had noticed that the dominant strains in different geographic regions were inherently different. Some researchers suspected the varying mortality rates could, in part, be caused by mutations but they had no direct proof.

The issue was further complicated because survival rates depended on many factors, such as age, underlying health conditions or even blood type.

In hospitals, Covid-19 has been treated as one disease and patients have received the same treatment regardless of the strain they have. Li and her colleagues suggested that defining mutations in a region might determine actions to fight the virus.

"Drug and vaccine development, while urgent, need to take the impact of these accumulating mutations ... into account to avoid potential pitfalls," they said.

Li was the first scientist to propose the Wuhan lockdown,according to state media reports. The government followed her advice and in late January, the city of more than 11 million residents was shut down overnight.

The sample size in this most recent study was remarkably small. Other studies tracking the virus mutation usually involved hundreds, or even thousands, of strains.

Li's team detected more than 30 mutations. Among them 19 mutations – or about 60 per cent – were new.

They found some of these mutations could lead to functional changes in the virus' spike protein, a unique structure over the viral envelope enabling the coronavirus to bind with human cells. Computer simulation predicted that these mutations would increase its infectivity.

To verify the theory, Li and colleagues infected cells with strains carrying different mutations. The most aggressive strains could generate 270 times as much viral load as the weakest type. These strains also killed the cells the fastest.

It was an unexpected result from fewer than a dozen patients, "indicating that the true diversity of the viral strains is still largely underappreciated," Li wrote in the paper.

Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: Xinhua

The mutations were genes different from the earliest strain isolated in Wuhan, where the virus was first detected in late December last year.

The coronavirus changes at an average speed of about one mutation per month. By Monday, more than 10,000 strains had been sequenced by scientists around the globe, containing more than 4,300 mutations, according to the China National Centre for Bioinformation.

Most of these samples, though, were sequenced by a standard approach that could generate a result quickly. The genes were read just once, for instance, and there was room for mistakes.

Li’s team used a more sophisticated method known as ultra-deep sequencing. Each building block of the virus genome was read more than 100 times, allowing the researchers to see changes that could have been overlooked by the conventional approach.

The researchers also found three consecutive changes – known as tri-nucleotide mutations – in a 60-year-old patient, which was a rare event. Usually the genes mutated at one site at a time. This patient spent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeces were infectious with living viral strains.

“Investigating the functional impact of this tri-nucleotide mutation would be highly interesting,” Li and colleagues said in the paper.

Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for Information Science and Technology at Tsinghua University, said ultra-deep sequencing could be an effective strategy to track the virus’ mutation.

“It can produce some useful information,” he said.

But this approach could be much more time consuming and costly. It was unlikely to be applied to all samples.

“Our understanding of the virus remains quite shallow,” Zhang said. Questions such as where the virus came from, why it could kill some healthy young people while generating no detectable symptoms in many others still left scientists scratching their heads.

“If there is a discovery that overturns the prevailing perception, don’t be surprised.”

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 00:16:44 +0000
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Subject: FW: For your attention
Attachments: COVAX2020 - A GLOBAL EFFORT for the ACCELERATED DEVELOPMENT, PRODUCTION and EQUITABLE ACCESS to COVID-19 VACCINES_16Apr2020_DRAFT.docx

See attachment that Hilary sent me. [redacted] (b) (5)

From: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 7:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Re: For your attention

[redacted] (b) (5)

From: Anthony Fauci [redacted] (b) (6)>
Date: Tuesday, April 21, 2020 at 7:30 PM
To: Hilary Marston < [redacted] (b) (6)v>
Subject: FW: For your attention

Have you heard of this on any of the calls where you represent me??

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 7:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Freire, Maria (FNIH) [T] <mfreire@fnih.org>; Wholley, David (FNIH) [T] <dwholley@fnih.org>
Subject: FW: For your attention

Hi all,

See note below from Victor Dzau about a global effort on COVID-19. I can't tell if this is more than a fund-raising effort. I know we have Gates reps on our ACTIV working groups – has any of this plan come up, David?

Francis

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Tuesday, April 21, 2020 4:10 PM
To: Collins, Francis (NIH/OD) [E] < [redacted] (b) (6)
Cc: Kanarek, Morgan <MKanarek@nas.edu>
Subject: For your attention

Dear Francis,

Congratulations on your launch of Public Private Partnership to speed COVID 19 vaccine and treatment options. This is very timely and much needed. Kudos to your leadership.

I am sure you are aware of a global coordinating effort to accelerate vaccines, diagnostics and therapeutics. I have been part of the conversation and planning along with Jeremy Farrar, Richard Hatchett, Seth Berkley, Chris Elias, Paul Stoffels etc. Recently WHO, Gates Foundation and European Commission have been leading the planning. This has advanced rapidly and is in the final stages in development that will be soon announced. It has involved European Commission, Germany, Japan, UK, Norway, France, Saudi as well as Gates Foundation, WHO, World Bank, Wellcome Trust, GAVI, Global Fund, CEPI, GPMB and private sector industry. The initiative will begin with a Pledge conference for $8B as a starting point. This will be led by President von der Leyen and is co-chaired by the above country leaders. This will occur on May 4. In addition by the end of this week or early next week there will be an announcement on the global coordinating structure with will involve Gates, WHO etc.

I am writing to be sure that you and the White House are aware of these upcoming events. Can you share this information with the White House? Besides you, who else should I share this information with? I will be happy to send you background documents if you wish.

Please call me anytime.

Best,

Victor

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 23:10:36 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Consideration of IM COVID Immune Globulin for Prevention of COVID-19 Infection
Attachments: Prophylactic Intramuscular COVID-IG - Oxman.pdf, FURTHER ARGUMENTS IN FAVOR OF INTRAMUSCULAR COVID-IG Version 4 - Oxman.pdf

Email from Gary Noble, advisor to Bob Windom in the 1980s.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Gary Noble [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 4:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: McGowan, John J. (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Oxman, Michael [redacted] (b) (6)
Subject: Consideration of IM COVID Immune Globulin for Prevention of COVID-19 Infection

Dear Tony,

I will always remember our amazing collaboration during the HIV/AIDS days in the 1980s, when I served as AIDS Advisor to Bob Windom, the DHHS Assistant Secretary for Health during President Reagan's administration. And now, I am delighted and amazed to watch you so adroitly maneuver the COVID-19 scientific policies and keep them front and center in the current White House!!

[redacted] (b) (6), Michael Oxman, has worked with John Zaia at City of Hope, and a Mayo/Hopkins/Michigan State consortium for a trial of IM COVID-IG as a preferred method for treatment and prevention of COVID-19.

This week, Mike expects to complete the protocol for a placebo (normal IG)-controlled trial of IM COVID-IG prophylaxis in at-risk healthcare workers who are engaged in direct patient care at UCSD, but they need a modicum of support. Mike asked if I would reach out to see if NIAID might provide of support for this effort, using IM, as opposed to IV, COVID-IG.

I've copied Mike, who has provided the attached background information.

Tony, with all my respect and admiration for what you are doing for the U.S. and for all of us.

Gary

Gary R. Noble, MD, MPH, MA (Oxon)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 22:14:24 +0000
To: NIAID OD AM
Subject: FW: Invitation to Speak at UC Berkeley COVID-19 Hackathon

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Saahil Chadha <saahil@calhacks.io>
Sent: Tuesday, April 21, 2020 11:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Invitation to Speak at UC Berkeley COVID-19 Hackathon

Dear Dr Fauci,

My name is Saahil, and I'm a director at Cal Hacks, a student organization at the University of California, Berkeley. This upcoming weekend, we will be hostinghack:now, a 36-hour global online hackathon to foster innovative and technical solutions to tackle the challenges faced around the current COVID-19 pandemic. We're projected to have 1,500 participants from around the world. I'm reaching out to invite you to be our opening ceremony speaker.

Specifically, this Friday night, April 24, from 7-8pm Pacific Daylight Time, we're going to be hosting the opening ceremony of our event. At this time, we want to inspire our hackers to help solve global challenges related to health and community. **We would be absolutely honored if you would join us to speak at our opening ceremony for just a few minutes to share your experiences with and response to the COVID-19 pandemic.** Your unique perspective and expanse of knowledge makes you the most qualified person, and we would be humbled to include you as our opening ceremony speaker. Please let us know if you are able to accept this invitation.

Stay safe,

Saahil Chadha
(b) (6)
Calhacks.io

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 22:06:57 +0000
To: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Message for Dr Anthony FAUCI

OK. Please take care of this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 11:31 AM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Message for Dr Anthony FAUCI

I would be extremely grateful to you if you can provide me with the most recent and pertinent scientific and population data concerning covid-19. I know how extremely busy you are but maybe a collaborator of yours whether he can send me the data via e-mail [redacted] (b) (6).

Not exactly sure what he wants but I can send him some links that will get him the latest CoV info from pubmed, preprints, CDC etc

---

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 11:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Message for Dr Anthony FAUCI

Can we direct her somewhere? Gray?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jean-Louis Touraine [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 11:06 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Potential SPAM:Message for Dr Anthony FAUCI

I would be very grateful to you if you can forward the following mail to Dr Anthony FAUCI.

Many thanks.
Sincerely yours,

Pr Jean-Louis TOURAINE, Lyon and Paris, France.

Dear Tony,

You may remember, that we have met repeatedly and worked in parallel and in association, during the early years of the HIV epidemic.

You and I have been trained in immunoly. Both of us are much sollicitated to help facing and fighting the covid-19 epidemic.

During the past years , as well as recently, I have followed with great interest and respect your accomplishments and your advices in the fights against epidemics. I would be extremely grateful to you if you can provide me with the most recent and pertinent scientific and population data concerning covid-19. I know how extremely busy you are but maybe a collaborator of yours whether he can send me the data via e-mail [redacted] (b) (6) This will allow me to give more documented informations to the French President and Government. Cooperation between countries will be crucial against covid-19 as it has been against HIV and other agents.

I look forward to seeing you again in quieter times.
Many thanks and very best personal regards.

Jean-Louis TOURAINE, M.D., Ph. D., M.P.

Ce message, ainsi que les pièces jointes, sont établis, sous la seule responsabilité de l'expéditeur, à l'intention exclusive de ses destinataires ; ils peuvent contenir des informations confidentielles. Toute publication, utilisation ou diffusion doit être autorisée préalablement.
Ce message a fait l'objet d'un traitement anti-virus.
Il est rappelé que tout message électronique est susceptible d'altération au cours de son acheminement sur Internet.

Vous pouvez consulter le site de l'Assemblée nationale à l'adresse suivante : http://www.assemblee-nationale.fr

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 21:39:30 +0000
To: Collins, Francis (NIH/OD) [E] ([redacted] (b) (6)
Cc: Myles, Renate (NIH/OD) [E];Burklow, John (NIH/OD) [E];Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: STAT: Director of U.S. agency key to helming vaccine development leaves role suddenly amid coronavirus pandemic https://bit.ly/2XRZqKa

[redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 3:01 PM
Subject: STAT: Director of U.S. agency key to helming vaccine development leaves role suddenly amid coronavirus pandemic https://bit.ly/2XRZqKa

Director of U.S. agency key to helming vaccine development leaves role suddenly amid coronavirus pandemic

By Nicholas Florko @NicholasFlorko
April 21, 2020

Rick Bright *HHS*

WASHINGTON — Rick Bright, one of the nation's leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization, officials told STAT.

The shakeup at the agency, known as BARDA, couldn't come at a more inopportune time for the office, which invests in drugs, devices, and other technologies that help address infectious disease outbreaks and which has been at the center of the government's coronavirus pandemic response.

Bright, whose departure was confirmed by three industry sources and two current Trump administration sources, will instead move into a narrower role at the National Institutes of Health overseeing a similar but limited public-private partnership aimed at vaccine development. Gary Disbrow, Bright's former deputy at BARDA, will serve as the acting director of the office, an HHS spokesperson confirmed to STAT.

BARDA was expected to play an even larger role in the coming months; Congress more than tripled BARDA's budget in the most recent coronavirus stimulus package. Already, the office has a role in some of the splashiest Covid-19 projects, including partnerships with Johnson & Johnson and Moderna Therapeutics, both of which are developing potential Covid-19 treatments.

Related:

This tiny federal agency was built to respond to a crisis like coronavirus. Now that it's here, is BARDA ready?

BARDA has been plagued with management issues virtually since its creation in 2006, with much of the criticism aimed at a contracting department that some say is unresponsive to industry partners. The office has only had two permanent directors since its creation in 2006. Bright has led the organization since 2016.

None of the sources articulated the reason for Bright's departure, though several mentioned recent chafing between Bright and Bob Kadlec, the HHS Assistant Secretary for Preparedness and Response, which has oversight over BARDA.

An HHS spokesperson confirmed that Bright will work on a recently announced NIH public-private partnership with 16 drug makers aimed at developing vaccines and treatments for Covid-19.

"Dr. Rick Bright will transfer the skills he has applied as Director of the [BARDA] to the [NIH]. ... Dr. Bright brings extensive experience and expertise in facilitating powerful public-private partnerships that advance the health and well-being of the American people," the spokesperson said.

Bright did not immediately respond to requests for comment.

Bright's career has largely centered around vaccine and drug development. His work at the Centers for Disease Control and Prevention focused on influenza viruses, antiviral drugs and tests. He has also worked in the biotechnology industry and served as an advisor to the World Health Organization. Before becoming BARDA director, he led the agency's Influenza and Emerging Infectious Diseases Division.

Lev Facher contributed reporting.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 21:18:24 +0000
To: Crawford, Chase (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E];McGowan, John J. (NIH/NIAID) [E];Harper, Jill (NIH/NIAID) [E];Gilles, Sharon (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E];Johnson, Martin S. (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E]
Subject: RE: Attention: COVID-19 legislative package bill text released

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Crawford, Chase (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 21, 2020 3:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6); Johnson, Martin S. (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6)
Cc: Haskins, Melinda (NIH/NIAID) [E] (b) (6); Selgrade, Sara (NIH/NIAID) [E] (b) (6)
Subject: Attention: COVID-19 legislative package bill text released
Importance: High

Good Afternoon,

At 4p.m. today (4/21), the U.S. Senate is expected to hold a vote by unanimous consent on the "Paycheck Protection Program and Health Care Enhancement Act" (bill text attached). In particular please note that the legislative package includes the following supplemental appropriations for diagnostic testing (pages 13-15 of attached):

- **NIH/OD** – not less than **$1B** to develop, validate, improve, and implement testing and associated technologies; to accelerate research, development, and implementation of point of care and other rapid testing; and for partnerships with governmental and non-governmental entities to research, develop, and implement the activities outlined in this proviso.
  - funds in the preceding proviso may be transferred to the accounts of the Institutes and Centers of the National Institutes of Health for the purposes specified in the preceding proviso
  - the transfer authority provided in the preceding proviso is in addition to all other transfer authority available to the NIH
- **NCI** – not less than **$306M** to develop, validate, improve, and implement serological testing and associated technologies for the purposes specified under this paragraph in this Act:
- **NIBIB** – not less than **$500M** to accelerate research, development, and implementation of point of care and other rapid testing related to coronavirus:
- **CDC** – not less than **$1B** for surveillance, epidemiology, laboratory capacity expansion, contact tracing, public health data surveillance and analytics infrastructure modernization, disseminating information about testing, and workforce support necessary to expand and improve COVID–19 testing
- **BARDA** – not less than **$1B** for necessary expenses of advanced research, development, manufacturing, production, and purchase of diagnostic, serologic, or other COVID–19 tests or related supplies, and other activities related to COVID–19 testing at the discretion of the Secretary
- **FDA** – **$22M** to support activities associated with diagnostic, serological, antigen, and other tests, and related administrative activities

We will keep you updated on any developments related to this legislation. Please let us know if you have any questions.

Thanks,
Chase

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 21:01:27 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Ryan Zimmerman

If cleared, I would love to. [redacted] (b)(5) - PCP

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 4:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Ryan Zimmerman

Would you be interested in doing something with Ryan Zimmerman? Format TBD. We'll pursue further discussion if you give the green light.

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 21, 2020 4:41 PM
To: Judee Ann Williams <judeeann.williams@caa.com>
Cc: Christine Lancman <christine.lancman@caa.com>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Hi – thanks for your message – we will check and someone will get back to you in the next few days. One caveat is that as a Federal official, Dr. Fauci cannot be associated with fundraising in any way. Please confirm that is something you would be able to work around?

From: Judee Ann Williams <judeeann.williams@caa.com>
Sent: Monday, April 20, 2020 5:21 PM
To: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Christine Lancman <christine.lancman@caa.com>
Subject: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Jennifer & Courtney-

Hello! Our friends from Steph Curry's team passed along your contact information to us and we work at CAA where we represent World Series Champion, Ryan Zimmerman.

Ryan wanted to express his gratitude first & foremost to Dr. Fauci, the entire team and all those behind the scenes working around the clock.

Ryan recently launched the Pros for Heroes Covid-19 Fund last week, with more than 30 professional athletes supporting and over $300,000 raised across 1,400 separate donations. (www.prosforheroes.org). Since its launch last Tuesday, contributions from the Pros For Heroes Fund have gone directly towards PPE needs throughout the Inova hospital network throughout the mid-Atlantic and have helped provide meals to those critical care front-line workers - keeping these front-line heroes covered at work and comfortable at home.

If Dr. Fauci was up to it, Ryan would love to host either a short 15 minute Q&A on his Facebook to continue raising awareness for how we need to be responding to the ongoing crisis. Or even simply thank Dr. Fauci for the tireless work he is doing and shine a light on how folks can support these critical frontline workers.

We are also open to what you think would work best! Would there any openings that would work best?

We know Dr. Fauci is big baseball fan, and of course we are all huge fans of his! If we can ever be supportive or help navigate anything in the world of pop culture, please do not hesitate to ask.

Warmest wishes,

Judee Ann

Judee Ann Williams | Co-Head, CAA Social Impact
T: 212-277-5294| M [redacted] (b) (6) | Washington, DC
NEW YORK - LONDON -NASHVILLE- MUNICH - LOS ANGELES -BEIJING - SHANGHAI
https://www.caa.com/

Pros For Heroes

“Teamwork is the ability to come together towards a common goal. We are looking forward to attracting as many supporters to help join this cause and give back as much as we can to those who have given us so much,” said Washington National All-Star, Ryan Zimmerman, the fund’s founder.

Social Links:
https://www.instagram.com/prosforheroes/
https://twitter.com/prosforheroes

Today Show:
https://www.today.com/video/ryan-zimmerman-talks-pros-for-heroes-fund-for-feeding-health-care-workers-82202693577

Washington Post Launch Article:
https://www.washingtonpost.com/sports/2020/04/14/nationals-ryan-zimmerman-starts-fund-health-care-workers-with-100k-gift/

This e-mail and any files transmitted with it are intended solely for the use of the individual or entity to whom they are addressed. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any use dissemination, forwarding, printing or copying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients are free to do their best work without experiencing harassment and want to ensure they have the relevant resources they need. Clients can go to https://www.caa.com/legal/sexual-harassment-guidelines-caa-clients to learn more about their rights, and how to report violations.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 20:44:40 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];clane@niaid.nih.gov
Subject: RE: urgent: CNN request

Cliff should do this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 4:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: urgent: CNN request

Sent from my iPhone

Begin forwarded message:

> **From:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Date:** April 21, 2020 at 4:31:46 PM EDT
> **To:** "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Fwd: urgent: CNN request**
>
> Sent from my iPhone
>
> Begin forwarded message:

From: "Billet, Courtney (NIH/NIAID) [E]" <[redacted] (b) (6)
Date: April 21, 2020 at 2:49:39 PM EDT
To: "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
Cc: "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: FW: urgent: CNN request

Patty – can you please check with Dr. Fauci if he'd like to speak to Elizabeth Cohen about the treatment guidelines.

From: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 2:48 PM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Pau, Alice (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6); Masur, Henry (NIH/CC/CCMD) [E] [redacted] (b) (6); Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>
Subject: Re: urgent: CNN request

I think Dr. Fauci would want the option of first refusal. He has anticipated he will be asked about these.

From: "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, April 21, 2020 at 1:35 PM
To: "Pau, Alice (NIH/NIAID) [E]" [redacted] (b) (6)>
Cc: Laurie Doepel [redacted] (b) (6)>, "Masur, Henry (NIH/CC/CCMD) [E]" [redacted] (b) (6), "Lane, Cliff (NIH/NIAID) [E]" [redacted] (b) (6), "Myles, Renate (NIH/OD) [E]" [redacted] (b) (6)>
Subject: RE: urgent: CNN request

HI Alice – thanks for sending this along. We will confer about how best to handle media requests about the guidelines – we're calling them NIH guidelines and the press release came from NIH, so I'd like to involve the NIH media office in this, hence I've cc'd Renate Myles. I think it's sort of an unsettled question as to who the spokespeople will be. Drs. Lane and Masur – do you have a preference?

Also, who is Claire? (The person who forwarded the CNN request to you and Dr. Masur. Would be good to have a last name so we can confer with her as needed going forward.)

From: Pau, Alice (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 1:24 PM

To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6) Masur, Henry (NIH/CC/CCMD) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6) >
Subject: FW: urgent: CNN request

Hi Courtney,

Please see below the request from CNN. Per Laurie, I will forward other requests to you.

Thanks, Alice

From: COVID19 Treatment Guidelines <COVID19TreatmentGuidelines@nih.gov>
Date: Tuesday, April 21, 2020 at 1:06 PM
To: Henry Masur [redacted] (b) (6), Alice Pau [redacted] (b) (6) >
Subject: Fw: urgent: CNN request

Hi Henry and Alice,

I am not sure how we want to handle interview requests like this. Would someone on the Panel want to/be allowed to speak to the press about the guidelines?

I am happy to politely decline if we want to handle it that way.

It is nice to see that we are being picked up by the press already though. I am glad people are already expressing interest.

Just let me know!
Claire

From: Nigam, Minali <Minali.Nigam@turner.com>
Sent: Tuesday, April 21, 2020 4:03 PM
To: COVID19 Treatment Guidelines <COVID19TreatmentGuidelines@nih.gov>
Cc: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>; Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>
Subject: urgent: CNN request

To the NIH Covid-19 Treatment Guideline Team:

My name is Minali Nigam and I work with Elizabeth Cohen at CNN Health. We wanted to reach out and request to speak with someone over the phone involved with the NIH treatment guidelines for covid-19. Please let us know as soon as possible for an available time today.

We appreciate your help, as we inform our viewers of important health information.

Best,
Minali

Dr. Minali Nigam
CNN Health
(b) (6)

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 19:42:03 +0000
To: Birx, Deborah L. EOP/NSC;Hahn, Stephen;Redfield, Robert R. (CDC/OD)
Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

See below

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: afauci@niaid.nih.gov
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 20, 2020 1:53 PM
Subject: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

China / Science

Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

- The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as the least potent type
- New York may have a deadlier strain imported from Europe, compared to less deadly viruses elsewhere in the United States

Stephen Chen in Beijing
Published: 10:41pm, 20 Apr, 2020
Updated: 1:33am, 21 Apr, 2020

A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possible implications for the pandemic. Photo: EPA-EFE

A new study by one of China's top scientists has found the ability of the new coronavirus to mutate has been vastly underestimated and different strains may account for different impacts of the disease in various parts of the world.

Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patients many mutations not previously reported. These mutations included changes so rare that scientists had never considered they might occur.

They also confirmed for the first time with laboratory evidence that certain mutations could create strains deadlier than others.

"Sars-CoV-2 has acquired mutations capable of substantially changing its pathogenicity," Li and her collaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday.

Li's study provided the first hard evidence that mutation could affect how severely the virus caused disease or damage in its host.

Li took an unusual approach to investigate the virus mutation. She analysed the viral strains isolated from 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, and then tested how efficiently they could infect and kill cells.

The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe, while the milder strains were the predominant varieties found in parts of the United States, such as Washington state, according to their paper.

A separate study had found that New York strains had been imported from Europe. The death rate in New York was similar to that in many European countries, if not worse.

But the weaker mutation did not mean a lower risk for everybody, according to Li's study. In Zhejiang, two patients in their 30s and 50s who contracted the weaker strain became severely ill. Although both survived in the end, the elder patient needed treatment in an intensive care unit.

This finding could shed light on differences in regional mortality. The pandemic's infection and death rates vary from one country to another, and many explanations have been proposed.

Genetic scientists had noticed that the dominant strains in different geographic regions were inherently different. Some researchers suspected the varying mortality rates could, in part, be caused by mutations but they had no direct proof.

The issue was further complicated because survival rates depended on many factors, such as age, underlying health conditions or even blood type.

In hospitals, Covid-19 has been treated as one disease and patients have received the same treatment regardless of the strain they have. Li and her colleagues suggested that defining mutations in a region might determine actions to fight the virus.

"Drug and vaccine development, while urgent, need to take the impact of these accumulating mutations ... into account to avoid potential pitfalls," they said.

Li was the first scientist to propose the Wuhan lockdown,according to state media reports. The government followed her advice and in late January, the city of more than 11 million residents was shut down overnight.

The sample size in this most recent study was remarkably small. Other studies tracking the virus mutation usually involved hundreds, or even thousands, of strains.

Li's team detected more than 30 mutations. Among them 19 mutations – or about 60 per cent – were new.

They found some of these mutations could lead to functional changes in the virus' spike protein, a unique structure over the viral envelope enabling the coronavirus to bind with human cells. Computer simulation predicted that these mutations would increase its infectivity.

To verify the theory, Li and colleagues infected cells with strains carrying different mutations. The most aggressive strains could generate 270 times as much viral load as the weakest type. These strains also killed the cells the fastest.

It was an unexpected result from fewer than a dozen patients, "indicating that the true diversity of the viral strains is still largely underappreciated," Li wrote in the paper.

Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: Xinhua

The mutations were genes different from the earliest strain isolated in Wuhan, where the virus was first detected in late December last year.

The coronavirus changes at an average speed of about one mutation per month. By Monday, more than 10,000 strains had been sequenced by scientists around the globe, containing more than 4,300 mutations, according to the China National Centre for Bioinformation.

Most of these samples, though, were sequenced by a standard approach that could generate a result quickly. The genes were read just once, for instance, and there was room for mistakes.

Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of the virus genome was read more than 100 times, allowing the researchers to see changes that could have been overlooked by the conventional approach.

The researchers also found three consecutive changes – known as tri-nucleotide mutations – in a 60-year-old patient, which was a rare event. Usually the genes mutated at one site at a time. This patient spent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeces were infectious with living viral strains.

"Investigating the functional impact of this tri-nucleotide mutation would be highly interesting," Li and colleagues said in the paper.

Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for Information Science and Technology at Tsinghua University, said ultra-deep sequencing could be an effective strategy to track the virus' mutation.

"It can produce some useful information," he said.

But this approach could be much more time consuming and costly. It was unlikely to be applied to all samples.

"Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the virus came from, why it could kill some healthy young people while generating no detectable symptoms in many others still left scientists scratching their heads.

"If there is a discovery that overturns the prevailing perception, don't be surprised."

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 18:01:06 +0000
To: Jim Yong Kim
Subject: RE: My article

Jim:

Very nice paper! Thanks for sending it.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jim Yong Kim <Jim.Yong.Kim@global-infra.com>
Sent: Monday, April 20, 2020 3:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: My article

Tony,

Hope you're well and thank you again for all that you are doing. I got this out today in the New Yorker and I'll be talking to most of the Democratic caucus today about what we're doing in Mass and the developing world.

Hang in there and let me know if there is anything more I can do. Mass is tough but we're going to have a 1000 contact tracers very soon. Every day we learn so much, which is why it's so important for everyone to get started.

Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 17:43:21 +0000
To: EDWARD SCOLNICK
Cc: Mascola, John (NIH/VRC) [E];Cassetti, Cristina (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: RE: for your consideration
Attachments: Scientists_to_Stop_COVID19_2020_04_15_FINAL.pdf

Ed:

Thank you for your note and for sending this. The outline that you provide is exactly in sync with what we are already doing and have definitive plans to do with regard to classic antivirals, monoclonal antibodies, and a variety of vaccine candidates. As you know, the candidate developed here at NIH in collaboration with Moderna is well into phase 1 trials and at least 2 others are entering into phase 1 trials.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: EDWARD SCOLNICK (b) (6)
Sent: Sunday, April 19, 2020 5:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: David R. Liu (b) (6); Schreiber, Stuart (b) (6); Michael Rosbash (b) (6)>; Ramnik Xavier (b) (6)
Subject: for your consideration

Tony . I hope your mail box is not so full that there is room for this. A group of concerned scientists from different parts of the country was organized to try to encapsulate and focus the national effort against Covid. This document has been shared with the White House although we are not sure if it has had any effect on their plans. It has also been shared with The Gates Foundation and a few other business and academic leaders. We think we have been fairly comprehensive in our considerations and recommendations. I hope you will find this helpful. We would greatly appreciate a conversation with you after you have had an opportunity to digest the content of the proposal. If there is anything else we can do to help you in this National emergency, we stand ready to help. When I was at Merck ,we led the successful
effort to make HIV a manageable disease and we dramatically lowered the death rate as a result of the drugs we made ,and the first triple therapy trial during the HIV pandemic. We hope we can help do the same for The Covid Pandemic Best wishes Ed scolnick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 15:12:29 +0000
To: Grady, Christine (NIH/CC/BEP) [E]
Subject: FW: Thank you

See part about you. ☺

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 11:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Thank you

This is a cute note...you can skip most of it and see highlight - that is the cute part

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: JOAN HUSSEY [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 9:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Thank you

Dear Dr. Fauci,
I just wanted to say thank you for everything you are doing to educate us in this country, and keep us safe during this horrendous coronavirus pandemic. I can't even begin to imagine how difficult it is to maintain your composure and persevere with your focus, being constantly in the public eye and also trying to expertly guide a president who seems more preoccupied with his own image (and sound of his own voice), and political aspirations than with the actual well being of his country's citizens.
By now, it should be perfectly clear to us that we can't have a healthy economy without a healthy population.
[redacted] (b) (6)
(b) (6) We all have been diligent about staying at home [redacted] (b) (6) ordering food and other things to be delivered to our house (we all wash our hands 'religiously'). [redacted] (b) (6) is the only one of us who occasionally goes to a grocery store or drug store if necessary and then, he always wears a mask, gloves, and keeps at least six feet between himself and anyone else, and gets in and out as quickly as possible. In addition, [redacted] (b) (6) are so intent on keeping me well and alive, we haven't even, any of us, physically visited with each other, in person, inside our house for months.

In the past two months, I've been outside only four times - twice on our deck and twice in my car, dropping off a couple of shopping bags at a friend's house and at [redacted] (b) (6) group home - both times leaving the bags in the driveway, and then driving right back home.

I'm so thankful for FaceTime, but we miss hugs and kisses. I know all this must sound extreme, and it is, but I'm terrified of becoming a statistic so we're doing whatever we can to stay healthy for ourselves and one another.

[redacted] (b) (6)

[redacted] (b) (6) My family is hearing what you're saying and taking your advice.

I'm sorry this email is so long but my intention, more than anything, is to thank you for your wisdom and advice, both grounded in years of experience.

I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. I met you once, briefly, about 40 years ago (+/-) in Bldg. 31's fitness room. I had been working in the CC, in the Patient Activities Dep't. (on the POB out- and in-patient units)at the time. I was incorrectly using a piece of equipment and you were kind enough to come over and show me the correct way to use it. I recognized you immediately, and have never forgotten that experience and how gracious you were.

I'm well aware from the news that you are up against some very tough people and some very tough times but please know you also have an army of grateful followers in this country who are completely convinced that what you are advising is in their very best interest.

Thank you again for all you've done for all of us over the years. My family and I are more grateful than I can express.

PS I read all about your wife who sounds amazing also. You two make an "All-Star" team.

Be well.

Gratefully, Joan ("Joanie") Hussey

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 15:11:29 +0000
To: [redacted] (b) (6)
Subject: FW: Thank you

Joanie:

Many thanks for your kind note. It is much appreciated. Stay safe!

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: JOAN HUSSEY [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 9:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Thank you

Dear Dr. Fauci,

I just wanted to say thank you for everything you are doing to educate us in this country, and keep us safe during this horrendous coronavirus pandemic. I can't even begin to imagine how difficult it is to maintain your composure and persevere with your focus, being constantly in the public eye and also trying to expertly guide a president who seems more preoccupied with his own image (and sound of his own voice), and political aspirations than with the actual well being of his country's citizens.

By now, it should be perfectly clear to us that we can't have a healthy economy without a healthy population.

[redacted] (b) (6)

[redacted] (b) (6). We all have been diligent about staying at home [redacted] (b) (6) [redacted], ordering food and other things to be delivered to our house (we all wash our hands 'religiously'). [redacted] (b) (6) is the only one of us who occasionally goes to a grocery store or drug store if necessary and then, he always wears a mask, gloves, and keeps at least six feet between himself and anyone else, and gets in and out as quickly as possible. In addition, [redacted] (b) (6) [redacted] are so intent on keeping me well and alive, we haven't even, any of us, physically visited with each other, in person, inside our house for months.

In the past two months, I've been outside only four times - twice on our deck and twice in my car, dropping off a couple of shopping bags at a friend's house and at [redacted] (b) (6) - both times leaving the bags in the driveway, and then driving right back home.

I'm so thankful for FaceTime, but we miss hugs and kisses. I know all this must sound extreme, and it is, but I'm terrified of becoming a statistic so we're doing whatever we can to stay healthy for ourselves and one another.

[redacted] (b) (6)

[redacted] (b) (6) My family is hearing what you're saying and taking your advice.

I'm sorry this email is so long but my intention, more than anything, is to thank you for your wisdom and advice, both grounded in years of experience.

I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. I met you once, briefly, about 40 years ago (+/-) in Bldg. 31's fitness room. I had been working in the CC, in the Patient Activities Dep't. (on the POB out- and in-patient units)at the time. I was incorrectly using a piece of equipment and you were kind enough to come over and show me the correct way to use it. I recognized you immediately, and have never forgotten that experience and how gracious you were.

I’m well aware from the news that you are up against some very tough people and some very tough times but please know you also have an army of grateful followers in this country who are completely convinced that what you are advising is in their very best interest.

Thank you again for all you’ve done for all of us over the years. My family and I are more grateful than I can express.

PS I read all about your wife who sounds amazing also. You two make an “All-Star” team.

Be well.

Gratefully, Joan (“Joanie”) Hussey

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 14:52:49 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: White House Coronavirus Task Force PowerPoint - 4.21.20
Attachments: PowerPoint April 21.pptx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 02:52:55 +0000
To: Corey, Larry
Subject: manuscript
Attachments: COVID vaccine editorial_prefinal April20 wfigure -with Fauci tracked edits.docx

Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Mon, 20 Apr 2020 19:24:58 -0400
To: Mascola, John (NIH/VRC) [E]
Subject: Fwd: COVID-19 vaccine

Let us discuss. I am not sure how to answer Adrian.

Begin forwarded message:

> **From:** Adrian Hill [redacted] (b) (6)
> **Date:** April 20, 2020 at 6:16:30 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** Hildegund Ertl [redacted] (b) (6)>, Sarah Gilbert [redacted] (b) (6)
> **Subject: FW: COVID-19 vaccine**
>
> Dear Dr Fauci
>
> [redacted] (b) (4)
>
> Thank you for your consideration of this at an exceptionally busy time.
>
> Yours sincerely
>
> Adrian Hill
>
> Professor Adrian V. S. Hill

Director, The Jenner Institute
Nuffield Department of Medicine
University of Oxford
Old Road Campus Research Building
Oxford OX3 7DQ

Tel: (b) (6)
Email: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 20:43:18 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Update: White House Coronavirus Meeting - 4.21.20

Yikes……………………. That would make 4 days in a row without a Press Conference for me – Saturday, Sunday, Monday and tomorrow ☺☺

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hurst, Natalie R. EOP/OVP [redacted] (b) (6)
Sent: Monday, April 20, 2020 4:38 PM
Subject: Update: White House Coronavirus Meeting - 4.21.20
Importance: High

All –

There will be no **White House Coronavirus Task Force Meeting** on Tuesday, April 21st.

Enjoy your evening,

Natalie Hurst
Operations Coordinator, White House Coronavirus Task Force
Executive Assistant to the Chief of Staff
The Office of the Vice President
[redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Mon, 20 Apr 2020 13:29:37 -0400
To: Charles McCall
Cc: Rotrosen, Daniel (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: Re: Tony and Dan, this is Cash. I seek your advice.

Dan:
Please bring this to the attention of appropriate NIAID people.
Thanks,
Tony

> On Apr 19, 2020, at 10:34 PM, Charles McCall <[redacted] (b) (6)> wrote:
>
> Dear Tony and Dan,
>
>
>

[redacted] (b) (4)

>
>
>
> Thank you for considering this idea. Be safe.

>
>
>
> Cash
>
>
>
> Sent from iPad
> Charles (Cash) McCall, MD
> Professor of Internal Medicine, Translational Sciences, Microbiology & Immunology
> Wake Forest University School of Medicine
> Wake Forest Biotech Place, suite 350, room 3W-007
> 575 N. Patterson Avenue
> Winston-Salem, NC 27101
>

(b)(5) - PCP

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 15:03:51 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: A National Testing Action Plan by the Rockefeller Foundation: Embargoed till midnight Monday April 20
Attachments: RF National COVID-19 Testing Action Plan_LAST FINAL_04.20.2020.docx

Set up

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Connor, Eileen <EOConnor@rockfound.org>
Sent: Monday, April 20, 2020 7:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>; Anthony.s.fauci@nih.gov; AFAURCI@niaid.nih.gov
Subject: A National Testing Action Plan by the Rockefeller Foundation: Embargoed till midnight Monday April 20

Dear Tony:

Thank you for all you are doing. Not sure you remember me [redacted] (b) (6) we talked a lot when I was at CNN. I have not wanted to bother you but wanted to make sure you had the National Testing Action Plan that we have put together with top researchers from all the various roadmaps, etc. I joined The Rockefeller Foundation after working in Afghanistan and Pakistan with State and coerced Christy Feig to join me. We would be happy to get on a call today with Raj and Jonathan Quick and other authors like Mike Pellini and Mark McLellan and Rick Klausner.

Given our history with public health and our ability to convene, we hoped we could help by working out a consensus plan. I have been briefing Caleb McCarry at the White House. We have worked with industry to also figure out the solutions to the supply chain issues and the other logistical issues. We are going to put $10 million into helping this standup. This plan doesn't just say what we need but the steps to get it done to open more safely.

Please let me know if you would like a call.

Regards
Eileen

Eileen O'Connor
Senior Vice President
Communications, Policy and Advocacy
The Rockefeller Foundation
Office: 212 852 8436
Mobile: [redacted] (b) (6)
eoconnor@rockfound.org
www.rockfound.org
(For scheduling purposes, please contact my assistant, [redacted] (b) (6), at
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 14:22:57 +0000
To: Anderson, Jennifer (NIH/NIAID) [E]
Subject: FW: Potential Postbac IRTA Fellowship
Attachments: CV 4.19.pdf

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Monday, April 20, 2020 9:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Potential Postbac IRTA Fellowship

[redacted] (b) (6)

(b) (6)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 11:58:51 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: ASF: Today's YES Network interview

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, April 20, 2020 7:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: ASF: Today's YES Network interview

You have an interview today with Jack Curry of the YES Network (Yankees). Just last night, The NY Post ran a story that includes Jack among the many sports broadcasting stars that have come out of Fordham [redacted] (b) (6); Jack and I have talked about this). Thought you might like to see it. Parts of your interview are also going to run on Michael Kay's show, and Kay also features prominently in this piece.

How Fordham has produced a generation of sports media stars

April 19, 2020 | 4:04pm | Updated April 19, 2020 | 9:16pm

John Giannone, MIchael Kay and Mike Breen; Chris Carrino Courtesy of Michael Kay, Chris Carrino

Long before he was an electee to the Basketball Hall of Fame, Mike Breen was an intimidated 18-year-old freshman attending a workshop at Fordham's renowned college radio station, WFUV, in the fall of 1979.

Breen felt sheepish next to the juniors and seniors leading the seminar and contemplated delaying the start of his broadcasting training. Soon, a couple of upperclassmen, including future NBA writer Dave D'Alesandro, made him feel more comfortable.

But he still didn't have any friends until one day on campus he saw a confident sophomore trying to sweet talk a young woman. "I know you like me," he said. "I can see it in your eyes."

The woman responded by saying she would not date him if he were the last man on earth. She essentially was saying, "See ya" … to Michael Kay.

That is how Breen first became friends with Kay.

"For him to have the confidence to do this in front of everybody with this beautiful student, I thought, 'Man, this guy has a great sense of humor,'" Breen said.

Four decades later, Breen and Kay are still good friends.

Michael Kay and Mike Breen Courtesy of Michael Kay

Fordham, the private Jesuit university in The Bronx that launched the legendary Vin Scully, for decades has been a powerhouse sportscasting pipeline, especially in New York. And the school ties that first united Breen and Kay are webbed throughout the industry.

Fordham is the alma mater for the voice of the NBA Finals/Knicks (Breen, Class of 1983), the Yankees' lead TV play-by-player/ESPN New York afternoon radio host (Kay, '82), the voice of the Giants (Bob Papa, '86), the radio voice of the Nets (Chris Carrino, '92) MSG's John Giannone ('86), YES' Jack Curry ('86), WFAN's Paul Dottino ('86) and YES/ESPN's Ryan Ruocco ('08). And that's just New York-based sportscasters.

For good measure, the school produced CBS' Spero Dedes ('01), ESPN's Tony Reali ('00) and the Washington Nationals' Charlie Slowes ('83). There are many more, and not just in front of the camera. If you need a field producer, Jim Johnson ('86) works for ESPN. A radio engineer? WFAN's Chris Majkowski ('89) will set things up. Media relations? Louis Barricelli ('09) is leading things at MLB Network.

Like everyone else, they are all dealing with the halt of sports due to the coronavirus pandemic. It is a jarring timeout for people so used to being on the run.

Ryan Ruocco, Mike Breen Courtesy of Ryan Ruocco

Take Carrino, who has done so much to raise money and awareness for facio scapulo humeral dystrophy (FSHD), a form of muscular dystrophy that afflicts him. A fundraising event was supposed to take place in March at a Nets game at Barclays Center. His 10th annual fundraising dinner, corresponding with his 50th birthday, was slated for August, and now is in question.

“I don’t know if it is going to be safe to have people together still,” Carrino said. “Are the restrictions going to be there in terms of how many people can gather in one place? The other aspect of it for me is: How comfortable am I asking people for money when I know the economy and certain businesses are affected so badly?”

Ruocco was supposed to get married in Italy in June. He and his fiancée, Andrea Ferzoco, are now going to punt the wedding until June 2021.

“It sucks,” Ruocco said. “Andrea and I were so excited and so were our guests. We have been feeling all the joy leading us to this. There are people dealing with much more dire circumstances than rescheduling a wedding. That is kind of the perspective we have tried to take.”

While most of the successful sports media alumni are worried about the current direction of Fordham and WFUV because of a de-emphasis on sports during the pandemic, to a man they say how Fordham molded them and led them to where they are today.

They were helped by famous names such as the legendary Marty Glickman, a mentor, and Stan Fischler, who taught classes. Then there were the less famous, equally instrumental figures in the program, such as Bob Ahrens, who ran WFUV as its executive producer during many of these notable students’ formative years.

John Giannone punting at FordhamCourtesy of John Giannone

The experiences that they shared forged many of them, such as Breen and Kay, into close friends.

Giannone went to Fordham after being recruited to be a punter on the football team. During training camp his freshman year, he quickly figured out the third-string punter would never see the field. He went to Kay, then the WFUV sports director as a senior, to try to help on the station. Kay said Giannone could do stats for him during the football season.

Kay went on to work at The Post, and later helped Giannone land an entry-level position at the paper. When Giannone transferred into television at CNN/Sports Illustrated, it was through a Kay connection. And Giannone landed at MSG Network after Kay left to become the TV voice of the Yankees when YES Network began.

When it was Giannone's turn as WFUV sports director, he made Papa and Curry a play-by-player and an analyst when they were sophomores.

WFUV also got its staff access to locker rooms at places like Yankee Stadium and Madison Square Garden to learn the craft next to professionals at the highest level. That remains largely true today.

"WFUV allowed you to believe you were a professional broadcaster before you really were," Curry said. "We were in the heart of New York City, and, even if we weren't Marv Albert, we felt as if what Marv Albert was doing for the Knicks, we were doing for Fordham."

There is a lineage that unites. Carrino learned how to describe the geography of a basketball court from Glickman. Later, Carrino returned to Fordham and taught Ruocco the same lessons. These days, at some Nets games, Ruocco is on TV, sitting next to Carrino, calling the game on the radio.

Jack Curry Courtesy of Jack Curry

Papa also was mentored by Glickman. Papa and Carrino each were told by their fathers that if they majored in communications, they would have to pay for school themselves. Both ended up in the Business School, but had their eyes on WFUV the whole time.

Carrino ended up working as a producer for Papa, beginning when Papa hosted a tailgate show on WFAN. Carrino eventually followed Papa as the radio voice of the Nets.

The Fordham sports alums want everyone to be safe during this time — and they can’t wait to get back to what they love to do.

“I’m desperate to get back to work,” Breen said. “I’m hoping there is NBA basketball. This is the best time of the year.”

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 11:14:21 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: the Strategy document
Attachments: COVID vaccine editorial_prefinal April19 wfigure.docx

Email below is from Larry Corey.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Corey MD, Larry [redacted] (b) (6)>
Sent: Sunday, April 19, 2020 11:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>; Miner PhD, Mindy < [redacted] (b) (6)
Subject: the Strategy document

Here is the working draft of the article for the NEJM . It , in my opinion, reads really well . I have embellished it today with a figure that conceptually outlines what we are talking about ; the old axiom that a picture is worth a thousand words .
The editorial guidelines of the NEJM has 2 potential categories . One is Perspectives which is 1200 words an 5 references . We are at 1750 words and I think losing 500 words takes away a lot from the message . The other category is a special report which is over 2500 words and allows lots of references (40) I think this is best and was one reason I thought about adding the conceptual figure which does outline in a single picture what we are talking about .

Tony , If you feel its best to have Francis on this paper we both support it . Your call . I do however lean on including Francis . I would say politicly to achieve our goal and bring all these companies into the tent while you are away at the White House having him buy into this plan through the ACTIV program seems important to us . I think we get to our goal if he is out there publicly embracing this; using the NIAID networks labs DSMB and the correlates programs . This type of granularity really puts him deep into understanding what we are doing . If this means you are first and he is last author we are ok with that , For me I need to have him use me for interfacing with the company in defining these collaborations . If you were present all the time this would be unnecessary , but as he will be the link with BARDA linking him to John and I increases the likelihood of success.

[redacted] (b) (6)

Ok enough .. as they say on the news Goodnight ..

Larry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 02:39:49 +0000
To: 'Thomas Quinn'
Subject: FW: Fauci photo
Attachments: Fauci ISSTDR 1983.pdf

Thanks, Tom!

From:
From: Thomas Quinn [redacted] (b) (6)>
Sent: Sunday, April 19, 2020 6:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Hunter Handsfield <hhh@uw.edu>
Subject: FW: Fauci photo

Hi Tony,
It was great to see you and present our work to you this last Friday. I really enjoyed our discussion and feedback.
As I said on zoom, we all really appreciate your leadership in the COVID-19 crisis. Thank you for providing the guiding way through this.
[redacted] (b) (4)

In the meantime, your photos are getting passed around and Hunter Handsfield wanted you to have this one (from the HIV archives—1983 in Seattle).

All the best,
Tom

p.s. [redacted] (b) (6) Stay healthy!

From: Hunter Handsfield <hhh@uw.edu>
Date: Sunday, April 19, 2020 at 3:52 PM
To: Thomas Quinn [redacted] (b) (6)
Subject: Fauci photo

Hi, Tom. Going through old boxes I came across this, from 5th ISSTDR, Seattle 1983. Give Tony my greetings if you forward to him.

Cheers— Hunter

H. Hunter Handsfield, MD
Professor Emeritus of Medicine
Center for AIDS and STD
University of Washington

Phone +1 206 935-5225
Mobile (b) (6)

Seattle Sheraton Hotel

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 01:58:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Fauci photo
Attachments: Fauci ISSTDR 1983.pdf

Email from Tom Quinn to you.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Thomas Quinn [redacted] (b) (6)
Sent: Sunday, April 19, 2020 6:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Hunter Handsfield <hhh@uw.edu>
Subject: FW: Fauci photo

Hi Tony,
It was great to see you and present our work to you this last Friday. I really enjoyed our discussion and feedback.
As I said on zoom, we all really appreciate your leadership in the COVID-19 crisis. Thank you for providing the guiding way through this.
[redacted] (b) (4)
.

In the meantime, your photos are getting passed around and Hunter Handsfield wanted you to have this one (from the HIV archives—1983 in Seattle).

All the best,
Tom

p.s. [redacted] (b) (6)
. Stay healthy!

From: Hunter Handsfield [redacted] (b) (6)
Date: Sunday, April 19, 2020 at 3:52 PM
To: Thomas Quinn [redacted] (b) (6)>
Subject: Fauci photo

Hi, Tom. Going through old boxes I came across this, from 5th ISSTDR, Seattle 1983. Give Tony my greetings if you forward to him.

Cheers— Hunter

H. Hunter Handsfield, MD
Professor Emeritus of Medicine
Center for AIDS and STD
University of Washington

(b) (6)
Phone + [redacted]
Mobile

Seattle Sheraton Hotel

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 01:56:21 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: A proposal to stop COVID-19 and reopen our schools and businesses

Email from David Liu to FC with a cc to you.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: David R. Liu [redacted] (b) (6)
Sent: Sunday, April 19, 2020 9:08 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Michael Rosbash [redacted] (b) (6)>; Ramnik Xavier [redacted] (b) (6)>; EDWARD SCOLNICK [redacted] (b) (6)>; Stuart Schreiber [redacted] (b) (6)>; Michael Z Lin [redacted] (b) (6)>; Ben Cravatt [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Austin, Christopher (NIH/NCATS) [E] [redacted] (b) (6)>; Wholley, David (FNIH) [T] [redacted] (b) (6); Freire, Maria (FNIH) [T] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Thomas Cahill [redacted] (b) (6)>
Subject: Re: A proposal to stop COVID-19 and reopen our schools and businesses

Thank you, Francis, for your speedy reply. Please let us know if we can help ACTIV, Fauci, or any other leaders who might want to engage.

Best,
David

David R. Liu
Richard Merkin Professor and Director of the Merkin Institute
of Transformative Technologies in Healthcare
Broad Institute Core Institute Member and Vice-Chair of the Faculty
Director of the Chemical Biology and Therapeutic Sciences Program
Howard Hughes Medical Institute Investigator
Harvard University Professor of Chemistry and Chemical Biology
75 Ames Street
Cambridge, MA 02142

On Apr 19, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> wrote:

Dear David et al.,

Thanks for forwarding this very thoughtful document, which presents a series of important recommendations – most of which I agree with. I don't know if you saw Friday's announcement (attached) of the new public private partnership called ACTIV (for Accelerating COVID-19 Therapeutic Interventions and Vaccines), but it has taken on most of the points you raise in sections 1 – 3 of your letter. I share your hopes that remdesivir will show benefit, and the current large NIH-sponsored RCT has completed enrollment and should reveal results in about a month. But of course we want to test multiple other interventions – both small molecules and antibody-based therapies, so we need our trial system to be optimized like never before. I will share your letter with the leaders of ACTIV, who are working with unprecedented speed to prioritize the next set of therapeutic candidates as well as pushing vaccine development programs to adopt exceptionally creative trial designs to test safety and efficacy (with full engagement by FDA).

Best regards, Francis

From: David Liu [redacted] (b) (6)>
Sent: Sunday, April 19, 2020 5:20 PM
To: OD Labc (NIH/OD) [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)
Cc: Michael Rosbash [redacted] (b) (6)>; Ramnik Xavier [redacted] (b) (6)>; EDWARD SCOLNICK [redacted] (b) (6)>; Stuart Schreiber [redacted] (b) (6) Michael Z Lin <[redacted] (b) (6); Ben Cravatt [redacted] (b) (6)
Subject: A proposal to stop COVID-19 and reopen our schools and businesses

Dear Francis,

I hope you are well.

I write on behalf of a group of citizen-scientists, most or all of whom you know. Motivated solely by our desire to help defeat the serious threat our nation and the world now faces, we wrote a set of four actionable, non-partisan proposals (attached) to produce safe and effective COVID-19 therapeutics and vaccines in the shortest possible timeframe, and to reopen our society in a manner that reduces the risk of future COVID-19 outbreaks.

We hope you find these ideas interesting, and might be willing to share this set of proposals with Dr. Tony Fauci, along with our willingness to discuss any part of the proposals with him if we can be helpful. We understand from our efforts to contact Dr. Fauci through email routes that his standard inbox may be too overwhelmed for our proposal to reach him.

The four proposals attached describe: (1) How to rapidly repurpose an antiviral drug to treat COVID-19 patients; (2) How to expedite the development of human antibody drugs to treat patients and to provide short-term protection for healthy individuals; (3) How to develop COVID-19 vaccines on an expedited time scale; and (4) How to reopen our businesses and schools in a manner that reduces the risk of future outbreaks and deaths.

Thank you for any help or thoughts you might be able to provide.

Sincerely yours,
Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin (Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brandeis), Stuart Schreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier (MGH/Broad)

____

David R. Liu
Richard Merkin Professor and Director of the Merkin Institute
of Transformative Technologies in Healthcare
Director of the Chemical Biology and Therapeutic Sciences Program
Core Institute Member and Vice-Chair of the Faculty, Broad Institute
Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of the Natural Sciences
and Professor of Chemistry & Chemical Biology, Harvard University
75 Ames Street
Cambridge, MA 02142

<NIH_ACTIV_Release_041720.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 01:25:42 +0000
To: bgertz@washingtontimes.com
Cc: Miller, Katie R. EOP/OVP;Short, Marc T. EOP/OVP
Subject: Scientific paper on origin of coronavirus

Bill:

Here are the links to the scientific papers and a commentary about the scientific basis of the origins of SARS-Cov-2.

The proximal origin of SARS-CoV-2. Andersen KG, Rambaut A, Lipkin WI, **Holmes** EC, Garry RF. Nat Med. 2020 Apr;26(4):450-452. doi: 10.1038/s41591-020-0820-9. No abstract available.
A Genomic Perspective on the Origin and Emergence of SARS-CoV-2.Zhang YZ, **Holmes** EC. Cell. 2020 Apr 16;181(2):223-227. doi: 10.1016/j.cell.2020.03.035. Epub 2020 Mar 26.
Also this statement from Eddie Holmes
https://bit.ly/2ym1UGe

Best regards,
Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

> On Apr 19, 2020, at 2:21 PM, Bill Gertz <bgertz@washingtontimes.com> wrote:
>
> Katie,
>
> Dr. Fauci on Friday said he would share a scientific paper with the press on the origin of the coronavirus. Can you please help me get a copy of that paper? Thanks in advance.
>
> Bill Gertz

National Security Correspondent
@BillGertz | direct 202-636-3274
TheGertzFile.com

<twtlogo.jpg>

3600 New York Ave NE | Washington DC, 20002

The information contained in this electronic transmission is intended for the exclusive use of the individuals to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is prohibited by law. If the reader of this transmission is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. In addition, any unauthorized copying, disclosure or distribution of the material in this e-mail and any attachments is strictly forbidden.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 01:22:40 +0000
To: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: IMPORTANT

Thanks Greg.
Patty:
Please respond to Dr. Dzau's questions.
Thanks,
Tony

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, April 19, 2020 7:06 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Subject: RE: IMPORTANT

Patty I had spoken to ASF about using a few slides and he said yes / I will have them done short;y

- V Dzau: I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.
- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.

- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Sunday, April 19, 2020 7:01 PM
To: Folkers, Greg (NIH/NIAID) [E] <[redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>
Subject: FW: IMPORTANT

We need to discuss tomorrow on our daily meeting/call – do you want to do slides.

Again this event is on a Saturday and is tentative as we do not know when the TF meeting will be scheduled that day.

So – if you can do it - will you use slides?

So if you cant do this – do you want a surrogate and who?

I will make sure David is on board for zoom.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Sunday, April 19, 2020 3:11 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>; [redacted] (b) (6)
Mun, Jenny <JMun@nas.edu>
Subject: IMPORTANT

Dear Patty,

I hope this finds you well. I know how terribly busy Tony is and I hate to trouble him, however, the NAS Annual Meeting panel on COVID-19 is less than a week away and my team needs answers to the questions below. Can you call this to his attention or assist him in providing the signed form and requested information? We hope to have this by Tuesday (4/23) morning, if possible.

- Please provide a **cell number** where you can be reached in case you do not connect in time (if you prefer, you can provide the number of your assistant if they will be able to reach you directly by cell or at home).

- Will you have slides to display during your talk?

- Are you able to use Zoom 'share your screen' to show the slides directly during your talk or do you need someone from NAS to show your slides for you?

- Will you need a test session with our Zoom techs? Please let me know as soon as possible as staff are available to hold training sessions through Monday, April 20 (9 AM to 5 PM EDT).

- If you would like to promote your participation in our meeting on social media, please let me know the contact of your social media contact from your institution.

Finally, because this is going to be a remote meeting, we would like panelists to log into Zoom 30 minutes before the session starts – that is at 1:30 pm ET to go over the technology and any last minute speaker prep. So far, more than 800 Academy members have registered for the meeting and there will be additional members of the public and possibly the press tuning in.

Best,
Victor

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Apr 2020 03:29:42 +0000
To: Peter Daszak
Subject: RE: Thank you for your public comments re COVID-19's origins

Peter:
Many thanks for your kind note.
Best regards,
Tony

From: Peter Daszak [redacted] (b) (6)
Sent: Saturday, April 18, 2020 9:43 PM
To: Morens, David (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Stemmy, Erik (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Aleksei Chmura [redacted] (b) (6)
Subject: Thank you for your public comments re COVID-19's origins
Importance: High

Tony (cc'ing David so that you might pass this on to Tony once he has a spare second)

As the PI of the R01 grant publicly targeted by Fox News reporters at the Presidential press briefing last night, I just wanted to say a personal thankyou on behalf of our staff and collaborators, for publicly standing up and stating that the scientific evidence supports a natural origin for COVID-19 from a bat-to-human spillover, not a lab release from the Wuhan Institute of Virology.

[redacted] (b) (7)(A)

From my perspective, your comments are brave, and coming from your trusted voice, will help dispel the myths being spun around the virus' origins.

Once this pandemic's over I look forward thanking you in person and let you know how important your comments are to us all.

Cheers,

Peter

(b) (7)(A)

[redacted]

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Apr 2020 01:23:00 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: cotton swabs

Followup email from Jake Tapper.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Jake Tapper (b) (6)
Sent: Saturday, April 18, 2020 4:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: cotton swabs

Got it
Thanks

On Sat, Apr 18, 2020 at 4:52 PM Fauci, Anthony (NIH/NIAID) [E] (b) (6)> wrote:

> This is what I was referring to. They are not ready for prime time, since they have to get the right media and wrapping.
>
> **Subject: Qtip announcement**
>
> https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-gates-foundation-unitedhealth-group-quantigen-and-us-cotton
>
> ## Coronavirus (COVID-19) Update: FDA, Gates Foundation, UnitedHealth Group, Quantigen, and U.S. Cotton Collaborate to Address Testing Supply Needs

The U.S. Food and Drug Administration announced a further expansion of COVID-19 testing options through the recognition that spun synthetic swabs – with a design similar to Q-tips – could be used to test patients by collecting a sample from the front of the nose.

As part of this effort, U.S. Cotton, the largest manufacturer of cotton swabs and a subsidiary of Parkdale-Mills, developed a polyester-based Q-tip-type swab that is fully synthetic for compatibility with COVID-19 testing. Harnessing its large-scale U.S.-based manufacturing capabilities, U.S. Cotton plans to produce these new polyester swabs in large quantities to help meet the needs for coronavirus diagnostic testing.

"This action today demonstrates the ingenuity that results from the FDA working in partnership with the private sector. The Trump Administration has been working side-by-side with our industry partners to fight this pandemic, and today is a great example of that work. We appreciate work by UnitedHealth Group, Quantigen, and the Gates Foundation to perform and support the clinical studies necessary for this advancement. We also want to acknowledge U.S. Cotton's efforts to manufacture a new type of swab for COVID-19 testing that can be produced at scale. We appreciate the work of these collaborators to consider how these test supplies could be broadly distributed to meet not only the testing needs of the United States but also global needs around the pandemic. All of these actions by these American organizations will help continue to expand our testing capability," said FDA Commissioner Stephen M. Hahn, M.D.

This finding that spun synthetic swabs could be used for COVID-19 testing is based on results from a clinical investigation that represents a collaboration between the FDA, UnitedHealth Group, the Gates Foundation, and Quantigen. The type of testing at the front of the nose used in this study is notable because it allows self-collection by patients thereby limiting exposure of healthcare providers; it is more comfortable for patients and it can be performed by a swab that is more readily available and manufacturable at scale.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 22:21:02 +0000
To: Corey MD, Larry;Conrad, Patricia (NIH/NIAID) [E]
Cc: Mascola, John (NIH/VRC) [E]
Subject: RE: [redacted] (b) (6)
Attachments: COVID vaccine editorial_16April 7pm - with Fauci edits.docx

Larry:

I have gone over the manuscript and have made a number of edits that are tracked into the attached document. Please take a look, accept the changes (unless you have issues with them), add the references and then let us discuss next steps, i.e. add or not Francis to authors and where in the order.

John:

Please also give it another good look.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Corey MD, Larry [redacted] (b) (6)>
Sent: Saturday, April 18, 2020 12:34 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Subject: working draft of NEJM

Here is the working draft . My manuscript typist too tired to work tonight so it reflects several changes I made tonight ; it should be readable ;

Larry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 20:40:34 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers [redacted] (b) (6))
Subject: FW: You are a Hero

Please see me about this on Monday. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kathy Ireland [redacted] (b) (6)
Sent: Tuesday, April 7, 2020 4:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: You are a Hero

Dear Dr. Fauci,

Thank you for everything you're doing for America and the world. I'm writing to you today, rather than calling, because it's impossible to imagine the degree to which leading science during this COVID-19 pandemic is impacting your life and your family. Please know, that your wisdom and passion brings so much comfort to millions, including our family and me, specifically. You may recall from our previous talks, that [redacted] (b) (6) What a vicious virus, Dr. Fauci ... unlike anything I've ever seen.

In addition to my work as Ambassador for the Elizabeth Taylor AIDS Foundation, it is also an honor and responsibility to serve as International Youth Chair for the National Pediatric Cancer Foundation. In that position, people approach with questions for our government that I am uncomfortable giving opinions on in ignorance. So reluctant to bother you - I'm seeking to learn who at the NIH I should bring this to?

The question comes from my associate [redacted] (b) (6), (b) (4)

[redacted] (b) (4)

Thank you so much for all that you do.

Always,

Kathy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 20:21:32 +0000
To: [redacted] (b) (6)
[redacted] (b) (6)
Subject: FW: article and bb rim
Attachments: The Mentor Who Made Dr. Anthony Fauci - WSJ - large text.pdf

This article about my relationship with Shelly Wolff is worth reading

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barton Haynes, M.D. <barton.haynes@duke.edu>
Sent: Thursday, April 16, 2020 12:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: article and bb rim

Hi tony:

Glad this worked out. Wonderful article. Great tribute to both you and Shelly. But the socks in the last picture.......

On another note, [redacted] (b) (6).

[redacted] (b) (6) So when the pandemic is over or when you are down there and want a break, I can put you in touch with him to see the Regis bb goal.

He has been following your career for many years. Very nice fellow.

Thanks for all you are doing Tony, it only sounds like it is getting more and more difficult. But you are doing an amazing job....

So proud of you and that (b) (6)

Best Bart

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 20:12:02 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers [redacted] (b) (6);Billet, Courtney (NIH/NIAID) [E]
Subject: FW: From Jack Curry/ YES Network (Yankees)

Have we decided to set this up. Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, April 16, 2020 1:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: ASF: From Jack Curry/ YES Network (Yankees)

Jack Curry (broadcaster with the YES Network, which is like MASN, but for the Yankees) is appealing to you as a New Yorker and lifelong Yankees fan for a 10-minute interview via Zoom. Jack covered the Yankees for 22 years at the NYT. The interview would run on YES (largest regional sports network in the country) as the focus of one of the original shows they are producing 3x/week called "YES, WE'RE HERE." It would be run across all of their social media platforms (reach of over 1M). They would also air clips on the Michael Kay Radio Show (TV play-by-play announcer for the Yankees), which is simulcast on YES and is the highest-rated drive time talk show in New York.

Questions below, including a few at the end about your lifelong baseball fandom. Is this something you'd be willing to do? If so we will seek clearance.

POSSIBLE QUESTIONS

DOCTOR FAUCI, I KNOW YOUR DAYS ARE FILLED WITH OFFERING ADVICE AND COUNSEL TO SO MANY PEOPLE ABOUT THE CORONAVIRUS. WITH THE SOBERING POSITION WE HAVE BEEN IN FOR A WHILE, WHAT WOULD BE YOUR MOST URGENT MESSAGE TO AMERICANS?

THE PHRASE 'FLATTENING THE CURVE' HAS BECOME COMMONPLACE IN OUR VERNACULAR IN RECENT WEEKS. HOW MUCH CLOSER ARE WE GETTING TO FLATTENING THE CURVE?

YOU'VE SAID SEVERAL TIMES THAT THE VIRUS IS THE CLOCK. WHAT IS THE VIRUS TELLING YOU ABOUT THAT TIME FRAME?

AS THE COUNTRY TRIES TO WORK ITS WAY BACK, THERE HAS BEEN SPECULATION ABOUT HOW PROFESSIONAL SPORTS CAN RETURN. WHAT ARE YOUR THOUGHTS ON HOW, FOR INSTANCE, MAJOR LEAGUE BASEBALL WOULD BE ABLE TO START ITS SEASON?

BASEBALL IS A SPORT IN WHICH SHAKING HANDS IS AS COMMON AS BALLS AND STRIKES. NOT JUST IN BASEBALL, OBVIOUSLY, BUT IN LIFE OVERALL, HOW MUCH DO YOU ADVOCATE NOT SHAKING HANDS ANYMORE?

THE NEW YORK TIMES REFERRED TO YOU AS THE EXPLAINER-IN-CHIEF IN COMPLIMENTING YOUR ABILITY TO SPEAK BLUNTLY AND TRUTHFULLY. SO HOW SHOULD AMERICANS PLAN ON BEHAVING AS WE MOVE FORWARD IN THESE UNCERTAIN TIMES?

AND…IF DR FAUCI WAS COMFORTABLE WITH IT, A COUPLE OF QUESTIONS ABOUT HIS BASEBALL FANDOM…

WITH ALL THAT'S HAPPENING AROUND US AND YOUR IMPORTANT ROLE IN IT, IT MIGHT SEEM TRITE TO DISCUSS BASEBALL. BUT I KNOW YOU'VE BEEN A YANKEE FAN FOR MORE THAN 70 YEARS. AND I WOULD LIKE TO ASK YOU A FEW BASEBALL QUESTIONS.

WHEN AND HOW DID YOUR YANKEE FANDOM BEGIN?

YOU WERE A YOUNGSTER WHEN THE YANKEES WON 5 STRAIGHT WORLD SERIES TITLES FROM 1949-1953, THE ONLY TIME THAT'S EVER HAPPENED IN BASEBALL HISTORY. WHAT ARE YOUR MEMORIES OF THOSE YEARS?

HOW HAS YOUR BACKGROUND IN SPORTS HELPED YOU IN YOUR ROLE WITH THE NIAID?

AND, FINALLY, YOU'VE SPOKEN ABOUT HOW NEW YORK IS THE EPICENTER OF THE VIRUS. FOR NEW YORKERS WHO ARE LOOKING FOR SOME LIGHT AT THE END OF THE TUNNEL, WHAT WOULD YOU SAY TO THEM?

From: [redacted] (b) (6)
Sent: Mon, 27 Apr 2020 07:00:08 -0400
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: The global health leaders call, THURSDAY 30 April at 14.30 CET

FYI

Begin forwarded message:

> **From:** "RYAN, Michael J." [redacted] (b) (6)t>
> **Date:** April 27, 2020 at 5:34:56 AM EDT
> **To:** SHOC [redacted] (b) (6)>, Office of the Director-General <DGOffice@who.int>, "Redfield, Robert R. (CDC/OD)" [redacted] (b) (6) (b) (6) (b) (6) David Heymann [redacted] (b) (6)>, "Felicity Harvey [redacted] (b) (6)" [redacted] (b) (6) "Chris.Elias" [redacted] (b) (6) [redacted] (b) (6) (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6) "GREIN, Thomas" [redacted] (b) (6)"COX, Paul Michael" [redacted] (b) (6)>, "SCHWARTLANDER, Bernhard F." [redacted] (b) (6), "MINHAS, Raman" [redacted] (b) (6) "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "MAHJOUR, Jaouad" [redacted] (b) (6)>, "FALL, Ibrahima Soce" [redacted] (b) (6), "Thomas R. Frieden" [redacted] (b) (6) Lynn Banks < [redacted] (b) (6), President | Resolve to Save Lives <president@resolvetosavelives.org>, "Amadou.SALL" [redacted] (b) (6) "AL-SHORBAJI, Farah" [redacted] (b) (6) ; , Robynn Leidig [redacted] (b) (6)>, "DRURY, Patrick Anthony" [redacted] (b) (6)t>, "Dr VAN KERKHOVE, Maria" [redacted] (b) (6) "GRAAFF, Peter Jan" [redacted] (b) (6)"POOLE, Marcia" [redacted] (b) (6)Tarik Mohammed

[redacted] (b) (6) Carlos
Navarro Colorado [redacted] (b) (6)
[redacted] Ryan Morhard [redacted] (b) (6)>,
"BRIAND, Sylvie" [redacted] (b) (6), "MORGAN, Oliver" [redacted] (b) (6)
"Harries, Jenny" [redacted] (b) (6), "Awwad, David (NIH/NIAID)
[C]" [redacted] (b) (6), "SIMONSON, Stewart" [redacted] (b) (6)
"SINGER, Peter Alexander" [redacted] (b) (6) "Jayatunga, Wikum"
[redacted] (b) (6)
[redacted] "Julie.HALL" [redacted] (b) (6)>, Amelie
RIOUX [redacted] (b) (6)>, "KABIR, Sophia" [redacted] (b) (6)>,
[redacted] (b) (6)
[redacted], "SHIN, Young-Soo"
[redacted] (b) (6)
Feng Ding [redacted] (b) (6)
[redacted]
ASMA, Samira" [redacted] (b) (6)>
Cc: SHOC <shoc@who.int>, Office of the Director-General <DGOffice@who.int>,
"SCHWARTLANDER, Bernhard F." [redacted] (b) (6)>, "MAHJOUR,
Jaouad" [redacted] (b) (6), "FALL, Ibrahima Soce" [redacted] (b) (6)>, "GREIN,
Thomas" [redacted] (b) (6), "MINHAS, Raman" [redacted] (b) (6)>, "COX, Paul
Michael" [redacted] (b) (6)>, "AL-SHORBAJI, Farah" [redacted] (b) (6),
"POOLE, Marcia" [redacted] (b) (6)>, "DRURY, Patrick Anthony"
[redacted] (b) (6)>, "GRAAFF, Peter Jan" [redacted] (b) (6)>, "Dr VAN
KERKHOVE, Maria" [redacted] (b) (6)>, "KABIR, Sophia"
[redacted] (b) (6)>, "FARES, Christine Youssef" [redacted] (b) (6),
"AYLWARD, Raymond Bruce J." [redacted] (b) (6)>, "SMITH, Ian Michael"
[redacted] (b) (6)
Subject: The global health leaders call, THURSDAY 30 April at 14.30 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted on THURSDAY, 30 April at 14:30 CET and Zoom details are copied below.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227915533

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email (b) (6); mobile no. (b) (6)

The agenda and background documents will be shared ahead of the call.

Best,

Mike

Join Zoom Meeting
https://who.zoom.us/j/ (b) (6), (b) (4)
Meeting ID: (b) (6), (b) (4)
Password: (b) (6), (b) (4)
Dial by your location
+41 43 210 71 08 Switzerland
+41 43 210 70 42 Switzerland
0 800 561 252 Switzerland Toll-free
0 800 002 622 Switzerland Toll-free
+1 253 215 8782 US (Tacoma)
+1 213 338 8477 US (Los Angeles)
888 475 4499 US Toll-free
877 853 5257 US Toll-free
+33 7 5678 4048 France
+33 1 7095 0350 France
0 800 944 049 France Toll-free
0 800 940 415 France Toll-free
Meeting ID: (b) (6), (b) (4)
Find your local number: https://who.zoom.us/u/aeFZfwUgUc
Join by SIP
(b) (6), (b) (4) @zoomcrc.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 10:54:50 +0000
To: Duchin, Jeff
Subject: RE: High Praise

Jeff:
Well-deserved recognition of your fine work. Keep it up.
Best regards,
Tony

From: Duchin, Jeff [redacted] (b) (6)
Sent: Sunday, April 26, 2020 11:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: High Praise

Tony - in a recent shoddy "investigative journalism" piece about our work here in Seattle (https://www.seattletimes.com/seattle-news/times-watchdog/why-the-seattle-sounders-game-went-on-despite-coronavirus-emergency/) the reporter referred to me as being to the Seattle area what Anthony Fauci would become to the country. So despite the crappy reporting he bestowed upon me the highest of praise and reminded me again of the incredible service you are doing for our country. Hang in there and take care of your self. We need you. Jeff

Why the Seattle Sounders game March 7 went on despite coronavirus emergency

As virus fears grew, public officials and sports execs debated health risks — and PR messages — but let 33,000 into a March 7 Sounders match. At what cost?

www.seattletimes.com

Jeffrey S. Duchin, MD (he/him)
Health Officer and Chief, Communicable Disease Epidemiology & Immunization Section
Public Health - Seattle and King County
Professor in Medicine, Division of Infectious Diseases, University of Washington
Adjunct Professor, School of Public Health
401 5th Ave, Suite 1250, Seattle, WA 98104
Tel: (206) 296-4774; Direct [redacted] (b) (6); Fax: (206) 296-4803
E-mail: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 02:47:49 +0000
To: Shapiro, Neil (NIH/OD) [E];Collins, Francis (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E];Johnson, Alfred (NIH/OD) [E];Hallett, Adrienne (NIH/OD) [E]
Subject: RE: NIAID facilities in the CARES Act spend plan

I suggest that [redacted] (b) (6)

From: Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6)>
Sent: Sunday, April 26, 2020 10:32 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] < [redacted] (b) (6)>
Subject: NIAID facilities in the CARES Act spend plan
Importance: High

Francis and Tony,

I have been working to get OMB/ASFR clearance for the 3rd Supplemental spend plan, and have encountered a hitch with OMB concerning the VRC/RML proposal. They say they [redacted] (b) (5)

I raised the issue to Norris, and he asked me to [redacted] (b) (5)

[redacted] (b) (5) Thanks,

Neil

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 02:46:32 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: New England Journal of Medicine 20-13479

Yes, please.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Sunday, April 26, 2020 10:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: New England Journal of Medicine 20-13479

Want me to call [redacted] (b) (6)?

From: Corey MD, Larry [redacted] (b) (6)>
Sent: Sunday, April 26, 2020 1:44 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Subject: RE: New England Journal of Medicine 20-13479

I think it would be very helpful , I see no downside ..

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Sunday, April 26, 2020 6:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E] [redacted] (b) (6); Corey MD, Larry [redacted] (b) (6)>
Subject: RE: New England Journal of Medicine 20-13479

If it would be helpful, I'd be glad to do the outreach to Holden Thorp – Tony and I can discuss.

Francis

From: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>
Sent: Sunday, April 26, 2020 8:37 AM
To: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>; Corey MD, Larry [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Subject: RE: New England Journal of Medicine 20-13479

All good options. Let us go with *Science* first. If they do not want it, I am certain that *Science Translational Medicine* will take it. I will discuss with Francis and John.

From: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Sent: Saturday, April 25, 2020 5:59 PM
To: Corey MD, Larry < [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)

Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: New England Journal of Medicine 20-13479

In looking at NEJM, they have had 4 COIVD-19 perspectives in last 6 weeks, and they may have impacted their thinking.

Agree with talking to editors. If interest in Science or Nature, suggestions below.

Priscilla Kelly, editor at science emailed me a while about their interest in papers. So if interest in Science, we could check with her.
If Nature, Ursula Weiss.

John

From: Corey MD, Larry [redacted] (b) (6)>
Sent: Saturday, April 25, 2020 5:50 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E]
[redacted] (b) (6)>
Subject: Re: New England Journal of Medicine 20-13479

You and Tony decide. Science or Nature accomplish the same but it seems we need a discussion with the editor first to explain the importance of the manuscript.

Sent from my iPhone

> On Apr 25, 2020, at 2:18 PM, Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> wrote:
>
> Very surprised.
>
> Do you want me to push back?
>
> Francis
>
> ---
>
> **From:** Corey MD, Larry <[redacted] (b) (6)>
> **Sent:** Saturday, April 25, 2020 3:55 PM
> **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E]
> <[redacted] (b) (6)
> **Cc:** Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)>
> **Subject:** RE: New England Journal of Medicine 20-13479
>
> A do have to say I am surprised . but ok

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, April 25, 2020 12:53 PM
To: Corey MD, Larry [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E]
[redacted] (b) (6)>
Cc: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Subject: Fwd: New England Journal of Medicine 20-13479

Let us discuss next steps

Begin forwarded message:

> **From:** New England Journal of Medicine
> <onbehalfof@manuscriptcentral.com>
> **Date:** April 25, 2020 at 12:31:26 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <afauci@niaid.nih.gov>
> **Subject: New England Journal of Medicine 20-13479**
> **Reply-To:** "editorial@nejm.org" <editorial@nejm.org>
>
> Dear Dr. Fauci,
>
> I am sorry to inform you that your submission, "A Strategic Approach to Successful COVID-19 Vaccine Development," has not been accepted for publication in the Journal. It was evaluated by members of our editorial staff. After considering its focus, content, and interest, we made the editorial decision not to consider your submission further. We are informing you of this promptly so that you can submit it elsewhere.
>
> Thank you for the opportunity to consider your submission.
>
> Sincerely yours,
>
> Eric Rubin, M.D., Ph.D.
> Editor-in Chief
>
> New England Journal of Medicine
> 10 Shattuck Street
> Boston, MA 02115
> (617) 734-9800
> Fax: (617) 739-9864
> http://www.nejm.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 00:48:28 +0000
To: Adrian Hill
Cc: Hildegund Ertl;Sarah Gilbert;Redfield, Robert R. (CDC/OD)
Subject: RE: COVID-19 vaccine

Adrian:

Thank you for you note. Sorry that I took a few days to get back to you, but I have been swamped. It is good to know of your work on the chimpanzee adenoviral vectors. The biosafety classification of viral vectors in the U.S. is within the purview of the CDC, and so I have copied CDC Director Bob Redfield on this e-mail. He would be able to point you in the right direction.

Best regards,
Tony

From: Adrian Hill [redacted] (b) (6)
Sent: Monday, April 20, 2020 6:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Hildegund Ertl [redacted] (b) (6); Sarah Gilbert [redacted] (b) (6)>
Subject: FW: COVID-19 vaccine

Dear Dr Fauci

[redacted] (b) (4)

Thank you for your consideration of this at an exceptionally busy time.

Yours sincerely

Adrian Hill

Professor Adrian V. S. Hill
Director, The Jenner Institute
Nuffield Department of Medicine
University of Oxford
Old Road Campus Research Building
Oxford OX3 7DQ

Tel: + (b) (6)
Email (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 00:45:21 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 260 County Models of COVID-19 Outbreaks across the US

Please see me or give me a call about this. Thanks.

From: Rubin, David M [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 9:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Offit, Paul [redacted] (b) (6); Tasian, Gregory E [redacted] (b) (6)>; Huang, Jing [redacted] (b) (6)>
Subject: 260 County Models of COVID-19 Outbreaks across the US

Hi Dr. Fauci,

Jon Yewdell suggested I contact you directly to expedite a briefing on the new county-level models that our center, PolicyLab, at CHOP, will be releasing tomorrow. He shared with us your note below about including Ambassador Birx and Bob Redfield as well. We'd be happy to do so, and had been in touch with Ambassador Birx last week. We have also stayed in contact with the analytics team led by Irum Zaidi and Chuck Vitek. I am also tasked to Governor Wolf's crisis team in Pennsylvania and shared the data with the Governor today.

Let us know next steps for arranging a video conference. Will arrange our schedule at your convenience. Will have Drs. Paul Offit, Greg Tasian, and Jing Huang join from our team.

Best,

Dave

David Rubin, MD MSCE
Director of Population Health Innovation
Director of PolicyLab

Children's Hospital of Philadelphia
Office: [redacted] (b) (6)
Cell: [redacted] (b) (6)
www.policylab.chop.edu | @PolicyLabCHOP

Children's Hospital of Philadelphia

Professor of Pediatrics
Perelman School of Medicine
University of Pennsylvania

Perelman
School of Medicine
University of Pennsylvania

From: "Yewdell, Jon (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, April 21, 2020 at 8:55 PM
To: "Rubin, David M" [redacted] (b) (6)>
Cc: Paul Offit [redacted] (b) (6)>
Subject: <no subject>

David,
At this point, I think it is best to contact Tony directly. He's at [redacted] (b) (6).
Good luck!
jon
Jonathan Yewdell MD, PhD
Chief, Cellular Biology Section
Laboratory of Viral Diseases
NIAID, NIH

Truth Wins: A Practical Guide to Succeeding in Biomedical Research
free eBook download of my book

Link to Ohio State Science Sunday video on scientific method

From: Rubin, David M < [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 8:43 PM
To: Yewdell, Jon (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Offit, Paul [redacted] (b) (6)
Subject: FW: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Hi Jon,

Paul forwarded me your email back to him. Our team would be happy to present to him, Ambassador Birx, and Bob Redfield. We have shared the models with Governor Wolf in Pennsylvania today, and they are informing strategy here. The 260 county models will post to our PolicyLab website tomorrow. Of note, Paul and I had spoken to Ambassador Birx in the last couple of weeks, and we have been in contact with Irum Zaidi, Chuck Vitek, and the analytics team.

Let us know how would be best to set up a group webinar to present the information. Or feel free to connect us directly with their schedulers. Think the models illustrate the low margin of error in the large cities for resurgence risk, even as other less densely populated counties may be tolerant to reopening strategies.

Dave

David Rubin, MD MSCE
Director of Population Health Innovation
Director of PolicyLab

Children's Hospital of Philadelphia
Office: (b) (6)
Cell: (b) (6)
www.policylab.chop.edu | @PolicyLabCHOP

Children's Hospital
of Philadelphia

Professor of Pediatrics
Perelman School of Medicine
University of Pennsylvania

Perelman
School of Medicine
University of Pennsylvania

From: Paul Offit (b) (6)>
Date: Tuesday, April 21, 2020 at 5:46 PM
To: "Rubin, David M" (b) (6)
Subject: Fw: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Tony has seen our memo. His response is below.

From: Yewdell, Jon (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 21, 2020 5:45 PM
To: Offit, Paul
Subject: FW: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Tony never ceases to amaze me….

See immediate reply below

Jonathan Yewdell MD, PhD

Chief, Cellular Biology Section

Laboratory of Viral Diseases

NIAID, NIH

Truth Wins: A Practical Guide to Succeeding in Biomedical Research free eBook download of my book

Link to Ohio State Science Sunday video on scientific method

From: Fauci, Anthony (NIH/NIAID) [E] [redacted](b) (6)>
Sent: Tuesday, April 21, 2020 5:06 PM
To: Yewdell, Jon (NIH/NIAID) [E] [redacted](b) (6)>
Cc: Shaffer, Meredith (NIH/NIAID) [E] [redacted](b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted](b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted](b) (6)>
Subject: RE: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Jon:

Thanks for the note. It would be even better if they could present not only to me, but to Deb Birx and Bod Redfield.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Yewdell, Jon (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 4:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Shaffer, Meredith (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Tony,

Paul and David asked me to pass this on to you.

Forwarded message from David:

"I think the time has come, with our models on 260 counties across the country releasing in the next 48 hours, to offer Tony Fauci, and potentially other task force members, a preview of the work. Our models have incorporated local area differences due to weather, population and social distancing. They reveal that the large, densely populated cities will struggle to re-open, and are not well aided by weather effects given their density. However, in less densely populated areas, in which case counts are lower, weather has been a mitigating factor. These latter counties may have better success when they re-open assuming they are smart about workplace safety and have testing and surveillance strategies in place"

Dave

David Rubin, MD MSCE

Director of Population Health Innovation
Director of PolicyLab

Children's Hospital of Philadelphia
Office: (b) (6)

Cell: (b) (6)
www.policylab.chop.edu | @PolicyLabCHOP

Children's Hospital of Philadelphia

Professor of Pediatrics
Perelman School of Medicine
University of Pennsylvania

Perelman
School of Medicine
University of Pennsylvania

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 00:43:24 +0000
To: Young, Neal S (NIH/NHLBI) [E]
Subject: RE: Lambris

Thanks, Neal.
Best regards,
Tony

From: Young, Neal S (NIH/NHLBI) [E] [redacted] (b) (6)>
Sent: Wednesday, April 22, 2020 8:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Lambris

Dear Tony

'Forwarding to you at the request of two colleagues, experts in anti-complement therapies.

Thanks, and 'stay healthy.

Neal

From: "John D. Lambris" [redacted] (b) (6)>
Date: Tuesday, April 21, 2020 at 2:43 PM
To: Skype [redacted] (b) (6)
Cc: Antonio M Risitano [redacted] (b) (6)
Subject: Lambris

Hi Neal,

I hope all is well and you are staying healthy.

[redacted] (b) (4)

Could you please bring us in contact with Antony Fauci to see if he can help our program?

All the best and Stay Healthy

John

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 00:42:34 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Update: Inhibit cytokine storm in COVID-19 patients by Proteasome Inhibitors
Attachments: [redacted] (b) (4)

Please respond to this person. Thanks.

From: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Sent: Wednesday, April 22, 2020 9:41 AM
To: Coomes, Stephanie (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: [redacted] (b) (6); Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Subject: Update: Inhibit cytokine storm in COVID-19 patients by Proteasome Inhibitors
Importance: High

Dear Dr. Fauci,
dear Dr. Coomes,

thank you for your reply from 13. April with the notice that the information has been shared with NIAID's COVID-19 research team.

Has the project already been initially evaluated by the team?

Are there any questions or need for additional information?

- I have summed up the relevant data regarding the use of proteasome inhibitors for treatment of COVID-19 patients with acute lung and systemic organ failure in a position paper, please find a Preview draft attached.

- With regard to currently ongoing trials with monoclonal antibodies against the IL-6 receptor, i.e. tocilizumab or sarilumab: These approaches go into the same direction as the present suggestion, however, inhibition of NF-κB by proteasome inhibitors could provide the unique potential to inhibit the release of multiple cytokines simultaneously, in particular strongly pro-inflammatory cytokines including IL-1, IL-6, TNFα and chemokines, such as MIP-1 and CXCL1.

- This simultaneous inhibition of multiple cytokines/chemokine seems to be advantegeaus compared to single target approaches (as with the mAb) to compensate for redundant and synergistic effects of multiple cytokines released during highly pathogenic CoV or H5N1 infection.

Looking forward to hearing from you.

Kind regards,

Ralf

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis
Director R&D
Research & Development

Mail: RKircheis@syntacoll.de
Phone: +49 9441 686048

syntacoll

Syntacoll GmbH, Donaustrasse 24, D-93342 Saal a. d. Donau
Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 1612
USt-IdNr. DE 128580796
Geschäftsführerin: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter www.syntacoll.de/datenschutz

---

Von: Coomes, Stephanie (NIH/NIAID) [E] [redacted] (b) (6)
Gesendet: Montag, 13. April 2020 02:37
An: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Betreff: RE: Inhibit cytokine storm in COVID-19 patients by Velcade Bortezomib

Dear Dr. Kircheis,

Thank you for your recent email to Dr. Anthony Fauci. Your message was forwarded to the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID). As a member of DMID's Office of Scientific Coordination and Program Operations, I am pleased to respond.

I want to thank you for reaching out to share this information and let you know that your message has been shared with NIAID's COVID-19 research team.

Sincerely,
Stephanie

Stephanie M. Coomes, Ph.D.
Health Scientist Administrator
Office of Scientific Coordination and Program Operations
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Room 7G68
Rockville, MD 20892
[redacted] (b) (6)
(b) (6) v

Disclaimer: The information in this email and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the originally intended recipient. If you have received this email in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Sent: Wednesday, April 8, 2020 2:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E]
[redacted] (b) (6)>; NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>
Cc: Fischer, Elizabeth (NIH/NIAID) [E] [redacted] (b) (6)>; Foster, Erin (NIH/NIAID) [E]
[redacted] (b) (6)>; Foster, Sarah (NIH/NIAID) [E] [redacted] (b) (6); Vasilenko, Olga
(NIH/NIAID) [E] [redacted] (b) (6)>; Vasquez, Aurelio (NIH/NIAID) [E]
[redacted] (b) (6); Vostal, Alexander (NIH/VRC) [F] [redacted] (b) (6)>; Vazquez-
Maldonado, Nancy (NIH/NIAID) [E] <[redacted] (b) (6); Austin, James (NIH/NIAID) [E]
<[redacted] (b) (6)>; Agulto, Liane (NIH/NIAID) [E] [redacted] (b) (6)>; Deckhut, Alison
(NIH/NIAID) [E] [redacted] (b) (6)>; Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Subject: WG: Inhibit cytokine storm in COVID-19 patients by Velcade Bortezomib
Importance: High

Inhibition of cytokine storm in COVID-19 patients with acute respiratory distress syndrom by PROTEASOME INHIBITORS e.g. Velcade (Bortezomib)

Dear Dr. Fauci,
dear Madams/Sirs,
I want to bring to your attension some potentially important experimental data and a new proposal for treatment of COVID-19 patients with acute respiratory distress syndrome and organ failure. Sorry for the broad distribution but I wanted to make sure that my message reaches you.

Similarly as has been described earlier for SARS-CoV, MERS-CoV (Channappanavar & Perlman, 2017), H5N1 and some heavy H1N1 Influenza A infections, also COVID-19 patients have been reported to show significantly increased systemic cytokine release (i.e. cytokine storm), particularly those patients with lung failure or systemic organ failure (***Chaolin Huang et al. Lancet vol 395, 2020, ref 1***).

Previous studies at **Virologik GmbH, Erlangen, Germany,** in colaboration with the **Friedrich-Loeffler-Institut, Tuebingen, Germany** have shown, that H5N1 (or alternatively LPS) -induced **Cytokine storm *in vivo* can be inhibited by application of Proteasome Inhibitors** (***E. Haasbach et al, Antiviral Res. 91, 2011, ref. 2***), via **the inhibition of translocation of the NF-κB transcription factor** to the nucleus (see ***Fig. below***). The mechanism of NF-κB inhibition by proteasome inhibitors is well described, and works via the inhibition of the proteasomal degradation of the cytosolic inhibitor IκB, this way keeping NF-κB bound in the cytosol and thereby inhibiting the otherwise induced (by cytokine or LPS- or RNA virus) translocation of NF-κB to the nucleus where it would initiate the transcription of many cytokines. This effect of proteasome inhibitors seems to work in most cell types, we could demonstrate this effect in several different cell types (including macrophages) after stimulation with TNFa in vitro and in H5N1 (or LPS) treated mice in vivo (see manuscript and Figs. attached).

Inhibition of NF-κB by proteasome inhibitors provides the unique potential to inhibit the release of many cytokines simultaneously, in particular strongly proinflammatory cytokines **IL-1α, IL-6, TNFα, MIP-1β...)** (whereas some other cytokines involved in antiviral immune response, such as IFNγ probably seem to be not/less affected (because of different transcription pathway).

Importantly, beside the **anti-inflammatory activity**, proteasome inhibitors showed also **significant anti-fibrotic activity** (Lueftenegger et al., manuscript and figs attached), which may be also important in the treatment of COVID-19 patients with heavy lung disease.

Furthermore, there have been several publications showing that **in particular early phases of the replication cycle of Corona virus seem to be dependent on interaction with the ubiquitin-proteasomal system (UPS) of the host cell**, and were effectively inhibited by **selective 20S proteasome inhibitors (such as Velcade)** ***(Wang et al. Virology J 2010, 7:99 (ref. 3); M. Raaben et al. J. Virology, 84(15), 2010, ref. 4).***
There are several registered **proteasome inhibitors (Bortezomib (Velcade®)** e.g. produced by **Millennium Pharmaceuticals** (i.e Takeda Oncology); **Carfilzomib (Kyprolis®), Ixazomib (Ninlaro®))** for treatment of multiple myeloma and Mantel cell lymphoma, *i.e.* there are registered drugs with well known side effects available to be tested in small clinical studies for evaluation of their therapeutic efficacy in COVID-19 patients with heavy lung disease and other organ failure. ***Noteworthy***: in contrast to the chronical oncological indications where up to 8 treatment cycles (and sometimes even more) are applied, it seems plausible that just one or two treatment cycles of proteasome inhibitors might be sufficient to downregulate the cytokine storm in COVID-19 patients, which would be associated also with much lower side effects.

Early first experience on efficacy could be gained from compassionate use applications in heavily ill COVID-19 patients very quickly. Beside the registered application forms , i.e. infusions, probably also inhalative application should be tested as well, because it may be better suited to reach the respective target cells in the lung, i.e. alveolar epithelial cell and alveolar macrophages. There are multiple inhalative devices available, e.g. the Handyhaler by Boehringer Ingelheim used for Spiriva (for COPD treatment).

Although there are still many open questions, the potential to control the cytokine storm-induced heavy lung and other organ failure by using already registered drugs, ie. proteasome inhibitors may be a real chance to get an additional treatment option, hopefully decreasing the cases necessary for artificial aeration.

Please forward this mail to the colleages you consider relevant for evaluation, discussion and consideration for your clinical strategy for COVID-19.

Please let me know if additional informations are necessary.

To my person: I have MD PhD degree and have many years experience in pharmaceutical development (Boehringer Ingelheim), Biotech (Igeneon, Aphton, Virologik GmbH) (for reference see also PubMed Kircheis r) currently leading R&D activities at Syntacoll (part of Innocoll). I am providing this information personally in order to help to find a treatment for COVID-19 patients.

Looking forward to getting feedback from you,

With kind regards,

Ralf Kircheis (MD PhD)

(b) (6)

rkircheis@syntacoll.de

(b) (6)



PIs inhibit TNFα induced nuclear NFκB translocation

- PI inhibit TNFα induced nuclear NFκB translocation in a variety of cells, including tumor cells, stellate cells and macrophages

July 2013 Page 34 VIROLOGIK

Antiviral Res. 2011 Sep;91(3):304-13. doi: 10.1016/j.antiviral.2011.07.006. Epub 2011 Jul 13.

Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.

Haasbach E[1], Pauli EK, Spranger R, Mitzner D, Schubert U, Kircheis R, Planz O.
Author information

Abstract

The appearance of highly pathogenic avian influenza A viruses of the H5N1 subtype being able to infect humans and the 2009 H1N1 pandemic reveals the urgent need for new and efficient countermeasures against these viruses. The long-term efficacy of current antivirals is often limited, because of the emergence of drug-resistant virus mutants. A growing understanding of the virus-host interaction raises the possibility to explore alternative targets involved in the viral replication. In the present study we show that the proteasome inhibitor VL-01 leads to reduction of influenza virus replication in human lung adenocarcinoma epithelial cells (A549) as demonstrated with three different influenza virus strains, A/Puerto Rico/8/34 (H1N1) (EC50 value of 1.7 µM), A/Regensburg/D6/09 (H1N1v) (EC50 value of 2.4 µM) and A/Mallard/Bavaria/1/2006 (H5N1) (EC50 value of 0.8 µM). In in vivo experiments we could demonstrate that VL-01-aerosol-treatment of BALB/c mice with 14.1 mg/kg results in no toxic side effects, reduced progeny virus titers in the lung (1.1 ± 0.3 log10 pfu) and enhanced survival of mice after infection with a 5-fold MLD50 of the human influenza A virus strain A/Puerto Rico/8/34 (H1N1) up to 50%. Furthermore, treatment of mice with

VL-01 reduced the cytokine release of IL-α/β, IL-6, MIP-1β, RANTES and TNF-α induced by LPS or highly pathogen avian H5N1 influenza A virus. The present data demonstrates an antiviral effect of VL-01 in vitro and in vivo and the ability to reduce influenza virus induced cytokines and chemokines.

Copyright © 2011 Elsevier B.V. All rights reserved.

PMID:21777621

DOI:10.1016/j.antiviral.2011.07.006

[Indexed for MEDLINE

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis
Director R&D
Research & Development

Mail: RKircheis@syntacoll.de
Phone: +49 9441 686048
syntacoll

Syntacoll GmbH, Donaustrasse 24, D-93342 Saal a. d. Donau
Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 1612
USt-IdNr. DE 128580796
Geschäftsführerin: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter
www.syntacoll.de/datenschutz

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 00:40:50 +0000
To: Xizhong, Cui (NIH/CC/CCMD) [E]
Subject: RE: remdesivir and Present's words on disinfectant

Brian:
Thank you for your note. [redacted] (b) (5)

Best regards,
Tony

From: Xizhong, Cui (NIH/CC/CCMD) [E] [redacted] (b) (6)>
Sent: Sunday, April 26, 2020 8:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: remdesivir and Present's words on disinfectant

Dear Dr. Fauci,

I am an investigator in CCMD, CC, National Institutes of Health, I am studying coronavirus infection in animal models on preclinical treatment. I was a doctor when I was in China, now I am just a preclinical investigator on infectious diseases.

[redacted] (b) (5)

[redacted] (b) (6), (b) (5)

Best wish to you and be safe. Thanks your efforts to all Americans!!

Brian X. Cui, MD, Ph.D
Critical Care Medcicine Department
Clinical Center
National Institutes of Health
Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 23:13:59 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: Re: Keynote Speaker- Keystone Vaccinology eSymposia (directions to record & upload talk)
Attachments: image001.png, image002.png, image003.png, image004.png, image005.png

Agree.

> On Apr 26, 2020, at 6:38 PM, Folkers, Greg (NIH/NIAID) [E] <[redacted] (b) (6)> wrote:
>
> I think Hilary is closest to this and should get the assignment
>
> ---
>
> **From:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> **Sent:** Sunday, April 26, 2020 5:12 PM
> **To:** NIAID OD AM <NIAIDODAM@niaid.nih.gov>
> **Subject:** FW: Keynote Speaker- Keystone Vaccinology eSymposia (directions to record & upload talk)
>
> Greg and team:
> Let us discuss.
> Tony
>
> **Anthony S. Fauci, MD**
> **Director**
> **National Institute of Allergy and Infectious Diseases**
> **Building 31, Room 7A-03**
> **31 Center Drive, MSC 2520**
> **National Institutes of Health**
> **Bethesda, MD 20892-2520**
> **Phone:** [redacted] (b) (6)
> **FAX: (301) 496-4409**
> **E-mail:** [redacted] (b) (6)
>
> **The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.**

From: Kristina Horton <kristinah@keystonesymposia.org>
Sent: Friday, April 24, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: rino.r.rappuoli@gsk.com; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: Keynote Speaker- Keystone Vaccinology eSymposia (directions to record & upload talk)

Greetings Dr. Fauci:

Thank you for agreeing to participate as the keynote speaker for the Keystone eSymposia: **Vaccinology in the Age of Pandemics: Strategies Against COVID-19 & Other Global Threats**, a virtual conference which will be held on, **Monday, June 15 and Tuesday, June 16, 2020**.

Understanding how busy you are right now, we would like to make this process as easy as possible. We are hoping to receive pre-recorded talks by Monday, May 18. Please keep us apprised on your timeline and we will work with your schedule. Here are the details on next steps.

Next Steps:

- **Keynote Talk Title:** Transforming Vaccinology: COVID-19 Emergency and Considerations for the Next Decade
    - **Please review your talk title and return any changes.** Changes can be made up to two-weeks prior to the event.

- **Please follow this link to upload your talk recording, by Monday, May 18.** Click here to learn more about recording your presentation. Our media team can assist you with recording on your personal computer.
    - Similar to the face-to-face conference, we envision approximately 50-60 minutes for the keynote lecture.

For questions about the scientific programming of this meeting, please contact Dr. Rappuoli at rino.r.rappuoli@gsk.com and I will serve as the administrative/logistics contact at KristinaH@KeystoneSymposia.Org.

Best,
Kristina

Kristina H. Richardson, MS
Scientific Advisory Board Coordinator
Administrative Assistant: CSO & Global Development
+ (b) (6) | kristinah@keystonesymposia.org

<image001.png>

PO Box 1630 | Silverthorne | CO 80498 | USA (regular mail only)
160 US Highway 6, Ste. 200 | Silverthorne | CO 80498 | USA (courier only)

970.262.1230 | 800.253.0685 | www.keystonesymposia.org
Visit virtual.keystonesymposia.org to view our digital content.

<image002.png>

<image003.png>

<image004.png>

<image005.png>

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

INCLUDE
DIVERSITY IN THE SCIENTIFIC WORKFORCE

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology

Accelerating Life Science Discovery

INCLUDE

DIVERSITY IN THE SCIENTIFIC WORKFORCE

in



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 23:13:04 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C];Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Subject: Re: Thank you, and...
Attachments: image002.png

Gayle [redacted] (b) (6) and so I would like to do it if they clear it

> On Apr 26, 2020, at 7:08 PM, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
>
> You sent this to me on Friday but we have not had a chance to discuss.
>
> [redacted] (b)(5) - PCP
>
> Please advise if you want to do this – again, adding others here as well..
>
> -p
>
> ---
>
> **From:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
> **Sent:** Sunday, April 26, 2020 5:44 PM
> **To:** Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
> **Cc:** Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
> **Subject:** FW: Thank you, and...
>
> Have we discussed this already? Gayle [redacted] (b) (6)
>
> **Anthony S. Fauci, MD**
> **Director**
> **National Institute of Allergy and Infectious Diseases**
> **Building 31, Room 7A-03**
> **31 Center Drive, MSC 2520**
> **National Institutes of Health**
> **Bethesda, MD 20892-2520**

Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gayle Smith <gayle.smith@one.org>
Sent: Thursday, April 23, 2020 1:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Tom Hart <tom.hart@one.org>
Subject: Thank you, and...

Dear Tony,

I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. As an American, a former colleague, a long-time admirer and student of your wisdom – thank you. We are all safer because of you, and the world will be a better place because of you. Again.

As you know, I am now leading the ONE Campaign. We've been quite active with the ONEWorld Campaign, dedicated to the fight against this newest virus, and focused on Africa. We've made some progress on debt, and next up is a focus on ensuring that a vaccine, when it comes, is available to everyone.

One of the things we want to do is educate people, in all of the places we work. It won't surprise you that of particular urgency amongst our partners in Africa is that facts and information get to people across the continent, but we also know that more facts are needed everywhere. So next month we are going to launch #PassTheMic, where every day for 19 days we will ask a celebrity to turn his or her social media channels over to an expert on COVID-19 for one day. So Julia Roberts might turn her Twitter account to you to talk about the critical elements needed to flatten the curve and slow the spread. Or Idris Elba could give up his Instagram to the head of the African CDC so that he can illustrate the impact COVID-19 will have across Africa and what that means for the rest of the world.

We know artists want to be helpful right now, but that it is hard to know what to do. And we know there are experts like you out there who have the answers. We've thought about this a lot at ONE and wanted to do something we felt would truly have an impact. As we look ahead we know COVID-19 does not know borders and until it is beaten everywhere we are not in the clear. We need a global response plan and we need it now. By turning over their platforms for the day, celebrity influencers will be donating one of their biggest assets – their followers – to YOU, giving you the platform you need (and we all need) to tell the world why a global response is critical. Because none of us are safe until all of us are safe.

We will work with each expert/celebrity pair to personalize the content to our and our celebrity partners' audiences – in North America, Europe and Africa, and help create content that both parties are happy with. We are now confirming our talent partners, and so far are getting a terrific response.

We know you're a busy man, so we've planned it so that the amount of time on your end would be minimal. But the impact would be maximal.

I'm attaching more information about the campaign. Please let me know what you think and if you have questions. Ideally we would like to get this off the ground in early May, so are hoping to confirm folks by April 28th at the latest. Our team will be in touch with your office to follow up.

Thanks as always for everything you do. All my best to you, Gayle

<image002.png>

Gayle Smith | President & Chief Executive Officer | (b) (6)
ONE.ORG | Twitter | Facebook | Instagram

ONE is a global movement campaigning to **end extreme poverty and preventable disease by 2030** so that everyone, everywhere can lead a life of dignity and opportunity.

<PasstheMic Expert Outreach.pdf>

ONE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:50:57 +0000
To: Broas, Timothy
Cc: Grady, Christine (NIH/CC/BEP) [E]
Subject: RE: Greetings

Tim:

Thank you for your kind note. It was great to hear from you. I hope that all is well with you and your family and that we get a chance to re0connect when the situation begins to return to some form of normality..

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Broas, Timothy <timothy.broas@bclplaw.com>
Sent: Thursday, April 23, 2020 10:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Greetings

Dear Tony:

.

It's been a long time. Honestly, I can't remember when we last saw each other. I recall that wonderful day we went to the Nats game together, although I cannot remember who else came with us. And of course I will always remember when you came to my Partners in Health fundraiser and introduced Paul Farmer. I will never forget your speech (and neither will Paul!). Once [redacted] (b) (6) I apologize for dropping out of touch.

Those events were so many years ago, (b) (6) no? So much has happened and changed since then, and now, seeing you and listening to your wise words and advice every day, I am reminded that we need to reconnect, when it's safe and you have time. We have so much to catch up on! I have been meaning to write to you or call you, but I had misplaced your email address and phone numbers. I hope this address works and this message reaches you.

Meantime, thank you for your service to our country, indeed the world. You have been a solid, wise, steady voice, Tony, and, despite all the naysayers and fools on social media, you have earned the respect of billions of people. I am very proud of you, and am humbled and honored that I can call you my friend.

I hope you and your family are well, and staying safe. The Broas family is doing well, thanks in no small part to your daily advice and objective analysis. Thank you! Please let me know if there is anything I can do for you or your family.

Looking forward to seeing you on the other side of this, and having a good catch up. Who knows, maybe at a Nats game?

Best regards,

Tim

BRYAN CAVE LEIGHTON PAISNER BCLP
AMBASSADOR (RET) TIMOTHY M. BROAS
timothy.broas@bclplaw.com
T: +1 202 508 6115 M: (b) (6)

BRYAN CAVE LEIGHTON PAISNER LLP.
1155 F Street NW, Washington, DC 20004-1357

bclplaw.com

COVID-19 / CORONAVIRUS RESOURCES ▶

This electronic message is from a law firm. It may contain confidential or privileged information. If you received this transmission in error, please reply to the sender to advise of the error and delete this transmission and any attachments.

We may monitor and record electronic communications in accordance with applicable laws and regulations. Where appropriate we may also share certain information you give us with our other offices (including in other countries) and select third parties. For further information (including details of your privacy rights and how to exercise them), see our updated Privacy Notice at www.bclplaw.com.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:44:20 +0000
To: Greg Folkers [redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Thank you, and...
Attachments: PasstheMic Expert Outreach.pdf

Have we discussed this already? Gayle [redacted] (b) (6).

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gayle Smith <gayle.smith@one.org>
Sent: Thursday, April 23, 2020 1:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Tom Hart <tom.hart@one.org>
Subject: Thank you, and...

Dear Tony,

I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. As an American, a former colleague, a long-time admirer and student of your wisdom – thank you. We are all safer because of you, and the world will be a better place because of you. Again.

As you know, I am now leading the ONE Campaign. We've been quite active with the ONEWorld Campaign, dedicated to the fight against this newest virus, and focused on Africa. We've made some progress on debt, and next up is a focus on ensuring that a vaccine, when it comes, is available to everyone.

One of the things we want to do is educate people, in all of the places we work. It won't surprise you that of particular urgency amongst our partners in Africa is that facts and information get to people across the continent, but we also know that more facts are needed everywhere. So next month we are going to launch #PassTheMic, where every day for 19 days we will ask a celebrity to turn his or her social media channels over to an expert on COVID-19 for one day. So Julia Roberts might turn her Twitter account to you to talk about the critical elements needed to flatten the curve and slow the spread. Or Idris Elba could give up his Instagram to the head of the African CDC so that he can illustrate the impact COVID-19 will have across Africa and what that means for the rest of the world.

We know artists want to be helpful right now, but that it is hard to know what to do. And we know there are experts like you out there who have the answers. We've thought about this a lot at ONE and wanted to do something we felt would truly have an impact. As we look ahead we know COVID-19 does not know borders and until it is beaten everywhere we are not in the clear. We need a global response plan and we need it now. By turning over their platforms for the day, celebrity influencers will be donating one of their biggest assets – their followers – to YOU, giving you the platform you need (and we all need) to tell the world why a global response is critical. Because none of us are safe until all of us are safe.

We will work with each expert/celebrity pair to personalize the content to our and our celebrity partners' audiences – in North America, Europe and Africa, and help create content that both parties are happy with. We are now confirming our talent partners, and so far are getting a terrific response.

We know you're a busy man, so we've planned it so that the amount of time on your end would be minimal. But the impact would be maximal.

I'm attaching more information about the campaign. Please let me know what you think and if you have questions. Ideally we would like to get this off the ground in early May, so are hoping to confirm folks by April 28th at the latest. Our team will be in touch with your office to follow up.

Thanks as always for everything you do. All my best to you, Gayle

Gayle Smith | President & Chief Executive Officer | (b) (6)
ONE.ORG | Twitter | Facebook | Instagram

ONE is a global movement campaigning to **end extreme poverty and preventable disease by 2030** so that everyone, everywhere can lead a life of dignity and opportunity.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:36:37 +0000
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: RE: Potential treatment breakthrough from Milan

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lusso, Paolo (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Sunday, April 26, 2020 5:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Lane, Cliff (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Re: Potential treatment breakthrough from Milan

Dear Tony:

I am trying to reach the PI of the study, but on a Sunday afternoon/evening I doubt I will be successful. I should be able to get more information tomorrow morning and pass it on to you, Cliff and Joe Kovacs.

All the best,

Paolo

Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of Immunoregulation
Bldg. 10, Rm. 6A11
NIAID, NIH
Bethesda, MD 20892

Phone: [redacted] (b) (6) (personal)
[redacted] (b) (6) (lab)
Fax: (301) 480-5291
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Sunday, April 26, 2020 at 3:47 PM
To: "Lusso, Paolo (NIH/NIAID) [E]" [redacted] (b) (6)
Cc: "Lane, Cliff (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: RE: Potential treatment breakthrough from Milan

Thanks, Paolo. [redacted] (b) (5)
[redacted] (b) (5)

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lusso, Paolo (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, April 26, 2020 12:22 PM

To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Potential treatment breakthrough from Milan

Dear Tony:

[redacted] (b) (5)

Congratulations to Brad Pitt for impersonating you! All the best,

Paolo

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:17:22 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Washington Post story re: Sammies finalists

Please set up an interview as requested below. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Davidson, Joe <joe.davidson@washpost.com>
Sent: Friday, April 24, 2020 12:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: Washington Post story re: Sammies finalists

Hello Tony,

Congratulations on being a Career Achievement finalist for the Samuel J. Heyman Service to America Medals (Sammies). I'm writing a Federal Insider column about the finalists and would like arrange a telephone interview with your for the story.

My questions include:
Why did you join the federal service?
Is there one example or anecdote that makes you particularly proud of you work?
What do you like most about your job?
What do you like least about your job?
Why would you recommend, or not, your agency and/or the federal government to those seeking career advice?

I know this is an incredibly busy time for you. I appreciate that the life and death issues related to the coronavirus are more important than any award. Nonetheless, I hope you can spare 10 or 15 minutes for a telephone interview on Tuesday or Wednesday, April 28 or 29. I can also make other days that week work.

Thank you.

Best,
Joe

Joe Davidson, columnist
The Washington Post
1301 K Street, NW
Washington, DC 20071
202.334.6415 – work
(b) (6) *– cell*
joe.davidson@washpost.com
Twitter: @JoeDavidsonWP
Website: wapo.st/JoeDavidson

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:14:32 +0000
To: Greg Folkers [redacted] (b) (6)
Cc: [redacted] (b) (6);Grady, Christine (NIH/CC/BEP) [E]
Subject: FW: COG - Helen Branswell/STAT request / challenge studies

Please have her speak with Chris and/or Cliff. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, April 24, 2020 3:04 PM
To: NIAID COGCORE <COGCORE@mail.nih.gov>
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: COG - Helen Branswell/STAT request / challenge studies

Helen would like to speak with someone (ASF, Cliff, C Grady?) to discuss current thinking here on challenge studies for COVID-19. Not sure of deadline.

[redacted] (b) (6)
helen.branswell@statnews.com

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:12:06 +0000
To: NIAID OD AM
Subject: FW: Keynote Speaker- Keystone Vaccinology eSymposia (directions to record & upload talk)
Attachments: Vaccinology eSymposia_DRAFT Program Description & Schedule.pdf

Greg and team:
Let us discuss.
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kristina Horton <kristinah@keystonesymposia.org>
Sent: Friday, April 24, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: rino.r.rappuoli@gsk.com; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Keynote Speaker- Keystone Vaccinology eSymposia (directions to record & upload talk)

Greetings Dr. Fauci:

Thank you for agreeing to participate as the keynote speaker for the Keystone eSymposia: **Vaccinology in the Age of Pandemics: Strategies Against COVID-19 & Other Global Threats**, a virtual conference which will be held on, **Monday, June 15 and Tuesday, June 16, 2020**.

Understanding how busy you are right now, we would like to make this process as easy as possible. We are hoping to receive pre-recorded talks by Monday, May 18. Please keep us apprised on your timeline and we will work with your schedule. Here are the details on next steps.

Next Steps:

- **Keynote Talk Title:** Transforming Vaccinology: COVID-19 Emergency and Considerations for the Next Decade
    - **Please review your talk title and return any changes.** Changes can be made up to two-weeks prior to the event.

- **Please follow this link to upload your talk recording, by Monday, May 18.** Click here to learn more about recording your presentation. Our media team can assist you with recording on your personal computer.
    - Similar to the face-to-face conference, we envision approximately 50-60 minutes for the keynote lecture.

For questions about the scientific programming of this meeting, please contact Dr. Rappuoli at rino.r.rappuoli@gsk.com and I will serve as the administrative/logistics contact at KristinaH@KeystoneSymposia.Org.

Best,
Kristina

Kristina H. Richardson, MS
Scientific Advisory Board Coordinator
Administrative Assistant: CSO & Global Development
+(b) (6) | kristinah@keystonesymposia.org

KEYSTONE SYMPOSIA
on Molecular and Cellular Biology
Accelerating Life Science Discovery

INCLUDE
DIVERSITY IN THE SCIENTIFIC WORKFORCE

PO Box 1630 | Silverthorne | CO 80498 | USA (regular mail only)
160 US Highway 6, Ste. 200 | Silverthorne | CO 80498 | USA (courier only)
970.262.1230 | 800.253.0685 | **www.keystonesymposia.org**
Visit **virtual.keystonesymposia.org** to view our digital content.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:11:15 +0000
To: Hahn, Stephen
Subject: FW: Thank You! (FDA Submission: EUA200258)
Attachments: 2AML - COVID-19_ACCREDITATION 1 PAGER.PDF, IMG-20200330-WA0002.jpg

Steve:
They have contacted me, but have you seen this? I am sure that it is one of many that you see.
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eli J. Safdieh [redacted] (b) (6)>
Sent: Friday, April 24, 2020 4:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Thank You! ([redacted] (b) (4))

Dear Dr. Fauci,

Hope all is well. Since this crisis has begun, I have been working [redacted] (b) (4).

[redacted] (b) (4) I look forward to your positive response.

[redacted] (b) (4)

Best Regards,

Eli J. Safdieh

From: "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)> on behalf of "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Thursday, March 19, 2020 at 10:59 AM
To: Eli Safdieh [redacted] (b) (6)>
Subject: RE: Thank You!

Dr. Fauci wanted me to thank you for you note.

Best regards,

Patricia L. Conrad

Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eli J. Safdieh (b) (6)>
Sent: Thursday, March 19, 2020 5:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Thank You!

Hi Dr.,

Hope all is well with you and your family.

You are a symbol of integrity, nationalism, humanity, brilliance and perseverance. God bless you in all that you do for our country, for human beings and society.

We are praying for your success in mitigating and destroying this epidemic!

Best Regards,

Eli J. Safdieh

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:06:30 +0000
To: Dieffenbach, Carl (NIH/NIAID) [E]
Subject: RE: Documents as discussed

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Dieffenbach, Carl (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, April 24, 2020 6:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Documents as discussed

Dr. Fauci,

I feel compelled to let you know directly when ever I talk to or correspond with an IC Director. I know you asked him to reach out. Just closing the loop.

Carl

-----Original Message-----
From: Dieffenbach, Carl (NIH/NIAID) [E]
Sent: Friday, April 24, 2020 6:11 PM
To: Singer, Dinah (NIH/NCI) [E] [redacted] (b) (6)>; Sharpless, Norman (NIH/NCI) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Documents as discussed

Dinah and Ned,

It was a pleasure talking to you about what you are considering. As we discussed, here is the NIAID Strategic Plan that was just published, and two models of funding opportunity announcements for you to consider as models. I also think the Cancer Centers have aspects of collaboration, shared facilities, and research focus that you can borrow. So much of what NIAID has built is modeled on the Cancer Centers.

NIAID strategic plan for COVID-19
https://www.niaid.nih.gov/sites/default/files/NIAID-COVID-19-Strategic-Plan-2020.pdf

Current Centers for AIDS Research FOA
https://grants.nih.gov/grants/guide/pa-files/par-20-106.html

This is a very old RFA. I am sending it because it was NIAID's first attempt to build research capacity for the Level 3 and Level 4 pathogens after the Anthrax events. The current versions of the RFAs have been limited competitions and are a less relavant.
https://grants.nih.gov/grants/guide/rfa-files/rfa-ai-04-032.html

With best regards,

Carl

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
5601 Fishers Lane, Room 8D34
(he, him, his)
Rockville, MD 20852-9831
Phone: (b) (6)
Cell: (b) (6)
Fax: (240) 627-3466

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your maibox or any other storage devices. The NIAID shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:05:18 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Interview - john lauermann

Yes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, April 24, 2020 7:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6)>
Subject: FW: Interview - john lauermann
Importance: High

Ok to schedule? This is cleared

From: John Lauerman (BLOOMBERG/ NEWSROOM:) At: 04/14/20 18:46:16
To: [redacted] (b) (6)
Cc: [redacted] (b) (6), [redacted] (b) (6)
[redacted] (b) (6)
Subject: RE: Interview

Hi Jennifer et al: Here are a few questions for Dr. Fauci.

Scientists from the University of Bristol found that the coronavirus has unexpected tendency to large mutations in the spike protein when its grown in monkey cells. This had been seen before as a virus that was unwilling to mutate. Does this create any concerns about vaccine design and effectiveness?

It now appears that some people who recover from Covid have no antibodies to the SARS-Cov2. What are the possible explanations for this? Has it occurred in other viral diseases? Does it have any implications for the effectiveness of vaccines? Is NIAID investigating this? Is there a possibility that the virus sequesters in cells?

Another feature of coronaviruses appears to be rapidly waning immunity. Has this been seen in any NIAID experiments? What does this suggest about the virus's ability to evade the immune system?

A laboratory at Oxford has suggested that, if all goes well, they may be finished with phase 3 trials in 5000 people by the fall, which could mean as early as September. Does that sound realistic to you?

Some companies are asking regulators to make sure that safety standards are upheld for makers of Covid vaccines, and that corners aren't cut. Is it worth cutting some safety corners to get a Covid vaccine ready for distribution?

How many people should the Moderna vaccine be tested in in phase 3? How long would you expect those trials to take?

Thanks very much, hope we can set this up soon. All best, JL +44 2035 251028

From: [redacted] (b) (6) At: 04/12/20 22:38:36
To: John Lauerman (BLOOMBERG/ NEWSROOM:)
Cc: [redacted] (b) (6) [redacted] (b) (6),
[redacted] (b) (6)
Subject: RE: Interview

Hi John – sorry we are still trying to get something arranged. Could you send your questions.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations

National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:00:27 +0000
To: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: RE: BOLIVIAN COVID-19 GUIDELINES

I cannot co-author anything with them. Make sure they do not slip my name in.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, April 25, 2020 7:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: BOLIVIAN COVID-19 GUIDELINES

Sent from my iPhone

Begin forwarded message:

> **From:** Quispe Cornejo Armin Alvaro [redacted] (b) (6)>
> **Date:** April 25, 2020 at 5:30:30 AM EDT
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "Barasch, Kimberly (NIH/NIAID) [C]" [redacted] (b) (6)>
> **Cc:** ' [redacted] (b) (6) [redacted] >, Armin Quispe Cornejo [redacted] (b) (6), [redacted] (b) (6)
> **Subject: BOLIVIAN COVID-19 GUIDELINES**
>
> Dear Ms. Patricia Conrad

Dear Ms. Kimberly Marie Barasch

I hope you are well despite the current devastating world pandemic.

The **Bolivian Society of Intensive Care** together with the **Bolivian Healthcare Ministry** are writing the national guidelines for the management of COVID-19 in the critically ill patient, an issue that is an emergency worldwide and may become **disastrous** in the low-middle income countries of Latin America if not managed since the beginning with precise, accurate and uniform approaches.

With our team in Erasme University Hospital in Brussels, Belgium, together with Professors **Jean - Louis Vincent, Fabio Taccone, Jean Charles Preiser, Jacques Creteur**, etc., we are preparing the material with other Bolivian and Mexican intensivists, internists, infectologists, imagenologists.

I wonder if Dr. Anthony Fauci would honor us coauthoring and reviewing our last version of some chapters of our guidelines.

Best regards,

AAQC

--

SPE - CORNEJO,

edicine PhD fellow (Fell.)

M/MX] — Internista

ritica [UNAM] —

A]

betología — Educación

- SIZ member

8177

Hôpital Erasme

ULB

Cliniques universitaires d
Route de Lennik 808 - B -
S www.erasme.ulb.ac.be

Hôpital
Erasme

ULB

Cliniques universitaires de Bruxelles
Route de Lennik 808 - B - 1070 Bruxelles
S www.erasme.ulb.ac.be

Lien vers Disclaimer

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 20:12:51 +0000
To: Alberti Saverio
Subject: RE: spreading determinants of SARS-CoV-2

Thank you!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alberti Saverio [redacted] (b) (6)
Sent: Sunday, April 26, 2020 9:10 AM
To: Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)
Subject: spreading determinants of SARS-CoV-2

Dear Tony,

we are all witnessing the great effort your collaborators and yourself are investing over this pandemic emergency.

As you well know, in Europe and Italy we had the unfortunate privilege of having been first hit hard by the pandemic, after China.

We had the opportunity of meta-analyzing data from 170.000 patients in European countries, for associated determinants of the spreading force of COVID-19.

If this may provide a useful, albeit non gratifying, contribution for the US and other countries, we would feel we had done our job.

best wishes

Saverio

--

Prof. Saverio Alberti

Genetica Medica

Dipartimento di Scienze Biomediche

Università di Messina

Policlinico "G. Martino"

via Consolare Valeria

98125 Messina

(b) (6)

[redacted]

Skype: (b) (6)

email: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:58:06 +0000
To: [redacted] (b) (6)
Subject: RE: Covid 19 Double Mechanism. By Dr Brogna Carlo

Thank you for sending this.
Best regards,
AS Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: c.brogna@libero.it [redacted] (b) (6)
Sent: Friday, April 17, 2020 7:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Covid 19 Double Mechanism. By Dr Brogna Carlo

Dear Dr A. Faucy,

we don't know each other. I was born [redacted] (b) (6) I am a simple doctor in Medicin and live in a remote Italian region. I am no one. I trust in God that you can read my paper, being published. I send it to you to anticipate the exit times because I trust that we can really understand what Covid 19 is. Being nobody, I did what nobody would have done. I used the few tools I had available and questioned all the papers and data published so far. I describe what the dual mechanism of the Covid-19 can be. I anticipate that the result conclusioni is not to my credit but I have been helped. I wish you a good read. May God bless us.

Sincerely with love,

Dr. Carlo Brogna M.D.
(b) (6)
Italia
Avellino-Isernia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:56:13 +0000
To: Goletti Delia
Cc: Fabrizio Cantini; [redacted] (b) (6) Lerner, Andrea (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Greg Folkers ([redacted] (b) (6)
Subject: RE: impact of baricitinib in COVID-19-an off label study CONFIDENTIAL

Thank you, Delia. I appreciate the information.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goletti Delia [redacted] (b) (6)>
Sent: Friday, April 17, 2020 8:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Fabrizio Cantini [redacted] (b) (6)
Subject: impact of baricitinib in COVID-19-an off label study CONFIDENTIAL

dear dr Fauci, good morning. I hope you are fine.

Apologies to disturb you but it may be of your interest. I saw in the web that you (NIAID/Fauci)(https://investor.lilly.com/news-releases/news-release-details/lilly-begins-clinical-testing-therapies-covid-19) will be support a trial using Baricitinib as part of the ACTT trial...

I collaborated with Fabrizio Cantini (he reads in cc), a reumathologist of Prato to write a letter to J Infection (pdf attached). He conducted an off- label study in patients with mild-moderate pneumonia with COVID-19 [(SpO2) >92% at room-air, and ratio arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) 100-300 mmHg] to evaluate the impact of baritinib (tablet 4 mg/day) in terms of safety, clinical respiratory improvements , discharge, ICU transfer in 2 weeks; these patients received also lopinavir/ritonavir therapy. The last consecutive patients with moderate COVID-19 pneumonia receiving standard of care therapy (lopinavir/ritonavir and hydroxychloroquine) admitted before the date of the first baricitinib-treated patient served as controls.

The results of this off-label study, with the limit of not been a RCT, are encouraging:

1. Safety: only 1/12 case of transaminase elevation at day 10, likely due to lopinavir ritonavir co-administration because baricitinib is mainly renal secreted
2. Respiratory improvement: SpO2 and ratio arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) significantly improved;
3. Discharge in 7/12 vs 1/12
4. ICU transfer (0/12 vs 4/12)

I do hope it may be a useful, although I am aware that it is a very preliminary info for you.

Thank you for your attention.

All the best
Delia

Da: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Inviato: giovedì 16 aprile 2020 00:02
A: Goletti Delia [redacted] (b) (6)
Oggetto: RE: Italian press...for you!

Delia:
Thank you very much for sending these.
Best regards,
Tony

From: Goletti Delia [redacted] (b) (6)>
Sent: Wednesday, April 15, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Italian press...for you!

Dear dr Fauci, I disturb you only to let you know that the Italian press is with you!
Dr Ippolito asked me to contribute to prepare a document in support of you which I did with all my hearth. I gave my very minor contribution in supporting the scientific journalist, but with a lot of proud for you.

If you do not have it, below are the some of the links in your favor.

https://apnews.com/27feaca21519a5eaf555c01313d33b91
https://apnews.com/b59d0a2c4c53f1c63a074b0d375fec23
https://www.nytimes.com/aponline/2020/04/15/world/europe/ap-eu-virus-outbreak-italy-fauci.html
https://www.nytimes.com/aponline/2020/04/15/business/ap-virus-outbreak-the-latest.html
https://www.washingtonpost.com/world/europe/italian-virus-hospital-offers-fauci-work-if-trump-fires-him/2020/04/15/9b9afac0-7f16-11ea-84c2-0792d8591911_story.html
https://abcnews.go.com/Health/wireStory/italian-virus-hospital-offers-fauci-work-trump-fires-70160122
https://www.ilfattoquotidiano.it/2020/04/15/coronavirus-direttore-spallanzani-scrive-a-mattarella-e-conte-il-licenziamento-di-fauci-sarebbe-un-disastro-e-non-solo-per-usa/5770793/

https://www.repubblica.it/salute/medicina-e-ricerca/2020/04/15/news/per_favore_non_silurate_anthony_fauci-254087254/
https://www.sanitainformazione.it/politica/emergenza-covid-19-negli-usa-anthony-fauci-rischia-il-licenziamento-lappello-di-ippolito-spallanzani/
https://www.adnkronos.com/fatti/cronaca/2020/04/15/coronavirus-pazienti-dimessi-dallo-spallanzani_puDuaZKkoJNyLCZ1lDlgPN.html

all the best
Delia

Da: Goletti Delia
Inviato: domenica 12 aprile 2020 19:57
A: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Oggetto: R: all my gratitude and an update

Thank you for your time!
Best regards

Da: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Inviato: domenica 12 aprile 2020 19:53
A: Goletti Delia [redacted] (b) (6)
Oggetto: RE: all my gratitude and an update

Delia:

Many thanks for your kind note. It is much appreciated. I am pleased to see that you are getting involved in COVID-19 work. Keep up your excellent work.
Best regards,
Tony

From: Goletti Delia [redacted] (b) (6)
Sent: Sunday, April 12, 2020 11:02 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: all my gratitude and an update

dear dr Fauci, apologies to write you in these busy days. It is only to express **all my gratitude** for what you have done in your life to fight infectious diseases and what you are doing now for COVID-19. **Your efforts and achievement are in front of the whole world** and for me it is a great honor to have been with you in 1992-1996 at the time of HIV fight. As I told you many times, **you are a model of excellence**!

Only to keep you updated in my life, I am fine, and I mainly work as an ID specialist and scientist at the same place in Rome, the National Institute for Infectious Diseases L. Spallanzani. I am doing 2 days a week outpatients TB clinic and I run a small laboratory on TB research. However, given the pandemia, I shifted the lab activities on COVID-19, in particular on:

1. the role of coinfection (COVID-19 coinfection with tuberculosis, or COVID-19 coinfection with HIV) on the modulation of the in vitro immune specific-response to SARS-CoV-2, or M. tuberculosis or HIV in cells from COVID-19 patients at different clinical stage

2. in vitro evaluation of the immunological and virological effect of baricinib, an anti-JAK1 and –JAK2 drugs, used in reumathoid arthritis, that has shown using BenevolentAI's proprietary artificial intelligence-derived knowledge graph, as an agent that reduces the SARS-CoV-2 endocytosis into target cells potentially inhibiting the entry.

Moreover, I **would be happy to contribute in any activity you may think I am useful.**

I wish you a happy Easter in this blessed day.

Thank you for your attention and for **having had the possibility of working with you that has been crucial in my personal and professional life.**

All the best
Delia

Delia Goletti, MD, PhD
Clinical Investigator, Laboratorio del Vecchio, Room 13
Head of Translational Research Unit
Department of Epidemiology and Preclinical Research National Institute for Infectious Diseases L. Spallanzani
Via Portuense 292, Roma 00149 Italy
Tel: (b) (6), Fax: +39-06-5582-825
E-mail address (b) (6)
http://www.inmi.it/ricerca_traslazionale.html; http://www.inmi.it/ricerca_traslazionale_english.html

Professor of Pathology,
Unicamillus University
Rome, Italy

Visiting Professor,
Centre for Immunobiology,
Bizard Institute,
Queen Mary University of London, UK

Top Italian Women Scientist

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 14:41:51 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Please send me our press release related to the guidelines

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 8:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Your thoughts on Cliff et al doing a COCA call about the new guidelines?
(COCA= CDC's Clinician Outreach and Communication Activity)

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 21, 2020 8:37 PM
To: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Masur, Henry (NIH/CC/CCMD) [E] [redacted] (b) (6)
Cc: Pau, Alice (NIH/NIAID) [E] [redacted] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Expert U.S. panel develops NIH treatment guidelines for COVID-19

[redacted] (b) (5)

[redacted] (b) (5) We don't have to decide this tonight....

From: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 8:20 PM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Masur, Henry (NIH/CC/CCMD) [E] [redacted] (b) (6)>
Cc: Pau, Alice (NIH/NIAID) [E] [redacted] (b) (6) Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: Expert U.S. panel develops NIH treatment guidelines for COVID-19

[redacted] (b) (5)

From: "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, April 21, 2020 at 3:49 PM
To: "Lane, Cliff (NIH/NIAID) [E]" < [redacted] (b) (6), "Masur, Henry (NIH/CC/CCMD) [E]" [redacted] (b) (6)>
Cc: "Pau, Alice (NIH/NIAID) [E]" [redacted] (b) (6), Laurie Doepel [redacted] (b) (6)
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Please advise?

From: Hall, Bill (HHS/ASPA) [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 3:46 PM
To: Billet, Courtney (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Would Cliff and company want to participate in a COCA call that CDC could put on?

From: Bonds, Michelle E. (CDC/OD/OADC) [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 2:44 PM
To: Hall, Bill (HHS/ASPA) [redacted] (b) (6)
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

I see the NIH treatment guidelines news release is out. Are you still interested in hosting a COCA call on these guidelines?

Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Just out, press release from NIH:

Expert U.S. panel develops NIH treatment guidelines for COVID-19

04/21/2020 11:30 AM EDT

"Living document" expected to be updated often as new clinical data accrue.

Expert U.S. panel develops NIH treatment guidelines for COVID-19

"Living document" expected to be updated often as new clinical data accrue.

Colorized scanning electron micrograph of an apoptotic cell (green) infected with SARS-COV-2 virus particles (orange), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland.*NIAID*

A panel of U.S. physicians, statisticians, and other experts has developed treatment guidelines for coronavirus disease 2019 (COVID-19). These guidelines, intended for healthcare providers, are based on published and preliminary data and the clinical expertise of the panelists, many of whom are frontline clinicians caring for patients during the rapidly evolving pandemic. The guidelines are posted online (covid19treatmentguidelines.nih.gov) and will be updated often as new data are published in peer-reviewed scientific literature and other authoritative information emerges.

The guidelines consider two broad categories of therapies currently in use by healthcare providers for COVID-19: antivirals, which may target the coronavirus directly, and host modifiers and immune-based therapies, which may influence the immune response to the virus or target the virus.

The panel's conclusions about treating COVID-19 with various agents that fall into these two classes of therapies are distilled in summary recommendations. Subsequently, the document provides background information about each agent—such as clinical data about its use, ongoing clinical trials, and known interactions with other drugs—that forms the basis for the Recommendation. Tables briefly outline the same information.

The guidelines also describe the evaluation and stratification of patients based on their risk of infection and severity of illness. Recommendations in this section address best practices for managing patients at different stages of infection, for example:

- Outpatients who are either asymptomatic or who have mild to moderate symptoms and are self-isolating
- Inpatients with severe illness or critical disease

Special considerations for pregnant women and for children who are infected are also included.

A comprehensive section of the guidelines addresses a range of considerations for clinicians caring for the most critically ill hospitalized patients. This section includes multiple recommendations for patients needing critical care, including infection control procedures, hemodynamic and ventilatory support, and drug therapy.

Finally, the guidelines include recommendations concerning the use of concomitant medications. These include statins; corticosteroids; non-steroidal anti-inflammatory drugs; and certain drugs used to control hypertension, known as ACE inhibitors and ARBs.

The treatment guidelines panel is co-chaired by Roy M. Gulick, M.D., chief of the Infectious Disease Division at Weill Medical Hospital of Cornell University, New York City; H. Clifford Lane, M.D., clinical director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health; and Henry Masur, M.D., chief of the Critical Care Medicine Department at the NIH Clinical Center. Members of the guidelines panel, appointed by the co-chairs, were chosen based on their clinical experience and expertise in patient management, translational and clinical science, and/or the development of treatment guidelines. They include 30 experts drawn from U.S. healthcare and academic organizations, federal agencies, and professional societies.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

From: National Institutes of Health (NIH) <nih.ocpl@service.govdelivery.com>
Sent: Tuesday, April 21, 2020 12:32 PM
To: Bedrosian, Sara (CDC/OD/OADC) [redacted] (b) (6)
Subject: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Having trouble viewing this email? View it as a Web page.

You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).

Expert U.S. panel develops NIH treatment guidelines for COVID-19

04/21/2020 11:30 AM EDT

“Living document” expected to be updated often as new clinical data accrue.

Update Your E-mail Address | Add Subscriptions | Unsubscribe

If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website.

This service is provided to you by the National Institutes of Health.
NIH…Turning Discovery Into Health®

This email was sent to eri7@cdc.gov using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 01:11:10 +0000
To: Marks, Peter;Collins, Francis (NIH/OD) [E]
Cc: Mascola, John (NIH/VRC) [E];Disbrow, Gary (OS/ASPR/BARDA);Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C];[redacted] (b) (6)
Subject: RE: Vaccine Development
Attachments: Warp Speed Brief Deck 0800 042220.pptx

Peter:
Happy to discuss at your convenience – sooner rather than later. Let us make sure that we [redacted] (b) (5)

[redacted] (b) (5). Happy to discuss this in detail with you.
Best regards,
Tony

From: Marks, Peter [redacted] (b) (6)>
Sent: Thursday, April 23, 2020 5:50 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Mascola, John (NIH/VRC) [E] [redacted] (b) (6); Disbrow, Gary (OS/ASPR/BARDA) [redacted] (b) (6)
Subject: Vaccine Development

Dear Francis and Tony,

I know that you have heard murmuring about Project Warp Speed. We had a call today with John Mascola, Carl Dieffenbach, Hilary Marston, Mary Marovich and Emily Erbelding to go through the proposal and discuss how it could feed into the ACTIV effort. [redacted] (b) (5) They suggested that I contact you to try to set up a brief call to go over the plan. I am attaching a slide deck that provides an overview and am happy to find the time whenever you are available.

Thanks so much for considering,
Peter

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 00:29:08 +0000
To: Collins, Francis (NIH/OD) [E] (b) (6))
Subject: Viral Clades Brufsky 42020 Accepted Final.pdf
Attachments: Viral Clades Brufsky 42020 Accepted Final.pdf

Here is the paper from Pittsburg on the mutations. I will send on separate e-mail the commentary from China on another study

---

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tuesday, April 21, 2020 3:43 PM
To: Graham, Barney (NIH/VRC) [E] (b) (6)>
Cc: Mascola, John (NIH/VRC) [E] (b) (6)
Subject: FW: Viral Clades Brufsky 42020 Accepted Final.pdf

This is really getting interesting. See attachment.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)>
Sent: Tuesday, April 21, 2020 3:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Redfield, Robert R. (CDC/OD)
< (b) (6)>; Debi Birx (b) (6)>
Subject: Viral Clades Brufsky 42020 Accepted Final.pdf

Sorry for all of the emails. I spoke to Adam who is an oncologist. I thought this might be of interest.
Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 20:29:10 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE: Serology Test Calculator

[redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 4:06 PM
To: Hahn, Stephen [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>; Giroir, Brett (OS) < [redacted] (b) (6)>
Subject: Re: Serology Test Calculator

[redacted] (b) (5) Deb

From: "Hahn, Stephen" [redacted] (b) (6)>
Date: Tuesday, April 21, 2020 at 3:23 PM
To: "Birx, Deborah L. EOP/NSC" < [redacted] (b) (6), "Fauci, Anthony S (NIH)" [redacted] (b) (6)>, "Redfield, Robert R (CDC)" [redacted] (b) (6)>, "Giroir, Brett (OS)" [redacted] (b) (6)
Subject: Fwd: Serology Test Calculator

From: Shuren, Jeff < [redacted] (b) (6)
Date: April 20, 2020 at 6:26:14 PM EDT
To: Hahn, Stephen [redacted] (b) (6)>, Lenihan, Keagan [redacted] (b) (6)>, Shah, Anand

[redacted] (b) (6)>, Rom, Colin [redacted] (b) (6)

Subject: Serology Test Calculator

Attached is a very rudimentary calculator that you are welcome to share with the WHTF/HHS serology WG to calculate the positive predictive value and negative predictive value of individual serology tests and the use of two tests by plugging in the known or estimated sensitivity, specificity, and population prevalence of COVID-19. [redacted] (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 20:28:43 +0000
To: [redacted] (b) (6)
Subject: FW: Serology Test Calculator
Attachments: Calculator for PPV and NPV for individual tests and combined protected.xlsx

I will call you about this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen [redacted] (b) (6)>
Sent: Tuesday, April 21, 2020 3:23 PM
To: Debi Birx [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>; Giroir, Brett (OS) [redacted] (b) (6)>
Subject: Fwd: Serology Test Calculator

From: Shuren, Jeff [redacted] (b) (6)>
Date: April 20, 2020 at 6:26:14 PM EDT
To: Hahn, Stephen [redacted] (b) (6), Lenihan, Keagan [redacted] (b) (6)>, Shah, Anand
[redacted] (b) (6), Rom, Colin [redacted] (b) (6)>
Subject: Serology Test Calculator

Attached is a very rudimentary calculator that you are welcome to share with the WHTF/HHS serology WG to calculate the positive predictive value and negative predictive value of individual serology tests and the use of two tests by plugging in the known or estimated sensitivity, specificity, and population prevalence of COVID-19. [redacted] (b) (5)

Calculator for Positive Predictive Value (PPV) and Negative Predictive Value (NPV) for individual tests and combined

Prevalence	5.0%

Test 1

Sen1	Sp1
97.0%	93.2%

Test 2

Sen2	Sp2
88.0%	96.0%

Test 1

%Pos1 (Test1=pos)	**PPV1 for (Test1=pos)**	%Neg1 (Test1=neg)	NPV1 for (Test1=neg)
11.3%	**42.9%**	88.7%	99.8%

Test 2

%Pos2 (Test2=pos)	**PPV2 for (Test2=pos)**	%Neg2 (Test2=neg)	NPV2 for (Test2=neg)
8.2%	**53.7%**	91.8%	99.3%

Combined

%Pos (Test1=pos, Test2=pos)	**PPV for (Test1=pos, Test2=pos)**	%Discordant (Test1=pos, Test2=neg)	NPV for (Test1=pos, Test2=neg)	%Neg (Test1=neg)	NPV for (Test1=neg)
4.5%	**94.3%**	6.8%	91.4%	88.7%	99.8%

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 22:21:37 +0000
To: Hahn, Stephen
Cc: Birx, Deborah L. EOP/NSC;Redfield, Robert R. (CDC/OD);Kadlec, Robert (OS/ASPR/IO);Caliguiri, Laura (FDA/OC);Lenihan, Keagan (FDA/OC);Shuren, Jeff (FDA/CDRH);Lane, Cliff (NIH/NIAID) [E];Shah, Anand (FDA/OC)
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Great idea!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen [redacted] (b) (6)>
Sent: Saturday, April 18, 2020 6:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Birx, Deborah L. EOP/NSC [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6); Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6); Caliguiri, Laura (FDA/OC) [redacted] (b) (6); Lenihan, Keagan (FDA/OC) [redacted] (b) (6); Shuren, Jeff (FDA/CDRH) [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Shah, Anand (FDA/OC) [redacted] (b) (6)
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Team,
Anand Shah, Deputy Commissioner, reached out to the Stanford investigators on our behalf. Very interesting information regarding their research and the test that they are using. They are interested in partnering with us. I'll let Anand give the details.

Anand will be reaching out to the MGH folks, as well. [redacted] (b) (5)

Steve

From: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Date: April 18, 2020 at 3:38:39 PM EDT
To: Hahn, Stephen (b) (6)
Cc: Birx, Deborah L. EOP/NSC (b) (6)>, Redfield, Robert R (CDC) (b) (6) Kadlec, Robert P (OS) (b) (6), Caliguiri, Laura (b) (6), Lenihan, Keagan (b) (6)>, Shuren, Jeff < (b) (6)>, Lane, Henry C (NIH) (b) (6)>
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Steve:

John Ioannidis is the one that most of us know. He is the person one of your people could reach out to.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)
Sent: Saturday, April 18, 2020 3:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Birx, Deborah L. EOP/ (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)>; Kadlec, Robert (OS/ASPR/IO) (b) (6)>; Caliguiri, Laura (FDA/OC) (b) (6)>; Lenihan, Keagan (FDA/OC) (b) (6); Shuren, Jeff (FDA/CDRH) (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

We can certainly work with them. Does anyone know any of these folks?

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Date: April 18, 2020 at 10:51:33 AM EDT

To: Hahn, Stephen [redacted] (b) (6)
Cc: Birx, Deborah L. EOP/NSC [redacted] (b) (6), Redfield, Robert R (CDC) [redacted] (b) (6)>, Kadlec, Robert P (OS) [redacted] (b) (6), Caliguiri, Laura [redacted] (b) (6)>, Lenihan, Keagan < [redacted] (b) (6) Shuren, Jeff [redacted] (b) (6)>, Lane, Henry C (NIH) [redacted] (b) (6)
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Steve:

Thanks for the quick reply. The data from the Stanford group [redacted] (b) (5) (b) (5)

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen [redacted] (b) (6)>
Sent: Saturday, April 18, 2020 10:31 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Birx, Deborah L. EOP/NSC [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>; Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>; Caliguiri, Laura (FDA/OC) [redacted] (b) (6)v>; Lenihan, Keagan (FDA/OC) < [redacted] (b) (6); Shuren, Jeff (FDA/CDRH) [redacted] (b) (6)
Subject: Re: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Tony,

[redacted] (b) (5)

[redacted] (b) (5)

[redacted] (b) (5).

Steve

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Date: April 18, 2020 at 10:03:32 AM EDT
To: Hahn, Stephen [redacted] (b) (6)
Cc: Birx, Deborah L. EOP/NSC [redacted] (b) (6)>, Redfield, Robert R (CDC) [redacted] (b) (6)
Kadlec, Robert P (OS) [redacted] (b) (6)>
Subject: FW: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Steve:

[redacted] (b) (5)

Thanks,
Tony

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, April 17, 2020 5:44 PM
Subject: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

COVID-19 Antibody Seroprevalence in Santa Clara County, California

Eran Bendavid, Bianca Mulaney, Neeraj Sood, Soleil Shah, Emilia Ling, Rebecca Bromley-Dulfano, Cara Lai, Zoe Weissberg, Rodrigo Saavedra, James Tedrow, Dona Tversky, Andrew Bogan, Thomas Kupiec, Daniel Eichner, Ribhav Gupta, John Ioannidis, Jay Bhattacharya

doi: https://doi.org/10.1101/2020.04.14.20062463

- **Abstract**
- Info/History
- Metrics
- Preview PDF

Abstract

Background Addressing COVID-19 is a pressing health and social concern. To date, many epidemic projections and policies addressing COVID-19 have been designed without seroprevalence data to inform epidemic parameters. We measured the seroprevalence of antibodies to SARS-CoV-2 in Santa Clara County. Methods On 4/3-4/4, 2020, we tested county residents for antibodies to SARS-CoV-2 using a lateral flow immunoassay. Participants were recruited using Facebook ads targeting a representative sample of the county by demographic and geographic characteristics. We report the prevalence of antibodies to SARS-CoV-2 in a sample of 3,330 people, adjusting for zip code, sex, and race/ethnicity. We also adjust for test performance characteristics using 3 different estimates: (i) the test manufacturer's data, (ii) a sample of 37 positive and 30 negative controls tested at Stanford, and (iii) a combination of both. Results The unadjusted prevalence of antibodies to SARS-CoV-2 in Santa Clara County was 1.5% (exact binomial 95CI 1.11-1.97%), and the population-weighted prevalence was 2.81% (95CI 2.24-3.37%). Under the three scenarios for test performance characteristics, the population prevalence of COVID-19 in Santa Clara ranged from 2.49% (95CI 1.80-3.17%) to 4.16% (2.58-5.70%). These prevalence estimates represent a range between 48,000 and 81,000 people infected in Santa Clara County by early April, 50-85-fold more than the number of confirmed cases. Conclusions The population prevalence of SARS-CoV-2 antibodies in Santa Clara County implies that the infection is much more widespread than indicated by the number of confirmed cases. Population prevalence estimates can now be used to calibrate epidemic and mortality projections.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 03:05:43 +0000
To: clane@niaid.nih.gov
Subject: FW: FYI - "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines"

Go for it. Congratulations!!! ☺

From: Hall, Bill (HHS/ASPA) [redacted] (b) (6)>
Sent: Monday, April 20, 2020 10:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Myles, Renate (NIH/OD) [E]
[redacted] (b) (6); Burklow, John (NIH/OD) [E] [redacted] (b) (6)
Subject: Re: FYI - "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines"

Hi Tony,

[redacted] (b)(5) PCP. I've told John B/Renate/Courtney that everything can post first thing tomorrow morning.

Best regards,
Bill

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, April 20, 2020 11:53 AM
To: Miller, Katie R. (ovp.eop.gov) [redacted] (b) (6); Short, Marc T. EOP/OVP
[redacted] (b) (6)>
Cc: Birx, Deborah L. EOP/NSC [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD)
[redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Hall, Bill (HHS/ASPA)
[redacted] (b) (6)>; O'Malley, Devin M. EOP/OVP [redacted] (b) (6); [redacted] (b) (6)
[redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Myles, Renate (NIH/OD) [E]
[redacted] (b) (6)
Subject: FYI - "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines"

Katie/Marc:

Just as an FYI - "The Coronavirus Disease 2019 (COVID-19) Treatment Guidelines" that were developed here at NIH, and a copy of which I provided to Deb Birx and ultimately to Mark Meadows is moving forward. Mark Meadows

[redacted] (b) (5)

[redacted] (b) (5)

[redacted] (b) (5). Press release will come from NIH with clearance through the appropriate channels (see attachment as an FYI). I anticipate that this will happen in the next day or two. Thanks.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 23:05:49 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: ask to highlight the incredible work of key federal workers

Correct again.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, April 20, 2020 5:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] < [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: ask to highlight the incredible work of key federal workers

[redacted] (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, April 20, 2020 4:52 PM
To: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6) Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6); Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: ask to highlight the incredible work of key federal workers

I agree.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6) 3
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] <gfolkers@niaid.nih.gov>
Sent: Monday, April 20, 2020 4:52 PM
To: Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] <kathy.stover@nih.gov>; Routh, Jennifer (NIH/NIAID) [E] <jennifer.routh@nih.gov>
Subject: RE: ask to highlight the incredible work of key federal workers

[redacted] (b) (5)

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, April 20, 2020 4:40 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: ask to highlight the incredible work of key federal workers

Let us discuss. [redacted] (b) (5) Any suggestions?

From: Boyse, Natalie (OS/ASPA) [redacted] (b) (6)>
Sent: Monday, April 20, 2020 4:28 PM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>; Burklow, John (NIH/OD) [E] [redacted] (b) (6)>
Cc: Bird, Catherine (OS/OGC) < [redacted] (b) (6); Brennan, Patrick (OS/ASPA) [redacted] (b) (6)>
Subject: FW: ask to highlight the incredible work of key federal workers

Hi John, Renate and Courtney –

[redacted] (b) (5)

Let me know if you have any questions re: this request. I am available and happy to chat this afternoon.
Thanks,
Natalie

Natalie Boyse
Special Assistant, Immediate Office of the Secretary
U.S. Department of Health & Human Services
M [redacted]
b

From: Baldwin, Brittany L. EOP/WHO < [redacted] (b) (6)>
Sent: Monday, April 20, 2020 3:00 PM
To: Boyse, Natalie (OS/ASPA) [redacted] (b) (6)
Subject: ask to highlight the incredible work of key federal workers

Hi Natalie – great talking just now. [redacted] (b) (5)

(b) (5)

[redacted] (b) (5)

Please do not hesitate to reach out with questions!

Brittany L. Baldwin
Special Assistant to the President
Speechwriter
O: [redacted] (b) (6)
C: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 12:01:43 +0000
To: Collins, Francis (NIH/OD) [E];Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];McManus, Ayanna (NIH/OD) [E];Wood, Gretchen (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Pursuant to My Email on Friday

I agree. Let us do it another time.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Monday, April 20, 2020 4:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); McManus, Ayanna (NIH/OD) [E] [redacted] (b) (6)>; Wood, Gretchen (NIH/OD) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
Subject: RE: Pursuant to My Email on Friday

With apologies, I just realized that the ACTIV Vaccines working group (which involves John in a significant way, and will be joined today by Tal Zaks from Moderna) meets this morning from 9 – 10 am. Probably we need to pick another time for this pow-wow about the CVP?

Francis

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, April 19, 2020 9:41 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; McManus, Ayanna (NIH/OD) [E] [redacted] (b) (6)>; Wood, Gretchen (NIH/OD) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6) >
Subject: RE: Pursuant to My Email on Friday

Patty:
Please see if we can incorporate this call into our regularly scheduled 9:00 AM call that actually includes some of the same cast of people.
Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Sunday, April 19, 2020 9:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>; Mascola, John (NIH/VRC) [E] <[redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>; McManus, Ayanna (NIH/OD) [E] [redacted] (b) (6)>; Wood, Gretchen (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)v>
Subject: RE: Pursuant to My Email on Friday

Got it, [redacted] (b) (5)

Can we have a phone call about this tomorrow at 9:15 am? Anyone else to include (Emily? Cliff?)

Francis

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, April 19, 2020 9:30 PM
To: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)

Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Pursuant to My Email on Friday

Francis:
[redacted] (b) (5)
Best,
Tony

From: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)
Sent: Sunday, April 19, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E]
[redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Pursuant to My Email on Friday

<< File: Cov Vaccine Program HHS (draft) 19April20.pptx >>

Tony, Francis,

[redacted] (b) (5)

[redacted] (b) (5)

Happy to discuss.

John

[redacted] (b) (6)

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)
Sent: Sunday, April 12, 2020 8:59 PM
To: Hassell, David (Chris) (OS/ASPR/IO) [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6); Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>; Bright, Rick (OS/ASPR/BARDA) [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Disbrow, Gary (OS/ASPR/BARDA) [redacted] (b) (6); Patrick, Vanessa (OS/ASPR/BARDA) (CTR) [redacted] (b) (6)>; Moughalian, Jen (HHS/ASFR) [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Marks, Peter (FDA/CBER) [redacted] (b) (6)>; Yeskey, Kevin (OS/ASPR/IO) [redacted] (b) (6)
Cc: Harrison, Brian (HHS/IOS) <[redacted] (b) (6)>; Dareshori, Zack (HHS/IOS) [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6) Stecker, Judy (OS/IOS) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6); Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)
Subject: Pursuant to My Email on Friday

I want to share with you the product of the BCG team who drafted the attached briefing and Decision Memo drafted for the Secretary's review tomorrow. I want to thank all those who contributed over this holiday weekend to offer their ideas and concepts that is represented in these products. This represents just a first step of many steps that first outlines a concept that will then be operationalized into a historic effort for not only the Department and agencies who will contribute to it, but to our Nation. Again, thank you for your contributions and commitment. Best Bob

<< File: Vaccine strategy-200411-v 13.pptx >> << File: Secretary Determination Memorandum-Project Warp Speed-041120 1825 draft.doc >>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 01:34:55 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Pursuant to My Email on Friday

OK. Let us discuss tomorrow.

From: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Sent: Sunday, April 19, 2020 6:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: FW: Pursuant to My Email on Friday

Tony,

One key point that may be easier to review with 5 min call, whenever you get the chance.

[redacted] (b) (5)

John

From: Mascola, John (NIH/VRC) [E]
Sent: Sunday, April 19, 2020 5:13 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Pursuant to My Email on Friday

Francis,

[redacted] (b) (5)

If still not so clear, feel free to call.

John
[redacted] (b) (6)

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Sunday, April 19, 2020 5:04 PM
To: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Pursuant to My Email on Friday

Hi John,

Thanks for your thoughtful note. [redacted] (b) (5)

[redacted] (b) (5)

Francis

From: Mascola, John (NIH/VRC) [E] <[redacted] (b) (6)>
Sent: Sunday, April 19, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Pursuant to My Email on Friday

<< File: Cov Vaccine Program HHS (draft) 19April20.pptx >>

Tony, Francis,

[redacted] (b) (5)

Happy to discuss.

John

[redacted] (b) (6)

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)
Sent: Sunday, April 12, 2020 8:59 PM
To: Hassell, David (Chris) (OS/ASPR/IO) [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>; Bright, Rick (OS/ASPR/BARDA) [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Disbrow, Gary (OS/ASPR/BARDA) [redacted] (b) (6)>; Patrick, Vanessa (OS/ASPR/BARDA) (CTR) [redacted] (b) (6)>; Moughalian, Jen (HHS/ASFR) [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Marks, Peter (FDA/CBER) [redacted] (b) (6); Yeskey, Kevin (OS/ASPR/IO) [redacted] (b) (6)>
Cc: Harrison, Brian (HHS/IOS) [redacted] (b) (6)>; Dareshori, Zack (HHS/IOS) [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Stecker, Judy (OS/IOS) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)
Subject: Pursuant to My Email on Friday

I want to share with you the product of the BCG team who drafted the attached briefing and Decision Memo drafted for the Secretary's review tomorrow. I want to thank all those who contributed over this holiday weekend to offer their ideas and concepts that is represented in these products. This represents just a first step of many steps that first outlines a concept that will then be operationalized into a historic effort for not only the Department and agencies who will contribute to it, but to our Nation. Again, thank you for your contributions and commitment. Best Bob

<< File: Vaccine strategy-200411-v 13.pptx >> << File: Secretary Determination Memorandum-Project Warp Speed-041120 1825 draft.doc >>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 14:55:57 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Coronavirus Questions for the Office of the Surgeon General

Please make sure that I call this person tomorrow [redacted] (b) (6).

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6) MEDCOM (USA) [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 9:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Coronavirus Questions for the Office of the Surgeon General

Dr. Fauci,

Thank you for responding to my request for information. Please be safe.

[redacted] (b) (6)

[redacted] (b) (6) My cell phone number is [redacted] (b) (6).

r/
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 12:49 PM
To: [redacted] (b) (6) MEDCOM (USA) [redacted] (b) (6)
Cc: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [Non-DoD Source] FW: Coronavirus Questions for the Office of the Surgeon General

All active links contained in this email were disabled. Please verify the identity of the sender, and confirm the authenticity of all links contained within the message prior to copying and pasting the address to a Web browser.

(b) (6)

Thank you for your note. Shown below are my answers to your questions. I hope that you find them helpful.

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?
   This is indeed an unprecedented and stressful time. Stress can often come from the unknown. In times of stress it is critical to take care of one's physical health, by eating well, getting enough sleep, and exercising. In addition, maintaining connections with family and friends (via phone calls, email, or video chatting) while physically socially distancing is very important.

2. Can COVID-19 be contracted from a corpse?
   Infection control measures should be undertaken when dealing with deceased individuals with known or suspected COVID-19. The CDC provides guidance on this issue here:Caution-https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html < Caution-https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html >

3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?
   Clinical trials are underway to determine if hydroxychloroquine is effective in preventing COVID-19 in exposed persons. Until we know the answer to this question, persons who take hydroxychloroquine on a daily basis for another medical condition should consider themselves vulnerable to COVID-19 and take appropriate and recommended measures to protect themselves.

4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?
   I believe that infection control strategies which include proper use of personal protective equipment (PPE) as recommended by the CDC are effective._
   Caution-https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html?CDC_AA_refVal=https%3A%2F%2FCaution-www.cdc.gov%2Fcoronavirus%2F2019-ncov%2Finfection-control%2Fcontrol-recommendations.html < Caution-https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html?CDC_AA_refVal=https%3A%2F%2FCaution-www.cdc.gov%2Fcoronavirus%2F2019-ncov%2Finfection-control%2Fcontrol-recommendations.html >
   In cases where inadequate PPE is worn, or if is not put on/taken off according to proper procedure, the risk of contracting COVID is increased. In addition, healthcare workers on the front lines can be exposed if they encounter a patient who is not initially suspected of having COVID-19 without PPE, especially if they are exposed to aerosol generating processes.

5. What is the most important thing we should be doing, other than social distancing?
   Social distancing is key in order to avoid coming into contact with someone with COVID-19, but washing one's hands often (or using an alchohol-based hand sanitizer) and avoiding touching one's face with unwashed hands are critical as well, especially when coming into contact with surfaces that may have been touched by others or public places.

6. Finally, what keeps you up at night, regarding COVID-19?
   I have said in the past that what keeps me up at night is the possibility of a pandemic respiratory infection. We are in that reality now, and what keeps me up at night is the response, a major part of which is the development of an effective vaccine and treatments for COVID-19.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E- (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) MEDCOM (USA) (b) (6)-
(b) (6)_>>
Sent: Tuesday, April 14, 2020 9:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)_>>
Subject: Coronavirus Questions for the Office of the Surgeon General

Dr. Fauci,

I am (b) (6), the antiterrorism and insider threat officer for the Office of the Surgeon General (Army) / U.S. Army Medical Command. I have been in government for nearly thirty-four years, and this is new to me. I see and hear the concerns of many people. You are the voice of reason for millions of concerned citizens. I have a few questions for you:

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?

2. Can COVID-19 be contracted from a corpse?
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?
4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?
5. What is the most important thing we should be doing, other than social distancing?

Finally, what keeps you up at night, regarding COVID-19?

Thank you for your time and please be safe.

r/
[redacted] (b) (6) Antiterrorism and Insider Threat Officer
Office of the Surgeon General and U.S. Army Medical Command
Mission Assurance and Protection Division
Fort Sam Houston, TX 78234
Cell phone: [redacted] (b) (6)
☎ [redacted] (b) (6)
✉NIPRNet: [redacted] (b) (6)
✉SIPRNet:
Level I Antiterrorism Awareness Training:
Caution-http://jko.jten.mil/courses/atl1/launch.html < Caution-http://jko.jten.mil/courses/atl1/launch.html >

Organizational Mailbox:
[redacted] (b) (6) < Caution-mailto: [redacted] (b) (6) >

To submit contracts for AT/OPSEC review:
Caution- [redacted] (b) (6) Caution- [redacted] (b) (6) >

"Not on My Watch"

CONFIDENTIALITY NOTE: This electronic transmission, including all attachments, is directed in confidence solely to the person(s) to whom it is addressed, or an authorized recipient, and may not otherwise be distributed, copied or disclosed. The contents of the transmission may also be subject to intellectual property rights and all such rights are expressly claimed and are not waived. If you received this transmission in error, please notify the sender immediately by returning the electronic transmission and then immediately delete this transmission, including all attachments, without copying, distributing or disclosing same.

"PRIVACY ACT INFORMATION"

In compliance with the Privacy Act of 1974, this information is Personal Data and must be protected from public disclosure.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 17:48:36 +0000
To: (b) (6)
Cc: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus Questions for the Office of the Surgeon General

(b) (6)

Thank you for your note. Shown below are my answers to your questions. I hope that you find them helpful.

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?
   This is indeed an unprecedented and stressful time. Stress can often come from the unknown. In times of stress it is critical to take care of one's physical health, by eating well, getting enough sleep, and exercising. In addition, maintaining connections with family and friends (via phone calls, email, or video chatting) while physically socially distancing is very important.

2. Can COVID-19 be contracted from a corpse?
   Infection control measures should be undertaken when dealing with deceased individuals with known or suspected COVID-19. The CDC provides guidance on this issue here: https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html

3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?
   Clinical trials are underway to determine if hydroxychloroquine is effective in preventing COVID-19 in exposed persons. Until we know the answer to this question, persons who take hydroxychloroquine on a daily basis for another medical condition should consider themselves vulnerable to COVID-19 and take appropriate and recommended measures to protect themselves.

4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?
   I believe that infection control strategies which include proper use of personal protective equipment (PPE) as recommended by the CDC are effective._
   https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Finfection-control%2Fcontrol-recommendations.html
   In cases where inadequate PPE is worn, or if is not put on/taken off according to proper procedure, the risk of contracting COVID is increased. In addition, healthcare workers on the front lines can be exposed if they encounter a patient who is not initially suspected of having COVID-19 without PPE, especially if they are exposed to aerosol generating processes.

5. What is the most important thing we should be doing, other than social distancing?
   Social distancing is key in order to avoid coming into contact with someone with COVID-19, but washing one's hands often (or using an alchohol-based hand sanitizer) and avoiding touching one's face with unwashed hands are critical as well, especially when coming into contact with surfaces that may have been touched by others or public places.

6. Finally, what keeps you up at night, regarding COVID-19?
   I have said in the past that what keeps me up at night is the possibility of a pandemic respiratory infection. We are in that reality now, and what keeps me up at night is the response, a major part of which is the development of an effective vaccine and treatments for COVID-19.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) MEDCOM (USA) (b) (6)
Sent: Tuesday, April 14, 2020 9:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus Questions for the Office of the Surgeon General

Dr. Fauci,

I am (b) (6) the antiterrorism and insider threat officer for the Office of the Surgeon General (Army) / U.S. Army Medical Command. I have been in government for nearly thirty-four years, and this is new to me. I see and hear the concerns of many people. You are the voice of reason for millions of concerned citizens. I have a few questions for you:

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?
2. Can COVID-19 be contracted from a corpse?
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?
4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?
5. What is the most important thing we should be doing, other than social distancing?

Finally, what keeps you up at night, regarding COVID-19?

Thank you for your time and please be safe.

r/
[redacted] (b) (6), Antiterrorism and Insider Threat Officer
Office of the Surgeon General and U.S. Army Medical Command
Mission Assurance and Protection Division
Fort Sam Houston, TX 78234
Cell phone: [redacted] (b) (6)
☎ [redacted] (b) (6)
✉ NIPRNet: [redacted] (b) (6)
✉ SIPRNet:
Level I Antiterrorism Awareness Training:
http://jko.jten.mil/courses/atl1/launch.html

Organizational Mailbox:
[redacted] (b) (6)

To submit contracts for AT/OPSEC review:
[redacted] (b) (6)

"Not on My Watch"

CONFIDENTIALITY NOTE: This electronic transmission, including all attachments, is directed in confidence solely to the person(s) to whom it is addressed, or an authorized recipient, and may not otherwise be distributed, copied or disclosed. The contents of the transmission may also be subject to intellectual property rights and all such rights are expressly claimed and are not waived. If you received this transmission in error, please notify the sender immediately by returning the electronic transmission and then immediately delete this transmission, including all attachments, without copying, distributing or disclosing same.

"PRIVACY ACT INFORMATION"

In compliance with the Privacy Act of 1974, this information is Personal Data and must be protected from public disclosure.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 20:35:32 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers [redacted] (b) (6)
Subject: FW: Coronavirus Questions for the Office of the Surgeon General

Please fashion some responses to his questions for me to send back to him
Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6) USARMY MEDCOM (USA) [redacted] (b) (6)>
Sent: Tuesday, April 14, 2020 9:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Coronavirus Questions for the Office of the Surgeon General

Dr. Fauci,

I am [redacted] (b) (6) the antiterrorism and insider threat officer for the Office of the Surgeon General (Army) / U.S. Army Medical Command. I have been in government for nearly thirty-four years, and this is new to me. I see and hear the concerns of many people. You are the voice of reason for millions of concerned citizens. I have a few questions for you:

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?
2. Can COVID-19 be contracted from a corpse?
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?
4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?
5. What is the most important thing we should be doing, other than social distancing?

Finally, what keeps you up at night, regarding COVID-19?

Thank you for your time and please be safe.

r/
[redacted] (b) (6), Antiterrorism and Insider Threat Officer
Office of the Surgeon General and U.S. Army Medical Command
Mission Assurance and Protection Division
Fort Sam Houston, TX 78234
Cell phone: [redacted] (b) (6)
☎ [redacted] (b) (6)
✉ NIPRNet: [redacted] (b) (6)
✉ SIPRNet: [redacted]
Level I Antiterrorism Awareness Training:
http://jko.jten.mil/courses/atl1/launch.html

Organizational Mailbox:
[redacted] (b) (6)

To submit contracts for AT/OPSEC review:
[redacted] (b) (6)

"Not on My Watch"

CONFIDENTIALITY NOTE: This electronic transmission, including all attachments, is directed in confidence solely to the person(s) to whom it is addressed, or an authorized recipient, and may not otherwise be distributed, copied or disclosed. The contents of the transmission may also be subject to intellectual property rights and all such rights are expressly claimed and are not waived. If you received this transmission in error, please notify the sender immediately by returning the electronic transmission and then immediately delete this transmission, including all attachments, without copying, distributing or disclosing same.

“PRIVACY ACT INFORMATION”

In compliance with the Privacy Act of 1974, this information is Personal Data and must be protected from public disclosure.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:51:12 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: COVID-19 - Potential Treatment

Please take a look and handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Benoit Ponton <bponton@cpa-qc.ca>
Sent: Friday, April 17, 2020 8:57 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Contact [redacted] (b) (6)
Subject: COVID-19 - Potential Treatment

COVID-19 – Potential Treatment

April 17, 2020

National Institute of Allergy and Infectious Diseases,
National Institutes of Health
31 Center Drive MSC 2520
Building 31, Room 7A03
Bethesda, MD 20892-2520

C/O Anthony S. Fauci, M.D.

Hello Dr. Fauci,

In the current state of medical knowledge and research in the pharmaceutical industry, there is no short- or medium-term solution to prevent disease or cure patients with SARS-Cov-2 (COVID-19).

With this letter, I would like to make you aware of the preventive and curative potential of essential oils (EOs); **lives could be saved.**

Scientific aromatherapy: use of aromatic compounds extracted from plants – essential oils – for medical purposes; 'hard' science of nature, based among other things, on in-depth knowledge of organic chemistry. We are not talking about perfumery or occult sciences.

According to Mr. Dominique BAUDOUX, an internationally known Belgian pharmacist and ''aromatologist'': ***there is a multitude of research on the antiviral properties of essential oils. The results are impressive and indisputable. Here are some viruses for which we have real data:***

- Severe acute respiratory syndrome virus SARS-Cov (it is a coronavirus)
- The H1N1 flu virus
- Avian influenza virus type H5N1 and subtypes H7N3 and H9N2
- The anti-infectious bronchitis virus (IBV)
- Herpes simplex virus HSV
- Dengue virus DEN
- Newcastle disease virus NDV
- Junin virus (an arena virus responsible for hemorrhagic fever)

Source : https://www.pranarom.com/blog/guide-des-huiles-essentielles/les-huiles-essentielles-efficaces-contre-lecoronavirus-vrai-ou-faux: See references 1 to 28 below.

To add meat to the bone, if you visit the **National Center for Biotechnology Information** (U.S.) :

- You will find nearly **225 000 references** on ''**essential oil.**''
  See : https://www.ncbi.nlm.nih.gov/search/all/?term=essential%20oil
- You will find approximately **22 000 references** on ''**essential oil + viral.**''
  See : https://www.ncbi.nlm.nih.gov/search/all/?term=essential%20oil%20+%20viral

In addition, according to a brief email exchange with Mr. Pierre FRANCHOMME, a French researcher, one of the leading experts in the field of medicinal essential oils, he informed me that: ***a recent Indian study (March 31) highlights the potential activity of 1,8 cineole (eucalyptol) on SARS-Cov-2****, as I suspected from my experience on other* ***enveloped viruses****.*

Note: the molecule 1,8 cineole is found in high concentration in eucalyptus EOs.

- Sharma, A.D.; Kaur, I. **Eucalyptol (1,8 cineole) from Eucalyptus Essential Oil a Potential Inhibitor of COVID 19 Corona Virus Infection by Molecular Docking Studies** .
  Preprints 2020, 2020030455 (doi: 10.20944/preprints202003.0455.v1).
  Source : https://www.preprints.org/manuscript/202003.0455/v1

Another study (2008) provided by Mr. Franchomme, **shows a high antiviral activity of bay laurel/leaf essential oil (*Laurus nobilis*) on SARS-Cov**, which appeared in November 2002 in Guangdong province, China and which prevailed until 2004.

- Loizzo, M. R., Saab, A. M., Tundis, R., Statti, G. A., Menichini, F., Lampronti, I., ... Doerr, H. W. (2008). **Phytochemical Analysis and in vitro Antiviral Activities of the Essential Oils of Seven Lebanon Species.** Chemistry & Biodiversity, 5(3), 461–470. doi :10.1002/cbdv.200890045
  Source : https://onlinelibrary.wiley.com/doi/abs/10.1002/cbdv.200890045

Since SARS-Cov and SARS-Cov-2 (COVID-19) are close relatives, it is quite possible that *Laurus nobilis* essential oil will be as effective on SARS-Cov-2.

Here are two other studies that should be of interest to researchers, according to Mr. FRANCHOMME:

- See reference 20 below **Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial.** *Cough* **9,** 25 (2013).
  Source : https://doi.org/10.1186/1745-9974-9-25

Conclusions of this study : *The effects of Cineole in the treatment of acute bronchitis were clearly measurable and could be proven after a treatment period of merely 4 days. This study corroborates the fact that cineole actively and significantly reduces cough frequency after four days. Therefore it has been shown to have a great socioeconomic impact.*

- See also reference 22 below.

Also, according to Mr. FRANCHOMME, **a clinical study on the treatment of essential oils in patients with COVID-19 has just been undertaken in a hospital setting (100 patients), double blind against placebo.** I will know the results at the same time as everyone else and will inform you.

Here is a summary of Mr. FRANCHOMME's analysis:

(b) (4)

[redacted]

The scientific community is launched in search of a miracle drug in the basket of molecules already known for other indications. Our design is to trust the plant world, a great provider of remarkable molecules.

CONCLUSION

We need to think outside the box of allopathic medicine and synthetic drugs that offer no solution and put pressure on our leaders to **release funds for clinical research** on the treatment of patients suffering from COVID-19 using essential oils, as advocated by Mr. Franchomme.

To this end, M. FRANCHOMME confirmed to me this: *I am at the disposal of your authorities to provide and explain a protocol based on essential oils.*
His email address is : (b) (6)

In terms of a double-blind placebo clinical study, there is, as of today, a huge cohort of hospitalized patients, a significant portion of whom I suspect would be enthusiastic about voluntary enrolment.

For patients in critical care with a life-threatening prognosis, it is undoubtedly possible, given the circumstances, to bypass the usual research protocols and offer a last-resort treatment to these patients in an attempt to save their lives, with their permission or that of their legal representatives in case of temporary or permanent incapacity.

Even if it doesn't work, I don't think patients or their loved ones will blame your government for trying everything, but if you don't, I wouldn't like to be in your shoes!

Cordially,

Benoit Ponton
BP/bp

CC: M. Pierre FRANCHOMME

2150, rue Marianne-Baby
Chambly, QC, Canada J3L 0A3
Office (450) 447-4872
Cell phone (b) (6)
Email bponton@cpa-qc.ca

SCIENTIFIC PUBLICATIONS

Source : https://www.pranarom.com/blog/guide-des-huiles-essentielles/les-huiles-essentielles-efficaces-contre-lecoronavirus-vrai-ou-faux

1. Garozzo, A., Timpanaro, R., Bisignano, B., Furneri, P. M., Bisignano, G., & Castro, A. (2009**). In vitro antiviral activity of Melaleuca alternifolia essential oil**. Letters in applied microbiology, 49(6), 806-808. https://sfamjournals.onlinelibrary.wiley.com/doi/full/10.1111/j.1472-765X.2009.02740.x

2. Reichling, J., Schnitzler, P., Suschke, U., & Saller, R. (2009). **Essential oils of aromatic plants with antibacterial, antifungal, antiviral, and cytotoxic properties–an overview.** Complementary Medicine Research, 16(2), 79-90. https://www.karger.com/Article/Abstract/207196

3. Schnitzler, P., Schon, K. and Reichling, J. (2001) **Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture**. Pharmazie 56, 343–347. https://www.ncbi.nlm.nih.gov/pubmed/11338678

4. Mohammad, A., & Mehmood, D.**In Vivo Anti-Viral Effect of Melaleuca alternifolia (Tea Tree Oil) and Olea europaea (Olive Leaf Extract) on Vero Cell Adapted Avian Influenza Virus**. Human Journals. Research Article December 2018 Vol.:14, Issue:1 Citation: Mohammad Danish Mehmood et al. Ijppr.Human, 2018; Vol. 14 (1): 7-19. https://www.researchgate.net/publication/331149520_In_Vivo_Anti-Viral_Effect_of_Melaleuca_alternifolia_Tea_Tree_Oil_and_Olea_europaea_Olive_Leaf_Extract_on_Vero_Cell_Adapted_Avian_Influenza_Virus

5. Usachev, E. V., Pyankov, O. V., Usacheva, O. V., & Agranovski, I. E. (2013). **Antiviral activity of tea tree and eucalyptus oil aerosol and vapour**. Journal of aerosol science, 59, 22-30. https://www.sciencedirect.com/science/article/pii/S0021850213000086

6. Ankita, S., Chandra, S. S., & Arti, T. (2013). **Phytochemical study and antimicrobial activities of cinnamomum camphora**. World Journal of Pharmaceutical research Volume 3, Issue 2, 2287-2294. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=2ahUKEwildfj5OHoAhUEZN8KHZDjBdMQFjABegQIBBAB&url=https%3A%2F%2Fwjpr.net%2Fdownload%2Farticle%2F1400323946.pdf&usg=AOvVaw0WLdK22oqsjVQCt6bqmXeb

7. Astani, A., & Schnitzler, P. (2014). **Antiviral activity of monoterpenes beta-pinene and limonene against herpes simplex virus in vitro**. Iranian journal of microbiology, 6(3), 149. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393490/

8. Astani, A., Reichling, J., & Schnitzler, P. (2010). **Comparative study on the antiviral activity of selected monoterpenes derived from essential oils.** Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives, 24(5), 673-679. https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.2955

9. Bisignano, B. (2009). **Attività antivirale e studio del meccanismo d'azione di estratti di melaleuca alternifolia nei vonfronti del virus dell'influenza A**. Area 06 – Scienze mediche. http://hdl.handle.net/10761/1767

10. Blanchard, J. M. (2007). **Cinnamomum camphora à cinéole (ravintsara), une plante au service de la prévention des infections nosocomiales en milieu hospitalier**?. Phytothérapie, 5(1), 15-20.

11. Carson, C.F., Ashton, L., Dry, L., Smith, D.W. and Riley, T.V. (2001) **Melaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis**. J Antimicrob Chemother 48, 450–451. https://academic.oup.com/jac/article/48/3/450/736091

12. Carson, C.F., Smith, D.W., Lampacher, G.J. and Riley, T.V. (2008**) Use of deception to achieve double-blinding in a clinical trial of Melaleuca alternifolia (tea tree) oil for the treatment of recurrent herpes labialis**. Contemp Clin Trials 29, 9–12. https://www.contemporaryclinicaltrials.com/article/S1551-7144(07)00053-5/fulltext

13. Galan, D. M., Ezeudu, N. E., …, & Malcolm, B. J. (2020). **Eucalyptol (1, 8-cineole): an underutilized ally in respiratory disorders?**. Journal of Essential Oil Research, 1-8. https://www.tandfonline.com/doi/abs/10.1080/10412905.2020.1716867?journalCode=tjeo20

14. Garozzo, A., Timpanaro, R., Stivala, A., Bisignano, G., & Castro, A. (2011). **Activity of Melaleuca alternifolia (tea tree) oil on Influenza virus A/PR/8: study on the mechanism of action**. Antiviral research, 89(1), 83-88. https://www.sciencedirect.com/science/article/abs/pii/S0166354210008120?via%3Dihub

15. Hamidpour, R., Hamidpour, S., Hamidpour, M., & Shahlari, M. (2014). **Chemistry, Pharmacology and Medicinal Property of Camphor (Cinnamomum Camphora) Traditional Remedy with the History of Treating Several Diseases.** Global Journal of Medical Research. https://scholar.google.com/citations?user=xrGgDigAAAAJ&hl=en

16. Jean Michel Blanchard (2007***). Cinnamomum camphora CT cineole (ravintsara), a plant to help prevent nosocomial infections in the hospital environment**. International Journal of Clinical Aromatherapy Vol. 4 issue 1

17. Li, X., Duan, S., Chu, C., Xu, J., Zeng, G., Lam, A. K. Y., … & Gu, H. (2013). **Melaleuca alternifolia concentrate inhibits in vitro entry of influenza virus into host cells**. Molecules, 18(8), 9550-9566. https://www.mdpi.com/1420-3049/18/8/9550

18. Li, Y., Xu, Y. L., … & Xu, P. P. (2017). **Intranasal co-administration of 1, 8-cineole with influenza vaccine provide cross-protection against influenza virus infection**. Phytomedicine, 34, 127-135. https://www.sciencedirect.com/science/article/abs/pii/S0944711317301034?via%3Dihub

19. Loizzo, M. R., Saab, A. M., Tundis, R., Statti, G. A., Menichini, F., Lampronti, I., … & Doerr, H. W. (2008). **Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species**. Chemistry & biodiversity, 5(3), 461-470. https://onlinelibrary.wiley.com/doi/abs/10.1002/cbdv.200890045

20. Mansard, M., Laurain-Mattar, D., & Couic-Marinier, F. (2019). **Huile essentielle de Ravintsara***.* Actualités Pharmaceutiques, 58(585), 57-59. https://www.sciencedirect.com/science/article/pii/S0515370019300734?via%3Dihub

21. Morales-Rico, C. L., … & González-Camejo, I. (2012).**Composición química del aceite esencial de las partes aéreas de Melaleuca quinquenervia.** Revista CENIC. Ciencias Químicas, 43, 1-2.

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=2ahUKEwig4qLa7uHoAhWhnuAKHSDZAasQFjABegQIAhAB&url=http%3A%2F%2Fwww.revistas.usach.cl%2Fojs%2Findex.php%2Fblacpma%2Farticle%2Fdownload%2F2401%2F2210%2F&usg=AOvVaw3k2Urazeofgeg_ftc7wdK_

22. Janine Müller, Johannes F.W. Greiner, Marie Zeuner, Viktoria Brotzmann, Johanna Schäfermann, Frederique Wieters, Darius Widera, Holger Sudhoff, Barbara Kaltschmidt, Christian Kaltschmidt; *Clin Sci (Lond)* 1 August 2016; 130 (15): 1339–1352. **1, 8-Cineole potentiates IRF3-mediated antiviral response in human stem cells and in an ex vivo model of rhinosinusitis**. *Clinical Science (Lond)* 1 August 2016; 130 (15): 1339–1352. https://doi.org/10.1042/CS20160218 et https://portlandpress.com/clinsci/article-abstract/130/15/1339/71448/1-8-Cineole-potentiates-IRF3-mediatedantiviral?redirectedFrom=fulltext

23. Riley, T. V. (2005). **Antiviral Activity of Tea Tree Oil–In Vitro and In Vivo**. TV Riley – 2005 – academia.edu https://www.agrifutures.com.au/product/antiviral-activity-of-tea-tree-oil-in-vitro-and-in-vivo/

24. Siddique, S., et al. (2018). **Chemical characterization, antioxidant and antimicrobial activities of essential oil from Melaleuca quinquenervia leaves**. Indian Journal of Experimental Biology, 56, 686-693. https://www.researchgate.net/publication/327829462_Chemical_characterization_antioxidant_and_antimicrobial_activities_of_essential_oil_from_Melaleuca_quinquenervia_leaves

25. Timpanaro, R., Garozzo, A., Bisignano, B., Stivala, A., Furneri, P. M., Tempera, G., & Castro, A. (2007). **Inhibitory effect of Melaleuca alternifolia (tea tree oil) on influenza A/PR/8 virus replication**. International Journal of Antimicrobial Agents, (29), S202-S203. https://www.sciencedirect.com/science/article/abs/pii/S0166354210008120?via%3Dihub

26. Worth, H., ..& Dethlefsen, U. (2009). **Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled doubleblind trial**. Respiratory research, 10(1), 69. https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-10-69

27. Yang, Z., Wu, N., .. & Efferth, T. (2010). **Anti-infectious bronchitis virus (IBV) activity of 1, 8-cineole: Effect on nucleocapsid (N) protein**. Journal of Biomolecular Structure and Dynamics, 28(3), 323-330. https://www.tandfonline.com/doi/abs/10.1080/07391102.2010.10507362

28. Zamora, A. C. P. (2015). **The Antiviral Properties of Melaleuca alternifolia concentrate (MAC) against West Nile virus** (Doctoral dissertation, Griffith University). https://pdfs.semanticscholar.org/fc36/83837c5d872444e51c452bdd3f6a644fa079.pdf

OTHER SCIENTIFIC PUBLICATIONS

Source : https://www.aude-maillard.fr/4-huiles-essentielles-contre-le-coronavirus/

29. Brun, P., Bernabè, G., Filippini, R. *et al.* **In Vitro Antimicrobial Activities of Commercially Available Tea Tree (*Melaleuca alternifolia*) Essential Oils.** *Curr Microbiol* **76,** 108–116 (2019). https://doi.org/10.1007/s00284-018-1594-x

30. Shih-Yu Lee, Po-Yu Chen, Jung-Chun Lin, Nicholas S. Kirkby, Ching-Huei Ou and Tsu-Chung Chang **Melaleuca alternifolia Induces Heme Oxygenase-1 Expression in Murine RAW264.7 Cells through Activation of the Nrf2-ARE Pathway.** The American Journal of Chinese MedicineVol. 45, No. 08, pp. 1631-1648 (2017) https://doi.org/10.1142/S0192415X17500872

31. Akram Astani, Jürgen Reichling and Paul Schnitzler. **Screening for antiviral activities of isolated compounds from essential oils.** Hindawi. Evidence-Based Complementary and Alternative Medicine / 2011 https://doi.org/10.1093/ecam/nep187

32. Schnitzler P. **Essential Oils for the Treatment of Herpes Simplex Virus Infections.** Chemotherapy 2019;64:1-7. https://doi.org/10.1159/000501062

CONFIDENTIALITY NOTICE: The information contained in this transmission (including any files attached to it) is legally privileged
and confidential and is intended solely for the use of the individual or entity to whom it is addressed. Any other use, dissemination,
distribution, disclosure or copying of this message is strictly prohibited. If you have received this communication in error, please
immediately notify the sender so that we may ensure the intended recipient receives a copy of the original transmission. We then
ask that you kindly destroy your copy and delete the entire message from your computer system.

AVIS DE CONFIDENTIALITÉ : L'information contenue dans cette transmission (et tout document ci-joint) est confidentielle et
privilégiée et est à l'usage exclusif de la personne ou de l'entité à qui elle est adressée. Tout autre usage, distribution, divulgation,
ou copie de cette communication est strictement prohibé. Si vous avez reçu cette transmission par erreur, veuillez nous en aviser
immédiatement pour que nous puissions envoyer le message au destinataire. Aussi, nous vous demandons de détruire toutes les
copies et le supprimer de votre système informatique.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:46:44 +0000
To: Del Rio, Carlos
Subject: RE: released.

Thanks, Carlos.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Del Rio, Carlos [redacted] (b) (6)>
Sent: Friday, April 17, 2020 11:16 AM
To: 'Birx, Deborah L. EOP/NSC' [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Rochelle Walensky MD, MPH [redacted] (b) (6)>
Subject: released.

Here is link to the paper entitled "From Mitigation to Containment of the COVID-19 Pandemic – Putting the SARS-CoV-2 Genie Back in the Bottle" that Rochelle and I wrote for JAMA. Hope you find it useful. Feel free to distribute. Thanks again for all you are doing!

https://jamanetwork.com/journals/jama/fullarticle/2764956

Sincerely,

Carlos

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:40:55 +0000
To: Walensky, Rochelle,M.D.,M.P.H.
Subject: RE: released.

Thanks, Rochelle!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Walensky, Rochelle,M.D.,M.P.H. [redacted] (b) (6)>
Sent: Friday, April 17, 2020 11:54 AM
To: Carlos del Rio [redacted] (b) (6)>; 'Birx, Deborah L. EOP/NSC' [redacted] (b) (6);
Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: released.

Dear Drs. Birx and Fauci (Debbie and Tony, if I may),
So grateful for all you are doing. Please let us know if there is any way we can help.
My best from Boston,
Rochelle

Rochelle P. Walensky, MD, MPH
Chief, Division of Infectious Diseases
Steve and Deborah Gorlin MGH Research Scholar
Massachusetts General Hospital
Division of Infectious Disease
Professor, Harvard Medical School

55 Fruit Street, GRJ 504J floor
Boston, MA 02114-2696
Phone: [redacted] (b) (6)
Fax: 617-726-7416
Email: [redacted] (b) (6)
Pronouns: she/her/hers

From: Del Rio, Carlos (b) (6)]
Sent: Friday, April 17, 2020 11:16 AM
To: 'Birx, Deborah L. EOP/NSC' (b) (6)>; 'Fauci, Anthony (NIH/NIAID) [E]' (b) (6)>
Cc: Walensky, Rochelle,M.D.,M.P.H. (b) (6)>
Subject: released.

External Email - Use Caution

Here is link to the paper entitled "From Mitigation to Containment of the COVID-19 Pandemic – Putting the SARS-CoV-2 Genie Back in the Bottle" that Rochelle and I wrote for JAMA. Hope you find it useful. Feel free to distribute. Thanks again for all you are doing!

https://jamanetwork.com/journals/jama/fullarticle/2764956

Sincerely,

Carlos

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at http://www.partners.org/complianceline . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:34:53 +0000
To: Jeffrey V. Ravetch
Cc: Lusso, Paolo (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];[redacted] (b) (6);Cassetti, Cristina (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E]
Subject: FW: new manuscript
Attachments: Bournazos, et al.docx, Extended Figures.pdf

Jeff:

Very interesting paper. Could have wide applicability in viral disease. I will pass it on to our program people.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeffrey V. Ravetch [redacted] (b) (6)>
Sent: Friday, April 17, 2020 1:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: new manuscript

Tony,

I've attached a pre-print of the story I briefly told you about related to Fc optimization of anti-viral antibodies to induce CD8 protective responses.

I'd be grateful for your comments.

And my sincere gratitude for keeping science at the front of this pandemic.

Best regards,

Jeff

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:30:56 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Concept Paper for NEJM on Novel Clinical Trial in COVID-19
Attachments: Composite EPO COVID-19.pdf

Andrea:

This is a former post-doc in my lab. Please read this, get back to her apologizing that I could not respond [redacted] (b) (5) I obviously can have no part in it.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ehrenreich, Hannelore [redacted] (b) (6)>
Sent: Friday, April 17, 2020 1:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Concept Paper for NEJM on Novel Clinical Trial in COVID-19

Dear Tony,

I am aware of the heavy load that is on your shoulders these days but I sincerely hope to get a brief answer to my E-mail.

In light of the present therapeutic situation in COVID-19, any measure to improve course and outcome of seriously affected individuals is of utmost importance. In the attached

(b) (6), (b) (4) [redacted]

(b) (6), (b) (4)
[redacted]

We all would be extremely grateful for your feedback and for your collaboration!
In fact, I personally would be so proud to have you as senior coauthor as in former times! Please let me know what you think.

We could also discuss over the phone if you let me know which time would be convenient.

All my best, Hannelore

-----Ursprüngliche Nachricht-----
Von: Ehrenreich, Hannelore
Gesendet: Samstag, 21. März 2020 13:24
An: 'Fauci, Anthony (NIH/NIAID) [E]' <[redacted] (b) (6)>
Betreff: THANK YOU from Germany

Dear Tony,

I know you are extremely busy these days... now even more than before due to this terrible corona crisis!

Just a brief note to let you know that I watched your excellent interviews and that I am extremely proud of you! For people here in our Max Planck Institute and the many biomedical institutions in Göttingen you are the greatest hero indeed in a tough time...

I wish you all strength and endurance needed to lead the world out of this crisis (despite questionable politicians)!
STAY HEALTHY!

All my best, Hannelore

Professor Hannelore Ehrenreich, MD, DVM
Clinical Neuroscience
Max Planck Institute of Experimental Medicine
Hermann-Rein-Str.3

37075 Göttingen
GERMANY
Tel: (b) (6)
Fax: 49-551-3899 670
E-Mail: (b) (6)
Prof. hon. University of Göttingen
Faculty of Biology & Psychology

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:21:39 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft MA re: NIAID COVID 19 Strategic Research Plan

Looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, April 17, 2020 2:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FOR ASF REVIEW: Draft MA re: NIAID COVID 19 Strategic Research Plan

Hi Dr. Fauci,

Please find attached for your review a draft media availability about NIAID's COVID-19 strategic research plan. We've named you as the spokesperson in the media avail.

Best,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E

Bethesda, MD 20892
Phone: (b) (6)
E-mail: (b) (6)
NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 18:30:03 +0000
To: Hahn, Stephen;Birx, Deborah L. EOP/NSC;Redfield, Robert R. (CDC/OD);Kadlec, Robert (OS/ASPR/IO);[redacted] (b) (6)
Subject: FW: Boston Globe: Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus

Steve:

[redacted] (b) (5)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Saturday, April 18, 2020 1:54 PM
Subject: Boston Globe: Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus

Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus

Mass. General researcher says the results point to a 'raging epidemic,' but may also indicate the city is further along the disease curve than some other municipalities

By Jonathan Saltzman Globe Staff,Updated April 17, 2020, 6:26 p.m.

First responders loaded a patient into an ambulance from a nursing home where multiple people have contracted COID-19 in Chelsea, which has the highest concentration of COVID-19 infections in the state.Scott Eisen/Getty

Nearly one third of 200 Chelsea residents who gave a drop of blood to researchers on the street this week tested positive for antibodies linked to COVID-19, a startling indication of how widespread infections have been in the densely populated city.

Sixty-four residents who had a finger pricked in Bellingham Square on Tuesday and Wednesday had antibodies that the immune system makes to fight off the coronavirus, according to Massachusetts General Hospital physicians who ran the pilot study.

The 200 participants generally appeared healthy, but about half told the doctors they had had at least one symptom of COVID-19 in the past four weeks.

Public health experts already knew Chelsea hadthe state's highest rate of confirmed COVID-19 cases and that the actual rate was probably higher. At least 39 residents have died from the virus, and 712 had tested positive as of Tuesday, a rate of about 1,900 cases per 100,000 residents, or almost 2 percent.

Get Talking Points in your inboxAn afternoon recap of the day's most important business news, delivered Monday through Friday.

But the Mass. General researchers — who excluded anyone who had tested positive for the virus in the standard nasal swab test — found that 32 percent of participants have had COVID-19, and many didn't know it.

"I think it's both good news and bad news," said Dr. John Iafrate, vice chairman of MGH's pathology department and the study's principal investigator. "The bad news is that there's a raging epidemic in Chelsea, and many people walking on the street don't know that they're carrying the virus and that they may be exposing uninfected individuals in their families."

"On the good-news side, it suggests that Chelsea has made its way through a good part of the epidemic," he said. "They're probably further along than other towns."

Scientists suspect that people who recover from COVID-19 may be at least temporarily immune from catching it again. Several biotechs and academic laboratories, in fact, are seeking blood donations from people who have recovered, in the hopes that their antibodies can help create a treatment or vaccine.

Chelsea's city manager, Thomas Ambrosino, said he learned the results of the pilot study Thursday in a conference call with the researchers. He was dismayed, but not shocked.

Related: Chelsea city manager sounds urgent alarm, calls for residents to stay home 24 hours a day

"We've long thought that the reported numbers are vastly under-counting what the actual infection is," said Ambrosino, who has called his city the epicenter of the crisis in Massachusetts. "Those reported numbers are based on positive COVID-19 tests, and we're all aware that a very, very small percentage of people in Chelsea and everywhere are getting COVID-19 tests."

"Still," he added, "it's kind of sobering that 30 percent of a random group of 200 people that are showing no symptoms are, in fact, infected. It's all the more reason for everyone to be practicing physical distancing."

Indeed, one of the doctors who tested volunteers in Bellingham Square said it's possible that some of the people who had the antibodies are still contagious.

"Just because you have the antibodies doesn't mean you've cleared the virus," said Dr. Vivek Naranbhai, a clinical fellow in hematology and oncology.

Researchers said the test results, which had yet to be shared with state officials late Friday, couldn't necessarily be extrapolated for the city's roughly 40,000 residents. Still, the findings provided a valuable snapshot of a community that medical experts say is especially vulnerable to COVID-19.

Chelsea covers only about two square miles, across the Mystic River from Boston. For generations, it has attracted new immigrants, and about 65 percent of its residents are Latino. Many live in three-decker houses, Ambrosino said, where it's hard for people to isolate themselves. Many work in the hospitality industry and health-related fields, where exposure to the virus is greater. And a lot of them must go to work during the pandemic.

To get Chelsea residents to participate in the study — which included a questionnaire that was available in English, Spanish, and Portuguese — investigators allowed them to remain anonymous. But that meant none of the participants received the results of the blood tests.

The doctors used a diagnostic device made by BioMedomics, of Morrisville, N.C., to analyze drops of blood. It resembled an over-the-counter pregnancy test and generated results on the street in about 10 minutes. Although the test hasn't won the approval of the Food and Drug Administration, Iafrate, the principal investigator, said Mass. General determined it's reliable.

Within days, the physicians said, they hope to set up a medical tent outside the Mass. General Chelsea Healthcare Center to perform more antibodies tests with the device. The site will be located near a tent set up weeks ago to run standard PCR, or polymerase chain reaction, tests for people with active coronavirus symptoms. The latter uses nasal swabs to detect whether the virus is present at the time; the antibodies blood test reveals whether someone was infected in the past.

In addition to the new testing site, the researchers want to expand the study to other Massachusetts cities and towns. For all of those studies, Mass. General doctors plan to obtain the identities of participants so physicians can provide the results. But first the researchers need to come up with guidelines for what participants should do if they test positive for antibodies.

Dr. Dean Xerras, medical director of the Mass. General Chelsea Healthcare Center and a co-investigator in the study, said it illustrates why it's essential for Chelsea and other communities to perform more tests, regardless of whether they detect antibodies or the virus itself.

"Knowing how many people are infected is critical," said Xerras, a longtime member of the city's board of health. "We need to get them isolated. We need to get masks delivered to the city. We need to launch more safe isolation sites. We need to be able to identify cases and then give people the things they need to prevent perpetuation of the spread."

Chelsea and Revere officials, with help from the state Department of Public Health and the Massachusetts Emergency Management Agency, secured almost 150 rooms at a Quality Inn in Revere this week for residents who are recovering from COVID-19 and unable to isolate themselves at home, according to Ambrosino. So far, only a handful of those rooms are occupied.

Governor Charlie Baker on Thursday staunchly defended the state's handling of the escalating outbreak in Chelsea, including asserting, without offering details, that city leaders have turned down help from his administration.

The governor's claim surprised officials in Chelsea who told the Globe this week that the state, and even health care providers, should have recognized the virus's rapid spread through the city sooner.

Jonathan Saltzman can be reached at jonathan.saltzman@globe.com

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: [redacted] (b) (6)
Sent: Sat, 18 Apr 2020 12:28:50 -0400
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Fwd: working draft of NEJM
Attachments: COVID vaccine editorial_16April 7pm.docx, ATT00001.htm

Sent from my iPhone

Begin forwarded message:

> **From:** "Corey MD, Larry" [redacted] (b) (6)>
> **Date:** April 18, 2020 at 12:34:13 AM EDT
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** "Mascola, John (NIH/VRC) [E]" [redacted] (b) (6)
> **Subject: working draft of NEJM**
>
> Here is the working draft . My manuscript typist too tired to work tonight so it reflects several changes I made tonight ; it should be readable ;
>
> Larry

From: [redacted] (b) (6)
Sent: Sat, 18 Apr 2020 12:27:56 -0400
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Fwd: JAMA - Heroes
Attachments: heroes.pdf, ATT00001.htm

Sent from my iPhone

Begin forwarded message:

> **From:** Howard Bauchner <Howard.Bauchner@jamanetwork.org>
> **Date:** April 18, 2020 at 5:10:15 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** Phil Fontanarosa <Phil.Fontanarosa@jamanetwork.org>
> **Subject: JAMA - Heroes**
>
> There are many many heroes in this tragedy – but none more so than you, Maurizio, and Dr. Wenilang.
>
> Howard Bauchner, MD
> Editor in Chief of JAMA and the JAMA Network
>
> Please respect the confidentiality of this email
>
> Listen to my chats with authors
>
> ---
>
> **From:** Howard Bauchner <Howard.Bauchner@jamanetwork.org>
> **Date:** Saturday, April 18, 2020 at 4:07 AM
> **To:** CECCONI HUNIMED <[redacted] (b) (6)
> **Subject:** Re: Hello
>
> I am well – [redacted] (b) (6) – but you know all about that – remain in Chicago – at work everyday – no one is in; [redacted] (b) (6) – he will quarantine for the 2 weeks he is up there.
>
> Yes – NY, London, Paris – all difficult times – great vector – the subway, underground, and metro – unmasked folks who were asymptomatic carriers – terrible.

Most of the US managing although still a heavy heavy lift in some places – NY, Boston, some in Chicago – but most of the US managing. The big issue like everywhere is how do we put society back together.

Will be published on Monday – our tribute to many people and 3 individuals.

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my chats with authors

From: CECCONI HUNIMED (b) (6)>
Date: Friday, April 17, 2020 at 2:07 PM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Subject: Hello

[Warning External Email]
Hello Howard,

I hope you are well. Just a line to say that the podcasts are incredible.
I hope you are ok. I am very sorry for the colleagues in New York. I know it's very tough there and also in other parts of US.
Things are getting better here.

Keep up the amazing work.

Kind regards,

Maurizio

Maurizio Cecconi MD FRCA FFICM MD(Res)
Head of Department Anaesthesia and Intensive Care Units
Humanitas Research Hospital
Professor of Anaesthesia and Intensive Care
Humanitas University

President Elect ESICM

Nota di riservatezza. Il presente messaggio, corredato dei relativi allegati, contiene informazioni da considerarsi strettamente riservate, ed è destinato esclusivamente al destinatario sopra indicato, il quale è l'unico autorizzato ad usarlo, copiarlo e, sotto la propria responsabilità, diffonderlo. Chiunque ricevesse questo messaggio per errore o comunque lo leggesse senza esserne legittimato è avvertito che trattenerlo, copiarlo, divulgarlo, distribuirlo a persone diverse dal destinatario è severamente proibito, ed è pregato di rinviarlo immediatamente al mittente distruggendone l'originale.
Grazie
Confidentiality Notice. This message, together with its annexes, contains information to be deemed strictly confidential and is destined only to the addressee(s) identified above who only may use, copy and, under his/their responsibility, further disseminate it. If anyone received this message by mistake or reads it without entitlement is forewarned that keeping, copying, disseminating or distributing this message to persons other than the addressee(s) is strictly forbidden and is asked to transmit it immediately to the sender and to erase the original message received.

Thank You

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 13:46:56 +0000
To: Greg Folkers [redacted] (b) (6);Morens, David (NIH/NIAID) [E]
Subject: FW: CDC: [redacted] (b) (5) [redacted] https://bit.ly/2Ki5Ry4

We really need to talk about this. [redacted] (b) (5)

From: Morens, David (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, April 17, 2020 6:49 PM
To: Folkers, Greg (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Re: CDC: [redacted] (b) (5) [redacted] https://bit.ly/2Ki5Ry4

[redacted] (b) (5)

Sent from my iPhone
David M Morens
OD, NIAID, NIH

On Apr 17, 2020, at 18:30, Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6) wrote:

(b) (5)

[redacted]

The estimates on this page have been updated from an earlier report published in December 2018 based on more recently available information. There is a trade-off between timeliness and accuracy of the burden estimates. To provide timely burden estimates to the public, clinicians, and public health decision-makers, we use preliminary data that may lead to over- or under-estimates of the true burden. However, each season's estimates will be finalized when data on testing practices and deaths for that season are available.

For the revised 2017-2018 estimates, we included additional information in our estimation regarding influenza testing practices. The surveillance system used to estimate influenza-related hospitalizations, FluSurv-NET, collects data on patients hospitalized with laboratory-confirmed influenza. Influenza testing is done at the request of the clinician, but not everyone is tested and influenza tests are not perfectly accurate. Thus, the reports of laboratory-confirmed influenza-related hospitalizations to FluSurv-NET are likely underestimates of the true number of hospitalizations. To adjust for this, CDC collects data annually from participating FluSurv-NET sites on the amount of influenza testing and the type of test that is used at the site, and this information is used to correct for the possible underestimate of influenza-related hospitalizations. These testing data are often not available for up to two years after the end of an influenza season, and thus the estimates are revised when additional testing data become available. For the original preliminary 2017-2018 burden estimates, data on testing practices during the 2014-2015 season were used to make preliminary estimates because this season had the highest levels of testing among the prior seasons for which data were available and resulted in the most conservative (lowest) estimates of burden. More recent data from the 2016-17 season show that influenza testing has been increasing among most age groups. The current estimates were made using the highest testing rate for each age-group during 2010-11 to 2016-17 and has resulted in some burden estimates being lower than previously estimated.

Additionally, the method we use to estimate influenza-associated deaths relies on additional data from FluSurv-NET and the National Center for Health Statistics (data on cause of deaths and numbers of deaths that occur in versus outside the hospital) that are also not available for up to two years after the end of the season being estimated.

The 2017-2018 estimates are still preliminary because not all of the required data are currently available. When those data become available, these estimates will be updated again and the results may change.

More answers to frequently asked questions about CDC's influenza burden estimates are available.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: [redacted] (b) (6)
Sent: Fri, 17 Apr 2020 14:45:56 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Invitation to speak at virtual TIME 100 event

Let us make sure that we discuss this.

Begin forwarded message:

> **From:** Alice Park <alice.park@time.com>
> **Date:** April 17, 2020 at 2:07:17 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** Cate Matthews <cate.matthews@time.com>
> **Subject: Re: Invitation to speak at virtual TIME 100 event**
>
> Hi Dr. Fauci -- I also should have added that we are happy to pre-tape the interview so it does not have to happen on April 23. In order for it to run on that date, we would love to record it some time Wed during the day or on Thurs morning. Hoping that helps with timing, and looking forward to hearing from you. Best, Alice
>
> **PLEASE NOTE NEW PHONE NUMBER**
> Alice Park
> TIME
> [redacted] (b) (6)
> alice.park@time.com
> @aliceparkny
>
> On Fri, Apr 17, 2020 at 9:35 AM Alice Park <alice.park@time.com>wrote:
>
> Dear Dr. Fauci,
>
> Thank you for making time to talk to me during the early weeks of the pandemic. I know your schedule is tight, but wanted to pass along an invitation to speak at a unique virtual summit we're holding next week, that I hope we can make work.
>
> Building on the impact of our annual TIME 100 and TIME 100 Health summits, as well as our ongoing coverage of COVID-19, on **Thursday, April 23**, TIME will launch its first-ever virtual event series, "TIME Talks: Finding Hope." Our goal is to convene a group of the world's leading voices, including TIME 100 honorees, to spotlight the important work they're doing to combat this crisis, and to help our viewers navigate this new reality.

As part of our launch event, scheduled to take place between noon and 3 p.m. ET, we'd like to invite you
to participate in a short, 10- to 20-minute video interview with a TIME editor on public health policies that could be implemented at the national level to strengthen the responses to this and future pandemics—addressing in particular lessons learned from the initial response to the coronavirus.
We would also welcome your thoughts on how we plan to navigate out of the pandemic and what the new normal will look like. (Please note that we are open to discussing other topics as well.)
Each conversation will be streamed and promoted across TIME's platforms, which reach a combined audience of 100 million people around
the world.
As
one of our invited speakers, you would also be part of an extraordinary community of leaders who are shaping our world. Past speakers at TIME events include House Speaker
Nancy Pelosi,
Apple CEO
Tim Cook,
Primatologist
Jane Goodall,
White House Adviser
Jared Kushner,
Chef
José Andrés,
Me Too Movement Founder **Tarana Burke**,
Producer Director
Ryan Murphy,
and many others.
Thank
you in advance for considering this invitation. Cate, our program coordinator, and I are happy to help with any questions you may have.
Looking forward to hearing from you.
Best,
Alice

PLEASE NOTE NEW PHONE NUMBER

Alice Park
TIME
(b) (6)
alice.park@time.com
@aliceparkny

(b)(5) PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Apr 2020 16:00:09 +0000
To: Thomas R. Frieden
Subject: Re: Box It In
Attachments: image001.png, image002.png, image003.jpg

Thanks, Tom. I totally agree with this approach. I have been trying to catch you by phone but have gotten a voicemail with a message that the mailbox is full. Do I have the correct number?
Thanks, Tony

> On Apr 17, 2020, at 11:00 AM, Thomas R. Frieden
> [redacted] (b) (6) wrote:
>
> Tony,
>
> Wishing you well. Wanted you to be aware that we're releasing a report at a media briefing this morning on how to "Box in COVID." This plan includes prioritized expansion of testing and building a corps of contact tracers in the US, using tried-and-true public health measures at scale. There are four essential actions to box in the virus: 1) Expand testing; 2) Isolate infected people to prevent spread; 3) Identify contacts who may have exposed; 4) Quarantine contacts. As you know, all four are crucial; if any one is lacking, the virus can escape and spread explosively again. Success requires a massive expansion of our public health capacity around the country and world.
>
> The report is attached and can be downloaded here. Please let me know how we can continue to be as supportive as possible.
>
> All the best,
>
> Tom
>
> **Tom Frieden, MD, MPH**
> President and CEO
> www.DrTomFrieden.net
> [redacted] (b) (6)
>
> <image001.png>
>
> <image002.png>
>
> **<image003.jpg>**

RESOLVE TO SAVE LIVES
An initiative of Vital Strategies

STAY CONNECTED
www.resolvetosavelives.org facebook twitter

<COV035_BoxItInBriefing_FINAL.pdf>

RESOLVE TO SAVE LIVES
AN INITIATIVE OF VITAL STRATEGIES


in

RESOLVE
TO SAVE LIVES
AN INITIATIVE OF VITAL STRATEGIES

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Apr 2020 10:15:13 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: [redacted] (b) (4)

Please take a look at this and respond. Thanks.

From: Alfonso Arana <alfonso.arana@bizsecure.us>
Sent: Friday, April 17, 2020 5:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: David Katz [redacted] (b) (6)>; Robert.Thompson@crlcorp.com
Subject: [redacted] (b) (4)

Dr. Fauci, good morning thank you for all you do for this great nation! We are very blessed to have you at the forefront of this pandemic. Not sure if you recall, [redacted] (b) (6) we have

(b) (4) [redacted]

Alfonso Arana
President / CEO
Craft Artisan Design Inc. HUBZone
DBA. BizSecure
https://bizsecure.us
(b) (6)

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended only for the person or entity to which it is addressed and may contain confidential and /or privileged material. Any review, use, disclosure or distribution of such confidential information without the written authorization of Craft Artisan Design Inc. DBA A&A Solutions. is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message, by receiving this e-mail you acknowledge that any breach by you and/or your representatives of the above provisions may entitle A&A Solutions., to seek for damages.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Apr 2020 02:48:07 +0000
To: Greg Folkers [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Hilary Marston's COVID-19 talk now archived for viewing

Greg:
Please see me tomorrow about some ideas that I have about COBID-19 slides.
Thanks,
Tony

-----Original Message-----
From: Roberts, Jacqueline (NIH/OD) [E] [redacted] (b) (6)
Sent: Thursday, April 16, 2020 3:12 PM
To: NIH-STAFF@LIST.NIH.GOV
Subject: Hilary Marston's COVID-19 talk now archived for viewing

Dear Colleagues,

Thank you all for your support as we launch the new COVID-19 lecture series. The live videocast of yesterday's talk was in high demand and, unfortunately, many of you were unable to gain access. This was partly because of the large number of viewers. We are working to remedy the issues in preparation for next week's lecture.

Dr. Marston's talk, "The Biomedical Research Response to COVID-19: A View from NIAID," is now archived at https://videocast.nih.gov/watch=36375.

- The COVID-19 SIG Moderators

For more information about the COVID-19 Scientific Interest Group, refer to https://oir.nih.gov/sigs/covid-19-scientific-interest-group.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Apr 2020 02:45:01 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: conspiracy gains momentum

Francis:

[redacted] (b) (5)

Best,
Tony

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Thursday, April 16, 2020 5:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Burklow, John (NIH/OD) [E] [redacted] (b) (6)
Subject: conspiracy gains momentum

[redacted] (b) (5)

https://www.mediaite.com/tv/foxs-bret-baier-sources-increasingly-confident-coronavirus-outbreak-started-in-wuhan-lab/

[redacted] (b) (5)

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Apr 2020 02:28:05 +0000
To: Pottinger, Matthew F. EOP/WHO;Birx, Deborah L. EOP/NSC
Cc: [redacted] (b) (6)
Subject: RE: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Matt:

[redacted] (b) (5)

[redacted] (b) (5). Let us discuss further.

Best regards,
Tony

From: Pottinger, Matthew F. EOP/WHO [redacted] (b) (6)
Sent: Thursday, April 16, 2020 7:54 PM
To: Birx, Deborah L. EOP/NSC <[redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Deb, Tony,

[redacted] (b) (5)

Best,
Matt

From: Skinner, James B. EOP/NSC [redacted] (b) (6)
Sent: Thursday, April 16, 2020 6:53 PM
To: Pottinger, Matthew F. EOP/WHO [redacted] (b) (6)>
Cc: DL NSC NSA FO Staff <DL.NSAFOStaff@whmo.mil>
Subject: FW: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Matt,

I spoke to Leland earlier this afternoon and he asked I pass this along to you.

James

From: Leland Schwartz [redacted] (b) (6)>
Sent: Thursday, April 16, 2020 6:08 PM

To: Skinner, James B. EOP/NSC (b) (6)>
Cc: Ralph Crafts (b) (6); BARBARA SCHEIDE < (b) (6); Ed Betts (b) (6)
Subject: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Matt,

Oxygen therapy scientists can treat patients using the grounded airliners all over the country as mass treatment chambers.

Please watch this explanation from Extivita in Durham:

>https://www.youtube.com/watch?v=SWCHDuUQHSM&feature=youtu.be<

Please help us connect to the right people.

This could help save lives, get our economy restarted, and ensure continuity in the government.

Hope you're good. Catch up on the other side. Have figured out how to save local news.

Leland
(b) (6)

James,
Thanks very much for your help.
Leland

FAUQUIER CHANNEL ONE
COMMUNITY BROADCASTING FOR FAUQUIER

Leland Schwartz
Editor & Publisher
Fauquier Channel One
540 422 1376
editor@fauquierchannel.com
www.fauquierchannel.com

April 16, 2020

Matt Pottinger
Deputy National Security Advisor
The White House
1650 Pennsylvania Avenue, NW
Washington, DC 20502

Dear Sir,

Many of us in the hyperbaric medicine community believe ~~that~~ there exists a simple therapy to halt the inflammatory process and reverse the lung damage.

This process will also simultaneously provide many times over the amount of oxygenation offered by the coma-inducing intubation ventilator procedure.

We are reaching out to our network to make contact with the airlines to secure the use of an airplane with an onboard APU (Auxiliary Power Unit--used to pressurize the aircraft) for a month, to treat COVID-19 patients and show the effectiveness of the concept.

Initial testing indicates in one trial study 100% improvement while all others underway, although small scale, are showing great benefit at extremely low cost and patient risk.

So what is this new procedure? Hyperbaric Oxygen Therapy or HBOT; first used successfully in 1918 for Spanish Flu cases. HBOT is viable and appears to work well but we do not have the number of pressure vessels / HB chambers available to treat the possibly 100,000+ who need the therapy now.

Several of us in our small community have arrived at the same idea in several countries.

The idea is no longer new or unique.

Again, I am proposing use an aircraft as the pressure vessel. Every airplane with a pressurized cabin (i.e., all commercial airline aircraft) is routinely pressurized to around 9 psi (some go higher) while they are on the ground, as part of their normal airworthiness testing.

Myself and others have suggested that one or more of the hundreds of grounded aircraft be provided to complete the trial test.

737 Max are not flying but are a perfect pressure vessel for the procedure.

Could you help us contact Boeing, the airlines or the military?

No aircraft modification is required whatsoever so that is one of the issues off the table.

The aircraft remains parked on the ground with access for ambulatory patients via a stairway. No jetway is required unless we expand this in the future for non-ambulatory patients.

We would need to place standard DOT portable oxygen tanks in the cabin along with the associated manifold, pressure regulator, flow-meters and tubing.

Each patient will have his/her own anesthesia mask and breathing circuit.

There is no cross contamination between patients or the cabin environment atmosphere as each mask incorporates a Viral Filter Kit to help protect the technicians who are also breathing from a secure, clean source.

All safety issues are addressed in the plan.

The same process, once proven could be utilized by our military and of course our Navy who is experiencing possible outbreaks as we speak.

This is important to me personally [redacted] (b) (6)

The Patriot Clinic in Oklahoma City is my personal charity where we have provided over 15,000 free HBOT treatments for our beloved vets and 30,000+ at cost or below.

We are not asking for money. Nor, am I selling anything in this effort. With the help of a small group of supporters, (Ralph Crafts & family) my company is willing to provide the equipment, training and technical support to begin the process.

Thank you for your ongoing service to our country, and thank you for reading and considering my proposal.

I sure would appreciate your help.

Semper Fi!

Sincerely,
Edward A. Betts

Edward A. Betts
ANDI American Nitrox Divers International
74 Woodcleft Avenue
Freeport, NY USA 11520
[redacted] (b) (6)
>http://www.andihq.com/<

[redacted] (b) (6)

Matt Pottinger
Deputy National Security Advisor
The White House
1650 Pennsylvania Ave., NW
Washington, DC 20502

Sir:

As one old Marine to another Marine, this letter contains the "straight scoop," and is intended to provide information that can help stop the spread of COVID-19, and ensure the continuity of critical segments of government.

Hyperbaric Oxygen Therapy (HBOT) has been in use for over 100 years, and was the only effective treatment for the 1918 flu pandemic. HBOT is being used worldwide to treat a variety of serious diseases, and has been proven to be immediately effective in treating severe COVID-19 cases, with a success rate close to 100%.

HBOT is simply breathing high-purity oxygen (92% or higher) for 60-90 minutes in a pressurized environment (typically between 8 and 15psi—the higher pressure is about the same pressure as doing a SCUBA dive to 33 feet). HBOT chambers can be 1-2 person sizes and portable, up to 12-seat chambers which are used for Navy operations. [redacted] (b) (6) I have a one-person chamber in our home, and we can attest to its effectiveness in treating severe breathing problems, like pneumonia, infections, and wounds.

The currently publicized and widely accepted statement that there is no effective treatment for COVID-19 is wrong. HBOT treatments, usually just a single one-hour session, provide immediate improvements in lung function, blood-oxygen levels, and organ recovery. Unlike respirators, which do more damage than good and are basically a death sentence, HBOT provides an immediate path for recovery and healing.

A team of very experienced scientists and HBOT experts have developed a concept that will enable the effective treatment of large numbers of people by using some of the thousands of grounded commercial aircraft as large HBOT chambers.

I'm an old Marine Corps jet pilot, and we use our [redacted] (b) (6) so I have the professional contacts to confirm and verify the efficacy of the concept.

Every airplane with a pressurized cabin (i.e., all airline aircraft) is routinely pressurized to around 9psi (some go higher) while they are on the ground, as part of their normal airworthiness testing.

We have equipment staged and ready to go now, to treat 25 COVID-19 patients at a time—we need an airplane, and we can be treating people and saving lives in about 36 hours.

The aircraft we need remain parked on the ground, no modifications are needed—we will simply place portable oxygen tanks in the cabin with the associated tubing, manifold, and pressure regulators, and each patient will have his/her own anesthesia mask.

There is no cross contamination between patients, because everyone is breathing oxygen from their own personal mask.

We are reaching out to our contacts in the airlines to ask for the use of an airplane and APU (Auxiliary Power Unit—used to pressurize the aircraft) for a month, to treat COVID-19 patients and show the effectiveness of the concept.

We could do the same thing with a single military transport aircraft (many of which have been configured for medical use).

As a Marine, and with my knowledge of HBOT, the recent death of the Theodore Roosevelt sailor is particularly upsetting, knowing that a couple of Senior Chiefs or Marine Master Sergeants could have configured an aircraft in Guam in a couple of hours and be treating all the sailors from the carrier.

We are not asking for money—my wife and I are paying for all the required equipment and support personnel.

HBOT chambers are easily implemented and supported—you could have one in your office (ours is 8' long and 34" in diameter when pressurized) and it would only take a couple of hours to train your corpsmen to operate it. I don't know of a better guarantee of continuity in the current pandemic.

Please note that [redacted] (b) (6) I have no financial or political interests in the HBOT treatment concept, companies, or manufacturers—we receive no benefits/rewards, other than helping to save many lives.

You will receive a letter from Ed Betts—he's a good man, really knows his stuff, and I trust him with my life—please take what he says seriously.

Thank you for your ongoing service to our country, and thank you for reading and considering the information in this letter.

Semper Fi!

Respectfully,

Ralph E. Crafts
Marshall, Virginia
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 12:37:38 +0000
To: Dr. Josh Backon
Subject: RE: Covid-19. thromboxane inhibitors, and heme binding (O2 desaturation)

You are not being ignored. The National Heart Lung and Blood Institute will take a look at this.

From: Dr. Josh Backon <backon@mail.huji.ac.il>
Sent: Thursday, April 16, 2020 8:09 AM
To: Coleman, Amanda (NIH/NIAID) [C] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)
[redacted]
Subject: Fwd: Covid-19. thromboxane inhibitors, and heme binding (O2 desaturation)

Continue to ignore me.

http://www.htct.com.br/en-hemoglobin-value-may-be-decreased-avance-S2531137920300298?fbclid=IwAR3zdsUZE_1M5gxNpqzrIf862lNlbRMFPJ9qfRLnsC2FqZNkjCrsw4KDtGc

Dr. Josh Backon
backon@mail.huji.ac.il

---------- Forwarded message ---------
From: **Coleman, Amanda (NIH/NIAID) [C]** < [redacted] (b) (6)
Date: Thu, Apr 9, 2020 at 6:18 PM
Subject: RE: Covid-19. thromboxane inhibitors, and heme binding (O2 desaturation)
To: Dr. Josh Backon <backon@mail.huji.ac.il>

Dear Dr. Backon,

We very much appreciate the information you've provided, and I am sharing your updates with the relevant staff at NIH. We have directed you to the information we think is relevant for your request, and we hope that this has been helpful. We have no additional information to provide at this time. NIAID staff members will not be responding further.

Thank you,

Amanda Coleman, MPH [C]
Office of Scientific Coordination and Program Operations
Division of Microbiology and Infectious Diseases
NIAID, NIH, DHHS

From: Dr. Josh Backon <backon@mail.huji.ac.il>
Sent: Wednesday, April 8, 2020 7:37 AM
To: Coleman, Amanda (NIH/NIAID) [C] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Covid-19. thromboxane inhibitors, and heme binding (O2 desaturation)

I have a suggestion for 3 potent antiviral agents, cheap and readily available, that may prevent viral shedding. No viral shedding? No infectivity. The concept is that EVERYONE should take these items. Two of the items also positively affect heme binding. Covid-19 binds to heme causing O2 desaturation, lung failure and death.

First a short bio:

Dr. Josh Backon was affiliated with the Hebrew University Faculty of Medicine for over 33 years. He has a good track record (84+ publications quoted by over 750 other researchers www.google.com/scholar?start=0&q=%22backon++j.%22&hl=en&as_sdt=0,5 and in over 250-300 texts as per https://www.google.com/search?tbo=p&tbm=bks&q=%22backon+j.+%22&num=100).
In the 1980's he was Consulting Editor of the Journal of Pediatric Endocrinology, Editor of Reviews in Pure and Applied Pharmacological Sciences, and Associate Editor of the International Journal of Adolescent Medicine and Health. From 1990-2004, he was a consultant on emergency planning and management at Israel's National Police Headquarters with Nitzav Mishneh Danny Fisher.
===

Chloroquine, an antimalarial drug, is now being used to treat Covid-19. Its mechanism was found in the 1970's to inhibit thromboxane https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=chloroquine+thromboxane&btnG= The problem with chloroquine was that it also elevated levels of prostaglandin F2alpha. In 1980, Srivastava, an Indian biochemist working in Denmark found that GINGER is a potent inhibitor of thromboxane synthetase. I wrote a number of papers in the 1980's on use of ginger: https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=backon+ginger&btnG=

-

CHLOROQUINE FOR TREATING COVID-19

-

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=chloroquine+covid-19&oq=ch&fbclid=IwAR1lLe376M22_IUr3UsD6_yz-sASmpGgIpI3h3PTOpCHA4Ycu321ZPevD-A

GINGER IS A POTENT ANTIVIRAL

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=ginger+antiviral&oq=gin

THE SECOND ANTIVIRAL AGENT IS TURMERIC [add black pepper since piperine dramatically increases oral bioavailability of turmeric]

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=turmeric+antiviral&oq=tur

Multisite inhibitors for enteric **coronavirus**: antiviral cationic carbon dots based on curcumin

D Ting, N Dong, L Fang, J Lu, J Bi… - ACS Applied Nano …, 2018 - ACS Publications
… These results offer theoretical support for the development of CCM-CDs as a hopeful antiviral drug for the treatment of **coronavirus** infections, including PEDV … Curcumin (CCM) is a polyphenol compound obtained from **turmeric** roots…

NAC AND PIPERINE TO INHIBIT INFLAMMATORY CYTOKINES (iNOS, NF KappaB, TNFalpha) INVOLVED IN ARDS

Mortality in COVID-19 patients is usually from ARDS (acute respiratory distress syndrome) via inflammatory cytokines. Apart from N-acetylcysteine which was found 3 years ago to elevate atrial natriuretic factor [found by Kiemer in 2001 to zap inflammatory cytokines: iNOS, NF KappaB, and TNFalpha) now piperine in black pepper was found to inhibit inflammatory cytokines [piperine also dramatically increases oral bioavailability of turmeric [which has been used as a potent antiviral]:

N-ACETYLCYSTEINE
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=n-acetylcysteine+%22inflammatory+cytokines%22&btnG=

PIPERINE

https://scholar.google.com/scholar?hl=en&as_sdt=0,5&q=piperine%20inflammatory%20cytokines&btnG=&fbclid=IwAR0kXZxI66JPLFPry2MDTDxOAelgGnmBZdKBw7c1v78Hfi7t0JJnx0Y2zuE

COVID-19 BINDS TO HEME
http://web.archive.org/web/20200405061401/https://medium.com/@agaiziunas/covid-19-had-us-all-fooled-but-now-we-might-have-finally-found-its-secret-91182386efcb

COVID-19: HYPOXIA, 02 DESATURATION, COVID-19 BINDS TO HEME. THUS NO MAX PEEP !! IT'S A PROBLEM OF FREE RADICAL BIOCHEMISTRY.

THROMBOXANE AND HEME BINDING
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=thromboxane+%27heme+binding%22&oq=th&fbclid=IwAR3f5ECaUUnrSSyhCA6kpJ9z0nPaMM3ba7HtuFPpQ9B1PVrF9kdwayATcY0

INDIA: POPULATION 1,300,000,000: as of April 8th, only 5000 cases and 164 deaths:
[Indians eat GINGER, TURMERIC and BLACK PEPPER plus other spices which are thromboxane inhibitors]:
https://www.business-standard.com/article/current-affairs/coronavirus-live-updates-covid-19-cases-in-india-global-death-toll-state-wise-delhi-maharasthra-tablighi-nizamuddin-lockdown-extension-latest-news-120040800236_1.html

11 classic Indian spices: saffron, fenugreek, cardamom, cloves, cassia, cumin, coriander, and nutmg
https://www.thekitchn.com/11-essential-spices-for-indian-cooking-223152

Access http://scholar.google.com for THROMBOXANE (and the name of each spice) and you'll see that each one is a thromboxane inhibitor

ANTIPARASITIC DRUG IVERMECTIN KILLS COVID-19
https://pharmafield.co.uk/pharma_news/study_shows_anti-parasitic_drug_ivermectin_kills_coronavirus/

IVERMECTIN AFFECTS THROMBOXANE
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=%22ivermectin%22+thromboxane+&btnG=

CARBON DIOXIDE AS THROMBOXANE INHIBITORS
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1433448/

https://www.sciencedirect.com/science/article/abs/pii/0306987786900952

Effect of carbon dioxide on **platelet** aggregation in cats

ÉS **Gabrielyan**, ÉA **Amroyan** - Bulletin of Experimental Biology and …, 1984 - Springer

Products of the arachidonic acid cascade have been shown to play an important role in regulation of the blood supply to several organs, including the brain [i, 8]. Cyclic derivatives of arachidonic acid play a definite role in the mechanisms of action of many known …

https://link.springer.com/article/10.1007/BF00829637

WHY CATS (FELINES) ARE MORE SUSCEPTIBLE TO COVID-19 THAN DOGS

https://www.the-scientist.com/news-opinion/cats-ferrets-susceptible-to-sars-cov-2-study-67374?utm_campaign=TS_DAILY+NEWSLETTER_2020&utm_source=hs_email&utm_medium=email&utm_content=85706789&_hsenc=p2ANqtz--SZXoVVbO1SHcR025FPiWgMcM3_nz7fHSHOrKRp9f-LxTy9Bxj0JsI7hJtDQ_oDM2xsozsH438n5c_1Mj-78bT3Rz2mQ&_hsmi=85706789&fbclid=IwAR3bW76GVI4rConuw7YPcDL9IZE9JkQQSm9Lu_y-RE4y2LNmo0o6v_taFUk

https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1476-5381.1983.tb09393.x?fbclid=IwAR1SzFky0R4mVyVvh9ayQP_U-zj4Cw1Vo4I9b2jRHebfjmSQCD6BykteHqQ

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 11:48:56 +0000
To: [redacted] (b) (6)
Subject: RE: Standing Up for Truth

David:

Many hanks for your kind note. It is much appreciated.

Best regards,

Tony [redacted] (b) (6)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Monday, April 13, 2020 2:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Standing Up for Truth

4/13/20

Anthony S. Fauci, M.D.
Director, NIAID

Dear Dr. Fauci:

As a fellow graduate of Regis High School [redacted] (b) (6) and very active alumnus, I am writing to you out of deep concern for our nation. I am reading reports in The NY Times that President Trump may be considering firing you for telling the truth about the negative consequences of delays in mobilizing the American response to the coronavirus threat. The Times had run articles in recent days detailing the pertinent facts that place the blame for this delay squarely on President Trump. We can reasonably infer that significant loss of life and financial harm resulted from this delay.

The mission of Regis was to mold young men with leadership potential to be "men for others" in the Jesuit tradition. To achieve that goal Regis also sought to hone our intellectual talents and imbue us with Christian morality to succeed throughout our lives in a persistent pursuit of excellence, which embodies the truth. A mission to relentlessly pursue and proclaim the truth.

The fact that you have consistently and courageously pursued that mission during one of the darkest times in our history explains the extraordinary admiration in which you are held by millions of Americans. You have won their confidence, which has enabled so many to make exquisite sacrifices to win this crucial battle. People will follow heroes, which is precisely how the vast majority views you.

I am writing because I want you to know how important you are to America. We cannot lose you and we can not lose the value of truth. Truth must prevail or our precious democracy is in grave peril.

Consequently, and I know I speak for the vast majority of Americans whose decency is beyond question, if Donald Trump seeks your removal, please resist for the sake of our nation. An appeal to the populace will not go unanswered. Religious leaders will flock to your defense, as will the media and leading political leaders, including Biden and Cuomo. Republicans can not afford to alienate what you stand for. Jeopardizing the Catholic vote would be suicide.

In closing, know how proud all Regians are of you. You will always be an inspiration to those who understand the value of service to others.

Our prayers are with you.

David G. O'Brien (b) (6)
Attorney at Law
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 11:35:55 +0000
To: Daniel Bednarik
Cc: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: BARDA Presentation

Thanks, Dan.
Best,
Tony

From: Daniel Bednarik <dbednarik@neximmune.com>
Sent: Tuesday, April 14, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: BARDA Presentation

Dear Tony:

[redacted] (b) (4)

Be well – we are all in your corner (and you have your own bobblehead likeness)!

Best,

Dan

Daniel Bednarik, Ph.D.
Senior Vice President
Molecular Engineering
NexImmune, Inc.
9119 Gaither Road
Gaithersburg MD 20877
[redacted] (b) (6) (m)
www.neximmune.com
NexImmune
Directing T cell function to restore natural immunity

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 11:33:57 +0000
To: Schwetz, Tara (NIH/OD) [E]
Cc: Marston, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C];Walsh, Elizabeth (NIH/OD) [E]
Subject: RE: Flagging NIH Media Products

Thanks, Tara. I appreciate the heads up. Stay well and safe.
Best,
Tony

From: Schwetz, Tara (NIH/OD) [E] [redacted] (b) (6)>
Sent: Tuesday, April 14, 2020 4:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>; Walsh, Elizabeth (NIH/OD) [E] [redacted] (b) (6)>
Subject: Flagging NIH Media Products

Tony,

Hope all is well and that you are staying safe and healthy. [redacted] (b)(5) PCP. Our plan is to batch and send these to Hilary, Patty, and Kim on Thursdays/Fridays each week, unless there is a time sensitivity to them. For the time-sensitive requests, I will flag them for you (after a couple levels of filtering).

So, that said, I am reaching out to flag the following time-sensitive items for your awareness and sharing with the remainder of the Task Force, as appropriate. You'll note that both of these are yours, so this email may be unnecessary. If so, apologies for adding to your (what much be crazy) inbox.

Item 1: **National Institute of Allergy and Infectious Diseases Strategic Plan for COVID-19 Research (NEW)**

> **Activity Type**: Strategic Plan
>
> **Summary:** A new strategic research plan from the National Institutes of Health aims to build on — and accelerate — new and existing research efforts to prevent, diagnose, and treat COVID-19, as well as understand the underlying causative agent of this disease, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Plan prioritizes research to improve fundamental knowledge of SARS-CoV-2 virus and COVID-19 disease, develop diagnostics and assays, characterize and test therapeutics, as well as develop safe and effective vaccines targeted toward decreasing disease incidence, mitigating morbidity, and prevention mortality from this disease.

Impact on COVID-19 Pandemic Response: The strategic plan outlines a research plan targeted at prevention and mitigation of COVID-19 disease.

Office: NIAID, Office of the Director

NIH Point-of-Contact: Anthony Fauci, M.D.

NIH Point-of-Contact Email: [redacted] (b) (6)
Action Date: Estimated 4/17/2020_
Type of Action: Publication

Potential for Press Coverage: Mainstream Press

Press Release in Development?: Yes

Item 2: NIH study validates decontamination methods for re-use of N95 respirators

- **Activity Type**: Significant scientific finding

Summary: NIAID/NIH-funded study shows that N95 respirators can be decontaminated effectively and maintain functional integrity for up to three uses. Researchers tested the decontamination of small sections of N95 filter fabric that had been exposed to SARS-CoV-2. Decontamination methods tested included vaporized hydrogen peroxide (VHP), 70-degree Celsius dry heat, ultraviolet light, and 70% ethanol spray. All four methods eliminated detectable viable virus from the N95 fabric test samples. The results will be posted on a preprint server (timing TBD). The findings are not yet peer-reviewed but are being shared to assist the public health response to COVID-19.

Impact on COVID-19 Pandemic Response: Study shows that respirators could be used multiple times (2-3 times depending on decontamination method)

ICO: NIAID

NIH Point-of-Contact: Vincent Munster, Ph.D., and Marshall Bloom, M.D., from NIAID's Laboratory of Virology are available to comment on this study.

POC Email: [redacted] (b) (6)

Action Date: TBD week of April 13, 2020

Type of Action: Report/Publication

Potential for Press Coverage: Mainstream Press

Press Release in Development?: Yes

Hope you're getting some rest and taking care of yourself!

Best,

Tara A. Schwetz, PhD
Acting Director, NINR
Associate Deputy Director, NIH
A: Building 1, Room 138
P: (b) (6) | **M:** (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 11:32:27 +0000
To: [redacted] (b) (6)
Subject: FW: New web portal --- UW IDEA: COVID-19 Treatment https://bit.ly/3ckkv48

Please take a look at this and then let us talk.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 14, 2020 5:19 PM
Subject: New web portal --- UW IDEA: COVID-19 Treatment https://bit.ly/3ckkv48



University of Washington / IDEA Program

COVID-19 Treatment

Our main goal is to provide up-to-date information and teaching slide decks focused on clinical trials and published data related to potential high-impact treatments of persons with COVID-19.

U.S. Clinical Trials

Quick links to COVID-19 clinical trials and expanded access programs in the United States. The treatment regimens and trial list are organized alphabetically.

Treatments

Selected high-impact and high interest COVID-19 treatments. Includes medication summaries, studies, and treatment specific references.

Teaching Resources

COVID-19 treatment PowerPoint slide decks. All slide decks can be downloaded and used for educational purposes without obtaining permission from our website.

About this website

This website was developed at the University of Washington and is produced by the

Editors

David H. Spach, MD
Professor of Medicine

Gretchen Snoeyenbos Newman, MD

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 11:24:00 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] ([redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E];Harper, Jill (NIH/NIAID) [E]
Subject: FW: Request: Proposal Summaries - POCs Due 4/15; Summaries Due 4/20
Attachments: 2020-04-14_Proposal POC Sign up.xlsx, IC Specific Proposals 4.14.pdf, ER Proposals 4.14.pdf

Please handle.

From: Schwetz, Tara (NIH/OD) [E] [redacted] (b) (6)
Sent: Tuesday, April 14, 2020 8:52 PM
To: ICDDIR-L@list.nih.gov
Cc: List DEPDIR-L <DEPDIR-L@list.nih.gov>; NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>
Subject: Request: Proposal Summaries - POCs Due 4/15; Summaries Due 4/20

Colleagues,

As discussed this afternoon, please find attached the POC sign-up sheet (tab 1; tabs 2-3 list the various proposals by category, theme, and IC), the IC-specific proposals, and the economic recovery proposals. We ask that you please complete the POC sign-up and send it to Jordan Gladman [redacted] (b) (6) by **5 pm on Wednesday April 15**. We will then collate and distribute the completed spreadsheet to the Chairs for each of the themes and post it on the ICD SharePoint site. The individual proposals are imbedded in the pdf as folders sorted by theme. If you feel your proposal would fit better with a different working group, please feel free to engage with them.

We ask that, once the POCs have been have been identified, you quickly assemble to begin refining and synergizing your proposals. Each Chair should coordinate with their group to develop a 2 page max summary of the theme's research, along with a single combined budget. The summary should integrate the IC proposals as much as possible; however, it is fine (for valid/justifiable reasons) to describe a few unique projects that fall under the theme as well. That is, if they don't make sense to integrate, you don't have to, but please be sure to include them in the summary. These summaries should be sent to Larry and me (cc Jordan Gladman) by **noon on April 20**. We will build off these summaries to generate a document for Francis' review, which we ultimately hope will be informative as we prepare for a potential fourth supplement.

The ask in short:

- **April 15 at 5 pm** – send your POCs to Jordan, who will then distribute the completed spreadsheet to the chairs
- **April 20 at 12 pm** – chairs to send a 2 page summary of their theme (with combined budget)

Best,

Tara A. Schwetz, PhD
Acting Director, NINR

Associate Deputy Director, NIH
A: Building 1, Room 138
P: (b) (6) | **M:** (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 02:51:30 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Emergency clinical trial COVID PE
Attachments: 4_OVID_protocol_15042020.docx

Please take a look at this and take care of it. Thanks.

From: Kucher Nils <[redacted] (b) (6)>
Sent: Wednesday, April 15, 2020 5:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Emergency clinical trial COVID PE

Dear Anthony

My background is clinical VTE research. I spent many years in Boston (Harvard Medical School).

We may have a solution for improving survival in COVID outpatients.

[redacted] (b) (4), (b) (5)

Would you be willing to discuss this urgent clinical trial proposal which was submitted today to Swiss authorities

My mobile is [redacted] (b) (6)

You can call me anytime.

Best regards

Nils

Prof. Dr. med. Nils Kucher
Director of Vacular Medicine

University Hospital Zurich
Switzerland
Rämistrasse 100, RAE C 13
CH-8091 Zürich
Tel: [redacted] (b) (6)
www.angiologie.usz.ch

USZ Universitäts Spital Zürich

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 02:50:34 +0000
To: DuBois, Raymond N.
Subject: RE: Mask wearing policy at our University Hospital

Ray:
Thank you for your note. I would keep the policy "voluntary" but I would "encourage" employees to wear them.
Best regards,
Tony

From: DuBois, Raymond N. [redacted] (b) (6)
Sent: Wednesday, April 15, 2020 7:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Mask wearing policy at our University Hospital

Dear Dr. Fauci,

My name is Ray DuBois and in addition to being the Dean of Medicine here at the Medical University of South Carolina in Charleston, I chair the Board of Scientific Councilors for the NCI. The mask wearing policy for our Health System is developed by our infection control group and not by the College of Medicine.

Currently, we have a **"voluntary"** mask wearing policy for the health system and our main University Hospital. Based on your recent comments about asymptomatic and pre-symptomatic carriers of COVID-19, do you agree that keeping this voluntary is the correct approach?

Obviously, your opinion here is extremely well respected and I would like for us to provide the safest environment possible for our faculty, employees and patients.

Ray DuBois, M.D., Ph.D.
Dean of Medicine
The Medical University of South Carolina....Charleston, SC
Member of the National Academy of Medicine

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 02:35:18 +0000
To: Bertuzzi, Stefano
Subject: RE: Announcement--ASM's COVID-19 Research Registry

Stefano:

Congratulations! Excellent idea and much needed. Our community will find it very valuable.
Best regards,
Tony

From: Bertuzzi, Stefano <sbertuzzi@asmusa.org>
Sent: Wednesday, April 15, 2020 10:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6); Beigel, John (NIH) [E] [redacted] (b) (6)>
Subject: Announcement--ASM's COVID-19 Research Registry

Dear Tony and NIAID friends –

the mission of the American Society for Microbiology (ASM) to promote and advance the microbial sciences has perhaps never been more clearly in focus than during the current SARS-CoV-2 pandemic. Accelerating basic research is key to ASM's mission– it is where cure and prevention begin. It is impressive how rapidly research on SARS-CoV-2 /COVID-19 has advanced in just a few weeks, but easily accessing new and relevant research has been a challenge for basic researchers. When ASM's Council on Microbial Sciences held a COVID-19 summit to identify the most significant scientific work on the virus, the coronavirus researchers and clinical microbiologists raised the need for the scientific community to curate important COVID-19 research.

ASM is excited to announce the launch of the COVID-19 Research Registry, a platform curated and vetted by experts in the field of virology and related disciplines to provide immediate access to top COVID-19 research.

I am proud that **Lynn Enquist**, Ph.D., Henry L. Hillman Professor in Molecular Biology, Princeton University and former ASM President, will serve as Chief Curator for this Registry. **Dr. Harold Varmus**, Lewis Thomas University Professor of Medicine, Weill Cornell Medicine has agreed to join us as Chief Consultant on the project.

We are honored to have the following as Assistant Curators-in-Chief:

- Rozanne M. Sandri-Goldin, Ph.D., Chancellor's Professor, Microbiology & Molecular Genetics, University of California, Irvine and Editor-in-Chief of ASM's *Journal of Virology*
- Vaughn Cooper, Ph.D., Professor, Microbiology & Molecular Genetics, University of Pittsburgh, and current ASM Board member

The entire curatorial board is listed on the Registry site.

ASM is proud to add this initiative to our ongoing efforts. Through its capillary network of clinical microbiologists around the country and the world, ASM has accelerated communication and cleared roadblocks to ramp up SARS-CoV-2 testing. We continue to work closely with our dedicated colleagues, the indefatigable clinical microbiologists manning the front lines in hospitals and testing labs during this unprecedented global emergency. We send our thanks—and admiration--to these ASM members who are contributing directly to saving lives in this perilous time.

Our COVID-19 resource page provides important ASM updates and current information on the coronavirus. We are also working with the news media to provide authoritative ASM experts and reliable material on the microbiology of viral epidemics. ASM journals is also providing free access to more than 50 research articles published over the last year in our 16 scholarly journals and expediting review for submitted papers related to coronavirus, ensuring that new research is quickly made available to the scientific community.

We are hoping that researchers will find the COVID-19 Research Registry a useful resource. We look forward to your comments, questions or suggestions, since your input will be critical for improving this platform and making it useful for the scientific community. All feedback can be sent to covid19registry@asmusa.org. We are all in this together.

Sincerely,

Stefano Bertuzzi
Chief Executive Officer, ASM

Stefano Bertuzzi, Ph.D., M.P.H.
Chief Executive Officer
American Society for Microbiology (ASM)
1752 N St., NW
Washington, DC 20036-2904
Phone + (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 02:08:26 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] ([redacted] (b) (6))
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Request: Proposal Summaries - POCs Due 4/15; Summaries Due 4/20
Attachments: 2020-04-14_Proposal POC Sign up v1.0[1].xlsx, IC Specific Proposals 4.15[1].pdf, ER Proposals 4.15[1].pdf, COVID-19 Initiative Management-revised[1][6].docx

Please take a look at this and handle. Thanks.

From: Schwetz, Tara (NIH/OD) [E] [redacted] (b) (6)>
Sent: Wednesday, April 15, 2020 8:59 PM
To: ICDDIR-L@list.nih.gov
Cc: List DEPDIR-L <DEPDIR-L@list.nih.gov>; NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>; Gladman, Jordan (NIH/OD) [E] <[redacted] (b) (6)>
Subject: Re: Request: Proposal Summaries - POCs Due 4/15; Summaries Due 4/20

All,

Please find attached the compiled sign-up sheet with IC POCs for the 12 themes, as well as updated packets to match the shifts that were brought to our attention (attachments #1-3).

As a reminder, please send the 2 page summaries for each theme (with combined budget), using the attached template (attachment #4), to Jordan Gladman by **April 20 at 12 pm.** Thanks to you and your staff for developing these!

Best,

Tara A. Schwetz, PhD
Acting Director, NINR
Associate Deputy Director, NIH
A: Building 1, Room 138
P: [redacted] (b) (6) | **M:** [redacted] (b) (6)

From: Tara Schwetz [redacted] (b) (6)>
Date: Tuesday, April 14, 2020 at 9:01 PM
To: "ICDDIR-L@list.nih.gov" <ICDDIR-L@list.nih.gov>
Cc: List DEPDIR-L <DEPDIR-L@list.nih.gov>, NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>
Subject: Request: Proposal Summaries - POCs Due 4/15; Summaries Due 4/20

Colleagues,

As discussed this afternoon, please find attached the POC sign-up sheet (tab 1; tabs 2-3 list the various proposals by category, theme, and IC), the IC-specific proposals, and the economic recovery proposals. We ask that you please complete the POC sign-up and send it to Jordan Gladman (jordan.gladman@nih.gov) by **5 pm on Wednesday April 15**. We will then collate and distribute the completed spreadsheet to the Chairs for each of the themes and post it on the ICD SharePoint site. The individual proposals are imbedded in the pdf as folders sorted by theme. If you feel your proposal would fit better with a different working group, please feel free to engage with them.

We ask that, once the POCs have been have been identified, you quickly assemble to begin refining and synergizing your proposals. Each Chair should coordinate with their group to develop a 2 page max summary of the theme's research, along with a single combined budget. The summary should integrate the IC proposals as much as possible; however, it is fine (for valid/justifiable reasons) to describe a few unique projects that fall under the theme as well. That is, if they don't make sense to integrate, you don't have to, but please be sure to include them in the summary. These summaries should be sent to Larry and me (cc Jordan Gladman) by **noon on April 20**. We will build off these summaries to generate a document for Francis' review, which we ultimately hope will be informative as we prepare for a potential fourth supplement.

The ask in short:

- **April 15 at 5 pm** – send your POCs to Jordan, who will then distribute the completed spreadsheet to the chairs
- **April 20 at 12 pm** – chairs to send a 2 page summary of their theme (with combined budget)

Best,

Tara A. Schwetz, PhD
Acting Director, NINR
Associate Deputy Director, NIH
A: Building 1, Room 138
P: (b) (6) | **M:** (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 01:58:31 +0000
To: Myles, Renate (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E];Wolinetz, Carrie (NIH/OD) [E];Burklow, John (NIH/OD) [E];Fine, Amanda (NIH/OD) [E];Lane, Cliff (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: FOR YOUR REVIEW: Draft ACTIV News Release
Attachments: OD_ACTIV_PPP_Release_4.15.2020 - with minor tracked edits.docx

Looks good. See my very minor tracked edits in attached document.
Thanks,
Tony

From: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>
Sent: Wednesday, April 15, 2020 9:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Collins, Francis (NIH/OD) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6) Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)>; Burklow, John (NIH/OD) [E] [redacted] (b) (6); Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FOR YOUR REVIEW: Draft ACTIV News Release

Hi Dr. Fauci:

Dr. Collins asked that I send the draft ACTIV release for you review.

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Office of Communications and Public Liaison
National Institutes of Health
Tel: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 22:26:51 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers [redacted] (b) (6);Billet, Courtney (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: AIRI Presents Dr. Fauci with 2020 Public Service Award
Attachments: Fauci 2020 AIRI Public Service Award Letter.pdf

Patty:
Please put together (or have Kim do so) a letter of thanks, honor, and appreciation...yada yada. So that they know I have received the letter and look forward to receiving it at an appropriate time.
Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Wednesday, April 15, 2020 4:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Subject: FW: AIRI Presents Dr. Fauci with 2020 Public Service Award

Congrats, Tony! Please try to take a minute to savor this. Or at least 15 seconds. ☺

Francis

From: Parker, Nicole <Nicole@lewis-burke.com>
Sent: Wednesday, April 15, 2020 4:10 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6); Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)>; Lauer, Michael (NIH/OD) [E] [redacted] (b) (6)>
Cc: O'Hare, Libby <libby@lewis-burke.com>
Subject: AIRI Presents Dr. Fauci with 2020 Public Service Award

Good Afternoon,

On the behalf of the Association of Independent Research Institutes (AIRI), I wanted to notify you that AIRI has awarded Dr. Tony Fauci with its 2020 Public Service Award in recognition of his exemplary leadership during the novel coronavirus pandemic. The AIRI Public Service Award is the highest honor awarded by our organization and we're very pleased to present this award to Dr. Fauci. A list of past awardees can be found here.

Please see the official award letter attached and let us know any questions.

Regards,

Nicole Parker, Ph.D.
AIRI Washington Office - Lewis-Burke Associates, LLC
440 1st Street NW Suite 700
Washington, DC 20001
202-289-7475
Nicole@lewis-burke.com
www.lewis-burke.com

Disclaimer: This message is intended only for the named recipient. If you are not the intended recipient you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 15:57:38 +0000
To: Awwad, David (NIH/NIAID) [C]
Subject: Threat assessment 4/14
Attachments: Total Fauck Up, Re: Finis Covid Opus, Re: Total Fauck Up, Untitled

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 10:45:28 +0000
To: Birx, Deborah L. EOP/NSC;Troye, Olivia EOP/NSC
Subject: RE: Does G6PD Deficiency Relate to COVID-19 Infection? | MedPage Today

The issue also comes up when people are on certain drugs.

From: Birx, Deborah L. EOP/NSC [redacted] (b) (6)>
Sent: Wednesday, April 15, 2020 6:16 AM
To: Troye, Olivia EOP/NSC <[redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)
Subject: Re: Does G6PD Deficiency Relate to COVID-19 Infection? | MedPage Today

This one always comes up when we have differential responses to an infection [redacted] (b)(5) PCP – in HIV there are genetic links to better outcomes.

From: "Troye, Nsc" <[redacted] (b) (6)
Date: Tuesday, April 14, 2020 at 11:03 PM
To: "Birx, Deborah L. EOP/NSC" [redacted] (b) (6)>, "Anthony Fauci [E]"
[redacted] (b) (6)>
Subject: Does G6PD Deficiency Relate to COVID-19 Infection? | MedPage Today

Follow up article to some previous emails. Just wanted to send this your way.

https://www.medpagetoday.com/infectiousdisease/covid19/85929

Olivia Troye
Special Advisor for Homeland Security and Counterterrorism
Office of the Vice President
White House Coronavirus Task Force
Office: [redacted] (b) (6)
Mobile: [redacted] (b) (6) (Does not receive texts)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 02:32:49 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: ASF - here that proposed op-ed for you and Dr. Birx penned by VP office
Attachments: Birx.Fauci Op-Ed clean - with Fauci tracked changes.docx

Greg:
Nice job. I have made a few edits that are tracked into the attached document. Please accept the changes and submit back to them.
Thanks,
Tony

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, April 13, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: ASF - here that proposed op-ed for you and Dr. Birx penned by VP office

ASF – [redacted] (b) (5). Please review if/when u have a chance.
Clean version and tracked version.

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 7:20 PM
To: Folkers, Greg (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: ASF / FW: proposed op-ed for you and Dr. Birx?

[redacted] (b) (5)

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, April 8, 2020 5:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: ASF / FW: proposed op-ed for you and Dr. Birx?

From: Billet, Courtney (NIH/NIAID) [E] <[redacted] (b) (6)>

[redacted] (b) (5)

From: Miller, Darin B. EOP/OVP [redacted] (b) (6)
Sent: Tuesday, April 7, 2020 3:07 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6); Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Courtney, Patricia - op-ed by Fauci/Birx?

Hi Courtney and Patricia,

[redacted] (b) (6), (b) (5)

Thanks!

Darin Miller
Deputy Press Secretary
Director of Strategic Communications
Office of the Vice President
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 01:44:02 +0000
To: Johnson, Carolyn
Cc: Collins, Francis (NIH/OD) [E] [redacted] (b) (6) Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Washington Post
Attachments: NIAID COVID-19 Strategic Plan Final 10April 2020.docx

Carolyn:

Thanks for the note. I understand that you will be hearing from Francis Collins on the Public Private Partnership (PPP) that we have put together to combine the resources and assets of industry and the academic community that is largely supported by NIH, particularly NIAID in the context of COBID-19. It is the functional equivalent of a National Strategy. We at NIAID and to some extent other institutes are leveraging our vast clinical trials networks that we built for other infectious diseases, particularly, but not exclusively HIV/AIDS, to provide the capacity to conduct clinical trials (NIH-sponsored as well as industry-sponsored) for both vaccines and therapeutics for COVID-19. For your interest, I am attaching a copy (not yet released) of the NIAID Strategic Plan for COVID-19 Research. It is an outline that will be supplemented with an implementation plan.

Best regards,
Tony

From: Johnson, Carolyn <Carolyn.Johnson@washpost.com>
Sent: Tuesday, April 14, 2020 10:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Washington Post

Dear Tony,

Is there a national strategy at the task force level to coordinate clinical research efforts nationally? We have heard lots of complaints that there isn't a national strategy. I talked to Cliff Lane about this, but we want to give you the chance to respond.

Carolyn

Carolyn Johnson
Washington Post
202-334-6248 (desk)
[redacted] (b) (6) (cell)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 01:35:53 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Call with VP and Senators on Thursday 4/15

I guess in person since I will have to be down there anyway

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 14, 2020 6:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Call with VP and Senators on Thursday 4/15

[redacted] (b) (5)

From: Edwards, Sara L. EOP/OVP < [redacted] (b) (6)>
Sent: Tuesday, April 14, 2020 4:43 PM
To: McGuffee, Tyler Ann A. EOP/OVP < [redacted] (b) (6); Good-Cohn, Meredith (CMS/OA) [redacted] (b) (6)>; Shirley.Gathers [redacted] (b) (6) [redacted] (b) (6); Amerau, Colin C LT USN JS J4 (USA) < [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Rom, Colin (FDA/OC) [redacted] (b) (6)>
Cc: Lankford, Hannah A. EOP/OVP < [redacted] (b) (6)>
Subject: Call with VP and Senators on Thursday 4/15

Good afternoon,

Vice President will be joining a call with Senate Democrats on Thursday April 16 at 1:00pm. The call will be routed through the [redacted] (b) (5) similar to last week's call. Please have your principal dial into the [redacted] (b) (5) at [redacted] (b) (5) at 5 minutes prior to the start. They will be patched into the Vice President and then together into the Senate calls.

1PM-2PM **Senate Democratic Caucus**
[redacted] (b) (5)

Please confirm your principal Thursday 4/16

Secretary Steven Mnuchin, Department of the Treasury ***–by phone***
Administrator Seema Verma, Center for Medicare and Medicaid Services (CMS) ***- by phone***
Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases ***– by phone***
Dr. Stephen Hahn, Commissioner of Food and Drugs, Food and Drug Administration ***– by phone***
Rear Admiral John Polowczyk, Vice Director for Logistics, J4 ***– by phone***
Ambassador Debbie Birx, M.D., White House Coronavirus Response Coordinator ***- in-person***

Thank you,

Sara Edwards
Office of the Vice President

From: [redacted] (b) (6)
Sent: Tue, 14 Apr 2020 13:55:46 -0400
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: Dr. Fauci - FROM NBC4
Attachments: image001.png, ATT00001.htm, manuscript final draft revised.pdf, ATT00002.htm

Please check this out and respond as appropriate.

Begin forwarded message:

> **From:** Melissa Mollet [redacted] (b) (6)>
> **Date:** April 14, 2020 at 10:22:13 AM EDT
> **To:** [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6), Melissa Mollet [redacted] (b) (6) "Mollet, Melissa (NBCUniversal, WRC)" <Melissa.Mollet@nbcuni.com>, Jeremy Schulman <jschulman@schulmanbh.com>
> **Subject: Dr. Fauci - FROM NBC4**
>
> Hello Dr. Fauci,
> This is Melissa Mollet, reporter with NBC4 in Washington. I hope you are well - and safe - and are hanging in there during this unprecedented time. You have been doing an incredible job.
> I know you're getting a million emails, so my apologies in advance. I really think this information (attached and below) could help and I feel a responsibility to pass it along.
> There is an extremely promising COVID-19 therapy being used right now in Italy. The creator is a client of [redacted] (b) (6) Bethesda law firm. The managing member of that firm, Jeremy Schulman, is CC'd on this e-mail. The creator is willing to work with the NIH to quickly bring his therapy to the U.S.
> Please reach out with any questions at all.
> Best -
> Melissa Mollet
> NBC Washington
> 4001 Nebraska Avenue NW
> Washington, D.C. 20016
> [redacted] (b) (6) (Cellular)
> Get Outlook for iOS
> **From:** Jake Schaller <jschaller@schulmanbh.com>
> **Sent:** Monday, April 13, 2020 5:36 PM

To: Mollet, Melissa (NBCUniversal, WRC)
Subject: [EXTERNAL] Therapy for COVID-19; Results of Trial in Italy

Melissa,

I wanted to expand a bit on the COVID-19 therapy I mentioned and provide some information about the man who is developing it. Hoping that you can get this into the right hands, as it seems like a very promising lead in this fight.

The therapy, invented by Professor Claudio De Simone, has shown extremely encouraging results in a preliminary trial at the Infectious Diseases Clinic of the University "La Sapienza" in Rome, Italy. Professor De Simone convinced the doctors there to start a trial on patients affected by COVID-19. Considering the excellent results obtained, the number of patients enrolled is increasing day after day. Our firm became aware of these results directly from Professor De Simone, who has been a client of our managing partner, Jeremy Schulman, since 2015.

The formulation employed in these patients at the La Sapienza Infectious Diseases Clinic is manufactured in France and known as "SIVOMIXX." The product is a specialized blend of eight different freeze-dried bacteria with considerable antiviral and anti-inflammatory activity. Patients admitted to the clinic at La Sapienza, presenting as positive for COVID-19 and with the typical symptoms of the disease, are being treated by oral bacteriotherapy utilizing SIVOMIXX. In each case, SIVOMIXX administration was followed by a dramatic improvement in their conditions. The key takeaways are that use of SIVOMIXX correlated with fewer deaths (zero in the treated group), fewer patients transferred to the ICU, and a dramatically reduced risk of patient intubations. The sponsors of the trial using SIVOMIXX are now beginning to enroll patients with severe cases who have been admitted to the ICU.

Attached to this email is a confidential dossier about the SIVOMIXX product and a summary of the ongoing study. Upon request, I am also able to send you an Excel file containing the raw data from the study, so NIH can review them, with the understanding that this should be treated as "highly confidential." Since the clinical trial is continuing in Italy, we expect to have results covering additional patients on a rolling basis. The researchers conducting the study intend to publish their results in the coming weeks. However, considering the pandemic and the lack of effective treatment options, we want to make NIH aware of Professor De Simone's therapy without any delay.

SIVOMIXX is a relatively new formulation developed by Professor De Simone, currently in limited commercial production at a manufacturing facility in France. Professor De Simone has sufficient supply available to utilize with 100-150 COVID-19 patients immediately. Professor De Simone could, on his own, arrange a small-scale supply to use with hundreds of additional patients in the United States. He is willing to provide his current inventory of the product to the United States government. He expects that the Trump administration could quickly confirm the efficacy of SIVOMIXX to significantly improve symptoms of COVID-19 and reduce the duration of patient hospital stays. After that, Professor De Simone is willing to collaborate with the administration to bring a large-scale production of SIVOMIXX for use throughout the United States, Italy (where he was born), and Switzerland (where he lives). Professor De Simone already has ongoing partnerships with a number of manufacturing companies, including one in the United States, for the production of another one of his products (Visbiome, referenced below). With appropriate guidance and instruction from the Trump administration, we believe the U.S. manufacturing companies could re-tool to produce SIVOMIXX on a large scale within several weeks.

Professor De Simone (more information about him below) and Jeremy will do whatever it takes to bring this critical therapy to as many Americans as possible on an urgent basis. Jeremy can be reached at anytime on his cell phone– (b) (6)

Thanks so much for passing this on.

Best,

Jake

About Professor De Simone. Professor De Simone is a world-renowned expert in gastroenterology and the inventor of several highly successful probiotic medical foods. Until 2010, he was an Associate Professor for the Infectious Diseases Group at the Department of Medicine and Surgery of the University of L'Aquila, Italy. Subsequently, he was appointed Head of the Infectious Disease Department and Director of the AIDS Coordination Group of the Abruzzi region, Italy. He is currently a retired Professor of Internal Medicine, still collaborating with the University, and a Fellow of the American Gastroenterology Association. Professor De Simone's research specialties have been in the fields of immuno-pathogenesis of infectious diseases. He has published the results of his research activities in over 200 scientific articles, reviews, case reports, and book chapters. Professor De Simone is both a researcher and a medical practitioner. He tests his laboratory hypotheses in the university hospital clinic on patients with serious diseases. He was responsible for controlling the AIDS pandemic in Italy's Abruzzi region in the 1990's.

Products developed according to Professor De Simone's know-how have shown positive results in patients with serious diseases. One of his signature formulations, known as the "De Simone Formulation," is now sold in the United States as "Visbiome." The De Simone Formulation has been the subject of more than 70 published human clinical trials demonstrating its efficacy in managing severe gastrointestinal symptoms from such diseases as ulcerative colitis, pouchitis, and liver diseases. Concerning pouchitis, the De Simone Formulation is recognized by the world's professional gastroenterology societies as a "standard of care," an achievement that no other probiotic substance previously has attained. The De Simone Formulation became the "gold standard" in its therapeutic class. Its role in patient care has been endorsed in the guidelines published by the American Gastroenterology Association ("AGA"), the European Crohn's and Colitis Organization ("ECCO"), and the British Society of Gastroenterology, as well as in the New England Journal of Medicine.

—

SCHULMAN [illegible]

James "Jake" Schaller
Attorney

jschaller@schulmanbh.com

www.SchulmanBH.com

Direct: (240) 356-9508
Cell: (b) (6)

Main Office:

The Clark Building
7500 Old Georgetown Road, Suite 901
Bethesda, Maryland 20814
Receptionist: (240) 356-8550
Fax: (240) 356-8558

Bio-Tech Corridor Office:

The GSK Building
14200 Shady Grove Road, Suite 600
Rockville, Maryland 20850

The information contained in this electronic message and any attached documents may be privileged, confidential, and protected from disclosure. If you are not the intended recipient, please note that any review, disclosure, copying, distribution, or use of the contents of this electronic message or any attached documents is prohibited. If you have received this communication in error, please destroy it and notify us immediately by telephone (240-356-8550) or by electronic mail to the sender of this email. Thank you.

Internal Revenue Service Circular 230 Disclosure: Schulman Bhattacharya, LLC does not provide tax advice. In compliance with IRS requirements, you are on notice that any advice contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party, for tax purposes, any transaction or matter addressed herein.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 14 Apr 2020 16:15:32 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Mike Milken new Podcast Series: COVID-19 - will you join me as my guest? All the best, Mike

What do you think? Let us discuss.

From: Michael Milken (mmilken@knowledgeu.com) <mmilken@knowledgeu.com>
Sent: Tuesday, April 14, 2020 5:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Billie Griffin (bgriffin@knowledgeu.com) <bgriffin@knowledgeu.com>; Katie Dinsmore (kdinsmore@knowledgeu.com) <kdinsmore@knowledgeu.com>
Subject: Mike Milken new Podcast Series: COVID-19 - will you join me as my guest? All the best, Mike

Dear Tony, I hope this email finds you well. I wanted to see if you had a few minutes to talk over the next few weeks. I recently began hosting a daily podcast that focuses on the COVID-19 pandemic and responses from thought leaders across industries – I would like for you to join me as my guest. I have also reached out to Hugh Auchincloss as well but still waiting to hear.

Our guests so far include Francis Collins, Alex Gorsky, David Baltimore*(Nobel Laureate)*, Jim Allison*(Nobel Laureate)/*Pam Sharma, Jo Ann Jenkins, Eric Schmidt, Rod Hochman, Carmine Di Sibio, Arie Belldegrun, Peggy Hamburg, Rodney McMullen, Bruce Broussard, Vas Narasimhan , Joe Tsai, Steve Ballmer, Jeff Skoll, Sue Desmond-Hellmann, Rob Manfred, Judy Faulkner, Bob Bradway, Tal Zaks, Ray Dalio, David Solomon, Barbara Humpton, Dr. Steven Rosenberg, Dr. Richard Stone, Dr. Kurt Newman, Vivek Ramaswamy, Francis deSouza

I record the interviews on Mondays, Wednesdays-Fridays starting at 7:30 a.m. Pacific/10:30 a.m. Eastern. Each episode will last 10-20 minutes. Our team would get you set-up to join remotely by phone.

The interviews are available on the Milken Institute website as well as on Spotify and Apple Podcasts. . I opened up the series with Francis Collins a few weeks ago , click here to have a listen.

If you're interested in joining me, my team (copied) will circle back to you with another email detailing the subject matter and technical information.

Please stay safe & healthy.

All the best,
Mike

From: [redacted] (b) (6)
Sent: Tue, 14 Apr 2020 10:32:21 -0400
To: Tengiz Tsertsvadze
Subject: Re: US-Georgia biomedical collaboration

Tengiz:
Thank you for your kind note. I am pleased to see that Georgia has controlled the outbreak very well. Stay well.
Best regards,
Tony

> On Apr 14, 2020, at 10:24 AM, Tengiz Tsertsvadze [redacted] (b) (6)>wrote:
>
> Dear Dr. Fauci,
>
> I am writing this letter on behalf of the community of infectious diseases specialists of Georgia to express our deepest respect to you. I recall with great pleasure all our previous meetings, especially the last one in 2017, when I, together with my team members, had an opportunity to visit you at NIH.
>
> We are grateful to you and your team for the most important contribution to establishing US-Georgia biomedical collaboration that significantly increased our country's research and practical capacities. Your personal role in combating HIV and other emerging epidemics such as SARS, MERS, Zika, Ebola, cannot be overestimated. I am confident that your leading role in this fight against COVID-19 will be crucial for defeating the pandemic not only in the United States, but around the globe.
>
> We closely follow your briefings and interviews on COVID-19 (including recent very interesting conversation with Dr. Howard Bauchner at JAMA) and as always your views are very apt and to the point. We fully agree that the approaches you suggest are the most effective way to defeat the pandemic. Most importantly your recommendations are applicable not only to the United States, but to other countries as well and we eagerly take them into consideration while planning our strategies here in my country of Georgia.
>
> I would like to use this opportunity to update you on COVID-19 situation in my home country of Georgia: The country quickly responded to this threat first by stopping flights with China in January, followed by more strict measures after the first case was diagnosed on February 26. These measures included national lockdown, active contact tracing, isolation and quarantine. The Government of Georgia appointed me to lead the National Committee on the clinical management

of COVID-19. Our effort to contain the spread of the virus had been effective so far with 296 cases of COVID-19 and 3 lethal cases reported up to now.

We are impatiently awaiting results of vaccine and therapeutic trials supported by NIAID, which I am confident will help to defeat this pandemic disease. On our side, Georgia is committed to make its modest but important contribution to the global efforts.

Sincerely,

Tengiz Tsertsvadze, MD, PhD
Director General, Infectious Diseases, AIDS and Clinical Immunology Research Center
Professor of Medicine, Ivane Javakhishvili Tbilisi State University

<photo.jpg>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 14 Apr 2020 03:29:04 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Covid-19 logical treatment strategy based on patient's immunological response
Attachments: MEDRXIV-2020-058420v1-Gali Filho.pdf

From: Julio Gali [redacted] (b) (6)
Sent: Monday, April 13, 2020 12:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Covid-19 logical treatment strategy based on patient's immunological response

Good afternoon Dr. Anthony Fauci.

After reading a lot of papers and studying basic science we have elaborated a treatment approach to the disease.

[redacted] (b) (4)

[redacted] (b) (4)

Julio C. Gali Filho, MD

Research and Development, JJMED, Sorocaba, SP, Brazil

[redacted] (b) (6)

[redacted] (b) (6)

Julio C. Gali, MD, PhD

Department of Orthopaedics

Faculty of Medical Science and Health

Catholic University of Sao Paulo

Sorocaba/SP – Brazil

[redacted] (b) (6)

[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 14 Apr 2020 02:13:45 +0000
To: Hiatt, Fred
Subject: RE: fred checking in

Fred:
Thank you for you kind note. Am glad to hear that Joe is working on COVID-19. We need all the brightest minds we can get on this problem. Stay safe and well.
Best regards
Tony

From: Hiatt, Fred <fred.hiatt@washpost.com>
Sent: Monday, April 13, 2020 2:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: fred checking in

Tony,
I haven't wanted to bother you, but wanted to say thanks for all you are doing, and hope you are at least to a small extent finding a way to take care of yourself.
(b) (6) is hard at work at (b) (6) on a couple of coronavirus projects, so we're counting on him.
Of course any time you want to write something, our page is available.
Warmly,
Fred

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 14 Apr 2020 02:03:49 +0000
To: Glass, Roger (NIH/FIC) [E]
Cc: Kilmarx, Peter (NIH/FIC) [E];Redfield, Robert R. (CDC/OD);Birx, Deborah L. EOP/NSC
Subject: RE: Support for a "U.S. COVID-19 Response Corps"

Great idea!!

From: Glass, Roger (NIH/FIC) [E] [redacted] (b) (6)>
Sent: Monday, April 13, 2020 12:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Glass, Roger (NIH/FIC) [E] [redacted] (b) (6)>; Kilmarx, Peter (NIH/FIC) [E] [redacted] (b) (6)>
Subject: Support for a "U.S. COVID-19 Response Corps"

Hi Tony,

Greetings from [redacted] (b) (6)

It's been good to see all the calls for ramping up a public health workforce to manage contact tracing and other aspects of the second phase of the response. I wanted to let you know that Peter Kilmarx has been calling for the formation of a "U.S. COVID-19 Response Corps" since March 21 (unrelated to NIH work). FEMA could hire thousands of temporary workers quickly with existing authorities and funding. CDC could provide training and technical assistance. The workforce would be deployed to and managed by state and local health departments at their request. There's a lot of enthusiasm for this from Jeff Duchin in Seattle, to Tom Frieden, CSIS, ASTHO, and 40 members of Congress (bicameral, bipartisan) who sent a letter to FEMA asking them to do this. The 7,000+ recently evacuated Peace Corps volunteers could be one recruiting source. Another approach is for CDC to fund state and local authorities for those who are able to hire at this speed and scale. There's more information in the string below.

This workforce issue is now such a critical part of the response, I wanted to share with you what we've learned and offer to help in any way.

Tony, all of NIH is so proud of your leadership and rooting for you to get this outbreak under control. Please keep up fight and let us know if and how we can help.

Warm wishes,
Roger

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Monday, April 13, 2020 8:45 AM
To: 'Conover, Craig' [redacted] (b) (6) 'Angela Dunn' [redacted] (b) (6) 'Cindy Burnett' [redacted] (b) (6)>; 'Duchin, Jeff' [redacted] (b) (6)>; 'Stephen Morrison'

[redacted] (b) (6)>; 'John Monahan' [redacted] (b) (6)>; 'Charles Holmes'
[redacted] (b) (6)>; 'Jeremy Konyndyk [redacted] (b) (6)'
[redacted] (b) (6)>; 'Rebecca Katz' [redacted] (b) (6); 'Tom Inglesby'
[redacted] (b) (6)>; 'Glenn Blumhorst' [redacted] (b) (6)>; Glass, Roger (NIH/FIC) [E]
[redacted] (b) (6)>; 'Marcus Plescia' [redacted] (b) (6)>; 'Vanessa Kerry'
[redacted] (b) (6)g>; 'Kenyon, Thomas' < [redacted] (b) (6)>; 'Anna Carroll'
[redacted] (b) (6)>; 'Scott Dowell' [redacted] (b) (6)>; 'Jonathan Pearson'
[redacted] (b) (6); 'suzannemarks@me.com' < [redacted] (b) (6)>; 'O'Connor,
Eileen' [redacted] (b) (6)>; 'Myers, Michael' [redacted] (b) (6)>; 'Robynn Leidig'
[redacted] (b) (6)>; 'Ariel Pablos' [redacted] (b) (6); 'Gavin Yamey'
[redacted] (b) (6)>; 'Jody Olsen' [redacted] (b) (6)>; Bialy, Kevin (NIH/FIC) [E]
[redacted] (b) (6)>; 'John Auerbach' < [redacted] (b) (6)>; Brooks, John T.
(CDC/DDID/NCHHSTP/DHPSE) [redacted] (b) (6)>; 'Dara Lieberman' [redacted] (b) (6)>; David
Gittelman [redacted] (b) (6)>
Subject: RE: COVID-19 Response Corps

Hi all,

Updates:

1. Johns Hopkins and ASTHO released "A National Plan to Enable Comprehensive COVID-19 Case Finding and Contact Tracing in the U.S." calling for 100,000 contact tracers. (Kudos!) "Potential workforce recruits may include . . . Peace Corps members." http://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/a-national-plan-to-enable-comprehensive-COVID-19-case-finding-and-contact-tracing-in-the-US.pdf
2. WaPo article: "A plan to defeat coronavirus finally emerges, but it's not from the White House" covers the JHU/ASTHO plan and notes: "Experts [CSIS] have proposed transforming the Peace Corps into a national response corps that could perform many tasks, including contact tracing." [Not quite accurate. Peace Corps would be unchanged, but the evacuated volunteers would be hired into COVID-19 response.]
3. NY Times editorial from Tom Frieden calls for a "giant public health effort." "Recruits could include Peace Corps volunteers who were brought home when the pandemic spread." https://www.nytimes.com/2020/04/12/opinion/cdc-coronavirus.html
4. Bill introduced by Sens. Susan Collins (R-ME), Chris Murphy (D-CT) and Dianne Feinstein (D-CA) would require federal agencies and departments facing special hiring needs during the pandemic to establish a process to expedite hiring of returned Peace Corps volunteers https://riponadvance.com/stories/collins-bipartisan-bill-would-ensure-benefits-for-evacuated-peace-corps-volunteers/
5. From March 29: Policy report from former FDA Commissioners Scott Gottlieb and Mark McClellan calls for "massively" scaling contact tracing. "Surge the existing public-health workforce to conduct case finding and contact tracing." https://www.aei.org/research-products/report/national-coronavirus-response-a-road-map-to-reopening/
6. Mark McClellan responded to my email yesterday: "I'd suggest adding outreach to mayors and county execs if that hasn't happened yet. They are really on the front lines for this next phase."
7. I understand legislation is in the works, but don't have details.
8. No news from FEMA or indication to my knowledge that they are planning a substantial ramping up of staffing.
9. A key limitation on the impact of contact tracing will be the relative importance of asymptomatic spread.

10. A note on serology: The current U.S. cumulative incidence is 0.169%. The specificity of FDA EUA Cellex test is 95.6%. Not accounting for undiagnosed cases, Positive Predictive Value is only 3.5%. If underdiagnosis is 10:1, the PPV is still only 26.8%. Will be higher in higher-risk individuals, of course.

Any other updates please send to me.

Advocacy needed for scaling up public health workforce especially with governors and mayors.

PK

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Friday, April 10, 2020 1:53 PM
To: 'Conover, Craig' [redacted] (b) (6)>; 'Angela Dunn' [redacted] (b) (6); 'Cindy Burnett' [redacted] (b) (6)>; 'Duchin, Jeff' < [redacted] (b) (6)>; 'Stephen Morrison' [redacted] (b) (6)>; 'John Monahan' [redacted] (b) (6)>; 'Charles Holmes' [redacted] (b) (6); 'Jeremy Konyndyk [redacted] (b) (6))' [redacted] (b) (6)>; 'Rebecca Katz' [redacted] (b) (6); 'Tom Inglesby' [redacted] (b) (6)>; 'Glenn Blumhorst' [redacted] (b) (6)>; Glass, Roger (NIH/FIC) [E] [redacted] (b) (6); 'Marcus Plescia' [redacted] (b) (6)>; 'Vanessa Kerry' [redacted] (b) (6)>; 'Kenyon, Thomas' [redacted] (b) (6); 'Anna Carroll' [redacted] (b) (6)>; 'Scott Dowell' [redacted] (b) (6); 'Jonathan Pearson' [redacted] (b) (6)>; 'suzannemarks@me.com' < [redacted] (b) (6)>; 'O'Connor, [redacted] (b) (6)>; 'Myers, Michael' [redacted] (b) (6)>; 'Robynn Leidig' [redacted] (b) (6)>; 'Ariel Pablos' [redacted] (b) (6); 'Gavin Yamey' [redacted] (b) (6)>; 'Jody Olsen' [redacted] (b) (6)>; Bialy, Kevin (NIH/FIC) [E] [redacted] (b) (6); 'John Auerbach' [redacted] (b) (6); Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) [redacted] (b) (6); 'Dara Lieberman' [redacted] (b) (6)>
Subject: RE: COVID-19 Response Corps

+ John Auerbach, president and CEO of Trust for America's Health

Thanks all for the robust discussion. Some updates:

1. ASTHO sent the attached memo to Congress today *RE: Contact Tracing Workforce* calling for "flexible long term and emergency supplemental funding to expand the . . . contact tracing workforce" at state, local, and related levels. It recommends against using FEMA for hiring. ASTHO notes that currently there are only 2,200 DIS nationwide while JHU estimates that 100,000 contact tracing employees are needed to address COVID-19 in the immediate future. The memo mainly calls for 1) $3.6 B *emergency* funding through the CDC Crisis Cooperative Agreement to eligible jurisdictions, plus 2) a $4.5 B *annual* Public Health Infrastructure Fund.
2. Resolve to Save Lives (Tom Frieden) is advocating for CDC to have the needed authority and political support to provide training, systems, and technical expertise, while the CDC Foundation and ASTHO provide staffing through direct assistance to health departments.
3. CDC could support curriculum development and training through the National Network of STD Clinical Prevention Training Centers https://nnptc.org/ and/or TB Centers of Excellence https://www.cdc.gov/tb/education/tb_coe/default.htm

My take: We share the goal of rapidly and substantially ramping up the public health workforce and should emphasize that message. It would be very challenging for any of these potential approaches to reach 100,000 in the short term. I don't have any special allegiance to FEMA, but their traditional role in emergency response is quickly hiring many thousands of workers. They are hiring now, but not at this speed and scale. CDC and FEMA should have an MOU through which FEMA can hire staff and detail to CDC , but they don't seem to be pursuing. One model could be FEMA detailing staff to state and local authorities to manage the hiring process. FEMA is proud of their ability to get people from "door to desk" in one week. This would not be "federalizing" contact tracing or other public health activities. In all cases, the invitations and the oversight would come from the state and local authorities, who are best able to decide what mechanism(s) work for them. Lastly, this concept includes more than contact tracing. Congresswoman Susan Brooks (R-IN) in her podcast Wednesday noted that the state 211 call line has gone from 2,000 to 25,000-35,000 calls per day. So this concept would still have a role even if not direct public health functions.

Thanks,
PK

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Friday, April 10, 2020 8:05 AM
To: Conover, Craig < [redacted] (b) (6)>; Angela Dunn < [redacted] (b) (6); Cindy Burnett [redacted] (b) (6)>; Duchin, Jeff < [redacted] (b) (6)>; Stephen Morrison [redacted] (b) (6)>; John Monahan [redacted] (b) (6)>; Charles Holmes [redacted] (b) (6)>; Jeremy Konyndyk ([redacted] (b) (6)) [redacted] (b) (6); Rebecca Katz [redacted] (b) (6)>; Tom Inglesby [redacted] (b) (6)>; Glenn Blumhorst [redacted] (b) (6)>; Glass, Roger (NIH/FIC) [E] [redacted] (b) (6)>; Marcus Plescia < [redacted] (b) (6)>; Vanessa Kerry [redacted] (b) (6)>; Kenyon, Thomas [redacted] (b) (6); Anna Carroll [redacted] (b) (6)>; Scott Dowell [redacted] (b) (6)>; Jonathan Pearson [redacted] (b) (6); [redacted] (b) (6); O'Connor, Eileen [redacted] (b) (6)>; Myers, Michael < [redacted] (b) (6)>; Robynn Leidig [redacted] (b) (6)>; Ariel Pablos [redacted] (b) (6)>; Gavin Yamey [redacted] (b) (6)>; Jody Olsen [redacted] (b) (6)>; Bialy, Kevin (NIH/FIC) [E] [redacted] (b) (6)>
Subject: COVID-19 Response Corps - CDC calling for public health army

Thanks Craig. This NEJM article is mainly about heath care workers, but does mention other roles in social support.

Important development: CDC's Bob Redfield is calling for a public health army for contact tracing after this acute phase:
https://www.npr.org/sections/health-shots/2020/04/10/831200054/cdc-director-very-aggressive-contact-tracing-needed-for-u-s-to-return-to-normal
It turns out that the Centers for Disease Control and Prevention has been working on a plan to allow the U.S. to safely begin to scale back those policies. CDC Director Robert Redfield spoke with NPR on Thursday, saying that the plan relies on not only ramped-up testing but "very aggressive" contact tracing of those who do test positive for the coronavirus, and ***a major scale-up of personnel to do the necessary work.***

I'm not sure CDC has the authority, capacity, or political support to hire an army at this time. This is a traditional FEMA role. CDC can provide training and technical assistance.

PK

From: Conover, Craig (b) (6)
Sent: Friday, April 10, 2020 7:27 AM
To: Kilmarx, Peter (NIH/FIC) [E] (b) (6)>; Angela Dunn (b) (6)>; Cindy Burnett (b) (6)>; Duchin, Jeff (b) (6)>; Stephen Morrison <(b) (6)>; John Monahan <J (b) (6); Charles Holmes (b) (6); Jeremy Konyndyk (b) (6)) <(b) (6); Rebecca Katz (b) (6)>; Tom Inglesby (b) (6); Glenn Blumhorst (b) (6)>; Glass, Roger (NIH/FIC) [E] (b) (6); Marcus Plescia (b) (6)>; Vanessa Kerry (b) (6)>; Kenyon, Thomas (b) (6)>; Anna Carroll (b) (6); Scott Dowell <(b) (6)>; Jonathan Pearson (b) (6) O'Connor, Eileen (b) (6)>; Myers, Michael (b) (6)>; Robynn Leidig (b) (6)>; Ariel Pablos (b) (6)>; Gavin Yamey (b) (6)
Subject: NEJM- ensuring and sustaining a pandemic workforce

attached

From: Kilmarx, Peter (NIH/FIC) [E] (b) (6)>
Sent: Wednesday, April 8, 2020 5:53 PM
To: Conover, Craig (b) (6)>; Angela Dunn (b) (6); Cindy Burnett (b) (6)>; Duchin, Jeff (b) (6)>; Stephen Morrison (b) (6)>; John Monahan (b) (6)>; Charles Holmes (b) (6) >; Jeremy Konyndyk (b) (6)) (b) (6)>; Rebecca Katz (b) (6)>; Tom Inglesby (b) (6)>; Glenn Blumhorst (b) (6)>; Glass, Roger (NIH/FIC) [E] (b) (6)>; Marcus Plescia (b) (6)>; Vanessa Kerry (b) (6)>; Kenyon, Thomas (b) (6)>; Anna Carroll (b) (6)>; Scott Dowell <(b) (6)>; Jonathan Pearson (b) (6) O'Connor, Eileen (b) (6); Myers, Michael (b) (6)>; Robynn Leidig (b) (6)>; Ariel Pablos (b) (6)>; Gavin Yamey (b) (6)>
Subject: [External] RE: UPDATE: COVID-19 Response Corps

Welcome Marcus Plescia, chief medical officer of ASTHO!

Updates:

1. CSIS podcast "Coronavirus Crisis Update" with Congresswoman Susan Brooks (R-IN). She cosigned the CSIS OpEd with Ami Bera on the CRC and opens the episode with a discussion of engaging the returned Peace Corps volunteers https://www.csis.org/podcasts/take-directed/coronavirus-crisis-update-hunker-down-hoosiers-congresswoman-susan-brooks (This is a great series by the way.)
2. On Mar 27, 2020, Congressman Mike Quigley (D-IL-05) introduced the Mobilizing America to Help Act, "which would direct President Trump to invoke his existing authority to detail Peace Corps volunteers who have returned to the US from their posts, to the Federal Emergency Management Agency (FEMA) to support emergency relief in the wake of COVID-19." https://quigley.house.gov/media-center/press-releases/quigley-urges-trump-assign-peace-corps-volunteers-covid-19-emergency
3. Baltimore Sun column DAN RODRICKS, APR 03, 2020, "Put Peace Corps volunteers to work on U.S. soil to fight COVID-19": https://www.baltimoresun.com/opinion/columnists/dan-rodricks/bs-md-rodricks-0405-20200403-viqbgjhwsnhe3fuqzy72nfcsoe-story.html
4. Good conversations with Marcus @ASTHO and others today. Important to emphasize that state and local authorities have the lead. This would not be "federalizing" the response. It would be making federal employees available by request to integrate in state- and local-led activities. Some will welcome the extra hands. Some will prefer to have funding to do their own hiring. Paying salaries of state employees at risk for furlough to work on COVID-19 will make a lot of sense, but won't be enough. Need a menu of options.
5. Many concepts and plans for public health and social response are being circulated. All of them will need an expanded workforce.

Outreach:

6. I'm in touch with someone in Adam Boehler's office. Other outreach welcome.
7. I emailed Peggy Hamburg. No reply yet. Other outreach welcome.
8. Anyone who can contact Scott Gottlieb?
9. Here again is Monday's list: NGA and individual governors. Republicans who will be most interested and helpful are Baker (MA), DeWine (OH) and Hogan (MD). Democrats: Cuomo, Pritzker, Newsom, Whitmer, Inslee. AMA, ASTHO (done), APHA all good potential champions

Please amplify these links on social media.

Other updates and suggestions welcome as always. Send to me and I can send to others in a digest to reduce email traffic.

Thanks,
PK

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Tuesday, April 7, 2020 8:19 AM
To: 'Conover, Craig' <[redacted] (b) (6)>; 'Angela Dunn' [redacted] (b) (6) 'Cindy Burnett' [redacted] (b) (6)>; 'Duchin, Jeff' <[redacted] (b) (6)>; Stephen Morrison [redacted] (b) (6)>; 'John Monahan' [redacted] (b) (6)>; 'Charles Holmes' [redacted] (b) (6)>; 'Jeremy Konyndyk [redacted] (b) (6)' [redacted] (b) (6)>; 'Rebecca Katz' [redacted] (b) (6); 'Tom Inglesby' <[redacted] (b) (6)>; 'Glenn Blumhorst' [redacted] (b) (6)>; Glass, Roger (NIH/FIC) [E]

< [redacted] (b) (6)>; 'Vanessa Kerry' [redacted] (b) (6); 'Kenyon, Thomas'
[redacted] (b) (6); 'Anna Carroll' < [redacted] (b) (6)>; 'Scott Dowell'
[redacted] (b) (6)>; 'Jonathan Pearson' [redacted] (b) (6)>;
[redacted] (b) (6) [redacted] (b) (6); 'O'Connor, Eileen' [redacted] (b) (6)
'Myers, Michael' [redacted] (b) (6)>; 'Robynn Leidig' [redacted] (b) (6)>; 'Ariel
Pablos' [redacted] (b) (6)>; 'Gavin Yamey' < [redacted] (b) (6)>
Subject: UPDATE: COVID-19 Response Corps - FEMA challenges

Here's a report about a challenge I didn't see until this morning. I don't know if grants to state and local authorities would be quicker than federal hiring by FEMA. Either way, the workforce is needed, but will take longer than one would like.

https://www.nytimes.com/2020/04/03/climate/fema-staff-shortage-coronavirus.html
FEMA, Racing to Provide Virus Relief, Is Running Short on Front-Line Staff

WASHINGTON — The Federal Emergency Management Agency, the office leading the federal government's coronavirus response nationwide, is running short of employees who are trained in some of its most important front-line jobs, according to interviews with current and former officials.

At the same time, the agency has been forced to halt a major hiring initiative, and has closed training facilities to avoid spreading the infection.

The number of available personnel who are qualified to lead field operations has fallen to 19 from 44 in less than six weeks, and staff members have been pulled from responding to other disasters, but training centers in Maryland and Alabama have been shuttered until mid-May. In addition, an effort to recruit new employees called "Harness" is on hold, according to a senior administration official with direct knowledge of FEMA's operations . . . .

Craig Fugate, who ran the agency during the Obama administration, said FEMA's ability to deploy enough people was a significant challenge. "Can it be done? Yeah," Mr. Fugate said. "Will it be pretty? No."

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Monday, April 6, 2020 5:22 PM
To: Conover, Craig < [redacted] (b) (6)>; Angela Dunn [redacted] (b) (6)>; Cindy Burnett
[redacted] (b) (6); Duchin, Jeff [redacted] (b) (6); Stephen Morrison
[redacted] (b) (6)>; John Monahan < [redacted] (b) (6); Charles Holmes
< [redacted] (b) (6)>; Jeremy Konyndyk [redacted] (b) (6)
[redacted] (b) (6)>; Rebecca Katz [redacted] (b) (6) Tom Inglesby
[redacted] (b) (6)>; Glenn Blumhorst [redacted] (b) (6); Glass, Roger (NIH/FIC) [E]
[redacted] (b) (6); Vanessa Kerry < [redacted] (b) (6)>; Kenyon, Thomas
[redacted] (b) (6)>; Anna Carroll [redacted] (b) (6)>; Scott Dowell
< [redacted] (b) (6)>; Jonathan Pearson < [redacted] (b) (6)
[redacted] (b) (6) O'Connor, Eileen [redacted] (b) (6)>; Myers, Michael
[redacted] (b) (6)>; Robynn Leidig [redacted] (b) (6) Ariel Pablos
[redacted] (b) (6)>; Gavin Yamey [redacted] (b) (6)
Subject: NEWS: Bera-Brooks OpEd published in support of COVID-19 Response Corps

Welcome Vanessa Kerry!
Welcome Ariel Pablos-Méndez!
Welcome Gavin Yamey!

Hi all,

1. The OpEd is out on the CSIS website: https://www.csis.org/analysis/covid-19-response-corps-can-help-stop-pandemic It is co-authored by Congresswoman Susan Brooks (R-IN) and Congressman Ami Bera (D-CA), members of the CSIS Commission on Strengthening America's Health Security. Thanks very much to Steve Morrison for making this happen.
2. Here's the link to the press release on the 40-member letter to FEMA, Peace Corps, and CNCS from Senator Van Hollen:
    a. https://www.vanhollen.senate.gov/news/press-releases/sen-van-hollen-rep-phillips-lead-bipartisan-bicameral-letters-in-support-of-peace-corps-americorps-volunteers
    b. Includes link to letter: vanhollen.senate.gov/imo/media/doc/Peace%20Corps%20covid19%20service%20opportunties%20letter%2004.02.20.pdf

With this new, bipartisan OpEd, it's time to reach out to national, state and local authorities and opinion leaders to encourage implementation and create demand. Suggestions from one of us: NGA and individual governors. Republicans who will be most interested and helpful are Baker (MA), DeWine (OH) and Hogan (MD). Democrats: Cuomo, Pritzker, Newsom, Whitmer, Inslee. AMA, ASTHO, APHA all good potential champions.

Please also amplify on social media.

Updates and suggestions welcome as always.

PK

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Sunday, April 5, 2020 8:45 AM
To: Conover, Craig (b) (6); Angela Dunn (b) (6); Cindy Burnett (b) (6); Duchin, Jeff <(b) (6)>; Stephen Morrison (b) (6); John Monahan (b) (6)>; Charles Holmes (b) (6)>; Jeremy Konyndyk ((b) (6)) (b) (6)>; Rebecca Katz (b) (6)>; Tom Inglesby (b) (6)>; Glenn Blumhorst <(b) (6)>; Glass, Roger (NIH/FIC) [E] (b) (6); Kenyon, Thomas (b) (6) Anna Carroll (b) (6)>; Scott Dowell <(b) (6)>; Jonathan Pearson (b) (6); O'Connor, Eileen (b) (6)>; Myers, Michael (b) (6); Robynn Leidig (b) (6)>
Subject: UPDATES: Next steps on COVID-19 Response Corps

Thanks all for our call Friday. (Glenn, Jonathan, Craig, Jeremy, Roger, Anna, Suzanne, Eileen, Michael.)

A few items from the call:

- Jonathan reported Sen Markey's office working on legislation for 10,000+ (?) response workforce
- Michael reported positive response from National Governors Association
- Eileen reaching out to Tom Bossert. Adam Boehler not yet. Shared OpEd in WSJ emphasizing testing - https://www.wsj.com/articles/testing-is-our-way-out-11585869705
- Jeremy has an OpEd in Daily Beast with Beth Cameron – https://www.thedailybeast.com/coronavirus-shows-we-need-an-apollo-project-for-public-health
- Craig in touch with Durbin's office. IL has ongoing need for large workforce. Much easier to get staff from feds. Slower to hire at state level. MA implementing 1,000-person contact tracing effort.
- John in touch with Pelosi's office, DeLauro, Conf of Mayors, League of Cities.
- Other potential champions – ASTHO, APHA, Josh Scharfstein @JHSPH
- General agreement that for bipartisan emergency approval should emphasize near-term (e.g., 2 year) imperatives of COVID-19 and economic emergencies, not a new permanent work force.
- General agreement that Peace Corps is the low-hanging fruit, but not all 7,000 RPCVs would do this and the need is much greater.
- CSIS OpEd with Ami Bera (D-CA) and Susan Brooks (R-IN) coming out in Politico or CSIS website by Monday

Other updates:

- Telcon Friday with Brooks staffer. They are putting together legislation, ideally bipartisan with Bera. Now fully briefed on CRC concept and potential implementation model. Clarified not duplicative of USPHS Ready Reserve Corps which is now authorized but not being implemented (to my knowledge) and would be different profile, i.e., USPHS has physicians, nurses, engineers, etc.
- Telcon Saturday with CDC COVID-19 Chief Medical Officer. Confirms many are thinking about the workforce issue. Notes that CDC unlikely to "own," but great suggestion to engage CDC-funded National Network of STD Clinical Prevention Training Centers for training. https://nnptc.org/ with eight centers around the country. CRC concept may be brought to national response discussions with FEMA in Washington DC.
- FEMA contacts report they are hiring RPCVs, but do not report major speed up or scale up. FEMA recruiting email attached.
- Charles shared Vanessa Kerry OpEd emphasizing same themes: response workforce and jobs: https://www.bostonherald.com/2020/04/01/massachusetts-general-hospital-infectious-disease-team-calls-on-state-to-harness-people-power/

Next steps:

- Executive – support/impetus to FEMA to increase speed and scale
- Legislation – new appropriations for FEMA or CDC if needed
- National advocacy – media, opinion leaders
- Demand signal – state and local authorities requests
- Implementation and management details working out

Overall goal: Greatly increase COVID-19 response workforce to control disease and provide jobs. A COVID-19 Response Corps would be a (big) part of solution. RPCV ideal first cadre for CRC.

Please share any corrections, updates, suggestions.

Thanks,
PK

-----Original Appointment-----
From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Thursday, April 2, 2020 5:34 PM
To: Conover, Craig; Angela Dunn; Cindy Burnett; Duchin, Jeff; Stephen Morrison; John Monahan; Charles Holmes; Jeremy Konyndyk [redacted] (b) (6); Rebecca Katz; Tom Inglesby; Glenn Blumhorst; Glass, Roger (NIH/FIC) [E]; Kenyon, Thomas; Anna Carroll; Scott Dowell; Jonathan Pearson; [redacted] (b) (6); O'Connor, Eileen; Myers, Michael; Robynn Leidig
Subject: *** Time correction - 8 am*** Next steps on COVID-19 Response Corps
When: Friday, April 3, 2020 8:00 AM-9:00 AM (UTC-05:00) Eastern Time (US & Canada).
Where: Zoom meeting

Peter Kilmarx (Fic Zoom2) is inviting you to a scheduled Zoom meeting. Zoom link below.

Agenda:

1. Welcome and introductions
2. Current status of advocacy
3. Implementation issues
4. Next steps:
    a. Advocacy
    b. Implementation
5. AOB

Topic: Next steps on COVID-19 Response Corps
Time: Apr 3, 2020 08:00 AM Eastern Time (US and Canada)

Join Zoom Meeting
[redacted] (b) (4)

Meeting ID: [redacted] (b) (4)

One tap mobile
+16465588656,, [redacted] (b) (4) US (New York)
+13126266799,, [redacted] US (Chicago)

Dial by your location
[redacted] (b) (4) (New York)
(Chicago)

(Houston)
(San Jose)
Meeting ID: [redacted] (b) (4)

Find your local number: https://zoom.us/u/ad1j8UhXN5

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Thursday, April 2, 2020 1:29 PM
To: 'Conover, Craig' [redacted] (b) (6)>; 'Angela Dunn' [redacted] (b) (6)>; 'Cindy Burnett' [redacted] (b) (6); 'Duchin, Jeff' < [redacted] (b) (6)>; Stephen Morrison [redacted] (b) (6)>; 'John Monahan' [redacted] (b) (6)>; 'Charles Holmes' [redacted] (b) (6)>; 'Jeremy Konyndyk [redacted] (b) (6)' [redacted] (b) (6)>; 'Rebecca Katz' < [redacted] (b) (6)>; 'Tom Inglesby' [redacted] (b) (6)>; 'Glenn Blumhorst' [redacted] (b) (6)>; Glass, Roger (NIH/FIC) [E] [redacted] (b) (6)>; 'Kenyon, Thomas' [redacted] (b) (6)>; 'Anna Carroll' [redacted] (b) (6) 'Scott Dowell' [redacted] (b) (6); 'Jonathan Pearson' [redacted] (b) (6) [redacted]; 'O'Connor, Eileen' [redacted] (b) (6)>; 'Myers, Michael' [redacted] (b) (6)>
Subject: NEWS: Congressional letter to Peace Corps, CNCS, and FEMA on COVID-19 Response Corps

Hi all,
Big news. Herewith is a letter signed by 40 members of Congress asking FEMA, Peace Corps, and AmeriCorps to form a "COVID-19 Response Corps." This is now in the public domain. Press release forthcoming.

Please save the time for Zoom call 8 am tomorrow on next steps.
Also: Check out: https://www.npr.org/sections/goatsandsoda/2020/04/01/825231838/coronavirus-sent-peace-corps-volunteers-home-it-could-also-give-them-a-new-missi
The National Peace Corps Association is hoping to create and fund a group that draws on the evacuated volunteers and their skills to respond to the COVID-19 crisis in the United States. Workers would take on work like tracing the contacts of diagnosed individuals, monitoring the health of those in quarantine and staffing call centers. An agency such as the Federal Emergency Management Agency, the U.S. Centers for Disease Control and Prevention or AmeriCorps could potentially manage the group, says Blumhorst, who has been advocating for the project. Salaries could come from funding that's already been allotted to the COVID-19 response but hasn't yet been spent. The NPCA has discussed the idea with the offices of several members of Congress that are receptive and supportive, Blumhorst says, and they're planning to speak with more congresspeople and federal agencies and also hope to draw public attention to this potential project.

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Sunday, March 29, 2020 4:47 PM
To: Conover, Craig [redacted] (b) (6)>; Angela Dunn [redacted] (b) (6)>; Cindy Burnett [redacted] (b) (6)>; Duchin, Jeff < [redacted] (b) (6)>; Stephen Morrison [redacted] (b) (6)>; John Monahan [redacted] (b) (6)>; Charles Holmes [redacted] (b) (6); Jeremy Konyndyk [redacted] (b) (6) [redacted] (b) (6)>; Rebecca Katz < [redacted] (b) (6)>; Tom Inglesby [redacted] (b) (6)>; Glenn Blumhorst < [redacted] (b) (6); Glass, Roger (NIH/FIC) [E] [redacted] (b) (6)>; Kenyon, Thomas [redacted] (b) (6)>; Anna Carroll

[redacted] (b) (6); Scott Dowell [redacted] (b) (6)
Jonathan Pearson [redacted] (b) (6)
Subject: INFO: Update on COVID-19 Response Corps

Hi all and thanks for your support for a U.S. COVID-19 Response Corps engaging returned Peace Corps volunteers (RPCV). The latest (March 26) 2-page concept note attached.

Updates:

1. Steve is working on getting the OpEd out in press and/or on CSIS website by Tuesday. We'll let you know.
2. Glenn and Charles have found very good receptivity on the Hill.
3. I've had a couple very good calls with FEMA folks at senior levels (extensive RPCV network). They are already reaching out to RPCV and are well funded. They can get an RPCV on board in a week. They have a few different hiring mechanisms that would be appropriate. **The scale and speed need to be ramped up substantially.**
4. I've reached out to contacts at national mayors and governors associations with no reply. Also no reply from CDC (Jernigan and Schuchat).

Next steps – when OpEd comes out, amplify multiple levels to publicize and create demand.

The need for this is great. The feasibility looks very good.

Please share your suggestions.

Thanks to all,
PK

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Tuesday, March 24, 2020 6:02 PM
To: Charles Holmes [redacted] (b) (6); Angela Dunn [redacted] (b) (6)>; Cindy Burnett [redacted] (b) (6)>; Conover, Craig [redacted] (b) (6) Duchin, Jeff [redacted] (b) (6)>; Glass, Roger (NIH/FIC) [E] [redacted] (b) (6)>; Glenn Blumhorst [redacted] (b) (6); Stephen Morrison [redacted] (b) (6) John Monahan [redacted] (b) (6)
Subject: RE: Call - follow-up: COVID-19 Response Corps

Hi again,
A draft Op Ed attached. It is largely drawn from the concept note.

Is there an appropriate champion among us who can take this forward?

Please share your suggestions and comments by noon tomorrow if possible.

Thanks,

PK

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Tuesday, March 24, 2020 2:17 PM
To: Charles Holmes [redacted] (b) (6)>
Cc: Angela Dunn [redacted] (b) (6)>; Cindy Burnett [redacted] (b) (6); Conover, Craig [redacted] (b) (6) Duchin, Jeff [redacted] (b) (6)>; Glass, Roger (NIH/FIC) [E] [redacted] (b) (6)>; Glenn Blumhorst [redacted] (b) (6) Stephen Morrison [redacted] (b) (6); John Monahan < [redacted] (b) (6)
Subject: RE: Call - follow-up: COVID-19 Response Corps

Thanks Charles. This is very helpful.

I've updated the concept note – attached. Now a two-pager. Added training and prevention bullet. Decreased the numbers and budget based on feed back to date. Draft OpEd forthcoming.

Grateful if others can advocate as they are able (and others of us are not).

Glenn – please add anything on your meetings on the hill yesterday, the FEMA call, or advocacy plans.

My takeaway is that a FEMA disaster corps or FEMA-Americorps Corps is feasible.

- Call yesterday with Glenn and former FEMA staff: George Haddow and Micheal Coen
    - FEMA Corps is a partnership of FEMA and Americorps with about 1,200-1,800 members. Part of Americorps. FEMA pays 100%. Mainly younger, lower-skilled supervised work.
    - FEMA reservist disaster corps has 3,000-4,000 members. Mostly shorter-term deployments as temp employees. Many retired military. Can be activated with State of Emergency declarations.
    - FEMA currently has sent 3-4 liaisons to each state. Disaster corps not activated.
    - Onboarding 5,000 would be a big lift. Peace Corps has seconded staff to other agencies in past, so this could be an option.
    - Only private sector partner for FEMA is Red Cross. Not recommended for this.

More input:

- Jen Kates (KFF) and her colleague Josh Michaud – "think it is a great idea"
- Tom Frieden -"It's a good idea."
    - Robynn Leidig, Manager, Strategic Initiatives, Resolve To Save Lives – "Compelling idea and worth exploring"
        - Concern about risk to RPCVs, training and oversight needed
        - Lack of PPE, best to focus on tasks that don't need PPE
        - Resentment of current staff worried about threat to their jobs
        - Fairness: should open to others - Americorps, VISTA, CDC PHAP, CSTE fellows, USAID Global Health Fellows
        - Management absorptive capacity limited at CDC. Consider ASTHO/ NACCHO or PHI.

From: Charles Holmes [redacted] (b) (6)
Sent: Tuesday, March 24, 2020 7:36 AM
To: Kilmarx, Peter (NIH/FIC) [E] <[redacted] (b) (6)>
Cc: Angela Dunn [redacted] (b) (6)>; Cindy Burnett [redacted] (b) (6)>; Conover, Craig [redacted] (b) (6)>; Duchin, Jeff [redacted] (b) (6)>; Glass, Roger (NIH/FIC) [E] [redacted] (b) (6); Glenn Blumhorst [redacted] (b) (6)
Stephen Morrison [redacted] (b) (6)
Subject: Re: Call - follow-up: COVID-19 Response Corps

Sen Van Hollen's office is interested and I'm slated to talk w them later today or tomorrow. Interested to know how the idea was received by others on the Hill. Best

On Mon, Mar 23, 2020 at 7:44 AM Kilmarx, Peter (NIH/FIC) [E] [redacted] (b) (6) wrote:

> Thanks Charles.
>
> Draft OpEd forthcoming today. Everyone please think about authors.
>
> Bill Frist and Tom Daschle? https://www.rollcall.com/2018/07/09/opinion-an-open-health-diplomacy-hand-works-better-than-a-fist/ By Tom Daschle and Bill Frist, July 9, 2018.
>
> **From:** Charles Holmes <[redacted] (b) (6)>
> **Sent:** Monday, March 23, 2020 7:37 AM
> **To:** Kilmarx, Peter (NIH/FIC) [E] [redacted] (b) (6)>
> **Cc:** Angela Dunn [redacted] (b) (6); Cindy Burnett [redacted] (b) (6)>; Conover, Craig <[redacted] (b) (6)>; Duchin, Jeff [redacted] (b) (6)>; Glass, Roger (NIH/FIC) [E] [redacted] (b) (6)>; Glenn Blumhorst [redacted] (b) (6);
> Stephen Morrison [redacted] (b) (6)>
> **Subject:** Re: Call - follow-up: COVID-19 Response Corps
>
> Great feedback, Peter. More from Vanessa Kerry:
>
> "Initial reaction is that this is fantastic and I would be happy to help in any capacity to support it. Please let me know how. Devil is in the details and the training of course. Truly a smart idea though"
>
> Charles
>
> On Mon, Mar 23, 2020 at 7:11 AM Kilmarx, Peter (NIH/FIC) [E] [redacted] (b) (6)> wrote:
>
>> Thanks Craig. This looks very comprehensive and something a trained RPCV (returned Peace Corps Volunteer) could help implement.
>>
>> Glenn – good luck on the Hill today. Will be eager to hear about the reception.
>>
>> Some feedback from others:
>>
>> - John Monahan (Georgetown) – "Very creative, kudos!"

    - Try to get authority on one of these COVID-19 response bills for returning Peace Corps folks to be redeployed notwithstanding other provisions of law.
    - Explore whether CRC could be incorporated into the programs FEMA already has to bring in short-term employees to help with emergency responses.
    - Some functions (home-delivered meals, staffing call centers, homeless populations and shelters) would more sense to supplement programs run by Americorps.
    - Cost seems high.

- Scott Dowell (Gates Foundation) – "A good and important idea"

    - Need a massive surge in the public health and community testing workforce over the coming months.
    - They are considering engaging the 30,000 medical students through AMSA (American Medical Student Association).

- Tom Inglesby (Johns Hopkins) – "A fantastic idea and am very supportive"

    - Important issue to be worked through: How to address risk to individuals involved? (My response: training, equipping, and monitoring. Will add to next iteration of concept note. Note that Singapore has had no infections in HCW and in China after January/Wuhan, most HCW infections were from home, not from work.)
    - Tom's working on concept to engage presumably immune COVID-19 survivors (as was done with Ebola).

- Jeremy Konyndyk (CGD) – "Great idea."

    - Need to think creatively about how to expand the public health workforce for the coming 18 months, especially for tasks like contact tracing. We'll need to view CDC and local health dept folks not as boots on the ground but rather as force multipliers - sharing their skills with others and mentoring/managing larger teams to extend their reach.

From: Conover, Craig [redacted](b) (6)>
Sent: Sunday, March 22, 2020 5:01 PM
To: Kilmarx, Peter (NIH/FIC) [E] [redacted](b) (6); Stephen Morrison [redacted](b) (6)
Glass, Roger (NIH/FIC) [E] [redacted](b) (6)>; Charles Holmes
[redacted](b) (6); Glenn Blumhorst [redacted](b) (6)
[redacted](b) (6); Duchin, Jeff <[redacted](b) (6)>; Angela Dunn
[redacted](b) (6)>; Cindy Burnett [redacted](b) (6)>
Subject: Re: Call - follow-up: COVID-19 Response Corps

Thanks for all your work on this, Peter!

Re LTCs--attached is a draft document listing all the capabilities that need to be in place for LTCFs to respond to Covid-19.

Developing and disseminating guidance aimed at LTCFs is relatively easy--the failures are going to be around implementation.

This is one area where assistance would be valuable.

CC

From: Kilmarx, Peter (NIH/FIC) [E] [redacted] (b) (6)>
Sent: Sunday, March 22, 2020 3:16 PM
To: Stephen Morrison < [redacted] (b) (6)>; Glass, Roger (NIH/FIC) [E] [redacted] (b) (6); Charles Holmes [redacted] (b) (6)>; Glenn Blumhorst [redacted] (b) (6) Duchin, Jeff [redacted] (b) (6)>; Conover, Craig [redacted] (b) (6); Angela Dunn [redacted] (b) (6); Cindy Burnett [redacted] (b) (6)
Subject: [External] RE: Call - follow-up: COVID-19 Response Corps

Thanks all for our call and support for this concept. Please let me know any critical additions or corrections to these notes.

- Jeff Duchin (Seattle) noted multiple possible roles in contact tracing, mitigation with homeless and incarcerated, adverse consequences of social distancing, infection control support, alternative care site coordination, lab specimen collection and transport. He shared concerns about infection prevention and their PPE shortage. CDC had 40 people deployed, but they departed. Longer deployments (e.g., >90 days) needed to validate onboarding and training effort. He will follow up with more detail on potential roles and numbers.
- Angela Dunn (Utah) agreed with roles in contact tracing, also staffing a call center, rural outreach and specimen collection. She said Utah was not a current priority for FEMA and CDC was conducting a transmission study. She shared Jeff's concern about the onboarding effort.
- Cindy Burnett (Utah) mentioned the need for social support in rural settings.
- Craig Conover (Illinois) added that for them the long-term care centers and homeless populations were priority concerns. It would be feasible and helpful to have staff able to collect specimen swabs.
- Charles Holmes (Georgetown) made an analogy to community health workers in Zambia and how much can be accomplished and enhanced with tablet-based approaches, work-flow apps, and video instructions.
- Steve Morrison (CSIS) emphasized the importance of finding an organizational home, mentioning potential challenges for both CDC and FEMA. He noted timing of response packages being considered, the hunger for creative ideas, and urgency for this to be brought forward. He noted potential champions, listed with others below. He thinks the Peace Corps connection is a compelling factor.
- Glen Blumhorst (NPCA) expressed his support and insights on potential champions, e.g., three RPCV in the house. He is going to Capitol Hill tomorrow.
- Jody Olsen (Peace Corps) (prior to the call) expressed interest and noted that Peace Corps has no authority to operate in the United States. (The possibility of an Executive Order

detailing returned volunteers from Peace Corps to state and local authorities was mentioned by others on the call.) She also noted that Barbara Stewart, Director of CNCS (AmeriCorps and VISTA) has been inviting RPCVs to join.

Next steps:

1. Revise document (done, attached) to be shared with subject matter experts and potential champions. (There was not an exact delineation of who would share with whom. I will aim to CC: or ask for help with some contacts.)
2. Will draft Op-Ed in next 2 days.

Action: Share concept sheet with SMEs and champions avoiding any obvious minefields and duplication. Report back useful feedback.

SMEs/champions:

- Tom Ingelsby
- Beth Cameron
- Jeremy Konyndyk
- Rebecca Katz
- Scott Gottlieb
- Tom Frieden
- Scott Dowell
- John Monahan

Champions:

- Paul Allen Foundation
- Dick Durbin
- Biden campaign
- Chris Christie
- Carrie Hessler-Radelet
- Aaron Williams
- Patrick Leahy
- Chris Van Hollen
- Dick Durbin
- Debbi Birx
- Donna Shalala (RPCV – Iran 1962-64)
- Joseph P. Kennedy III (RPCV Dominican Republic 2004-06)
- John Garamendi (Ethiopia 1966-68)
- Aumua Amata (PC staff Northern Mariana Islands 1967-68)

Note – GS-7, Step 1 salary is $37,301, Step 5 is $42,273. I've re-set the budget at $100,000 per person to account for benefits, training, travel, per diem, management, evaluation, PPE, phones, laptops, etc.

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Sunday, March 22, 2020 12:35 PM
To: Stephen Morrison (b) (6)>; Glass, Roger (NIH/FIC) [E] (b) (6);
Charles Holmes <(b) (6); Blumhorst, Cathy (NIH/NINR) [E]

[redacted] (b) (6); Glenn Blumhorst [redacted] (b) (6)>;
[redacted] (b) (6) Olsen, Jody [redacted] (b) (6)>; Duchin, Jeff
[redacted] (b) (6); Conover, Craig [redacted] (b) (6); Angela Dunn
[redacted] (b) (6)>
Subject: RE: Call: COVID-19 Response Corps

Hi all,
I'm looking forward to our WebEx meeting in 90 minutes. The concept note (unchanged) is attached. The WebEx info is below.

Here's an updated agenda:

1. Welcome and introductions
2. Background and proposal
3. Round robin perspectives
   a. Public health – WA, IL, UT
   b. Peace Corps – Jody
   c. Strengthening the concept - all
   d. Advocacy - all
   e. Implementation - all
4. Next steps and way forward

-----Original Appointment-----
From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Saturday, March 21, 2020 9:29 PM
To: Stephen Morrison; Glass, Roger (NIH/FIC) [E]; Charles Holmes; Blumhorst, Cathy (NIH/NINR) [E]; Glenn Blumhorst; [redacted] (b) (6) Olsen, Jody; Duchin, Jeff; Conover, Craig; Angela Dunn
Subject: Call: COVID-19 Response Corps
When: Sunday, March 22, 2020 2:00 PM-3:00 PM (UTC-05:00) Eastern Time (US & Canada).
Where: WebEx

Please join tomorrow for WebEx discussion of developing a U.S. COVID-19 Response Corps. Concept sheet attached.

Agenda:
1. Welcome and introductions
2. Background and proposal
3. Round robin perspectives
4. Discussion
5. Next steps and way forward

-- Do not delete or change any of the following text. --

Join Webex meeting
Meeting number (access code): [redacted] (b) (4) Meeting password: [redacted] (b) (4)

Join from a video system or application
Dial [redacted] (b) (4)
You can also dial [redacted] (b) (4) and enter your meeting number.

Join by phone
Tap to call in from a mobile device (attendees only)
1-650-479-3208 Call-in toll number (US/Canada)
Global call-in numbers

Join using Microsoft Lync or Microsoft Skype for Business

Dial [redacted] (b) (4)
Can't join the meeting?

If you are a host, go here to view host information. IMPORTANT NOTICE: Please note that this Webex service allows audio and other information sent during the session to be recorded, which may be discoverable in a legal matter. By joining this session, you automatically consent to such recordings. If you do not consent to being recorded, discuss your concerns with the host or do not join the session.

State of Illinois - CONFIDENTIALITY NOTICE: The information contained in this communication is confidential, may be attorney-client privileged or attorney work product, may constitute inside information or internal deliberative staff communication, and is intended only for the use of the addressee. Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify the sender immediately by return e-mail and destroy this communication and all copies thereof, including all attachments. Receipt by an unintended recipient does not waive attorney-client privilege, attorney work product privilege, or any other exemption from disclosure.

--
Charles B. Holmes, MD, MPH
Professor of Medicine
Faculty Co-Director, Center for Global Health Practice and Impact
Georgetown University Medical Center
Building D, Suite 120
4000 Reservoir Rd NW, Washington DC 20057
Phone [redacted] (b) (6)

--
Charles B. Holmes, MD, MPH
Professor of Medicine
Faculty Co-Director, Center for Global Health Practice and Impact
Georgetown University Medical Center
Building D, Suite 120
4000 Reservoir Rd NW, Washington DC 20057
Phone [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 15:25:44 +0000
To: Corey, Larry
Subject: FW: perhaps useful in the physical mitigation battle to buy 6 weeks
Attachments: [redacted] (b) (4)

Larry:

I will call you about this today. This is really important. [redacted] (b) (4)

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)> **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 13, 2020 7:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: perhaps useful in the physical mitigation battle to buy 6 weeks

An email below from Larry Corey.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Corey MD, Larry (b) (6)>
Sent: Sunday, April 12, 2020 11:31 PM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: perhaps useful in the physical mitigation battle to buy 6 weeks

Here is data from Seattle up to this weekend

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 14:37:16 +0000
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: Wayne and Catherine Reynolds and Bob Langer/MIT innovations

Thanks!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, April 13, 2020 8:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Wayne and Catherine Reynolds and Bob Langer/MIT innovations

Possible response below:

Dear Wayne,

[redacted] (b) (5)

Please give my best to Catherine and take care during these difficult times.
Best personal regards,
Tony

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 9:27 PM

To: Auchincloss, Hugh (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)
Subject: FW: Wayne and Catherine Reynolds and Bob Langer/MIT innovations

Hugh:
Please take a look at these 3 ideas. You may have heard of Bob Langer. He is somewhat of an inventive genius with whom we have worked before. I need to get back to Wayne and Catherine and I would like your help in my fashioning a response.
Thanks,
Tony

From: WAYNE REYNOLDS (b) (6)
Sent: Monday, April 6, 2020 2:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Grady, Christine (NIH/CC/BEP) [E] (b) (6)
Subject: Wayne and Catherine Reynolds and Bob Langer/MIT innovations

Tony,

Obviously, you have a few other issues on your daily agenda but, when you have a minute, we would appreciate your thoughts and guidance on three new Bob Langer biotech developments. We have attached three links to recent MIT News articles. These three innovations at the Langer Lab were originally funded by the Gates Foundation. We thought the last two breakthroughs, in particular, may be applicable to your current work. Thank you again for your continued guidance.

Best wishes,

Wayne Reynolds
Cell: (b) (6)
Home: (b) (6)

Heat stable micronutrients for better nutrition
http://news.mit.edu/2019/microparticles-fight-malnutrition-1113

On-patient invisible vaccination record
http://news.mit.edu/2019/storing-vaccine-history-skin-1218

Self-boosting vaccine platform for faster and stronger immune response
http://news.mit.edu/2017/one-vaccine-injection-could-carry-many-doses-0914

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 13:03:45 +0000
To: Jenny Fauci
Cc: [redacted] (b) (6)
[redacted] (b) (6)
Subject: RE: FW: Google Alert - Fauci AND Tony OR Anthony

[redacted] (b) (6)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] >
Sent: Monday, April 13, 2020 7:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: Re: FW: Google Alert - Fauci AND Tony OR Anthony

Just finished it. Wow. [redacted] (b) (6)

On Sat, Apr 11, 2020 at 1:27 PM Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:

> If you have time, click to link on the bottom: "How Anthony Fauci Became America's Doctor". It is a long article in *New York* magazine written by Michael Spector a former Washington Post and NY Times writer who has known me for over 30 years. It is the most comprehensive report on me and my career – very insightful.
>
> **Anthony S. Fauci, MD**
> **Director**
> **National Institute of Allergy and Infectious Diseases**

Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Google Alerts <googlealerts-noreply@google.com>
Sent: Saturday, April 11, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Google Alert - Fauci AND Tony OR Anthony

Google Alerts

Fauci AND Tony OR Anthony

As-it-happens update · April 11, 2020

WEB

Fauci: Virus antibody tests expected next week

North Platte Post

Dr. **Anthony Fauci** answers questions during Thursday's Coronavirus Task Force briefing. WASHINGTON — The top U.S. infectious disease official ...

Flag as irrelevant

anthony fauci

The Bulwark Podcast

anthony fauci, anti-anti-trumpism, china, coronavirus, covid-19, donald trump, elections, hydroxychloroquine, masks, navy, peter navarro, white house, ...

Flag as irrelevant

CBS Evening News with Norah O'Donnell

Facebook

Dr. **Anthony Fauci** of the National Institute of Allergy and Infectious Diseases (NIAID): "This is not the time to feel that, since we have made such...

Flag as irrelevant

How **Anthony Fauci** Became America's Doctor by Michael Specter

Longform

A profile of the doctor who has run the National Institute of Allergy and Infectious Diseases for 36 years.

Flag as irrelevant

You have received this email because you have subscribed to **Google Alerts**.

Unsubscribe

Receive this alert as RSS feed

Send Feedback

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 10:16:00 +0000
To: Nicola Pizzoli
Subject: RE: COVID 19: Possible main cause of fatalities, it could be not respiratory

Thank you, Nicola

From: Nicola Pizzoli [redacted] (b) (6)
Sent: Monday, April 13, 2020 6:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: COVID 19: Possible main cause of fatalities, it could be not respiratory

Good morning Dr Fauci,

I ve been following you on COVID briefings from the White House every night. I trust your experience, professionality and above all your wisdom in these weeks.

While I am a mechanical engineer and I run my food company fro living, I have been interested and passionate to the global fight to the Coronavirus.

SUGGESTION: Could it be possible that people die of **pulmonary micro thrombosis** rather than respiratory issues? If this is the case, this is more a cardiovascular issue than a respiratory, and ventilation or intubation do not count as much as, instead, to give patients some drugs to prevent the thrombosis, such as ANTI-INFIAMMATORIES. If you ventilate a lung where blood doesn't get there, may be it's useless! In fact 9 out of 10 die. If the problem were cardiovascular and not respiratory, then it could be a venous microthrombosis and not pneumonia that determines fatality. And why are thrombi formed? Because there is an inflammation that induces thrombosis through a complex but well-known pathophysiological mechanisms.

I know this thesis is right the contrary of some recommendations that several doctors all over the world (in China first) had made so far: no ibuprofene, no anthibiotics etc etc.
But I believe that some researches on the cardiovascular problem induced by inflammation would be worth doing it.

An apology for my English.
Thank you for your attention,

Stay healthy!
Kindest regards

Nicola

Nicola Pizzoli
President & CEO

T (b) (6) - C + (b) (6) - F +39 0516920293

Pizzoli S.p.A.
Via Zenzalino Nord, 1 – 40054 Budrio - Bologna

www.pizzoli.it

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 02:17:18 +0000
To: [redacted] (b) (6) (NIH/NHLBI) [E]
Cc: Redfield, Robert R. (CDC/OD)
Subject: RE: Comparison of COVID-19 statistics in US vs. China

[redacted] (b) (6)

Thank you for you note. This pandemic has been extremely challenging for many countries around the globe including China and the USA. I can only say that I (and I am sure that Bob Redfield feels the same way) prefer to look forward and not to assign blame or fault. There are enough problems ahead that we must face together.
Best regards,
Tony

From: [redacted] (b) (6) (NIH/NHLBI) [E] [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 9:51 PM
To: Redfield, Robert R. (CDC/OD) [redacted] (b) (6) Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: [redacted] (b) (6) (NIH/NHLBI) [E] [redacted] (b) (6)>
Subject: RE: Comparison of COVID-19 statistics in US vs. China

Dear Dr. Redfield and Dr. Fauci,

After some hesitation, I decided to write you this message anyway and hope you don't mind.

I am concerned about the recent fight between the US and WHO because it may adversely impact the current global efforts in controlling the spread of COVID-19. As we all know, US has been leading WHO's efforts for decades and essentially WHO's role is mostly coordinating responses in low- and middle-income countries with support from the US and other high income countries. Frankly I was looking for leadership from the US CDC rather than WHO when I was doing [redacted] (b) (6). Until COVID-19 is controlled in all countries, the infection could come back to hit us in this country again. Therefore it is now the worst time to undermine WHO's global coordinating capabilities.

What I learned from my former colleagues and friends in [redacted] (b) (6) where I attended medical school and obtained my MSc in epidemiology might offer some explanation for the differences in COVID-19 statistics in US vs. China. Please find attached a couple of articles published by my former colleagues [redacted] (b) (6), of which the 1st attachment is a more updated version.

- First, the maximum lockdown in Wuhan that started on January 23 and also in the rest of the entire Hubei province of 59 million people during the subsequent 2-3 days, coupled with maximum efforts in early identification, immediate isolation of identified infected individuals and close monitoring of contacts, did work and had to work according to epidemiological principles. China did it by invoking level 1 public health response that was historically reserved for smallpox, plague or cholera, which essentially enabled the entire country to be completely locked down for several weeks. Many villages and townships set up checkpoints to refuse anyone to come in or go out; a driver from Hubei had to stay on an inter-provincial highway for 20 days surviving by begging instant noodles from people policing exits; all front doors of residents in a township in Hubei were sealed by local government officials and volunteers to prevent them from getting out of their houses.

- Second, there must be under-reporting of COVID-19 cases and deaths because the public health and hospital systems in Wuhan and a few other hardest hit municipalities were overwhelmed for one to two weeks; conceivably many infected individuals were not getting a chance for testing and some of them must have died without being identified as COVID-19. I'd say that this kind of under-reporting is unavoidable, especially in the epicenter of a new pandemic. Actually I suspect that such under-reporting could have happened in this country as well although perhaps to a lesser degree.
- Third, there could be a third category of casualties, that is, patients who were suffering from chronic diseases but couldn't get necessary treatments because hospitals were overwhelmed. I read a sad story in social media in which a patient who needed frequent dialysis committed suicide by jumping out of his window. It is highly likely that many such patients died during the lockdown even though I couldn't confirm the specific case or find any statistics. There could be many other collateral damages including socio-psychological effects.

Combined, the effect of the maximum lockdown, the under-reporting of COVID-19 cases and COVID-19 deaths as well as collateral deaths of other causes that were associated with the lockdown could be several times of the reported statistics from China. Here I'd not say that China purposely under-reported COVID-19 cases or deaths but rather, China pursued an extreme approach and achieved an extreme result, including severe collateral damages. Of note, Dr. LI Wenliang (the whistleblower) voiced concern on 12/30/2019 and was criticized for having not followed the legally proper reporting process but nevertheless the WHO China Office was informed on 12/31/2019 of a pneumonia of unknown cause, detected in the city of Wuhan in Hubei province, China (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen).

We in the US and many other countries pursued different approaches, which are more humane but less effective in terms of blocking transmissions. This is the reality, which needs to be communicated with and recognized by the public; to make the humane approaches work as effectively as possible, we need everyone's support and cooperation, which cannot be achieved by blaming China or WHO. The public has to understand that we are in a pandemic, which means that tens of millions are supposed to be infected and millions are supposed to die from it, unless we take necessary actions to block the transmission and to take good care of the infected.

Finally, I'd like to say a few words for public health colleagues in China. In my personal view, to be fair, they have done their best to inform the global public health community of the COVID-19 outbreak in Wuhan, China by briefing WHO and many countries as soon as they identified COVID-19 (12/31/2019 – 1/3/2020); they shared the genetic sequence of the virus on 1/12/2020; and the number of scientific and medical publications in English shortly afterwards was unprecedented. I did a brief search and identified the following:

A Novel Coronavirus from Patients with Pneumonia in China, 2019 (1/24/2020)
https://www.nejm.org/doi/full/10.1056/NEJMoa2001017

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster (1/24/2020)
https://www.sciencedirect.com/science/article/pii/S0140673620301549?via%3Dihub

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China (1/24/2020)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia (1/29/2020)
https://www.nejm.org/doi/full/10.1056/NEJMoa2001316

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding (1/30/2020)
https://www.thelancet.com/article/S0140-6736(20)30251-8/fulltext

A new coronavirus associated with human respiratory disease in China (2/3/2020)
https://www.nature.com/articles/s41586-020-2008-3

Early estimation of the case fatality rate of COVID-19 in mainland China: a data-driven analysis (2/12/2020)
http://atm.amegroups.com/article/view/36613/html

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China (2/24/2020)
https://jamanetwork.com/journals/jama/fullarticle/2762130

It is my hope that US and China could join forces to help low- and middle-income countries to control the pandemic so that it will not come back and hit us again after the current wave in this country is controlled.

I am not sending this message through the official channel because this is not part of my official duty and is purely my personal opinion.

Sincerely,

(b) (6)

[redacted]

Doing human subjects research? New policies will impact you! Learn more.
Looking for NHLBI Clinical Trial Funding Opportunities? Learn more here.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 01:37:27 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: [COVID-19 Pneumonia] Official Letter from ImmuneMed Inc.
Attachments: Official Letter from ImmuneMed-NIAID.pdf

Please take a look at this and respond.

From: Sungpill Park <sppark@immunemed.co.kr>
Sent: Sunday, April 12, 2020 9:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: [COVID-19 Pneumonia] Official Letter from ImmuneMed Inc.

Dear **Dr. Anthony S. Fauci**,

My name is Sungpill Park, and I'm a representative of ImmuneMed, Inc. located in Korea.

We specialize in diagnosing and treating the infectious diseases.

Our company's **hzVSF(humanized Virus Suppressing Factor) v13** is under curable usage for COVID-19 pneumonia, utilizing Korea's compassionate use system for patients who do not have an alternative treatment.

I am writing with a strong conviction that the partnership between **the National Institute of Allergy and Infectious Diseases** and ImmuneMed, Inc. will bring the decrease of death rate for COVID-19 pneumonia.

I ask you humbly to please spend a minute of your busy time reading the attached letter from our CEO, Dr. Yoon-Won Kim, to find out more about the hzVSF treatment and how we can work together to cure COVID-19 pneumonia patients.

With Regards,

Sungpill Park, MBA
Vice President, Global Business Development
ImmuneMed, Inc.
C: (b) (6) / **E:** sppark@immunemed.co.kr
W: www.immunemed.co.kr/en/

Notice : *The above message (and any attachment) is intended solely for the named address and may contain information that is privileged, confidential or otherwise protected under applicable law. Any unauthorized dissemination, distribution, copying or use of the information contained in this communication is strictly prohibited. If you have received this communication in error, please notify the sender by email and erase this communication immediately.*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 23:20:22 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Let us discuss.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Thursday, April 9, 2020 11:01 AM
To: Mun, Jenny <JMun@nas.edu>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6);
[redacted] (b) (6) >
Cc: ([redacted] >; Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6) 'ben.tinker@cnn.com' <ben.tinker@cnn.com>; 'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>; 'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>; 'Tia.Miller@turner.com' <Tia.Miller@turner.com>; ' [redacted] (b) (6)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.

- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny <JMun@nas.edu>
Sent: Wednesday, April 8, 2020 10:56 AM
To: [redacted] (b) (6)
Cc: Dzau, Victor J. <VDzau@nas.edu>; [redacted] (b) (6) Mun, Jenny <JMun@nas.edu>; Hannon, Emma <EHannon@nas.edu>; [redacted] (b) (6)
'ben.tinker@cnn.com' <ben.tinker@cnn.com>; 'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>; 'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>; 'Tia.Miller@turner.com' <Tia.Miller@turner.com>
Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (https://www.youtube.com/user/theNASciences) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13.**

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT**) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases
Jeremy Farrar, Director, Wellcome Trust
George F. Gao, Director-General, Chinese Center for Disease Control & Prevention
Sanjay Gupta, Chief Medical Correspondent, CNN
Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations
Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as "sharing your screen" (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

****

Jenny Mun
Membership Director
National Academy of Sciences
jmun@nas.edu
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 23:00:07 +0000
To: Seth Berkley (Private)
Subject: RE: Checking in

Thanks, Seth!

From: Seth Berkley (Private) [redacted] (b) (6)>
Sent: Saturday, March 28, 2020 3:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Checking in

Hi Tony: You are doing an amazing job during these very difficult times!

Doing everything we can here to support WHO to work on global acceleration of SARS-CoV-2 vaccine development as well as support our 73 poorest countries for COVID-19 preparation and hopefully keeping routine vaccine coverage as high as possible. We are prepared to ultimately roll out a vaccine when one is ready. No need to respond, but wanted to give you a friendly shout-out. We are all thinking of you!

Best,

Seth

The private email account of
Dr Seth Berkley

Chief Executive Officer
Gavi, the Vaccine Alliance

Tel: [redacted] (b) (6)
Skype
Twitter @GaviSeth

Email: [redacted] (b) (6)

The Global Health Campus, Chemin du Pommier 40,
1218 Le Grand-Saconnex, Switzerland
Tel: [redacted] (b) (6)
Web: http://www.gavi.org

With the support of donors and partners, Gavi, the Vaccine Alliance is working to immunise an additional 300 million children between 2016 and 2020, preventing a further 5-6 million deaths. Join us and help to reach every child. Visit www.gavi.org, sign up for the Gavi newsletter and follow us on Facebook and Twitter.

NOTICE: This email, including any attachments to it, may be confidential and does not create any binding contract on behalf of Gavi or its partners. If this email was sent to you in error, please notify the sender immediately by reply e-mail, and please do not use, distribute, retain, print or copy the e-mail or any attachment.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 22:58:02 +0000
To: Herbert Mathewson
Subject: RE: PERSONAL: My April 1 blog on Tony Fauci, CUMC [redacted] (b) (6)

Hub:
Many thanks for your kind note.
Warm regards,
Tony

From: Herbert Mathewson [redacted] (b) (6)
Sent: Saturday, March 28, 2020 1:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: PERSONAL: My April 1 blog on Tony Fauci, CUMC [redacted] (b) (6)

Tony, I have been writing an annual April 1 column for 30 years, first in my monthly newsletter at Cape Cod Hospital and now as my biweekly blog of medical fun facts at www.hubslist.org. This is a heads up before publication of this year's April 1blog about you and Biden.
I suspect that most of our classmates are, like me, boasting a bit about having you as a classmate. Your honesty and "truthiness" is most appreciated and greatly valued by us amidst the leadership chaos. Your success at "walking the line" is extraordinary.
Enjoy. Hub

HUB's LIST of medical fun facts

A data-based biweekly newsletter of medical fun facts

- Home
- Hub's List of Medical Fun Facts

Vol. 230 April 1, 2020 Biden Picks His Running Mate

Press Conference

Former Vice President

Joe Biden

April 1, 2020

(Official Transcript)

BIDEN: Good morning everyone. I am glad to see all you reporters sitting 6 feet from each other. I know it is burdensome, but we must work together to defeat this awful Zika. . . Rebola. . . the flu . . . er, what?, . . . I mean, you know, the Coroner virus.

Speaking of the current virus crisis . . . boy that has a nice ring to it, doesn't it? . . . it almost rhymes . . .I would like to announce my pick of a running mate; Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Disease of NIH since 1984. . . almost twenty. . . er. . . many years ago.

Now before I start to answer your questions, let me give you some reasons for my choice.

Number 1: Dr. Fauci is smarter than I am, but I am taller and younger than he is.

Number 2: He is very experienced. He has worked with many Presidential administrations since he came to Washington . . . in the 1980's as I remember. He told Ronald Reagan about the AIDS epidemic, advised two Bushs . . . one of them gave him the Presidential Medal of Freedom . . . by the way, Ben Carson got his medal during that same ceremony, . . . where was I? Oh, yeh . . .two Clintons . . . yes two, remember Hilary's Health Care Plan?. . . and, of course, Obama or two.

Number 3: He gives very good TV interviews, even on Fox News with Sean Hannity trying to mislead the viewers.

Number 4: His medical training has given him that special skill that all physicians must have to succeed — "Always sound right, and if you don't know an answer, make one up." But he is like one of my famous namesakes on Dragnet . . . Sergeant Joe Friday . . ."Just the facts, Ma'am."

Now I'll take your questions.

[Sounds of shouting, general loud babbling, a baby crying, a chair falls over]

REPORTER: " Mr. Biden have you moved away from your promise to pick a female running mate?"

BIDEN: Did I say that? When was that? . . . Oh, it was during one of those debates? . . . I wouldn't call it a promise. It was a statement from which I am now socially distancing myself, and that makes it a very timely question. . . .This social distancing is for the pits. I haven't smelled a good head of hair in weeks. . . for the record, my test was negative . . . and I will ensure that women's voices will be heard in my administration by appointing several to my cabinet. Elizabeth Warren naturally will be Secretary of the Treasury. Kamala Harris as an experienced prosecutor would be an excellent head of the Department of Justice . . . I think she is Latino too, isn't she?. . . I am not sure about Senator Amy Kolbuchuck from Minnesota and she has great hair, but Marianne Williamson, . . . remember, the physic healer. . . could serve as Chief of the Alternate Universe . . .excuse me, Alternate Therapies within HHS. Adding Senator Gillibrand to the cabinet would weigh the group too heavily towards New York, since Dr. Fauci is from Brooklyn. I will, of course, appoint Tulsi Gabbard as Ambassador to America Samoa.

REPORTER: "Do you have any concerns about any regrettable incidents in Dr. Fauci's past?"

BIDEN: Not really. My staff has vetted him very thoroughly. The only whiff of scandal we found was his medical school yearbook picture where he was being lifted by two of his taller classmates so as to appear as even taller than they. None of them were in black face.

Also some people may have difficulty knowing how to pronounce his name correctly. It is pronounced as "Fow-chi" with the soft "c" sound common to many Italian names, . . . and as the Senator from Nevada I wish to say that I have many Italian-American friends who are hard-working, decent citizens, but I must excuse myself from this Corleone hearing for another important committee meeting . . . oh, sorry . . . was I channeling the Godfather again?. . . a great movie.

There is another small concern, since he is from New York City and his name ends in a vowel people may think he is associated with Rudy Giuliani. . . . but we know that he is taller than Mike.

We have completely debunked the New Yorker Magazine stories that Dr. Fauci has recommended internal alcohol to kill the coronavirus since external alcohol really doesn't work. In fact, he only recommended it as an antidote to the daily briefings of the White House Coronavirus Task Force. Dr. Fauci also noted that internal alcohol effects may be briefer than the briefings, so viewers may repeat a dose PRN (as necessary).

REPORTER: " Is it true that as noted in your background Press Release just handed out that Dr. Fauci was born on Christmas Eve, and are you concerned about any back lash from Trump supporters who regard Trump as the Second Coming."

BIDEN: Dr. Fauci is an American. Even though he was born in Brooklyn, there is no question about his citizenship eligibility for this office. I think that a resurgence of the Birther Movement which was so viscously directed at my close friend and mentor, Barrack Obama, . . . there I finally got his name out there. . . would be very unfortunate. Next question.

REPORTER: "Has Dr. Fauci made any significant contributions in fields other than virology and infectious diseases."

BIDEN: Well let me tell you a down-to-earth, fascinating story of one of his most significant contributions. It will be a short one, I promise. Since the Coroner virus pandemic has taken over all the headlines, editorial pages, social media memes, political cartoons, TV shows, graphic artist shops, and a lot of other things swamping articles about the Opioid Deaths epidemic, Dr. Fauci has developed a new attention-getting graphic to replace the familiar 1-10 faces of pain levels; the 1-4 faces of Pandemic Panic levels.



REPORTER: "But face 4 is the same as face 2. Isn't that a confusing message."

BIDEN: Exactly

"Thank you Mr. Biden, and **Happy April Fools Day.**"

PS: [redacted] (b) (6) yearbook picture that won't be in the blog.

[redacted] (b) (6)

This entry was posted on Saturday, March 28th, 2020 at 10:01 AM and is filed under coronavirus, current events, humor, Infectious Disease, politics. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site. Edit this entry.

Post navigati

- RECENT ISSUES

○ Vol. 229 March 15, 2020 Beware the Ides of March

- Vol. 228 March 1, 2020 Physician Speeders, Roundup Off One Hook, and Don't Shoot the Cows
- Vol. 227 February 15, 2020 Milk is NOT Good For You?!
- Vol. 226 February 1, 2020 Current Controversies . . . other than impeach ment.

-

- YOU ARE FOLLOWING THIS BLOG

You are following this blog, along with 216 other amazing people (manage).

Blog at WordPress.com.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 22:38:10 +0000
To: Holdren, John P.
Subject: RE: Antiviral SNA white paper

Thanks, John.

From: Holdren, John P. [redacted] (b) (6)
Sent: Wednesday, March 25, 2020 4:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Antiviral SNA white paper

Dear Tony –

I know you are overwhelmed, but the attached whitepaper on a vaccine-development idea might be worth a look. You may member Chad Mirkin as a member of the Obama PCAST whose extraordinary contributions across a range of science and engineering issues have landed him in the NAS, NAE, and NAM, among other distinctions—a very smart guy.

Aside from that, thank you for your courageous truth-telling in the incredibly demanding situation in which we find ourselves.

My best,
John

John P. Holdren
Teresa and John Heinz Professor of Environmental Policy
John F. Kennedy School of Government
Professor of Environmental Science and Policy
Department of Earth and Planetary Sciences
Affiliated Professor
John A. Paulson School of Engineering and Applied Science
HARVARD UNIVERSITY

Assistant: [redacted] (b) (6)

From: Chad A Mirkin [redacted] (b) (6)
Sent: Wednesday, March 25, 2020 3:57 PM
To: Holdren, John P. [redacted] (b) (6)>
Cc: Robert A Lamb [redacted] (b) (6); Andrew Lee [redacted] (b) (6)
Subject: Antiviral SNA white paper

(b) (4)

[redacted]

Thanks and best regards, Chad


Dr. Fauci's March Madness Bracketology Picks
EAST
Coronavirus
Norwalk
SARS
MERS
Coronavirus
MERS
Coronavirus
SOUTH
Smallpox
Chickenpox
Herpes
Measles
Smallpox
Measles
Measles
Coronavirus
Ebola
Coronavirus
CHAMPION!
-Tony F.
WEST
Influenza H1N1
Monkeypox
West Nile
Rabies
Influenza H1N1
West Nile
Influenza H1N1
MIDWEST
Ebola
Polio
Hepatitis B
Zika
Ebola
Zika
Ebola
© 3/16/20
(b) (6)

Cheers,

John T. Brooks, MD
Chief Medical Officer, CDC COVID-19 Response
Email: (b) (6)
Apologies for errors in my messages that may be due to my need to dictate.

KEEP
CALM
AND
WASH
YOUR
HANDS
CDC
U.S. Department of
Health and Human Services
Centers for Disease
Control and Prevention

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 22:18:05 +0000
To: John Dirks
Subject: RE: Great leadership

John:
Thanks for the note, Much appreciated.
Best,
Tony

From: John Dirks [redacted] (b) (6)
Sent: Wednesday, March 18, 2020 5:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Great leadership

Tony, I admire the tremendous leadership and expertise you are providing during this COVID-19 crisis –I know it not easy –but your advice is so credible and listened to, Best John Dirks

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 22:17:08 +0000
To: Lewis M Drusin
Subject: RE: Coronavirus

Thanks, Lew

-----Original Message-----
From: Lewis M Drusin [redacted] (b) (6)>
Sent: Wednesday, March 18, 2020 11:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Coronavirus

Tony

When people ask me about coronavirus, I just tell them to listen to you. Your calm, steadfast explanation of the science is a major factor in the public trusting government to resolve this incredible public health crisis. Hope you are doing well.

Best wishes as always
Lew

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 20:21:16 +0000
To: El-Gabalawy, Nadia (PHAC/ASPC)
Cc: (b) (6)
Subject: RE: Hello from Canada!

Nadia:
Many thanks for your kind note.
Best regards,
Tony

From: El-Gabalawy, Nadia (PHAC/ASPC) (b) (6)
Sent: Monday, March 30, 2020 2:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Hello from Canada!

Hi Dr. Fauci,

I thought I would reach out to you amidst this crisis; I respect the work you're doing a great deal. (b) (6) Hani El-Gabalawy, did a research sabbatical at NIH (b) (6)

Amazing work that you're doing. I've been following your discussions and scientific innovation regarding COVID-19. I've been working for the federal government in Intelligence for about thirteen years and recently moved to the Canadian Public Health Laboratory Network Secretariat to support the Emergency Operations Centre at the National Microbiology Lab. I've been with the NML for almost my whole career.

Just a quick hello and deep respect for your work. My colleagues and Director have said that we're on the exact same page as you, in terms of your perspective and assessment of the pandemic. Although there is a border between us, know that we are in agreement with your work and I'm thrilled to see you advising the public. There is no better person to do the job.

Kindest regards,

Nadia El-Gabalawy
Team Lead, Support Services, Canadian Network for Public Health Intelligence
Public Health Agency of Canada/Government of Canada
(b) (6)
(b) (6)
Chef d'équipe, Services de soutien, Réseau canadien de renseignements sur la santé publique
Agence de la santé publique du Canada / Gouvernement du Canada
(b) (6)
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 20:19:01 +0000
To: Anderson, Jennifer (NIH/NIAID) [E]
Cc: Lane, Cliff (NIH/NIAID) [E];Clifton, Dawn (NIH/NIAID) [E]
Subject: RE: LIR Requests for DIR Supplemental Funding (non-COVID related) - PLEASE REVIEW

Looks fine.

From: Anderson, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, March 30, 2020 9:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Clifton, Dawn (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: LIR Requests for DIR Supplemental Funding (non-COVID related) - PLEASE REVIEW

Hi Dr. Fauci,

Please review the attached requests for DIR Supplemental Funding on behalf of LIR investigators. I have further summarized the requests in the table below. I took the liberty to provide a suggested ranking based on funding need. Dr. Lane has reviewed the requests and agrees with the rankings as well.

[redacted] (b) (5)

Sincerely,
Jennifer

PI	Supplement Description	Cost	Priority Order for LAB
[redacted]	[redacted]	[redacted]	(b) (5) [redacted]

[redacted] (b) (5)

Jennifer M. Anderson, PhD

Deputy Branch Chief
IAMB/OAS/NIAID
9000 Rockville Pike, Bldg. 10 Rm. 6A19A
Bethesda, Maryland 20892
Office Phone : [redacted] (b) (6)
NIH Cell: [redacted] (b) (6)
Personal Cell: [redacted] (b) (6)
FAX: 301-402-4122

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 20:18:33 +0000
To: Brian Kelsall
Subject: RE: What can be done?

Thanks, Brian. That recommendation is in the works.

From: Brian Kelsall (b) (6)
Sent: Monday, March 30, 2020 10:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: What can be done?

Dear Tony,
I'm lucky to have thoughtful neighbors. Please see the email that I received from Sue Edwards. Because of the likelihood that there are so many asymptomatic cases, isn't it time to recommend everyone where a mask of some kind? Not N95 masks or even surgical masks that should be reserved for first responders and hospital staff, but some face covering?
Best, Brian

Sent from my iPhone

Begin forwarded message:

> **From:** Sue Edwards (b) (6)>
> **Date:** March 30, 2020 at 1:15:06 PM EDT
> **To:** Brian Kelsall (b) (6)
> **Subject: What can be done?**
>
> Why can't the CDC make a public service announcement that everyone should be wearing some kind of mask 😷 in public? It doesn't have to be N95 or even surgical though that would be ideal (as is done in every Asian country) given that the virus is actually aerosolized (several studies confirm this) and that it can be spread by asymptomatic carriers (which account for possibly more than half of the positive cases - we will never know) it seems obvious that food markets are no different from hospitals and in many cases worse since at least in hospitals people are wearing some protective equipment... just say wear a cotton mask, a scarf, a bandanna, a DIY paper towel mask.. whatever- but no one should be going to a market without one and absolutely no one working in a store or stocking supplies or delivering food, packages, mail etc should be allowed to work without something covering the face- this includes pharmacists as well, obviously □ wtf is wrong with this country?
>
> What use are gloves? When the offending particles are escaping our faces and floating around for several hours, landing on everything around us... the only place it shouldn't be as critical is outdoors in the sunshine where UV light should deactivate viruses fairly quickly...

Sue

Hope you are all well - and can give me some hope that this message get through the thick skulls of the so called experts... even during the 1918 flu epidemic, everyone wore some facial covering when out in public places - what is going on?

EVERY ASIAN country is employing this approach with much greater success at slowing the rate of transmission — even India!

https://www.nytimes.com/2020/03/27/health/us-coronavirus-face-masks.html

https://medium.com/better-humans/a-practical-guide-to-covid-containment-orifice-by-orifice-80c2f3f167be

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 20:07:20 +0000
To: Harold Slavkin
Cc: Collins, Francis (NIH/OD) [E]
Subject: RE: reaching out thinking of you

Hal:

Thanks for your note. These divergent phenotypes are truly puzzling. I have copied Francis on this e-mail in case he has any additional thoughts.

Best regards,
Tony

From: Harold Slavkin [redacted] (b) (6)>
Sent: Thursday, April 2, 2020 4:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: reaching out thinking of you

Begin forwarded message:

From: "Harold C. Slavkin" [redacted] (b) (6)>
Subject: reaching out thinking of you
Date: April 2, 2020 at 11:39:40 AM PDT
To: [redacted] (b) (6)
Cc: "Somerman, Martha (NIH/NIDCR) [E]" [redacted] (b) (6)>

Hi Toni,

You continue to be "the role model" for leaders in biomedical research these many decades. I am so proud of your efforts during these remarkable times in history. Thank you!!! I cherish those 5 years (1995-2000) that I served as Director of NIDR (that became NIDCR) when we were able to co-sponsor efforts to utilize saliva as an informative fluid for HIV detection. For me that was an invaluable opportunity to be part of

Harold Varmus' leadership team and to continue my research within NIAMS.

I was inspired by your public comments a few nights ago on CNN regarding your observations of significant variance in the pathogenesis or phenotypes noted for subsets of critically ill patients with COVID-19 on ventilators in ICU. I was immediately reminded of David Feinberg (CEO of UCLA Health Sciences, more recently 5 years at Geisingers, and currently CEO of Google Health Companies) who used genotyping for populations around Lancaster PA and discovered about 3-4% with undiagnosed genetic diseases that translated into reduced costs of hospitalization, treatments, etc. Kaiser-Permanente Northern California, and many other systems, have also used this approach since sequencing has become cost effective. Perhaps a select sample of people who require ICU, and another that require ventilator, might inform the genotype of the most susceptible people and might also inform a target to use to discover what existing drug or therapy could be mobilized. Through your position, might there already be a large data set of whole genome sequences (e.g. military) that could be rapidly explored using bioinformatics?

As you may recall, my personal research activities have focused on craniofacial diseases and disorders. For example, Osteogenesis Imperfects (O.I.) presents cardiopulmonary disorders in addition to bone and tooth disorders. Since penetrance varies, cases of rare conditions can illuminate “hidden” SNP abnormalities in key gene clusters (e.g. MHC gene clusters, etc.). Considering lung disorders as you mentioned in your comments about pathogenesis, already known gene mutations that present several major phenotypes including pulmonary diseases could become very useful. Perhaps Francis and others at the NIH could create a trans-NIH approach that is enabled to visit this pandemic from the perspective of human phenotype variance discovered via genomics?

I asked Martha Somerman to explore the talents available at NIDCR (and beyond) related to connective tissue genetic diseases that associate with Types 1 and 111 collagens, elastics, and hyaluronic acid glycoproteins AND lung tissue fibrosis, etc. She may also reach out to you.

Meanwhile, thank you for your untiring efforts to use science to inform health policy. Of course, let me know if I can be of any use to you.

Always, Hal

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 19:42:21 +0000
To: Susan Corrigan
Subject: RE: Coronavirus

Susan:
Thank for the note. I hope that all is well with you.
Best regards,
Tony

From: Susan Corrigan [redacted] (b) (6)>
Sent: Wednesday, April 1, 2020 10:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Coronavirus

Dear Dr. Fauci,
I have seen quite a bit of you on television. I live in Miami now. South Florida is the epicenter of the coronavirus. I wish Governor DeSantis would shut down the state of Florida. Thank you from [redacted] (b) (6)

Susan Corrigan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 19:41:04 +0000
To: Nader, Ralph
Subject: RE: COVID-19 Question

Ralph:

I am so sorry that I took so long to get back to you. I receive over 1000 e-mails per day and even with staff screening, I do not see them for days. There is still an issue/problem with serologic tests in that they need to be validated as being sensitive and specific. Many tests that have been used thus far are not accurate and ARE MISLEADING. The UK bought millions of these from China and found that they were inadequate. The FDA is in the process of validating certain tests this week and if they pass, then we can expect to have tests within the next few weeks to do the things that you have suggested.
Best regards,
Tony

From: Nader, Ralph (b) (6)
Sent: Wednesday, April 1, 2020 9:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: COVID-19 Question

Dear Dr Fauci,

I hope this email finds you well.

Thank you for everything you are doing for our country in these difficult times.

I realize your time is extremely valuable - especially during these times.

I have one question - if you can help me answering it.

Why are serologic tests not made abundantly available during these times?

This will help in so many ways:

- Can it be used to triage healthcare workers? Naturally "vaccinated" healthcare workers may be better triaged to be on the front lines for example, taking care of COVID-19 patients. (In times of limited PPE, documentation of natural immunity is probably one of the best PPE's out there)

-Another major use for it:

People can be asked to remain home, until they have documentation of natural immunization.

Serologic tests are very cheap, can be mailed, and done at home.

Immunized individuals can carry the test as "proof" of immunity - and may be able to go back to work etc.

It is just a thought. It may be a very candid question that I am asking.

But while we are waiting for a vaccine (and this will take several months), some people may be able to benefit from a very cheap test (that can be done at home) to short-circuit that waiting time.

Thank you for everything you are doing to our country,

You are such an inpiration to us all.

I wish you all the best.

Thank you.

Ralph

Ralph Nader, MD

Renal Fellow - Boston Medical Center

Instructor of Medicine - Boston University School of Medicine

Email: (b) (6)

Phone: (b) (6)

Pager: (b) (6)

This electronic transmission may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended recipient, please notify me immediately as use of this information is strictly prohibited.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 19:29:52 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: documentary interview request: PBS + Topspin Productions

Let us discuss this tomorrow before we do anything. No one has any "exclusives" on anything about me.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 3:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: documentary interview request: PBS + Topspin Productions

[redacted] (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Sunday, April 12, 2020 3:01 PM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: documentary interview request: PBS + Topspin Productions

[redacted] (b) (5)

[redacted] (b) (5) Happy to discuss.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 2:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E]

[redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: ASF: documentary interview request: PBS + Topspin Productions

We have received a request from the PBS program "American Masters" and Topspin Productions to do a documentary about you. Their near-term ask is one or two brief video-link phone interviews during the next few months. After the coronavirus pandemic has subsided, they would like to do "a proper sit-down in which you could tell us the stories that speak to the key moments in your remarkable career."

On the face of it, this might seem to overlap with the Tobias/Hoffman project, but in the end I think they'd be quite different products. Please let me know if you'd like us to seek clearance to proceed.

On Apr 7, 2020, at 9:26 AM, Lia Carney <lia@topspincontent.com> wrote:

Hi Laura,

Nice to speak yesterday. See below for formal request and information about the series. If you wouldn't mind confirming receipt of this email, I can make sure to let me partners in this project know it is in the correct hands. Stay safe and thank you.

Dear Dr. Fauci,

To re-introduce myself, I am Lia Dosik Carney, [redacted] (b) (6) and an executive producer in Los Angeles. As you'll remember, we filmed with you last summer as a major participant in a documentary we were producing centered around infectious disease. Thank you again for participating and taking the time. It was great to hear about your extraordinary career as well as a few interesting stories about [redacted] (b) (6)

Obviously events have taken over all of our lives. Like everyone else in this country, I am very grateful for your honest and steadfast leadership as we navigate our new reality. During this time, we've been rethinking how we want to proceed with our documentary and have come to realize focusing on you, your experiences over the decades, how you have met every challenge presented to you, would give all of us a roadmap for the future.

To that end we are now in partnership with AMERICAN MASTERS, PBS' flagship series that profiles and honors outstanding Americans. Together we would like to produce a comprehensive look at your life, your experiences and your insights into how to deal with the recurring diseases that continue to plague our lives.

I have included below an introductory email from American Masters Executive Producer, Michael Kantor, which will give you a broader sense of that exceptional PBS series and the extraordinary work they produce.

We all know how limited your time is now — and all of us are so appreciative of what you are doing. We respectfully hope you will allow us to chronicle your life in medicine. We know that as we emerge from this latest crisis — understanding how you were able to deal with earlier plagues (HIV-Aids for instance) will — we hope — give all of us a better understanding of the challenges all of us will continue to face.

Appreciate your consideration. With respect, Lia

Dear Dr. Fauci,

My name is Michael Kantor and I am the Executive Producer of the PBS AMERICAN MASTERS series. I believe you know [redacted] (b) (6) I am writing today to see if you would allow us to make a film on your life and career. We would require very little of your precious time right now, perhaps one or two very brief video-link phone interviews over the next few months, just as you have appeared on Trevor Noah's *The Daily Show* and spoken with basketball star Steph Curry. Later this year, after the current crisis has subsided, we would find time in your busy schedule for a proper sit-down in which you could tell us the stories that speak to the key moments in your remarkable career.

I am excited to work with Lia Carney and Topspin Productions on this project, because it has been important to me to expand the roster of AMERICAN MASTERS films to include scientists. Over its 33 year history, our series has profiled artists such as Leonard Bernstein, Maya Angelou and Raul Julia, athletes including Billie Jean King and Ted Williams, and now we are presenting the stories of James Watson and Oliver Sacks in our pantheon of great films. Our series is dedicated to telling biographies with the utmost care, and for that reason we have been honored with awards like the Emmy, the Peabody, the Grammy and even an Oscar.

We would be honored to have you join us in our public television effort to educate Americans about the domestic and global health issues that have been the focus of your career. This letter is brief because we respect your time, but we sincerely hope that you will join us in creating a documentary of distinction for a broad and diverse national audience.

Sincerely yours,

Michael Kantor

Michael Kantor
Executive Producer
American Masters
Thirteen | WNET
825 Eighth Avenue
New York, NY 10019-7435

212-560-6975 (office)
<image001.png>
American Masters website
Facebook |Twitter | Tumblr

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 18:25:39 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Clarification in the chapters on Human Immunodeficiency virus disease: AIDS and related disorders (Chapter 197) page 1445 and Toxoplasma infections (Chapter 223) page 1615, in Harrison's principles of internal medicine -20 th Ed

Thanks.

From: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, April 12, 2020 2:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Clarification in the chapters on Human Immunodeficiency virus disease: AIDS and related disorders (Chapter 197) page 1445 and Toxoplasma infections (Chapter 223) page 1615, in Harrison's principles of internal medicine -20 th Ed

I responded to him and copied Kami Kim. He misread the two sections. We are saying the same things. I did not copy you.

From: Anthony Fauci < [redacted] (b) (6)
Date: Sunday, April 12, 2020 at 2:13 PM
To: "Lane, Cliff (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: FW: Clarification in the chapters on Human Immunodeficiency virus disease: AIDS and related disorders (Chapter 197) page 1445 and Toxoplasma infections (Chapter 223) page 1615, in Harrison's principles of internal medicine -20 th Ed

Please take a look at this. We get these inquiries from Indians all the time. They read HPIM very carefully. Is there anything we need to change here?

From: Viswanathan Neelakantan [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 3:35 AM
To: [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Lane, Cliff (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Clarification in the chapters on Human Immunodeficiency virus disease: AIDS and related disorders (Chapter 197) page 1445 and Toxoplasma infections (Chapter 223) page 1615, in Harrison's principles of internal medicine -20 th Ed

Dear Professor Anthony Fauci and Professor Kami Kim,
Greetings from Pondicherry, India. This is Dr K Neelakantan Viswanathan, Senior Professor of Medicine in a medical school here.

Going through your excellent chapter, (Chapter 197) in page 1445, on AIDS and related disorders in HPIM-20, under secondary prophylaxis / maintenance therapy for Toxoplasmosis it is said that **"it may be discontinued in the setting of effective cART and increases in CD4+ T cell counts to > 200 / microliter for 6 months".**

In page 1615, another wonderfully written chapter, (Chapter 223) on Toxoplasma infections, Professor Kami Kim has mentioned that " **individuals who have completed initial therapy for TE should receive treatment indefinitely unless immune reconstitution with a CD4 + T cell cont of >200 occurs as a consequence of cART".**

Since both feature in the same textbook followed worldwide by medicos, could you please clarify the above?
I stand subject to any corrections.

Hoping that we fight Covid-19 effectively very soon. Stay safe.

Regards and best wishes,

Professor Dr K N Viswanathan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 18:19:06 +0000
To: Daniel Lucey
Subject: RE: COVID-19: Rembrandt's Belshazzar's Feast in a time of chiaroscuro 2020 | Science Speaks:

Thanks, Dan.

-----Original Message-----
From: Daniel Lucey [redacted] (b) (6)>
Sent: Saturday, April 11, 2020 5:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Daniel Lucey <[redacted] (b) (6)>
Subject: COVID-19: Rembrandt's Belshazzar's Feast in a time of chiaroscuro 2020 | Science Speaks:

Tony, Thank you for the immense 24/7 contribution you are making to our nation. Your wife is right: Pls get more sleep and meals! Before Easter tomorrow I am sharing this brief Old Testament story to which I gave a 2020 interpretation. Today's IDSA posting I am emphasizing that simultaneous antibody and virus RNA tests should be done on "relapsed" or "reinfected" Covid-19 patients e.g., South Korea (N=91), China, elsewhere. I am looking forward to giving NIAID Grand Rounds May 1st with Barney Graham and John Beigel. Dan [redacted] (b) (6)
https://sciencespeaksblog.org/2020/04/09/covid-19-rembrandts-belshazzars-feast-in-a-time-of-chiaroscuro-2020/

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 18:12:01 +0000
To: Barton Haynes, M.D.
Subject: RE: coach K video for DHVI

Thanks, Bart. Glad to have you working on the COVID-19 issue.

From: Barton Haynes, M.D. [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 8:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: coach K video for DHVI

Coach K and I came to duke on the same day in 1980 and [redacted] (b) (6) ...when I was chair and he wasn't quite so famous, he used to see all my division chief recruits and help me recruit. He is a really good guy, as you know.

Am on the francis Collins-appointed NIH working group for COVID19 vaccines, first meeting in the am...

Will continue to flog CoV2 simultanelously while making good progress on HIV. This past week had 4 HIV SABS, CHAVD, an IPCAVD, an HIVRAD we have with Scripps, and our GMP unit.....all on line. Not messing around.... All went really, really well.

Thanks for all you continue to do.

Best bart

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, April 11, 2020 10:32 PM
To: Barton Haynes, M.D. [redacted] (b) (6)>
Subject: RE: coach K video for DHVI

Very nice!!

From: Barton Haynes, M.D. <[redacted] (b) (6)
Sent: Friday, April 3, 2020 8:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: coach K video for DHVI

Hi tony; if you get a chance, here is a 3 min. video Coach K did last week for DHVI. I sent it to all 270 DHVI members and they were very inspired!

Thanks for sending your interview with K. it is terrific.

All the best B

From: Jon Jackson [redacted] (b) (6)>
Sent: Thursday, March 26, 2020 12:59 PM
To: Barton Haynes, M.D. [redacted] (b) (6)>
Subject: Re: saw your video

https://www.dropbox.com/s/2f6b142lv63e10f/IMG_0250.MOV?dl=0

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 17:27:46 +0000
To: Folkers, Greg (NIH/NIAID) [E];NIAID OD AM
Cc: Stover, Kathy (NIH/NIAID) [E];Leifman, Laura (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: Serosurvey

OK. We can discuss.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, April 12, 2020 11:26 AM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Leifman, Laura (NIH/NIAID) [E] [redacted] (b) (6); Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Serosurvey

Marilyn Marchione: I'm writing to request a chance to embed with a team doing a coronavirus serosurvey, to tell a public health story from the front lines as I believe I'm uniquely positioned to do.

[redacted] (b) (5)

Let us discuss in a.m.

-----Original Message-----
From: Marchione, Marilynn <MMarchione@ap.org>
Sent: Sunday, April 12, 2020 10:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] <[redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Leifman, Laura (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: FW: Serosurvey

Hello Dr. Fauci,
I hope you are staying well in these trying times.

I'm writing to request a chance to embed with a team doing a coronavirus serosurvey, to tell a public health story from the front lines as I believe I'm uniquely positioned to do. I've made a similar request to the CDC, but the nationwide reach of the NIAID serosurvey might make my proposal easier to consider, so I'm coming hat in hand to you as well.

Twenty years ago, as a temporary CDC employee during a four-month Knight Journalism fellowship, I had the opportunity to take the EIS course in Atlanta and then work on several CDC outbreak and disease investigations. One was a serosurvey on Long Island after West Nile virus had recently emerged in the U.S.
I headed one of a dozen CDC teams that included a driver, a phlebotomist and a health aide from the New York state and Suffolk County health departments. We went door-to-door to consent participants, get blood samples and do interviews on exposure and symptoms.

I appreciate the tremendous scientific value that serosurveys offer and the kind of attention to detail and study rigor that's needed to get reliable information. I'm also a longtime medical journalist who understands and is sensitive to confidentiality, ethical and privacy concerns. I've been recognized by my peers as a science writing leader.
https://casw.org/casw/article/marilynn-marchione-associated-press-wins-victor-cohn-prize

I've attached some letters from CDC and other health officials regarding my work on the serosurvey, a photo of the EIS and CDC team (that's me toward the right in the front row) and the MMWR report resulting from our work. The field supervisor -- Dr. Anthony Marfin, now with the global vaccine group PATH ((b) (6) is willing to speak to you on my behalf. Dr. Richard Besser, now president of the Robert Wood Johnson Foundation, was my fellowship supervisor and mentor at CDC. Others I worked with include Dr. Anne Schuchat, Dr. John Ward, Dr. Robert Tauxe and Dr. Lyle Petersen.

And of course, you know me from nearly three decades of medical writing, including the HIV/AIDS government trip to Africa when Tommy Thompson was healthy secretary.

The Associated Press reaches half of the world's population every day. I hope to offer a story that I and the AP are uniquely able to provide, to show and explain how public health is done and how science is accomplished during a pandemic. Thank you for considering my request.

Marilynn Marchione
Chief Medical Writer
The Associated Press
(b) (6)
mmarchione@ap.org
Twitter: @MMarchioneAP

The information contained in this communication is intended for the use of the designated recipients named above. If the reader of this communication is not the intended recipient, you are hereby notified that you have received this communication in error, and that any review, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify The Associated Press immediately by telephone at +1-212-621-1500 and delete this email. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 17:12:57 +0000
To: Barton Haynes, M.D.
Subject: RE: Wall Street Journal story

Of course. No problem.

From: Barton Haynes, M.D. <[redacted] (b) (6)
Sent: Sunday, April 12, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Wall Street Journal story

If he wants also to talk to me should I also talk to him?

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 1:09 PM
To: Barton Haynes, M.D. [redacted] (b) (6)
Subject: RE: Wall Street Journal story

Yes to your questions.

From: Barton Haynes, M.D. [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 1:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: RE: Wall Street Journal story

I know you don't have time to answer these but if you do fine, if not, ok.

Just don't want to screw something up.

Is it fair to say that shelly was not only a mentor but a father figure. You and shelly were very close.

also fair to say shelly was your most important mentor in your career?

Tx bart

From: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Sunday, April 12, 2020 12:44 PM
To: Barton Haynes, M.D. [redacted] (b) (6)
Subject: RE: Wall Street Journal story

Bart:
No problem. Go for it!
Best.
Tony

From: Barton Haynes, M.D. <[redacted] (b) (6)>
Sent: Sunday, April 12, 2020 12:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Wall Street Journal story

Hi tony; the fellow who wrote the article about you as point guard for St. Regis and the nation from the Wall street journal wants to talk to me about shelly wolff and you per below . is that ok? I will of course say only those things that are unbelievable but true....which are all wonderful..... best bart

From: Ben Cohen <ben.cohen@wsj.com>
Sent: Sunday, April 12, 2020 10:31 AM
To: Barton Haynes, M.D. [redacted] (b) (6)
Subject: Wall Street Journal story

Dr. Haynes,

I'm a reporter from the Wall Street Journal and, more important, a friend of Ben's from Duke. I've written quite a bit about your mentor and friend Dr. Fauci in the last few weeks, and I'm working on another story now that I was hoping you might be able to help with.

This story is about *his* mentor, Dr. Wolff, and how Dr. Wolff helped turn Dr. Fauci into the person he is today. I would love to hear more about their relationship from your perspective. I know this is an insanely busy time, but would you have a few minutes to chat by phone?

Thanks very much for your help. I hope you're safe and well in Durham.

All best,
Ben

--
Ben Cohen
The Wall Street Journal
212-416-3420 (o)
[redacted] (b) (6) c)
ben.cohen@wsj.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 17:10:22 +0000
To: Barton Haynes, M.D.
Subject: RE: Wall Street Journal story

Thanks.

From: Barton Haynes, M.D. [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: RE: Wall Street Journal story

I am going to refer him to you per the last note. Best bart

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 1:09 PM
To: Barton Haynes, M.D. [redacted] (b) (6)>
Subject: RE: Wall Street Journal story

Yes to your questions.

From: Barton Haynes, M.D. [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 1:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Wall Street Journal story

I know you don't have time to answer these but if you do fine, if not, ok.

Just don't want to screw something up.

Is it fair to say that shelly was not only a mentor but a father figure. You and shelly were very close.

also fair to say shelly was your most important mentor in your career?

Tx bart

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 12:44 PM
To: Barton Haynes, M.D. [redacted] (b) (6)
Subject: RE: Wall Street Journal story

Bart:
No problem. Go for it!
Best.
Tony

From: Barton Haynes, M.D. <(b) (6)>
Sent: Sunday, April 12, 2020 12:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Wall Street Journal story

Hi tony; the fellow who wrote the article about you as point guard for St. Regis and the nation from the Wall street journal wants to talk to me about shelly wolff and you per below . is that ok? I will of course say only those things that are unbelievable but true....which are all wonderful..... best bart

From: Ben Cohen <ben.cohen@wsj.com>
Sent: Sunday, April 12, 2020 10:31 AM
To: Barton Haynes, M.D. (b) (6)
Subject: Wall Street Journal story

Dr. Haynes,

I'm a reporter from the Wall Street Journal and, more important, a friend of Ben's from Duke. I've written quite a bit about your mentor and friend Dr. Fauci in the last few weeks, and I'm working on another story now that I was hoping you might be able to help with.

This story is about *his* mentor, Dr. Wolff, and how Dr. Wolff helped turn Dr. Fauci into the person he is today. I would love to hear more about their relationship from your perspective. I know this is an insanely busy time, but would you have a few minutes to chat by phone?

Thanks very much for your help. I hope you're safe and well in Durham.

All best,
Ben

--
Ben Cohen
The Wall Street Journal
212-416-3420 (o)
(b) (6) c)
ben.cohen@wsj.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 17:08:21 +0000
To: Neil Lacey - CDOT
Subject: RE: THANK YOU

Thanks, Neil. I appreciate your note.
Best,
Tony

From: Neil Lacey - CDOT <neil.lacey@state.co.us>
Sent: Sunday, April 12, 2020 1:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: THANK YOU

Thank you Dr. Birx and Dr. Fauci:

At a time when America needs it most both of you have courageously stood at the podium at the White House press briefings and explained what we all need to be doing during this paralyzing COVID-19 pandemic. When others have failed to lead, multiple task forces have struggled prioritizing safety first before economics, both of you have tag teamed presenting the data and the analytics of COVID-19 by decoding its complexities and giving us the "honest truth" in language that is easy to understand. The virus will end when it ends and not before. Thank you both for your service to the nation and for doing your jobs with conviction and commitment in doing the right thing - sticking to science and not yielding to politics. America is immensely grateful for both of you telling us all what we need to hear and what we need to do. You are both giants in the world of medicine.

Very appreciative,

Neil Lacey
[redacted] (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 17:07:23 +0000
To: Barton Haynes, M.D.
Subject: RE: Wall Street Journal story

Bart:

I would be happy to talk to him about Shelly. People like to make stories as opposed to reporting on a story. Shelly was one of my best friends and mentor, but I was me way before I met Shelly, and so I am not really sure what he means by saying that Shelly "...helped turn Dr. Fauci into the person he is today".

Best,
Tony

From: Barton Haynes, M.D. [redacted] (b) (6)
Sent: Sunday, April 12, 2020 12:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Wall Street Journal story

Of course the reason I am asking is that it is presumptious for me to talk to him about shellys influence on you....perhaps I should just refer him to you?

Don't want to do anything either inappropriate, non helpful or what you don't what. Best bart

---

From: Barton Haynes, M.D.
Sent: Sunday, April 12, 2020 12:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Wall Street Journal story

Hi tony; the fellow who wrote the article about you as point guard for St. Regis and the nation from the Wall street journal wants to talk to me about shelly wolff and you per below . is that ok? I will of course say only those things that are unbelievable but true....which are all wonderful..... best bart

From: Ben Cohen <ben.cohen@wsj.com>
Sent: Sunday, April 12, 2020 10:31 AM
To: Barton Haynes, M.D. [redacted] (b) (6)
Subject: Wall Street Journal story

Dr. Haynes,

I'm a reporter from the Wall Street Journal and, more important, a friend of Ben's from Duke. I've written quite a bit about your mentor and friend Dr. Fauci in the last few weeks, and I'm working on another story now that I was hoping you might be able to help with.

This story is about *his* mentor, Dr. Wolff, and how Dr. Wolff helped turn Dr. Fauci into the person he is today. I would love to hear more about their relationship from your perspective. I know this is an insanely busy time, but would you have a few minutes to chat by phone?

Thanks very much for your help. I hope you're safe and well in Durham.

All best,
Ben

--

Ben Cohen
The Wall Street Journal
212-416-3420 (o)
(b) (6) (c)
ben.cohen@wsj.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 12:30:56 +0000
To: Conley, Sean P. CDR USN WHMO/WHMU;Short, Marc T. EOP/OVP
Cc: Birx, Deborah L. EOP/NSC;Lane, Cliff (NIH/NIAID) [E]
Subject: RE: 15 minute Coronavrius machines

Thanks, Sean.

From: Conley, Sean P. CDR USN WHMO/WHMU [redacted] (b) (6)
Sent: Saturday, April 11, 2020 11:18 PM
To: Short, Marc T. EOP/OVP [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Birx, Deborah L. EOP/NSC <[redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: 15 minute Coronavrius machines

[redacted] (b)(5) PCP

I'll look into the possibility of freeing up a machine for investigation.

Sean

Sent from my iPhone

> On Apr 11, 2020, at 10:15 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
>
> Marc:
>
> [redacted] (b) (5)

[redacted] (b) (5)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 12:30:19 +0000
To: Short, Marc T. EOP/OVP
Subject: RE: 15 minute Coronavrius machines

Marc:
Thanks for the note. Understood. I wish you a peaceful and enjoyable day with your family.
Best regards,
Tony

From: Short, Marc T. EOP/OVP [redacted] (b) (6)
Sent: Saturday, April 11, 2020 11:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Conley, Sean P. CDR USN WHMO/WHMU [redacted] (b) (6)>; Birx, Deborah L. EOP/NSC [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: 15 minute Coronavrius machines

Dr Fauci,

You correctly noticed the symptoms but misdiagnosed the root cause. [redacted] (b)(5) PCP
[redacted] (b)(5) PCP

Apologies for a poor poker face. Best wishes to you and your family for a blessed Easter celebration of our Savior's resurrection .

Thanks for all you do,

Marc

Sent from my iPhone

> On Apr 11, 2020, at 10:15 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:
>
> Marc:

(b)(5) PCP

[redacted]

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 12:28:27 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Fearing appointment

Please respond as appropriate.

-----Original Message-----
From: Daniel Kölliker (b) (6)>
Sent: Sunday, April 12, 2020 4:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Fearing appointment

Dear Mr Fauci,

We are really wondering over here in Europe why you don't take a dedicated opinion on COVID-19 and share your opinion at the daily briefings to the extent of your personal believes.

We really expect you to oppose the president wherever you have a different opinion, which we believe is based on facts.

Please consider our request and don't let the president keep spreading his lies to the people of the United States.

We would really appreciate watching you on the briefings telling the nation the truth that is based on your experience straight to the point.

Thank you so much,
Daniel Kölliker and acquaintances

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 12:27:36 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: [redacted] (b) (4)
Attachments: [redacted] (b) (4)

Please take a look at this and respond as you see fit. Thanks.

From: [redacted] (b) (6)
Sent: Sunday, April 12, 2020 5:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: [redacted] (b) (4)

Dear Dr. Fauci

I know that you are very occupied.
[redacted] (b) (4)

Please handle the draft confidentially.

Thank you very much!
Sincerely, D. Novosel, Switzerland

www.novosel.ch

From: (b) (6)
Sent: Sat, 11 Apr 2020 22:57:51 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C];Mascola, John (NIH/VRC) [E]
Subject: Teleconference next week

I have asked john Mascola to connect with you to set up a conference call with john, me, Carl, Emily some time next week. Subject is out of the box thinking about COVID-19

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 22:08:16 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Letter sent on behalf of Chancellor Jeffrey P. Gold, M.D.

This is another email from Jeff Gold at UNMC in response to an email that you sent him.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Gold, Jeffrey P [redacted] (b) (6)>
Sent: Saturday, April 11, 2020 3:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: Letter sent on behalf of Chancellor Jeffrey P. Gold, M.D.

Tony,
Many thanks for taking the time to respond. Please let me know if I can help in any way.
Our mobile device app (developed with Apple) has been quite helpful and is growing in use (over 10K) as a screening, referral and surveillance tool for several user sets.
Just one of the many areas we continue to develop.
Best wishes
jeff

From: "M. Anthony S. Fauci" [redacted] (b) (6)>
Date: Saturday, April 11, 2020 at 1:52 PM
To: "Gold, Jeffrey P" [redacted] (b) (6)
Subject: RE: Letter sent on behalf of Chancellor Jeffrey P. Gold, M.D.

Non-UNMC email

Jeff:
Many thanks for your kind note. Hope that all is well with you.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6) **On Behalf Of** Gold, Jeffrey P
Sent: Friday, April 10, 2020 12:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Gold, Jeffrey P [redacted] (b) (6)
Subject: Letter sent on behalf of Chancellor Jeffrey P. Gold, M.D.
Importance: High

April 10, 2020

Anthony S. Fauci, M.D.
Director
National Institute of Allergy and Infectious Diseases
5601 Fishers Lane, MSC 9806
Bethesda, MD 20892-9806
[redacted] (b) (6)

Dear Dr. Fauci:

I write simply to thank you and congratulate you for your incredible efforts during the management of this pandemic as it reaches across our nation. The unique challenges that this pandemic has created have also created opportunities, and we here at the University of Nebraska Medical Center have proudly participated with our federal, state and local partners during this COVID-19 pandemic as well as over the last 16 years, having matured an extensive program in the research, education, and clinical components of highly infectious diseases and biocontainment.

The UNMC Center for Global Health Security has been the umbrella organization that has organized all of these components and continues to have strong leadership from retired military public health as well as gifted research scientists from across the nation. As a co-founding partner of NETEC, as a recipient of the Regional Disaster Health Service Awards, and as a close collaborator with the Department of Health and Human Services, the Department of Defense, the Department of Homeland Security and the Department of State, we have enjoyed the opportunity to always "lean in" as the need arises.

I am sure your days are full not only of the complex logistics and tension that fill leadership roles at this time but also maintaining a "steady hand on the rudder" as we navigate these challenging waters. I think back to my days at New York Presbyterian and Cornell Med, knowing that we are both Cornell Med grads, both did our residency and fellowship training in New York, and have had the opportunity to interact back so many years ago. I do remember quite well the first time that we met and have always reflected warmly at having even a brief opportunity to interact.

I do not write to ask for anything but to just simply thank you for all that you continue to do and know that you always have a friend here in Nebraska. I wish you and your family the very best as we continue this journey.

Most sincerely,

(b) (6)

Jeffrey P. Gold, M.D.
Chancellor

JPG (b) (6)

(b) (6)
Administrative Associate I
Chancellor Jeffrey P. Gold's Office

University of Nebraska Medical Center
986605 Nebraska Medical Center | Omaha, NE 68198-6605
(b) (6) | fax 402.559.4396
(b) (6)

UNMC | Facebook [facebook.com] | Twitter [twitter.com] | Instagram [instagram.com] | YouTube [youtube.com] | Flickr [flickr.com]

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 22:02:38 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Please send me your cell phone #.
Attachments: COVID-19 Craig Schirmer Memo 04.10.20.pdf

This email is from Jeffrey Sachs.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

-----Original Message-----
From: Jeffrey Sachs [redacted] (b) (6)
Sent: Saturday, April 11, 2020 4:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: Please send me your cell phone #.

[redacted] (b) (4)

Looking forward to speaking,

Jeff

On 4/11/20, 4:28 PM, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)> wrote:

> Mine is [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Sat, 11 Apr 2020 16:25:18 -0400
To: Evans, Michele (NIH/NIA/IRP) [E]
Subject: Re: Covid-19 Health Disparities

Michele:
Many thanks for your note.
Best regards,
Tony

> On Apr 7, 2020, at 8:28 PM, Evans, Michele (NIH/NIA/IRP) [E] [redacted] (b) (6)>wrote:
>
> Dear Dr. Fauci,
>
> Thank you from the bottom of my heart for highlighting the health disparities and disproportionate burden of disease influencing outcome of Covid-19 infections in African Americans. Participants in my observational, longitudinal, epidemiologic Baltimore-based study, HANDLS https://handls.nih.gov/ are terrified by the level of disease they are seeing in their communities across Baltimore. We have been on the phone with and texting participants to educate them, support them in their efforts to get tested, remind them of the importance of social distancing and self-isolation when appropriate to protect their health. We are acutely aware of their fragility. Testing in Baltimore is limited. The National Guard has set up community testing at the Pimlico Race Track; however, although we have deployed our mobile medical research vehicles to Pimlico in the past to conduct our study, the current crime rate is such that our participants and community residents in general do not go to the Pimlico area especially if they are on foot. The other issue with testing for African Americans and our participants is the need to have a health care provider that one can contract to discuss symptoms to get a referral for testing. The unravelling of the Affordable Care Act has severely impacted access for African Americans across the nation and especially in Baltimore. Our participants are calling my staff clinician and nurse practitioner for referrals if they have symptoms. We have reached out to colleagues at

Health Care for the Homeless, JHU and other medical entities to facilitate access.

Thank you all you are doing. Since I work in Baltimore, I haven't seen you in person since [redacted] (b) (6) [redacted]. The current pandemic however, reminds me of the days of the AIDS epidemic when I worked as Sam Broder's special assistant for underserved populations while Peggy Hamburg worked for you. I was in awe of you and Sam then and I remain in awe of you today. I have known many Regis men...but you are clearly head and shoulders above them all.

Michele K. Evans, M.D.
Deputy Scientific Director &Chief,
Health Disparities Research Section
National Institute on Aging
National Institutes of Health
NIH Biomedical Research Program
251 Bayview Boulevard
Suite 100 Room 4C-222
Batimore, Maryland 21224
Email: [redacted] (b) (6)
Tel. [redacted] (b) (6)
https://irp.nih.gov/pi/michele-evans
https://handls.nih.gov/

From: [redacted] (b) (6)
Sent: Sat, 11 Apr 2020 16:22:40 -0400
To: Janet Tobias
Cc: Conrad, Patricia (NIH/NIAID) [E]; [redacted] (b) (6)
Subject: Re: Updates: Film

Janet
All this sounds fine and workable.
Thanks,
Tony

> On Apr 7, 2020, at 8:31 PM, Janet Tobias <janet@ikanamedia.com>wrote:
>
> Dear Tony and Patty:
> Responses to Burklow's questions to me from your group call yesterday:
> 1) I think we have landed in the right place for the film about your life. Nat Geo, Disney, and Bob Iger himself, all understand the need for discretion now but are wildly supportive about releasing a film that will celebrate the importance of your life, science and public health. I wanted the best home, broadest distribution, and strongest team for your film. You have entrusted me with your story, so I just want to do right by it. We are really happy with the filming that we have done so far personal [redacted] (b) (6) home, school) to work (office etc).
> 3) The other film we have been working on (ENDING AIDS), which follows globally the HVTN trials/latest Aids research to complete "the toolbox" is definitely still happening. It is now in pause with COVID-19….but will move forward again when we get through this. Filming at research sites in South Africa, US, and Latin America has been great...and when you have time — in the future — I will outline. You obviously are a key subject in ENDING AIDS also, but ENDING AIDS will spend a lot of time with doctors at the field research sites and with volunteers in the trials. The Aids conference and meetings footage we have shot with you will be shared between films, smartly and distinctly. ENDING AIDS will be released a year plus later than the release of your biographical film—I am focused on your film now. Howard Hughes Medical Institute remains the educational partner on ENDING AIDS. In the fall we will finalize the broadcast/streaming partner for ENDING AIDS. So, bottom line it will be released a year after your film, and will be a film focused on showing in detail where we are now with aids research and the key people in the chain from you to a young female volunteer in South Africa/a young male volunteer in Birmingham.
> FILMING REQUESTS for your film now.
> 4) NO more asking to film with the Task Force.
> 5) I do have two personal filming requests for you — would it be possible to drive to NIH with you once or twice a week and capture your working/appropriate conversations in the car. That will be so helpful narratively to tracking your scientific and communication leadership. The footage we did that first day is truly

great. We will just turn around and come back after the ride there--- in our follow car (we have NIH access badges). Secondly, would it be possible to sit down with you on camera for 15 minutes once a week (on the weekend?) at the office or on the back deck/some safe location to talk with me in real time about what you are managing with treatments, vaccines, etc. so we can pull the scientific/communication narrative on COVID-19 through your film.

6) We love the live truck and the walks, so whenever that works we will be there.

7) I NEVER ever want to interfere with the work on the Task Force, lives are at stake. IF something doesn't work for filming no questions asked we don't do it, we stop, cancel/pivot. No need to explain, the team here understands and only wants to do what works for you, your team…. (b) (6).

With appreciation,

Janet

From: [redacted] (b) (6)
Sent: Sat, 11 Apr 2020 16:14:53 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Invitation to speak to ABEA in virtual meeting

No

Begin forwarded message:

> **From:** "Allen, Clint (NIH/NIDCD) [E]" [redacted] (b) (6)>
> **Date:** April 8, 2020 at 9:16:55 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" < [redacted] (b) (6)>
> **Subject: Invitation to speak to ABEA in virtual meeting**
>
> Dr. Fauci –
>
> Almost embarrassed to ask, but would you be willing/able to speak virtually to the **American Broncho-Esophagological Association** (abea.net) on Friday April 24th? This year marks the 100th anniversary of this venerable organization that brings together clinicians (mainly Otolaryngologists) who care for patients with complex upper aerodigestive tract disorders. Our annual National Meeting has been cancelled and we are hosting a virtual meeting it it's stead.
>
> As Otolaryngologists, we are currently and expect to continue to be dramatically impacted by the current pandemic, given that our care for patients routinely includes upper airway endoscopy (30-40 scope procedures a day is routine) which as you know is a high-risk aerosolizing procedure. As I'm sure you are aware, Otolaryngolgists have been amongst the hardest hit clinicians in terms of patient-to-provider transmission of COVID-19.
>
> Your input for 10-15 minutes would be an honor. Discussion topics could include general comments about the pandemic, a sense of what to expect in the coming months and years, and *what we can do as medical leaders to prepare for these changes in the US and abroad.*
>
> If this is something you are interested in, with whom on your communications team could I communicate?
>
> Thanks so much for the consideration – your brief presence and input would mean a great deal to our society.

Clint Allen

From: [redacted] (b) (6)
Sent: Sat, 11 Apr 2020 16:08:26 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Council of Scientific Society Presidents Support of Science Award
Attachments: Fauci_CSSP_Award.pdf, ATT00001.htm, CSSP Brochure_2019 v3.pdf, ATT00002.htm

Let us discuss. They want to give me an award virtually. Probably should accept if it requires no time or work

Begin forwarded message:

> **From:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Date:** April 9, 2020 at 10:52:49 AM EDT
> **To:** NIAID OD AM <NIAIDODAM@niaid.nih.gov>
> **Subject: FW: Council of Scientific Society Presidents Support of Science Award**
>
> Patricia L. Conrad
> Public Health Analyst and
> Special Assistant to the Director
> National Institute of Allergy and Infectious Diseases
> The National Institutes of Health
> 31 Center Drive, MSC 2520 - Room 7A03
> Bethesda, Maryland 20892
> [redacted] (b) (6)
> 301-496-4409 fax
>
> Disclaimer:
> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
>
> ---
>
> **From:** Mosher, Sharon <smosher@jsg.utexas.edu>
> **Sent:** Thursday, April 9, 2020 10:31 AM
> **To:** Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
> **Cc:** Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>; Conrad, Patricia

(NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Council of Scientific Society Presidents Support of Science Award

Dear Dr. Fauci;

Council of Scientific Society Presidents (CSSP) would like to honor you with our Support of Science Award at our May Leadership Workshop (virtual). The purpose of this award is to honor those who have proven their outstanding support of U.S. science, free scientific communication, and a support of basic science research. The expertise with which you guide the United States through these unprecedented COVID-19 times simply reinforces the dedication you exhibit to ensure the greatest safety to the greatest number of US citizens.

Dr. Martin Apple talked to Kim Barasch earlier this week. Please find the attached formal invitation letter she indicated that was needed. I have also attached a PDF of a brochure, though most information is on our website.

If you or Kim have any questions, please let me know by email or phone.
Sincerely,
Sharon Mosher

Sharon Mosher
Farish Chair and Professor
The University of Texas at Austin
Jackson School of Geosciences
2305 Speedway, Stop C1160
Austin, TX 78712-1692
[redacted] (b) (6) (cell)
smosher@jsg.utexas.edu

From: [redacted] (b) (6)
Sent: Sat, 11 Apr 2020 16:04:03 -0400
To: Alison Galvani
Cc: Conrad, Patricia (NIH/NIAID) [E];Seyed Moghadas;Singer,Burton H
Subject: Re: Your Submission THELANCETID-D-20-01518R1

Thanks, Alison

> On Apr 9, 2020, at 7:46 PM, Alison Galvani [redacted] (b) (6) >wrote:
>
> Hi Tony,
> I thought you might be interested in our projections regarding ventilator needs in the US. The brief report (attached) was accepted at Lancet ID yesterday. Funded by NIAID :)
> Take care,
> Alison
>
> ---------- Forwarded message ---------
> From: **Phoebe Hall** <em@editorialmanager.com>
> Date: Wed, Apr 8, 2020 at 9:36 AM
> Subject: Your Submission THELANCETID-D-20-01518R1
> To: Galvani, Alison [redacted] (b) (6)
>
> Dear Professor Galvani,
>
> Reference: THELANCETID-D-20-01518R1, Projecting the demand for ventilators at the peak of COVID-19 outbreaks in the United States
>
> I am pleased to tell you that your submission, Projecting the demand for ventilators at the peak of COVID-19 outbreaks in the United States, has been accepted for publication in The Lancet Infectious Diseases.
>
> In due course you will receive, electronically, a set of pdf proofs of your article. Please note that because of our varied and international readership, The Lancet Infectious Diseases edits heavily to a strict house style. Thus, changes will inevitably be made to your manuscript at this time. There will also probably be a few final editorial queries at this stage. Please correct and return these pages by the deadline stated in the covering email.
>
> Finally, please note that The Lancet Infectious Diseases is committed to support authors in making their work publicly and freely available. The editors encourage authors to post a word-processed document (NOT the published journal article as

PDF) of their peer-reviewed, accepted article on personal or institutional websites any time after publication in print or online. Your document should include the article citation and a link to The Lancet Infectious Diseases's homepage. Please note that posting and distribution of PDF or HTML documents, however, is not acceptable and breaches your copyright agreement.

Please complete the following Journal Publishing Agreement:
https://nam05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.thelancet.com%2Ffor-authors%2Fforms%3Fsection%3Djpa&amp;data=02%7C01%7Calison.galvani%40yale.edu%7C1c0ddd00e9ca413f771008d7dbc1e529%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637219498130294598&amp;sdata=WoXBAmJNsM9SBkFaeGKAzvANg%2BSzbZAw94aQ5%2BAtP%2FY%3D&amp;reserved=0

Please retain a copy for your files and email a completed copy to HALLP@science.regn.net. Please ensure all the pages are returned.

WHO AUTHORS
If you or any of your co-authors are employed directly by the World Health Organization, you have the option of either signing Elsevier's standard agreement or our WHO/Elsevier non-exclusive licence agreement. Please contact our Deputy Operations Manager, Marco Conforti (m.conforti@elsevier.com) for a copy of the WHO agreement.

Yours sincerely,

Phoebe Hall
Senior Editor
The Lancet Infectious Diseases

E-mail: phoebe.hall@lancet.com

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: https://nam05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.editorialmanager.com%2Fthelancetid%2Flogin.asp%3Fa%3Dr&amp;data=02%7C01%7Calison.galvani%40yale.edu%7C1c0ddd00e9ca413f771008d7dbc1e529%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637219498130294598&amp;sdata=jK1kjtzfbMH6UMOPZ%2BvavnATDZkEB9y2up55tmxUA5A%3D&amp;reserved=0). Please contact the publication office if you have any questions.

--
Alison Galvani, PhD

Director, Yale Center for Infectious Disease Modeling and Analysis (CIDMA)

Burnett and Stender Families Professor of Epidemiology
Yale School of Public Health
Yale School of Medicine
New Haven, CT 06520

(b) (6)
http://cidma.yale.edu/
Follow me at @Alison_Galvani
Follow CIDMA @YCIDMA
<Brief report on ventilator needs.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 19:56:00 +0000
To: Jack Killen
Cc: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: From Jack Killen & Fred Boykin

Jack:

Many thanks for your kind note. [redacted] (b) (6)

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jack Killen [redacted] (b) (6)
Sent: Tuesday, April 7, 2020 1:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)
Subject: From Jack Killen & Fred Boykin

Dear Tony:

This is a quick note to say Fred and I have been watching you every day, in awe, for weeks now. We could not be more grateful for your leadership, wisdom, courage, and integrity. Our country could not be more fortunate that you are still there in guiding us through this terrible time. Needless to say, many memories of our years working together have been in the forefront of our minds.

On a personal note, [redacted] (b) (6) (b) (6)

My epidemic battling skills are rusty, but if there is anything I can do to help in any way, please know I are here for you. Fred is as well.

Godspeed, and please take care of yourself. Best to you, [redacted] (b) (6) and your family.

Jack Killen MD

[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 19:50:06 +0000
To: George GAO
Subject: RE: Vaccine—confidential PPT

George:

Thank you for your kind note. All is well despite some crazy people in this world.

Warm regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: George GAO [redacted] (b) (6)
Sent: Wednesday, April 8, 2020 4:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Vaccine—confidential PPT

Tony

I saw some news（hope it is fake）that are being attacked by some people. Hope you are well under such a irrational situation.

[redacted] (b) (4) Thank you for your introduction.

All the best and stay safe.
Bw
George

发自我的iPhone

在 2020年3月29日， 09:07， Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
写道：

George:
Thanks for the note. I understand completely. No problem. We will get through this together.
Bed regards,
Tony

On Mar 28, 2020, at 8:50 PM, George GAO [redacted] (b) (6) wrote:

Dear Tony
I know you are working extremely hard with a lot of pressure. Hope the US situation is getting better eventully. I saw the Science interview， how could I say such a word “big mistake” about others？That was journalist's wording. Hope you understand. It was NOT a real interview but a QaA through social media for several days when ge asked me what China has done and is working on. Lets work together to get the virus out of the earth.
Best wishes
George

发自我的iPhone

在 2020年3月3日， 21:10， Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6) 写道：

George:
Thanks for the note. I will send this to Dr. John Mascola Director of the NIAID Vaccine Research Center and Dr. Barney Graham to follow-up with you.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: George GAO [redacted] (b) (6)
Sent: Tuesday, March 3, 2020 7:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Vaccine—confidential PPT

Dear Tony
Hope this email finds you well and the US will soon get the COVID-19 down.

[redacted] (b) (4)

All the best
George

发自我的iPhone
<20200303 For Gao laoshi.pptx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 19:27:03 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: ASF - note from Mary Jane Walker !! FW: Catching up

Thanks, Mary Jane!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, April 9, 2020 10:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Mary jane Walker (b) (6)
Subject: ASF - note from Mary Jane Walker !! FW: Catching up

From: Mary jane Walker < (b) (6)
Subject: Catching up
Date: April 6, 2020 at 9:23:13 PM EDT
To: (b) (6)

Hi Tony,

I hope that you are doing well despite all that you are dealing with around COVID-19. It has been many years since I had the opportunity to work with you but my job at NIAID was one of my favorite positions and gave me a great start to my career. So, when I saw the below graphic, it made me smile and I wanted to send you a note.

I truly appreciate how you are handling the COVID-19 situation. Your comments are a breath of fresh air amidst politics and uncertainty. With daily White House press briefings, increased security and scrutiny, 24/7 media interviews and great popularity, you seem to be holding up well - as you always do. Your recent interview with JAMA's Editor-in-Chief Howard Bauchner was particularly well done and very enlightening.

Thank you for everything that you are doing and please stay healthy!

Kind regards,

Mary Jane


SUPERHERO
FAUCI
NIAID
Orlando
Anthony Fauci

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 18:35:53 +0000
To: Crawford, Chase (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Haskins, Melinda (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E]
Subject: RE: Attn Dr. Fauci: Key Points for Congressional Black Caucus Briefing Call - Monday 11:30a.m.

Thanks. Please make sue that it is printed out mand given to me before the briefing.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Crawford, Chase (NIH/NIAID) [E] (b) (6)
Sent: Friday, April 10, 2020 7:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Haskins, Melinda (NIH/NIAID) [E] (b) (6)>; Selgrade, Sara (NIH/NIAID) [E] (b) (6)
Subject: RE: Attn Dr. Fauci: Key Points for Congressional Black Caucus Briefing Call - Monday 11:30a.m.

Dr. Fauci,

Attached is an updated "one-pager" for your call on Monday with members of the Congressional Black Caucus. At Greg's recommendation, we have added information on the NIH-supported serosurvey that was announced this afternoon.

Please let me know if I can be of further assistance (Chase cell: (b) (6))

Thanks,
Chase

From: Crawford, Chase (NIH/NIAID) [E]
Sent: Friday, April 10, 2020 5:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)>; Selgrade, Sara (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Attn Dr. Fauci: Key Points for Congressional Black Caucus Briefing Call - Monday 11:30a.m.

Dr. Fauci,

On Monday, April 13th, at 11:30 a.m., you are scheduled to participate in an informal discussion/telebriefing regarding health disparities and COVID-19 with members of the Congressional Black Caucus (CBC). Rep. Barbara Lee (D-CA, including Oakland and Berkeley) – former CBC chair – made the request. A list of expected call participants is below the signature line of this email.

I have attached a "one-pager" to provide some background on health disparities and COVID-19 that includes information on NIH COVID-19 research that may be relevant to the discussion. As you are aware, we do not have any COVID-19 studies directly focused on the African American community. Hilary and Greg have provided input.

Please let me know if I can be of further assistance (Chase cell: [redacted] (b) (6))

Thanks,
Chase

List of CBC call participants
Rep. Barbara Lee
Rep. Karen Bass (CBC Chair)
Rep. Robin Kelly (CBC Health Braintrust Chair)
Rep. G.K. Butterfield
Rep. Yvette Clarke
Rep. Cedric Richmond
Rep. Brenda Lawrence

Rep. Steve Horsford
Rep. Ayanna Pressley

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 18:10:39 +0000
To: [redacted] (b) (6)
Subject: FW: Wpost: Gilead's experimental drug remdesivir shows `hopeful' signs in small group of coronavirus patients https://wapo.st/2wzjsy2

Geeez....

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, April 10, 2020 5:30 PM
Subject: Wpost: Gilead's experimental drug remdesivir shows `hopeful' signs in small group of coronavirus patients https://wapo.st/2wzjsy2

Business

Gilead's experimental drug remdesivir shows `hopeful' signs in small group of coronavirus patients

Two-thirds of severely ill patients showed improvement in their oxygen therapy level when treated with the antiviral drug

Two ampuls of remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, April 8, 2020, as the spread of coronavirus disease (covid-19) continues. Ulrich Perrey/Pool via REUTERS (Pool/Reuters)

By

Christopher Rowland

April 10, 2020 at 5:25 p.m. EDT

A majority of a small group of patients showed improvements after being treated with an experimental coronavirus treatment made by Gilead Sciences, bolstering hopes for finding a treatment for the disease, according to a study published in the New England Journal of Medicine Friday.

The group of patients received the anti-viral drug remdesivir as part of a "compassionate use" trial, not a double-blind placebo-controlled trial which would offer more definitive evidence. Also, the cohort of patients was small, only 53 patients in the United States and around the world. Those limiting factors prevent scientists from declaring that the drug works.

Still, the improvements offered positive news about a drug seen by global health authorities as offering the best shot at becoming a treatment for the disease.

Thirty six patients out of 53 — or two-thirds — showed improvement in oxygen support, trial authors said. Seventeen of 30 patients who were on ventilators were able to be taken off the life-support machines.

"We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful," said Jonathan D. Grein, MD, Director of Hospital Epidemiology, Cedars-Sinai Medical Center, Los Angeles, and lead author of the journal article. "We look forward to the results of controlled clinical trials to potentially validate these findings."

While 68 percent of the patients showed improvement in the level of oxygen support they needed, 13 percent died, the NEJM study said. That 13 percent compares favorably to mortality rates of 17 to 78 percent in China among severely ill patients, the authors wrote.

Gilead's stock has been bolstered for weeks by expectations over remdesivir.

Remdesivir was discovered by Gilead in the hunt for antiviral drugs about a decade ago, and the National Institutes of Health has partnered with the company to explore its benefits. It was shown to work against an array of viruses in laboratory tests.

It showed effectiveness in primates infected with Ebola but failed in a trial in the Democratic Republican of Congo in humans with the deadly disease. It has shown effectiveness as a preventive therapy in primates for MERS, which is a coronavirus cousin of the Covid-19 virus.

There are no treatments approved by the Food and Drug Administration to treat coronavirus, but the FDA has granted an emergency use authorization for the use of hydroxychloroquine and chloroquine, two decades-old anti-malarial drugs. There is scant evidence that the therapy works, but President Trump has repeatedly boosted the promise of the drugs.

Even while multiple full clinical trials of remdesivir continue, Gilead hasbeen swamped with requests for "compassionate use" of the drug. Under compassionate use rules, physicians can obtain experimental drugs for their seriously ill patients when there is nothing else to try.

Gilead said last week that it had enough of the experimental drug on hand to treat up to 140,000 people under compassionate use programs.

0 Comments

Christopher Rowland

Chris Rowland joined The Washington Post business team in 2018 after serving as the Washington bureau chief for the Boston Globe, leading coverage of two presidential elections and overseeing political enterprise reporting. He previously covered health care for the Globe in Boston.Follow

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 18:09:19 +0000
To: [redacted] (b) (6)
[redacted]
Subject: FW: New Yorker: How Anthony Fauci Became America's Doctor https://bit.ly/2y3h3fi

This is the actual article for which I previously sent you a link.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, April 10, 2020 4:30 PM
Subject: New Yorker: How Anthony Fauci Became America's Doctor https://bit.ly/2y3h3fi

Annals of Medicine

April 20, 2020 Issue

How Anthony Fauci Became America's Doctor

An infectious-disease expert's long crusade against some of humanity's most virulent threats.

By Michael Specter

April 10, 2020



"You stay completely apolitical and non-ideological," Fauci says. "I'm a scientist and I'm a physician. And that's it." Illustration by Tyler Comrie. Photograph by Win McNamee / Getty

Just before midnight on March 22nd, the President of the United States prepared to tweet. Millions of Americans, in the hope of safeguarding their health and fighting the rapidly escalating spread of COVID-19, had already begun to follow the sober recommendation of Anthony S. Fauci, the country's leading expert on infectious disease. Fauci had warned Americans to "hunker down significantly more than we as a country are doing." Donald Trump disagreed. "WE CANNOT LET THE CURE BE WORSE THAN THE PROBLEM ITSELF," he tweeted.

Trump had seen enough of "social distancing." In an election year, he was watching the stock market collapse, unemployment spike, and the national mood devolve into collective anxiety. "I would love to have the country opened up, and just rarin' to go by Easter," he said, on Fox News. "You'll have packed churches all over our country. I think it'll be a beautiful time."

Trump's Easter forecast came more than two months after the first U.S. case of COVID-19 was identified, in Washington State, and more than a hundred days after the novel coronavirus emerged, first from bats and then from a live-animal market in the Chinese city of Wuhan. Every day, more people were falling sick and dying. Despite a catastrophic lack of testing capacity, it was clear that the virus had reached every corner of the nation. With the Easter holiday just a few weeks away, there was not a single public-health official in the United States who appeared to share the President's rosy surmises.

Anthony Fauci certainly did not. At seventy-nine, Fauci has run the National Institute of Allergy and Infectious Diseases for thirty-six years, through six Administrations and a long procession of viral epidemics: H.I.V., SARS, avian influenza, swine flu, Zika, and Ebola among them. As a member of the Administration's coronavirus task force, Fauci seemed to believe that the government's actions could be directed, even if the President's pronouncements could not. At White House briefings, it has regularly fallen to Fauci to gently amend Trump's absurdities, half-truths, and outright lies. No, there is no evidence that the malaria drug hydroxychloroquine will provide a "miracle" treatment to stave off the infection. No, there won't be a vaccine for at least a year. When the President insisted for many weeks on denying the government's inability to deliver test kits for the virus, Fauci, testifying before Congress, put the matter bluntly. "That's a failing," he said. "Let's admit it."

When Trump was not dismissing the severity of the crisis, he was blaming others for it: the Chinese, the Europeans, and, as always, Barack Obama. He blamed governors who were desperate for federal help and had been reduced to fighting one another for lifesaving ventilators. In one briefing, Governor Andrew Cuomo, of New York, said, "It's like being on eBay with fifty other states, bidding on a ventilator." Trump even accused hospital workers in New York City of pilfering surgical masks and other vital protective equipment that they needed to stay alive. "Are they going out the back door?" Trump wondered aloud.

As a reporter who writes mainly on science and public-health issues, I've known Fauci since the H.I.V./AIDS epidemic exploded, in the mid-eighties. He once explained to me that he has developed a method for dealing with political leaders in times of crisis: "I go to my favorite book of philosophy, 'The Godfather,' and say, 'It's nothing personal, it's strictly business.' " He continued, "You just have a job to do. Even when somebody's acting ridiculous, you can't chide them for it. You've got to deal with them. Because if you don't deal with them, then you're out of the picture."

Since his days of advising Ronald Reagan and George H. W. Bush, Fauci has maintained a simple credo: "You stay completely apolitical and non-ideological, and you stick to what it is that you do. I'm a scientist and I'm a physician. And that's it." He learned the value of candor early. "Some wise person who used to be in the White House, in the Nixon Administration, told me a very interesting dictum to live by," he told me in 2016, during a public conversation we had at the fifty-year reunion of his medical-school class. "He said, 'When you go into the White House, you should be prepared that that is the last time you will ever go in. Because if you go in saying, I'm going to tell somebody something they want to hear, then you've shot yourself in the foot.' Now everybody knows I'm going to tell them exactly what's the truth."

Americans have come to rely on Fauci's authoritative presence. Perhaps not since the Vietnam era, when Walter Cronkite, the avuncular anchor of the "CBS Evening News," was routinely described as the most trusted man in America, has the country depended so completely on one person to deliver a daily dose of plain talk. In one national poll, released last Thursday, seventy-eight per cent of participants approved of Fauci's performance. Only seven per cent disapproved.

On March 23rd, Fauci failed to appear at the daily briefing in the White House pressroom. Twitter promptly lost its mind. #NoFauci became a top trending topic, followed closely by #whereisFauci and #letTonyspeak. There was speculation that Trump, who is inclined to fire anyone who disagrees with him or, worse, garners some praise in the media, had lost patience with Fauci. As one of Fauci's old friends told me, "This is a President who doesn't give a shit about Fauci's accomplishments, his history, or his learning. If anything, they're negatives."

The truth was less alarming. "I was tied up in a task-force meeting, and we were trying to work out some difficult policies," Fauci said. "I have no trouble with the President. When I talk to him, he listens." My experience with Fauci suggested that this last statement was perhaps a triumph of pragmatism over accuracy. His priority, as he's made clear, is to do what is necessary to save lives. So I was not surprised to receive an e-mail from Fauci the following day, saying that he had been asked to refrain from participating in personal profiles. It seemed that it was one thing for him to talk about the news with reporters or even to chat on Instagram with Stephen Curry, the Golden State Warriors star. But focussing on himself, rather than on the President, was another thing entirely.

Fauci and Trump are about as odd a duo as American political life has ever produced. Both men are in their seventies. Both come from the outer boroughs of New York City. Both are direct, even blunt. But that's where the resemblance ends. Fauci has always been a person of unusual discipline. Nearing eighty, he works about eighteen hours a day. Long ago, when his three children were young, he and his wife, Christine Grady, who runs the bioethics department at the National Institutes of Health, decided to maintain the sanctity of family dinners by starting them when he got home from the office, at around nine o'clock. For decades, Fauci has taken long lunchtime runs, but, during the crisis, he's cut back his routine to power walking—and only on weekends. Fauci parses his words with care and believes, above all, in the power of facts and the efficacy of data.

ADVERTISEMENT

David Baltimore, a Nobel laureate and a pioneer of molecular biology, told me, "Tony is unique, in that he has such credibility with politicians that he's been able to insert hard facts into the conversation. That has been wonderful for our country and the world." According to David Relman, a microbiologist at Stanford University who for years has advised the government on biological threats, "Tony has essentially become the embodiment of the biomedical and public-health research enterprise in the United States. Nobody is a more tireless champion of the truth and the facts. I am not entirely sure what we would do without him."

Fauci can be impatient with the compromises of politics. In my conversations with him, he has responded furiously when a dicey amendment, a bogus rider, or a "poison pill" is attached to a public-health bill. He recalled one congressional provision, in 2016, that tried to make it "legally permissible to fly the Confederate flag at national cemeteries. I am not kidding." When dealing with politicians, he told me, he relies on the pseudo-Latin expression *Illegitimi non carborundum:* Don't let the bastards grind you down. But he has inspired respect throughout the political world and beyond. Fauci's office walls are covered with scores of photographs of him with Presidents, senators, visiting Prime Ministers, business leaders, actors. In October, 1988, George H. W. Bush, during a Presidential debate with Michael Dukakis, was asked who his heroes were. "I think of Dr. Fauci," Bush replied. "You've probably never heard of him. . . . He's a very fine researcher, a top doctor at the National Institutes of Health, working hard, doing something about research on this disease of AIDS." These days, nearly everyone has heard of Fauci. Pandemic-memorabilia entrepreneurs have put his face on bottle openers, coffee mugs, and bumper stickers: "In Dr. Fauci we trust." The National Bobblehead Hall of Fame and Museum has produced a seven-inch likeness of him, partly to raise money to produce protective gear for medical workers. There's a Facebook group called Dr. Fauci Speaks, We Listen, and another called Dr. Fauci Memes for Social Distance Teens. A petition has circulated to nominate him as *People's* "sexiest man alive."

On right-wing social media and talk radio, Fauci has a different image: he is routinely disparaged as a closet lefty who is exaggerating the threat of the coronavirus. "Has anyone else noticed that every suggestion by Dr. Doom Fauci just happens to also be the worst possible thing for the economy?" the conservative Internet TV host Bill Mitchell tweeted. "That's not an accident folks." An analysis in the *Times* found more than seventy Twitter accounts that have pushed the hashtag #FauciFraud, with some tweeting out anti-Fauci bile hundreds of times a day. "There seems to be a concerted effort on the part of Trump supporters to spread misinformation about the virus," Carl Bergstrom, a professor of biology at the University of Washington who has studied misinformation, told the paper. "There is this sense that experts are untrustworthy, and have agendas that aren't aligned with the people." Fauci has received so many personal threats that the Justice Department recently approved a security detail for him. Fauci shrugged it off, telling reporters, “I’ve chosen this life.”

The crisis that the world now faces comes as no surprise to Fauci. On January 10, 2017, ten days before Trump took the oath of office, Fauci delivered the keynote address at a conference at Georgetown University, titled “Pandemic Preparedness for the Next Administration.” After describing his years of managing epidemics, he posed a series of questions to the audience: “Will there be a resurgence of Zika? We’re getting into the summer in South America. Are we going to see a resurgence or not? What about influenza? Are we going to get a new pandemic?”

Fauci’s last point, he emphasized, was almost certainly the most important: the possibility that some unknown, powerfully infectious pathogen could emerge to threaten the world. “What about things that we’re not even thinking about?” he said. He let the question drift out over the hall. “What is for sure,” he concluded, “is that, no matter what, history has told us definitively that it will happen.”

On the day that Anthony Stephen Fauci was born, the front-page headline in the *Times* was “PRESIDENT TO GIVE EMERGENCY FACTS TO NATION ON RADIO.” It was Christmas Eve, 1940. The Second World War had begun, and the United States was less than a year away from joining the fight.

Fauci grew up in southwest Brooklyn, first in Bensonhurst and later in Dyker Heights, where his family ran a pharmacy and lived in an apartment upstairs. The pharmacy was across the street from the Shrine Church of St. Bernadette. When Mass was finished on Sundays, Fauci recalled, people would walk over to get prescriptions filled and to buy whatever else they needed for the coming week. Tony’s father, Stephen, dispensed medications, and was known to customers as Doc. His mother, Eugenia, worked the register, along with his older sister, Denise. From an early age, Tony spent evenings and weekends riding around the neighborhood on his Schwinn, making deliveries.

Fauci’s parents were born in New York; one set of grandparents had emigrated from Naples, the other from Sicily. Anthony first took Communion at the age of seven and was confirmed at twelve. He went to elementary school at Our Lady of Guadalupe, in Bensonhurst. “I had no idea at the time when I was there, being taught by the Dominican nuns, that I would be interested in science,” he said. “I was interested in a lot of things, mostly sports, but certainly not science.”

In those days, baseball was the social glue of Brooklyn. The borough was Dodger territory and Ebbets Field was consecrated ground—but Fauci was devoted to the Yankees, who played in the faraway Bronx. In the midst of the coronavirus crisis, I e-mailed to ask about this anomaly, not necessarily expecting an answer. He replied almost instantly. “You probably are unaware, but half the kids in Brooklyn were Yankee fans,” he wrote. “We spent our days arguing who was better: Duke Snider versus Mickey Mantle; Roy Campanella versus Yogi Berra; Pee Wee Reese versus Phil Rizzuto and on and on. Those were the days, my friend.”

Fauci has often referred to his father as “laid-back,” which, if true, must be a characteristic that skips a generation. “Tony has always been driven,” Michael Osterholm, the director of the University of Minnesota’s Center for Infectious Disease Research and Policy, and a longtime friend of Fauci’s, told me. “Whatever he was doing, he had to do it better than anybody else. I don’t know if it was certainty or something else. But he was meant to lead. Always. Everyone who knew him knew that. And Tony knew it, too.”

In 1954, he began attending Regis, a private Jesuit high school on the Upper East Side. Rigorous, small, competitive, and tuition-free, Regis is considered one of the finest all-male schools in the country. Fauci thrived there, though the commute between Dyker Heights and Eighty-fourth and Madison was long. He once estimated that he had spent the equivalent of seventy days of his teen-age life on the various subways and buses he took to get to and from school.

Fauci revelled in the demanding coursework. “We took four years of Greek, four years of Latin, three years of French, ancient history, theology,” he recalled. He developed an ability to set out an argument and to bolster it with evidence—good preparation, it turned out, for testifying before Congress. Last year, at a dinner that Regis held in his honor, he said that the school had taught him "to communicate scientific principles, or principles of basic and clinical research, without getting very profuse and off on tangents."

At the time, though, Fauci had no interest in becoming a doctor. "I was captain of the Regis High School basketball team," he once told me. "I thought this was what I wanted to do with myself. But, being a realist, I very quickly found out that a five-seven, really fast, good-shooting point guard will never be as good as a really fast, good-shooting seven-footer. I decided to change the direction of my career."

At school, Fauci's accomplished peers were headed to careers in medicine, engineering, and the law. At home, he was steeped in the humanities: "Virtually all my relatives on my mother's side—her father, her brother, and her sister's children—are artists." His mother helped tip the balance. "She never really pressured me in any way, but I think I subtly picked up the vibrations that she wanted very much for me to be a physician," Fauci said. "There was this tension—would it be humanities and classics, or would it be science? As I analyzed that, it seemed to me that being a physician was the perfect melding of both of those aspirations."

From Regis, Fauci went on to another Jesuit institution, Holy Cross, in Worcester, Massachusetts. His high-school faculty had left him little choice in the matter. "They just wouldn't write a recommendation for you if you wanted to apply to Harvard or to Cornell, or Columbia," he said. Fauci enrolled in 1958 and was pleased to find that the university took a broad view of premedical studies. He signed up for a program called Bachelor of Arts–Greek Classics–Premed. "It was really kind of bizarre," he recalled. "We did a lot of classics, Greek, Latin, Romance languages. . . . We took many credits of philosophy, everything from epistemology to philosophical psychology, logic, etc. But we took enough biology and physics and science to get you into medical school."

During the summers, Fauci worked construction jobs. One year, he found himself assigned to a crew that was building a new library at

Cornell Medical College, on the Upper East Side. “On lunch break, when the crew were eating their hero sandwiches and making catcalls to nurses, I snuck into the auditorium to take a peek,” Fauci recalled in 1998, at the medical school’s centennial celebration. “I got goosebumps as I entered, looked around the empty room, and imagined what it would be like to attend this extraordinary institution. After a few minutes at the doorway, a guard came and politely told me to leave, since my dirty boots were soiling the floor. I looked at him and said proudly that I would be attending this institution a year from now. He laughed and said, ‘Right, kid, and next year I am going to be Police Commissioner.’ ”

Fauci graduated first in his class from Cornell in 1966, just as America’s involvement in Vietnam was accelerating. Every new physician was required to perform some kind of military service. “We were gathered in the auditorium at Cornell, early in our fourth year of medical school,” Fauci recalled. “Unlike today, we had only two women in the class and seventy-nine men. The recruiter from the armed forces came there and said, ‘Believe it or not, when you graduate from medical school at the end of the year, except for the two women, everyone in this room is going to be either in the Army, the Air Force, the Navy, or the Public Health Service. So you’re going to have to make your choice. Sign up and give your preferences.’ ”

Fauci wanted to work in the U.S. Public Health Service; his fallback was the Navy. He got his first choice, and ended up at the National Institutes of Health, which was then establishing itself as the country’s primary center for biomedical research. Nearly everyone in academic medicine spent some time at one of its branches; except for three years back at Cornell to complete his internship and residency, Fauci has spent five decades there.

In 1972, Fauci started as a senior researcher at the National Institute of Allergy and Infectious Diseases. He was drawn to investigating ailments that were difficult but not impossible to treat. “I wanted something that could make you very sick and kill you unless I intervened. And if I intervene, you're essentially cured," he told Ushma Neill, the editor of *The Journal of Clinical Investigation*, in 2014. "Now, that seems a little bit too simplistic, but that's really the nature of most infectious diseases."

Working in the lab of Sheldon Wolff, Fauci studied the molecular nature of fever. The field of immunology was still young, but scientists were rapidly learning how to manipulate the smallest components of individual cells, which opened the way to a decade of discovery. Chronic fevers can have a number of underlying causes, among them an uncommon condition known as vasculitis—an inflammation of the blood cells that often occurs when the body's immune system mistakenly attacks its own blood vessels. Many of Fauci's vasculitis patients suffered from rare inflammatory diseases, such as granulomatosis with polyangiitis, which damages blood vessels in the lungs, kidneys, and other organs. The disease was almost always fatal. Fauci and his infectious-disease colleagues at the N.I.H. were frequently asked to visit the National Cancer Institute, which was in the same building as his lab, to consult on patients who were receiving chemotherapy. The drugs suppressed tumors, but they were highly toxic. And they had another side effect, Fauci told me: "Those people are susceptible to a lot of things like infections and bleeding, because the treatment has destroyed their immune systems."



In 1990, Fauci was the government's leading researcher focussed on the AIDS *epidemic.* Photograph by George Tames / The New York Times / Redux

Fauci, together with Wolff, his mentor, wondered if this side effect could be harnessed to help vasculitis patients, whose immune systems were overactive. "I thought if we could somehow give a cancer drug at a low enough dose perhaps we could turn the disease off without any of the secondary complications," he recalled recently. "First we did it in a few patients, and, much to our delight, they had a total remission. Before you know it, we ended up curing a very, very lethal, albeit uncommon, disease."

For the first time, this technique enabled researchers to do effective work on lupus, rheumatoid arthritis, and transplant rejection. "If you look at immunology, it has from the very beginning been inextricably linked to infectious diseases," Fauci said. "What is the immune system for? The immune system protects you against invaders from without—microorganisms—as well as, in some cases, the emergence of certain tumors from within."

In 1981, a strange new syndrome emerged that transformed Fauci's research and, eventually, the lives of millions of people around the world. “All of a sudden, this new disease comes along,” Fauci recalled, referring to what would soon come to be known as AIDS. “Even before the cause of it was proven to be H.I.V., everybody in the field knew that it had to be a virus. I said to myself, ‘Here it is, a virus, still to be determined, that’s affecting profoundly and destroying the human immune system.’ ” Fauci believed that he had been training all his life for a threat like this one. He was an expert in viruses and in the immune system—and he had always been attracted to combatting serious, even fatal diseases. “I wanted to be where the action was,” he said.

At first, few public-health officials seemed to care. In June of 1981, the *Morbidity and Mortality Weekly Report*, a publication of the Centers for Disease Control, issued a paper that included an account of five young men, all gay, who had contracted pneumocystis, a form of pneumonia that had previously been reported only in people with dramatically impaired immune systems. The young men described in the study had all been healthy. “I thought it was a fluke,” Fauci recalled. “I put it aside on my desk, thinking that maybe this was some drug that they had taken that suppressed their immune system.”

A month later, an even more alarming report arrived from the C.D.C. Fauci read it with an uneasy sense that a disaster was looming: “I made the decision that I was going to stop what I was doing, much to the chagrin of my mentors, who were saying, ‘Why do you want to give up a great trajectory of a career to study a handful of gay men with this strange disease?’ But, deep down, I really knew that this was going to explode.”

Fauci wrote a paper to sound the alarm. “I called it my *apologia pro vita sua*—an explanation for what I’m doing,” he said. In the paper, Fauci pointed out that, although the disease “seems to selectively affect a particular segment of our society,” it demanded a medical solution. Moreover, he warned, “any assumption that the syndrome will remain restricted to a particular segment of our society is truly an assumption without a scientific basis.” Fauci sent the manuscript to *The New England Journal of Medicine*, in late 1981. It was rejected. “One of the reviewers said I was being alarmist,” Fauci said. He tried a different journal, *The Annals of Internal Medicine*, and the following June the paper was published.

In the laboratory, Fauci began making progress. He had been investigating B cells, which are involved in the production of antibodies. In 1983—before H.I.V. was even known by that name—his lab became the first to report that B cells became hyperactive in patients with AIDS. When a healthy person is invaded by a virus, antibodies mount a defense, but, when H.I.V. hijacked B cells, the antibody system went awry. Fauci and his team had identified one of the crucial features of AIDS. "We made that observation without having any idea of what we were dealing with," he said in an interview for an N.I.H. oral history. "I think that speaks for sound scientific and clinical observation." The politics of seeking a cure, though, would be far harder to manage.

On October 11, 1988, more than a thousand AIDS activists gathered outside the headquarters of the Food and Drug Administration, in Rockville, Maryland, to protest the agency's glacial reaction to the epidemic. The activists knew that their community needed new treatments if they were to avoid catastrophe—but they were stymied by the F.D.A.'s drug-approval process, a remarkably inflexible system that typically took years.

That same day, another group of protesters marched onto the campus of the National Institutes of Health, in Bethesda, Maryland. They were headed for Building 31, the home of the National Institute of Allergy and Infectious Diseases. Fauci, who had become the institute's director in 1984, was now the government's leading scientist focussed on the AIDS epidemic. Even though he was not running the F.D.A., he appeared almost daily in the media to discuss the crisis. "My face was the face of the federal government," Fauci told me. He was asked the same question nearly every day: why wasn't the government moving faster? It didn't help that the Reagan Administration seemed so indifferent to the plague.

Fauci watched from his office window as activists surrounded the building and tried to scale its walls. Some were dressed in black robes and carried scythes. Many waved pink-and-black banners, bearing the words "NIH Wake Up!" or "Stop Killing Us!" All over campus, a chant could be heard: "Fuck you, Fauci!"

"God, I hated him," Larry Kramer, the writer and activist who helped establish the two most important AIDS advocacy groups in the country, the Gay Men's Health Crisis and ACT UP, said. "As far as I was concerned, he was the central focus of evil in the world." Kramer attacked Fauci relentlessly in the media. He called him an "incompetent idiot" and a "pill-pushing" tool of the medical establishment, insulted his wife, and even compared him to Adolf Eichmann. In 1988, Kramer published a scathing open letter. "Anthony Fauci, you are a murderer," he wrote. "Your refusal to hear the screams of AIDS activists early in the crisis resulted in the deaths of thousands of Queers."

As the epidemic spread and the death toll rose, it was common for gay activists to view Fauci and NIAID with rage. Fauci did not control the drug-approval process, but he was seen as a barrier to opening access to clinical trials, in which volunteers could receive potentially lifesaving medications.

For most people infected with H.I.V., taking experimental drugs was the only alternative to simply waiting for death. Yet the F.D.A.'s arcane rules prevented the vast majority of patients from qualifying for trials. For instance, a significant number of H.I.V. patients suffered from pneumocystis pneumonia. The condition—the same one observed in the initial C.D.C. report—could be fatal, so many who had it used an experimental antimicrobial medication called pentamidine, which had proved highly effective. But people who took experimental medications were barred from participating in other clinical trials.

At first, Fauci held to the standard N.I.H. line that research need not focus on the immediate welfare of patients. "When we had clinical trials, we, the scientific community and the regulatory community, did not listen" to the activists, he recalled. "It was, at the time, an attitude that many of us had, and I probably had it myself." He was right about that. I covered the AIDS epidemic for the Washington *Post*, and it was clear to me that Fauci was inclined to enforce the paternalistic medical tradition in which he had trained: doctors and scientists were unquestioned authorities, and drug development had to follow a rigid process that included animal testing and rigorous clinical trials. Otherwise, the benefits and the risks of these drugs could not be adequately assessed. In 1987, the F.D.A. approved the first drug to treat H.I.V.—azidothymidine, or AZT—and the announcement was met with a burst of hope. But the drug's liabilities were evident almost instantly. It had harsh side effects, and the benefits wore off; the virus itself soon became resistant to the drug. When new clinical studies began, involving cocktails of AZT and similar compounds, tens of thousands of people asked to participate. Again, though, volunteers were not accepted if they used other experimental drugs. The anger among activists grew more intense. "They started becoming amazingly iconoclastic and confrontational, and that scared the hell out of the scientists, who were fundamentally quite conservative," Fauci told me at his medical-school reunion. "When they were demonstrating on the N.I.H. campus, disrupting Wall Street, disrupting St. Patrick's Cathedral, instead of listening to them, scientists withdrew."

Without entirely understanding his own motives, Fauci decided to look beyond the activists' furious rhetoric and style. He recalls telling himself, "Let me put aside the goth dress—the earrings and the Mohawk haircuts and the black jackets—and just listen to what they have to say. And what they were saying made absolutely perfect sense." It helped that Fauci had something in common with the activists: "They were all New York guys. I had a little affinity to them because I'm a New Yorker. And I said, What would I do if I were in their shoes? And it was very clear: I would have done exactly the same thing."

The activists knew that they were facing a mercilessly lethal disease. In the summer of 1985, I travelled to New York to write my first long story on the toll that the epidemic was taking on the city's gay community. I interviewed dozens of men. To the best of my knowledge, only two of them are still alive: Larry Kramer, who is now eighty-four, and a political activist who prefers to remain anonymous.

Fauci, too, came to understand the severity of the crisis. "Everyone died," he said. "I was used to treating people who had little hope and then saving their lives—that was so wonderful. But, with AIDS in those days, I saved no one. It was the darkest time of my life." Faced with mounting evidence that his cautious approach made no sense, he did something that few public officials do: he reversed himself. Fauci transformed from a conventional bench scientist into a public-health activist who happened to work for the federal government. "I had to change," he told me.

When the demonstrators marched on the N.I.H. campus in 1988, Fauci no longer saw a threat. "I looked at them, and I saw people who were in pain," he recalled in an article in *Holy Cross Magazine*. He asked the police and the F.B.I. not to arrest any of them. Then he invited a handful of protest leaders to his office. "That began a relationship over many years," Fauci said. "They let me into their camp. I went to the gay bathhouses and spoke to them. I went to San Francisco, to the Castro District, and I discussed the problems they were having, the degree of suffering that was going on in the community, the need for them to get involved in clinical trials, since there were no other possibilities for them to get access to drugs. And I earned their confidence."

Fauci, in his mid-forties, was the youngest director of an N.I.H. institute in a century, and he lacked the political influence to act independently. Even in his own field, he struggled to recruit allies. "I couldn't convince my own people in infectious-disease leadership to take on H.I.V./AIDS," he told me. So he created a division within his institute devoted to the disease.

One day, in the late eighties, Fauci asked me to stop by his office in Building 31 on the N.I.H. campus. He told me that he had a wild idea: he wanted to hire Mark Harrington, ACT UP's point man on drug-treatment trials. Harrington, a prominent AIDS researcher and activist, had no formal scientific training. But Fauci, like most of those who had seen him testify before Congress or speak to a crowd, was dazzled by his brilliance.

Harrington discussed the idea with Fauci, but decided that the job would be a disaster for him. "There's no way I could have functioned within that bureaucracy," he told me recently. "The people I respect would have seen me as a sellout." Yet Harrington continued to make a profound impression on Fauci's thinking.

Harrington was passionately committed to loosening up the F.D.A.'s restrictive regime. "It was murder," he told me. "I don't know any other way to describe it." Harrington, who went on to win a MacArthur "genius" grant for his work on the disease, established himself as the most knowledgeable student of the agency's byzantine regulations. In meetings with Fauci and other officials, he urged them to move faster and with greater compassion for those who were suffering.

There are three stages in most F.D.A. clinical trials. The first tests whether a drug is safe. The second assesses its efficacy. The last stage, conducted in larger groups, confirms that the drug works and that there are no serious adverse reactions. Harrington argued that people with no alternative should be granted access to those drugs as soon as they had been proved safe, even if their effectiveness remained unknown.

At first, Fauci was concerned that, if people taking multiple experimental medications joined clinical trials, the results would be hopelessly muddled. He was also afraid that granting sick people unrestricted access to unapproved drugs would deter them from participating in the trials at all. Harrington and other activists reassured him that they were committed to strictly monitored drug trials that would provide enough data to know what worked and what did not.

Fauci is a realist, and the facts were obvious to anyone who cared to look. Traditional methods of testing drugs weren't working. Underground networks were growing everywhere. With so many AIDS patients taking untested medications, federal health officials had to concede that their system was broken. Even the most fundamental protocol of a clinical trial—giving some participants a placebo—came into question. In a study conducted in San Francisco in 1989, nearly all the volunteers had their medicine analyzed, to see whether they were receiving an active dose. Those who learned that they had been given placebos almost invariably dropped out.

"There was a feeling in science that doctors know best, scientists know best," Fauci said. "We love our patients, but they don't really know what's best for them. Then, when we dealt with this disease that was brand new—that was frightening, that was killing people in a way that was historic—the people who were impacted by the disease wanted to have something to say about how we conducted research."

There were still moments of confrontation. In May, 1990, hundreds of ACT UP activists returned to the N.I.H., demanding more AIDS treatments and greater representation of women and people of color in clinical trials. At a planning session for the protest, a young activist named Tony Malliaris performed a rap song called "Storm the NIH," which included the lyrics "I don't know what Fauci thinks, but this ain't Denmark, and something stinks." (Malliaris died five years later, still in his early thirties.)

Fauci was undeterred. He threw his influence behind a program called Parallel Track, which made unapproved AIDS drugs available as soon as they were demonstrated to be safe, even as clinical trials were continuing. The initiative would not have succeeded without Fauci. But he always acknowledged that his approach had been shaped largely by the constructive pressure he received from AIDS advocacy groups and from leaders like Harrington.

This more inclusive approach ushered in a revolution in American medicine. Patients today demand as much information as possible about treatments they might receive, and no longer act as if their doctors' advice came straight from Mt. Olympus. They scour the Internet, assemble statistics, and often arrive at the hospital with a folder full of medical information. The F.D.A., for its part, will no longer consider approving a new drug until it has consulted representatives of groups who would use it. "There are strict scientific principles that have to be adhered to in medicine," Fauci told me. "At the same time, a humanistic touch is needed in dealing with people. You have to combine social aspects, ethical aspects, personal aspects with cold, clean science."

In 2002, I wrote a Profile of Larry Kramer for this magazine. By then, he and Fauci had become friends, with each expressing gratitude for the other's work in those years. Fauci told me, "In American medicine, there are two eras: before Larry and after Larry. There is no question in my mind that Larry helped change medicine in this country. When all the screaming and the histrionics are forgotten, that will remain." Kramer, who spent years in a constant rage at Fauci, now calls him "the only true and great hero" among government officials in the AIDS crisis.

As Trump defends his Administration's response to the pandemic, he has suggested repeatedly that COVID-19 was impossible to predict. "There's never been anything like this in history," he said, at a press conference on March 19th. "Nobody knew there would be a pandemic or epidemic of this proportion."

As everyone with even a casual interest in the history of science knows, pandemics have altered the destiny of humanity at least since 430 B.C., when Athens was struck by a plague that killed as many as two-thirds of its residents, just as the Spartans were laying siege. Beginning in 165 A.D., smallpox helped ruin the Roman Empire, sowing more destruction than foreign armies ever could. And, in the fourteenth century, the Black Death swept through Europe, killing more than half the population, according to recent estimates.

Yet, by the middle of the twentieth century, many scientists had begun to conceive of a world that was largely free of infectious epidemics. In 1951, Sir Frank Macfarlane Burnet, a future Nobel laureate in medicine, wrote, "The fever hospitals are vanishing or being turned to other uses. With full use of the knowledge we already possess, the effective control of every important infectious disease"—with the exception of polio—"is possible." His optimism was understandable. Antibiotics had made many lethal diseases easy to treat; improvements in sanitary conditions had transformed the lives of hundreds of millions of people. In developed countries, typhoid, cholera, and measles—major killers throughout history—had largely passed into memory; even tuberculosis, one of the great scourges of humanity, had been in decline for nearly half a century. By 1972, Macfarlane, writing with the microbiologist David White, was predicting that the "most likely forecast about the future of infectious diseases is that it will be very dull."

When Fauci was a young trainee, these kinds of predictions sometimes made him wonder if he had picked the wrong career. "I became concerned that I was entering . . . an area of biomedical research that was disappearing," he recalled in one speech. But, since 1984, when Fauci became the director of NIAID, there has not been a single day in which some epidemic has not threatened the globe. According to the World Health Organization, AIDS has killed more than thirty million people, and nearly forty million are now living with H.I.V. Tuberculosis, far from sliding into obscurity, infects roughly a quarter of the human population; the W.H.O. says that one and a half million people died from the disease in 2018.

But the greatest threat that humanity faces, by far, is a global outbreak of a lethal virus for which no treatment has been found. In just a few months, COVID-19 has forced billions of people, in nearly every country on earth, into a panicked withdrawal from society. Another pandemic like this might appear in two years, or in ten, or in a century. But I have never met a virologist or an epidemiologist who believes we won't encounter one.

For a deadly virus to flourish, it must meet three critical conditions. First, a new virus—one to which no one has yet developed immunity—must emerge from the animal reservoirs that produce and harbor such pathogens. Second, the virus has to make humans sick. (The vast majority do not.) Finally, it must be able to spread efficiently, through coughing, sneezing, or shaking hands. That combination is rare, but, when it appears, the consequences are almost always disastrous.

The Nobel Prize-winning molecular biologist Joshua Lederberg, who died in 2008, was for years the world's most visionary voice about emerging infectious diseases. "Some people think I am being hysterical, but there are catastrophes ahead," he once wrote. "We live in evolutionary competition with microbes—bacteria and viruses. There is no guarantee that we will be the survivors."

In 2003, Lederberg joined the future F.D.A. commissioner Margaret Hamburg and the pandemic specialist Mark Smolinski to edit a seminal report, in which prominent scientists argued for a much more aggressive defense of the planet. Titled "Microbial Threats to Health," the report recommended that the U.S. greatly expand its early-warning systems, particularly in the developing world. It also urged leaders to strengthen their ability to respond to microbial threats, with new efforts on the federal, state, and local levels. The recommendations were almost completely ignored.

The next year, a highly pathogenic form of avian influenza, H5N1, leaped from waterfowl to chickens and then to humans. Public-health officials were petrified. In Bangkok, I met with Scott Dowell, who led the Thailand office of the C.D.C.'s International Emerging Infections Program. "The world just has no idea what it's going to see if this thing comes," he told me. He paused and then reframed his thought. "When, really. It's when. I don't think we can afford the luxury of the word 'if' anymore."

In a sense, the world was lucky with H5N1. Although the U.S. and other countries mounted a diffident response, the virus turned out to be deadly but not very contagious. Five years later, the situation was reversed. A new influenza virus, designated H1N1, infected nearly a quarter of the global population before vaccines became widely available. This time, the virus was highly contagious but not nearly as deadly as most strains of influenza. The fact that the outbreak was less virulent than public-health officials had feared created its own danger; by encouraging complacency, it did more to expose the world to the risk of a devastating new pandemic than anything else that had happened in decades.

Although Congress had appropriated money to stockpile antiviral medications and protective gear, many scientists felt that the effort was grossly insufficient. "We spend many billions of dollars every year on missile-defense systems," Seth Berkley, a medical epidemiologist who leads the Global Vaccine Alliance, told me. "And yet we will not spend pennies on the dollar to prepare for a catastrophe that is far more likely to affect us all."

After the Ebola outbreak of 2014, Barack Obama implemented one of Lederberg's central recommendations: he established the White House's National Security Council Directorate for Global Health Security and Biodefense, an early-warning system for disease in the developing world. Trump disbanded it in 2018, as part of an effort to streamline the N.S.C. In an appearance before Congress, Fauci was asked if the decision was a mistake. He responded diplomatically: "I wouldn't necessarily characterize it as a mistake. I would say we worked very well with that office. It would be nice if the office was still there."

The combination of money and political will can have extraordinary effects on public health. Under the George W. Bush Administration, Fauci was the principal architect of a landmark program called PEPFAR, the President's Emergency Plan for AIDS Relief.

By the time Bush took office, therapies for H.I.V. had become widely available in Western countries. But, for millions of people in the developing world, these drugs were too expensive or too difficult to obtain. Bush felt that it was unacceptable for the poorest people on earth to die because they could not afford medication that was dispensed routinely in the rich world. He asked Fauci to implement an initiative to prevent and treat H.I.V. on a global scale. It has been uniformly held up as a model of the ways in which global public-health programs can save lives. "PEPFAR has turned around declining life expectancies in many countries and likely saved some countries—even an entire continent—from economic ruin," Harold Varmus, a former director of the N.I.H. and of the National Cancer Institute, wrote in the quarterly journal *Science & Diplomacy*.

But Fauci has at times struggled to compel politicians and businesses to attack the problems that he considers most worrisome. Over the years, he has become concerned about the possible impact of new viruses, particularly a lethal strain of influenza. Other viruses are more consistently deadly; some, like measles, are more contagious. But no virus that we know of is capable of killing as rapidly and as efficiently. "We need a major paradigm shift with influenza vaccines," Fauci told me, four years ago. "The situation is a mess."

Because the flu virus evolves so rapidly, experts deciding how to formulate vaccines can make only a highly educated guess about which strains are most likely to make people sick. Each February, epidemiologists study outbreaks around the world—especially in the Southern Hemisphere, where flu season is under way—to assess which strains might make their way north. The result is always better than nothing. In many years, though, it is woefully inadequate. In the flu season of 2014-15, the vaccine protected less than a fifth of the people who received it. In 2017-18, it worked for a little more than a third. Fauci has long supported the development of an alternative: a universal influenza vaccine, which would provide lasting defense against all strains. “Similar to tetanus, a universal flu vaccine probably would be given every ten years,” he said. “And, if you get one that is really universal, you can vaccinate just about everyone in the world.” But such a vaccine would cost hundreds of millions of dollars to develop and test—and would replace a product that most consumers already think of as good enough. No one has come close to raising the money that such a project will require.

By the beginning of the new millennium, it had become clear that the next microbial threat might not come from a bat or a duck. It could just as well be created by a human being. After the terrorist attacks of September 11, 2001, anonymous letters laced with deadly anthrax spores began arriving at media companies and congressional offices. In the following months, twenty-two people were infected by inhaling anthrax and five died. Suddenly, biological terror posed an entirely new threat—one that has become only more significant and complex in the ensuing years. In 2016, James Clapper, who was the director of National Intelligence during the Obama Administration, listed gene editing as a potential weapon of mass destruction. Many scientists were furious, but he had a point. Researchers have deployed these tools to rewrite the genes of mosquitoes so that they are unable to transmit malaria. If their success in the lab translates to the field, it will be a historic triumph. But the research also raises an alarming possibility: if a scientist can modify the genes of an insect to protect people from malaria, he could almost certainly use the same technology to add a deadly toxin.

Fauci often cites a similar but more immediate paradox. Thanks to genetic engineering, we are more equipped than ever to respond to the threat of a viral pandemic. After the COVID-19 outbreak began, it took scientists less than a month to sequence the genome of the virus. By the end of February, the instructions were on the Internet, and the virus had been re-created in laboratories around the world, by scientists seeking to develop drugs and vaccines.

And yet, despite our mastery of molecular biology, we live in an era in which someone can wake up with an infection in China—or France, Australia, or any other place with an airport—and fly to San Francisco in time for dinner, spreading the virus long before he suspects that there's anything wrong. For most of human history, a virus like COVID-19 might have killed many people in the community where it originated, but then stopped spreading. According to a comprehensive analysis carried out by the *Times*, at least four hundred and thirty thousand people have arrived in the U.S. on direct flights from China since the outbreak began. Forty thousand have arrived in the two months since Trump imposed restrictions on travellers from China trying to enter the country.

Fauci insists that an adequate defense against future pandemics will have to be flexible. "I have been saying for eight, ten years that we should make a list of microbes and try to develop a basic platform vaccine," he told me in 2016. A platform vaccine addresses an entire class of virus, not just a particular strain. "We keep trying to develop a vaccine for one thing—usually the last one—and it's a waste of time," he said. "Every time we get hit, it is always something we didn't expect. So, instead of predetermining what it is you're going to prepare for, make universal platforms."

Such an approach is eminently possible. Using gene-sequence information and synthetic DNA, biologists are now capable of making parts of a vaccine in advance. It takes almost no time to sequence a viral strain, and with that information it should be possible to complete a bespoke vaccine in a matter of weeks. "You could build a chassis for the vaccine, and you would have it on the shelf," Fauci said. "Then all you would need to do is insert the gene of the protein you want to express and make a gazillion doses and send it out."

There are even more futuristic aspirations: the genomics pioneer J. Craig Venter has proposed using a sort of 3-D printer to manufacture vaccines on demand. It is already possible to print the nucleotides that make up DNA and assemble them. Venter argues that, in the time it takes for an infected person to fly from one side of the world to the other, we should be able to print, assemble, and administer a vaccine.

To even contemplate creating these kinds of treatments, Fauci says, would require building an entirely new system for making vaccines before a pandemic arises. But, in addition to the scientific obstacles, this would cost billions of dollars, and no company or politician has been willing to spend the money. Perhaps, just as AIDS transformed our approach to clinical trials, our experience with COVID-19 will change our attitudes about preventing infectious diseases. A proper investment in both research and emergency preparedness would have prevented at least some of the unspeakable human loss we are now experiencing and the economic crash that has just begun.

The COVID-19 epidemic will eventually fade, but the public will demand a reckoning. Inevitably, there will be an investigation, along the lines of the 9/11 Commission, to look into the ramifications of the President's denialism, the shortages in testing and medical equipment, and the dismissal of so many warning signs. Fauci will not necessarily escape criticism. He is an excellent spokesman for the value of scientific research, but he runs a single institute, and he lacks the authority to broadly reshape our response to pandemics. "The kinds of things we really desperately need as foundational tools for dealing with this stuff aren't necessarily research enterprises," Harold Varmus told me. "Tony isn't running C.D.C. He's not running FEMA. To tell him to stockpile defense mechanisms or to move forward surveillance tools into massive operations around the world—that's just not his remit."

Even Fauci's current value as a scientific adviser has been limited by the President's contempt for expertise. Trump's coronavirus kitchen cabinet consists of people like his son-in-law, Jared Kushner, who has no medical knowledge or experience managing crises—yet has been appointed to direct the response to the biggest medical emergency since the influenza pandemic of 1918. Trump has also turned for advice to Dr. Mehmet Oz, who for years has endorsed worthless treatments and used his television show to promote notorious quacks. Trump even seems to think that his trade adviser, Peter Navarro, should debate Fauci about the value of specific drugs. When Navarro, who has a doctoral degree in economics, was asked about his medical qualifications, he said, “I have a Ph.D. And I understand how to read statistical studies, whether it’s in medicine, the law, economics, or whatever.”

Among Navarro’s enthusiasms is the malaria drug hydroxychloroquine, which he believes could cure COVID-19. There is currently no evidence to support this conclusion, as Fauci has pointed out on several occasions. On April 5th, as Trump continued to tout the drug as a miracle cure, a reporter at the daily briefing asked Fauci to comment. Trump refused to allow him to speak. In an appearance two days later, Trump kept up the hype. “I say try it,” he said. “You’re not gonna die from this pill.” Not long afterward, he even suggested that zinc might help.

To plan a coherent biological future, rather than simply scramble to contain each new pandemic, will require an entirely new kind of political commitment. It would certainly include the creation of a permanent position, a special assistant to the President for biological defense. Similar jobs have existed in the past, but not for long, and not with enough influence to matter. David Relman, the Stanford professor, told me, “This kind of job needs somebody with the authority to preside over domestic and international threats, both natural and deliberate. And that person has to sit in the White House with immediate access to the President. Without that, we will really have nothing that can work.”

Until then, we have Fauci, a seventy-nine-year-old infectious-disease expert pinned between Donald Trump and the American people. It can’t be easy. As Fauci recently put it, with characteristic candor, “I give the appearance of being optimistic. But, deep down, I just do everything I possibly can, assuming that the worst will happen, and I’ve got to stop the worst from happening.” ◆

Published in the print edition of the April 20, 2020, issue, with the headline “The Good Doctor.”

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 16:30:40 +0000
To: Del Rio, Carlos; [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: RE: Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection

Thanks, Carlos. As you know since Cliff has been in touch with the IDSA, the HHS guidelines will be coming out this week.
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Del Rio, Carlos [redacted] (b) (6)>
Sent: Saturday, April 11, 2020 12:08 PM
To: [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection

IDSA guidelines are out
https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

Carlos del Rio, MD.
Sent from my iPhone

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 16:25:29 +0000
To: (b) (6)
Subject: FW: Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Del Rio, Carlos (b) (6)>
Sent: Saturday, April 11, 2020 12:08 PM
To: (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection

IDSA guidelines are out
https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

Carlos del Rio, MD.
Sent from my iPhone

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Apr 2020 15:12:24 +0000
To: [redacted] (b) (6)
[redacted]
Subject: FW: Atlantic's coverage - Fauci as "heartthrob"

David Bradley is the Chairman of *The Atlantic.* Geeez….

From: David Bradley <dbradley@theatlantic.com>
Sent: Friday, April 10, 2020 10:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Atlantic's coverage - Fauci as "heartthrob"

Hi Tony,

[redacted] (b) (6) I send you greetings and the deepest appreciation.

I am only one of your millions of followers who feel in your debt. But, I am the only one with a magazine that has dedicated a whole article to "the thirst for Tony Fauci."

This will be the least important item on today's to-do list. But, someday, your grandchildren and their children, in turn, will want to read this: https://www.theatlantic.com/technology/archive/2020/04/anthony-fauci-coronavirus-crush/609544/

My best wishes to you.

David

David G. Bradley
Chairman
Atlantic Media

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Apr 2020 15:10:47 +0000
To: David Bradley
Subject: RE: Atlantic's coverage - Fauci as "heartthrob"

David:

Many thanks for sending this. I could not have even begun to make this up..... Please stay safe and well.
Warm regards,
Tony

From: David Bradley <dbradley@theatlantic.com>
Sent: Friday, April 10, 2020 10:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Atlantic's coverage - Fauci as "heartthrob"

Hi Tony,

(b) (6) I send you greetings and the deepest appreciation.

I am only one of your millions of followers who feel in your debt. But, I am the only one with a magazine that has dedicated a whole article to "the thirst for Tony Fauci."

This will be the least important item on today's to-do list. But, someday, your grandchildren and their children, in turn, will want to read this: https://www.theatlantic.com/technology/archive/2020/04/anthony-fauci-coronavirus-crush/609544/

My best wishes to you.

David

David G. Bradley
Chairman
Atlantic Media

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Apr 2020 01:37:52 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Letter from Rep. C. Smith to Sec Azar and Dir Fauci
Attachments: 2020-04-09 Smith to Azar and Fauci re Lyme and COVID19.pdf

FYI

From: Griswold, Kelsey <(b) (6)
Sent: Thursday, April 9, 2020 8:41 PM
To: Griswold, Kelsey (b) (6)>
Subject: Letter from Rep. C. Smith to Sec Azar and Dir Fauci

Good Evening All,

Attached is a letter from Congressman Smith to Secretary Azar and Director Fauci. Please let me know if there are questions or concerns associated with this.

Best,

Kelsey A. Griswold | Legislative Director
Congressman Christopher H. Smith (NJ-04)
2373 Rayburn HOB
Washington, DC 20515
p: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Apr 2020 01:35:00 +0000
To: [redacted] (b) (6)
Subject: RE: We Believe in You

[redacted] (b) (6):

Many thanks for your e-mail. Stay well and safe.
Best regards,
Tony

From: [redacted] (b) (6)
Sent: Thursday, April 9, 2020 8:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: We Believe in You

Tony,
I would only hope that one of your staff see my email and are prudent to know that this is being sent to him by one of his kin and passes it along to you.

Sincerely,

[redacted] (b) (6)

On Thursday, April 9, 2020, 05:54:17 PM EDT, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 9 Apr 2020 21:24:50 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: COVID 19 Briefing Document and COVID Vaccine Overview
Attachments: Overview of COVID-19 Vaccine Development_April9.pdf, Briefing Document NIAID Involvement with Pharma in COVID19_April 9_with table.pdf

The email below is from Larry Corey.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Corey MD, Larry [redacted] (b) (6)>
Sent: Thursday, April 9, 2020 3:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Mascola, John (NIH/VRC) [E] [redacted] (b) (6); Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Dieffenbach, Carl (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Subject: COVID 19 Briefing Document and COVID Vaccine Overview

Tony,

We are sending you two documents relating to our strategy for COVID vaccine development . The

(b) (4)
[redacted]

(b) (4)

[redacted]

Larry

From: [redacted] (b) (6)
Sent: Thu, 9 Apr 2020 17:18:14 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: INTERVIEW REQUEST with Dr Anthony Fauci - Radio-Canada News Program 24h/60min

Let us discuss

Begin forwarded message:

> **From:** NATHALIE LEMIEUX <nathalie.lemieux@radio-canada.ca>
> **Date:** April 9, 2020 at 5:02:20 PM EDT
> **To:** "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: INTERVIEW REQUEST with Dr Anthony Fauci - Radio-Canada News Program 24h/60min**
>
> Hello
>
> My name is Nathalie Lemieux and I am a research journalist for 24h in 60min, an information and public affairs program hosted by Anne-Marie Dussault and broadcast on the CBC/Radio-Canada's French national news network. https://ici.radio-canada.ca/tele/24-60/site We are based in Montréal and the broadcast is aired across Canada weekdays on prime time (between 7pm and 8PM ET)
>
> As we are also living through this Covid-19 pandemia, we would be delighted to do an interview with Dr Anthony Fauci
> *Of course, host Anne-Marie Dussault can do the interview in English
>
> When: subject to Dr Fauci's availability ...
> How: Skype or Facetime (in respect of containment obligations)
> How long: 7-8 min
>
> Could this proposal be of interest to Dr Fauci?
>
> Thank you for letting me know the possibilities... we are aware of Dr Fauci's tight

schedule

You can reach me at any time via this email nathalie.lemieux@radio-canada.ca or on my cell phone: (b) (6)

--
Nathalie Lemieux
Journaliste à la recherche
Émission 24 heures en 60 minutes
RDI/Radio-Canada
Cell: (b) (6)

RADIO-CANADA

From: [redacted] (b) (6)
Sent: Thu, 9 Apr 2020 16:51:32 -0400
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 serosurvey study launch

Looks fine! Thanks

> On Apr 9, 2020, at 1:48 PM, Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>wrote:
>
> Hi Dr. Fauci,
>
> Please find attached for your review a draft press release announcing the launch of Dr. Memoli's serostudy to detect previously undiagnosed coronavirus infections. Your draft quote is as follows:
>
> "This study will give us a clearer picture of the true magnitude of the COVID-19 pandemic in the United States by telling us how many people in different communities have been infected without knowing it, because they had a very mild, undocumented illness or did not access testing while they were sick," said Anthony S. Fauci, M.D., NIAID director. "These crucial data will help us measure the impact of our public health efforts now and guide our COVID-19 response moving forward."
>
> Thanks much,
> Kathy
>
> Kathy Stover
> Branch Chief
> News and Science Writing Branch
> National Institute of Allergy and Infectious Diseases (NIAID)
> Office of Communications and Government Relations
> National Institutes of Health/HHS
> 31 Center Drive, Room 7A17E
> Bethesda, MD 20892
> Phone: [redacted] (b) (6)
> E-mail: [redacted] (b) (6)

NIAID Media Line: (301) 402-1663

<SARSCoV2 serosurvey Release FOG cleared.docx>
<SARSCoV2 serosurvey NSWB Clearance Form.doc>
<SARS_COV2_SERUM_SAMPLING_Clean Changes_Copy_4.2.2020.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 9 Apr 2020 16:40:28 +0000
To: (b) (6) E]
Subject: FW: New Yorker: Fauci Urges Trump to Attack the Coronavirus as if It Were an Inspector General

This Borowitz guy is something else....

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Thursday, April 9, 2020 12:33 PM
To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: New Yorker: Fauci Urges Trump to Attack the Coronavirus as if It Were an Inspector General

Satire from The Borowitz Report

Fauci Urges Trump to Attack the Coronavirus as if It Were an Inspector General

By Andy Borowitz
April 8, 2020

Photograph by Lo Scalzo / Bloomberg / Getty

WASHINGTON (The Borowitz Report)—In what he described as a "potentially major breakthrough," Dr. Anthony Fauci has convinced Donald Trump to attack *COVID*-19 as if it were an inspector general.

Fauci, who has been frustrated in his efforts to get through to Trump, compared the global pandemic to an inspector general while in a closed-door meeting with the President on Wednesday.

"What do you hate more than anything, Mr. President?" Fauci asked.

"Jim Acosta," Trump immediately replied.

"O.K., fine. But, besides Jim Acosta," Fauci said, "it would be an inspector general, right?"

"You're right, Tony," Trump agreed. "I hate those losers."

"Well, think of *COVID*-19 as the worst inspector general in the world," Fauci continued. "It's overseeing everything you do and making you follow the law. It's keeping you from spending taxpayer money on anything you want. You wouldn't stand for that, would you?"

Reportedly, Trump appeared shaken by Fauci's analogy. "Damn it, Tony, when you put it that way, we've got to do something about *COVID*-19," he said.

Speaking to reporters, Fauci said that he was "cautiously optimistic" that his inspector-general analogy would finally spur Trump to action, but added, "Jared could still screw this up."

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 9 Apr 2020 10:17:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Mediaset, Italian television broadcast, interview request

FYI

From: Alessandro Matarante <alessandro.matarante@outlook.it>
Sent: Thursday, April 9, 2020 5:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>
Subject: Mediaset, Italian television broadcast, interview request

Hello Dr. Anthony Fauci,

I'm Alessandro Matarante, an italian reporter, currently working for Mediaset, Italy's most important television broadcast. Specifically, I work for Quarta Repubblica, a program aired every Monday in prime-time, leaded by reporter Nicola Porro.
I'm writing this e-mail because it would be a pleasure and an honor for us to interview you about the coronavirus emergency and the way the United States are facing it.
Clearly, we are available to consider any kind of day and hour to make the interview, and so we are to consider together the contents of the interview.

Hoping for a positive answer,
I wish you a pleasant day.

Alessandro - [redacted] (b) (6)

https://www.mediasetplay.mediaset.it/programmi-tv/quartarepubblica_b100002038

From: [redacted] (b) (6)
Sent: Wed, 8 Apr 2020 17:17:42 -0400
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: Re: Research Day organized by the Italian Embassy

Paolo:
I am very, very sorry, but I just cannot do this right now. I am swamped and my time is not my own. I hope that they understand.
Best,
Tony

> On Apr 8, 2020, at 4:00 PM, Lusso, Paolo (NIH/NIAID) [E]
> [redacted] (b) (6)>wrote:
>
> Dear Tony:
>
> I am sorry to bother you with another request during this period. The Italian Embassy is organizing its yearly Research Day (Giornata della Ricerca) that this year will be held strictly online (via Zoom or other e-meeting tool) and centered entirely on the Coronavirus pandemic.
>
> The Italian Ambassador, Mr. Varricchio, would be delighted if you accept to be his guest of honor at the event and asked me to informally enquire with you, before sending an official invitation, if there is any chance you could participate. He understands how crazy your schedule is during this crisis. They would like you to deliver a 30 min lecture on a theme of your choice, preferably related to the state of the art of the pandemic management. The tentative date for the event is between April 20 and April 30, but they are waiting to finalize the date based on your preference, if you are able to accept (even in early May).
>
> Please, let me know if you can accommodate this additional engagement. You will make them very very happy!
>
> All the best,
>
> Paolo
>
> --
>
> Paolo Lusso, M.D., Ph.D.
> Chief, Section of Viral Pathogenesis
> Laboratory of Immunoregulation
> Bldg. 10, Rm. 6A11
> NIAID, NIH
> Bethesda, MD 20892

Phone: [redacted] (b) (6) (personal)
[redacted] (b) (6) (lab)
Fax: (301) 480-5291
E-mail [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Wed, 8 Apr 2020 16:58:55 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: request of interview by Giuseppe Sarcina, corriere della Sera

Let us discuss

Begin forwarded message:

> **From:** Sarcina Giuseppe <gsarcina@rcs.it>
> **Date:** April 8, 2020 at 4:16:32 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
> **Subject: R: request of interview by Giuseppe Sarcina, corriere della Sera**
>
> Dear Doc. Fauci,
> this is Giuseppe Sarcina, the us correspondent of Corriere della Sera, the main italian newspaper.
> I understood that you are looking at the italian case with great attention.
> I wonder if you can grant me a short interview.
> I have sent an email march 21. But then I saw that you spoke with an other italian newspaper. So I would like to have a chance to have your voice for our Readers as well. Corriere della Sera is a newspaper based in Milano, Lombardy, The region most affected by the coronavirus.
> Thank you
> Warm Regards
> Giuseppe Sarcina
> Washington dc
>
> (b) (6)>
> **Oggetto:** request of interview by Giuseppe Sarcina, corriere della Sera
>
> Dear Doc. Fauci,
> this is Giuseppe Sarcina, the us correspondent of Corriere della Sera, the main italian newspaper.
> I understood that you are looking at the italian case with great attention.
> I wonder if you can grant me a short interview.
> That would be really helpful for our readers

Thank you
Warm Regards
Giuseppe Sarcina
Washington dc

From: [redacted] (b) (6)
Sent: Wed, 8 Apr 2020 16:57:55 -0400
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: Global Health Leaders Call, Thursday, 8 April at 14:30 CET
Attachments: image001.png, ATT00001.htm, COVID19 Strategy Update V3.2.docx, ATT00002.htm

Please print out for tomorrow. Thanks

Begin forwarded message:

> **From:** "KABIR, Sophia" [redacted] (b) (6)>
> **Date:** April 8, 2020 at 4:21:00 PM EDT
> **To:** SHOC <shoc@who.int>, Office of the Director-General <DGOffice@who.int>, "Redfield, Robert R. (CDC/OD)" [redacted] (b) (6)>, David Heymann <[redacted] (b) (6), "Felicity Harvey [redacted] (b) (6) "Chris.Elias" [redacted] (b) (6) >, "J.Farrar" <[redacted] (b) (6) "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6) "GREIN, Thomas" [redacted] (b) (6), "COX, Paul Michael" [redacted] (b) (6) "SCHWARTLANDER, Bernhard F." [redacted] (b) (6)>, "MINHAS, Raman" [redacted] (b) (6) "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "MAHJOUR, Jaouad" [redacted] (b) (6) "FALL, Ibrahima Soce" [redacted] (b) (6)>, "Thomas R. Frieden" [redacted] (b) (6) Lynn Banks <[redacted] (b) (6), President | Resolve to Save Lives <president@resolvetosavelives.org>, [redacted] (b) (6) >, "AL-SHORBAJI, Farah" [redacted] (b) (6) [redacted] Robynn Leidig [redacted] (b) (6), "DRURY, Patrick Anthony" [redacted] (b) (6)>, "Dr VAN KERKHOVE, Maria" [redacted] (b) (6)

[redacted] (b) (6) "GRAAFF, Peter Jan" [redacted] (b) (6)>, "POOLE, Marcia" [redacted] (b) (6), Tarik Mohammed [redacted] (b) (6), Carlos Navarro Colorado [redacted] (b) (6), Ryan Morhard < [redacted] (b) (6),
"BRIAND, Sylvie" [redacted] (b) (6), "MORGAN, Oliver" [redacted] (b) (6)>,
"Harries, Jenny" < [redacted] (b) (6), "Awwad, David (NIH/NIAID) [C]" [redacted] (b) (6)>, "SIMONSON, Stewart" [redacted] (b) (6),
"SINGER, Peter Alexander" [redacted] (b) (6)>, "Jayatunga, Wikum" [redacted] (b) (6) "Julie.HALL" < [redacted] (b) (6)>, Amelie RIOUX [redacted] (b) (6) "SHIN, Young-Soo" [redacted] (b) (6)>, [redacted] (b) (6)>, Feng Ding < [redacted] (b) (6) "SMITH, Ian Michael" [redacted] (b) (6)>, "AYLWARD, Raymond Bruce J." [redacted] (b) (6)>, [redacted] (b) (6)

Cc: SHOC <shoc@who.int>, Office of the Director-General <DGOffice@who.int>, "SCHWARTLANDER, Bernhard F." [redacted] (b) (6)>, "MAHJOUR, Jaouad" [redacted] (b) (6), "FALL, Ibrahima Soce" [redacted] (b) (6)>, "GREIN, Thomas" [redacted] (b) (6)>, "MINHAS, Raman" [redacted] (b) (6)>, "COX, Paul Michael" [redacted] (b) (6)>, "AL-SHORBAJI, Farah" [redacted] (b) (6)>, "POOLE, Marcia" < [redacted] (b) (6)>, "DRURY, Patrick Anthony" [redacted] (b) (6)>, "GRAAFF, Peter Jan" [redacted] (b) (6)>, "Dr VAN KERKHOVE, Maria" [redacted] (b) (6)>, "FARES, Christine Youssef" [redacted] (b) (6)

Subject: Global Health Leaders Call, Thursday, 8 April at 14:30 CET

Dear colleagues,

On behalf of Mike Ryan, allow me to share with you the draft COVID-19 Strategy Update, which will be subject of discussion at tomorrow's Global Health Leaders Call at 14.30 CET.

The epidemiological update and analysis, as well as the **Zoom connection** will be shared tomorrow morning.

Please find below, the key questions for your consideration and input.

1. What is your view on the latest epidemiology, virus transmission and severity in affected countries ?
2. What are the emerging issues/challenges that you see as important ?
3. What should be the priorities for the 1-2 weeks?
4. Any other issues you see as important?

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: **+41 22 79 15 533**

Kind regards,

Sophia

Sophia Kabir
Executive Officer
Office of the Executive Director
WHO Health Emergencies Programme (WHE)
Tel. (b) (6)
Mobile (b) (6)

Website: WHO in emergencies | WHO Facebook | WHO Twitter

World Health Organization

HEALTH EMERGENCIES programme

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 17:28:01 +0000
To: Awwad, David (NIH/NIAID) [C]
Subject: FW: NIAID Information RE: Update Your PIV Card (HHS ID Badge) Certificates Before They Expire

Do I need to do anything?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: afauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: NIAID News and Information (NIH/NIAID) <niaidnewsinfo@niaid.nih.gov>
Sent: Wednesday, April 8, 2020 10:18 AM
To: NIAID Announcements <NIAID-announce@niaid.nih.gov>
Subject: NIAID Information RE: Update Your PIV Card (HHS ID Badge) Certificates Before They Expire

(b) (2)

[redacted]

-----Original Message-----
From: ORS Information Line <orsinfo@ors.od.nih.gov>
Sent: Tuesday, April 7, 2020 6:23 PM

To: NIH-STAFF@LIST.NIH.GOV
Subject: Update Your PIV Card (HHS ID Badge) Certificates Before They Expire

(b) (2)

[redacted]

If you need help, please contact the NIH IT Service Desk: http://itservicedesk.nih.gov/
301-496-4357 (HELP), 301-496-8294 (TTY), or 1-866-319-4357 (HELP)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 17:25:25 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Doepel, Laurie (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: RE: PR HHS Treatment Guidelines for COVID-19

We should include in the statement something about [redacted] (b) (5) [redacted].

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Wednesday, April 8, 2020 12:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6) Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Subject: ASF: PR HHS Treatment Guidelines for COVID-19

This is a press release that we (Laurie) drafted for HHS to announce the HHS treatment guidelines. Cliff has reviewed. I know how slammed you are. In the interest of time, I would like to move this to Bill Hall now, with the understanding that we can catch up with any changes you might have before the release is actually issued.

FYI, the release includes a quote for you as follows:

[redacted] (b) (5)

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 16:59:29 +0000
To: Barillas, Carolina (NIH/NIAID) [E]
Cc: Holland, Steven (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: Article - BCG protection from COVID-19 mortality

Thanks, Carolina.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barillas, Carolina (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Wednesday, April 8, 2020 12:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] [redacted] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Article - BCG protection from COVID-19 mortality

Hello everyone,

I found this article that comes to a similar conclusion regarding the protective role of universal BCG vaccination on COVID-19 mortality. I will be working with an epidemiologist from Virginia Tech to see if we can provide stronger quantitative analysis and modelling.
All the best,

Carolina

Carolina Barillas Mury, M.D., Ph.D.
Chief, Mosquito Immunity and Vector Competence Section
Laboratory of Malaria and Vector Research
National Institutes of Health
12735 Twinbrook Parkway, Room 2E-20C

Rockville, MD 20852
Phone: (b) (6) Fax: (301) 480 0930
E-mail: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 15:09:38 +0000
To: [redacted] (b) (6)
Subject: FW: Google Alert - Fauci AND Tony OR Anthony

Click on the "Cuomo Crush" and "Fauci Fever" link below. It will blow your mind. Our society is really totally nuts.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Google Alerts <googlealerts-noreply@google.com>
Sent: Tuesday, April 7, 2020 11:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Google Alert - Fauci AND Tony OR Anthony

Google Alerts

Fauci AND Tony OR Anthony

As-it-happens update · April 8, 2020

NEWS

Dr. **Anthony Fauci**, Trump address Iowa's lack of shelter-in-place
Little Village
Speaking at President Trump's press conference late Monday afternoon, Dr. **Anthony Fauci** mentioned Iowa, and a clip of his comments was quickly ...

Flag as irrelevant

Dr. **Fauci**: 'We need to put our foot on the accelerator' to see an end to COVID-19 pandemic

fox4kc.com

WASHINGTON – Even though he says the worst is yet to come, Dr. **Anthony Fauci**, the nation's top infectious-disease expert, has seen signs of ...

Flag as irrelevant

Fauci: African-American Community at Higher Risk for Coronavirus Complications

NBC4 Washington

Dr. **Anthony Fauci**, director of the NIAID, spoke on Tuesday about the impact the coronavirus pandemic is having on the ... Read More ...

Flag as irrelevant

John Calipari Confirms Bill Clinton, Mark Cuban, and Dr. **Fauci** as Guests on "Coffee With Cal"

kentuckysportsradio.com

Anthony Fauci. Every Monday for the next 25 weeks, Calipari's show will "feature positive messaging and conversation with high-profile guests from the ...

Flag as irrelevant

'Cuomo Crush' and '**Fauci** Fever' — Sexualization Of These Men Is a Real Thing on The Internet

Talent Recap

The coronavirus pandemic has led brothers Andrew and Chris Cuomo and Dr. **Anthony Fauci** to the forefront COVID news and updates, but it also ...

Flag as irrelevant

Before the White House, Trump called NIH 'terrible,' questioned vaccines

KPQ

President Donald Trump speaks to the press while Director of the National Institute of Allergy and Infectious Diseases **Anthony Fauci** speaks during a ...

Flag as irrelevant

You have received this email because you have subscribed to **Google Alerts**.
Unsubscribe

Receive this alert as RSS feed

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 13:23:07 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: On the record

Yes. Please point him to what I said yesterday.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, April 8, 2020 9:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: On the record

Pls see below....Bob Franken...

-----Original Message-----
From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, April 8, 2020 9:03 AM
To: Conrad, Patricia (NIH/NIAID) [E] < (b) (6)>
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6) Routh, Jennifer (NIH/NIAID) [E]
(b) (6)
Subject: RE: On the record

I think he probably knows Bob Franken personally so I'm wondering if you might want to flag this for him, as he might decide it warrants a personal response.

Otherwise, he did speak about health disparities at yesterday's WH press conference, and we could certainly point Franken to those comments and then also direct him to NIMHD. (b) (5)
(b) (5)

-----Original Message-----
From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, April 8, 2020 8:56 AM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E]
(b) (6) Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Cc: NIAID OCGR NSWB <NIAIDOCGRNSWB@mail.nih.gov>
Subject: FW: On the record

Defer to you to decide on this

-----Original Message-----
From: Bob Franken (b) (6)>
Sent: Wednesday, April 8, 2020 5:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: On the record

Tony:

For my syndicated column, I want to do a piece on the racial aspect of coronavirus. I'm not seeing any breakdown of deaths in the poorer areas as opposed to the more prosperous ones.

Isn't that the telling statistic here that the economically less well off live in areas where medical services are inadequate and as a result they have more underlying conditions that make theM more vulnerable? Isn't it relevant that people of color are predominantly among the poorer in our country for a variety of reasons?

I will appreciate your comments, particularly since you have so little to do these days.

Warmest regards,

Bob

Bob Franken
www.bobfranken.tv

From: [redacted] (b) (6)
Sent: Wed, 8 Apr 2020 07:18:27 -0400
To: [redacted] (b) (6)
Subject: Re: last questions, i promise

In first response, I meant to say "I always qualified the statement....." .not "I almost qualified the statement..."

On Apr 8, 2020, at 7:04 AM, Michael Specter [redacted] (b) (6)>wrote:

Thank you. Will do all this and take out [redacted] (b) (6)

On Wed, Apr 8, 2020 at 03:59 Fauci, Anthony (NIH/NIAID) [E]
<[redacted] (b) (6)>wrote:

Michael:

See comments below in red.

Thanks,

Tony

From: Michael Specter <[redacted] (b) (6)>
Sent: Wednesday, April 8, 2020 1:25 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: last questions, i promise

Hi. Mostly these are two second yes or no answers - though I need to understand the b cell issue better.

Thank you for all this. Hang in there:

1.)

Fauci has at times struggled to compel politicians and businesses to attack the problems that he considers most worrisome. Over the years, he has become especially concerned about the possible impact of a lethal strain of influenza." **True, but I almost qualified the**

statement and said it most likely would be influenza, but I was concerned with any type of novel respiratory virus that efficiently spread from human to human and that had a high degree of morbidity and mortality

2.) Dyker Heights versus Bensonhurst:

-
- What do we say about where he grew up.? He always says Bensonhurst. The apartment was technically in Dyker Heights, though the neighborhood lines shift. And I never see him mention moving neighborhoods. Did he move? **Yes. I moved. I was born at** [redacted] (b) (6) **in the middle of the Bensonhurst section of Brooklyn. When I was 9 years old my father opened a Pharmacy on 8302-13th Avenue at the outer edge of the Dyker Heights Section of Brooklyn (only We moved into an apartment over the pharmacy.**
-

3.) [the question below is the meaning of hyperactive. Does it mean producing too many B cells or that they were too active, as in working too hard, producing too many antibodies??] **Not necessarily too many B cells. It means that the B cells that are there, are aberrantly turned on**

He had been investigating B-cells, which are involved in the production of antibodies. In 1983—before H.I.V. was even known by that name—his lab became the first to report that B-cells became hyperactive in patients with AIDS. The virus was somehow leading its hosts to overproduce a defense that normally would keep them healthy. Fauci had identified one of the crucial features of AIDS. "We made that observation without having any idea of what we were dealing with," he said. "I think that speaks for sound scientific and clinical observation." The politics of seeking a cure, though, would be far harder to manage.

- 4.). This I asked before you could not speak to me but we can take me out of it. Or do whatever you like: I asked Fauci if he thought that novel coronavirus would force a change in attitude among political leaders and funding agencies. [redacted] (b) (6) (b) (6)
-

5.). This you have said in more than one place. People kind of became alarmed when you were absent so just want to be sure you don't mind it in here: **No problem.**

Fauci said that there was nothing meaningful about his absence from the Mar.23 White House briefing, "I was tied up in a task force meeting, and we were trying to work out some difficult policies **and the topic of the briefing that day was more related to other members of the Task Force**. He also said, "I have no trouble with the President. When I talk to him, he listens.''

Michael Specter
Staff Writer
The New Yorker

Adjunct Professor of Bioengineering

Stanford University
(b) (6)
Phone: (Work, Cell, SMS) + (b) (6)

--
Michael Specter
Staff Writer
The New Yorker
Adjunct Professor of Bioengineering
Stanford University
(b) (6)
Phone: (Work, Cell, SMS) (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 10:42:24 +0000
To: Perez-Stable, Eliseo (NIH/NIMHD) [E]
Subject: RE: WH Briefing

Thanks, Eliseo. Stay safe and well.
Best,
Tony

From: Perez-Stable, Eliseo (NIH/NIMHD) [E] (b) (6)>
Sent: Tuesday, April 7, 2020 11:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: WH Briefing

Hey Tony, you are the man! Best, Eliseo

From: Natasha Williams (b) (6)
Date: Tuesday, April 7, 2020 at 8:42 PM
To: Eliseo Perez Stable (b) (6)>, Courtney Aklin (b) (6)>
Subject: WH Briefing

Hello Eliseo and Courtney,

During the White House briefing on COVID-19 this evening, there was a discussion on the disproportionate impact of COVID-19 on African Americans, health disparities and data collection. Please see CSPAN Clips below I cued up.

https://www.c-span.org/video/?c4866877/user-clip-covid-19-african-american-community

https://www.c-span.org/video/?c4866892/user-clip-dr-fauci-health-disparities-african-american-community

https://www.c-span.org/video/?c4866897/user-clip-data-collection-question-african-american-community

I know we are not commenting but I would like to recommend that we have some talking points prepared and on hold in case we receive congressional inquiries. These topics are also receiving coverage on the networks.

Thank you,
Natasha

Natasha H. Williams, PhD, JD, LLM, MPH
Legislative Liaison

National Institute on Minority Health and Health Disparities
National Institutes of Health
Bethesda, MD 20892

Email: (b) (6)
Phone: (b) (6) | www.nimhd.nih.gov
Connect with us: Twitter | Facebook | YouTube | Email Updates

NIMHD
National Institute on Minority Health and Health Disparities

NIH National Institute on Minority Health and Health Disparities

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 03:06:30 +0000
To: Grogan, Joseph J. EOP/WHO
Cc: Bonner, Maria K. EOP/WHO;Campana, Alexandra D. EOP/WHO;[redacted] (b) (6);Barasch, Kimberly (NIH/NIAID) [C];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [EXTERNAL] RE: Good news

Joe:

I would be happy to speak with him. However, it would have to wait until Thursday since tomorrow is impossible. I believe that we can work this out. Perhaps we can arrange for a call between me ,the CEO and some knowledgeable people in my program.

Best regards,

Tony

From: Grogan, Joseph J. EOP/WHO [redacted] (b) (6)>
Sent: Tuesday, April 7, 2020 10:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Bonner, Maria K. EOP/WHO [redacted] (b) (6)>; Campana, Alexandra D. EOP/WHO [redacted] (b) (6)>
Subject: Fwd: [EXTERNAL] RE: Good news

Dr., I would never abuse your personal email, but since the ceo of Lilly wants to speak with you, I thought I would share this request. Just let
me know how to respond [redacted] (b) (5)

Sent from my iPhone

Begin forwarded message:

> **From:** Shawn O'Neail [redacted] (b) (6)
> **Date:** April 7, 2020 at 10:07:37 PM EDT
> **To:** "Grogan, Joseph J. EOP/WHO" [redacted] (b) (6)>, "Bonner, Maria K. EOP/WHO" [redacted] (b) (6)
> **Subject: [EXTERNAL] RE: Good news**
>
> You bet.
>
> Joe – Have an enormous request – for help or counsel.
>
> [redacted] (b) (4)

My CEO, Dave Ricks, would like to speak with Dr. Fauci in this regard (given his role at the Institute). I know that is a tall order – but underscores the importance.

I did reach out to Dr. Fauci's Chief but received an automated reply indicated he was behind in email – any thoughts in the regard greatly appreciated....

Best, Shawn

========================

Shawn O'Neail
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) (office) | (b) (6) (mobile)
(b) (6) | >www.lilly.com<

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Grogan, Joseph J. EOP/WHO <(b) (6)>
Sent: Tuesday, April 7, 2020 9:31 AM
To: Shawn O'Neail (b) (6) Bonner, Maria K. EOP/WHO
(b) (6)
Subject: [EXTERNAL] RE: Good news

EXTERNAL EMAIL: Use caution before replying, clicking links, and opening attachments.

This is great. Thank you for sharing and everything you are doing. Joe

---

From: Shawn O'Neail (b) (6)>
Sent: Tuesday, April 7, 2020 9:26 AM
To: Grogan, Joseph J. EOP/WHO <(b) (6)>; Bonner, Maria K. EOP/WHO (b) (6)>
Subject: [EXTERNAL] Good news

Hi Joe and Maria

I want to share an important update about Lilly's efforts to address insulin affordability. In response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance - and those without insurance - to fill their monthly prescription of Lilly insulin for $35. The program is effective today and covers most Lilly insulins. Details and more information can be found in the press release here attached.

Lilly has introduced several solutions in recent years to help meet the individual financial circumstances of people living with diabetes that are still in effect during the COVID-19 crisis, including:

- The Lilly Diabetes Solution Center, through which representatives can direct people to the $35 savings card, as well as affordability options that may reduce their out-of-pocket costs further – such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.
- Three non-branded versions of our insulin options with list prices 50 percent lower than the branded versions.
- In January, the company announced plans to donate at least 200,000 KwikPens® to relief agencies over the next three years.

Hope all is well with you....

Shawn

========================
Shawn O'Neail
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) office) | (b) (6) (mobile)
(b) (6) | >>www.lilly.com<<

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 02:41:56 +0000
To: [redacted] (b) (6)
Subject: FW: [EXTERNAL] RE: Good news

Cliff:
Let us discuss this. How do you think that I should respond?
Thanks,
Tony

From: Grogan, Joseph J. EOP/WHO [redacted] (b) (6)
Sent: Tuesday, April 7, 2020 10:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Bonner, Maria K. EOP/WHO [redacted] (b) (6); Campana, Alexandra D. EOP/WHO [redacted] (b) (6)
Subject: Fwd: [EXTERNAL] RE: Good news

Dr., I would never abuse your personal email, but since the ceo of Lilly wants to speak with you, I thought I would share this request. Just let me know how to respond, [redacted] (b) (5)

Sent from my iPhone

Begin forwarded message:

> **From:** Shawn O'Neail [redacted] (b) (6)
> **Date**: April 7, 2020 at 10:07:37 PM EDT
> **To:** "Grogan, Joseph J. EOP/WHO" < [redacted] (b) (6)>, "Bonner, Maria K. EOP/WHO" [redacted] (b) (6)
> **Subject: [EXTERNAL] RE: Good news**
>
> You bet.
>
> Joe – Have an enormous request – for help or counsel.
>
> [redacted] (b) (4)
>
> My CEO, Dave Ricks, would like to speak with Dr. Fauci in this regard (given his role at the Institute). I know that is a tall order – but underscores the importance.
>
> I did reach out to Dr. Fauci's Chief but received an automated reply indicated he was behind in email – any thoughts in the regard greatly appreciated....

Best, Shawn

=========================

Shawn O'Neail
Vice President, Government Affairs
Eli Lilly and Company
[redacted] (b) (6) (office) | [redacted] (b) (6) (mobile)
(b) (6) | >www.lilly.com<

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Grogan, Joseph J. EOP/WHO [redacted] (b) (6)>
Sent: Tuesday, April 7, 2020 9:31 AM
To: Shawn O'Neail [redacted] (b) (6) Bonner, Maria K. EOP/WHO
[redacted] (b) (6)>
Subject: [EXTERNAL] RE: Good news

EXTERNAL EMAIL: Use caution before replying, clicking links, and opening attachments.

This is great. Thank you for sharing and everything you are doing. Joe

---

From: Shawn O'Neail [redacted] (b) (6)
Sent: Tuesday, April 7, 2020 9:26 AM
To: Grogan, Joseph J. EOP/WHO [redacted] (b) (6) Bonner, Maria K. EOP/WHO [redacted] (b) (6)>
Subject: [EXTERNAL] Good news

Hi Joe and Maria

I want to share an important update about Lilly's efforts to address insulin affordability. In response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance - and those without insurance - to fill their monthly prescription of Lilly insulin for $35. The program is effective today and covers most Lilly insulins. Details and more information can be found in the press release here attached.

Lilly has introduced several solutions in recent years to help meet the individual financial circumstances of people living with diabetes that are still in effect during the COVID-19 crisis, including:

- The Lilly Diabetes Solution Center, through which representatives can direct people to the $35 savings card, as well as affordability options that may reduce their out-of-pocket costs further – such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.
- Three non-branded versions of our insulin options with list prices 50 percent lower than the branded versions.
- In January, the company announced plans to donate at least 200,000 KwikPens® to relief agencies over the next three years.

Hope all is well with you….

Shawn

========================
Shawn O'Neail
Vice President, Government Affairs
Eli Lilly and Company
[redacted] (b) (6) (office) | [redacted] (b) (6) (mobile)
[redacted] (b) (6) | >>www.lilly.com<<

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 22:58:33 +0000
To: Chris Joffe;Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Supporting Schools In Covid-19

Due to the high demand on Dr. Fauci's time during the current outbreak – we must decline your request at this time. Thank you for your understanding.

Best,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institues of Health
[redacted] (b) (6) (office)
[redacted] (b) (6) (cell)

From: Chris Joffe <Chris@joffeemergencyservices.com>
Sent: Tuesday, April 7, 2020 6:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Supporting Schools In Covid-19

Dr. Fauci -

I'm a safety/security consultant to independent and charter schools. I run a firm supporting ~1,000 of them. What, if anything, would you want them to know? **I'm wondering if there's any chance in the world you'd be willing to join us and a few hundred schools for a 15 - 30-minute webinar one day next week?**

Specifically, schools are looking for information/perspective as it relates to what to expect as we return to a new normal and the like. Beyond that, they've begun to ask questions such as what we can be thinking about for this short period of time between the return to school and the development of a vaccine. What would best practice look like for us to educate, but maintain social distance? I believe we can manage a lot of the operationalizing but would be immensely grateful for some high-level guidance to follow.

I recognize how incredibly busy this time is for you and would be so incredibly grateful for any time you might be willing to spare for this audience.

With immense gratitude,

Chris Joffe

--
Chris Joffe
CEO | Joffe Emergency Services
HQ | Santa Monica, CA
Twitter: @joffechris

[redacted] (b) (6)
Executive Assistant
E: [redacted] (b) (6)
P: [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Tue, 7 Apr 2020 13:12:39 -0400
To: Lane, Cliff (NIH/NIAID) [E]
Subject: Fwd: [redacted] (b) (4)
Attachments: [redacted] (b) (4)

Here it is

Begin forwarded message:

> **From:** "Gelfand, Jeffrey A.,M.D." [redacted] (b) (6)
> **Date:** April 7, 2020 at 9:39:51 AM EDT
> **To:** "Callahan, Michael V.,M.D." [redacted] (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject:** [redacted] (b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 15:45:18 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: NFLPA-NFL Task Force

[redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 7, 2020 11:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: NFLPA-NFL Task Force

Pls see below – [redacted] (b) (5)

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, April 4, 2020 12:06 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: NFLPA-NFL Task Force

[redacted] (b) (5)

From: [redacted] (b) (6)
Sent: Saturday, April 4, 2020 11:01 AM

To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Thom Mayer [redacted] (b) (6)>
Subject: NFLPA-NFL Task Force

Hi Courtney,

1st, I hope you, your family and your loved ones are harboring safely through this storm. 2nd, thanks for your efforts and those of Dr. Fauci-he is truly a national treasure during this crisis and it is deeply appreciated.

I appreciate your help and introductions on how our players can be helpful. As you know Drew and Brittany Brees made a $5M contribution to the Louisiana coronavirus efforts and they have done a lot of press. Drew's message has been "Hang in there-hang tough! We are in this together."

I've done several webinars with our players and their families, both educating them and pointing out their role both with friends and family as well as on social media to let NFL fans know that whether or not we have an NFL season depends to a large extent upon those fans following the guidelines zealously-as zealously as they follow NFL games!

That message seems to be getting through.

I write now with a request for a little bit of Dr. Fauci's time in about 2 weeks. I requested that we stand up a joint NFLPA-NFL Task Force to scenario plan a pathway to getting NFL Club facilities open, with a view towards if and when we might look towards an NFL season, even if games are played with no fans. My request is to have Dr. Fauci give a telephone briefing to our group on this difficult topic, which would of course be confidential. The floor would be his and I can brief him prior to the call on what we have been working on. If he were willing, we can do the call anytime, probably during the week of April 13, although of course the modeling shows that would be during the peak of the outbreak. We could also do it the week before or after.

Thanks so much for considering this. We are mindful of the psychological toll the virus is taking and the lift NFL games would give to a sports-starved population, but only if it can be done safely for the players and the fans who (ultimately) allow them to play this great game.

Again, thanks!

Best,

Doc

Thom Mayer, MD, FACEP, FAAP, FACHE
Medical Director
NFLPA
NFL Players Association
11150 Sunset Hills Road, Ste 305
Reston, VA 20190

Mobile: [redacted] (b) (6)
NFLPA.COM

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 15:24:35 +0000
To: Barillas, Carolina (NIH/NIAID) [E]
Cc: Holland, Steven (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E];[redacted] (b) (6)
Subject: RE: BCG protection from COVID-19 mortality

Carolina:

(b) (5)
[redacted]

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barillas, Carolina (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Tuesday, April 7, 2020 11:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] [redacted] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: BCG protection from COVID-19 mortality

Good morning Tony,

[redacted]
(b) (5)

All the best,

Carolina

Carolina Barillas Mury, M.D., Ph.D.
Chief, Mosquito Immunity and Vector Competence Section
Laboratory of Malaria and Vector Research
National Institutes of Health
12735 Twinbrook Parkway, Room 2E-20C
Rockville, MD 20852
Phone: [redacted] (b) (6) Fax: (301) 480 0930
E-mail: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:51:59 +0000
To: Alison Galvani
Subject: RE: Your PNAS article "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published

Alison:
Thanks for sending this. I hope that all is well with you. Keep up your great work.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alison Galvani [redacted] (b) (6)
Sent: Friday, April 3, 2020 3:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Singer,Burton H [redacted] (b) (6); Seyed Moghadas [redacted] (b) (6)
Subject: Fwd: Your PNAS article "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published

Hi Tony,

Please find attached our second COVID publication. This one focuses on projections of the number of ICU beds that will be needed at the peak of the outbreak.

Please don't hesitate to let me know if we can be of any assistance.

Take care,
Alison

---------- Forwarded message ---------
From: <journalstaff@pnascentral.org>
Date: Fri, Apr 3, 2020 at 2:06 PM
Subject: Your PNAS article "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published
To: [redacted] (b) (6)

PNAS is pleased to announce that your paper "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published online at: www.pnas.org. Did you know article-level metrics data and article downloads are now available for all PNAS articles? Article-level metrics provide a new way of measuring the reach and impact of an article by tracking the mentions it receives online. Clicking on the "Authors & Info" tab near the top of each article and scrolling down will reveal a summary of mentions of the article across news sites, blogs, social media, and other online sources- which are visualized in a colorful icon, or "badge." The number in the middle of the badge is the Altmetric score, which is based on the volume, type, and author of the mentions. You can click on the badge or "view more" to explore the individual mentions from each source. Article downloads by month and by article format appear below the badge.

Stay connected to PNAS:

Follow Us on Twitter

Find Us on Facebook

--
Alison Galvani, PhD

Director, Yale Center for Infectious Disease Modeling and Analysis (CIDMA)
Burnett and Stender Families Professor of Epidemiology
Yale School of Public Health
Yale School of Medicine
New Haven, CT 06520

[redacted] (b) (6)
http://cidma.yale.edu/

Follow me at @Alison_Galvani
Follow CIDMA @YCIDMA

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:47:59 +0000
To: Glass, Roger (NIH/FIC) [E]
Subject: RE: To cheer you up!

Thanks, Roger!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Glass, Roger (NIH/FIC) [E] [redacted] (b) (6)>
Sent: Friday, April 3, 2020 12:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: To cheer you up!

Tony

Read the last lines and see the photo! Your words from the past are remembered and have changed the careers of our fellows.

No need to respond.

Roger

Sent from my iPad

Begin forwarded message:

> **From:** [redacted] (b) (6)
> **Date:** April 3, 2020 at 11:30:23 AM CDT
> **To:** "Glass, Roger (NIH/FIC) [E]" [redacted] (b) (6)>
> **Subject: Hello**
>
> Dr. Glass,

I hope you are well and I wanted to check in to see how you are doing in this scary and traumatic time for our world.

During these times, I'm especially thankful for the training I received from the Fogarty Institute. I remember your wise words at our Fogarty orientation in 2011- on why investing in Global health is so critical. No truer words have been spoken especially at times like these!

I'm currently communicating with my former colleagues in Zambia (Mpanji and Innocent pictured here with me https://www.thermofisher.com/blog/behindthebench/using-sanger-sequencing-to-detect-drug-resistance-mutations-in-hiv-in-zambia/) from CIDRZ to see how testing can be brought up via the public health infrastructure in place currently. Thankfully, the number of cases is very low, although the unreported cases are much higher than likely captured (https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6). My friend who is a Lieutenant Physician actually likely contracted COVID-19 in January and wrote that she and others had treated a patient returning from Wuhan who was pregnant of respiratory illness upon coming back to Lusaka to deliver, only to die of pleural effusion later. They subsequently developed flu-like symptoms and resolved, but these are the types of cases that likely go undetected and can potentially contribute to community spread of the disease.

Thank you again for being such a wonderful role model, and I look to leaders like you and Dr. Fauci to help our nation think with prudent but difficult decisions.

Kind regards,
Lillian



Why invest in global health ?

Good for science- the new frontier
Good for diplomacy – "smart power"
Good for humanity – correct health disparities
Good for business & competition
Good for our war on terrorism
Good for our own future

just the right thing to do !

JOHN E. FOGARTY
INTERNATIONAL



Research to Develop and Optimize Interventions Against Infectious Disease Threats

Implementation: Delivery o
Proven Interventions to
Patients and Populations

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:44:25 +0000
To: [redacted] (b) (6)
Subject: FW: [redacted] (b) (4)
Attachments: [redacted] (b) (4)

What do you think of this study?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: afauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gelfand, Jeffrey A.,M.D. [redacted] (b) (6)>
Sent: Tuesday, April 7, 2020 9:39 AM
To: Callahan, Michael V.,M.D. < [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: [redacted] (b) (4)
Importance: High

Dear Tony and Michael: [redacted] (b) (4)
(b) (4)

Hang in there –
Jeff Gelfand
Mark Poznansky
Vaccine and Immunotherapy Center
Division of Infectious Diseases
Massachusetts General Hospital

[redacted] (b) (6) (C)-Jeff
(b) (6) -Mark

From: Chen, Huabiao, M.D. <[redacted] (b) (6)
Sent: Monday, April 6, 2020 9:07 PM
To: Gelfand, Jeffrey A.,M.D. [redacted] (b) (6)>; Poznansky, Mark,M.B.,Ch.B.,Ph.D.
[redacted] (b) (6)
Subject: Re: [redacted] (b) (4)
[redacted]

Dear Jeff and Mark,

[redacted] (b) (4)

Thanks,
Huabiao

From: Chen, Huabiao, M.D. [redacted] (b) (6)
Sent: Monday, April 6, 2020 12:41 PM
To: Gelfand, Jeffrey A.,M.D. [redacted] (b) (6)>
Subject: Re: [redacted] (b) (4)
[redacted]

attached please find the supporting information in PDF

From: Chen, Huabiao, M.D. [redacted] (b) (6)>
Sent: Monday, April 6, 2020 12:23 PM
To: Gelfand, Jeffrey A.,M. [redacted] (b) (6)
Subject: Re: [redacted] (b) (4)
[redacted]

If needed please download the supporting information [redacted] (b) (4)
[redacted]

From: Gelfand, Jeffrey A.,M.D. <[redacted] (b) (6)>
Sent: Monday, April 6, 2020 12:16 PM
To: Chen, Huabiao, M.D. [redacted] (b) (6)>

Subject: RE: [redacted] (b) (4)
[redacted]

Wow! Reading it now...Jeff

From: Chen, Huabiao, M.D. [redacted] (b) (6)
Sent: Monday, April 6, 2020 11:46 AM
To: Gelfand, Jeffrey A.,M.D. [redacted] (b) (6)>
Subject: [redacted] (b) (4)
[redacted]
Importance: High

Dear Jeff,

I had a Chance getting this information from [redacted] (b) (6) Dr. Danlei Mou who works very diligently and seriously on this clinical study. You may be interested in this primary information. Please keep it confidential.

Best, Huabiao

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at http://www.partners.org/complianceline . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 23:21:25 +0000
To: Upton, Fred
Subject: RE: GOP lawmakers: Fauci may be doing more harm than good | TheHill

Thanks, Fred. I appreciate your note.
Best regards,
Tony

-----Original Message-----
From: Upton, Fred [redacted] (b) (6)>
Sent: Saturday, April 11, 2020 6:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: GOP lawmakers: Fauci may be doing more harm than good | TheHill

Update. Biggs and Buck are the only 2 members of Congress that voted agn the first two bills dealing with COVID-19. The first vote had only the 2 of them vote no. NRN

Sent from my iPhone

> On Apr 11, 2020, at 5:45 PM, Upton, Fred [redacted] (b) (6)> wrote:
>
> It's upton again and no need to respond. U may get asked about this story and u should know that both Buck and Biggs were among the 40 that voted no on the 2nd package which provided assistance and testing (think it was $13B). It was not a surprise that they voted no as they r joined with Tom Massie in almost everything. Keep being a science truth teller□□
> https://thehill.com/homenews/coronavirus-report/492359-gop-lawmakers-fauci-may-be-doing-more-harm-than-good
>
>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 19:26:02 +0000
To: Upton, Fred
Subject: RE: It's Fred upton

Fred:
Thanks for the note. The answer is almost certainly yes, but there would not be enough of them whereby we can compare the results in those who were receiving Hydroxychloroquine or not for their lupus. Large natural history studies, which we will be initiating could possibly answer that question.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Upton, Fred (b) (6)
Sent: Friday, April 10, 2020 6:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: It's Fred upton

U gave me your email at the Capitol briefing. Question, with all the discussion on hydrox.—have there been any Covid-19 cases that have struck lupus victims? TY

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 22:29:20 +0000
To: Bergmann, Kenneth
Cc: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Thanks, Ken. Interesting concept. I will run it by our program people.

From: Bergmann, Kenneth [redacted] (b) (6)>
Sent: Wednesday, April 15, 2020 4:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Hi, Tony
This is not my field but I had some ideas, so thank you for indulging me in thinking about "why not kids." I attached citations I found useful. Hope you are not sorry you asked... ☺

(b) (5)
[redacted]

[redacted] (b) (5)

Best regards,

Ken

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 07, 2020 9:50 AM
To: Bergmann, Kenneth [redacted] (b) (6)
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Ken:

Thanks for the note. I have thought about the same or similar issues. [redacted] (b) (5)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bergmann, Kenneth [redacted] (b) (6)>
Sent: Saturday, April 4, 2020 9:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: a thought on selective vulnerability to SARS-CoV-2

Dear Dr. Fauci
I read with interest your JAMA Viewpoint of February 25.

[redacted] (b) (6), (b) (5)

Thank you for all you do.
Sincerely
Ken

Kenneth J. Bergmann, MD, FAAN
Senior Medical Officer
Division of Neurology I. Office of Neuroscience
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 22, Room 4143
10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002
Office: [redacted] (b) (6)
Mobile: [redacted] (b) (6)
Email [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 22:28:57 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: a thought on selective vulnerability to SARS-CoV-2
Attachments: 1_Mab induced Cytokine Storm NEJM 2006.pdf, 2_Covid_pregnancy.pdf, 3_Neonate _innate_immunity_2018.pdf, 4_nihms832701.pdf, 5_12948_2017_Article_77.pdf

Please check this out with program people. Thanks.

From: Bergmann, Kenneth <[redacted] (b) (6)>
Sent: Wednesday, April 15, 2020 4:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Hi, Tony
This is not my field but I had some ideas, so thank you for indulging me in thinking about "why not kids." I attached citations I found useful. Hope you are not sorry you asked... ☺

(b) (5)
[redacted]

(b) (5) [redacted]

Best regards,

Ken

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, April 07, 2020 9:50 AM
To: Bergmann, Kenneth < [redacted] (b) (6)>
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Ken:

Thanks for the note. I have thought about the same or similar issues. (b) (5) [redacted]

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not

accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bergmann, Kenneth [redacted] (b) (6)
Sent: Saturday, April 4, 2020 9:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: a thought on selective vulnerability to SARS-CoV-2

Dear Dr. Fauci
I read with interest your JAMA Viewpoint of February 25.

[redacted] (b) (6), (b) (5)

Thank you for all you do.
Sincerely
Ken

Kenneth J. Bergmann, MD, FAAN
Senior Medical Officer
Division of Neurology I, Office of Neuroscience
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 22, Room 4143
10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002
Office: [redacted] (b) (6)
Mobile: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 22:44:30 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Collection of COVID-19 patient data from medical records

Please take a look at this and figure out whether we should do something.

From: Hahn, Stephen <(b) (6)>
Sent: Thursday, March 26, 2020 5:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6); Debi Birx <(b) (6)>
Cc: Abernethy, Amy (FDA/OC) <(b) (6)>; Lenihan, Keagan (FDA/OC) (b) (6)
Subject: Collection of COVID-19 patient data from medical records

Tony, Bob and Debi,
Amy is working on a pathway to collect data from electronic medical records in selected areas of the country (addressing all of the appropriate privacy concerns). We're looking for data elements to collect and wonder if your teams could give us some insight from a public health perspective. I am copying Amy to see if she has anything else to add. Perhaps you could assign someone to work with Amy.
Thanks
Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 18:55:23 +0000
To: Kamoie, Brian
Subject: RE: Thank You

Thanks, Brian. I appreciate your note.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kamoie, Brian [redacted] (b) (6)>
Sent: Saturday, April 18, 2020 12:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Thank You

Tony,

Thank you for all that you are doing in the fight against COVID-19. Your steady leadership and grounding in the science, and your ability to communicate complex information clearly to policymakers and the public, are what the world needs during this crisis. I know we will see the other side of this pandemic, and you will have once again saved many lives with your work.

I am one step removed from this response, as I am on a detail assignment from FEMA to the Naval Academy, but have been sharing information with the Superintendent and his senior leadership team so that they can make good decisions to protect the community while meeting the Academy's mission. I have thought back to the H1N1 response in 2009-2010 many times since this began.

Again, thank you for what you're doing. My best wishes to you and your family.

Best,
Brian

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 03:00:26 +0000
To: Collins, Francis (NIH/OD) [E];Myles, Renate (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E];Wolinetz, Carrie (NIH/OD) [E];Lane, Cliff (NIH/NIAID) [E]
Cc: Burklow, John (NIH/OD) [E];Fine, Amanda (NIH/OD) [E];Wojtowicz, Emma (NIH/OD) [E];Fritz, Craig (NIH/OD) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: For review tonight: draft Sec. Azar statement on ACTIV

Ditto.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Wednesday, April 15, 2020 10:57 PM
To: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] < [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Burklow, John (NIH/OD) [E] [redacted] (b) (6) Fine, Amanda (NIH/OD) [E] [redacted] (b) (6); Wojtowicz, Emma (NIH/OD) [E] [redacted] (b) (6); Fritz, Craig (NIH/OD) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: For review tonight: draft Sec. Azar statement on ACTIV

Looks generally OK
FC

From: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>
Sent: Wednesday, April 15, 2020 10:44 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Burklow, John (NIH/OD) [E] [redacted] (b) (6); Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>; Wojtowicz, Emma (NIH/OD) [E] [redacted] (b) (6)>; Fritz, Craig (NIH/OD) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: For review tonight: draft Sec. Azar statement on ACTIV
Importance: High

Good evening:

I'm sending this directly to principals given the quick turnaround. I've let ASPA know that the goal is to issue the release sometime tomorrow.

Thanks,
Renate

From: Brennan, Patrick (OS/ASPA) [redacted] (b) (6)
Sent: Wednesday, April 15, 2020 10:20 PM
To: Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Fritz, Craig (NIH/OD) [E] [redacted] (b) (6); Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>; Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>; Wojtowicz, Emma (NIH/OD) [E] [redacted] (b) (6)>; Akinso, Woleola (NIH/OD) [E] [redacted] (b) (6)>; Stimson, Brian (HHS/OGC) [redacted] (b) (6)>; Charrow, Robert (HHS/OGC) [redacted] (b) (6)>
Cc: Murphy, Ryan (OS/ASPA) [redacted] (b) (6)>; Pratt, Michael (OS/ASPA) [redacted] (b) (6)>; Oakley, Caitlin B. (OS/ASPA) <[redacted] (b) (6)>
Subject: For review tonight: draft Sec. Azar statement on ACTIV

NIH and OGC,

Can you let me know if the below and attached statement from the Secretary looks OK? **Assuming it is going tonight from NIH, approval as soon as possible would be great.** Thank you!

- Patrick

[redacted] (b) (5)

Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office: [redacted] (b) (6) | Cell: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 01:14:17 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Erbelding, Emily (NIH/NIAID) [E];'Dieffenbach, Carl (NIH/NIAID) [E]';Marston, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Pursuant to My Email on Friday
Attachments: Vaccine strategy-200411-v 13.pptx, Secretary Determination Memorandum-Project Warp Speed-041120 1825 draft.doc

John:
Let us briefly discuss this tomorrow AM. [redacted] (b) (5)

Best,
Tony

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 8:59 PM
To: Hassell, David (Chris) (OS/ASPR/IO) [redacted] (b) (6); Collins, Francis (NIH/OD) [E] [redacted] (b) (6) Mascola, John (NIH/VRC) [E] [redacted] (b) (6); Bright, Rick (OS/ASPR/BARDA) [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Disbrow, Gary (OS/ASPR/BARDA) [redacted] (b) (6); Patrick, Vanessa (OS/ASPR/BARDA) (CTR) [redacted] (b) (6)>; Moughalian, Jen (HHS/ASFR) [redacted] (b) (6) Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Marks, Peter (FDA/CBER) [redacted] (b) (6)>; Yeskey, Kevin (OS/ASPR/IO) [redacted] (b) (6)
Cc: Harrison, Brian (HHS/IOS) [redacted] (b) (6); Dareshori, Zack (HHS/IOS) [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Stecker, Judy (OS/IOS) [redacted] (b) (6) Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)>
Subject: Pursuant to My Email on Friday

I want to share with you the product of the BCG team who drafted the attached briefing and Decision Memo drafted for the Secretary's review tomorrow. I want to thank all those who contributed over this holiday weekend to offer their ideas and concepts that is represented in these products. This represents just a first step of many steps that first outlines a concept that will then be operationalized into a historic effort for not only the Department and agencies who will contribute to it, but to our Nation. Again, thank you for your contributions and commitment. Best Bob

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 00:32:55 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: RE: daily data call from Sec Ofc

This looks really good. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, April 12, 2020 7:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Subject: ASF: daily data call from Sec Ofc

Per request from the Secretary's office that I sent you this morning, below is what I propose to submit tomorrow morning for the new daily 9am data call. I will plan to submit pretty much the same thing every day. I will not clog your in-box with it unless there is a significant update.

RFI from Staff Sec:

1. For tomorrow's press conference, what information or topics do you recommend be included in the President's remarks? Please provide talking point-level details and support.

Nothing specific from NIAID at this time.

2. For tomorrow's press conference, on what information (if any) do you intend to speak?

Specific topics will depend on questions from reporters. Dr. Fauci has been asked about the effect of social distancing; considerations that would factor into returning the country to normal life; off-label use of treatments such as hydrochloroquine; the status of clinical trials; and the disproportionate impact of COVID-19 on communities of color.

NIAID-specific talking points:

- NIAID has mobilized a rapid research response to quickly develop effective countermeasures for COVID-19, including diagnostics, vaccines to prevent disease and treatments.

- NIAID is supporting a clinical trial of the antiviral remdesivir and is investigating other treatments, including antibody therapies and other antivirals, for their activity against SARS-CoV-2. Well-designed clinical trials are the best way to evaluate potential treatments for safety and efficacy.

- NIAID is supporting an early-stage clinical trial of an investigational vaccine called mRNA-1273, developed by NIAID scientists and the biotechnology company Moderna. The study launched first in Seattle, with a second site recently added in Atlanta. NIAID is researching additional vaccine candidates.

- NIAID has launched a serosurvey study that aims to determine how many adults in the United States without a confirmed history of COVID-19 have antibodies to the virus. Researchers will collect and analyze blood samples from as many as 10,000 adult volunteers without a confirmed history of COVID-19. The results will help illuminate the extent to which the novel coronavirus has spread undetected in the United States and provide insights into which communities and populations are most affected. [NOTE: This serosurvey is for research purposes. It is not meant to be a way for people to access antibody testing for personal knowledge of prior infection history. If it is portrayed as a way for people to "get tested" to understand their own infection history, we can expect that people will inaccurately blame the government for not receiving results in a timely manner. People can request to learn about their results, which will be available only after weeks or months of analysis.]

- NIAID is expanding its portfolio of basic research on coronaviruses and emerging pathogens to characterize SARS-CoV-2 (the virus that causes COVID-19) and understand how it causes disease. NIAID also is using animal models to better understand the infection and to investigate optimal ways to treat and prevent COVID-19.

3. Are there topics or announcements for future press conferences (other than tomorrow's) that you would like to flag for the President's speechwriting team?

For HHS to consider mentioning: [redacted] (b) (5) [redacted].

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, April 12, 2020 1:55 PM
To: Billet, Courtney (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: RE: Staff Sec POC - NIAID

OK. Sounds fine. Do what you can do.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, April 12, 2020 10:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Staff Sec POC - NIAID

FYI – per request below, HHS is setting up a daily data call. We need to tell them at 9am what you are going to discuss at the daily press conference at the end of the day. My observation is that this may be hard to predict. However, we can certainly come up with some boilerplate talking points that we re-submit every day, emphasizing the importance of properly designed clinical trials as the best way to identify treatments.

From: Boyse, Natalie (OS/ASPA) [redacted] (b) (6)
Sent: Saturday, April 11, 2020 7:04 PM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Bird, Catherine (OS/OGC) [redacted] (b) (6)>; Puesan, Cesar (HHS/OS/IOS) [redacted] (b) (6)>; Agnew, Ann (HHS/IOS) [redacted] (b) (6)>; Brennan, Patrick (OS/ASPA) < [redacted] (b) (6)
Subject: Staff Sec POC - NIAID

Hi Courtney -

I hope you're having a good weekend. Just wanted to touch base because starting tomorrow, we will be receiving requests for information from Staff Sec **each evening** ahead of the next day's press conference - for a turnaround **by 9am the following morning**. Staff Sec is requesting feedback (see the questions below) from task force experts, including Dr. Fauci, on information they recommend be included in the next day's press conference.

Could you please help me identify a primary POC at NIAID that I can work with to get information to Staff Sec?

(b) (5)
[redacted]

[redacted] (b) (5)

Thank you,
Natalie

Natalie Boyse
Special Assistant, Immediate Office of the Secretary
U.S. Department of Health & Human Services
M: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 03:05:04 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E];Lane, Cliff (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E]
Subject: RE: COVID-19 Advisory Panel Recommendations Following UP on Secretary Meeting this Am.

I am sorry, but I am way behind on e-mails and I just saw this. What is going on here?

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Friday, April 10, 2020 11:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Mascola, John (NIH/VRC) [E] [redacted] (b) (6)
Subject: FW: COVID-19 Advisory Panel Recommendations Following UP on Secretary Meeting this Am.
Importance: High

Just saw this. Huh? [redacted] (b) (5) [redacted]?

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>
Sent: Friday, April 10, 2020 7:27 PM
To: Hassell, David (Chris) (OS/ASPR/IO) [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6); 'sh1@fda.hhs.gov' [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E] [redacted] (b) (6) Dareshori, Zack (HHS/IOS) < [redacted] (b) (6)>; Bright, Rick (OS/ASPR/BARDA) [redacted] (b) (6)>; Disbrow, Gary (OS/ASPR/BARDA) [redacted] (b) (6)>; Blatner, Gretta (OS/ASPR/BARDA) [redacted] (b) (6)>; Patrick, Vanessa (OS/ASPR/BARDA) (CTR) [redacted] (b) (6); Moughalian, Jen (HHS/ASFR) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6); Redd, John (OS/ASPR/SPPR) [redacted] (b) (6); Redfield, Robert R. (CDC/OD) [redacted] (b) (6); Strength-McGaughey, Tracie (CDC/DDNID/NCIPC/OD) [redacted] (b) (6)>; Yeskey, Kevin (OS/ASPR/IO) [redacted] (b) (6)>; Marks, Peter (FDA/CBER) [redacted] (b) (6)>; Cochran, Norris (HHS/ASFR) [redacted] (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Johnson, Robert (OS/ASPR/BARDA) [redacted] (b) (6)>; Gershman, Lynn E. (CDC/DDPHSIS/OD) [redacted] (b) (6)>; Lenihan, Keagan (FDA/OC) < [redacted] (b) (6); Mark Hartell [redacted] (b) (6) Mascola, John (NIH/VRC) [E]

[redacted] (b) (6)>; Suhana, Tina (NIH/VRC) [E] [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>; Mango, Paul (HHS/IOS) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)
Cc: Harrison, Brian (HHS/IOS) [redacted] (b) (6)>; Stecker, Judy (OS/IOS) [redacted] (b) (6)>; Ford-Barnes, Arwenthia (OS/ASPR/IO) [redacted] (b) (6); Tignor, Beth (HHS/IOS) [redacted] (b) (6)>; Moreno, Rafael (OS/ASPR) [redacted] (b) (6)>; Callahan, Victoria (OS/ASPR/IO) (CTR) [redacted] (b) (6)>; Kemp, Micha (OS/ASPR/MFHC) [redacted] (b) (6); Holland, Tara (OS/ASPR/EMMO) [redacted] (b) (6)>
Subject: RE: COVID-19 Advisory Panel Recommendations Following UP on Secretary Meeting this Am.
Importance: High

First thank you all for participating on Wednesday's evening call and producing the briefing memo for the Secretary's review. As a consequence of that meeting and discussion, he fully endorsed the recommendations of the vaccine portfolio you recommended. He, however, expressed, concern about [redacted] (b) (5)

[redacted] (b) (5)

This is an ambitious and challenging undertaking but one driven by the necessity to mitigate the public health, economic and national security threat this virus represents to our citizens, nation and our way of life. The Secretary is confident that together with our private sector partners this is achievable.

Have a restful holiday weekend.

Bob

From: Hassell, David (Chris) (OS/ASPR/IO) [redacted] (b) (6)
Sent: Thursday, April 9, 2020 3:13 PM
To: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>;

[redacted] (b) (6)>; Dareshori, Zack (HHS/IOS) [redacted] (b) (6)>; Bright, Rick (OS/ASPR/BARDA) [redacted] (b) (6); Disbrow, Gary (OS/ASPR/BARDA) [redacted] (b) (6)>; Ford-Barnes, Arwenthia (OS/ASPR/IO) <[redacted] (b) (6); Blatner, Gretta (OS/ASPR/BARDA) [redacted] (b) (6)>; Patrick, Vanessa (OS/ASPR/BARDA) (CTR) [redacted] (b) (6)>; Moughalian, Jen (HHS/ASFR) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6) Redd, John (OS/ASPR/SPPR) [redacted] (b) (6); Tignor, Beth (HHS/IOS) [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>; Strength-McGaughey, Tracie (CDC/DDNID/NCIPC/OD) [redacted] (b) (6)>; Yeskey, Kevin (OS/ASPR/IO) [redacted] (b) (6)>; Callahan, Victoria (OS/ASPR/IO) (CTR) [redacted] (b) (6)>; Moreno, Rafael (OS/ASPR) [redacted] (b) (6)>; Marks, Peter (FDA/CBER) [redacted] (b) (6)>; Cochran, Norris (HHS/ASFR) [redacted] (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>; Windom, Robert (OS/ASPR/IO) [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6) Holland, Tara (OS/ASPR/EMMO) [redacted] (b) (6)>; Johnson, Robert (OS/ASPR/BARDA) [redacted] (b) (6)>; Gershman, Lynn E. (CDC/DDPHSIS/OD) [redacted] (b) (6)>; Kemp, Micha (OS/ASPR/MFHC) [redacted] (b) (6)>; Lenihan, Keagan (FDA/OC) [redacted] (b) (6)>; Mark Hartell [redacted] (b) (6)>; Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>; Suhana, Tina (NIH/VRC) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] <[redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)

Subject: COVID-19 Advisory Panel Recommendations

Dear Panel members—

Secretary Azar requested a summary paper with a recommendation from the Panel re the BARDA vaccine portfolio. His deadline was 3:30pm today.

Based on the discussion last night and other discussions with the BARDA team, [redacted] (b) (5) Please let me know as soon as possible if this is not the case.

Apologies for the fast turn. Thank you again for your participation in the Panel.

Chris
<< File: COVID Vaccines Briefing Memo V.3.docx >>

-----Original Appointment-----
From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>
Sent: Monday, April 6, 2020 1:36 PM

To: Kadlec, Robert (OS/ASPR/IO); Conrad, Patricia (NIH/NIAID) [E]; Collins, Francis (NIH/OD) [E]; [redacted] (b) (6); Dareshori, Zack (HHS/IOS); Bright, Rick (OS/ASPR/BARDA); Disbrow, Gary (OS/ASPR/BARDA); Ford-Barnes, Arwenthia (OS/ASPR/IO); Blatner, Gretta (OS/ASPR/BARDA); Patrick, Vanessa (OS/ASPR/BARDA) (CTR); Moughalian, Jen (HHS/ASFR); Shuy, Bryan (OS/ASPR/IO); Redd, John (OS/ASPR/SPPR); Tignor, Beth (HHS/IOS); Redfield, Robert R. (CDC/OD); Strength-McGaughey, Tracie (CDC/DDNID/NCIPC/OD); Hassell, David (Chris) (OS/ASPR/IO); Yeskey, Kevin (OS/ASPR/IO); Callahan, Victoria (OS/ASPR/IO) (CTR); Moreno, Rafael (OS/ASPR); Marks, Peter (FDA/CBER); Cochran, Norris (HHS/ASFR); Messonnier, Nancy (CDC/DDID/NCIRD/OD); Windom, Robert (OS/ASPR/IO); Lane, Cliff (NIH/NIAID) [E]; Holland, Tara (OS/ASPR/EMMO); Johnson, Robert (OS/ASPR/BARDA); Gershman, Lynn E. (CDC/DDPHSIS/OD); Kemp, Micha (OS/ASPR/MFHC); Lenihan, Keagan (FDA/OC); Mark Hartell [redacted] (b) (6) Mascola, John (NIH/VRC) [E]; Suhana, Tina (NIH/VRC) [E]; Marston, Hilary (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: #2 - COVID-19 Advisory Panel
When: Wednesday, April 8, 2020 5:15 PM-6:30 PM (UTC-05:00) Eastern Time (US & Canada).
Where: WEBEx - [redacted] (b) (5)

Presentation for Wednesday. THIS IS THE UPDATED VERSION 4:26pm
<< File: BARDA COVID Vaccines White Paper 20200405b.docx >>

Meeting Objective:

(1) Complete review of BARDA vaccine portfolio (to include related NIH and DoD programs), with emphasis on discussion among Panel members;
(2) Formulate a recommendation to Secretary Azar to either endorse or modify current vaccine strategy, plans, proposed funding and contracts.

Agenda

Brief review of vaccine programs

- BARDA (deeper dive after Sunday overview)
- NIAID
- DoD

Discussion
Recommendation to Secretary Azar

For convenience, below are the presentation and White Paper from last Sunday evening.
<< File: BARDA COVID Portfolio Review 20200405b.pptx >> << File: Vaccine Discussion with S1 and HHS Leadership V2 FINAL - Gary.pdf >>

Hi Arwenthia Ford-Barnes,

You updated this WebEx meeting:

#2 COVID-19 Advisory Panel on behalf of Dr. Robert Kadlec

Host: Arwenthia Ford-Barnes

When it's time, start your meeting from here:

Start the meeting

When: Wednesday, April 8, 2020, 5:15 pm (1 hr 15 mins), Eastern Daylight Time (New York, GMT-04:00).

Access Information

Meeting Number:
(b) (5)

Password:
(This meeting does not require a password.)

Host Key:
(b) (5) (Use this key during the meeting if you ever need to reclaim the host role.)

Audio Connection

(b) (5) (Meeting Server Main Number)

Access Code:
(b) (5)

Delivering the power of collaboration
The meetingserver.hhs.gov team

© 2020 Cisco and/or its affiliates. All rights reserved

<< File: BARDA COVID Vaccines White Paper 20200405b.docx >> << File: BARDA COVID Portfolio Review 20200405b.pptx >> << File: Vaccine Discussion with S1 and HHS Leadership V2 FINAL - Gary.pdf >>

From: [redacted] (b) (6)
Sent: Thu, 9 Apr 2020 16:48:20 -0400
To: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Hello

How do we nicely say no to this person?

Begin forwarded message:

> **From:** "Sachdev, Amit (HHS/IOS)" [redacted] (b) (6)
> **Date:** April 9, 2020 at 2:04:56 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Hello**
>
> Hi Dr. Fauci, my name is Amit Sachdev. I am a White House fellow and physician most recently at the Brigham.
>
> I know you are super busy and I would love to partner with you and write a op ed on coronavirus and unite the nation.
>
> If you have a few minutes, I would love to speak. I think [redacted] (b) (5).
>
> Thank you for your time and consideration.
>
> Sincerely,
> Amit
>
> [redacted] (b) (6)
>
> Sent from my iPhone

From: [redacted] (b) (6)
Sent: Wed, 8 Apr 2020 20:14:10 -0400
To: Adams, Jerome (HHS/OASH)
Subject: Re: Blacks/ minorities

Please text to me your cell phone number

> On Apr 8, 2020, at 7:29 PM, Adams, Jerome (HHS/OASH)
> [redacted] (b) (6)
>
> Also, Deb has the data and knows it better than anyone, [redacted] (b) (5)
> (b) (5)
>
> VADM Jerome Adams
> 20th US Surgeon General
>
>> On Apr 8, 2020, at 7:13 PM, Adams, Jerome (HHS/OASH)
>> [redacted] (b) (6)>wrote:
>>
>> With greatest of respect to the two of you, [redacted] (b) (5)
>> (b) (5)

[redacted] (b) (5).
Jerome

VADM Jerome Adams
20th US Surgeon General

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 14:38:40 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stecker, Judy (OS/IOS) [redacted] (b) (6)
Sent: Wednesday, April 8, 2020 9:59 AM
To: Harrison, Brian (HHS/IOS) [redacted] (b) (6)
Cc: [redacted] (b) (6) (OS/IOS) [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

Thank you. Will have Beth connect with Patricia ASAP.

Sent from my iPhone

> On Apr 8, 2020, at 9:48 AM, Harrison, Brian (HHS/IOS) [redacted] (b) (6)> wrote:
>
> Sounds good, Dr, Fauci - we greatly appreciate the effort that you/Cliff and your team have put into this.
>
> Look forward to receiving and discussing the guidelines (no need for a separate meeting with me first - we can go straight to the Secretary) and agree that they will not be subjected to additional layers of formal clearance given the circumstances.

Adding Judy to quickly help coordinate a time to meet with the Secretary.

Thanks again,

BH

Brian Harrison
Chief of Staff
U.S. Department of Health and Human Services
[redacted] (b) (6)
[redacted] (b) (6)

> On Apr 8, 2020, at 7:46 AM, [redacted] (b) (6) (OS/IOS) [redacted] (b) (6)> wrote:
>
> Thank you Tony. Obviously we will prioritize time to meet/discuss. I'm at your disposal.
> AMA
>
>> On Apr 7, 2020, at 11:01 PM, Fauci, Anthony (NIH/NIAID) [E]
>> [redacted] (b) (6)> wrote:
>>
>> Brian:
>>
>> [redacted] (b)(5) - PCP

[redacted] (b) (5)

[redacted] (b) (5) Happy to discuss further before I brief the Secretary.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 13:49:56 +0000
To: Harrison, Brian (HHS/IOS)
Subject: RE: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

Thanks, Brian.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harrison, Brian (HHS/IOS) [redacted] (b) (6)>
Sent: Wednesday, April 8, 2020 9:49 AM
To: (b) (6) (OS/IOS) [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Stecker, Judy (OS/IOS) [redacted] (b) (6)
Subject: Re: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

Sounds good, Dr, Fauci - we greatly appreciate the effort that you/Cliff and your team have put into this.

Look forward to receiving and discussing the guidelines (no need for a separate meeting with me first - we can go straight to the Secretary) and agree that they will not be subjected to additional layers of formal clearance given the circumstances.

Adding Judy to quickly help coordinate a time to meet with the Secretary.

Thanks again,

BH

Brian Harrison
Chief of Staff
U.S. Department of Health and Human Services
[redacted] (b) (6)

[redacted] (b) (6)

On Apr 8, 2020, at 7:46 AM, [redacted] (b) (6) (OS/IOS) [redacted] (b) (6)> wrote:

Thank you Tony. Obviously we will prioritize time to meet/discuss. I'm at your disposal.
AMA

> On Apr 7, 2020, at 11:01 PM, Fauci, Anthony (NIH/NIAID) [E]
> [redacted] (b) (6)> wrote:

Brian:

[redacted] (b) (5)

[redacted] (b) (5). Happy to discuss further before I brief the Secretary.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:48:49 +0000
To: Becks, Karen (HHS/IOS)
Subject: RE: Crazy COVID-19 face cover idea

Karen:
Thanks for your note.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Becks, Karen (HHS/IOS) [redacted] (b) (6)
Sent: Friday, April 3, 2020 12:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Crazy COVID-19 face cover idea

Hi, Dr. Fauci.

Thank you so much for keeping things honest and know that I am such a champion of you.

I hope that reaching out is okay. I work at HHS/IOS team. As I sit here at home and have been thinking about the shortage of medical supplies, doggie cones actually can be used as protection for our health care workers. Just a thought that looks and sounds crazy but can help.

Stay safe.

Kindest Regards,

Karen Becks
U.S. Department of Health and Human Services
Immediate Office of the Secretary
200 Independence Avenue, SW
Washington, DC 20201
Desk: (b) (6)
Mobile: (b) (6)

Brian Kamoie
DHS/FEMA
(b) (6) (mobile)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 22:05:53 +0000
To: (b) (6)
Subject: RE: Greetings from your former employee (UNCLASSIFIED)

(b) (6)

Many thanks for your kind note. I hope that all is well with you.
Best regards,.
Tony

-----Original Message-----
From: (b) (6) (b) (6)
Sent: Thursday, April 2, 2020 4:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Greetings from your former employee (UNCLASSIFIED)

CLASSIFICATION: UNCLASSIFIED

Dear Dr. Fauci,

I was in touch with (b) (6) back in January and he said you all were underwater there with coronavirus. I can only imagine how much busier you are now, with COVID-19 taking hold across America.

We (myself, husband, and family) have followed the news since the start. In watching, I was reminded of the old sign we had posted on the printer between (b) (6) and my desk for quite some time that read, "Keep Calm and Trust Fauci". I can't recall whether we put that up during the Ebola outbreak or Zika, but never has it been more true. We never cease to be amazed at how well you carry yourself, respond to politically loaded questions, and get the truth out in such a way that any viewer can understand.

You also never seem to frustrate from answering the same questions which I am sure must get old. There has been one question I have yet to hear asked however. Who is cutting your hair? I know you used to have a regular gal but with social distancing, we are speculating that perhaps there is a White House barber you use. Of course we know how busy you are so don't expect a reply, just wanted to throw you a question you may not have had yet. I am also wondering how your office tree is doing. How many bungee cords are supporting it these days?

We have found plenty of reasons to smile with the whole family getting in on what we're dubbing the ASF #1 Fan Club. From memes, to cartoons, to t-shirts, we are all here supporting you and wishing for your continued health and success. I am attaching some of our shenanigans in hopes you get a kick out of it and to provide some comic relief.

You've been thanked over and over but I must say it too. Thank you, Dr. Fauci, for all that you do. And thank you to the staff behind the scenes that makes it happen. (b) (6) is no doubt just as busy as you as always ((b), are you reading this email? Hi!). When we see you at all hours from the NIH studio and your office, I think of the media staff support you receive, and especially assistance from (b) (6) for helping the ship run smoothly while you are constantly engaged, (b) (6) and your family, the list goes on. Thank you and thanks to your team.

Best wishes,
(b) (6)

(b) (6)
Directorate of Human Resources
USAG Fort Detrick

CLASSIFICATION: UNCLASSIFIED

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 27 Mar 2020 11:23:56 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Reaching out about partnerships and COVID-19. // confidential

The email below is from Maria Freire.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Freire, Maria (FNIH) [T] (b) (6)
Sent: Friday, March 27, 2020 6:03 AM
To: Collins, Francis (NIH/OD) [E] (b) (6); Wholley, David (FNIH) [T] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Subject: Re: Reaching out about partnerships and COVID-19. // confidential

Yes, quite a note. It is good to see such willingness to pitch in and the things J&J is doing. Let us know what he says. We stand ready to help. Best, M.

From: "Collins, Francis (NIH/OD) [E]" (b) (6)>
Date: Friday, March 27, 2020 at 4:37:15 AM
To: "Wholley, David (FNIH) [T]" <(b) (6)>
Cc: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>, "Lane, Cliff (NIH/NIAID) [E]" (b) (6)>, "Freire, Maria (FNIH) [T]" (b) (6)
Subject: FW: Reaching out about partnerships and COVID-19. // confidential

HI David,

Quite a message from Paul below. He seems open to the idea of a virtual meeting, to see what collaborative efforts might be most important. I'll try to speak with him today or tomorrow.

Francis

From: Stoffels, Paul [JJCUS] (b) (6)>
Sent: Friday, March 27, 2020 3:54 AM

To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Cc: Castillejos, Carlos [JJCUS] [redacted] (b) (6)
Subject: Re: Reaching out about partnerships and COVID-19. // confidential

Francis,

[redacted] (b) (4)

Lots to talk about. Happy to find a productive way to contribute in the discussion you are planning to have.

we can talk this afternoon US time or over the weekend.
I'm working [redacted] (b) (6) at the moment.

Carlos can provide more information on the [redacted] (b) (6) if you want.

Best regards,

Paul

Sent from my iPad

On Mar 27, 2020, at 1:37 AM, Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> wrote:

WARNING: This email originated from outside the company. Do not click on links unless you recognize the sender and have confidence the content is safe. If you have concerns about this email, send it as an attachment to 'SuspiciousEmail@ITS.JNJ.COM'.

Hi again Paul,

One more question – is the pharma collaboration mentioned in the BioCentury story below the same thing as the Gates COVID Therapeutic Accelerator Program? Or is this something different? I'm just trying to understand the landscape.

Best, Francis

Pharmas on one page with action plan to solve COVID-19 together
BIOCENTURY IS PROVIDING THIS STORY FOR FREE GIVEN THE URGENT NEED FOR INFORMATION ABOUT THE COVID-19 CRISIS.
BY C. SIMONE FISHBURN, EDITOR IN CHIEF | MAR 25, 2020 | 9:17 PM EDT
A grand-scale behind-the-scenes effort by the pharmaceutical companies is under way to expedite the creation of therapies and vaccines to treat COVID-19.

According to the participants who spoke with BioCentury under conditions of anonymity, R&D heads from at least 10 companies have been gathering several times a week, setting in motion an action plan to use their top talent in different disciplines to produce an industry-wide response, the likes of which haven't been seen since the private sector's coordinated contribution during World War II.

Regulatory heads and manufacturing heads have been holding meetings as well, coordinating to minimize duplication of effort, streamline work and advance efficient testing of compounds and vaccines.

The R&D group is creating working principles to accelerate new COVID-19 therapies and vaccines agnostic to their market potential, eliminating bureaucratic and technical or scientific barriers, and focusing on filling gaps not adequately filled by other initiatives and which the consortium is uniquely suited to address.

The pharma group's leaders also intend to offer resources to biotechs and academic groups pursuing countermeasures who may not want to join the effort but could benefit from expert guidance.

Flying the plane as they build it, the collaborators intend to create a clearing house of ideas for testing of molecules and vaccines, with working groups to vet the ideas and expedite testing on the most promising via clinical or preclinical testing.

According to the participants who spoke to BioCentury, the structure will probably evolve over time. Currently, the model involves five working groups, for clinical phase repurposing, novel small molecule antivirals, novel antibodies, preventive vaccines and preclinical repurposing. Each will be headed by a pharma R&D executive and will be responsible for prioritizing potential compounds and specifying actions.

Two platform groups will integrate across modalities: a clinical trial acceleration group and a data sharing group.

"This is not a time to think about proprietary information or IP or margins. We need to break down the barriers and solve the problem," said one participant involved in the consortium.

From: Collins, Francis (NIH/OD) [E]
Sent: Thursday, March 26, 2020 4:25 PM
To: Stoffels, Paul [JJCUS] (b) (6)>
Subject: RE: Reaching out about partnerships and COVID-19

Hi Paul,

I have done some work on the idea of an "AMP like" COVID project. As I mentioned, Mikael Dolsten has been quite enthusiastic. For FDA, Peter Marks, Janet Woodcock, and Steve Hahn were all extremely positive about this opportunity for a shared consideration about priorities. Tony Fauci and his team are totally in favor, and the FNIH (David Wholley and Maria Freire) stands ready to serve as convener. I thought the first step would be a 90 to 120-minute virtual meeting – hopefully next week. Attached is a draft precis of what this might look like; I have left out the roster because that is very much a work in progress.

Meanwhile I saw reports that there are related partnership discussions going on amongst pharmas: https://www.globenewswire.com/news-release/2020/03/26/2006713/0/en/Novartis-and-life-sciences-companies-commit-expertise-and-assets-to-the-fight-against-COVID-19-pandemic-alongside-Bill-Melinda-Gates-Foundation.html

I am wondering how this might all fit together.

Do you have a few minutes to speak with me about this? I'm at [redacted] (b) (6), and I'd greatly value your advice. Just let me know when you might be able to call, so that I'm not in the midst of a Zoom meeting.

Best, Francis

From: Stoffels, Paul [JJCUS] [redacted] (b) (6)>
Sent: Tuesday, March 24, 2020 12:58 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Subject: Re: Reaching out about partnerships and COVID-19

Absolutely worthwile. I will write an email in the next hours.
[redacted] (b) (4).

Paul

Verstuurd vanaf mijn iPhone

> Op 24 mrt. 2020 om 17:55 heeft Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> het volgende geschreven:
>
> Hey again Paul,
>
> Really hoping to hear your thoughts on this proposal. FDA is highly enthusiastic. Dolsten is in. Other pharma R&D Chiefs that would be most helpful? Jay Bradner? John Reed? Roger Perlmutter?
>
> Thanks, Francis
>
> ---
>
> **From:** Collins, Francis (NIH/OD) [E]
> **Sent:** Monday, March 23, 2020 5:17 PM
> **To:** Stoffels, Paul [redacted] (b) (6)>
> **Subject:** Reaching out about partnerships and COVID-19
>
> Dear Paul,
>
> I've been thinking that this is a time where we ought to have the best and brightest minds from industry, NIH, academia, and FDA around the same table to identify ways that we can move the coronavirus agenda forward to life-saving products as quickly as possible. Several pharmas and biotechs have been reaching out to NIH to identify viral assays and animal models that can

be run in a BSL-3 facility. Other similar contacts I've had with pharma and biotech tell me that there is a high degree of interest and willingness to combine forces at this time of crisis.

This isn't exactly a precise recipe for AMP-COVID, but it has some of the same flavor. Would it be useful for FNIH to convene a virtual meeting with a few heads of R&D (hopefully you; Mikael Dolsten has already expressed enthusiasm; and I'd be interested in your suggestions of others), FDA (Marks and Woodcock), leaders from NIAID and a few other NIH Institutes with equity in this space. We might be able to make a short list of catalytic actions that neither sector can do optimally right now, but together we can do rapidly.

The focus would be on therapeutics and vaccines. But I can imagine a separate session on diagnostics.

Does this sound worthwhile to you?

Thanks, I always value your advice and partnership.

Francis

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Thu, 2 Apr 2020 10:58:08 +0000
To:	Mascola, John (NIH/VRC) [E]
Subject:	FW: Secretary's Medical Countermeasure Advisory Panel

As per our discussion.

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)>
Sent: Thursday, April 2, 2020 6:46 AM
To: Bright, Rick (OS/ASPR/BARDA) (b) (6); Disbrow, Gary (OS/ASPR/BARDA) < (b) (6); Lambert, Linda (OS/ASPR/BARDA) (b) (6)
Cc: Shuy, Bryan (OS/ASPR/IO) (b) (6)>; Harrison, Brian (HHS/IOS) (b) (6); Hassell, David (Chris) (OS/ASPR/IO) (b) (6)>
Subject: Secretary's Medical Countermeasure Advisory Panel
Importance: High

Rick, Gary and Linda:

The Secretary has directed me to establish a HHS Senior Advisory Panel of key HHS Operating Divisions((NIH, CDC & FDA) to include head of agencies or their designees to oversee and provide recommendations to the Secretary concerning the development and procurement medical countermeasures (MCM), (vaccines, therapeutics, diagnostics and devices). In meeting this directive, I have asked Dr. Chris Hassell to organize and serve as the intermediary to schedule and coordinate. It is the intent to hold the first virtual meeting of this panel Sunday, 4 April time TBD. The frequency of further meetings will be determined at the inaugural meeting.

The Agenda should include :

- Overall COVID-19 Strategy & Plan (5 min)
- Activities to Date (e.g. industry outreach, RFP BAA etc.) (5 min)
- High level overview of current MCM portfolio (5 min)
- Detailed briefing of current vaccine technical development efforts, timeline and costs (30 min)
- Discussion by participants (30 min)

I ask that the materials for this meeting be submitted by noon April 3 to the APSR IO to be reviewed and be distributed to the Panel membership by noon Saturday April 4. Thank you

Bob

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 31 Mar 2020 01:57:13 +0000
To: Kavesh, William
Subject: RE: Medical staff need COVID-19 NIH survival data on N-95 respirators to help alleviate shortage

Dr. Kavesh:

Thanks for your note. This issue is now being actively discussed at the Task Force meetings. No guarantee, but I believe that there will be movement in that direction.

Best regards,

Tony

From: Kavesh, William <(b) (6)>
Sent: Monday, March 30, 2020 5:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: Medical staff need COVID-19 NIH survival data on N-95 respirators to help alleviate shortage

Dear Dr. Fauci,

The biggest concern of my hospital colleagues is the shortage of protective masks. If any research is being done that might drive safe reuse of N-95 respirators, no one I know has seen it. These should be simple studies to do.

If the virus is shown to die within a few days and moisture dries up, then the number of masks needing disposal could drop drastically.

In that situation, each provider at risk could be given five N-95 masks, one for each day of the week. The provider would wear the N-95 mask for one working day, say Monday. and then place it into a paper bag in a secure location. The provider would not use that mask again until the following Monday; ie seven days later.

The only question, then, would be: how many times can this be repeated? Will the mask lose any protective qualities over time?

Please assign someone to do these studies soon.

I'm also very pleased that our national leaders now seem to be listening to you more closely.

Thank you for your efforts.

William Kavesh MD, MPH
CMC Philadelphia VA Medical Center

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 15:26:47 +0000
To: Gottlieb, Lawrence A.
Subject: RE: Support

Many thanks!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gottlieb, Lawrence A. [redacted] (b) (6)
Sent: Tuesday, March 24, 2020 11:19 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Support

Dr. Fauci,

Just want to express my support for your indefatigable efforts to thwart the spread of the Coronavirus. Many, many years ago, I was a lab assistant for Dr. Edward L. Kuff and Dr. Karen Lueders, at NCI in building 37!!! Bravo for all you are doing.

Lawrence Gottlieb, PMP, MBA, COR, FAC/PPM III
Senior IT Project Manager
Enterprise Portfolio Management Division
Office of Information & Technology
US Department of Veterans Affairs
810 Vermont Avenue, NW
Washington, DC 20420
[redacted] (b) (6)
Office: [redacted] (b) (6)
Cell: [redacted] (b) (6)

"Alea iacta est" - Caesar

VA Core Values: Integrity Commitment Advocacy Respect Excellence

U.S. Department of Veterans Affairs

Office of Information and Technology

Enterprise Program Management Office

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 13:42:04 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6))
Subject: FW: Keynote Speaker Invitation - 8th International mRNA Health Conference

No!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)> **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Tuesday, April 7, 2020 9:33 AM
To: NIAID OD AM (b) (6)>
Subject: FW: Keynote Speaker Invitation - 8th International mRNA Health Conference

---

From: Pardi, Norbert <pnorbert@pennmedicine.upenn.edu>
Sent: Tuesday, April 7, 2020 9:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Keynote Speaker Invitation - 8th International mRNA Health Conference

Dear Dr. Fauci,

On behalf of the organizing committee, **I am writing to invite you to Keynote the 8th International mRNA Health Conference** (http://www.mrna-conference.com/) to be held at the Boston Park Plaza Hotel on Nov 9-10, 2020.

The International mRNA Health Conference is a yearly non-profit event collaboratively organized by Curevac, BioNTech and Moderna. It brings together academic and industry thought leaders in the mRNA design and delivery space to explore the rapidly evolving science, business and regulatory landscape of mRNA medicines. Over the last seven years, this 2-day conference has become the premier destination for industry and academic professionals to network with colleagues, learn about the latest advances in mRNA technology, and to attend scientific presentations given by the most esteemed experts in the field. Notably, it is the only annual conference dedicated solely to mRNA therapeutics.

As a scientist with tremendous experience and the director of NIAID, the organizing committee thought that conference attendees would very much appreciate hearing about your thoughts about mRNA therapeutics, particularly vaccines, and any perspectives you wish to share.

The organizing committee recognizes that your calendar is likely filled years in advance, but we all have our fingers crossed that you might be able to fit this into your busy schedule.

I look forward to hearing from you.

all best wishes,

Norbert

P.S. In the event that the COVID-19 crisis is still curtailing travel in the fall, our backup plan would be to have a completely virtual meeting on the same dates. We plan to make that decision in late August/early September.

Norbert Pardi, Ph.D.

Research Assistant Professor of Medicine

Infectious Disease Division

Perelman School of Medicine

University of Pennsylvania

Philadelphia, PA 19104

PH: 215-746-6552

pnorbert@pennmedicine.upenn.edu

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 13:01:12 +0000
To: Mark Feinberg
Subject: RE: Greetings and an Update: VSV-SARS-CoV-2 Vaccine Development

Thanks, Mark. This e-mail is very informative and helpful.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mark Feinberg [redacted] (b) (6)
Sent: Saturday, April 4, 2020 4:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Greetings and an Update: VSV-SARS-CoV-2 Vaccine Development

Dear Tony,

I hope you doing well despite your heroically busy schedule and the complexity and magnitude of the critically important issues you are working so hard and effectively to address. You are providing such amazing and valuable leadership in the response to COVID-19 and the world is so fortunate to have you in this key role!

[redacted] (b) (4)

[redacted] (b) (4)

Please let me know if you have any questions or would like any additional information. I will keep you posted [redacted] (b) (4).

Be well and hang in there!

Very best,

Mark

Mark Feinberg, MD, PhD

(b) (6)

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 17:30:06 +0000
To: Anki Wolf
Subject: RE: Elizabeth Glaser

Anki:
Many thanks for your kind note.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Anki Wolf [redacted] (b) (6)>
Sent: Sunday, April 5, 2020 5:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Elizabeth Glaser

HI Dr. Fauci,

I am [redacted] (b) (6) you diagnosed with AIDS back in the mid 1980's. It was in those early days of the AIDS epidemic that you were instrumental in diagnosing and researching this dreadful disease.

[redacted] (b) (6)

My family had been associated with the NCI through my uncle, Lou Wasserman, who was a researcher for a period of time. Lou did much research on polycythemia vera and was a hemotologist at Mt. Sinai in NYC. I'm glad that he's no longer around to witness the devastation of Covid-19.

I was impressed with your knowledge at the time of [redacted] (b) (6) diagnosis and I am even more so in these times of the Covid-19 pandemic. Thanks for being the intelligent and informative face of the facts on the virus. There are many around the country who rely on your wisdom but also on your facts and data.

Stay well, stay healthy, and keep providing the country with what we need to know and do.

Best,

Anki Wolf

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 17:27:18 +0000
To: [redacted] (b) (6)
Subject: FW: clinical trials of Oral LL-37 on COVID-19
Attachments: LL-37 ethic.pdf, three patients clinical study.pdf, CAS001 Subchronic toxicity experiment.pdf, International research programme(1).pdf, Wanzhu Jin CV.pdf

Any suggestion of what to do with this type of thing? Can you have someone respond to them.
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: JINWan-Zhu [redacted] (b) (6) >
Sent: Sunday, April 5, 2020 11:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) >; sunok301 [redacted] (b) (6)
Subject: clinical trials of Oral LL-37 on COVID-19

Dear Dr. Anthony S Fauci:

Thank you very much for your hard work on COVID-19. You are the hero of word!

This is Prof. Wanzhu Jin prof. Institute of Zoology, Chinese Academy of Sciences.

[redacted] (b) (4)

(b) (4)

[redacted]

(b) (4)

[redacted]

Many thanks in advances!

Wanzhu Jin & Gang Sun

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 16:41:38 +0000
To: info@marianneorlando.com
Cc: Grady, Christine (NIH/CC/BEP) [E]
Subject: FW: Fauci superhero

Marianne:

Many thanks for doing and sending this.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marianne Orlando <info@marianneorlando.com>
Sent: Friday, April 3, 2020 6:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Thank you, sir

Dear Dr. Fauci,

Being a freelance illustrator, I am trying to keep myself productive during this life-altering pandemic by doing a series of COVID-19 inspired drawings.

This is my latest, that I call: "My Personal Superhero."

I dedicated it to you like this: "In his own, quiet way, he is a BadAss: Disseminating info about this disease calmly and, always, backed by science."

Here is my drawing:


SUPERHERO
FAUCI
NIAID
Orlando
Anthony Fauci

So, Thank you, Sir. You are the voice of reason in what has been a dangerous, frightening situation. You are a real leader.

Thank you,
Marianne Francesca Orlando

Thank you,

Marianne Orlando
Marianne Orlando Illustrations
(b) (6)
[redacted]

cell: (b) (6)
landline: (b) (6)

MARIANNE ORLANDO *illustrations*

home, pet and people portraits
... and more

info@marianneorlando.com
www.marianneorlando.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 14:57:23 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Request for your support in promoting new WHO recommendation for emergency response operation to provide universal access to mandatory hand hygiene against COVID-19
Attachments: who-interim-recommendation-on-obligatory-hand-hygiene-against-transmission-of-covid-19.pdf

Let us discuss. I am not sure what I should do with this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: HOYER, Stefan Detlef Leo [redacted] (b) (6)>
Sent: Monday, April 6, 2020 8:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Emanuele CAPOBIANCO [redacted] (b) (6)>; GORDON, Bruce Allan [redacted] (b) (6) t>; ROGERS, Paul < [redacted] (b) (6)
Subject: Request for your support in promoting new WHO recommendation for emergency response operation to provide universal access to mandatory hand hygiene against COVID-19
Importance: High

Dear Dr. Fauci

Please find enclosed the new WHO recommendation on establishing universal access to hand hygiene stations at thresholds of publicly accessible buildings and means of public transport. It is now officially published at : https://who.int/who-documents-detail/interim-recommendations-on-obligatory-hand-hygiene-against-transmission-of-covid-19 I attach a pdf copy for easy reference.

I would like to request your support in promoting the recommendation as part of an international emergency response operation providing universal access to mandatory hand hygiene and/or sanitation against COVID-19 infections. Provided it is now made available and made obligatory whenever entering and leaving a facility to which the general public has access, it could become possible to prevent most smear infections by decontaminating all hands prior *and* after each possible contamination, both active or passive. In addition, the measure should massively reduce transmission of other viruses and bacteria currently burdening differential diagnosis of COVID-pneumonias. Based on the excellent experiences made with the acceptability and adherence during Ebola outbreaks, repeated mandatory hand hygiene or sanitation should thus become an almost unconscious routine of everyday life for any person having to leave his or her private home in Corona-affected countries.

I have been asked by senior WHO emergency management to promote the WHO recommendation for rapid implementation with particular focus on current COVID-19 transmission epicenters such as the USA. Providing a systematic access to hand hygiene stations and making their use obligatory prior to entering and whenever leaving any public facility will also provide a safety net whenever current restrictions on movements and commerce are to be progressively reduced. Given the high resource settings in the current COVID-epicentres, and the negligible cost of implementing this public health emergency measure compared to prolonged mass confinement without safe exit strategy, I do presume that the wherewithal to carry it out will not be limiting factor.

Thank you for considering the collaboration in this emergency measure proposed within the USA at the largest possible scale. WHO has requested IFRC to alert the American Red Cross to support large scale implementation should your Government decide to implement the public health measure proposed.

With best wishes for success in all of your endeavours,

Stefan Hoyer

Dr Stefan Leo Hoyer
Medical Officer
Focal Point for Emergencies
Global **Malaria** Programme

t: [redacted] (b) (6) e: [redacted] (b) (6)
m: [redacted] w: www.who.int/malaria

World Health Organization

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 13:40:45 +0000
To: Jameson, James L
Subject: RE: COVID-19 Rx

Thanks, Larry.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jameson, James L [redacted] (b) (6)>
Sent: Monday, April 6, 2020 9:35 AM
To: Anthony Fauci [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: COVID-19 Rx

Tony,

I completely understand – we are all thinking about you as you help the country navigate this crisis – thanks so much. Let me know if there is any way that I, or people at Penn, can be helpful. Our scientists, several of whom are Coronavirus experts (Susan Weiss, Paul Bates), have coalesced form a Center to focus on potential treatments and immunology related to the virus. I list few below and you might triage to others to f/u further:

[redacted] (b) (4)

[redacted] (b) (4)

Best regards,
Larry

From: Anthony Fauci [redacted] (b) (6)>
Date: Monday, April 6, 2020 at 8:25 AM
To: "J. Larry Jameson" [redacted] (b) (6)>
Cc: Dennis Kasper <[redacted] (b) (6)>, Joseph Loscalzo [redacted] (b) (6) James Shanahan <[redacted] (b) (6)
Subject: Re: COVID-19 Rx

Larry:
I am so sorry that I have not gotten back to you and others in so long. I am completely swamped (3 to 4 hours sleep per night just does not work very well) and have not been able to even check my non-NIH [redacted] (b) (6). I will try my best to catch up soon. Thank for your understanding.
Best regards,
Tony

On Fri, Mar 13, 2020 at 9:33 AM Jameson, James L [redacted] (b) (6)wrote:

> Dennis and Tony,
>
> [redacted] (b) (4)
>
> Best regards,
> Larry

--
Anthony S. Fauci, M.D.
Editor, *Harrison's Principles of Internal Medicine*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 02:27:39 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Cc: Conrad, Patricia (NIH/NIAID) [E];schoofs@usc.edu
Subject: FW: 2nd try: Mark Schoofs reaching out

Kim:
Please have me call Mark tomorrow.
Thanks,
Tony

From: Mark Schoofs <schoofs@usc.edu>
Sent: Sunday, April 5, 2020 7:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: 2nd try: Mark Schoofs reaching out

Hi Tony,

God knows you are doing the world's most important work right now, but if possible, I would love to talk with you for my COVID-19 project. I promised to keep it under 10 minutes, probably just 5.

My cell: [redacted] (b) (6)

All best,

Mark

From: Mark Schoofs
Sent: Saturday, March 28, 2020 10:04 AM
To: [redacted] (b) (6)
Subject: Mark Schoofs reaching out

Hi Tony,

I hope you're hanging in there! If you have 5 minutes — 10 max — I'd like to talk with you for a COVID-19 project I'm working on.

My cell is [redacted] (b) (6).

Thank you.

All best,

Mark Schoofs
Visiting Professor of Journalism
University of Southern California

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 5 Apr 2020 15:59:51 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST
Attachments: Statement on the COVID-19 pandemic and the Extraordinary G20 Leaders' Summit - 1Apr2020 .pdf, GPMB Teleconference 30 March 2020 - Meeting Report 1 Apr 2020.pdf

Please check this out and let me know if there is anything we need to do. Thanks.

From: RIOUX, Amelie [redacted] (b) (6)
Sent: Sunday, April 5, 2020 11:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Steven T. Smith [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; SMITH, Ian Michael [redacted] (b) (6)
Subject: FW: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

Dear Dr Fauci,

Please find attached the meeting report from the GPMB teleconference on 30 March 2020 and the GPMB co-Chairs' *Statement on the COVID-19 pandemic and the Extraordinary G20 Leaders' Summit on COVID-19.* I apologize, your email was deleted by mistake in the last two messages to the GPMB.

With kind regards,

Amélie
GPMB Secretariat

From: RIOUX, Amelie
Sent: Friday, 3 April 2020 14:18
To: 'VDzau@nas.edu' [redacted] (b) (6)>; J.Farrar [redacted] (b) (6)>; 'hfore@unicef.org' [redacted] (b) (6)>; 'Gao Fu' [redacted] (b) (6) [redacted] 'Gashumba Diane' [redacted] (b) (6)>; Ilona Kickbusch [redacted] (b) (6); 'Skvortsova Veronika' [redacted] (b) (6)>; 'Vega Morales Jeanette' [redacted] (b) (6) [redacted] (b) (6) [redacted] >
Cc: Gro [redacted] (b) (6) 'As Sy' [redacted] (b) (6); SMITH, Ian Michael [redacted] (b) (6)>; SCHWARTLANDER, Bernhard F. [redacted] (b) (6)>; 'Pate Muhamed' [redacted] (b) (6)
Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

Dear Board Members,

Please find the link to the GPMB co-Chairs' *Statement on the COVID-19 pandemic and the Extraordinary G20 Leaders' Summit on COVID-19* (also attached):
https://apps.who.int/gpmb/assets/pdf/Statement%20on%20the%20COVID-19%20pandemic%20and%20the%20Extraordinary%20G20%20Leaders'%20Summit%201Apr2020.pdf

We encourage you to circulate the Statement through your channels. You may wish to use the original hashtag from our report #AWorldatRisk in social media posts.

With kind regards,

Amélie
GPMB Secretariat

This message is being sent to GPMB members and their designated staff in copy.

From: RIOUX, Amelie
Sent: Wednesday, 1 April 2020 16:42
To: 'VDzau@nas.edu' < (b) (6); J.Farrar < (b) (6)
[redacted]; 'Gao Fu' (b) (6)
[redacted]; 'Gashumba Diane' (b) (6)>; Ilona Kickbusch (b) (6);
'Skvortsova Veronika' (b) (6)>; 'Vega Morales Jeanette' (b) (6)
(b) (6)
Cc: 'Gro' (b) (6); 'As Sy' (b) (6); SMITH, Ian Michael
(b) (6); SCHWARTLANDER, Bernhard F. (b) (6)>; 'Pate Muhamed'
(b) (6)>
Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

Dear Board Members,

On behalf of the co-Chairs, please find attached the report from Monday's teleconference.

With kind regards,

Amélie
GPMB Secretariat

This message is being sent to GPMB members and their designated staff in copy.

From: RIOUX, Amelie
Sent: Tuesday, 31 March 2020 09:17
To: 'VDzau@nas.edu' < (b) (6)>; J.Farrar (b) (6)
[redacted]; 'Gao Fu' (b) (6)
[redacted] 'Gashumba Diane' (b) (6)>; Ilona Kickbusch (b) (6)>;

'Skvortsova Veronika' [redacted] (b) (6)>; 'Vega Morales Jeanette' [redacted] (b) (6)>;
[redacted] (b) (6)
Cc: Gro [redacted] (b) (6)>; 'As Sy' < [redacted] (b) (6); SMITH, Ian Michael
[redacted] (b) (6)>; SCHWARTLANDER, Bernhard F. < [redacted] (b) (6); RYAN, Michael J.
[redacted] (b) (6); 'Pate Muhamed' < [redacted] (b) (6)>; 'Godal, Tore' [redacted] (b) (6)
'Tore Godal' < [redacted] (b) (6); Alveberg, Benedikte Louise [redacted] (b) (6);
[redacted] (b) (6)
Scott Dowell
[redacted] (b) (6) William
Hall [redacted] (b) (6)'Teresa Miller de
Vega' < [redacted] (b) (6)
[redacted] 'Marston Hilary'
[redacted] (b) (6)
[redacted] Carlos Navarro Colorado < [redacted] (b) (6)
[redacted] >; 'Zacharie Gahungu'
[redacted] (b) (6)
; 'office-psa@nic.in' <office-psa@nic.in>; Toomas
Palu [redacted] (b) (6)>; GPMB Secretariat <gpmbsecretariat@who.int>; GABEDAVA, Tsira
[redacted] (b) (6)>; 'Steve Landry' [redacted] (b) (6)>
Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

MESSAGE ON BEHALF OF THE GPMB CO-CHAIRS DR BRUNDTLAND AND MR SY

Dear GPMB Members,

Many thanks for your contributions to our teleconference, and to Jeremy and Victor for their very helpful report on the GPMB COVID-19 advocacy.

Several of you mentioned that you had additional points that you might wish to make in writing; please do so as soon as possible, copying them to all Board members.

If you have not already nominated a 'sherpa' to represent you in the informal support group that will work with the secretariat, please do so as soon as possible. The secretariat is organizing a teleconference with the informal support group to follow up on the direction given by the Board on the annual report and work plan.

Kind regards,

Gro & As
GPMB Co-chairs

From: RIOUX, Amelie
Sent: Monday, 30 March 2020 12:19
To: 'VDzau@nas.edu' [redacted] (b) (6)>; J.Farrar [redacted] (b) (6)
[redacted] 'Gao Fu' [redacted] (b) (6)
[redacted]; 'Gashumba Diane' [redacted] (b) (6); Ilona Kickbusch < [redacted] (b) (6)>;
'Skvortsova Veronika' [redacted] (b) (6); 'Vega Morales Jeanette' [redacted] (b) (6);
[redacted] (b) (6)
[redacted] >
Cc: Gro < [redacted] (b) (6) 'As Sy' [redacted] (b) (6)>; SMITH, Ian Michael
[redacted] (b) (6); SCHWARTLANDER, Bernhard F. [redacted] (b) (6); RYAN, Michael J.
[redacted] (b) (6)>; 'Pate Muhamed' [redacted] (b) (6); 'Godal, Tore' < [redacted] (b) (6)>;
'Tore Godal' [redacted] (b) (6)>; Alveberg, Benedikte Louise [redacted] (b) (6)>;
[redacted] (b) (6)
[redacted] Scott Dowell
[redacted] (b) (6) William
Hall [redacted] (b) (6) 'Teresa Miller de
Vega' [redacted] (b) (6)
[redacted] 'Marston Hilary'
[redacted] (b) (6)
[redacted]; Carlos Navarro Colorado [redacted] (b) (6)
[redacted] 'Zacharie Gahungu'
[redacted] (b) (6)
[redacted]
[redacted] 'office-psa@nic.in' <office-psa@nic.in>; Toomas
Palu < [redacted] (b) (6)>; GPMB Secretariat [redacted] (b) (6); GABEDAVA, Tsira
[redacted] (b) (6); 'Steve Landry' < [redacted] (b) (6)>
Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

Dear Board Members and Colleagues,

A kind reminder that Europe has switched to Daylight Saving Time over the weekend.

The call takes place today at 15:00 Geneva time, which is 06:00 Seattle time, 09:00 DC time, 21:00 Beijing time, and 22:00 Tokyo time.

Best,

Amélie

From: SMITH, Ian Michael [redacted] (b) (6)>
Sent: Friday, 27 March 2020 19:19
To: [redacted] (b) (6)>; Chris.Elias < [redacted] (b) (6)>; J.Farrar

<[redacted] (b) (6)>; 'Anthony Fauci' [redacted] (b) (6)
[redacted] 'Gao Fu' [redacted] (b) (6)
[redacted]; 'Gashumba Diane' [redacted] (b) (6)>; Ilona Kickbusch <[redacted] (b) (6)>;
'Skvortsova Veronika' [redacted] (b) (6)'Vega Morales Jeanette' [redacted] (b) (6)
[redacted] (b) (6)
[redacted]
Cc: Gro <[redacted] (b) (6)>; 'As Sy' [redacted] (b) (6); SCHWARTLANDER, Bernhard F.
<[redacted] (b) (6)>; RYAN, Michael J. [redacted] (b) (6)>; 'Pate Muhamed'
[redacted] (b) (6); 'Godal, Tore' [redacted] (b) (6); 'Tore Godal' [redacted] (b) (6)
Alveberg, Benedikte Louise [redacted] (b) (6)
[redacted]
[redacted]; Scott Dowell [redacted] (b) (6)
[redacted] William Hall <[redacted] (b) (6)
[redacted] 'Teresa Miller de Vega'
[redacted] (b) (6)
[redacted] 'Marston Hilary' [redacted] (b) (6)
[redacted]>; Carlos
Navarro Colorado [redacted] (b) (6)
[redacted] 'Zacharie Gahungu' [redacted] (b) (6)>;
'[redacted] (b) (6)
[redacted]
[redacted]>; 'office-psa@nic.in' <office-psa@nic.in>; Toomas Palu [redacted] (b) (6)
GPMB Secretariat <gpmbsecretariat@who.int>; GABEDAVA, Tsira [redacted] (b) (6); 'Steve Landry'
[redacted] (b) (6) RIOUX, Amelie [redacted] (b) (6)
Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

Dear Board members, dear Colleagues,

Thank you very much to those of you who confirmed your participation in the teleconference on Monday from 15.00-16.00 CET. If you have not done so yet, we would be grateful if you could let us know as soon as possible.

If you cannot attend, the co-Chairs would welcome your written comments in advance of the call.

In preparation for the call, please find attached:

1. Agenda
2. Extraordinary G20 Leaders' Summit Statement on COVID-19 (shared with you earlier)
3. Update on the GPMB urgent COVID-19 funding call from the GPMB COVID-19 sub group
4. Overview of Existing Global Appeals and Funding Mechanisms for COVID-19 (for information)

The call-in details are copied below.

Please note that as several of you have nominated an Alternate to attend on your behalf, the co-chairs will invite Board Members to speak first, followed by Alternates speaking on behalf of Board members.

Given the very limited time, the co-Chairs have asked that keep your interventions as short as possible.

We look forward to the call. Please let us know if you have any questions.

With kind regards,

Ian Smith
GPMB Secretariat

****

Call-in Details:
By clicking on the link Access via Web, you will find local and toll-free call-in numbers.

Participant access

[redacted] (b) (4)

Security code: For this conference a Security code is not necessary.

Optional dial-in numbers international
+41 58 262 07 22 (English) +41 58 262 07 44 (Italiano) +41 58 262 07 11 (Deutsch) +41 58 262 07 33 (Français)

Access via Web

From: RIOUX, Amelie
Sent: Wednesday, 25 March 2020 14:16
To: [redacted] (b) (6) Jeremy Farrar' [redacted] (b) (6)
Anthony Fauci [redacted] (b) (6); Gao Fu [redacted] (b) (6)>;
[redacted] (b) (6); Gashumba Diane [redacted] (b) (6)>; Ilona Kickbusch
[redacted] (b) (6)>; Skvortsova Veronika [redacted] (b) (6)>; Vega Morales Jeanette
[redacted] (b) (6)
Cc: [redacted] (b) (6); As Sy [redacted] (b) (6); SMITH, Ian Michael [redacted] (b) (6)t>;
SCHWARTLANDER, Bernhard F. [redacted] (b) (6) RYAN, Michael J. [redacted] (b) (6)>; Pate
Muhamed [redacted] (b) (6)>; Godal, Tore < [redacted] (b) (6)>; Tore Godal [redacted] (b) (6);
Alveberg, Benedikte Louise [redacted] (b) (6)
'Teresa Miller de Vega'
[redacted] (b) (6); 'Marston Hilary'
[redacted] (b) (6)
Zacharie Gahungu
[redacted] (b) (6)

Toomas Palu [redacted] (b) (6)>; GPMB Secretariat [redacted] (b) (6); GABEDAVA, Tsira [redacted] (b) (6)>

Subject: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE - 30 MARCH 15:00 CEST

MESSAGE ON BEHALF OF THE GPMB CO-CHAIRS DR BRUNDTLAND AND MR SY

Dear Board Members,

We would like to propose to hold a Board teleconference on **Monday 30 March 2020, 15:00-16:00 CEST time.** The purpose of the call will be to update you on the GPMB's COVID-19 advocacy and to discuss next steps. A more detailed agenda and call-in details will be shared shortly.

We would appreciate if you could confirm your participation to Amélie Rioux [redacted] (b) (6)

Thank you for your continued support and engagement.

With kind regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 5 Apr 2020 01:57:37 +0000
To: Teri McPeak
Subject: RE: Association between Proton Pump Inhibitors and increased risk of Covid-19 death

Thanks, Teresa.

From: Teri McPeak <t.mcpeak@live.ca>
Sent: Saturday, April 4, 2020 5:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Association between Proton Pump Inhibitors and increased risk of Covid-19 death

Dr. Fauci,

There is a wealth of medical research papers about the association between Proton Pump Inhibitors (PPI) and increased risk of community acquired pneumonia. Long term use of PPIs reduce the pH of the stomach from 1 to 5. This reduction in stomach acid reduces the body's ability to fight viruses.

In addition, the lower stomach pH reduce the ability to absorb key nutrients that require gastric acid for breakdown and absorption (calcium, vitamin C & B12, iron, magnesium, potassium, zinc). Lack of proper nutrients lead to a compromised immune system.

Seniors and individuals with chronic illnesses are at higher risk of ploypharmacology and dying from Covid-19 due to PPIs. The more medications an individual takes, the more likely they will suffer from acid reflux and thus be prescribed a PPI.

Thank you for your commitment and compassion during the pandemic. God bless you.

Regards,

Teresa McPeak
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 5 Apr 2020 01:54:27 +0000
To: Silver, David (NIH/NCI) [C]
Subject: RE: Question

David:

Thanks for the note. Since they both effected adequate quarantine, they are OK with each other....provided that they practice physical distancing with everyone else, i.e. 6 feet apart and masks when out in situations where they cannot guarantee 6ft distance. With regard to your second question, it is not a question of temperature, it is a question of what surface the virus in on – stainless steel versus cloth, versus cardboard. Each of these have differ time frames of survival of replication competent virus from a couple of hours to about 2 days.

Best regards,
Tony

From: Silver, David (NIH/NCI) [C] [redacted] (b) (6)
Sent: Saturday, April 4, 2020 9:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Question

Dr. Fauci,

You are doing a great job and I am sure that things must be very challenging.

Please let me know your thoughts on this, although I think I know the answer. [redacted] (b) (6) Is it safe for them to see each other at this point?

I was also wondering if it has been determined how long COVID-19 can live in a refrigerator or freezer.

Thank you.

Stay Healthy.

David

David Silver - Contractor
[redacted] (b) (6)
National Institutes of Health, NCI
Center for Biomedical Informatics and Information Technology (CBIIT)
9609 Medical Center Dr.

Rockville, MD 20850

From: [redacted] (b) (6)
Sent: Sat, 4 Apr 2020 15:50:32 -0400
To: anthony trocchi
Subject: Re: An aquaintence from the past

Tony:
Thank you for your note. I hear you!
Best regards,
Tony

> On Apr 4, 2020, at 12:25 PM, anthony trocchi [redacted] (b) (6)> wrote:
>
>
> Hi Tony, You probably don't remember me, I was [redacted] (b) (6) husband back when she was at NIH, you came to dinner at our house once. We also hung out in Boulder and drank beer together. I am just a working class guy, but keep up with science and politics for what it is worth. I don't know what you hear from the street level, but from here in. NY we are pretty concerned with the risk of Covid-19 and the Federal response to the pandemic. You have been the only reasonable voice in the administration. The leadership from the top is utterly lacking and incompetent and dangerous to the American people. You have had a long and venerable career and I am asking you to stand up to power and speak the harsh truth to the people of this country and the without regard to your personal consequences. We need a unified and professional federal response to this unprecedented crisis. I think you may be the only person of repute and status that has the power to change the course of history. I have spoken with a good friend of mine who is a respected epidemiologist and he said that Covid-19 will infect half the population of the world and those numbers are frightening statistically. My dad was born during the first worldwide modern pandemic and I don't really want to see him leave from this current one. I know I am somewhat out of place writing to you, but one can only do what one can do to influence the events that history arises from. With utmost respect. Tony Trocchi
> Sent from my iPhone

From: [redacted] (b) (6)
Sent: Sat, 4 Apr 2020 15:42:37 -0400
To: Stuart Coulter
Subject: Re: Early Successes in Clinical Trial on COVID-19 Patients with High Dose IV Vitamin C

Thanks, Stuart. I appreciate your sending me this information. I will pass it on to relevant program people.
Best regards,
Tony

> On Apr 4, 2020, at 3:38 PM, Stuart Coulter [redacted] (b) (6)>wrote:
>
> Dear Dr. Fauci,
>
> **Early Successes in Clinical Trial on COVID-19 Patients with High Dose IV Vitamin C**
>
> Thank you for the invaluable work that you are doing in guiding the United States through the current COVID-19 pandemic.
>
> I hope that you do not mind me contacting you, but I wanted to bring your attention to a clinical trial that is currently taking place in China on COVID-19 patients with high dose IV Vitamin C.
>
> There are reports of some early successes with this treatment and I wondered if this could be a possible stop gap treatment - that could possibly save many lives - while we await the development of suitable drug treatments and a reliable vaccine.
>
> The trial in China is not due to conclude until September of this year, however, previous trials of IV Vitamin C have shown it to be a very safe treatment with little or no adverse side effects. I have read that the Northwell Hospital Group in New York, which operates 23 hospitals, have already started to give this treatment to many of their COVID-19 patients.
>
> This treatment also appears to meet the normally required criteria for a clinic trial. The treatment has been shown to be:
>
> 1) Effective (Please see the link below to the promising trial results currently taking place in China).
>
> 2) Safe (The treatment has been shown to be safe in many previous trials going back well over 40 years).
>
> 3) Correct dosage is understood (The dosage is fully understood - please see the attached Protocol).
>
> 4) The correct patients to give this treatment to (Virtually everyone in hospital infected with COVID-19).
>
> 5) The correct time in the illness to give the treatment (As soon as the infected patient comes into hospital).

I hope that you and your team find the details of this clinical trial of some interest. The hospital protocol for this treatment is attached and here is a link to details of the current trial in China along with some other relevant links:

http://www.orthomolecular.org/resources/omns/v16n18.shtml

http://www.orthomolecular.org/resources/omns/v16n19.shtml

http://www.orthomolecular.org/resources/omns/v16n07.shtml

http://orthomolecular.org/resources/omns/v16n21.shtml

https://www.sciencedirect.com/science/article/pii/S2590098620300154?via%3Dihub
Kind regards,
Stuart Coulter

<Journal Pre-proof - Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019.pdf>
<Protocol - IVAA-COVID19-Hospital-Use-Anderson-03.24.2020.pdf>

From: (b) (6)
Sent: Sat, 4 Apr 2020 12:42:38 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview Request: #1 Hiking Podcast

FYI

Begin forwarded message:

> **From:** Zach Davis <zach@thetrek.co>
> **Date:** April 4, 2020 at 12:39:25 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
> **Subject: Interview Request: #1 Hiking Podcast**
>
> Hey Dr. Fauci-
>
> My name is Zach Davis, I'm the founder and editor-in-chief at The Trek, a media company dedicated to long distance backpackers. Thank you for the tremendous service and leadership you've given this country during a time of great need.
>
> I'm reaching out to inquire about the possibility of your doing a short interview for our flagship podcast, Backpacker Radio, the #1 rated hiking podcast on iTunes. We're putting together an episode related to how COVID-19 has impacted this year's class of backpackers, and would love to feature your expert insight on why social distancing is important, and what the future may hold for our community.
>
> The interview would be about 20-25 minutes, though if you're only available for a shorter period, we'll take what we can get!
>
> Thanks for your time and thank you again for your terrific service to this country.
>
> Happy hiking,
>
> --
>
> **Zach Davis**
> founder || editor-in-chief
> hikerlink | thetrek.co | backpacker radio

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 4 Apr 2020 16:25:36 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: AFRICA CDC: STATEMENT ON MEDICATIONS TO TREAT NOVEL CORONAVIRUS DISEASE

Good for them!!!

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Saturday, April 4, 2020 12:21 PM
Subject: AFRICA CDC: STATEMENT ON MEDICATIONS TO TREAT NOVEL CORONAVIRUS DISEASE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 4 Apr 2020 15:18:14 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Excellent start to COVID PPP
Attachments: COVID PPP April 3 actions.docx, Introductory call short bios - 3 Apr 2020 final.docx

Please print out these attachments and put into a folder labelled "COVID-19 Public Private Partnerships" Thanks.

From: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)>
Sent: Saturday, April 4, 2020 10:26 AM
To: [redacted] (b) (6) (OS/IOS) <[redacted] (b) (6)
Cc: Harrison, Brian (HHS/IOS) [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Excellent start to COVID PPP

Hi Mr. Secretary,

Just wanted to let you know – we had a very productive and significant two-hour virtual meeting with leaders of industry, FDA, and NIH yesterday. I attach the bios of those who attended – which includes the heads of R&D of nine major pharmaceutical companies. There is unanimous support for bringing together all of the sectors to accelerate development of therapeutics and vaccines for COVID-19. Tony compared this to what happened in the early 1990s that led to successful antivirals for HIV.

I attach the action items that came out of this meeting. Working groups for each of the four main topics will be rapidly organized. I will keep you posted.

Best, Francis

From: [redacted] (b) (6)
Sent: Fri, 3 Apr 2020 16:42:08 -0400
To: Cantor, Harvey I.,M.D.
Cc: NIAID OD AM
Subject: Re: COVID-19

Harvey:
Thank you for your kind note. It is much appreciated. I will let the team know about your willingness to serve on committees and study sections.
Best regards,
Tony

> On Apr 3, 2020, at 1:20 PM, Cantor, Harvey I.,M.D. [redacted] (b) (6)>wrote:
>
> Dear Tony,
>
> In these unsettling times, you are a much-appreciated voice of reason and proponent of rational science.
> A great credit to NIH and NIAID...we're all very proud of you.
>
> I know that you have long advocated preparation of viral vaccines against future pandemic threats.
> I'm sure that it has been difficult to convince pharmas, charitable agencies and even the government to fund these efforts.
> which would include vaccine production and storage for indefinite periods. Perhaps there will be a greater willingness to
> revisit a cost-benefit analysis of this effort in the near future.
>
> I would be happy to serve on committees, study sections etc. in an effort to increase our ability to identify and fund first-rate
> Immunology research that might accelerate innovative, safe and effective approaches to improved viral vaccines going forward.
>
> All very best regards, h.
>
> Harvey Cantor, MD
> Baruj Benacerraf Professor of Immunology
> Department of Immunology,
> Harvard Medical School
> Dept. of Cancer Immunology &Virology,
> Dana-Farber Cancer Institute

Boston MA 02215

(b) (6)
[redacted]

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at http://www.partners.org/complianceline . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

From: [redacted] (b) (6)
Sent: Fri, 3 Apr 2020 16:29:45 -0400
To: Hasenkrug, Kim (NIH/NIAID) [E]
Subject: Re: Thanks from the troops

Kim:
Many thanks for your kind note .
Best regards,
Tony

On Apr 3, 2020, at 1:56 PM, Hasenkrug, Kim (NIH/NIAID) [E]
[redacted] (b) (6)

Hi Tony, I just want to express my sincere gratitude for all you are doing to get us through this crisis. Everyone I've talked to at RML expresses their deep admiration and appreciation for your strong leadership, and we feel proud to be working for you. We listen to your hoarse voice every day. Personally, I have started two new lines of research to develop and test possible therapeutics for COVID-19. The cooperation and collaboration from everyone I've talked to, both here and around the nation, has been unbelievable. Please take care of yourself and stay strong and healthy for the sake of all of us!

Best regards,

Kim

Kim J Hasenkrug, Ph.D.
Senior Investigator
Chief, Retroviral Immunology Section
Laboratory of Persistent Viral Diseases
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 S. 4th Street
Hamilton, MT 59840
phone [redacted] (b) (6)

FAX (406)363-9286
(b) (6)

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who
is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other
storage devices. National Institute of Allergy and Infectious Diseases

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 3 Apr 2020 11:07:58 +0000
To: Ghafoor, Azam (NIH/NCI) [E]
Cc: NIAID OD AM
Subject: RE: Help

Thanks for your note. I will circulate to others in NIAID

From: Ghafoor, Azam (NIH/NCI) [E] [redacted] (b) (6)>
Sent: Thursday, April 2, 2020 11:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Help

Dear Dr. Fauci,

I am thoracic oncologist at the NCI. I wanted to commend you on your tremendous (and exhausting) job on managing and steering our country with the COVID-19 pandemic. If you need additional any personnel to help with any clinical or non-clinical aspects of the current situation, I am more than happy to help. As you know we have scaled down our clinical operations and trials at the NIH CC and so I have more time.

Best regards,

Azam Ghafoor, MD
Assistant Research Physician & Staff Oncologist
Thoracic Oncology Section
Thoracic and GI Malignancies Branch
National Cancer Institute, National Institutes of Health
10 Center Drive, Building 10, Room: 4G-5330
Bethesda, MD 20892
e: [redacted] (b) (6)
o: [redacted] (b) (6)
c:
page ID [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 3 Apr 2020 02:40:47 +0000
To: David Barr
Cc: Giroir, Brett (HHS/OASH);Conrad, Patricia (NIH/NIAID) [E]
Subject: Introduction

David:

I am using this e-mail to introduce you to Adm. Brett Giroir who is the Assistant Secretary for Health at HHS and a key member of the Coronavirus Task Force. I have explained to Brett the issues that you and your colleagues brought up over the phone with me the other night. Brett is willing o get on the phone with the group and go over some of these issues and perhaps help to resolve them. He is waiting o hear from you. Many thanks.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 3 Apr 2020 02:10:12 +0000
To: Stephen Hahn
Cc: [redacted] (b) (6)
Subject: FDA release

Steve:

My staff just pointed out to me a proposed FDA press release regarding convalescent plasma and hyperimmune globulin. The press release reads as follows:

(b) (5)

[redacted]

I just wanted to bring this to your attention for further consideration. Many thanks.

Best regards,

Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 3 Apr 2020 01:53:59 +0000
To: Emilio Emini
Cc: Conrad, Patricia (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Erbelding, Emily (NIH/NIAID) [E];Bright, Rick (OS/ASPR/BARDA);Collins, Francis (NIH/OD) [E] [redacted] (b) (6);'Trevor Mundel'
Subject: RE: Connection Request per Bill Gates

Emilio:

Thanks for your note. As I had mentioned to Bill yesterday evening, I am enthusiastic about moving towards a collaborative and hopefully synergistic approach to COVID-19 on the part of NIAID/NIH, BARDA and the BMGF. I will ask John Mascola and Emily Erbelding to connect with you to stay a conversation. Perhaps they can organize a call with you including BARDA. I will try to engage as much as I can given my current circumstances. We look forward to working with you.

Best regards,

Tony

From: Emilio Emini [redacted] (b) (6)>
Sent: Thursday, April 2, 2020 9:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Connection Request per Bill Gates

Tony—I received a note from Trevor and Bill that they connected with you yesterday and they asked me to reach out. I've taken on the role of coordinating the foundation's contributions to the global COVID vaccine efforts, in particular for those approaches that are (or soon will be) in early development. There's an obvious need for coordination among the various primary funders or the focus we need to have given the state of the pandemic will become lost through uncoordinated activities.

Bill tells me that you will take on a central role in coordinating BARDA's funding to the ongoing efforts. And, of course, there are the NIH/VRC activities. I'm reaching out to ask how we can coordinate and cross-inform each other's activities. I am very sensitive to how busy you are and very grateful for your engagement. I see you on TV almost every day, and although you continue to have considerable energy, I am seriously worried about you. The nation and the world absolutely need your leadership.

As a next step we can connect 1:1 briefly or you can pass this on to an appropriate member of your staff.

If you wish, you can always reach out to me directly at any time though my personal mobile at [redacted] (b) (6)

Please stay well....Emilio

Emilio A. Emini, Ph.D., FCPP, FAAM
Director

TB and HIV Program
Bill & Melinda Gates Foundation

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 23:50:04 +0000
To: Glass, Roger (NIH/FIC) [E]
Subject: RE: COVID-19 in Africa: Tanzania

Thanks, Roger.

From: Glass, Roger (NIH/FIC) [E] [redacted] (b) (6)
Sent: Thursday, April 2, 2020 6:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: COVID-19 in Africa: Tanzania

Tony,

You have a fan club in Tanzania—Julie Makani and Lucio with your textbook!

Keep up the heroic work.

Roger

From: Julie Makani <jmakani@blood.ac.tz>
Sent: Wednesday, April 1, 2020 5:46 PM
To: Glass, Roger (NIH/FIC) [E] [redacted] (b) (6)
Subject: Re: COVID-19 in Africa: Tanzania

Please pass greetings to Dr Fauci

His authorship on Google Scholar including of Harrison's has been under discussion on social media

Lucio has been writing the chapter on hemolytic anemia

He is heading to Italy for 3 months. He has been incredible. He was leaving his copies with the Sickle cell programme as we plan on getting keen scientists to read them

Stay safe

Prof Julie Makani, T:+[redacted] (b) (6) E: jmakani@blood.ac.tz

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 21:52:30 +0000
To: Lerner, Andrea (NIH/NIAID) [E];NIAID OD AM
Subject: RE: My take on masks

Thanks, Andrea

From: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, April 2, 2020 1:01 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: My take on masks

Given our discussion this AM, just thought I would summarize my take on masks across varying scenarios:

[redacted] (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 21:14:40 +0000
To: Balasundaram, David (NIH/CSR) [E]
Subject: RE: Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study

Thanks, David.

From: Balasundaram, David (NIH/CSR) [E] [redacted] (b) (6)
Sent: Wednesday, April 1, 2020 7:19 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Balasundaram, David (NIH/CSR) [E] [redacted] (b) (6)
Subject: Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study
Importance: High

Dear Dr. Fauci,
I thought that you may be interested in reading this paper (Unless you already know about this of course!). This is obviously a data-driven set of correlative observations, but could be worth looking into.
I salute your outspoken efforts to galvanize this country into action in the midst of so many mixed messages and dragging of feet.

Cheers,
david
David Balasundaram, PhD.,
Scientific Review Officer,
Cell Biology Integrated Review Group,
http://public.csr.nih.gov/StudySections/IntegratedReviewGroups/CBIRG/Pages/default.aspx
Referral Officer,
Division of Receipt and Referral
NIH Center for Scientific Review
6701 Rockledge Drive, Room 5136, Bethesda, MD 20892-7768
Office: [redacted] (b) (6) | Fax: 301-480-1988 I Email: [redacted] (b) (6)

Integrity matters. Say something! For concerns or questions about possible violations of peer review integrity, please contact your Scientific Review Officer, or the CSR Review Integrity Officer at csrrio@mail.nih.gov, or the NIH Review Policy Officer at reviewpolicyofficer@mail.nih.gov. See the NIH Guide Notice on integrity in review.

From: [redacted] (b) (6)
Sent: Thu, 2 Apr 2020 13:29:05 -0400
To: Vollmer, Sebastian
Subject: Re: Estimate of undetected COVID-19 infections

Thanks, Sebastian. Very helpful

> On Apr 2, 2020, at 8:43 AM, Vollmer, Sebastian [redacted] (b) (6)> wrote:
>
> Dear Dr. Fauci,
>
> we have used estimates of COVID-19 age specifc infection fatality rates and time from onset to death that were recently published in The Lancet Infectious Disease to estimate COVID-19 detection rates and the true number of infected people (in contrast to confirmed cases that are widely reported) for the 40 most affected countries. We estimate a detection rate of on average six percent and number of cases of a few tenth of millions. We thought you might be interested and have attached the note to this email.
>
> Thanks for doing such a great job in such a difficult time. I lived in Boston for a few year when I was a postdoc and later adjunct professor at the Harvard Chan School of Public Health. My thoughts are with my friends in the United States, particularly in New York.
>
> Warmly,
> Sebastian Vollmer
>
>
>
> <Bommer & Vollmer (2020) COVID-19 detection April 2nd.docx>

From: (b) (6)
Sent: Thu, 2 Apr 2020 13:02:41 -0400
To: Jim West
Subject: Re: THANK YOU TONY!

Jim:
Thank you for your kind note. It is much appreciated.
Best regards,
Tony

> On Apr 2, 2020, at 10:08 AM, Jim West (b) (6)>wrote:
>
> Dear Tony,
>
> My name is Jim West and (b) (6) Most people did not know (b) (6), except his immediate family, close friends and of course Jack Whitescarver. I am writing to congratulate you on the job you are doing with the Coronavirus. There is no doubt in my mind it has been exceedingly stressful for you and your family, and I just wanted to offer my support and reassurance that you are indeed doing a great job. I know (b) (6) could have never handled the stress of all of this, and he would be most proud of the job you are doing.
>
> Take good care of yourself and keep steadfast in what you are doing. You are the true *medical advisor* of the United States during this pandemic, and millions of us are incredibly grateful.
>
> Sincerely yours,
>
> Jim West

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 13:21:29 +0000
To: WAYNE REYNOLDS
Subject: RE: Heads Up - Dr. Fauci Bobblehead with a Cause

Wayne and Catherine:

Thank you for your kind note. Much appreciated. Please stay safe and well so that we can some time soon (I hope) resume our normal lives together.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: WAYNE REYNOLDS [redacted] (b) (6)>
Sent: Wednesday, April 1, 2020 3:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Grady, Christine (NIH/CC/BEP) [E] [redacted] (b) (6)>
Subject: Fwd: Heads Up - Dr. Fauci Bobblehead with a Cause

Tony,

You've finally hit the big time. The National Bobblehead Hall of Fame and Museum. Thank you for all you're doing for the country.

Warmest wishes,

Wayne and Catherine

Sent from my iPhone

Begin forwarded message:

From: "Jordan, Mary" <Mary.Jordan@washpost.com>
Date: April 1, 2020 at 3:39:44 PM EDT
To: Wayne Reynolds [redacted] (b) (6)>
Subject: Fw: Heads Up - Dr. Fauci Bobblehead with a Cause

Who knew there was a National Bobblehead Hall of Fame and Museum!

From: Phil Sklar <phil.sklar@bobbleheadhall.com>
Sent: Wednesday, April 1, 2020 3:34 PM
To: Jordan, Mary <Mary.Jordan@washpost.com>
Subject: Heads Up - Dr. Fauci Bobblehead with a Cause

CAUTION: EXTERNAL SENDER

Hi Mary,

I hope you are staying well during these unprecedented times! I wanted to give you a heads up that we will be unveiling a bobblehead of Dr. Anthony Fauci this Friday, April 3rd. Dr. Fauci has become America's voice of reason as one of the lead members of the White House Coronavirus Task Force. The National Bobblehead Hall of Fame and Museum will be donating $5 from every Dr. Fauci Bobblehead sold to the American Hospital Association in support of the 100 Million Mask Challenge [icm-tracking.meltwater.com]. The bobbleheads will be available for pre-order on our website beginning on Friday.

Bobbleheads are the ultimate honor, and we think Dr. Fauci deserves it given what he has done and continues to do for our country and the world in the battle against COVID-19. The bobblehead will join a growing number of items including donuts, socks and t-shirts featuring Dr. Fauci. We received a lot of requests for a bobblehead of Dr. Fauci and are excited to be able to use the bobblehead to raise funds for a vital organization that is helping limit the spread of the Coronavirus while making people smile during these unprecedented times.

Let me know if you would like the press release, pictures and graphics in advance of Friday's release. Please hold off on publicizing anything related to the bobblehead until Friday—any time on Friday is okay. Please also let me know if you would like a sample when they arrive or if you have any questions.

Thank you,

Phil

Phil Sklar
Co-Founder and CEO
National Bobblehead Hall of Fame and Museum
Phil.Sklar@bobbleheadhall.com
414-519-2625
www.bobbleheadhall.com [icm-tracking.meltwater.com]

This email was sent to mary.jordan@washpost.com
National Bobblehead Hall of Fame and Museum, PO Box 0982, Milwaukee, WI 53201-0982, US
Unsubscribe [icm-tracking.meltwater.com]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 12:59:53 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C]
[redacted] (b) (6)
Subject: FW: COVID-19 Planning

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Sent: Wednesday, April 1, 2020 7:35 PM
To: ICDDIR-L@LIST.NIH.GOV; List DEPDIR-L <DEPDIR-L@list.nih.gov>
Cc: NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>
Subject: Re: COVID-19 Planning
Importance: High

Colleagues,

The momentum behind a 4th COVID supplement seems to be building in the Congress even more quickly than we had expected. We have received a TA request to provide rough numbers for NIH efforts **by Friday afternoon**. With regrets for adding more burdens to the intense efforts you are already engaged in, I ask that you submit a rough estimate of the first year and the five year budget for your (i) IC-specific initiative(s) and/or your (ii) proposals to contribute to economic recovery, no later than *Friday April 3 at noon*. This will be non-binding, and you are free to revise it for the submission that we already asked you for by Friday COE. The only thing we need Friday at noon is the budget – the narrative can come later in the day (or the night).

Please use the second page of the template we sent you yesterday to provide this draft budget. Send to me.

I apologize for the impossible turn-around and appreciate all the hard work that will be needed to get us this information by the Friday noon deadline.

Many thanks,
Larry

From: "Tabak, Lawrence (NIH/OD) [E]" <[redacted] (b) (6)>
Date: Tuesday, March 31, 2020 at 4:20 PM
To: "ICDDIR-L@LIST.NIH.GOV" <ICDDIR-L@LIST.NIH.GOV>, List DEPDIR-L <DEPDIR-L@list.nih.gov>
Cc: NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>
Subject: COVID-19 Planning

Colleagues,

Francis is sending out a note shortly to the co-chairs of each of the ten trans-NIH initiatives, asking for their assistance in putting together workplans and budgets for those projects. But in addition to these trans-NIH activities, we invite ICDs to submit a short description of no more than two IC-specific ideas that you believe merit consideration for support in a fourth supplemental bill, should one be put forward. Please use the same template that is being used for the trans-NIH activities, but just check the appropriate tick box. Your submission should include budget estimates for the first year and subsequent outyears (for a total of 5 years). [redacted] (b) (5). Please send these to me by COE, Friday, April 3rd.

Finally, _if_ we are asked about technical assistance regarding economic recovery, please send ideas for that option. As part of this, Mike Lauer and Michael Gottesman will submit estimates on what might be needed for extramural institutions and the IRP to "make them whole". However beyond that there are infrastructure, training, and other requests that would with help national economic recovery by creating new jobs (construction, IT, biomedical, etc.) and help prepare the nation for COVID-202X. Please use the same template that will be used for the trans-NIH activities (again, checking the correct box) and include budget estimates for the first year and subsequent outyears (for a total of 5 years). Please send these to me by COE, Friday, April 3rd.

Many thanks,
Larry

From: [redacted] (b) (6)
Sent: Thu, 2 Apr 2020 07:28:32 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: media inquiry on COVID-19

Begin forwarded message:

> **From:** "stefano.valentino@globalreporter.it" <stefano.valentino@globalreporter.it>
> **Date:** April 2, 2020 at 5:54:54 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Subject: media inquiry on COVID-19**
>
> Dear Dr. Fauci,
>
> I am a Brussels-based journalist, member of the European Data Journalism Network (EDJNet), a digital news-making platform that affiliates media outlets across Europe.
>
> I found a quote from you in this article which seems to be quite prophetic: https://www.theatlantic.com/health/archive/2020/02/covid-vaccine/607000/
>
> I contact you to have a discussion about the effectiveness of the epidemic outbreak preparedness and response measures put in place by governments, particularly in terms of vaccine development.
>
> I would like to know if we could ave a chat on skype. Or, if you prefer, I can send you some questions by email.
>
> I wait for your kind feedback
>
> Regards
>
> Stefano Valentino
>
> Founder
> *MobileReporter*
>
> Special Investigations Contributor
> *Vox Europ*

Fatto Quotidiano

Fullbright Alumni
Berkley School of Journalism

Memberships:
Italian Press Association
European Data Journalism Network
Italian Science Writers Association
Society of Environmental Journaslists
Online News Association

Tel: [redacted] (b) (6)
Whatsapp: [redacted] (b) (6)
Skype: globalreporter
Twitter: @M0BILEREP0RTER
info@mobilereporter.info
www.mobilereporter.info

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 10:58:29 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Possible Ineterview via FaceBook

fyi

From: Brendan Taglianetti <btaglianetti@milford.nh.gov>
Sent: Thursday, April 2, 2020 6:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Possible Ineterview via FaceBook

Dear Dr. Anthony S. Fauci,

My name is Brendan Taglianetti; I am a Full-Time Advanced EMT provider for Milford Ambulance Service in Milford, NH. I want to help relay your message of COVID-19 information for state of New Hampshire, by conducting a Facebook Live chat with myself to project information and messages to the citizens of New Hampshire. This is a chance for us to chat for around 10 minutes and talk with a first responder to the general public.

I have seen you do interviews with the media/ daytime talk shows, a Facebook live chat with Mark Zuckerberg, and even an Instagram live video with Stephen Curry from the Golden State Warriors.

I run the social media aspect of the department, and I would love to do a 10-15 minute discussion (with information to the public, as well as some question and answer) with you on Facebook (live) to have the general public watch us talk about the pandemic and the next steps, and also maybe take some questions asked of the public watching when they comment. I also will be reaching out to the New Hampshire State Governor Chris Sununu and Dr. Benjamin P. Chan (who is the state's epidemiologist). I would love to have them chat with me, and have you join in on the discussion as well. I have no confirmed with them if they are available yet, but I am putting things in motion.

I know that if I was able to set up a time and date that would work around your busy and important schedule, then I could with ample time promote it. I would love to not only get the town on Milford to watch this, but have the state of New Hampshire and other states nearby tune in. I know this is a long shot and that you have way more important aspects of your job to complete, but I think this an important time to have the public hear you talk.

Please let me know if this could be possible and I would love to set this up, I don't expect to take too much of your time if this can happen. Sometimes in life you just need to ask and see what happens and this is a time where that risk is worth it to have a conversation with you about this pandemic we are facing, especially as we ramp up for starting to "peak" in the number of people affected.

Please let me know if this is possible and tell me if you are interested in doing this with us for the greater good of the general public to keep them informed.

Sincerely,

Brendan J. Taglianetti

Full-Time Advanced EMT/ Field Training Officer

Milford Ambulance Service

66 Elm Street, Milford, NH 03055

Phone: (603) 249-0610 (ext. 275)

Email: btaglianetti@milford.nh.gov

From: [redacted] (b) (6)
Sent: Wed, 1 Apr 2020 22:15:42 -0400
To: McNeil Jr, Donald G
Subject: Re: Heads Up - Dr. Fauci Bobblehead with a Cause

Yikes!!!

On Apr 1, 2020, at 9:55 PM, McNeil Jr, Donald G <mcneil@nytimes.com>wrote:

I'm ordering one for my office desk and maybe another for [redacted] (b) (6)

---------- Forwarded message ---------
From: **Phil Sklar** <phil.sklar@bobbleheadhall.com>
Date: Wed, Apr 1, 2020 at 3:35 PM
Subject: Heads Up - Dr. Fauci Bobblehead with a Cause
To: <mcneil@nytimes.com>

Hi Donald,

I hope you are staying well during these unprecedented times! I wanted to give you a heads up that we will be unveiling a bobblehead of Dr. Anthony Fauci this Friday, April 3rd. Dr. Fauci has become America's voice of reason as one of the lead members of the White House Coronavirus Task Force. The National Bobblehead Hall of Fame and Museum will be donating $5 from every Dr. Fauci Bobblehead sold to the American Hospital Association in support of the 100 Million Mask Challenge. The bobbleheads will be available for pre-order on our website beginning on Friday.

Bobbleheads are the ultimate honor, and we think Dr. Fauci deserves it given what he has done and continues to do for our country and the world in the battle against COVID-19. The bobblehead will join a growing number of items including donuts, socks and t-shirts featuring Dr. Fauci. We received a lot of requests for a bobblehead of Dr. Fauci and are excited to be able to use the bobblehead to raise funds for a vital organization that is helping limit the spread of the Coronavirus while making people smile during these unprecedented times.

Let me know if you would like the press release, pictures and graphics in advance of Friday's release. Please hold off on publicizing anything related to the bobblehead until Friday—any time on Friday is okay. Please also let me know if you would like a sample when they arrive or if you have any questions.

Thank you,

Phil

Phil Sklar
Co-Founder and CEO
National Bobblehead Hall of Fame and Museum
Phil.Sklar@bobbleheadhall.com
414-519-2625
www.bobbleheadhall.com

This email was sent to mcneil@nytimes.com
National Bobblehead Hall of Fame and Museum, PO Box 0982, Milwaukee, WI 53201-0982, US
Unsubscribe

--
Donald G. McNeil Jr.
Science Correspondent
The New York Times

Tel: [redacted] (b) (6)
mcneil@nytimes.com

Articles: https://www.nytimes.com/by/donald-g-mcneil-jr

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 1 Apr 2020 19:59:55 +0000
To: Awwad, David (NIH/NIAID) [C]
Attachments: message,, Re message.oft, Re message1.oft, u r hypocrite.oft, Call the National Guard in.oft, message,

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Wed, 1 Apr 2020 17:51:34 -0400
To: Duchin, Jeff
Subject: Re: FEMA Test Kits

Jeff:
Thanks for your note. It was very helpful to me to speak with your group last night. I caused quite a stir at theTask Force meeting when I reported on our telephone conversation. I believe that this fixed the FEMA issue.
Best regards,
Tony

> On Apr 1, 2020, at 5:43 PM, Duchin, Jeff [redacted] (b) (6)>wrote:
>
> Tony,
>
> Thank you for taking some precious time to hear from some of the folks on the ground confronting COVID-19 around the country. I can't tell you how much we all value your engagement and leadership on behalf of the nation. I'd love to get your take on whether you think the types of things described it eh recent AEI report are realistic. I have serious doubts.
>
> Quick question – I mentioned the problem we had with FEMA test kits being recalled from us because we did not want to use their call line and lab because too slow, – just wondering if that came up in your meeting today because I just heard the kits were released to us without restrictions on how we use them. So either way, apparently resolved.
>
> Stay well and best regards,
>
> Jeff
>
> ---
>
> Jeffrey S. Duchin, MD
> Health Officer and Chief, Communicable Disease Epidemiology &Immunization Section
> Public Health - Seattle and King County
> Professor in Medicine, Division of Infectious Diseases, University of Washington
> Adjunct Professor, School of Public Health
> 401 5th Ave, Suite 1250, Seattle, WA 98104
> Tel: [redacted] (b) (6); Direct: [redacted] (b) (6); Fax: (206) 296-4803
> E-mail: [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Wed, 1 Apr 2020 16:54:57 -0400
To: Kadlec, Robert (OS/ASPR/IO)
Subject: Fwd: [redacted] (b) (5)

Bob:
See email below. [redacted] (b) (5)

Thanks,
Tony

Begin forwarded message:

From: "Mascola, John (NIH/VRC) [E]" [redacted] (b) (6)>
Date: April 1, 2020 at 4:40:39 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6), "Erbelding, Emily (NIH/NIAID) [E]" <[redacted] (b) (6)>, "Marston, Hilary (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: [redacted] (b) (5)

Tony,

[redacted] (b) (5)

John

(b) (5)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 1 Apr 2020 16:02:51 +0000
To: Barasch, Kimberly (NIH/NIAID) [C];Conrad, Patricia (NIH/NIAID) [E]
Subject: [redacted] (b)(5) - PCP

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

[redacted] (b)(5) - PCP

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 1 Apr 2020 16:01:03 +0000
To: Gallo, Robert
Cc: Barasch, Kimberly (NIH/NIAID) [C];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: information

I got it. I will have my staff try to set something up.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gallo, Robert [redacted] (b) (6)
Sent: Wednesday, April 1, 2020 11:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: information

TONY—this is from me—Bob Gallo

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Wednesday, April 1, 2020 11:08 AM
To: Gallo, Robert [redacted] (b) (6)
Subject: RE: information

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 1 Apr 2020 14:04:37 +0000
To: Berkowitz, Avrahm J. EOP/WHO;Gidley, Hogan H. EOP/WHO
Subject: RE: Quick call

[redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Berkowitz, Avrahm J. EOP/WHO [redacted] (b) (6)>
Sent: Wednesday, April 1, 2020 9:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>; Gidley, Hogan H. EOP/WHO [redacted] (b) (6)>
Subject: Quick call

Dr Fauci – can you please jump on a quick call with Hogan about a press inquiry we received at the White House? He is at [redacted] (b) (6)
(and I am at [redacted] (b) (6).
Thank you!
Avi

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 1 Apr 2020 13:22:58 +0000
To: [redacted] (b) (6)
Subject: RE: FW: Wpost: Fauci socks, Fauci doughnuts, Fauci fan art: The coronavirus expert attracts a cult following

It is not at all pleasant, that is for sure.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Wednesday, April 1, 2020 9:14 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: FW: Wpost: Fauci socks, Fauci doughnuts, Fauci fan art: The coronavirus expert attracts a cult following

Completely surreal [redacted] (b) (6) Dizzying, even. Can't imagine what it is like for you, especially in the midst of all this.

On Tue, Mar 31, 2020 at 10:58 AM Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:

> Truly surrealistic.   Hopefully, this all stops soon.
>
> **Anthony S. Fauci, MD**
> **Director**
> **National Institute of Allergy and Infectious Diseases**
> **Building 31, Room 7A-03**
> **31 Center Drive, MSC 2520**
> **National Institutes of Health**
> **Bethesda, MD 20892-2520**
> **Phone:** [redacted] (b) (6)
> **FAX: (301) 496-4409**
> **E-mail:** [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, March 31, 2020 10:43 AM
Subject: Wpost: Fauci socks, Fauci doughnuts, Fauci fan art: The coronavirus expert attracts a cult following

Fauci socks, Fauci doughnuts, Fauci fan art: The coronavirus expert attracts a cult following

Doughnuts bearing the likeness of Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, rest on a plate at Donuts Delite in Rochester, N.Y., on March 25. (Shawn Dowd/Rochester Democrat & Chronicle/AP)

By
Antonia Noori Farzan
March 31, 2020 at 5:15 a.m. EDT

Early last week, Nick Semeraro wanted to find a way to honor Anthony S. Fauci. As the owner of a small doughnut shop in Rochester, N.Y., he had been closely tracking the latest news about the coronavirus pandemic. And night after night, he'd been impressed by how Fauci, the director of the National Institute of Allergy and Infectious Diseases, approached the crisis in a calm, knowledgeable manner.

So, as a tribute, Semeraro put the renowned immunologist's face on a doughnut. Expecting to sell a few hundred, he was shocked when the store sold out day after day, with thousands flying off the shelves. Donuts Delite was besieged with requests to ship the buttercream-frosted creations all over the country, and one Fauci fan drove three hours just to pick up a dozen. Soon, bakeries in Wisconsin and Pennsylvania followed suit, using edible paper to decorate pastries with Fauci's likeness.

"We had no idea it was going to blow up this big," Semeraro told CNN. "We didn't know everyone else felt the same way we did."

While Fauci was already a respected scientist before the outbreak, his appearances during White House press briefings have made him a household name and an unlikely celebrity. With his straightforward demeanor and willingness to contradict President Trump, he's begun to develop the same kind of cult following as Supreme Court Justice Ruth Bader Ginsburg and former special counsel Robert S. Mueller III, who inspired countless "Plank like RBG" tank tops and a bizarre illustrated children's book, respectively.

Even as whole swaths of the global economy collapse, the pandemic has created a robust cottage industry of Fauci-themed merchandise, including bottle openers, magnets and mugs. On Etsy, you can buy "Honk for Dr. Fauci" bumper stickers, prayer candles depicting "St. Fauci" and socks printed with Fauci's face. Graphic T-shirts bear slogans such as "I Need a Hero" and "In Dr. Fauci We Trust."

If so inclined, you can even decorate your home with an "I Heart Dr. Fauci" throw pillow, or purchase a replica of Fauci's jersey from the time he captained the basketball team at Manhattan's Regis High School. Lingua Franca, which sells cashmere sweaters embroidered with resistance-friendly slogans for $380 and up, recently began taking orders for an army-green "Dr. Fauci Fan Club" knit.

In honor of Fauci's Italian heritage, a clam bar in Long Island named a linguine dish after him this week. (Available for pickup only, "the linguine with white clam sauce shares origins with Fauci, as the sauce itself was invented in the Fauci Family's native Sciacca, Italy," the restaurant claimed in a statement.)

As countless Americans remain glued to the news while trying to stay indoors, a robust Fauci fandom has flourished online. On Facebook, the "Dr. Anthony S. Fauci Fan Club" has over 32,000 members. Thousands more congregate in groups with names such as "Dr. Anthony S. Fauci, the Man, the Myth, the Legend," "Dr. Fauci Speaks, We Listen" and "Dr. Fauci Memes for Social Distance Teens."

An unassuming 79-year-old public servant who has advised six presidents, Fauci has become a "reliable constant in a time of uncertainty," The Washington Post's Ellen McCarthy and Ben Terris reported. But his admirers — and there are a lot of them — worry that it's only a matter of time before he's sidelined by Trump.

When Fauci missed a White House news conference earlier this month, panic erupted on Twitter, along with speculation that he could be sick. There was palpable relief when he resumed his regular position at the podium the following day and appeared to hide some exasperation as Trump referenced "the deep state."

Fauci later explained that he had simply been trying to dislodge a lozenge from his throat. But the much-analyzed "Fauci facepalm" had already become a meme, deployed by liberal members of what's known as the resistance.

Fauci's newfound fame can be partially attributed to his willingness to engage with all forms of media — in recent weeks, he's gone on a Barstool Sports podcast, chatted with basketball star Steph Curry on Instagram Live as Barack Obama listened in, and appeared on "The Daily Show With Trevor Noah." But it also undoubtedly helps that his fans tend to take social distancing seriously and consequently have ample spare time to produce fan art or perform songs written (or modified) in his honor.

On social media, Fauci's virtual fan clubs peruse old photos of the infectious disease expert in search of "comfy turtleneck vibes," stitch his face on embroidery hoops and discuss erecting statues as tribute. They frost his name on cookies and joke about constructing shrines in his honor. Prominent activists and entertainers confess to wanting to marry him, or have him tuck them into bed.

Fauci has remained characteristically modest about his new status as a cult figure. "Well, that's very nice," he responded when McCarthy and Terris mentioned that people all over the country were praying for him. Of course, that means that his fan base has only continued to grow.

"I never met a guy that, worldwide, he is so loved," Semeraro, the Rochester doughnut shop owner,told CNN. "And a month ago, we never knew his first and last name."

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: [redacted] (b) (6)
Sent: Wed, 1 Apr 2020 06:26:32 -0400
To: DMID Word Nerds
Subject: Fwd: Covid-19 comments on UK response
Attachments: image001.png, ATT00001.htm, Covid19, UK pharmavaccine response.pdf, ATT00002.htm, Covid19, UK Urgent Action response.pdf, ATT00003.htm, VACCINEarticle.pdf, ATT00004.htm

Sent from my iPhone

Begin forwarded message:

> **From:** Karl Simpson <[redacted] (b) (6)>
> **Date:** April 1, 2020 at 5:46:14 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Covid-19 comments on UK response**
>
> Dear Dr Fauci
>
> I was just re-reading your January 23 Viewpoint article in JAMA. So little time has passed, but so much has changed, and your comments seem prescient.
>
> I have been working on emergent/re-emergent infectious agents for some time, and authored a 2018 report for the UK government on vaccine responses that was summarised in a Vaccine publication last October attached. As almost everyone else, my attention has been redirected to Covid-19, although monkeypox remains a focus of my interest.
>
> You and your colleagues may be interested in two short documents I produced for the UK government on the 20th and 22nd of March. That also seems long ago now!
>
> As fellow citizen of our planet, I thank you and colleagues for your unstinting efforts to control infectious disease and Covid-19 in particular.
>
> Warmest wishes
>
> Karl

J. Karl Simpson CBiol FRSB
CEO, JKSBioscience Limited

JKSbioscience

2 Midanbury Court, 44 Midanbury Lane

Southampton SO18 4HF, UK

Tel: [redacted] (b) (6)

Mobile: [redacted] (b) (6)

Mail: [redacted] (b) (6)

Website: http://www.jksbioscience.co.uk

Skype: [redacted] (b) (6)

Company Number: 10051396

VAT number: 238 0528 12

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 31 Mar 2020 21:07:00 +0000
To: NIAID OD AM
Subject: FW: Additional data on masks
Attachments: MacIntyre BMJ.pdf, Figure 3.jpg

Adding everyone since it was discussed in am meeting. thx

From: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, March 31, 2020 5:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] <[redacted] (b) (6) Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Additional data on masks

Dr. Fauci,

In addition, I found the attachedd review on masks that addresses use in the community settings. Attached are the paper and figure 3, which summarizes the data from 9 very diverse RCTs (overlapping with what I had sent earlier).

Bottom line: generally there were not differences in ILI/URI/or flu rates when masks were used, although when early use and compliance was taken into account, a few times a difference was seen.

In addition:
This case control study noted that, among SARS patients in Hong Kong without a known source of infection, cases (27.9%) were less likely than uninfected controls (58.7%) to report wearing a mask frequently in public, for what that's worth.
https://wwwnc.cdc.gov/eid/article/10/4/03-0628_article

[redacted] (b) (5)

Andrea

From: (b) (6)
Sent: Tue, 31 Mar 2020 07:25:55 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Harvard Business School / Wharton Business School

Sent from my iPhone

Begin forwarded message:

> **From:** Arash Farin <arash@arash.tv>
> **Date:** March 30, 2020 at 10:32:04 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
> **Subject: Re: Harvard Business School / Wharton Business School**
>
> Hi Dr. Fauci,
>
> I just wanted to confirm you received this.
>
> I also just read a great story on you in the WSJ, which discussed your amazing basketball and leadership skills when you were in college. Not surprisingly, even then, your teammates were seeking your advice on leading them through difficult times.
>
> Talk to you soon.
>
> Regards,
> Arash
>
> On Sat, Mar 28, 2020, at 7:54 AM, Arash Farin wrote:
>
> > Hi Dr. Fauci,
> >
> > I'm a graduate of both Harvard Business School and The Wharton School, and have truly enjoyed watching the leadership you have shown our nation during these challenging times. Your steady hand, calm demeanor, incisive thoughts, and intellectual rigor, have all been quite comforting to us the last few weeks.
> >
> > I would like to see if you may have a few minutes to participate in a webcast interview with myself and classmates from Harvard and

Wharton this coming week or next week. We would love to hear your thoughts on dealing with the coronavirus, lessons learned from other countries, and how we can prepare for a potential recurrence, as has been discussed in the media, along with other topics you deem important.

I may also be able to get students from Oxford University to join, as I attended there as well, and I know the UK is dealing with its own set of challenges.

I look forward to hearing from you, and can be reached at [redacted] (b) (6) or via email (arash@arash.tv).

God bless you, and thank you for everything you have been doing.

Best Regards,
Arash

From: [redacted] (b) (6)
Sent: Tue, 31 Mar 2020 07:24:50 -0400
To: DMID Word Nerds
Subject: Fwd: VVIP information for diagnostic and therapy for COVID-19- Kindly do not delete

Sent from my iPhone

Begin forwarded message:

> **From:** "anahar ." <anahar@abgenics.in>
> **Date:** March 31, 2020 at 3:38:38 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Fwd: VVIP information for diagnostic and therapy for COVID-19- Kindly do not delete**
>
> Dear Sir
>
> We request you to spare a few minutes to read this email.
>
> Abgenics is a life-sciences company (Abgenics Life sciences Pvt Ltd, www.abgenics.in) based in Pune, India conducting pioneering research in the area of drug discovery using camelid antibody against infectious diseases in the past 10 years. Abgenics Life Sciences was founded in 2010 and is managed by Anil Nahar (Entrepreneur) and Dr Sanjiban K Banerjee (Technical). Dr Banerjee has studied and lived in the USA for more than 7 y and worked in the area of infectious diseases all his life. He has conducted extensive research in the area of camelid antibody technology in USA. After returning to India and with an urge to help the people of India in area of infectious diseases. Dr Banerjee in association with Anil Nahar started this venture. Since then, the company has extensively worked and developed novel camelid antibody technology for various infectious diseases causing bacteria (Multi drug resistant) and fungus like Pseudomonas, Staphylococcus Aureus, Candida Albicans and other

important pathogens. Our company is the only company in India working on Camelid antibody platform. Camelid antibody is a very robust and novel technology and can be used to develop drugs against any kind of antigen generated from bacteria and viruses. The specialty of camel antibody, it occurs in nanosize, high temperature and high Ph stable. It has very high affinity towards any antigen. **A video explaining our technology is attached in the email.**

An Abgenics Life science was warded twice by [redacted] (b) (4) [redacted] USA in the form of research projects to develop technology for

(b) (4)
[redacted]

(b) (4)

[redacted]

Corona virus is a spiked virus and the spikes are used by the virus to first attach to and then invade into the host cells. Subsequently the genetic materials, RNA are injected where it hijacks the host replication machinery to multiple and re-infect more cells. If the initial attachment or the fusion of the virus and host membranes can be blocked, the virus replication cycle can be stopped, bringing the infection under control. The spike protein consists of two components, a globular head, S1 that helps the initial attachment and a spiral part S2 that is responsible for membrane fusion which forms the channel for the entry of the

(b) (4)
[redacted]

--
Regards

Anil Nahar
MD
Abgenics Life sciences Pvt Ltd
Kant Helix
Bhoir Colony
Chinchwad
Pune
India
Ph- [redacted] (b) (6)

--

From: [redacted] (b) (6)
Sent: Tue, 31 Mar 2020 07:23:59 -0400
To: DMID Word Nerds
Subject: Fwd: New biological disinfection automates, also effective against new Corona virus and multi-resistant germs, from a Florida Company
Attachments: PastedGraphic-1.png, ATT00001.htm, MSDS_Saniswiss_biosanitizer_aHP_P_rev_16032018.pdf, ATT00002.htm, br_automate_aHP_HTA_EN.pdf, ATT00003.htm, br_biosanitizer aHP C_EN2.pdf, ATT00004.htm, ABSA conclusion Kopie.pdf, ATT00005.htm, SHS_23082019_WEB.pdf, ATT00006.htm

Sent from my iPhone

Begin forwarded message:

> **From:** Alexander Friedrich <a.friedrich@biosanitize.us>
> **Date:** March 31, 2020 at 6:02:53 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** Tayfun Taylor <mr.taylor@mailbox.org>, "ceo@biosanitize.us" <ceo@biosanitize.us>
> **Subject: New biological disinfection automates, also effective against new Corona virus and multi-resistant germs, from a Florida Company**
>
> Dear Mr.Fauci,
> I know you're busy. But at this special time for all of us, I just need to write to you. The new Corona Virus is changing the world. It affects all of us in health, social and economic terms. The importance of hygiene and disinfection can be seen especially now in the pandemic.
>
> (b) (4)
> [redacted]

(b) (6), (b) (4)

[redacted]

(b) (4)

[redacted]

do not hesitate to contact us.
Yours, sincerely

Alexander Friedrich
Repr. Biosanitize USA

Alexander Friedrich
Repr. Biosanitize USA
contact: a.friedrich@biosanitize.us

Bio-Sanitize USA LCC
12601 New Brittany Blvd
33907 Fort Myers, Florida, USA

BIO-SANITIZE-USA

Cleaner spaces. Safer places.

✓your home ✓ambulance ✓hotel room ✓airplane cabin ✓hospital

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 31 Mar 2020 02:07:49 +0000
To: Moshe Levi
Cc: Graham, Barney (NIH/VRC) [E]
Subject: RE: Question from Georgetown

Moshe:

I am not sure that I can help you with this. I am referring your e-mail to Dr. Barney Graham of the NIAID VRC. Perhaps he can help you.

Best regards,
Tony

From: Moshe Levi [redacted] (b) (6)
Sent: Monday, March 30, 2020 3:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Question from Georgetown

Dear Tony:

I know that you are busy 7/24 with the current crisis.

BUT I have a question for you or for one of your colleagues.

[redacted] (b) (4)

Please let me know.

Meanwhile there are not adequate ways to thank you for all you do.

I should have seen that when you were my attending while you were at Cornell as a Visiting Professor Professor around [redacted] (b) (6)

Moshe

Cell: [redacted] (b) (6)

--
Moshe Levi, MD
Dean for Research
Professor of Biochemistry and Molecular & Cellular Biology
Georgetown University
3900 Reservoir Road

Med Dent NW 105
Washington, DC 20057
Office: (b) (6)
E-mail: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 31 Mar 2020 02:02:50 +0000
To: David Katz
Subject: RE: COVID-19 -- URGENT (Please do not disregard!)

David:

I know that it is you. I am sorry, but I am getting more than 2000 e-mails pe day. I totally agree with you and this issue is being actively discussed as recently as today at the task Force meeting. I am not sure what you mean by aerial "eradication" procedures that could be practically implemented. There are some data from NIH that indicate that mere speaking without coughing elicits aerosols that travel a foot or two. If that is the case, then perhaps universal wearing of masks in the most practical way to go.

Best regards,
Tony

From: David Katz [redacted] (b) (6)>
Sent: Monday, March 30, 2020 5:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: COVID-19 -- URGENT (Please do not disregard!)

For God's sake, Tony -- this is me, not simply an unknown "messenger" from the general public! We go back together for many, many years (to our days together at the NIH, remember?). As you may recall, we worked (successfully) during the infamous 1969 "March on Washington", among other historically important events.
Although I am now [redacted] (b) (6) I continue to pay careful attention to world events, and this is one that exceeds any others that have occurred in our lifetime!

As I wrote in my previous e-mail, I have become convinced that COVID-19 is behaving as an *airborne virus, and*, therefore, we should be directing our mitigation efforts toward more comprehensive *aerial eradication procedures!*

Think about the most recent reports -- namely that imprisoned inmates, and a young baby, have recently been reported as "infected" with this virus.

Person-to-person infection in these circumstances is difficult to explain! But transmission by viable *airborne virus* could certainly happen!

I look forward to your response, with best wishes,
David

David H. Katz, M.D.
La Jolla, California

On Sun, Mar 29, 2020 at 11:18 AM Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:

> My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.
>
> Thank you, and best regards.
>
> Anthony S. Fauci, M.D.

From: [redacted] (b) (6)
Sent: Mon, 30 Mar 2020 16:29:31 -0400
To: [redacted] (b) (6)
Subject: Fwd: Hello from Canada!

Could you please respond to her for both of us. Thanks

Begin forwarded message:

> **From:** "El-Gabalawy, Nadia (PHAC/ASPC)" [redacted] (b) (6)>
> **Date:** March 30, 2020 at 2:48:41 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Hello from Canada!**
>
> Hi Dr. Fauci,
>
> I thought I would reach out to you amidst this crisis; I respect the work you're doing a great deal. [redacted] (b) (6) Hani El-Gabalawy, did a research sabbatical at NIH [redacted] (b) (6) [redacted]
>
> Amazing work that you're doing. I've been following your discussions and scientific innovation regarding COVID-19. I've been working for the federal government in Intelligence for about thirteen years and recently moved to the Canadian Public Health Laboratory Network Secretariat to support the Emergency Operations Centre at the National Microbiology Lab. I've been with the NML for almost my whole career.
>
> Just a quick hello and deep respect for your work. My colleagues and Director have said that we're on the exact same page as you, in terms of your perspective and assessment of the pandemic. Although there is a border between us, know that we are in agreement with your work and I'm thrilled to see you advising the public. There is no better person to do the job.
>
> Kindest regards,
>
> Nadia El-Gabalawy
> Team Lead, Support Services, Canadian Network for Public Health Intelligence
> Public Health Agency of Canada/Government of Canada
> [redacted] (b) (6)

Chef d'équipe, Services de soutien, Réseau canadien de renseignements sur la santé publique
Agence de la santé publique du Canada / Gouvernement du Canada
(b) (6)
[redacted]

(b)(5)-PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 30 Mar 2020 12:23:38 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Invitation to be the keynote speaker at an Insurance Medicine Conference in Washington, DC in October.

RSVP sorry no.

From: Pinho, Paulo <Paulo.Pinho@optimumre.com>
Sent: Monday, March 30, 2020 8:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Invitation to be the keynote speaker at an Insurance Medicine Conference in Washington, DC in October.

Dear Dr. Fauci,

I hope this email finds you well. It is abundantly obvious from the countless sifts through data and tallies of cases, interviews and press conferences, social media appearances, etc. that your schedule is crazy these days. As a practicing physician and an American, I am proud to be represented by you and thank you for your efforts on our behalf. I realize with your schedule and with the thousands of emails, this one may not make it, but I wanted to take a shot in the dark.

I am currently the Chief Medical Officer of a reinsurer and am on the planning committee for the American Academy of Insurance Medicine's annual meeting which will be held in DC this year October 18-21. Dr. Michael Osterholm had agreed to speak at the conference back in January as our first keynote speaker on the subject of pandemics, preparedness. I'd heard him speak before at Prudential (I was medical director there and we were a member company of CIDRAP) and his talk mirrored his book which I've also read. Regretfully, 2 weeks ago I received notice from Laurel, his EA, that he is unable to attend the meeting because he needs to travel to London that week for a meeting he is heading. I think that a talk on the topic is a must at any medical meeting and after hearing your pressers and coming to rely on your sage status updates and advice, coupled with the fact that the conference is in DC, I thought I'd give this a shot. Would you be AAIM's keynote speaker this year?

In the midst of the current COVID-19 pandemic, we understand many industry conferences have had to be canceled. We are continuing to closely monitor the trend of the COVID-19 virus, and may have to do the same for the AAIM meeting in October, but if there is an opportunity to gather and learn, we'd like to prepare for it.

The audience is medical directors that work in the life, health, disability and longterm care space. Some are clinically active. Some of them are resources for health emergency planning for their companies. The audience comes mostly from North America, although other countries/continents are well represented.

The purpose of the meeting is really to illustrate novel trends in the industry that will likely impact morbidity and mortality in the near or distant future. We've had talks on CRISPR, marijuana, precision medicine, data analytics. They're not hard core morbidity or mortality focused, but do touch on it.

Given the scope of the meeting and the attendees and industries they represent, I think that a lecture on pandemics, bioterrorism and emerging infectious disease, especially in light of COVID-19, is necessary. I think you would teach new concepts to a team of doctors that would identify with some of the system gaps in our current supply chain and their impact on human health, wellbeing and survival. You'd provide experience and insight on what went wrong and what could be fixed in the future to make us collectively better prepared.

We would be honored to have you speak and I'm glad to continue discussion of logistics with someone else on your team. If you needed more information about scope, I can certainly provide that. We do provide an honorarium and will cover travel and hotel expenses.

Thanks so much in advance for any consideration you might give this request/offer and most of all thank you for your direction, demeanor and dedication at this global time of crisis.

Best,
Paulo

Paulo Bandeira Pinho, MD, FAAP, FACP
Chief Medical Director
OPTIMUM RE INSURANCE COMPANY

☎ +1 214 528-2020, ext. 30984
✉ Paulo.Pinho@optimumre.com

1345 River Bend Drive, Suite 100
Dallas, TX 75247, U.S.A.
optimumre.com

OPTIMUM
Life Reinsurance

This email and its attachments is confidential and is intended only for the individual(s) to whom it is addressed. Distribution or copying of this email by anyone other than the named recipient is prohibited. If you receive this email in error, please notify us by email and permanently delete this email and its attachments.

From: [redacted] (b) (6)
Sent: Mon, 30 Mar 2020 06:06:00 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview with Dr Anthony Fauci in The Times of London

Sent from my iPhone

Begin forwarded message:

> **From:** "Rivalland, Monique" <monique.rivalland@the-times.co.uk>
> **Date:** March 30, 2020 at 4:30:39 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Interview with Dr Anthony Fauci in The Times of London**
>
> Dear Anthony,
>
> I'm an editor at The Times of London. I'm getting in touch to discuss the possibility of interviewing you this week for our Saturday Interview slot next weekend. You have an incredibly tricky role in the fight against coronavirus and have spoken with great clarity. We would love to speak to you about your position and predictions for America.
>
> The interview slot in question is the most prestigious in the weekend edition of The Times - a double-page spread reserved each week for the most influential individuals in public life. Former interviewees range from Boris Johnson to Jeremy Farrar.
>
> We would need 40 - 50 minutes of your time before Friday morning, but preferably by Thursday evening. The interview can be conducted over Skype/Google Hangouts/Zoom or whichever method of video chat you prefer.
>
> We would be delighted if you were to consider our request.
>
> Kind regards
> Monique
>
> --
> **Monique Rivalland**
> **Features Editor**
> **THE TIMES**

(b) (6)
@MoniqueLouiseR

--
"Please consider the environment before printing this e-mail"

This e-mail and any attachments are confidential, may be legally privileged and are the property of News Corp UK &Ireland Limited on whose systems they were generated. News Corp UK &Ireland Limited is the holding company for the News UK group, is registered in England &Wales under number 81701, has its registered office at 1 London Bridge Street, London, SE1 9GF and is registered with VAT number GB 243 8054 69. If you have received this e-mail in error, please notify the sender immediately and do not use, distribute, store or copy it in any way. Statements or opinions in this e-mail or any attachment are those of the author and are not necessarily agreed or authorised by News Corp UK &Ireland Limited or any member of its group. News Corp UK &Ireland Limited may monitor outgoing or incoming emails as permitted by law. It accepts no liability for viruses introduced by this e-mail or attachments.

News Corp UK &Ireland Limited and its titles are committed to abiding by IPSO's regulations and the Editors' Code of Practice that IPSO enforces.

From: (b) (6)
Sent: Mon, 30 Mar 2020 06:05:28 -0400
To: DMID Word Nerds
Subject: Fwd: Chloroquine is a thromboxane inhibitor: there is a readily available analog

Sent from my iPhone

Begin forwarded message:

> **From:** "Dr. Josh Backon" <backon@mail.huji.ac.il>
> **Date:** March 30, 2020 at 5:52:32 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
> **Subject: Chloroquine is a thromboxane inhibitor: there is a readily available analog**
>
> Dear Dr. Fauci,
>
> I'm (b) (6) internist.
>
> I have a suggestion for 2 potent antiviral agents, cheap and readily available, that may prevent viral shedding. No viral shedding? No infectivity. The concept is that EVERYONE should take these items.
>
> First a short bio:
>
> Dr. Josh Backon was affiliated with the Hebrew University Faculty of Medicine for over 33 years. He has a good track record (84+ publications quoted by over 750 other researchers in journal articles https://scholar.google.com/scholar?start=0&q=%22backon++j.%22&hl=en&as_sdt=0,5
> and in over 250-300 texts as per
> https://www.google.com/search?tbo=p&tbm=bks&q=%22backon+j.+%22&num=100).
> In the 1980's he was Consulting Editor of the Journal of Pediatric Endocrinology, Editor of Reviews in Pure and Applied Pharmacological Sciences, and Associate Editor of the International Journal of Adolescent Medicine and Health. From 1990-2004, he was a consultant

on emergency planning and management at Israel's National Police Headquarters with Nitzav Mishneh Dannny Fisher.

===

Chloroquine, an antimalarial drug, is now being used to treat Covid-19. Its mechanism was found in the 1970's to inhibit thromboxane https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=chloroquine+thromboxane&btnG= The problem with chloroquine was that it also elevated levels of prostaglandin F2alpha. In 1980, Srivastava, an Indian biochemist working in Denmark found that GINGER is a potent inhibitor of thromboxane synthetase. I wrote a number of papers in the 1980's on use of ginger:
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=backon+ginge
r&btnG=

-

GINGER IS A POTENT ANTIVIRAL

-

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=ginger+antiviral&oq=gin

-

THE SECOND ANTIVIRAL AGENT IS TURMERIC [add black pepper since piperine dramatically increases oral bioavailability of turmeric]

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=turmeric+antiviral&oq=tur

Multisite inhibitors for enteric **coronavirus**: antiviral cationic carbon dots based on curcumin

D Ting, N Dong, L Fang, J Lu, J Bi… - ACS Applied Nano …, 2018 - ACS Publications
… These results offer theoretical support for the development of CCM-CDs as a hopeful antiviral drug for the treatment of **coronavirus** infections, including PEDV … Curcumin (CCM) is a polyphenol compound obtained from **turmeric** roots…

NAC AND PIPERINE TO INHIBIT INFLAMMATORY CYTOKINES (iNOS, NF KappaB, TNFalpha) INVOLVED IN ARDS

-

Mortality in COVID-19 patients is usually from ARDS (acute respiratory distress syndrome) via inflammatory cytokines. Apart from N-acetylcysteine which was found 3 years ago to elevate atrial natriuretic factor [found by Kiemer in 2001 to zap inflammatory cytokines: iNOS, NF KappaB, and TNFalpha) now piperine in black pepper was found to inhibit inflammatory cytokines [piperine also dramatically increases oral bioavailability of turmeric [which has been used as a potent antiviral]:

N-ACETYLCYSTEINE
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=n-acetylcysteine+%22inflammatory+cytokines%22&btnG=

PIPERINE
https://scholar.google.com/scholar?hl=en&as_sdt=0,5&q=piperine%20inflammatory%20cytokines&btnG=&fbclid=IwAR0kXZxI66JPLFPry2MDTDxOAelgGnmBZdKBw7c1v78Hfi7t0JJnx0Y2zuE
================

BTW the thromboxane hypothesis explains the increased male to female ratio in infectivity as well as the low incidence in younger people.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1433448/



Gut. 1987 Oct; 28(10): 1323.
doi: 10.1136/gut.28.10.1323

PMCID: PMC1433448
PMID: 18668886

Ginger and carbon dioxide as thromboxane synthetase inhibitors: potential utility in treating peptic ulceration

Josh Backon

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 30 Mar 2020 02:06:21 +0000
To: Tim Boyd
Subject: RE: You Rock!

Nancy:
Thank you for your kind note.
Best regards,
Tony

-----Original Message-----
From: Tim Boyd (b) (6)
Sent: Sunday, March 29, 2020 8:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: You Rock!

Dear Dr. Fauci,

After reading the article about you on the front of the New York Times this morning, I was distressed to learn that you have recently been negatively targeted via social media by members of a certain US political faction. The unfairness of these personal attacks upon you is shocking, and I cannot imagine something so hurtful happening to someone like you who possesses such a depth of knowledge and unimpeachable integrity. You are the affable, truthful and reassuring centre of calm during this deadly coronavirus storm. Your job is difficult enough without people taking verbal pot-shots every time you speak.

I wish you all the best during this trying time. Stay well (and I hope you don't completely lose your voice, too)! I look forward to seeing and hearing more from you on CNN and other media outlets.

Best wishes,
Nancy Hill
(b) (6)
Canada

Sent from my iPhone

(b)(5) - PCP

[redacted]

(b)(5) - PCP

From: [redacted] (b) (6)
Sent: Sun, 29 Mar 2020 11:31:58 -0400
To: Auchincloss, Hugh (NIH/NIAID) [E];DMID Word Nerds
Subject: Fwd: Intro to Tony Fauci

From party

Hugh- I thought u responded to Carmona the former
Surgeon general?

Sent from my iPhone

Begin forwarded message:

> **From:** Richard Carmona <rcarmona@canyonranch.com>
> **Date:** March 29, 2020 at 9:42:33 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)
> **Subject: Fwd: Intro to Tony Fauci**
>
> Tony, first and foremost.... thank u for ur continued leadership and integrity in the " combat zone".
> I know u r drinking from the proverbial fire hose so I would not send anything ur way if I didn't think it may have merit to address our current challenge with Coronavirus.
> I e mail introduced u to this group some time ago. Their science has advanced and in particular there seems to be a potential opportunity to address the sometimes lethal " cytokine storm" in some coronavirus patients as described in the attached e mail.
> So I forward to you for your consideration as an adjunct.
> On a daily basis I receive numerous " ideas" to address coronavirus from many well intended people. A few have merit. Is there a Fed innovation review group that some of these potential ideas could be funneled too?
> I pray for you and your family
> Be well
> Rich
>
> **Richard Carmon**
> **a**
> 17th Surgeon General of The United States
> Chief of Health Innovations
> Distinguished Professor University of Arizon
> a

CANYONRANCH.

8600 E. Rockcliff Road | Tucson, AZ 85750

O: 520.749.7754

M: [redacted] (b) (6)
canyonranch.com

Begin forwarded message:

From: James Thacker <jim_thacker@therimunex.com>
Date: March 29, 2020 at 06:04:40 MST
To: Richard Carmona <rcarmona@canyonranch.com>
Cc: Patricia Maxwell <PMaxwell@canyonranch.com>, "dgrange@ospreyglobalsolutions.com" <dgrange@ospreyglobalsolutions.com>
Subject: Intro to Tony Fauci

External Sender

Dear Rich,

(b) (4)

[redacted]

I hope you and the family are healthy. As you can tell, I am still kickin ass and takin names. □□

Be well and be safe my Brother! DOL!

Sine Pari,

Jim

TherimuneX
DEVELOPING ADVANCED IMMUNOTHERAPIES
James D. Thacker, PhD
President/Founder - Head of Discovery &Science
1250 Sussex TPKE, Unit 647
Mount Freedom, NJ 07970
Cell: (b) (6)
Email: jim_thacker@therimunex.com
URL: www.therimunex.com

Privileged, confidential and/or copyright information may be contained in this e-mail. This e-mail is intended for the sole use of the addressee. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may not copy, forward, disclose or otherwise use this message, or any part of it in any way whatsoever, to do so is prohibited and may be unlawful. If you receive this e-mail by mistake, please advise the sender immediately by using the reply facility in your e-mail software.

From: [redacted] (b) (6)
Sent: Sun, 29 Mar 2020 11:25:38 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Phone Interview- COVID19

Sent from my iPhone

Begin forwarded message:

> **From:** "mtorres8@myseneca.ca" <mtorres8@myseneca.ca>
> **Date:** March 29, 2020 at 11:06:49 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: RE: Phone Interview- COVID19**
>
> Hi Dr. Fauci,
> I'm looking to do a quick 10 minute phone interview on COVID-19. I've seen your interviews on CNN and they are very informative so I think you would be perfect for our podcast.
>
> This would be for a podcast available to faculty and students at Seneca Media Department in Toronto.
>
> Thanks,
>
> Monika Torres
> www.senecajournalism.ca

From: [redacted] (b) (6)
Sent: Sun, 29 Mar 2020 11:24:55 -0400
To: DMID Word Nerds
Subject: Fwd: URGENT ATTN DR FAUCI RE: COVID-19 IDEA FROM AUSTRALIAN GP!
Please just read and see it this has the merit I believe it does!!

Sent from my iPhone

Begin forwarded message:

> **From:** Stevie <stevie@empowerme.enterprises>
> **Date:** March 29, 2020 at 11:18:55 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: URGENT ATTN DR FAUCI RE: COVID-19 IDEA FROM AUSTRALIAN GP! Please just read and see it this has the merit I believe it does!!**
>
> Dear Sir,
> My GP friend, Dr P'ng is a genius. He has a radical idea for fighting COVID-19. Please find his idea, petition, projections and research attached to the petition. I told him he needed to get this is front of you and Bill Gates. Please consider it. I believe it is viable and the best shot we have. I know you are the expert but I think this is viable way we can help save millions of lives!
> Yours sincerely,
> Stephanie
> Stephanie Russell-Farnham
> Founder &CEO
> EmpowerME Enterprises
> M [redacted] (b) (6)
> E stevie@empowerme.enterprises
>
> > https://www.change.org/p/world-health-organisation-help-defeat-covid-19-save-the-world?recruiter=1066780682&utm_source=share_petition&utm_medium=facebook&utm_campaign=share_petition&utm_term=share_petition&recruited_by_id=40795060-71ab-11ea-a9f8-13e6b487f548&utm_content=starter_fb_share_content_en-au%3Av11

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 29 Mar 2020 11:23:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: New Zealand interview request

fyi

From: Pat Brittenden <info@blindfish.media>
Sent: Sunday, March 29, 2020 7:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: New Zealand interview request

Hey Dr Fauci,

Am wondering if you would be interested in having a chat with us in NZ, over Zoom, as we all sit in our houses fighting Coronavirus

I do a podcast which is normally live streamed but we currently have a country wide lockdown and lots of us have moved our gear home to continue providing content for people who are stuck in their homes

the US is like out big brother, we love you guys and would like to connect in solidarity about COVID19 so I'm hoping that maybe you could find us sometime to have a chat over the internet. Some content would also help us give some more content to Kiwi's who have gotten to the end of Netflix ;)

Find out more about the podcast at www.theDOC.nz and more about me at www.patbrittenden.com/about

Can make anytime happen, fingers crossed we'll hear back from 'someone'.

Pat Brittenden
www.theDOC.nz
www.patbrittenden.com/about
(b) (6)

From: [redacted] (b) (6)
Sent: Sat, 28 Mar 2020 19:01:58 -0400
To: Idonae Lovetrue
Subject: Re: COVID-19 aetiology and treatment for critically ill patients: irinotecan+etoposide

Thank you for your note
AS Fauci

Sent from my iPhone

> On Mar 28, 2020, at 6:36 PM, Idonae Lovetrue <idonae@demiurge.technology>wrote:
>
> Dear Dr. Fauci,
>
> In addition, I'd like to share with you the following clinically relevant genetic differences between patients in the US and in East Asia:
>
> [redacted] (b) (4)
>
> Please find attached dosage recommendation and my team is standing by if you need any further assistance.
>
> Sincerely,
> Idonae
>
> **Idonae Lovetrue | CEO, Demiurge Technologies AG, Switzerland**
>
> www.demiurge.technology
>
> --
>
> This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto. This email is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. While some information used on this document may have been obtained from

various published and unpublished sources considered to be reliable, Demiurge Technologies AG neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use.Thank you.

From: Idonae Lovetrue <idonae@demiurge.technology>
Date: Saturday, 28 March 2020 at 15:53
To: [redacted] (b) (6)
Subject: COVID-19 aetiology and treatment for critically ill patients: irinotecan+etoposide

Dear Dr. Anthony S Fauci,

This is Idonae, CEO at Demiurge Technologies AG, a Swiss AI-biopharma company making accurate and rapid drug discoveries for diseases with limited available clinical data. We are committed to the non-profit dissemination of our COVID-19 discoveries to the public to facilitate the search for COVID-19 effective treatments.

SARS-CoV-2 is fundamentally different from all the other viruses that the world has hitherto known, so treatments must be rationally designed to avoid fueling the adaptive mutation and the latent infection of SARS-CoV-2.

Demiurge is the world's first company that has discovered the detailed aetiology of COVID-19 that consistently explains the clinical features of COVID-19 and the McA-based scientific rationale of the candidate treatments for COVID-19 (https://www.preprints.org/manuscript/202003.0341/v1).

[redacted] (b) (4)

(b) (4)

[redacted]

Thank you for your consideration and my team is standing by for any further assistance.

Sincerely,
Idonae

Idonae Lovetrue | CEO, Demiurge Technologies AG, Switzerland

www.demiurge.technology

--

This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto. This email is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. While some information used on this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge Technologies AG neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use.Thank you.

<mime-attachment>

From: [redacted] (b) (6)
Sent: Sat, 28 Mar 2020 17:58:32 -0400
To: Hallett, Adrienne (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E];Wolinetz, Carrie (NIH/OD) [E];Shapiro, Neil (NIH/OD) [E];Lauer, Michael (NIH/OD) [E]
Subject: Re: Brad Sherman

Thanks to everyone.

> On Mar 28, 2020, at 5:32 PM, Hallett, Adrienne (NIH/OD) [E] <[redacted] (b) (6)>wrote:
>
> Thanks Francis. I just spoke to his Deputy Chief of Staff [redacted] (b) (6)
>
> [redacted] (b) (5)
>
> I'll share what I see when I see it.
> Adrienne
>
>> On Mar 28, 2020, at 2:27 PM, Collins, Francis (NIH/OD) [E] [redacted] (b) (6):
>>
>> Hi Adrienne,

I spoke with Brad Sherman (D-CA) yesterday. He had originally reached out to Tony, and Cliff Lane spoke to him Thursday, but I stepped in to try to lift one task off of Tony's plate.

(b) (5)

[redacted]

He said he is sending a letter to Tony and me, asking what we need to go flat out against COVID-19. He wanted to know who from my office his staff could work with. I said you!

Francis

From: [redacted] (b) (6)
Sent: Sat, 28 Mar 2020 17:31:25 -0400
To: Jiaxian Zhou Wu
Subject: Re: Thank you for your service!

Many thanks for your kind note.

> On Mar 28, 2020, at 4:40 PM, Jiaxian Zhou Wu [redacted] (b) (6)> wrote:
>
>
> Dear Dr.Fauci,
>
> I am writing this email to personally thank you for your invaluable service to our country, The United States of America. This virus, COVID-19, is really dangerous and I am very scared of it. I am really worried about my country, about the countless deaths . Your advice to the president has proven really important to prevent the spread of the disease, however, in this nation, there is another epidemic based on lies and self-interest , now the people behind the fake news are targeting to you, one example is the post of an email that relates to you with the former Secretary of State, Hillary Clinton. This is why I decided to write a letter of support, I am sick of fake news,personal attacks and violation of the First Amendment , the right to have an opinion,to civil servants serving this country.
>
> I am still young but I still want to live in a United country. I ask you to continue your job, I want you to know that most Americans regardless of ideology are grateful of your service and sacrifice . A virus does not understand boundaries nor ideology , I am not an expert on this topic nor the president and politicians. Please guide us with the truth in these dire and dark days.

From: [redacted] (b) (6) (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 19:43:52 +0000
To: [redacted] (b) (6)
Subject: RE: medRxiv: Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients

[redacted] (b) (6)

Thanks for the note. [redacted] (b) (6)

[redacted] (b) (6)

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)>
Sent: Friday, March 27, 2020 2:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: medRxiv: Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients

Hi Tony,

Thanks for the update. All of this early science is certainly confusing - (b) (6) Much the same thing that we are hearing from Am College of Cardiology. I appreciate your keeping me informed.

How are you doing? (b) (6)

Best,
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Friday, March 27, 2020 1:29 PM
To: (b) (6)>
Subject: [EXTERNAL] FW: medRxiv: Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients

** ATTENTION: This email originated from outside the MedStar network.
** DO NOT CLICK links or attachments unless you recognize the sender and know the content is safe.

(b) (6):

See below. The situation continues to get more complicated.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients

Yingxia Liu, Fengming Huang, Jun Xu, Penghui Yang, Yuhao Qin, Mengli Cao, Zhaoqin Wang, Xiaohe Li, Shaogeng Zhang, Lu Ye, Jingjun Lv, Jie Wei, Tuxiu Xie, Hong Gao, Kai-Feng Xu, Fusheng Wang, Lei Liu, Chengyu Jiang

doi: https://doi.org/10.1101/2020.03.20.20039586

This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should *not* be used to guide clinical practice.

- Abstract
- Info/History
- Metrics
-
-
- Preview PDF

Abstract

Summary Background The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak started at the end of 2019 in Wuhan, China, and spread over 100 countries. SARS-CoV-2 uses the membrane protein Angiotensin I converting enzyme 2(ACE2) as a cell entry receptor. Indeed, it was reported that the balance of Renin-Angiotensin System (RAS), regulated by both ACE and ACE2, was altered in COVID-19 patients. It is controversial, however, whether commonly used anti-hypertensive drugs Angiotensin I converting enzyme inhibitor (ACEI) and Angiotensin II receptor blocker (ARB) shall be continued in the confirmed COVID-19 patients. This study was designed to investigate any difference in disease severity between COVID-19 patients with hypertension comorbidity. The included COVID-19 patients used ACEI, ARB, calcium channel blockers (CCB), beta blockers (BB), or thiazide to treat preexisting hypertension prior to the hospital were compared to patients who did not take any of those drugs. Methods In this multicentre retrospective study, clinical data of 511 COVID-19 patients were analyzed. Patients were categorized into six sub-groups of hypertension comorbidity based on treatment using one of anti-hypertension drugs (ACEI, ARB, CCB, BB, thiazide), or none. A meta-analysis was performed to evaluate the use of ACEI and ARB associated with pneumonia using published studies. Findings Among the elderly (age>65) COVID-19 patients with hypertension comorbidity, the risk of COVID-19-S (severe disease) was significantly decreased in patients who took ARB drugs prior to hospitalization compared to patients who took no drugs (OR=0.343, 95% CI 0.128-0.916, p=0.025). The meta-analysis showed that ARB use has positive effects associated with morbidity and mortality of pneumonia. Interpretation Elderly (age>65) COVID-19 patients with hypertension comorbidity who are taking ARB anti-hypertension drugs may be less likely to develop severe lung disease compared to patients who take no anti-hypertension drugs. Funding National Natural Science Foundation of China, Chinese Academy of Medical Sciences

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

MedStar Health is a not-for-profit, integrated healthcare delivery system, the largest in Maryland and the Washington, D.C., region. Nationally recognized for clinical quality in heart, orthopaedics, cancer and GI.

IMPORTANT: This e-mail (including any attachments) may contain information that is private, confidential, or protected by attorney-client or other privilege. If you received this e-mail in error, please delete it from your system without copying it and notify sender by reply e-mail, so that our records can be corrected... Thank you.

Help conserve valuable resources - only print this email if necessary.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 19:26:52 +0000
To: Real.Francisco
Subject: RE: A thank you note

Paco:
Thank you for your kind note.
Warm regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Real.Francisco <freal@cnio.es>
Sent: Saturday, March 28, 2020 3:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: A thank you note

Dear Tony,

please allow me to call you Tony as I feel somewhat close to you (although there is no reason why you should remember me). In early 1981 I was doing a clinical fellowship in Immunology/Oncology at Memorial Sloan-Kettering Cancer Center and wrote to you [redacted] (b) (6) During my period at Memorial I worked extensively on AIDS and Kaposi's sarcoma... and ever since - I moved in 1988 to Spain, my home country - I have followed and admired your work.

[redacted] (b) (6) I always felt close to you and your amazing work. Now, when I see you taking care of your country's action against Covid-19, I am proud to have been attracted and inspired by your work in biomedical research and I am proud of what we - physician-scientists - can do for your societies and for human beings.

From my very modest end as a human being, thanks for your responsible, honest, scientific leadership.

Best wishes, we need people like you

Francisco X. Real (Paco)

Epithelial Carcinogenesis Group
Molecular Oncology Programme
Centro Nacional de Investigaciones Oncológicas
Melchor Fernández Almagro, 3
28029-Madrid (Spain)
Phone +34 917328000 ext 3660
E-mail preal@cnio.es

www.cnio.es

HAZTE AMIGO/A
DEL CNIO

más INVESTIGACIÓN
menos CÁNCER

Fb Hazte Amigo del CNIO | **Tw** @HazteAmigoCNIO | **Youtube** canalcnio

ADVERTENCIA LEGAL: Este correo electrónico, y en su caso los ficheros adjuntos, pueden contener información protegida para el uso exclusivo de su destinatario. Se prohíbe la distribución, reproducción o cualquier otro tipo de transmisión por parte de otra persona que no sea el destinatario. Si usted recibe por error este correo, se ruega comunicarlo al remitente y borrar el mensaje recibido.
De conformidad con lo dispuesto en el Reglamento (UE) 2016/679 relativo a la protección de los datos personales de las personas físicas, la información personal que nos pueda facilitar a través de este correo electrónico quedará registrada por la Fundación CNIO con la finalidad de tramitar el objeto del presente correo electrónico. El tratamiento de sus datos personales se encuentra legitimado por ser necesario para gestionar el objeto del presente mensaje. Estos datos personales no serán comunicados a ningún destinatario salvo a aquellos que usted nos autorice o así venga exigido por una ley. Ud. podrá

ejercer los derechos de acceso, rectificación, supresión, limitación de tratamiento, portabilidad y oposición en la siguiente dirección: c/Melchor Fernandez Almagro 3, 28029 (Madrid). Podrá ponerse en contacto con el Delegado de Protección de Datos en: delegado_lopd@cnio.es. Para el caso de que Ud. precise conocer información adicional sobre el tratamiento de sus datos personales, puede consultar dicha información adicional en el siguiente enlace dentro de nuestra página web: https://www.cnio.es/es/privacidad/index.asp

LEGAL NOTICE: This email and any attached files may contain protected information for the sole use of its intended recipient or addressee. Anyone other than the intended recipient or addressee is strictly prohibited from distributing, reproducing or transmitting the email and its contents in any way. If you receive this email in error, please notify the sender and delete the message.
Pursuant to the provisions of EU Regulation 2016/679 regarding the protection of personal data, any personal information you provide through this email will be registered by the CNIO Foundation in order to deal with content of this email. Your personal data must be processed in order to be able to deal with the content and purpose of this message. Your personal details will not be passed on to anyone else unless you authorise us to do so or we are required to do so by law. You may exercise your rights regarding access, rectification, suppression, limitation of processing, portability and opposition by writing to the following address: c/Melchor Fernandez Almagro 3, 28029 (Madrid). You may contact the Data Protection Delegate (Delegado de Protección de Datos) at: delegado_lopd@cnio.es. If you require further information about the processing of your personal data, go to the following link on our webpage: https://www.cnio.es/es/privacidad/index.asp

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 19:00:32 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] [redacted] (b) (6);Harper, Jill (NIH/NIAID) [E];McGowan, Robert (Kyle) (CDC/OD/OCS)
Cc: [redacted] (b) (6)
Subject: FW: Time-Sensitive OSTP Request - Due 12 pm Monday, March 30
Attachments: 2020-03-28_COVID-19 FOAs-Projects.xlsx

Please respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schwetz, Tara (NIH/OD) [E] [redacted] (b) (6)>
Sent: Saturday, March 28, 2020 2:57 PM
To: ICDDIR-L@list.nih.gov
Cc: List DEPDIR-L <DEPDIR-L@list.nih.gov>; NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>; NIH P&E Principals and Alternates <NIHP&EOfficers@mail.nih.gov>; Walsh, Elizabeth (NIH/OD) [E] [redacted] (b) (6)>
Subject: Time-Sensitive OSTP Request - Due 12 pm Monday, March 30
Importance: High

Good afternoon,

We received a time-sensitive request from OSTP that we are asking for your help to complete. Apologies in advance for the short turn-around.

Action – Complete the attached template to provide FOAs and projects on "innovation" and COVID-19, specifically focused on the topics described below. If your ICO has no nothing to report, please let us know.

Requestor – OSTP

[redacted] (b) (5)

POCs and Due Date – Please send the completed template to Elizabeth Walsh (Elizabeth.walsh@nih.gov) by **noon on Monday, March 30**

Timeline –

NIH Receipt Date	**Institute Response to OD Due Date**	**OD Office Review Date**	**NIH Final Response Due Date**
3/28/20	**3/30/20**	3/30/20	3/30/20

Additional Instructions –

- I pulled all the COVID-19 FOAs from the Guide; however, I did not sort through which ones are relevant to this request. Please submit only those that your IC is the lead on that meet the criteria listed above. Delete any that do not apply.

Attachments –

- Response template (FOAs tab, Grants-Contracts tab)

Do let me know if you have any questions.

Best,

Tara A. Schwetz, PhD
Acting Director, NINR
Associate Deputy Director, NIH
A: Building 1, Room 138
P: [redacted] (b) (6) | **M:** [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 18:43:17 +0000
To: [redacted] (b) (6)
Subject: FW: Washingtonian: You Can Now Buy Anthony Fauci Swag

Geeeez

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, March 27, 2020 6:11 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>; [redacted] (b) (6)
Subject: Washingtonian: You Can Now Buy Anthony Fauci Swag

You Can Now Buy Anthony Fauci Swag

T-shirts, mugs, pillows—and, yes, even a Fauci prayer candle.

Written by Daniella Byck
| Published on March 27, 2020



About Coronavirus 2020

Washingtonian is keeping you up to date on the coronavirus around DC.

More from Coronavirus 2020

Fauci stans, assemble! **Dr. Anthony Fauci,** director of the National Institute of Allergy and Infectious Disease, has emerged as *the* celebrity of the coronavirus crisis. Like others before him (remember Mueller mania?), his prominence has yielded buttons, t-shirts, and gifts, all flaunting the Fauci.

Fauci face socks

Another reason you won’t want to wear your shoes inside. *$9.99, Etsy.*

Dr. Anthony Fauci
Fan Club

"Dr. Anthony Fauci Fan Club" button

Fauci-fy any look with this pin. *$3.16, Etsy.*

I Need a Hero

“I need a hero” T-shirt

Paying homage to Fauci *and* Bonnie Tyler? This shirt is working overtime. *$19.99,* *Etsy*.

HONK
FOR
DR.FAUCI

"Honk for Dr. Fauci" lawn sign

A social distancing win: Show your support without leaving the house. *$14.95, Etsy*.

Fauci Prayer Candle

Praying you washed your hands. *$20.20,* *Etsy*.

"Fauci 2020" T-shirt

Finally, a shirt for those White House coronavirus briefings. *$18, Etsy.*

"Hope" sweatshirt

Thanks, Fauci. *$18.99, Amazon.*


KEEP
CALM
AND
WASH
YOUR
HANDS

"Keep calm and wash your hands" mug

A little PSA to go with your morning coffee. *$19.95, Etsy*.

Dr. Anthony Fauci T-shirt

A perfectly acceptable day-to-evening look in your self-quarantine. *$29.00, Esty.*

"I Heart Dr. Fauci" throw pillow

For sweet, scientific dreams. *$20.66, Redbubble.*

Keep Up on DC's Latest Fashions with Our Shopping Newsletter

Fashion finds and deals, and the latest trends for you and your home.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 18:26:42 +0000
To: [redacted] (b) (6)
Subject: FW: Wpost: How the Vietnam War may have changed Anthony Fauci's life

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, March 27, 2020 6:15 PM
Subject: Wpost: How the Vietnam War may have changed Anthony Fauci's life

Opinions

How the Vietnam War may have changed Anthony Fauci's life

Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, speaks with the coronavirus task force at the White House on Tuesday. (Jabin Botsford/The Washington Post)

By Ray Greenberg

March 27, 2020 at 3:34 p.m. EDT

Ray Greenberg is a physician epidemiologist, former executive vice chancellor for health affairs at the University of Texas System and the author of "Medal Winners: How the Vietnam War Launched Nobel Careers."

Americans may have the war in Vietnam to thank for Anthony S. Fauci.

An adviser to six presidents and now the trusted public face of the scientific response to the coronavirus pandemic, Fauci has worked at the National Institutes of Health (NIH) for more than a half-century — beginning in 1968 with a group of doctors cheekily known as Yellow Berets.

During the conflicts in Korea and Vietnam, the U.S. military faced a pressing need for physicians. In 1966, during Fauci's senior year at Cornell University Medical College, a military recruiter came to tell the assembled students: "After you finish medical school, every one of you except the two women will either be in the Air Force, the Army, the Navy, or the Public Health Service." The last option, entering the Public Health Service, entailed assignment at the NIH, the Centers for Disease Control or the Indian Health Service.

Those who were selected to serve at the NIH were known officially as clinical associates, but informally they were referred to as Yellow Berets. Whether the designation was born in jest or derision, it was intended as a foil to the Green Berets of the Army Special Forces. Fauci never liked the label because it implied an unwillingness to serve in harm's way. "As a physician," Fauci said, "I felt if I had to go [to Vietnam], I would gladly do my part to try to help."

The competition for the limited number of Yellow Beret slots was so intense that only the best and brightest young physicians were selected. Fauci, the top graduate in his medical school class, was one of seven chosen from 140 applicants to train in his laboratory of interest. As described in my book "Medal Winners: How the Vietnam War Launched Medical Careers," the class of Yellow Berets that entered with Fauci included four future Nobel laureates: Joseph Goldstein, Michael Brown, Harold Varmus and Robert Lefkowitz.

Each new appointee completed two years of clinical training before arriving at the NIH. Their primary responsibility was learning how to conduct basic research under the guidance of a senior scientist. The second job was to care for patients at the NIH Clinical Center. Fauci and his fellow infectious disease colleagues also helped to care for wounded service members at the nearby National Naval Medical Center.

Fauci, who had some research experience in medical school, trained at the NIH for three years under the tutelage of Sheldon Wolff — a pioneer in the relationship between the immune system and infectious diseases. Following a year of additional clinical training back in New York, Fauci returned to the NIH as a senior scientist conducting pioneering work, first on autoimmune conditions, then transitioning to study the newly emerging disease that would become known as AIDS.

When he entered the clinical associate program, Fauci's ambition was to become a medical school professor. Had the Vietnam War not brought him to the NIH, Fauci probably would have remained in academia and the country never would have benefited from his extraordinary public service.

Instead, from his position as director of the National Institute of Allergy and Infectious Diseases, Fauci has helped shape national policies related to HIV, bioterrorism and a series of pandemic threats including avian influenza, H1N1 (swine) influenza, Ebola and severe acute respiratory syndrome. It is hard to imagine any other physician who has had such a sustained and profound impact on the health of our nation.

While Fauci remained at the NIH for his entire professional career, most of his fellow Yellow Berets left Bethesda after their training was completed and headed for jobs at universities. Across the nation, the former Yellow Berets became medical school scientists, department chairs and deans. More than 60 former clinical associates, including Fauci, were elected to the prestigious National Academy of Sciences, and he also was one of the more than 125 Yellow Beret alumni elected to the Institute of Medicine (now the National Academy of Medicine). In addition, Fauci was one of 10 alumni to receive the National Medal of Science.

For all the scars left by the Vietnam War, we should not overlook the fact that in its absence, 50 years later the country would probably not have Anthony Fauci guiding us through our current crisis. Dr. Fauci, we salute you and your fellow Yellow Berets.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 17:52:04 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Dr. Fauci hits and requests

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, March 27, 2020 6:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Dr. Fauci hits and requests

[redacted] (b) (5)

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Friday, March 27, 2020 6:23 PM
To: O'Malley, Devin M. EOP/OVP <[redacted] (b) (6)>
Subject: RE: Dr. Fauci hits and requests

Devin – [redacted] (b) (5)

[redacted] (b) (5)

From: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, March 27, 2020 6:18 PM

To: O'Malley, Devin M. EOP/OVP [redacted] (b) (6); Love, Kelly A. EOP/OVP [redacted] (b) (6)>; Henning, Alexa A. EOP/WHO <[redacted] (b) (6)>; Bowman, Lauren K. EOP/WHO [redacted] (b) (6); Porter, Macaulay V. EOP/OVP [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6); Hall, Bill (HHS/ASPA) [redacted] (b) (6)>; Murphy, Ryan (OS/ASPA) <[redacted] (b) (6)>
Subject: RE: Dr. Fauci hits and requests

Thanks, Devin. We have declined and scheduled as you advised. Below is an updated list and schedule.

Friday 3/27
- Pittsburgh, PA (also airs in OH and WV) – Bloomdaddy radio - 634 am live hit completed
- Baton Rouge, LA – Morning News w/ Brian Haldane - 7:05 am live hit completed

Saturday 3/28
Showtime Desus and Mero – taping at 2 p.m. scheduled

Sunday 3/29
CNN State of the Union – live hit 9:15 a.m. scheduled

Monday 3/30
- AppleTV+ Oprah – tape 11:30 a.m. scheduled
- Radio – Rantz show Seattle – 8 p.m. live hit scheduled
- Radio – John/Ken show California – 8:30 p.m. live hit scheduled

Tuesday 3/31
- CBS The Late Show with Stephen Colbert – tape 11 a.m. scheduled
- CNN Coronavirus podcast with Sanjay Gupta – tape 12 noon scheduled
- Wall Street Journal The Journal Podcast – tape 1 p.m. ET

Wednesday 4/1
New York Times The Daily podcast – tape 12 noon scheduled

[redacted] (b) (5)

Thanks,
Jen

Jennifer Routh [E]

News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Malley, Devin M. EOP/OVP (b) (6)
Sent: Thursday, March 26, 2020 6:58 PM
To: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Love, Kelly A. EOP/OVP (b) (6)>; Henning, Alexa A. EOP/ (b) (6) Bowman, Lauren K. EOP/WHO (b) (6); Porter, Macaulay V. EOP/OVP (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Hall, Bill (HHS/ASPA) (b) (6) Murphy, Ryan (OS/ASPA) (b) (6)
Subject: RE: Dr. Fauci hits and requests

Yellow means schedule
Green means let's revisit
Crossed out means please decline

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Thursday, March 26, 2020 6:52 PM
To: O'Malley, Devin M. EOP/OVP (b) (6)>; Love, Kelly A. EOP/OVP (b) (6); Henning, Alexa A. EOP/WHO (b) (6); Bowman, Lauren K. EOP/WHO (b) (6)>; Porter, Macaulay V. EOP/OVP (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] < (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] < (b) (6)>; Hall, Bill (HHS/ASPA) (b) (6)>; Murphy, Ryan (OS/ASPA) < (b) (6)>
Subject: RE: Dr. Fauci hits and requests

Good evening –

Below is a list of pending hits and requests for Dr. Fauci:

Thursday 3/26

- WTOP – 6:10 a.m. completed
- NPR Morning Edition – 7:07 a.m. completed
- YouTube content creator interviews – 11 a.m. completed.

  - The content creators will publish the interviews on YouTube over the next few days. We expect Trevor Noah will publish tonight.
- Instagram Live video with Steph Curry – 1 p.m. completed
- CNN Town Hall – scheduled 8 p.m. live

Friday 3/27

- Pittsburgh, PA (also airs in OH and WV) – Bloomdaddy radio - 634 am live hit scheduled
- Baton Rouge, LA – Morning News w/ Brian Haldane - 7:05 am live hit scheduled

(b) (5)

[redacted]

[redacted] (b) (5)

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Malley, Devin M. EOP/OVP [redacted] (b) (6)
Sent: Wednesday, March 25, 2020 9:24 PM
To: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Love, Kelly A. EOP/OVP [redacted] (b) (6)>; Henning, Alexa A. EOP/WHO [redacted] (b) (6)>; Bowman, Lauren K. EOP/WHO [redacted] (b) (6); Porter, Macaulay V. EOP/OVP [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Hall, Bill (HHS/ASPA) [redacted] (b) (6)>; Murphy, Ryan (OS/ASPA) < [redacted] (b) (6)>
Subject: RE: Dr. Fauci hits and requests

[redacted] (b) (5)

From: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Wednesday, March 25, 2020 5:07 PM
To: O'Malley, Devin M. EOP/OVP [redacted] (b) (6); Love, Kelly A. EOP/OVP

[redacted] (b) (6) Henning, Alexa A. EOP/WHO [redacted] (b) (6)>;
Bowman, Lauren K. EOP/WHO [redacted] (b) (6)>; Porter, Macaulay V. EOP/OVP
[redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E]
[redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Hall, Bill
(HHS/ASPA) [redacted] (b) (6)>; Murphy, Ryan (OS/ASPA) [redacted] (b) (6)
Subject: RE: Dr. Fauci hits and requests

Good evening –

Below is a list of pending hits and requests for Dr. Fauci. Flagging a few new inquiries:

(b) (5)
[redacted]

Wednesday 3/25

- Bob Rose Radio Show - Gainsville Fl – 6:33 am live hit – completed
- Bernie and Sid Radio Show – NYC – 7:05 am live hit – completed
- CNN Cuomo – scheduled live hit 9:05 p.m.

Thursday 3/26

- WTOP – scheduled live hit 6:10 a.m.
- NPR Morning Edition – scheduled live hit 7:07 a.m.
- YouTube content creator interviews – scheduled 11 a.m.
- Instagram Live video with Steph Curry – scheduled remote conversation 1 p.m.
- CNN Town Hall – scheduled 8 p.m. live

Podcasts:

(b) (5)
[redacted]

[redacted] (b) (5)

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E]
Sent: Tuesday, March 24, 2020 8:00 PM
To: 'O'Malley, Devin M. EOP/OVP' <[redacted] (b) (6)>; 'Love, Kelly A. EOP/OVP' [redacted] (b) (6)>; 'Henning, Alexa A. EOP/WHO' [redacted] (b) (6)>; 'Bowman, Lauren K. EOP/WHO' [redacted] (b) (6)>; 'Porter, Macaulay V. EOP/OVP' [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Hall, Bill (HHS/ASPA) [redacted] (b) (6); Murphy, Ryan (OS/ASPA) <[redacted] (b) (6)
Subject: RE: Dr. Fauci hits and requests

[redacted] (b) (5)

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E]
Sent: Tuesday, March 24, 2020 7:48 PM
To: O'Malley, Devin M. EOP/OVP [redacted] (b) (6)>; Love, Kelly A. EOP/OVP [redacted] (b) (6); Henning, Alexa A. EOP/WHO [redacted] (b) (6)>; Bowman, Lauren K. EOP/WHO [redacted] (b) (6)>; Porter, Macaulay V. EOP/OVP [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Hall, Bill (HHS/ASPA) [redacted] (b) (6)>; Murphy, Ryan (OS/ASPA) < [redacted] (b) (6)
Subject: RE: Dr. Fauci hits and requests

[redacted] (b) (5)

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Malley, Devin M. EOP/OVP [redacted] (b) (6)
Sent: Tuesday, March 24, 2020 7:41 PM
To: Love, Kelly A. EOP/OVP [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Henning, Alexa A. EOP/WHO [redacted] (b) (6)>; Bowman, Lauren K. EOP/WHO [redacted] (b) (6)>; Porter, Macaulay V. EOP/OVP [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Hall, Bill (HHS/ASPA) [redacted] (b) (6)>; Murphy, Ryan (OS/ASPA) [redacted] (b) (6)>
Subject: RE: Dr. Fauci hits and requests

[redacted] (b) (5)

From: Love, Kelly A. EOP/OVP [redacted] (b) (6)>
Sent: Tuesday, March 24, 2020 7:34 PM
To: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Henning, Alexa A. EOP/WHO [redacted] (b) (6); Bowman, Lauren K. EOP/WHO [redacted] (b) (6); Porter, Macaulay V. EOP/OVP [redacted] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] < [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Hall, Bill (HHS/ASPA) [redacted] (b) (6)>; Murphy, Ryan (OS/ASPA) < [redacted] (b) (6)>; O'Malley, Devin M. EOP/OVP [redacted] (b) (6)>
Subject: RE: Dr. Fauci hits and requests

[redacted] (b) (5)

From: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, March 24, 2020 7:26 PM
To: Love, Kelly A. EOP/OVP [redacted] (b) (6)>; Henning, Alexa A. EOP/WHO < [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] < [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Hall, Bill (HHS/ASPA) [redacted] (b) (6)>; Murphy, Ryan (OS/ASPA) [redacted] (b) (6)>
Subject: Dr. Fauci hits and requests

Good evening –

Below is an updated list of the hits and pending requests for Dr. Fauci. [redacted] (b) (5) (b) (5)

Tuesday 3/24

- 7 am firm live hit Chris Stigall Radio Show (Philly) – completed
- WMAL in WDC – completed
- 10 pm live with Laura Ingraham truck from his house - scheduled

Wednesday 3/25

- Bob Rose Radio Show - Gainsville Fl – 6:33 am live hit – scheduled
- Bernie and Sid Radio Show – NYC – 7:05 am live hit – scheduled
- WTOP – working to schedule
- NPR Morning Edition – working to schedule

[redacted] (b) (5)

[redacted] (b) (5)

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 17:17:12 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Proposta da un medico ricercatore italiano per arginare l'infezione da Coronavirus

Bob:

Can you figure out a way to get this translated so that we can figure out what he wants and whether we can help him.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: sandragiudici@libero.it <sandragiudici@libero.it>
Sent: Saturday, March 28, 2020 1:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Proposta da un medico ricercatore italiano per arginare l'infezione da Coronavirus
Importance: High

Egregio Professor Fauci,

[redacted] foreign language

foreign language

[redacted]

foreign language

[redacted]

dott.ssa Sandra Liliana Giudici

Oggetto: Proposal from an Italian research doctor to stem the Coronavirus infection

Dear Professor Fauci,

I'm an Italian research doctor, with a qualification in Internal Medicine, who trained at the Polyclinic Hospital of Milan.

(b) (4)

[redacted]

(b) (4)

[redacted]

(b) (4)

[redacted]

I'm very grateful for the precious time and for the attention that You will want to devote to my "application hypothesis". Trusting in Your kind reply, I send my best regards.

dr. Sandra Liliana Giudici

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 17:15:57 +0000
To: Janet Tobias
Cc: Conrad, Patricia (NIH/NIAID) [E]; [redacted] (b) (6)
Subject: FW: Update on Film details, Task Force conversations, etc.

Janet:

Thanks for the note to Patty. We can do some of #4 below. Patty will contact you and we can also chat by phone today to update me on details. As you might imagine, thing are very hectic and the most important thing is for me to get my job done. And so we will do what we can but may not be able to do everything that you would like. I look forward to speaking with you later.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, March 28, 2020 7:28 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: Update on Film details, Task Force conversations, etc.

Sent from my iPhone

Begin forwarded message:

> **From:** Janet Tobias <janet@ikanamedia.com>
> **Date:** March 28, 2020 at 7:24:48 AM EDT
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>

Cc: "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)>, "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: Update on Film details, Task Force conversations, etc.

Hi Patty: A few important updates. And a request for this weekend/Sunday.

(b) (4)
[redacted]

2) We have been working with John Burklow/Dr. Collins/HHS on access to the Task Force. The Task Force came back to us and asked us for more details about our approach, we gave them a written description of the overall approach of documenting for history the role of the Task Force, it's leadership, NIH, NIAID, and Dr. Fauci. Burklow is working with us on this.

3) Could I have a ten minute phone conversation with Dr. Fauci this weekend, important—I think—to update him on details personally.

4) We would like, if possible to start filming with Dr. Fauci this weekend. Could we film Dr. Fauci exiting his house and going to the live truck for Sunday morning interviews and then going back home or off to the WH. We would then match that in the film with the feed from the truck of him sitting down and get archive from the shows he appears. We are close by. Zac (DP, who Dr. Fauci knows) has been in complete self-quarantine for two weeks before he left New York State and we are now here a week. He is completely good by self-quarantine rules for above filming.

Thanks to the three of you for the work. The communication is life-saving. I have a couple of close friends on the frontline and they asked me to relay how deeply grateful they are for the work you are all doing.

Janet

On Mar 24, 2020, at 3:38 PM, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6) wrote:

Hi Janet

I gave him a hardcopy of your email earlier today...he does have it – we had to add some meetings at the WH prior to his Task Force meeting so I know he was a bit distracted..

Will keep trying...

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Janet Tobias <janet@ikanamedia.com>
Sent: Monday, March 23, 2020 9:26 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Here and working

Hi Patty:

Zac and I are here and situated. I know you are drinking through ten firehoses. I want to preserve sleep and health for Dr. Fauci. But it would be fantastic to have a 15 minute video (with distancing) Q and A in the garden of his house or in the house this week--- what he is working on just scientifically—vaccines, treatments, disease understanding. I want to capture the focus and urgency of the real time scientific work on COVID-19. If we need to we can figure out how to do it with audio, but would love to see if we could do this in 15 minutes on video. Again, anytime this week.

Thanks,

Janet

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 17:00:15 +0000
To: Auchincloss, Hugh (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E]
Cc: [redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: NIAID-NIBIB discussion
Attachments: COVID_ICD_Tromberg.pptx

Hugh/Emily:

Please handle this and respond to Bruce for me.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tromberg, Bruce (NIH/NIBIB) [E] [redacted] (b) (6)
Sent: Saturday, March 28, 2020 10:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Heemskerk, Jill (NIH/NIBIB) [E] [redacted] (b) (6)>; George, David (NIH/NIBIB) [E] [redacted] (b) (6)>
Subject: NIAID-NIBIB discussion

Hi Tony, Hugh, and Emily
Hope you are doing well and getting a chance to pause (especially Tony!) after another breathless sprint of a week.

The NIBIB community has unique capacity to design, build, and deploy an array of powerful biomedical technologies. Much of our attention over the past year has been on early disease detection and prevention, and the integration of digital/personal health with conventional medicine. The COVID-19 crisis seems to have many challenges that are ideally matched for our capabilities. With the $60M NIBIB will receive in the supplement, we are in a unique position to make a contribution.

I am hoping we can meet with you to refine ideas and coordinate as we develop mechanisms to marshal these resources. Your insight will play an essential role in helping us move forward wisely. NIBIB has never received anything remotely like this before and we are in unfamiliar territory. I think it reflects, in part, the confidence---and hope, that people have in advanced technologies to change lives. We are determined to convert these dollars into tangible methods and devices and need your help in optimizing our strategy.

I am forwarding my slide from the science presentation on Wednesday and my follow up email to Francis and Larry to give you a sense of our direction (apologies for the information blast!). We have also been drafting a NOSI with several topic areas that I am adding below…note that we are in the process of condensing and refining these to simplify and more closely resemble our pay plan. I had a great conversation with Francis in a follow up call Thursday and he suggested [redacted] (b) (5)

I look forward to your thoughts/comments and hope we (cc'd NIBIB leadership Jill Heemskerk and David George) can schedule a time to talk. Thank you for considering this, I know you are overflowing with emails and requests! If it's easier to just give me a call, my cell is [redacted] (b) (6), I can give you the quick "cliff notes" summary.
Best,
Bruce

[redacted] (b) (5)

From: "Tromberg, Bruce (NIH/NIBIB) [E]" [redacted] (b) (6)> on behalf of "Tromberg, Bruce (NIH/NIBIB) [E]" [redacted] (b) (6)>
Date: Thursday, March 26, 2020 at 7:22 AM
To: "Collins, Francis (NIH/OD) [E]" [redacted] (b) (6)>, "Tabak, Lawrence (NIH/OD) [E]"

[redacted] (b) (6)

Subject: Summary thoughts

Hi Francis and Larry,
Thanks for the opportunity to present yesterday. [redacted] (b) (5)

(b) (5) [redacted]

(b) (5)
[redacted]

Best,
Bruce

Bruce J. Tromberg, Ph.D.
Director
National Institute of Biomedical Imaging and Bioengineering
National Institutes of Health
Building 31, Room 1C14
Bethesda, MD 20892-2281
[redacted] (b) (6)
301-480-0679 - FAX
[redacted] (b) (6)
http://www.nibib.nih.gov

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 16:19:28 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: What's new for 'fauci as' in PubMed

thanks

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, March 28, 2020 11:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: What's new for 'fauci as' in PubMed

Will see to that these are on your cv

From: NLM/NCBI efback <efback@ncbi.nlm.nih.gov>
Sent: Saturday, March 28, 2020 6:17 AM
To: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: What's new for 'fauci as' in PubMed

This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.

Sender's message: Search: fauci as

Sent on Saturday, 2020 March 28
Search: **fauci as**

View complete results in PubMed (results may change over time).

Edit saved search settings, or unsubscribe from these e-mail updates.

PubMed Results

Items 1 - 2 of 2

1 Covid-19 - Navigating the Uncharted.

.

Fauci AS, Lane HC, Redfield RR.
N Engl J Med. 2020 Mar 26;382(13):1268-1269. doi: 10.1056/NEJMe2002387. Epub 2020 Feb 28. No abstract available.
PMID: 32109011 [PubMed - indexed for MEDLINE]
Similar articles

2 Role of T-cell trafficking in the pathogenesis of HIV disease.

.

Cicala C, Arthos J, Fauci AS.
Curr Opin HIV AIDS. 2019 Mar;14(2):115-120. doi: 10.1097/COH.0000000000000529. Review.
PMID: 30601238 [PubMed - indexed for MEDLINE]
Similar articles

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 14:18:32 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Updates, In DC

Email below from Janet Tobias.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

-----Original Message-----
From: Janet Tobias <janet@ikanamedia.com>
Sent: Saturday, March 28, 2020 7:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Updates, In DC

Dear Tony: I sent a note to Patty with updates. Task Force in progress (asked for more information) and we have finalized plans for distribution/release of the film for when this is over next year and we all feel good about being together in a theater. Will now push to do tiny bits of filming and audio a couple of times a week.

Thanks for everything and thanks yesterday for talking to the frontline. Close friends there have asked me to pass on their gratitude.

See you soon and follow Chris' advice about taking care of yourself.

Janet

> On Mar 22, 2020, at 10:19 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
>
> My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov <http://www.coronavirus.gov> for the latest information and guidance related to COVID-19.
>
> Thank you, and best regards.
>
> Anthony S. Fauci, M.D.
>
>
>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 12:29:31 +0000
To: Burklow, John (NIH/OD) [E]
Subject: RE: Great videos!

Thanks, John!

From: Burklow, John (NIH/OD) [E] (b) (6)
Sent: Friday, March 27, 2020 6:32 PM
To: Myles, Renate (NIH/OD) [E] (b) (6)>; Fine, Amanda (NIH/OD) [E] (b) (6); Akinso, Woleola (NIH/OD) [E] (b) (6)>; Olander, Alyson (NIH/OD) [E] (b) (6)>; Cox, Todd (NIH/CIT) [E] (b) (6); Rosado, Andrew (NIH/CIT) [E] (b) (6) Collins, Scott (NIH/CIT) [E] (b) (6) Chen, Josephine (NIH/CIT) [E] (b) (6); Welch, Will (NIH/CIT) [E] <(b) (6)>; Diane Baker (b) (6); Awwad, David (NIH/NIAID) [C] <(b) (6)>; Rice, David (NIH/OD) [E] <(b) (6)>
Cc: Collins, Francis (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6); Norris, Andrea (NIH/CIT) [E] (b) (6); Alboum, Stacie (NIH/CIT) [E] (b) (6)>; Johnson, Alfred (NIH/OD) [E] (b) (6)Prince, Scott (NIH/OD) [E] (b) (6) Chew, Debra (NIH/OD) [E] <(b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6) Billet, Courtney (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Great videos!

Congratulations to all of you who made today's COVID-19 videos a tremendous success! I know there were a lot of quickly moving, intricate parts and it went off flawlessly—all remotely, to boot! Everyone worked as a team, under very tight timelines, and thanks to Renate, who orchestrated the FC Home Edition! I know NIH staff will greatly appreciate the videos—they're chockful of content! And special thanks to Dr. Fauci, who took time out of his "leisurely" day to devote more than an hour to the taping—incredible!

You all make us very proud!

John

From: [redacted] (b) (6)
Sent: Fri, 27 Mar 2020 17:51:23 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Reaching out from Frame/Urgent

Begin forwarded message:

> **From:** Ben Moe <ben@frame.media>
> **Date:** March 27, 2020 at 5:47:50 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Re: Reaching out from Frame/Urgent**
>
> Dear Dr. Fauci,
>
> I hope all goes well. I wanted to quickly follow up and see if you might be free for a quick interview on Monday — it would mean so much to include your voice in the piece.
>
> Is there a time on Monday that might work for you? We can jump on the phone for a 5 - 10 minute call if that works better for you.
>
> Best,
>
> Ben
>
> On Thu, Mar 26, 2020 at 5:10 PM Ben Moe <ben@frame.media>wrote:
>
> > Dear Dr. Fauci,
> >
> > I hope this finds you well and thank you for all the work you are doing. I run the digital magazine, Frame, which publishes interactive documentaries made for mobile phones. We are working on a story about the current effort to create a coronavirus vaccine and would love to interview you for the piece.
> >
> > We've interviewed Regeneron's Chief Scientific Officer, George Yancopoulos, and the piece will tell the story of Regeneron's push to create a coronavirus vaccine in record time. I was hoping you could speak to the broader issue of the often undercovered global threat of diseases and the lack of funding going toward infectious diseases.

Would you potentially be available for a short video interview sometime between 10am - 7pm EST tomorrow? Alternatively, would you be free sometime between 12pm - 2pm or 5pm - 7pm EST on Monday?

Look forward to hearing back and we'd be honored to have your voice in the story.

Here's a brief overview of Frame:

Frame is a newsmagazine that publishes interactive documentaries made for mobile phones. Every Frame story tells a compelling, human story that helps shine a light on a major social or political issue.
Frame stories include interactive features throughout, from maps to timelines, that allow viewers to engage more deeply with the piece. Our stories are delivered through a messaging platform that allows subscribers to have conversations with our journalists and subscribe to news updates on topics they want to follow, all through SMS. Frame has been covered by TechCrunch, Poynter, and Journalism.co.uk, and our investors include Snap Inc.'s Yellow Accelerator.

The very best,

Ben Moe

--

Founder and CEO, Frame
ben@frame.media
@beneliasmoe

--

Founder and CEO, Frame
ben@frame.media
@beneliasmoe

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 27 Mar 2020 17:48:31 +0000
To: Hirsch, Vanessa (NIH/NIAID) [E]
Subject: RE: appreciation

Thanks, Vanessa. I appreciate your note.
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hirsch, Vanessa (NIH/NIAID) [E] (b) (6)
Sent: Friday, March 27, 2020 10:28 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: appreciation

Hi Tony,

I just wanted to express my appreciation for your sane voice during the Covid-19 crisis. Keep up the good work. I know it has to be exhausting.

Best regards,

Vanessa Hirsch
NHPVS, NIAID, NIH

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 27 Mar 2020 15:57:33 +0000
To: Morens, David (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: [redacted] (b) (4)

David:

Provided you [redacted] (b) (6), if you could do this within the next 2 to 3 weeks, that would be great.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Morens, David (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, March 27, 2020 11:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [redacted] (b) (4)

Tony, [redacted] (b) (4), so I will start to think about what might work.

Do you have a hoped-for timetable? We are both overwhelmed, but I will try to do at least a bit daily as long as [redacted] (b) (6). david

From: Morens, David (NIH/NIAID) [E]
Sent: Friday, March 27, 2020 11:24 AM
To: Narasimhan, Sri Devi (ELS-CMA) <srnarasimhan@cell.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>
Subject: RE: Subject: [redacted] (b) (4)

Dear Sri, thank you and we wish you and colleagues well too. These are certainly difficult times for all.

I will discuss again with Tony. [redacted] (b) (4). We'll ponder that some more and get back to you later. Thanks, again, and stay safe

David M. Morens, M.D.
CAPT, United States Public Health Service
Senior Advisor to the Director
Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Building 31, Room 7A-03
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520
☎ [redacted] (b) (6) (assistants: Kimberly Barasch; Whitney Robinson)
📠
💻

Disclaimer: This message is intended for the exclusive use of the recipient(s) named above. It may contain information that is PROTECTED, PRIVILEGED, and/or CONFIDENTIAL, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. All sensitive documents must be properly labeled before dissemination via email. If you are not the intended recipient, any dissemination, distribution, or copying is strictly prohibited. If you have received this communication in error, please erase all copies of the message and its attachments and notify us immediately.

From: Narasimhan, Sri Devi (ELS-CMA) <>
Sent: Thursday, March 26, 2020 9:23 PM
To: Morens, David (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted]
Subject: Re: Subject: [redacted] (b) (4)

Dear Tony and David,

Thank you for writing back. Firstly I would like to say thank you for all that you are doing. On [redacted] (b) (4)

I hope you, your families and colleagues stay safe and healthy through this. Please take care.

I look forward to staying in touch.

Best wishes,
Sri.

Sri Devi Narasimhan, PhD
Deputy Editor, Cell
Cell Press/Reed Elsevier
50 Hampshire St., Cambridge, MA 02139
srnarasimhan@cell.com

From: Morens, David (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, March 26, 2020 4:53 PM
To: Narasimhan, Sri Devi (ELS-CMA) <srnarasimhan@cell.com>
Subject: Subject: [redacted] (b) (4)

Dear Sri, we're responding, at long last, to your invitation to Tony Fauci several weeks back, to [redacted] (b) (4)

First, apologies are in order. We tried to meet about this and get you a quick response the day after you and Tony emailed, but then coronavirus chaos ensued. We had to cancel 5 successive meetings to go over this; in one case minutes before we were to start he got an urgent call to go down to the White Hose asap, and that was that. Few of us in the office have even seen Tony in recent weeks as he is down at the White Hose daily from early morning until late at night.

Finally this morning we sat down and had a relaxed discussion. Assuming you are still interested, [redacted] (b) (4) (b) (4) (b) (4). Crazy times, for sure.

Thank you, I look forward to hearing from you,

<< OLE Object: Picture (Device Independent Bitmap) >>

David M. Morens, M.D.

CAPT, United States Public Health Service
Senior Advisor to the Director
Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Building 31, Room 7A-03
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520
☎ [redacted] (b) (6) stants: Kimberly Barasch; Whitney Robinson)
📠
💻

Disclaimer: This message is intended for the exclusive use of the recipient(s) named above. It may contain information that is PROTECTED, PRIVILEGED, and/or CONFIDENTIAL, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. All sensitive documents must be properly labeled before dissemination via email. If you are not the intended recipient, any dissemination, distribution, or copying is strictly prohibited. If you have received this communication in error, please erase all copies of the message and its attachments and notify us immediately.

<< OLE Object: Picture (Device Independent Bitmap) >>

From: Narasimhan, Sri Devi (ELS-CMA) <srnarasimhan@cell.com>
Sent: Monday, January 27, 2020 4:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: [redacted] (b) (4)

Dear Tony,

I hope all is well. I had the great pleasure of meeting you in person when you were the keynote speaker at our Cell Symposium on Emerging and Re-emerging Viruses in 2017. You then gave a wonderful talk that covered AIDS to Zika and your experiences across different outbreaks, administrations and the challenges you encountered.

[redacted] (b) (4)

My best wishes,
Sri.

Sri Devi Narasimhan, PhD
Deputy Editor, Cell
Cell Press/Reed Elsevier
50 Hampshire St., Cambridge, MA 02139
srnarasimhan@cell.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 27 Mar 2020 15:56:36 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Offering help to fight the Civod-19
Attachments: Presentation Doc-line.pdf

Please check it out and respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Peter Lermen [redacted] (b) (6)
Sent: Friday, March 27, 2020 11:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Offering help to fight the Civod-19

Dear Dr. Fauci,

I don't want you to waste too much time in this stressful situation.

As the doctor in charge of the hygiene of the Berner clinic in Crans-Montana in Switzerland, as well as being in contact with my colleagues in private practice, I see every day how important the need for information and consultation of the population in this situation of insecurity is. At the same time, we are under threat of a shortage of doctors if we have to strictly apply the federal swiss guidelines (Art. 10b and 10c, regulation 2 COVID-19) or if the wave of illness reduces the number of colleagues available for consultations.

[redacted] (b) (4)

Thank you for your time

Good luck

Best regards,

Doc-line

Peter Lermen
MD internal medicine, internal oncological rehabilitation
Co-President oncoreha.ch

(b) (6)
www.doc-line.ch

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 27 Mar 2020 13:30:18 +0000
To: Mascola, John (NIH/VRC) [E]
Subject: FW: Vir update
Attachments: Vir Barda TechWatch_05Mar20_vF.pptx

Please take a look at this and respond if appropriate.. Too long an e-mail for me to tackle. I have 745 others.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Skip Virgin [redacted] (b) (6)>
Sent: Tuesday, March 10, 2020 11:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Vir update

Tony

My apologies for the slow update. You asked that I get back to you after [redacted] (b) (4) and so here I am. Notes in sections.

(b) (4)

[redacted]

(b) (4)

[redacted]

[redacted] (b) (4)

Any advice welcome

Happy to talk [redacted] (b) (6)

Be well and thanks for all of your public work to help us prepare. I wish they listened more.

Skip

Herbert W. 'Skip' Virgin M.D., Ph.D.
Executive Vice President, Research
Chief Scientific Officer
Vir Biotechnology
499 Illinois Avenue
San Francisco CA 94158
he/him/his

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 16:19:31 +0000
To: Giroir, Brett (HHS/OASH)
Cc: Kadlec, Robert (OS/ASPR/IO);Birx, Deborah L [redacted] (b) (6);Lerner, Andrea (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Redd, Stephen (CDC/DDPHSIS/OD)
Subject: FW: Draft of email for ASF to send to Brett Giroir cc'ing Kadlec
Attachments: IMG_2072.mov

Brett:

The proposal below was sent to my office by David Margulies (Harvard/Boston Childrens) who is part of a group of prominent physicians and healthcare executives in Boston developing this idea (David Martin of the Brigham, Gary Gottlieb of Partners and others). See this op-ed they wrote in the Boston Globe yesterday regarding their proposal https://www.bostonglobe.com/2020/03/25/opinion/mass-needs-comprehensive-care-response-coronavirus/).

[redacted] (b) (5)

Can you take a look at this and let me know what you think? [redacted] (b) (5). David Margulies can be contacted directly at [redacted] (b) (6) or [redacted] (b) (6) if you need additional information.

Thanks,
Tony

[redacted] (b) (4), (b) (5)

(b) (4), (b) (5)

[redacted]

David Margulies, M.D.

[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 13:25:30 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR TASK FORCE Consideration -- Some sound thinking on COVID-19

We have been discussing each and every one of these suggestions and they are all on the table for consideration of implementation.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, March 26, 2020 9:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: FOR TASK FORCE Consideration -- Some sound thinking on COVID-19
Importance: High

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Wednesday, March 25, 2020 6:31 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: FOR TASK FORCE Consideration -- Some sound thinking on COVID-19
Importance: High

From: Pierce, William <wpierce@apcoworldwide.com>
Sent: Wednesday, March 25, 2020 4:24 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FOR TASK FORCE Consideration -- Some sound thinking on COVID-19
Importance: High

Patty:

I know Tony is the expert, but I thought this memo would be of interest and perhaps of help to him in his battles.

The attached memo is from Dr. Paul Offit (U of Penn) and a colleague of his David Rubin. Tony may know him, I would not be surprised.

But for you, Paul is one of the country's topic vaccinologists and virologists. Paul developed a vaccine for a deadly disease. I know him well and he's the real deal. Next to Tony he is my go to science source.

Paul in particular is a highly credible, well known national expert.

They wrote this memo on the 19th of March and it has many suggestions that are incredibly smart and I thought tony would want to see this immediately. Paul and David are obviously available to talk asap.

Let me know.

Bill

William Pierce
Senior Director

APCO Worldwide
1299 Pennsylvania Ave, N.W.
Suite 300
Washington, DC 20004

(t) +1 202 659 7931 (m) [redacted] (b) (6)

wpierce@apcoworldwide.com
@apcoworldwide

::::: Learn more about APCO resources available during the COVID-19 outbreak :::::

CONFIDENTIALITY

This email may contain material that is confidential, privileged and/or work product for the sole use of the intended recipient. Any review, reliance or distribution by others or forwarding without express permission is strictly prohibited. If you are not the intended recipient, please contact the sender and delete all copies.

William Pierce
APCO Worldwide
(t) +1 202 659 7931 (m) [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 12:44:24 +0000
Bcc: Crew, Page (NIH/NIAID) [E];Davey, Richard (NIH/NIAID) [E];Doepel, Laurie (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Higgs, Elizabeth (NIH/NIAID) [E];Kuriakose, Safia (NIH) [C];Lerner, Andrea (NIH/NIAID) [E];Nason, Martha (NIH/NIAID) [E];Seam, Nitin (NIH/CC/CCMD) [E];Singh, Kanal (NIH/NIAID) [E];[redacted] (b) (6);Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE);Pau, Alice (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: Memo to NIH/CDC/VA Support Staff for the HHS Panel on COVID-19 Treatment Guidelines

Dear colleagues,

The purpose of this email is to thank-you for agreeing to provide support to the HHS COVID19 Treatment Guidelines Panel. As you are aware clinicians are doing their best to navigate a complicated landscape with little to guide them. I realize everyone is very busy and I appreciate you taking on this additional work at a difficult time.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 10:42:30 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Awwad, David (NIH/NIAID) [C]
Subject: FW: BBC News

Let us see if we can do this from my NIH office today during the day.

From: Chris Foote <chris.foote@bbc.co.uk>
Sent: Thursday, March 26, 2020 5:02 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: BBC News

Hello Dr Fauci

I'm the programme editor of The Nine, a nightly news and current affairs programme on the BBC. I was hoping you could spare ten minutes at some point today (March 26) to speak to us over Skype or FaceTime about the US response the Coronavirus pandemic.

If that's possible, I'll ask one of my producers to arrange it at a time convenient for you.

Chris Foote
Senior Journalist
BBC News

+[redacted] (b) (6)

----

http://www.bbc.co.uk
This e-mail (and any attachments) is confidential and may contain personal views which are not the views of the BBC unless specifically stated.
If you have received it in error, please delete it from your system.
Do not use, copy or disclose the information in any way nor act in reliance on it and notify the sender immediately.
Please note that the BBC monitors e-mails sent or received.
Further communication will signify your consent to this.

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 02:27:28 +0000
To: Joubert, Bonnie (NIH/NIEHS) [E]
Subject: RE: Thank you

Bonnie:
Thanks for the note. Much appreciated.
Best regards,
Tony

From: Joubert, Bonnie (NIH/NIEHS) [E] [redacted] (b) (6)
Sent: Wednesday, March 25, 2020 9:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Thank you

Dear Dr. Fauci,

I just want to say THANK YOU for all that you are doing for the country to address the COVID-19 pandemic. As an epidemiologist at NIEHS, it is inspiring and encouraging to be part of NIH and to have leaders like you involved in the national and global response during this critical time.

Regards,
Bonnie

Bonnie Joubert, MPH, PhD
Population Health Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
Research Triangle Park, NC 27709
Phone: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 17:20:55 +0000
To: Friedmann, Theodore
Subject: RE: George Church interview

Thanks, Ted. I appreciate your note.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Friedmann, Theodore <tfriedmann@health.ucsd.edu>
Sent: Tuesday, March 24, 2020 4:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: George Church interview

Dear Tony: I sent a brief note to my friend Jon Cohen to congratulate him on what I thought was his fine interview with you. In his response, he suggested that I should send a copy to you. I've been a little reluctant to do that because of what I assumed must be a flood of comments and advice that you are getting in your role on the task force. I attach the message to Jon below and I hope that some of the thoughts are useful and maybe a little comforting for you. With my very warmest regards and best wishes,

Ted

Begin forwarded message:

From: Theodore Friedmann <tfriedmann@health.ucsd.edu>
Subject: Re: George Church interview
Date: March 24, 2020 at 12:09:20 PM PDT
To: Jon Cohen <jcohen@aaas.org>

Dear Jon: Greetings from La Jolla. Congratulations on your interview with Tony Fauci. I have to admit that, until a couple of weeks ago, I have been quite critical of Tony's apparent acquiescence with so much dangerous, incorrect and politically motivated misinformation from the administration. I feared that the upside-down explanations from the administration had the effect of destroying the concepts and tenets of epidemiology and even rationalizing a completely wrong concept of communicable disease that holds that it is unnecessary to screen for carriers in an epidemic but only important to screen symptomatic people. That is upside-down from what we all know about dealing with epidemics and has even been endorsed by Trump, Pence and other members of the COVID-19 task force. It seems to have become a new normal concept of communicable disease management. Like so many things in the Trump era, facts and history are thrown out the window and replaced by governmentally espoused but obviously wrong concepts. We assume to be preparing to completely deny established concepts of communicable disease - screen only the prime suspects or the afflicted. In conversations with colleagues here I wondered "where is Tony Fauci?" They suggested that he must be quietly and heroically working hard being the scenes and at his personal peril to educate our leaders rather than correcting them publicly. But I thought that, in desperate times, the public must hear and see clear truth and denials of lies. My concept of heroes are people who act at their personal peril - Rosa Parks, Martin Luther King, Martin Niemöller, Dietrich Bornhoffer, Thankfully, I think that the real Tony Fauci has emerged, obviously to his peril. I wish him good luck and survival. I find myself wondering what the responses will be to Trump's likely premature lifting of isolation and quarantining procedures and if the concept of disobeying illegal and unethical orders will survive the times.

In any event, good interview! By the way, [redacted] (b) (6) . All the best regards,

Ted

On Dec 6, 2018, at 11:17 AM, Jon Cohen <jcohen@aaas.org> wrote:

So good to hear from you and do tell Carl to contact me.

Yes, George has received ample criticism, but my job is to air his views, regardless of what I think. And I like his independent, damn the torpedoes approach. He speaks his mind. As for He, everything about this is bizarre, from ethics to science to PR to regulation.

Best,

Jon

On Dec 6, 2018, at 1:19 PM, Friedmann, Theodore <tfriedmann@ucsd.edu> wrote:

Hello Jon - Greetings from [redacted] (b) (6). It has been a long time since we last connected and talked about gene therapy, etc. and [redacted] (b) (6)

I was very interested to read George Church's troublesome responses in your interview with him in Science and to see his ethical evaluation of He's CCR5 editing experiment in China. I'm not as generous to He as George seems to be and I think that this work is clearly unethical. George inexplicably conjures up the sad history of Jess Gelsinger and the effect of his death on the evolution of the field of gene therapy. Happily, he's right about the fact that gene therapy is now proving itself in a growing list of intractable diseases (underscored by the 2015 Japan Prize). That has happened because studies are now much more carefully designed and carried out. But sadly, we are in an environment in which some people conclude that human medical manipulations - gene therapy, genome editing, stem cell therapy - are ethical as long as they "work". The rationale is, "let's do the study and if it works and doesn't kill or otherwise harm, it's OK". It's not a post-factor evaluation that determines if an instance of human experimentation is ethical and permissible - it is the design of a study that determines if it is ethical or not. George should be reminded of that fact and should re-read the Helsinki declarations or similar codes of human experimentation.

In any event, your interview was fascinating. Best regards,

Ted Friedmann

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 16:59:20 +0000
To: [redacted] (b) (6)
Subject: FW: Developing Control Charts for Covid 3 24 20 with graphs.docx
Attachments: Developing Control Charts for Covid 3 24 20 with graphs.docx

Please take a look at this. What do you think?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Steve Sternberg [redacted] (b) (6)>
Sent: Wednesday, March 25, 2020 8:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Developing Control Charts for Covid 3 24 20 with graphs.docx

Tony,

Here are reconfigured charts which factor in the guidance from mathematicians at Rockefeller. As you can see, the trend in the U.S. is visibly worse. If this pattern holds, we're going to see many more deaths before things get better.

We would be grateful for a comment. Could you offer a perspective? We're going to try to publish today.

Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 15:01:21 +0000
To: DELFRAISSY Jean-francois
Cc: [redacted] (b) (6)
Subject: RE: France situation COVID-19

Jean-Francois:

Thank you for your note. I do not see Yazdan copied on your e-mail, andl so please forward this e-mail to him. The NIH position is that we should preferably make drugs available on randomized, controlled clinical trials and not freely distribute them. There is a strong push in the USA , favored by the President, to make certain of these drugs more widely available outside of an RCT using mechanisms such as "compassionate usage". In the USA, as you know, HC (plaquenil) is an approved drug for malaria as well as for certain autoimmune diseases such as SLE. Thus, physicians can prescribe the drug on an "off label" usage. This likely will be the major modality of distribution of this drug in the USA , at least for the foreseeable future.

I am copying Cliff Lane on this e-mail. Please include him on any further correspondence on this subject.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: DELFRAISSY Jean-francois [redacted] (b) (6)>
Sent: Wednesday, March 25, 2020 10:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: DELFRAISSY Jean-francois [redacted] (b) (6)>
Subject: France situation COVID-19

Hello,

I am once again in service since the global sanitary crisis COVID-19 hit France a couple of weeks ago. I am now leading the Scientific Council for COVID-19, composed of 10 persons, serving the French President , Emmanuel Macron.

The Council was created on March the 10th and we were heavily involved in advisory activities in relation to the President's decision to put the generalized quarantine into force, because we didn't have any better choice.

Firstly

We have a limited number of diagnosis tests, this prevents us from taking up a Korean-like strategy within the next few days. However, by the end of the quarantine (within the following six weeks), we will be able to have a generalisation of the diagnosis test and develop korean-like apps, as well as a strategy for testing and treatment if we have any drugs available by this time. Before this, we will go through a difficult phase in the following weeks, because we won't have enough beds in our care units in some part of France ...

Secondly

On the therapeutic level, Yazdan Yazdanpanah has taken my place and who is now leading REACTing.

Tomorrow morning a french-european medical trial will begin, under the control of the WHO, with 5 arms (placebo/kalatra/kalatra +interferon béta / product of Guilead / hydroxychloroquine alone or in combination for next week).

As you may know, we are currently facing a press buzz since the announcement made by Dr. Raoult about the effectiveness of hydroxy-chloroquine. His data is not particularly convincing. We can distinguish a slight positive signal but it must be confirmed by a well made randomised trial. We also started a monkey-model study with HC and we should have the results by the end of next week. Also a cohort of severe COVID+ patients have been created and some will be treated with HC : we will analyse those results with all the consciousness needed. It will also be possible to do a prevention trial for healthcare professionals and aging people with HC. I have an enormous political pressure to release HC and to give it to everyone but I am currently resisting...

How is the situation in the USA, especially after Trump's announcement ? What is the NIH position ? What will be put into force ?

Thanks for your answer.

I put Yazdan Yazdanpanah in a copy of this email.

Best regard

Pr. Jean-François Delfraissy
Président | *President*
Comité consultatif national d'éthique pour les sciences de la vie et de la santé
National Ethical Consultative Commitee for life sciences and health
Ancien Directeur de l'ANRS | *ANRS former Director*
M [redacted] (b) (6)
T [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 13:57:28 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [redacted] (b) (4)
PANTHEON

Agree. Skip this and please try to get David back on my morning schedule to start working on the original paper that we had agreed upon.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Wednesday, March 25, 2020 9:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [redacted] (b) (4)

[redacted] (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 12:08:27 +0000
To: [redacted] (b) (6)
Subject: RE: with love from Italy

Rita:

Many thanks for your kind note. It is much appreciated.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: rita.apgar@alice.it [redacted] (b) (6)
Sent: Wednesday, March 25, 2020 7:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: with love from Italy

Dear Doctor Fauci. My name is Rita Apgar and if by chance you noticed my last name, as my father said many years ago, '[redacted] (b) (6)!" I have lived in Italy for almost 50 years and the sagacious finger of destiny pointed my way to Italy, the true home of my heart, although not a drop of Italian blood flows through it. But the love of Italy and the Italians pumps through my heart every second of my existence.

That sagacious finger of destiny pointed the way, and I followed it in faith to [redacted] (b) (6) where I had lived. As soon as I set foot for the first time in the house in this funky ghost town of a medieval village, I felt that we belonged together. And, practically speaking, at the time, it was the perfect solution to some weighty personal problems. Heart and mind were in peaceful agreement.

I have a dear friend who is an infectious disease specialist at the hospital in Asti. She is, obviously, extremely busy these days but she took the time to call me Sunday evening and we talked about you. She said to me, " you know, when I was just a graduate student, I was a secret groupie of Dr. Fauci, and once when he was at a meeting or a conference or something (I'm not sure where or when) I was able to ask him a few questions." I was thrilled, of course, since I also try to watch every appearance you make on TV. I will not add anything in this regard.

But I did say to Maria, Doctor Maria Degioanni, "Maria, I want to invite Dr. Fauci to come and visit us for a few days when this crisis is over, God willing and maybe he would come together with [redacted] (b) (6). who has promised to come and visit again after 20 years. We can put them up in the fancy Relais San Damian above Isolalunga where I live and take them out to dinner at Gente di Mare. Dear Doctor Fauci, I like to joke when people ask how we are doing in this time of Covid-19 by saying : A Name, a guarantee: ISOLAlunga= ISOLAtion! Legend says that the Benedictine monks who got into mischief centuries ago were sent here as punishment to work in the olive groves: long isolation. Today it's the perfect place to be with a view of the Mediterranean as well as the Maritime Alps from the kitchen window and hardly a soul to practice social distancing with!
Grazie per esistere as an Italian song goes, "thank you for being you! I would adore getting a reply from you, but realize how miraculous that woudl be! We would be over the moon if you accepted our invitation, at any time and at the drop of a hat!

Sincerely, Rita Apgar

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 10:27:40 +0000
To: Jon LaPook
Subject: FW: Serology for the novel coronavirus

Try Barney Graham at the NIAID VRC. You have interviewed him more than once.

-----Original Message-----
From: Jon LaPook [redacted] (b) (6)>
Sent: Tuesday, March 24, 2020 2:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Serology for the novel coronavirus

Sigh. Who would you suggest I try to interview?
Thanks,
Jon

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, March 24, 2020 1:57 PM
To: Jon LaPook [redacted] (b) (6)>
Subject: Re: Serology for the novel coronavirus

Lots of talk. Not sure about progress

> On Mar 23, 2020, at 6:27 PM, Jon LaPook [redacted] (b) (6)> wrote:
>
> Tony,
> Any progress? Obviously, if we had widespread serologic testing, we could identify people with likely immunity, and put them on the front lines.
> Thanks,
> Jon
>
> Jonathan LaPook, M.D.
> Chief Medical Correspondent, CBS News
> Professor of Medicine
> NYU Langone Health
> Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 02:26:42 +0000
To: [redacted] (b) (6)
Subject: FW: Serology for the novel coronavirus

Cliff:
Who is the most knowledgeable about serologies for COVID-19? If you know, could you please respond to Jon.
Thanks,
Tony

-----Original Message-----
From: Jon LaPook [redacted] (b) (6)>
Sent: Tuesday, March 24, 2020 2:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: RE: Serology for the novel coronavirus

Sigh. Who would you suggest I try to interview?
Thanks,
Jon

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, March 24, 2020 1:57 PM
To: Jon LaPook [redacted] (b) (6)
Subject: Re: Serology for the novel coronavirus

Lots of talk. Not sure about progress

> On Mar 23, 2020, at 6:27 PM, Jon LaPook [redacted] (b) (6)> wrote:
>
> Tony,
> Any progress? Obviously, if we had widespread serologic testing, we could identify people with likely immunity, and put them on the front lines.
> Thanks,
> Jon
>
> Jonathan LaPook, M.D.
> Chief Medical Correspondent, CBS News
> Professor of Medicine
> NYU Langone Health
> Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 01:53:06 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: COVID-19 West Virginia Phenomenon

From: Daniel Ries [redacted] (b) (6)>
Sent: Tuesday, March 24, 2020 8:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: COVID-19 West Virginia Phenomenon

Dear Dr Anthony Fauci

[redacted] (b) (4)

Best regards

Daniel Ries
PhD Food Technology
Massey University
NEW ZEALAND

[redacted] (b) (4)

(b) (4)

[redacted]

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 17:48:57 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: COVID reagent allocation issue

Email response from Jeremy Berg

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Berg, Jeremy [redacted] (b) (6)
Sent: Tuesday, March 24, 2020 1:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: COVID reagent allocation issue

You are welcome, Tony. We appreciate anything that you can do with regard to the reagent allocation issue. The view from the trenches is pretty stark.

Keep up the good work and do not hesitate to reach out to me if I can be helpful in any way.

Best, Jeremy

Jeremy M. Berg, Ph.D.
University of Pittsburgh
Associate Senior Vice Chancellor for Science Strategy and Planning
in the Health Sciences
Professor of Computational and Systems Biology
Scaife Hall, S304
3550 Terrace Street
Pittsburgh, PA 15213
(b) (6)
[redacted] (cell)

From: Anthony Fauci [redacted] (b) (6)>
Date: Tuesday, March 24, 2020 at 1:44 PM
To: Jeremy Berg [redacted] (b) (6)>
Cc: "Lerner, Andrea (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: Re: COVID reagent allocation issue

Thanks, Jeremy

> On Mar 23, 2020, at 9:00 PM, Berg, Jeremy [redacted] (b) (6)> wrote:
>
> Dear Tony: I am sure you are overwhelmed, but I think it is important to share the attached with you (which will be sent to you directly through regular channels). [redacted] (b) (6)is a pathologist who is in charge of testing in a large medical system in Rochester, New York, who has been extremely concerned and frustrated by the lack of access to reagents for the Roche coronavirus testing platform. They have the platform but cannot use it because of a lack of reagents (which were apparently pre-purchased by Quest, LabCorp, and other national groups). The turnaround time for Quest is approximately 5 days and this is completely useless for making clinical decisions about admission compared with local testing with 24 hour per around time.
>
> Thank you for your attention and for everything that you are doing to help our country through this great challenge.
>
> Best, Jeremy
>
> P.S. I enjoyed the interview with you in *Science* and admire your clarity of purpose.
>
> Jeremy M. Berg, Ph.D.
> University of Pittsburgh
> Associate Senior Vice Chancellor for Science Strategy and Planning
> in the Health Sciences
> Professor of Computational and Systems Biology
> Scaife Hall, S304
> 3550 Terrace Street
> Pittsburgh, PA 15213
> [redacted] (b) (6)

(b) (6) (cell)
(b) (6)

<Fauci-Rochester-Reagents.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 16:27:17 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: You may be able to help ....

Linda is a former NIH Institute Director. Please figure out what she is talking about and respond to her on my behalf

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birnbaum, Linda (NIH/NIEHS) [V] [redacted] (b) (6)>
Sent: Tuesday, March 24, 2020 12:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: You may be able to help ....

Hi Tony,

Thank you for your tireless efforts to clearly communicate about the pandemic, including correcting the President when necessary. You do it in such a non-threatening and respectful style. I think everyone appreciates it.

[redacted] (b) (6) runs a home health care company in NC and many other states in the nation. He has managed to get some of the largest home care companies as well as the Home Care Association of America (their trade organization) to sign off on this call for guidance for their industry which provides professional care givers, largely CNAs, to those needing assistance with daily living throughout the nation.

I am reaching out hoping that you might know to whom this message should really go.

Thanks again for all you do – and take care of yourself! The nation needs you.

Sincerely, Linda

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S
Scientist Emeritus (Retired)
Former Director, National Institute of Environmental Health Sciences
and National Toxicology Program
phone: [redacted] (b) (6)
cell [redacted] (b) (6)
e-mail: [redacted] (b) (6)
personal email: [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Monday, March 23, 2020 10:45 PM
To: Linda Birnbaum [redacted] (b) (6)>
Subject: Message to Dr. Fauci

Dear Dr. Fauci,

The home care industry cares for tens of millions of our most vulnerable citizens in their homes every day. We provide assistance with activities of daily living and instrumental activities of daily living, which keeps our clients in their homes and in the lowest risk setting. **Our professional Caregivers are able and willing to continue to provide care to clients who test positive for COVID-19 or have been exposed to the virus**.

But we need your help so that home care companies do not face unreasonable liability for providing such care. To that end, we ask for your support in getting a bill through congress like the Public Readiness and Emergency Preparedness Act (PREP Act), 42 USC 247d-6d, that will insulate providers like us from claims related to the care we will be providing in these extraordinary times.

We also ask that you support creating a fund that will provide appropriate personal protective equipment to our caregivers. Our clients should not have to bear the additional burden of the added cost of PPE.

Additionally, we would like you to encourage the CDC to clarify its guidance on caring for COVID-19 patients (found here, here and here) that the guidance is applicable to "professional, licensed and insured, home based care agencies."

This clarification will give the industry a workable standard to protect caregivers caring for COVID-19 clients. In essence, it would establish that facemasks and gloves are sufficient PPE to care for COVID-19 clients in the home, and not require its caregivers to comply with the healthcare setting requirements of wearing N95 respirators, eye protection (goggles or face shields) or gowns. This is important as a practical matter because respirators and gowns are not readily available at this time. Moreover, most home care workers are not trained in the proper use of respirators.

Finally, we need your help in pressuring congress to provide day care for the children of our caregivers. If they cannot find adequate care for their children, then our clients will suffer. This is a vital step to keep our clients in their homes.

With you help, home care companies will be able to:

1. Relieve the burden on the healthcare system by keeping our clients out of the hospital; and

2. Adhere to shelter-in-place measures which will flatten the curve of COVID-19's spread.

Warmly,
(b) (6) [redacted]

On behalf of:
Michael Coccaro, Chief Operating Officer and General Counsel, Synergy Home Care
Emma Dickison, Chief Executive Officer and President, Home Helpers
Lisa Foster, Chief Clinical Officer, MGA Homecare
Daniel Gottschalk, Co-owner and President, Genova Health
Margaret Haynes, Chief Operating Officer, Right at Home
Vicki Hoak, Executive Director, Home Care Association of America
Peter Ross, Chief Executive Officer and Co-Founder, Senior Helpers
Timothy Ryan, General Counsel, AccentCare, Inc.
Shelly Sun, Founder, BrightStar Care

--
(b) (6) [redacted]
www.nursecarenc.com
www.livhome.com

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 15:33:11 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: The global health leaders call, Wednesday 25 March at 13:00 CET
Attachments: (b) (4) Swisscom Call code.pdf

Please print this out for me for possibility doing the call tomorrow. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. (b) (6)
Sent: Tuesday, March 24, 2020 10:59 AM
To: SHOC <shoc@who.int>; Office of the Director-General <DGOffice@who.int>; Redfield, Robert R. (CDC/OD) (b) (6)
[redacted]; David Heymann (b) (6); Felicity Harvey (b) (6)
(b) (6)>; Chris.Elias (b) (6);
(b) (6) J.Farrar (b) (6)
[redacted]; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
[redacted] GREIN, Thomas (b) (6)>; COX,
Paul Michael (b) (6); SCHWARTLANDER, Bernhard F. (b) (6); MINHAS,
Raman (b) (6)'; Conrad, Patricia (NIH/NIAID) [E]
(b) (6); MAHJOUR, Jaouad (b) (6)>; FALL, Ibrahima Soce
(b) (6); Thomas R. Frieden (b) (6)
[redacted] Lynn Banks (b) (6); President | Resolve to Save Lives
<president@resolvetosavelives.org>; (b) (6); AL-SHORBAJI,
Farah (b) (6); Robynn Leidig
(b) (6); DRURY, Patrick Anthony (b) (6)>; Dr VAN KERKHOVE,
Maria (b) (6)
[redacted] cherylc (b) (6); GRAAFF, Peter Jan
(b) (6); POOLE, Marcia < (b) (6); Tarik Mohammed
(b) (6) Carlos Navarro Colorado
(b) (6) Ryan Morhard

[redacted] (b) (6) BRIAND, Sylvie [redacted] (b) (6)>; MORGAN, Oliver
[redacted] (b) (6); Harries, Jenny [redacted] (b) (6); Awwad, David (NIH/NIAID) [C]
[redacted] (b) (6); SIMONSON, Stewart [redacted] (b) (6)>; SINGER, Peter Alexander
[redacted] (b) (6) Jayatunga, Wikum < [redacted] (b) (6)
[redacted]; Julie.HALL [redacted] (b) (6); Amelie RIOUX < [redacted] (b) (6);
KABIR, Sophia [redacted] (b) (6)
[redacted] SHIN, Young-Soo [redacted] (b) (6);
[redacted] (b) (6); Feng Ding [redacted] (b) (6)
[redacted]
Cc: SHOC <shoc@who.int>; Office of the Director-General <DGOffice@who.int>; SCHWARTLANDER, Bernhard F. [redacted] (b) (6); MAHJOUR, Jaouad [redacted] (b) (6)>; FALL, Ibrahima Soce [redacted] (b) (6)>; GREIN, Thomas [redacted] (b) (6)>; MINHAS, Raman [redacted] (b) (6); COX, Paul Michael [redacted] (b) (6)>; AL-SHORBAJI, Farah [redacted] (b) (6)>; POOLE, Marcia [redacted] (b) (6); DRURY, Patrick Anthony [redacted] (b) (6)>; GRAAFF, Peter Jan [redacted] (b) (6); Dr VAN KERKHOVE, Maria [redacted] (b) (6); KABIR, Sophia [redacted] (b) (6)>; FARES, Christine Youssef [redacted] (b) (6); AYLWARD, Raymond Bruce J. [redacted] (b) (6)>; SMITH, Ian Michael [redacted] (b) (6)
Subject: The global health leaders call, Wednesday 25 March at 13:00 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted on Wednesday, 25 March at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email: kabirso@who.int ; mobile no. [redacted] (b) (6)

The agenda and background documents will be shared ahead of the call.

Best,

Mike

Dear participant

To join the upcoming teleconference, please call:

From inside WHO
(b) (4)

From others countries please call:

Country	Number	Access Code
Argentina	+54 115 984 12 00	(b) (4)
Australia	+61 280 147 967	
Austria	+43 720 880 876	
Belgium	+32 280 835 50	
Brazil	+55 213 958 07 18	
Bulgaria	+35 924 917 399	
Canada	+1 613 686 43 59	
Chile	+56 225 95 28 26	
China	+86 105 789 7457	
Croatia	+38 51 777 63 03	
Cyprus	+35 72 503 02 78	
Czech Republic	+42 024 601 95 32	
Denmark	+45 699 182 15	
El Salvador	+50 32 113 37 10	
Estonia	+37 26 68 12 68	
Finland	+35 894 270 50 03	
France	+33 1 77 69 68 25	
Germany	+49 698 991 47 25	
Georgia	+99 57 067 773 41	
Greece	+30 211 198 00 81	
Hong Kong	+85 258 084 851	
Hungary	+36 180 881 90	
Ireland	+35 314 845 940	
India	+91 11 712 79 153	
Israel	+97 237 219 661	
Italy	+39 02 479 211 40	
Japan	+81 345 209 476	
Kazakhstan	+771 727 274 71	
Lathvia	+37 16 765 25 76	
Lithuania	+37 052 05 89 83	
Luxembourg	+352 208 801 72	
Malaysia	+603 921 220 20	
Malta	+35 62 778 01 98	
Mexico	+52 554 624 02 27	
Netherlands	+31 108 920 271	
New Zealand	+64 99 25 03 39	
Norway	+47 210 189 41	
Panama	+507 836 51 38	
Peru	+51 17 08 54 63	
Philippines	+632 231 22 15	
Poland	+48 221 168 469	
Portugal	+351 308 800 872	
Puerto Rico	+17 879 05 73 62	
Russia	+749 540 220 27	
Romania	+40 318 107 181	
Singapore	+65 315 813 05	
Slovakia	+42 123 300 69 18	
Slovenia	+38 61 600 49 18	
South Africa	+27 10 590 11 04	
South Korea	+82 707 488 31 02	
Sweden	+46 840 309 949	
Switzerland (English)	+41 58 262 07 22	
Switzerland (Italiano)	+41 58 262 07 44	
Switzerland (Deutsch)	+41 58 262 07 11	

Switzerland (Français)	+41 58 262 07 33
Spain	+34 931 816 661
Tadzhikistan	+99 242 782 22 70
Turkey	+90 21 290 025 60
United Kingdom	+44 203 370 57 19
United States	+1 646 381 08 89

(b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 15:32:02 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: interview request

Tell them no.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Raphael De Montferrand <rdemontferrand@rttv.fr>
Sent: Tuesday, March 24, 2020 11:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: interview request

dr Faucy,

Hello, my channel is doing a section of its news tonight (at 3:45pm your time) on the coronavirus situation in New York. I wondered if we could interview you over skype. Do you think that might be possible at 3:45pm today your time?
We have a simultaneous translator as we operate in french from our studio in Paris.

Looking forward to hear from you,

Raphaël de Montferrand
RT France
0033608662642

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 14:30:50 +0000
To: [redacted] (b) (6)
[redacted]
Subject: FW: Boston Globe: In order to save Dr. Fauci, we must destroy him

Yikes! You have to read this. Things are getting unbelievably crazy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, March 24, 2020 10:16 AM
To: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>; NIAID COGCORE <COGCORE@mail.nih.gov>
Subject: Boston Globe: In order to save Dr. Fauci, we must destroy him

In order to save Dr. Fauci, we must destroy him

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, is a study of calm and competence in the middle of a pandemic. Which makes him an endangered species, working as he does for a boss who is notoriously insecure and made his name shouting “You’re fired!” on a reality TV show.

ByKevin Cullen Globe Columnist,Updated March 23, 2020, 5:25 p.m.
209

Dr. Anthony Fauci's calm, reassuring competence in response to the coronavirus pandemic is placing him at serious risk of hearing the words that made his boss famous: You're fired.Jabin Botsford/The Washington Post

Dr. Anthony Fauci is a bum.

A quack, a snake oil salesman.

He got his degrees online, not from Holy Cross and Cornell.

He watches Wheel of Fortune but not Jeopardy.

He's a Yankees fan.

Such character assassination is unsavory but necessary because Fauci's calm, reassuring competence in response to the coronavirus pandemic is placing him at serious risk of hearing the words that made his boss famous: You're fired.

President Trump is watching and listening to the same thing we are, i.e., Fauci going to the podium to rebut with facts the latest outbreak of paranoid anxiety or the president'sregularly reckless statements.

Fauci is an oasis of rigor and reason in a barren desert of confusion and fear.

Which, given who he works for, makes him an endangered species.

During the Vietnam War, some US Army officer supposedly suggested that in order to save a village from the Vietcong they had to destroy it.

And so, to save Dr. Fauci, we must destroy him — at least in Trump's eyes.

Now that might sound crazy, but we're dealing with a crazy president in crazy circumstances.

It's not as if there's no relevant precedent here.

Two words: Bill Bratton.

Two other words: Rudy Giuliani. Who happens to be Trump's BFF.

Before Giuliani grew old, deranged, and more qualified to be a spokesman for Miracle Ear than the president's lawyer, he was the reform-minded mayor of New York City.

Rudy rode into Dodge, which is what Times Square resembled at the time, and vowed to clean it up. His hand-picked sheriff was Dorchester's own Bill Bratton.

As police commissioner, Bratton did much to stem violent crime in the nation's biggest city, but even more remarkably got his cops to reduce the incidence of more minor, so-called quality of life crimes that had made New York less livable, from the tony sections of Manhattan to the Tony Fauci sections of Brooklyn.

Bratton did his job too well. He ended up on the cover of Time magazine, hailed as the guy who pulled the worm out of the Big Apple. He became more popular than the mayor.

This drove Giuliani nuts. Rudy had to be the smartest guy in the room, had to get all the credit. Sound familiar?

So Bratton had to go.

That wasn't Bratton's first rodeo. Long before he landed in New York, he became the face of progressive, modern policing in his hometown, the youngest-ever Boston Police superintendent. Police Commissioner Joe Jordan resented his overly-ambitious No. 2 so he busted Bratton.

The point is, insecure bosses don't like being shown up by smarter, more competent subordinates. Small men make big mistakes.

It may be too late to save Fauci. He just got the star treatment from Maureen Dowd in The New York Times.

There used to be a thing called the Sports Illustrated curse, that after an athlete appeared on its cover his or her career tanked.

Similarly, being in the Trump administration and getting praised by The New York Times is the kiss of death.

Now, normally, you could print something in the Times and chances were the president wouldn't read it. He routinely dismisses the Gray Old Lady as fake news, except when his and his family's lousy books are mass-bought onto the newspaper's bestsellers list. He is not fond of polysyllabic words and prefers to get his news from "Fox & Friends" or whatever white nationalist website his aide Stephen Miller might recommend.

But Trump reads Mo Dowd because they have known each other forever and she writes about him at a nuanced, personal level that drives him especially cuckoo.

We're way past the theoretical here.

Tony Fauci is in real danger, and by extension so are the rest of us who expect — nay, pray for — one person in the White House to be trustworthy and competent in a time of unprecedented crisis.

So, again, repeat after me, Dr. Anthony Fauci is a bum.

Long live the bum.

Kevin Cullen is a Globe columnist. He can be reached at kevin.cullen@globe.com.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 14:13:33 +0000
To: [redacted] (b) (6)
Subject: RE: Update #2: Traffic Advisory: Street Closures

Thanks

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Tuesday, March 24, 2020 10:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Update #2: Traffic Advisory: Street Closures

A lot of street closures. I don't think it will interfere with your trip downtown, but just in case

---

From: AlertDC <noreply@everbridge.net>
Sent: Tuesday, March 24, 2020 7:33 AM
To: [redacted] (b) (6)>
Subject: Update #2: Traffic Advisory: Street Closures

This is an important message from the District of Columbia AlertDC system.

On Tuesday, March 24, 2020, in coordination with the National Park Service, the Metropolitan Police Department will make several street closures beginning at 7:00 a.m. through approximately 8:00 p.m at the following locations:

- The Memorial Bridge
- Lincoln Memorial Circle
- Potomac River Freeway (all exits to Ohio Drive and Independence Avenue)

- Rock Creek Parkway/Potomac Parkway Drive between Virginia Avenue and Independence Avenue, SW (to include Ohio Drive, SW)
- Independence Avenue between Ohio Drive and 14th Street, SW
- 23rd Street between Constitution Avenue and Lincoln Memorial Circle
- Henry Bacon Drive between Constitution Avenue and Lincoln Memorial Circle
- 17th Street between Constitution Avenue, NW and Independence Avenue, SW
- 15th Street between Constitution Avenue, NW and Independence Avenue, SW
- Maine Avenue between Independence and 12th Street, SW
- All vehicular exits to East Potomac Park and West Potomac Park

All street closures and listed times are subject to change based upon prevailing or unexpected conditions.

The public should expect parking restrictions along the street and should be guided by the posted emergency no parking signage. All vehicles that are parked in violation of the emergency no parking signs will be ticketed and towed.

Individuals and groups will encounter delays in the vicinity of this closure. To help flatten the curve, we strongly discourage any Tidal Basin visits because social distancing has not been possible due to visitor volume.

For more information about the District's coronavirus response, visit coronavirus.dc.gov

Click Here to update your profile.

To stop receiving future email notifications from this organization **unsubscribe here**.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 14:12:54 +0000
To: Miller, Katie R. EOP/OVP
Cc: Short, Marc T. EOP/OVP;Conrad, Patricia (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];O'Malley, Devin M. EOP/OVP
Subject: RE: Please advise

I called the reporter and she was very receptive to my corrections of the record and presentation of the facts.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Miller, Katie R. EOP/OVP [redacted] (b) (6)>
Sent: Tuesday, March 24, 2020 9:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Short, Marc T. EOP/OVP [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6) Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6) O'Malley, Devin M. EOP/OVP < [redacted] (b) (6)>
Subject: Re: Please advise

[redacted] (b) (5)

Sent from my iPhone

> On Mar 24, 2020, at 9:27 AM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
>
> Marc/Katie:

(b) (5)

[redacted]

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Abutaleb, Yasmeen <Yasmeen.Abutaleb@washpost.com>
Sent: Tuesday, March 24, 2020 9:05 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Parker, Ashley <Ashley.Parker@washpost.com>
Subject: Washington Post fact check on Fauci/scientists story

Hi Patty,

Thanks very much for your help yesterday and hope you're doing well. We're working on a story today about Trump's relationship with the scientific and medical experts in the coronavirus response, including Dr. Fauci. We're reporting this out today but wanted to send you what we've been hearing as we get it so there's ample time to fact check everything today. Here are some points we'd love to discuss with the best person in your office or, better yet, Dr. Fauci himself.

- Fauci was apoplectic about Trump's tweet yesterday saying the cure couldn't be worse than the virus and indicating that he wants to reopen businesses soon.
- Fauci has been forceful privately that unproven drugs should not be advertised to Americans as a panacea (and he of course has publicly spoken about these drugs).
- We are also reporting in a separate story that Larry Ellison is building a website for the federal government that will collect data on the efficacy of remdesivir, chloroquine and hydroxychloroquine. Our understanding is Fauci is vehemently opposed to this idea and has pushed back on it, citing patient privacy concerns with the website and collecting data in this way outside of an approved FDA trial.

Again, we'd love to speak with Dr. Fauci and any others in your office who may have insight into these particular issues and other aspects of the coronavirus response. Please feel free to give me a call on my cell at any time at (b) (6)

Thanks very much,

Yasmeen Abutaleb
The Washington Post
Health policy reporter
o: 202-334-8387 c: (b) (6)
@yabutaleb7

From: [redacted] (b) (6)
Sent: Tue, 24 Mar 2020 07:47:49 -0400
To: Pottinger, Matthew F. EOP/WHO
Subject: Re: regarding masks and Covid-19

Very good point.

[redacted] (b)(5) - PCP

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: [redacted] (b) (6)
Sent: Mon, 23 Mar 2020 15:45:21 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Media Request: NPR's 1A Show

Begin forwarded message:

> **From:** Amanda Williams <amandaw@wamu.org>
> **Date:** March 23, 2020 at 3:41:06 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>
> **Subject: Media Request: NPR's 1A Show**
>
> Hello Dr. Fauci,
>
> I'm a producer with National Public Radio's 1A show and we'd like to invite you to join our program to talk about coronavirus in the near future. We've built our show on answering our 4+ million listeners' questions and we know Americans have a lot of questions for you right now. We don't take live calls, but we do curate input from voicemails and social media.
>
> We would love to have you join us. Please let me know if you are available and interested anytime soon. We are very flexible.
>
> A bit more about *1A*: We launched in January 2017 and we're ranked among the top 10 public radio programs on a list that includes Morning Edition, All Things Considered and Marketplace. We reach 4+ million listeners every week and air on more than 365 stations across the country. Our major markets include Chicago, LA, NYC, DC, Atlanta, Boston, Philadelphia, San Francisco, Miami, Houston, Minneapolis and Seattle.
>
> Best,
> Amanda
>
> Amanda Williams
> Across America Producer
> 1A, from WAMU and NPR
> [redacted] (b) (6) (c) | @amandwms | the1a.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 19:32:28 +0000
To: [redacted] (b) (6)
Cc: [redacted] (b) (6)
[redacted]
Subject: Re: USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need
Attachments: image002.jpg

Love you all

> On Mar 23, 2020, at 3:07 PM, [redacted] (b) (6) wrote:
>
> So True!
>
> In a message dated 3/23/2020 2:06:15 PM Eastern Standard Time, [redacted] (b) (6) writes:
>
> > Lots of a very kind and thoughtful and well-earned words of respect coming your way [redacted] (b) (6)
> >
> > On Mon, Mar 23, 2020 at 12:35 PM [redacted] (b) (6) wrote:
> >
> > > That's a very nice piece about you, (b) (6)
> > >
> > > I hope you got some rest this weekend. Sending lots of love.
> > >
> > > On Sun, Mar 22, 2020 at 6:34 PM Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:
> > >
> > > > Wow. David Rubenstein [redacted] (b) (6) used to work for him) was really nice to me.
> > > >
> > > > ---
> > > >
> > > > **From:** Folkers, Greg (NIH/NIAID) [E] <[redacted] (b) (6)
> > > > **Sent:** Sunday, March 22, 2020 11:36 AM
> > > > **Subject:** USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

Fauci is the world's leading authority on infectious diseases and the best person in the country to help us deal with the COVID-19 crisis.

David M. Rubenstein

Opinion contributor

Some viewers of the daily White House coronavirus briefings may wonder why everyone increasingly defers to a diminutive, Brooklyn-accented 79-year-old doctor, Tony Fauci.

They do because, as I have learned over many years of talking with and more recently interviewing this man, he is without doubt the world's leading authority on infectious diseases. In any area of human activity or knowledge, there always seems to be one person who is the global gold standard. In the world of infectious diseases that person is Tony Fauci.

So the American people — indeed, people around the globe — should be grateful that Tony has dug into this crisis with the same work-around-the-clock, just-the-facts ma'am style that he has used while serving under and working with six U.S. presidents. He is as apolitical as anyone can be. I have no idea if he is registered with any political party; I suspect though that he is rabidly Independent. His only focus is getting the facts out, providing the best health care treatment and information possible, and saving lives.

A top expert from AIDS to Ebola

Tony Fauci joined the National Institutes of Health in 1968, after completing his medical training at Weill Cornell Medical Center, and he has led the National Institute of Allergy and Infectious Disease since 1984 — 36 years. Hard to believe anyone can run anything that long and still be at the top of his game. But Tony is. During this period, he has dealt with every serious infectious disease challenge — malaria, Among Tony's best known accomplishments, beyond simply running the institute and training dozens of the world's top infectious disease professionals, has been helping to discover how HIV leads to AIDS and, later, leading the effort to create (at President George W. Bush's direction) the President's Emergency Plan for AIDS Relief (PEPFAR), which has transformed the treatment of HIV/AIDS in Africa, and other parts of the developing world. Millions of lives have been saved by this program alone. More recently, he has been an architect and powerful advocate of President Donald Trump's plan for ending the AIDS epidemic in the U.S. through HIV antiretroviral therapy targeted to disease hotspots.

In his spare time, Tony has been involved with writing or editing more than 1,100 scholarly articles and several textbooks, and, in the process, has become one of the most cited authorities of the entire medical profession.

For these breakthrough activities and his dedicated service (at a government salary) for more than a half century (he worked at NIH for 16 years before assuming his current role), Tony has received, and earned, the Presidential Medal of Freedom and a Lasker Award (called the American Nobel by many).

With this long service and universal acclaim, one might think Tony would let it get to his head, at least a little bit. Not the case, though.

Selfless commitment to public service

He is readily accessible to those who need treatment — he still runs a lab at NIH — or need information. Tony still lives in the same house he bought when he first moved to Washington, and it is there that he and his wife Christine have raised their three talented daughters (though none of them chose to attend medical school).

Until the latest crisis, Tony has often commuted to NIH by Metro, typically after running three miles for his daily exercise. And when he has been invited to make speeches in the Washington area or on Capitol Hill, he invariably turns down a car and driver for the Metro. (This practice has had to change of late for the obvious reasons).

There are, of course, many other dedicated federal servants who also view their commitment to the country and its people over financial rewards. But surely no federal civil servant, in any area, can exceed Tony Fauci's long-term and selfless commitment to this country and the health of its people.

<image002.jpg>

I tried years ago, when Tony was approaching a normal retirement age, to see if he might want after a normal lifetime of federal service, to take some of his considerable skills and knowledge to the private sector. He quickly said no — money did not motivate him, serving the country did. And he stayed at NIH — to the country's good fortune.

If there is any one medical professional who can help the country deal with the COVID-19 crisis, it is Tony Fauci, an example of the best this country has to offer.

He is not a miracle worker. No one is.

But Tony Fauci has the decades of experience needed to understand infectious disease problems and prescribe a treatment that should, in time, provide the requisite comfort, even if, in the short term, the medicine is painful and inconvenient.

David M. Rubenstein is the co-executive chairman of The Carlyle Group.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

--

(b) (6)

<image002.jpg>

From: [redacted] (b) (6)
Sent: Mon, 23 Mar 2020 15:16:17 -0400
To: Barasch, Kimberly (NIH/NIAID) [C]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Meeting on the science of COVID-19, Wed. 3/25, 2 - 5 pm

Please print out for me and have ready in case I do this on Wednesday

Begin forwarded message:

> **From:** "Tromberg, Bruce (NIH/NIBIB) [E]" [redacted] (b) (6)>
> **Date:** March 23, 2020 at 1:22:18 AM EDT
> **To:** "Collins, Francis (NIH/OD) [E]" [redacted] (b) (6)>
> **Cc:** "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Re: Meeting on the science of COVID-19, Wed. 3/25, 2 - 5 pm**
>
> Hi Francis,
> Thanks, I'm looking forward to the meeting. Probably not directly relevant to this upcoming discussion, [redacted] (b) (5)
>
> (b) (5)
> [redacted]

(b) (5)
[redacted]

Best,
Bruce

From: "Collins, Francis (NIH/OD) [E]" [redacted] (b) (6)
Date: Sunday, March 22, 2020 at 9:38 PM
To: "ICDDIR-L@LIST.NIH.GOV" <ICDDIR-L@LIST.NIH.GOV>
Cc: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6) "Wolinetz, Carrie (NIH/OD) [E]" [redacted] (b) (6), "Anderson, James (NIH/OD) [E]" [redacted] (b) (6), "Parker, Ashley (NIH/OD) [E]" [redacted] (b) (6)>, "McManus, Ayanna (NIH/OD) [E]" [redacted] (b) (6), "Wood, Gretchen (NIH/OD) [E]" [redacted] (b) (6)
Subject: Meeting on the science of COVID-19, Wed. 3/25, 2 - 5 pm

Colleagues,

I'm glad to hear that most of you are able to join a three-hour virtual meeting on Wednesday March 25 to discuss scientific opportunities in the effort to conquer the COVID-19 pandemic. While NIAID rightly has the lead in this effort for NIH, and is deeply invested in projects in both their intramural and extramural programs, it's clear that a number of other ICs have creative ideas and a strong motivation to try to help with this global crisis. So this certainly seems like a time where we should gather (virtually of course) to brainstorm together, led by NIAID, and seek to identify any additional areas of contribution that could be subject to acceleration and/or collaboration.

Hilary Marston recently convened a Deputies meeting on this subject, and ICs were then asked to submit examples last Friday of projects they are pursuing in the COVID-19 space. Those were forwarded from Bob Eisinger to me. I have used those submissions, including a detailed list of NIAID projects, to put together a tentative agenda for Wednesday's meeting. That is attached.

[redacted] (b) (5)

There are admittedly a lot of themes and topics here, so this will require some real discipline in the one-slide presentations. I will try to serve as time-keeper – or maybe I'll ask Larry to do that. □□

All IC Directors are invited to have one or two subject matter experts join them for this virtual discussion.

Ashley Parker [redacted] (b) (6) will be helping me with the logistics and will have further instructions about how the log in will work.

Here's the specific follow up request that needs your immediate attention:

1. If your IC is pursuing a highly relevant project that's not listed here, and that you want the group to hear about, please send me that information ASAP.
2. If your IC is on the draft agenda to make a presentation, please submit your one slide (except for NIAID, who gets more) to me and Ashley by COB Tuesday 3/24. That way we can put the whole set together as a single ppt file.

Many thanks! This should provide a welcome respite from the many other tasks we are all facing right now.

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 19:06:06 +0000
Bcc: Aberg, Judith;Adaora Adimora;Grund, Birgit;Glidden, David;Daar, Eric;Erica Hardy;Gandhi, Rajesh Tim,M.D.;Jason Baker;Jeff Lennox;Johnson, Steven C - ID;Kim, Arthur Y.,M.D.;Marla Keller;Tebas, Pablo (NIH);Susan Davis;Susan Swindells;Susanna Naggie;Tien, Phyllis;Amy Dzierba;Mitchell Levy;Laura Evans;Craig Coopersmith;Greg Martin;Uyeki, Timothy M. (CDC/DDID/NCIRD/ID);Walker, Robert (OS/ASPR/BARDA);Sheikh, Virginia (FDA/CDER);Anne Collier;Francis, Joe (Contact NLM/OD-External);[redacted] (b) (6)
Subject: Invitation to join the HHS Panel on Guidelines for The Management of COVID-19

Dear Colleague,

At the request of the Office of the Secretary, HHS and in conjunction with the White House Task Force we are creating a COVID-19 management guidelines panel to provide frequently updated information to the public regarding the treatment of patients with COVID-19.

This guidance will be an HHS document, will be updated frequently and will be modeled to some degree after the ART guidelines. The Panel will include academicians and clinicians currently caring for persons with COVID-19 and representatives from multiple US government agencies (CDC, BARDA, FDA, VA, DoD) and professional societies. Cliff Lane, M.D. Henry Masur, M.D. and Trip Gulick, M.D. will co-chair, and Alice Pau, Pharm.D. will be the exec. sec. for this new panel. Those of you who are appointed to represent your federal agencies will be ex-officio. Other federal employees will be voting members.

I would like to invite you to be a member of this new Panel based on your expertise. We anticipate that work will begin this week and we hope to be able to put out the first guidance in 1-2 weeks. We appreciate your willingness to join this very important effort and your work in caring for patients during this pandemic.

The first meeting (by teleconference) will be Tuesday, March 24 at 11:00AM EDT. More details will be provided soon.

Thank-you for considering this and for all you are doing during this most challenging time.

Sincerely,

Anthony S. Fauci, MD
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 18:38:21 +0000
To: [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: RE: FW: USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

Love you all.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)>
Sent: Monday, March 23, 2020 12:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: [redacted] (b) (6)
Subject: Re: FW: USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

That's a very nice piece about you, [redacted] (b) (6)

I hope you got some rest this weekend. Sending lots of love.

On Sun, Mar 22, 2020 at 6:34 PM Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:

> Wow. David Rubenstein [redacted] (b) (6) used to work for him) was really nice to me.
>
> ---
>
> **From:** Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
> **Sent:** Sunday, March 22, 2020 11:36 AM
> **Subject:** USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

Fauci is the world's leading authority on infectious diseases and the best person in the country to help us deal with the COVID-19 crisis.

David M. Rubenstein
Opinion contributor

Some viewers of the daily White House coronavirus briefings may wonder why everyone increasingly defers to a diminutive, Brooklyn-accented 79-year-old doctor, Tony Fauci.

They do because, as I have learned over many years of talking with and more recently interviewing this man, he is without doubt the world's leading authority on infectious diseases. In any area of human activity or knowledge, there always seems to be one person who is the global gold standard. In the world of infectious diseases that person is Tony Fauci.

So the American people — indeed, people around the globe — should be grateful that Tony has dug into this crisis with the same work-around-the-clock, just-the-facts ma'am style that he has used while serving under and working with six U.S. presidents. He is as apolitical as anyone can be. I have no idea if he is registered with any political party; I suspect though that he is rabidly Independent. His only focus is getting the facts out, providing the best health care treatment and information possible, and saving lives.

A top expert from AIDS to Ebola

Tony Fauci joined the National Institutes of Health in 1968, after completing his medical training at Weill Cornell Medical Center, and he has led the National Institute of Allergy and Infectious Disease since 1984 — 36 years. Hard to believe anyone can run anything that long and still be at the top of his game. But Tony is. During this period, he has dealt with every serious infectious disease challenge — malaria,

Among Tony's best known accomplishments, beyond simply running the institute and training dozens of the world's top infectious disease professionals, has been helping to discover how HIV leads to AIDS and, later, leading the effort to create (at President George W. Bush's direction) the President's Emergency Plan for AIDS Relief (PEPFAR), which has transformed the treatment of HIV/AIDS in Africa, and other parts of the developing world. Millions of lives have been saved by this program alone. More recently, he has been an architect and powerful advocate of President Donald Trump's plan for ending the AIDS epidemic in the U.S. through HIV antiretroviral therapy targeted to disease hotspots.

In his spare time, Tony has been involved with writing or editing more than 1,100 scholarly articles and several textbooks, and, in the process, has become one of the most cited authorities of the entire medical profession.

For these breakthrough activities and his dedicated service (at a government salary) for more than a half century (he worked at NIH for 16 years before assuming his current role), Tony has received, and earned, the Presidential Medal of Freedom and a Lasker Award (called the American Nobel by many). With this long service and universal acclaim, one might think Tony would let it get to his head, at least a little bit. Not the case, though.

Selfless commitment to public service

He is readily accessible to those who need treatment — he still runs a lab at NIH — or need information. Tony still lives in the same house he bought when he first moved to Washington, and it is there that he and his wife Christine have raised their three talented daughters (though none of them chose to attend medical school).

Until the latest crisis, Tony has often commuted to NIH by Metro, typically after running three miles for his daily exercise. And when he has been invited to make speeches in the Washington area or on Capitol Hill, he invariably turns down a car and driver for the Metro. (This practice has had to change of late for the obvious reasons).

There are, of course, many other dedicated federal servants who also view their commitment to the country and its people over financial rewards. But surely no federal civil servant, in any area, can exceed Tony Fauci's long-term and selfless commitment to this country and the health of its people.

I tried years ago, when Tony was approaching a normal retirement age, to see if he might want after a normal lifetime of federal service, to take some of his considerable skills and knowledge to the private sector. He quickly said no — money did not motivate him, serving the country did. And he stayed at NIH — to the country's good fortune.

If there is any one medical professional who can help the country deal with the COVID-19 crisis, it is Tony Fauci, an example of the best this country has to offer.

He is not a miracle worker. No one is.

But Tony Fauci has the decades of experience needed to understand infectious disease problems and prescribe a treatment that should, in time, provide the requisite comfort, even if, in the short term, the medicine is painful and inconvenient.

David M. Rubenstein is the co-executive chairman of The Carlyle Group.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

--
Ali Fauci

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 18:14:25 +0000
To: Barry Albertson
Subject: RE: Pooled Smaples

Thanks, Barry.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barry Albertson <barry@fannocreek.com>
Sent: Monday, March 23, 2020 1:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Pooled Smaples
Importance: High

Hi Tony,
I'm forwarding an email I just sent to Paul Cieslak, MD.....one of the lead docs at the Oregon Health Authority ([redacted] (b) (6); he gives my clinic's Internal Medicine docs an 'ID Update' for my CME Grand Rounds each year) ...with this email note from Dr. David Brandon...hope you remember David....he was with Lynn's & Mort Lipsett's group at The Clinical Center.

...I'd bet a coke you know all about pooled sampling .....but wanted to pass it along.

You have no idea how many people tell me that your COVID-19 messages on TV, etc. are top flight, enormously helpful and encouraging for them with the best information, in a sea now of poor information.

Andrew Cuomo is also doing a great job informing all of NY (and the rest of us) about what's going on, and his expectations for the public.

Whatever they're paying you ...it's not enough.

You keep your powder dry, and extra flints in your pocket!
Barry

From: Barry Albertson
Sent: Monday, March 23, 2020 9:49 AM
To: 'Cieslak Paul R'
Subject: Pooled Smaples
Importance: High

Good morning, Paul.

Hope you guys at OHA are holding up OK.

I'm fine, family is fine... (b) (6) is dong lots of telemedicine and seeing actual PEDS patients at Westside Hosp. now a few days a week.
My clinic is still open but pretty quiet... we need to stay open at some level no matter what.

One of my colleagues from the NIH (Dr. David Brandon ...he actually published with Tony Fauci back in the late '70s I believe !)..sent me this email on Saturday morning
I suspect you all know about pooled sampling,.....David did it at the NIH for a study that I have long forgotten about. ...thought I'd pass it along to you ......

" I just looked up to see if pooled sampling has been used to detect viruses in the past, and found that it has been used in a number of cases including during the HIV scare. I am including a link thttps://www.israel21c.org/israelis-introduce-method-for-accelerated-covid-19-testing/ to an article in the lay press reporting on an RT-PCR based test that uses swabs from 30-60 individuals to determine if the pooled sample has Covid-19. The study was successful and they are developing it to test workers in the front line work places such as hospitals. There is a body of literature using this method for other mass screenings."

Then I heard that CEPHEID will be getting their Genexpert instrument validated to measure COVID-19. Turns out we have one in my Lab, use it for Chlamydia & Gonorrhea (we have lots of patients here needing this testing). But as you so well know, having the instrumentation without the collection swabs/M4 media, etc. Is a bit like biking up a blind alley. I would hope we'll hear more about this.

Give me a shout if I can do anything to help you all ......best tack for me, I believe, is to stay out of your way!

Barry

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 18:09:12 +0000
To: O'Grady, Naomi (NIH/CC/CCMD) [E]
Subject: RE: vent rationing

Naomi:
I am not aware of any efforts on rationing ventilators. They speak of making sure the high priority areas such as NYC get what they need, but there is no talk at this time of "rationing"
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Grady, Naomi (NIH/CC/CCMD) [E] [redacted] (b) (6)>
Sent: Monday, March 23, 2020 1:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: vent rationing

Hi Tony-
I know you are very busy but I wanted to see if you know of any effort on the part of the federal government to issue guidance on the rationing of ventilators when the time comes? Many of my colleagues in critical care across the country have been asking for some such guidance on a federal level. Both for the guidance itself and to protect themselves from legal liability. Are you aware of any such efforts? Thanks for any insights on this. And thanks for **all** you are doing on the coronavirus effort!
Best regards,
Naomi

Naomi P. O'Grady, MD
Chief, Internal Medicine Services
NIH Clinical Center

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 16:48:31 +0000
To: Dan Hurley
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: 2 questions from NY Times Mag reporter who interviewed you about EV-D68

Dan:

Thanks for the note. The work on an EV-D68 vaccine will continue. The Coronavirus vaccine research is the highest priority. Both come out of Barney Graham's group in our VRC. Best to call Barney about the degree of possible interference. Books are not on my mind right now.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dan Hurley (b) (6)
Sent: Monday, March 23, 2020 11:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: 2 questions from NY Times Mag reporter who interviewed you about EV-D68

Hi Dr. Fauci and Patty: In addition to the two items mentioned in my original email, the NY Times Magazine is also interested in publishing an interview with Dr. Fauci. Thank you, Dan Hurley

On Thu, Mar 19, 2020 at 6:04 PM Dan Hurley < (b) (6) wrote:

> Hi Dr. Fauci: I interviewed you by telephone a few months ago for an article in the New York Times Magazine about enterovirus D68, the putative causal agent of acute flaccid myelitis. At the time you said that NIAID was working hard on developing a vaccine for EV-D68. I have two questions:

1. Is work on developing a vaccine against the novel coronavirus interrupting or slowing work on EV-D68? Hard to believe it wouldn't have an effect.

2. When things calm down with COVID-19, would you consider allowing me to write a biography about you, or helping you write a memoir? This pandemic has kind of turned you into the face of medical science in the United States. I'm the author of four prior science books, and have profiled countless scientists in the Times, The Atlantic, and elsewhere. I know this is not the time for such things. I just want to put the idea out there. I hope and pray you do not find it offensive for me suggest such a thing at this time of danger and stress.

Let me know about that EV-D68 vaccine if you can. I'm also reaching out to Barney Graham. Thank you, Dan Hurley

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 14:51:53 +0000
To: [redacted] (b) (6)
Subject: FW: Dinarello Proposal
Attachments: Dinarello Proposal for COVID-19.doc

Cliff:

[redacted] (b) (5).

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: charles dinarello [redacted] (b) (6)>
Sent: Sunday, March 22, 2020 9:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Dinarello Proposal

[redacted] (b) (6)

I watch CNN almost constantly to listen to your impressive wisdom. The world listens to you. Shelly would be so proud of you in this world crisis as he was in the HIV-1 crisis. We will not see each other at the National Academy of Sciences meeting end of April, but hopefully next year. I very much enjoyed hearing you place the anecdotal use of chloroquine in its correct context. "Chloroquine is an awfully blunt tool and an indication of our desperation", Peter Libby wrote me recently. Tony, attached is a proposal [redacted] (b) (4) I need your guidance. I know you are terribly busy so I am copying Cliff. If there is anyone else who can help me, just forward the attachment.

[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 14:48:07 +0000
To: (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 23-3-2020 FAO Dr Birx and Dr Fauci - Covid-19 Task Force RE:- Favipiravir = Avigan

Please have someone handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Monday, March 23, 2020 8:32 AM
To: (b) (6) Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: NST Rogers (b) (6)
Subject: 23-3-2020 FAO Dr Birx and Dr Fauci - Covid-19 Task Force RE:- Favipiravir = Avigan
Importance: High

23-3-2020

Dear Dr Birx and Dr Fauci,

As promised, sorry about the delay.

Please see below two articles relating to Favipiravir which has the brand name Avigan. This appears to have some beneficial effects with regard to the treatment of Covid-19.

I have also included the Wikipedia for Favpiravir.

Good Luck with regard to managing the epidemic/pandemic.

Yours Sincerely

Nicholas Rogers

Favipiravir

Drug

Description

Favipiravir, also known as T-705, Avigan, or favilavir is an antiviral drug being developed by Toyama Chemical of Japan with activity against many RNA viruses. Like certain other experimental antiviral drugs, it is a pyrazinecarboxamide derivative. Wikipedia

Formula: $C_5H_4FN_3O_2$

ChemSpider ID: 431002

ChemSpider ID: 431002

PubChem CID: 492405

Favipiravir

From Wikipedia, the free encyclopedia
Jump to navigationJump to search
Experimental antiviral drug with activity against many RNA viruses.

Favipiravir



Names
IUPAC name 6-Fluoro-3-hydroxypyrazine-2-carboxamide
Other names T-705; Avigan; favilavir
Identifiers

CAS Number	259793-96-9
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL221722
ChemSpider	431002
PubChem CID	492405
UNII	EW5GL2X7E0 ✓Y
CompTox Dashboard (EPA)	DTXSID60948878

InChI[show]

InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)

Key: ZCGNOVWYSGBHAU-UHFFFAOYSA-N

InChI=1/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)

Key: ZCGNOVWYSGBHAU-UHFFFAOYAM

SMILES[show]

Oc1ncc(F)nc1C(=O)N

Properties	
Chemical formula	$C_5H_4FN_3O_2$
Molar mass	$157.104\ g{\cdot}mol^{-1}$
Pharmacology	
ATC code	J05AX27 (WHO)

Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Infobox references

Favipiravir, also known as **T-705**, **Avigan**, or **favilavir** is an antiviral drug being developed by Toyama Chemical (Fujifilm group) of Japan with activity against many RNA viruses. Like certain other experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. In experiments conducted in animals Favipiravir has shown activity against influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses.[1] Activity against enteroviruses[2] and Rift Valley fever virus has also been demonstrated.[3] Favipiravir has showed limited efficacy against Zika virus in animal studies, but was less effective than other antivirals such as MK-608.[4] The agent has also shown some efficacy against rabies,[5] and has been used experimentally in some humans infected with the virus.[6]

In February 2020, Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 (novel coronavirus disease).[7][8] On March 17, Chinese officials suggested the drug had been effective in treating COVID in Wuhan and Shenzhen.[9][10]

As of 23 March 2020, it seems that Japan and China have issued an export ban on the substance. Japan and China are the only countries in which favirapir is produced and approved as a medical compound. Some Chinese pharmaceutical companies assure that export rights are still granted via international diplomatic means by the Chinese Ministry of Industry and Information Technology (MIIT).

[ ]

Contents

- 1Mechanism of action
- 2Approval status
- 3Ebola virus trials
- 4Coronavirus disease 2019 (COVID-19)
- 5See also
- 6References

Mechanism of action[edit]

The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase.[11] Other research suggests that favipiravir induces lethal RNA transversion mutations, producing a nonviable viral phenotype.[12] Favipiravir is a prodrug that is metabolized to its active form, favipiravir-ribofuranosyl-5'-triphosphate (favipiravir-RTP), available in both oral and intravenous formulations.[13][14] Human hypoxanthine guanine phosphoribosyltransferase (HGPRT) is believed to play a key role in this activation process.[15] Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them.[1] In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.[16] However, favipiravir has not been shown to be effective in primary human airway cells, casting doubt on its efficacy in influenza treatment.[17]

Approval status[edit]

In 2014, Japan approved Favipiravir for treating viral strains unresponsive to current antivirals.[18] Toyama Chemical initially hoped that Avigan would become a new influenza drug that could replace Tamiflu. However, animal experiments show the potential for teratogenic effects on fetuses, and the approval of production by The Ministry of Health, Labor and Welfare was greatly delayed and the production condition is limited only in an emergency in Japan.[19]

In March 2015, the US Food and Drug Administration completed a Phase III clinical trial studying the safety and efficacy of Favipiravir in the treatment of influenza.[20]

On March 15, 2020 the drug was approved in China with the name Favilavir for the treatment of influenza.[21] The drug was also approved for use in clinical trials for treating coronavirus disease 2019 pneumonia.[21]

On 22 March, 2020 Italy has approved the drug for experimental use against COVID-19 and has begun conducting trials in 3 regions most affected by the disease.[22] The Italian Pharmaceutical Agency, however, has reminded the public that the existing evidence in support of this drug is scant and preliminary.[23]

Ebola virus trials[edit]

Some research has been done suggesting that in mouse models Favipiravir may have efficacy against Ebola. Its efficacy against Ebola in humans is unproven.[24][25][26] During the 2014 West Africa Ebola virus outbreak, it was reported that a French nurse who contracted Ebola while volunteering for MSF in Liberia recovered after receiving a course of favipiravir.[27] A clinical trial investigating the use of favipiravir against Ebola virus disease was started in Guéckédou, Guinea, during December 2014.[28] Preliminary results showed a decrease in mortality rate in patients with low-to-moderate levels of Ebola virus in the blood, but no effect on patients with high levels of the virus, a group at a higher risk of death.[29] The trial design has been criticised by Scott Hammer and others for using only historical controls.[30] The results of this clinical trial were presented in February 2016 at the annual Conference on Retroviruses and Opportunistic Infections (CROI) by Daouda Sissoko[31] and published on March 1, 2016 in PLOS Medicine.[32]

Coronavirus disease 2019 (COVID-19)[edit]

On 17 March 2020, Chinese officials suggested that Favipiravir seemed to be effective in treating COVID-19 in Wuhan and Shenzhen.[33][34][35]

A study on 80 patients comparing it to lopinavir/ritonavir found that it significantly reduced viral clearance time to 4 days, compared to 11 for the control group, and that 91.43% of patients had improved CT scans with few side effects.[36][37]

As of 23 March 2020, it seems that Japan and China have issued an export ban on the substance. Japan and China are the only countries in which favirapir is produced and approved as a medical compound. Some Chinese pharmaceutical companies assure that export rights are still granted via international diplomatic means by the Chinese Ministry of Industry and Information Technology (MIIT).[*citation needed*]

See also[edit]

- BCX4430
- Brincidofovir
- FGI-106
- JK-05
- REGN-EB3
- TKM-Ebola
- Triazavirin
- ZMapp

References[edit]

1. ^ Jump up to: ***a*** ***b*** *Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD (June 2009). "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections". Antiviral Research.* ***82*** *(3): 95–102. doi:10.1016/j.antiviral.2009.02.198. PMID 19428599.*
2. ^ *Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (November 2013). "Favipiravir (T-705), a novel viral RNA polymerase inhibitor". Antiviral Research.* ***100*** *(2): 446–54. doi:10.1016/j.antiviral.2013.09.015. PMC 3880838. PMID 24084488.*
3. ^ *Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL (April 2014). "Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever". PLOS Neglected Tropical Diseases.* ***8*** *(4): e2790. doi:10.1371/journal.pntd.0002790. PMC 3983105. PMID 24722586.*
4. ^ *Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP (2016). "Zika Virus: Where Is the Treatment?". Current Treatment Options in Infectious Diseases.* ***8*** *(3): 208–11. doi:10.1007/s40506-016-0083-7. PMC 4969322. PMID 27547128.*
5. ^ *Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (April 2016). "Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis". The Journal of Infectious Diseases.* ***213*** *(8): 1253–61. doi:10.1093/infdis/jiv586. PMC 4799667. PMID 26655300.*
6. ^ *Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina RE, Enfield KB, Shiferaw M, Gigante C, Condori E, Gruszynski K, Wallace RM (January 2019). "Human Rabies - Virginia, 2017". MMWR. Morbidity and Mortality Weekly Report.* ***67*** *(5152): 1410–14. doi:10.15585/mmwr.mm675152a2. PMC 6334827. PMID 30605446.*
7. ^ Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nature Reviews Drug Discovery* 2020 Feb doi:10.1038/d41573-020-00016-0
8. ^ BRIEF-Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus. Reuters Healthcare, February 16, 2020.
9. ^ NHK World News ‘China: Avigan effective in tackling coronavirus’
10. ^ Huaxia. "Favipiravir shows good clinical efficacy in treating COVID-19: official." Xinhuanet.com, 17 March 2020

11. ^ *Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). "The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase". PLOS One.* ***8*** *(7): e68347. Bibcode:2013PLoSO...868347J. doi:10.1371/journal.pone.0068347. PMC 3707847. PMID 23874596.*
12. ^ *Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA (April 2013). "T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro". Journal of Virology.* ***87*** *(7): 3741–51. doi:10.1128/JVI.02346-12. PMC 3624194. PMID 23325689.*
13. ^ *Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, et al. (March 2018). "Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques". PLOS Medicine.* ***15*** *(3): e1002535. doi:10.1371/journal.pmed.1002535. PMC 5870946. PMID 29584730.*
14. ^ *Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y (October 2009). "Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells". The Journal of Antimicrobial Chemotherapy.* ***64*** *(4): 741–46. doi:10.1093/jac/dkp274. PMC 2740635. PMID 19643775.*
15. ^ *Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J (October 2013). "Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)". Molecular Pharmacology.* ***84*** *(4): 615–29. doi:10.1124/mol.113.087247. PMID 23907213.*
16. ^ *Koons C (7 August 2014). "Ebola Drug From Japan May Emerge Among Key Candidates". Bloomberg.com.*
17. ^ *Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, et al. (August 2018). "Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses". Antimicrobial Agents and Chemotherapy.* ***62*** *(8): e00766–18. doi:10.1128/AAC.00766-18. PMC 6105843. PMID 29891600.*
18. ^ *Hayden, Frederick (2019). "Influenza virus polymerase inhibitors in clinical development". Current Opinion in Infectious Diseases.* ***32*** *(2): 176–186. doi:10.1097/QCO.0000000000000532. PMC 6416007. PMID 30724789.*
19. ^ *条件付き承認で普及に足かせ 富山化学インフル薬の"無念". Retrieved 25 February 2014.*
20. ^ *"Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316". FDA. Retrieved 17 March 2020.*
21. ^ Jump up to: ***a*** ***b*** *陈子琰. "Potential coronavirus drug approved for marketing - Chinadaily.com.cn".* www.chinadaily.com.cn*. Retrieved 2020-03-21.*
22. ^ *"Coronavirus, il Veneto sperimenta l'antivirale giapponese Favipiravir. Ma l'Aifa: "Ci sono scarse evidenze scientifiche su efficacia"". Il Fatto Quotidiano (in Italian). 2020-03-22. Retrieved 2020-03-23.*
23. ^ *"AIFA precisa, uso favipiravir per COVID-19 non autorizzato in Europa e USA, scarse evidenze scientifiche sull'efficacia". aifa.gov.it (in Italian). Retrieved 2020-03-23.*

24. ^ *Gatherer D (August 2014). "The 2014 Ebola virus disease outbreak in West Africa". The Journal of General Virology.* ***95*** *(Pt 8): 1619–24. doi:10.1099/vir.0.067199-0. PMID 24795448.*
25. ^ *Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (May 2014). "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model". Antiviral Research.* ***105****: 17–21. doi:10.1016/j.antiviral.2014.02.014. PMID 24583123.*
26. ^ *Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS (April 2014). "Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model". Antiviral Research.* ***104****: 153–55. doi:10.1016/j.antiviral.2014.01.012. PMID 24462697.*
27. ^ *"First French Ebola patient leaves hospital". Reuters. 4 October 2016.*
28. ^ *"Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea". AllAfrica – All the Time. Retrieved 28 December 2014.*
29. ^ *Fink S (4 February 2015). "Ebola Drug Aids Some in a Study in West Africa". The New York Times.*
30. ^ *Cohen J (26 February 2015). "Results from encouraging Ebola trial scrutinized". Science. doi:10.1126/science.aaa7912. Retrieved 21 January 2016.*
31. ^ *"Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea | CROI Conference". croiconference.org. Retrieved 2016-03-17.*
32. ^ *Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, et al. (March 2016). "Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea". PLOS Medicine.* ***13*** *(3): e1001967. doi:10.1371/journal.pmed.1001967. PMC 4773183. PMID 26930627.*
33. ^ *"Japanese flu drug 'clearly effective' in treating coronavirus, says China". The Guardian. 2020-03-18. Retrieved 2020-03-18.*
34. ^ NHK World News 'China: Avigan effective in tackling coronavirus'
35. ^ Huaxia. "Favipiravir shows good clinical efficacy in treating COVID-19: official." Xinhuanet.com, 17 March 2020
36. ^ *Cai, Qingxian; Yang, Minghui; Liu, Dongjing; Chen, Jun; Shu, Dan; Xia, Junxia; Liao, Xuejiao; Gu, Yuanbo; Cai, Qiue; Yang, Yang; Shen, Chenguang (2020-03-18). "Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study". Engineering. doi:10.1016/j.eng.2020.03.007. ISSN 2095-8099.*
37. ^ *Dong, L; Hu, S; Gao, J (2020). "Discovering drugs to treat coronavirus disease 2019 (COVID-19)". Drug Discoveries & Therapeutics.* ***14*** *(1): 58–60. doi:10.5582/ddt.2020.01012. PMID 32147628.*

show

- **v**
- **t**
- **e**

RNA virus antivirals (primarily J05, also S01AD and D06BB)

Hepatitis C	**NS3/4A**	• Asunaprevir

	protease inhibitors (–previr)	• Boceprevir[‡] • Ciluprevir[§] • Danoprevir[†] • Faldaprevir[‡] • Glecaprevir • Grazoprevir • Narlaprevir • Paritaprevir • Simeprevir • Sovaprevir[†] • Telaprevir[‡] • Vaniprevir • Vedroprevir[§] • Voxilaprevir
	NS5A inhibitors (–asvir)	• Daclatasvir[#] • Elbasvir • Ledipasvir • Odalasvir[†] • Ombitasvir • Pibrentasvir • Ravidasvir[†] • Ruzasvir[†] • Samatasvir[†] • Velpatasvir
	NS5BRNA polymerase inhibitors (–buvir)	• Beclabuvir[†] • Dasabuvir[#] • Deleobuvir[§] • Filibuvir[§] • GS-6620[§] • Setrobuvir[§] • Sofosbuvir[#] • Radalbuvir[†] • Uprifosbuvir[†]
	Combination drugs	• Elbasvir/grazoprevir • Glecaprevir/pibrentasvir • Ledipasvir/sofosbuvir[#] • Ombitasvir/paritaprevir/ritonavir[#] • Sofosbuvir/daclatasvir • Sofosbuvir/velpatasvir[#] • Sofosbuvir/velpatasvir/voxilaprevir
Picornavirus	• *viral entry:* Pleconaril[†]	
Anti-influenza	• Baloxavir marboxil	

agents

- Pimodivir†
- Umifenovir

- *adamantane derivatives/M2 inhibitors* (Adapromine
- Amantadine
- Rimantadine)

- *neuraminidase inhibitors/release phase* (Oseltamivir#
- Zanamivir
- Peramivir, Laninamivir†)

Interferon

- Interferon alfa 2b
- Peginterferon alfa-2a#
- Peginterferon alfa-2b#

Multiple/general

Multiple/unknown

- EICAR§
- Favipiravir
- Galidesivir†
- Remdesivir†
- Mericitabine†
- MK-608§
- NITD008§
- Moroxydine
- Presatovir†
- Ribavirin#
- Taribavirin†
- Triazavirin

- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
  - †Phase III
  - §Never to phase III

show

- **v**
- **t**
- **e**

Filoviridae

Ebolavirus **Species**

- *Bundibugyo ebolavirus*
  - BDBV
- *Reston ebolavirus*
  - RESTV

- *Sudan ebolavirus*
    - SUDV
- *Taï Forest ebolavirus*
    - TAFV
- *Zaire ebolavirus*
    - EBOV

Outbreaks

- 1976 Sudan outbreak
- 1976 Zaire outbreak
- 2013–2016 West African Ebola virus epidemic
    - Timeline
    - Reported cases and deaths
    - Responses
    - United Nations Ebola Response Fund
    - Operation United Assistance
    - in Guinea
    - in Liberia
    - in Mali
    - in Nigeria
    - in Sierra Leone
    - in Spain
    - in the US
    - in the UK
    - Ouse to Ouse Tock
    - Womey massacre
- 2014 DR Congo outbreak
- 2017 DR Congo outbreak
- 2018 Équateur, DR Congo outbreak
- Kivu Ebola epidemic

Drug candidates

- BCX4430
- Brincidofovir
- DZNep
- Favipiravir
- FGI-103
- FGI-104
- FGI-106
- JK-05
- Lamivudine
- mAb114
- TKM-Ebola(failed)
- Triazavirin
- ZMapp

		• Vaccines o cAd3-ZEBOV o rVSV-ZEBOV
	Notable people	• William Close • Jean-Jacques Muyembe-Tamfum • Peter Piot • Selected patients o Ameyo Adadevoh o Kent Brantly o Pauline Cafferkey o Thomas Eric Duncan o Salome Karwah o Sheik Umar Khan o Matthew Lukwiya o Mayinga N'Seka o Patrick Sawyer
	Popular culture	• *The Hot Zone*(1995 book by Richard Preston) • *Outbreak*(1995 film) • *Ebola Syndrome*(1996 film) • *Executive Orders*(1996 novel) • *93 Days*(2016 film)
	Miscellaneous	• Ebola virus disease • Ebola virus disease treatment research • Ebola River
Marburgvirus	**Species**	• *Marburg marburgvirus* o MARV o RAVV
	Outbreaks	• 1967 Marburg virus outbreak in West Germany • 2017 Uganda Marburg virus outbreak
	Drug candidates	• BCX4430 • FGI-103 • FGI-106
	Popular culture	• *The Hot Zone*(1995 book)
	Miscellaneous	• Marburg virus disease • Marburg
Cuevavirus	**Species**	• *Lloviu cuevavirus* (LLOV)
Dianlovirus	**Species**	• Mengla virus (MLAV)

- Commons
- Wikispecies

Retrieved from "https://en.wikipedia.org/w/index.php?title=Favipiravir&oldid=946951189"
Categories:

- Anti-RNA virus drugs

- Pyrazines
- Carboxamides
- Organofluorides
- Ebola
- Hydroxyarenes
- Experimental drugs

---

https://www.theguardian.com/world/2020/mar/18/japanese-flu-drug-clearly-effective-in-treating-coronavirus-says-china

Guardian Newspaper article dated 18 March 2020 regarding Favipiravir = Avigan (which is the Brand Name) with URL https://www.theguardian.com/world/2020/mar/18/japanese-flu-drug-clearly-effective-in-treating-coronavirus-says-china

---

Japanese flu drug 'clearly effective' in treating coronavirus, says China

Patients given the medicine in Shenzhen turned negative in a median of four days Photograph: John Minchillo/AP

Medical authorities in China have said a drug used in Japan to treat new strains of influenza appeared to be effective in coronavirus patients, Japanese media said on Wednesday.

Zhang Xinmin, an official at China's science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.

"It has a high degree of safety and is clearly effective in treatment," Zhang told reporters on Tuesday.

Patients who were given the medicine in Shenzhen turned negative for the virus after a median of four days after becoming positive, compared with a median of 11 days for those who were not treated with the drug, public broadcaster NHK said.

In addition, X-rays confirmed improvements in lung condition in about 91% of the patients who were treated with favipiravir, compared to 62% or those without the drug.

Coronavirus: the week explained - our expert correspondents put a week's worth developments in context in one email newsletter
Fujifilm Toyama Chemical, which developed the drug – also known as Avigan – in 2014, has declined to comment on the claims.

Shares in the firm surged on Wednesday following Zhang's comments, closing the morning up 14.7% at 5,207 yen, having briefly hit their daily limit high of 5,238 yen.

Doctors in Japan are using the same drug in clinical studies on coronavirus patients with mild to moderate symptoms, hoping it will prevent the virus from multiplying in patients.

But a Japanese health ministry source suggested the drug was not as effective in people with more severe symptoms. “We’ve given Avigan to 70 to 80 people, but it doesn’t seem to work that well when the virus has already multiplied,” the source told the Mainichi Shimbun.

The same limitations had been identified in studies involving coronavirus patients using a combination of the HIV antiretrovirals lopinavir and ritonavir, the source added.

In 2016, the Japanese government supplied favipiravir as an emergency aid to counter the Ebola virus outbreak in Guinea.

Favipiravir would need government approval for full-scale use on Covid-19 patients, since it was originally intended to treat flu.

A health official told the Mainichi the drug could be approved as early as May. “But if the results of clinical research are delayed, approval could also be delayed.”

---

https://asia.nikkei.com/Business/Pharmaceuticals/China-says-Japan-developed-drug-Avigan-works-against-coronavirus2

Nikkei Asian Review article dated 18th March 2020 regarding Favipiravir = Avigan (which is the Brand Name) with URL https://asia.nikkei.com/Business/Pharmaceuticals/China-says-Japan-developed-drug-Avigan-works-against-coronavirus2

China says Japan-developed flu drug works against coronavirus - . Fujifilm Toyoma Chemical developed favipiravir, sold under the brand Avigan.

Coronavirus

China says Japan-developed flu drug works against coronavirus

Fujifilm group member's Avigan to be recommended for treatment

SHIN WATANABE, Nikkei staff writer March 18, 2020 07:50 JST

处方药区 PRESCRIPTION DRUGS AREA

The Chinese government has been conducting clinical research on a treatment for COVID-19.
© AP

DALIAN, China -- An influenza medicine developed by a Fujifilm Holdings group member is effective against the novel coronavirus, the Chinese government said Tuesday.

The government plans to officially recommend the drug's use for treatment. Fujifilm Toyoma Chemical developed favipiravir, sold under the brand Avigan.

"It has a high degree of safety and is clearly effective in treatment," said Zhang Xinmin, director of the science ministry's China National Center for Biotechnology Development, in a news conference. Fujifilm Toyoma Chemical developed the drug in 2014, and it has been provided to patients in Japan as treatment for the novel cornonavirus since February.

Zhejiang Hisun Pharmaceutical signed a patent-licensing agreement for favipiravir with Fujifilm in 2016. The drugmaker received clearance to produce the drug from Chinese authorities in February and can ramp up output of a generic version.

The clinical trial was conducted at hospitals in Wuhan and Shenzhen, with 200 patients participating. Test results for those receiving the drug turned negative in a shorter period, and their pneumonia symptoms improved at a higher rate.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 14:47:18 +0000
To: Beigel, John (NIH) [E]
Cc: [redacted] (b) (6)
Subject: FW: IFN treatment for COVID-19
Attachments: Manuscript and Supplement.pdf

John:
  Please handle this.
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Young, Howard (NIH/NCI) [E] [redacted] (b) (6)>
Sent: Monday, March 23, 2020 9:57 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Beigel, John (NIH) [E] [redacted] (b) (6)>
Cc: Eleanor Fish [redacted] (b) (6)>
Subject: IFN treatment for COVID-19

Dear Drs. Fauci and Beigel

Dr. Fish has asked me to share with you this manuscript that has been submitted [redacted] (b) (4)

Regards,
  Howard

From: Eleanor Fish [redacted] (b) (6)>
Sent: Saturday, March 21, 2020 5:25 PM
To: Young, Howard (NIH/NCI) [E] [redacted] (b) (6)
Subject: IFN treatment for COVID-19

Dear Howard,
I wanted to share with your our findings from a clinical study [redacted] (b) (4) .
Please keep this confidential.
The manuscript has been submitted for consideration for publication.

Eleanor N. Fish, PhD, FAAS
UHN Emerita
Professor & Associate Chair
International Initiatives & Collaborations
Dept. Immunology, University of Toronto

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 13:40:42 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW:

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schur, Peter H.,M.D. <[redacted] (b) (6)>
Sent: Monday, March 23, 2020 9:33 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject:

Dear Dr Fauci

I am looking for help and informagtion.

I am still working fulltime at Brigham and Women's Hospital (BWH) as a Rheumatologist--although with the pandemic I am currently working from home

I am also the Medical Director of the BWH Clinical Immunology Lab.

We are looking for a company that can provide us with kits to assess IgG and IgM antibodies to COVID-19. Can you, or one of your staff help us find those companies

When I was at WRAIR many years ago [redacted] (b) (6) they had a walk in -70C freezer with [redacted] (b) (4)

(b) (4)

[redacted]

Thank you for your help. Applaud what you are doing on TV. Applaud what you are doing for this pandemic

Trust you are well

Peter H Schur MD
Senior Physician Brighasm and Women's Hospital
Professor of Medicine Harvard Medical School
Boston MA
Tel: 617-732-5350

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at http://www.partners.org/complianceline . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Mon, 23 Mar 2020 13:02:15 +0000
To:	Stephen Hahn
Subject:	FW: Quick Review: Press Conference Open - March 23
Attachments:	Press Conference Open - March 23 - with Fauci edits.docx

Here it is

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 14:53:22 -0400
To: Adams, Jerome (HHS/OASH);Brett Giroir
Subject: Fwd: Revised social distancing documents - word and powerpoint versions
Attachments: US Social Distancing Recommendations - CDC 1151am_3_16_2020 clean.docx, ATT00001.htm, US Social Distancing Recommendations - CDC 1151am_3_16_2020 track changes.docx, ATT00002.htm, Social Distancing v5 3 16 2020.pptx, ATT00003.htm

FYI

Begin forwarded message:

> **From:** "Schuchat, Anne MD (CDC/OD)" [redacted] (b) (6)>
> **Date:** March 16, 2020 at 12:04:14 PM EDT
> **To:** "Birx, Deborah L. EOP/NSC" [redacted] (b) (6)>, "Azar, Alex (OS/IOS)" [redacted] (b) (6), "Giroir, Brett (HHS/OASH)" [redacted] (b) (6), "Harrison, Brian (HHS/IOS)" [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6) "Kadlec, Robert (OS/ASPR/IO)" < [redacted] (b) (6)>
> **Cc:** "Redfield, Robert R. (CDC/OD)" < [redacted] (b) (6)>, "McGowan, Robert (Kyle) (CDC/OD/OCS)" [redacted] (b) (6)>, "Schuchat, Anne MD (CDC/OD)" [redacted] (b) (6), "Green, Hugh (CDC/OD/OCS)" [redacted] (b) (6)>, "Hoo, Elizabeth (CDC/OD/OCS)" [redacted] (b) (6)>
> **Subject: Revised social distancing documents - word and powerpoint versions**
>
> On behalf of Dr Redfield, I am forwarding a revised word document (clean and track changes) and a revised powerpoint with two slides.
>
> These drafts incorporate feedback that Dr Redfield received from the WHTF as well as the emerging evidence-base. Thus we have combined prior advice on yesterday's version that
>
> [redacted] (b) (5)
>
> Anne Schuchat, MD
> Principal Deputy Director
> Centers for Disease Control and Prevention
> Rear Admiral, US Public Health Service (Retired)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 14 Mar 2020 12:37:15 +0000
To: Howard Bauchner;Butler, Jay C. (CDC/DDID/OD);Preeti Malani;Eli Perencevich;Phil Fontanarosa
Cc: Edward Livingston
Subject: RE: Testing - JAMA - Important

Howard/Jay:

I liked Jay's answers to Howard's questions even though there were still some open issues. I will have to leave it to Jay and the CDC to continue with the discussion since I am really swamped. Sorry.

Thanks,
Tony

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Saturday, March 14, 2020 7:48 AM
To: Butler, Jay C. (CDC/DDID/OD) [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Preeti Malani <pmalani@med.umich.edu>; Eli Perencevich <Eli-perencevich@uiowa.edu>; Phil Fontanarosa <Phil.Fontanarosa@jamanetwork.org>
Cc: Edward Livingston <Edward.Livingston@jamanetwork.org>
Subject: Re: Testing - JAMA - Important

Thanks Jay

Have also copied Ed –

This is going to become very very important – [redacted] (b) (4)

This is crossing my desk 4-5 times per day now – and will only get more important (and sadly confusing) – in the weeks to come.

Some questions would focus on public others on HCW (where I am sure general guide; talk with your CMO).

I do love the mention of monopoly – [redacted] (b) (6)

What you think?

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my chats with authors

From: "Butler, Jay C. (CDC/DDID/OD)" [redacted] (b) (6)>
Date: Saturday, March 14, 2020 at 6:42 AM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>, Tony Fauci [redacted] (b) (6)>, Preeti Malani <pmalani@med.umich.edu>, Eli Perencevich <Eli-perencevich@uiowa.edu>, Phil Fontanarosa <Phil.Fontanarosa@jamanetwork.org>
Subject: Re: Testing - JAMA - Important

[Warning External Email]
Good morning, Howard—some answers and non-answers. As is the case for most answers, the most accurate is "it depends", but I realize that is not helpful in busy clinical settings:
No symptoms – get test positive – can you work

At this point in the pandemic, no. While we do not know what role asymptomatic infection may play in transmission and it is plausible that someone who is NOT coughing and sneezing (or any other respiratory droplet self-generating acts)is going to be less infectious than someone who is, persons known to be infected should self-isolate. This, of course, is particularly important for someone who has closed contact with someone at greater risk of severe illness and health care providers.

Symptoms – test negative – can you work – or do you need 2 negatives – or the test has to be done 2-3-4 days after you develop symptoms

Even before COVID-19, working while ill with a respiratory illness puts others at risk. Particularly during when flu activity is high. Not toughing it out and going into work while sick is more important now than ever and is an important component of social distancing—this is one of the foundational ways that we distribute the impact of the pandemic over aS long of a period as possible. (We are all getting good a drawing the two pandemic curves in the air on imaginary x- and y-axes.). One of the critical areas where we need more data is on when someone who is infected becomes test-positive. Presumably, test-positivity would correlate with viral load in the respiratory tract and a + would indicate greater likelihood of infectiousness. But the real challenge of the return-to-work issue lies in your next question:

Test positive – back to work when – do you need negative tests – or just time - ? 2 weeks after first symptoms, first test positive.

Ah, there is the rub—currently, the recommendations vary—CDC has gone with 2 negative swabs 24 hours apart, but we do not believe that positivity during recovery necessarily proves infectiousness. This is a crucial question. We are reviewing the available data, examining at how PCR positivity, cycle threshold, and viral culture line up—the goal is to develop good, clinical parameters to justify ending precautions, rather than requiring microbiological tests. A Get Out of Isolation Free card, if you will. The hypothesis we are testing to 2 weeks after onset and >72 hours without symptoms. Currently the published recommendations are not satisfying:

https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html

I may have more information on this topic later today.

Finally, in all complex epidemics, there is a tendency to search for a silver bullet—that one thing that will solve all of our problems. When an intervention is in short supply, the bullet turns platinum—"if only we could do x, the problem would be solved". This was vaccine in 2009 H1N1, naloxone in the opioid crisis, and now testing in coronavirus. Increased access to testing is desperately needed to control the COVID-19 pandemic. However, it is going to take a scientifically and wholistic and systemic approach to mitigate the impact. You have nicely outlined some of the "next questions" that are raised when testing is more widely available.

More to follow.

Best regards,
Jay

Get Outlook for iOS

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Saturday, March 14, 2020 5:53 AM
To: Butler, Jay C. (CDC/DDID/OD); Fauci, Anthony (NIH/NIAID) [E]; Preeti Malani; Eli Perencevich; Phil Fontanarosa
Subject: Testing - JAMA - Important

Jay/Tony

Some very complicated questions around testing have come up and will only increase.

No symptoms – get test positive – can you work

Symptoms – test negative – can you work – or do you need 2 negatives – or the test has to be done 2-3-4 days after you develop symptoms

Test positive – back to work when – do you need negative tests – or just time - ? 2 weeks after first symptoms, first test positive.

As tests become more widely available this will be devil folks.

Any ideas who can write about this.

Jay – does CDC have specific recommendations.

Sorry to bother on Saturday morning -but would like to get up a VP as soon as Tuesday.

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my chats with authors

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 23:06:12 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Antibody Tests and Follow-on Use of 'Survivors'

From: Estes, Franklin J (Frank) LTC USARMY 335 SIG CMD (USA) [redacted] (b) (6)
Sent: Sunday, March 22, 2020 12:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Antibody Tests and Follow-on Use of 'Survivors'

Dr. Fauci,

I apologize in advance for bugging you but please read and pass along to the appropriate person, if useful.

In the coming weeks, an antibody test for COVID-19 should be available (I suspect). As 'survivors' are identified in the general population and are determined to be largely 'immune' to COVID-19, I think those people should be given the opportunity to administer testing to others in the general population. The employment of VOLUNTEER survivors in the administration of tests would allow immune individuals to quickly learn how to collect samples and deal with potential infected patients face-to-face without fear of jeopardizing their own health or the health of the communities in which they live. This would free up highly trained nurses and doctors from testing and have an exponential benefit as survivors administer tests for infection and tests for antibodies and, thus, identify additional survivors. This would support more aggressive testing to bring about the eventual end of this virus when we try to identify every last infected individual who needs to be quarantined.

Note: I understand we haven't yet determined whether survivors can be re-infected. So early volunteers may be subjected to further sickness. But the rate of re-infection should be less as a percentage than the rate of infection among the general population. And re-infection would likely be less severe.

Note2: Creating a VOLUNTARY REIGSTRY of survivors (those with sufficient antibodies) may have a secondary benefit to businesses. It would allow businesses to quickly hire employees who could come in contact with the general public (thinking of current food delivery, grocery stores, daycare...and later...teachers, anyone in the medical or dental field, other retail businesses).

I do understand my recommendations would generate HIPAA concerns but these are extraordinary times which call for out-of-the-box ideas...and this would all be voluntary.

Thank you for taking a couple of minutes to read this and thank you for managing a very difficult crisis. You and others on your team have saved a lot of lives and we are eternally grateful.

Respectfully,

Frank Estes
[redacted] (b) (6) (cell)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 11:17:11 +0000
To: (b) (6) USAR MEDCOM (USA)
Subject: RE: Recommendation

(b) (6)

Thank you for your note.
Best regards,
Tony

From: (b) (6) USAR MEDCOM (USA) (b) (6)>
Sent: Tuesday, March 17, 2020 6:52 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Recommendation

Dr. Fauci,
I am a Nurse Practitioner (b) (6) for the US Army. I have a recommendation as we move through this terrible time in the US as well as the world. To preserve the healthcare workforce why not give 25% of all health workers in the military the trial vaccine? Keep these workers away from patients until which time that the body can build immunity. Let's not expose the entire medical workforce to the COVID-19. The idea is that this 25% can take care of the population (post-vaccine) without worry of getting ill and causing further spread of the disease. If there is possibility of the vaccine, trial age cohorts and demographics could play a crucial part in testing. Thank you for all you are doing to protect the health of our Nation.
Respectfully,
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 23:47:21 +0000
To: Hahn, Stephen
Cc: Redfield, Robert R. (CDC/OD);Birx, Deborah L. EOP/NSC;Lane, Cliff (NIH/NIAID) [E];[redacted] (b) (6);Rom, Colin (FDA/OC)
Subject: RE: Treatment Document

Sounds good to me.
Thanks,
Tony

From: Hahn, Stephen [redacted] (b) (6)>
Sent: Friday, March 20, 2020 7:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Redfield, Robert R. (CDC/OD) [redacted] (b) (6) Birx, Deborah L. EOP/NSC [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); [redacted] (b) (6); Rom, Colin (FDA/OC) [redacted] (b) (6)>
Subject: Re: Treatment Document

Tony,
Looks like [redacted] (b) (5). The group wants to make some more edits and then send out this evening for review. We would like to meet up prior to or after the task force meeting tomorrow. Sound OK?
Steve

Sent from my iPad

> On Mar 20, 2020, at 7:06 PM, Hahn, Stephen [redacted] (b) (6)> wrote:
>
> I have a couple of comments
>
> [redacted] (b) (5)
>
> I'll await for other comments.
>
> Thanks
> Steve
>
> Sent from my iPad

On Mar 20, 2020, at 6:45 PM, Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)> wrote:

Team:

As per my discussion with Steve a few minutes ago, I have made some changes in the document. [redacted] (b) (5) [redacted] (b) (5) [redacted] (b) (5) I am attaching a tracked version of the document that was your FINAL as well as a clean copy with all of the changes accepted. Please take a look and Steve said that he would like to set up a quick call to discuss after you have had a look. I am very sorry to come in with these changes at this late point, but I really did not get a chance to have a good look at the document as I was in a car.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

<dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked changes showing.docx>
<dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked Clean copy.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 12:58:59 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Respiratory Protection Program: Temporary Suspension of Fit Testing

For my clinical center Certification folder.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Wu, Sarah (NIH/OD/ORS) [E] [redacted] (b) (6)
Sent: Monday, March 23, 2020 8:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Respiratory Protection Program: Temporary Suspension of Fit Testing

Respiratory Protection Program Participants:

Due to the recent COVID-19 outbreak and supply chain shortage, we are temporarily suspending annual fit tests for employees at this time. You will still be required to complete fit testing if:

- you have experienced significant physical changes likely to impact the fit of your respirator such as:
  - substantial weight loss/gain
  - dental surgery
  - cosmetic surgery including the neck area and above
  - an accident
  - a new medical diagnosis
- you are directly involved in the COVID-19 response and are expected to be in close contact with potential COVID-19 patients
- you are emergency response personnel (police, fire department, etc.) required to be on-site throughout this pandemic

If you do not meet these criteria, you are not required to complete your fit test at this time. Please be advised that you will still need to complete the online training despite the suspension of fit testing. *Regular fit testing will resume once the COVID-19 emergency has subsided.*

Any questions concerning the HealthRx website should be directed toward support@healthrx.com. Please visit the manufacturer's websites for details on your particular respirator model. If you have questions about N95 respirators in general, feel free to email nihrespirator@mail.nih.gov. Thank you for your efforts and consideration during this event.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 12:58:16 +0000
To: Karen Backman
Subject: RE: Your Unprecedented Leadership and Professionalism

Karen:

Many thanks for your kind note.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Karen Backman (b) (6)
Sent: Monday, March 23, 2020 8:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Your Unprecedented Leadership and Professionalism

Good morning Dr. Fausi,

I am not one to write emails to our leaders in government as I am sure that the message doesn't get to where it always needs to go. At the risk of you possibly seeing this email, you need to know that you are doing an incredible job.

I doubt you will be broadcasting this note but you should know that my husband and I take great comfort in seeing you up on the podium next to our country's leadership on the COVID-19 pandemic. You are a steady voice of reason and the right person for the job. Even when the President doesn't get it quite right, you manage to be professional in your delivery, information and steadfast manner. We can easily look past the President but we listen when you speak.

From the first time I heard you say on a Sunday morning talk show, "If you think we are overacting then we are probably doing the right things." I live in Maine and we are a rural state so we probably won't see the numbers that are elsewhere but we are listening and acting on your words of caution.

I can't imagine how much pressure you are under doing your job but we need more leadership such as yours. How you choose your words so carefully without getting flustered is a gift. I can only hope that you will continue to be the voice to get this country through this unprecedented event.

Stay healthy and keep doing what you're doing as it matters so much to this nation.

Sincerely,

Karen L. Backman

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 12:46:08 +0000
To: [redacted] (b) (6)
Subject: Confidential
Attachments: Press Conference Open - March 23 - with Fauci edits.docx

Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 12:25:31 +0000
To: info@mail.mlblists.com
Subject: RE: Fill the baseball void: Trivia, A-Rod clinic, classic games

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Mon, 23 Mar 2020 07:32:09 -0400
To: DMID Word Nerds
Subject: Fwd: COVID-19- NOVEL DRUG
Attachments: [redacted] (b) (4) 3_17_2020.pdf, ATT00001.htm

Sent from my iPhone

Begin forwarded message:

> **From:** Radka Milanova [redacted] (b) (6)>
> **Date:** March 23, 2020 at 1:43:46 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: COVID-19- NOVEL DRUG**
>
> Dear Dr. Anthony Fauci:
>
> I am involved with a US-based Company Bioxytran [redacted] (b) (4) (b) (4)

[redacted] (b) (4)

I look forward to hearing from you.

Kind regards,

==========================

Radka Milanova, Ph.D.
Office: + 604 488 8880
Mobile: [redacted] (b) (6)
Email: milanova@shaw.ca

This message and any attachments are intended only for the use of the addressee and may contain information that is privileged and confidential. If the reader of the message is not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any dissemination of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by e-mail and delete the message and any attachments from your system.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 01:37:39 +0000
To: David Rubenstein
Subject: FW: USA Today/David M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

David:
You were so very kind to me in this article. Thank you so much.
Warm regards,
Tony

Coronavirus hero: Anthony Fauci is a great public servant in a time of great public need

Fauci is the world's leading authority on infectious diseases and the best person in the country to help us deal with the COVID-19 crisis.

David M. Rubenstein
Opinion contributor

Some viewers of the daily White House coronavirus briefings may wonder why everyone increasingly defers to a diminutive, Brooklyn-accented 79-year-old doctor, Tony Fauci.

They do because, as I have learned over many years of talking with and more recently interviewing this man, he is without doubt the world's leading authority on infectious diseases. In any area of human activity or knowledge, there always seems to be one person who is the global gold standard. In the world of infectious diseases that person is Tony Fauci.

So the American people — indeed, people around the globe — should be grateful that Tony has dug into this crisis with the same work-around-the-clock, just-the-facts ma'am style that he has used while serving under and working with six U.S. presidents. He is as apolitical as anyone can be. I have no idea if he is registered with any political party; I suspect though that he is rabidly Independent. His only focus is getting the facts out, providing the best health care treatment and information possible, and saving lives.

A top expert from AIDS to Ebola

Tony Fauci joined the National Institutes of Health in 1968, after completing his medical training at Weill Cornell Medical Center, and he has led the National Institute of Allergy and Infectious Disease since 1984 — 36 years. Hard to believe anyone can run anything that long and still be at the top of his game. But Tony is. During this period, he has dealt with every serious infectious disease challenge — malaria,
Among Tony's best known accomplishments, beyond simply running the institute and training dozens of the world's top infectious disease professionals, has been helping to discover how HIV leads to AIDS and, later, leading the effort to create (at President George W. Bush's direction) the President's Emergency Plan for AIDS Relief (PEPFAR), which has transformed the treatment of HIV/AIDS in Africa, and other parts of the developing world. Millions of lives have been saved by this program alone. More recently, he has been an architect and powerful advocate of President Donald Trump's plan for ending the AIDS epidemic in the U.S. through HIV antiretroviral therapy targeted to disease hotspots.

In his spare time, Tony has been involved with writing or editing more than 1,100 scholarly articles and several textbooks, and, in the process, has become one of the most cited authorities of the entire medical profession.

For these breakthrough activities and his dedicated service (at a government salary) for more than a half century (he worked at NIH for 16 years before assuming his current role), Tony has received, and earned, the Presidential Medal of Freedom and a Lasker Award (called the American Nobel by many).

With this long service and universal acclaim, one might think Tony would let it get to his head, at least a little bit. Not the case, though.

Selfless commitment to public service

He is readily accessible to those who need treatment — he still runs a lab at NIH — or need information. Tony still lives in the same house he bought when he first moved to Washington, and it is there that he and his wife Christine have raised their three talented daughters (though none of them chose to attend medical school).

Until the latest crisis, Tony has often commuted to NIH by Metro, typically after running three miles for his daily exercise. And when he has been invited to make speeches in the Washington area or on Capitol Hill, he invariably turns down a car and driver for the Metro. (This practice has had to change of late for the obvious reasons).

There are, of course, many other dedicated federal servants who also view their commitment to the country and its people over financial rewards. But surely no federal civil servant, in any area, can exceed Tony Fauci's long-term and selfless commitment to this country and the health of its people.

I tried years ago, when Tony was approaching a normal retirement age, to see if he might want after a normal lifetime of federal service, to take some of his considerable skills and knowledge to the private sector. He quickly said no — money did not motivate him, serving the country did. And he stayed at NIH — to the country's good fortune.

If there is any one medical professional who can help the country deal with the COVID-19 crisis, it is Tony Fauci, an example of the best this country has to offer.

He is not a miracle worker. No one is.

But Tony Fauci has the decades of experience needed to understand infectious disease problems and prescribe a treatment that should, in time, provide the requisite comfort, even if, in the short term, the medicine is painful and inconvenient.

David M. Rubenstein is the co-executive chairman of The Carlyle Group.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 01:23:55 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; [redacted] (b) (6)
Subject: FW: Possible agenda for Wednesday
Attachments: COVID-19 TransNIH_032520 hm.docx

Please take the lead in putting together slides for Wednesday. If I can make it (which is uncertain),I will need them to make a presentation.
Thanks,\Tony

From: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, March 22, 2020 7:10 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6) Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6); Anderson, James (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Lane, Cliff (NIH/NIAID) [E] < [redacted] (b) (6)>
Subject: Re: Possible agenda for Wednesday

Thanks for the chance to weigh in. I have it blocked on my calendar and would look forward to the discussion. And I'm happy to pull slides together as outlined.

Here are some minor comments on the agenda, which looks excellent.

Looking forward to it,

Hilary

From: "Collins, Francis (NIH/OD) [E]" [redacted] (b) (6)
Date: Sunday, March 22, 2020 at 5:09 PM
To: Hilary Marston < [redacted] (b) (6)>
Cc: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)>, "Wolinetz, Carrie (NIH/OD) [E]" [redacted] (b) (6)>, "Anderson, James (NIH/OD) [E]" [redacted] (b) (6), Anthony Fauci [redacted] (b) (6)>, Henry Lane [redacted] (b) (6)
Subject: Possible agenda for Wednesday

Hi Hilary,

I've been through the COVID-19 ideas collected from your Deputies meeting, plus reaching out for a few other inputs. What I hope to do is to assemble this into a lively three-hour discussion on Wednesday afternoon (2 - 5 PM). Tony is enthusiastic about our doing this, but his presence is unfortunately doubtful, given all of the other demands he faces. I'm counting on you and Cliff to be there, however – is this etched on your calendars?

Please see attached for my rather rough first attempt at an agenda. It's a lot of topics and the list will probably need to be culled – [redacted] (b) (5)

I would want there to be time for discussion in each theme, so that other ideas could be floated.

Please let me know your thoughts, ideally this evening. I'm also asking for input from others who are cc'd here.

Best, Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 00:56:30 +0000
To: Jon LaPook
Subject: RE: Tony, my three minute shpiel on CBS Sunday Morning today.

Very well done as usual.

-----Original Message-----
From: Jon LaPook (b) (6)>
Sent: Sunday, March 22, 2020 8:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Tony, my three minute shpiel on CBS Sunday Morning today.

Https://www.cbsnews.com/news/coronavirus-covid-19-social-distancing-how-to-reduce-risk-together/

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 00:51:49 +0000
To: McNeil Jr, Donald G
Subject: RE: big story of mine just posted

Donald:

You not only got it right, but it was an extraordinarily comprehensive, informative and sobering article. I do not agree with everything that is being done by various countries, and you have indicated that many of these approaches are controversial. However, your reporting of them is accurate and well-articulated. Bottom line is that this is an outstanding article.
Best,
Tony

From: McNeil Jr, Donald G <mcneil@nytimes.com>
Sent: Sunday, March 22, 2020 7:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: big story of mine just posted

I would have interviewed you for it, but I know you're busy. I hope you think I got it right....

https://www.nytimes.com/2020/03/22/health/coronavirus-restrictions-us.html

--
Donald G. McNeil Jr.
Science Correspondent
The New York Times

Tel: +1 212 556 1142
mcneil@nytimes.com

Articles: https://www.nytimes.com/by/donald-g-mcneil-jr

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 23:27:37 +0000
To: Murphy, Philip (NIH/NIAID) [E]
Subject: RE: Suggestion

Phil:

Thanks for the note. Very important point.

Best,
Tony

From: Murphy, Philip (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, March 22, 2020 7:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Suggestion

Yeoman work, Tony. One suggestion: [redacted] (b) (5)

All the best,
Phil

[redacted] (b) (5)

(b) (5)

[redacted]

Phil

From: [redacted] (b) (6)
Sent: Sun, 22 Mar 2020 17:23:08 -0400
To: Cicala, Claudia (NIH/NIAID) [E]
Subject: Re: Your idea about COVID-19

Thanks, Claudia

> On Mar 22, 2020, at 5:17 PM, Cicala, Claudia (NIH/NIAID) [E] [redacted] (b) (6)
>
> Dear Tony,
>
> Thank you for taking the time to answer. I want you to know that a huge number of people here and in Italy asked me to pass along a message of support. Thank you for all you are doing.
> Take a good care of yourself,
> Claudia
>
> Sent from my iPhone
>
>> On Mar 22, 2020, at 1:27 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6):
>>
>> Jim:
>> [redacted] (b) (5)
>> [redacted] Needless to say, this is a overwhelmingly compelling public health and scientific issue. Keep me posted.
>> Thanks,
>> Tony
>>
>> **Anthony S. Fauci, MD**
>> **Director**
>> **National Institute of Allergy and Infectious Diseases**
>> **Building 31, Room 7A-03**
>> **31 Center Drive, MSC 2520**
>> **National Institutes of Health**
>> **Bethesda, MD 20892-2520**
>> **Phone:** [redacted] (b) (6)

FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 17:29:47 +0000
To: Hallett, Adrienne (NIH/OD) [E]
Subject: RE: Senate Supplemental #3

Thanks!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hallett, Adrienne (NIH/OD) [E] <[redacted] (b) (6)>
Sent: Sunday, March 22, 2020 1:21 PM
To: icddir-l@LIST.NIH.GOV
Subject: Senate Supplemental #3

NATIONAL INSTITUTES OF HEALTH NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

For an additional amount for ''National Heart, Lung, and Blood Institute'', $103,400,000, to remain available until September 30, 2024, to prevent, prepare for, and re- spond to coronavirus, domestically or internationally: *Pro- vided*, That such amount is designated by the Congress as being for an emergency requirement pursuant to sec- tion 251(b)(2)(A)(i) of the Balanced Budget and Emer- gency Deficit Control Act of 1985.

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

For an additional amount for ''National Institute of Allergy and Infectious Diseases'', $706,000,000, to re- main available until September 30, 2024, to prevent, pre- pare for, and respond to coronavirus, domestically or internationally:

Provided, That not less than $156,000,000 of the amounts provided under this heading in this Act shall be provided for the study of, construction of, demolition of, renovation of, and acquisition of equipment for, vaccine and infectious diseases research facilities of or used by NIH, including the acquisition of real property: *Provided further*, That such amount is designated by the Congress as being for an emergency requirement pursuant to section 251(b)(2)(A)(i) of the Balanced Budget and Emergency Deficit Control Act of 1985.

NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING

For an additional amount for ''National Institute of Biomedical Imaging and Bioengineering'', $60,000,000, to remain available until September 30, 2024, to prevent, prepare for, and respond to coronavirus, domestically or internationally: *Provided*, That such amount is designated by the Congress as being for an emergency requirement pursuant to section 251(b)(2)(A)(i) of the Balanced Budget and Emergency Deficit Control Act of 1985.

NATIONAL LIBRARY OF MEDICINE

For an additional amount for ''National Library of Medicine'', $10,000,000, to remain available until September 30, 2024, to prevent, prepare for, and respond to coronavirus, domestically or internationally: *Provided*, That such amount is designated by the Congress as being for an emergency requirement pursuant to section 251(b)(2)(A)(i) of the Balanced Budget and Emergency Deficit Control Act of 1985.

NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

For an additional amount for ''National Center for Advancing Translational Sciences'', $36,000,000, to remain available until September 30, 2024, to prevent, prepare for, and respond to coronavirus, domestically or internationally: *Provided*, That such amount is designated by the Congress as being for an emergency requirement pursuant to section 251(b)(2)(A)(i) of the Balanced Budget and Emergency Deficit Control Act of 1985.

OFFICE OF THE DIRECTOR

For an additional amount for ‘‘Office of the Director’’, $30,000,000, to remain available until September 30, 2024, to prevent, prepare for, and respond to coronavirus, domestically or internationally: *Provided*, That these funds shall be available for the Common Fund established under section 402A(c)(1) of the PHS Act: *Provided further*, That such amount is designated by the Congress as being for an emergency requirement pursuant to section 251(b)(2)(A)(i) of the Balanced Budget and Emergency Deficit Control Act of 1985.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 17:28:59 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Cc: Crawford, Chase (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Dr. Fauci: Senate Draft COVID-19 Supp

Thanks. [redacted] (b) (5).

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, March 22, 2020 1:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Crawford, Chase (NIH/NIAID) [E] [redacted] (b) (6)>; Selgrade, Sara (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Dr. Fauci: Senate Draft COVID-19 Supp

From: [redacted] (b) (6)
Sent: Sun, 22 Mar 2020 10:58:06 -0400
To: Michela Carluccio
Subject: Re: telmisartan and covid-19

Ms. Carluccio:
Thank you for your note. [redacted] (b) (6)

Best regards,
AS Fauci

> On Mar 22, 2020, at 9:33 AM, Michela Carluccio [redacted] (b) (6)>wrote:
>
> Dear Professor Fauci,
>
> sorry for the disturb.
>
> My name is Michela, I contacted her from Italy and I am (b) (6) [redacted] years old.
>
> I hope you understand my concern, I will contact you for advice if possible:
>
> [redacted] (b) (6)

(b) (6)

[redacted]

Sincerely,



Ms. Michela Carluccio

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 05:29:11 +0000
To: guy@vidaldesigncollaborative.com
Subject: RE: ● Suggestion from former Israel Defense Forces member

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 21 Mar 2020 23:02:34 +0000
To: Redfield, Robert R. (CDC/OD)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: TF Agenda for tomorrow (Sunday)
Attachments: White House Coronavirus Task Force Agenda 3.22.20.docx

Bob:

See attached TF Agenda for tomorrow. [redacted] (b) (5) (b) (5) (b) (5). Many thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Sat, 21 Mar 2020 18:17:02 -0400
To: Auchincloss, Hugh (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]
Subject: Fwd: Positive COVID-19 test result for [redacted] (b) (6)

Sent from my iPhone

Begin forwarded message:

> **From:** "Holland, Steven (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Date:** March 21, 2020 at 4:40:28 PM EDT
> **To:** "McGowan, Colleen (NIH/OD/ORS) [E]" [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>, "Lane, Cliff (NIH/NIAID) [E]" <[redacted] (b) (6), "Harper, Jill (NIH/NIAID) [E]" [redacted] (b) (6)>, "McGowan, John J. (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** " [redacted] (b) (6)
> **Subject: Re: Positive COVID-19 test result for** [redacted] (b) (6)
>
> Thanks, Colleen. [redacted] (b) (6), to bring him into the loop. I am also [redacted] (b) (6) into this for her knowledge.
>
> Steve
>
> --
> Director, Division of Intramural Research
> National Institute of Allergy and Infectious Diseases
> National Institutes of Health
> Bldg. 10/11N248 MSC 1960
> Bethesda, MD 20892-1960
> [redacted] (b) (6) voice
> 301-480-4507 fax
> [redacted] (b) (6) email
>
> Assistant lab: Eva Portillo
> [redacted] (b) (6) email
> [redacted] (b) (6) voice

Assistant to SD: Beth Schmidt
[redacted] (b) (6)
[redacted] (b) (6) voice

From: "McGowan, Colleen (NIH/OD/ORS) [E]" <[redacted] (b) (6)>
Date: Saturday, March 21, 2020 at 4:17 PM
To: Steven Holland [redacted] (b) (6)>, Anthony Fauci [redacted] (b) (6) Henry Lane [redacted] (b) (6)>, Jill Harper [redacted] (b) (6), John J McGowan [redacted] (b) (6)>
Subject: Positive COVID-19 test result for [redacted] (b) (6)

I'm writing to share that we have received a positive COVID-19 test result of an [redacted] (b) (6) These results just came out of the 2pm test run today. The [redacted] (b) (6) supervisor is [redacted] (b) (6) The person reported being symptomatic on 3/13/2020, contacted OMS on Monday, but didn't get scheduled for testing till Friday 3/20/20. I'm told [redacted] (b) (6) continued to work [redacted] (b) (6) even when feeling ill. I'm not permitted to share PHI, but I am told that OMS has notified the employee, and if they haven't done so already, OMS will contact the supervisor with general information regarding the person's general health status. They will not divulge a positive test result for COVID-19, but rather state a general health condition which precludes the staff member from working.

Since [redacted] (b) (6) is working in [redacted] (b) (6), I presume [redacted] (b) (5), but please let me know if this isn't the case. ORF typically closes down the location for 7 days to allow environmental dissipation of contact surface contamination. I know this area is mission critical, so I will help you contact ORF about prioritizing cleaning procedures. We ask that you take great care in keeping that information as confidential as you can.

Thanks
Colleen

Colleen A. McGowan, MHA, FACHE
Director, NIH Office of Research Services
Bldg 31, Room 4B54
Office Phone: [redacted] (b) (6)

1979 - 2019
LOOKING
FORWARD
AT 40

OFFICE OF
RESEARCH SERVICES

From: (b) (6)
Sent: Sat, 21 Mar 2020 18:13:55 -0400
To: NIAID Public Inquiries
Subject: Fwd: Jafri_Research Volunteering

Sent from my iPhone

Begin forwarded message:

> **From:** Riaz Jafri (b) (6)>
> **Date:** March 21, 2020 at 5:34:20 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
> **Subject: Jafri_Research Volunteering**
>
> Hi Dr. Fauci,
> Hope you are doing well and thanks for your leadership during this pandemic situation.
> I have a medical degree and has experience in basic and clinical research for almost 30 years. Currently in clinical trials, doing studies monitoring. I would like to volunteer during this COVID-19 situations. Please let me know if I can share in anyway.
>
> I appreciate it.
> Best regards and be safe..
>
> Dr. Syed R. Jafri
> Ph: (b) (6)
>
> Sent from my iPhone

From: [redacted] (b) (6)
Sent: Sat, 21 Mar 2020 18:13:34 -0400
To: Cassetti, Cristina (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E];Handley, Gray (NIH/NIAID) [E]
Subject: Fwd: Possible joint collaboration Polish -American Collaboration

Hoping one of you can handle. Taking this out of ASF inbox

If we need to discuss with him let me know.

Sent from my iPhone

Begin forwarded message:

> **From:** Aleksandra Wesołowska [redacted] (b) (6)>
> **Date:** March 21, 2020 at 6:08:46 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Possible joint collaboration Polish -American Collaboration**
>
> Dear Dr Anthony Fauci ,
>
> I am writing in connection to email from Prof Robert Schwartz about possible Polish - American collaboration in the clinical trial focus on treatment patients suffer from COVID-19
>
> As a Polish Medical Research Agency we desire facing this pandemic
> with NIAID leading vaccine and therapy efforts against SARS-Cov-2.
>
> F. Gray Handley has got in contact with the President of our Agency last week but from that time we have no further information in this pressing issue.
>
> I will be very appreciated if we could discussed with you or your eminent staff any possibility for polish scientists to joint collaboration with NIAID to fight coronavirus for patients all of the world.
>
> I will be personally responsible to hold this topic on behalf of Polish Medical Research Agency.

Thank you for your time and incredible efforts you made to global health and safety.

I remain at your disposal,

Aleksandra Wesołowska, PhD
Senior Research Coordinator

Agencja Badań Medycznych
ul. Moniuszki 1A
00-014 Warszawa
www.abm.gov.pl

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 21 Mar 2020 16:43:19 +0000
To: NIAID OD AM
Subject: FW: Virtual Town Hall with College Students (30+ Schools)?

From: John Monahan <John.Monahan@georgetown.edu>
Sent: Saturday, March 21, 2020 10:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Virtual Town Hall with College Students (30+ Schools)?

Tony --

First of all, thank you for all you are doing to lead our country's response during this crisis.

I hesitate to reach out to you with so much on your plate, but I think this idea might help with the national response.

In light of the continuing challenge of engaging young people in social distancing measures, combined with the fact that so many colleges and universities are now teaching online, Georgetown's Global Health Initiative and Institute for Politics and Public Service are considering a "virtual town hall" in which you could speak directly with students at colleges and universities via Zoom (or some other platform) about the collective challenge of COVID-19 and its risk to their health and to other members of their communities.

This could be a unique forum for you, as the most trusted person in the public dialogue, to make the case directly to young people about their vital role in social distancing to flatten the curve in their communities. We would use social media, of course, to push out key segments and messages from this event more broadly.

While Georgetown would organize this "virtual town hall", we would work closely with a network of more than 30 colleges and universities with which our Institute of Politics and Public Service regularly collaborates. We would also reach out to other schools to ensure a geographic reach and a mix of public and private institutions. Of course, our team would work closely with your staff to manage all logistics so as to use your scarce time as efficiently as possible.

Before we go any further in planning or thinking about this, I wanted to see if you would have time to participate or think this is a good idea.

Best!

John

John T. Monahan, JD

Senior Advisor to the President of Georgetown University
Senior Fellow, McCourt School of Public Policy
Senior Scholar, O'Neill Institute for National and Global Health Law
Georgetown University
3307 M Street NW, Suite 202
Washington, DC 20057
202-431-6556

From: [redacted] (b) (6)
Sent: Sat, 21 Mar 2020 07:48:05 -0400
To: KEN GLEN
Subject: Re: COVID-19

Thank you for your note.
AS Fauci

Sent from my iPhone

> On Mar 21, 2020, at 7:43 AM, KEN GLEN [redacted] (b) (6)>wrote:
>
> Good morning, from Vancouver, Canada.
>
> We hope you are keeping yourself, and your families safe.
>
> Your calm approach, and real life experience being shared during the daily briefings is what everyone looking towards the USA for information needs to see.
>
> As in anything, real knowledge, both sharing and accepting is critical to get everyone focused on overcoming the current situation.
>
> We don't see social distancing between everyone at the news conferences, and that is disappointing, we also don't see Donald Trump acquiring the skills and abilities to truly turn over communication and leadership to people such as yourself and your colleagues on the podium.
>
> While that is also disappointing, it has come to be expected, therefore easy to tune out.
>
> Our Global world needs a Global approach of honesty and transparency, we can't afford to get this one wrong due to our normal tribal tendencies.
>
> Best regards, be safe,
>
> Ken &Cathy Glen [redacted] (b) (6))

From: [redacted] (b) (6)
Sent: Sat, 21 Mar 2020 07:44:54 -0400
To: Lerner, Andrea (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: Provider's question!

From Patty

Can one of u pls take this.

Sent from my iPhone

Begin forwarded message:

> **From:** "Rostami, Nahid" <[redacted] (b) (6)>
> **Date:** March 20, 2020 at 7:25:06 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** "Rostami, Nahid" [redacted] (b) (6)
> **Subject: Provider's question!**
>
> Dear Dr. Fauci,
>
> I am one of the UCSF neonatologist and I have been [redacted] (b) (6) I am [redacted] (b) (6) now. As you know, in neonatal intensive care unit at least one parent stays at bedside. Considering the recent coronavirus outbreak, I am [redacted] (b) (6) for both potential patient [redacted] (b) (6) and staff exposures. I appreciate your advice and recommendation for [redacted] (b) (6) who is working in an intensive care unit. Since I have to go to work, do I need to have extra percussions besides hand washing? If so, what would you recommend?
>
> I appreciate your help.
>
> Thanks,
>
> Nahid Rostami

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:42:07 -0400
To: Parks, Donna (djholmes@uidaho.edu)
Subject: Re: Thank you

Thank you for your note.
AS Fauci

Sent from my iPhone

> On Mar 20, 2020, at 8:49 PM, Parks, Donna (djholmes@uidaho.edu) <djholmes@uidaho.edu> wrote:
>
> Dear Dr.Fauci:
>
> I want to thank you and commend you for all you're doing during the COVID-19 pandemic. You are the voice of science and reason - and you seem to be able to get through to President Trump in a subtle way yet with a great deal of integrity. I don't envy you this gig - particularly with an administration that is so hostile to science, reason, and preparedness on the federal level.
>
> I'm still squirming from Trump's latest declarations that hydroxquinolone could be used for COVID. The more you can explain why this might not be the place to put federal resources right now, the better. Friends of mine are buying it off label in Mexico now, and as a biologist and medical educator I find this alarming.
>
> Thanks. You're the best.
>
> Donna Holmes Parks | djholmes@uidaho.edu
> WWAMI Medical Education Program
> University of Idaho and University of Washington
>
>

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:39:16 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Coronavirus interview

Sent from my iPhone

Begin forwarded message:

> **From:** "Lindenberger, Isaac D." <lindenberger.9@buckeyemail.osu.edu>
> **Date:** March 21, 2020 at 1:19:57 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
> **Subject: Coronavirus interview**
>
> Dr. Fauci,
> I have Paul Offit coming on my podcast tomorrow to discuss coronavirus, and I would love to have you on after him to talk about your thoughts and what we should do. My friend Nikki Roy recommended you who I have also interviewed for my vaccine show "Straight To The Point." If you're interested we can do an interview at your earliest convenience. My listeners would benefit greatly from it, thank you for your consideration.
> Get Outlook for Android

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:38:39 -0400
To: Friedmann, Theodore
Subject: Re: COVID-19 information for the public

Thank you for your note.
AS Fauci

Sent from my iPhone

> On Mar 21, 2020, at 2:01 AM, Friedmann, Theodore <tfriedmann@health.ucsd.edu> wrote:
>
> Dear Tony: I'm sure that you realize how dismayed and saddened many of us are at the inaccurate and harmful comments coming from our political leaders regarding the COVID-19 pandemic. That feeling hit a new height today with the irresponsible and nonsensical anncuncement from President Trump regarding his claimed effectiveness of chloroquine and hydroxychloroquine. This announcement and many other untruths were delusional, irrational, un-scientific and revealed a profoundly harmful and unethical betrayal by President Trump his responsibility to protect the health of the public that pus th republic in sever danger. I was very glad to hear your public comments that countered this horribly dangerous misinformation. I hope that your message falls on receptive ears in the public and leads to a major change in the kind of public announcements that are currently being foisted on the desperate public who depend on knowing and acting based on the truth. Please continue and even expand your role as the truth teller in the who crowded collection of muzzled officials and sycophants who seem to be more devoted to deceiving the public rather than preparing the public for hard truths and solving the logistics failures of masks, availability of testing its. Please continue your brave and essential role as honest broker that you play valiantly privately during your policy discussions that the public also deserves to know about the wrong and unethical self-serving propaganda that the public is fed by President Trump and some other members of the Corona Virus task force. It is a deadly governmental game. I wish you good luck in alerting the public to this immoral, unethical and deadly plague of governmental misinformation designed to shape political quandaries rather than public welfare. Please continue speaking out about public misinformation.
>
> Ted Friedmann, MD
>

From: [redacted] (b) (6)
Sent: Sat, 21 Mar 2020 07:38:11 -0400
To: DMID Word Nerds
Subject: Fwd: hypertensive drug - ACE2- inhbitor related and our work
Attachments: A Combinatorial Antihypertensive Drug (Reserpine and Hydrazine) Does Not Cause Severe Depression.pdf, ATT00001.htm, medrxivcognitionandadelphanel.pdf, ATT00002.htm

Sent from my iPhone

Begin forwarded message:

> **From:** "Dr.Jamuna R Subramaniam" <jamuna17@sriramachandra.edu.in>
> **Date:** March 21, 2020 at 2:04:14 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6), jamuna subramaniam [redacted] (b) (6)>
> **Subject: hypertensive drug - ACE2- inhbitor related and our work**
>
> Dear Prof. Anthony Fauci,
>
> Good Morning!
>
> I am Dr. Jamuna R. Subramaniam. I did my Ph.D from Georgetown University and postdoc in Johns Hopkins on neurodegenerative diseases. After returning to India I started working on biogenic amine neuortransmitters. One of the major trajectory of my research career was on an FDA approved, antihypertensive drug.
> Given the current scenario of ACE2 being the receptor for Covid-19, and the widely used antihypertensive drugs also target the same. I thought of sensitizing you on a very effective antihypertensive drug, adelphane and adelphane esidrex made and sold by Novaritis This contains a historical VMAT - biogenic amines loading in synaptic vesicles, molecule, reserpine. Here, in India, a well known Nephrologist, has used this to treat a community of close to 3000 patients for almost two decades. From him and others I have heard that it is a very effective, well tolerated antihypertensive. Reserpine is a historical molecule that it had been used in the Indian system of medicine, Ayurveda. But adelphane has the single specific purified molecule, reserpine, an alkaloid. Now Novaritis has stopped making it. One of the reasons being given is reserpine's negative publicity when it was used an antipsychotic drug. The reason given was a side effect of severe depression. We did a study on these patients on adelphane and find that it had not caused depression. Further, it seems to be retaining cognition in these patients. I could not publish these in big journals as you can understand. I am enclosing these two papers.

As many lives are at stake, I thought I will sensitize you on this. Hope something good will come out of this. I am telling whomever I come across about the same. That is the best I can do. Hope the current scenario will show the living daylight for reserpine and helps the humanity.

Thank you

With regards
Jamuna

--
Dr. Jamuna R. Subramaniam
Associate Professor
Center for Preclinical and Translational Medicine Research
Central Research Facility
Sri Ramachandra Institute of Higher Education and Research
Porur, Chennai 600 116, India
Extn:8170 ; Tel: 91-44-45928500;
Cell: (b) (6)
www.sriramachandra.edu.in

Academic Editor, PLoS One, Public Library of Science, San Francisco, USA
Website:
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/?term=Subramaniam+JR

Research Gate: https://www.researchgate.net/profile/Jamuna_Subramaniam

Google Scholar:
https://scholar.google.co.in/citations?user=T4Z2VMAAAAAJ&hl=en

Quote: "I remain an Optimist. Not that I can give any evidence that right is going to prosper, but because of my unflinching faith that right should prosper in the end" - Mahatma Gandhi

From: [redacted] (b) (6)
Sent: Sat, 21 Mar 2020 07:37:38 -0400
To: Mr Chiogna
Subject: Re: The Virucidal Efficacy of Blue light (222 nm) UV light with Respect to CoronaVirus

Thank you for your note.
AS Fauci

Sent from my iPhone

> On Mar 21, 2020, at 2:46 AM, Mr Chiogna <jchiogna@holycross.bc.ca>wrote:
>
> Dear Dr. Fauci,
>
> My name is John Chiogna. I work as a Physics teacher in Vancouver British Columbia. Attached below is a short write up on a possible inexpensive means of quickly sanitizing private and public locations such as care facilities, hospitals, schools, churches, government workplaces, arenas, etc.
>
> I'm sure that the efficacy of 222 nm light has been considered by some already. However, I have included some numbers that take into account human safety limits, as well as references to peer-reviewed journals that support my claims. It is my hope that this may make this simple idea more plausible.
>
> Please consider the merits of such an idea and implement it as you wish, thank you.
>
> Yours sincerely,
> John Chiogna
>
> **What is the Virucidal Efficacy of Blue light (2...**
>
> ---
>
> *This e-mail is intended only for the individual named above.*
> *Any distribution, use or copying of this e-mail or the information*
> *it contains by other than an intended recipient is unauthorized.*
> ***If you have received this e-mail in error, please delete immediately.***

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:35:58 -0400
To: DMID Word Nerds
Subject: Fwd: Note from a NIH "alumnus" re. SARS-CoV-2

Sent from my iPhone

Begin forwarded message:

> **From:** Robert Wiskocil (b) (6)>
> **Date:** March 21, 2020 at 4:30:43 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
> **Subject: Note from a NIH "alumnus" re. SARS-CoV-2**
>
> Dear Dr. Fauci,
> I used to work in Bob Goldberg's division at the NCI (Blgd 37) from '78-'80. I'm now a rheumatologist in the SF Bay Area.
> I'm including a Letter to the Editor (submitted 3.19.20) for the NEJM that proposes a cost-effective therapy for COVID-19. (I've included a slightly longer version with more references):
>
> ----------------------------
>
> **N-acetyl cysteine for Coronavirus**
> Robert Wiskocil, MD
>
> Affiliation: Private Practice Rheumatology
> Date: March 19, 2020
> Telephone Number: (b) (6)
> Email: (b) (6)
> Abbreviations: N-acetyl cysteine (NAC), porcine epidemic diarrhea virus (PEDV)
>
> In a recent letter to Cell Research, Remdesivir and chloroquine were found to inhibit the SARS CoV-2 (COVID-19) virus activity and replication in Vero cells (1). That study was the basis for current clinical trials involving those medicines.
> There might be a more cost-effective treatment for the Coronavirus. I believe it will be sensitive to oral high dose N-acetyl Cysteine
>
> A final common pathway to host destruction (autophagy) in infected cells in both Corona and Rota viral infections involves the PI3K/AKT/mTOR pathway (2,3). This pathway is inhibited by "rapalogues" (like Rapamycin) where the

viral infection is stopped and the host cell survives. N-acetyl-cysteine, a potent anti-oxidant and glutathione precursor, alters the redox state of treated cells and can quench this same pathway (4,5). NAC (N-acetyl cysteine) has been used to rapidly clear Rotavirus diarrheal infections in children (6). Furthermore, the porcine epidemic diarrhea virus (PEDV) coronavirus has been studied in Vero cells. *In vitro*, NAC blocks that particular virus (7), and *in vivo,* NAC blocks intestinal damage caused by this virus (8). NAC likely provides a "redox clamp" on the autophagy pathway this virus exploits.

Since the PEDV coronavirus is effectively blocked in Vero cells by NAC, the SARS-CoV-2 (COVID-19) will likely also be inhibited. This test should be done, and if positive, clinical trials ought to follow.

Doses of 2.4-3.5 g/d of NAC have been used to treat patients with Lupus (4). That dose is well tolerated and inexpensive.

If NAC were effective in symptomatic patients, it could add a cost-effective measure of protection to healthcare workers and exposed individuals.

References:

1) Wang, M., Cao, R., Zhang, L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. **Cell Res**

Y Yin et. al. PI3K-AKT-mTOR axis sustains rotavirus infection via the 4E-BP1 mediated autophagy pathway and represents an antiviral target. **Virulence**, 2018 VOL. 9, NO. 1, 83–98

3) J Kindrachuk et. al, Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis **Antimicrobial Agents and Chemotherapy** February 2015 Volume 59 Number 2 p 1088-1099

4) Zhi-Wei Lai, et al, N-Acetylcysteine reduces disease activity by blocking mTOR in T cells of Lupus patients, **Arthritis Rheum**. 2012 September; 64(9): 2937–2946

5) C. C. Xu, S. F. Yang, L. H. Zhu, X. Cai, Y. S. Sheng, S. W. Zhu, J. X. Xu, Regulation of N-acetyl cysteine on gut redox status and major microbiota in weaned piglets, **Journal of Animal Science**, Volume 92, Issue 4, April 2014, Pages 1504–1511, https://doi.org/10.2527/jas.2013-6755

6) C Guerrero et al. N-Acetylcysteine Treatment of Rotavirus-Associated Diarrhea in Children **Pharmacotherapy**

7) Xu X, Xu Y, Zhang Q, et al. Porcine epidemic diarrhea virus infections induce apoptosis in Vero cells via a reactive oxygen species (ROS)/p53, but not p38 MAPK and SAPK/JNK signaling pathways. **Vet Microbiol**. 2019;232:1–12.

8) Wang L, Zhou J, Hou Y, et al. N-Acetylcysteine supplementation alleviates intestinal injury in piglets infected by porcine epidemic diarrhea virus. **Amino Acids**. 2017;49(12):1931–1943.

I hope you find this helpful!

Sincerely,

(b) (6)

Robert Wiskocil, MD
(b) (6)

From: (b) (6)
Sent: Sat, 21 Mar 2020 07:19:19 -0400
To: PITTMAN, RYAN D
Subject: Re: Preparing for COVID-19 in my Neighborhood

Sent from my iPhone

> On Mar 21, 2020, at 12:10 AM, PITTMAN, RYAN D <rpittman@email.sc.edu>wrote:
>
> Good Evening Dr. Fauci,
> My name is Ryan Pittman. I live in (b) (6) South Carolina, right outside of (b) (6)
> The virus is here. Seeing as this is likely to get worse before it gets better, I want to be prepared to help people in my neighborhood when they start developing symptoms and the hospitals are not ready for them.
> How do you recommend I go about doing this. I am prepared to acquire a modest stockpile of supplies to give to those suffering through this, but I am not entirely sure what would be best. The hope is to take your information and pass it on to those in other neighborhoods in the area, so we can come together and help as many people as we can get through this pandemic.
> Thank you for your time.
> Ryan Pittman, MS
> University of South Carolina Department of Statistics

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 21 Mar 2020 02:19:38 +0000
To: Priscilla Kelly
Subject: RE: Thank you from Science

Priscilla:
Thank you for your kind note.
Best regards,
Tony

From: Priscilla Kelly <pkelly@aaas.org>
Sent: Friday, March 20, 2020 9:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Thank you from Science

Dear Tony,

I wanted to send our sincerest thanks from everyone at *Science*, for the superb leadership that you are showing the United States (and the world) during this pandemic. Thank you also for educating the public that the most productive countermeasures will be based on data-driven science. We will continue to do our part here at *Science* to publish the strongest COVID-19 studies to help advance research as rapidly as possible.

All the best,

Priscilla

---

Priscilla N. Kelly, Ph.D

Biomedicine Editor, *Science*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 22:45:24 +0000
To: Stephen Hahn;Redfield, Robert R. (CDC/OD);Birx, Deborah L.
EOP/NSC;[redacted] (b) (6)
Subject: Treatment Document
Attachments: dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked changes showing.docx, dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked Clean copy.docx

Team:

As per my discussion with Steve a few minutes ago, I have made some changes in the document. [redacted] (b) (5) I am attaching a tracked version of the document that was your FINAL as well as a clean copy with all of the changes accepted. Please take a look and Steve said that he would like to set up a quick call to discuss after you have had a look. I am very sorry to come in with these changes at this late point, but I really did not get a chance to have a good look at the document as I was in a car.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 21:08:04 +0000
To: [redacted] (b) (6)
Subject: therapy
Attachments: dbInformation for Clinicians on COVID-19 Therapies3.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 11:52:45 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Modeling of COVID-19 from Mike Levit

It would be a good idea to get a feel for what our modelling people think about this.
Thanks,
Tony

From: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, March 19, 2020 3:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Modeling of COVID-19 from Mike Levit

Dr. Fauci,

Just re-upping this as your inbox is hopefully less stuffed now. See original email at the bottom from Larry Tabak letting you know about this modeling work.

My summary is below and if you'd like me to ask some NIAID modeling SMEs what they think, let me know.

Andrea

……

Dr. Fauci—

I took a look at this and here is my impression:

[redacted] (b) (5)

I would defer to our modeling experts at NIAID as to the validity of his model—let me know if you'd like me to reach out to them. [redacted] (b) (5).
CC'ing Hilary if she has additional thoughts.

Sincerely,

Andrea

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
Date: Monday, March 16, 2020 at 10:59 PM
To: "Lerner, Andrea (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: FW: Modeling of COVID-19 from Mike Levit

Please take a look and see what you think.

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Sent: Friday, March 6, 2020 8:46 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Lauer, Michael (NIH/OD) [E] [redacted] (b) (6)>
Subject: Modeling of COVID-19 from Mike Levit

Francis, Tony –
Mike Levitt (Nobel prize in Chemistry, 2013) sent the attached modeling of the COVID-19 epidemic to Mike Lauer. I don't know if this will prove useful but wanted to pass it along in case.

He indicated that he was amazed to see how an Excel level analysis could allow him to predict the China epidemic would end as early at 2-Feb and get what he considers the best estimates for case fatality ratio. His first report from 2-Feb is attached as well as his most recent two-part report.

Larry

From: (b) (6)
Sent: Fri, 20 Mar 2020 06:56:52 -0400
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: Fwd: COVID-19 multidisciplinary FAQ article
Attachments: COVID Question_v2.docx, ATT00001.htm

Begin forwarded message:

> **From:** Andreas Kronbichler (b) (6)
> **Date:** March 20, 2020 at 3:50:20 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>, (b) (6) [redacted]
> **Subject: COVID-19 multidisciplinary FAQ article**
>
> Dear Prof. Fauci,
> May I briefly introduce myself: My name is Andreas Kronbichler, I am nephrologist based in Austria, and do have an interest in renal autoimmune disease. As such, I know your landmark study about cyclophosphamide use in GPA published in 1971; and I have learned that you were involved in the management of David Fajgenbaum MCD, whose story is so impressive.
> I am contacting you and asking you for your help regarding a multidisciplinary FAQ article we would like to write and which does make sense in our eyes, given the rapid spread of this devastating infectious disease.
> We would like to invite experts in the field to comment on a selected topic and then summarize this as a paper with hopefully high impact in the field.
> If you agree, can you answer this question (around 400 words max.):
> ***Can you describe the pathophysiology and some of the immunological aspects of SARS-CoV-2 infection and COVID-19 disease?***
> I would be personally very honored to work together with you. A selection of topics is attached to this e-mail.
> With best regards,
> Andreas Kronbichler M.D. Ph.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 10:42:16 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C];Folkers, Greg (NIH/NIAID) [E];Myles, Renate (NIH/OD) [E]
Subject: RE: COVID-19 science brainstorm at NIH, and town meeting

Thanks, Francis.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Friday, March 20, 2020 5:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6) Barasch, Kimberly (NIH/NIAID) [C] < [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Myles, Renate (NIH/OD) [E] [redacted] (b) (6)
Subject: RE: COVID-19 science brainstorm at NIH, and town meeting

Thanks, Tony. The town meeting runs from 1 to 2. If your press conference runs late, I'd be glad to have you call in at any other time during that hour – we would squeeze you in!

Francis

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, March 19, 2020 10:54 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: COVID-19 science brainstorm at NIH, and town meeting

Francis:
I was just told by the VP's office that I will have to be at the press conference between 11:00 and 12:30 PM. And so I definitely cannot be at NIH physically at 1:00 PM and if the press conference starts and finishes late, I may not even be able telephone in. My guess is that it will end before 1:00 PM and so I will likely be able to phone in. Let us see how tomorrow unfolds. Regarding the session of IC Directors, this would be fine with me.
Best,
Tony

Patty:
Please let us discuss the phone in logistics if I cannot physically get there.
Thanks,,
Tony

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Thursday, March 19, 2020 9:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Subject: COVID-19 science brainstorm at NIH, and town meeting

Hi Tony,

Nice Facebook session with Zuck! And I heard you were just on CNN, but I missed that one. I did an interview with Sheila Kaplan late this afternoon – and she greatly appreciated your message of apology. I don't think [redacted] (b) (5).

When we spoke yesterday, you were enthusiastic about the convening of a 2 – 3 hour session of IC Directors and SMEs from their ICs, to brainstorm about additional scientific efforts that could be mounted at NIH to address COVID-19. It looks as if this can be arranged for an early afternoon next week. Obviously there would be nothing better than to have you there in person for this. While I know your schedule is not exactly under your control, is there any 2 – 3 hour period next week that might have a chance of being open for you? If not, who would you want to be the presenter of the current portfolio of NIAID investments? [redacted] (b) (5)

We have the NIH virtual Town Meeting at 1 PM tomorrow. Is there any chance you can come to Wilson Hall in person for that? If not, is there a chance you can call in? I will serve as moderator, and after a few minutes of opening remarks, would hope to turn this over to you for ten minutes or so of the unique Fauci perspective. After that, Larry and Alfred will talk for a few minutes about the NIH COVID Response Team, and Jim Gilman will talk about what's happening at the CC. Then we'll open it up to questions, which we can accept in real time from the estimated 20,000 staff who will be logged in. But you wouldn't need to stay for all that – if we could somehow have your participation (either in person or on the phone) from about 1:10 to 1:20, that would be really wonderful. Please let me know if that will be possible.

Sorry about the long e-mail. Get some sleep!

Best, Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 03:01:09 +0000
To: Besser, Richard
Subject: RE: Checking in

Rich:
Thanks for the note. Much appreciated. I hope that all is well with you.
Best regards,
Tony

From: Besser, Richard <rbesser@rwjf.org>
Sent: Thursday, March 19, 2020 3:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Checking in

Hi Tony:

I hope you are well. I want to applaud you and thank you for your incredible leadership in communicating about this pandemic. I wish CDC were standing with you but I know that is not likely to happen. I hope that you will continue to talk about all that is being done to learn what works to mitigate the impact of the pandemic. Your absence these two days has been quite noticeable. If there is anything I can do to support you, please let me know.

Best regards,

Rich

Richard E. Besser, MD, President and CEO
Office [redacted] (b) (6) | rbesser@rwjf.org
Connect with me on Twitter | LinkedIn | Facebook

Robert Wood Johnson Foundation
Building a Culture of Health in America. Learn more at rwjf.org.
Follow the Foundation Twitter |Facebook | YouTube

……

***Please note**: In light of the requests made for increased social distancing related to the coronavirus (COVID-19), we have closed all three RWJF campuses in Princeton, New York City, and Washington until further notice. All RWJF employees are now working remotely, and all in-person meetings are either cancelled or will be conducted virtually. For the most up-to-date information regarding COVID-19 please see resources on CDC, NIH as well as your state health department websites.*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 02:39:21 +0000
To: Jonathan E. Shoag
Cc: Elemento, Olivier
Subject: RE: Specimens

Would be much more useful [redacted] (b) (5)

From: Jonathan E. Shoag [redacted] (b) (6)
Sent: Thursday, March 19, 2020 9:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Elemento, Olivier [redacted] (b) (6)
Subject: FW: Specimens

Hi Dr. Fauci,

[redacted] (b) (5)

All the best,

Jonathan Shoag MD

From: Denny, Joshua (NIH/OD) [E]
Sent: Monday, March 16, 2020 6:17 PM
To: Jonathan E. Shoag
Cc: Olson, Janet E., Ph.D.; Cicek, Mine; Olivier Elemento; Thibodeau, Steve; Gebo, Kelly (NIH/OD) [G]
Subject: [EXTERNAL] Re: Specimens

Jonathan -
Thanks for the thoughts and the offer to help. This is indeed something we have discussed [redacted] (b) (5) I'm copying our chief medical & science officer, Kelly Gebo.
Best,
Josh

> On Mar 16, 2020, at 2:16 PM, Jonathan E. Shoag [redacted] (b) (6) wrote:
>
> Hi Dr. Denny,

[redacted] (b) (5)

All the best,

Jonathan Shoag MD

> On Mar 16, 2020, at 12:47 PM, Thibodeau, Stephen N., Ph.D. [redacted] (b) (6)> wrote:
>
> Dear Jonathan
>
> I am one of the Co-PI's of the Biobank for the All of Us Research Program. Although samples are store here at Mayo, [redacted] (b) (5)
>
> [redacted] (b) (5)
>
> Sorry, the situation is evolving quite rapidly, so no additional information at this point.
>
> Hope this helps.
>
> Steve
>
> ---
>
> **From:** Jonathan E. Shoag [redacted] (b) (6)]
> **Sent:** Monday, March 16, 2020 3:35 AM
> **To:** Biobank
> **Subject:** [EXTERNAL] Specimens
>
> To Whom it May Concern,
>
> I imagine someone has thought of this already- but do you know if [redacted] (b) (5)

(b) (5)

[redacted]

I study prostate cancer epidemiology at Weill Cornell, and in discussing this idea with the head of our precision medicine initiative, was informed that the AllofUs specimens reside at Mayo.

All the best,

Jonathan Shoag MD

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 22:16:02 +0000
To: [redacted] (b) (6)
Subject: RE: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

(b) (6)

All of the therapy stuff is anecdotal. We are trying to get randomized clinical trials done instead of just compassionate use for all of these unproven drugs. [redacted] (b) (6)

Best regards,
Tony

From: [redacted] (b) (6)>
Sent: Thursday, March 19, 2020 4:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

Fascinating - thanks for sharing with me. The question that I have is whether COVID 19 adheres and infects epithelial cells through the same mechanism as SARS did. Why the increased lethality and how to we decrease likelihood of infection?

Just saw today that antiretroviral therapy and malaria agents are being touted as potential therapies - how well founded is this - anything more than anecdotal data to support this?

Hope you are getting a few moments of rest. [redacted] (b) (6) and do not hesitate to call me if I can help.

Best,
Ken

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Wednesday, March 18, 2020 7:09 PM
To: [redacted] (b) (6)>
Cc: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [EXTERNAL] FW: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

** ATTENTION: This email originated from outside the MedStar network.
** DO NOT CLICK links or attachments unless you recognize the sender and know the content is safe.

The situation gets confusing. See attached brief commentary and e-mail string. As you can see, I was too tired to make any sense of it. However, my deputy (Cliff Lane) notes that this

paper argues the opposite, i.e. that ACE inhibitors might have a benefit and counters the argument to stop ACE inhibitor.s Bottom line is that we really do not know what the effect will be clinically with respect to COVID-19. In any event, [redacted] (b) (6)
Best,
Tony

From: Lane, Cliff (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Wednesday, March 18, 2020 5:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

A 2005 paper post-SARS advocating for use of ACE inhibitors to increase ACE2. The opposing argument to stopping ACE inhibitors.

From: Anthony Fauci [redacted] (b) (6)
Date: Wednesday, March 18, 2020 at 5:22 PM
To: "Lane, Cliff (NIH/NIAID) [E]" <[redacted] (b) (6)>
Subject: FW: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

I cannot make heads or tails of this. Please take a look and let me know what you think. Thankjs.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ste McCon [redacted] (b) (6)
Sent: Wednesday, March 18, 2020 5:09 PM
Subject: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

"Clearly, the potential therapeutic utility of recombinant **ACE2 and angiotensin II receptor-inhibitors. [ARB's ?]**s—**already in clinical use for control of blood pressure**—for acute lung injury resulting from viruses and other causes will be a productive field for investigation. This is particularly relevant as we prepare to **confront a potential avian flu pandemic**, [***COVID-19*** **?**]armed with onlya limited number of therapeutic options."

Regards,

Stephen D. McConnell, BS, MSc-CCP, CIS

Lipidemiologist - Clinical Application Specialist

Medicare-CMS ACO/MSSP/Direct-Contracting Consultant

Medical Science Liaison

Mobile: [redacted] (b) (6)

[redacted] (b) (6)

Sent from my iPhone

MedStar Health is a not-for-profit, integrated healthcare delivery system, the largest in Maryland and the Washington, D.C., region. Nationally recognized for clinical quality in heart, orthopaedics, cancer and GI.

IMPORTANT: This e-mail (including any attachments) may contain information that is private, confidential, or protected by attorney-client or other privilege. If you received this e-mail in error, please delete it from your system without copying it and notify sender by reply e-mail, so that our records can be corrected... Thank you.

Help conserve valuable resources - only print this email if necessary.

From: [redacted] (b) (6)
Sent: Thu, 19 Mar 2020 08:30:51 -0400
To: Holland, Steven (NIH/NIAID) [E]
Subject: Re: Link to Wash post article re: Kim Hasenkrug

He is a good guy, but this is the second time for him

> On Mar 19, 2020, at 8:20 AM, Holland, Steven (NIH/NIAID) [E]
> [redacted] (b) (6)
>
> https://www.washingtonpost.com/health/trump-ban-on-fetal-tissue-research-blocks-coronavirus-treatment-effort/2020/03/18/ddd9f754-685c-11ea-abef-020f086a3fab_story.html
>
> Just making you aware of the WP article this morning. This was a surprise to us and I have to believe that Kim was unaware of its preparation or release.
>
> Steve
>
> Director, Division of Intramural Research
> National Institute of Allergy and Infectious Diseases
> National Institutes of Health
> Bldg. 10/11N248 MSC 1960
> Bethesda, MD 20892-1960
> [redacted] (b) (6) voice
> 301-480-4507 fax
> [redacted] (b) (6) email
>
> Assistant lab: Eva Portillo
> [redacted] (b) (6) email
> [redacted] (b) (6) voice
>
> Assistant to SD: Beth Schmidt
> [redacted] (b) (6)
> [redacted] (b) (6) voice
>
> ---
>
> **From:** Karyl Barron [redacted] (b) (6)>
> **Date:** Thursday, March 19, 2020 at 7:35 AM
> **To:** Amy Agrawal [redacted] (b) (6)
> **Subject:** Link to Wash post article re: Kim Hasenkrug
>
> https://www.washingtonpost.com/health/trump-ban-on-fetal-tissue-research-blocks-coronavirus-treatment-effort/2020/03/18/ddd9f754-685c-11ea-abef-020f086a3fab_story.html

From: [redacted] (b) (6)
Sent: Thu, 19 Mar 2020 08:29:22 -0400
To: Verma, Seema (FDA/CDER) (CTR)
Subject: Fwd: Long term care facilities

See below. As per your prior discussion

Begin forwarded message:

> **From:** Dorothy Franklin [redacted] (b) (6)
> **Date:** March 19, 2020 at 8:22:24 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Long term care facilities**
>
> Based on studies at Kirkland care facility indicating staff were spreading the coronavirus to multiple facilities sharing staff, is there or will there be guidance to require these facilities to retain a dedicated staff only?

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:33:41 +0000
To: Redfield, Robert R. (CDC/OD);Stephen Hahn;Birx, Deborah L. EOP/NSC
Cc: [redacted] (b) (6);Troye, Olivia EOP/NSC;Short, Marc T. EOP/OVP;Miller, Katie R. EOP/OVP;Hicks, Hope C. EOP/WHO;kellyanne conway
Subject: FW: NEJM: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 http://bit.ly/2x9IJi0

As per my prior e-mail. The medical people likely are aware of this. It just came out tonight. [redacted] (b) (5).

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Wednesday, March 18, 2020 10:14 PM
Subject: NEJM: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 http://bit.ly/2x9IJi0

Access provided by NIH Library

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

List of authors.

- Bin Cao, M.D., et al.

Abstract

Background

No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.

Methods

We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao_2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao_2) to the fraction of inspired oxygen (Fio_2) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir–ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first.

Results

A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir–ritonavir group, and 100 to the standard-care group. Treatment with lopinavir–ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.24; 95% confidence interval [CI], 0.90 to 1.72).

Mortality at 28 days was similar in the lopinavir–ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, −5.8 percentage points; 95% CI, −17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir–ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir–ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir–ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events.

Conclusions

In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308. opens in new tab.)



Figure 2. Time to Clinical Improvement in the Intention-to-Treat Population.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:20:05 +0000
To: sheila.kaplan@nytimes.com
Cc: Collins, Francis (NIH/OD) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Coronavirus interview with Dr. Collins

Sheila:

I do not recall getting a request from you. I am completely swamped and so it may have just gotten buried in a pile and I did not see it. I apologize. I am mostly locked into the White House where we must give up our phones and so it makes it very difficult for me to return calls. I talk to Francis all the time and he is very well versed in these issues. He will do a fine job of providing you with the information you need. If you would still like to speak with me later on, we can try to make that work. Again, I am sorry if you felt snubbed.

Best regards,
Tony

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>
Sent: Wednesday, March 18, 2020 4:10:58 PM
To: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)
Cc: Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)
Subject: Re: Coronavirus interview with Dr. Collins

Hi Renate,
Thank you.... We appreciate it. SK

On Wed, Mar 18, 2020 at 3:56 PM Myles, Renate (NIH/OD) [E] < [redacted] (b) (6) wrote:

> Hi Sheila:
>
> The questions you shared with Amanda were really for Dr. Fauci; he's our spokesperson on all research specific questions. I know he's really backed up and NIAID is doing the best they can with his incredibly packed schedule. The interview with the Atlantic was really intended as a profile, but ended up covering a lot of COVID questions. We can check in with NIAID to see what we can do.
>
> Thanks,
>
> Renate

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>
Sent: Wednesday, March 18, 2020 3:27 PM
To: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>; Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Fine, Amanda (NIH/OD) [E] < [redacted] (b) (6)>
Subject: Re: Coronavirus interview with Dr. Collins

Hi there,

Why were we told we could not do an interview, when, after our request, he did one with The Atlantic. You referred us to Dr. Fauci but he isn't talking, either. This doesn't seem fair to us. Can we really not speak to either of them for a story this weekend?

Thanks, SK

On Sun, Mar 15, 2020 at 4:00 PM Kaplan, Sheila <sheila.kaplan@nytimes.com> wrote:

> Dear Renate, John and Amanda:
>
> Sheri Fink and I would like to interview Dr. Collins as soon as possible for a story on coronavirus.
>
> Can you please let me know when he might be available.
>
> Thank you,
>
> Sheila
>
> --
>
> Sheila Kaplan
>
> Reporter, Washington Bureau
>
> *The New York Times*
>
> *Office: (202) 862-0312*
>
> *Cell:* [redacted] (b) (6)

--

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: (b) (6)

--
Sheila Kaplan
Reporter, Washington Bureau
The New York Times
Office: (202) 862-0312
Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:13:35 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Coronavirus interview with Dr. Collins

Francis:
Go for it. We need all the help we can get. I do not remember getting a request from Sheila. I will write and apologize.
Best,
Tony

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Wednesday, March 18, 2020 9:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>; Burklow, John (NIH/OD) [E] [redacted] (b) (6)
Subject: FW: Coronavirus interview with Dr. Collins

Hi Tony,

I could use your guidance on press interviews. I understand that only Task Force members are supposed to do television events – and I declined the NewsHour tonight to be consistent with that. But what is your preference for printed press pieces, when you can't do them all? Would it help the cause for me to accept some of those, or is it better to hold off? If I were to engage, I would certainly seek to provide answers that are 100% with what you are doing.

An example is the thread from Sheila Kaplan of the New York Times. I have declined so far – but is this the kind of query that you would like some help with?

Francis

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>
Sent: Wednesday, March 18, 2020 4:10:58 PM
To: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)
Cc: Burklow, John (NIH/OD) [E] [redacted] (b) (6); Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)
Subject: Re: Coronavirus interview with Dr. Collins

Hi Renate,
Thank you.... We appreciate it. SK

On Wed, Mar 18, 2020 at 3:56 PM Myles, Renate (NIH/OD) [E] [redacted] (b) (6)> wrote:

Hi Sheila:

The questions you shared with Amanda were really for Dr. Fauci; he's our spokesperson on all research specific questions. I know he's really backed up and NIAID is doing the best they can with his incredibly packed schedule. The interview with the Atlantic was really intended as a profile, but ended up covering a lot of COVID questions. We can check in with NIAID to see what we can do.

Thanks,

Renate

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>
Sent: Wednesday, March 18, 2020 3:27 PM
To: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>; Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>
Subject: Re: Coronavirus interview with Dr. Collins

Hi there,

Why were we told we could not do an interview, when, after our request, he did one with The Atlantic. You referred us to Dr. Fauci but he isn't talking, either. This doesn't seem fair to us. Can we really not speak to either of them for a story this weekend?

Thanks, SK

On Sun, Mar 15, 2020 at 4:00 PM Kaplan, Sheila <sheila.kaplan@nytimes.com> wrote:

> Dear Renate, John and Amanda:
>
> Sheri Fink and I would like to interview Dr. Collins as soon as possible for a story on coronavirus.
>
> Can you please let me know when he might be available.
>
> Thank you,
>
> Sheila
>
> --

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: [redacted] (b) (6)

--

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: [redacted] (b) (6)

--
Sheila Kaplan
Reporter, Washington Bureau
The New York Times
Office: (202) 862-0312
Cell: ([redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:12:30 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: typo, etc. fixed, [redacted] (b) (6)

Too long for me to read

From: Erik Nilsen <enilsen@bio-signal.com>
Sent: Wednesday, March 18, 2020 10:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: typo, etc. fixed, [redacted] (b) (6)

Hi Dr. Fauci,

I'm now back in my office. I typed the original message on phone. I just noticed a bunch of typos. Below is a better version.

Regards,

Erik

Dear Dr. Fauci,

You're beyond busy but I hope you read this message.

[redacted] (b) (4) I'm only mentioning this so you don't think I'm a paranoid freak. I'm convinced you already know the outbreak is way past the point of containment, and, unfortunately, herd immunity will soon ensue. Then, outbreak 2 will happen shortly after, and, hopefully, not ad infinitum.

I'm writing to make sure you already know or at least suspect everything I'm about to tell you. I need to clear my conscience because it's possible (albeit unlikely) that some of what tell you is new and possibly useful in, at least, saving lives in the USA.

I'm a physicist and have been modeling this outbreak since January. My panic started minutes after I learned ~5M people left Wuhan around January 22 a few days before the CCP starting locking the country down. The 5M people scattered to 13,000+ cities in China to visit family & friends for the Lunar Festival (Chinese New Year). I've been communicating with quite a few people around the world including an NYU epidemiologist [redacted] (b) (6) . We've both been warning our families, to mostly deaf ears at first, since January. It's been frustrating and exhausting, but, finally, most are as prepared as possible for what's about to happen.

I have lots of information about China due to my business, scientific, friendship, and other ties with many there, including immunologists & virologists at top-tier institutions and laboratories. My WeChat account (like Skype / Whatapp) was blocked by the CCP for 3 days late February / early March, but, after a warning message, it is now unblocked. I'm willing to share with you everything I know, think I know, or seriously suspect.

Here are a few examples:

I'm confident that China stop counting dead COVID-19 infected bodies since ~January 7, 2020. They've been adding fabricated data daily to show (to save face) the world and their own people an impressive flattening of China outbreak curve. It's easy to prove this via data analysis because, for example, improbable coincidences occurred in much of the data. My suspicions were eventually confirmed by at least two of my sources in China ([redacted] (b) (6)). The data posted by China is not only garbage, it has misled the world into a false sense of security wrt death rate, age vs death, and other things; that is, if people analyzed the world's data including China, the results are heavily biased towards nonsense, because China's number of cases accounted for the majority of cases worldwide (until a day or so ago).

I want to emphasize that I do not believe China intentionally did this to harm the world. I sincerely believe it was done for saving-face reasons. Saving face is possibly the most powerful motivating force in China. it is the key to understanding how most Chinese think and why they do what they do. China wanted the world to believe that their Herculean quarantining efforts contained the outbreak. However, I don't think this is true, even after spraying ~billions of gallon of "Clorox" all the country. The number of body bags my contacts told me about about, even after short 15-minutes walk to/from grocery stores in one city during CCP-authorized time slots, suggest the number of deaths is several orders of magnitude larger than what China's posted data indicates. Also, everyone I know in China continues to be in lock down (~6+ weeks now), and several went "silent" since about a week ago. This greatly troubles me because those who went silent live in Wuhan. And, yesterday, the CCP revoked permits/license for several Foreign reporters who were trying to learn about about the situation in Wuhan and other parts of China. Several of my sources have told me, in coded language, that the situation in at least Wuhan is not under control at all. In my opinion, China is continues to be extremely concerned about saving face (first) and their economy (second). Their economy is already suffering terribly, and they can't afford to lose the many large manufacturing and other business agreements with foreign countries. This is why I believe they're trying, and succeeding to convince many, to convince most of their population that the outbreak is under control, and it will soon be ok to return to work -- even though it will not be safe, because of current outbreak and outbreak # 2 that will likely start soon. Citizens are not allowed to travel beyond a few stores and, in special cases, their work office, so even people who live their have no idea what's really going on especially in Hubei province including Wuhan. Also, an H15N outbreak seems to have recently started in humans in Hunan province (which neighbors Hubei/Wuhan area).

I also have lots of information about USA.

Here is some:

I believe that many COVID-19 deaths were incorrectly labelled at 2019-2020 flu deaths. The spreading in the USA is almost certainly already homogeneous, because it's been going on since last year without any containment whatsoever. Once massive testing finally starts, this truth/reality will, unfortunately, become obvious. It will manifest itself as hyper exponential (hyperbolic) growth starting a day or two after the millions of testing kits arrive and start being used. The hyper exponential dynamics will eventually evolve to a more accurately calibrated exponential curve once the number to tests is large enough to properly sample the population. I don't think Italy is ahead of us. I think we're ahead and by a large amount.

A few other quick bits of info...

The time between infection and death seems to have decreased from about ~20 days (a few months) ago to possibly as short as ~8 days. And, the incubation period seems to be significantly longer. Both, and other data I've looked at, strongly suggest at least one mutation has occurred. This is extremely concerning to me. Another concern is the distribution of deaths vs. age appears to not be as strongly biased, compared to when China data was included, towards older people and/or people with chronic health conditions.

Over the past 15+ years, I've traveled to China multiple times per year. I'm pretty sure you've known this for a while, but I truly believe the outbreak tsunmai in the USA is either already happened or is about to happen. As you know, as soon as a surge is sensed, the Tsunami will immediately follow. I believe we missed the containment boat quite a while ago. I've been closely listening to your comments on TV, and I'm pretty sure you've already come to the same conclusion but don't want to cause mass panic (I understand that).

I'm 99% sure that SARS-CoV-2 been spreading in the USA since late November / early December last year. I [redacted] (b) (6)

(b) (6) [redacted]

[redacted] (b) (6) She works at [redacted] (b) (6) and it's possible that everyone in her office got infected too. Who knows how many people in Alaska got it too, but I suspect many tens of thousands possible much more. [redacted] (b) (6) [redacted] but it has been impossible to get tested. I've called 5 places in Alaska and none wanted me to come it for the test.

I've instructed my family and, recently (after family), close friends to get some Alvesco (ciclesonide) for emergency use only. I've been told by colleagues on the front-line in Japan, China, and Korea, and found several pre-print papers, that it is an effective treatment for late-stage COVID-19 patients. Some patients on ventilators who were approaching death have fully recovered after treatment with ciclesonide; ciclesonide has much smaller particles than other corticosteroids so it reaches deeper into lungs and alveolis) . Also, the treatment seems to be a potent suppressor of virus replication. Recovered patients have tested negative shortly after the treatment. Of course, data is limited so can't be sure the treatment is effective. However, because Alvesco has been shown to be safe for infant - 100+ year-old patients, I'm ok with my family and I having it for emergency use. That is, only if healthcare facilities are unable to accept them or me as a patient to treat with ventilator, corticosteroids (or whatever the best available treatment is at that time). Having Alvesco in our emergency kits is a much better option that someone avoidably dying because of an overburdened healthcare facility. The other drug I have, and have told my family and some friends to get, is called hyroxychloriquine -- also seem to be effective and safe. But, I think Alvesco is better because it appears to prevent the virus from replicated so infection is wiped out and no longer contagious. Alvesco seems to be two silver bullets in one.

I don't believe in coincidences and I'm not a conspiracy theorist, but there are many things out of Iran that also concern me greatly. That's all I say right now.

If all of this is old news to you, then I would greatly appreciate a response. It can be as short as "yes". Anyway, I had to share this information with you. Now my conscience is clear. My concern is that it's possible you don't have some of the above info, so I decided to send you this message.

I wrote this quickly, so I apologize in advance for any typos, etc.

I truly appreciated your efforts, and I'm now confident that President Trump, you, and everyone else involved is doing everything possible to ensure the best possible outcomes. I was deeply concerned a few weeks ago, when the gravity of the situation seemed to not be fully recognized by several in DC.

Feel free to call me anytime. My cell # is below. If you do call, I will keep anything we discuss confidential (if necessary).

Sincerely,

Erik

Erik A. Nilsen, PhD

(b) (6) | www.bio-signal.com | Request a demo or quote

Bio-Signal Technologies

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:07:41 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Coronavirus interview with Dr. Collins

See yellow highlight. Has Sheila Kaplan tried to get to me and has anyone said that I am "...not talking"? I doubt that.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Wednesday, March 18, 2020 9:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Myles, Renate (NIH/OD) [E] [redacted] (b) (6); Burklow, John (NIH/OD) [E]
[redacted] (b) (6)
Subject: FW: Coronavirus interview with Dr. Collins

Hi Tony,

I could use your guidance on press interviews. I understand that only Task Force members are supposed to do television events – and I declined the NewsHour tonight to be consistent with that. But what is your preference for printed press pieces, when you can't do them all? Would it help the cause for me to accept some of those, or is it better to hold off? If I were to engage, I would certainly seek to provide answers that are 100% with what you are doing.

An example is the thread from Sheila Kaplan of the New York Times. I have declined so far – but is this the kind of query that you would like some help with?

Francis

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>
Sent: Wednesday, March 18, 2020 4:10:58 PM
To: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] < [redacted] (b) (6); Fine, Amanda (NIH/OD) [E]
[redacted] (b) (6)>
Subject: Re: Coronavirus interview with Dr. Collins

Hi Renate,
Thank you.... We appreciate it. SK

On Wed, Mar 18, 2020 at 3:56 PM Myles, Renate (NIH/OD) [E] < [redacted] (b) (6)> wrote:

> Hi Sheila:

The questions you shared with Amanda were really for Dr. Fauci; he's our spokesperson on all research specific questions. I know he's really backed up and NIAID is doing the best they can with his incredibly packed schedule. The interview with the Atlantic was really intended as a profile, but ended up covering a lot of COVID questions. We can check in with NIAID to see what we can do.

Thanks,

Renate

From: Kaplan, Sheila <sheila.kaplan@nytimes.com>
Sent: Wednesday, March 18, 2020 3:27 PM
To: Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>; Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)
Subject: Re: Coronavirus interview with Dr. Collins

Hi there,

Why were we told we could not do an interview, when, after our request, he did one with The Atlantic. You referred us to Dr. Fauci but he isn't talking, either. This doesn't seem fair to us. Can we really not speak to either of them for a story this weekend?

Thanks, SK

On Sun, Mar 15, 2020 at 4:00 PM Kaplan, Sheila <sheila.kaplan@nytimes.com> wrote:

> Dear Renate, John and Amanda:
>
> Sheri Fink and I would like to interview Dr. Collins as soon as possible for a story on coronavirus.
>
> Can you please let me know when he might be available.
>
> Thank you,
>
> Sheila
>
> --
>
> Sheila Kaplan
>
> Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: (b) (6)

--

Sheila Kaplan

Reporter, Washington Bureau

The New York Times

Office: (202) 862-0312

Cell: (b) (6)

--
Sheila Kaplan
Reporter, Washington Bureau
The New York Times
Office: (202) 862-0312
Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:05:42 +0000
To: Doug Brust
Subject: RE: Please Help

Doug:

Thanks for the note. I have pushed hard on PPEs and as you may know, the POTUS has involved the Department of Defense to provide 5 million N-95 respirators. Hopefully that will alleviate at least a portion of the PPE shortage. Regarding the bars and beaches, I have been screaming on TV 2 to 5 times per night to tell the younger generation to start taking this seriously. I am very surprised that Gov. DeSantis has not completely closed the bars, even if they serve food. Take out only. I will bring this up at the Task Force meeting tomorrow. Please take care of yourself. You are an indispensable front line warrior.
Best regards,
Tony

From: Doug Brust [redacted] (b) (6)>
Sent: Wednesday, March 18, 2020 8:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Please Help

Tony-

I know you're ridiculously busy so please do not be upset with me, but I am frustrated and yes angry. Again, I think you have to hear from the front line while formulating policy.

- Today at the RW clinic I dealt with at least 12 URI's with fever.
- We cannot test.
- We have no PPE in clinic.
- We have a case that tested positive for influenza then SARS-CoV-2--this scared me the most given I'm trying to r/o COVID-19 by doing PCR for other respiratory viruses.
- On the drive home just now, the gyms, bar-grilles and restaurants still packed. Yes, bars are closed in Florida--but if they serve food (which they all do).......they're open. Ans, so much for the 50% capacity "suggestion".
- The beaches still full for Spring Break. Look at the pics of St Pete.
- The DOH? This is from the the FL DOH just a few hours ago. Yes, this is **TODAY.**

> "If a cluster of confirmed cases were to be discovered in Florida, the department would move quickly to engage with and isolate any infected individuals to prevent further spread," said Alberto Moscoso, the state health department's spokesman.

I don't have to explain to you how ridiculous that statement is.

- I've written to our DOH and Governor DeSantis three times (including speaking with his staff) asking to close restaurants (aside from take-out), gyms, beaches etc. They are "monitoring".

I'm the HIV doc here. I'm it. You know how seriously I take caring for my patients. I have (b) (6) I am putting my life on the line so folks can go pump iron, drink beer, have a burger and get a tan.

The band is playing on. Again.

Please help.

With tons of respect and admiration,
Doug

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 01:59:12 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus

Please respond to this person.

-----Original Message-----
From: Beth Abramson (b) (6)>
Sent: Wednesday, March 18, 2020 9:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus

Wondering whether it has been considered that only the vulnerable population (those over 60 and/or those with underlying health conditions)be isolated ? I am a (b) (6)psychiatrist and after contemplating this option was wondering if this could still reduce the risk to healthcare Systems with less disruption to our society. I await your response and appreciate all you are doing. Beth Abramson MD (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 01:54:06 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Plaquenil Shortage Causing National Health Emergency for Lupus Patients

Please respond.

From: Bruce Wilder [redacted] (b) (6)>
Sent: Wednesday, March 18, 2020 9:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Plaquenil Shortage Causing National Health Emergency for Lupus Patients

[redacted] (b) (6) When I tried to refill Plaquenil today, I learned that there was a national shortage due to doctors prescribing Plaquenil to their well patients and themselves. Recent news articles have reported its success in preventing and treating the coronavirus. What can you do to protect the life of [redacted] (b) (6) and the millions of other Americans who depend on this drug to stay alive?

Brenda Wilder
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 01:53:32 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Please read- idea for Mask Shortage

Please take a look and handle.

From: Dusti Rainey < (b) (6)
Sent: Wednesday, March 18, 2020 9:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Please read- idea for Mask Shortage

I have an idea to HELP with the MASK SHORTAGE!
Please don't disregard this, as this could help our whole country!
I know we are concerned as a nation about a mask shortage and I have an idea to what might help.
I Don't know who to go to that can help implement this and want your input if you think this is a viable aid, then maybe you can help me reach the right people to make the biggest impact, maybe even up to the Coronavirus team in the White House.
I have (b) (6) & when I first heard about China quarantining 43 million people I got worried about masks, I looked up how to sew a mask for myself & family. I found a site that talked about sewing masks for cancer treatment patients and to use 100% quilters cotton for outside & 100% flannel cotton on inside. I started sewing several. I know they aren't the N95, but they are better than nothing IF needed. My Dr just told me yesterday not to go anywhere without a mask because it's too much of a risk for my health. It got me thinking. What if while people across the country were in home quarantine, ALL those who know how to sew, they sew these masks to donate in their communities. Not for use against Coronavirus, but for other things normal masks are used (food prep, non-sickness medical reasons, etc) then they aren't using up the valuable higher rated masks that are needed for doctors, nurses & first responders fighting Coronavirus. These masks can also be washed as needed again and again which will just keep saving other masks.
During the WH Press Release this morning, Seema expresses the need for masks & Dr Birx explained how the virus is being spread from surfaces, but that it can't survive in fabric. Which means maybe these cloth masks will even help against the spread of the virus.
Either way, if you can help ok for these to be used in some manner vs a medical mask being used will help prolong the need for more masks and hopefully 3M can have more made by then so we never have to experience an lack of masks.
What do you think?

Dusti Bacon
(b) (6)

From: [redacted] (b) (6)
Sent: Wed, 18 Mar 2020 19:56:42 -0400
To: John Brouse
Subject: Re: Covid19 treatment

Thank you for your note.
A.S. Fauci

Sent from my iPhone

> On Mar 18, 2020, at 7:02 PM, John Brouse [redacted] (b) (6)>wrote:
>
> Sent from Mail for Windows 10
> Dear Dr. Fauci
>
> I understand that South Korea has been administering Hydroxl Chloroquine, a treatment for Malaria, to her citizens that have contracted Coronavirus. Is America considering this drug to help lessen the symptoms of this virus? This drug may not prevent anyone from getting ill, but may be a viable treatment to speed the recovery of individual afflicted with this disease.
>
> Respectfully,
>
> John Brouse

From: [redacted] (b) (6)
Sent: Wed, 18 Mar 2020 19:55:14 -0400
To: Holly Kreutter
Subject: Re: airport screenings

Thank you for your note.
A.S. Fauci

Sent from my iPhone

> On Mar 18, 2020, at 7:10 PM, Holly Kreutter [redacted] (b) (6)>wrote:
>
> Dear Dr Fauci,
> First of all, thank you for all the hard work you've done to help mitigate the coronavirus outbreak. We're clearly not there yet, but are further along with your efforts.
> I'm not sure whom to contact about this, and so am writing you because I'm confidant you can get it to the right hands. With regards to the recent closures to Europe and so many Americans coming home, I was at first heartened to hear that all Americans returning would be medically screened and encouraged to/made to quarantine for 14 days. However, I was then disheartened to learn that that hasn't been the case, at least through this past Saturday.
> [redacted] (b) (6) was on business in Amsterdam last week and rushed home last Thursday after hearing on Wednesday evening about President Trump's Friday midnight shutdown. He came in through LAX from Amsterdam, and wasn't asked any medical questions, nor was he asked to quarantine. Then a friend came in through Miami from Paris on Saturday, and was only given a short medical form to fill out, and then let go. No medical check, no temperature screening, no further questions. From touchdown to taxi (plus picking up bags), 45 minutes total.
> Having lived in Singapore through SARS, I'm deeply disturbed. We had medical/temperature checks at all airports, and mandatory quarantines for anyone with possible contact with a SARS contact/patient. The virus was quickly and efficiently contained, and the same has been done in Singapore to date with Covid 19.
> I was heartened last Friday as I learned that the federal government was onboard, and hearing about significant measures that would be taken *soon.* I must say I've been disheartened as of today, with not enough tests, mask, respirators and ventilators in place. And then hearing of the lack of medical screenings at airports. Please help, as I know you've so desperately been trying to do. And please help to stem any incorrect information going out from our President, information which

gives us hope for a couple of days, and then dashes that and puts many into a frenzied despair. We can cope with what's happening, and will continue to change our behavior per the guidelines, but only with information that's accurate.
Thank you, and keep safe,
Holly Kreutter
Virginia Resident

From: [redacted] (b) (6)
Sent: Wed, 18 Mar 2020 19:54:24 -0400
To: NIAID Public Inquiries
Subject: Fwd: Volunteer status for current nursing students

Sent from my iPhone

Begin forwarded message:

> **From:** Ivan Bocardo [redacted] (b) (6)>
> **Date:** March 18, 2020 at 7:16:25 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Volunteer status for current nursing students**
>
> Dear Dr. Anthony Fauci,
>
> My name is Ivan Bocardo, and am a [redacted] (b) (6) U.S. Army Medic (68W) deployed to Afghanistan in 2011-2012. I can send you my resume so you can see my skills and abilities that I can bring to the table. Am currently in nursing school (R.N.) in Rego Park, Queens with a [redacted] (b) (6)
> My school ([redacted] (b) (6)) has recieved a request from New York Governor Cuomo's office looking for nursing students to help volunteer. However many students like myself are very hesitant to volunteer for the simple fact that it will interfere with our studies and we will still have to comply with class assignments and class exams and especially with final exams this current semester coming up at the middle to end of April 2020. Yet many of my fellow classmates would love a chance to stand up and deliver help during these trying times. However our school will not except any excuses for lateness or absence even though we are now on an online learning as of this moment. So our greatest fear is that we wont finish this semester and will not be able to start next semester (it starts April 28, 2020 for our school)... basically 2 semesters wasted and it will push back our graduation date and furthermore incur more student loans in order to continue with school.
>
> This is why I am writing to your office if an exception can be made and we can have OTJ (on the job training for nursing) and recieve credit and for our current semester and possibly our next semester. Many of the students I speak about already have a Bachelor's degree (I myself have a B.S. in Biology from [redacted] (b) (6)) and many are or have worked as Nurse aides in many NYC area local hospitals with many years of excellent experience. Imagine if you are able to approve this for many nursing school students in just the New York City area and Long Island Suburbs.This would be virtually an untapped experienced workforce of literally hundreds perhaps maybe thousands of hands on personnel ready to go to help relieve the over burdened health system workers and provide additional reinforcements due to the coronavirus. In not only my area of New York city but possibly all over the country where we can help providing help and additional assistance and reinforcements
>
> Dr. Fauci, I am humbly asking for special permission, we all will need all the help we can get. Please consider this option as this can be a win/ win situation for not only NYC residents but for other areas of the country hit hard by this crisis. I have spoken to many of my fellow classmates and they all understand the risk and would be willing to share the burden with the

extreme pressures put on the health care system at this time. Many of us including myself would be willing to work on site or what ever site you may need us the most, many us fully understand that we could potentially be away from our families for an extensive unknown period of time which we are ready for and prepared for or possibly put our health on the line too.

I implore you to give us a chance and only ask for special permission for OTJ in order to fully finish our R.N. nursing degree.
Thank you for your time in reading this letter.
You are doing one fine heck of job in providing outstanding information and keeping the public informed

Sincerely,

Ivan Bocardo

Personal Cell phone (b) (6)

From: [redacted] (b) (6)
Sent: Wed, 18 Mar 2020 19:52:49 -0400
To: Margaret Wilbur
Subject: Re: coronavirus immunity

Thank you for your note.
A.S. Fauci

Sent from my iPhone

> On Mar 18, 2020, at 7:25 PM, Margaret Wilbur <[redacted] (b) (6)>wrote:
>
> Have we reached a time when it might be useful to prove who is immune to Covid-19? I understand that there is an antibody test already available. If we could identify who is already immune, we could then let those people return to daily life, work safely in essential positions, and feed the economy.
>
> I practiced internal medicine in Cleveland, Ohio for [redacted] (b) (6). I was amazed on a daily basis by the breakthrough that was PCR testing. Right now old-fashioned antibody tests might make a critical difference to us.
>
> Margaret Wilbur, MD
> [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Wed, 18 Mar 2020 19:52:29 -0400
To: Ronald Frank
Subject: Re: Dental offices and the coronavirus IMPORTANT

Thank you for your note.
A.S. Fauci

Sent from my iPhone

> On Mar 18, 2020, at 7:28 PM, Ronald Frank [redacted] (b) (6)> wrote:
>
> Dear Dr Fauci,
>
> Firstly, I would like to commend you on your expertise and leadership.
>
> As we develop a comprehensive plan to tackle the coronavirus pandemic, I believe that we have failed to address a critical piece of the puzzle to contain the virus.
>
> I am a physician and urologist, but I am astutely aware of the dental profession. I have a older brother who is a practicing dentist and I have voiced my concerns to him.
>
> Each and everyone of us who has had an appointment with a dentist knows the procedure of pressure irrigation in the mouth resulting in a mist and aerosol of secretions and saliva depositing on the faces of patients, the dentist and on all the surfaces in the treatment rooms. While the dentist wears a face mask, the spray of secretions, in a potential coronavirus carrier, widely contaminates surfaces, other employees and patients.
>
> I pose the question, should dental offices be actively treating patients during this critical phase in the Coronavirus pandemic? Everything which I have mentioned is corroborated by several practicing dentists. Is the he CDC and the NIH obligated to set guidelines and restrictions on dental care during this critical time as we try to get control of increasing numbers of cases. Should the ADA take a stronger stance during this crisis?
>
> I respectively reserve these decisions and recommendations to you and your colleagues Thank you
>
> Sincerely,
>
> Ronald G. Frank, M.D.
> 1500 Pleasant Valley Way
> Suite 201
> West Orange, New Jersey 07052
> o. 973•731•6600
>
>
> Sent from my iPhone

From: [redacted] (b) (6)
Sent: Wed, 18 Mar 2020 19:51:14 -0400
To: dalt222
Subject: Re: Plaquenil for Covid 19

Thank you for your note.
A.S. Fauci

Sent from my iPhone

> On Mar 18, 2020, at 7:41 PM, [redacted] (b) (6) wrote:
>
> Dr Fauci,
>
> I hope all is well with you. I am a Dermatologist practicing in the Metropolitan Detroit area. I have done some literature searching on potential treatments for the novel coronavirus and stumbled across a few case case reports from China in 2005 at the time of the SARS outbreak. They detailed some successes in treatment of severe cases with chloroquine. I saw a more recent study showing hydroxychloroquine had better in vitro efficacy than chloroquine. Have you heard of this? Plaquenil is so innocuous, I wonder if we shouldn't just try it.
>
> I think you are doing phenomenal work and really presenting a level, measured and realistic view of this epidemic to the world. Please keep up the great work. It is much appreciated
>
> David A. Altman MD FAAD
> Assistant Clinical Professor
> Division of Internal Medicine
> Michigan State University College
> Of Human Medicine
>
> Sent from my Verizon, Samsung Galaxy smartphone

From: [redacted] (b) (6)
Sent: Wed, 18 Mar 2020 19:50:23 -0400
To: DMID Word Nerds
Subject: Fwd: Interest in collaboration on COVID-19 antibody development

Pls handle

Sent from my iPhone

Begin forwarded message:

> **From:** Dea Shahinas <[redacted] (b) (6)>
> **Date:** March 18, 2020 at 7:41:40 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** [redacted] (b) (6)>
> **Subject: Interest in collaboration on COVID-19 antibody development**
>
> Dear Dr. Fauci,
> We learned about your research on COVID-19 at NIAID and are interested in collaborating with you in order to fast-track our efforts in developing antibodies against this infection.
> We have two decades of experience with single domain antibody (nanobody) technology.
> I will provide below a brief summary about our company:
> Virotek is a private Canadian biotech with focus on the development of novel biologics for the treatment of viral infections. Our primary focus area has been in the areas of infectious diseases and immuno-oncology in animal and human verticals. [redacted] (b) (4)
> [redacted] (b) (4)

We are also proposing [redacted] (b) (4)
[redacted] Please let us know if you are interested and we are happy to arrange for a time to discuss in further detail with you.
Best regards,

Dea Shahinas
Director, R&D
Virotek Inc.
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 23:09:32 +0000
To: [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: FW: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf
Attachments: Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Annotated-YELLOW Nicholls S Peiris M NATURE-Med 9-2005.pdf

(b) (6)

The situation gets confusing. See attached brief commentary and e-mail string. As you can see, I was too tired to make any sense of it. However, my deputy (Cliff Lane) notes that this paper argues the opposite, i.e. that ACE inhibitors might have a benefit and counters the argument to stop ACE inhibitor.s Bottom line is that we really do not know what the effect will be clinically with respect to COVID-19. In any event, [redacted] (b) (6)
Best,
Tony

From: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Wednesday, March 18, 2020 5:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

A 2005 paper post-SARS advocating for use of ACE inhibitors to increase ACE2. The opposing argument to stopping ACE inhibitors.

From: Anthony Fauci [redacted] (b) (6)
Date: Wednesday, March 18, 2020 at 5:22 PM
To: "Lane, Cliff (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: FW: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

I cannot make heads or tails of this. Please take a look and let me know what you think. Thankjs.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)

FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ste McCon [redacted] (b) (6)>
Sent: Wednesday, March 18, 2020 5:09 PM
Subject: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

"Clearly, the potential therapeutic utility of recombinant **ACE2 and angiotensin II receptor-inhibitors. [ARB's ?]**s—**already in clinical use for control of blood pressure**—for acute lung injury resulting from viruses and other causes will be a productive field for investigation. This is particularly relevant as we prepare to **confront a potential avian flu pandemic**, [***COVID-19*** **?**]armed with onlya limited number of therapeutic options."

Regards,

Stephen D. McConnell, BS, MSc-CCP, CIS

Lipidemiologist - Clinical Application Specialist

Medicare-CMS ACO/MSSP/Direct-Contracting Consultant

Medical Science Liaison

Mobile: [redacted] (b) (6)

[redacted] (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 23:03:32 +0000
To: SWAMINATHAN, Soumya
Cc: Collins, Francis (NIH/OD) [E] ([redacted] (b) (6));Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Confidential and urgent request regarding

Thanks, Soumya.

From: SWAMINATHAN, Soumya [redacted] (b) (6)
Sent: Wednesday, March 18, 2020 6:49 PM
To: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Confidential and urgent request regarding

Dear Francis

I am sure you have seen the results which came out today, and are inconclusive. The DG announced the launch of the WHO Solidarity trial, which will hopefully provide a definitive answer to all these questions. Many thanks to NIAID for their support.
Warm regards
Soumya

Sent from my iPhone

> On 17 Mar 2020, at 18:50, Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> wrote:
>
> Hi Soumya,
>
> See below. Is it possible for WHO to [redacted] (b) (4)
>
> Thanks for any help you can give.
>
> Francis
>
> ---
>
> **From:** Hudson, Thomas J [redacted] (b) (6)>
> **Sent:** Tuesday, March 17, 2020 10:15 AM
> **To:** Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
> **Cc:** Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6) Fauci, Anthony (NIH/NIAID)

[E] [redacted] (b) (6)>; Hudson, Thomas J [redacted] (b) (6)>
Subject: RE: Confidential and urgent request regarding

Dear Francis,

I have not received any response from Dr. Swaminathan to my message sent yesterday
(b) (4) [redacted]

I expect that we are not the only group trying to get to WHO leaders. A call from Tony or you may be more successful.

In addition to my contact information below, I can be reached via my cell phone: (b) (6) [redacted].

Tom

THOMAS HUDSON
Senior Vice-President, R&D
Chief Scientific Officer

AbbVie, North Chicago
1 North Waukegan Rd
R473, Building AP9-1
N Chicago, IL 60064
TEL (OFFICE) [redacted] (b) (6)
EMAIL [redacted] (b) (6)

abbvie.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

From: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)>
Sent: Monday, March 16, 2020 8:43 AM
To: Hudson, Thomas J [redacted] (b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: [EXTERNAL] RE: Confidential and urgent request regarding

Tom,

Thanks again for reaching out. I can only imagine [redacted] (b) (4)

[redacted] (b) (4)

The best contacts would be the WHO Chief Scientist Soumya Swaminathan [redacted] (b) (6) and potentially Director General Tedros [redacted] (b) (6)

Let me know if you hit a roadblock with WHO. I might then want to weigh in too.

Francis

From: Hudson, Thomas J [redacted] (b) (6)
Sent: Monday, March 16, 2020 9:16 AM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Subject: RE: Confidential and urgent request regarding

Thank you.

THOMAS HUDSON

Senior Vice-President, R&D
Chief Scientific Officer

AbbVie, North Chicago
1 North Waukegan Rd
R473, Building AP9-1
N Chicago, IL 60064
TEL (OFFICE) [redacted] (b) (6)
EMAIL [redacted] (b) (6)

abbvie.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Monday, March 16, 2020 8:14 AM
To: Hudson, Thomas J [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: [EXTERNAL] RE: Confidential and urgent request regarding

Hi Tom,

Got your message, am looking into it, hope to get back to you later today.

Best, Francis

From: Hudson, Thomas J [redacted] (b) (6)
Sent: Monday, March 16, 2020 9:10 AM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Subject: RE: Confidential and urgent request regarding

This follow-up message is a duplicate that I am sending to another e-mail address that I have on file.

Dear Francis,

I am sending this brief note as a request for guidance on an evolving situation with

(b) (4) [redacted]

[redacted] (b) (4)

I am reaching out to you to see if you have any suggestions or individuals that we should contact.

Best wishes,

Tom

THOMAS HUDSON
Senior Vice-President, R&D
Chief Scientific Officer

AbbVie, North Chicago
1 North Waukegan Rd
R473, Building AP9-1
N Chicago, IL 60064
TEL (OFFICE) [redacted] (b) (6)
EMAIL [redacted] (b) (6)

abbvie.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

[redacted] (b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 20:09:47 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Covid-19

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ann Beloten (b) (6)
Sent: Wednesday, March 18, 2020 4:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Covid-19

Dear Dr. Fauci,
I am writing to you because I have a question regarding Covid-19. How come you do not tell the compete truth to the American people regarding this virus? All I hear is the bad facts about it. Why not give people some help and tell us the good facts about it? Good facts such as the number of actual patients is very small compared to the whole population, most people who get it make a full and complete recovery. Are you enjoying the senseless panic you made? Panic where people are hoarding food/goods, stealing full shopping carts from the elderly, losing their jobs/wages, inadequate education now that schools are closed.
The number of people who will actually be sickened by the virus will be dramatically dwarfed by the people who lose their jobs, receive a poor education despite their teachers best efforts and miss out on once in a lifetime events such as weddings, graduations, communions.
What you are doing is not right for the American people!! You need to stop playing GOD and tell the people the complete truth!! The country and the people need to get back to our normal lives NOW!!
Sincerely,
Ann Beloten

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 20:07:28 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Rapid diagnostic support for Covid-19

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tony Lemmo [redacted] (b) (6)>
Sent: Wednesday, March 18, 2020 3:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Rapid diagnostic support for Covid-19

Hi Dr Fauci,

Hello from [redacted] (b) (6)

I'm sure you are swamped. I'll be brief. I am CEO of the world's leading provider of dispensing equipment for the diagnostics market, BioDot Inc. We have been around for 25 years and provide enabling technology to virtually every rapid immunoassay and molecular diagnostics company in the world. We are actively involved today with companies around the globe to help commercialize lateral flow point of care products to help fight Covid-19. If there is anybody in your organization or on the task force that could help facilitate getting us involved with companies looking to produce tests - we are here to help! For example we are actively working with Biomedomics to get their LFD test into the community as fast as possible.

We will move heaven and earth to help the country in any way we can.

Thank you for all you have done and best of luck in fighting this pandemic

[redacted] (b) (6)

Tony

Anthony V. Lemmo, Ph.D
CEO and President

BioDot Inc.
2852 Alton Parkway
Irvine, CA 92606
P (b) (6)
F 949-440-3694
www.biodot.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 20:05:50 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Fabric Face Masks

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: AmiSimms (b) (6)>
Sent: Wednesday, March 18, 2020 4:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Fabric Face Masks

Dr Fauci,
Thank you for your guidance and expertise at this difficult time.

My friend and I are quilters. She lives in (b) (6) and I live in (b) (6). She has created a pattern for a fabric face mask. We read Dr. Tufekci's op ed in the NYT yesterday and have been brainstorming together ever since on ways we can help.
https://www.nytimes.com/2020/03/17/opinion/coronavirus-face-masks.html

Several years ago I mobilized quilters throughout the US and we raised more than $1.1 million for Alzheimer's Disease research. All grass roots, all volunteer. There are 7-10 million quilters in the US.

My friend and I would like to make a fabric face mask pattern available at no charge so that quilters, sewers, and crafters can make face masks. We understand these are nowhere near medical grade, but they would be better than nothing at all. (See research cited in link above.) They would be made from fabric scraps and supplies on hand; no trips to the fabric store would be necessary.

At this time there are no masks available to the public at all. Sewing for a cause would give purpose to those of us staying home. Wearing a mask on rare occasions when we do venture outside has the benefits signaling others to step back even if the masks do not protect against transmission of the virus.

We are just two individuals wanting to help. I've been advised by an attorney that sharing this free pattern might open us up to scrutiny from regulatory agencies or possible law suits. We don't want to step on any toes, nor do we want any legal entanglements.

Could the NIH make this pattern available? Or the CDC? There are millions of sewers who would be delighted to step up and help right now. It would be great for morale, and even though it's one step up from nothing, IT IS SOMETHING. This could even be scaled beyond individuals making fabric face masks for themselves. Masks could be sewn for others.

Could we please work with you?

Thank you for your consideration,
Ami Simms (b) (6) and Emanuela D'Amico (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 19:07:06 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Covid-19 symptoms outside of China

Point this person in the right direction

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: W W (b) (6)>
Sent: Wednesday, March 18, 2020 3:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Covid-19 symptoms outside of China

Dear Dr. Fauci,

Many insist on coughs as one of the requirements for self-isolation or testing for covid-19. However, I have read about instances where coughs were not experienced by those who tested positive.

Is it possible to share a list of covid-19 symptoms that *exclude* the patients in China and perhaps France due to their fairly high number of smokers? Does coughing remain a symptom? I am concerned about the health of our nursing home residents, as well as the financial well-being of service sector workers.

Thank you,
Winnie

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 18:27:08 +0000
To: Redfield, Robert R. (CDC/OD);Stephen Hahn;Birx, Deborah L. EOP/NSC
Cc: [redacted] (b) (6);Troye, Olivia EOP/NSC;Short, Marc T. EOP/OVP;Miller, Katie R. EOP/OVP;Hicks, Hope C. EOP/WHO;kellyanne conway
Subject: Follow-up of today's conversation

Folks:

[redacted] (b) (5)

[redacted] (b) (5). Happy to discuss.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not

accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 15:09:54 +0000
To: [redacted] (b) (6)
Subject: FW: Bloomberg: 99% of Those Who Died From Virus Had Other Illness, Italy Says

Look at the hypertension percentage

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, March 18, 2020 9:52 AM
Subject: Bloomberg: 99% of Those Who Died From Virus Had Other Illness, Italy Says

99% of Those Who Died From Virus Had Other Illness, Italy Says

By Tommaso Ebhardt, Chiara Remondini, and Marco Bertacche
March 18, 2020, 8:56 AM EDT

More than 99% of Italy's coronavirus fatalities were people who suffered from previous medical conditions, according to a study by the country's national health authority.

After deaths from the virus reached more than 2,500, with a 150% increase in the past week, health authorities have been combing through data to provide clues to help combat the spread of the disease.

Prime Minister Giuseppe Conte's government is evaluating whether to extend a nationwide lockdown beyond the beginning of April, daily La Stampa reported Wednesday. Italy has more than 31,500 confirmed cases of the illness.

Italy Coronavirus Deaths By prior illnesses (%)



Source: ISS Italy National Health Institute, March 17 sample

The new study could provide insight into why Italy's death rate, at about 8% of total infected people, is higher than in other countries.

The Rome-based institute has examined medical records of about 18% of the country's coronavirus fatalities, finding that just three victims, or 0.8% of the total, had no previous pathology. Almost half of the victims suffered from at least three prior illnesses and about a fourth had either one or two previous conditions.

More than 75% had high blood pressure, about 35% had diabetes and a third suffered from heart disease.

The average age of those who've died from the virus in Italy is 79.5. As of March 17, 17 people under 50 had died from the disease. All of Italy's victims under 40 have been males with serious existing medical conditions.

While data released Tuesday point to a slowdown in the increase of cases, with a 12.6% rise, a separate study shows Italy could be underestimating the real number of cases by testing only patients presenting symptoms.

According to the GIMBE Foundation, about 100,000 Italians have contracted the virus, daily Il Sole 24 Ore reported. That would bring back the country's death rate closer to the global average of about 2%.

— With assistance by Karl Maier

From: Folkers, Greg (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 18:13:38 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: RE: Covid-19 coverage in Nature Reviews Immunology

Dear Alexandra,

Thank you for your kind words.
Yes, we can send yuu references of notable papers
My chief of staff, Greg Folkers (cc'd here), will be my conduit/surrogate.

Regards,

AS Fauci

From: Alexandra Flemming <A.Flemming@nature.com>
Sent: Tuesday, March 17, 2020 10:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Covid-19 coverage in Nature Reviews Immunology

Dear Tony,

Thank you again for contributing the fabulous year in review article to Nature reviews Immunology last year!

Given the current pandemic, we can only imagine how incredibly busy you are at the moment. At Nature Reviews Immunology we have decided that we would like to introduce an in-brief section that provides a brief overview of the most notable/important research on SARS-CoV-2, particularly with regards to its immunopathology and vaccine development. To this end, we are recruiting a small number of advisors to point us in the right direction – this would involve no actual writing, just sending us references to the papers as and when they come out. Would you, or a member of your team, be willing to act as an advisor for this project, by sending us between 1-5 references for notable papers per month? We feel that particularly in this fast evolving situation, it is of paramount importance that amongst the deluge of data, scientists are guided towards the most important papers.

I look forward to hearing from you,

With best regards,

Alexandra

Dr Alexandra Flemming

Chief Editor
Nature Reviews Immunology

Nature Research
4 Crinan Street, London N1 9XW, UK
(b) (6)
a.flemming@nature.com
www.nature.com/nri

150 nature CELEBRATING 150 YEARS
1869–2019

DISCLAIMER: This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage mechanism. Springer Nature Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of Springer Nature Ltd or one of their agents.
Please note that Springer Nature Limited and their agents and affiliates do not accept any responsibility for viruses or malware that may be contained in this e-mail or its attachments and it is your responsibility to scan the e-mail and attachments (if any).
Springer Nature Limited. Registered office: The Campus, 4 Crinan Street, London, N1 9XW. Registered Number: 00785998 England.

From: [redacted] (b) (6)
Sent: Tue, 17 Mar 2020 10:42:33 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C];Lane, Cliff (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: Fwd: Invitation: BIO Coronavirus Collaboration Initiative
Attachments: INVITATION_Fauci BIO COVID19 Virtual Summit 15Mar2020.pdf, ATT00001.htm

Let us discuss and decide one way or another.

Begin forwarded message:

> **From:** Hannah Dorsey <hdorsey@bio.org>
> **Date:** March 16, 2020 at 3:51:02 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Cc:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "Marston, Hilary (NIH/NIAID) [E]" <[redacted] (b) (6)>, Phyllis Arthur <parthur@bio.org>
> **Subject: Invitation: BIO Coronavirus Collaboration Initiative**
>
> Dear Dr. Fauci,
>
> On behalf of BIO, I would like to invite you to participate in our multi-stakeholder COVID-19 Collaboration Virtual Summit which will take place March 24-25. We are hosting this summit in order to facilitate near-term collaboration among industry, government, academic and non-governmental experts to help confront this growing and unpredictable public health crisis.
>
> We would like you to be a speaker during the Plenary session on March 24th. We would like you to give 5-10 minutes of opening remarks to the Summit participants. Please note that the plenary session of the event will be open to the press, while the remaining sessions will be closed to just invited guests to ensure a robust discussion and maximum collaboration. You are welcome to attend any of the subsequent Breakout sessions scheduled over the two days.
>
> This virtual meeting will take place over two days:
>
> - March 24th: 10:00am – 11:45am - Plenary Session
> - March 24th: 12:00pm – 2:30pm – Treatment Break Out Session
> - March 25th: 10:00am – 12:30pm – Prevention Break Out Session
> - March 25th: 1:00pm – 3:30pm – Diagnostics Break Out Session

Attached is the full invitation to our event from our CEO Jim Greenwood, the full agenda will be to follow. Please let us know if you would be available as a speaker for the Plenary session on March 24th.

Best,
Hannah Dorsey
Coordinator, Health Policy
Biotechnology Innovation Organization (BIO)
1201 Maryland Ave. SW, Ste. 900
Washington, DC 20024
Office: (202) 962-6644
hdorsey@bio.org
www.bio.org

From: [redacted] (b) (6)
Sent: Tue, 17 Mar 2020 07:30:48 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Updates

Sent from my iPhone

Begin forwarded message:

> **From:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Date:** March 17, 2020 at 7:14:00 AM EDT
> **To:** Janet Tobias <janet@ikanamedia.com>
> **Subject: RE: Updates**
>
> Thanks, Janet. Please continue to work with Patty to make this happen.
> Best regards,
> Tony
>
> ---
>
> **From:** Janet Tobias <janet@ikanamedia.com>
> **Sent:** Tuesday, March 17, 2020 7:00 AM
> **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
> **Subject:** Updates
>
> Dear Tony:
> Quick updates, we have partnered with Story Syndicate/John Hoffman (who was in charge of First In Human and Alzheimer's and Obesity projects) on the film about your life. This will help us make sure that next year this film has maximum impact and we carry the message widely of "men serving men" and public health. NIH Communications head John Burklow, and the main office, knows and is very supportive and excited about the potential impact. They have worked super closely with John in the past.
>
> We are putting in the request for filming with the Vice President's office and we will work with Patty to figure out how to film your work and NIAID's work on COVID-19, which is important. But safety and

modelling appropriate behavior always first and foremost. Crews on my side tiny and all from Unseen Enemy.

Thanks for everything, every day, and stay healthy,

Janet

PS The Aids project, and the educational partnership with Howard Hughes Medical Insitute continues in good state, just on hold as it should be.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 03:04:31 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Question about COVID-19 Mechanism of Transmission

Please respond.

From: EDWARD EITZEN [redacted] (b) (6)
Sent: Sunday, March 8, 2020 3:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Question about COVID-19 Mechanism of Transmission

Hi Tony:

Thank you for what you are doing for our country to try and limit the consequences of COVID-19. Many Americans are hanging on your every word, as they should be, and that includes me.

A question about COVID-19 mechanism of spread: The reported reproductive number from China of about 2.6 indicates a likelihood of large droplet spread as the mode of transmission from person to person. My question is - could there be a component of airborne spread (droplet nuclei) with this virus? If super spreaders exist with COVID-19, is airborne spread possible? Knowing the answer to this question would help to inform decisions about PPE and Decontamination in settings such as Emergency Departments. If this is not already known definitively, could NIOSH and some key partners possibly study it in current quarantine settings?

Thanks, Tony. God bless you and your important work!

Best, Ed

Edward Eitzen, M.D., M.P.H.
Senior Partner, Biodefense and Public Health Programs
Martin-Blanck and Associates
2034 Eisenhower Avenue, Suite 270
Alexandria, VA 22314-4678

Office Phone: 719-548-9207
Cell Phone: [redacted] (b) (6)

Email: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 03:02:00 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Flu statistics

Please respond for me.

-----Original Message-----
From: Candace Gunn [redacted] (b) (6)
Sent: Sunday, March 8, 2020 10:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Flu statistics

Dear Dr. Fauci,

First of all, thank you so much for the wonderful job you are doing regarding the information on the coronavirus. You were excellent with Chris Wallace!

Is it possible to give facts on the FLU - number of people who have had it and how many have died - during the past month? I wonder if that might perhaps slow down the media frenzy.

Many thanks for your consideration of my question.

Best regards,

Candace Gunn

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 03:00:44 +0000
To: Anderson, Roy M
Subject: RE: Lancet Commentary on COVID-19

Roy:
Thank you for your kind note. Very nice article! I hope that all is well with you.
Best,
Tony

From: Anderson, Roy M [redacted] (b) (6)>
Sent: Saturday, March 7, 2020 5:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Lancet Commentary on COVID-19

Dear Tony,

I thought the attached may be of interest to you.

You have been doing a very good job in communicating the important issues around this epidemic – well done.

Kind regards,

Roy

Professor Sir Roy Anderson FRS FMedSci
Director
London Centre for Neglected Tropical Disease Research (LCNTDR)
Department of Infectious Disease Research,
Faculty of Medicine
Imperial College London Praed Street
London W2 1PG

Te [redacted] (b) (6)
[redacted] (b) (6)

Assistant – [redacted] (b) (6)
Project Manager – [redacted] (b) (6)
Manager LCNTDR – [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 02:59:48 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Modeling of COVID-19 from Mike Levit
Attachments: 1.Analysis_of_Coronavirus-2019_Data_Michael_Levitt-v1.pdf, 1.The_Corona_Chronologies. Part II - Rest of the World. Michael_Levitt,Stanford.pdf, 30.The_Corona_Chronologies. Part I - China. Michael_Levitt,Stanford.pdf

Please take a look and see what you think.

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Sent: Friday, March 6, 2020 8:46 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Lauer, Michael (NIH/OD) [E] [redacted] (b) (6)>
Subject: Modeling of COVID-19 from Mike Levit

Francis, Tony –
Mike Levitt (Nobel prize in Chemistry, 2013) sent the attached modeling of the COVID-19 epidemic to Mike Lauer. I don't know if this will prove useful but wanted to pass it along in case.

He indicated that he was amazed to see how an Excel level analysis could allow him to predict the China epidemic would end as early at 2-Feb and get what he considers the best estimates for case fatality ratio. His first report from 2-Feb is attached as well as his most recent two-part report.

Larry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 02:54:15 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Community-Spread Covid-19 Contact Tracking

Take a look and handle.

From: John G. Boland <[redacted] (b) (6)>
Sent: Thursday, March 5, 2020 10:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Community-Spread Covid-19 Contact Tracking

Dear Dr. Fauci:

Without success, for more than a week, I have tried to reach any techie CDC person about the problem of community-spread Covid-19 contact tracking.

Though your workload is unimaginable, I thought you might personally know and could provide contact information of an appropriate CDC or NIH epidemiologist.

Brief Summary of Conceptskip to End, if obvious***

Had I been to a doctor or ER with a virulent disease, they would immediately have asked where I had been, with whom, and for what duration. With that information, epidemiologists can notify and test those contacts... and their contacts... before their symptoms are evidenced.

This manual contact tracking process is workload intensive, calendar-day wasting, data-poor, and inaccurate.

"Location tracking" can provide the raw data needed to identify potential contacts automatically, early, and thoroughly, from information routinely collected by network providers.

The location, at a date and time, of a vast number of anonymous cell phones, over the preceding two weeks, would be very useful for identifying the index case and subsequent contacts of an individual.

As an illustration, the New York Times published, on 19 December 2019, "Twelve Million Phones, One Dataset, Zero Privacy" about the commercial location tracking industry:
https://www.nytimes.com/interactive/2019/12/19/opinion/location-tracking-cell-phone.html

End of Summary

Ignoring the techie and legal details, can you suggest an appropriate contact, while Covid-19 infections in the United States are few?

Your continuing dedication, candor, and data-driven focus are refreshing and very much appreciated, Dr. Fauci.

Best,

John G. Boland

[redacted] (b) (6)
[redacted] (24 hr, text or leave msg if no answer)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 02:53:27 +0000
To: Tom Frieden
Subject: RE: FYI

I tried to call you this evening but got voice mail that said you were not accepting calls. Let us try to connect soon.

-----Original Message-----
From: Tom Frieden (b) (6)
Sent: Wednesday, March 4, 2020 11:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FYI

https://thehill.com/policy/healthcare/485604-meet-the-federal-governments-coronavirus-expert

I know you don't read the papers but "super smart, super able to communicate very clearly, with a very deep ethical commitment to doing the right thing" is exactly what I think, not just what I'm telling the media.

All the best,

Tom

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 02:48:31 +0000
To: Pardis Sabeti
Subject: RE: Planning for a hearing on Global Health Security Team

Pardis:

Sorry that I did not respond sooner. I am getting over 1500 emails per day and this one got lost in the pile. Anything that you can do to help would be welcome.

Best,
Tony

From: Pardis Sabeti [redacted] (b) (6)
Sent: Tuesday, March 3, 2020 9:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: Planning for a hearing on Global Health Security Team

Dear Tony,

I hope that all is well given our current circumstances. I am sure you are very busy, so apologize for the intrusion, but would love your insight if you have a moment.

I just had a very interesting talk today with Wendy Ginsberg on the House Committee on Oversight and Reform, with an opportunity to testify at a hearing next Wednesday (email attached).

While I am very excited for an opportunity to advocate for further funding and operational support for pandemic preparedness, I also recognize that this format may not be the right one to do so. Moreover, I may not be the right person to do so, as I think you, Francis, or Eric Lander would do far better than me.

I imagine they have already asked you to participate, and would just love any insight you might have as to whether I should consider doing this, and if so, how I should proceed. I really only would want to do so if it is a place where I can help the larger infectious disease community and make a positive nonpolitical impact.

Thanks so much for your consideration,

Pardis

---------- Forwarded message ---------
From: **Ginsberg, Wendy** <[redacted] (b) (6)>
Date: Mon, Mar 2, 2020 at 8:54 AM
Subject: Planning for a hearing on Global Health Security Team
To: [redacted] (b) (6)>

Richard Preston pointed me in your direction, saying you would be the right person to help me think through a potential hearing on codifying the global health security team on the National Security Council.
The hearing (as of right now in my mind) would

1. Examine the lessons learned from the Ebola and other previous outbreaks about how federal government design and operations can facilitate or hinder global health and stemming pandemics;
2. Analyze how eliminating the global health security team has put us several steps behind where we need to be in fighting coronavirus; and
3. Argue for codifying the team and its leadership as part of the larger national security apparatus and avoid kowtowing to outbreak fatigue.

I'm hoping you might be willing to speak with me about your expertise and thoughts in this area. I'm definitely not the expert and I would love someone with your background to ensure I'm getting this story right – and that I have the right people at the witness stand to tell it.

Would you have time to talk today or some time very soon? We are hoping to have this hearing next week.
Yours,
Wendy

Committee on Oversight and Reform

Wendy Ginsberg, Ph.D.
Staff Director
House Committee on Oversight and Reform
Subcommittee on Government Operations
(b) (6) [redacted]

--
Pardis Sabeti, MD, DPhil
Professor, Harvard University & Harvard School of Public Health
Broad Institute of MIT and Harvard
Howard Hughes Medical Institute

Assistant: [redacted] (b) (6)
Phone: [redacted] (b) (6)
Website: www.sabetilab.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 01:46:44 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Wall Street Journal request

Please decide if we can do this.

From: Willick, Jason <jason.willick@wsj.com>
Sent: Monday, March 16, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Wall Street Journal request

Dear Dr. Fauci,
My name is Jason Willick with the Wall Street Journal. I was wondering if you would be willing to talk to me for the WSJ weekend interview section on pandemics and the coronavirus—the US response but also the broader challenges from infectious disease. I know you are beyond busy, but I thought I'd ask. Let me know if this is a possibility and I can discuss more details.

Jason

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 00:27:13 +0000
To: Michael liu
Subject: RE: Great advice from Chinese expert

Michael:

Thank you for your note. We indeed have learned much from our Chinese colleagues. I appreciate your bringing these issues to our attention.

Best regards,
Tony

From: Michael liu [redacted] (b) (6)>
Sent: Monday, March 16, 2020 8:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Great advice from Chinese expert

Dear Dr. Fauci,

Dr. Wenhong Zhang, has become very famous in China's war against COVID-19 because of his great excellence in anti-virus. Dr. Zhang is the Director of the Infectious Disease Department of Huashan Hospital in Shanghai. He is very good according to my observation all long. Another great doctor in China is Dr. Nanshan Zhong.

According to Dr. Zhang's video at https://www.thepaper.cn/newsDetail_forward_6537248, COVID-19 can really be prevented with 3 key measures, i.e. to keep social distancing, wash hands frequently and **wear masks**. I strongly suggest American people should wear masks like Chinese, South Korean people, etc., because even China's highest leader, Mr. Jinping Xi, wears masks. If it is difficult for all the US people to do this now, I suggest working staff in airports, supermarkets and other public places should wear masks firstly in order to avoid crossing infection.

Further, Dr. Zhang said, if a person is still infected though he/she takes the above 3 measures carefully, the person must be infected by his/her family members. So I propose the **concentrated isolation** of mild confirmed cases should be considered as I advised yesterday.

I strongly suggest American government should learn precious experience of anti-COVID-19 from and cooperate with the mainland China, Taiwan, South Korea with an open mind. If you need any help to contact with Dr. Zhang, I will do what I can.

I am very confident that the US government will lead American people to win the anti-COVID-19 war by you and other great experts. Science, expertise and great learning are best medicines.

God bless you! God bless America, China and the whole world!

Best regards,

Michael Liu

发件人: Fauci, Anthony (NIH/NIAID) [E] [mailto:[redacted] (b) (6)

发送时间: 2020年3月15日 13:28

收件人: Jingming Liu (Michael) <[redacted] (b) (6)

主题: Re: Great Advice on How to Avoid Family Spread of COVID-19

Thank you for your note
A.S. Fauci.

Sent from my iPhone

On Mar 15, 2020, at 1:26 PM, Jingming Liu (Michael) [redacted] (b) (6)> wrote:

Dear Dr. Fauci,

My name is Michael Liu. My family are living in [redacted] (b) (6) now. I have been following spread of COVID-19 (Corona Virus) closely because such virus is very contagious and dangerous.

If a person is mildly sick with COVID-19, the CDC now suggests the person should "stay home except to get medical care", i.e. home-isolation, according to https://www.cdc.gov/coronavirus/2019-ncov/downloads/sick-with-2019-nCoV-fact-sheet.pdf

However, the home isolation may result in family spread of COVID-19 in certain kinds of families, e.g., parents are infected but their kids are too young to take care of them, adults are infected but their parents are too old and risky to look after them (if they live together), an old husband/wife is infected but the spouse is too vulnerable to take care of him/her, etc. In such scenarios, the home isolation may increase family spread and even community spread risks in the US.

A great method to avoid home-isolation risks is the concentrated isolation, i.e. to isolate mild symptomatic people in a concentrated place instead of their homes.

The concentrated isolation can avoid the above family spread risks, provide professional medical help to isolated people, reduce mental pressure of other family members, etc., so that it can reduce community spread risks. Such method has been proved to be effective by China's war against COVID-19.

The concentrated place can be a hotel, university dorm building, etc., which should be easily managed for medical surveillance.

The concentration isolation may be voluntarily chosen by relevant families at the beginning, and adjusted to apply subject to different conditions.

Hope the above advice helpful!

Best regards,

Michael Liu

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 00:23:16 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: offer from Mark Zuckerberg

I will write to or call Mark and tell him that I am interested in doing this. I will then tell him that you will get for him the name of the USG point of contact. I agree it should be Bill Hall who could then turf to the White House Comms if he wishes

---

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, March 16, 2020 6:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: ASF: offer from Mark Zuckerberg

Per email below, Mark Zuckerberg has extended a few offers to do videos with you that we would be happy to seek clearance on for you to do, if you are amenable. These would have the weight and impact of television – really, more so. Please advise if you want to do and we will seek clearance with VP office and work with Patty to sort out the logistics.

But an even bigger deal is his offer [redacted] (b) (4) The sooner we get that offer up the food-chain the better. I gave Bill Hall a heads-up about this opportunity and he is standing by to discuss this with HHS and WH comms, but I didn't want him to do anything without you being aware of the offer. Is it OK if I hand this aspect off to Bill to determine who the best point of contact would be so the Administration can take advantage of this offer, soonest?

Do you plan to call MZ? His cell number is in his message below.

From: Mark Zuckerberg [redacted] (b) (6)
Sent: Sunday, March 15, 2020 12:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Thanks and ideas

Tony:

I wanted to send a note of thanks for your leadership and everything you're doing to make our country's response to this outbreak as effective as possible. I also wanted to share a few ideas of ways we could help you get your message out, but I understand you're incredibly busy, so don't feel a need to reply unless these seem interesting.

This isn't public yet, but we're building a Coronavirus Information Hub that we're going to put at the top of Facebook for everyone (200+ million Americans, 2.5 billion people worldwide) with two goals: (1)

make sure people can get authoritative information from reliable sources and (2) encourage people to practice social distance and give people ideas for doing this using internet tools. This will be live within the next 48 hours.

As a central part of this hub, I think it would be useful to include a video from you because people trust and want to hear from experts rather than just a bunch of agencies and political leaders. This could be done in a number of formats if you're open to it. Probably best would be recording a Q&A where you answer people's top questions, but we'd be open to other formats too.

I'm also doing a series of livestreamed Q&As with health experts to try to use my large following on the platform (100 million followers) to get authoritative information out as well. I'd love to have you do one of these Q&As. This could be the video we put in the Coronavirus Hub or it could be a different thing that we distribute separately, but I think it could be effective as well.

Finally, [redacted] (b) (4)

Again, I know you're incredibly busy, so don't feel the need to respond if this doesn't seem helpful. If it's easy to talk live, give me a call anytime on my mobile phone: [redacted] (b) (6).

Thanks again for everything you're doing.

Mark

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 17 Mar 2020 00:22:45 +0000
To: Mark Zuckerberg
Cc: Conrad, Patricia (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Thanks and ideas

Mark:

Thank you for your kind note. I tried to call you, but got voice mail. FYI, my cell phone number is (b) (6) Your idea and proposal sound terrific. I would be happy to do a video for your hub. We need to reach as many people as possible and convince them to take mitigation strategies seriously or things will get much, much worse. Also, your idea about (b) (4) is vey exciting. I am copying my Special Assistant, Patty Conrad. Her office number is (b) (6) (b) (6). Please have your people contact her to arrange for the video. I am also copying the Director of my Communications and Government Relations group. She can put your people in contact with the best person who could be the US Government point of contact for (b) (4).
Best regards,
Tony

From: Mark Zuckerberg (b) (6)>
Sent: Sunday, March 15, 2020 12:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Thanks and ideas

Tony:

I wanted to send a note of thanks for your leadership and everything you're doing to make our country's response to this outbreak as effective as possible. I also wanted to share a few ideas of ways we could help you get your message out, but I understand you're incredibly busy, so don't feel a need to reply unless these seem interesting.

This isn't public yet, but we're building a Coronavirus Information Hub that we're going to put at the top of Facebook for everyone (200+ million Americans, 2.5 billion people worldwide) with two goals: (1) make sure people can get authoritative information from reliable sources and (2) encourage people to practice social distance and give people ideas for doing this using internet tools. This will be live within the next 48 hours.

As a central part of this hub, I think it would be useful to include a video from you because people trust and want to hear from experts rather than just a bunch of agencies and political leaders. This could be done in a number of formats if you're open to it. Probably best would be recording a Q&A where you answer people's top questions, but we'd be open to other formats too.

I'm also doing a series of livestreamed Q&As with health experts to try to use my large following on the platform (100 million followers) to get authoritative information out as well. I'd love to have you do one of these Q&As. This could be the video we put in the Coronavirus Hub or it could be a different thing that we distribute separately, but I think it could be effective as well.

Finally, [redacted] (b) (4)

Again, I know you're incredibly busy, so don't feel the need to respond if this doesn't seem helpful. If it's easy to talk live, give me a call anytime on my mobile phone: [redacted] (b) (6)

Thanks again for everything you're doing.

Mark

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 19:40:27 -0400
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: Coronavirus antibodies

Please handle

Begin forwarded message:

> **From:** Andrew Sprouse [redacted] (b) (6)
> **Date:** March 16, 2020 at 4:00:44 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Re: Coronavirus antibodies**
>
> If millennials are spreading the coronavirus should we allow them to be tested with milder symptoms? Otherwise they have no idea they have it.
>
> > On Mar 13, 2020, at 5:27 AM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>wrote:
> >
> > It likely would
> >
> > > On Mar 13, 2020, at 2:58 AM, Andrew Sprouse [redacted] (b) (6):
> > >
> > > How about human breast milk? Would it have the antibodies as well?
> > >
> > > Sent from my iPhone
> > >
> > > > On Mar 12, 2020, at 7:53 PM, Andrew Sprouse [redacted] (b) (6)>wrote:
> > > >
> > > > Dr. Fauci,
> > > >
> > > > If China is taking patients and using the plasma/antibodies from them to help cure other patients why couldn't we do that to healthy people to give them immunity to the virus?
> > > >
> > > > Andrew

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 23:19:56 +0000
To: Monticone, Giulia
Subject: RE: COVID19 emergency

Your arguments are solid.

From: Monticone, Giulia <[redacted] (b) (6)>
Sent: Monday, March 16, 2020 7:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: COVID19 emergency

Dear Dr. Fauci,

I am a postdoc researcher working at LSU health sciences center In New Orleans. I would like to communicate my concern about the COVID19 in the US.

I am Italian and my partner is Chinese and we have been carefully following the COVID19 spread first in China and now in Italy and Europe. Based on my scientific and personal knowledge I am confident to say that the US is only few weeks ahead of What is happening in Italy now and this could only be stopped if strict measures will be taken in the entire country as soon as possible.

If you have the power, I ask you to please try to convince the government to apply such measures, even if this means to shut down the entire country for some weeks. I know that the economy and money interests are what often prevents to take such decision, but in this case we are talking about life and death and we cannot risk this high price.

We have a very clear example of how severe the COVID19 can be if we do not act on time and this is unfortunately my country at this time. We also have a good example, China, in which very aggressive measures have been applied and, despite some delay in their application at first, they now have reached a strong regression in the virus spread and they gradually can restart the country. China measures were to close every city borders, close working places and every non essential activity. They asked the population to stay at home and go out only for food and health emergencies. I think this is what we should do in US too.

A recent study from Italy in which they tested every person in one Italian city showed that the 50-70% of the people positive for the virus were asymptomatic. This is such an important information that tells us the only way to prevent the spread is to prevent the people from moving because we cannot really know who is caring the virus. Also, screening is important and should be ideally extended to everyone. https://www.repubblica.it/salute/medicina-e-ricerca/2020/03/16/news/coronavirus_studio_il_50-75_dei_casi_a_vo_sono_asintomatici_e_molto_contagiosi-251474302/

My lab is based in New Orleans where the number of COVID19 cases is now growing fast. However, there is no sign from the university or my institute to close. We are working as usual with only some mild restrictions even if we have colleagues that are at home sick, or worse, that showed up at work coughing. The city mayor applied some restrictions but the people are still celebrating events on the street. Up to today we were acknowledged that we have a presumptive positive case in the building where we live. We are doing what we can as responsible individuals but tomorrow we will go to work again not knowing if we are spreading the virus.

I thank you for reading this email and I hope my arguments are solid and accurate enough to encourage you to take action.

Best wishes,
Giulia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 21:28:51 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: INTERVIEW QUOTE FOR ESPN FROM YOUR CALL WITH CARLO DEL RIOS

I did not say that they necessarily should actually cancel the tournament, i.e. not play the games. They could still play the tournament and have it televised without having many spectators in the gym. There is a big difference there. And I did not say that all sports should make a similar call

---

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, March 16, 2020 3:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: INTERVIEW QUOTE FOR ESPN FROM YOUR CALL WITH CARLO DEL RIOS

PLEASE ADVISE

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6)>
Sent: Monday, March 16, 2020 3:19 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID Media Inquiries <mediainquiries@niaid.nih.gov>; NIAID FOG <fog@niaid.nih.gov>
Subject: Interview request: ESPN

ESPN
Tisha Thompson
[redacted] (b) (6)
Tisha.Thompson@espn.com

Deadline: COB today

Hi Patty,

This reporter is writing about the NCAA's reaction COVID-19, and would like confirmation that the following actually occurred:

Dr. Brian Hainline said two members of the NCAA's advisory panel, Dr. Colleen Kraft and Dr. Del Rio, spoke with Dr. Fauci, who said he would back the NCAA in its decision to cancel the tournament. That Dr. Fauci "wholeheartedly" agreed and said to the NCAA reps, "Not only would he back us that this was the right thing to do...he believed that all sports should make a similar call."

The reporter would like a quick call/confirmation this evening, before they publish the story.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 21:17:44 +0000
To: Jon LaPook
Subject: RE: Great news. [redacted] (b) (6)
[redacted]. Thanks again.

Wonderful!!

-----Original Message-----
From: Jon LaPook [redacted] (b) (6)>
Sent: Monday, March 16, 2020 4:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Great news. [redacted] (b) (6). Thanks again.

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 21:17:06 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Treatments that may be useful against the novel coronavirus

Please respond.

From: PEAK (b) (6)>
Sent: Monday, March 16, 2020 4:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Treatments that may be useful against the novel coronavirus

Dear Dr. Fauci:

I am a (b) (6) assistant attorney general of the States of New York and Oregon. I have received some information that may be useful in dealing with the novel coronavirus, but I am not able to evaluate this information personally. It is in an article authored by a former asst. secretary of the US Treasury. I would like to make this information available to you for evaluation, and to that end I am copying it immediately below.

Sincerely,

Robert Roth
Eugene, Oregon

Treatments for Coronavirus That Have Worked in China

Paul Craig Roberts • March 13, 2020

These are scientific papers showing effective treatments for coronavirus being used in China
Hydroxychloroquine
https://www.ncbi.nlm.nih.gov/pubmed/32150618
https://reader.elsevier.com/reader/sd/pii/S0924857920300820?token=92457EBC4E75F28D02F311F610DB2D48113E501DC04D49C824E6FD819F77BE34A9937B4AEAC0D115710BDB7BCC2175B5

These research papers show great antiviral promise for both Hydroxychloroquine and Chloroquine. The Chinese have started using them. So should we. The antiviral effects were originally discovered in Europe during SARS, but then forgotten about as SARS was so aggressive it killed the host too quickly and died out. French Prof Raoult and others have helped the Chinese advising them to proceed in this way and they had the good sense to trial it.

Unlike vaccines and costly new antivirals, Hydroxychloroquine and Chloroquine are generally safe, very well tested, cheap and readily available today. They could be a real game changer. Please publish and disseminate. Please also re-refer to the Blaylock cytokine paper to emphasize the importance of vitamin C, D3 etc.

Hydroxychloroquine and Chloroquine
https://www.ncbi.nlm.nih.gov/pubmed/32150618
https://reader.elsevier.com/reader/sd/pii/S0924857920300820?token=92457EBC4E75F28D02F311F610DB2D48113E501DC04D49C824E6FD819F77BE34A9937B4AEAC0D115710BDB7BCC2175B5
https://www.ncbi.nlm.nih.gov/pubmed/?term=chloroquine+coronavirus

(Republished from PaulCraigRoberts.org by permission of author or representative)

More at Roberts' homepage: https://www.paulcraigroberts.org/wp-content/uploads/2020/03/14_2020.01012.pdf

From: (b) (6)
Sent: Mon, 16 Mar 2020 16:23:09 -0400
To: Luo, Yiming (NIH/NIAMS) [E]
Cc: Kadlec, Robert (OS/ASPR/IO)
Subject: Re: concerns regarding CDC recommendations for COVID-19 prevention in healthcare settings

Yiming:
Thanks for your note. I will forward your email to dr. Robert Kadlec who is in charge of the SNS.
Best regards,
Tony

> On Mar 16, 2020, at 2:53 PM, Luo, Yiming (NIH/NIAMS) [E] (b) (6) >wrote:
>
> Dear Dr. Fauci,
>
> My name is Yiming and I am a clinical fellow in rheumatology at NIH/NIAMS. I have colleagues and friends working in community hospitals fighting against COVID-19 and we are deeply concerned regarding the CDC interim recommendations for COVID-19 prevention in healthcare settings saying that "facemasks are an acceptable alternative when the supply chain of respirators cannot meet the demand". Currently hospitals in New York City are asking their healthcare providers to wear surgical mask while treating COVID-19
>
> COVID-19 is highly contagious in healthcare settings with a large proportion of healthcare professionals being infected reported in early literature [1]. A recent study suggested that asymptomatic patients can transmit SARS-CoV-2 which puts potentially additional threats to healthcare providers [2].
>
> Although surgical mask can effectively prevent droplet transmission, whether and to what degree SARS-CoV-2 can transmit through aerosol approach is still uncertain. Studies with 2003 SARS virus suggest a high level of concerns for aerosol transmission [3], and a recent unpublished study from MedRxiv revealed that SARS-CoV-2 has similar aerosol stability compared to SARS [4].
>
> Healthcare professionals are our frontline force against the coronavirus emergency and we cannot afford even a slight probability of a large scale infections among healthcare workers due to insufficient personal protective equipment. We hope that accessing the Strategic National Stockpile (SNS) and any potential mass production program are actively being considered to protect, and ultimately, save lives for U.S. people.
>
> Sincerely,

Yiming Luo, MD

[1] Wang et al, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7. Doi: 10.1001/jama.2020.1585.
[2] Chang et al, Protecting health care workers from subclinical coronavirus infection, Lancet Respir Med. 2020 Mar;8(3):e13. doi: 10.1016/S2213-2600(20)30066-7.
[3] Jones et al, Aerosol transmission of infectious disease. J Occup Environ Med. 2015 May;57(5):501-8. doi: 10.1097/JOM.0000000000000448.
[4] Doremalen et al, Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. doi: https://doi.org/10.1101/2020.03.09.20033217 (MedRxiv)

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 14:31:15 -0400
To: Redfield, Robert R. (CDC/OD);Deborah Birx
Subject: Fwd: [redacted] (b) (4)
Algorithm for addressing people with mild upper respiratory symptoms in the age of Covid-19.

This is a [redacted] (b) (5)

Begin forwarded message:

> **From:** Jon LaPook [redacted] (b) (6)
> **Date:** March 16, 2020 at 1:52:57 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject:** [redacted] (b) (4) **Algorithm for addressing people with mild upper respiratory symptoms in the age of Covid-19.**
>
> Hi Tony,
> Thank you so much for calling me this morning, and for your terrific help last night trying to think through the issue [redacted] (b) (4), (b) (6)
> Given our discussion this morning, I think it would be very helpful if the task force on coronavirus came up with a clear algorithm for addressing issues related to people having symptoms that could be from a cold, flu, or other virus - and not related to the virus that causes COVID-19.
> Let's say there's a hypothetical patient with some combination of sore throat, aches and pain, low grade fever in the 99's by mouth, and cough; there's no shortness of breath. Let's say they are now proactively self-quarantined at home and are in the process of evaluation. Questions include:
>
> 1. Who, if any, of the person's contacts within the previous days should be contacted?
> 2. If it's only "close contacts" – those who were within 6 feet of the person for an extended period of time:
>   a. What's the definition of extended period of time?
>   b. Does any physical touching – such as a hug or handshake – immediately mean there is significant contact?
>   c. How far back from the onset of the person's illness do we need to check for "close contacts?" This gets to the issue of how long before symptoms begin can asymptomatic shedding occur.
> 3. If no Covid-19 testing is available or the person has been told they are not sick enough for testing: how do we think about the potential risk to that person's contacts, for example, at home or work?

4. If Covid-19 testing is available: before the result is back, what is the advice for a corporation or other entity where the person being tested may have infected others through asymptomatic shedding of virus? Should the possible exposure, even if relatively "low risk", set off any protocol that deals with trying to minimize possible spread of the virus?

Obviously, there are many other specific questions. [redacted] (b) (4), (b) (6)

Thanks!
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 14:23:32 -0400
To: Billet, Courtney (NIH/NIAID) [E]
Subject: Fwd: coronavirus vaccine using cow pox-small pox example

Niaid inquiries

Begin forwarded message:

> **From:** nishit sawal < [redacted] (b) (6)
> **Date:** March 16, 2020 at 1:39:58 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" < [redacted] (b) (6)>, "Auchincloss, Hugh (NIH/NIAID) [E]" < [redacted] (b) (6)>, "Barasch, Kimberly (NIH/NIAID) [C]" [redacted] (b) (6), "Conrad, Patricia (NIH/NIAID) [E]" < [redacted] (b) (6)>, "Lerner, Andrea (NIH/NIAID) [E]" [redacted] (b) (6), "Mascola, John (NIH/VRC) [E]" [redacted] (b) (6)>, "Graham, Barney (NIH/VRC) [E]" [redacted] (b) (6)
> **Subject: coronavirus vaccine using cow pox-small pox example**
>
> hi sir,
> currently an effective vaccine for covid-19 appears 12-16 months away. in view of rampant spread of disease , we can use the cow pox-small pox idea to minimize the disease mortality.
> if general population at large was purposefully infected with human coronavirus strains which classically cause mild URTI's , the chances of them getting infected or more probably getting severely ill with covid-19 would be definitely reduced. we do not need to make a vaccine of these strains - classically they cause mild, self-limiting URTI's.
> we have these resources and can do this in a very short period.
> think over it - time to innovate like Edward Jenner did.
> regards ,
> Dr Nishit sawal.
> Consultant Neurologist
> Government Medical College and Hospital
> Chandigarh,India

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 13:45:28 -0400
To: Jethro Pen
Subject: Re: Steven Hilton of Fox News' Covid19 Question to Dr Fauci et al.

Stay tuned

> On Mar 16, 2020, at 1:40 PM, Jethro Pen [redacted] (b) (6)>wrote:
>
> Dear Dr Fauci:
>
> Apologies for further burdening your staff at this time of Covid19 crisis, by submitting this question.
>
> Fox News' Host Steven Hilton posed a question to you on his March 15th program: my understanding of it - which my wife and I, [redacted] (b) (6), believe to be a "good" question - is as follows:
>
> "Given the relative safety of all but the elderly and those whose immune systems are compromised, and that they are far fewer than the rest of the population, why not quarantine only them?"
>
> Mr Hilton says he believes there to be an answer, but it's not yet been given to the public. For what it's worth, I too believe there's an answer. I'm less certain that it's not been given. Below is the link to this matter on the Fox website.
>
> https://www.foxnews.com/opinion/steve-hilton-on-coronavirus-dr-fauci-officials-must-answer-the-big-question-americans-are-asking
>
> Thanks for such attention as this may be given. If in the present circumstances, that means none, I get it; nothing further is necessary or expected.
>
> Happy to try to provide anything further which is needed or helpful.
>
> Sincerely,
>
> /s/ Jethro Pen

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 13:36:16 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: March 26th hearing postponed

Yeah!

Begin forwarded message:

> **From:** "Hallett, Adrienne (NIH/OD) [E]" [redacted] (b) (6)
> **Date:** March 16, 2020 at 1:23:40 PM EDT
> **To:** "Hodes, Richard (NIH/NIA) [E]" [redacted] (b) (6)>, "Volkow, Nora (NIH/NIDA) [E]" [redacted] (b) (6)>, "Sharpless, Norman (NIH/NCI) [E]"
> [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]"
> (b) (6) "Bianchi, Diana (NIH/NICHD) [E]"
> (b) (6)>, "Gordon, Joshua (NIH/NIMH) [E]"
> (b) (6), "Collins, Francis (NIH/OD) [E]" < [redacted] (b) (6)
> **Cc:** "Kelley, Melinda (NIH/NIA/ERP) [E]" [redacted] (b) (6)>, "Hobin, Jennifer (NIH/NIDA) [E]" < [redacted] (b) (6), "Holohan, MK (NIH/NCI) [E]" [redacted] (b) (6)>, "Haskins, Melinda (NIH/NIAID) [E]"
> [redacted] (b) (6)>, "Kaeser, Lisa (NIH/NICHD) [E]"
> (b) (6), "Ampofo, Phyllis (NIH/NIMH) [E]"
> (b) (6) "Mitchell, Michelle (NIH/OD) [E]"
> (b) (6)>
> **Subject: March 26th hearing postponed**
>
> OMB is putting a hold on sending HHS witnesses to the Hill through the end of March. This will indefinitely postpone our budget hearing.
>
> Thanks for your patience,
> Adrienne
>
> ---
>
> Dear Agency Legislative Affairs Teams:
>
> Due to the full Administration mobilization underway, we are placing a temporary hold on sending up government witnesses who are engaged in the coronavirus response. The Executive Branch needs all of its resources directly focused on executing its day-to-day response to coronavirus. We will continue to practice "radical transparency" with Congress

and the American people, but participation in hearings cannot continue to divert resources from our response effort.

This pause is effective immediately. It is intended to last for three weeks, through the end of March, though we will reevaluate if it needs to be extended at a later date.

Importantly, as noted above, this does not only include witnesses for hearings that are explicitly focused on coronavirus, but also, to be determined on a case-by-case basis, witnesses and agencies who are playing vital roles on the Task Force or the broader Administration response, whether or not the hearing topic is coronavirus.

Therefore, please do not accept hearing invitations from Congress for hearings through March if you believe they meet the above criteria. If you already have hearings confirmed that you believe fits this criteria, please notify us immediately. You will likely have to postpone those hearings.

Four corners leadership offices have already been notified of this policy.

Please reach out to OMB if you have any questions, and we will be happy to work with you as we implement this policy.

Thank you.

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 13:34:42 -0400
To: Billet, Courtney (NIH/NIAID) [E]
Subject: Fwd: A SIMPLE STRATEGY FOR PREVENTING CORONAVIRUS SPREAD

Niaid inquiries

Begin forwarded message:

> **From:** Walter Tengelsen < [redacted] (b) (6)
> **Date:** March 16, 2020 at 1:32:43 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: A SIMPLE STRATEGY FOR PREVENTING CORONAVIRUS SPREAD**
>
> To: Dr. Anthony S. Fauci, MD, Head of NIAID
>
> From: Walter Tengelsen, Chmn. of MACROSYSTEMS INST.
>
> First,, allow me to thank *and congratulate* you for telling the government, and the press, about our nation's
> *unpreparedness* for the coronavirus spread. But while we wait for Big Pharma to develop a vaccine for this
> disease, there is something that could be done NOW to prevent the spread of the virus … and it wouldn't
> cost the government anything! Allow me to explain.
>
> Decades ago, when I was a designer in Aerospace, and took my drawings up to the blueprint room for copies,
> I would always notice the 'aroma' of ammonia in the room. Inquiring about the safety of this constant exposure
> by the blueprinting staff I was told that there are three groups of people who **don't** get colds: 1) those working
> in salt mines, 2) those working in sewers, and 3) those working in blueprint rooms! A few decades later I was
> advised, *by an MD,* that the way to avoid colds is to keep saucers of household **ammonia** in my house rooms
> (and in the office rooms, if allowed), and that one would not even notice the smell after a few days. Since cold
> virus transmission is by aerosol particles from the already-infected, and the dilute ammonia fumes are able to

'inactivate' them, **might these ammonia fumes be able to protect us against the coronavirus?**

Admittedly, too much ammonia gas can be very irritating (and even fatal, as in WW!), but evidently people seem to survive and thrive at the just-noticeable gas levels being recommended here. If there is some potential lung damage from ammonia gas, that might be prevented by taking (freeze-dried) stinging nettles **leaf,** a widely recognized lung-cleaning supplement that is recommended by Naturopathic Doctors. But it would seem that the potential benefits of limiting the spread of the coronavirus in our entire population far outweighs the risks of lung damage. Since most homes already have bottles of ammonia (in their laundry area), **this preventive strategy could be implemented immediately**, and would provide the public with the satisfaction of feeling *they* are doing 'their part' in combatting this pandemic …and protecting themselves and their loved-ones.

NOTE: I am NOT a medical doctor, but an electronic systems engineer and scientist (who takes systems engineering as a license to meddle in all things), but I was the first male family member in 4 generations who did NOT become a pharmacist or physician. I'm emailing my (old address) CV separately, but the email and cell phone number -- [redacted] (b) (6) still reach me as I'm [redacted] (b) (6), and then plan to return to my new home in [redacted] (b) (6) (IF there's no travel restrictions in force)! I can be reached via email or cell phone to explain this preventive strategy further. Meanwhile, good luck on all your efforts to contain this pandemic; the next four weeks or so will be critical!

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 13:33:40 -0400
To: Carlos del Rio
Subject: Re: FYI...

Thanks, Carlos

On Mar 16, 2020, at 1:31 PM, Del Rio, Carlos [redacted] (b) (6)>wrote:

Dear super-star friends:
I wanted to give you a heads up about a letter (attached) that myself as well as two AAAS Lesher fellows have been working on. Our goal is to send this with as many signatures as possible to the WH. Most of what we ask for is what you are already doing or going to be doing but we are calling for **enforced social distancing measures, including closing or severely limiting all non-essential business and schools nationwide.** I hope this is useful in our efforts.

Sincerely,

Carlos del Rio, MD, FIDSA
Distinguished Professor for Emory Clinical and Academic Affairs at Grady
Professor of Medicine
Executive Associate Dean for Emory at Grady
Emory University School of Medicine
Professor of Global Health and Epidemiology
Rollins School of Public Health
Co-Director, Emory CFAR
Tel: [redacted] (b) (6)
Tweeter: [redacted] (b) (6)
Pronouns: he/him/his

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

<Open letter from the Infectious Disease scientific and medical community on COVID-19.docx>

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 13:19:42 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Can existing SARS vaccine be used to possibly limit severity of COVID-19 illness?

Please handle

Begin forwarded message:

> **From:** Benjamin Cintz <[redacted] (b) (6)>
> **Date:** March 16, 2020 at 1:10:48 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Can existing SARS vaccine be used to possibly limit severity of COVID-19 illness?**
>
> Dr. Fauci,
>
> I have read that COVID-19 is closely related to SARS.
>
> I am wondering if the existing SARS vaccine be used to possibly limit the severity of COVID-19 illness in highly at-risk populations?
>
> Thanks,
>
> Ben Cintz
> Mobile: [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 13:12:18 -0400
To: Marston, Hilary (NIH/NIAID) [E]
Subject: Fwd: Coronavirus Antidote
Attachments: Zn2+ Inhibits Coronavirus - 14 March 2020.pdf, ATT00001.htm

People respond

Begin forwarded message:

> **From:** FH Mughal [redacted] (b) (6)>
> **Date:** March 16, 2020 at 1:05:20 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Subject: Fw: Coronavirus Antidote**
>
> I'm anxiously waiting for your response. Kindly respond, the soonest - Thank you
>
> ----- Forwarded Message -----
> **From:** FH Mughal [redacted] (b) (6)
> **To:** [redacted] (b) (6)>
> **Sent:** Sunday, March 15, 2020, 03:54:48 AM PDT
> **Subject:** Coronavirus Antidote
>
> Dear Dr Anthony Fauci and Hilary D. Marston
>
> Kindly enlighten me on the following points:
>
> Can the high temperature (30-35 degrees C) kill the virus?
>
> Can the heatwave (40-49 degrees C) kill the virus?
>
> During last heatwave, the temperature in some cities of Pakistan was 47-49 degrees C.
>
> What is the antidote for coronavirus?
>
> In the following link, Pastor Jim Bakker is suggesting that the silver solution can kill the coronavirus within 12 hours. What are your views:
>
> Coronavirus 'Cure' Claims Get FTC Warning, So Maybe Don't Drink Silver

[redacted]

Coronavirus 'Cure' Claims Get FTC Warning, So Maybe Don't Drink Silver

Thomas Brewster

Science says drinking silver won't cure coronavirus, but companies offering the "cure" are trying to capitalize ...

[redacted]

Coronavirus 'Cure' Claims Get FTC Warning, So Maybe Don't Drink Silver

Thomas Brewster

Science says drinking silver won't cure coronavirus, but companies offering the "cure" are trying to capitalize ...

In the attached paper, the authors say zinc can inactivate the virus. Your comments on silver and zinc, please.

Could I kindly request for an early response, please.

Thank you,

Kind regards,

F H Mughal (Mr)
Karachi, Pakistan

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 13:04:59 -0400
To: Billet, Courtney (NIH/NIAID) [E]
Subject: Fwd: Hypothesis for reducing fatalities from Coronavirus

NIAID inquiries

Begin forwarded message:

> **From:** Patrick Hackenberry [redacted] (b) (6)
> **Date:** March 16, 2020 at 12:59:07 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Hypothesis for reducing fatalities from Coronavirus**
>
> Dear Dr. Fauci / to whom it may concern:
>
> I am not a medical doctor but I have an idea. I know you have every expert on earth working on this virus. I am watching the attempts to slow the transmission and "flatten the curve."
>
> What if we could reduce the fatality rate ? Wouldn't that be huge and assist in reducing the panic ?
> I am hearing that hospitals are going to be short on respirators and that the virus attacks the lungs. My idea - might help people to breath more efficiently.
>
> Summary:
> Here is my idea: Doctors need to utilize methods that endurance athletes have used in the past to **increase their red blood cells in order to increase their body's blood-oxygen carrying capacity.**
>
> Further description:
> Athletes like Lance Armstrong used blood doping and other ways to increase their Erythropoietin (EPO). This was called cheating in sports. However, the results gave him an advantage because his body could get more (VO-2 max) oxygen with a single breath compared to others. This helped Armstrong to become more "super human." I agree that this should be illegal in sports. However, I think it would be great if a person was fighting for their life to be super human.

There are natural ways to increase your EPO and there are drugs to trick your body into producing more EPO. One of the best natural ways is high altitude training (think Boulder, CO and Kenya marathon runners). Also, the risks involved in increased red blood cell count obviously include stroke, blood clot, heart attack and many others. But I think that if monitored closely and as a last resort this method might help some people to survive this outbreak.

Sincerely,

Patrick Hackenberry

From [redacted] (b) (6)
[redacted] (b) (6) cell

I have NO connections to the website(s) or companies below:
Reference the article below from www.hammernutrition.com

By: William Misner, Ph.D.

From 1996 until his retirement in 2006, Dr. Bill worked full-time as Director of Research & Development at Hammer Nutrition. Among his many accomplishments, both academically and athletically, he is an AAMA Board Certified Alternative Medicine Practitioner and the author of "What Should I Eat? A Food-Endowed Prescription For Well Being". - Dr Bill's Full Bio

---

What is EPO?

Erythropoietin (EPO) is a naturally occurring hormone that stimulates the production of red blood cells (RBC). Erythropoietin is a glycoprotein hormone produced in the kidneys, containing a 165-amino acids structure. Most erythropoietin is produced by the kidney's renal cortex, but some is also produced in the liver (mainly in the fetus), the brain and uterus.

Why is it important?

Erythropoietin production is stimulated by low oxygen levels in interstitial cells of the peritubular capillaries in the kidneys. Following its production in the kidneys, EPO travels to the bone marrow where it stimulates production of red blood cells

(RBC's) [2]. EPO increases the body's blood-oxygen carrying capacity, but only up to a point. An overabundance may compromise health and hinder blood flow dynamics with performance-limiting implications. In the absence of EPO, only a few RBC's are formed by the bone marrow.

Why are RBC's important?

Red blood cells carry iron-rich hemoglobin for up to 120-days, then they die. Unless there is a continual supply of Iron, Vitamin B-12, Vitamin C and Folacin, anemia and reduced oxygen carrying capacity manifests in two ways:

Low red blood cell count
Malformed red blood cells.

How can one increase their oxygen carrying capacity?

There is a distinct difference between unethical, harmful, EPO-blood doping methods and the safe nutrition that effectively increases individual oxygen-carrying capacity. Once can improve their health and oxygen carrying capacity similar to EPO without compromising the athlete's health or integrity. EPO levels up to 48% safely improve performance in males, however beyond this level, the risk of compromised health increases. Look to dietary suggestions below regarding vitamins, minerals, proteins, and avoiding anemia to ensure oxygen carrying capacity.

Can excess EPO can be lethal?

Yes. The margin between effective and lethal quantities of EPO is very narrow. EPO use can be LETHAL. Many athletes seeking to derive its performance-enhancing effects have died from incorrectly-administered EPO. Inappropriate use of exogenous EPO can cause elevated hematocrit levels (i.e. thickened blood that is difficult to pump). Elevated EPO increases the risk of heart attack due to the increase in hematocrit. Choosing sustainable, healthy choices is preferred.

Exogenous EPO is totally cleared from the urine within 48 hours of its administration and is cleared from the blood within 72 hours of its administration but its physiological effects prevail for several months).[3] A look at EPO's complex pathway further illustrates a complex physiological process below, see PATHWAYS[4]. Research followed over 7,000 middle-aged men for more than 12 years, and discovered that the risk of diabetes increases proportionate to hematocrit increase.[19] [20]. Men with hematocrits above 48 percent have a 400% increased risk of non-insulin-dependent-diabetes mellitus. The upper recommended levels for a female is slightly lower at 45%.

This nutritional intervention parallels exercise intensitys effect for increasing EPO. Nutritional and training interventions for resolving low EPO levels during iron supplementation (only prescribed by a physician who should monitored progress) should not be permitted above a reference range of 48% in males and 45% in females. Similar research confirms this report.[21] [22] [23]

Does exercise intensity increase EPO?

It's complicated. Roberts & Smith measured the effects of exercise-induced hypoxia on the physiological production of erythropoietin. Twenty athletes exercised for 3 min at 106-112% maximal oxygen consumption. The fitness of these athletes provides a physiological environment for increasing EPO naturally from short 3-minute all-out intervals. Estimated oxyhemoglobin saturation was measured by reflective probe pulse oximetry (Nellcor N200) and was validated against arterial oxyhemoglobin saturation by CO-oximetry in eight athletes. Serum erythropoietin concentrations, as measured using the INCSTAR Epo-Trac radioimmunoassay, increased significantly by 19-37% at 24 hours post-exercise in 11 participants who also had an arterial oxyhemoglobin saturation < or = 91%. Decreased ferritin levels and increased reticulocyte counts were observed at 96 hours post-exercise. However, no significant changes in EPO levels were observed in nine non-desaturating athletes and eight non-exercise controls. Good agreement was shown between arterial oxyhemoglobin saturation and percent estimated oxyhaemoglobin saturation (limits of agreement = -3.9 to 3.7. They concluded that a short 3 minutes supramaximal exercise period could induce both hypoxemia and increased erythropoietin levels in well-trained individuals. The decline of arterial hypoxemia levels below 91% during exercise appears to be necessary for the exercise-induced elevation of serum erythropoietin levels. Furthermore, reflective probe pulse oximetry was found to be a valid predictor of percent arterial oxyhemoglobin saturation during supramaximal exercise when percent estimated oxyhemoglobin saturation > or = 86%.[9]

What naturally occuring, nutritional building blocks aid in EPO production?

Protein adequacy is a factor in erythropoietin (EPO) production. Inadequate protein nutrition can reduce the EPO produced. The erythroid response to Erythropoietin (EPO) is highly dependent on dietary protein adequacy and quality. The mouse spleen is an erythropoietic organ, which contains an EPO-responsive cell population that can be easily amplified by administration of the hormone. Researchers determined the effect of a protein-free diet offered freely to mice up to two days after injection of r-Hu EPO (1000mU/200 ul) on the response of the above population. Splenic cell suspensions from control and experimental mice were prepared in microwells containing 400 mU r-Hu EPO and appropriate medium. The response to EPO was evaluated in terms of 3H-thymidine uptake. The results obtained indicate that acutely induced protein restriction suppressed the response of the EPO-responsive splenic cell population to EPO when it was imposed on mice immediately after hormone injection, and suggest the appearance of deficient rates of differentiation of erythropoietic units by protein restriction.[11] Adequate dietary protein intake is 1.4-1.7 grams/kilogram body weight per day for an endurance athlete.

What other nutritional elements and processes affect the natural production of EPO and the body's oxygen carrying capacity?

Dietary Iron. To ensure oxygen carrying capacity, one should take the recommended daily value of iron. Food sources of iron are red meat, liver, and egg yolks. Most flour, bread, and cereals are iron-fortified. If the diet continues to be iron-deficient, only a physician should prescribe and supervise iron supplementation.

Calories. Calories are needed for EPO production. Calorie sufficiency (in spite of exercise expense) is required for optimal EPO-release. If training is causing weight loss, then EPO loss may be occurring. In order to test the hypothesis that the early cessation of erythropoietin (Ep) production during hypobaric hypoxia is induced by lowered food intake, researchers compared the plasma Ep titer of rats after exposure to continuous hypoxia (42.6 kPa = 7000 m altitude) for 4 days in fed or fasted rats after exposure to discontinuous hypoxia. They found that plasma Ep was rather low after 4 days of continuous hypoxia. Their findings showed that fasting lowers the EPO-response to hypoxia in normal rats [12].

Hormone and Glucose. EPO production also has hormonal-dependant roots complexly related to glucose metabolism, and calorie adequacy. The effect of Thyroid-T3 replacement and glucose supplementation on erythropoietin production was investigated in fasted hypoxic rats. It was found that 48 hr of fasting significantly reduced the circulating levels of thyroid hormones and the production of renal and extrarenal erythropoietin in response to hypoxia. These effects of fasting were completely abolished when the animals had free access to 25% glucose solution as drinking water, despite their lack of protein intake. Replacement doses of T3 (0.5 micrograms/100 gm per day) restored erythropoietin production in the fasted animals but also increased the response of the fed controls. To avoid the effect of endogenous T3, the experiments were repeated in thyroidectomized rats. EPO production in athyroid rats was found to be markedly decreased, with values equivalent to those found in normal fasted animals, and were not affected by fasting or glucose supplementation. Replacement doses of T3 increased EPO production in all three groups, but the fasted animals needed five times as much T3 to obtain a response similar to that observed in the fed group. Glucose supplementation enhanced the effect of T3 in the fasted animals but did not completely restore them. These results indicate that caloric deprivation is primarily responsible for the decreased EPO production induced by fasting and that this effect is probably mediated by both a decreased level of T3 and a decreased responsiveness to it.[13] A calorie deficit therefore requires 500% more Thyroid Hormone (T3) to maintain EPO levels. This is a good reason for monitoring calorie intake during high training calorie expense.

Iron absorbtion. Dietary interventions significantly advance nonheme iron absorption rate during EPO production. It is very important to include foods to enhance nonheme iron absorption, especially when an exercise-induced iron loss is high or when no heme iron is consumed, such as in a vegetarian diet. Absorption of heme iron is very efficient; the presence of red meat increases absorption of non-heme iron +400%. Only 1-7% of the nonheme iron in vegetable staples in rice, maize, black beans, soybeans, and wheat are absorbed consumed alone. Vitamin C improves the rate of absorption of nonheme iron from red meats. Diets that include a minimum of 5 servings of fruits and vegetables daily provide adequate vitamin C to boost nonheme iron absorption. Calcium, polyphenols, tannins from tea, and phytates (a component of plant foods), rice, and grains inhibit the absorption of nonheme iron. Some of the protein found in soybeans inhibits nonheme iron absorption. Most healthy individuals maintain normal iron stores when the diet provides a wide variety of foods. However, if the diet contains large amounts of oxalates and phytates from dark green leafy vegetables and whole cereal grains the absorption of iron decreases due to binding with iron in the gut. High absorption of heme iron is further advanced by foods containing vitamin C in an acid environment found of the stomach. The recommended for daily iron intake is between 10-18 milligrams for adult males and postmenopausal females. Most endurance athletes consume too much iron. Iron is added to breads, cereals, and most packaged foods.

From a computer-generated dietary analysis on 16 endurance athletes and 9 non-athletes, iron intake from their reported food intake was assessed.

The results of this data is as follows:

GROUP

PERCENT DAILY IRON (RDI/RDA)

MALE ENDURANCE ATHLETE

279%

FEMALE ENDURANCE ATHLETE

193%

MALE SEDENTARY

158%

FEMALE SEDENTARY

115%

What are some food combinations that increase the absortion of iron?

How foods are combined may affect iron absorption rate. Excess iron overdose is unhealthy and should be avoided. Common side effects of acute iron overload are gastro-intestinal pain, constipation, nausea, and heartburn. Excess iron levels may generate a continuous low-grade infection. Foods are the best source of iron. The best food source of iron is liver and red meats. These foods contain heme iron, which is better absorbed than non-heme iron. Non-heme iron can be found in dark green, leafy vegetables (spinach, chard and kale) and whole cereal grains (bran and whole wheat bread). Include dark green, leafy vegetables and whole cereal grains in the daily diet. Oxalates and phytates found in dark green leafy vegetables and whole cereal grains decrease the absorption of iron because they bind with iron in the gastrointestinal tract. Iron fortified cereals increase iron from the diet. Anemia may develop on a meat-free diet and/or if the iron store or intake is low.

Red meat contains arachidonic acid, an EPO-precursor nutrient, but it also contains high levels of saturated fats and cholesterol suggesting a little (now and then) is good but too much will harmfully compromise cardiovascular lipid levels. Adding iron to the diet in supplemental form is not recommended except under the supervision of a physician who is monitoring blood serum levels for a specific outcome. It has been shown that eating red meat 1-2 per week may contribute to providing substrates known to regenerate EPO as shown in animal research. The ability of Arachidonic Acid (AA), the bisenoic prostaglandin precursor to stimulate erythropoiesis and Erythropoietin (EP) Production in exhypoxic polycythemic mice and the programmed isolated perfused canine kidney was found to stimulate erythropoiesis when administered to exhypoxic polycythemic mice in the lowest dose tested (50 microgram/kg i.p.). Endogenously synthesized prostaglandins, their intermediates and/or other products of AA metabolism, such as prostacyclin and prostaglandins play an important role in the control EPO production.[14] Hematocrit levels are restored through the supplying dietary or supplemental specific substrates to support the body's natural EPO-producing mechanisms during endurance exercise stress.

SUBSTRATES THAT ASSIST EPO METABOLISM[15]

Acidophilus - 15-30 Billion Count Probiotics
Coenzyme Q10 - 150-300 mg daily
Garlic - 2 cloves or 2 capsules up to 3 x day
Kelp - 100-225 micrograms
Vitamin B6 - 50-100 mg
Vitamin B12 - 200-1,000 mcg
Folic Acid - 800 mcg
Proteolytic enzymes - Bromelain & Papain
Selenium - 200 mcg
Vitamin A - 15,000 IU daily or Beta Carotene - 25,000 IU daily
Vitamin B Complex - 50-100 mg
Vitamin C plus Bioflavonoids - 1-3 grams (divided dose)
Vitamin E - 400 IU daily

Copper - 2 mg
Zinc 40 mg daily ---->(Do not take zinc in amounts over 40 mg daily as it may interfere with metabolism of iron and copper)

More DIetary Recommendations

There is a method to improve iron uptake in the absence of oxalate or phytate rich foods previously mentioned above. If hematocrit, hemoglobin, or ferritin blood lab measures are low, the athlete may add 1-gram of vitamin C to a 3-4 ounce lean cut of red meat cooked in an iron skillet one to two times each week. A complete dietary protocol for cancer patients going through chemotherapy and radiation was published and is applicable to over-trained endurance athletes who present low hematocrit levels.[16]

Conclusion

In normal adults, the kidneys produce EPO, which initiates approximately 90% of natural erythropoietin production. Tissue oxygenation exposure regulates the production of erythropoietin. Less oxygen saturation in the air we inhale (either by altitude or hypoxic interval training) stimulates the kidneys to activate the chemical messengers to instruct the bone marrow to increase the production of EPO to resolve the lack of oxygen exposure. Hypoxia or Anemia stimulates the kidney production of erythropoietin to increase production red blood cells. EPO released from the kidneys increases the rate of red blood cell division and differentiation of specific cells in the bone marrow.

Dietary deficiency of specific foods and micronutrients, hormone imbalance, and lack of specific hypoxic training stress inhibit the endogenous (natural) production of EPO. Additionally, nutritional imbalance from caloric restriction (or exercise related expense), dehydration, fluid intoxication, excess calcium, excess inositol, excess oxalates foods, excess phytic acid from cereal grains, or a lack of hypoxic interval training all inhibit the natural production of EPO also. [17] [18],

Manipulating diet for protein and total calorie adequacy, monitoring hydration, using supplements, timing food combinations, adding weekly hypoxic exercise followed by easy or rest days all increases the release of natural EPO for healthy maximal oxygen carrying capacity. Plus, there are many ways to use diet and wellness to ensure that the body's production of red blood cells is sound and that their oxygen carrying capacity is functioning.

[1] Director of Research & Product Development for HAMMER NUTRITION LTD. 1-800-336-1977, Whitefish, Montana.

[2] Courtesy of From Wikipedia, the free encyclopedia @: http://en.wikipedia.org/wiki/Main_Page

[3] In-Tele-Health 2002 (from Hyperhealth Pro CD-ROM)

[4] Courtesy of Biocarta @
http://www.biocarta.com/pathfiles/h_eponfkbPathway.asp

[5] CLINICAL PHARMACOLOGY OF PROCRIT@:
http://www.procrit.com/profonly/nephrology/what_is_procrit/clinical_pharmacology.html

[6] Fisher JW. Pharmacologic modulation of erythropoietin production. Annu Rev Pharmacol Toxicol. 1988;28:101-22.

[7] Plasmapheresis is the process of separating certain cells from the plasma in the blood by a machine; only the cells are returned to the person. Plasmapheresis can be used to remove excess antibodies from the blood.

[8] Roberts D, Smith DJ, Donnelly S, Simard S., Plasma-volume contraction and exercise-induced hypoxaemia modulate erythropoietin production in healthy humans. Clin Sci (Lond). 2000 Jan;98(1):39-45.

[9] Roberts D, Smith DJ. Erythropoietin concentration and arterial haemoglobin saturation with supramaximal exercise. J Sports Sci. 1999 Jun;17(6):485-93.

[10] Brun JF, Bouchahda C, Chaze D, Benhaddad AA, Micallef JP, Mercier J. The paradox of hematocrit in exercise physiology: which is the "normal" range from a hemorheologist's viewpoint? Clin Hemorheol Microcirc. 2000;22(4):287-303.

[11] Depressed response of the erythropoietin-responsive splenic cell population to erythropoietin in acutely protein restricted mice. In Vivo. 1995 Jan-Feb;9(1):71-3.

[12] Jelkmann W, Kurtz A, Bauer C., Effects of fasting on the hypoxia-induced erythropoietin production in rats. Pflugers Arch. 1983 Feb;396(2):174-5.

[13] Caro J, Silver R, Erslev AJ, Miller OP, Birgegard G., Erythropoietin production in fasted rats. Effects of thyroid hormones and glucose supplementation. J Lab Clin Med. 1981 Dec;98(6):860-8.

[14] Foley JE, Gross DM, Nelson PK, Fisher JW. The effects of arachidonic acid on erythropoietin production in exhypoxic polycythemic mice and the isolated perfused canine kidney. J Pharmacol Exp Ther. 1978 Nov;207(2):402-9.

[15] As with any supplement, always confirm with your physician as to the appropriate level and selection prior to use.

[16] Nutritional Interventions for Reducing the Negative Side Effects of Chemotherapy, Bill Misner, Ph.D. http://www.cancure.org/Chemo_support.htm

[17] Oxalate-rich foods are: Spinach, Cereals, Green Beans (steamed), Potato (raw), Peanut Butter, Tea (brewed), Celery, Chocolate, Ravioli, and White Bread.

[18] Phytate-rich foods are Grains, Corn, Oats, Rice Bran, Wheat Bran, Legumes, Peanuts, Soybeans, and Seeds.

[19] Catalano C, Muscelli E, Natali A, Mazzoni A, Masoni A, Bernardini B, Seghieri G, Ferrannini E. Reciprocal association between insulin sensitivity and the haematocrit in man. Eur J Clin Invest. 1997 Jul;27(7):634-7.

[20] Wannamethee SG, Perry IJ, Shaper AG. Hematocrit and risk of NIDDM. Diabetes. 1996 May;45(5):576-9.

[21] Sit D, Kadiroglu AK, Yilmaz ME, Kara IH, Isikoglu B. The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients. Ren Fail. 2005;27(4):403-7.

[22] Evrengul H, Dursunoglu D, Kaftan A, Kilicaslan F, Tanriverdi H, Kilic M. Relation of insulin resistance and left ventricular function and structure in non-diabetic patients with essential hypertension. Acta Cardiol. 2005 Apr;60(2):191-8.

[23] Amoah AG, Schuster DP, Gaillard T, Osei K. Insulin resistance, beta cell function and cardiovascular risk factors in Ghanaians with varying degrees of glucose tolerance. Ethn Dis. 2002 Fall;12(4):S3-10-7.

From: (b) (6)
Sent: Mon, 16 Mar 2020 13:00:10 -0400
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: natural course of the coronavirus pandemic

Please handle

Begin forwarded message:

> **From:** Martin Gelbaum (b) (6)>
> **Date:** March 16, 2020 at 12:52:24 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
> **Cc:** Martin Gelbaum (b) (6)>
> **Subject: natural course of the coronavirus pandemic**
> **Reply-To:** (b) (6)
>
> 2020-03-16
>
> Dear Dr. Fauci,
>
> Thank you very much for courageous and tireless efforts to defeat the coronavirus pandemic.
>
> One of the statements attributed to you puzzled me.
>
> The article
> **Dr. Anthony Fauci Says He Would Like a 'Dramatic' Reduction of Personal Interactions at Social Gatherings to Fight Coronavirus,** by Donica Phifer, newsweek.com
> March 15, 2020 02:20 PM
> https://www.newsweek.com/dr-anthony-fauci-says-he-would-like-dramatic-reduction-personal-interactions-social-1492410"
>
> quotes you as saying,
>
> "I've said many times if you just leave it alone and left the virus to its own devices then it'll go way up and it'll come down naturally over a period of several weeks," Fauci said. "Unfortunately for our colleagues in Italy, in France, and certainly in China, that's what happened."

Question: Is the implication that the virus would have stopped spreading rapidly in China even if their government had not instituted drastic measures to curtail the epidemic?

Put another way: Is it not correct that the drastic measures implemented by the Chinese government were very helpful in halting the spread of the virus in China?

From yet another angle: Is it correct that the public health measures adopted in South Korea and Taiwan have proved very effective in controlling the spread of the epidemic?

Thank you very much again for your hard work,
Martin

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 12:58:37 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: thank you

Please handle

Begin forwarded message:

> **From:** Robyn Cotter [redacted] (b) (6)
> **Date:** March 16, 2020 at 12:53:29 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: thank you**
>
> Hello Dr. Fauci,
>
> [redacted] (b) (6) I live a very normal life in a Tennessee suburb. We have always kept a modest supply of important survival items in our home, so we are prepared, not panicked. We are carefully following the information and facts regarding the Coronavirus and taking the appropriate safety suggestions.
>
> The reason for my email today is to thank you for your expertise. You must be exhausted from the stress. Not to mention having to continually repeat yourself... and stretch your political diplomacy to the breaking point while walking the fine line between stating facts and debunking myths (or outright lies).
>
> Please know that my family and I thank you for your continued professionalism, swift communication of facts and overall leadership while we ride this rollercoaster with our neighbors and the rest of the world.
>
> Sincerely,
> Robyn Cotter

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 12:56:53 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: [EXTERNAL] Re: Fox News Request for Dr. Fauci

FYI

Begin forwarded message:

> **From:** "Koerber, Ashley" <Ashley.koerber@FOXNEWS.COM>
> **Date:** March 16, 2020 at 12:56:25 PM EDT
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** "Deatrick, Elizabeth (NIH/NIAID) [C]" [redacted] (b) (6), "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)>, "Oplinger, Anne (NIH/NIAID) [E]" [redacted] (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Re: [EXTERNAL] Re: Fox News Request for Dr. Fauci**
>
> Hi Patricia,
> Would Dr. Fauci be available to join Bret Baier in the 6pm hour one night this week?
> I understand he is very busy, but we would accommodate him any night that he is available.
> Please get back to me when you can - thanks!
> -Ashley
>
> Ashley Koerber Moir
> Booking Producer
> *Special Report w/ Bret Baier*
> Fox News Channel - DC Bureau
> [redacted] (b) (6) (cell)
> Sent from my iPhone
>
> > On Mar 13, 2020, at 15:32, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>wrote:
> >
> > I am sorry – we cannot make this work. Apologies.
> >
> > Patricia L. Conrad

Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baier, Bret <bret.baier@FOXNEWS.COM>
Sent: Friday, March 13, 2020 3:30 PM
To: Koerber, Ashley <Ashley.koerber@FOXNEWS.COM>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: [EXTERNAL] Re: Fox News Request for Dr. Fauci

Thank you for considering.

I know Dr. Fauci has been a lot... and will be this weekend... but tonight to wrap the week.. after the national emergency declaration...

We'd love to have him

Bret

Bret Baier
Chief Political Anchor, Fox News Channel
Anchor &Executive Editor "Special Report with Bret Baier"

From: Koerber, Ashley
Sent: Friday, March 13, 2020 3:27 PM
To: 'Conrad, Patricia (NIH/NIAID) [E]' < [redacted] (b) (6)
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] < [redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Baier, Bret

<bret.baier@FOXNEWS.COM>
Subject: RE: [EXTERNAL] Re: Fox News Request for Dr. Fauci

Hi Patricia,

I know this is last minute, but any chance Dr. Fauci can join us in the 6pm hour tonight? Looping in Bret as well.

Please get back to us when you can – thanks!

-Ashley

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, March 12, 2020 8:58 AM
To: Koerber, Ashley <Ashley.koerber@FOXNEWS.COM>
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: [EXTERNAL] Re: Fox News Request for Dr. Fauci

Sorry – will not work.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Koerber, Ashley <Ashley.koerber@FOXNEWS.COM>
Sent: Thursday, March 12, 2020 8:55 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6) Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Oplinger, Anne

(NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: [EXTERNAL] Re: Fox News Request for Dr. Fauci

Hi Patricia,

Would Dr. Fauci be available to join Bret tonight in the 6pm hour?

Ashley Koerber Moir
Booking Producer
Special Report w/ Bret Baier
Fox News Channel - DC Bureau
[redacted] (b) (6)(cell)

Sent from my iPhone

> On Mar 10, 2020, at 11:20, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>wrote:
>
> Oh – tonight is even worse. I don't think it will work
>
> Patricia L. Conrad
> Public Health Analyst and
> Special Assistant to the Director
> National Institute of Allergy and Infectious Diseases
> The National Institutes of Health
> 31 Center Drive, MSC 2520 - Room 7A03
> Bethesda, Maryland 20892
> [redacted] (b) (6)
> 301-496-4409 fax
>
> Disclaimer:
> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
>
> ---
>
> **From:** Koerber, Ashley <Ashley.koerber@FOXNEWS.COM>
> **Sent:** Tuesday, March 10, 2020 11:08 AM
> **To:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
> **Cc:** Deatrick, Elizabeth (NIH/NIAID) [C]

<[redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E]
[redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E]
[redacted] (b) (6)>
Subject: Re: [EXTERNAL] Re: Fox News Request for Dr. Fauci @ 6pm on Tuesday

I'm asking about tonight.

Ashley Koerber Moir
Booking Producer
Special Report w/ Bret Baier
Fox News Channel - DC Bureau
[redacted] (b) (6)(cell)

Sent from my iPhone

> On Mar 10, 2020, at 10:51, Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>wrote:
>
> Hi Ashley I don't think we can make this work tomorrow. If anything changes will let you know.
>
> Sent from my iPhone
>
> > On Mar 10, 2020, at 10:49 AM, Koerber, Ashley <Ashley.koerber@foxnews.com>wrote:
> >
> > Hey Patricia,
> >
> > Just checking on this!
> >
> > Ashley Koerber Moir
> > Booking Producer
> > *Special Report w/ Bret Baier*
> > Fox News Channel - DC Bureau
> > [redacted] (b) (6) (cell)
> >
> > Sent from my iPhone
> >
> > > On Mar 9, 2020, at 15:11, Koerber, Ashley

<Ashley.koerber@foxnews.com>wrote:

Our special is actually 6-8pm tomorrow, so we could do either 6pm hour or 7pm hour.

From: Koerber, Ashley
Sent: Monday, March 9, 2020 11:48 AM
To: Patricia Conrad
[redacted] (b) (6)
[redacted]
Subject: Fox News Request for Dr. Fauci @ 6pm on Tuesday

Hey Patricia,

Would Dr. Fauci be available to join us in the 6pm hour tomorrow (Tuesday) to discuss the latest with COVID-19 from any of the NIH studios? Bret Baier and Martha MacCallum are co-anchoring from New York.

Please get back to me when you can - thanks!

-Ashley

Ashley Koerber Moir

Booking Producer
Special Report w/
Bret Baier
Fox News Channel -
DC Bureau
(b) (6) (cell)

This message and its attachments may contain legally privileged or confidential information. It is intended solely for the named addressee. If you are not the addressee indicated in this message (or responsible for delivery of the message to the addressee), you may not copy or deliver this message or its attachments to anyone. Rather, you should permanently delete this message and its attachments and kindly notify the sender by reply e-mail. Any content of this message and its attachments that does not relate to the official business of Fox News or Fox Business must not be taken to have been sent or endorsed by either of them. No representation is made that this email or its attachments are without defect.

From: (b) (6)
Sent: Mon, 16 Mar 2020 12:55:29 -0400
To: Victoria Baron
Subject: Re: Thank you

Victoria:
I saw it and thanks for sending it.
Best regards,
Tony

> On Mar 16, 2020, at 12:53 PM, Victoria Baron (b) (6)> wrote:
>
> Dear Dr Fauci,
>
> I am a California resident and wanted to take a moment to thank you for your professionalism and integrity during this crisis with the Coronavirus.
>
> It is so evidently clear that you are forced to work "around" the ignorance, ineptness and narcissism of Donald Trump, yet you continue to provide the country with the truth.
>
> I'm guessing that the odds of you actually seeing this email might be slim but I feel better for having sent it. You will be remembered as a hero during a very dark time.
>
> With Appreciation,
>
> Victoria Baron
> (b) (6)
>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 11:54:30 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: press release and "cheat sheet"
Attachments: NIAID press release mRNA Phase 1 FINAL.docx, CONDENSED mRNA phase 1 talking points 3.14 CB.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Sunday, March 15, 2020 10:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] < (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6) Routh, Jennifer (NIH/NIAID) [E (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Subject: ASF: press release and "cheat sheet"

Attached, per discussion.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 11:03:39 +0000
To: Marston, Hilary (NIH/NIAID) [E];Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: URGENT: Confidential and urgent request regarding [redacted] (b) (4)

Thanks!

From: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, March 16, 2020 7:00 AM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Subject: Re: URGENT: Confidential and urgent request regarding [redacted] (b) (4)

I will draft something for you today.

[redacted] (b) (5)

I will send a draft later today.

Best,
Hilary

On Mar 16, 2020, at 5:05 AM, Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)> wrote:

Hi Tony and Hilary,

See message below from Tom Hudson of Abbvie. [redacted] (b) (5)

Francis

From: Hudson, Thomas J [redacted] (b) (6)
Sent: Sunday, March 15, 2020 11:08 PM

To: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)>
Subject: Confidential and urgent request regarding

Dear Francis,

I am sending this brief note as a request for guidance on an evolving situation with

(b) (4)
[redacted]

I am reaching out to you to see if you have any suggestions or individuals that we should contact.

Best wishes,

Tom

THOMAS HUDSON
Senior Vice-President, R&D
Chief Scientific Officer

AbbVie, North Chicago
1 North Waukegan Rd
R473, Building AP9-1
N Chicago, IL 60064
TEL (OFFICE) [redacted] (b) (6)
EMAIL ([redacted]
b

abbvie.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: [redacted] (b) (6)
Sent: Mon, 16 Mar 2020 06:09:17 -0400
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: Dental

Respond

Sent from my iPad

Begin forwarded message:

> **From:** [redacted] (b) (6)
> **Date:** March 16, 2020 at 5:54:34 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Subject: Dental**
>
> I ask you to address the explosion of concerns among the dental community in regards to COVID-19. We, the dental community, already high risk personnel, are at an even higher risk at this point and time. Many of those who do not work in the dental community are not aware of how high risk our current situation is. For 8-12 hours a day we are creating aerosols while sitting 8-12 inches from a persons open mouth. These aerosols contain saliva and blood droplets, along with billions of other bacteria and materials. In dentistry, saliva is considered a blood borne pathogen. Although OSHA requires Level 3 masks for all aerosol producing procedures, not all offices are complying. This DOES NOT matter anyway as we know SURGICAL MASKS DO NOT FILTER OUT THE COVID-19 virus. I ask that you suspend non essential dental procedures such as dental cleanings and other procedures that are non-emergent. That we triage patients and accept EMERGENCIES ONLY. We are at such a HIGH risk, not only to ourselves and our families, but a HIGH RISK to spreading this virus COMMUNITY wide. Many of us are taking extra precautions but screening patients, but with a up-to-14 day incubation period, that obviously does not matter.
> Please hear our plea to address our concerns. The American Dental Association and the American Dental Hygienists Association has failed us.
>
> Thank you
> Alicia Jewell
>
> Sent from my Verizon, Samsung Galaxy smartphone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 10:07:04 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Lifting EUA
Attachments: COVID-19 ASM survey comments.docx

Hilary:
Please take a look at this and see if there is anything that we can do here.
Thanks,
Tony

From: Bertuzzi, Stefano [redacted] (b) (6)>
Sent: Sunday, March 15, 2020 8:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Segal, Allen [redacted] (b) (6); Melissa Miller [redacted] (b) (6)>; Stevens-Garcia, Jonathan [redacted] (b) (6)>; Watts, Mary Lee [redacted] (b) (6)
Subject: Lifting EUA

Hi Tony –

Per our conversation, see the attached email asking FDA to lift the EUA, which would allow CLIA hospital labs to ramp up test capacity significantly. We have sent this letter also to Francis and to Adam Boehler and were on a call with them. Jeff Shuren at FDA also knows, but we think it will be important to take action quickly.

Many thanks, let me know if you need anything else from me at this time.

Sincerely,
Stefano

Stefano Bertuzzi, Ph.D., M.P.H.
Chief Executive Officer
American Society for Microbiology (ASM)
1752 N St., NW
Washington, DC 20036-2904
Phone [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 10:07:03 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: TytoCare: COVID19 Telehealth Support

From: David Bardan <[redacted] (b) (6)>
Sent: Sunday, March 15, 2020 9:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Shriya Palekar <Shriyap@tytocare.com>
Subject: TytoCare: COVID19 Telehealth Support
Importance: High

Hi Dr. Fauci – good evening. I represent TytoCare, a company that built the industry's first and only all-in-one medical device that pairs with a virtual exam, going beyond the means of audio and visual. TytoHome, an OTC and FDA approved/cleared device is meant to either synchronously or asynchronously examine a patient with capabilities to capture heart/lung/gastrointestinal sounds, ear/throat/skin exams, and temperature.

Due to the outbreak of COVID-19, Tyto has experienced an influx of orders worldwide to support those that need to be monitored when quarantined. I would like to offer Tyto's assistance here in the U.S. and think through ways and opportunities that the product can make a difference.

Please see a few a couple of examples on how Tyto is making a difference below:

- **Patient Quarantine/Discharge at Home**
    - Design: patients receive TytoHome or have it delivered for remote evaluation by infectious disease specialists
        - Example: Home Admission Service with TytoCare
- **Create & manage quarantine locations, onsite or offsite**
    - Setup: Patients do a self-exam with TytoClinic while a provider evaluates them from a distance
        - Patient is remotely guided to fully disinfect the device and station before it's returned to staff for a second round disinfection
        - Example: Nursing Home Triage

Thank you for all that you do during this difficult time.

Thanks,
David

David Bardan
Vice President, Provider Solutions
-
m: [redacted] (b) (6)

215 W 40th Street, 9th Floor
New York, NY 10018
www.tytocare.com

tytocare™

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 10:07:03 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Leronlimab

Please check out and respond.

-----Original Message-----
From: nicholas Agresti [redacted] (b) (6)>
Sent: Sunday, March 15, 2020 9:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Leronlimab

Dr. Fauci,
I can't even imagine how busy you are. I am a gastroenterologist in [redacted] (b) (6) Georgia. I read about Leronlimab for coronavirus. Any word on results of the clinical trial?
Thank you
Nicholas Agresti MD

From: (b) (6)
Sent: Sun, 15 Mar 2020 22:52:40 -0400
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: COVID-19

Please handle

Sent from my iPad

Begin forwarded message:

> **From:** Deb Whitney (b) (6)>
> **Date:** March 15, 2020 at 10:28:48 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
> **Subject: COVID-19**
>
> Thank you for your frank speaking about COVID-19. I credit your willingness to stand up and speak aloud that "the emperor has no clothes" ... You have already helped so many through the current pandemic. I know you will understand my concern. But, please help me spread this message as well.
>
> In light of public school closures...these include children and young people from kindergarten through high school. These closures also include preschool programs (Voluntary Pre-K in Florida) for 4-year-olds that are part of a public elementary school.
>
> These school closures do not apply to children whose ages range from infants through preschool (including VPK) receiving care and education in private, corporate, or faith-based centers. My center is one of these, and we are not closing.
>
> This is a business decision.
> No kids = No money.
> At what price?
>
> We have more than 90 infants, toddlers and young children enrolled at our center, with 20-plus employees on premises throughout the day between the hours of 6:30 am and 6:00 pm. Ours is a 5-Star rated, NAEYC accredited preschool program. I have 17 three-year-old preschool children in my classroom on any given day, with 3 teachers assigned to this room. This is a high quality program.
>
> Please explain how I am supposed to take recommended precautions against COVID-19?
>
> Does social distance apply only to adults? If not, please help me know how to maintain social distance of 3 feet between children and adults at arrival or departure times when I am helping a child with separation from their primary care giver or saying goodbye at the end of the day? How do I maintain social distance between children during center time in the block area, in the

dramatic play area, in the classroom library or computer center, during story time or music circle? Our 3 table surfaces are used for multiple activities through the day including meals—and they seat six children at each table. Friday afternoon, I had 9 children sharing space and materials engaged in cooperative play for an extended period outside in a sandbox that measures 5'x10'...you do the math. Our spacing for cots at nap time is considerably less than 3 feet.

We have no hot water in our classroom for hand washing for children or staff which is considered a safety measure. We are relentless in our efforts to teach hygiene to 3-year-old children who cough, sneeze, vomit upon (and occasionally may spit, bite or lick) each other or a staff member. We work to teach them to use a tissue instead of their hand/arm/shirt to wipe a runny nose...then throw it in the trash and wash their hands again. Believe me when I say a determined child can sing "Happy Birthday" twice in an amazingly short time--definitely less than 20 seconds--all the while whipping through instructions to wash the tops, bottoms and fingers of their hands while they sing. Hand washing is monitored by 3 adults through the day to ensure it happens after each cough, sneeze, nose wipe and use of the bathroom. Hands are washed after sensory play indoors or out, before am snack, lunch, and pm snacks (and sometimes during), and when we transition from outside play. At a minimum, these 17 children are taking turns washing hands (at our single sink) six times during a full day at preschool—before we add in those runny noses, coughs or sneezes.

Avoid touching shared objects...seriously? We work daily to teach these 3-year-olds to share materials and space. Yes, we disinfect our toys regularly and our room daily--but that stuffed animal may move from dramatic play to the reading nook and to a nap cot all in one day and may be held by a different child with each move. Our families send a blanket from home for their child to use through the week at nap time—along with a soft "sleep toy" if this is needed, to sooth their child to sleep. These items are stored in the child's open "cubby box" in the classroom through the week. Do we know how log COVID-19 "lives" on soft surfaces?

I am convinced school closures are necessary at this time to stem community spread of COVID-19. I understand the strain on multiple levels this will inevitably put on families to provide care for and education of their own children for this period. But—young children can contract this virus and can spread it even though they may not demonstrate symptoms themselves. Or, what may be dismissed as allergies or "just a cold" may not be. Young children can carry this virus home to their family and neighborhoods just as easily as a school age child; and, they can certainly bring it into our center from their home. How many of our children in preschool depend upon elderly family members for their care? We have infants as young as 6 weeks old and children through 5 years old at our center. How many young children in care are we willing to expose? How many and which grandparents are we going to risk?

(b) (6)

[redacted] (b) (6) Forget sporting events, museums, concerts or even worship services--I am worried about going to work on Monday...and uncertain what may happen if I stay home.

Again...
This is a business decision.

No kids = No money
At what price?

--
Respectfully,

Deb Whitney

From: (b) (6)
Sent: Sun, 15 Mar 2020 22:48:23 -0400
To: Glen Goldmark
Subject: Re: Thank you

Glen:
Thank you for your kind note.
Best regards,
Tony

Sent from my iPad

> On Mar 15, 2020, at 10:39 PM, Glen Goldmark (b) (6)> wrote:
>
> Dr. Fauci,
>
> You are my hero! Thank you for being the voice of reason and credibility during the COVID-19 crisis.
>
> All the best,
>
> Glen Goldmark

From: (b) (6)
Sent: Sun, 15 Mar 2020 22:43:39 -0400
To: Emory Ford
Subject: Re: Great Job

Emory:
  Thank you for your kind note. It is much appreciated.
Best regards,
Tony

Sent from my iPad

> On Mar 15, 2020, at 10:23 PM, Emory Ford (b) (6) wrote:
>
> Dear Dr. Fauci:
>
> You are doing a great job and a great service to the country. Amid the chaos you are one of few voices that provides clear, accurate information on the coronavirus pandemic.
>
> Please continue providing that service despite the presidents continued effort(s) to spin the situation with misleading and false information. In the end biology wins, the virus ignores political needs and wants.
>
> Emory A. Ford PhD

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 19:38:20 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: "Leading Through A Time of Crisis In Healthcare" - ZRG Thought Leadership

Sent from my iPhone

Begin forwarded message:

> **From:** Greg Gerson <ggerson@zrgpartners.com>
> **Date:** March 15, 2020 at 7:34:59 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: "Leading Through A Time of Crisis In Healthcare" - ZRG Thought Leadership**
>
> Hi Dr. Fauci -
> I am reaching out as you have been doing an incredible job as part of the White House Coronavirus Task Force. These are difficult times and you seem to provide the most informative interviews without sending signals of panic to the American public.
>
> Not sure if you remember, but we were in touch years back through many executive clinical leadership searches I conducted during my 18 years at Korn Ferry. I am now leading the hospital/health system practice for ZRG. ZRG is an innovative global boutique firm disrupting the traditional executive search industry.
>
> As a result of the COVID-19 crisis, I am speaking with/interviewing many healthcare leaders (Chief Medical Officers, Hospital CEOs, Leading Scientists, etc.) as part of a thought leadership piece.
> The topic is "Leading Through a Time of Crisis in Healthcare". I know you are extremely busy with the task force, but I would very much appreciate if you have some time for an interview/call.
> As you know, strong leadership is crucial in times of crisis and we are facing weeks/months of extremely important decisions by our healthcare leaders nationwide.
>
> Do you have any availability over the next few weeks to connect? I will make myself available to meet and/or have a video or phone call at your convenience.
> Hope to hear from you soon.
> Regards,
> Greg

Greg Gerson
Managing Director

ZRG
STOP SEARCHING START BUILDING

ZRG Partners, LLC
Americas | EMEA | Asia Pacific
C: (b) (6)
O: 215-422-3576

ZRGpartners.com

** The information and attachments in this e-mail is the property of ZRG Partners, LLC and is confidential and may be privileged. If you are not the intended recipient, please destroy this communication and notify the sender immediately. You should not retain, copy or use the contents of this e-mail for any purpose, nor disclose all or any part of its contents to any other person or persons.

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 19:37:43 -0400
To: Lei Wu
Subject: Re: Please shut down the country NOW

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 7:35 PM, Lei Wu [redacted] (b) (6)>wrote:
>
> Dr. Fauci. This is Lei Harrison. In the coronavirus crisis, as a former [redacted] (b) (6) I have been calm until now. No one can anymore after seeing the photos of the international airports today where hundreds if not thousands of people standing in line for 5-6 hours and realizing immediately the virus transmission will explode exponentially because of this. I strongly request:
>
> 1. Shut down the country NOW. Mobility has to be as low as possible. We have to do the very best RIGHT NOW to break the transmission chain.
>
> 2. Please talk to Dr. Zhong Nanshan (钟南山）, the Chiense doctor and advisor during the coronavirus crisis. His advice and experience would be of tremendous value for the U.S. now.
>
> 3. Sofar, we've been acting in a reactive instead of proactive fashion. Not anymore. People need to realize that we are entering war time. We need to act fast, in light speed to beat the virus.
>
> 4. Healthcare workers need to most strongly protected- treat it as airborne if needed at the hospitals and pharmacies. Supplies of essential protective medical supplies for healthcare workers are equally important as supplies needed for the patients. Make sure supply chain from China is uninterrupted; and have American companies to start making masks, ventilators etc. Plan ahead.

5. Grocery store and restaurants can potentially become a hub too. They need to have high level of hygiene, and ideally no contact with the customers.

6. Garbage and belongs and bodies need to be burned.

7. Safety protocol at the labs, public and private labs that have access to the virus or experimental animals with the virus.

8. Plan ahead. Instruct patient to self-treat or be treated by family at home. If we ever come to it, recruit and train volunteers (how and whom?) to help taking care of patients.

Dr. Fauci. Clock is ticking. It's a race against time. And it's time that every single American takes responsibility. Please lead us through the crisis.

Respectfully,
Lei Harrison

From: (b) (6)
Sent: Sun, 15 Mar 2020 19:37:15 -0400
To: Lori Hall
Subject: Re: Real Estate Appraisals-Coronavirus (COVID-19)

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 7:35 PM, Lori Hall (b) (6)>wrote:
>
> Dr. Fauci,
> Thank you for your important work and for educating the public. Earlier today I sent the message below to President Trump. I am writing out of concern both for my husband's safety, others in the industry, and knowing refinances (especially with low rates) will help the American people through this unprecedented time. I understand that our Local and National Government continues to look at all potential solutions, with advice from experts such as yourself. I fully understand this suggestion from one mom and wife might be way too simplistic for banks/lenders to even consider. I am hoping to be ahead of the curve and that it starts/continues what I consider to be a much needed conversation for this industry, for the safety for appraisers and homeowners alike, and for the pipeline for the lenders. It's very much appreciated.
> Be Safe. Kindest Regards,
> Lori Hall
>
> Dear Mr President,
> First, our great appreciation to you and your staff for all you do every day and in keeping our country &citizens safe. We have a family real estate appraisal business (Chicago Metro Area). I handle all service related items from the comfort of my home. However, my husband, William Hall, who is a Certified General Real Estate Appraiser, is out in the field all day performing interior appraisals. I have reached out to all our appraisal management companies with this question to ask their lenders. Considering the abundance of caution everyone is taking and the refinance industry seeing unprecedented volume, is there any talk about lenders moving to exterior only appraisals (and possibly following up after with an interior)? We heard from ServiceLink, a Fidelity company, and they have not heard any word from their national banks/lenders changing to exterior only appraisals at this time. Thank you very much!
> God Bless,
> Lori Hall

Best Regards,
Lori Hall

For updated real estate news &more, please visit our website at: www.alphavalues.net

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 19:11:49 -0400
To: Gandam, Shyam Kiran
Subject: Re: Front line physicians in Limbo needing reassurance

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 4:13 PM, Gandam, Shyam Kiran [redacted] (b) (6)>wrote:
>
> Dear Dr.Fauci ,
>
> I would like to congratulate you for your excellent work and thank you for leading us in the fight against COVID-19 pandemic.
>
> We are 14 critical care physicians and almost 30 hospitalist physicians at Memorial medical center and HSHS St. John medical center in Springfield Illinois and are the frontline workers in dealing with the situation.
> We are developing protocols and creating safety net for the hospitals and community with the help of your guidance.
>
> I would like to bring up an issue plaguing us with concern for years and now even more so. It concerns us and more importantly our helpless families. It might be untimely to bring up this issue but it is very important for us and our families.
>
> [redacted] (b) (6) **During this pandemic, it's important that physicians can help other areas in the country in need.**
> **Immigrant work force on Work Visa (H-1 visa) constitutes at least 50% of physicians.**
>
> [redacted] (b) (6)
>
> [redacted] (b) (6) **Your assistance in bringing up these issues with the president will help us work with reassurance from government**
> **and help our community with peace of mind.**

Again, We thank you for the hard work you and your team are putting to guide us in these tumulus times.

Regards,
Shyam Kiran Gandam MD
Critical Care Medicine
Associate professor, SIU school of medicine
Springfield Clinic
Springfield, Illinois

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 19:10:41 -0400
To: ABCDE FGHIJK
Subject: Re: COVID-19 - The necessity of using fluorescent light lamps to prevent or reduce or slow down the spread of coronavirus

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 4:15 PM, ABCDE FGHIJK [redacted] (b) (6)>wrote:
>
> Dear Dr. Anthony S. Fauci,
>
> It's critical to disinfect droplets, aerosols and surfaces continuously to prevent or reduce or slow down the spread of COVID-19.
>
> The best way is using UVC ultraviolet light. UVC's wavelength is germicidal and it is capable to inactivate coronavirus by destroying nucleic acids and
>
> disrupting its DNA because Wavelengths between about 200nm and 300nm are strongly absorbed by nucleic acids. The absorbed energy can result in
>
> defects including pyrimidine dimers. These dimers can prevent replication or can prevent the expression of necessary proteins,resulting in the death or
>
> inactivation of the coronavirus.
>
> Fluorescent light lamps emit ultraviolet (UV) light, including UVC ultraviolet light.
>
> I think it's necessary to use fluorescent tube light lamps and CFL (Compact fluorescent lamps) lamps in hospitals, Health centers, stores, supermarkets,
>
> elevators, public lavatory, toilets, restrooms and other public places and should always be on 24 hours a day, 7 days a week in order to be effective.
>
> Research has shown that Fluorescent light lamps must be installed without any glass shade or decorative shade and should be at least 40 watts.
>
> I hope you find the UVC-based continuous disinfection solution helpful.
>
> Thank you for your time and consideration.
>
> Sincerely,
>
> P. Salimi

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 19:09:44 -0400
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd:

Sent from my iPhone

Begin forwarded message:

> **From:** Sia Hersini [redacted] (b) (6)
> **Date:** March 15, 2020 at 4:15:21 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
>
> Dear Dr. Fauci,
>
> Many years ago, I did some research on the effect of SIV infection on the Macaque immune response.
>
> I have some thoughts on the current COVID-19 spread and in general about other virus with unknown cure or immunity vaccine.
>
> In research, we have adhered to a scientific method necessary for the protection of the public in the development of new technology and treatment. There are times however when that Boyle method and philosophy should give way to Descartes approach.
>
> The current infection has thus far shown a predilection for causing severe illness in men more than women and in adults over 30 sparing children from mortality.
> I believe there is a reason for this and it's not because of past exposure to other coronovirus strains. I believe it is because of children being in the middle of or having recently completed their immunization schedule for school. These immunizations are absolutely not providing an immunity to COVID-19, BUT, they are causing an increase in the numbers of gamma delta t cells and NK cells. The children are responding better to a virus with an 5.1 day median incubation period because of the higher values of gd and nk cells. Women have a better gd and nk cell response to the flu and other viral infections which could explain why there is a gender difference in mortality. I would suggest that adults update their vaccines and especially the hep b. Interestingly, the hep viruses illicit a better gd and nk cell response and although most Western countries require hep b for health care workers, the immunization rate in China is only 60% which may explain the high mortality among health care providers.

This has been on my mind for a few days and I felt I should share.

Thank you for your time
Sia

From: (b) (6)
Sent: Sun, 15 Mar 2020 19:09:26 -0400
To: Eliot Robinson
Subject: Re: Prc guidance on coronavirus

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 4:15 PM, Eliot Robinson <eliot@robinsonmanagementservice.com> wrote:
>
> Dr. Fauci,
>
> thank you for all you do.
>
> one of my chinese friends sent me the attached prc guidance on coronavirus. it includes both western medicine as well as traditional medicine approached. On its face, it seems to be complete and very up to date.
>
> I apologise for your having to follow of dear leader trump's instructions to praise him.
>
> thanks
>
> eliot
>
> --
> Eliot Steele Robinson
> Robinson Management Service
> 4290 Bella Cascada Street
> Las Vegas, NV 89135-2436
> (b) (6)(cell) 702-330-9921 (fax)
> Eliot@RobinsonManagementService.com
> https://www.RobinsonManagementService.com
> DUNS 079879598 CAGE 7EEU6 JCP 0073645
> <Guidance+for+Corona+Virus+Disease+2019 : Prevention,+Control,+Diagnosis+and+Management.pdf>

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 19:06:03 -0400
To: Auchincloss, Hugh (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: Coronavirus

From patty

Pls respond.

Sent from my iPhone

Begin forwarded message:

> **From:** Kathleen Quinlan [redacted] (b) (6)>
> **Date:** March 15, 2020 at 5:16:22 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Coronavirus**
>
> Dear Dr. Fauci,
>
> I have a question which has been troubling me since we began checking people's temperatures. [redacted] (b) (6). I have seen the temperature cutoff is 99.5F. [redacted] (b) (6)? I doubt very much that in screening people the question is asked them whether they have taken a medicine for pain or for fever in the last 24 hours. I am a nurse and many people do realize that the common pain relievers also relieve fevers. Should we up our game and do better at screening?
> You seem to be the wisest person on the government task force for the Coronavirus. I hope this reaches you.
>
> Thanks,
> Kathy Quinlan
>
> P.S. Please practice social distancing during the White House briefing,etc. It is hard to watch all of you people bunched around the President and telling the public to stay 6 feet apart. If you do it maybe the others will follow suit.
>
> Sent from my iPad

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 19:04:54 -0400
To: flippi 333333
Subject: Re: Coronovirus

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 5:22 PM, flippi 333333 [redacted] (b) (6)>wrote:
>
> Dr. Fauci: Sending all **students home may be increasing the spread of Covid-19** in the US because the young people now off college, middle and high school, see this as a vacation to go out and frequent social businesses, parents are taking kids out to entertain them, and they are traveling to visit friends in other cities and states, all aiding the spread of Covid-19.
>
> Please consider more strict MANDATES TO ENFORCE TEMPORARY CLOSING OF RESTAURANTS, BARS, BOWLING ALLIES, MOVIE THEATERS, MALLS or other places of gathering and TRAVEL ONLY IF IT IS AN EMERGENCY, to mitigate the increasing cases of Covid-19 in the US. People are clearly not taking the advice given to minimize social or public gatherings.
>
> In order for our United States not to follow the same fate as Italy, we need mandated changes asap. Please consider telling **people over 60 or 65 to also stay home from work for a 2-week period.**
>
> Thank you very much for your fine leadership in this critical matter.
> Concerned parent and scientist,
> Robbin.

From: (b) (6)
Sent: Sun, 15 Mar 2020 19:02:51 -0400
To: Luanne Novak
Subject: Re: Corona virus suggestions

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 5:39 PM, Luanne Novak (b) (6)> wrote:
>
>
> Dear Dr. Fauci:
>
> First, thank you for your honest and forthright testimony and advice during this crisis. Your calm but serious approach is a great comfort to me. (b) (6).
>
> He is a Pharmacologist by training, and taught physiology at the School of Health Professions at Baylor College of Medicine until he retired in January. We have been discussing the COVID-19 situation and he has several suggestions. (b) (6)..
>
> 1. Since South Korea got such a quick handle on this situation, could we buy their tests? Since it has taken such a long time for the US to gear up, could we not just buy their system turn-key?
>
> NPR reported that there is a national stockpile of respirators - when will those be released?
> 2. Since China appears to be back online, can the US contract with them to build mechanical respirators to replenish our "strategic reserve"?
>
> I hope that you will continue to be able to speak the truth, and that you stay healthy.
>
> Many thanks,
> Luanne Novak and David Johnson, PhD
> (b) (6)

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 19:01:28 -0400
To: Daniel Gutstein
Subject: Re: Daniel Gutstein: Regarding Synagogue Services during the Covid-19 Pandemic

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 5:53 PM, Daniel Gutstein <[redacted] (b) (6)> wrote:
>
>
> Dear Dr. Fauci,
> I would like to commend you for providing needed doses of stability and reassurance to our nation at this troubled time. Your knowledge and professionalism have been indispensable to the masses. I am an assistant to the rabbi of a Jewish congregation in Chicago which holds services thrice daily. Due to the tight-nit nature of the larger Jewish community, many synagogues in the city and surrounding suburbs have closed indefinitely in order to limit the community spread of the Covid-19 virus. (One person visiting the community from New York and who interacted with numerous individuals has so far tested positive.) Our synagogue is few in parishioners though is an essential sanctum of sustenance and faith to those who make usage of its services. We would like to keep our doors open for the longest duration possible but remain cognizant of the realities of the pandemic. Considering that we gather in a sanctuary of impressive size with usually no more than 20 members who are stationed at a distance apart from one another, would it be responsible to continue services for the remainder of the week and this upcoming Sabbath so long as no specific member of the congregation itself has contracted the virus?
> Thank you.
> Wishing you sustained health and much success,
> Daniel Gutstein

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 23:00:03 +0000
To: Talbert, Patricia Y
Subject: Re: Public Health 101: -- Please listen to my Public Health Cry/Recommendation
Attachments: Outlook-1516124588.jpg

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 6:14 PM, Talbert, Patricia Y <patricia.talbert@howard.edu> wrote:
>
> Greetings Dr. Fauci,
> As you know, we are currently experiencing a public health pandemic, Coronavirus (COVID-19). I am asking that you take a moment to listen to Fareed Zakaria's show that was aired today, Sunday, March 15, 2020, at (https://www.cnn.com/shows/fareed-zakaria-gps). Please listen to the message and review the attached chart that was presented on Fareed's show. This is NOT about politics, but instead the people. Therefore, **let's call to action** that the United States of America government officials and leaders call for a mandate similar to other countries, such as China, Italy, and Spain (i.e., now, New York & Illinois) to help reduce the spread of this virus, flatten the curve, reduce the inundation to our healthcare system, (which is about to experience the worst morbidity and mortality outcomes), and work to save lives.
> There are too many unknowns for us to continue to go on as status quo. Let's be public health officials and petition to mandate the US Administration to move to action – by putting in place a Mandatory Shutdown of Movement throughout this Country.
>
> Currently, we have approximately (9 airports in the United States) in total chaos, which will be another wave and spread of this virus. We are not proactive; instead, we continue to react late. This is not the public health that I know and have seen throughout the duration of my public health vocation. We have to change this Pandemic, so let's get to work.
> **#Cry for Pubic Health Action Needed -----****We need this Administration/Government Committee to LockDown the United States of America. This can slow down the spread of this disease, save lives, and maybe within 30 days we can get back on our feet.**
> Warm and sincere regards - please push action.

Dr. Pat Talbert

Dr. Pat Y.B. Talbert

Patricia Y. B. Talbert, PhD, MPH, MS, CPHA, CHES, cPHN
Associate Dean of Academic Affairs and Administration
Howard University, College of Nursing and Allied Health Sciences
Health Sciences Executive Suite, Towers 6000
2041 Georgia Avenue NW
Washington DC 20059
Email: patricia.talbert@howard.edu
Howard U: https://home.howard.edu/
CNAHS: https://cnahs.howard.edu/
Cell#: (b) (6)

"Of all the forms of inequality, injustice in health care is the most shocking and inhumane." Rev. Martin Luther King, Jr.
"Once a task is just begun, never leave it till it's done. Be the labour great or small, do it well or not at all." Quincy Jones
<Outlook-1516124588.jpg>

<COVID-19 Testing Data 2020.jpeg>

---

150 THE TIME IS ALWAYS NOW
HOWARD UNIVERSITY SESQUICENTENNIAL
1867 - 2017
Excellence in Truth and Service

150
THE TIME IS ALWAYS NOW
HOWARD UNIVERSITY
SESQUICENTENNIAL
1867 - 2017

Excellence in Truth and Service

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 18:58:40 -0400
To: Lindley Lee
Subject: Re: Under 10 Minute P-O-C Testing Reported by Colorado

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 6:22 PM, Lindley Lee [redacted] (b) (6)>wrote:
>
> Dr. Fauci,
>
> I am not sure you are aware, but there is already a point-of-care solution available for Coronavirus, and the Denver newsrooms have been reporting about it. 9News and FoxNews are all reporting about Aytu BioScience of Englewood, Colorado. The kits have already been used in China, and are immediately available to assist burden the testing time and backlog. Who do we need to inform of this already available option? Thank you.
>
> Regards,
>
> Lindley Lee
> [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 18:58:19 -0400
To: JOHN Lightbody
Subject: Re: Thank You!

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 6:22 PM, JOHN Lightbody [redacted] (b) (6) wrote:
>
> Dear Dr. Fauci,
> Thank you for your service and your honesty.
> It is difficult for me to watch you telling the truth with all of the people of the Trump Administration spouting lies constantly!
> Keep up the good work!
> Our prayers are with you and those who are working to help this country deal with this coronavirus.
> Sincerely,
> Sonja C. Lightbody
> (proud [redacted] (b) (6) Federal employee)
> [redacted] (b) (6)

From: (b) (6)
Sent: Sun, 15 Mar 2020 18:58:06 -0400
To: Clarence Jones
Subject: Re: A Telemedicine Book to help Doctors & Staff Cope with the COVID-19 Overload

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 6:22 PM, Clarence Jones <cjones@winning-newsmedia.com> wrote:
>
> Dr. Fauci:
> If your predictions come true, the entire medical system will soon be overwhelmed. Only massive use of telemedicine will be able to cope with the overload.
>
> I'm a former TV reporter, now full-time writer, with nine books in print. One of them - "Webcam Savvy for Telemedicine" -- can help those in the medical community quickly learn how to use this medium. It is available at amazon.com in both print & digital versions. https://smile.amazon.com/Webcam-Savvy-Telemedicine-Clarence-Jones/dp/1546501894/ref=sr_1_fkmr0_1?keywords=webca%2C+savvy+for+telemedicine&qid=1584307097&sr=8-1-fkmr0
>
> I'll attach a PDF copy to this message & also send the same message without an attachment, just in case your system rejects messages with attachments. I can also overnight you a print copy if you'd like. Bulk pricing is available for both print & digital versions.
>
> You've become a rock star in the current crisis. As a long-time on-camera coach, I don't think I could teach you a THING you haven't already mastered. Congratulations.
>
> --
> Cheers,
> Clarence Jones
>
> (b) (6).

(b) (6)

Landline: (b) (6)
Cell: (b) (6)

website: www.winning-newsmedia.com
--
Books by Clarence Jones in both print and e-book versions:
--
LED Basics: Choosing and Using the Magic Light
Sweetheart Scams - Online Dating's Billion-Dollar Swindle
They're Gonna Murder You - War Stories From My Life at the News Front
Winning with the News Media - A Self-Defense Manual When You're the Story
Webcam Savvy - For the Job or the News
Webcam Savvy - For Telemedicine
Filming Family History - How to Save Great Stories for Future Generations
Sailboat Projects - Clever Ideas and How to Make Them
More Sailboat Projects - Clever Ideas and How to Make Them

<Webcam Savvy for Telemedicine & covers.pdf>

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 18:57:17 -0400
To: NIAID OD AM
Subject: Fwd: CANCELLATION amfAR Capitol Hill Briefing, Ending the HIV/AIDS Epidemic on Thursday, March 26th

Sent from my iPhone

Begin forwarded message:

> **From:** [redacted] (b) (6)
> **Date:** March 15, 2020 at 6:25:06 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** "Folkers, Greg (NIH/NIAID) [E]" < [redacted] (b) (6), "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: CANCELLATION amfAR Capitol Hill Briefing, Ending the HIV/AIDS Epidemic on Thursday, March 26th**
> **Reply-To:** [redacted] (b) (6)

Dear Tony:
amfAR, The Foundation for AIDS Research will be postponing our Capitol Hill Briefing, "Ending the HIV/AIDS Pandemic: Lessons Learned for the Coronavirus Outbreak" planned for Thursday, March 26th, due to the declaration of a National Emergency in our country.

Once the coronavirus public health crisis abates, amfAR will reschedule the briefing and hope that you will be able to speak as planned. At that meeting, you and several other of our nation's leading health officials will address two pandemics - AIDS and COVID-19. and the lessons learned from fighting both of these diseases. We will very much look forward to hearing your perspectives about global initiatives for ending AIDS and the work done to eradicate the coronavirus pandemic. We know your remarks will help provide a roadmap for ending HIV and other infectious disease threats now and in the years ahead.
I was proud to see the contributions of the US Public Health Service highlighted in today's WH briefing. You did an excellent job with your remarks.
Thanks for your work and dedication to safeguarding and advancing global health. Hope we get a chance to catch up soon.
Sincerely,
Susan
Susan Blumenthal, MD, MPA
Senior Policy and Medical Advisor, amfAR
Rear Admiral (ret)
Former US Assistant Surgeon General
First Deputy Asst Secretary for Women's Health

From: (b) (6)
Sent: Sun, 15 Mar 2020 18:56:55 -0400
To: Linda Jones
Subject: Re: Emulating Social Distancing During Press Conference

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 6:25 PM, Linda Jones (b) (6)> wrote:
>
> Thank you so much for all your EXTREMELY IMPORTANT info on COVID-19. You are a national treasure. Please emulate Social Distancing during ALL press conferences and the press Corp as well.
> Please be safe and stay well.
> Linda Jones
>
> Sent from my iPad

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 18:55:37 -0400
To: el
Subject: Re: Coronavirus Cases in New Jersey

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 6:30 PM, el [redacted] (b) (6)>wrote:
>
> Dear Dr. Fauci,
> My apologies if you have already spoken with Mike Maron, but it seems the political machine here in New Jersey is ignoring our own medical experts and I thought it important that your team be aware of how this crisis is manifesting on the front lines:
> https://www.roi-nj.com/2020/03/14/opinion/life-at-the-epicenter-of-n-j-s-coronavirus-outbreak/
> Our family is keeping you and your team in our thoughts and prayers.
>
> With infinite respect for you and the daunting task you face,
> Rosanna Galluccio

From: (b) (6)
Sent: Sun, 15 Mar 2020 18:52:24 -0400
To: Eva Sperling MD
Subject: Re: For your urgent attention (COVID-19)

Thank you for your note.
A.S. Fauci

Sent from my iPhone

On Mar 15, 2020, at 6:38 PM, Eva Sperling MD (b) (6)>wrote:

Dear Dr. Fauci,
Thank you for your leadership during the current COVID-19 crisis. We're writing to ask you to consider spearheading an additional initiative in this effort.

As you know, one of our greatest immediate needs is an adequate supply of **ventilators for use in hospitals.** We will face a severe shortage of this crucial equipment during a surge of COVID-19 hospitalizations. This will create a bottleneck in our ability to deliver care, a situation where we have to triage who should live and who should die. Tragically, we see this happening already in Italy. This is a situation we must avoid.

So we propose to immediately help existing factories to increase production, to convert other existing factories for the production of ventilators and to build new factories to do so.
Some of this will take a long time to accomplish but this pandemic is also predicted to be with us for a long time. We must stay ahead.

We should make an all-out effort to supply our hospitals properly and quickly. We are in a time of war and we must make the commensurate effort now.

We believe we have the knowledge and the resources to do such a thing.

We just need the will, and the leadership.

We're writing to urge you to use your position of leadership to make this happen.

Here is a link to NPR's report on this crucial issue: https://www.npr.org/sections/health-shots/2020/03/14/815675678/as-the-pandemic-spreads-will-there-be-enough-ventilators

Thank you,

Eva Sperling, MD
Elisabeth Sperling

From: (b) (6)
Sent: Sun, 15 Mar 2020 15:33:20 -0400
To: Xiaoyang Hua, M.D., Ph.D.
Subject: Re: COVID-19 some suggestions

Thank you for your note

Sent from my iPhone

> On Mar 15, 2020, at 3:17 PM, Xiaoyang Hua, M.D., Ph.D. (b) (6)> wrote:
>
> Dear Dr. Fauci:
> I am writing to you to express my deepest concerns on the COVID-19 outbreak in the USA and would like to share some thoughts with you.
>
> I am a (b) (6) and an otolaryngologist at the Duke Medical Center. I completed my training in Otolaryngology at the University of Iowa in 2019. From 2013 to 2015, I did a research fellowship with Dr. Stanley Perlman, an expert in coronavirus, to study SARS. Before I came to the States, I was an ENT doctor and had worked in the epicenter of the COVID-19 outbreak, Wuhan, China for several years. Many of my friends, neighbors, and colleagues were infected. Some of them have died or are dying. I truly appreciate what you have done to wake the Americans and warn them about this dangerous virus outbreak. I hope we are not repeating the mistakes that the Chinese and Italians have made earlier.
>
> I know many physicians and nurses who have been on the frontlines against this coronavirus outbreak in Wuhan China. Over the past a couple of months, I have been communicating with them about the COVID-19 outbreak. I have obtained much firsthand information about this virus from medical professionals, including the ICU directors of major hospitals in Wuhan. Here I want to share some thoughts with you and hope that I can help prevent the worst in the USA.
>
> For the government:
>
> 1. Close all public schools immediately. My family is in (b) (6). They are yet to decide if they should close the schools after the spring break. This is one example that has concerned me a lot. In the email from the (b) (6) School District, quote: "there are many factors to be considered any time a decision is made to close schools. These factors range from evaluating the consequences of missed instruction to providing meals to students who rely on the school's food service program", this is extremely short-sighted. These factors, as quoted above, will be very minor issues and easier to handle, compared with the potential catastrophic consequences should the virus outbreak be out of control and have paralyzed our already-overwhelmed medical system in the USA. I hope the federal government can issue an administrative order to close the public schools.
>
> 2. Cancel or postpone any large gathering events more than 20 people. Use tele-conference if necessary.
>
> 3. Every county in this country should have contingent plan in place and have one or several isolation facilities/temporary shelters in the remote areas using college dorms or hotels, in preparation of future large outbreaks of COVID-19 in the community.
>
> 4. Work with local or state media to inform the public of the status of basic life necessity (e.g. food, water, tissue paper) and essential medical supplies (including PPE). If there is a shortage, the estimated back-to-stock timeline should be provided. For PPEs, if the shortage cannot be solved within a short period of time, they should be saved for those who truly need them including medical professionals treating patients with COVID-19. All local medical supply businesses should turn in their inventories since the State Emergency has been declared. These timely updates will provide assurance to the public to avoid panic and chaos.

>

> 5. Encourage online shopping and drive-thru pick-up including groceries. Help the local businesses to expand their delivering capacities.
>
> 6. Provide the public live updates on the outbreak, including the number of confirmed cases, their current clinical status, strategies of tracing their close contacts, as well as the number of total cases being tested. From what I have learned, the more transparent the government is, the less panic the public will be.
>
> 7. Issue laws that prohibit intentional spread of COVID-19, irresponsible behaviors that put other innocent people or medical professionals at risk of contracting the virus.
>
>
>
> For medical professionals:
>
> Early January in Wuhan, many patients very likely contracted COVID-19 in the local hospitals when they visited their physicians for other medical conditions. In addition, the medical system in Wuhan China was almost paralyzed at that time. One of major reasons is that many medical professionals were infected and sick. The medical professionals are the backbone in the fight against this virus outbreak. We need to prepare for the worst scenario that this outbreak can last for a few or several months. We need to protect our medical professionals first.
>
> 1. Set up a centralized Fever/COVID-19 hotline operated by trained provider/nursing staff. This telephone line can use the current available state information hotline, with expanded functions serving as a gatekeeper and triage mechanism for potential COVID-19 patients to receive guidance on where to seek help before visiting a busy clinic, an urgent care, or a hospital emergency room to minimize the chances of cross-infection and over-whelming large medical centers.
>
> 2. Establish designated Fever/COVID-19 clinics or hospitals led by well-trained ID teams (MD, NP), especially in highly populated areas. These clinics will serve as the secondary triage and referral centers for the aforementioned Fever/COVID-19 hotline, plus for primary care clinics that are not equipped with adequate staff and testing tools. These clinics should have adequate staff including physicians and middle level providers, equipped with testing kits to perform COVID-19 test onsite. They should have the capacity of testing drive-through patients, securing airway for ventilation if needed before transferring severe patients to tertiary medical facilities. They should be operated collaboratively with larger healthcare systems like U Iowa, Unity Point, and Mercy who are setting up their own isolated COVID-19 centers for more severe cases.
>
> 3. Establish a clear communication and transfer protocol between Fever/COVID-19 hotlines, clinics and treating hospitals for management of suspicious and confirmed cases. For those with mild COVID-19 infection, they should be self-quarantined at home and monitored closely and remotely. If they cannot perform self-quarantine safely, such as living by themselves or in nursing homes, they should be kept in the county isolation facilities (as mentioned above), being monitored there.
>
> 4. If drive-through testing is available at CVS or Walgreen, patients with positive results should call the hotline or their PCPs first if clinically stable to receive guidance for self-quarantine, monitoring and follow-up. If they cannot perform self-quarantine safely, they should be kept in the county isolation facilities as mentioned above.
>
> 5. Inform the public and other healthcare providers of the availability of these Fever/COVID-19 hotline and clinics, encouraging patients with symptoms to utilize these resources first before visiting clinics, emergency rooms to reduce the chances of cross-infection, and the burden on large medical centers.
>
> 6. Encourage medical professionals to call their clinic patients for screening. Allow the medical providers to postpone all non-urgent medical visits for annual checkups, stable and non-urgent chronic conditions et al.
>
> 7. Encourage all physicians and healthcare professionals who provide direct patient care to wear personal protective equipment (PPE) such as masks, eye shields and gloves to protect themselves and to minimize the chances of spreading the virus to other patients, if necessary or based on their screening phone calls.

>
>
>
>
>
> Sincerely,
>
>
>
> Kind regards,
> -------------------------------
> Xiaoyang Hua, MD/PhD
> Duke Head and Neck Surgery
>
>
>
>
>
>
>

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 15:08:54 -0400
To: Jon LaPook
Subject: Re: TIME SENSITIVE; from Jon LaPook to Tony Fauci

I would not use an age number, but if you had to I would say 70. I would say "serious" underlying condition. Not sure about ACE inhibitors.

> On Mar 15, 2020, at 3:01 PM, Jon LaPook [redacted] (b) (6)>wrote:
>
> Tony,
> Since "elderly" means different things to different people (to me, it's 10 years older than me – and I'm [redacted] (b) (6) should I give a certain age after which people should voluntarily self-isolate now?
> And for underlying conditions, should I say "serious underlying conditions" or leave it vague at "underlying medical conditions?" I think the more specific the better.
> And, finally, I'm hearing that it's puzzling that hypertension is such a risk factor and that perhaps people on ACE inhibitors are upregulating receptors for ACE2 in the lung. Any evidence of that? If so, maybe we should switch people off ACE inhibitors for now.
> Thanks,
> Jon
>
> ---
>
> **From:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> **Sent:** Sunday, March 15, 2020 2:46 PM
> **To:** Jon LaPook [redacted] (b) (6)>
> **Subject:** RE: TIME SENSITIVE; from Jon LaPook to Tony Fauci
>
> Jon:
> Looks quite good. I suggest that you lean out there and explicitly say that the elderly and certainly those with underlying conditions should voluntarily self-isolate now.
> Best regards,
> Tony
>
> ---
>
> **From:** Jon LaPook [redacted] (b) (6)
> **Sent:** Sunday, March 15, 2020 2:20 PM
> **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> **Subject:** TIME SENSITIVE; from Jon LaPook to Tony Fauci
>
> Hi Tony,

I would like to post this widely today, but want your input first. Can you please make suggestions/additions/corrections?

Thanks so much!

Jon

The World Health Organization has declared the Covid-19 outbreak to be a pandemic -- official recognition that the virus respects no borders and now affects masses of people in countries all over the world. And there is no denying the world is changing, in painful ways. We see it in financial markets, where prices are plunging -- and in supermarkets, where customers are stripping shelves bare. All driven by fear, as the number of virus cases grows with each passing day. While we may feel powerless over this threat, we are not. There are important things we can and must do -- and right now.

To borrow a phrase from the war on terror, the coronavirus only has to be right once to infect us. We have to be right every time to prevent it. So, every time you cough or sneeze, use a tissue or the crook of your arm. Every time you think of it, wash your hands -- as frequently as you can. Every time you can, practice “social distancing” -- stay away from others during this outbreak. Social distancing is now being enforced throughout our society. Schools are closing, sporting events of every kind are being canceled. The curtain has even come down on Broadway shows as the Great White Way goes dark.

Despite our best efforts, it's likely many of us will eventually get infected by the virus, since we have no immunity to it. If that's the case, you may ask, does it really matter **when** we get infected? The answer is a resounding yes! And here's why: slowing the spread of coronavirus -- and consequently delaying infections -- can make an enormous difference in our ability to handle the pandemic.

Take a look at this illustration. It appeared in the Economist and is based on a CDC report. The blue curve shows what happens when you do nothing. The number of infections peaks relatively quickly. This can overwhelm a healthcare system that is not prepared to handle such a huge number of patients. Emergency rooms and hospitals can become overloaded. We may see shortages of medical supplies -- including protective gear and breathing machines -- and shortages of healthcare workers, especially if many of them become infected. But look at the yellow curve. It shows what can happen when you slow the epidemic. The outbreak is stretched out. And while it may last longer, the peak number of infections is much lower, putting less stress on the healthcare system and allowing better care for each patient. It also gives scientists more time to develop new treatments and vaccines.

Is there any evidence this works? Absolutely, especially when coupled with the time-proven technique of aggressive testing to find and isolate infected people as early as possible. In China, where there has been strict quarantine and social distancing in the epicenter of the outbreak, new infections have dramatically slowed. In South Korea, where health officials cleverly used drive-through testing, we're also seeing the number of new cases slow down. And there's a history lesson from the 1918 flu pandemic. Back then, Philadelphia held a parade attended by several hundred thousand people. Soon, every hospital bed in the city reportedly was filled with sick patients. Saint Louis, on the other hand, practiced social isolation and saw fewer cases.

So we have work to do, and it won't be easy, because it means changing the way we live our daily lives and how we interact with our neighbors. And we have to start now -- when we can make the most difference.

And here's something we need to keep in mind. We are all in this together. So even as we keep a distance from each other physically, we need to stay close emotionally. Social isolation is bad for your health! If ever there was a time to call or video chat with friends and loved ones. And don't forget to reach out to the elderly --who may be alone and afraid.

Demonstrating grace under pressure is easier said than done. But that is this doctor's prescription for getting through this. And, if we treat each other with kindness and empathy, we **will**.

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health

PLEASE NOTE: IF YOU LEAVE ME A MEDICAL MESSAGE AND DO NOT HEAR BACK WITHIN 24 HOURS, PLEASE CALL MY OFFICE AT 646-754-2000. PLEASE NEVER LEAVE AN EMAIL ABOUT AN URGENT MEDICAL ISSUE.

This message is confidential.
WARNING: THIS EMAIL MAY CONTAIN CONFIDENTIAL MEDICAL INFORMATION
The medical information in this message is confidential and privileged. It is unlawful for unauthorized persons to review, copy, disclose or disseminate confidential information. If the reader of this warning is not the intended email recipient, or the intended recipient's agent, you are hereby notified that you have received this email in error and that review or further disclosure of the information contained

therein is strictly prohibited. If you have received this email message in error, please notify us immediately at 646-754-2000 and delete the original message.

HIPAA regulations require proxy/patient approval before use of electronic media. By requesting and/or agreeing to email correspondence, you are agreeing to use of electronic media for transmission of information.

From: (b) (6)
Sent: Sun, 15 Mar 2020 15:02:52 -0400
To: Liz
Subject: Re: Concern for young 'Vapers' population; this will be serious for them. Vaping was already it's own epidemic.

Good point

> On Mar 15, 2020, at 2:42 PM, Liz (b) (6)> wrote:
>
> Hello Dr. Fauci,
>
> I hope you will see this message. The subject line is part of the equation, for Covid-19, in the US which is an unknown. I am highly concerned how It will affect this group. Please let all healthcare systems know to be aware and have this on their radar. We keep hearing it's for older adults but it's for people with compromised lungs among other all pre-existing conditions you've mentioned.
>
> Sincerely,
> Lyzzy Crouse

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 15:02:32 -0400
To: Schuchat, Anne MD (CDC/OD)
Subject: Fwd: Concern for young 'Vapers' population; this will be serious for them. Vaping was already it's own epidemic.

This person makes a good point.

Begin forwarded message:

> **From:** Liz [redacted] (b) (6)>
> **Date:** March 15, 2020 at 2:42:24 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Concern for young 'Vapers' population; this will be serious for them. Vaping was already it's own epidemic.**
>
> Hello Dr. Fauci,
>
> I hope you will see this message. The subject line is part of the equation, for Covid-19, in the US which is an unknown. I am highly concerned how It will affect this group. Please let all healthcare systems know to be aware and have this on their radar. We keep hearing it's for older adults but it's for people with compromised lungs among other all pre-existing conditions you've mentioned.
>
> Sincerely,
> Lyzzy Crouse

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 18:33:06 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Tools that may help you

Please handle.

From: Landrigan, David (b) (6)
Sent: Sunday, March 15, 2020 1:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Tools that may help you

Tony,

It has been about 20 years since you and I talked about SARS and my model that David Williams at WHO used. I didn't know if your old email still worked, so I'm using the directory listing by NIH in addition. I have some ideas to share with you about the use of tools in the current war on covid-19.

Your 'close the bars' statement is right on target with what I was writing when I heard you say it. It was a great illustration counterintuitive to what will work. You could have more correctly said keep the bars open only to those in their twenties and thirties. Five minutes later Mayor DeBlasio said everything is on the table including closing bars and restaurants! Below you will see me argue why there are better approaches and this total closure approach is the wrong move. Selective participation will work in our favor to blunt the curve! Total closure will not work and can work against us!

In a period of two weeks demand for medical treatment can go from 50% of hospital capacity to 200% due to disease progression and binomial expansion. You know the math and ideas, so there's no need to go into them. There is a need to closely consider how available tools are being used to mitigate an overwhelming of the health care system. I can tell you now that what needs to be done isn't being done and that the road we are on now will at most postpone crossing the threshold of 100% capacity. It will not achieve the desired result of distributing cases over a greater time period so that being overwhelmed is avoided.

Consider the curves:

The 'without protective measures' curve is the normal distribution as modeled by the binomial distribution. The 'with protective measures' distribution is what we want to achieve, although that would be foreign to an experimentalist. We don't want the number of cases to exceed capacity as indicated by the horizontal dotted line. If the 'protective measures' are social distancing, school closings, entertainment/sporting cancelations, restaurant closings, and hygiene and similar uniformly applied measures, the 'with' curve should have a shape similar to the 'without' curve, just shifted to the right, unless there is some unpartitioned factor interaction. The flattened curve WILL NOT RESULT because errors should be random and SAMENESS OF TREATMENT PRODUCES SAMENESS OF EFFECT. With UNIFORM application of measures the curve after application will still exceed a height showing the system capacity has been exceeded.

We could expect to flatten the mesokurtic 'without' curve into the platykurtic 'with' curve by systematic time staggering in the use of the protective measures and selectively applying the measures to drive toward herd immunity. As immunity builds toward HIT (Herd Immunity Threshold), there will be greater and greater slowing of infections as the linkages for transmission decrease. There are two points to consider here.

The first point is whether measures should be applied in a uniform and blanket manner. The answer is typically no when the effect is on an existing population because the curve won't flatten. There are two aspects of the application of measures to consider. Is the effect of the application defining the population or is it an effect within a defined population. In the instance of halting all air traffic to the US from China, the population is being defined and altered if influx is allowed and that would both increase the infections and population turbulence. There would be movement away from HIT. Any measure such as people influx, which moves the US away from HIT, is to be avoided.

School, restaurant, and sporting event closings need to be examined in relationship to their impact on an existing, not an increasing population. The actions have many criteria to influence them, but from the viewpoint of keeping the healthcare system from becoming overwhelmed closings that are staggered, variable, and alternating will work to increase movement toward HIT and promote flattening of the 'with' curve.

The second point to consider is whether we can move the US toward HIT by age selective application of available measures. The answer is yes and this could provide the best tool. Susceptibility and strengths of covid-19 infections covary with age. People less than 30 rarely have severe infections and the younger ones may not become infected. People under 40 show a low frequency of severe infection. It will be important to know if there is a large age cohort exempt from infection because that would undermine part of the result from selective application of measures or limit the sampling age because these people wouldn't develop immunity, but might contribute to delaying herd effects. If they develop immunity their contribution can be substantial and they can be kept separated from more vulnerable people until and unless it is established that there isn't a need.

Opening night clubs, sporting events, restaurants, and other places to people in their twenties and thirties will build immunities, break infection transmission links, and move toward HIT with little or no risk to the people or the rest of the herd. Have admission to the venues by existing ID, like a driver's license with age, and have agreement that they do not mingle with vulnerable older people. Leaving the bars open to people in their 20's and 30's will flatten the curve!

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 18:32:34 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE: [EXTERNAL] CNN question/German vaccine company?

This is the first that I have heard anything about this subject.

From: Birx, Deborah L. EOP/NSC [redacted] (b) (6)>
Sent: Sunday, March 15, 2020 1:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: [EXTERNAL] CNN question/German vaccine company?

Do you know anything about this?

Sent from my iPhone

Begin forwarded message:

> **From:** "Miller, Katie R. EOP/OVP" [redacted] (b) (6)
> **Date:** March 15, 2020 at 1:14:28 PM EDT
> **To:** "Birx, Deborah L. EOP/NSC" [redacted] (b) (6)>
> **Subject: Fwd: [EXTERNAL] CNN question/German vaccine company?**
>
> Sent from my iPhone
>
> Begin forwarded message:
>
>> **From:** "Liptak, Kevin" <Kevin.Liptak@turner.com>
>> **Date:** March 15, 2020 at 1:09:32 PM EDT
>> **To:** "Miller, Katie R. EOP/OVP" [redacted] (b) (6)>, "Fetalvo, Ninio J. EOP/OVP" [redacted] (b) (6)>, DL NSC Press [redacted] (b) (6)>
>> **Subject: [EXTERNAL] CNN question/German vaccine company?**
>>
>> Afternoon — checking to see whether the White House has any comment on these allegations in German media that President Trump is offering large sums of money to lure a German vaccine maker to the United States? >https://www.reuters.com/article/us-health-coronavirus-germany-usa-idUSKBN2120IV<
>>
>> Thanks
>> Kevin

Kevin Liptak
CNN White House
(b) (6)

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 13:30:08 -0400
To: Soumya Jayaraj
Subject: Re: Concern about Covid spread in South Padre Island Texas

Thank you for your note
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 1:29 PM, Soumya Jayaraj [redacted] (b) (6) wrote:
>
> Hello Dr. Fauci,
>
> I hope you get to read this and you can do something about it. I am writing from [redacted] (b) (6). Here at South Padre Island spring break events are going in full swing with no concern whatsoever about coronavirus spread. We do not have positive cases yet in the Rio Grande Valley but this is inviting the disease here.
>
> People come from all over USA, especially students in huge numbers for spring break to SPI. In spite of repeated requests by press and general public the authorities have not shut down the event. I am attaching a couple of articles below . It is very concerning to see the authorities do not seem to understand the gravity of the situation and the importance of social distancing which is the need of the hour. Kindly look into this and please do what you can to put a stop to this.
>
> Please note the crowd is expected to increase next week.
>
> Appreciate your help.
>
> Thanks
> Regards
> Soumya Jayaraj
>
> https://www.themonitor.com/2020/03/12/spi-spring-break-continue/
>
> https://www.facebook.com/KRGVChristian/videos/195404708568768/

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 13:29:23 -0400
To: Daphne Coley
Subject: Re: Confidence in you

Thank you for your note
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 1:22 PM, Daphne Coley [redacted] (b) (6) wrote:
>
> Dear Dr. Fauci,
>
> Out of this whole mess you are the voice of reason that is most comforting. Your intelligence, calm demeanor and lack of personal agenda (I hope) come through in your explanations of this recent crisis.
>
> I have read how many lives that you saved during the AIDS crisis and laude you for it. I trust, given enough rein, that you can do it for the COVID-19 crisis.
>
> You must be feeling the weight of crushing political and media forces___a real tightrope. Then, of course you do have to worry about the illness itself, which should be your primary concern but might be problematic given the infighting and
> territorial nature of politics.
>
> Anyway, I wanted you to know that you have a real fan in [redacted] (b) (6). If there are two there are many, many more. Just keep on doing what you do so well and know that you are appreciated by lots of Americans.
>
> Best,
> Daphne Coley

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 13:28:26 -0400
To: rclavalle
Subject: Re: Thank you!

Thank you for your note
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 1:25 PM, rclavalle [redacted] (b) (6)>wrote:
>
> Good afternoon Sir,
>
> Thank you for your continued vigilance in protecting the American people. Your wise guidance regarding a temporary national lockdown may greatly help in reducing the spread of COVID-19.
>
> If this action were to occur it should be in phases:
>
> Phase 1: Federal Quarantine. Effective Immediately until 4 MAY 2020 (or further notice) - ONLY Key and Essential federal employees of all agencies (IC included) should report to work. Everyone else is on administrative leave. While buildings are empty, staff remaining should conduct deep cleaning (air systems, etc.) to ensure a healthy environment when employees come back to work.
>
> Phase 2: Federal recall: Beginning 4 MAY 2020, federal employees are called back to work on an as-needed basis (indefinitely) depending on how the virus trends. Excluding postal workers, that accounts for nearly 2 million full-time employees. There should be a mandatory home-quarantine so people are not out spreading the disease.
>
> Phase 3: Mitigation and recovery. Federal agencies need to produce mitigation measures (crisis action plans) should something of this nature occur in the future. Federal agencies must be ready to respond in an organized manner when a crisis occurs.
>
> Throughout this COVID-19 event, military and law enforcement must have an increased presence to prevent mass hysteria and mob mentality. Increased military and law enforcement presence may help enforce the home quarantine measures and prevent looting and other crimes that tend to occur during crisis events.

The National messages may include the following:

The top priority is the safety and security of the people
We will make decisions based on health guidance and current conditions here and elsewhere
We will get through this together (share resources, express kindness etc.)
We need to care for each other - It is vital it is to unite around this crisis
As a Nation, we need to come together as a community to survive this international disaster
This health crisis is challenging each of us to make sacrifices and implement changes out of the norm.
Ultimately, this crisis is not about us. It's about our responsibility to each other.
Thank you for all you are doing during this difficult time.

Thank you, Sir, for taking the time to review this correspondence.

Best regards,
RC LaValle-McIntosh

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 13:21:50 -0400
To: Laetitia Moreau
Subject: Re: Alert: ADVIL = killer with COVID19 , references and more

Thank you for your note
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 1:16 PM, Laetitia Moreau [redacted] (b) (6)>wrote:
>
> Estimated doctor Fauci
>
> With covid there are dos and don'ts.
>
> An important DON'T first and a DO here
>
> I heard from France and Europe. USA to be advised.
>
> **Self medication / Unecessary medication of Advil &corticoids is highly dangerous with Covid**
>
> 4 young adults were in critical conditions in France with no special reasons except they self medicated on Advil
> https://www.theguardian.com/world/2020/mar/14/anti-inflammatory-drugs-may-aggravate-coronavirus-infection?CMP=share_btn_tw
>
> In French news
> https://www.lefigaro.fr/sciences/coronavirus-alerte-sur-l-ibuprofene-et-autres-anti-inflammatoires-20200314
>
> French people directly instructed by Health Minister to avoid Advil
> https://twitter.com/olivierveran/status/1238776545398923264
>
> Reference articles
> https://www.thelancet.com/action/showPdf?pii=S2213-2600%2820%2930116-8

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30317-2/fulltext

Also about Do. I have been sharing about sleep / morning sun and covid.

Sleep protects against virus. We should keep standard time permanently. A good move already in normal times. Covid is an additional reason.

https://www.ucsf.edu/news/2015/08/131411/short-sleepers-are-four-times-more-likely-catch-cold

https://www.ncbi.nlm.nih.gov/pubmed/26118561

"The impact of daytime light exposures on sleep and mood in office workers." High levels in the morning is associated with reduced sleep onset latency ... and increased sleep quality. ncbi.nlm.nih.gov/pubmed/2852625

Thank you for your work.

Laetitia Moreau

(b) (6)

<>

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 13:19:05 -0400
To: [redacted] (b) (6)
Subject: Re: Suggestion for the Coronavirus Task Force

Thank you for your note
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 12:05 PM, [redacted] (b) (6) [redacted] >wrote:
>
> Dear Director Fauci,
> While important stores with pharmacies (Walmart, CVS, Walgreens) remain open, many elderly folks are afraid to enter due to the mixing of young and old and the increased risk of coronavirus exposure. I suggest that these stores designate certain hours for for those 60 years of age and older. Now that stores are reducing hours to clean and restock the stores overnight, the best hours might be first thing in the morning. For example for Walmart, the hours designated for those 60 and over could be 6 a.m. to 9 a.m. This could reduce their exposure to younger people who might have the virus but who are asymptomatic (or relatively so). This same idea could be applied to grocery stores.
> Best wishes
> Alan R. Ertle, MD, MPH, MBA
> (b) (6) [redacted]

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 13:17:01 -0400
To: Herb
Subject: Re: Coronavirus

Thank you for your note
A.S. Fauci.

Sent from my iPhone

> On Mar 15, 2020, at 12:24 PM, Herb [redacted] (b) (6)>wrote:
>
> You may want to know that [redacted] (b) (6) I feel that the information I have might be of interest to your position in this matter. If so, please reply by return email. Thank you. Herbert E. Johnson
>
> Sent from Mail for Windows 10

From: (b) (6)
Sent: Sun, 15 Mar 2020 12:02:05 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Request for interview

Sent from my iPhone

Begin forwarded message:

> **From:** Larry Milian <lmilian@slammiami.com>
> **Date:** March 15, 2020 at 10:42:39 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
> **Cc:** Larry Milian <lmilian@slammiami.com>
> **Subject: Request for interview**
>
> Dr. Fauci,
>
> My name is Larry "The Amigo" Milian and I am the National General Manager and Program Director for SLAM Radio on Sirius XM 145. I would like to respectfully request to have you on with me on my national morning show to update and discuss Coronavirus.
>
> I will be on air tomorrow starting at 7am est. While my show normally ends at 11am, I have decided to stay on air in order to keep our listeners properly informed.
>
> I would like to thank you in advance. Kindly email me or call me back ((b) (6)) and let me know what might be the best time to come in the air with me.
>
> Larry "The Amigo" Milian
> National General Manager/Program Director
> SLAM Radio on Sirius XM - Channel 145
> LMilian@SLAMMiami.com
> (b) (6)

From: (b) (6)
Sent: Sun, 15 Mar 2020 11:57:49 -0400
To: Alex Tanner
Subject: Re: Nasal spray

Thank you for your note.
A.S. Fauci

Sent from my iPhone

> On Mar 15, 2020, at 11:56 AM, Alex Tanner (b) (6)> wrote:
>
> Greetings Dr. Fauci:
>
> Wouldn't some concoction/ratio of bleach to water put in a nose spray bottle help prevent or kill covid-19? What about hydrogen peroxide?
>
> Regards,
> Alex
>
> Charles A Tanner
> (b) (6)
>
> Sent from my iPhone

From: (b) (6)
Sent: Sun, 15 Mar 2020 11:57:34 -0400
To: Deborah Lowery
Subject: Re: Hospitalization of covid-19 positive patients

Thank you for your note.
A.S. Fauci

Sent from my iPhone

> On Mar 15, 2020, at 11:57 AM, Deborah Lowery (b) (6)> wrote:
>
> Every large US city has several hospitals within city limits. Would it be possible to set up at least one hospital for ONLY covid-19 positive patients requiring hospitalization. This could help prevent transfer of virus to those hospitalized that do not have the virus and could help reduce the need for more personal protective supplies needed for staff, since only those staff at that particular hospital would be taking care of those with covid-19. Thank You for your time.
> Deborah Lowery

From: (b) (6)
Sent: Sun, 15 Mar 2020 10:17:01 -0400
To: Esam.Almarzouq
Subject: Re: God bless you all

Thank you for your kind note.

> On Mar 15, 2020, at 10:13 AM, Esam.Almarzouq <esam.almarzouq@jsgroup.com.kw> wrote:
>
> Dear Dr Anthony
>
> My name is Esam AlMarzouq from (b) (6) a country that I am sure you know. My daughter is studying in one of the universities in (b) (6)
>
> I just wanted to take the opportunity to say God bless you for all the effort taken by you along with your colleagues in NIAID and President office to contain CoronaVirus. I am confident, with God help we shall all overcome Covid-19 pandemic.
>
> All the best wishes to you all
>
> Regards
> Esam AlMarzouq
> CEO - JS GROUP, private company in the area of general trading and construction in Kuwait

From: (b) (6)
Sent: Sun, 15 Mar 2020 09:28:21 -0400
To: Mary Lane
Subject: Re: Honest Communication

Thanks!

> On Mar 15, 2020, at 9:17 AM, Mary Lane (b) (6)> wrote:
>
> Thank you so much for being honest about the coronavirus. We feel we can trust what you say!
>
> Sent from my iPhone

From: [redacted] (b) (6)
Sent: Sun, 15 Mar 2020 09:15:29 -0400
To: NIAID Public Inquiries
Subject: Fwd: Indigenous Peoples - Bat Guano Harvesters - COVID-19

Sent from my iPhone

Begin forwarded message:

> **From:** Geoffrey Wilcox [redacted] (b) (6)
> **Date:** March 15, 2020 at 9:11:50 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Subject: Indigenous Peoples - Bat Guano Harvesters - COVID-19**
>
> Dear Mr Fauci:
>
> Is it possible to be immune to the virus? What if any research has been done on the indigenous people around the world, including the US, that have harvested guano for centuries?
>
> Geoff Wilcox

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 01:58:46 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: Draft all hands message
Attachments: Draft_All_Staff_First_NIHStaff_Coronavirus_3.14.20_V2 fsc clean - with minor Fauci edit.docx

Francis:
It looks fine, but I made one minor edit that is tracked.
Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Saturday, March 14, 2020 9:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Subject: Draft all hands message

Hi Tony,

If you have a couple of minutes to review it, please let me know if you see any problems with this draft all-hands message.

FC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 01:11:43 +0000
To: Robert Jones
Subject: RE: Avoiding Italy's Coronavirus Disaster

Thank you for the note.

From: Robert Jones <[redacted] (b) (6)
Sent: Saturday, March 14, 2020 8:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Avoiding Italy's Coronavirus Disaster

Dear Dr. Fauci,

Thank you for your leadership. I ask that you take two minutes to read the following article in today's Boston Globe written by an Italian journalist.

https://www.bostonglobe.com/2020/03/13/opinion/coronavirus-cautionary-tale-italy-dont-do-what-we-did/

Bottom line: Please consider a lockdown or some form of a lockdown by the end of this week.

Best regards,
Bob Jones

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 01:00:13 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Covid 19 Minocycline

From: Ramaswamy, Sriram [redacted] (b) (6)
Sent: Saturday, March 14, 2020 9:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Covid 19 Minocycline

Hi Dr. Fauci,

Pardon the intrusion into your email. I am sure you are super busy spearheading the fight against COVID-19, hence I will cut to the chase. If your research team is looking for ideas to manage this novel virus, perhaps you can consider adjuvant minocycline. Personally I conducted a small proof of concept study with minocycline in veterans with PTSD and am now collaborating with the San Francisco VA for a larger and definitive study. The point I am making that minocycline has potential benefits beyond antibacterial.. I see that there is preliminary evidence that it can slow down viral replication.

Anyway you are the international expert and we all THANK YOU for all that you do!

Best,

Sriram Ramaswamy, MD
Professor of Psychiatry
Vice Chair for Research

Department of Psychiatry
Creighton University School of Medicine
7710 Mercy Road, Suite 601
Omaha, Nebraska 68124-237

From: [redacted] (b) (6)
Sent: Sat, 14 Mar 2020 19:24:11 -0400
To: Fabien
Subject: Re: Great talk, as usual...

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 14, 2020, at 3:42 PM, Fabien [redacted] (b) (6)>wrote:
>
> Dear Professor,
> We see you every where at television in France currently.
> I fully understand that you have much more urgent to do than answering my previous email and I apologize to have bothered you.
> Bon courage...
> With all my respect and admiration, for decades,
> Fabien Sordet.
>
> Envoyé de mon iPhone
>
>> Le 10 mars 2020 à 19:09, Fabien [redacted] (b) (6)>a écrit :
>>
>> Dear Professor Fauci,
>>
>> Great talk at CROI... Thank you.
>>
>> I follow your works on HIV for 25 years.
>> [redacted] (b) (6) when I stated to work on HIV myself.
>> This give me the chance to have your email address, but it is not as health care professional that I write you today. Just as human, lambda human...
>> My parents are a bit older than you.
>> Imagine for yourself:
>> If tomorrow, whereas you are already vaccined against Flu, you have significative start of fever and cough, in an environment

where Covid-19 is epidemic, would you right away take Kaletra and Plaquenil (knowing the fact that if there is a little chance it works, the soonest is the best) ?

Kind Regards,
Dr Fabien Sordet, [redacted] (b) (6)
[redacted]

From: [redacted] (b) (6)
Sent: Sat, 14 Mar 2020 19:23:16 -0400
To: Janice Strauss
Subject: Re: Truthful science information

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 14, 2020, at 4:04 PM, Janice Strauss <[redacted] (b) (6)> wrote:
>
> Dr. Fauci,
>
> Thank you for your determination and stamina to inform the American public with science-based updates and information regarding the novel coronavirus.
>
> Without the appropriate data the virus trajectory will leave the country in a state of greater uncertainty and fear. Among many of the public who watch the task force briefings you remain a bulwark against chaos and panic.
>
> When politicians announce policy regarding the virus they may fear accusations of "flip flopping" when a fluid situation requires nimbleness through recalibration or reversal. That instinct is not party-based. However, an honest, neutral agent eschewing disinformation, misinformation, or omissions might better protect the public than a politician concerned with polls, contributions, and election results.
>
> Thank you, Dr. Fauci, for being the honest, neutral agent despite direct or untoward pressure to ignore science-based evidence.
>
> Sincerely,
> Janice Strauss

From: [redacted] (b) (6)
Sent: Sat, 14 Mar 2020 19:22:43 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Helping to mass produce more dosages of cornavirus vaccines and antibodies at lower cost with potentially greater potency

Pls respond

Sent from my iPhone

Begin forwarded message:

> **From:** Mark Emalfarb [redacted] (b) (6)
> **Date:** March 14, 2020 at 4:11:01 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Helping to mass produce more dosages of cornavirus vaccines and antibodies at lower cost with potentially greater potency**
>
> Dear Dr. Fauci
>
> I don't want to overburden you with a long email, so I'll try and get to the point.
>
> First, we have developed a gene expression system, our C1 cell line which is significantly more efficient than traditional cell lines being used by Big Pharma to manufacture recombinant vaccines and drugs. The hyper productive C1 cells can be grown at flexible commercial scales and are proving to be the most efficient, cost effective way to produce the tens of millions of preventative vaccines and/or antibody treatments the world so desperately needs.
>
> In a collaboration with Sanofi, C1 cells were developed to produce recombinant proteins for use in manufacturing a lower cost better performing influenza vaccine. After conducting a

mice trial Sanofi concluded that the use of our C1 platform resulted in equal or better influenza protection, using a lower amount of vaccine that could be produced at 10-30 times higher productivity levels.

The Original Sanofi Presentation can be found at the following link:

https://www.dyadic.com/wp-content/uploads/2018/01/Sanofi-Pasteur-C1-Presentation.pdf

(b) (4)

[redacted]

Working together we can "Keep America Safe" by helping to address the immediate coronavirus outbreak, be better prepared for future infectious diseases, pandemic, and epidemic outbreaks, and leveraging this unfortunate situation to advance biopharmaceutical manufacturing to help speed development, lower the cost and improve the performance of biologic vaccines and drugs such as insulin, seasonal flu and other vaccines and antibodies to make healthcare more accessible and affordable to patients.

I am confident that a meeting with you can be very productive in further stimulating big pharma and other research institutions to speed effective, low cost vaccines and antibodies to market.

Given the severity of the current coronavirus situation, I am prepared to make myself available for a meeting at your convenience.

My cell number is [redacted] (b) (6) should you want to reach me quickly.

Sincerely,

Mark Emalfarb
Chief Executive Officer

Mark Emalfarb
CEO
Dyadic International, Inc.
[redacted] (b) (6) (Office)
[redacted] (b) (6) (Cell)
www.dyadic.com

From: [redacted] (b) (6)
Sent: Sat, 14 Mar 2020 19:21:17 -0400
To: Richard Lynn
Subject: Re: So proud

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 14, 2020, at 4:41 PM, Richard Lynn [redacted] (b) (6)>wrote:
>
> So well said Carol.
> Be well
> Richard
>
> Richard A. Lynn, MD,FACS,RPVI
> (b) (6) [redacted]
>
> On Fri, Mar 13, 2020, 5:23 PM Carol Storey-Johnson <csjohnso@med.cornell.edu>wrote:
>
> Dear Dr. Fauci--
>
> I fully agree with Dr. Lynn's message. I have been following your commentary on the current COVID-19 pandemic. Our Dean, Dr. Augustine Choi, has also been a major positive voice at WCM, communicating frequently with our community and, in his role as an expert in pulmonary diseases, echoing your messages at WCM as we struggle to educate students and trainees and manage the overwhelming questions and administrative issues that present themselves at this time. The measures he has implemented at WCM have been scientifically sound and commensurate with national expert (yours included) recommendations.
>
> As a member of the Board of Directors of the Alumni Association, I am also so proud of your work in this critical time for our nation. I'm sure WCM is appreciative of your representing the quality of your training, career experience, scientific thinking, and academic acumen in your advice to the nation and its people in these challenging times.
>
> The Alumni Association has recognized your work in the past, but your continued efforts speak so well to the excellence in the rigor and standards of the

educational, research, and clinical experience that all of our alumni have had at WCM.

We wish you well and hope that you have continued influence in these matters.

Sincerely,
Carol Storey-Johnson MD
Professor Emerita of Medicine
Weill Cornell Medical College

Note: This information, transmitted from Weill Cornell Medical College, is intended only for the person or entity named above, and may contain legally confidential and/or privileged material. Any forwarding, copying, disclosure, distribution, or other use of this information by any person is prohibited. If you are not the intended recipient, any review or taking of any action in reliance upon this information is strictly prohibited. If you received this in error, please contact the sender and delete the material from all computers. Thank You.

From: Richard Lynn [redacted] (b) (6) >
Sent: Tuesday, March 3, 2020 8:22 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: nl121 <nl121@cumc.columbia.edu>; Natasha I Leibel <nl121@columbia.edu>; kathleen foley [redacted] (b) (6); Carol Storey-Johnson <csjohnso@med.cornell.edu>; Lewis M Drusin <ldrusin@med.cornell.edu>
Subject: [EXTERNAL] So proud

Dear Tony,
As a member of the Board of Directors of Weill Cornell Med Alumni Association, I am so proud of what you are doing and proud that it all started in Olin Hall and 1300 York Ave.
Drs McDermott, Hook, Kilbourne, Kean and Johnson must have great pride in how you are a voice of science and reason during this crisis.
Stay strong and thank you
Richard [redacted] (b) (6)

Richard A. Lynn, MD,FACS,RPVI
[redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Sat, 14 Mar 2020 19:19:57 -0400
To: Jim Edwards
Subject: Re: Nitrile gloves request for COVID19

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 14, 2020, at 4:49 PM, Jim Edwards [redacted] (b) (6) wrote:
>
>
> Dear Dr. Fauchi:
>
> Regarding testing by drive through cars, [redacted] (b) (6)
>
> It has been hard for me to grocery shop during this coronavirus illness because the retailers are allowing the employees and baggers to [redacted] (b) (6).
>
> I so wish you could address this for us [redacted] (b) (6)
>
> You do not know how much this would mean to me.
>
> Thank you for your service!
>
> Best Regards,
>
> Robbin Edwards
> [redacted] (b) (6)
>
>
>
>
>
>

From: [redacted] (b) (6)
Sent: Sat, 14 Mar 2020 19:19:29 -0400
To: Norm Harris
Subject: Re: Thank you VERY VERY much

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 14, 2020, at 4:51 PM, Norm Harris [redacted] (b) (6)> wrote:
>
>
> For your recent frequent, focused, knowledgeable and understandable assessments and recommendations regarding the COVID-19 pandemic.
>
> A clear and transparent voice makes a very positive difference.
>
> Thank you,
>
> Linda and Norm Harris
> [redacted] (b) (6)

From: (b) (6)
Sent: Sat, 14 Mar 2020 19:18:47 -0400
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: Our Company Offer of Assistance During this Critical Time of the Coronavirus.

Pls handle.
Sent from my iPhone

Begin forwarded message:

> **From:** Kay Savio <(b) (6)>
> **Date:** March 14, 2020 at 4:59:41 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
> **Cc:** "Auchincloss, Hugh (NIH/NIAID) [E]" (b) (6)>, "McGowan, John J. (NIH/NIAID) [E]" (b) (6)>
> **Subject: Our Company Offer of Assistance During this Critical Time of the Coronavirus.**
>
> Dear Dr. Fauci:
>
> I work for Focus Pointe Global, a Schlesinger Group Clinical Research Company that has a data base of over 6 million participants globally. Our company is the largest of its kind in the world. I wanted to reach out to the NIH &NIAID to see if there is any way our company can be of help during the coronavirus epidemic.
>
> We have the unique ability to survey this panel of participants online or in person, asking various questions getting data back fairly quickly (approximately 2 weeks). Our company utilizes industry leading techniques and can follow this group for years in the future. We have worked with the NIH, CDC &such institutions as Northwestern University, Stanford, Harvard, Battelle, NORC, ICF etc., for many years.
>
> Please contact me if this is of interest and our company can be of help.
>
> Kind Regards,
>
> **Kay Savio**
> VP Client Development &Clinical Research
> Focus Pointe Global – A Schlesinger Company
> (b) (6) | (b) (6)
>
> FPG Focus Pointe Global

-
Qualitative &Quantitative Solutions | Visit our website

SCHLESINGER
GROUP

Learning, Growing & Innovating
People, Passion & Purpose

From: [redacted] (b) (6)
Sent: Sat, 14 Mar 2020 19:16:32 -0400
To: NIAID Public Inquiries
Subject: Fwd: COVID-19 reporting

Sent from my iPhone

Begin forwarded message:

> **From:** G C [redacted] (b) (6)
> **Date:** March 14, 2020 at 5:18:16 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: COVID-19 reporting**
>
> In VA, there is a woman who says she had "the corona" back in November and her husband had it in December.
>
> If this is fact, how can we trust our government when it comes to Public Health?
>
> Sent from my iPad

From: [redacted] (b) (6)
Sent: Sat, 14 Mar 2020 19:15:18 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Proposal for new treatment of established COVID-19 - CORRECTED EMAIL
Attachments: PastedGraphic-10.tiff, ATT00001.htm

Pls respond.

Sent from my iPhone

Begin forwarded message:

> **From:** "Prof.Shimon Slavin" [redacted] (b) (6)
> **Date:** March 14, 2020 at 5:36:53 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Proposal for new treatment of established COVID-19 - CORRECTED EMAIL**
>
> I APOLOGISE FOR SOME TYPOS IN MY PREVIOUS EMAIL SENT TO YOU OUT OF SPONTANEOUS ENTHUSIASM. PLEASE CONSIDER THIS CORRECTED VERSION INSTED.
>
> Dear Dr. Fauci,
>
> You may not remember but we have met years back when I was at Stanford University and Training with the late Donald E Thomas to consider cell therapy of HIV based on the use of reduced intensity, non-myeloablative conditioning in preparation for stem cell transplantation to induce tolerance and then apply cell therapy with donor lymphocytes which I have proposed for consideration of treatment of patients with HIV with secondary malignancy.
>
> The purpose of this email is to try and capture your attention in order to consider a new treatment option for COVID-19 that can be applied for patients in need with evidence of disease with no delay. Whereas many companies focus on development of anti-corona vaccine, I believe the more rational approach should be to develop treatment for COVID-19 and then, if the virus will be deleted and/or the disease controlled or modified, vaccination will result without the need for specific corona-specific vaccination which is not yet available and by the time it may be available it may no longer be relevant.
>
> I am serving as the Medical Director of a company in Hungary and we believe that one simple and safe experimental treatment of patients with existing viral disease may already be at hand, [redacted] (b) (4)

(b) (4)

[redacted]

I will greatly appreciate if you could give me a call or have one of your colleagues contact me and then I will be able to discuss the concept in greater details, after I will provide supportive scientific and clinical literature.

I am available 24/7 on my mobile phone listed below.

Shimon Slavin, M.D.
Professor of Medicine
Scientific &Medical Director, Biotherapy International
The Center for Innovative Cancer Immunotherapy &Cellular Medicine
Weizmann Center, 14 Weizmann Street
Floor 15, Suite 1503
Tel Aviv 64239, Israel

Email: [redacted] (b) (6)
Mobile phone: [redacted] (b) (6)

Biotherapy
International

From: [redacted] (b) (6)
Sent: Sat, 14 Mar 2020 19:11:42 -0400
To: Alex Amonette
Subject: Re: Thank you for your leadership!

Thank you for your note.
A.S. Fauci.

Sent from my iPhone

> On Mar 14, 2020, at 5:43 PM, Alex Amonette <[redacted] (b) (6)>wrote:
>
> Dear Dr. Fauci,
>
> Thank you for your leadership and expertise on the coronavirus and for your other great works. You are a true hero. Thank goodness you are here for all of us right now.
>
> No reply expected.
>
> To your continued good health for many many years to come!
>
> Sincerely,
> Alexandra Amonette
> [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 14 Mar 2020 19:22:47 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Use SARS Drugs

From: [redacted] (b) (6)
Sent: Saturday, March 14, 2020 3:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Use SARS Drugs

Dr. Fauci; In germany they found the drug camostat mesilate they used on SARS in 2003 kills the coronavirus in a petri dish. why wouldn't you give it a try? Will drug companies lose too much monies? Makes sense to use an already approved drug with little side effects. God is watching !!!!!!!!!!!!!

From: Folkers, Greg (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 14 Mar 2020 17:49:09 +0000
To: Halula, Madelon (NIH/NIAID) [E];Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Thank you - It's worth it

Thank you!

From: Halula, Madelon (NIH/NIAID) [E] (b) (6)>
Sent: Monday, March 9, 2020 10:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Thank you - It's worth it

Dear Dr. Fauci,
Thank you for being willing to step up publicly and have your life overtaken by the coronavirus.
This can't be easy and is likely to be harder in the coming weeks and months.
Know that we appreciate it and that I am willing to do whatever needs doing to help.

Sincerely,
Madelon Halula

Madelon Halula, PhD
Initiative Coordinator
Email: (b) (6)
Tel: (b) (6)
FAX: 240-627-3466
DHHS NIH NIAID DAIDS
Scientific Programs & Operations Branch
MSC 9831 (rm 8C48)
5601 Fishers Lane
Rockville, MD 20852-9831

.~ The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives. ~.

From: [redacted] (b) (6)
Sent: Sat, 14 Mar 2020 13:15:38 -0400
To: Mike Betts
Subject: Re: Coronavirus response

Thank you for your note.
A.S. Fauci

Sent from my iPhone

> On Mar 14, 2020, at 12:19 PM, Mike Betts [redacted] (b) (6)>wrote:
>
> I wanted to convey an idea I had with regard to the coronavirus. It seems to me that trying to contain the virus as we are doing at present will be futile. Since the virus can be present for many days without a person having any symptoms, you would literally need to test everyone at the same time to determine who has it--an impossible task.
>
> I have a different thought. We know that the virus is especially dangerous for the old and/or immunosuppressed. IMO we should be focusing all of our efforts on keeping that group from becoming infected. To do so that group should be encouraged to self-isolate, to limit their social interactions and other groups should be instructed to avoid them. Sort of a reverse-quarantine idea. All testing would be done within those groups and all groups would also be encouraged to continue with the hygienic suggestions they've already received.
>
> The problem right now is that the media has created a panic. Last night my wife and I went to the local Whole Foods and many of the shelves were empty and healthy younger people were wearing masks.
>
> The message is not getting out that the virus is almost solely dangerous to the elderly and immunosuppressed. [Why aren't the demographics being released? That in itself could calm many people.] With my suggestion, exposures to them would be diminished, significantly reducing the number of deaths, as well as

the potential impact on hospitals. Any person outside of that group that was severely affected could be identified and treated. Quarantining otherwise healthy people outside of those groups who finally demonstrate symptoms--like the NBA players--is ridiculous. They are likely to get the sniffles and have also already spread the virus. As long as they're not spreading it to the endangered group we should not worry about it.

In sum, we need to isolate the vulnerable and realize that the mortality rate for people outside of that group is likely lower than the flu.

Of course, while this occurs we are working on finding treatments and vaccines. But sending home workers who have next to no likelihood of being significantly impacted by this virus is ridiculous. The virus hits hardest the old and infirm, two groups that are most likely NOT to even be in the workforce!

To me, this solution is a lot simpler than what is being tried right now and is much more likely of success. To everyone besides the endangered group this virus is literally less dangerous than the flu. There is no reason that anyone outside of the endangered group should have any concern at all and we need to make that clear. Please let me know what you think.

Sincerely,

Michael Betts
(b) (6)

From: (b) (6)
Sent: Sat, 14 Mar 2020 13:14:36 -0400
To: Sharon Ganderson
Subject: Re: Subject. Virus recommendations

Thank you for your note.
A.S. Fauci

Sent from my iPhone

> On Mar 14, 2020, at 12:42 PM, Sharon Ganderson <(b) (6)>wrote:
>
> Dear Dr. Fauci:
> Thank you for your incredible dedication &expertise in dealing with the coronavirus situation. My concern is that when the President &the virus team and others are seen together they stand close together &shake hands. This has been ill advised by all the medical experts, including you.
> I m hoping you and the other experts will strongly advise changes in this behavior in accordance with current recommendations. We need them to set a good example for all.
>
> Many thanks for your help - it s greatly appreciated.
>
> Sharon Fink
> (b) (6)

From: (b) (6)
Sent: Sat, 14 Mar 2020 13:12:23 -0400
To: Adrienne DeLucca
Subject: Re: THANK YOU

Thank you for your note.
A.S. Fauci

Sent from my iPhone

> On Mar 14, 2020, at 1:04 PM, Adrienne DeLucca (b) (6)> wrote:
>
>
> Dear Dr. Fauci:
>
> My name is Adrienne DeLucca and I live in Connecticut. I am a Labor Attorney and represent almost 40,000 public school teachers. You may not read this until months from now as I know you are working tirelessly on the Coronavirus Task Force. I just felt the need to send you a quick note to thank you. Your expertise and presence during interviews and White House briefing has offered me so much comfort at such an anxiety ridden time. I have heard from so many friends and family members who feel the same way about you. Without your involvement we would be lost as yours is the most credible voice that we have come to rely on. Thank you for all you are doing for our country. We are all so lucky to have you. I pray that you and your family stay healthy.
>
> Sincerely,
> Adrienne DeLucca

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 14 Mar 2020 13:10:59 +0000
To: Celia Lewis
Subject: RE: No BS

Celia and Jim:
Thank you for your kind note.
Berst,
Tony

From: Celia Lewis <[redacted] (b) (6)>
Sent: Saturday, March 14, 2020 6:44 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: No BS

Dear Dr. Fauci:

My husband and I are both [redacted] (b) (6) so we've followed a lot of TV news regarding COVID-19.

We want to express our appreciation for your "no BS" presentation of the realities of the disease spread and what we, as a country, can expect.

We hear the politicians and the news anchors, but we find our comfort in the unwavering truth you deliver through the lens of your decades of experience and expertise.

And we thank you, more than you know.

Highest regards,
Celia and Jim Lewis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 14 Mar 2020 13:09:28 +0000
To: Diane Gaary
Subject: RE: Thank you

Thanks, Diane. I will try your suggestions.

-----Original Message-----
From: Diane Gaary (b) (6)
Sent: Saturday, March 14, 2020 7:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Thank you

Dear Dr Fauci,

Thank you.

Your efforts to inform and help all of us during the Covid-19 situation are greatly appreciated.

You are in our prayers.

Sincerely,

Diane Gaary

PS. I am a speaking voice teacher.
If your voice is tired from the constant talking, here are 2 easy suggestions:

1) a closed mouthed yawn (as one might do in a boring class) is a quick stretch and tension reliever for the entire vocal mechanism

2) 10-20 minutes of constructive rest (on your back with knees bent and head on a book to keep it inline with your spine) will put your spine into a passive traction and give your back and neck muscles a chance to rest and release

I know you don't have much time for this sort of thing, but decreasing your physical stress will help your voice tremendously and help you work even more efficiently.

Once again, Thank you for your knowledge commitment, and integrity.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 14 Mar 2020 13:05:46 +0000
To: Deb Webster
Subject: RE: Thank you

Deborah:
Thank you for your kind note.
Best,
Tony

-----Original Message-----
From: Deb Webster (b) (6)>
Sent: Saturday, March 14, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Thank you

Dr. Fauci,

I have been so very heartened and impressed with your forthcoming and rational communications and actions around the COVID-19 crisis. This includes your insistence on speaking truth to power and taking more aggressive steps in this combat.

Don't relent, and keep up the great work. We all need you.

I wish you well.

Deborah Webster
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 14 Mar 2020 12:58:29 +0000
To: William Templeton
Subject: RE: Thank you

William. Thank you for your kind note.
Best,
Tony

From: William Templeton [redacted] (b) (6)>
Sent: Saturday, March 14, 2020 8:33 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Thank you

I [redacted] (b) (6) as an Infectious Diseases physician in southern Indiana and Louisville.
During my career I cared for hundreds of individuals with HIV/AIDS and remember well your tireless efforts in this regard.
Even in the midst of the current coronavirus pandemic, your knowledge and expertise continue to prevail- a model for many. There has never been a more important time for dissemination of facts not blind faith.
Again, congratulations !

William C. Templeton, MD

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 14 Mar 2020 00:32:38 +0000
To: Bill Canavan
Subject: RE: REGIS v FORDHAM [redacted] (b) (6)

Billy:

Thank you so much for you note. You brought back a flash of happy memory that was wedged in the bottom of my brain. What a game that was! Billy Canavan and Donnie Walsh versus Tony Fauci and Artie Guarino. You guys were clearly better than we were; yet we won which proved to me then that anything is possible. Thanks again for bringing back such amazing memories. I hope that you are well and I wish you all the best.
Warm regards,
Tony

From: Bill Canavan [redacted] (b) (6)>
Sent: Friday, March 13, 2020 8:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: REGIS v FORDHAM ....1958 ...

TONY ...
BEAT CORONAVIRUS THE WAY YOU AND ARTIE BEAT DONNIE AND ME [redacted] (b) (6) REGARDS ...
BILLY CANAVAN ...

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 13 Mar 2020 17:54:56 +0000
To: Alecia Siuta;Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Thank you and how can I help? From the wife of a hospitalist

Dr. Fauci asked me to thank you for your note.

Best,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Alecia Siuta (b) (6)>
Sent: Friday, March 13, 2020 1:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)>
Subject: Thank you and how can I help? From the wife of a hospitalist

Dr. Fauci,

Thank you so much for being the honest, clear minded medical leader that our country needs right now. You are doing a superb job handling this difficult situation. My (b) (6) a hospitalist in State College, PA is on the front lines of this impending crisis in our community (he is (b) (6) and also works clinically for both internal medicine and pediatrics).

I appreciate the clear and easy to understand campaign to the general public to "flatten the curve" and slow the inevitable spread so that we don't overwhelm the medical community's capacity to care for the seriously ill. I suggest that to add to this campaign (especially given the serious lack of testing; currently he is waiting 4-7 days for test results for hospitalized suspected covid-19 patients) that you make it clear to the American public that they should NOT go to their doctor/hospital/urgent care and instead stay at home, isolate themselves, and make a phone call to their doctor's office or some sort of dept of health hotline.

If everyone with mild/moderate symptoms (and their immediate contacts) are bringing the virus into medical facilities, it greatly increases exposure and puts healthcare workers (and their families and communities) at unnecessary risk. We need to convey to the American public the importance of keeping our healthcare workers from falling ill (and into quarantine) so that they can treat those that absolutely need to be hospitalized. There also should be a mandated no visitor policy for suspected/confirmed patients at every point of care.

I am interested in helping in any way I am able. Please let me know what I can do to increase awareness and spread the vital messages you are trying to convey.

Thank you for your service and sacrifice for the greater good of the American people,

Sincerely,
Alecia Fay Siuta

(b) (6) [redacted]

Sent from my iPhone

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 13 Mar 2020 15:52:12 +0000
To: Lynda Hayashi;Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: drive up covid-19 tests for Washington State

Dr. Fauci wanted me to thank you for your note.

Best,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lynda Hayashi [redacted] (b) (6)
Sent: Thursday, March 12, 2020 10:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: drive up covid-19 tests for Washington State

If South Korea can make this happen why can't we? At least here in the most hardest hit state.
Please make this happen. We're all scared.
Lynda C. Hayashi
[redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Fri, 13 Mar 2020 09:23:12 -0400
To: NIAID Public Inquiries
Subject: Fwd: Coronavirus question - please read

Sent from my iPhone

Begin forwarded message:

> **From:** Zofia Agee [redacted] (b) (6)>
> **Date:** March 13, 2020 at 8:02:50 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Coronavirus question - please read**
>
> Dr. Fauci,
>
> I'm not a medical professional. I'm just someone who is paying attention to what is going on.
> I'm hearing that in many cases people have died because they developed pneumonia due to coronavirus. Since there is no coronavirus vaccine and won't be for a while can pneumonia be prevented by getting pneumonia vaccination? To me, that seems like a very logical course. I was actually trying to get that vaccine but I was turned away because I do not have any medical history showing that I need it and I'm not 65 yet. Could this be some way to lower the death while working on the vaccine? I have sent this to a few other places/people but not sure I'm reaching the right people, so I'm hoping it will reach you or someone in your office that will read it:).
> If we can not cure the virus yet, maybe we could get in front of it and prevent it from being deadly...
> Just a thought.
> Zofia Agee
>
> --
> Zofia Agee
> [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Fri, 13 Mar 2020 09:18:32 -0400
To: NIAID Public Inquiries
Subject: Fwd: thanks very much for your honesty and clear-eyed scientific integrity about coronavirus! an analysis you might want to read or share

Sent from my iPhone

Begin forwarded message:

> **From:** Jonathan Fritz [redacted] (b) (6)
> **Date:** March 13, 2020 at 8:31:51 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: thanks very much for your honesty and clear-eyed scientific integrity about coronavirus! an analysis you might want to read or share**
>
> Hello Dr. Fauci,
> I would like to thank you for being one of the few honest and trustworthy scientific voices
> as the world and the US confront the challenges of coronavirus. I was recently sent this thoughtful statistical analysis and thought you or one of your colleagues might wish to see it.
> best wishes, yours, Dr. Jonathan Fritz
>
> > **https://medium.com/@tomaspueyo/coronavirus-act-today-or-people-will-die-f4d3d9cd99ca**

From: [redacted] (b) (6)
Sent: Fri, 13 Mar 2020 09:16:52 -0400
To: Cassetti, Cristina (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: NK Cells for COVED-19

Pls respond.

Sent from my iPhone

Begin forwarded message:

> **From:** Jeffrey Miller <[redacted] (b) (6)>
> **Date:** March 13, 2020 at 8:53:29 AM EDT
> **Cc:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Re: NK Cells for COVED-19**
>
> Dr. Fauci,
>
> I am working with Ashley Haase and others at Minnesota to think through the feasibility and wisdom of this approach. Let me know your thoughts if you have the time. You look busy lately!
>
> Jeff
>
> On Fri, Mar 13, 2020 at 7:49 AM Julian Adams <[redacted] (b) (6)>wrote:
>
>> Dear Dr Fauci (Tony),
>>
>> You may remember me from the early 90's as I was the inventor of nevirapine, the first NNRTi. We met several times at NIAID and FDA. I have since turned my scientific interests to cancer research and discovered and developed Velcade for multiple myeloma. And I have changed career paths again, turning to immunotherapy to treat cancer. I am currently the CEO of Gamida Cell with a focus on cellular therapies.
>>
>> One of our programs is the expansion of allogeneic NK cells. We are collaborating with Dr Jeff Miller at the University of Minnesota and are administering 10-20 billion freshly expanded NK cells in combination with rituximab to patients with NHL. The results are stunning with 8/11 patients

achieving CR or very good PR with a single infusion. (see EBMT abstract below). In addition, the safety profile has been remarkably good since two thirds of our patients have Karnofsky performance <80. (NO CRS or Tumor lysis syndrome or neurotoxicity has been observed)

(b) (4)

[redacted]

I thank you in advance, and look forward to your response, (also copied is Dr Simantov, our Chief Medical Officer)

Warmest regards,

Julian Adams, PhD

EBMT Abstract: (the conference due to have taken place in Madrid is postponed but the abstract is available online)

RESULTS OF A PHASE 1 TRIAL OF GDA-201, NICOTINAMIDE-EXPANDED ALLOGENEIC NATURAL KILLER CELLS (NAM-NK) IN PATIENTS WITH REFRACTORY NON-HODGKIN LYMPHOMA (NHL) AND MULTIPLE MYELOMA

Veronika Bachanova[1], David McKenna[1], Xianghua Luo[1], Todd Defor[1], Murali Janakiram[1], Claudio Brunstein[1], Daniel Weisdorf[1], Erica Warlick[1], Rose Wangen[1], Fiona He[1], Joseph Maakaron[1], Zuzan Cayci[1], Bartosz Grzywacz[1], Guy Brachya[2], Tony Peled[2], Jeffrey

Miller[1] [1]University of Minnesota, Masonic Cancer Center, Minneapolis, MN, United States, [2]Gamida Cell, Jerusalem, Israel

Background: NK cells have the capacity to kill tumor targets and potential in cancer therapy. Limitations include specificity, persistence after infusion and how to maximize NK cell activity in vivo. We report results of a Phase 1 clinical trial of GDA-201, a cellular product composed of Natural killer (NK) cells from healthy donors expanded ex-vivo with nicotinamide (NAM) and IL-15, a unique ex vivo activation strategy to induce persistence. Prior in vitro studies and pre-clinical models demonstrated that NAM-exposed NK cells exhibit augmented resistance against exhaustion and improved killing function, proliferation, and organ trafficking. We report safety and preliminary efficacy from a phase I trial of GDA-201 in patients (pts) with relapsed or refractory (R/R) NHL or MM.

Methods: Following donor apheresis, CD3-depleted mononuclear cells were cultured for 14-16 days with NAM (5mM) and IL-15 (20ng/ml), resulting in a 40-fold increase in NK cells and increased expression of CD62L from 2.9% to 21%. GDA-201 contained ~98% NK cells, and CD3 content was maintained at <0.5% (<5x10^5/kg/dose). Pts with R/R B-cell NHL or MM received cyclophosphamide (400mg/m^2 IV x 3d) and fludarabine (30 mg/m^2 /d IV x 3d), followed by two doses of GDA-201 (Days 0 and 2) and low-dose IL-2 (6 million units sc). Pts with NHL or MM received rituximab (375 mg/m^2) or elotuzumab (10 mg/kg), respectively, x 3 weekly infusions to enhance NK cell targeting through antibody-dependent cellular cytotoxicity (ADCC).

Results: 25 pts were enrolled:11 with NHL (5 follicular, 5 diffuse large cell lymphoma, 1 mantle cell lymphoma) and 14 with MM, in 3 cohorts of escalating GDA-201 dose; 14 pts received the maximum target dose (median 1.7 x 10^8 cells/kg, range 1.6-2.0 x 10^8 cells/kg). There were no dose limiting toxicities. The most common grade 3/4 adverse events were neutropenia and thrombocytopenia, febrile neutropenia (n=2), increased creatinine, hyponatremia, pulmonary edema; all events were transient. There were no neurotoxic events, confirmed CRS, GVHD or marrow aplasia. One patient died of E-coli sepsis.

Among 11 NHL pts, there were 7 CR and 1 PR with an overall response rate of 72%. Median duration of response is 11 months (CR patients) and 3 months (PR patients). In MM patients, 1 patient with extramedullary disease had CR and 4 had SD with median duration 2.5 months. In our previous study using overnight activated NK cells, persistence 7 days after adoptive transfer was limited. Using GDA-201, flow cytometry confirmed the persistence of donor NAM-NK in peripheral blood up to day 7-10 (day 7 range 2-55% donor NK cells; Figure 1), as well as enhanced in vivo proliferation (median Ki67 99%). In addition, the enhanced expression of the homing receptor CD62L correlated with trafficking to bone marrow and lymph nodes in vivo as confirmed by flow cytometry of biopsied tissues at day 4.

Conclusions: Cellular therapy using GDA-201 with monoclonal antibodies was safe, and demonstrated early evidence of clinical activity in heavily pre-treated pts with advanced NHL and MM. Laboratory studies show that the GDA-201 product shows better persistence. Larger phase II studies are warranted.

Clinical Trial Registry: clinicaltrials.gov NCT03019666

Disclosure: Funding for the trial is provided by Gamida Cell. BMS is providing drug only support.

Veronika Bachanova: Research Funding Gamida Cell , Advisory Board: Gamida Cell

Julian Adams, Ph.D.

Chief Executive Officer

Gamida Cell

673 Boylston St 4th Fl

Boston, MA 02116

(b) (6)

Heather DiVecchia

Chief of Staff

Gamida Cell Ltd. Cell Therapy Technologies

673 Boylston Street, 4th Floor

Boston, MA 02116

Direct: + (b) (6)

[redacted] (b) (6)

www.gamida-cell.com

gamida cell

--

Jeffrey S. Miller, M.D.
Professor of Medicine
Deputy Director, Masonic Cancer Center
Division of Hematology, Oncology and Transplantation, University of Minnesota
Roger L. and Lynn C. Headrick Family Chair in Cancer Therapeutics

Regular Mail:
Division of Hematology, Oncology, and Transplantation
420 Delaware St. SE, Mayo Mail Code 806
Minneapolis, MN 55455

Federal Express or courier delivery:
University of Minnesota Cancer Center, Room 654A
425 E. River Road
Minneapolis, MN 55455

E-mail: [redacted] (b) (6)
Phone: [redacted] (b) (6) Fax: 612-626-3941
Hospital Operator: 612-273-3000 beeper# [redacted] (b) (6)

CONFIDENTIALITY NOTICE:Electronic messages can be misdirected or intercepted by unintended parties. The University of Minnesota can not and does not guarantee the confidentiality of messages sent over the Internet. Messages sent to or received from work e-mail accounts also may be monitored or viewed by your employer. If you have received this communication in error, please notify the sender immediately and delete the information.

From: (b) (6)
Sent: Fri, 13 Mar 2020 09:10:05 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: UV light for COVID-19 prevention

Sent from my iPhone

Begin forwarded message:

> **From:** David Levi (b) (6)>
> **Date:** March 13, 2020 at 9:06:16 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)
> **Subject: UV light for COVID-19 prevention**
>
> Thank you for all your hard work trying to deal with this horrible pandemic. Please consider ways to get UV light cleaning devices throughout the U.S. that they are currently using in Wuhan, China to attempt to contain this virus. Closed schools and sports venues can be cleaned with UV light while workers wear PPE and sunglasses to protect themselves. This pandemic could be seen as an opportunity to help prevent the spread of other contagious diseases by implementing rational public policy such as UV cleaning when schools and sporting events have concluded. It may also help "flatten the curve" and hopefully rebuild consumer confidence so we can resume activities such as travel and commerce that is vital for the healthy of not only our economy but our citizens.
>
> Thank you again for your work and your time.
>
> Sincerely,
>
> Dr. David Levi

From: [redacted] (b) (6)
Sent: Fri, 13 Mar 2020 09:09:39 -0400
To: NIAID Public Inquiries
Subject: Fwd: Metrics

Sent from my iPhone

Begin forwarded message:

> **From:** Steve Fisher <[redacted] (b) (6)>
> **Date:** March 13, 2020 at 9:06:43 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)
> **Subject: Metrics**
>
> Thanks for your hard work on Coronavirus. What we desperately need are specific metrics (available daily to everyone) on the disease. We also need to know how to evaluate them. When will we know if it is getting better? It is really as bad as the media would have us believe? Please set some goals and objectives on the metrics so we know where we are and know when we have won or lost.
>
> Yesterday Rush Limbaugh compared this to data on the Swine Flu in 2009 (60 million cases, 275,000 hospitalizations, 12,500 deaths from your website) and suddenly the Corona virus doesn't sound very bad at all. Yet we have shut down the world economy and done irreparable harm to many lives. Can you explain this? Frankly no one even remembers the Swine Flu epidemic only 10 years ago.
>
> **Stephen Fisher**
> [redacted] (b) (6)

From: (b) (6)
Sent: Fri, 13 Mar 2020 07:22:03 -0400
To: Morris Flaum
Subject: Re: Thank you

Thanks, Morris. I appreciate your note

> On Mar 13, 2020, at 12:37 AM, Morris Flaum (b) (6)>wrote:
>
> Dear Tony,
>
> I had the good fortune of working with you and Harvey Gralnick when I was a Clinical Associate at the NIH from 1977-1979.
>
> I am writing to express my deep appreciation for speaking truth to power and being one of the few honest voices in the government at this time of crisis.
> Your confidence and approach to articulating the issue and ramifications have provided critical information to the American population.
> Although COVID-19 is a unique event, we would have been much better prepared had you been leading the efforts in dealing with this outbreak.
>
> The US owes you a great deal of gratitude.
>
> Morris Flaum
>
> **Morris A Flaum, MD, MBA**
> **Flaum Consultants, LLC**
> **Consultant to the Healthcare Industry**

From: [redacted] (b) (6)
Sent: Fri, 13 Mar 2020 07:18:58 -0400
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: Trial by fire?

Please handle

Begin forwarded message:

> **From:** Aaron Harber [redacted] (b) (6)
> **Date:** March 13, 2020 at 6:52:52 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Trial by fire?**
>
> Dear Tony,
>
> You're doing a great job under terrible circumstances so I hope you hang in there. I'm sure the President is driving you nuts at times.
>
> I know you're probably far too busy to do yet another program with me (**HarberTV.com/Fauci**) but, if you can send me a couple of quick answers this morning, that would be great.
>
> 1. Do you think it's realistic we could have an effective vaccine for the COVID-19 virus by this Fall? My guess is it will be more like the Fall of 2021 but tell me if I might be wrong.
>
> 2. Given that we've known about the probability of a pandemic, why are we so poorly prepared to address it (e.g., masks, testing kits, medical staffing et cetera)? I realize most of the needs rarely occur and when they do, there are extraordinary spikes in demand for certain products and expertise but one would think there are ways to address this far better than we have.
>
> 3. Is there anything people should know that is not being emphasized?
>
> Thanks for any response you can send, even if it's a few words. And keep up the good work. You are greatly appreciated.
>
> Best wishes,
>
> *Aaron*
>
> Aaron@HarberTV.com

P: (b) (6)(+voicemail) C: (b) (6) (+texts)
HarberTV.com/Info + HarberTV.com/Award

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 13 Mar 2020 01:26:08 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Moderna trial

Need less to say, [redacted] (b) (5).

-----Original Message-----
From: Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6)>
Sent: Thursday, March 12, 2020 8:23 PM
To: Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)>
Cc: Stecker, Judy (OS/IOS) [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>; Mango, Paul (HHS/IOS) [redacted] (b) (6); Harrison, Brian (HHS/IOS) < [redacted] (b) (6)>; Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6)>; Richardson, Juliana (HHS/OS/OGA) [redacted] (b) (6)
Subject: Re: Moderna trial

Correct - as of right now. [redacted] (b) (5).

Will let you know if there is an unforeseen delay.

On Mar 12, 2020, at 7:19 PM, Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6) wrote:
>
> Hilary,
>
> Paul mentioned that [redacted] (b) (5)
>
> Please let us know soonest.
>
> Many thanks!
>
>
>
>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 11 Mar 2020 10:28:35 +0000
To: [redacted] (b) (6) (OS/IOS);Giroir, Brett (HHS/OASH)
Cc: Harrison, Brian (HHS/IOS);Stecker, Judy (OS/IOS);Redfield, Robert R. (CDC/OD)
Subject: RE: High Risk from CDC Website

Just checked the CDC guidance, which I had not had the time to read before. **The secretary was correct** Here it is: [redacted] (b) (5) (b) (5)

From: [redacted] (b) (6) (OS/IOS) [redacted] (b) (6)>
Sent: Wednesday, March 11, 2020 5:28 AM
To: Giroir, Brett (HHS/OASH) [redacted] (b) (6)>
Cc: Harrison, Brian (HHS/IOS) [redacted] (b) (6)>; Stecker, Judy (OS/IOS) [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6)
Subject: Re: High Risk from CDC Website

Thanks Brett. Tony and Bob, [redacted] (b) (5) (b) (5)

On Mar 10, 2020, at 6:59 PM, Giroir, Brett (HHS/OASH) [redacted] (b) (6) wrote:

<Picture (Device Independent Bitmap) 1.jpg>

Brett P. Giroir, MD
ADM, US Public Health Service

Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 11 Mar 2020 01:59:54 +0000
To: Stecker, Judy (OS/IOS);Redfield, Robert R. (CDC/OD)
Cc: Conrad, Patricia (NIH/NIAID) [E];McGowan, Robert (Kyle) (CDC/OD/OCS);Lepore, Loretta (CDC/OD/OCS);Murphy, Ryan (OS/ASPA)
Subject: RE: URGENT- [redacted] (b) (5)

I am ok with this

From: Stecker, Judy (OS/IOS) [redacted] (b) (6)
Sent: Tuesday, March 10, 2020 9:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>; Lepore, Loretta (CDC/OD/OCS) [redacted] (b) (6); Murphy, Ryan (OS/ASPA) [redacted] (b) (6)>
Subject: URGENT- [redacted] (b) (5)

I understand you both know what this is regarding. Are you good with this?

[redacted] (b) (5)

Sent from my iPhone

From: [redacted] (b) (6)
Sent: Sun, 8 Mar 2020 09:02:09 -0400
To: Bright, Rick (OS/ASPR/BARDA)
Cc: Lane, Cliff (NIH/NIAID) [E]
Subject: Fwd: IL6 R

Rick;
See below.
Tony

Begin forwarded message:

> **From:** "Lane, Cliff (NIH/NIAID) [E]" < [redacted] (b) (6)
> **Date:** March 7, 2020 at 11:33:28 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Re: IL6 R**
>
> [redacted] (b) (5)
>
> If possible, it would be of interest to receive a copy of the Chinese treatment guidelines you reference.
> Thanks,
>
> > On Mar 7, 2020, at 10:13 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>wrote:
> >
> > Please advise.
> >
> > ---
> >
> > **From:** Bright, Rick (OS/ASPR/BARDA) [redacted] (b) (6)
> > **Sent:** Saturday, March 7, 2020 3:18 PM
> > **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>
> > **Cc:** Walker, Robert (OS/ASPR/BARDA) [redacted] (b) (6); Disbrow, Gary (OS/ASPR/BARDA) [redacted] (b) (6); Johnson, Robert (OS/ASPR/BARDA) [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6); Redd, John (OS/ASPR/SPPR) [redacted] (b) (6)
> > **Subject:** Fwd: IL6 R

Dr Fauci,

I know that Dr Kadlec has mentioned the news we heard from genentech about the evaluation of monoclonal antibodies to IL-6 and IL-6R in severely ill COVID-19 patients in China.

Additional information became available yesterday and we learned that China updated Their clinical guidelines to include anti-IL6.

(b) (4)

[redacted]

(b) (5)

[redacted]

I welcome your thoughts and would also make our team available for a quick call if you prefer.

Many thanks. I know you are very busy.

Rick

Begin forwarded message:

(b) (4)

[redacted]

(b) (4)

[redacted]

(b) (4)

[redacted]

From: [redacted] (b) (6)
Sent: Sat, 7 Mar 2020 15:35:47 -0500
To: Lane, Cliff (NIH/NIAID) [E]
Subject: Fwd: IL6 R

Sent from my iPhone

Begin forwarded message:

> **From:** "Bright, Rick (OS/ASPR/BARDA)" [redacted] (b) (6)
> **Date:** March 7, 2020 at 3:18:02 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" < [redacted] (b) (6), "Kadlec, Robert (OS/ASPR/IO)" < [redacted] (b) (6)>
> **Cc:** "Walker, Robert (OS/ASPR/BARDA)" [redacted] (b) (6)>, "Disbrow, Gary (OS/ASPR/BARDA)" [redacted] (b) (6)>, "Johnson, Robert (OS/ASPR/BARDA)' [redacted] (b) (6)>, "Marston, Hilary (NIH/NIAID) [E]" [redacted] (b) (6) "Shuy, Bryan (OS/ASPR/IO)" [redacted] (b) (6)>, "Redd, John (OS/ASPR/SPPR)" < [redacted] (b) (6)
> **Subject: Fwd: IL6 R**
>
> Dr Fauci,
> I know that Dr Kadlec has mentioned the news we heard from genentech about the evaluation of monoclonal antibodies to IL-6 and IL-6R in severely ill COVID-19 patients in China.
> Additional information became available yesterday and we learned that China updated Their clinical guidelines to include anti-IL6.
> [redacted] (b) (4)
> [redacted] (b) (5)
> Many thanks. I know you are very busy.
> Rick
>
> Begin forwarded message:

(b) (4)

[redacted]

(b) (4)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 11 Mar 2020 02:58:28 +0000
To: Redfield, Robert R. (CDC/OD);Birx, Deborah L. EOP/NSC
Subject: RE: County specific guidance
Attachments: Seattle_Community_Mitigtion_3_10 as version final with minor Fauci edits..docx, Santa Clara_Community_Mitigtion_3_10 as (002) - with Fauci minor edits.docx

Bob:
They look pretty good. I have made a few minor changes that are tracked in the attached documents.
Best regards,
Tony

From: Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>
Sent: Tuesday, March 10, 2020 6:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Birx, Deborah L. EOP/NSC [redacted] (b) (6)
Subject: Fwd: County specific guidance

Draft I am reviewing now but wanted you both now so not delay
Get Outlook for iOS

From: Schuchat, Anne MD (CDC/OD) [redacted] (b) (6)>
Sent: Tuesday, March 10, 2020 5:58:15 PM
To: Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>
Cc: Cohn, Amanda (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [redacted] (b) (6)>; Redd, Stephen (CDC/DDPHSIS/OD) [redacted] (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>; Schuchat, Anne MD (CDC/OD) [redacted] (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6); Berger, Sherri (CDC/OCOO/OD) [redacted] (b) (6)>; Warner, Agnes (CDC/OD/OCS) [redacted] (b) (6)>
Subject: FW: County specific guidance

Dr Redfield: Attached please find [redacted] (b) (5) (b) (5)

Note that if you are trying to send to Debbi Birx she mentioned that things going to her CDC email will not reach her so you may want to include Olivia Troye to make sure to meet your deadline.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 17:54:45 +0000
To: Mermin, Jonathan (CDC/DDID/NCHHSTP/OD)
Subject: RE: Great talk

Jon:

Thank you for your kind note. It is much appreciated. I hope that you are well.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mermin, Jonathan (CDC/DDID/NCHHSTP/OD) [redacted] (b) (6)>
Sent: Tuesday, March 10, 2020 1:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Great talk

Tony:

Superb presentation on COVID-19 today! [redacted] (b) (5) Excellent work with the media, Congress, and scientific community--you have made a great difference for the nation and world in a complex time.

Best,

Jono

From: [redacted] (b) (6)
Sent: Fri, 13 Mar 2020 06:26:43 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Urgent information about a Corona Virus Management Device
Attachments: Medixair Micro virus report.pdf, ATT00001.htm, Medixair White Paper - 2016 Jan.pdf 1.pdf, ATT00002.htm

Please handle

Begin forwarded message:

> **From:** Ani John [redacted] (b) (6)>
> **Date:** March 13, 2020 at 3:13:38 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Urgent information about a Corona Virus Management Device**
>
> Dear Dr. Fauci
> Given the gravity of the corona pandemic, my brother and I are reaching out to make you aware of product that we think could help mitigate the spread of the virus and protect health care workers as well as the public. We have already tried the usual channels to contact the White House and the emergency authorization use division at the FDA but also wanted to bring this to your attention also.
>
> Medixair^{TM}, an ultraviolet (UVc) air sterilizer with proven, well established unique patented germicidal technology to effectively and safely eradicate viruses and bacteria up to 99.9%. It is capable of delivering a log6 reduction in microbial concentration, by penetrating the nucleus of microorganisms, disrupting their DNA thus destroying the ability of the organism to reproduce; effectively rendering it harmless.
>
> Medixair^{TM} is a portable unit and can easily be installed in a variety of settings including hospitals, emergency rooms, waiting rooms, dentist offices, cruise ships and airport lounges. In both clinical trials and under in-vitro testing conditions (see attached white paper), Medixair^{TM} has been demonstrated to be highly effective in protecting patients and health care workers from pathogens (e.g. MRSA, Clostridium Difficile) and also by preventing cross infection. Specifically, Medixair^{TM} was tested and found effective for a strain of Coronavirus known as FCoV and thus COVID-19 would have the same susceptibility to eradication with UVc within a relatively short period of time (attached).

Medixair^{TM} has been on the market since 2005 and is fully CE marked to EN standards. Currently it has been safely and effectively used in acute hospitals, dental surgeries, in UK, Malaysia, India, Israel, and Southern Africa.

Please let us know how we can help make these units available for use in the US during this critical period of time.

Kind regards,

Ani John, BSN, MPH, PhD
San Ramon, California

Mathew Kaye,
Manufacturer of Medixair^{TM}
Dudley, United Kingdom

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 13 Mar 2020 03:19:54 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Question from Jefferson Health NE Philadelphia

Please respond or refer.

From: Robert Danoff [redacted] (b) (6)
Sent: Thursday, March 12, 2020 11:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Question from Jefferson Health NE Philadelphia

Hi Dr. Fauci,

Hope all is well.

Dr. Fauci, we will be setting up COVID-19 testing facilities and I wanted to ask your opinion regarding the following:

Is it ok to expand our testing beyond the current strict testing criteria to include those with lesser symptoms or potential exposure whom we want to rule out Covid-19?

We are concerned that while we isolate those with more severe symptoms who currently qualify for testing, the majority with lesser symptoms would be ambulatory and potentially spreading the illness to others. Plus, it is hard to get someone to isolate for 14 days without providing a diagnosis.

Just as we can test those we suspect for Influenza A, Influenza B and RSV, it would be helpful to be able to test those we suspect with Covid-19, including healthcare workers with no symptoms but with possible exposure.

Thank you for your time and your leadership for our nation's healthcare.

Be well.

Rob

Rob Danoff DO, MS, FACOFP, FAAFP

Program Director, Family Medicine Residency

Program Director, Combined Family Medicine/Emergency Medicine Residency

Jefferson Health - Northeast

Clinical Professor of Family and Community Medicine

Sidney Kimmel Medical College of Thomas Jefferson University

(b) (6)

Jefferson
Philadelphia University +
Thomas Jefferson University
HOME OF SIDNEY KIMMEL MEDICAL COLLEGE

The information contained in this transmission contains privileged and confidential information. It is intended only for the use of the person named above. If you are not the intended recipient, you are hereby notified that any review, dissemination, distribution or duplication of this communication is strictly prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.

CAUTION: Intended recipients should NOT use email communication for emergent or urgent health care matters.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 13 Mar 2020 03:18:51 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Varicella vaccine-COVID-19 connection

Please respond.

From: Rose Marie Codling <rosemarie@literacymatters.education>
Sent: Thursday, March 12, 2020 11:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Varicella vaccine-COVID-19 connection

Dr. Fauci,
Is it possible that the varicella vaccine could be playing a role in why children are not presenting with the COVID-19 virus? If the vaccine became common around 1995, we would be seeing little to no infection of children and young adults up to about 25 years old, which seems to be the case. Could something in the varicella vaccine have provided immunity to COVID-19?

Just an idea from a concerned citizen...

Thank you for your remarkable leadership during this crisis.
Sincerely,
Rose Marie Codling

--
Rose Marie Codling, Ph.D.
Educational Consultant

Literacy
MATTERS LLC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 13 Mar 2020 01:23:58 +0000
To: Collins, Francis (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E]
Cc: Erbelding, Emily (NIH/NIAID) [E]
Subject: RE: ASM Recommendations for speeding up COVID-19 testing

I would [redacted] (b) (5)

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Thursday, March 12, 2020 8:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: ASM Recommendations for speeding up COVID-19 testing

Hi Tony and Larry,

Bit of a story here - [redacted] (b) (5) (b) (5)

Thoughts would be most welcome.

Francis

From: Collins, Francis (NIH/OD) [E]
Sent: Thursday, March 12, 2020 8:07 PM
To: Bertuzzi, Stefano [redacted] (b) (6)>; [redacted] (b) (6)
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6); [redacted] (b) (6); Miller, Melissa [redacted] (b) (6); Stevens-Garcia, Jonathan [redacted] (b) (6)>; Segal, Allen [redacted] (b) (6); McNult, Peggy [redacted] (b) (6)>
Subject: RE: ASM Recommendations for speeding up COVID-19 testing

Hi Stefano,

Thanks for this rapid turnaround survey and concise recommendations.

Adam, I'm glad to help with conveying this message to FDA – though we should involve ADM Giroir as well. How would you like to proceed?

Francis

From: Bertuzzi, Stefano [redacted] (b) (6)>
Sent: Thursday, March 12, 2020 7:57 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6); Miller, Melissa [redacted] (b) (6)>; Stevens-Garcia, Jonathan [redacted] (b) (6)>; Segal, Allen [redacted] (b) (6)>; McNult, Peggy [redacted] (b) (6)
Subject: ASM Recommendations for speeding up COVID-19 testing

Dear Francis and Adam –

Sorry for the slight delay in getting to you the recommendations that ASM collected from clinical lab directors. See attached document.

ASM leaders remain available for any further discussion that may be helpful to solve the current impasse. Please do not hesitate to contact us, we are here to serve as a resource to you.

Sincerely,
Stefano

Stefano Bertuzzi, Ph.D., M.P.H.
Chief Executive Officer
American Society for Microbiology (ASM)
1752 N St., NW
Washington, DC 20036-2904
Phone [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 12 Mar 2020 23:20:57 +0000
To: Tabak, Lawrence (NIH/OD) [E];Collins, Francis (NIH/OD) [E]
Subject: RE: Time-sensitive

Please be "presumptuous" and go for it. Many thanks.

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Sent: Thursday, March 12, 2020 7:18 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Time-sensitive

Francis, Tony-

I am certainly willing to do this so that neither of you have to, but I did not want to be presumptuous in case either of you preferred a different spokesperson.
Please let me know how I should respond to Mary.

Thanks
Larry

From: Mary Woolley <mwoolley@researchamerica.org>
Date: Thursday, March 12, 2020 at 10:02 AM
To: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)
Cc: Ellie Dehoney <edehoney@researchamerica.org>
Subject: Time-sensitive

Larry,

I have a favor to ask. Would you or a designee be willing to join a teleconference next week with our alliance members to discuss NIH's efforts to mitigate the negative impact of COVID-19 on federally-funded research? We would need no more than 30 minutes of your time, and can schedule around you. Ideally, though, we could make this happen soon (to state the obvious, everyone is feeling the need for touchpoints right now, and you are a wonderfully calming one for our university members!).

We could arrange the teleconference for as early as this Monday, the 16th: if there is a 30-minute window for you or a designee between 1:00 pm and 3:00 pm on that day or within that same block of time Tuesday, the 17th, we'll commandeer it!

Thank you, Larry, for considering this ask. I'm sure it comes amidst many others.

I would love to close by saying something insightful about the indescribable times we were in, but all I can come up with is "indescribable."

My Best,

Mary

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 12 Mar 2020 23:10:14 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Feds say Florida has 'community spread' of coronavirus. Florida disagrees.

Check this out and get back to me. Not sure what he is talking about.

From: Robert Tober [redacted] (b) (6)>
Sent: Thursday, March 12, 2020 6:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Nancy Lascheid [redacted] (b) (6)>; Gail Dolan [redacted] (b) (6); Leslie Lascheid [redacted] (b) (6)
Subject: Fw: Feds say Florida has 'community spread' of coronavirus. Florida disagrees.

Dear Dr. Fauci,

I am medical director of a charity clinic in Naples, Florida. Although we try to screen pts for cough, fever, sore throat, URI sxs, dyspnea or unusual fatigue, apparently some patients are asymptomatic and neg for these 5 hallmarks but still contagious. There is conflict between what our Florida governor states and what CDC states. Do you believe all of our staff should be in goggles, mask, gown and gloves for AAL PATIENTS that we treat regardless of not meeting one of the 5 screening criteria above. If indeed there is community spread happening, I and many others are sitting ducks. It is not if but when!!
Thanks for any guidance you might be able to provide. I am copying to my administrative staff as well.

Good luck. This is quite the challenge.

Robert Boyd Tober, M.D., FACEP
Medical Director Neighborhood Health Clinic
Naples, Florida 34102
[redacted] (b) (6) -cell

To: Bob Tober [redacted] (b) (6)
Sent: Thursday, March 12, 2020, 04:46:08 PM EST
Subject: Feds say Florida has 'community spread' of coronavirus. Florida disagrees.

https://www.tampabay.com/news/health/2020/03/11/feds-say-florida-has-community-spread-of-coronavirus-florida-disagrees/

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 12 Mar 2020 23:07:14 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Hi Dr Fauci (re: URGENT: epiqar Systems & Coronavirus 2nd tier events)

Please handle.

From: Jason Ressler (b) (6)
Sent: Thursday, March 12, 2020 6:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Hi Dr Fauci (re: URGENT: epiqar Systems & Coronavirus 2nd tier events)

Hi Dr. Fauci,

epiqar (https://epiqar.com/) is the only system in the world that can help experienced surgeons continue to support teams of less experienced surgeons worldwide, which we're doing with Coronavirus quarantined surgeons in France & Italy now while we expand to other theaters.

For Coronavirus care we've just developed an easy plug in kit for remote hospital surgeries which US hospitals need to be made aware of before they get overwhelmed the way they are in Italy & China.

Here's an article on **epiqar** from today inThe Hill.

Please let me know how we can help your teams.

Thanks,

Jason Ressler
Director, Business Development
ENGAUGE/EPIQAR
www.eng.us
www.epiqar.com
The world's first low-cost telementoring, surgeon training and instant Cloud-archiving Platform
US 888.615.7874
EUROPE 44 2031399059

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 12 Mar 2020 23:06:46 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Very urgent Coronavirus [redacted] (b) (6)

NIAID inquiries, please.

From: Sushama Talwalkar [redacted] (b) (6)>
Sent: Thursday, March 12, 2020 7:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>
Subject: Very urgent Coronavirus [redacted] (b) (6)

March 12, 2020
Dr. Fauci,

[redacted] (b) (6)

Sincerely,
Sushama

Get Outlook for Android

From: [redacted] (b) (6)
Sent: Thu, 12 Mar 2020 14:22:38 -0400
To: El-Sadr, Wafaa M.
Subject: Re: Thank you

Thanks, Wafaa

> On Mar 11, 2020, at 8:33 PM, El-Sadr, Wafaa M. [redacted] (b) (6) wrote:
>
> Adding Tony's correct email address.
>
> Dear Zunyou, John, Ralph and Tony,
>
> Thank you for your superb presentations in the Special COVID-19 Session at the Virtual CROI 2020. As you can imagine, your presentations were very much appreciated by all the audience. There is great thirst for more information at this point in time, which made your presentations particularly timely and impactful.
>
> All the best,
> Wafaa
>
> Wafaa El-Sadr, MD, MPH, MPA
> Director, ICAP at Columbia University
> University Professor of Epidemiology and Medicine
> Mathilde Krim-amFAR Professor of Global Health
> Tel: [redacted] (b) (6)
> Fax: 212 342 1824
> www.icap.columbia.edu

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 12 Mar 2020 14:09:11 +0000
To: O'Donnell, Norah;Fauci, Anthony (NIH/NIAID) [E]
Cc: Verdugo, Adam
Subject: RE: Thursday night

WE are working with Adam. Thank you

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Donnell, Norah <NOD3@cbsnews.com>
Sent: Thursday, March 12, 2020 9:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Verdugo, Adam <VerdugoA@cbsnews.com>
Subject: Thursday night

Dear Tony and Patricia,

Hoping for tonight from the White House or in studio. Adam Verdugo has been in touch and hope we can lock down and confirm time.

Thank you 🙏□🙏□🙏□

Norah O'Donnell

On Mar 9, 2020, at 8:53 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:

External Email

Norah:

Sorry that I took so long to get back to you. Just got out of the White House a little while ago to get to my office where I am now and it is obviously too late. Please copy my assistant, Patty Conrad, (copied here) in future correspondence. I am so swamped with coronavirus "stuff", I rarely get to e-mail until late at night.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Donnell, Norah <NOD3@cbsnews.com>
Sent: Monday, March 9, 2020 10:33 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Verdugo, Adam <VerdugoA@cbsnews.com>
Subject: Monday night

Dear Dr. Fauci,

You are doing an amazing job helping to educate and inform during this crisis.

Are you available tonight or any night this week to join us for the Evening News?

I am also happy to come to your office.

Thank you for your consideration.

Norah O'Donnell

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 12 Mar 2020 10:48:06 +0000
To: Arthur Ammann
Subject: RE: Art again

Art:

Good idea. I will mention this to CDC during this AM's daily meeting. Hope that you are well.

Best,

Tony

From: Arthur Ammann [redacted] (b) (6)
Sent: Wednesday, March 11, 2020 9:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Art again

Tony. So good to see you now on TV in full charge. Your entire expression has changed almost like when I bumped into you in the Washington Metro after you had gotten off the plane with President Bush.

I have an interesting question regarding pneumococcal polysaccharide immunization. One of our staff members phoned. Her father is a physician in France and has many physician acquaintances. She was told that the doctors believe that the older patients who received pneumococcal vaccine have less of a mortality than those who did not get the vaccine.

When we did the studies and got the pneumococcal vaccine approved for the elderly in 1976 there was a battle about who should get it and whether was cost-effective. Since then, other studies have documented the benefit, especially in older people and you probably have received it. It is now routine but I know many elderly individuals have not gotten immunized. Historically, many, if not the majority of deaths from influenza in some of the past epidemics was a result of secondary infection with pneumococcus. I'm not hearing anything about urging people to get immunized with pneumococcal vaccine. The message would need to be clear so they don't confuse pneumococcal secondary infection with primary coronavirus infection. It would be a good idea for people to be urged to get the pneumococcal vaccine. If they had not received it. I'm not seeing any recommendations from the CDC or elsewhere regarding this.

--

Please note: this document has been produced by a voice recognition program and may contain errors or words that are out of context. Please let me know if clarification is required.

Arthur J Ammann M.D.

(b) (6)

www.GlobalStrategies.org
Ethics in Health
http://ethicsinhealth.org/

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 12 Mar 2020 10:23:36 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: News - Germ/Virus Containment
Attachments: XTI Deck - Key Information OSHA.pdf

Please handle.

From: [redacted] (b) (6)
Sent: Thursday, March 12, 2020 6:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: News - Germ/Virus Containment
Importance: High

Hi Dr. Fauci,

I have been following the news and some interviews with yourself. I was hoping you would be willing to speak with me about our technology?

Testing for the positive patients and finding a vaccine are essential, but containment is paramount.

We have the only GERM CONTAINMENT TECHNOLOGY of it's kind.

The ongoing Coronavirus and FLU viruses pose a significant threat to public health globally and here in the US.
We have the most powerful solution to minimize infection and maximize protection against SARS, EBOLA, FLU, and all types of germs and viruses.

With local 3rd party tested efficacy of 100%, no other technology anywhere can yield this result or sustainable 24/7/365 protection.

XTIO2 is a world exclusive containment technology with self-cleaning functions that can help minimize the risk of cross-contamination in hospitals, planes, public transportation, elevators, and public places.

XTIO2 technology works by forming an invisible protective layer on mostly ALL material surfaces (plastic, steel, glass, fabric, paper, walls, etc...). It is green, sustainable, and has yielded up to 100% efficacy proven by SGS LABS (US).

I look forward to hearing from you and attached is an information file for your review.

Thank you,

Michael Holbert

Cleancoating LLC
2522 State Rd., BLDG ISPBC
Bensalem, PA 19020
http://www.cleancoating.us
Email: (b) (6)
Direct: (b) (6)
Mobile: (b) (6)

DISCLAIMER
This e-mail message is intended for sole use of the above named recipient(s). If you are not the intended recipient, you may not review, copy or forward this e-mail message. If you have received this communication incorrectly, please notify Clean Coating Technologies LLC immediately via e-mail or phone and delete the message accordingly.

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 19:14:07 -0400
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: Fwd: CORONAVIRUS DATA SUPPORTING PROACTIVE EFFORT

Begin forwarded message:

> **From:** dennis malone [redacted] (b) (6)>
> **Date:** March 11, 2020 at 6:35:32 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: CORONAVIRUS DATA SUPPORTING PROACTIVE EFFORT**
>
> SIr,
>
> I appreciate the effort of your entire team in identification and resolution of the predicament the chinese government has gotten us into. That said, I believe you might add a more proactive edge by mining existing data. You're going to have to dig deep.
>
> It seems that the common denominator in originating vector, at least by your news releases, is plainly travel-related co-mingling of persons not otherwise in contact. Therefore, I would propose that there is a great trove of existing data waiting to be filtered within the travel manifests' history of US-bound airlines and US-bound cruise vessels. Suggest as a start the collection of every manifest from the last 4 months or so, filtered and compared with principle contractees known to exist in the US, and list every other person on said aircraft/vessel that disembarked on US soil. DO NOT WAIT FOR PEOPLE TO GET SICK - Employ the National Guard and Coast Guard to track these folks and put a swab in their nose. If positive, then contact trace this smaller group. If negative maintain them on the list and force compliant reporting if they develop suspected symptoms.
>
> I know it would seem to be a lot of work. However, I presume your are familiar with the FRAM Oil FIlter Guy from the 1970s, where it's better to pay now than later because you're going to pay one way or another. Get a proactive jump on DETECTION, IDENTIFICATION, CONTROL. We're burning daylight.
>
> Respectfully submitted,
>
> Dennis J. Malone
> [redacted] (b) (6)

(b) (6) [redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 11 Mar 2020 23:10:18 +0000
To: Sharon Cumbie
Subject: Re: Need to add cell phone disinfecting to the hand washing messaging
Attachments: image.png, POSTING.jpg

Thanks!

> On Mar 11, 2020, at 6:46 PM, Sharon Cumbie [redacted] (b) (6)> wrote:
>
> Dr. Fauci,
>
> First, thank you for all you are doing to keep the public informed in a clear, direct, and truthful manner. I am writing to offer a suggestion.
> The following is a post I just placed on my Facebook page:
>
> It's a 2-step process!!!
> We are seeing the ubiquitous pleas for proper hand-washing as a preventative against contracting the corona virus. BUT...I have observed people doing a great job of hand-washing, then picking up their dirty cell phones!! The cell phone should FIRST be wiped down using a disinfecting wipe (do NOT use sprays or household cleaning supplies). After cleaning the phone, THEN do a proper 20 second hand-washing. Now, CARRY ON!
>
> Step 1: https://www.tomsguide.com/news/how-to-clean-your-phone-to-protect-against-coronavirus?fbclid=IwAR1WHGawAANytkUQSmSV2SM-UcZ57761mAsp-XRkUEKDsLYhcLRKXFBOJio
>
> Step 2: Proper Hand Washing
> <image.png>
>
> Photo message montage:
>
> <POSTING.jpg>
>
> I honestly do not see people disinfecting their cell phones. I am active in our [redacted] (b) (6) community and am trying to get this information across to people in the community. They have told me it was helpful and something they had not considered. I thought it would be helpful for me to share with you.
> Best Regards,
> Sharon Cumbie
> --

Sharon Ann Cumbie, PhD, RN, CS, CNE
[redacted] (b) (6)

Professor of Nursing [redacted] (b) (6)
Research and Education Consultant, Certified Nurse Educator
Mental Health Counselor
[redacted] (b) (6)

Skype: [redacted] (b) (6)



(a) Wet hands under running water

(b) Apply soap and rub palms together to ensure complete coverage

(c) Spread the lather over the backs of the hands

(d) Make sure the soap gets in between the fingers

(e) Grip the fingers on each hand

(f) Pay particular attention to the thumbs

(g) Press fingertips into the palm of each hand

(h) Dry thoroughly with a clean towel

https://www.facebook.com/MedicalHumour

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 19:08:46 -0400
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: Fwd: Coronavirus

Please handle

Begin forwarded message:

> **From:** Terri Davis [redacted] (b) (6)
> **Date:** March 11, 2020 at 7:04:02 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Coronavirus**
>
> Dear Dr. Fauci;
> I live in [redacted] (b) (6) Last week there was the first incidence of the Coronavirus. The officials in Media gave no true information on the individual but that it was a female. When questioned by the press as to the location in which the individual was - the response was that that information could not be given. I have also heard that it is in a violation of a person's privacy. No one is asking for the person's name or address. If the public were given the general area of the affected person they would probably stay clear of the area. The people directly in the area would be more cautious. Knowing where the person frequented, for example, the market would be pertinent in preventing spread of this virus. There is so much information about this virus that is unknown yet most officials continue to underscore the severity of this virus.
>
> Sincerely,
> Terri Davis
>
> Sent from my iPad

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 19:08:05 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Application for NIH and Dr. Bruce Aylward from W.H.O.

Please handle

Begin forwarded message:

> **From:** David Craig [redacted] (b) (6)>
> **Date:** March 11, 2020 at 7:05:42 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Subject: Re: Application for NIH and Dr. Bruce Aylward from W.H.O.**
>
> Evening Dr. Fauci,
> My name is David Craig and I am one of the Founders of the Medsoft Group, a Analytics, Telemetry and Reporting medical platform out of Canada. We would like to offer our solution to the NIH free of charge, much like we have done with Dr. Bruce Aylward and the World Health Organization earlier today.
> Our application will track, log and provide a pathway to true two-way real time communication of COVID-19 as citizens around the US report their symptoms on their mobile device. We are currently implementing our technology with our partners at the University of Alberta, but we would like to refocus our immediate attention in helping with the novel coronavirus.
> Deployment of our application would allow the NIH to manage and understand potential clusters and outbreaks of the pandemic, taking advantage of the estimated 96% of Americans that use a smart phone to easily record a potential case, providing all stakeholders across the US with the latest information.
> Medsoft Group is ready to offer this immediately and without delay. With your cooperation we believe we could be up and running within a week, providing this invaluable tool to better understanding where and what the virus is doing around the country in real time.
> Please let me know if you would like to speak further. We would be happy to demonstrate our technology as well as discuss how we would put this ambitious plan into place.
>
> Best,
>
> David Craig
> Co-founder &Chief Executive Officer
> Medsoft Group Inc.

C: (b) (6) T: (b) (6)
U: www.medsoftgroup.com

IMPORTANT: The contents of this email and any attachments are confidential. They are intended for the named recipient(s) only. If you have received this email by mistake, please notify the sender immediately and do not disclose the contents to anyone or make copies thereof.

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 18:35:29 -0400
To: Stephen Chiarello
Subject: Re: Treatment of Corona virus

Thanks, Steve. I will forward to my program staff

> On Mar 11, 2020, at 6:22 PM, Stephen Chiarello [redacted] (b) (6) wrote:
>
> Anthony:
> This is [redacted] (b) (6) Stephen Chiarello from [redacted] (b) (6). I am a board-certified dermatologist and internist.
>
> Just a brief note and certainly somewhat quixotic: The treatment of toxic epidermal necrolysis With IV vitamin C and thiamine (benfotoxamine) May well stop the cytokine cascade with the coronavirus. This was used Wayback in the polio epidemic before the vaccine with great success but limited subscription.
> I'll send you the references.
> Sincerely,
> Steve chiarello
>
> Sent from my iPhone

From: (b) (6)
Sent: Wed, 11 Mar 2020 18:34:29 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Treatment of Corona virus

Please handle .

Begin forwarded message:

> **From:** Stephen Chiarello (b) (6)>
> **Date:** March 11, 2020 at 6:22:13 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
> **Subject: Treatment of Corona virus**
>
> Anthony:
> This is (b) (6) Stephen Chiarello from (b) (6).
> I am a board-certified dermatologist and internist.
>
> Just a brief note and certainly somewhat quixotic: The treatment of toxic epidermal necrolysis With IV vitamin C and thiamine (benfotoxamine) May well stop the cytokine cascade with the coronavirus. This was used Wayback in the polio epidemic before the vaccine with great success but limited subscription.
> I'll send you the references.
> Sincerely,
> Steve chiarello
>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 11 Mar 2020 11:53:45 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: From Whit Clark; possible theory and plausible new thinking about a Coronavirus

Please respond.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Whit Clark [redacted] (b) (6)>
Sent: Wednesday, March 11, 2020 7:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: From Whit Clark; possible theory and plausible new thinking about a Coronavirus

In Later November, [redacted] (b) (6). After a discussion with my daughter yesterday (an Asst. Principal in [redacted] (b) (6) area), we theorized that the Coronavirus May well have already been here before the close of 2019. China had likely had the outbreak begin much earlier but never acknowledged it; people traveling to China from the US could have returned and brought the virus with them at a much earlier date. When thinking about the number of people my daughter and I have known that had a bout of respiratory illness with a cough that continued much longer than the typical cold, we are proposing a theory that possibly Corona made its entry here much earlier....and this new expected outbreak may well be more of a continuation and less threatening than possibly theorized at this time. It is just a thought but I thought it was worth sharing. If true, we have already met the disease and the deaths attributed to "normal" flus and respiratory causes in the elderly and previously impaired, may have been caused by Coronavirus. This could be a slightly new twist and could present a slightly lower concern for a new major outbreak. Just a thought.....

Whit Clark (William W)
[redacted] (b) (6)

Sent from my iPhone

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 06:23:48 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: The Coronavirus

Pls respond

Sent from my iPhone

Begin forwarded message:

> **From:** LAB <[redacted] (b) (6)>
> **Date:** March 10, 2020 at 11:23:49 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: The Coronavirus**
>
> Dear Dr. Fauci,
>
> My name is Sargon Gorjian and I am a research chemist at Clean Plus Chemical in Sydney. Many years ago I was working at Nanosonics company in Sydney on (b) (4) [redacted]
>
> [redacted] (b) (4) I just wanted to share with you my experience with this type of work. I would suggest to have a look at Virox Patents. It will not do any harm. It might be the right way to go.
>
> Sorry to take up your valuable time.
>
> I wish you all the best and good luck!

Regards

Sargon Gorjian
Laboratory Manager

(b) (6)

Stop the spread.

Instant Hand Sanitiser is an alcohol based gel which kills bacteria (99.99%) within 30 seconds, no washing or rinsing required. Tested and approved according to TGA methods. Glycerin moisturiser & Vitamin E.

Contact us today to place your order.
Code number: 36430 (12 x 500mL CTN)

Instant Hand Sanitiser

Plus
icals Pty Ltd
rge Young St,
NSW 2144
7444 F:
77
lus.com

Any views expressed in this message are those of the individual sender, except where specifically stated to be the view of the Company, its subsidiaries or associates. When addressed to our customers, any opinions or advice contained in this email are subject to the relevant Company terms of business.

Be earth-smart. Please consider the environment and cost of paper before you print.

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 06:21:19 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Pls respond

Sent from my iPhone

Begin forwarded message:

> **From:** RJ Claymont [redacted] (b) (6)
> **Date:** March 11, 2020 at 4:22:35 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies**
>
> Dr. Fauci -
> Just thought I'd bring this article to your attention.
> Are your researchers trying Chloroquine?
>
> https://www.jstage.jst.go.jp/article/bst/advpub/0/advpub_2020.01047/_article
>
> Best Regards
> RJ Claymont

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 06:20:35 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: NIH ketone ester for Coronavirus treatment?

Pls respond

Sent from my iPhone

Begin forwarded message:

> **From:** Frank LLosa - KetoneAid [redacted] (b) (6)
> **Date:** March 11, 2020 at 4:14:08 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: NIH ketone ester for Coronavirus treatment?**
>
> Dear Dr. Fauci
>
> There was a paper recently showing a ketogenic diet helped tame the general flu, in mice.
>
> Meanwhile, there is a drink developed via DARPA and NIH (Dr Veech) that mimics the benefits of the diet. It is called a ketone ester. Even shown to block effects of nuclear bomb style radiation (LD-70 to 100% survival).
>
> Who can I soak to about testing this drink on mice for the general flu , or even humans with Coronavirus symptoms?
>
> Can I send you the paper?
>
> Thank you,
>
> Frank Llosa
> CEO KetoneAid
> [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 06:19:56 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Curevac, meeting with President Trump

Please respond
Sent from my iPhone

Begin forwarded message:

> **From:** Ingmar Hoerr [redacted] (b) (6)
> **Date:** March 11, 2020 at 2:20:51 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Subject: Curevac, meeting with President Trump**
>
> Dear Dr. Fauci,
> I am the new CEO of CureVac. Would be good to update you on our efforts on Covid-19 vaccine here in Europe. This is a global challenge, we should learn from each other to act fast and avoid mistakes. I do not accept any barriers from Stephane Bancel just for competitive reasons. Happy to call or to meet personally.
> Best regards, Ingmar Hoerr
>
> Gesendet über BlackBerry Work
> (www.blackberry.com)

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 06:19:13 -0400
To: NIAID Public Inquiries
Subject: Fwd: Coronavirus bioweapon production method

Sent from my iPhone

Begin forwarded message:

> **From:** Adam Gaertner [redacted] (b) (6)
> **Date:** March 11, 2020 at 6:16:40 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Coronavirus bioweapon production method**
>
> Hello Anthony,
>
> This is how the virus was created.
>
> Intervirion Fusion. HIV-luc(ACE2) (500 ng of p24) was mixed with 1,000 ng of p24 of HIV-gfp particles incorporating ASLV-A envelope, SARS-CoV S protein, or both envelopes in PBS at 4°C for 30 min to allow binding. Samples were raised to 37°C for 15 min to allow for conformational rearrangements. Virions were adjusted to the desired pH with 0.1 M citric acid. PBS, TPCK-trypsin (final concentration 10 μg/ml), CTSL, cathepsin B (CTSB) (final concentrations 2 μg/ml) or CTSL buffer alone was then added. Recombinant CTSL (R &D Systems) was preactivated by incubation for 15 min at 10 μg/ml in 50 mM Mes, pH 6.0, on ice. Recombinant CTSB (R &D Systems) was preactivated in 25 mM Mes, 5 mM DTT, pH 5.0, for 30 min at 25°C. After a 10-min incubation at 25°C, proteolysis was halted by the addition of 300 μl of DMEM10 containing leupeptin (25 μg/ml) and STI (75 μg/ml). Virions were then incubated at 37°C for 30 min to allow membrane fusion. 100 μl of the virion mixture was added in quadruplicate to HeLa-Tva cells pretreated for 1 h with leupeptin (20 μg/ml). The cells were spin-infected and incubated at 37°C for 5 h

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 06:15:22 -0400
To: NIAID Public Inquiries
Subject: Fwd: Prevalence of smoking, and reported mortality rates in COVID-19

Sent from my iPhone

Begin forwarded message:

> **From:** Charles Knight [redacted] (b) (6)
> **Date:** March 10, 2020 at 10:40:45 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Prevalence of smoking, and reported mortality rates in COVID-19**
>
> To whom it may concern:
>
> I assert that the frequency of clinically significant disease, as well as severe disease and mortality of COVID-19 is much higher in smokers, as is the case with any pulmonary infection, such as influenza, or bacterial pneumonia.
>
> This is clearly in addition to that due to the prevalence of elderly and immunocompromised patients; but smoking status overall may be a more significant risk factor for clinically significant disease.
>
> In listening to the news media, smoking has not been addressed as a significant risk factor for disease.
>
> I would suspect that smoking is at least one reason that such a high mortality has recently been seen in Italy, and China, and I expect that mortality rates, as well as rates of clinically significant cases, will also be increased in other populations with increased prevalences of smokers, and strongly associated with the prevalence of smoking in the given population.
>
> Of course, the reporting of severe disease will be modulated by the effectiveness of the given population in containing the virus, as well as the effective reporting of clinical disease within the community, whether severe or not.
>
> In listening to the news media, smoking has not been addressed as a significant risk factor for disease. I think that it should be addressed.
>
> One wonders if it could be a modifiable risk factor, at least in certain patients (such as those who have not smoked for very long).

One also wonders whether this could be another good prognostic factor for limited reported/ clinically significant cases (and thus limited perceived spread) in the United States, obviously in addition to our early, effective containment measures.

Just thought this might be helpful.

Dr. Charles W. Knight, MD

Sent from my iPhone

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 06:12:10 -0400
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: Covid-19 patient in hospital without negative pressure room

Sent from my iPhone

Begin forwarded message:

> **From:** [redacted] (b) (6)
> **Date:** March 11, 2020 at 3:53:18 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Covid-19 patient in hospital without negative pressure room**
>
> Hi Dr. Anthony Fauci,
>
> I saw you on Meet the Press this weekend and you were so awesome! Very informative, calm, assuring but with the right amount of instilling the need for us all to move forward with the appropriate caution for ourselves. It's extremely reassuring to have you leading and guiding us during this time.
>
> I'm emailing you because I work at Kaiser Permanente Hospital in [redacted] (b) (6) [redacted]. Our administration initially said if any Covid-19 patient came into the hospital needing emergeny care and needing to be admitted they would be given an N95 mask and put in a negative pressure room. Now they reversed that decision and said they'd be put in a regular positive pressure roomn even after I showed them the CDC's recommendation for both confimed and possible Covid-19 cases needing to be placed in negative pressure rooms/AIIR.
>
> Well tonight a possible Covid-19 patient came to the Emergency Room and had to be admitted to the ICU. The patient was given just a regular mask and put in an elevator to the ICU. Management would not confirm if the patient was in a negative pressure room and wouldn't give staff N95 masks. I again showed them the CDC website hospital protocol Covid-19 recommendations but same response. And even was yelled at by the hospital nursing supervisor for asking about it.
>
> I feel this is not safe at all for other patients, visitors and staff if the air is being recirculated not vented outside or through a hepa filter before recirculating back

through the hospital. I don't know what to do. Please help. The hospital main phone number is (b) (6) the Chief of the hospital is (b) (6)

I know you're extremely busy now but any help or guidance is appreciated..even if it's just to confirm that any confirmed or suspected Covid-19 patient needs to be in a negative pressure room. Thanks so much!

Sincerely,

Kara Smalls

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 11 Mar 2020 01:38:17 +0000
To: NIAID OD AM
Subject: Fwd: Cancellation of 2020 Stanford Drug Discovery Symposium

Sent from my iPhone

Begin forwarded message:

> **From:** Joseph Wu <joewu@stanford.edu>
> **Date:** March 10, 2020 at 6:11:52 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
> **Cc:** "David L.M. Preston" <preston@stanford.edu>, Amanda Chase <chaseama@stanford.edu>, Sanjay Malhotra <svmalhot@stanford.edu>
> **Subject: RE: Cancellation of 2020 Stanford Drug Discovery Symposium**
>
> **SDDS** 2020
> Stanford Drug Discovery Symposium
> April 20-21, 2020
>
> Dear Dr. Fauci,
>
> We greatly appreciate your willingness to participate in the 2020 Stanford Drug Discovery Symposium (SDDS). As you undoubtedly know, with the further spread of the novel coronavirus COVID-19, Stanford is taking precautionary measures to minimize any preventable spread of this viral disease. After much consideration, we feel it is in the best interest of our speakers, guests, and community to cancel the April 20-21, 2020, symposium.
>
> We apologize for the inconvenience this may cause in your schedules. We do hope that you will agree to be our guest speaker NEXT year for our April 19-20, 2021. As soon as your schedule allows, please let us know if you would be able to speak at our 2021 SDDS meeting.

Please feel free to contact David Preston preston@stanford.edu or Amanda Chase chaseama@stanford.edu or myself joewu@stanford.edu if you have any questions.

Thank you for your understanding, and we hope to see you next year.

Lastly, THANK YOU for all service to our country and for educating the public about the coronavirus, we're a big fan of yours on all the news media.

Sincerely,

Joseph C. Wu, MD, PhD
Sanjay Malhotra, PhD
Kuldev Singh, MD
Mark Mercola, PhD

Joseph C. Wu, MD, PhD
Director, Stanford Cardiovascular Institute
Simon H. Stertzer, MD, Professor of Medicine & Radiology
Stanford University School of Medicine

265 Campus Drive, Rm G1120B
Stanford, CA 94305-5454
Ph: 650-736-2246; Fax: 650-736-0234
Email: joewu@stanford.edu
Twitter: @StanfordCVI
Lab Website: http://wulab.stanford.edu
Stanford CVI: http://med.stanford.edu/cvi.html

Stanford Cardiovascular Institute

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 21:25:59 +0000
To: NIAID OD AM
Subject: FW: Fields Symposium

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: David Knipe <david_knipe@hms.harvard.edu>
Sent: Tuesday, March 10, 2020 5:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Fields Symposium

Dear Tony,

I am sorry to write that we are going to have to cancel the Fields Symposium for April 24th, but we will re-schedule when we can. As you may know, Harvard has cancelled all meetings larger than 100 (and this morning limited that to 25) through at least April 30th. We are sad to have to do this, but we need to help mitigate the spread of the virus. Harvard even told the undergraduates today to go home this weekend and take their classes on line for maybe even the rest of the semester.

Thank you for all you are doing to keep everyone informed about the coronavirus outbreak. We are going to give you the Harvard "Veritas" award when you are next here.

Stay well.

Best regards,

David

David M. Knipe, Ph.D.
Higgins Professor and Head, Program in Virology
Dept. of Microbiology, Blavatnik Institute
Harvard Medical School
NRB Room 950B
77 Avenue Louis Pasteur
Boston, MA 02115
Ph. 617-432-1934
Lab web site: http://knipelab.med.harvard.edu

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 17:56:17 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] ([redacted] (b) (6)
Subject: FW: Funding, for Dr. Fauci

Please respond to this person.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Rena Patel [redacted] (b) (6)>
Sent: Tuesday, March 10, 2020 1:33 PM
To: [redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Funding, for Dr. Fauci

Responsiveness to emerging infectious disease threats is important. However, I worry that increasing funding is going away from global health priorities. It appears that the US Ending the HIV Epidemic has already diverted funding within NIH from global work to domestic. Will the NIH response to COVID-19 only worsen funding available for global health?

Thanks,
Rena

Rena Patel, MD, MPH
She/her
Assistant Professor
Division of Infectious Diseases, Dept. of Medicine
International Clinical Research Center, Dept. of Global Health
Email: [redacted] (b) (6)
Mobile: [redacted] (b) (6)
Skype: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 17:46:08 +0000
To: Gary Spinner
Subject: RE: Testing for Covid-19

Gary:

If you have the resources and capability to do it, you should.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gary Spinner (b) (6)
Sent: Tuesday, March 10, 2020 1:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Testing for Covid-19

Just heard your CROI talk. Thank you so much.
Should we be testing for Covid-19 in patients with flu like symptoms in our Community Health Center by using commercially available tests for patients without history of travel or known contacts? We have two cases thus far in (b) (6) where my center is located.

Gary Spinner
Southwest Community Health Center

Get Outlook for iOS

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 16:26:19 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: asymptomatic infections of COVID-19
Attachments: thelancetrm-S-20-00427.pdf

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: 何勇 [redacted] (b) (6)>
Sent: Tuesday, March 10, 2020 1:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: asymptomatic infections of COVID-19

Dear Prof. Anthony Fauci,

At first, I express regret if I am bothering you in your busy schedule.

I know you care about asymptomatic infection of COVID-19. COVID-19 is spreading rapidly all over the world, especially in Iran and Italy, and possibly even more widely. Asymptomatic infections and healthy carriers are possible sources for transmission. However, such sources of infection cannot be effectively identified due to the symptoms absent. The research evidence is very lacking so far.

(b) (4)
[redacted]

(b) (4)

[redacted]

This encourages me to write to you to seek help! I will be most grateful if you could give us some suggustion.

Look forward to hearing from you soon,

With kind regards,

Yours sincerely，

Yong He

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 16:21:12 +0000
To: Hahn, Stephen
Cc: Redfield, Robert R. (CDC/OD);r[redacted] (b) (6);Cassetti, Cristina (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];[redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E];Graham, Barney (NIH/VRC) [E];Mascola, John (NIH/VRC) [E];Lerner, Andrea (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Coronavirus test
Attachments: nCoV-ColorimetricLAMP.pdf

Steve:

Let us discuss this when we are together at the 4:00 PM TF meeting.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Roberts, Rich <[redacted] (b) (6)>
Sent: Tuesday, March 10, 2020 12:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Coronavirus test

Dear Tony:

If you can find a few minutes, I would very much like to talk with you briefly about a new diagnostic LAMP test for coronavirus COVID-19 that we have developed here at NEB. I attach a paper now in the MedRxiv that briefly describes the test. It has been used already in Wuhan and because of its simplicity, speed and visual output we think it would be very useful for use here in the US. We have just met with several people at Mass General Hospital and will be working with them for local validation here in MA. The test itself is very inexpensive, does not require any special equipment nor training of technicians. This would appear ideal for the FDA and the CDC to know about, but I have not so far been able to reach either Stephen Hahn or Robert Redfield. I would emphasize that our goals are to help deal with the humanitarian aspects of the current problems.

I can be reached on my cell at (b) (6) or in my office at the number below.

Rich

Sir Richard J. Roberts Ph.D. F.R.S.
1993 Nobel Laureate in Physiology or Medicine
Chief Scientific Officer
New England Biolabs
240 County Road
Ipswich, MA 01938-2723 USA

Tel: (b) (6)
Fax: (978) 412 9910
email: (b) (6)

Executive Assistant: (b) (6)
Tel: (b) (6)
Fax: (978) 412 9910
email: (b) (6)

From: [redacted] (b) (6)
Sent: Tue, 10 Mar 2020 11:13:29 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: Patented System - COVID-19

From Patty
Pls respond.

Sent from my iPhone

Begin forwarded message:

> **From:** JOHN FLYNN [redacted] (b) (6)>
> **Date:** March 10, 2020 at 10:49:44 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Patented System - COVID-19**
>
> Dear Dr. Fauci,
>
> **I know that you are extremely busy, but I would respectfully urge you to take 5 mins. of your time to review the information below as I believe that I have a disruptive technology that can help prevent the spread of COVID-19.**
>
> My name is John Flynn. I previously founded a startup medical equipment company that was focused within the area of orthopedics, which I ran for twelve years. I ultimately sold the company to a public competitor, DJO Global. I have worked on different healthcare projects, but have exclusively spent the last twenty months focused on a new medical product within the area of infection prevention. **My goal was to introduce what I believe is a disruptive product to help healthcare facilities to prevent the spread of MDRO's in order to reduce HAI's/SSI's; however, I believe that it can also help to reduce the spread of Coronavirus.**
>
> (b) (4) [redacted]

(b) (4)

[redacted]

(b) (4)

[redacted]

[redacted] (b) (4)

[redacted] (b) (4) **I hope that you will have an interest in a further discussion.**

Respectfully,

John Flynn
Cell: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 10:45:53 +0000
To: Houndsburgh
Subject: RE: Thinking of you

Linda:
Many thanks for your kind note. It is much appreciated.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Houndsburgh [redacted] (b) (6)>
Sent: Monday, March 9, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Thinking of you

Dear Dr. Fauci,

You have been a bulwark for me since I was a resident in the 1980s, dealing with the AIDS epidemic at LA County General. For so many years, you have provided expert guidance in a calm, rational manner. As the Coronavirus becomes closer and closer to a pandemic, I know you have so much on your plate (hoarse voice, no?).

I send you my best wishes to stay well yourself during these trying times, and hope that you know how much you have meant, and continue to mean, to all physicians out there. You have given so much.

May God bless you always.

Best,

Linda Schmidt, MD
Internal Medicine

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 10:16:29 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Predict the potential outbreak of COVID-2019 in the region based on the age information of reported COVID-2019 infected people
Attachments: COVID2019Prediction20200310.pdf, S1.xlsx

FYI

-----Original Message-----
From: [redacted] (b) (6)>
Sent: Tuesday, March 10, 2020 5:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Predict the potential outbreak of COVID-2019 in the region based on the age information of reported COVID-2019 infected people

Dear Prof. Anthony Fauci

My name is Chao Wu and I am a research staff in national clinical research center for infectious diseases, the first affiliated hospital of college of medicine of Zhejiang University of China.

Based on the public data of COVID-2019 infected people in China, I have developed a simple model to warn the potential outbreak of COVID-2019 in a region based on the age information of reported COVID-2019 infected people.

Hope this could provide useful information for preventing COVID-2019 spreading in US. And hope the two countries can be together to fight with COVID-2019

Best wishes!

Chao Wu
Room 6A1713
Qingchun Branch
The First Affiliated Hospital of College of Medicine of Zhejiang University. Hangzhou

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 02:20:57 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: FW: Coronavirus Remote Monitoring
Attachments: image001.png, image001.png

Please take a look.

From: ezriel kornel (b) (6)
Sent: Monday, March 9, 2020 7:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)>
Subject: Fwd: FW: Coronavirus Remote Monitoring

I think this may be a very valuable program. I have no involvement but was sent to me for my input.
Ezriel Kornel, MD

---------- Forwarded message ---------
From: **King, Nicholas** <nicholas.king@bernstein.com>
Date: Mon, Mar 9, 2020, 5:07 PM
Subject: FW: Coronavirus Remote Monitoring
To: (b) (6)

Hi Ed,

I thought you'd find this to be of interest. Greg is a (b) (6) and I think there may be an opportunity to help health agencies. Do you know anyone that this could be passed along to?

Nicholas King
Vice President – Financial Advisor
T (b) (6)
nicholas.king@bernstein.com

After Arts Group | Forbes

From: Greg OKeeffe (b) (6)
Sent: Monday, March 09, 2020 9:05 AM
To: King, Nicholas <nicholas.king@bernstein.com>
Subject: Coronavirus Remote Monitoring

External Email. Use caution when clicking links or opening file attachments.

Nick,

Following up on our conversation this weekend, I am including some information below about our Remote Patient Monitoring platform which we are making available for free to health agencies and organizations participating in the response to COVID-19 in the United States.

Remote Patient Monitoring with FollowApp is a HIPAA-Compliant system that helps health officials to diagnose, contain and treat this highly transmissible viral threat by enabling the effective screening of large numbers of potential patients and to triage/prioritize targeted clinical interventions including the use of test kits.

FollowApp's monitoring dashboard and patient mobile applications (iOS and Android) can be used to deliver two of the keys to an effective response plan: 1) encourage "self-quarantining" (a fundamental epidemiologic tenet) and 2) off-load exploding clinical volume threatening hospital Emergency Departments. Healthcare systems are thus able to maintain important contact with these populations and recommend targeted escalation of care when needed, while decreasing exposure to both clinicians and other patients.

The public perception of the lethality of this global pandemic is fueling panic which, in and of itself, is creating its own logistic issues that are already beginning to overwhelm hospital Emergency Departments. The dilemma for health care systems, then, becomes a question of identifying subpopulations at increased risk while at the same time, keeping these patients out of the hospital.

Please feel free to forward this email along with my contact information (cell (b) (6)) -- I would be happy to provide a demo to anyone who may be interested.

Thank you again,

Greg

--

Greg O'Keeffe
President & CEO
Human Resolution Technologies, LLC
www.PatientMonitoring.com

LinkedIn

The information contained in this e-mail is legally privileged and confidential information intended only for the use of the individual or entity to whom it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any viewing, dissemination, distribution, or copy of this e-mail message is strictly prohibited. If you have received and/or are viewing this e-mail in error, please immediately notify the sender by reply e-mail and delete this e-mail from your system. Thank you.

Virus-free. www.avast.com

……

For further important information about AllianceBernstein please click here
http://www.alliancebernstein.com/disclaimer/email/disclaimer.html

---

BERNSTEIN

BERNSTEIN

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 02:19:50 +0000
To: [redacted] (b) (6)
Subject: FW: Revised Nursing Home Guidance
Attachments: QSO20-14. COVID-19 Nursing Homes - REVISED NIAID.docx

I had my staff review this and their edits/suggestions are incorporated into the attached document.
Best regards,
Tony

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: CMS [redacted] (b) (6)
Sent: Sunday, March 8, 2020 9:02 PM
To: [redacted] (b) (6) Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: Revised Nursing Home Guidance

Would you mind reviewing our updated guidance to nursing homes? This is upgrading the policies around visiting etc. Would like to send this out tomorrow.

Thanks.

Sent from my iPhone

Begin forwarded message:

> **From:** "Shulman, Evan T. (CMS/CCSQ)" [redacted] (b) (6)>
> **Date:** March 8, 2020 at 8:52:14 PM EDT
> **To:** CMS [redacted] (b) (6)>
> **Cc:** "Hittle, Matthew (CMS/OA)" [redacted] (b) (6)>, "Brookes, Brady (CMS/OA)" [redacted] (b) (6), "Moody-Williams, Jean D. (CMS/CCSQ)" [redacted] (b) (6)>, "Wright, David R. (CMS/CCSQ)" [redacted] (b) (6)>
> **Subject: Revised Nursing Home Guidance**
>
> Seema,
>
> Attached is the Nursing Home memo with revised guidance (changes are in red/italics). This includes suggestions from Shari and Patti Meier, but they are still reviewing the full document. We sent this to the CDC this afternoon and I just received their feedback (while

on this call). I skimmed through their feedback and while they recommended some changes, they did not suggest any substantive changes.

Summary of revisions:

(b) (5)

[redacted]

We've also been in contact with the industry, and believe they will support the revisions. Happy to answer any questions.

Thanks,
Evan

Evan Shulman
Director, Division of Nursing Homes
Quality Safety and Oversight Group
Center for Clinical Standards and Quality
Centers for Medicare and Medicaid Services

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 02:11:06 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Coronavirus Case in Munich

Please respond to this person.

From: Rita DiCasagrande Olsen [redacted] (b) (6)
Sent: Monday, March 9, 2020 9:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Coronavirus Case in Munich

Carissimo Dr. Fauci -

Greetings from Munich, Germany! It's hard to believe so many years have passed since our time working avian influenza preparedness. I have watched every single interview during the past few months and I could not be more relieved to see you at the helm of this new, rapidly evolving crisis.
I know you have very little time, so I will make this quick - hopefully to be followed by a more fulsome and proper hello.

We have a prominent American businessman (age 64) here in Munich who tested positive a little over a week ago after skiing in the Dolomites in Italy. He has a history of respiratory illnesses, including double pneumonias and various other similar complications. In short, he is sedated and intubated, and was placed on ECMO during the past 24 hours. The team is administering ritonavir and lopinavir, as well as broad spectrum antibiotics.

The German doctor here would like to acquire Remdesivir to have on hand if all other treatments fail. Because it is not being tested here, he inquired whether we could access it in the States. Would you be able to point me in the right direction for how, if even possible, we could transfer some to the Munich-based hospital here?

Thank you so much in advance. Any other insights of course are certainly welcome. You continue to be a national treasure. All the best - Rita

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 02:09:14 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Science of COVID-19 Curriculum?

Please respond to him for me. Try to help him out.

From: michael dispezio [redacted] (b) (6)
Sent: Monday, March 9, 2020 9:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Science of COVID-19 Curriculum?

Dr. Fauci,

Twenty years ago, I wrote the US curriculum "The Science of HIV" and we were honored to have you featured in our accompanying television broadcast, which was nominated for an Emmy (Discovery Channel). Years prior to that, I snagged my Masters from BU on some novel, emergent retrovirus called HIV.

Now, its time for me to do my magic and educate this new generation on COVID-19. This is a familiar audience (my people), since most use the science programs I have authored for K-8 for the past 30 years!

How do I best proceed with developing materials in sync with the national needs that demystify the concepts surrounding COVID-19 ? My skillset is in education, but my background in biology and biochem.

Please Google me and/or check out the links below.



https://www.nsta.org/recommends/ViewProductPrint.aspx?ProductID=12138

https://www.hmhco.com/people/michael-dispezio

Sincerely,

Michael DiSpezio (another [redacted] (b) (6))

Virus-free. www.avg.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 00:58:15 +0000
To: Collins, Francis (NIH/OD) [E];Trevor Mundel
Cc: Dan Wattendorf;Jennifer Weisman
Subject: RE: COVID-19

Trevor:

Ditto what Francis said. If Bill is seeing the VP tomorrow, he will surely bring it up to me at our 4:00 PM daily Task Force meeting.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: ([redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6) >
Sent: Monday, March 9, 2020 8:25 PM
To: Trevor Mundel [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)>
Cc: Dan Wattendorf [redacted] (b) (6)>; Jennifer Weisman
[redacted] (b) (6)
Subject: RE: COVID-19

Hi Trevor,

Truly interesting opportunity. Tony is doing a media blitz (Sean Hannity on Fox right now) but I'm sure he will check in – and I would imagine that VP Pence will turn to him to decide how to respond to Bill's phone call. Doctor-based testing capability in the US has gone up substantially in the last couple of days – after admittedly a rocky start. But home testing presents a novel detection scheme. I assume from what you say that false negatives are uncommon and false positives are rare?

For Africa, this seems like a technology that ought to be deployed as soon as possible. It astounds me that there are no documented cases in East Africa yet – that defies everything we know about air traffic with China. Providing an opportunity for low-tech testing in Addis, or Kampala, or Nairobi, or Dar es Salaam seems like a highly desirable outcome.

My two cents.

Francis

From: Trevor Mundel [redacted] (b) (6)
Sent: Monday, March 9, 2020 5:57 PM
To: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Dan Wattendorf <[redacted] (b) (6); Jennifer Weisman [redacted] (b) (6)>
Subject: COVID-19

Dear Francis, Tony,

I wanted to give you a heads up on a call that Bill will have with Vice President Pence tomorrow around the COVID-19 situation. As you might be aware, we have been running an influenza transmission study in Seattle for the last 2 years. This involves at-home testing for ILI-symptomatic individuals (who log-in via a web app) and collection of nasal swabs, which are then sequenced for a range of respiratory pathogens. Dan can give you more details on this study if you have questions. When the Coronavirus situation arose, we added this to the list of pathogens and hence were able to detect some of the early cases in Washington.

The CDC has been very interested in the approach and at one point we had the highest screening capacity in the US (though only 400 samples per day, so I hope this is no longer true). At the same time, we have developed a COVID-19 at-home screening and information system with robust software that approximates what China was doing but also takes into account the opt-in requirements that are necessary in the US.

We want to propose going beyond the Seattle area- this would be gated only by availability of testing. We can deploy this ready-now system more broadly in the US. Ideally we would also do a parallel outreach to some African countries. I'd be interested in your views and would be happy to jump on a quick call.

Warm regards,
Trevor

Trevor Mundel, MD, PhD
President, Global Health Program
V +[redacted] (b) (6)
F +1.206.494.7041
E [redacted] (b) (6)

(b) (6)
Executive Assistant
Office of the President, Global Health
V (b) (6)
M
E (b) (6)
Bill & Melinda Gates Foundation
www.gatesfoundation.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 00:47:56 +0000
To: Del Rio, Carlos
Subject: RE: [External] Re: Nice job in Press Conference
Attachments: SSRN-id3549276.pdf

Not for distribution. It may still be under review

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Del Rio, Carlos <(b) (6)>
Sent: Monday, March 9, 2020 7:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: [External] Re: Nice job in Press Conference

Share the Australian paper when you can. Could not find it.

Carlos del Rio, MD.
Sent from my iPhone

> On Mar 9, 2020, at 7:54 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> wrote:
>
> Thanks, Carlos.
>
>> On Mar 9, 2020, at 7:21 PM, Del Rio, Carlos (b) (6)> wrote:
>>
>>
>>
>> Carlos del Rio, MD.
>> Sent from my iPhone
>>
>> ________________________________
>>
>> This e-mail message (including any attachments) is for the sole use
>> of the intended recipient(s) and may contain confidential and
>> privileged information. If the reader of this message is not the
>> intended recipient, you are hereby notified that any dissemination,
>> distribution or copying of this message (including any attachments)

>> is strictly prohibited.
>>
>> If you have received this message in error, please contact the sender
>> by reply e-mail message and destroy all copies of the original
>> message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 00:30:13 +0000
To: Michael Gerson
Subject: RE: My column, just FYI

Well done!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Michael Gerson (b) (6)
Sent: Monday, March 9, 2020 5:47 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: My column, just FYI

https://www.washingtonpost.com/opinions/coronavirus-isnt-another-hurricane-katrina-its-worse/2020/03/09/25c302f2-6224-11ea-acca-80c22bbee96f_story.html

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 00:26:59 +0000
To: Mark Harrington;Folkers, Greg (NIH/NIAID) [E]
Subject: RE: NYC community letter to Mayor De Blasio on social distancing measures to mitigate COVID-19

Thanks, Mark. Good letter.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mark Harrington [redacted] (b) (6)>
Sent: Monday, March 9, 2020 5:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: NYC community letter to Mayor De Blasio on social distancing measures to mitigate COVID-19

Attached.

Hope you're both well.

cheers,

Mark

--
Mark Harrington
Executive Director
Treatment Action Group
90 Broad Street, Suite 2503
New York, NY 10004 USA
[redacted] (b) (6) - tel.

(b) (6)
mark.harrington@treatmentactiongroup.org

From: [redacted] (b) (6)
Sent: Mon, 9 Mar 2020 19:56:50 -0400
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: Fwd: Requesting a copy of your article

Pls handle

Sent from my iPhone

Begin forwarded message:

> **From:** Mahendra De Silva [redacted] (b) (6)
> **Date:** March 9, 2020 at 7:52:52 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Requesting a copy of your article**
>
> Dear Dr. Fauci:
>
> Would you be kind enough to send me a copy of this important article (see below)?
>
> Thank you.
> Sincerely,
> Mahendra De Silva, PhD
>
> January 23, 2020
>
> # Coronavirus Infections—More Than Just the Common Cold
>
> Catharine I. Paules, MD[1]; Hilary D. Marston, MD, MPH[2]; Anthony S. Fauci, MD[2]

From: [redacted] (b) (6)
Sent: Mon, 9 Mar 2020 19:53:18 -0400
To: Krista Conley
Subject: Re: Terry Beirn

Krista:
Many thanks for your kind note.
Best regards,
Tony

> On Mar 9, 2020, at 7:25 PM, Krista Conley <[redacted] (b) (6)> wrote:
>
> Good evening Dr. Fauci:
>
> My name is Krista Conley and I was a staff assistant for Senator Kennedy's Labor and Human Resources Committee in 1987. I was supporting the committee on health-related issues until one day, this smart-aleck of a guy walked in and said "You work for me, now."
>
> That was Terry Beirn, and I spent the next year of my life working on the very first legislation for research funding and for anti-discrimination protections. Terry made me better, stronger, more empathetic than I ever thought possible. He worked me relentlessly - and it never felt like work. Those were very tough times, and we never let up, not even to eat.
>
> I fielded a lot of calls from you to Terry, and seeing the coronavirus press conference tonight, I wanted to thank you for your tireless public health efforts. You changed lives to the good for millions - Terry did his bit, too.
>
> It's good to hear your voice at the lectern - makes me feel like we'll get through it. Thank you for always jumping in - Krista Conley

From: [redacted] (b) (6)
Sent: Mon, 9 Mar 2020 19:43:06 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: The Economist Asks request for Dr. Anthony Fauci

Let us discuss

Begin forwarded message:

> **From:** Sujata Thomas <sujatathomas@economist.com>
> **Date:** March 9, 2020 at 7:41:03 PM EDT
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" < [redacted] (b) (6)>
> **Subject: Re: The Economist Asks request for Dr. Anthony Fauci**
>
> Hi,
>
> I just wanted to follow up on this request for The Economist. The interview could happen at Dr. Fauci's convenience.
>
> Thanks for the consideration.
>
> Best,
> Sujata
>
> On Thu, 5 Mar 2020 at 08:48, Sujata Thomas <sujatathomas@economist.com>wrote:
>
> > Dear Dr. Fauci,
> >
> > "The Economist Asks", The Economist's award-winning interview podcast would love to have you join the program this spring.
> >
> > "The Economist Asks" is the Economist's flagship show, a current, frank and engaging profile-style interview, in a series that includes heads of state, cultural pioneers and business leaders, and hosted by Anne McElvoy.
> >
> > Anne would like to discuss with you, your thoughts on coronavirus, its spread and the management of this global public health emergency.
> >
> > We'd record 20 mins of interview, very flexible as to date and location - though we'd love to do it soon - and are open to include subjects you feel

need to be covered. We know you are likely inundated with requests, so if you could connect me with the appropriate person handling your speaking requests, we'd greatly appreciate it.

Economist Radio has over 12 million listens a month worldwide, with a core audience in the US and the UK. Previous guests on "The Economist asks" include Melinda Gates, Tony Blair, Hillary Clinton, Imran Khan, Salman Rushdie, Annie Lennox, Anna Wintour, Darren Aronofsky, David Sedaris, David Mamet, Margaret Atwood, Ursula Burns, Juan Manuel Santos, Christine Lagarde, Jacinda Ardern, Michael Bloomberg, Pussy Riot, Pete Buttigieg among many others. You can listen to previous episodes here acast.com/theeconomistasks.

Thank you for your consideration and hope to hear from you or someone from your office.

Thanks,
Sujata

(b) (6)

This e-mail may contain confidential material. If you are not an intended recipient, please notify the sender and delete all copies. It may also contain personal views which are not the views of The Economist Group. We may monitor e-mail to and from our network.

Sent by a member of The Economist Group. The Group's parent company is The Economist Newspaper Limited, registered in England with company number 236383 and registered office at The Adelphi, 1-11 John Adam Street, London, WC2N 6HT. For Group company registration details go to http://legal.economistgroup.com

From: [redacted] (b) (6)
Sent: Mon, 9 Mar 2020 19:25:47 -0400
To: NIAID Public Inquiries
Cc: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: [redacted] (b) (6)

Sent from my iPhone

Begin forwarded message:

> **From:** Laura [redacted] (b) (6)
> **Date:** March 9, 2020 at 5:48:06 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Still positive after 30 days**
>
> Dear Dr. Fauci,
>
> [redacted] (b) (6)
>
> Thank you,
> Laura Umphries
> [redacted] (b) (6)
>
> Sent from my Verizon, Samsung Galaxy smartphone

From: (b) (6)
Sent: Mon, 9 Mar 2020 19:22:39 -0400
To: Auchincloss, Hugh (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: Testing for COVID-19

From patty

Pls respond.

Sent from my iPhone

Begin forwarded message:

> **From:** Robert Langston < (b) (6)
> **Date:** March 9, 2020 at 6:38:20 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" < (b) (6)
> **Subject: Testing for COVID-19**
>
> Hello Dr. Fauci,
> Are you able to provide false positive and false negative values for patients with Corona Virus infection and colonization?
> Thank you for taking time to read and respond my question.
> My regards,
> Robert Langston MD

From: [redacted] (b) (6)
Sent: Mon, 9 Mar 2020 19:21:36 -0400
To: Handley, Gray (NIH/NIAID) [E]
Subject: Fwd: CoV collaboration with Polish Medical Research Agency
Attachments: image001.png

From
Patty. Does asf need to see this

I am trying to empty his emails. Pls advise ASAP

Sent from my iPhone

Begin forwarded message:

> **From:** "Handley, Gray (NIH/NIAID) [E]" [redacted] (b) (6)
> **Date:** March 9, 2020 at 6:51:14 PM EDT
> **To:** [redacted] (b) (6)
> **Cc:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6) "Lane, Cliff (NIH/NIAID) [E]" < [redacted] (b) (6)>, "Auchincloss, Hugh (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: CoV collaboration with Polish Medical Research Agency**
>
> Dear Dr. Sierpiński,
>
> Dr. Fauci referred your message to me and other NIAID colleagues with a request that we respond on his behalf so as to avoid further delay. We certainly sympathize with your situation, as we also are working urgently to prevent, control and manage COVID-19 in the United States.
>
> During his visit to NIH in 2018, I was pleased to meet Minister Szumowski and, although I was traveling when you visited Dr. Fauci last year, I am aware that the meeting was productive and that we remain interested in encouraging further U.S.-Poland scientific collaboration. In part, as a result of that meeting, we are also very pleased to be planning an NIH and ABM-sponsored clinical research training workshop in Poland later this year.
>
> As you are likely aware, NIAID is collaborating with a number of organizations to develop vaccines for SARS-CoV-2. We are expecting the first vaccine to start Phase I trials within the next month. As vaccines move through Phase I testing, there may be opportunities to collaborate.
>
> In addition, with NIAID as the regulatory sponsor, we have initiated a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral

remdesivir in hospitalized adults diagnosed with COVID-19. This adaptive design trial will allow for the addition of new treatment arms as promising new therapeutics for COVID-19 become available. Eventually, this trial may be expanded to include international sites, potentially including some that have been affiliated with our INSIGHT Network in the past. Three sites in Poland have participated in INSIGHT trials:

Site Name: Wroclawskie Centrum Zdrowia (Wroclaw)
Site Leader: Brygida Knysz

Site Name: Wojewodzki Szpital Zakazny (Warsaw)
Site Leader: Andrzej Jerzy Horban

Site Name: Uniwersytecki Szpital Kliniczny (Bialystok)
Site Leader: Robert Flisiak

It might be a good idea to let any Polish sites/investigators considering participation in this trial know that ABM might have available funding to support international collaborative research, if that is the case. This may be important information as Polish scientists interact with other European scientists considering the development of a multi-site clinical trial.

In addition, there may be other opportunities for collaborative research engaging Polish Institutions with access to COVID-19 patients, particularly through the sharing of biological samples and research data. Another approach would be for interested Polish scientists to explore shared interests with U.S. colleagues who are planning to apply for COVID-19 funding in response to current Funding Opportunity Announcements in the NIH Guide to Grants and Contracts. To do what we can to facilitate possible collaborations, we would also welcome receiving additional information on specific COVID-19 research interests, capabilities and activities current in Poland.

Thank you again for reaching out to Dr. Fauci. We look forward to continuing to discuss potential areas of collaboration.

Best regards,

F. Gray Handley
Associate Director for International Research Affairs
National Institute of Allergy and Infectious Diseases
National Institute of Health
U.S. Department of Health and Human Services

Tel: (b) (6)
Fax: 301 480 2954
(b) (6)

5601 Fishers Lane, Room 1E50
Bethesda, MD 20892-9802

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-

From: Radosław Sierpiński (b) (6)>
Date: March 9, 2020 at 6:42:08 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: "Gupta, Ranjan (NIH/FIC) [E]" (b) (6)
Subject: CoV collaboration with Polish Medical Research Agency

Dear Doctor Fauci,

I hope this e -mail is finding you well and your efforts in fight against Coronavirus epidemics is giving some effects. As you know in Poland we have currently 15 cases of CoV infection and we are also fighting mostly with general society worries than epidemics. We would like also to take part in research on CoV vaccine or drug and Polish Medical Research Agency is planning to start financing some project on it as soon as possible. Both polish medical universities and institutes are fully prepared to take part in such project.
On behalf of Polish Minister of Health Prof. Lukasz Szumowski I would like to kindly ask you for some support and collaboration options with NIH in this very delicate issue. Maybe NIH can take some advisory role in our scientific project or Polish scientists may take some part in your work bilaterally.

Looking forward to hearing from you,

Radosław Sierpiński MD, PhD
President of Medical Research Agency in Poland
(b) (6)
<image001.png>
Medical Research Agency
ul. S. Moniuszki 1A
00-014 Warszawa
www.abm.gov.pl

AGENCJA
BADAŃ
MEDYCZNYCH

AGENCJA
BADAŃ
MEDYCZNYCH

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 20:13:17 +0000
To: NIAID OD AM
Subject: FW: Opp to speak to U.S. CEO Community
Attachments: CEO overview_updated_5_31_19_ (1) (2).pdf

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Greg Reilly <Greg@theceoforumgroup.com>
Sent: Monday, March 9, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Opp to speak to U.S. CEO Community

Dr. Fauci,

Our national radio and magazine audience is the U.S. CEO community, and this is an invitation to be interviewed for The CEO Show and The CEO Forum Magazine. The opportunity is to deliver your words directly, verbatim, with no reporter's interpretation. [Company Overview attached.]

The line of questioning would be about advice for corporate leaders during a health crisis, such as we are experiencing now with COVID-19 and such that we may experience again in the future.

We could do the 19-minute interview by phone or in person in New York City.

Certainly we honor your service and excellence as a spokesperson.

Our outlets would be effective for your messages specific to business leaders.

Please consider this invitation.

Thank you
Greg Reilly

Greg Reilly | Associate Publisher
(b) (6) | greg@theceoforumgroup.com | www.theceoforumgroup.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 18:23:56 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]; [redacted] (b) (6)
Subject: RE: Appropriations - second supp for cornavirus - professional judgement request

We will have additional needs. Will get back to you today about the amount and what the plan is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tabak, Lawrence (NIH/OD) [E] <[redacted] (b) (6)>
Sent: Monday, March 9, 2020 1:01 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Appropriations - second supp for cornavirus - professional judgement request
Importance: High

How do you want this approached please?
Thanks
Larry

From: "Mitchell, Michelle (NIH/OD) [E]" [redacted] (b) (6)>
Date: Monday, March 9, 2020 at 12:43 PM
To: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)>, "Shapiro, Neil (NIH/OD) [E]" [redacted] (b) (6)>, "Hallett, Adrienne (NIH/OD) [E]" <[redacted] (b) (6), "Higgins, Lauren (NIH/OD) [E]" [redacted] (b) (6)
Cc: "LaMontagne, Karen (NIH/OD) [E]" [redacted] (b) (6)>, "Bauer, Jenna (NIH/OD)

[E]" (b) (6)>
Subject: Appropriations - second supp for cornavirus - professional judgement request

Hi everyone,

Jen Cama with DeLauro just reached out to request our professional judgement on a second supplemental for the coronavirus. Below is her question. Would you let me know what I should tell her?

Question: Does NIH, in its professional judgment, recommend any additional funding for coronavirus?

Thanks.

Michelle

From: (b) (6)
Sent: Mon, 9 Mar 2020 13:49:31 -0400
To: Oplinger, Anne (NIH/NIAID) [E]
Subject: Fwd: Media Request: CBC News

From Patty pls decline

Sent from my iPhone

Begin forwarded message:

> **From:** Adam Miller <adam.miller@cbc.ca>
> **Date:** March 9, 2020 at 1:44:59 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
> **Subject: Media Request: CBC News**
>
> Hi Dr. Fauci,
>
> I'm a senior journalist with the health unit at Canada's public broadcaster, CBC News, and I'm hoping to speak with you for a national story on COVID-19 preparedness in the U.S. and Canada.
>
> I'm wondering if you'd be free for a brief phone interview on how prepared the U.S. has been throughout this outbreak and what further efforts need to be taken.
>
> Thanks, I would only need five minutes of your time by phone.
>
> Best,
>
> Adam
>
> --
> Adam Miller
> Senior Writer
> **CBC News**
> **Desk:** 416-205-5719
> **Cell:** (b) (6)
> **Twitter:** @adamsmiller

From: [redacted] (b) (6)
Sent: Mon, 9 Mar 2020 13:23:24 -0400
To: NIAID Public Inquiries
Subject: Fwd: Celiac and Coronavirus

Pls handle

Sent from my iPhone

Begin forwarded message:

> **From:** Tenley Willock [redacted] (b) (6)>
> **Date:** March 9, 2020 at 1:00:11 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Subject: Celiac and Coronavirus**
>
> Hello Dr. Fauci,
> I am a teacher from [redacted] (b) (6) in a school district that closed this week due to the virus scare [redacted] (b) (6) I am [redacted] (b) (6) years old and I have [redacted] (b) (6) What is my vulnerability to getting this virus teaching around young children. I know you have mentioned heart issues and chemotherapy. Can you please give me advice? Thank you so much! Thank you for your hard work!
> Sincerely,
> Tenley Willock
> [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Mon, 9 Mar 2020 13:22:31 -0400
To: Haskins, Melinda (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: Senator Barbara Boxer

Pls advise. Set this up?

Sent from my iPhone

Begin forwarded message:

> **From:** Nicole Burak [redacted] (b) (6)
> **Date:** March 9, 2020 at 1:18:11 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Senator Barbara Boxer**
> **Reply-To:** [redacted] (b) (6)
>
> Dr. Fauci – my name is Nicole Kaneko and I work for Senator Barbara Boxer from California. I know the Senator is [redacted] (b) (6) and she is hoping you may have a few minutes to talk to her via phone regarding an exciting way to test for the COVID-19 virus. Thank you in advance.
>
> Nicole Kaneko
> [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Mon, 9 Mar 2020 13:19:45 -0400
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: Virus Transmission

From Patty
Not sure who responded. Can u take this repeat email.

Sent from my iPhone

Begin forwarded message:

> **From:** DANIEL GAGNON [redacted] (b) (6)
> **Date:** March 9, 2020 at 1:16:07 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Fwd: Virus Transmission**
>
> Dr. Fauci:
>
> I appreciated your office calling me last Thursday regarding my email concern below on the **Covid 19** virus epidemic. The fact that China has a larger percentage of smokers in its population may have something to do with the faster spreading of the virus there. Male smokers out number females by a huge number and are therefore dying in much higher numbers because of that fact.
>
> Has anyone at CDC looked into when a person is around cigarette smokers that the particles of smoke land onto a persons clothing. That person then comes home with those smoke particles on their clothing and they can be shed when the clothes are removed from their body thus placing the possible virus laden particles back into the air at home to infect others. Just smell your clothes the next day and you can no doubt smell smoke on them. Has this case in point been looked into as a possible means of spreading the virus? Since a side effect of the virus is the patient developing pneumonia would giving an elderly person the Prevar 13 shot help strengthen their immune system before the virus ever strikes them?
>
> I wish you &other virologist God Speed with finding a vaccine that will stop the spread of this epidemic.
>
> Daniel Gagnon
> [redacted] (b) (6)

Begin forwarded message:

From: DANIEL GAGNON [redacted] (b) (6)>
Subject: Virus Transmission
Date: February 24, 2020 at 3:48:33 PM EST
To: [redacted] (b) (6)

Hi Dr. Fauci:

I have been a long time admirer of you in the field of modern medicine. This question I have relates to the current Coronavirus circulating around the world. For many years I have informed people that the ways a virus can be passed from person to person isn't always by a sneeze, cough or by touching someones face with their hands. Has anyone in your medical community thought that if someone were smoking and was an infected person that once they expel the smoke particles into the air that those micro smoke particles may contain viruses that were in the respiratory system of an infected person. Everyone I mention this to don't believe that this is possible. What are your thoughts on this matter? If so why hasn't the medical community warned the public about this possibility as I stay away from all establishments that allow smoking on their premises.

Thank you,

Daniel Gagnon
[redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Mon, 9 Mar 2020 13:18:14 -0400
To: Lerner, Andrea (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: Question re: coronavirus infection & pneumococcal vaccination

From patty

Can one of you pls respond. Thx

Sent from my iPhone

Begin forwarded message:

> **From:** Manon Cox <[redacted] (b) (6)>
> **Date:** March 9, 2020 at 1:06:33 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Question re: coronavirus infection &pneumococcal vaccination**
>
> Dear Dr. Fauci,
>
> This is Manon Cox, former CEO of Protein Sciences, the developer of Flublok® .
>
> First of all I would like to thank you for your realistic comments around the ongoing coronavirus outbreak. I am glad to see that not everyone is presenting a "Spanish Flu"- like scenario.
>
> I am reaching out to you b/c I am noticing that so many people including professionals (MD's!) appear to be thinking that people with a coronavirus infection are dying from a cytokine storm whereas my understanding is that pneumonia (whether viral or bacterial) is generally the underlying of the lung failure.
>
> My question to you is: Do we know whether people that have previously received a pneumococcal vaccination might be better protected from death after contracting a severe coronavirus infection? i.e., would it be possible that the coronavirus causes tissue damage resulting in a secondary pneumococcal infection?
>
> I know better than anyone (after working over 15 years on Flublok approval) that it is not realistic to expect a coronavirus anytime soon but if we could message that a pneumococcal vaccine could be beneficial in ultimate outcome it would be good for vaccines in general as we do have pneumovax and Prevnar available.
>
> Thank you for your consideration.

Kind regards, Manon Cox

Sent from Mail for Windows 10

From: (b) (6)
Sent: Mon, 9 Mar 2020 13:16:15 -0400
To: Oplinger, Anne (NIH/NIAID) [E]
Subject: Fwd: Time for an interview with America Magazine?

This is from patty
Pls decline.

Sent from my iPhone

Begin forwarded message:

> **From:** Kevin Clarke <clarke@americamedia.org>
> **Date:** March 9, 2020 at 1:07:02 PM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
> **Subject: Time for an interview with America Magazine?**
>
> Dear Dr. Fauci,
>
> America magazine is the flagship effort of America Media in New York. We are a ministry of the Jesuits of the United States and Canada. America magazine may be the best known Catholic publication in the United States, publish for more than 100 years.
>
> I realize you must be supremely busy under the circumstances, but I thought I would ask if you could spare a few minutes for an interview in New York, over the phone or on remote via Skype for one of our internet programs to talk about the coronavirus landfall here in the United States, how the public can best respond. We would also love to hear how your faith is helping you cope personally, perhaps how your Jesuit background is assisting your decision-making in this drama.
>
> Let me know if you think anything might be possible.
>
> Thanks,
>
> Kevin Clarke
>
> --
> **Kevin Clarke**
> **Senior Editor and Chief Correspondent**
> 1212 Sixth Ave, 11th Floor
> New York, NY 10036
> Phone: 212-515-0130 (office)

Phone: (b) (6) (mobile)
Phone (b) (6) (Friday)
Email: clarke@americamedia.org
Web: www.americamedia.org
America | MEDIA
A JESUIT MINISTRY
Join the conversation: **Twitter <http://twitter.com/Americamag>** | Facebook <http://facebook.com/Americamag> | YouTube <http://youtube.com/Americamag> | Tumblr <http://americaliterary.tumblr.com/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 16:07:16 +0000
To: Alison Galvani
Subject: RE: In press paper about impact of travel restrictions attached

Thanks, Alison.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alison Galvani [redacted] (b) (6)
Sent: Tuesday, March 3, 2020 4:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: In press paper about impact of travel restrictions attached

Hi Tony,

It may not be as pertinent as it was when we submitted it, but I thought you might be interested in our modeling on the global spread of COVID-19. It is in press at PNAS.

We also have a paper submitted to them about ICU and ventilator inadequacy in the US. I'd be happy to send it to you now or wait until after the peer-review process.

Thank you for everything you do to lead us through these crises.

All the best,
Alison

--
Alison Galvani, PhD

Director, Yale Center for Infectious Disease Modeling and Analysis (CIDMA)

Burnett and Stender Families Professor of Epidemiology
Yale School of Public Health
Yale School of Medicine
New Haven, CT 06520

(b) (6)
http://cidma.yale.edu/

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 16:02:31 +0000
To: Jacquelyn (Jackie) Madry-Taylor
Subject: RE: Dr. Marilyn Madry Lightfoote

Thank you.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jacquelyn (Jackie) Madry-Taylor [redacted] (b) (6)>
Sent: Tuesday, March 3, 2020 11:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Dr. Marilyn Madry Lightfoote

Good Morning, Dr. Fauci,

I am [redacted] (b) (6) Dr. Jacquelyn Madry-Taylor. I know she would want me to congratulate you on the outstanding information you are providing the nation about the Coronavirus. The success of [redacted] (b) (6) career was directly related to you allowing her to work in your labs as she began her career in molecular immunology. Your name was mentioned quite frequently during those early years and throughout her work in the federal government. I, [redacted] (b) (6) and other family members miss her so much and know that she would be on top of the information about this new virus as you present it. Thank you so much for being such a catalyst for her success and we applaud your efforts in identifying the source of the virus and finding a vaccine.

Sincerely,

Jacquelyn Madry-Taylor, EdD

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 13:18:02 +0000
To: Kate Dickman
Subject: RE: Thank You

Thank you!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kate Dickman [redacted] (b) (6)>
Sent: Monday, March 9, 2020 9:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Thank You

Dear Dr. Fauci,

I have been reading about your efforts to learn quickly about COVID-19, and subsequently educate the American public about its risks. I wanted to say how grateful I am for your expertise, perseverance and candor.

Updates about what Americans should do to keep safe, and understanding what may be deemed risky for personal and community health, are greatly needed in these days of information (and possibly misinformation) overload. Giving American people current information and clear, updated guidance is the best way to create grassroots, coordinated, widespread effort, while the CDC, NIH, and other government health organizations organize the tops-down approaches to regional screening, emergency care, and COVID-19 research/testing for hopeful vaccination or treatment protocols.

I'm very relieved and assured to have strong voices of reason, experience, and merit helping 'us' navigate these murky waters. I'm grateful for your courage.

Thank you again.

Kate Dickman

[redacted] (b) (6)
resident of [redacted] (b) (6) Northern California

--
Sent from Postbox

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 12:57:57 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Containment Measures

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alex Wolf, Esq. (212)717-2510 <awolf@wolflawyer.com>
Sent: Monday, March 9, 2020 8:43 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Containment Measures

Dear Dr. Fauci,

Why doesn't CDC counsel entire country on need for containment measures as indicated by the following study:

Rapid Response was Crucial to Containing the 1918 Flu Pandemic

black box appears in original

Rapid Response was Crucial to Containing the 1918 Flu Pandemic

Historical Analyses Help Plan for Future Pandemics.

(b) (6)

Would you know whether pulmonary sarcoidosis which has been in remission for years without medication puts one at greater risk of Covid-19 hospitalization as an underlying condition, or would only be higher risk if it was active and one was taking immunosuppressive drugs?

Thank you.

Alexander Wolf, Esq.
60 East 42nd Street
Suite 4600
New York, NY 10165
(b) (6)

From: (b) (6)
Sent: Mon, 9 Mar 2020 06:49:10 -0400
To: Handley, Gray (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C];Erbelding, Emily (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: Fwd: CoV collaboration with Polish Medical Research Agency

Gray:
Please work with Emily to see what we can do for this person, if only with advice.
Thanks,
Tony

Begin forwarded message:

> **From:** Radosław Sierpiński (b) (6)
> **Date:** March 9, 2020 at 6:42:08 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
> **Cc:** "Gupta, Ranjan (NIH/FIC) [E]" (b) (6)
> **Subject: CoV collaboration with Polish Medical Research Agency**
>
> Dear Doctor Fauci,
>
> I hope this e -mail is finding you well and your efforts in fight against Coronavirus epidemics is giving some effects. As you know in Poland we have currently 15 cases of CoV infection and we are also fighting mostly with general society worries than epidemics. We would like also to take part in research on CoV vaccine or drug and Polish Medical Research Agency is planning to start financing some project on it as soon as possible. Both polish medical universities and institutes are fully prepared to take part in such project.
> On behalf of Polish Minister of Health Prof. Lukasz Szumowski I would like to kindly ask you for some support and collaboration options with NIH in this very delicate issue. Maybe NIH can take some advisory role in our scientific project or Polish scientists may take some part in your work bilaterally.
>
> Looking forward to hearing from you,
>
> **Radosław Sierpiński MD, PhD**
> **President of Medical Research Agency in Poland**
> (b) (6)
>
> AGENCJA
> BADAŃ
> MEDYCZNYCH

Medical Research Agency
ul. S. Moniuszki 1A
00-014 Warszawa
www.abm.gov.pl

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 09:57:48 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: (b) (6)
Subject: FW: Connecting with Tony Fauci
Attachments: Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.pdf

Please take a look and respond

-----Original Message-----
From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Monday, March 9, 2020 5:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6)>; Austin, Christopher (NIH/NCATS) [E] (b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Subject: FW: Connecting with Tony Fauci

Passing this on in case Bill Chin's idea might be of interest.

Francis

-----Original Message-----
From: William Chin (b) (6)>
Sent: Sunday, March 8, 2020 10:48 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Baker, Rebecca (NIH/OD) [E] (b) (6)>; Austin, Christopher (NIH/NCATS) [E] (b) (6)>; Roger Glass (b) (6)
Subject: Connecting with Tony Fauci

Hi Francis et al, I write to get a message to Tony, who clearly is on the COVID-19 front lines of these days and "everywhere." At this early stage, you may agree that it is possible that containment and/or mitigation will not completely solve the current pandemic. Instead, effective treatment or amelioration of the worst complications is necessary. In this spirit, I have an idea that was spurred by a letter in Lancet last month authored by AI Benevolent (attached). In this communication they suggest that baricitinib (Oluminant; a JAK1/2 inhibitor registered by Lilly for the treatment of rheumatoid arthritis), using in silico techniques. might be useful in the treatment advanced COVID-19 pneumonia/ARDS identified . Baricitinib could possibly blunt the cytokine storm seen in the most severely affected patients via inhibition of JAK1/2, but also decrease viral entry in AT2 pulmonary cells and myocardial cells via inhibition of GAK and AAKI. It is has a relatively short plasma half-life and hence could be more useful than Roche's tocilizumab/Actemra). Baricitinib has a good safety profile although as a drug to treat autoimmunity it is formally contraindicated in patients with infections, this could be offset by treatment patients with anti-virals such as Gilead's remdesivir, etc. Perhaps you folks have already thought about/discussed its use but if not I'd like a chance to chat about my additional thoughts. Thanks. Bill

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 03:10:28 +0000
To: Glenda Gray;Rancourt, Anne (NIH/NIAID) [E];Dieffenbach, Carl (NIH/NIAID) [E]
Subject: RE: 'You don't want to go to war with a president'

Thanks, Glenda!

From: Glenda Gray <Glenda.Gray@mrc.ac.za>
Sent: Tuesday, March 3, 2020 9:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Rancourt, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Dieffenbach, Carl (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: 'You don't want to go to war with a president'

Dear Tony

Wonderful article, proud to be associated with you

Subject: 'You don't want to go to war with a president'

https://www.politico.com/news/2020/03/03/anthony-fauci-trump-coronavirus-crisis-118961

regards
Glenda

Glenda Gray
President & CEO South African Medical Research Council : Executive Management

South African Medical Research Council
Tel: +27 21 9380905 | Cell: [redacted] (b) (6)
Francie van Zijl Drive, Parow Valley | Cape Town | Western Cape
www.samrc.ac.za

Disclaimer - The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful. This email has been automatically archived by Mimecast SA (Pty) Ltd This e-mail and its contents are subject to the South African Medical Research Council e-mail legal notice available at http://www.samrc.ac.za/about/EmailLegalNotice.htm.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 03:04:02 +0000
To: Birnbaum, Linda (NIH/NIEHS) [V]
Subject: RE: Thank you

Linda;
Thanks for the note. I would cancel if I were you.
Tony

From: Birnbaum, Linda (NIH/NIEHS) [V] [redacted] (b) (6)
Sent: Sunday, March 8, 2020 1:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Thank you

Hi Tony,

Just wanted to say thank you as a former colleague and friend for speaking truth to power during this coronavirus crisis.

So, am I right in thinking traveling to California for my major science meeting and some university lectures in a week should be canceled? I am [redacted] (b) (6)

Thx

Linda

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 02:59:07 +0000
To: Thomas R. Frieden
Subject: RE: FYI - guess which [redacted] (b) (6) I was thinking of....

Great article. Glad to be the anonymous subject of your discussion. ☺

From: Thomas R. Frieden [redacted] (b) (6)
Sent: Sunday, March 8, 2020 3:32 PM
To: Deborah Birx [redacted] (b) (6); Deborah Birx [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Redd, Stephen (CDC/DDPHSIS/OD) [redacted] (b) (6)>; Schuchat, Anne MD (CDC/OD) [redacted] (b) (6)>
Subject: FYI - guess which [redacted] (b) (6) I was thinking of....

New article re nursing home restrictions and more here.

From: Tom Frieden [redacted] (b) (6)>
Date: Sunday, March 8, 2020 at 2:35 PM
To: Tom Frieden [redacted] (b) (6)
Subject: Nursing homes are ground zero for COVID19 -- and what more we can do to save lives in the pandemic

Dear Colleague,

Two weeks ago it was clear that COVID-19 would become a pandemic, and, sadly it has.

Now the United States is in the acceleration phase and cases, clusters, and large outbreaks will occur in many parts of the country.

I outline steps we can take to reduce the harms. The core concept to protect the most vulnerable. First, restrict visits to nursing homes. All of us can play a part reducing infections. Medically vulnerable people can protect themselves by reducing social contacts. I'm not sure I'd go quite as far as my good friend Bill Schaffner and say they should become semi-hermits, but that's certainly a helpful frame of reference. Health care needs to get much safer, and ready to surge safely. And we need to stop mass gatherings, consider telework, figure out whether closing schools will help, and more.

Read what I've posted about ground zero in the COVID-19 pandemic in the US here.

I've shared on Twitter if you'd like to disseminate.

We'll all be working together to protect as many people as quickly as possible.

Thank you,

Tom

Tom Frieden, MD, MPH
President and CEO
(b) (6)t
(b) (6)

RESOLVE
TO SAVE LIVES
AN INITIATIVE OF VITAL STRATEGIES

RESOLVE TO SAVE LIVES
An initiative of Vital Strategies

STAY CONNECTED
www.resolvetosavelives.org facebook twitter

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 01:49:23 +0000
To: Mark Feinberg
Subject: RE: Thanks so much

Mark:
Thanks for the note. Much appreciated.
Bet,
Tony

-----Original Message-----
From: Mark Feinberg <[redacted] (b) (6)>
Sent: Sunday, March 8, 2020 9:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Thanks so much

Dear Tony,

I hope you are doing well despite your extraordinarily busy schedule addressing the COVID-19 outbreak.

I just wanted to send you a note to offer sincere thanks and deep admiration for your tremendous efforts to provide the public with clear, insightful and accurate information about this very serious public health threat and for your great leadership in helping to guide efforts to respond to it in the most effective and scientifically grounded way.

Our nation is so fortunate to have your full and expert engagement in this response.

I can only imagine how busy you are and you need not worry about responding to this note. However, I did want to share one voice of appreciation and thanks.

Very best,

Mark

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 01:37:26 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Countering COVID-19

From: Clayton Conger [redacted] (b) (6)>
Sent: Sunday, March 8, 2020 9:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Countering COVID-19

Dr. Anthony Fauci
Director of the National Institute of Allergy and Infectious Diseases

Dear Dr. Fauci:

It occurred to me that if viruses contain an iron atom, perhaps a form of magnetic treatment might stop or reduce the severity of the COVID-19 virus, so I investigated and found that viruses have one atom of iron. My suggestion is that experimentation on victims of the virus be conducted, perhaps by inserting a tiny magnet into their lungs to see if it might gather up the viruses circulating in the victim. Perhaps external application of magnetism would work as well, I'm sure your scientists will have even better approaches to solving this problem. I'm a problem solver, having published a book that solves many of the Earth´s problems: "Thinking Outside The Oven -- Concomitant Concepts and Synergistic Solutions for the 21st Century" (available at Barnes & Noble and Amazon). I'm working on a sequel and if you find my idea useful I´ll include a chapter on it.

Very respectfully,
Ned Conger

[redacted] (b) (6)

C.N. Conger
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 01:33:55 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Record a short interview with me for a UPenn course?

Sorry no.

From: Scheyder, Elizabeth C [redacted] (b) (6)>
Sent: Sunday, March 8, 2020 6:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Record a short interview with me for a UPenn course?

Dear Dr. Fauci,

I am embarrassed to admit that I was not familiar with your name when I read the story about you in today's NY Times, but I was most impressed by the statement in the first sentence that you are "widely respected for [your] ability to explain science without talking down to [your] audience".

I'm putting together the first offering of CLCH 300: Communicating Science, as part of the University of Pennsylvania's new online Certificate in Climate Change. (https://lpsonline.sas.upenn.edu/academics/certificates/climate-change) A brief recorded conversation with you about your strategies for communicating without being patronizing would be most enlightening for my students.

The students in this course will be coming from a wide variety of backgrounds, and potentially from all over the globe. I think they would love to hear from a scientist who is so good at communicating his field of study to different audiences. And let's face it, as soon as you say "NIH" as COVID-19 swirls around the globe, their ears will certainly perk up! I think the students would find our interview very engaging and informative.

The first run of the course will be from May 26 to July 20, 2020, but we can record the interview (online) any time, since I know you are already over-extended right now. I think 15 minutes would be plenty, and I would be happy to send you questions that I plan to use to guide the conversation in advance. If a synchronous conversation is impossible given your schedule, I would be happy to just send you a couple of questions and ask you to use them to guide a 10-15 minute video that you record yourself.

Please let me know what you think of this, and I will send you the syllabus when it's finalized, including where our interview would fit. Then I can begin the process of coordinating this with the Associate Director of our Online Learning Studio.

Sincerely,
Elizabeth

--
Elizabeth C. Scheyder, Ph.D., P.E.
SAS Computing
Senior Instructional Technology Project Leader

& Lecturer in SAS
Williams 441B

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 01:32:52 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: can you use a miRNA-seq assay to detect covid-19 in blood samples?
Attachments: GSE81852 MERS vs Mock control PCA p=2.1e-8 q=7.79e-7 2 variables 8March2020.tif, GSE81852 MERS vs Mock control Hierarchical clustering heatmap p=2.1e-8 q=7.79e-7 2 variables 8March2020.tif, GSE81852 MERS vs Mock control PCA p=6.4e-7 q=4.2e-5 10 variables 8March2020.tif, GSE81852 MERS vs Mock control Hierarchical clustering heatmap p=6.4e-7 q=4.2e-5 10 variables 8March2020.tif

---

From: Hellmich, Helen <[redacted] (b) (6)
Sent: Sunday, March 8, 2020 5:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: can you use a miRNA-seq assay to detect covid-19 in blood samples?

Dr. Fauci, how are you sir?

Long ago, in the early 90's, I was a post-doctoral fellow in the Laboratory of Viral and Molecular Pathogenesis at NIH. I don't know if the same lab is still there. Now I work on brain injury and Alzheimer's but my interest in viruses and mechanisms of viral pathogenesis has not waned and the recent covid-19 outbreak prompted me to do a little investigation on my own.

My studies of blood microRNA changes after TBI and AD suggest that principal component analysis of distinct changes in circulating miRNAs can identify the patient population. MicroRNA alterations can be measured by real-time PCR which I presume is the basis of the test that is developed for this disease but I am analyzing blood miRNA-seq expression profiles and now it is possible to quickly sequence blood samples in a few hours and get accurate results. Blood gene expression in my studies was more variable (lots of RNases in blood) so I found that microRNAs are much more stable in blood and serum samples.

I attach an example of a PCA/hierarchical clustering heatmap analysis of a GEO dataset for MERs-coV from 2016 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81852
I performed the PCA and heatmap analyses at two different stringencies and you can see that the patients can be unequivocably distinguished from the controls at very significant p and FDR values.

Just a thought but many clinical centers, hospitals, academic institutions can quickly perform transcriptome-wide sequencing. Blood RNA can be isolated in 1-2 hrs, sequencing libraries made in a few hres and one miRNA sequencing run can handle up to 48 samples and the data can be quickly analyzed.

Just my two cents on how NIH could accelerate the analysis of new blood samples for this new strain of coronanvirus. You could mobilize hundreds of sequencing centers to help in the analysis.

Regards

Helen Hellmich, PhD
Associate Professor
Department of Anesthesiology
University of Texas Medical Branch
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 01:32:20 +0000
To: Erik Blutinger
Subject: RE: Fighting the fight

Thanks, Erik.

From: Erik Blutinger [redacted] (b) (6)
Sent: Sunday, March 8, 2020 7:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fighting the fight

Tony,

It's been so inspiring seeing you fight tirelessly against COVID-19, sticking to the facts and stepping up to explain on a daily basis.

If there's anything I can do to help from the world of emergency medicine beyond patient care, please let me know. Whether that means taking on a new project or pushing my specialty organization, the American College of Emergency Physicians (ACEP). I sit on their board and keep looking for ideas to help fight this pandemic.

Best wishes,
Erik

—
Erik J. Blutinger, MD, MSc
Department of Emergency Medicine
Mount Sinai Queens Hospital
(c) [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 01:30:35 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID-19 model

From: William Schiesser [redacted] (b) (6)
Sent: Sunday, March 8, 2020 6:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: William Schiesser [redacted] (b) (6)>
Subject: COVID-19 model

Hello Dr. Fauci,

May I bring to your attention a prototype computer-based mathematical model for COVID-19 dynamics. I will be glad to send some details if you think they would be of interest.

Thank you for your consideration of this query.

W. E. Schiesser, PhD, ScD
http://www.lehigh.edu/~wes1/id_cover2.pdf

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 01:27:36 +0000
To: [redacted] (b) (6)
Subject: RE: California DMV Coronavirus exposure danger

I recommend that you keep trying to work with Governor Newsom's office since this is vey specific for the state of California.

From: [redacted] (b) (6)>
Sent: Sunday, March 8, 2020 8:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: California DMV Coronavirus exposure danger

Dear Dr. Fauci,

I am writing to alert you to what I believe is a serious coronavirus health threat in California that is being posed by the California Department of Motor Vehicles.

It has long been the policy of the California DMV that all drivers OVER 70 YEARS OLD must renew their drivers licenses IN PERSON at DMV offices.

DMV offices are notorious for being extremely crowded and requiring long wait times where people are breathing on each other touching each other and undisinfected surfaces and touch screens for hours.

As far as I am aware DMV offices are never sanitized so germs from thousands of people can remain there
for weeks on end.

This is obviously a dangerous environment for anyone in the current worldwide coronavirus emergancy yet nobody in the news media is reporting on it or even seems aware of the danger.
In light of your recent statement warning people over to 60 to avoid crowds this California DMV policy seems to be incredibly irresponsible and even life threatening but nobody is doing anything about it.

[redacted] (b) (6) . Only one day earlier on March 4 California Governor Gavin Newsom
declared a State of Emergency in California to prevent the spread of coronavirus.

I find this situation to be utterly absurd since Newsom is allowing California citizens to be exposed to exactly the kind of coronavirus danger he claims to be preventing and apparently does not even know that the DMV is totally contradicting his emergency declaration, the CDC recommendations, the California State Health Department, the Los Angeles County Health Department, and the Pasadena City Health Department.

[redacted] (b) (6) . I am concerned that nobody seems to see the obvious public health threat. None of the relevant public health agencies have any information about this on their websites and the California DMV website makes NO MENTION WHATSOEVER of Coronavirus as a health threat in there overcrowded offices.

I would sincerely like to know what you make of this dangerous DMV policy. I also want to tell you that the Californai DMV is currently advertising on the radio asking even more people to crowd DMV offices in order to
get the REAL ID license.

REAL ID further exacerbates the danger by drawing in more than NINE MILLION Californians to leave their germs in DMV offices over the next few months at the exact time we are in the midst of the greatest health emergency of this century and the most important recommendation is to AVOID CROWDS and stay at least six feet away from other people. Try staying six feet away from anyone in a crowded DMV office where hundreds of people are stuffed in like sardines.

Obviously a rational policy would be to suspend the requirement for drivers over 70 to renew in person and simply
let them renew by mail until the coronavirus emergency is over.
The same should be done for REAL ID. A total suspension to protect public health in a crisis is the only sane thing to do.

If I were the Director of the California DMV I would close all offices immediately and disinfect every inch of them, and not reopen until the coronavirus emergency is over.
I would require that all DMV business should be done by mail or internet until the coronavirus threat is over.

Please tell me what you think about all this and I will forward your response to local Pasadena officials since state level officials are almost impossible to contact even in an emergency when they most need to get this kind of information from the public but apparently do not want to know about bad news.

I greatly appreciate your voice of reason in these scary times. I wish the officials of the State of California
were as reasonable but they are apparently oblivious to a serious and unnecessary danger being created by
one of their own state agencies.

Sincerely

Robert Maine
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 01:24:37 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: URGENT: [redacted] (b) (4)
[redacted] (b) (4)
Attachments: [redacted] (b) (4)

Please handle.

From: Michael Matin <michael.matin@hdltherapeutics.com>
Sent: Sunday, March 8, 2020 8:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: URGENT: [redacted] (b) (4)
Importance: High

Dear Dr. Fauci:

[redacted] (b) (4)

Please contact us at your earliest convenience so that we may provide you with further data and information concerning this treatment.

Best,

Michael M. Matin
Chairman & CEO
HDL Therapeutics, Inc.
60HDL Theapeutics1 21st Street, Suite 300
Vero Beach, FL 32960
[redacted] (b) (6)

From: [redacted] (b) (4)
Date: Friday, March 6, 2020 at 6:18 PM
To: [redacted] (b) (4)
Cc: [redacted] (b) (4)
[redacted]
Subject: [redacted] (b) (4)

Dear [redacted] (b) (4)::

(b) (4)

[redacted]

(b) (4)

[redacted]

(b) (4)

[redacted]

(b) (4)

[redacted]

(b) (4)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 01:23:24 +0000
To: Krasne, Robert
Subject: RE: Thank you!!!

Bob:

Many thanks for your note.

Best,
Tony

From: Krasne, Robert <rkrasne@steinmancommunications.com>
Sent: Sunday, March 8, 2020 7:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Thank you!!!

Tony,

Thank you for the science-based sanity you are bringing to the COVID-19 challenges. I follow your public comments with great interest (and publish them in our newspapers here in Pennsylvania) and find solace that you are leading the efforts to address this extraordinary health care challenge.

I cannot imagine the challenges you are facing, from disinformation to pure exhaustion, not to mention the scientific challenges that this virus brings. However, if anyone is capable of wrestling these challenges to the ground, it is you.

You have my profound appreciation and admiration.

Best wishes to you, (b) (6) and your family.

Bob

Robert M Krasne | Chief Executive Officer
STEINMAN COMMUNICATIONS
(b) (6) | SteinmanCommunications.com
8 West King St, Lancaster, PA 17603

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 01:19:21 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus Treatment Question

Please handle.

From: Barb E [redacted] (b) (6)
Sent: Sunday, March 8, 2020 7:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Coronavirus Treatment Question

3-8-2020

Dr. Anthony S. Fauci;

I have attached an article I read online about a doctor in Taiwan treating patients with Coronavirus, with a combination of anti-viral drugs. Since the treatment helped the patients, I was wondering why they are not treating patients in the United States with those drugs.

Thank you.

Sincerely,
Barbara Eagan

https://www.yahoo.com/news/cocktail-flu-hiv-drugs-appears-124753996.html

By Panu Wongcha-um

,
Reuters•February 2, 2020

Cocktail of flu, HIV drugs appears to help fight coronavirus: Thai doctors

Reuters•February 2, 2020

By Panu Wongcha-um

BANGKOK (Reuters) - Thai doctors have seen success in treating severe cases of the new coronavirus with combination of medications for flu and HIV, with initial results showing vast improvement 48 hours after applying the treatment, they said on Sunday.

The doctors from Rajavithi Hospital in Bangkok said a new approach in coronavirus treatment had improved the condition of several patients under their care, including one 70-year-old Chinese woman from Wuhan who tested positive for the coronavirus for 10 days.

The drug treatment includes a mixture of anti-HIV drugs lopinavir and ritonavir, in combination with flu drug oseltamivir in large doses.

"This is not the cure, but the patient's condition has vastly improved. From testing positive for 10 days under our care, after applying this combination of medicine the test result became negative within 48 hours," Dr. Kriangska Atipornwanich, a lung specialist at Rajavithi, told reporters.

"The outlook is good but we still have to do more study to determine that this can be a standard treatment."

Chinese health officials have already been administering the HIV and flu drugs to fight the coronavirus. The use of the three together in a cocktail seemed to improve the treatment, the Thai doctors said.

Another doctor said that a similar approach in two other patients resulted in one displaying some allergic reaction but the other showed improvement.

"We have been following international practices, but the doctor increased the dosage of one of the drugs," said Somsak Akkslim, director-general of the Medical Services Department, referring to the flu medicine Oseltamivir.

Thailand has recorded 19 cases of coronavirus. Of the Thai patients, eight have recovered and gone home while 11 are still under treatment in hospitals.

Somsak said the health ministry will meet on Monday to discuss the successful treatment in the case of the 70-year-old but said it is still too soon to say that this approach can be applied to all cases.

Initially we will apply this approach only to severe cases," he said.

(Reporting by Panu Wongcha-um; Editing by Peter Graff)

Sent from Mail for Windows 10

✓ Virus-free. www.avast.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 00:45:58 +0000
To: Collins, Francis (NIH/OD) [E];Erbelding, Emily (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E]
Cc: Austin, Christopher (NIH/NCATS) [E];Tabak, Lawrence (NIH/OD) [E];Conrad, Patricia (NIH/NIAID) [E];[redacted] (b) (6);Marston, Hilary (NIH/NIAID) [E]
Subject: RE: ACE2

Emily/Cristina:
Please contact Chris Austin and see if there is anything that we can do to help/coordinate with them.
Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Sunday, March 8, 2020 2:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Austin, Christopher (NIH/NCATS) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Subject: FW: ACE2

Hi Tony,

[redacted] (b) (5). Can your team help?

Best, Francis

From: Austin, Christopher (NIH/NCATS) [E] [redacted] (b) (6)>
Sent: Sunday, March 8, 2020 1:51 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Subject: RE: ACE2

Hi Francis,

Very interesting paper. Larry likely let you know about the enclosed exchange, but enclosed if not.

[redacted] (b) (5)

Chris

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Saturday, March 7, 2020 11:07 PM
To: Austin, Christopher (NIH/NCATS) [E] [redacted] (b) (6)
Subject: RE: ACE2

Structure of the coronavirus spike protein and ACE2 interaction is just out...

From: Collins, Francis (NIH/OD) [E]
Sent: Saturday, March 7, 2020 10:58 PM
To: Austin, Christopher (NIH/NCATS) [E] [redacted] (b) (6)
Subject: ACE2

Yo Chris,

[redacted] (b) (5)

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 00:37:42 +0000
To: Greg Simon
Cc: Erbelding, Emily (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: TXA127 for COVID-19 pneumonia--CONFIDENTIAL

Greg:
Thanks for this. I will bring it to our group. I hope that all is well with you.
Warm regards,
Tony

From: Greg Simon [redacted] (b) (6)>
Sent: Friday, March 6, 2020 7:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: TXA127 for COVID-19 pneumonia--CONFIDENTIAL

here is the paper i mentioned from a friend of mine for your consideration. Thank you for all you're doing
Greg

---------- Forwarded message ---------
From: **Rick Franklin** [redacted] (b) (6)>
Date: Mon, Mar 2, 2020 at 5:46 PM
Subject: TXA127 for COVID-19 pneumonia--CONFIDENTIAL
To: Greg Simon [redacted] (b) (6)>

Here's the paper. Let me know what you think.

Best, Rick

--
Greg Simon
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 23:55:07 +0000
To: Redd, Stephen (CDC/DDPHSIS/OD);Birx, Deborah L ([redacted] (b) (6));Grigsby, Garrett (HHS/OS/OGA);Kadlec, Robert (OS/ASPR/IO);Redfield, Robert R. (CDC/OD)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6);Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: [redacted] (b) (5)
[redacted]
Attachments: SSRN-id3549276.pdf

Team:

[redacted] (b) (5)

Thanks,
Tony

Paper attached.

Dalton, Craig and Corbett, Stephen and Katelaris, Anthea, Pre-Emptive Low Cost Social Distancing and Enhanced Hygiene Implemented before Local COVID-19 Transmission Could Decrease the Number and Severity of Cases. (March 5, 2020). Available at SSRN: https://ssrn.com/abstract=3549276 or http://dx.doi.org/10.2139/ssrn.3549276

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 22:56:20 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: For Novel Coronavirus of Antiviral Treatment .

FYI

From: 黑羽硝子 [redacted] (b) (6)>
Sent: Sunday, March 8, 2020 9:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: For Novel Coronavirus of Antiviral Treatment .

Dear Director of NIAID , Anthony S. Fauci MD . :

Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs

Version 2

Preprint

revised on 20.02.2020, 00:05 and posted on 20.02.2020, 16:51 by Rimanshee Arya Amit Das Vishal Prashar Mukesh Kumar

The cases of 2019 novel coronavirus (SARS-CoV-2) infection have been continuously increasing ever since its outbreak in China last December. Currently, there are no approved drugs to treat the infection. In this scenario, there is a need to utilize the existing repertoire of FDA approved drugs to treat the disease. The rational selection of these drugs could be made by testing their ability to inhibit any SARS-CoV-2 proteins essential for viral life-cycle.

We chose one such crucial viral protein, the papain-like protease (PLpro), to screen the FDA approved drugs in silico. The homology model of the protease was built based on the SARS-coronavirus PLpro structure, and the drugs were docked in S3/S4 pockets of the active site of the enzyme. In our docking studies, sixteen FDA approved drugs, including chloroquine and formoterol, was found to bind the target enzyme with significant affinity and good geometry, suggesting their potential to be utilized against the virus.

FUNDING

Department of Atomic Energy, Government of India

Dear Dr. Fauci :

We are an individual researcher from Taiwan Biochemical Papain, my name is Terry Wang. Without funding support, [redacted] (b) (4)

[redacted] (b) (4)

I am willing to participate in the process in the United States.

@@@There are many ways to perform the treatment !

Sincerely,

Terry Wang in Taiwan.

Please contact me :

Email: [redacted] (b) (6)

Address: [redacted] (b) (6)

Cell phones : [redacted] (b) (6)

Line ID [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 18:55:46 +0000
To: Gregg Gonsalves
Subject: RE: We Are Desperate for Advice

Gregg:

Understood. I appreciate your note. I will keep pushing.

Best regards,
Tony

From: Gregg Gonsalves [redacted] (b) (6)
Sent: Sunday, March 8, 2020 2:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: We Are Desperate for Advice

Tony, that part of the message was not directed at you. Peter Staley and I have seen you in action on TV and I've forced [redacted] (b) (6) to watch you talking about social distancing, since she says the President says she has nothing to worry about. Bob Redfield and Secretary Azar haven't been as forthright as you have.

The main thing that concerns many people I know: the roll-out of testing, surveillance has been botched and we're likely to have cases of COVID in our communities already without knowing it. Meanwhile some corporations, some universities, some other institutions have started to put social distancing into place, with a few municipalities doing the same, but there is no real guidance from CDC on when to act for most of us. There are plenty of instructions about getting prepared, but all seem to point towards waiting until there is an outbreak in one's community to do anything substantial, which seems if you'll excuse my language, ass-backwards, as one you see multiple cases, you're likely to already have widespread community transmission.

I think this piece by Bill Hanage at Harvard explains where a lot of us are right now:
https://www.washingtonpost.com/outlook/coronavirus-testing-united-states/2020/03/05/a6ced5aa-5f0f-11ea-9055-5fa12981bbbf_story.html

Stay well, we need you more than ever (and I mean that from the bottom of my heart). Most of the career civil servants on the email were copied not to chastise, it's the political appointees that most think got us into this mess.

g

From: Anthony Fauci <[redacted] (b) (6)
Date: Sunday, March 8, 2020 at 1:50 PM
To: Gregg Gonsalves [redacted] (b) (6)>
Subject: RE: We Are Desperate for Advice

Gregg:

I am surprised that you included me in your note. I genuflect to no one but science and always, always speak my mind when it comes to public health. I have consistently corrected misstatements by others and will continue to do so. I am including two links from Sunday

Shows today where I am extremely explicit and forceful. I would be happy to chat with you about this.

https://app.criticalmention.com/app/#/clip/public/2beb07d0-f72d-45b9-9ed6-60754bd93fa7?show_sentiment=false

https://app.criticalmention.com/app/#/clip/public/183207e9-e6e1-4164-b1e5-53e0dddbc363?show_sentiment=false

Best regards,
Tony

From: Gregg Gonsalves [redacted] (b) (6)>
Sent: Sunday, March 8, 2020 11:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Jeff Trammell [redacted] (b) (6)>; Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>; Schuchat, Anne MD (CDC/OD) [redacted] (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6) Birx, Deborah L [redacted] (b) (6)>; Azar, Alex (OS/IOS) [redacted] (b) (6); Redfield, Robert [redacted] (b) (6)>; Harrison, Brian (HHS/IOS) [redacted] (b) (6)>
Subject: We Are Desperate for Advice

Dear Tony, Bob and Deb et al,
The AIDS experts among you know me well. We've been first adversaries then colleagues for over 30 years.
They also know I can't keep my mouth shut, which is a virtue and a failing, depending on the context.
Now:
There are thousands of people waiting for advice from our federal government on broader social distancing measures in light of the fact that our failure in early testing and surveillance means the coronavirus is likely already spreading in our communities.
If you thought the ire of AIDS activists 30 years ago was tough, the anger now spreading among researchers, scientists, clinicians *and activists* is going to be a conflagration.
All we see is genuflection in word and deed from most of you to a White House that wants this all to magically go away.
Yes, I know you're all doing your best and behind the scenes our federal government is hard at work. For those I know, I don't doubt your commitment to public service.
But time is running out.
We need vocally, unequivocal leadership now, that offers real guidance to communities about what to do, what might happen next.
Your own legacies will be defined by this moment, what you do and what you don't, what you shy away from saying because you fear for your jobs or your short-term fortunes in the eyes of the President.
The status quo is untenable.
It's going to get people killed by this virus.

Gregg

Gregg Gonsalves PhD
Assistant Professor, Epidemiology of Microbial Diseases
Yale School of Public Health

Associate Professor (Adjunct) and Research Scholar
Yale Law School

Co-Director, Yale Global Health Justice Partnership
Co-Chair, Global Health Studies Faculty Committee, Yale College
Affiliated Faculty, Addiction Medicine
Affiliated Faculty, Jackson Institute for Global Affairs

(b) (6) [redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 17:06:22 +0000
To: Conley, Sean P. CDR USN WHMO/WHMU
Cc: Munster, Vincent (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];[redacted] (b) (6);Lerner, Andrea (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Birx, Deborah L ([redacted] (b) (6))
Subject: FW: Stability data - spoke to Vincent.
Attachments: 2020-03-03 Manuscript Stability_MASTER.docx

Sean:
As per our recent conversation, here is a paper that is under review at the NEJM. It is from Dr. Vincent Munster who works in my institute. It confirms what we surmised that after almost two weeks, the chances of viable virus being present in the facility is extremely low based on his studies reported in this paper. Figure 1B in the paper is of particular relevance regarding our discussion of surfaces.
Best regards,
Tony

From: Marston, Hilary (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Saturday, March 7, 2020 3:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Stability data - spoke to Vincent.

Talked to Vincent. Attaching his manuscript, under review with NEJM. Vincent is available at [redacted] (b) (6) if you need him.

How the experiments were done:
Aerosol – A solution of live virus was made and aerosolized in a rotating drum (keeping it in aerosol form); at various time points, air was removed and amount of virus measured (using end-point titration on Vero cells).

Surface – A base solutions of live virus was made and placed on specific surfaces (plastic, etc) and at various time points, coating was taken away and virus contained was titrated.

Note that surface experiments with proteinaceous material (e.g., respiratory secretions) are underway, as are variations in relative humidity and temperature.

How do you interpret aerosol data?
Decay in aerosols occurs over three hours, so if the virus is aerosolized (via aerosol-generating procedures or cough), the moment it drops below a certain threshold, it would be hard to get an infectious dose/infection. Of course we do not actually know the infectious dose, which limits our ability to give firm guidance based on this data.

How do you interpret the surface stability data?
Copper seems to have some virucidal effect, as is seen with other viruses. Plastic and stainless steel don't have much of an effect on the virus itself, and the virus persists for some time. As for cardboard, difficult to interpret because the surface absorbs a good deal, but there is some immediate decay.

Should we be concerned about packages based on your data?
This is of far lower concern than droplet and other fomite transmission. Typical shipping will allow ample time for viral decay, and the cardboard itself seems to have some direct effect on the virus (either through absorption or other effect). For example, in the experiment, Vincent applied
10e5 viral particles/mL and it drops 2 logs to 10e3 immediately, indicating that either due to absorption or direct effect on the virus.

Of course, if a mail carrier coughs on a package and then someone touches it directly after, there may be a risk. The typical shipping situation is likely not a concern.

Why are SARS-CoV-2 vs. SARS-CoV-1 different?
For the cardboard data in particular, there is a difference seen between SARS-CoV-2 and 1, which is likely due to error/variation in surface.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 14:30:13 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: A Coronavirus Deterrent?

From: Ron Jacobs [redacted] (b) (6)>
Sent: Sunday, March 8, 2020 10:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: A Coronavirus Deterrent?

Would the use of a facial steam inhalator cause nonviability of the virus in someone who had contracted the virus?

Would spending time in a steam room have a similar effect?

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 14:29:44 +0000
To: [redacted] (b) (6);'Birx, Deborah L';Redfield, Robert R. (CDC/OD);Kadlec, Robert (OS/ASPR/IO);Redd, Stephen (CDC/DDPHSIS/OD)
Subject: FW: Hazardous use of Remdesivir in CoV-19
Attachments: COVID19 linee guida trattamento 01MAR.pdf.pdf.pdf

There may be nothing to this, but we should at least be aware.

From: rosario leopardi [redacted] (b) (6)>
Sent: Sunday, March 8, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Hazardous use of Remdesivir in CoV-19

Dear Dr Fauci,

I am copying below a letter I just sent to the editors of Lancet and NEJM that I think you should also read. It's informal as it is not meant for publication but just as a concern. Since I no longer work as a virologist, I am formally out of the field. I am however active as chief psychiatrist in Stockholm, Sweden. If you have doubts as to my expertise as a virologist or a physician, Dr Bernard Roizman at U of C knows me very well, as Markus Heilig does here in Sweden.

"I have noticed a striking difference in mortality by CoV-19 in different countries. China and Italy have a mortality that's at least 6-fold higher than that in South Korea. So far Germany and Scandinavia, totalling over 1300 cases, have not reported a single death. That's over a 35-40 fold difference.

Looking at the data more closely, I have found that China and Italy have been using the antiviral Remdesivir (Gilead Sciences) extensively on many patients in intensive care, justified as "compassionate use". In the epidemic areas of Italy this drug is now part of treatment guidelines for hospitalised patients, used on every single patient in "critical condition". (see attachment). The "rationale" is simply that the first two cases treated at the Spallanzani Hospital in Rome received this drug, and...well, actually survived.

Remdesivir has never passed a Phase 3 trial, but has already made big headlines in major international newspapers. Neither South Korea nor Germany or Scandinavian countries have yet used this drug.

I understand that this is a (relatively) long shot, but given the number of lives at stake, I would recommend that a carefully scrutiny by the scientific community on the use of this drug is warranted.

I have no conflict of interest.

Thank you for your attention".

Sincerely,

Rosario Leopardi, MD, PhD

Forensic Psychiatry Care Clinic

[redacted] (b) (6), Sweden

cell: [redacted] (b) (6)

Sent from Outlook

From: [redacted] (b) (6)
Sent: Sun, 8 Mar 2020 09:59:21 -0400
To: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: BIO Coronavirus Collaboration Initiative March 12th Summit - POSTPONED

Begin forwarded message:

> **From:** Phyllis Arthur <parthur@bio.org>
> **Date:** March 8, 2020 at 9:51:46 AM EDT
> **To:** Phyllis Arthur <parthur@bio.org>
> **Cc:** Jennifer Alton <jenn.alton@pathwaypolicy.com>, Ellen Carlin [redacted] (b) (6)>, Amy Walker <awalker@bio.org>, Gregory Frank <gfrank@bio.org>, Hannah Dorsey <hdorsey@bio.org>
> **Subject: BIO Coronavirus Collaboration Initiative March 12th Summit - POSTPONED**
>
> Dear Colleagues,
>
> BIO is heartened that so many of you have expressed interest in joining us for the BIO Coronavirus Collaboration Initiative Summit planned for March 12, 2020. Given the evolving circumstances surrounding the COVID-19 outbreak, and after discussions with our Board leadership, we have decided to postpone the BIO Summit so that we can make adequate arrangements to hold the meeting virtually. We made this decision out of an abundance of caution, so as to avoid placing anyone at unnecessary risk of exposure while we work together to improve our nation's ability to respond to this outbreak. We will re-schedule this virtual meeting within the next two weeks using a digital technology that can allow for robust discussion among the participants.
>
> In the interim, we plan to send out a short questionnaire on Monday to all company participants requesting information on your product, technology or service, which we plan to compile in a digital "book" and share with all participants in advance of the meeting. We believe this approach will help to make the meeting more efficient, allowing us to quickly shift to discussions of the

most important shared challenges and potential opportunities that exist between industry members, government leaders and non-government partners.

Please feel free to reach out to me with any questions. We will move quickly to establish a new date for this meeting and appreciate your flexibility in this regard. We look forward to talking with many of you then.

Thanks again for your commitment to enhancing the health and safety of people facing this outbreak around the globe.

Sincerely,

Phyllis A Arthur
Vice President, Infectious Diseases and Diagnostics Policy
Biotechnology Innovation Organization (BIO)
1201 Maryland Ave SW, Suite 900
Washington, D.C. 20024
T: 202-962-6664
C (b) (6)
parthur@bio.org

Join us at the 2020 BIO International Convention
June 8-11, 2020 in San Diego, CA
www.convention.bio.org

Phyllis A Arthur
Vice President, Infectious Diseases and Diagnostics Policy
Biotechnology Innovation Organization (BIO)
1201 Maryland Ave SW, Suite 900
Washington, D.C. 20024
T: 202-962-6664
C: (b) (6)
parthur@bio.org

Join us at the 2020 BIO International Convention
June 8-11, 2020 in San Diego, CA
www.convention.bio.org

From: [redacted] (b) (6)
Sent: Sun, 8 Mar 2020 09:50:00 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: COVID19, ACEIs and ARBs

Please handle

Begin forwarded message:

> **From:** Martin Engman <[redacted] (b) (6)
> **Date:** March 8, 2020 at 9:30:51 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: COVID19, ACEIs and ARBs**
>
> Is there any evidence to suggest that patients already on treatment with angiotensin receptor blockers have a better or worse COVID-19 outcome than patients not on these medications? Similar question for initiating ARB treatment once COVID-19 has been diagnosed. And similar questions for ACE inhibitors. Thank you.
>
> ML Engman, MD
> [redacted] (b) (6)
> [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Sun, 8 Mar 2020 09:23:28 -0400
To: Kristian G. Andersen
Cc: Jeremy Farrar;Collins, Francis (NIH/OD) [E];Robert Garry;Edward Holmes;Andrew Rambaut;Ian Lipkin;Chris Emery
Subject: Re: SARS-CoV-2 article to be published in Nature Medicine

Kristian:
Thanks for your note. Nice job on the paper.
Tony

> On Mar 6, 2020, at 4:23 PM, Kristian G. Andersen [redacted] (b) (6)>wrote:
>
> Dear Jeremy, Tony, and Francis,
>
> Thank you again for your advice and leadership as we have been working through the SARS-CoV-2 'origins' paper. We're happy to say that the paper was just accepted by Nature Medicine and should be published shortly (not quite sure when).
>
> To keep you in the loop, I just wanted to share the accepted version with you, as well as a draft press release. We're still waiting for proofs, so please let me know if you have any comments, suggestions, or questions about the paper or the press release.
>
> Tony, thank you for your straight talk on CNN last night - it's being noticed.
>
> Best,
> Kristian
>
> ---
>
> **Kristian G. Andersen, PhD**
> Associate Professor, Scripps Research
> Director of Infectious Disease Genomics, Scripps Research Translational Institute
> Director, Center for Viral Systems Biology
>
> **The Scripps Research Institute**
> 10550 North Torrey Pines Road, SGM-300A
> Department of Immunology and Microbial Science
> La Jolla, CA 92037
>
> [redacted] (b) (6)

Assistant: [redacted] (b) (6)

ANDERSENlab
The Scripps Research Institute

<Andersen Coronavirus Nature 2020 Press Release Draft 4.docx>
<Manuscript.pdf>

From: [redacted] (b) (6)
Sent: Sun, 8 Mar 2020 09:04:10 -0400
To: Lane, Cliff (NIH/NIAID) [E]
Subject: Re: COVID-19 Real Time, Sensitive Detection Breakthrough

Please take care of this yourself. Thanks

> On Mar 7, 2020, at 11:30 PM, Lane, Cliff (NIH/NIAID) [E] <[redacted] (b) (6)>wrote:
>
> They claim to have an improved diagnostic developed through DoD funding. It is a DNA platform that they claim to have adapted to COVID-19. They provide no data, only claims.
>
> [redacted] (b) (5)
>
>> On Mar 7, 2020, at 10:03 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>wrote:
>>
>> Please read this and figure out what the heck he is talking about and act according to your judgment. Only 498 emails to go tonight.
>>
>> **From:** [redacted] (b) (6)
>> **Sent:** Saturday, March 7, 2020 4:09 PM
>> **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
>> **Subject:** COVID-19 Real Time, Sensitive Detection Breakthrough
>>
>> Tony--
>> It has been awhile since we have worked together since my time as the senior SES standing up DTRA (with the help of Josh Lederberg M.D. &Dave Franz DVM who you know), at Argonne/UofChicago establishing your NIAID RBL with Olaf Schneewind M.D., and as the DHS Director of Research reporting to SEC Michael Chertoff &U/S Jay Cohen (RADM-ret). Michael &Jay brought me aboard when Jay was our Chief of Naval Research at ONR and I was ONR's Executive Director &Chief Scientist. I know you have your hands very full with the

COVID-19 threat, so I wanted to give you a heads up that a game changer for enhanced detection of COVID-19 has emerged. Thanks to DARPA &DHS S&T sponsorship in years past of ANDE developing a real time Rapid DNA microfluidics system for human identification, the ANDE group has a breakthrough for detection of COVID-19 and to the future, other emerging threat viruses.

As you may know the ANDE system for human identification (e.g. CT &DHS missions) is mature and now deployed operationally/tactically by CENTCOM, DIA, the IC and used most recently by DHS in their recent test bed in El Paso to demonstrate its effective capabilities to determine family relationship in undocumented minors. Additionally ANDE is in use by law enforcement and by officials responding to mass casualty events (CA 2018 Camp Fire disaster, 2019 Conception dive boat fire, and the very recent 2020 tragic helicopter crash) to ID the victims.

The ANDE system now provides 2 hour turnaround with no special training requirements as a stand-alone system for all the above users. Our warfighters and special operators are using the ANDE system now in field forward operations and it meets MIL specs &is the only system certified for data submission to the DoD ABIS/DIA DNA repository and FBI CODIS data base. The

(b) (4)

[redacted]

executive summary and a more in-depth document for your teams review. Hope the above is helpful and I stand ready to provide any additional information. I have cc'd Jim Davis (ANDE Chief Federal Officer). Additionally since it has been some time since we have worked together I have attached my bio and that of ANDE's Chief Scientific Officer &Founder, Richard Selden M.D., Ph.D.

Tony thanks for considering this in your very busy life now and I will look forward to seeing you again.
Best regards--
Starnes
Dr. Starnes E. Walker

Member-Homeland Security Experts Group, MITRE

Global Strategy Officer-Defense &Homeland Security/Intelligence

ANDE Corporation

p: [redacted] (b) (6) m:

e: [redacted] (b) (6)

Rapid DNA for a Safer World

[redacted] (b) (4)

<CUsersstarnDesktopSEW Bio, October 2019.docx>
<CUsersstarnDesktopANDE BiosRFS CV 05 March 2020.pdf>

From: [redacted] (b) (6)
Sent: Sun, 8 Mar 2020 07:41:41 -0400
To: NIAID Public Inquiries
Subject: Fwd: Ems Personnel & Ambulance Teams

Sent from my iPhone

Begin forwarded message:

> **From:** "Nabial, Nasir M" [redacted] (b) (6)
> **Date:** March 7, 2020 at 10:54:39 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Ems Personnel &Ambulance Teams**
>
> Dear Dr. Fauci:
>
> Im a first responder, and I believe an oral vaccine platform is the best delivery method for situations of national emergency like the coronavirus.
>
> If the vaccine is a tablet, we would be able to keep them on our ambulances and get medical authorization whenever the situation arises. First responders can then treat patients before doctors and nurses and also instead of having the patient make an appointment Or having them wait in line for a shot, which can ultimately cause more spread.
>
> This method that will enable the EMS teams of the nation to combat outbreaks because you would allow EMT (Emergency Medical Technicians) and Paramedics to diffuse situations through our Ambulances. This will lead to more control and get a hold of the situations as fast as possible and lower the spread of the virus on our people.
>
> Thank you.

From: [redacted] (b) (6)
Sent: Sun, 8 Mar 2020 07:40:53 -0400
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: from Dr Mike Meyer (CEO - Sensible Biotherapeutics) Finding the answer to halting replication of COVID-19

Pls respond

Sent from my iPhone

Begin forwarded message:

> **From:** Michael Meyer [redacted] (b) (6)>
> **Date:** March 8, 2020 at 12:28:03 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>, philip meyer [redacted] (b) (6)>, "Perkins, Miriam (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: from Dr Mike Meyer (CEO - Sensible Biotherapeutics) Finding the answer to halting replication of COVID-19**
>
> DR ANTHONY FAUCI
> [redacted] (b) (6)
>
> Dear Dr. Fauci,
>
> I am a Neurologist and Nuclear Medicine Physician who has a passionate interest in developing antisense medications to treat disease and have formed a drug discovery company here in Buffalo New York (SENSIBLE BIOTHERAPEUTICS, LLC).
>
> [redacted] (b) (4)

[redacted] (b) (4)

I very much appreciate any advise you may be able to provide about this project

Sincerely,
Michael A. Meyer MD
cell [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Sun, 8 Mar 2020 07:39:47 -0400
To: NIAID Public Inquiries
Subject: Fwd: Set up county hotline for people to contact if they think they have coronavirus or are sick instead of going to hospital

Sent from my iPhone

Begin forwarded message:

> **From:** rebecca hagenberg [redacted] (b) (6)
> **Date:** March 8, 2020 at 3:06:34 AM EDT
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Set up county hotline for people to contact if they think they have coronavirus or are sick instead of going to hospital**
>
> Dear Sir,
>
> I am sending this message to assist in an idea to help minimize the impact of Coronavirus. Instead of people going to the hospital or urgent care. Each county health department needs to have a direct number of a national number that distributes information to local county government health department. If you are sick and show or exhibit signs of the coronavirus you should call the appropriate number, a technician will come to your home, draw lab specimen needed. Of course if someone is extremely ill they should call 911 and advise 911 they are exhibiting signs of the virus. There should be special protocols in place for how to transport the patient into the hospital as well (to limit exposure to everyone involved. This means finding alternative entrance at hospitals for a suspected coronavirus patient. These patients should be brought in by a least used location of the hospital into a special unit that has a barrier from the rest of the emergency department.
> Home lab work will keep someone from sitting in a waiting room for 3_ 5 hours. The county unit to conduct lab work will act in response much like calling 911 or the police. Each hospital needs to set up an emergency entrance for Coronavirus patients only, and the unit must be sealed from the remainder of the unit. We begin having a coronavirus team that does not cross contaminate to any other unit on the emergency room floor. I am thinking of the best plausible way to minimize outbreak. This helps.
>
> Rebecca Hagenberg
> [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 03:34:45 +0000
To: Michael Oldstone
Subject: RE: item

Thanks, Michael. I appreciate your note.

From: Michael Oldstone <mbaobo@scripps.edu>
Sent: Friday, March 6, 2020 2:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: item

Dear Tony
A note to let you know how much over the years I have appreciated your active support of biologic research, public health and your directorship of NIAID. Impressive, intelligent, high integrity and management skills has placed you at the head of the curve. I reached this conclusion from personal observations of your work and style as well as having served as a consultant for NIAID and several other NIH Institutions, WHO, Pasteur and Karolinska.

After nearly 50 years of continuous research from my original AI09484 grant studying viral pathogenesis[acute and persistent infections] using the LCMV model, I decided to close my laboratory. I have had other generous NIH support as well especially for investigations of other negative strand viruses[primarily measles and influenza, Lassa ,arenavirus receptor], Ebola, cytokine storm and autoimmunity. The AI09484 grant was credited by 300 peer reviewed papers, training of 61 postdoctoral fellows[including Rafi Ahmed, Christine Biron, Persephone Borrow, Ray Welsh, Ian Lipkin, Dorian McGavern and other successes including the late Patrick Sissons who was the Reagent Professor of Medicine at Cambridge. Over 85% of these folk are in academic medicine/biology at research institutes or universities.

Good luck and smooth sailing with the current coronavirus pandemic. With your involvement this work is in good hands.

Best wishes
Michael

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 03:26:22 +0000
To: Liz Cheney
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C];Greg Folkers
(b) (6)
Subject: RE: Test Kits

Sorry, Liz. In White House all day. Will try to call tomorrow.

From: Liz Cheney (b) (6)>
Sent: Friday, March 6, 2020 2:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Haskins, Melinda (NIH/NIAID) [E] (b) (6)>
Subject: Re: Test Kits

Dr. Fauci - Who can I speak with about the status of the test kits? I am also concerned about reports from CDC that there are six states, including Wyoming, with no certified lab in which to conduct tests.

Thank you,
Liz Cheney
(b) (6)

On Tue, 25 Feb 2020 at 10:28 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> wrote:

Liz:

Thank you for your note. I would have been very happy to provide remarks at the weekly meeting of the Republican Conference. However, I have a late afternoon 2nd panel Congressional Hearing with Secretary Azar followed by a meeting with the President in the Roosevelt Room of the White House, which overlaps with the time frame of your meeting tomorrow. I would be most happy to do this at another time. If you could have your office contact my Special Assistant, Patty Conrad (copied here), she will help arrange setting up something at a mutually convenient time.

Best regards,
Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended

recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Liz Cheney (b) (6)
Sent: Tuesday, February 25, 2020 6:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: House GOP Conference Mtg

Dr. Fauci - I am the House Republican Conference Chair and we are holding our weekly mtg at 5 pm tomorrow in the Capitol. I wanted to see if you'd be available to provide remarks and an update on Coronavirus. It is by far the topic in which our members are most Interested, and you would be the best person to provide an update.

I realize this is short notice. If tomorrow doesn't work, let me know if we could arrange another time.

My cell is (b) (6), office is (b) (6)

Thank you,
Liz Cheney

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 03:23:05 +0000
To: Hilary Rosen
Subject: RE: You!

Hilary:
Thanks for your note. I would postpone it. The situation is very fluid.
best,
Tony

From: Hilary Rosen [redacted] (b) (6)
Sent: Saturday, March 7, 2020 9:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: You!

Tony,
I am so proud of you. It is so comforting to see your face on TV explaining the world of coronavirus. I know it is exhausting for you but it is so important. Your dedication my friend has always been so admirable.
Quick question, CDC isn't giving much guidance on this. Our company has its annual retreat this week. About 80 people coming from NYC and LA meeting in a DC Hotel ballroom for two days with an additional 100 people from DC. SO approximately 180 in total. Would you postpone this if you were me?
xo
Hilary

Hilary Rosen
Vice Chair
SKDKnickerbocker
202.464.6969 w
[redacted] (b) (6) ***m***

2019 Holmes Report Public Affairs Agency of the Year

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 03:06:52 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers ((b) (6)
Subject: FW: media request from spain an old journalist friend, patricia matey

Cannot do. No time

From: Patricia Matey Corada <pmatey@elconfidencial.com>
Sent: Saturday, March 7, 2020 3:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: media request from spain an old journalist friend, patricia matey

Hi doctor Fauci, Can you remember me. I am a Patricia Matey, oldest journalist of health from spain. I work in the past in El MIUndo, now I am a chief editor in El Confidencial, the first newspaper online in Spain. Can you give me little time for answer some questions. I want to do an article of the coronavirus, but the eyes of science, I read three days ago te article in New Yor Times by Gina Kolata, the best woman health journalist of the world, I want to do an article without panic and false concept
I send you some questions

What is really the difference in this conoravirus and the past?
Can one of the muteate, change in one strain more aggressive in short time
The flu always affect a all the countries in same time. Why the new coronavirus only star enChina,
Is because became from one animal,,,
What are your opinion for the really impact of this virus
What are you opinion for the press and the paper in this problem.
What are you opinion for the evolution in the next month

Best regard for all, but best regard for yourtime

Patricia Matey
Jefa de Alimente
www.elconfidencial.com
Vía de las Dos Castillas, 33. Edificio 7. Planta 1- Oficinas E,F, G, H
28224 Pozuelo de Alarcón (Madrid)
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 03:03:28 +0000
To: [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: COVID-19 Real Time, Sensitive Detection Breakthrough
Attachments: [redacted] (b) (4) CUsersstarnDesktopSEW Bio, October 2019.docx, CUsersstarnDesktopANDE BiosRFS CV 05 March 2020.pdf

Please read this and figure out what the heck he is talking about and act according to your judgment. Only 498 emails to go tonight.

From: [redacted] (b) (6)
Sent: Saturday, March 7, 2020 4:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: COVID-19 Real Time, Sensitive Detection Breakthrough

Tony--
It has been awhile since we have worked together since my time as the senior SES standing up DTRA (with the help of Josh Lederberg M.D. & Dave Franz DVM who you know), at Argonne/UofChicago establishing your NIAID RBL with Olaf Schneewind M.D., and as the DHS Director of Research reporting to SEC Michael Chertoff & U/S Jay Cohen (RADM-ret). Michael & Jay brought me aboard when Jay was our Chief of Naval Research at ONR and I was ONR's Executive Director & Chief Scientist. I know you have your hands very full with the COVID-19 threat, so I wanted to give you a heads up that a game changer for enhanced detection of COVID-19 has emerged. Thanks to DARPA & DHS S&T sponsorship in years past of ANDE developing a real time Rapid DNA microfluidics system for human identification, the ANDE group has a breakthrough for detection of COVID-19 and to the future, other emerging threat viruses.

As you may know the ANDE system for human identification (e.g. CT & DHS missions) is mature and now deployed operationally/tactically by CENTCOM, DIA, the IC and used most recently by DHS in their recent test bed in El Paso to demonstrate its effective capabilities to determine family relationship in undocumented minors. Additionally ANDE is in use by law enforcement and by officials responding to mass casualty events (CA 2018 Camp Fire disaster, 2019 Conception dive boat fire, and the very recent 2020 tragic helicopter crash) to ID the victims.

The ANDE system now provides 2 hour turnaround with no special training requirements as a stand-alone system for all the above users. Our warfighters and special operators are using the ANDE system now in field forward operations and it meets MIL specs & is the only system certified for data submission to the DoD ABIS/DIA DNA repository and FBI CODIS data base. The [redacted] (b) (4)

[redacted] (b) (4)

attached an executive summary and a more in-depth document for your teams review. Hope the above is helpful and I stand ready to provide any additional information. I have cc'd Jim Davis (ANDE Chief Federal Officer). Additionally since it has been some time since we have worked together I have attached my bio and that of ANDE's Chief Scientific Officer & Founder, Richard Selden M.D., Ph.D.

Tony thanks for considering this in your very busy life now and I will look forward to seeing you again.
Best regards--
Starnes
Dr. Starnes E. Walker
Member-Homeland Security Experts Group, MITRE
Global Strategy Officer-Defense & Homeland Security/Intelligence
ANDE Corporation
p: [redacted] (b) (6) m: [redacted] (b) (6)
w: www.ANDE.com e: [redacted] (b) (6)

Rapid DNA for a Safer World

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 03:00:50 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona Virus planning

Please respond.

From: K.A. Traul [redacted] (b) (6)
Sent: Saturday, March 7, 2020 4:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Corona Virus planning

Dear Dr. Fauci;

I am a toxicologist and have spent time, years ago, working in the arena of oncogenic virology as part of NCI programs. I am very concerned about what I see in the news media about the NIH approach to the COVID-19 pandemic (yes, pandemic) that has arrived in our country. There is much talk about development of a vaccine, however, I believe that this is a long-term strategy. You and I both know, from working as scientists, that the development and trial of an antiviral vaccine is a months-long program, at best. I am surprised, even disappointed, that there seems to be no visible focus on the part of the NIH on the development of anti-viral treatments (drugs etc) . It is my professional opinion that anti-virals would take a shorter time to develop than vaccines, yet it appears that this may be a back burner focus of NIH.

I realize that there are many political pressures on your office and I support your strong efforts to apply science to the resolution of this growing problem. Please do not give short shrift to the potential of antiviral treatments in favor of the longer-term promise of a vaccine.

Respectfully yours,

Karl A. Traul

K.A. Traul, Ph.D.
K.A. Traul Pharmaceutical Consulting
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 02:59:37 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Interview request

I really do not have time for this.

From: Kopelman, Hannah <Hannah.Kopelman@bmc.org>
Sent: Saturday, March 7, 2020 5:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Ross Kopelman [redacted] (b) (6)
Subject: Interview request

Dear Dr. Fauci,

My name is Dr. Kopelman. I am currently a resident at Boston Medical Center. I am reaching out because I would like to interview you on my podcast along with [redacted] (b) (6), on our podcast called MedChatMonday which reaches thousands of millennials a day. We want to discuss Coronavirus. I know you are very busy so any of your time would be appreciated. I want to discuss the implications of Coronavirus, symptoms, understanding of why it has become a global scare, what people should do to combat and lower their risks. Podcast will be done remotely through Skype.

I hope to hear from you soon.

Best regards,
Dr. Hannah Kopelman and Dr. Ross Kopelman
-
Hannah B. Kopelman

This electronic transmission may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended recipient, please notify me immediately as use of this information is strictly prohibited.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 02:58:52 +0000
To: [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: One Step COVID-19 test kitS - IMMEDIATE AVAILABILITY
Attachments: DoN SARS-CoV tests 200305.pdf, IFU One Step COVID-19 Test.pdf, 002.png, 0005.jpg, 0099.jpg, 9999.jpg, 0001.png

What do you think of this. Do what you need to do.

From: [redacted] (b) (6)>
Sent: Saturday, March 7, 2020 6:26 PM
To: vice.president@whitehouse.gov
Cc: secretary@hhs.gov; Hahn, Stephen (FDA) [redacted] (b) (6); Redfield, Robert R. (CDC/OD) [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); secretary@state.gov
Subject: One Step COVID-19 test kitS - IMMEDIATE AVAILABILITY

Dear Mr. Vice President & Task Force Members -

My name is Jeffrey "Scott" Smith. I live in [redacted] (b) (6) KS. For the past 35 years I have been a Purchasing Agent in the private sector. Much of my career has dealt with China sourcing and supplier development. I have established a wide network of suppliers and contacts throughout China. You can see from my US Passport number [redacted] (b) (6) that I have traveled to China for the past 20 years... including spending nearly [redacted] (b) (6) my time in 2018 & 2019 visiting China suppliers. (Thankfully I returned on 15-Nov-2019, prior to the outbreak... [redacted] (b) (6).)

I was invited by one of my trusted suppliers to offer One Step COVID-19 test kits to the United States. The Guangzhou based supplier has [redacted] (b) (4) test kits available now for immediate shipment. They can produce [redacted] (b) (4) kits per week at their factory. Please see the information below and the materials attached for more information. This is a very cost effective test - and provides results in 15 minutes. I will trust you to determine the efficacy of the diagnostics.

To be clear - this is not my business. I will profit in no way from providing these kits to the American healthcare public -- except for the satisfaction of doing my patriotic duty to assist my fellow Americans. I fully understand the gravity and seriousness of this disease. All of my factories in China have, and are, suffering from the effect and fall out. My business in [redacted] (b) (6) is dealing with the effects of the supply chain disruptions.

I hope that this offer, and availability of a additional test kit pipeline, will help ease the test kit shortage that we are experiencing in the USA. If you and your Procurement

Offices would like more information or would like to secure these test kits, please contact me. I can assist in arranging supplier contacts and immediate air shipments.

I certainly thank you and the many dedicated leaders in the USA for your great work to combat COVID-19 - and for the care that you are showing the American public.

Best regards,

Scott Smith

[redacted] (b) (6)

M: [redacted] (b) (6) [redacted] (b) (6)

-------- Original Message --------

Subject: One Step COVID-19 test kit
Date: 2020-03-07 2:41 am
From: "Jack Scientek" <info@scientekpower.com>
To: [redacted] (b) (6)
Reply-To: <info@scientekpower.com>

Dear Scott,

How are you? It was a great pleasure talking with you on Wechat, As we discussed, I have a friend who works in Wandfo Biotech Company in Guangzhou (a public listing company). They have developed a One Step COVID-19 test kit to screen the Corona virus in only 15 minutes. This test kit is been massively used in China and it's been supplied to Japan,South Korea, Ukraine and Iran to cope with the Corona Virus, It has also been certified by Chinese health organization and EU. I am wondering if you have any connection with any medical organizations, if they need this kit, Wondfo is able to supply. [redacted] (b) (4) , Wondfo provide international shipping worldwide. Maybe this can be helpful for some people.

Here below please refer to the most concerned information:
Name of the test kit: One Step COVID-19 Test (Chromatography Assay)
Manufacturer: GuangZhou Wondfo Biotech Co.,Ltd

Name	Quantity	Unit Price	Packages	Carton Measurement	Volume(CBM)	Gross weight(Kgs)
One Step COVID-19 Test Kit	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted] (b) (4)
One Step COVID-19 Test Kit	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
One Step COVID-19 Test Kit	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
One Step COVID-19 Test Kit	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

Price availability: 1 week

Payment terms: [redacted] (b) (4).
Delivery term: [redacted] (b) (4)
Availability: [redacted] (b) (4).
production capacity [redacted] (b) (4)

For your information, this testing kit has been supplied to Japan, and south Korea, Iran,Ukraine, their production schedule is very tight, the factory may raise up price a week later.

Other Available documents are attached for your reference.

Best Regards

Jack Jiang

Scientek

Scientek Electrical Co.,Ltd. | Danzao. | Nanhai District | Foshan,Guangdong | China 528216
☎ 86-189-4246-9075 🖳 [redacted] (b) (6) 🖱 www.scientekpower.com ✉ info@scientekpower.com
| Mob/WhatsApp/Wechat: +[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 02:57:55 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: [redacted] (b) (6)
Subject: RE: NSC inquiry on treatment study

See my changes in Red

From: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, March 7, 2020 6:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)
Subject: NSC inquiry on treatment study

Sorry to add to the inbox. [redacted] (b) (5), (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 02:08:47 +0000
To: Gregory Klomp
Subject: RE: COVID-19 treatment

We are pursuing this idea.

From: Gregory Klomp [redacted] (b) (6)>
Sent: Saturday, March 7, 2020 8:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: COVID-19 treatment

It seems COVID-19 causes greater problems for the elderly and those with chronic illnesses, as you have said.

Why not try giving those with active disease, or those at risk, gamma-globulin, to ameliorate the effects of the illness?

It would be especially interesting to prepare batches of gamma globulin using the blood (2,000- 3,000 donors) of people who have, or who have recovered from, COVID-19 infection.

There is ample precedent for using Gamma-globulin to prevent or treat viral illnesses (Hepatitis A, B) or diseases of unknown etiology (ie Kawasaki's).

This could be useful especially while we wait for the development of a vaccine.

What do you think?

Gregory Klomp, MD
[redacted] (b) (6)
(I trained at Columbia-Presbyterian Hospital
I see you were at Weil Cornell)

From: [redacted] (b) (6)
Sent: Sat, 7 Mar 2020 17:06:39 -0500
To: NIAID Public Inquiries
Subject: Fwd: From ER Provider, Some Common sense COVID-19 addl. suggestions

Sent from my iPhone

Begin forwarded message:

> **From:** [redacted] (b) (6)
> **Date:** March 7, 2020 at 4:08:23 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: From ER Provider, Some Common sense COVID-19 addl. suggestions**

Dr. Fauci:
I have been following you and others on CSPAN with appreciation.
1) Please ensure you are all getting adequate sleep.
(There is too much yahoo-machismo in our field) Please put forth recommendations for providers and their employers.
2) I see the CDC warning about herbals, which I agree with except for one: echinacea, just about the only herbal with proven medical usefulness, not as it is recommended on the bottles or websites, but as only a single 2 capsules, on day one of viral illness. Echinacea demarginates the matured bone marrow leukocytes. Used as a "one shot deal"
may decrease COVID-19 duration/severity as eg.: "take right away on day one, drink plenty of water and sleep as long as necessary".
Please at least study the use of Echinacea in this manner for COVID-19. (Google is suddenly missing Echinacea's mechanism/use info, so please have this corrected, if for nothing else to prevent hoarding. One bottle can be for a whole neighborhood and please ask the drug stores to offer "two packs" with proper instructions.
eg.: "take only two as soon as ill with cold or flu and not take more, but to replenish the immune system follow up with fresh fruits and vegetables, etc.
3) Make sure we have enough Ventolin, Proventil available so those with new asthmatic component due to COVID-19 can call their Dr. for RX if they cannot blow out a match, for
instance, and use the drive through instead of goin into the pharmacy. Consider hazmat for drive through testing and Rx pharmacy staff (as in S. Korea). I would be interested in knowing the percent of COVID-19 respiratory sufferers who can stay home but will need Ventolin. 10%? (just a guess from seeing bronchitis in the ER).

4) Ensure all the medical providers with offices, give out their office telephone numbers and have staff trained to triage calls so people can stay home until they are well.

5) Ensure levothyroxine (the US most common Rx) is made in the USA from ingredients made in the USA. Ditto for down the line of the most necessary and common RX, including Ventolin, and the antibiotics that would treat bacterial superinfection of COVID-19 (particularly the ones that can be used at home: macrolides, etc.)

6) Encourage prevention of superinfection with clean respiratory toilet, hydration, chest PT preferred over suctioning, clean environment, including cleaning floors daily. One of the most successful methods of chest PT involves the patient lying on the bed with their face near the floor. Decreasing the load of pulmonary sputum is critical.

7) There is very large number of semi-retired physicians, such as myself who would probably like to be utilized (an paid a little) for telemedicine to assist with triage.

We can do telemedicine at home. I am not set up to do this but will soon be set up and able. We need to know which companies we can trust to hire us.

There should be telemedicine training and tracking coming from the CDC or other state and national governments.

8) Is the 3/3/20 John Kehoe Financial Times article correct? Is it not best to predict mortality so as to more realistically prepare for post-COVID-19 recovery economically and socially and give confidence by being transparent?

I see recovery jobs being the young taking care of the old after most have had it and been cured or succumbed. Then the other half of the people will get it, too...

Is there some stigma attached to the word "infrastructure" that would prevent recovery of our economy?

9) I do not wee the recommendations for Flu and both pneumovax vaccines, but the recommendation needs to get out broadly right away.

10) Wuhan had to truck in food...how are we planning? Canned food decreases one's immune system. Fresh fruits and vegetables, frozen or dried are needed.

11) China closed all the theaters...and we should also start closing the use of public places, particularly asking folks in their 60's and older to stay home now.

12) Recommend providers write three month supply of Rx for all patients, to decrease visits out and ensure availability.

13) The closure of schools might spread COVID-19 unless children have food to eat at home and the parents comply.

14) Will census takers spread it? Should the census be postponed or performed via hazmat suit or in another fashion?

This is a long list. Please look into 2-packs of Echinacea with instructions.

Get enough sleep/stay well.

Thank you.

Best regards,

Gretchen Boise, MD

LL (b)(6) (caller must announce who they are)

(b) (6)

From: [redacted] (b) (6)
Sent: Sat, 7 Mar 2020 16:15:52 -0500
To: Lane, Cliff (NIH/NIAID) [E]
Subject: Fwd: Covid-19 Pandemic -- update

FYI. I get 100 of these per day.

Begin forwarded message:

> **From:** David Katz [redacted] (b) (6)
> **Date:** March 6, 2020 at 7:46:18 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Covid-19 Pandemic -- update**
>
> Dear Tony:
>
> As I continue to follow the evolution of this disastrous calamity, I continue to think of possible approaches to dealing with therapeutic options that might be "off the beaten trail" but nonetheless worth considering – especially for those patients who are at high risk for debilitation and, possibly, death. I share one such thought with you here.
>
> Several years ago, recombinant Human Growth Hormone (rHGH) was reported to be significantly effective in restoring/enhancing T cell anti-viral activity in patients infected with HIV (citation below):
>
> ## Growth hormone resurrects adult human thymus during HIV-1 infection
>
> Kiki Tesselaar, Frank Miedema
> *J Clin Invest.* 2008;118(3):844-847. https://doi.org/10.1172/JCI35112.
>
> My thought is that since, in many ways, elderly patients afflicted with COVID-19 fall into a similar category, that treatment with

rHGH might be an effective treatment alternative to employ during this immediate time frame while you are exploring more specific alternatives.

I look forward to your thoughts on this, and best wishes,

David

(PS: I think you have handled yourself magnificently during these incredible press conferences, etc.!)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 7 Mar 2020 19:06:14 +0000
To: Megan B.
Cc: Conrad, Patricia (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Greg Folkers [redacted] (b) (6)
Subject: RE: Thank you, Dr. Fauci

Ms. Fender:

There is no such a thing right now as "no risk" given the uncertainty of the current situation. However, in the context of what we do know, since you are [redacted] (b) (6) years old, you have [redacted] (b) (6)

[redacted]

Go about your usual business. You have no reason to panic.

I hope that this is helpful.

Best regards,
A.S. Fauci

From: Megan B. <[redacted] (b) (6)>
Sent: Saturday, March 7, 2020 11:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: Thank you, Dr. Fauci

Dr. Fauci,

I apologize to reach out, I know how extremely busy you must be. But I have always invested a great deal of trust in you.

[redacted] (b) (6)

Thank you greatly.

Sincerely,

Megan Fender

On Sun, Feb 9, 2020, 6:27 PM Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:

Megan:

Many thanks for your kind words. They are much appreciated.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Megan B. [redacted] (b) (6)>
Sent: Sunday, February 9, 2020 4:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Thank you, Dr. Fauci

Dr. Fauci,

As a citizen and mother, I would just like to take a short moment to say thank you for all of your great work and service to the American people. I have admired your work for many years, and appreciated your transparency during the Ebola crisis, as well as this most recent situation. As a citizen, I appreciate that you relay facts, both good and bad, and have established a sense of trust with the people.

[redacted] (b) (6) . With the Ebola crisis, and with Coronavirus, I feel better when I see your press conferences and hear all of the work you and your team do to protect both US citizens, and the world community. Friday I was very happy to hear you announce the extreme progress that's been made in just two week's time on the vaccine, and that there have been no roadblocks. This has been done at unprecedented speeds, by what I'm sure are very talented scientists.

Again, thank you for your lifetime of service in disease prevention, and for making citizens like myself feel better knowing we have people like you and your team working tirelessly for the people. (b) (6) [redacted], but I take comfort in knowing we have such great, talented individuals leading our public health system.

Dr. Fauci, you are truly a saint. Thank you for all that you do.

Sincerely,

Megan Fender

From: [redacted] (b) (6)
Sent: Sat, 7 Mar 2020 13:37:51 -0500
To: NIAID Public Inquiries
Subject: Fwd: a question

Sent from my iPhone

Begin forwarded message:

> **From:** Leonard Trudell [redacted] (b) (6)
> **Date:** March 7, 2020 at 1:34:34 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: a question**
>
> Dr. Fauci,
> May I suggest a question that you might ask of COVID-19 identified patients? Could you ask them if they had received a current flu shot for this season? Since the COVID-19 corona virus basic construct is a basic flu version with a bio-engineered HIV or other(?) component, is it possible that our flu vaccines might have some degree of protection against this new COVID-19 viral construct? I think it is important to ask this question!
> Dr. Len Trudell
> [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 7 Mar 2020 18:36:42 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: a question

Please have someone respond.

From: Leonard Trudell [redacted] (b) (6)
Sent: Saturday, March 7, 2020 1:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: a question

Dr. Fauci,
May I suggest a question that you might ask of COVID-19 identified patients? Could you ask them if they had received a current flu shot for this season? Since the COVID-19 corona virus basic construct is a basic flu version with a bio-engineered HIV or other(?) component, is it possible that our flu vaccines might have some degree of protection against this new COVID-19 viral construct? I think it is important to ask this question!
Dr. Len Trudell
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 7 Mar 2020 18:10:15 +0000
To: Richard Carmona
Subject: RE: Kudos

Rich:

Many thanks for your kind note. Much appreciated. I hope that all is well with you.
Best regards,
Tony

From: Richard Carmona [redacted] (b) (6)>
Sent: Saturday, March 7, 2020 11:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Kudos

Tony, as always and for many decades and most importantly now, thank you for being the voice of reason and integrity that emanates from the political swamp to quell uncertainty and fear. Ironically your words now as a " vaccine" against the disease of public fear and uncertainty may be as important as the eventual immunologically derived vaccine against coronavirus you are working on.
Be well,
Rich Carmona

Richard Carmona

17th Surgeon General of The United States
Chief of Health Innovations
Distinguished Professor University of Arizona

CANYONRANCH.

8600 E. Rockcliff Road | Tucson, AZ 85750
O: 520.749.7754
M: [redacted] (b) (6)
canyonranch.com

From: (b) (6)
Sent: Sat, 7 Mar 2020 11:19:16 -0500
To: NIAID Public Inquiries
Subject: Fwd: university coronavirus

From patty on asf phone.

Pls handle

Sent from my iPhone

Begin forwarded message:

> **From:** [redacted]
> **Date:** March 7, 2020 at 10:06:21 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
> **Subject: university coronavirus**
>
> Hello and thank you for all of your tireless efforts in dealing with the coronavirus.
>
> I have a concern about the universities and the spread of this virus. Many schools brought back students from study abroad before the 14 day quarantine was put into place, and even after the quarantine was put in place, many students did not follow the quarantine rules. Also, with shared dorms and apartments it was not possible for student's who returned to campuses and not their homes. By the times schools came up with a plan for quarantining the student's it was well over a week after some were back. Therefore, there is potential for widespread infection.
>
> The vice president said the elderly and those with underlying medical conditions are at risk and should take caution in where they go, avoid crowded places etc..Millions of students have asthma, diabetes, auto-immune disorders, and they do not have a choice other than to go to class. The government does not seemed concerned about the potential spread among campuses and what a disaster this could be. They have voiced why grade schools are not closed (since younger are not at risk s better for them to be at school) but they are ignoring college kids are at risk and the impact of widespread infection on a campus could be huge. Students ir (b) (6) colleges travel back and forth to the city all the time, and I am concerned schools are not temporarily closing until more testing is available and we see where this goes. At minimum, giving student's with underlying medical conditions the option to go home and work remotely. Right now they do not have

any option other than to go to class. When questioned they say they are listening to the CDC and state government. [redacted] (b) (6) and students are not following the advice to stay home sick and nobody seems concerned about trying to prevent infection.

Can the government please look at a temporary ban on classes at Universities in states where infection is rapidly spreading, especially knowing there are not enough test available yet. The schools are not taking action on their own and this is a frustrating situation seeing delays in decisions making.

Thank you for your time in consideration in addressing these concerns,

Prefer to remain anonymous for the protection of [redacted] (b) (6)

Sent from Mail for Windows 10

From: [redacted] (b) (6)
Sent: Sat, 7 Mar 2020 11:16:57 -0500
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Re: Plasmapherese pediatricians to obtain anti-corona virus antibodies

Sorry this is from patty. I have an iPhone just to manage his emails so some of these are from me. Will add the letter p to the ones I send you so you know they are from me.

Sent from my iPhone

> On Mar 7, 2020, at 10:46 AM, Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>wrote:
>
> Tony, as I told Patty yesterday, I am handling all that you send me but I'm not going to fill your inbox with an acknowledgement each time.
>
> Sent from my iPad
>
> > On Mar 7, 2020, at 9:15 AM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>wrote:
> >
> > Pls handle
> >
> > Sent from my iPhone
> >
> > Begin forwarded message:
> >
> > > **From:** David Chung [redacted] (b) (6)>
> > > **Date:** March 6, 2020 at 12:45:17 PM EST
> > > **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> > > **Subject: Plasmapherese pediatricians to obtain anti-corona virus antibodies**
> > >
> > > Dr. Fauci,
> > > I appreciate the efforts of the WHO taking a look into the temperature question. It is helpful to understand the virus and know what to expect. [redacted] (b) (6) is a professional data analyst of large datasets like census

data, for example. I was wondering if it would be possible to obtain the WHO dataset to see if there were any angles not considered. I am certain that the WHO's biostatisticians know what they are doing, but data is a funny thing. You get the answers to the questions you ask. If the right questions were not asked, you may miss useful information.
Regarding the subject line, if the theory is true that children have some cross-reactive protection due to antibody production to the harmless coronavirus population, that would mean that pediatricians would also carry very high levels of protective antibody. If this is true, then plasmapheresis might provide anti-coronavirus antibody as potential treatment. I do not know enough about plasmapheresis to know if this could be applied to scale but I wanted to pass along the thought. [redacted] (b) (6) .

David Chung
On Monday, March 2, 2020, 07:46:51 AM EST, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) >wrote:

Thank you for your careful and well thought out note. Worthy of consideration.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: David Chung [redacted] (b) (6)
Sent: Sunday, March 1, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Pls advise to allow return air travel only, stop all other air travel

Dear Dr. Fauci,

Thank you for your leadership and guidance in this difficult time. I am a pediatrician in Massachusetts, and as you know, direct-linkage from travel cases are popping up on the East Coast. In order to keep the community viral load down, keeping new cases from moving around the country and the world will delay the spread and amplification of the viral load. According to my observations, hot climates seem to be having a favorable new case rate. Based on the city of Qom versus the experience in Singapore and Australia, it appears that the transition temperature for efficient spread is somewhere above when there are highs around 50 degrees F, similar to H1N1. According to my observations, prior to seasonal flu, the transition temperature was closer to highs of 40 degrees F. This theory should be testable. For example, there are new cases in Kuwait and Bahrain. If I am right, if you tested a subset of these populations, you would find a very high rate of asymptomatic infection, probably 80-90%, because that's how many people it would take to shed small amounts of virus to create a community viral load to make someone sick enough to get tested. If this is true, this bodes well for the virus burning itself out to endemic status relatively quickly. This would be very reassuring data you could provide to reduce panic - if you can tell people you know how long this pandemic is going to last rather than saying that we don't know.

Although some experts may say that restricting travel will only delay the inevitable, this is not a valid statement if the transition temperature for effect spread really is 50 degrees. A delay of significant community spread in the US until highs reach the 50s for the Northeast where the population is the most dense would have a massive life-saving effect, but if this is to occur, the flight restriction needs to happen now.

Stopping all flights would be impractical and inhumane, but allowing return flights only and stopping all other air travel would be effective. It would have a massive effect on the economy, but so will overwhelming corona virus infection. No one will die because they can't take a vacation or business trip. Financial losses would need to be settled later, so this would require emergency declarations, etc. If you wanted to take it in a step-wise manner, you could start with international flights and then move on to domestic flights if necessary - this would probably be wise and would have a less severe impact on the economy.

Thank you again, and I am sure this is one of thousands of unsolicited emails. I wish you the very best and God grant you wisdom.

Best,

David Chung

Pediatric Associates of Brockton

From: [redacted] (b) (6)
Sent: Sat, 7 Mar 2020 09:17:55 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: ACE2 neutralizing antibody from R&D Systems
Attachments: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor.pdf, ATT00001.htm, Crystal structure of the 2019-nCoV spike receptor binding domain bound with ACE2 receptor.pdf, ATT00002.htm

Sent from my iPhone

Begin forwarded message:

> **From:** Hung Trinh [redacted] (b) (6)
> **Date:** March 5, 2020 at 11:04:51 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Fwd: ACE2 neutralizing antibody from R&D Systems**

From: [redacted] (b) (6)
Sent: Sat, 7 Mar 2020 09:12:07 -0500
To: Auchincloss, Hugh (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: Fwd: Blog Clearance Request: COVID-19: Potential Implications for Individuals with Substance Use Disorders
Attachments: COVID SUD blog ebe3 ew6 sw2 ndv4 CLEAN.docx, ATT00001.htm

Pls handle

Sent from my iPhone

Begin forwarded message:

> **From:** "Volkow, Nora (NIH/NIDA) [E]" [redacted] (b) (6)>
> **Date:** March 6, 2020 at 4:46:06 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** "Hobin, Jennifer (NIH/NIDA) [E]" [redacted] (b) (6)>, "Volkow, Nora (NIH/NIDA) [E]" [redacted] (b) (6)>
> **Subject: Blog Clearance Request: COVID-19: Potential Implications for Individuals with Substance Use Disorders**
>
> Dear Toni. John Burklow asked NIAID to review a Blog I wrote on the need to evaluate vulnerabilities among patients with substance use disorders to COVID-19. Let me know if u or your staff have concerns or suggestions. I realize u are totally swamped and I apologize for burdening u with it. Best nora

From: [redacted] (b) (6)
Sent: Sat, 7 Mar 2020 09:11:12 -0500
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: JID 2006, 193:1244-1249
Attachments: SARS & gd T cells.pdf, ATT00001.htm

Pls respond if required

Sent from my iPhone

Begin forwarded message:

> **From:** MIROSLAV MALKOVSKY [redacted] (b) (6)
> **Date:** March 6, 2020 at 4:46:28 PM EST
> **To:** "Redfield, Robert R. (CDC/OD)" [redacted] (b) (6)
> **Cc:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: JID 2006, 193:1244-1249**
>
> Dear Bob,
>
> Long time, no see. Our SARS study (JID 2006, 193:1244-1249; see the attachment) showed selective expansions of Vγ9Vδ2 T cells in survivors of SARS-CoV infection. Interestingly, stimulated Vγ9Vδ2 T cells also display an interferon-γ-dependent anti-SARS-CoV activity and are able to directly kill SARS-CoV-infected cells. Since it is very easy to activate human Vγ9Vδ2 T cells *in vivo* (*e.g.*, using FDA-approved and relatively non-toxic drugs for treating bone-demineralization) and given the similarities between SARS-CoV and SARS-CoV-2, I thought that it could be potentially useful to bring these facts to your and Tony's attention, in spite of knowing that both of you are probably slightly busier these days than you would like to be.
>
> All the best and good luck with everything,
> Yours as ever,
> Mirek
>
> M. Malkovsky, MD, PhD, FRCPath
> Professor Emeritus, UW School of Medicine and Public Health
> Mobile: [redacted] (b) (6)
> Office telephone and fax: [redacted] (b) (6)
> E-mail: [redacted] (b) (6)

From: [redacted] (b) (6)
Sent: Sat, 7 Mar 2020 09:07:07 -0500
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: Pneumococcus vaccination in relation to coronavirus infection.

Pls respond

Sent from my iPhone

Begin forwarded message:

> **From:** Lars Nielsen [redacted] (b) (6)>
> **Date:** March 6, 2020 at 8:07:37 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Pneumococcus vaccination in relation to coronavirus infection.**
>
> Dear Anthony Fauci,
> As I understand the fatal cases of covid-19 develop pneumonia after several days of symptoms of the acute viral infection.
> In this way the present conoravirus infection is very like our present and previous fatal influenza virus infections. In the 1918 pandemic many if not most of the fatal cases were caused by bacterial superinfection with hemolytic streptococci and pneumococci. The former is rather seldom now, but the pneumococcal infections are common.
> Should we advice persons over >65 y as well as people with chronic diseases with increased risk of fatal coronavirus diseases to be vaccinated against pneumococci now?
> My best regards and thank you for your significant contribution to inflammatory medicine and infections.
> Lars P. Nielsen, M.D.
> Specialist in Medical Microbiology and Virology
> Former head of the Danish National Influenza Laboratory.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 7 Mar 2020 13:25:29 +0000
To: Elizabeth Stevens
Subject: RE: Thank you for staying front and center, and in the public eye re COVID-19

Ms. Stevens:
Thank you for your kind note.
Best regards,
A.S. Fauci

From: Elizabeth Stevens [redacted] (b) (6)
Sent: Friday, March 6, 2020 10:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Thank you for staying front and center, and in the public eye re COVID-19

Dear Dr. Fauci,

I am so happy to continue seeing you in press conferences and on news broadcasts.

Please keep making those public appearances. Americans need to hear the facts from someone who is trustworthy.

I am sure that tiptoeing around Donald Trump has dramatically complicated your life. I hope that you will find ways to "correct" or "clarify" the constant stream of misstatements that he makes – our lives depend upon it. (Maybe Trump could wear a hazmat suit – to protect his fragile ego from any possible bruising caused by a collision with the truth. Just kidding.)

Seriously, Doctor, it is a huge relief to see and hear you and your expert colleagues. It is to the point that we cannot believe a single word that comes out of Trump's mouth.

Very sincerely,
Elizabeth Stevens
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 7 Mar 2020 13:23:54 +0000
To: [redacted] (b) (6)
Subject: FW: [redacted] (b) (4)

fyi

From: Lipkin, Ian W. [redacted] (b) (6)>
Sent: Saturday, March 7, 2020 8:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [redacted] (b) (4)

Tony,
Happy to connect you with Zhu. [redacted] (b) (4)
(b) (4) [redacted]

(b) (4)

[redacted]

(b) (4)

[redacted]

(b) (4)

[redacted]

(b) (4)

[redacted]

[redacted] (b) (4)

>>>> With best regards,
>>>>
>>>> Zhu
>>>>
>>>>
>>>> 发件人: Lipkin, Ian W. [redacted] (b) (6)
>>>> 发送时间: 2020年2月9日 23:01
>>>> 收件人: Zhu Chen
>>>> 抄送: George Gao; zhangzongwei
>>>> 主题: Re: important info
>>>>
>>>> Zhu,
>>>> Please call me on [redacted] (b) (6)
>>>>
>>>> Ian
>>>>
>>>>
>>>>
>>>> W. Ian Lipkin, MD
>>>> John Snow Professor of Epidemiology and Director
>>>> Center for Infection and Immunity
>>>> Mailman School of Public Health
>>>>
>>>> Professor of Pathology and Neurology
>>>> College of Physicians & Surgeons
>>>> Columbia University
>>>> 722 West 168th Street, 17th Floor
>>>> New York, NY 10032
>>>> Voice: [redacted] (b) (6)
>>>> Fax: (212) 342-9044
>>>> Email: [redacted] (b) (6)

>>>>
>>>> Administrative Coordinator
>>>> (b) (6)
>>>> Voice: (b) (6)
>>>> Email: (b) (6)
>>>>
>>>> www.cii.columbia.edu
>>>> Follow CII on Twitter: CII_Columbia | Facebook: CII.Columbia
>>>>
>>>>
>>>>
>>>>
>>>>
>>>>
>>>> On Feb 9, 2020, at 9:43 AM, ZhuChen (b) (6)> wrote:
>>>>
>>>> Dear Ian,
>>>> I have an important info to be shared with you. According to the latest report from the National Health Commission, the number of confirmed cases of NCP (2019-nCoV pneumonia) in other Provinces than Hubei (Wuhan is the capital city) was decreased from 890/day on Feb 3rd to 509/day on Feb 8th. So it is still possible for this outbreak to be basically contained in China.
>>>> Therefore, my suggestion is that we support the current public health policies and strategy to concentrate quality medical human resources and other resources to save more life of severe patients, even though the cost is high, very high. And then, we shall continuously analyze the situation for possible adjustment of policies and measures.
>>>> Best,
>>>> Zhu
>>>>
>>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 7 Mar 2020 13:23:10 +0000
To: Lorne Brandes
Subject: RE: Coronavirus immunity

We have thought about it.

-----Original Message-----
From: Lorne Brandes (b) (6)>
Sent: Saturday, March 7, 2020 12:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus immunity

Hi Dr Fauci,
Has anyone considered the possibility that previous coronavirus infection(s) associated with common colds may result in at least partial immunity to the COVID-19 virus? This may explain why the disease is generally mild in 80% of adults and apparently rare in children (most of whom get more frequent colds than adults). I would be pleased to hear your thoughts.
Sincerely,
Lorne Brandes, MD, FRCPC
Professor, University of Manitoba (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 7 Mar 2020 13:21:56 +0000
To: Ann Job
Subject: RE: 2020 Census and COVID-19

Ms. Job:
Thank you for your note.,
Best regards,
A.S. Fauci

From: Ann Job [redacted] (b) (6)>
Sent: Saturday, March 7, 2020 12:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: 2020 Census and COVID-19

Dear Dr. Fauci,

Today I wrote and mailed a letter to both you and Dr. Redfield.

I will not duplicate nor attach it here, but I did want you to make you aware of my letter in case it doesn't reach your desk on Monday. In it I ask you and Dr. Redfield to explore the possibility of using 2020 Census Enumerators as an "on-the-ground army" to help stop COVID-19.

Because as you know better than anyone else that time is of the essence, I thought it useful to give you a heads-up about my letter via this email.

I am probably being naive, but just in case it makes sense to you, I thought it couldn't hurt to write you.

Thank you for being there for us. We really need you.

Yours,

Ann E. Job (pronounced like the Book of Job in the Bible)

[redacted] (b) (6) (iPhone)
(home)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 7 Mar 2020 13:13:58 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: A vaccine with anti immunosuppressive properties
Attachments: (b) (6)

Please respond on my behalf

From: Avraham Halbreich (b) (6)>
Sent: Saturday, March 7, 2020 7:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: A vaccine with anti immunosuppressive properties
Importance: Low

Dear Dr Fauci,

Common wisdom tells us that the inability to immunize against HIV, malaria etc. as well as the need to repeat evry year anti flu vaccination result from the excessive, or limitless, genetic variability of the underlying pathogens. While not doubting the reality of this genetic variability, best observed in an orderly manner in the case of HIV, I considered the possibility that these pathogens are endowed wiith an immunosuppressive capacity that is not inactivated during vaccine production, and that current vaccines do not induce immunity against such immunosuppression. I applied this reasonning when I worked on an AIDS vaccine in 1991 in Zagury's lab (Halbreich A et al. (1992) Vaccine Research,4 :397-412). Indeed, we tested then, in suitably immunized animals, the effect of the various preparations on the cellular response to tuberculin and the capacity of animals to be Immunized against tuberculin and tetanus as a function of the exrent of treatment. The immune response to these agents was indeed higher in the presence of hivions compared to heat inactivated préparations. This HIVION preparation was used on 6 patients in Zaire (Zagury et al. (1992) J Acquired Immune Deficiency Syndromes, 5 :676-681).

Unfortunately, when I tried to make a greater prep for a phase I trial, the viral preparation turned out (too late),

by SDS gel elecrophoresis, not to contain any viral protein, due either to degradation or another mishap. I left Zagury's lab soon after and it was impossible for me later to obtain material (either viral or from recombinant protein) to further advance the matter. I do believe that tuning vaccine preparation to counter immunosuppressive effect of the virus (parasite) while preserving its capacity to induce anti viral immunity should resolve the need to revaccinate every year against the same virus. In fact, identifying the épitopes, acting for immunity and those

acting against immunosuppression, at a later stage should allow a better result than we obtained. (It is not yet known whether corona virus also mutates rapidly, but I heard that a woman was reinfected after having recovered from covid-19 infection and this might indicate a capacity of the virus to counteract the host's immune response.

In [redacted] (b) (6) I have been itching ever since to go back to unfinished projects, but did not

find an avenue. Now, with the outburst of the corona virus pandemic this surfaces again.

(b) (6)

[redacted]

Sincerely

Avraham Halbreich

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 7 Mar 2020 13:06:00 +0000
To: Anderson, Jennifer (NIH/NIAID) [E]
Subject: RE: unit heads

If I am available, I would be happy to discuss COVID-19

From: Anderson, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Saturday, March 7, 2020 8:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Fwd: unit heads

Good morning Dr Fauci

We are - for the moment - scheduled for a Unitheads meeting on Tuesday. Tae Wook is next to present but suggested (see below) that we make it a round table and discuss COVID-19.

Question: IF Unitheads isn't canceled how do you feel about having a Roundtable instead of Tae Wook presenting? Or would you prefer to take a break from Coronavirus for a moment and hear about HIV!

Thanks
Jen

Sent from my iPhone

Begin forwarded message:

> **From:** "Chun, Tae-Wook (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Date:** March 6, 2020 at 9:53:11 AM EST
> **To:** "Anderson, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Re: unit heads**
>
> Can we do round table? I want to talk to him about corona not to mention the MTA will get canceled anyway. If you want me to I will present.
>
>> On Mar 6, 2020, at 9:47 AM, Anderson, Jennifer (NIH/NIAID) [E] [redacted] (b) (6) wrote:
>>
>> Hi Tae Wook,

I think you are up for Unitheads? It's been so long, I've lost track. I think you were supposed to present back on Jan 14th but it got canceled and I don't think we've had a presentation since. Im being told we might have a UH on Tuesday – ASF is free so far. Can you present?
Jen

Jennifer M. Anderson, PhD
Deputy Branch Chief
IAMB/OAS/NIAID
Scientific Operations Manager
LIR/DIR/NIAID
9000 Rockville Pike, Bldg. 10 Rm. 6A19A
Bethesda, Maryland 20892
Office Phone : (b) (6)
NIH Cell: (b) (6)
Personal Cell: (b) (6)
FAX: 301-402-4122

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 7 Mar 2020 13:02:34 +0000
To: Cassetti, Cristina (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: FW: Plasma therapy

FYI

-----Original Message-----
From: Lipkin, Ian W. [redacted] (b) (6)
Sent: Saturday, March 7, 2020 7:50 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Plasma therapy

Tony,
Just reviewed paper [redacted] (b) (4) on pilot study of plasma therapy for COVID-19. Sufficiently encouraging that I'd begin collecting plasma for compassionate use as well as larger randomized trial.
Ian

Ian

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 7 Mar 2020 13:02:18 +0000
To: Lipkin, Ian W.
Subject: RE: Plasma therapy

Thanks, Ian

-----Original Message-----
From: Lipkin, Ian W. [redacted] (b) (6)>
Sent: Saturday, March 7, 2020 7:50 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Plasma therapy

Tony,
Just reviewed paper [redacted] (b) (4) on pilot study of plasma therapy for COVID-19. Sufficiently encouraging that I'd begin collecting plasma for compassionate use as well as larger randomized trial.
Ian

Ian

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 23:44:54 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Crawford, Chase (NIH/NIAID) [E]
Subject: Re: ASF ------- AIPAC reports that two people who attended its conference tested positive for the coronavirus
Attachments: image001.jpg

Yikes!

> On Mar 6, 2020, at 6:23 PM, Folkers, Greg (NIH/NIAID) [E] < [redacted] (b) (6)> wrote:
>
> Just fyi – folks from this delegation were in the hallway on the Hill when you and Chase were there
>
> ---
>
> **From:** Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
> **Sent:** Friday, March 6, 2020 6:18 PM
> **Subject:** JTA: AIPAC reports that two people who attended its conference tested positive for the coronavirus
>
> # AIPAC reports that two people who attended its conference tested positive for the coronavirus
>
> MARCH 6, 2020 5:45 PM
> <image001.jpg>
>
> Outside the American Israel Public Affairs Committee (AIPAC) annual conference in Washington, DC on March, 01, 2020. (Marvin Joseph/The Washington Post via Getty Images)

WASHINGTON (JTA) — The American Israel Public Affairs Committee said that at least two people who attended the lobby's policy conference have tested positive for the coronavirus.

The conference, which ran from Feb. 28-March 2, drew 18,000 activists to Washington.

The AIPAC statement posted late Friday on Twitter said the two people who tested positive are from New York. The outbreak has been especially hard on the Orthodox Jewish community in Westchester County, and AIPAC listed the county's health department as among the authorities with which it is in communication.

The others are the New York Health Department, national health authorities and the District of Columbia Health Department. The statement also said the lobby was consulting with Edward Septimus, a professor of internal medicine at Texas A&M University.

The statement posted on Twitter said an email was going out to all attendees as well as to congressional offices. The conference routinely attracts a majority of Congress members and their staffers.

BY RON KAMPEAS

AIPAC 2020
TODAY. TOMORROW. TOGETHER.


AIPAC 2020
TODAY. TOMORROW. TOGETHER.

From: [redacted] (b) (6)
Sent: Fri, 6 Mar 2020 18:35:49 -0500
To: NIAID Public Inquiries
Subject: Fwd: Important & Emergency Nature (COVID-19) Related

Sent from my iPhone

Begin forwarded message:

> **From:** Udita Katugampola [redacted] (b) (6)
> **Date:** March 6, 2020 at 6:29:16 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: Important &Emergency Nature (COVID-19) Related**
>
> Dear Dr. Fauci,
> I saw that you are discussing the steps we need to take to make the impact of COVID-19 a minimum in CNN and decided to write to you what we did as faculty in this aspect.
> I believe that prevention is much more important than treatment later. As a preparation for the COVID-19 outbreak, two days ago, I made a personal decision to make all my homework online submission so that we may avoid the spread of the virus anymore.
> Students work on homework for hours and can easily spread the virus without knowing it. Once it goes to graders (my TAs) , they then spread it to the rest of the class, again without knowing it. Thus, an innocent act can be devastating. So, in simply two-three days it may spread to another 100 new individuals easily.
> Graders may act as hubs in this case. The danger is, it may have spread to another hundred or more new individuals even before it comes to a detectable level from any test.
> I also want to emphasis the following points:
>
> 1. We hear in all news that elderly people are the most vulnerable. But I think it should be corrected as people with immunodeficiency are the most vulnerable and elderly are in that category. Some one who is 10 years old and have diabetic or HIV has the same danger as an elderly person.
> 2. We should come up with a test such as a pregnancy test, which can be done at home without leaving their homes. This stops further spreading.
> 3. We should discuss foods that help cure it fast and things that we should not do.

I have shared my thoughts with CNN (Dr. Sanjay Gupta and Anderson Cooper as well). Thank you for your time and everything you do to our community at this critical moment.

Best,
Udita

Udita Katugampola, Ph.D.
Assistant Professor of Mathematics
Florida Polytechnic University
Office: IST 2015
Tel: [redacted] (b) (6)
Email: [redacted] (b) (6) edu
Web: https://sites.google.com/site/uditanalin/

From: [redacted] (b) (6)
Sent: Fri, 6 Mar 2020 18:32:06 -0500
To: NIAID Public Inquiries
Subject: Fwd: MOSQUITOES

Sent from my iPhone

Begin forwarded message:

> **From:** JAMES NUTILE [redacted] (b) (6).
> **Date:** March 6, 2020 at 5:58:58 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: MOSQUITOES**
>
> Dr. Fauci,
>
> No ones addressing the possibility of the Coronavirus being transferred by mosquitoes this summer. Is that a possibility?
> Thank you,
> James Nutile
>
> Sent from my iPhone

From: [redacted] (b) (6)
Sent: Fri, 6 Mar 2020 18:31:39 -0500
To: NIAID Public Inquiries
Subject: Fwd: I am not spam. Possible consideration for Coronavirus

Sent from my iPhone

Begin forwarded message:

> **From:** Karen Bender [redacted] (b) (6)>
> **Date:** March 6, 2020 at 6:07:58 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: I am not spam. Possible consideration for Coronavirus**
>
> Good Evening Dr Fauci,
> I have an idea for your consideration for the Coronavirus vaccine/treatment. Noting that the virus is attacking our elderly more and knowing their lungs are older and not as functional to fight this infection. Have you considered artificial surfactant to boost lung function. [redacted] (b) (6)
> Perhaps if their lungs are stronger to expand they could fight the virus better.
> Thank you for listening, My prayers are with our Healthcare Professionals to achieve a treatment/vaccine.
> Karen Bender

From: [redacted] (b) (6)
Sent: Fri, 6 Mar 2020 18:28:43 -0500
To: Lerner, Andrea (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: Kidney Disease (NS-MCD) and Covid-19 Coronavirus

Can one of you take this?

Sent from my iPhone

Begin forwarded message:

> **From:** Raja R [redacted] (b) (6)>
> **Date:** March 6, 2020 at 6:15:37 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Subject: Kidney Disease (NS-MCD) and Covid-19 Coronavirus**
>
> Dear Dr. Fauci,
>
> I live in the United Kingdom and listen to your recent press briefings from White House. First of all, I want to convey my sincerest thanks to you for providing valuable information to the general public.
>
> I would greatly appreciate it if you can advise on what precautions I should take (b) (6) [redacted] in order to safeguard against the Covid-19 corona virus. [redacted] (b) (6). Should he try to avoid all social contact, and of course avoid any cruise, air or public transport to prevent him from getting the infection?
>
> I would greatly appreciate your advice on this.
>
> Regards
> Raja

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 15:26:21 +0000
To: Dzau, Victor J.
Subject: RE: URGENT - GPMB COVID-19 FUNDING NOTE

Please leave m name off.   Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. [redacted] (b) (6)
Sent: Friday, March 6, 2020 10:02 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Alex Harris [redacted] (b) (6); Jeremy Farrar [redacted] (b) (6)>
Subject: Re: URGENT - GPMB COVID-19 FUNDING NOTE

Tony,
I know you are extremely busy. I am following up on GPMB business.
Given our conversation 3 days ago, would you like to sign on the statement or do you prefer us to leave you name off? Please let us know ASAP.
Best,
Victor

> On Mar 5, 2020, at 9:31 AM, Alex Harris [redacted] (b) (6)> wrote:
>
> Dear Board Members,
>
> Thank you for your input on the call yesterday regarding the COVID-19 [redacted] (b) (4)

(b) (4)

With many thanks,

Alex

Alex Harris
Head of Global Policy & Advocacy
Wellcome

T: (b) (6)
(b) (6)

G7 leaders and Sherpas

Country	Rep	Sherpa (amendments welcome)	GPMB lead(s)
Canada	Justin Trudeau, Prime Minister	(b) (6)	
France	Emmanuel Macron, President	[redacted]	
Germany	Angela Merkel, Chancellor	[redacted]	Jeremy Farrar
Italy	Giuseppe Conte, Prime Minister	[redacted]	
Japan	Shinzō Abe, Prime Minister	[redacted]	
United Kingdom	Boris Johnson, Prime Minister	[redacted]	Jeremy Farrar
United States	Donald Trump,	[redacted]	Victor Dzau

	President		
Participants			
European Union	Charles Michel, President of the European Council	[redacted] (b) (6)	
European Union	Ursula von der Leyen, President of the European Commission	[redacted]	Victor Dzau Jeremy Farrar

International financial institutions

Institution	Leadership	Sherpa/equivalent or suggested contacts	GPMB lead
[redacted]	[redacted]	[redacted] (b) (6), (b) (4)	Victor Dzau
[redacted]	[redacted]	[redacted]	As Sy
[redacted]	[redacted]	[redacted]	
[redacted]	[redacted]	[redacted]	
[redacted]	[redacted]	[redacted]	
[redacted]	[redacted]	[redacted]	
[redacted]	[redacted]	[redacted]	Jeremy Farrar
[redacted]	[redacted]	[redacted]	

From: Alex Harris
Sent: 03 March 2020 23:06
To: 'Amelie RIOUX' [redacted] (b) (6)>; Dzau, Victor J. [redacted] (b) (6) Jeremy Farrar < [redacted] (b) (6)>; Anthony Fauci [redacted] (b) (6)>; Fore Henrietta [redacted] (b) (6)>; Gao Fu [redacted] (b) (6)>; Gashumba Diane < [redacted] (b) (6) Ilona Kickbusch [redacted] (b) (6)>; Suzuki Yasuhiro < [redacted] (b) (6); [redacted] (b) (6); Vega Morales Jeanette [redacted] (b) (6); VijayRaghavan Krishnaswamy [redacted] (b) (6)>; Skvortsova Veronika [redacted] (b) (6)>
Cc: Gro Brundtland [redacted] (b) (6)>; As Sy [redacted] (b) (6)>; Elhadj SY [redacted] (b) (6)>; Tore Godal < [redacted] (b) (6); Godal, Tore [redacted] (b) (6)>; [redacted] (b) (6); SCHWARTLANDER, Bernhard F. [redacted] (b) (6)>; RYAN, Michael J. [redacted] (b) (6)>; Pate Muhamed [redacted] (b) (6)>; Kanarek, Morgan [redacted] (b) (6) [redacted] (b) (6) [redacted]; 'Sheila Austria' [redacted] (b) (6); William Hall [redacted] (b) (6); Teresa Miller de Vega < [redacted] (b) (6)>; 'Marston Hilary' [redacted] (b) (6) [redacted]; Zacharie Gahungu [redacted] (b) (6) [redacted] Toomas Palu [redacted] (b) (6)
Subject: RE: GPMB: COVID-19 FUNDING NOTE

Dear Board Members,

Ahead of the GPMB Board call on Wednesday, I'm pleased to attach a note (on behalf of Jeremy Farrar, Victor Dzau and a small working group) setting out the urgent need for new funding for the global COVID-19 response.

You will have seen the strong announcement today from the World Bank of up to $12bn to support country response, which we warmly welcome. We are asking for your feedback on the call and [redacted] (b) (4)

(b) (4) [redacted]

[redacted] (b) (4)

We look forward to the discussion.

With best wishes,

Alex

Alex Harris
Head of Global Policy & Advocacy
Wellcome

T: [redacted] (b) (6)
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 15:23:33 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: Phase 1 mRNA coronavirus vax launch

Looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, March 6, 2020 10:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FOR ASF REVIEW: Draft PR re: Phase 1 mRNA coronavirus vax launch

Good morning, Dr. Fauci,

Please find attached for your review a draft press release about the launch of the Phase 1 study of the mRNA COVID-19 vaccine. We are tentatively planning to issue the release on Wed., March 11 once we've received confirmation that the first participant has been vaccinated. For ease of reference, the following is the quote we have crafted for you:

"Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority," said NIAID Director Anthony S. Fauci, M.D. "This Phase 1 study, launched in record speed, is an important first step toward achieving that goal."

Thanks,

Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A17F
Bethesda, MD 20892
(b) (6)
Media line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 14:50:15 +0000
To: [redacted] (b) (6)
Subject: FW: Developing Immunity to SARS-CoV-2 and Ivlg

Please respond to this person.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dr. Art Kamm <art@kammconsultinginc.com>
Sent: Friday, March 6, 2020 7:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Developing Immunity to SARS-CoV-2 and Ivlg

Dear Dr. Fauci and Dr. Lane:

I have been following the growing international outbreak of COVID-19 and wanted to share a thought with you, understanding that this may have already been thought of. My early academic research (reference provided, PNAS) involved cancer immunology where it contributed to a growing body of information that certain tumor cells could possess unique surface antigens that could be used for immunologic therapy (https://www.pnas.org/content/pnas/75/12/5912.full.pdf). My career then took me to executive and senior executive/corporate officer positions in publicly-held pharmaceutical corporations (Glaxo and Salix, respectively) overseeing R&D of therapeutic agents. My experience has included both pharmaceuticals and biologics.

[redacted] (b) (6)

Our current understanding of COVID-19 mortality is that it appears to be concentrated in the elderly and those with underlying medical conditions. In healthy individuals (although still early) it appears that many of those infected with SARS-CoV-2 may remain symptom free or develop mild disease, or recover from more severe illness. Currently there are tens of thousands of individuals who have been identified as having been infected but are considered 'recovered'. That being case it would seem plausible that they have mounted an antibody response to the virus.

The question is whether these individuals are being tested for antibody titre to the virus, and if that is occurring whether they are being approached to donate plasma to move into IgIv production. With this illness still in its early stages and being international, I would imagine that such an effort would involve a public/private sector endeavor. Understanding the difficulty in developing a vaccine for 'cold viruses', IvIG may be a way to at least reduce the mortality in our most vulnerable patients. So, the slow start we have had in testing the US population for this virus goes beyond disease prevention - it would certainly be affecting our ability, to some degree, of rapidly developing a more targeted intervention for high risk patients.

Again, you may have already thought of this, but as a concerned citizen having some background and an (b) (6),I wanted to share these thoughts. Understanding your busy schedules, I have copied both the Director and Deputy Director for Clinical Research and Special Projects.

Respectfully submitted,

Arthur R. Kamm, PhD

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 14:48:03 +0000
To: Corey MD, Larry
Subject: RE: A query

Visit where?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Corey MD, Larry [redacted] (b) (6)>
Sent: Friday, March 6, 2020 8:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: A query

Should i and I the younger Glenda Gray give these 702 talks at CROI on This coming Tuesday in Boston. If I fly East for this Tuesday evening talk are you at all free Wednesday to come visit and talk about HIV antibodies ? Or are you so programmed with coronavirus this is not realistic. ?

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 12:56:55 +0000
To: McNeil, Donald (mcneil@nytimes.com)
Subject: FW: NYT: Inside China's All-Out War on the Coronavirus

Donald:

Your interview with Bruce Aylward was the best discussion of COVID-19 that I have seen thus far. Great job!

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, March 5, 2020 11:19 PM
Subject: NYT: Inside China's All-Out War on the Coronavirus

Q&A

Inside China's All-Out War on the Coronavirus

Dr. Bruce Aylward, of the W.H.O., got a rare glimpse into Beijing's campaign to stop the epidemic. Here's what he saw.

Dr. Bruce Aylward, leader of the W.H.O. team that visited China to assess the country's response to the coronavirus outbreak.Credit...Salvatore Di Nolfi/Keystone, via Associated Press

By Donald G. McNeil Jr.

- March 4, 2020

As the leader of the World Health Organization team that visited China, Dr. Bruce Aylward feels he has been to the mountaintop — and has seen what's possible.

During a two-week visit in early February, Dr. Aylward saw how China rapidly suppressed the coronavirus outbreak that had engulfed Wuhan, and was threatening the rest of the country.

New cases in China have dropped to about 200 a day, from more than 3,000 in early February. The numbers may rise again as China's economy begins to revive. But for now, far more new cases are appearing elsewhere in the world.

China's counterattack can be replicated, Dr. Aylward said, but it will require speed, money, imagination and political courage.

For countries that act quickly, containment is still possible "because we don't have a global pandemic — we have outbreaks occurring globally," he added.

Dr. Aylward, who has 30 years experience in fighting polio, Ebola and other global health emergencies, detailed in an interview with The New York Times how he thinks the campaign against the virus should be run.

This conversation has been edited and condensed.

Do we know what this virus's lethality is? We hear some estimates that it's close to the 1918 Spanish flu, which killed 2.5 percent of its victims, and others that it's a little worse than the seasonal flu, which kills only 0.1 percent. How many cases are missed affects that.

There's this big panic in the West over asymptomatic cases. Many people are asymptomatic when tested, but develop symptoms within a day or two.

In Guangdong, they went back and retested 320,000 samples originally taken for influenza surveillance and other screening. Less than 0.5 percent came up positive, which is about the same number as the 1,500 known Covid cases in the province. (*Covid-19 is the medical name of the illness caused by the coronavirus.)*

There is no evidence that we're seeing only the tip of a grand iceberg, with nine-tenths of it made up of hidden zombies shedding virus. What we're seeing is a pyramid: most of it is aboveground.

Once we can test antibodies in a bunch of people, maybe I'll be saying, "Guess what? Those data didn't tell us the story." But the data we have now don't support it.

That's good, if there's little asymptomatic transmission. But it's bad in that it implies that the death rates we've seen — from 0.7 percent in parts of China to 5.8 percent in Wuhan — are correct, right?

I've heard it said that "the mortality rate is not so bad because there are actually way more mild cases." Sorry — the same number of people that were dying, still die. The real case fatality rate is probably what it is outside Hubei Province, somewhere between 1 and 2 percent.

Patients waiting to be transferred from one hospital in Wuhan to Leishenshan Hospital, a newly built medical center to address the epidemic that is also in Wuhan, China.Credit...Agence France-Presse — Getty Images

What about children? We know they are rarely hospitalized. But do they get infected? Do they infect their families?

We don't know. That Guangdong survey also turned up almost no one under 20. Kids got flu, but not this. We have to do more studies to see if they get it and aren't affected, and if they pass it to family members. But I asked dozens of doctors: Have you seen a chain of transmission where a child was the index case? The answer was no.

Why? There's a theory that youngsters get the four known mild coronaviruses so often that they're protected.

That's still a theory. I couldn't get enough people to agree to put it in the W.H.O. report.

Does that imply that closing schools is pointless?

No. That's still a question mark. If a disease is dangerous, and you see clusters, you have to close schools. We know that causes problems, because as soon as you send kids home, half your work force has to stay home to take care of them. But you don't take chances with children.

Are the cases in China really going down?

I know there's suspicion, but at every testing clinic we went to, people would say, "It's not like it was three weeks ago." It peaked at 46,000 people asking for tests a day; when we left, it was 13,000. Hospitals had empty beds.

I didn't see anything that suggested manipulation of numbers. A rapidly escalating outbreak has plateaued, and come down faster than would have been expected. Back of the envelope, it's hundreds of thousands of people in China that did not get Covid-19 because of this aggressive response.

Is the virus infecting almost everyone, as you would expect a novel flu to?

No — 75 to 80 percent of all clusters are in families. You get the odd ones in hospitals or restaurants or prisons, but the vast majority are in families. And only 5 to 15 percent of your close contacts develop disease. So they try to isolate you from your relatives as quickly as possible, and find everyone you had contact with in 48 hours before that.

You said different cities responded differently. How?

It depended on whether they had zero cases, sporadic ones, clusters or widespread transmission.

First, you have to make sure everyone knows the basics: hand-washing, masks, not shaking hands, what the symptoms are. Then, to find sporadic cases, they do fever checks everywhere, even stopping cars on highways to check everyone.

As soon as you find clusters, you shut schools, theaters, restaurants. Only Wuhan and the cities near it went into total lockdown.

How did the Chinese reorganize their medical response?

First, they moved 50 percent of all medical care online so people didn't come in. Have you ever tried to reach your doctor on Friday night? Instead, you contacted one online. If you needed prescriptions like insulin or heart medications, they could prescribe and deliver it.

Grocery delivery to a quarantine area in Wuhan, China.Credit...Agence France-Presse — Getty Images

But if you thought you had coronavirus?

You would be sent to a fever clinic. They would take your temperature, your symptoms, medical history, ask where you'd traveled, your contact with anyone infected. They'd whip you through a CT scan …

Wait — "whip you through a CT scan"?

Each machine did maybe 200 a day. Five, 10 minutes a scan. Maybe even partial scans. A typical hospital in the West does one or two an hour. And not X-rays; they could come up normal, but a CT would show the "ground-glass opacities" they were looking for.

(Dr. Aylward was referring to lung abnormalities seen in coronavirus patients.)

And then?

If you were still a suspect case, you'd get swabbed. But a lot would be told, "You're not Covid." People would come in with colds, flu, runny noses. That's not Covid. If you look at the symptoms, 90 percent have fever, 70 percent have dry coughs, 30 percent have malaise, trouble breathing. Runny noses were only 4 percent.

The swab was for a PCR test, right? How fast could they do that? Until recently, we were sending all of ours to Atlanta.

They got it down to four hours.

So people weren't sent home?

No, they had to wait. You don't want someone wandering around spreading virus.

If they were positive, what happened?

They'd be isolated. In Wuhan, in the beginning, it was 15 days from getting sick to hospitalization. They got it down to two days from symptoms to isolation. That meant a lot fewer infected — you choke off this thing's ability to find susceptibles.

What's the difference between isolation and hospitalization?

With mild symptoms, you go to an isolation center. They were set up in gymnasiums, stadiums — up to 1,000 beds. But if you were severe or critical, you'd go straight to hospitals. Anyone with other illnesses or over age 65 would also go straight to hospitals.

What were mild, severe and critical? We think of "mild" as like a minor cold.

No. "Mild" was a positive test, fever, cough — maybe even pneumonia, but not needing oxygen. "Severe" was breathing rate up and oxygen saturation down, so needing oxygen or a ventilator. "Critical" was respiratory failure or multi-organ failure.

So saying 80 percent of all cases are mild doesn't mean what we thought.

I'm Canadian. This is the Wayne Gretzky of viruses — people didn't think it was big enough or fast enough to have the impact it does.



A sports stadium converted to a makeshift hospital in Wuhan, China.Credit...China Daily/Reuters

Hospitals were also separated?

Yes. The best hospitals were designated just for Covid, severe and critical. All elective surgeries were postponed. Patients were moved. Other hospitals were designated just for routine care: women still have to give birth, people still suffer trauma and heart attacks.

They built two new hospitals, and they rebuilt hospitals. If you had a long ward, they'd build a wall at the end with a window, so it was an isolation ward with "dirty" and "clean" zones. You'd go in, gown up, treat patients, and then go out the other way and de-gown. It was like an Ebola treatment unit, but without as much disinfection because it's not body fluids.

How good were the severe and critical care?

China is really good at keeping people alive. Its hospitals looked better than some I see here in Switzerland. We'd ask, "How many ventilators do you have?" They'd say "50." Wow! We'd say, "How many ECMOs?" They'd say "five." The team member from the Robert Koch Institute said, "Five? In Germany, you get three, maybe. And just in Berlin."

(ECMOs are extracorporeal membrane oxygenation machines, which oxygenate the blood when the lungs fail.)

Who paid for all of this?

The government made it clear: testing is free. And if it was Covid-19, when your insurance ended, the state picked up everything.

In the U.S., that's a barrier to speed. People think: "If I see my doctor, it's going to cost me $100. If I end up in the I.C.U., what's it going to cost me?" That'll kill you. That's what could wreak havoc. This is where universal health care coverage and security intersect. The U.S. has to think this through.

What about the nonmedical response?

It was nationwide. There was this tremendous sense of, "We've got to help Wuhan," not "Wuhan got us into this." Other provinces sent 40,000 medical workers, many of whom volunteered.

In Wuhan, our special train pulled in at night, and it was the saddest thing — the big intercity trains roar right through, with the blinds down.

We got off, and another group did. I said, "Hang on a minute, I thought we were the only ones allowed to get off." They had these little jackets and a flag — it was a medical team from Guangdong coming in to help.

How did people in Wuhan eat if they had to stay indoors?

Fifteen million people had to order food online. It was delivered. Yes, there were some screw-ups. But one woman said to me: "Every now and again there's something missing from a package, but I haven't lost any weight."

A yoga class being taught online from a studio in Beijing.Credit...Roman Pilipey/EPA, via Shutterstock

Lots of government employees were reassigned?

From all over society. A highway worker might take temperatures, deliver food or become a contact tracer. In one hospital, I met the woman teaching people how to gown up. I asked, "You're the infection control expert?" No, she was a receptionist. She'd learned.

How did technology play a role?

They're managing massive amounts of data, because they're trying to trace every contact of 70,000 cases. When they closed the schools, really, just the buildings closed. The schooling moved online.

Contact tracers had on-screen forms. If you made a mistake, it flashed yellow. It was idiot-proof.

We went to Sichuan, which is vast but rural. They'd rolled out 5G. We were in the capital, at an emergency center with huge screens. They had a problem understanding one cluster. On one screen, they got the county headquarters. Still didn't solve it.

So they got the field team. Here's this poor team leader 500 kilometers away, and he gets a video call on his phone, and it's the governor.

What about social media?

They had Weibo and Tencent and WeChat giving out accurate information to all users. You could have Facebook and Twitter and Instagram do that.

Isn't all of this impossible in America?

Look, journalists are always saying: "Well, we can't do this in our country." There has to be a shift in mind-set to rapid response thinking. Are you just going to throw up your hands? There's a real moral hazard in that, a judgment call on what you think of your vulnerable populations.

Ask yourself: Can you do the easy stuff? Can you isolate 100 patients? Can you trace 1,000 contacts? If you don't, this will roar through a community.

Isn't it possible only because China is an autocracy?

Journalists also say, "Well, they're only acting out of fear of the government," as if it's some evil fire-breathing regime that eats babies. I talked to lots of people outside the system — in hotels, on trains, in the streets at night.

They're mobilized, like in a war, and it's fear of the virus that was driving them. They really saw themselves as on the front lines of protecting the rest of China. And the world.

A medical worker in a hospital in Wuhan working with traditional medicines to treat patients.Credit...Agence France-Presse — Getty Images

China is restarting its economy now. How can it do that without creating a new wave of infections?

It's a "phased restart." It means different things in different provinces.

Some are keeping schools closed longer. Some are only letting factories that make things crucial to the supply chain open. For migrant workers who went home — well, Chengdu has 5 million migrant workers.

First, you have to see a doctor and get a certificate that you're "no risk." It's good for three days. Then you take the train to where you work. If it's Beijing, you then have to self-quarantine for two weeks. Your temperature is monitored, sometimes by phone, sometimes by physical check.

What's going on with the treatment clinical trials?

They're double-blind trials, so I don't know the results. We should know more in a couple of weeks. The biggest challenge was enrolling people. The number of severe patients is dropping, and there's competition for them. And every ward is run by a team from another province, so you have to negotiate with each one, make sure they're doing the protocols right.

And there are 200 trials registered — too many. I told them: "You've got to prioritize things that have promising antiviral properties."

And they're testing traditional medicines?

Yes, but it's a few standard formulations. It's not some guy sitting at the end of the bed cooking up herbs. They think they have some fever-reducing or anti-inflammatory properties. Not antivirals, but it makes people feel better because they're used to it.

What did you do to protect yourself?

A heap of hand-sanitizer. We wore masks, because it was government policy. We didn't meet patients or contacts of patients or go into hospital dirty zones.

And we were socially distant. We sat one per row on the bus. We ate meals in our hotel rooms or else one person per table. In conference rooms, we sat one per table and used microphones or shouted at each other.

That's why I'm so hoarse. But I was tested, and I know I don't have Covid.

Dr Bruce Aylward
TEAM LEAD
WHO-CHINA JOINT MISSION ON COVID-19

Dr. Aylward offered an elbow in lieu of a handshake during a briefing in Geneva on the W.H.O. mission to China.Credit...Salvatore Di Nolfi/EPA, via Shutterstock

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 12:31:28 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Nicolle Wallace / MSNBC interview request for today or next week...

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Robinson, Querry (NBCUniversal) <querry.robinson@msnbc.com>
Sent: Friday, March 6, 2020 7:17 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Nicolle Wallace / MSNBC interview request for today or next week...

Hi Patricia,

This is Querry Robinson with Nicolle Wallace at MSNBC's 'Deadline: White House' in New York again.

I am writing to request an interview with Dr. Fauci today during the 4 pm ET or at some point next week if his schedule may allow.

Nicolle is hoping to speak with Dr. Fauci about growing concerns over the spread coronavirus and what the public should be doing now in the wake of this pandemic.

We would gladly have Dr. Fauci join us from the NIH camera if his schedule may allow..

Please let me know if today may be a possibility or if another day next week may be better for the schedule when you may have a moment.

All the best,

Querry

Querry Robinson
‘Deadline: White House’ with Nicolle Wallace
30 Rockefeller Plaza, NY, NY 10112
W – 212-664-3923
C – (b) (6)
querry.robinson@nbcuni.com

Sent from my iPhone - please overlook any misspellings or grammatical errors

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 11:02:56 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Emergency Preparedness, Coronavirus, and Products from MPI
Attachments: MPI - CloroxPro_Scrubs_2019 (1).pdf, MPI - CloroxPro_LabCoats_2019.pdf, MPI - PrimeMedical_Curtains_Flyer.pdf, MPI - POW_HOSP_Barrier_Protection_28update29.pdf, MPI - EvaClean Tri Fold 2019.pdf

Please take a look and handle if necessary

From: Brad Wicklas [redacted] (b) (6)>
Sent: Friday, March 6, 2020 3:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Emergency Preparedness, Coronavirus, and Products from MPI

Hi Anthony Fauci,

I know you're busy, but I wanted to introduce our Company, Medical Partners International, and talk for a quick minute about what we do and how it can help you. As you know, the CDC has asked all healthcare facilities to prepare for the "worst case scenario" around the Novel Coronavirus. As much of our medical supply manufacturing in the US comes from overseas, it is of critical import to look at potential shortages of key products that will be needed to perform basic IP functions in your facility. We have already seen challenges with N95 masks, and I have heard about potential shortages of items like disinfection wipes. We at MPI have a couple of unique solutions you need to consider:

PureTabs and PureOne NaDCC tablets that are diluted in tap water to create HOCl for surface disinfection. They are currently used in electrostatic sprayers to offer greater coverage around your equipment. If, for some reason, there's a challenge getting the electrostatic sprayers in the future (and we've already seen shortages and delays in getting new units), simply use our NaDCC tablets with spray bottles from your local store to apply the HOCl for disinfection. Our tablets have kill claims for C. diff in four minutes, and like a number of other cleaning agents, we believe we can be effective against the Novel Coronavirus. The problem with the other products out there comes down to availability, particularly of the N95 masks that are required on their IFU's. With our product, an N95 mask is recommended, but not required, which is a huge distinction if you have run out of N95 masks.

Secondly, we have our protective scrubs, lab coats and privacy curtains from Prime Medical. Co-branded with Clorox, these products create a 3 log (99.9%) barrier against bacteria and viruses when washed with bleach. The barrier lasts for 12 weeks, so there's a dramatically lower chance of passing something along. These are a great protective measure for your staff. The CDC mentioned that sodium hypochlorite (bleach) may be effective against Novel Coronavirus, so it stands to reason that our scrubs will help against unwanted spreading as well.

Finally, we have our Path-O-Wrap, which protects mattresses and gurneys from the harsh chemicals used during cleaning. It also can help dramatically when a catastrophic event happens, as you simply put these on a gurney or mattress and remove them between patients. It was invented by an EMT for just this purpose, and may be exactly what you need for your Emergency Preparedness Program.

We also have other great IP products such as:

- UV Disinfection Boxes to create a "touch-less check-in" to protect staff and patients alike
- HealthySole UV solutions for the bottom of feet for OR and other sensitive areas
- Bowman Cover Your Cough Stations

I have attached a couple of brochures for your review. We can provide you with a quote, or have our local representative bring in samples of some of the products to show. Simply write me back with what you would like more information on. We feel our products will make a difference for your facility; let us know how we can help.

Sincerely,

Medical Partners International

Brad Wicklas
Managing Partner
Cell: [redacted] (b) (6)
Website: www.bwicklas@medpint.com

MPI

Medical Partners Int'l

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 11:00:51 +0000
To: Corey MD, Larry;Dieffenbach, Carl (NIH/NIAID) [E]
Subject: RE: coronovirus vaccine testing

Anything that works is fine with me.

From: Corey MD, Larry (b) (6)>
Sent: Friday, March 6, 2020 12:23 AM
To: Dieffenbach, Carl (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: coronovirus vaccine testing

I know the VTEU's are first in line but I am sure the HVTN sites would be quite willing to participate in any coronavirus vaccine testing and if you need international populations the sub Saharan African sites will I am sure be interested . so our informal polling of sites revealed enthusiasm.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 04:07:20 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: SARS CoV entry inhibition for the masses
Attachments: Novel Inhibitors of SARS CoV Entry.pdf

Please handle.

From: Chris Sorg [redacted] (b) (6)>
Sent: Wednesday, March 4, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: SARS CoV entry inhibition for the masses

Dear Dr. Fauci: I really think you should look at this email trail. I can't seem to [redacted] (b) (4)

Respectfully,

John C. Sorg, M.D.
Cell: [redacted] (b) (6)

Chris Sorg
Hospitalist
North Arkansas Regional Medical Center
620 North Main Street, Harrison, AR 72601
Office: [redacted] (b) (6)

From: Chris Sorg
Sent: Monday, March 2, 2020 1:16 PM
To: [redacted] (b) (6)
Subject: FW: SARS CoV entry inhibition for the masses

Continuing to think outloud.

(b) (4)
[redacted]

J.C. Sorg, M.D.

Chris Sorg
Hospitalist
North Arkansas Regional Medical Center
620 North Main Street, Harrison, AR 72601

Office: [redacted] (b) (6)

From: Chris Sorg
Sent: Monday, March 2, 2020 12:11 PM
To: [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: SARS CoV entry inhibition for the masses

[redacted] (b) (4)

Respectfully,

J.C. Sorg, M.D.
Internal Medicine

Chris Sorg
Hospitalist
North Arkansas Regional Medical Center
620 North Main Street, Harrison, AR 72601
Office: [redacted] (b) (6)

Confidentiality Notice:

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. The recipient of this information is required to destroy the information after its stated need has been fulfilled. If you are not the intended recipient of the transmission, or an employee or agent responsible for delivering this transmission to the intended recipient, you must not review, retransmit, convert to hard copy, copy or use this transmission or any attachments transmitted within. If you have received this transmission in error, have any problems with this transmission, or need additional information, please notify the originator of the message immediately by phone (870) 414-4000 and permanently delete this email. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of North Arkansas Regional Medical Center.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 04:06:51 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Meeting to Assess Evaluation of COVID-19 vaccine candidates for risk of enhanced disease
Attachments: March 12th-Tentative list of questions to be discussed_JPC mg-sb[16212]-version4March-1239-CLEAN.docx, Draft agenda.Acc Assess ED.4Mar202011_with annexes.pdf

Please handle. I cannot meet with them.

From: Steve Black [redacted] (b) (6)
Sent: Wednesday, March 4, 2020 4:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Robert Chen [redacted] (b) (6)
Subject: Meeting to Assess Evaluation of COVID-19 vaccine candidates for risk of enhanced disease

Dear Doctor Fauci,

I am writing to you as a member of the SPEAC project which CEPI has funded to assist with the evaluation of the safety of vaccines in their portfolio. As part of this effort, we are assisting with developing preclinical and clinical testing criteria to evaluate the risk of enhanced disease following vaccination with COVID-19 vaccine candidates. As you know, this had been an issue with some prior SARS vaccine candidates.

We are convening a two day virtual meeting of experts via video conference next week on March 12 and 13 between 8 am and 1 pm Eastern time each day. Participants in the meeting are shown in the attached agenda but include Paul Henri Lambert from Geneva and Barney Graham from NIH. The meeting will actively involve the participants on the agenda the first day and on the second day the meeting will be open for several peer reviewers including Stanley Plotkin and Andy Pollard to review and comment on possible small and NHP animal models as well as appropriate immunologic testing to be done in early phase one trials.

I am wanted to make you aware of the meeting so that you could attend all or part as an observer if you wish but also to invite you to consider joining on day two as one of our formal peer reviewers. The goal of the meeting would be to share recommendations with CEPI COVID-19 developers as well as other interested parties.

Any comments you have on the agenda or draft questions for consideration would be greatly appreciated.

I look forward to hearing back from you.

ATTACHMENTS: DRAFT AGENDA; DRAFT QUESTIONS FOR CONSIDERATION

Steve

Steven Black MD
SPEAC Project work package lead for CEPI

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 04:04:44 +0000
To: [redacted] (b) (6)
Subject: FW: medRxiv: Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

fyi

From: Folkers, Greg (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Wednesday, March 4, 2020 4:27 PM
Subject: medRxiv: Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Xiaohua Chen, Binghong Zhao, Yueming Qu, Yurou Chen, Jie Xiong, Yong Feng, Dong Men, Qianchuan Huang, Ying Liu, Bo Yang, Jinya Ding, Feng Li

doi: https://doi.org/10.1101/2020.02.29.20029520

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should *not* be used to guide clinical practice.

- Abstract
- Info/History
- Metrics
-
- Preview PDF

Abstract

Background: Although the SARS-CoV-2 viral load detection of respiratory specimen has been widely used for novel coronavirus disease (COVID-19) diagnosis, it is undeniable that serum SARS-CoV-2 nucleic acid (RNAaemia) could be detected in a fraction of the COVID-19 patients. However, it is not clear that if the incidence of RNAaemia could be correlated with the occurrence of cytokine storm or with the specific class of patients. Methods: This study enrolled 48 patients with COVID-19 admitted to the General Hospital of Central Theater Command, PLA, a designated hospital in Wuhan, China. The patients were divided into three groups according to the Diagnosis and Treatment of New Coronavirus Pneumonia (version 6) published by the National Health Commission of China. The clinical and laboratory data were collected. The serum viral load detection and serum IL-6 levels were determined. Except for routine statistical analysis, Generalized Linear Models (GLMs) analysis was used to establish a patient status

prediction model based on real-time RT-PCR Ct value. Findings: The Result showed that cases with RNAaemia were exclusively confirmed in critically ill patients group and appeared to reflect the illness severity. Further more, the inflammatory cytokine IL-6 levels were significantly elevated in critically ill patients, which is almost 10-folds higher than those in other patients. More importantly, the extremely high IL-6 level was closely correlated with the incidence of RNAaemia (R=0.902) and the vital signs of COVID-19 patients (R= -0.682). Interpretation: Serum SARS-CoV-2 viral load (RNAaemia) is strongly associated with cytokine storm and can be used to predict the poor prognosis of COVID-19 patients. Moreover, our results strongly suggest that cytokine IL-6 should be considered as a therapeutic target in critically ill patients with excessive inflammatory response.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 04:01:59 +0000
To: James Krellenstein
Subject: RE: 2019-nCoV Testing for Public Health Labs

James:

Thanks for the note. Be assured that I am trying to break this log jam.

Best,
Tony

From: James Krellenstein [redacted] (b) (6)
Sent: Wednesday, March 4, 2020 6:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: 2019-nCoV Testing for Public Health Labs

Tony:

I am loath to contact you given that I am sure you are overwhelmed. However, we are now being contacted by sources at tertiary academic hospitals with CLIA-high complexity clinical labs who are alarmed about their inability to scale up SARS-CoV2 qRT-PCR testing in their facilities in the time frame they feel is neccesary, even after Saturday's FDA regulatory guidance and the availability of Integrated DNA Technology's testing reagents. (An example of such an email is below.) I am passing this along with the hopes that if you can do something about it, you will. From an email:

> "We have experience bringing up laboratory developed tests. We have never submitted an EUA before. For our current LDTs, they are typically for pathogens that we have some experience with, positive clinical samples are readily available, and/or appropriate control materials (e.g. bacteria, viral genomes) are readily commercially available. None of those are true for SARS-CoV2. There is tremendous concern about deploying a suboptimal test into a challenging environment.
>
> The EUA guidance from FDA is not unreasonable for the validation of a new respiratory virus test, and it gives an accurate picture of the amount of testing that is required to bring on a new test by the lab. Federal law requires us to perform accuracy, reproducibility, analytical sensitivity / LOD, and analytical specificity (cross reactivity) studies. Those studies require positive control material *including*intact virus or RNA. Clinical labs are not prepared to generate RNA transcript, and we don't usually source these ourselves. We can't get the virus without filling out extensive paperwork that requires multiple signatures. Getting control material for validation one of the biggest issues.

> Prior to the EUA change, the calculus for our labs was that it would take 3 to 4 weeks to actually validate a test, and then we would submit to the FDA for EUA (a process none of us has ever done), and then we would wait for the FDA to respond (hopefully in the affirmative). I think we all expected the FDA EUA review to be at least 4 weeks. Based on that time-line, many commercial vendors would have reagents available with their own EUAs that would be able to be performed on large automated instruments including potentially STAT. None of the LDT assays (or CDC assay) can be performed STAT or on demand.
>
> With the EUA change, the process to validate the test is still the same and will still take 3 or more weeks. Once validated, we can perform clinical testing (like any other LDT) while we submit the EUA. This would likely allow us to begin testing several weeks before commercial vendors have EUA reagents available based upon our best current information. Most of us expect to transition a commercial EUA at some point.
>
> The recent statement that IDT reagents can be used under the EUA from CDC is misleading. It applies to a very limited number of lots (currently 1, likely 2 soon), it assumes reagents are available, and it requires strict adherence to the CDC protocol using identical extraction methods (2 choices) and amplification / detection methods (1 instrument). It still specifies the use of an N1, N2, and N3 reactions, but CDC has dropped the N3 reaction. The EUA has not yet been updated. Neither of our hospitals have the complete extraction or amplification instruments so we have to do the EUA anyway."

Hope you are coping ok,

James

--
James B. Krellenstein
109 S 5th St,
Brooklyn, NY 11249
(b) (6) (mobile)
(b) (6)

On Sun, Feb 2, 2020 at 7:36 PM James Krellenstein (b) (6)> wrote:

> Tony:
>
> I hope this email finds you well. Over the past 48 hours, PrEP4All has received multiple requests from leaders of public health departments and public health practitioners to begin publicly pressuring

CDC/HHS to ensure that properly equipped public health labs (besides CDC's lab in Atlanta) can perform real time reverse transcription PCR (qRT-PCR) testing for 2019 Novel-Coronavirus (2019-nCoV).

Our understanding is that given the public health emergency declared by HHS, an emergency use authorization (EUA) from the FDA is required for public health labs to perform their own lab developed test for 2019-nCoV, even if it is using the CDC's published qRT-PCR protocol and primer/probe sequences (
https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-for-detection-instructions.pdf
)
, and the lab is capable of handling BSL3+ samples.

We understand the extreme delicateness of this situation, and also that it is outside of our normal wheelhouse. But given the concerns of our colleagues in the public health sector, we thought it was important to give you a heads up regarding this request.

Let us know if there is anyway we can help.

Sincerely,

James Krellenstein
Data, Science and Policy Committee
The PrEP4All Collaboration
109 S 5th St, Brooklyn, NY 11249
(b) (6)
--
James B. Krellenstein
he - him - his
(b) (6)
(Sent from a mobile device)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 04:00:31 +0000
To: [redacted] (b) (6)
Subject: FW: Covid-19 causes CRS (and source of mortality)
Attachments: Ruan2020_Article_ClinicalPredictorsOfMortalityD.pdf

FYI

From: Pavletic, Steven (NIH/NCI) [E] [redacted] (b) (6)>
Sent: Wednesday, March 4, 2020 10:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Covid-19 causes CRS (and source of mortality)

Dear Dr Fauci, this is not an area of my expertise, but given the urgency of situation with the Covid-19 and some of our experiences with treating CART induced cytokine release syndrome in cancer patients, just wanted to share this email with you in case you find it of interest. Dr Betts is my brilliant junior BMT colleague at University of Minnesota. I realize this may be old news to you but wanted to share just in case.
Warm regards
Steve Pavletic

From: Brian Betts [redacted] (b) (6)>
Sent: Wednesday, March 4, 2020 2:06 PM
To: Pavletic, Steven (NIH/NCI) [E] [redacted] (b) (6)>
Subject: Covid-19 causes CRS (and source of mortality)

Hi Steve,

This is an interesting paper from intensivists in Wuhan. The IF of the journal is 18 too.

Looks like covid-19 causes an IL-6 mediated CRS with myocarditis, which is associated with mortality (more so than the pneumonitis).

This suggests we should be more concerned with getting tocilizumab for critically ill covid-19 patients, rather than tamiflu and ARVT...

Do you have a friend at the CDC that could use this info?

Thanks, Brian

--
Brian C. Betts MD
Associate Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota

The information transmitted in this e-mail is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material, including "protected health information." If you are not the intended recipient, you are hereby notified that any review, retransmission, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please destroy and delete this message from any computer and contact us immediately by return e-mail.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 03:57:38 +0000
To: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers [redacted] (b) (6)
Subject: FW: COVID-19 event Friday @CSIS Tony March 20, 1:30pm-3:30pm

Let us discuss.

From: Stephen Morrison <SMorriso@csis.org>
Sent: Thursday, March 5, 2020 7:02 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Samantha Stroman <SStroman@csis.org>
Subject: Re: COVID-19 event Friday @CSIS Tony March 20, 1:30pm-3:30pm

Hi Tony
Will March 20 work for you?
Best Steve

On Mar 2, 2020, at 10:07 AM, Stephen Morrison <SMorriso@csis.org> wrote:

> Tony
> I know the demands on you have skyrocketed, so I am circling back to confirm you are still available on Friday March 20 for the COVID-19 event, and also to seek your advice, as we amend the layout of the event, including possibly having it run a little longer.
>
> I am still hoping you can do a big picture scene setter (15-20 minutes with slides)
>
> (i) The state of the science surrounding the virus, what we know and do not know,
> (ii) Progression of the outbreak
> (iii) Testing
> (iv) Status of accelerated early work on vaccines, antivirals
>
> We will have a panel that covers China, and we may add a panel on the epicenters in Italy, ROK, Iran
>
> I would like to carve out ample space for discussion of the United States. In your view, is it advisable to put a request forward to Secy Azar or VP Pence? Neither needs a platform to have their voices heard. But perhaps they would see this sort of setting as an opportunity. If not the Secy or VP, is there anyone else you might propose? I had reached out earlier to Steve Biegun to speak on the foreign policy dimensions, especially regarding China, but have not heard back.
>
> I have separately reached out to the NGA about possibly enlisting a governor to speak.

If you are free and wish to speak by phone about any of this, please let me know.

Best of luck with everything. You seem to be making progress!

Best Steve

Cell (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 03:56:47 +0000
To: MAVILIO Domenico ICH
Subject: RE: Ciao

Domenico:

Thanks for the note. Indeed, this outbreak has changed the lives of many people, including me. I am doing nothing else but coronavirus. I cannot predict when the travel restriction for Northern Italy will be removed. I hope soon, but I doubt that. STAY WELL.

Best regards,
Tony

From: MAVILIO Domenico ICH [redacted] (b) (6)
Sent: Thursday, March 5, 2020 7:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Ciao

Hi Tony,

just a short notice to tell you that you are becoming even more popular in Italy as your face and interviews are everywhere on the main Italian broadcasting news and journals.

It seems like to be in USA again for me, as I see you every day and I can tell you are doing well although you must be overwhelmed with all this. I was supposed to be at NIH in tre weeks from now, but I have cancelled the flight and travel due to highest restrictions from CDC and HHS for Italian travellers from Lombardia and Veneto (and I live in Milan).

Can we estimate how long all this will last? Weeks or months according to you knowledge?

Hope to see you soon anyway and I really hope U.S. outbreak will not turn as bad as the Italian one. Indeed, Milan is living a real unprecedented (for modern time) and surrealistic situation with a mix of fear, panic and incredulity among people. It almost seems a movie! The government shut down half country by closing all schools and universities, by not allowing meetings of any kind, by limiting travels in many places and by placing severe restrictions in social life. They even stopped the Fashion week in Milan that is a big thing here.

Maybe too late, but they didi it and we hope it will work somehow to reach a plateau in contagious.

have a nice day
Ciao

Domenico

Domenico Mavilio, M.D., Ph.D.
Associate Professor of Translational Medicine

Department of Medical Biotechnologies and Translational Medicine
Medical School of Milan University, Milan , Italy

Principal Investigator
Head, Unit of Clinical and Experimental Immunology
Humanitas Research Hospital, Rozzano, Milan, Italy

Adjunct Investigator
Laboratory of Cardiovascular Regenerative Medicine,
National Hearth, Lung and Blood Institute
National Institutes of Health, Bethesda, MD, USA

(b) (6)
Phone: (b) (6)
Fax: +39 02 8224 5191
emails: (b) (6)
(b) (6);
(b) (6)
webpage: http://www.humanitas-research.org/category/principal-investigator/mavilio/

Nota di riservatezza. Il presente messaggio, corredato dei relativi allegati, contiene informazioni da considerarsi strettamente riservate, ed è destinato esclusivamente al destinatario sopra indicato, il quale è l'unico autorizzato ad usarlo, copiarlo e, sotto la propria responsabilità, diffonderlo. Chiunque ricevesse questo messaggio per errore o comunque lo leggesse senza esserne legittimato è avvertito che trattenerlo, copiarlo, divulgarlo, distribuirlo a persone diverse dal destinatario è severamente proibito, ed è pregato di rinviarlo immediatamente al mittente distruggendone l'originale.
Grazie
Confidentiality Notice. This message, together with its annexes, contains information to be deemed strictly confidential and is destined only to the addressee(s) identified above who only may use, copy and, under his/their responsibility, further disseminate it. If anyone received this message by mistake or reads it without entitlement is forewarned that keeping, copying, disseminating or distributing this message to persons other than the addressee(s) is strictly forbidden and is asked to transmit it immediately to the sender and to erase the original message received.

Thank You

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 03:51:21 +0000
To: Phillips, Kyra
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Hi Tony! Univ of Nebraska.....

Kyra:
Thanks for the note. You would have to go through my Special Assistant, Patty Conrad, who is copied on this e-mail.
Best,
Tony

-----Original Message-----
From: Phillips, Kyra <Kyra.Phillips@abc.com>
Sent: Thursday, March 5, 2020 9:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Hi Tony! Univ of Nebraska.....

Good morning! I made contact and it's in the works! We even have them in our 20/20 special tomorrow night!

Question: do you think you could go live with me from NIH or WH one day next week for our Noon Coronavirus show? It's live steamed so we have millions of viewers. We would take viewer questions (I would give you ahead of time) and you would answer only those you want to.
It's a half hour show , but we would do whatever amount of time your schedule allows.
It would be so impactful for the average viewer.
V/R
Kyra

@KyraPhillips, ABC News
Investigative Correspondent
KyraPhillips.Com
[redacted] (b) (6)

> On Mar 3, 2020, at 10:32 PM, Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)> wrote:
>
> Kyra:
> They very well might let you do it. It is worth a try. The containment there is excellent and there is no evidence of community spread in Omaha.
> Best,
> Tony
>
> -----Original Message-----
> From: Phillips, Kyra <Kyra.Phillips@abc.com>
> Sent: Tuesday, March 3, 2020 6:21 PM
> To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> Subject: Hi Tony! Univ of Nebraska.....
>
> Tony,
> Do you think the University of Nebraska would let me in to do a story for ABC News on the therapeutics they are working on?
> Would it even be safe for me to do it?

> Appreciate how you are holding court during this crisis.
> Respectfully,
> Kyra
>
>
> @KyraPhillips, ABC News
> Investigative Correspondent
> KyraPhillips.Com
> (b) (6)
>

(b)(5) - PCP

[redacted]

From: [redacted] (b) (6)
Sent: Tue, 10 Mar 2020 14:57:59 -0400
To: Short, Marc T. EOP/OVP
Subject: Re: White House Coronavirus Task Force Meeting at **3:30pm** on 3/10/20

Marc:
I likely will be several minutes late since I have to come down from Bethesda by Metro and the time change threw me off. Sorry.
Tony

> On Mar 10, 2020, at 2:49 PM, Short, Marc T. EOP/OVP <[redacted] (b) (6)> wrote:
>
>
> <White House Coronavirus Task Force Meeting at **3:30pm** on 3_10_20>

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 15:59:26 +0000
To: Hurst, Natalie R. EOP/OVP
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Important Updates - White House Coronavirus Subtask Force Calls

Natalie:

Please add my Assistant, Dr. Hilary Marston, to the list of invitees to the Subtask Force Calls. She reports directly to me and is my source of de-briefing after the calls. I am copying her on this e-mail. Many thanks.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hurst, Natalie R. EOP/OVP [redacted] (b) (6)
Sent: Tuesday, March 10, 2020 11:22 AM
Subject: Important Updates - White House Coronavirus Subtask Force Calls
Importance: High

Good morning all,

I wanted to send a note to clarify the White House Coronavirus Subtask Force Calls moving forward.

There will be a White House Coronavirus Subtask Force Call **every day,** unless otherwise directed by Olivia Troye, Dr. Debi Birx, or me.

- Monday – Friday, the call will take place at **9:00am**
- Saturday – Sunday, the call will take place at **10:00am**

Starting this evening, I will send a new calendar invite for the remainder of this week's calls (Wednesday, March 11 / Thursday, March 12 / Friday, March 13). On Friday, March 13, I will send a calendar invite for this weekend's calls (Saturday, March 14 & Sunday, March 15).

Looking ahead –

- Invites for weekday calls will be sent on Sunday nights.
- Invites for weekend calls will be sent on Friday nights.
- **Please note: Call-in numbers for Saturday & Sunday will be different from the number used Mondays – Fridays.**

** If you would like to be removed from this distribution list, please respond to this email before 5:00 pm tonight, so that you will be removed starting Thursday morning.**

Please do not hesitate to reach out with any questions or concerns.

Thank you,

Natalie Hurst
Operations Coordinator, White House Coronavirus Task Force
Executive Assistant to the Chief of Staff
The Office of the Vice President
(b) (6)

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

(b)(5) - PCP

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 8 Mar 2020 01:38:49 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: White House Coronavirus Task Force Meeting on 3.8.20 at 4:00pm

I need WAVES, please. Thanks.

From: Hurst, Natalie R. EOP/OVP (b) (6)
Sent: Saturday, March 7, 2020 8:30 PM
Subject: White House Coronavirus Task Force Meeting on 3.8.20 at 4:00pm
Importance: High

All –

There will be a **White House Coronavirus Task Force Meeting** on **Sunday, March 8th at 4:00 pm** in the **White House Situation Room**. Agenda will be forthcoming.

Thank you,

Natalie Hurst
Operations Coordinator, White House Coronavirus Task Force
Executive Assistant to the Chief of Staff
The Office of the Vice President
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 04:03:24 +0000
To: Greg Folkers ([redacted] (b) (6)
Subject: FW: 2020 03 03 SC POTUS NIH Roundtable. Email #1
Attachments: P20200303SC-0059.jpg, P20200303SC-0066.jpg, P20200303SC-0088.jpg, P20200303SC-0109.jpg, P20200303SC-0123.jpg, P20200303SC-0182.jpg, P20200303SC-0272.jpg

For the file

From: Hansen, Daniel E. EOP/WHO <[redacted] (b) (6)>
Sent: Wednesday, March 4, 2020 6:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: 2020 03 03 SC POTUS NIH Roundtable. Email #1

Photos from POTUS visit Tuesday NIH For Your Personal Archives

2020 03 03 SC POTUS NIH Roundtable. Email #1

P20200303SC 0088

President Donald J. Trump listens as Dr. Francis Collins, director of the National Institute of Allergy and Infectious Diseases, addresses his remarks during a coronavirus roundtable briefing Tuesday, March 3, 2020, at the National Institutes of Health in Bethesda, Md. (Official White House Photo by Shealah Craighead)

P20200303SC 0066 0109

President Donald J. Trump participates in a coronavirus roundtable briefing Tuesday, March 3, 2020, at the National Institutes of Health in Bethesda, Md. (Official White House Photo by Shealah Craighead)

P20200303SC 0059 0123 0182

President Donald J. Trump listens as Dr. Anthony S. Fauci, director of the National Institute of Health, addresses his remarks during a coronavirus roundtable briefing Tuesday, March 3, 2020, at the National Institutes of Health in Bethesda, Md. (Official White House Photo by Shealah Craighead)

P20200303SC 0272

President Donald J. Trump answers questions from reporters during a coronavirus roundtable briefing Tuesday, March 3, 2020, at the National Institutes of Health in Bethesda, Md. (Official White House Photo by Shealah Craighead)

Please note that these photos are being sent to you for personal use only. If you share them with friends or family, make sure to include the disclaimer below. Thank you.

If posting to social media the following byline must be used: Official White House Photo by Shealah Craighead

This photograph is provided by THE WHITE HOUSE as a courtesy and may be printed by the subject(s) in the photograph for personal use only. The photograph may not be manipulated in any way and may not otherwise be reproduced, disseminated or broadcast, without the written permission of the White House Photo Office. This photograph may not be used in any commercial or political materials, advertisements, emails, products, promotions that in any way suggests approval or endorsement of the President, the First Family, or the White House.

Dan Hansen

WH Photo Office

Presidential Briefing
navirus Disease 2019 (COVID-19)
The NIH Research Response
ccine Research Center • National Institutes of Health
March 3, 2020

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 04:02:46 +0000
To: Greg Folkers [redacted] (b) (6)
Subject: FW: 2020.03.03 WH bSouth Lawn Arrival from NIH and Press gaggle
Attachments: P20200303JB-1347.jpg, P20200303JB-1380.jpg, P20200303JB-1393.jpg, P20200303JB-1473.jpg, P20200303JB-1531.jpg, P20200303JB-1554.jpg, P20200303JB-1606.jpg, P20200303JB-1630.jpg, P20200303JB-1708.jpg, P20200303JB-1742.jpg

For the file

From: Hansen, Daniel E. EOP/WHO [redacted] (b) (6)>
Sent: Wednesday, March 4, 2020 6:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: 2020.03.03 WH bSouth Lawn Arrival from NIH and Press gaggle

Subject: 2020.03.03 WH South Lawn Arrival and Press gaggle for Personal Archives

P20200303JB-1347, 1380, 1393

President Donald J. Trump, joined by Dr. Anthony S. Fauci, director of the National Institute of Health, and Secretary of Health and Human Services Alex Azar, disembarks Marine One on the South Lawn of the White House after attending a coronavirus roundtable briefing Tuesday, March 3, 2020, at the National Institutes of Health in Bethesda, Md. (Official White House Photo by Joyce N. Boghosian)

P20200303JB-1473

President Donald J. Trump, joined by Dr. Anthony S. Fauci, director of the National Institute of Health, listens as Secretary of Health and Human Services Alex Azar answers a reporter's question following President Trump's return from attending a coronavirus roundtable briefing Tuesday, March 3, 2020, at the National Institutes of Health in Bethesda, Md. (Official White House Photo by Joyce N. Boghosian)

P20200303JB-1531, 1554, 1606

President Donald J. Trump, joined by Secretary of Health and Human Services Alex Azar, listens as Dr. Anthony S. Fauci, director of the National Institute of Health answers a reporter's question following President Trump's return from attending a coronavirus roundtable briefing Tuesday, March 3, 2020, at the National Institutes of Health in Bethesda, Md. (Official White House Photo by Joyce N. Boghosian)

P20200303JB-1630, 1708

President Donald J. Trump, joined by Dr. Anthony S. Fauci, director of the National Institute of Health, and Secretary of Health and Human Services Alex Azar, speaks with reporters following his return to the White House after attending a coronavirus roundtable briefing Tuesday, March 3, 2020, at the National Institutes of Health in Bethesda, Md. (Official White House Photo by Joyce N. Boghosian)

P20200303JB-1742

President Donald J. Trump, Dr. Anthony S. Fauci, director of the National Institute of Health, and Secretary of Health and Human Services Alex Azar, walk to the Oval Office Tuesday, March 3, 2020, at the White House. (Official White House Photo by Joyce N. Boghosian)

Dan Hansen
White House Photo Office
(b) (6)

UNIT

STATES OF AMERICA

From: [redacted] (b) (6)
Sent: Mon, 2 Mar 2020 08:32:20 -0500
To: Tabak, Lawrence (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E];Marston, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: TIME SENSITIVE

Larry:
Let Hilary do this. I am on a conference call.
Thanks,
Tony

> On Mar 2, 2020, at 8:27 AM, Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>wrote:
>
> Tony –
> Could one of your folks give me a quick read out on this please? (should I reach out to Hilary Marston?). This is the paper that DOE alluded to in the initial conference call we had with OSTP. I will respond informed by your staff's guidance.
> Larry
>
> ---
>
> **From:** "Mango, Paul (HHS/IOS)" [redacted] (b) (6)>
> **Date:** Monday, March 2, 2020 at 8:19 AM
> **To:** Stephen Hahn < [redacted] (b) (6)>, "Lenihan, Keagan (FDA/OC)" [redacted] (b) (6)>, Anthony Fauci < [redacted] (b) (6), "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6), "Redfield, Robert R. (CDC/OD)" [redacted] (b) (6) "McGowan, Robert (Kyle) (CDC/OD/OCS)" [redacted] (b) (6)>, "Berger, Sherri (CDC/OCOO/OD)" [redacted] (b) (6)>
> **Cc:** "Harrison, Brian (HHS/IOS)" [redacted] (b) (6)>
> **Subject:** TIME SENSITIVE
>
> Dr Hahn and the FDA team in particular, but with input from relevant SMEs at CDC and NIH, please give the brief attached document and quick read on comment on the usefulness of us setting up a session with the folks at DOE today to discuss further.
> Many thanks
>
> Sent from my iPhone
>
> Begin forwarded message:

From: "Harrison, Brian (HHS/IOS)" <[redacted] (b) (6)>
Date: March 1, 2020 at 6:15:54 AM EST
To: [redacted] (b) (6) (OS/IOS)" <[redacted] (b) (6)>
Cc: "Stecker, Judy (OS/IOS)" [redacted] (b) (6), "Mango, Paul (HHS/IOS)" [redacted] (b) (6)>
Subject: FW:

With attachment. I've asked CDC, FDA, NIH, and ASPR to review.

From: Brouillette, Dan [redacted] (b) (6)
Sent: Friday, February 28, 2020 9:58 PM
To: Harrison, Brian (HHS/IOS) [redacted] (b) (6)
Subject:

Brian:

As we discussed earlier this evening, here's a preliminary finding from scientists at Oak Ridge National Laboratory using the Summit supercomputer system. We stand ready to assist in any manner helpful to you and Secretary Azar. Very best,

Dan

Sent with BlackBerry Work
(www.blackberry.com)

<coronavirus.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 11:15:02 +0000
To: Kadlec, Robert (OS/ASPR/IO);Redd, John (OS/ASPR/SPPR);Yeskey, Kevin (OS/ASPR/IO);Shuy, Bryan (OS/ASPR/IO);Phillips, Sally (OS/ASPR/SPPR)
Cc: Redfield, Robert R. (CDC/OD)
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

We really need to discuss this.

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>
Sent: Sunday, February 23, 2020 11:31 PM
To: Redd, John (OS/ASPR/SPPR) [redacted] (b) (6); Yeskey, Kevin (OS/ASPR/IO) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) <[redacted] (b) (6); Phillips, Sally (OS/ASPR/SPPR) [redacted] (b) (6)>
Cc: Redfield, Robert R. (CDC/OD) [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Read this! This is unsettling if true efficient spreading in asymptomatics with negative test. Is that possible? Report is intermittent shedding is that true or artifact of poor sample collection or lack of sensitivity of pcr testing?

From Dr Eva Lee GaTech

> "**Means of spread** A study from AMA confirmed many of the parameters assumed in our models:
>
> - A 20-year old infected with COVID-19 left Wuhan and went on infecting 5 relatives. When they tested positive, she was finally isolated, but tested negative still, and later tested positive, and remain normal on chest CT with no fever, stomach or respiratory symptoms (cough or sore throat as late as Fen 11 (time of the papert study duration).
>
> So spreading and its wide scope is unavoidable because there exists these very healthy individuals who can spread effectively -- even during incubation period -- while they remain perfectly healthy. It also showcases difficulty in testing -- negative test -- may not be the end of it. "

Sent from my iPhone

Begin forwarded message:

From: "Dr. Eva K Lee" [redacted] (b) (6)>
Date: February 23, 2020 at 7:37:12 AM EST
To: Carter Mecher [redacted] (b) (6)>
Cc: Richard Hatchett [redacted] (b) (6)>, Tracey McNamara
[redacted] (b) (6)>, "Caneva, Duane" <[redacted] (b) (6),
[redacted] (b) (6)>, "Dodgen, Daniel (OS/ASPR/SPPR)"
<[redacted] (b) (6)>, "DeBord, Kristin (OS/ASPR/SPPR)"
[redacted] (b) (6)>, "Phillips, Sally (OS/ASPR/SPPR)" [redacted] (b) (6)>,
David Marcozzi [redacted] (b) (6)>, "Hepburn, Matthew J CIV USARMY
(USA)" [redacted] (b) (6)>, Lisa Koonin [redacted] (b) (6) "Walters,
William (STATE.GOV)" [redacted] (b) (6)>, "HARVEY, MELISSA"
[redacted] (b) (6), "WOLFE, HERBERT" [redacted] (b) (6)>,
"Eastman, Alexander" [redacted] (b) (6)>, "EVANS, MARIEFRED"
[redacted] (b) (6), "Callahan, Michael V.,M.D."
[redacted] (b) (6)
>, "Johnson, Robert (OS/ASPR/BARDA)"
[redacted] (b) (6)>, "Yeskey, Kevin" [redacted] (b) (6), "Disbrow, Gary
(OS/ASPR/BARDA)" [redacted] (b) (6)>, "Redd, Johnt(OS/ASPR/SPPR)"
[redacted] (b) (6)>, "Hassell, David (Chris) (OS/ASPR/IO)" <[redacted] (b) (6),
"Hamel, Joseph (OS/ASPR/IO)" [redacted] (b) (6)>, "Dean, Charity A@CDPH"
[redacted] (b) (6)>, "Lawler, James V" [redacted] (b) (6), "Kadlec,
Robert (OS/ASPR/IO)" [redacted] (b) (6) "'Martin, Gregory J
[redacted] (b) (6)>, "Borio, Luciana" [redacted] (b) (6),
"Hanfling, Dan" [redacted] (b) (6) "McDonald, Eric"
[redacted] (b) (6) "Wade, David" [redacted] (b) (6)
"TARANTINO, DAVID A" [redacted] (b) (6)>, "WILKINSON, THOMAS"
[redacted] (b) (6)>, "David Gruber [redacted] (b) (6)"
[redacted] (b) (6)>, "KAUSHIK, SANGEETA" [redacted] (b) (6)>,
Nathaniel Hupert [redacted] (b) (6)>
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start
Reply-To: "Dr. Eva K Lee" [redacted] (b) (6)>

A few things I want to highlight --

1. **Means of spread** A study from AMA confirmed many of the parameters assumed in our models:
- A 20-year old infected with COVID-19 left Wuhan and went on infecting 5 relatives. When they tested positive, she was finally isolated, but tested negative still, and later tested positive, and remain normal on chest CT with no fever, stomach or respiratory symptoms (cough or sore throat as late as Fen 11 (time of the papert study duration).

So spreading and its wide scope is unavoidable because there exists these very healthy individuals who can spread effectively -- even during incubation period -- while they remain perfectly healthy. It also showcases difficulty in testing -- negative test -- may not be the end of it.

2. **Iranian cases**, though mysterious since the origin was not traced to China, may very well show that COVID-19 virus is very adaptable and mutating rapidly.

3. **Long recovery** The long recovery period is troubesome and must be taken seriously by health providers as they prepare for hospitalization. Therei s not much surge capacity in hospitals. So they must be innoative in the staggering process and isolation is of paramount importance. Government/Local should be readied for supplementing medical tents outside hospitals when needed (clearly extra staff too).

4. **Citizes' view** I was traveling so I did a real-time on-the-road analysis of human behavior and anxiety level. I overheard many people
-- (a) asked when CDC would tell us more on what to do.
-- (b) wish they could pull their kids out of school but there is no such option as part of the preventive measure (not announced by CDC).
-- (c) wish CDC would recommend tele-work options so they don't have to travel and expose themselves and their family to unneccessary risk.
-- (d) have no clue what the government is doing to keep the risk low as it is now. What exactly is being implemented to keep it low.

5. **Resource-limited countries** I pray that it would not reach the resource-limited countries like many in Africa (though it seems unavoidable). I cannot imagine the consequence.

6. **What we must do:** We must leverage the knowledge from other countries to better prepare ourselves. Japan's Crusis shows the importance of TIMELY proper isolation and STRATEGIC operations logistics in testing and in quarantine. South Korea (contrasting with Hong Kong, Singapore) demonstrates critical importance of EARLY social distancing and high compliance community NPI intervention. China's latest lockdown of 1/2 billion people truly signifies that gravity and unchartered terrority of this virus. No country would take to such extreme measure.

7. **CFR** Since over 90% of influenza is never recorded/known, this COVID-19 seems to fall into similar spirit now, with so many cases of asymptomtic and transmission while incubating. While the true CFR remains unknown, the CFR of tested positive cases should offer a good comparison to the CFR of tested positive flu cases. That gives us a clearer estimate of health-resource burden.

[redacted] (b) (6)

mobile: [redacted] (b) (6)

Sent with ProtonMail Secure Email.

------- Original Message -------
On Saturday, February 22, 2020 10:19 PM, Carter Mecher [redacted] (b) (6)> wrote:

Updates

South Korea (+123 with +2 deaths)—Total cases 556; Total deaths 4

https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030

Singapore (+3)--Total cases 89; Total deaths 0

Hong Kong (unchanged)--Total cases 69; Total deaths 2

Japan—Total cases 135; Total deaths 1

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Saturday, February 22, 2020 6:28 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6))'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Roundup this morning.

Singapore and Hong Kong are holding steady—both have implemented NPIs pretty early and have good surveillance.

Things are really accelerating in South Korea. Case count increased to 433 with 2 deaths.

https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030

Report below of COVID hitting Samsung's mobile device factory, which has now been shut down. This is what will happen here. The greatest concern is what this would mean for critical infrastructure sectors (including components of our healthcare system), The strategies I outlined for outpatient clinics could be used by business (most especially CI sectors) to maintain business continuity. It is as simple as the old saying, "Don't put all your eggs in one basket." It is both contingency planning (continuity of operations/continuity of business) and application of NPIs/TLC (especially social distancing in the community supported by home isolation and home quarantine).

We now have COVID in several countries across the ME (Iran, Israel, Egypt, Lebanon, UAE). We added Iran the day before yesterday and 3 countries yesterday (Israel, Egypt and Lebanon). Iran already appears to have a well established outbreak that will be tough to slow down given the estimated size with 5 deaths already (that is where Wuhan was by Jan-20). Japan is also seeing acceleration with local transmission (119 cases).

Italy is another area to watch.

https://protect2.fireeye.com/url?k=c92f3372-957b2a0e-c92f024d-0cc47adc5fa2-927014023819d8ec&u=https://www.ilgazzettino.it/nordest/...D0yaqI09ac4o84 Numerous infected in the hospital of Schiavonia (Padua)
"And unfortunately, what the experts feared since yesterday has occurred, when it was discovered that two patients had been hospitalized for about ten days at the Schiavonia hospital (Padua) without knowing that they had contracted the Coronavirus: since yesterday evening everyone those who attended the hospital were subjected to a swab to detect any infections, and the examination gave positive results in numerous cases. It means that there are other people, probably among those who attended the ward where two patients were hospitalized, who are now positive for the virus and consequently could in turn have spread the infection. Already yesterday evening the Governor of Veneto Luca Zaia ordered the progressive evacuation of the Padua hospital which should take place within 5-6 days."

“The hospital is surrounded by a 'sanitary cordon', with Carabinieri, workers of the Red Cross and Civil Protection. Cardiology chief Giampaolo Pasquetto arrived outside the hospital for a few minutes and reported the results of the swabs 'as far as I have been able to know from my colleagues so far,' he said. The modern structure is located between the towns of Este and Monselice and was recently inaugurated to serve the Euganean Hills area.”

https://www.reuters.com/article/us-china-health-southkorea-samsung-elec/samsung-electronics-confirms-coronavirus-case-at-phone-factory-complex-in-south-korea-idUSKCN20G0CG

SEOUL (Reuters) - Samsung Electronics said on Saturday that one coronavirus case had been confirmed at its mobile device factory complex in the southeastern city of Gumi, causing a shutdown of its entire facility there until Monday morning.

Samsung Electronics, the world’s top smartphone maker, said the floor where the infected employee worked would be shut down until the morning of Feb. 25.

“The company has placed colleagues who came in contact with the infected employee in self-quarantine and taken steps to have them tested for possible infection,” Samsung said in a news release.

Samsung’s factory in Gumi accounts for a small portion of its total smartphone production, and it makes high-end phones, mostly for the domestic market. Samsung produces most of its smartphones in Vietnam and India.

Gumi is close to the city of Daegu, home to a church at the center of South Korea’s largest coronavirus outbreak.

South Korea said on Saturday that the number of people infected with the coronavirus in the country had more than doubled to 433.

Samsung said production at its chip and display factories in other parts of South Korea would not be affected.

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Friday, February 21, 2020 6:52 PM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6); Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Wuhan to add 19 additional hospital (when combined with the other 3 hospitals, this would add 30,000 beds).

Just to put that in perspective.

- There are 2.8 hospital beds in the US per 1,000 population.
- 30,000 beds is about the number of beds we would have for a population of 11 M.

When you add the 30,000 beds plus the 13,348 other beds added (total of 43,300 beds)

- There are 4.5 hospital beds in China per 1,000 population
- 43,300 beds is about the number of beds in China for a population of 9.6 M
- Wuhan will have nearly doubled its bed capacity

How hard would that be for us to double bed capacity in any major US city? (Really isolation beds for mild illness)

https://www.straitstimes.com/asia/east-asia/coronavirus-wuhan-to-activate-one-more-temporary-hospital-with-3690-beds?fbclid=IwAR1otfl4xNxKIuBRuODJzoTDMJWHueF9gTc06u1IM9nM2u-3VTpohOtFt7s

WUHAN (XINHUA) – Wuhan, the epicentre of the coronavirus outbreak, plans to build another 19 makeshift hospitals to receive more infected patients, local authorities said Friday (Feb 21).

Upon their completion, all the makeshift hospitals in Wuhan are expected to offer 30,000 beds on Feb 25, said Mr Hu Yabo, deputy mayor of Wuhan at a press briefing on epidemic prevention and control.

To date, Wuhan has converted 13 existing venues into temporary hospitals, with a total of 13,348 beds, and about 9,313 beds have been put into use to treat patients with mild symptoms, said Mr Hu.

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Friday, February 21, 2020 1:59 PM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Weekly CDC update looks like flu might be on the downslope (good news). Watching the curves of % positive flu tests and ILI (should track one another as flu is receding). Trouble is the data reported today is for the week ending Feb 15 (so a week old).

Our inpatient nursing sick leave is tracking ILI (current thru 2/20)—nothing unusual

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Friday, February 21, 2020 10:54 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6) KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Singapore and Hong Kong are holding the line. Both implemented NPIs early. No change in numbers from Hong Kong and Singapore saw its case count increase by only 1 for the past two days.

Japan reported to have 107 cases. First reported case in young children (se below)

Hokkaido boy 1st Japan case of coronavirus infection under 10
February 21, 2020 (Mainichi Japan)

SAPPORO -- Two elementary school brothers and a woman in her 40s in Hokkaido have been infected with the new coronavirus, with the younger sibling becoming the first infection under 10 in Japan, Hokkaido Gov. Naomichi Suzuki announced on Feb. 21.

Some graphics of the drop off in travel in China (pretty dramatic)

Jan-23

Feb-13

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Friday, February 21, 2020 10:28 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6); Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6)KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030

Here is the best link to track cases in South Korea. South Korea is now up to 204 cases and 1 death (South Korea is where Wuhan was 1 month ago).

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Friday, February 21, 2020 10:02 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6); Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

On a totally different note. Others have been plying with and modifying the notional conops for a healthcare system.

I set up some simple rules:

1. Protect uninfected patients and staff from infectious patients and staff (using all the tools that we have including home isolation and home quarantine, cohorting/physical separation, PPE, telehealth, etc.)
2. Provide acute care for COVID patients (continuum of ER-inpatient care-intensive care)
3. Support mildly ill COVID patients in home isolation--telehealth
4. Support patients in voluntary home quarantine--telehealth

5. Continue to address the usual mix of healthcare needs for patients (from outpatient care to acute care to mental health care to long term care)
    a. Outpatient clinics and providers focus on wellness to minimize ER visits/hospitalization to unburden the acute care system—leverage telehealth
    b. Continue to provide acute care and inpatient mental health care (continuum of ER-inpatient care-intensive care) for non-COVID conditions
    c. Protect high-risk patients in residential/long term care (nursing homes, hospice, long term psychiatry, etc.)

The notional conops divides the healthcare system into hot and safe areas. The hot area is only acute care: ER-acute inpatient care-ICU care. The safe areas include a separate acute care area (ER-acute inpatient care-ICU care), all the outpatient clinics/care, other inpatient care areas such as mental health, as well as long term/residential care (nursing home, hospice, long term psychiatry, etc.).

Triage will not be easy (between hot and safe). Best I could come up with would be: (1) anyone already on home isolation or home quarantine (may need a medical record flag); (2) anyone with ILI (could narrow that down with a negative rapid flu test); (3) anyone with a sick household member with suspected COVID. Could be very difficult for an unconscious/confused, or trauma patient etc., but would probably err on the side of hot and think of additional layered strategies to minimize patient risk within that area (private rooms, patient PPE?). Triage would need to err on the side of keeping the safe area safe.

The mitigation measures are our best tools to reduce community transmission and reduce the probability of an infectious patient getting into a safe area. If we have a breach in a safe inpatient area, it pretty much converts that inpatient area into a hot area. That also means that we have the staff in that area exposed (because of limited availability of PPE, the staff in the safe area would not be PPE—PPE would have been directed to the staff in the hot area). Those staff would likely need to be placed on quarantine. The effect is we now have a much larger hot area with even fewer staff. That would really be a mess.

You have the same problem in the outpatient areas. Have a sick patient slip through and come in contact with a number of the clinic staff (not in PPE), and we now need to quarantine all those staff. In contrast to a breach for the inpatient area, the outpatient area can still operate as a safe area (just minus those staff who would now be on quarantine). But do that a few times and pretty soon you have nobody left to fight. One way I thought about dealing with this scenario is to take the outpatient staff and split them in two. One group works the clinic (physically present) for the usual clinic hours for a 14 day stretch (1 incubation period). Another group works from home (and practices social distancing, etc., really acting as if they are on home quarantine) and leverages telehealth technology to care for patients and help with monitoring those patients in home isolation and home quarantine. After 14 days the groups switch. [All along we monitor employees daily (whether at work or at home) for symptoms or sick household members] In the event of a breach, the groups immediately switch and the group that was working is placed on actual home quarantine (but still continues to work from home leveraging telehealth). That way if a breach does happen, we have a fallback response (that we are constantly practicing) that allows us to sustain outpatient care.

For the inpatient areas, I thought about the lone survivor model (holding back 1 Secretary and staff in the event that the government is decapitated). So think of a small group (would need to think thru what the composition of that team would look like for each area (acute care, inpatient mental health, long term care) that would at least provide the nucleus of the expertise necessary to reconstitute the service in the event of a major breach). This smaller group would vary in team members every 2 weeks and would rotate to work from home for 14 days stretches and practice social distancing (acting as if they were on home quarantine). They could also assist via telehealth (inpatient consultation, etc., while out of the hospital).

Is anyone thinking along these lines (really continuity of operations for the healthcare system)?

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Friday, February 21, 2020 8:35 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

https://www.cbc.ca/news/canada/ottawa/diamond-princess-coronavirus-trenton-cornwall-1.5470386

Canada flies home passengers from cruise line.

Data in article:

47 of 256 Canadians contract

https://protect2.fireeye.com/url?k=96ebd7bc-cabfcec0-96ebe683-0cc47adc5fa2-16a39afbec00c653&u=https://www.timesofisrael.com/israel...nee-diagnosed/

Israel confirms first coronavirus case as cruise ship returnee diagnosed
One of 11 Israelis who arrived in the morning after quarantine aboard Diamond Princess ship tests positive, after entering 14-day isolation at Sheba Medical Center

Trying to track cruises ship passenger/crew by country (data is sketchy)

Country	Passengers/Crew	Total Confirmed Cases	ICU Admissions	Deaths	% Infected
US	434	58	1?		13%

Hong Kong	330				
Canada	256	47			18%
Australia	241	48			20%
UK	78	6			8%
Italy	35				
South Korea	14				
Israel	11	1			9%
Japan				2	
Subtotal	1,399	160			
Total	3,711	634			17%

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Friday, February 21, 2020 5:46 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D. (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

China has again modified its reporting (first it added clinical cases to lab confirmed cases on Feb-12). Now it is subtracting out those clinical cases and limiting numbers to lab confirmed). Have continued to follow the hospitalization data from Hubei (see below).

Here is the data being reported by Hubei and Wuhan. Data is pretty sketchy prior to Jan-21.

	Hubei 2019-nCoV Confirmed Hospital Data							**Hubei and Wuhan Cases & Hospitalization Rates**				
Date	Total Current Inpatients	Mild Disease	Severely Ill	Critically Ill	Cum Discharges	Cum Deaths	Cum Inpatients	Hubei Cum cases	Wuhan Cases	Hubei Cum Hospitalization Rate per 100,000	Wuhan Cum Hospitalization Rate per 100,000	%Hubei Cases Hospitalized
1/14/20	6		6				6	41	41	0.01	0.5	
1/15/20	5		5			2	7	41	41	0.01	0.5	
1/16/20	5		5			2	7	45	45	0.01	0.5	
1/17/20	8		8			2	10	62	62	0.02	0.7	
1/18/20	136	100	33	3		3	139	121	121	0.2	1.4	
1/19/20	170	126	35	9		4	174	198	198	0.3	2.4	
1/20/20	239	176	51	12		7	246	270	258	0.4	3.1	
1/21/20						15		375	320	0.0	3.8	
1/22/20	399	304	71	24		17	416	444	390	0.7	4.7	
1/23/20	494	365	106	23	31	24	549	549	495	0.9	5.9	100%
1/24/20	658	472	129	57	32	39	729	729	572	1.2	6.8	100%
1/25/20	915		221		85	52	1,052	1,052	618	1.8	7.4	100%
1/26/20	1,645	1,013	563	69	44	76	1,423	1,423	698	2.4	8.3	100%
1/27/20	2,567	1,877	563	127	47	100	2,714	2,714	1,590	4.6	19.0	100%
1/28/20	3,349	2,450	671	228	80	125	3,554	3,554	1,905	6.1	22.8	100%
1/29/20	4,334	3,346	711	277	90	162	4,586	4,586	2,261	7.8	27.0	100%
1/30/	5,486	4,392	804	290	116	204	5,806	5,806	2,63	9.9	31.5	100%

20									9			
1/31/20	6,738	5,444	956	338	166	249	7,153	7,153	3,215	12.2	38.4	100%
2/1/20	8,565	7,003	1,118	444	215	294	9,074	9,074	4,109	15.5	49.1	100%
2/2/20	9,618	7,917	1,223	478	295	350	10,263	11,177	5,142	17.5	56.4	92%
2/3/20	10,990	8,857	1,557	576	396	414	11,800	13,522	6,384	20.2	66.6	87%
2/4/20	12,627	10,107	1,809	711	520	479	13,626	16,678	8,351	23.3	81.6	82%
2/5/20	14,314	11,230	2,328	756	633	549	15,496	19,665	10,117	26.5	95.3	79%
2/6/20	15,804	11,802	3,161	841	817	618	17,239	22,112	11,618	29.5	108.3	78%
2/7/20	19,835	14,640	4,188	1,007	1,113	699	21,647	24,953	13,603	37.0	141.1	87%
2/8/20	20,993	15,746	4,093	1,154	1,439	780	23,212	27,100	14,982	39.7	153.4	86%
2/9/20	22,160	16,655	4,269	1,236	1,795	871	24,826	29,631	16,902	42.4	169.3	84%
2/10/20	25,087	18,743	5,046	1,298	2,222	974	28,283	31,728	18,454	48.3	196.7	89%
2/11/20	26,121	18,880	5,724	1,517	2,639	1,068	29,828	31,728	18,454	51.0	207.4	94%
2/12/20	33,693	26,609	5,647	1,437	3,441	1,310	38,444	48,206	32,994	65.7	314.6	80%
2/13/20	36,719	27,081	7,953	1,685	4,131	1,426	42,276	51,986	35,991	72.3	349.9	81%
2/14/20	38,107	27,955	8,276	1,876	4,774	1,457	44,338	54,406	37,914	75.8	369.4	81%
2/15/20	39,447	29,051	8,439	1,957	5,623	1,596	46,666	56,249	39,462	79.8	391.4	83%
2/16/20	40,814	31,017	8,024	1,773	6,639	1,696	49,149	58,182	41,152	84.0	415.6	84%
2/17/20	41,957	30,987	9,117	1,853	7,862	1,789	51,608	59,989	42,752	88.2	439.7	86%
2/18/20	43,471	32,225	9,289	1,957	9,128	1,921	54,520	61,682	44,412	93.2	469.3	88%
2/19/20	43,745	32,567	9,128	2,050	10,337	2,029	56,111	62,013	45,027	95.9	487.0	90%
2/20/20	42,056	31,059	8,979	2,018	11,788	2,144	55,988	62,422	45,346	95.7	486.2	90%

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Friday, February 21, 2020 5:09 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; (b)(6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b)(6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b)(6) Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b)(6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

More on South Korea (sounds just like what happened at Jefferson Barracks, just outside St. Louis, in 1918, armed with the exact same tools they had more than 100 years ago to control an outbreak). I assume they must also be taking measures within the base to limit spread (keeping infectious individuals apart from those not yet infected with isolation and quarantine and social distancing).

https://en.yna.co.kr/view/AEN20200221003000325?section=national/defense

SEOUL, Feb. 21 (Yonhap) -- The military is making all-out efforts to prevent the new coronavirus from spreading further into the barracks, officials said Friday, after the country's first infections in the armed forces were confirmed.

Earlier in the day, a Navy sailor on the southern island of Jeju was confirmed to have contracted COVID-19 in the first such case among service personnel here.

Following the confirmation, the Navy has checked the temperature of all personnel at the base where the infected sailor served and quarantined all those who had contacts with the person, it said.

"We have carried out disinfection work at the base and are devoting all our efforts to preventing the spread of the new virus," the Navy said in a release.

An officer each from the Army and the Air Force were also confirmed to have the virus the same day.

The military is now working to identify personnel who have visited the southeastern city of Daegu and the surrounding North Gyeongsang Province since Feb. 10, as these areas have recently seen a surge in the number of infected people.

More than 5,000 service personnel are estimated to have visited the region during their vacation according to the military's preliminary investigation.

On Thursday night, the defense ministry said all personnel will be barred from vacationing, staying outside their bases and meeting visitors starting Saturday.

The decision was made at a meeting of top defense officials presided over by Defense Minister Jeong Kyeong-doo, during which he called for "extraordinary measures" to contain the spread of the virus.

Amid growing fears over the disease, the government called off a planned ceremony to mark the 60th anniversary of a pro-democracy movement in Daegu, which was designated a "special care zone" over the virus earlier in the day.

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Thursday, February 20, 2020 9:21 PM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b)(6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY,

MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6); Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

S. Korea reports 52 new virus cases, total now at 156

Welfare/Medicine 10:37 February 21, 2020

SEOUL, Feb. 21 (Yonhap) -- South Korea reported 52 new cases of the new coronavirus Friday, bringing the total number of infections in the nation to 156, with the potentially fatal illness spreading fast across the country.

The number of COVID-19 infections here has almost tripled in just three days, with most new infections traced to church services in the southeastern city of Daegu.

Of the 52 new cases, 41 are in Daegu, 300 kilometers southeast of Seoul, and the neighboring North Gyeongsang Province. Another three were reported in Seoul, the Korea Center for Disease Control and Prevention (KCDC) said in a statement.

Tour buses are parked at a logistics terminal in Daegu, 300 kilometers southeast of Seoul, on Feb. 20, 2020. Thirty-eight new coronavirus cases were reported in the city on Feb. 21, 2010. (Yonhap)

The spike of infections in Daegu and several cases in Seoul, where routes of infections are not immediately traceable, have prompted health officials to declare that COVID-19 has begun spreading locally.

The KCDC said two new cases were reported in South Gyeongsang Province. In a sign that the virus may broadly spread nationwide, six provinces, including Gyeonggi, Jeju, Chungcheong and North Jolla, each reported one case.

Of the 52 new cases, 39 are linked to the Shincheonji Church of Jesus in Daegu, where the 31st patient, the country's probable "super spreader," attended worship services, the KCDC said.

A 61-year-old South Korean woman, who tested positive for the virus earlier this week, attended worship services at the church on Feb. 9 and this past Sunday.

KCDC Director Jung Eun-kyeong told reporters Thursday that the agency is uncertain whether the woman, known as the 31st patient, was a "super spreader" of the virus but asked 1,001 members of the church to self-isolate to stem the spread of the virus.

The government decided to designate Daegu and neighboring Cheongdo as "special management zones," following the spike in the number of infected people and the nation's first death from the virus.

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Thursday, February 20, 2020 5:38 PM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6) Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6); Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

From Feb-15 to Feb-20 the number of confirmed cases increased from 355 to 634 (increase of 279). The number of asymptomatics increased from 73 to 322 (increase of 249). So from Feb-15 to Feb-20, 249 of the

279 confirmed cases (89%) were asymptomatic. Seems a little odd. Also, read reports that all passengers and crew have beem tested (but reports only note that 3,066 of the 3,711 have been tested).

Date	Event	Cumulative Number of Confirmed Cases	Cumulative Number of Deaths	Notes
20-Jan	Cruise ship departs from Yokohama Japan			
25-Jan	80 year old passenger disembarks in Hong Kong			
1-Feb	80 year old passenger confirmed to have COVID-19			
	When results known, certificate of landing canceled and ship under quarantine. Tests for the virus would be administered to three groups: those with symptoms, those who got off in Hong Kong, and those who had close contact with the infected passenger.			
3-Feb	Ship arrives in port of Yokohama Japan			
5-Feb	10 passengers and crew confirmed +	10		
6-Feb	31 more passengers and crew confirmed +	41		
7-Feb	30 more passenger and crew confirmed +	61		
8-Feb	9 more passenger and crew confirmed +	70		
10-Feb	66 more passenger and crew confirmed +	136		439 tested
11-Feb	39 more passenger and crew confirmed +	175		492 tested
12-Feb	28 more passenger and crew confirmed +	203		4 in ICU
13-Feb	15 more passenger and crew confirmed +	218		713 tested
14-Feb	67 more passenger and crew confirmed +	285		927 tested
15-Feb	70 more passenger and crew confirmed +	355		1,219 tested; 73 asymptomatic

16-Feb	329 American evacuated from cruise ship (14 of the evacuees found to be +) 61 Americans remained on board 44 Americans remained hospitalized in Japan	369		
17-Feb	85 more passenger and crew confirmed +	454		1,723 tested; 19 seriously ill
18-Feb	167 more passenger and crew confirmed +	621		3,011 tested
19-Feb	2 deaths	621	2	
20-Feb	13 more passenger and crew confirmed +	634	2	3,066 tested; 28 seriously ill; 322 asymptomatic

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Thursday, February 20, 2020 4:49 PM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6); Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

This is new

- Now 634 cases confirmed on the cruise ship (3,063 tested) (so not all the ship and crew have been tested 3.711)
- Slightly more than half are asymptomatic (previously we heard that 73 of 355 are asymptomatic)
- 28 in serious condition (4.4%)

Japan's Health Minister Katsunobu Kato told Parliament the two people from the Diamond Princess cruise ship who died had "received the best medical treatment" but couldn't be saved after catching the novel coronavirus on board. As of Thursday, 634 passengers and crew members were diagnosed with the virus out of 3,063 tested. Slightly more than half have no symptoms at all, officials said, and many of the remainder have only mild fever or a cough. Among patients who tested positive for the virus, 28 were reported in serious condition Thursday.

Doctors have said the virus can be particularly harmful in elderly patients, and one of the two fatal cases from the Diamond Princess, a Japanese man in his 80s, had pre-existing bronchial asthma and had been treated for angina. The other, a Japanese woman in her 80s without underlying illnesses, came down with a fever on Feb. 5, the same day passengers were told they would be quarantined in their cabins for two weeks, according to health ministry officials. The next day, she started suffering from diarrhea and saw a doctor on board.

She wasn't taken to a hospital until Feb. 12 when she started suffering shortness of breath. Her virus test came back positive the following day, and despite treatment with antiviral drugs normally used to treat HIV infection, she died Thursday.

Asked about the woman's case, health ministry official Hiroshi Umeda said, "I believe it was handled promptly." He said the ship was a difficult environment for medical staff but they worked day and night and tried to prioritize the most serious cases.

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Thursday, February 20, 2020 11:00 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA);

Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6))'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6) KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Keep an eye on South Korea too. Seeing rapid growth in cases in South Korea (see story below)

South Korea now reporting 104 cases and 1 death today. South Korea now implementing NPIs. This story is eerily reminiscent of the actions taken at Jefferson Barracks near St. Louis in 1918.

Also attached are update for Singapore (85 cases; 46 in hospital/4 in ICU; 4 kids, only 1 in hospital) and Hong Kong (69 cases, still no kids reported). Both have implemented NPIs (small increases in cases today). Japan has reported 10 new cases today—total now is 94.

South Korea reports first virus death as Daegu struggles to contain outbreak
https://protect2.fireeye.com/url?k=3b9075da-67c46ca6-3b9044e5-0cc47adc5fa2-08635f0e31f1241a&u=https://www.stripes.com/news/pacific...break-1.619407

SEOUL, South Korea — South Korea reported its first coronavirus-linked death Thursday, while the U.S. military tightened restrictions on travel to the southeastern city of Daegu due to an outbreak in infections in the area.

Daegu also urged residents to stay home as the city of 2.5 million people and surrounding areas struggled to contain an outbreak of the pneumonia-like disease.

The Army garrison in Daegu also restricted access and announced that schools and nonessential business would be closed for a second day on Friday.

In an exception to policy, U.S. service members were authorized to wear face masks in uniform "regardless of air quality conditions," according to the garrison's Facebook page.

Fast-moving developments this week were a blow to South Korea's hope that the crisis was easing.

Instead, dozens of new cases were confirmed in recent days, with the total number of infections soaring to 104 on Thursday, according to the Korea Centers for Disease Control and Prevention

U.S. Forces Korea said, "there remains zero confirmed cases of USFK personnel with COVID-19."

The virus first appeared in December in Wuhan, China, and spread to nearly 30 countries. More than 2,000 people have died — most in mainland China.

A South Korean man in his 60s died Wednesday at a hospital in the southeastern city of Cheongdo and posthumously tested positive for the virus, the KCDC said Thursday. It was South Korea's first death from the virus.

USFK **raised the risk level for the military community** to moderate on Wednesday and banned all nonessential travel to Daegu due to an outbreak linked to a church near the Army garrison in the city.

On Thursday, USFK added that all travel by American troops to, from and around Daegu requires authorization from their leadership. The precaution was "highly encouraged" for all family members, civilians and contractors as well.

"All off-installation travel for all USFK populations should be minimized to reduce potential contamination," USFK announced on its website.

U.S. Army Garrison Daegu, about 200 miles southeast of Seoul, also said visitors not performing mission essential or official business would be denied access as it implemented health checks at the gates.

Nonessential personnel were not required to go to work on Friday and most activities would be suspended, including the schools, it said.

The garrison also recommended that members of the military community avoid public places and transportation in the city, including stores, restaurants and other heavily congested areas until the situation is brought under control.

Self-quarantine measures were ordered for any American troops who had visited the affected New World Church, but garrison commander Col. Edward Ballanco said earlier Thursday that no Americans were known to have done so.

He also urged Americans to avoid a local hospital where the woman believed to have been a carrier was treated.

The garrison also lifted limits on wearing face masks for American troops in uniform, who normally are only allowed to wear them on days with extreme pollution.

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Thursday, February 20, 2020 8:20 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6) KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Last thing. Keep a very close eye on Japan. The outbreak is starting to take off there with numbers of cases scattered across the country with no link to known cases. We are also seeing nosocomial transmission (a number of healthcare workers infected). There is also a large number of cases hospitalized in Japan related to the cruise ship, and now the release of large numbers of passengers from the cruise ship into the community. Yesterday they reported a total of 84 cases—caught up to

Singapore. But unlike Singapore, Japan has been slow to implement NPIs. The other concern is that Japan's population is disproportionately aged (it has the highest % age 65 of any country). In Japan, 27% of the population is ≥ 65; in the US, 15.6% of the population is ≥ 65. And Japan can also claim the largest city in the world (metro Tokyo with 38 M people—pretty much the population of California crammed into an area smaller than the size of Connecticut). Japan also has the 10th largest city in the world (Osaka with 19 M people).

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Thursday, February 20, 2020 7:15 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6) Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6) Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6) KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

What has me worried is what happened on the cruise ship is a preview of what will happen when this virus makes its way to the US healthcare system (not to mention institutionalized high-risk populations in the US, like nursing homes). I'm not sure that folks understand what is just over the horizon.

Remember the story about Mann Gulch? We are at the equivalent of about 5:44. I anticipate that when we reach 5:45, there is going to be chaos and panic to get anything in place. I doubt that what we would then hurriedly put in place will be any better than what they did on that cruise ship. As a consequence, would expect much the same results.

I listened to the discussion yesterday. After listening to James and Michael describe the conditions on and around the cruise ship, I wondered whether anyone in healthcare leadership (outside the expertise at our biocontainment facilities) is thinking about infection control practices for any staff entering areas of a hospital caring for COVID patients (like changing clothes before entering and perhaps wearing scrubs, not bringing personal items into the area like iphones, ipads, stethoscopes, white coats, purses, briefcases, etc.)? And instituting policies that require all patients to phone for clearance to enter prior to presenting at safe acute and non-acute areas including community based clinics? Are we confident of the infection control practices of acute care staff (that they know the basics of how to don and doff PPE and behavior while in PPE?) Would HCWs in outpatient clinics or long term care facilities be any better prepared than the crew on board the cruise ship or the responders in Japan? I'm no expert in infection control and would defer to the expertise in this group. I was just a little surprised how little this seemed to be a concern for the healthcare leaders gathered yesterday.

I think we are getting close to the point where we need to drop those things that are not critical and focus on the most important things.

We are going to have a devil of time with lab confirmation—it is just too slow (they had a 2 day turnaround on the cruise ship) and we just don't have the capacity for the volume of tests we would anticipate. Charity has stressed this point again and again. That means we are going to have to fly blind early on. Perhaps the best we are going to be able to do in the near term if things begin to accelerate is screen all suspect cases (pretty much anyone with ILI symptoms) with a quick flu test and assume anyone who tests negative is suspected COVID until proven otherwise; and treat everyone who tests positive with Tamiflu. It will prove problematic early on, but as the epidemic barrels along, COVID will displace everything (at that point we will just assume that anyone with a fever or ILI has COVID). The problem is in the beginning. It is going to be so hard to sort things out. Matt, James and others are pushing for more rapid screening—but we just aren't there yet. The consequence is that we will be placing patients with resp illness (that is not flu and presumed to be COVID) in areas with actual

COVID patients. I hate to do that, but not sure how it could be avoided early on. But we would only do that for those who are ill enough to be hospitalized. The large number of asymptomatic and mildly ill patients would be under home isolation (so no worries about mixing confirmed and suspected patients). The downside is that we would have larger number of people is isolation and home quarantine than is really necessary (and the consequence of increased workplace absenteeism).

And it is because home isolation and home quarantine are so important, healthcare systems (and not just public health) have to grab a hold of operationalizing those NPIs with both hands. A while back, I created some prescriptions (tongue in cheek), just to underscore that physicians do have a role in isolation and quarantine (it is not limited to public health). We might not have pharmaceuticals available to treat COVID, but why can't we write prescriptions for non-pharmaceuticals? I don't think healthcare leaders appreciate this point. Every COVID patient we admit or see in the ER will require us to follow up with household members to make sure they know to home quarantine (need to do the same anywhere in our system we find a patient who is infected). You could not imagine the pushback I have received when I proposed that we must have an active role—people seem to think that state and local public health is alone responsible for this. I would think public health will be overwhelmed and taking charge of this is our best strategy to keep our safe areas safe.

I would be interested to hear how other healthcare systems and public health leaders are thinking about this.

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Thursday, February 20, 2020 6:39 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED;

Callahan, Michael V.,M.D.; [redacted] (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Keeping track of the outbreak aboard the cruise ship. The latest update is the announcement of 2 deaths (both patients in their 80s). An 87-year-old man and an 84-year-old woman, died on the 20th. Both were Japanese (the 87-year-old man was hospitalized on Feb-11 and the 84-year-old women on Feb-12). So time to death from recognition of infection was 8-9 days. On Feb-12, the total number of confirmed cases was 203. So estimated CFR back dating the denominator to Feb-12 is 1%. Assuming a denominator of 621, the CFR is 0.3%. if deaths are lagging by 8-10 days (and confirmed cases plateau), we should have a pretty good estimate of CFR for he entire group in another week or so. Will need to peel off the number of cases involving the crew member to get a better estimate of CFR in the elderly. These numbers are within the range we have been estimating.

The 2,666 passengers are similar in age (and likely in co-morbidities) to the population we see in a nursing home or residential care facility. The 1,045 crew are a proxy for a young healthy population. It will be important to look at the outcomes separately. One of the concerns is how a 'remake of this movie' could play out in similarly confined populations of elderly frail Americans. Here are the numbers of long term care facilities/programs in the US that care for the frail elderly. A large number of locations and a large number of residents/participants. I know that healthcare leaders were engaged yesterday, is anyone engaging this sector (long term care)? The healthcare leaders seemed more concerned about critical supply shortages (akin to the IV fluid shortage). Listening to them, it felt like their concerns seemed almost divorced from the threat of COVID.

	Number of Facilities / Communities	Number of Agencies / Centers	Number of Beds	Number of Residents	Number of Participants
Nursing Homes	15,600		1,700,000	1,300,000	
Residential Care	28,900		996,100	811,500	
Hospice Care		4,300			1,400,000
Adult Day Care		4,600			286,300

Source: https://www.cdc.gov/nchs/fastats/nursing-home-care.htm

The outbreak on the cruise ship should be the wake up call for leaders in long term care (and I would think healthcare overall).

Here is a summary of the cruise ship data (as of Feb 20)

Date	Event	Cumulative Number of Confirmed Cases	Cumulative Number of Deaths	Notes
20-Jan	Cruise ship departs from Yokohama Japan			
25-Jan	80 year old passenger disembarks in Hong Kong			
1-Feb	80 year old passenger confirmed to have COVID-19			
	When results known, certificate of landing canceled and ship under quarantine. Tests for the virus would be administered to three groups: those with symptoms, those who got off in Hong Kong, and those who had close contact with the infected passenger.			
3-Feb	Ship arrives in port of Yokohama Japan			
5-Feb	10 passengers and crew confirmed +	10		
6-Feb	31 more passengers and crew confirmed +	41		
7-Feb	30 more passenger and crew	61		

	confirmed +			
8-Feb	9 more passenger and crew confirmed +	70		
10-Feb	66 more passenger and crew confirmed +	136		439 tested
11-Feb	39 more passenger and crew confirmed +	175		492 tested
12-Feb	28 more passenger and crew confirmed +	203		4 in ICU
13-Feb	15 more passenger and crew confirmed +	218		713 tested
14-Feb	67 more passenger and crew confirmed +	285		927 tested
15-Feb	70 more passenger and crew confirmed +	355		73 asymptomatic; 1,219 tested
16-Feb	329 American evacuated from cruise ship (14 of the evacuees found to be +) 61 Americans remained on board 44 Americans remained hospitalized in Japan	369		
17-Feb	85 more passenger and crew confirmed +	454		1,723 tested; 19 seriously ill
18-Feb	167 more passenger and crew confirmed +	621		3,011 tested
19-Feb	2 deaths	621	2	

Data by country is a bit sketchy

Country	Passengers	Total Confirmed Cases	ICU Admissions	Deaths
US	434	58	1	
Hong Kong	330			
Canada	256	32		
Australia	241	46		
UK	78	6		
Italy	35			

South Korea	14			
Japan				
Subtotal	1,388	142		

New virus cruise ship disembarks and kills two Japanese passengers in hospital

February 20, 2020 11:38

Two Japanese men and women in their 80s who were hospitalized and treated for the virus were killed on the 20th in a cruise ship passenger who was confirmed to be infected with the new coronavirus. This is the first time a cruise ship passenger has died and three people have been killed in the country.

As of the 19th, 621 cruise ships out of approximately 3,700 crew members and passengers on the cruise ship where outbreaks of the new coronavirus were confirmed were confirmed.

According to government officials, two of them, a 87-year-old man and an 84-year-old woman, died on the 20th.

Both were Japanese and had a basic illness and were confirmed to have been infected with the virus, so it was said that men were hospitalized on the 11th of this month and women on the 12th to be treated.

This is the first time a cruise ship passenger has died.

In addition, three people have been killed in Japan, following the death of a woman in her 80s living in Kanagawa Prefecture on the 13th of this month.

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Wednesday, February 19, 2020 10:05 PM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED;

Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

More puzzle pieces.

Italy https://protect2.fireeye.com/url?k=e5d05247-b9844b3b-e5d06378-0cc47adc5fa2-e16553f827677d60&u=https://www.journalgazette.net/news/world/20200216/quarantine-ends-for-germans-italy-to-fly-citizens-from-ship

Italy plans to evacuate 35 Italians from the cruise ship

- 25 Italian crew members (including the ship's captain)
- 15 passengers

UK https://www.telegraph.co.uk/global-health/science-and-disease/coronavirus-news-uk-china-singapore-death-toll-latest/

UK plans to evacuate British passengers Friday 2/21

78 British passengers on board

4 confirmed COVID the Foreign Office

2 passengers on board say they are infected

Hong Kong
https://www.japantimes.co.jp/news/2020/02/16/national/science-health/canada-evacuate-passengers-coronavirus-covid19-diamond-princess-cruise-ship/

There are around 330 Hong Kong residents on board, including 260 holding Special Administrative Region of Hong Kong passports and roughly 70 people with foreign ones.

South Korea
https://www.japantimes.co.jp/news/2020/02/18/national/science-health/south-korea-evacuate-diamond-princess/

The South Korean government is sending a presidential plane to Japan on Tuesday afternoon to evacuate several citizens on a coronavirus-stricken cruise ship docked in Yokohama, a government official said Tuesday.

14 South Koreans — nine passengers and five crew members

Canada
https://www.japantimes.co.jp/news/2020/02/18/national/science-health/canada-diamond-princess-covid19/

Global Affairs Canada had confirmed that 32 out of 256 Canadians on the ship had tested positive.

Canadian passengers are set to be evacuated from the virus-hit boat soon, passengers will be screened before boarding the evacuation aircraft, and those who exhibit symptoms of COVID-19 will be transferred to the Japanese health care system

Australia https://www.news.com.au/travel/travel-updates/health-safety/unusual-rescue-flight-ahead-for-australian-evacuees-of-the-diamond-princess/news-story/564e590bec70b71825c897df85d0bc24

Australia evacuated passengers from the cruise ship today.

- ~180 evacuated
- 15 declined evacuation
- 36 confirmed COVID hospitalized in Japan
- 10 newly confirmed had to stay behind

So there were a total of ~241 Australians aboard the ship; 46 tested + (19%)

The story from Australia sounds familiar (see below).

Australian cruise passengers arrive to Darwin after Diamond Princess virus outbreak ordeal

Feb 20

A rescue mission of Australian cruise ship passengers from Japan has officially landed in Darwin, but the flight wasn't free from drama.

Thousands of people sharing toilets, pools and buffets – is this the petri dish of the sea?

The Qantas coronavirus rescue flight, carrying about 180 citizens and permanent residents on board from Japan, has landed in Australia.

Qantas flight 6032 touched down in Darwin at 8.11am local time, after being slightly delayed from takeoff our of Haneda.

The last-minute drama hit the rescue mission when 10 Australians, who were set to leave the coronavirus-hit Diamond Princess ship and head to the airport, were told they had tested positive to coronavirus and had to stay behind.

About 180 citizens and permanent residents, who have spent the past fortnight on the quarantined cruise ship off the coast of Japan, had taken up the Federal Government's offer of a seat on the repatriation flight to Australia.

They join another 36 Australians who contracted coronavirus on the *Diamond Princess* and are being treated in Japan. About 15 of their relatives declined the offer of repatriation to stay with them.

The Australians on board will be screened for coronavirus five times before they are taken to a quarantine facility at Howard

Qantas boss Alan Joyce praised the crew who took part in the repatriation flight as well as two previous Qantas chartered flights that brought Australians home from virus epicentre Wuhan.

"It took literally thousands of hours to plan complex operations like these," Mr Joyce said at t press conference today.

"The crew were all volunteers and they did us proud."

Yesterday, Australians who were cleared to finally disembark the *Diamond Princess* were driven by bus to Haneda Airport for the chartered flight home.

They first needed to pass a health check to receive an approval of disembarkation notice by Japanese quarantine officials.

They were then screened several more times before they could board the Qantas 747.

On the plane, they had no contact with Qantas crew, who remained upstairs for the flight. Food for passengers was already waiting for them at their seats when they boarded.

If they passed the latest health check, they would have been given "approval of disembarkation" notices by Japanese quarantine officials, which grant them permission to enter Japan.

From Yokohama Port, where the ship was docked, they boarded buses to Haneda Airport.

Brisbane student Tehya Pfeffer, 18, who has been quarantined on the *Diamond Princess* with her grandmother Cathy, was among them.

"At 10.30am (local time, 12.30pm AEDT) we will start to be screened and given luggage tags and wrist bands," Ms Pfeffer told news.com.au yesterday.

"At 5pm we have to have our luggage put outside, and at 6pm we will disembark the ship and go through a makeshift customs. This is where we use our wrist bands.

"And then we will take a bus to the airport and at around 12am Thursday we will fly to Darwin."

On the evacuation flight, cabin crew would not be making direct contact with evacuees.

Meals were already waiting for passengers at their seats when they boarded, and Qantas staff remained upstairs.

All those returning to Australia on the Qantas flight will spend two weeks in quarantine at the Howard Springs facility, in addition to the two weeks in lockdown they've had on the ship.

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Wednesday, February 19, 2020 8:36 PM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; (b) (6)w, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6); Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6) KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

South Korea cases are taking off.

S. Korea reports 31 more cases on 2/20; total now at 82

Singapore, Hong Kong, Japan, and South Korea are the new front lines. Matter of time before travel from those areas will raise concerns.

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Wednesday, February 19, 2020 4:45 PM
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Was listening to the discussion today. There was a discussion about the shortages of PPE. There was also discussion re NPIs, but I'm not sure that most folks appreciate that the NPIs that have been arrayed as part of the TLC strategy to reduce disease transmission in the community can be leveraged to create safer compartments or spaces by shunting disease toward the home. By implementing these interventions, one could reduce the likelihood of disease in workplaces (by home isolation and home quarantine-- keeping sick employees at home and keeping employees who are well but potentially infected because someone is sick in their household, at home). Adding in other social distancing measures including social distancing at work, helps to reduce community transmission (adds additional protection to the workplace). The consequence is shunting disease to the home--120 M different compartments in the US, and making the workplace the safe place. That is potentially very important for critical infrastructure. The answer is not PPE for these employees. And why would we expect that employees in these sectors would have any better IPC with the use of PPE than we saw with staff on the Diamond Princess?

Healthcare is a key critical infrastructure. It is different from the other sectors in that it will be attracting patients with COVID like a magnet. It is hard to imagine how one could makes healthcare a safe workplace. But it is only hard to imagine how one could do that unless you begin to look a little closer at the different components of the healthcare system and the roles each component might play during this pandemic.

To illustrate this, I took a stab at developing a conops or roadmap to look at the various pieces of the healthcare system. The shunting of disease is really fractal. Just as we can look at shunting disease across a community into one compartment (the home) to make other compartments safer, we can do the same within our healthcare system—shunt disease to the acute care area where COVID patients will be concentrated. What are the strategies to do that?

This conops is notional. It is purposely designed for a severe outbreak with severe disease and assumes that the healthcare system must somehow continue to limp along and continue to care for the background disease we see during normal times (strokes, AMIs, fractures and trauma, appendicitis, other serious infections, CHF, diabetic emergencies, psychotic episodes, preeclampsia, complicated deliveries, end stage renal disease and dialysis, etc.) as well as sustain outpatients with chronic conditions that require monitoring and care to keep them well and out of the ER and out of the hospital.

Sent from [Mail](#) for Windows 10

From: [redacted] (b) (6)
Sent: Wednesday, February 19, 2020 2:36 PM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6); Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Update for South Korea (see attached) 51 cases; 1 child

Colombia confirms first case of Coronavirus - citizen on Japan cruise ship

February 17th, 2020, 09:06 AM

@Stats_Alerts
BREAKING: Colombia confirms first case of Coronavirus Colombia confirms first case of coronavirus: citizen was on a Diamond Princess cruise

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Wednesday, February 19, 2020 10:05 AM

To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6))'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Update on HK (65 cases; no children) and Singapore (84 cases; 49 currently hospitalized/4 in ICU; still only 4 children (2 asymptomatic/2 hospitalized).

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Wednesday, February 19, 2020 8:20 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6))'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

As of yesterday, there are 251 Canadians on board the Diamond Princess, of whom 34 have tested positive.

https://globalnews.ca/news/6567907/c...hip-canadians/
Canada walks back expected departure date for evacuees of Japanese cruise ship
By Staff The Canadian Press
Posted February 19, 2020 7:47 am
Updated February 19, 2020 7:49 am

Global Affairs says the departure date for a plane that will carry Canadians home from a coronavirus-stricken cruise ship in Japan is yet to be confirmed. Spokeswoman Barbara Harvey says the departure will be settled once final arrangements are made with the Japanese government and the cruise ship company. A news release from the company operating the Diamond Princess cruise ship says the Canadian flight has been "shifted" to early Friday morning.

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Wednesday, February 19, 2020 8:09 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6))'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

621 cases on cruise ship (17% of the passengers and crew have been infected).

https://www.channelnewsasia.com/news...itive-12450498

79 more people test positive for COVID-19 on Diamond Princess cruise ship
19 Feb 2020 06:21PM
(Updated: 19 Feb 2020 06:30PM)

TOKYO: An additional 79 cases of coronavirus have been discovered aboard the Diamond Princess cruise ship in Japan, the health ministry said Wednesday (Feb 19), bringing the total to 621.

Sent from Mail for Windows 10

From: Carter Mecher
Sent: Wednesday, February 19, 2020 6:06 AM
To: Richard Hatchett; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva, Duane; (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6))'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6)); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

I saw a news story yesterday (WashPost) that testing was completed. So we should know in the next coupe of days.

Also saw a story about the 100 or so Americans left behind (44 in hospitals and 61 who declined evacuation).

https://mainichi.jp/english/articles/20200219/p2g/00m/0in/028000c

Hard to find data on the status of those still hospitalized in Japan.

James made a very important point yesterday. Although the passengers are elderly (2,666 passengers), the crew members are relatively young (1,045 crew members). James also expected the attack rates to be very high among the crew members (they were housed together in a relatively small space aboard the ship, perfect conditions for explosive disease transmission). So this combined data on passengers (elderly) and crew (young and healthy) will be invaluable in terms of helping understand severity. I would think that Japan also realizes how invaluable this data is. Japan will be in the best position to assess the impact on the crew, since they will know the results of lab screening and hospitalization of all + crew members (as well as the monitoring quarantine of the rest of the crew over the next 14 days). But now that the passengers are being dispersed, it will be important for several nations to share the data on these passengers—it is really our best chance to understand severity (would need collaboration of the US, Canada, Australia, Hong Kong, Japan).

Sent from Mail for Windows 10

From: Richard Hatchett
Sent: Wednesday, February 19, 2020 4:47 AM
To: Dr. Eva K Lee; Carter Mecher
Cc: Tracey McNamara; Caneva, Duane; (b) (6) Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

I understand from contacts at WHO that Japan is testing everyone on the Diamond Princess, so we should have a complete accounting of that closed population (and thus a nice dataset to inform severity estimates).

From: Dr. Eva K Lee (b) (6)
Sent: 19 February 2020 03:54
To: Carter Mecher (b) (6)
Cc: Tracey McNamara (b) (6)>; Caneva, Duane
(b) (6)>; Richard Hatchett < (b) (6)>;
(b) (6) Dodgen, Daniel (OS/ASPR/SPPR)
(b) (6) DeBord, Kristin (OS/ASPR/SPPR)
(b) (6)>; Phillips, Sally (OS/ASPR/SPPR)
(b) (6) David Marcozzi < (b) (6)>;
Hepburn, Matthew J CIV USARMY (USA) (b) (6)>;
Lisa Koonin (b) (6)>; Wargo Michael
(b) (6)>; Walters, William (STATE.GOV)
< (b) (6); HARVEY, MELISSA (b) (6)>;
WOLFE, HERBERT (b) (6)>; Eastman, Alexander
(b) (6)>; EVANS, MARIEFRED
(b) (6); Callahan, Michael V.,M.D.
(b) (6);
(b) (6) Johnson, Robert (OS/ASPR/BARDA)
(b) (6)>; Yeskey, Kevin (b) (6)
Disbrow, Gary (OS/ASPR/BARDA) < (b) (6)>; Redd,
Johnt(OS/ASPR/SPPR) < (b) (6)>; Hassell, David (Chris)
(OS/ASPR/IO) < (b) (6)>; Hamel, Joseph (OS/ASPR/IO)
(b) (6)>; Dean, Charity A@CDPH
(b) (6)>; Lawler, James V < (b) (6)>;
Kadlec, Robert (OS/ASPR/IO) (b) (6)>; 'Martin, Gregory J
(b) (6) Borio, Luciana
(b) (6)>; Hanfling, Dan (b) (6)>; McDonald, Eric
(b) (6)>; Wade, David (b) (6)>;
TARANTINO, DAVID A (b) (6)>; WILKINSON,
THOMAS (b) (6); David Gruber
(b) (6)v>; KAUSHIK,
SANGEETA (b) (6)>; Nathaniel Hupert
(b) (6)
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Just talked to a lab director in Hong Kong U. They tested 3,600 passengers and crews on World Dream in 24 hours, all using the definitive RT-PCR test. The tests were performed in government labs. They disembarked everyone after 3 days (all came back negative). And they are still performing contact tracing and monitoring on all at the moment.

old news:

https://www.scmp.com/news/hong-kong/health-environment/article/3049714/coronavirus-3600-passengers-and-crew-members

For surveillance, regional hospitals do an initial screening, then suspected cases are tested by a governmental lab for confirmation.

Schools are still closed for another month.

[redacted] (b) (6)

mobile: [redacted] (b) (6)

Sent with ProtonMail Secure Email.

------- Original Message -------

On Tuesday, February 18, 2020 7:56 PM, Carter Mecher [redacted] (b) (6)> wrote:

> Japan inching toward mitigation
>
> # Abe urges people with cold-like symptoms to avoid work, school
>
> Today 06:30 am JST 24 Comments

TOKYO

Prime Minister Shinzo Abe on Tuesday advised people across the country not to go to work or school if they develop cold-like symptoms, as the country grapples with the spread of a new coronavirus originating in China.

Workplaces in the country, known for their long hours, need to encourage people to take days off without hesitation if they do not feel well, Abe said.

"The first thing that I want the people of Japan to keep in mind is to take time off school or work and refrain from leaving the house if they develop cold-like symptoms such as fever," Abe told a meeting of a government task force on the viral outbreak.

Teleworking is an "effective alternative" to help prevent the virus from spreading further, Abe said.

He made the remarks as the government is scrambling to contain the virus that originated in Wuhan, with more people with no obvious link to China getting infected in Japan.

The global outbreak of the disease called COVID-19 has prompted some event organizers in Japan to rethink their plans for hosting mass gatherings.

The number of confirmed cases in Japan has topped 600, including over 500 passengers and crew on the Diamond Princess, a quarantined cruise ship docked at Yokohama near Tokyo with more than 3,000 confined.

The steady rise in infections in various parts of Japan has raised public concern, prompting the health ministry to ask people who develop symptoms such as a temperature of 37.5 C or higher for at least four days to consult local health care centers and go to designated hospitals. The period is set shorter for the elderly, those with underlying conditions and pregnant women.

As Tokyo and other major cities in the country are notorious for packed rush-hour trains, commuters have been encouraged by a government panel of medical experts to go to work earlier or later than usual as the risk of infection is increased in crowds.

On Tuesday, Fujitsu Ltd and Hitachi Ltd said they are expanding teleworking, though Japanese companies overall have been slow to introduce it.

Sent from Mail for Windows 10

From: Tracey McNamara

Sent: Tuesday, February 18, 2020 4:38 PM

To: Dr. Eva K Lee; Caneva, Duane

Cc: Carter Mecher; Richard Hatchett; [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

I must be psychic. This just came out. Like I said – Oxford Nanopore

Sequencers are being sent to China!

Tracey

https://protect2.fireeye.com/url?k=0a860669-56d21f15-0a863756-0cc47adc5fa2-4fc7adc96dfbde59&u=https://globalbiodefense.com/newswire/oxford-nanopore-sequencers-have-left-uk-for-china-to-support-rapid-near-sample-coronavirus-sequencing-for-outbreak-surveillance/

To: 'Caneva, Duane'
[redacted] (b) (6)>; Carter Mecher
[redacted] (b) (6)>; Richard Hatchett
[redacted] (b) (6)>; Dr. Eva K Lee
[redacted] (b) (6)
Cc: (b) ([redacted] Dodgen, Daniel
(OS/ASPR/SPPR) <[redacted] (b) (6);
DeBord, Kristin (OS/ASPR/SPPR)
[redacted] (b) (6)>; Phillips, Sally
(OS/ASPR/SPPR) [redacted] (b) (6);
David Marcozzi
[redacted] (b) (6)>; Hepburn,
Matthew J CIV USARMY (USA)
[redacted] (b) (6); Lisa Koonin
[redacted] (b) (6)>; Wargo Michael
[redacted] (b) (6)>; Walters,

William (STATE.GOV) [redacted] (b) (6);
HARVEY, MELISSA
[redacted] (b) (6); WOLFE,
HERBERT [redacted] (b) (6);
Eastman, Alexander
[redacted] (b) (6)>; EVANS,
MARIEFRED
[redacted] (b) (6)>;
Callahan, Michael V.,M.D.
[redacted] (b) (6)
;
Johnson, Robert (OS/ASPR/BARDA)
[redacted] (b) (6)>; Yeskey, Kevin
[redacted] (b) (6)>; Disbrow, Gary
(OS/ASPR/BARDA) [redacted] (b) (6)>;
Redd, John (OS/ASPR/SPPR)
[redacted] (b) (6)>; Hassell, David (Chris)
(OS/ASPR/IO) [redacted] (b) (6);
Hamel, Joseph (OS/ASPR/IO)
[redacted] (b) (6)>; Dean, Charity
A@CDPH <[redacted] (b) (6)>; Lawler,
James V [redacted] (b) (6)>; Kadlec,
Robert (OS/ASPR/IO) [redacted] (b) (6)>;
'Martin, Gregory J ([redacted] (b) (6)
[redacted] (b) (6)>; Borio, Luciana
[redacted] (b) (6)>; Hanfling, Dan
[redacted] (b) (6)>; McDonald, Eric
[redacted] (b) (6)>; Wade, David
[redacted] (b) (6); TARANTINO,
DAVID A [redacted] (b) (6)>;
WILKINSON, THOMAS
[redacted] (b) (6)>; David
Gruber [redacted] (b) (6))
[redacted] (b) (6)>; KAUSHIK,
SANGEETA <[redacted] (b) (6)>;
Nathaniel Hupert [redacted] (b) (6)>
Subject: RE: Red Dawn Breaking, COVID-19
Collaborative, Feb 16 start

Hello all - Clearly, the most important thing of all is a reliable, real-time diagnostic test that can differentiate between flu and COVID-19. CDCs test kits were recalled because states said they were not working. Now they have to remanufacture the faulty reagent. How long will that take? If and when more kits are available, will they be available in sufficient quantity that all health care providers will have access?

In all of this, I have not heard anyone talk about the Nanopore MinION technology that has been used for Ebola. What gives??? It is field deployable and can be run in-house. Hospital labs can run thousands of samples at once. It gives results of all viruses, bacteria, protozoa, fungi, in 2 hours. We all know this technology is quite promising. Why aren't we going gangbusters to validate this rapid technology and get it to all diagnosticians? If ever there was a time to invest in a diagnostic technology, this is it!

Tracey

From: Dr. Eva K Lee <[redacted] (b) (6)>

Sent: Tuesday, February 18, 2020 1:06 PM

To: Caneva, Duane [redacted] (b) (6)

Cc: Carter Mecher [redacted] (b) (6)>; Richard Hatchett [redacted] (b) (6)>; Tracey McNamara [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR) [redacted] (b) (6)>; DeBord, Kristin (OS/ASPR/SPPR) [redacted] (b) (6)>; Phillips, Sally (OS/ASPR/SPPR) <[redacted] (b) (6); David Marcozzi [redacted] (b) (6); Hepburn, Matthew J CIV USARMY (USA) [redacted] (b) (6)>; Lisa Koonin [redacted] (b) (6)>; Wargo Michael [redacted] (b) (6) Walters, William (STATE.GOV) [redacted] (b) (6)>; HARVEY, MELISSA [redacted] (b) (6)>; WOLFE, HERBERT [redacted] (b) (6); Eastman, Alexander [redacted] (b) (6)>; EVANS, MARIEFRED [redacted] (b) (6)>; Callahan, Michael V.,M.D. <[redacted] (b) (6)>; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA) <[redacted] (b) (6); Yeskey, Kevin [redacted] (b) (6)>; Disbrow, Gary (OS/ASPR/BARDA) <[redacted] (b) (6)>; Redd, Johnt(OS/ASPR/SPPR) <[redacted] (b) (6)>; Hassell, David (Chris) (OS/ASPR/IO) [redacted] (b) (6)>; Hamel, Joseph (OS/ASPR/IO) [redacted] (b) (6)>; Dean, Charity A@CDPH [redacted] (b) (6)>; Lawler, James V [redacted] (b) (6)du>; Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)v>; 'Martin, Gregory J ([redacted] (b) (6) Borio, Luciana [redacted] (b) (6)>; Hanfling, Dan [redacted] (b) (6)>; McDonald, Eric [redacted] (b) (6)>; Wade, David <[redacted] (b) (6)>; TARANTINO, DAVID A [redacted] (b) (6)>; WILKINSON, THOMAS [redacted] (b) (6); David Gruber [redacted] (b) (6))

[redacted] (b) (6); KAUSHIK, SANGEETA
[redacted] (b) (6); Nathaniel Hupert
[redacted] (b) (6)

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Carter,

Just listened in to our state COVID-19 response effort update. Georgia has no COVID-19 cases yet, and hence they remain in the containment period where they place medium-risk individuals on supervised monitoring of home quarantine, advise them to take temperature daily and report any respiratory symptoms (24/7). Educate them not to show up in ED, or any place without facilitation. To avoid potential disease spread, they are advised to remain at home.

The next stage will be mitigation when a confirmed case is reported. That will initiate the pandemic planning and community-based NPI will be considered. This includes social distancing -- telework, teleclass, etc.

I assume at cities where there are confirmed local COVID-19 cases, the public health leaders have already begun the mitigation phase now and hence are practicing some degree of social distancing and rolling out telework, and various strategies to protect health in the population and to maintain business continuity already. Is that true or they are still waiting to execute their operations?

There are not many tests needed here in Georgia. But rapid robust and reliable testing kits (Tracey's reporting of current bottleneck) remain critical in all communities with positive cases. If we have such means, testing can also be conducted (sampling) on some flu-like cases at strategic selected cities also.

------- Original Message -------

On Tuesday, February 18, 2020 2:20 PM, Dr. Eva K Lee
<[redacted] (b) (6)> wrote:

Duane, Yes. (asymptomatic or mild symptoms) this is the worry at the very start, and it remains the most critical. Hence even 1% of infection for us -- can balloon out of proportion and we can't handle. Shedding not only during infection period, but also post-recovery. It's a very long timeline that we have to deal with. Then you have all the university students. Students travelled to China and came back to school, they asked health service if they needed to quarantine or take any action, theadvice -- no need. Those are missed opportunities. Again, seasonal influenza affects 8-10% Americans, 0.7% of those infected required hospitalization, and morality is roughly 0.1%. So it is easy to "calculate" all these numbers backwards... So 20% ofCOVID-19 infected may need hospitalization, mortality is 10-30 times higher than seasonal flu. How much can we tolerate before anyone would spring into action? Keep in mind, some begin to infect rapidly upon contracting the virus, the incubation is so short (and so long) and infectious too during that period (with much being unknown).

Carter, I think you will expect heterogeneous approaches from different communities in the overall response strategy, since it depends on the social setting and the demographics and more importantly the local resources. We have to optimize for sure.

------- Original Message -------

On Tuesday, February 18, 2020 1:51 PM,
Caneva, Duane <(b) (6)>
wrote:

Seems to me a big challenge will be asymptomatic or mild symptoms in kids, spread through the schools, shed to parents who staff both categories acute and non-acute care clinics. If there are several days of asymptomatic shedding, how do you prevent spread to the vulnerable, high risk patients in each category?

Will mild symptoms drive complacent compliance?

From: Carter Mecher
<(b) (6)>

Sent: Tuesday, February 18, 2020
1:32 PM

Subject: RE: Red Dawn
Breaking, COVID-19
Collaborative, Feb 16 start

CAUTION: This email originated from outside of DHS. DO NOT click links or open attachments unless you recognize and/or trust the sender. Contact your component SOC with questions or concerns.

My thinking is evolving in terms of healthcare system response. Initially I described how I would refocus the outpatient clinics away from COVID care and leverage the NPIs of isolation and quarantine to help keep the workplace safe (for the clinic staff and other patients) rather than a strategy that employs PPE. I would only use the outpatient clinic staff to help with telephone/home care support of those patients under home isolation or home quarantine--to help with compliance/adherence to isolation and quarantine, monitoring their health, and optimizing the care of their other chronic medical conditions (to keep them out of the ER and the hospital). But as I thought more about this, it occurs to me that this can be generalized beyond outpatient clinics.

I would think about dividing our healthcare system into two big pieces: (1) acute care (EDs, acute inpatient care, critical care); and (2) non-acute care including outpatient clinics (PC/Family Practice, pediatrics, OB/GYN, medical specialty, surgical specialty, dental, mental health, rehab, etc.), as well as other inpatient areas (inpatient mental health, substance abuse, nursing homes, hospice care, memory care, assisted living, etc.). Inpatient surgery (and I suppose labor and delivery) is part of acute care, but for this outbreak, it probably best belongs bundled with the other non-acute inpatient areas. I would anticipate that the tripwire for implementing NPIs (community transmission), will also be the trigger for healthcare systems to dial down or turn off elective admissions (primarily surgical) to free up acute care and ICU/monitored meds. The most effective way to protect these non-acute areas is by shunting potential COVID patients away from these areas and either providing this type of care while the patients is hospitalized in acute care or thru telephone care/home care for patients with mild illness receiving care at home. And the most effective way to shunt these patients away from non-acute care areas is thru the implementation of early and aggressive NPIs of isolation of the ill and home quarantine of household contacts (and not fit testing the world and passing out PPE that we don't have).

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Tuesday, February 18, 2020 11:02 AM

To: Richard Hatchett; Caneva, Duane; Tracey McNamara; Dr. Eva K Lee; [redacted] (b) (6)

Cc: [redacted] (b) (6) [redacted]; Dodgen, Daniel (OS/ASPR/SPPR);

DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

More puzzle pieces re the cruise ship outbreak.

- About 2/3rds of the passengers

have been tested so far (2,404 out of 3,711).

- 61 Americans opted to remain onboard and not be evacuated.

Japan has completed tests for all passengers and crew aboard the ship as of Monday, but the results for the last batch of tests aren't expected until Wednesday, the day that the quarantine is slated to end. So far, results are back for 2,404 passengers and crew, out of the 3,711 who were on board the ship when the quarantine began on Feb. 5.

Japanese Health Minister Katsunobu Kato said Tuesday that people who have tested negative for the virus would start leaving on Wednesday, but that the process of releasing passengers and crew won't be finished until Friday, according to the Washington Post.

The remaining 61 American passengers on the DP who opted not to join the evacuation will not be allowed to return to the US until March 4, according to the American embassy in Tokyo. The governments of Australia, Hong Kong and Canada have also said they would evacuate passengers.

Elsewhere, Japan confirmed three more cases of the virus. This time, they were confirmed in Wakayama, a prefecture in eastern Japan.

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Tuesday, February 18, 2020 10:50 AM

To: Richard Hatchett; Caneva, Duane; Tracey McNamara; Dr. Eva K Lee; [redacted] (b) (6)

Cc: [redacted] (b) (6) >; Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) ; Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James

V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6) KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Maybe he was misquoted or it was a typo—perhaps what was meant was 4 per 100 (and that would be a low estimate)

Sent from Mail for Windows 10

From: Richard Hatchett

Sent: Tuesday, February 18, 2020 10:45 AM

To: Carter Mecher; Caneva, Duane; Tracey McNamara; Dr. Eva K Lee; [redacted] (b) (6)

Cc: (b) [redacted] >; Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David

Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Note that 4/100,000 would imply that only 440 people have been infected.

From: Carter Mecher [redacted] (b) (6)>

Sent: 18 February 2020 15:26

To: Caneva, Duane
[redacted] (b) (6)
Tracey McNamara
<[redacted] (b) (6)>; Dr.
Eva K Lee [redacted] (b) (6)
[redacted]

Cc: [redacted] (b) (6)
>; Dodgen,
Daniel (OS/ASPR/SPPR)
<[redacted] (b) (6)>;
DeBord, Kristin
(OS/ASPR/SPPR)
<[redacted] (b) (6);
Phillips, Sally (OS/ASPR/SPPR)
[redacted] (b) (6)>; David
Marcozzi
[redacted] (b) (6)
>; Hepburn, Matthew J CIV
USARMY (USA)
[redacted] (b) (6)
>; Lisa Koonin
[redacted] (b) (6)>; Wargo
Michael
[redacted] (b) (6)
Walters, William
(STATE.GOV)
[redacted] (b) (6);
HARVEY, MELISSA
[redacted] (b) (6)>;
WOLFE, HERBERT
[redacted] (b) (6)
Eastman, Alexander
(b) (6)>
; EVANS, MARIEFRED
[redacted] (b) (6)
Callahan, Michael
V.,M.D.
[redacted] (b) (6)
; Johnson,
Robert (OS/ASPR/BARDA)
[redacted] (b) (6)>;

Yeskey, Kevin
(b) (6)
Disbrow, Gary
(OS/ASPR/BARDA)
(b) (6)>; Redd,
John (OS/ASPR/SPPR)
(b) (6)>; Hassell,
David (Chris) (OS/ASPR/IO)
(b) (6);
Hamel, Joseph (OS/ASPR/IO)
(b) (6)>; Dean,
Charity A@CDPH
(b) (6)>;
Richard Hatchett
(b) (6)>;
Lawler, James V
(b) (6);
Kadlec, Robert (OS/ASPR/IO)
(b) (6)>;
'Martin, Gregory J
(b) (6)
>; Borio,
Luciana (b) (6)>;
Hanfling, Dan
(b) (6);
McDonald, Eric
(b) (6)
; Wade, David
<(b) (6)>;
TARANTINO, DAVID A
(b) (6)>;
WILKINSON, THOMAS
(b) (6)
David Gruber
((b) (6)
KAUSHIK, SANGEETA
(b) (6)>;
Nathaniel Hupert
(b) (6)>

Subject: RE: Red Dawn
Breaking, COVID-19
Collaborative, Feb 16 start

WHO estimates 80% of patient with COVID-19 have mild disease and recover; that implies that 20% have severe disease. WHO estimated that 14% develop pneumonia and 5% are considered critical. [We were estimating that 12% of cases needed hospitalization (so 88% did not) and 2% needed ICU care (with mortality of patients with pneumonia in the ICU generally between 15%-50% so a CFR of 0,3%-1.0%). Also noet his comment on sparing children. The latter comments are reminiscent of the early comments of public health leaders during the 1918 pandemic—always minimizing. I have no idea where an attack rate of 4 per 100,000 comes from.]

https://www.channelnewsasia.com/news/world/covid-19-coronavirus-who-china-patients-have-mild-disease-12445010

GENEVA: The new novel coronavirus only causes mild disease for 80 per cent of infected patients, said the World Health Organization on Monday (Feb 17). Speaking to reporters, WHO chief Tedros Adhanom Ghebreyesus said that 14 per cent of patients would have severe diseases such as pneumonia.

"Around five percent of cases are considered critical with possible multi-organ failure, septic shock and respiratory failure and, in some cases, death," he added.

Tedros also said there were "relatively few cases" among children and more research was needed to understand why.

The WHO chief also warned against "blanket measures" over the novel coronavirus outbreak, pointing out the epidemic outside of China was only affecting a "tiny" proportion of the population.

Ryan said that even at the epicentre of the crisis in the city of Wuhan in central Hubei Province, the "attack rate" - a measure of the speed of spread of the virus - was four per 100,000.

"This is a very serious outbreak and it has the potential to grow, but we need to balance that in terms of the number of people infected. Outside Hubei this epidemic is affecting a very, very tiny, tiny proportion of people," he said.

Tedros also referred to an apparent decline in new cases of the disease in recent days but said that the trend "must be interpreted very cautiously".

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Tuesday, February 18, 2020 10:15 AM

To: Caneva, Duane; Tracey McNamara; Dr. Eva K Lee; [redacted] (b) (6)

Cc: [redacted] (b) (6) [redacted] >; Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6); [redacted] (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Update on cruise ship, Japan (implementing NPIs) and South Korea (evacuating passengers)

https://www.channelnewsasia.com/news/asia/covid19-japan-virus-testing-complete-quarantine-cruise-ship-12445788

88 more people test positive for COVID-19 on Diamond Princess cruise ship.

The new cases take the total number of confirmed cases on the Diamond Princess to 542 - the biggest cluster outside the epicentre in China. [Almost 15% of the crew and passengers have been infected.]

Japan has also confirmed at least 65 cases domestically, including many involving people with no history of recent travel to China. Authorities have said the virus is being transmitted locally now, and have asked citizens to avoid crowds and non-essential gatherings. On Monday, the amateur portion of the Tokyo Marathon, which had been expected to attract some 38,000 runners, was cancelled. Only elite athletes will now be able to take part. The public celebration for Emperor Naruhito's birthday has also been scrapped over virus fears.

South Korea will send a presidential aircraft on Tuesday to fly back four nationals and one Japanese spouse, an official told reporters. There are 14 South Koreans on board in total, but the other ten have declined to be evacuated from the ship because they live in Japan, the Yonhap news agency reported.

Vietnam NPIs

https://protect2.fireeye.com/url?k=5a2fa482-067bbdfe-5a2f95bd-0cc47adc5fa2-a5b86bc1581cf39c&u=https://saigoneer.com/saigon-health/...ue-to-covid-19

Due to COVID-19: As of February 15, all 63 provinces and cities in Vietnam have extended their school closing time, 56 of which — including Saigon — have announced that schools will be closed until the end of February. Ho Chi Minh City's People Committee proposing students stay at home until the end of March.

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Tuesday, February 18, 2020 7:10 AM

To: Caneva, Duane; Tracey McNamara; Dr. Eva K Lee; (b) (6)

Cc: (b) [redacted]>; Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6) Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

More things to keep an eye on (attached links of stories and translations of news reports):

Yesterday a 5th flight of evacuees from Hubei arrived in Japan. There were 65 on board and 7 people were symptomatic (11%). Watch for the number of confirmed—it will provide a point estimate of prevalence of COVID-19 in Hubei as of yesterday. Sounds like this is the last flight japan will accept.

Yesterday, Japan provided an update of all cases in Japan:

- 53 people were infected in Japan and travelers from China
- 454 passengers and crew members on cruise ships, and
- 13 people returned on

charter aircraft.

- 520 people in total.
- 23 people were determined to be seriously ill

Watching for other countries to evacuate passengers from cruise ship

- 256 Canadians on the Diamond Princess cruise ship
- 32 tested + (as of Feb-17)
- A plane chartered by the Canadian government has left for Japan to evacuate its nationals aboard a virus-hit cruise ship off Yokohama, TV Asahi reported on Tuesday, citing a

tweet by
Canada's
foreign
minister

Can't find anything about other countries evacuating passengers (UK, Hong Kong, Italy, etc.)

Last thing. Am seeing stories from Japan re patients going from clinic to clinic with resp symptoms and fever and being confirmed. They are finding nosocomial transmission—so underscores the concerns outlined in the proposal I outlined for re-aligning outpatient clinics.

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Monday, February 17, 2020 10:39 PM

To: Caneva, Duane; Tracey McNamara; Dr. Eva K Lee; [redacted] (b) (6)

Cc: [redacted] (b) (6) [redacted] Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa

Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6); Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6) KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

I really need help thinking thru the testing piece (screening for COVID-19). How do we protect the staff in outpatient clinics (where all the ILI is typically seen) and conserve PPE by shifting all the mild illness away from clinics and toward patients' homes using telephone care/telehealth and home healthcare and employing home isolation for those who are infected and voluntary home quarantine for otherwise well (but exposed and potentially infected) household contacts? Having all the suspected patients coming in to clinics to be screened really defeats the purpose. So how would very large numbers of outpatients get screened? Home screening? Drive thru screening? Or creating a free standing screening facility for rapid screening? Has anyone thought this thru (how you screen for disease plus promote adherence/compliance to home isolation and home quarantine and shift outpatient care of patients with mild disease to telephone/home care to protect outpatient clinic staff? Looking for practical solutions.

Just to remind you, here are the estimates of demand (assuming we would need to screen all ILI)—about 88K per day in primary care clinics across the US.

US Data	
US population	325,700,000
Hospital Beds	924,107
ICU Beds	81,790
Hospital Admissions	36,353,946.00
ER Visits	145,600,000
Family Practice/PC Visits	481,963,000
Total Deaths	2,813,503
A Day in the US	
Hospital Admissions	99,600

Inpatient Census (85% occupancy)	785,491
ICU Census (85% occupancy)	69,522
ER Visits	398,904
Family Practice/PC Visits	1,320,447
Deaths	7,708
Current Background of Illness Similar to COVID-19	
2019-20 Flu Season MMWR Week 5 ILI Rate 6.7%	
1.4M hospitalizations annually for pneumonia	
Medicare Average LOS Pneumonia 6 days	
55,672 pneumonia & influenza deaths annually	
Daily Hospital Admissions Pneumonia	3,836
Hospital Census Pneumonia	23,014
Daily ILI cases seen in ERs	26,727
Daily ILI cases seen in FP/PC clinics	88,470
Daily pneumonia & influenza deaths	153

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Monday, February 17, 2020 9:04 PM

To: Caneva, Duane; Tracey McNamara; Dr. Eva K Lee; (b) (6)

Cc: (b) >; Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally

(OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

I tinkered with the strategy for integrating outpatient clinics and hospitals for the care of COVID-19 patients. Proposing this for my system.

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Monday, February 17, 2020 7:17 PM

To: Caneva, Duane; Tracey McNamara; Dr. Eva K Lee; [redacted] (b) (6)

Cc: [redacted] (b) (6) Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber

(b) (6));
KAUSHIK, SANGEETA;
Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

More details on evacuation of American passengers aboard the cruise ship.

Total evacuated: 177 + 151 = 328

https://www.usatoday.com/story/travel/cruises/2020/02/17/coronavirus-diamond-princess-evacuees-test-positive-allowed-fly-united-states/4783787002/

Fourteen evacuees from the Diamond Princess cruise ship quarantined in Japan were allowed to fly back to the United States Sunday despite testing positive for coronavirus, the U.S. State Department and Health and Human Services said in a joint statement. The evacuees were not symptomatic.

"These individuals were moved in the most expeditious and safe manner to a specialized containment area on the evacuation aircraft to isolate them in accordance with standard protocols," the statement, published Sunday, read.

The State Department was unaware the individuals had coronavirus when they were being removed from the ship; they had tested negative just a few days before, Robert Kadlec, the assistant secretary for preparedness and response at the U.S. Department of Health & Human Services, said on a phone call with reporters.

"If those results had come back four hours earlier before we'd started to disembark the ship and before these people were evacuees within an evacuation system, then it would've been a different discussion." Dr. William Walters, director of operational medicine at the U.S. Department of State, said on the call.

Kadlec said that individuals received multiple screenings when moving from ship to bus to plane and a more extensive medical assessment upon arrival.

Two charter flights carrying the Diamond Princess passengers landed at military bases in California and Texas overnight, starting the clock on a 14-day quarantine period to ensure those passengers don't have coronavirus. In total, approximately 380 Americans were on board the Diamond Princess ship for the duration of the cruise and quarantine at sea.

'Something went awry': Why did US break Diamond Princess coronavirus quarantine?

One plane carrying American passengers touched down at Travis Air Force Base in northern California just before 11:30 p.m. Sunday local time. A second flight arrived at Lackland Air Force Base in Texas around 2½ hours later, early Monday.

The California flight had 177 people on it, seven of whom tested positive for coronavirus, Walters said. An additional three people were isolated during the flight for fever. Upon arrival, 171 stayed in Travis while six traveled to Omaha.

It's unclear which passengers were transferred there and whether initial tests were positive or whether they were at risk for the virus.

The Texas flight had 151 people board and included the other seven who tested positive for coronavirus. Two additional passengers were isolated on account of fever. All passengers who tested positive for coronavirus then moved on to Omaha.

The aircraft design allowed passengers to sit in isolation thanks to a plastic divider at the tail of the aircraft.

13 high-risk passengers await test results at Nebraska Medical Center

Officials from the University of Nebraska Medical Center and Nebraska Medicine confirmed that they are assessing 13 adults at their quarantine and biocontainment facility in Omaha.

“Late last night at about 2 or 3 a.m., we were asked to bring some individuals here who had either tested positive or had a high likelihood of testing positive because of symptoms they were exhibiting,” said Dr. Chris Kratochvil, the executive director at the University of Nebraska Medical Center’s Global Center for Health Security.

Twelve of them are housed in the quarantine center while one man was transferred to the hospital’s biocontainment unit for testing and observation because of symptoms including cough, fever, shortness of breath, lightheadedness and an undisclosed chronic condition that would make him particularly vulnerable to the COVID-19 virus.

"He is doing good and in stable condition at this time,” reported Shelly Schwedhelm, Nebraska Medicine’s executive director of emergency management and biopreparedness.

She went on to note that “the folks in the quarantine center have all been tested, and we’re waiting for those results.”

She added that the other 12 are isolated in “very nice rooms with WiFi, TV and a small refrigerator

– a lot of the amenities at hotels but with engineering controls" to prevent contaminated air from escaping.

Their test results, which are due back Monday afternoon, will determine whether the patients will be allowed to see their spouses or leave their rooms.

Regardless of whether they test positive or negative, all of the new arrivals will spend at least 14 days in the facility, and any who test positive will likely stay longer, said Dr. Mike Wadman, the co-medical director of the National Quarantine Unit.

Kratochvil says it's possible that they may be asked to take more patients should more of the Diamond Princess passengers now in quarantine at the airbases test positive.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, told the USA TODAY editorial board and reporters Monday that the original idea to keep people safely quarantined on the ship wasn't unreasonable. But even with the quarantine process on the ship, virus transmission still occurred.

"The quarantine process failed," Fauci said. "I'd like to sugarcoat it and try to be diplomatic about it, but it failed. People were getting infected on that ship. Something went awry in the process of the quarantining on that ship. I don't know what it was, but a lot of people got infected on that ship."

USA TODAY reached out to Princess Cruises for clarification on how many Americans from the ship have the virus.

Sent from Mail for Windows 10

From: Caneva, Duane

Sent: Monday, February 17, 2020 4:51 PM

To: Carter Mecher; Tracey McNamara; Dr. Eva K Lee; (b) (6)

Cc: (b) (6) Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6)); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: Re: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

+ Bob Glass

Get Outlook for iOS

From: Carter Mecher <[redacted] (b) (6)>
Sent: Monday, February 17, 2020 4:47:38 PM
To: Tracey McNamara <[redacted] (b) (6)>; Dr. Eva K Lee [redacted] (b) (6) >
Cc: [redacted] (b) (6) >; Caneva, Duane [redacted] (b) (6); Dodgen, Daniel (OS/ASPR/SPPR) <[redacted] (b) (6)>; DeBord, Kristin (OS/ASPR/SPPR)

<[redacted] (b) (6)>;
Phillips, Sally (OS/ASPR/SPPR)
[redacted] (b) (6)>; David
Marcozzi
[redacted] (b) (6)
>; Hepburn, Matthew J CIV
USARMY (USA)
[redacted] (b) (6)
>; Lisa Koonin
[redacted] (b) (6) Wargo
Michael
[redacted] (b) (6)
>; Walters, William
(STATE.GOV)
[redacted] (b) (6)>;
HARVEY, MELISSA
[redacted] (b) (6);
WOLFE, HERBERT
[redacted] (b) (6)
Eastman, Alexander
(b) (6)>
; EVANS, MARIEFRED
[redacted] (b) (6)
>; Callahan, Michael
V.,M.D.
[redacted] (b) (6)
>;
Johnson, Robert
(OS/ASPR/BARDA)
[redacted] (b) (6)>;
Yeskey, Kevin
[redacted] (b) (6)>;
Disbrow, Gary
(OS/ASPR/BARDA)
[redacted] (b) (6)>; Redd,
John (OS/ASPR/SPPR)
[redacted] (b) (6) Hassell,
David (Chris) (OS/ASPR/IO)
[redacted] (b) (6)
Hamel, Joseph (OS/ASPR/IO)
[redacted] (b) (6)>; Dean,
Charity A@CDPH
[redacted] (b) (6)

Richard Hatchett
[redacted] (b) (6)>;
Lawler, James V
[redacted] (b) (6)>;
Kadlec, Robert (OS/ASPR/IO)
[redacted] (b) (6);
'Martin, Gregory J
[redacted] (b) (6)
>; Borio,
Luciana [redacted] (b) (6);
Hanfling, Dan
[redacted] (b) (6)>;
McDonald, Eric
[redacted] (b) (6)
; Wade, David
[redacted] (b) (6)
TARANTINO, DAVID A
[redacted] (b) (6)>;
WILKINSON, THOMAS
[redacted] (b) (6)
David Gruber
[redacted] (b) (6)
>;
KAUSHIK, SANGEETA
[redacted] (b) (6)>;
Nathaniel Hupert
[redacted] (b) (6)

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

CAUTION: This email originated from outside of DHS. DO NOT click links or open attachments unless you recognize and/or trust the sender. Contact your component SOC with questions or concerns.

A correction. Should not have included breakdown of hospitalized since we have spotty data 9or could have used a range). Only solid data we have is number confirmed (58), number in hospital (44), and number in ICU (≥1). Mix of hospital patients is unknown (from the Singapore data the ratio of hospitalized to ICU has ranged from 6:1 to 13:1 from two data points).

So estimates of severity looking only at the American passengers:

~400 total American passengers

58 confirmed to have COVID-19

12 Asymptomatic (20%)

46 Symptomatic (80%) (44 cases actually hospitalized)

~2% of total cases requiring ICU admission (1 case)

Expected mortality for patients with pneumonia admitted to ICU (15-50%); assuming 2% of those who become infected with COVID-19 require ICU care, these mortality rates equate to a CFR of 0.3%-1.0%

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Monday, February 17, 2020 4:15 PM

To: Tracey McNamara; Dr. Eva K Lee

Cc: (b) (6) Caneva, Duane; Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Latest data from Singapore (77 cases; 4 children, 2 are asymptomatic) and Hong Kong (60 cases; no children)

More puzzle pieces.

Singapore status:
https://protect2.fireeye.com/url?k=f6750fe4-aa211698-f6753edb-0cc47adc5fa2-76d29cc40fd8c03f&u=https://www.moh.gov.sg/news-highligh...tion-confirmed

Update on condition of confirmed cases

To date, a total of 24 cases have fully recovered from the infection and have been discharged from hospital. Of the 53 confirmed cases who are still in hospital, most are stable or improving. Four are in critical condition in the intensive care unit.

[Ratio of hospitalized to ICU of 53/4 or ~ 13:1] Consistent with estimates in earlier email. [On Feb-12 Singapore reported that 8 patients were in ICU.]

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Monday, February 17, 2020 2:57 PM

To: Tracey McNamara; Dr. Eva K Lee

Cc: Caneva, Duane; Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6) Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber

(b) (6);
KAUSHIK, SANGEETA;
Nathaniel Hupert;
(b) (6)

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Trying to estimate severity by bringing a number of pieces together.

The Diamond Princess Cruise Ship had a crew of 1,745 and 2,666 passengers (total pf 3,711) Approximately 400 of the passengers are Americans (11%). Several days ago (Feb-13) we attempted to estimate disease severity using the current data being reported by the media (number of confirmed cases and ICU cases) as well as data on the outbreak in Singapore (number of confirmed cases, number hospitalized, and number in ICU) (see attached Word file).

Given the additional information becoming available (including more specific information being reported by the media on the numbers of Americans infected), I was interested in an updated crude estimate of severity (and to see how well the early predictions of severity matched with what was being reported by the media on illness in the Americans. See

latest re the cruise ship outbreak below (two stories). We can glean from these stories that the number infected is now up to 454. And 14 positive passengers were included among the Americans who were evacuated to the US. Canada, South Korea, Italy and Hong Kong announced Sunday that they would also arrange charter flights to evacuate their citizens. A few additional pieces of data. News reports yesterday stated that 73 of the 355 confirmed cases from the cruise ship were asymptomatic (20%). Also, yesterday the media quoted Dr. Fauci that the total number of Americans who were confirmed to have COVID yesterday and who remained at hospitals in Japan at 44. Assuming that this number does not include the 14 confirmed cases that were evacuated, suggests that the total number of Americans with confirmed COVID is 58. An earlier news report from Feb-12 re a couple from California, noted the husband was in the ICU in Japan (so at least 1 American in the ICU). ["…remained in a hospital intensive care unit and has been able to communicate with his family, his wife said in a phone interview from the ship, where she remained in quarantine."
https://protect2.fireeye.com/url?k=5b014cc3-075555bf-5b017dfc-0cc47adc5fa2-5be62cf1a816fc6d&u=https://web.archive.org/web/20200212093725/https://www.ocregister.com/2020/02/11/southern-california-man-on-cruise-sent-to-a-hospital-in-tokyo-

with-a-high-fever-tested-for-coronavirus/]

So, piecing all the data together:

The ~400 Americans account for 11% of the 3,711 passengers and crew of the Diamond Princess.

The 58 confirmed cases among Americans account for 12% of the 454 total confirmed COVID cases

Assuming that proportion of asymptomatic cases in Americans is similar to the proportion of asymptomatic cases for the entire ship (73/355 or 20%), we would estimate the number of Americans with asymptomatic infection at ~12. Symptomatics would be 46. If 2% of cases result in ICU admission (based on earlier estimates on Feb-12 where 4 ICU cases were reported with 203 total confirmed cases), we would expect ~9 ICU cases overall with 454 infected. Media reports from today note 19 of the passengers are "seriously ill, with some of whom treated in intensive care units." (Would be helpful to quantify "some"—from the earlier data, we would estimate about half that number would require ICU care at some point). For the 54 Americans confirmed to have COVID, we would estimate 1 would require ICU care if 2% of cases required ICU care (we are already aware of at least 1 American who was receiving ICU care in Japan).

So estimates of severity looking only at the American passengers:

~400 total American passengers

58 confirmed to have COVID-19

12 Asymptomatic (20%)

46 Symptomatic (80%)

~55% of total cases mildly ill (hospitalized for isolation only) (31 cases)

~25% of total cases acutely ill requiring inpatient care (15 cases)

~2% of total cases requiring ICU admission (1 cases)

Expected mortality for patients with pneumonia admitted to ICU (15-50%); assuming

2% of those who become infected with COVID-19 require ICU care, these mortality rates equate to a CFR of 0.3%-1.0%

Those estimates fit pretty well with the estimates from Feb-13. To firm up these numbers it would be useful to have actual numbers from Japan on ICU admissions, number requiring mechanical ventilation, number in the hospital because they are acutely ill, and number in the hospital because of isolation only (mildly ill or asymptomatic). Also would be helpful to have more granular information on the Americans (hospital data in Japan including number acutely ill, number needing ICU admission, and number only in the hospital for isolation). Would also be critical to gather/compile the same information from Canada, South Korea, Italy, Hong Kong, and other nations as they also evacuate their citizens. The cruise ship is a circumscribed population where it is possible to get a handle on severity fairly early in an epidemic. The limitation though, is the population on board that ship is elderly (so need to be careful about generalizing to the entire population). But it is the best data we have.

The reason why this is so important is decisions re the implementation of NPIs depend upon severity (the more severe the more intense the NPIs). The sooner we have a more accurate assessment of severity, the better for making plans for NPIs.

Story #1

https://protect2.fireeye.com/url?k=fb4e1b73-a71a020f-fb4e2a4c-0cc47adc5fa2-6b70ca76908c81a4&u=https://www3.nhk.or.jp/news/html/20200217

/k10012289341000.html?utm_int=news_contents_news-main_001

Translation

New virus cruise ship confirmed 99 new infections

February 17, 2020 18:54

A new outbreak of the coronavirus was confirmed on February 17, with 99 new passengers and crew members infected on a cruise ship. As a result, 454 passengers and crew members of cruise ships have been infected, of which 19 are severely affected.

According to the Ministry of Health, Labor and Welfare, a total of 99 new passengers, including 85 passengers and 14 crewmembers, were revealed on March 17 on the cruise ship "Diamond Princess" anchored in Yokohama Port. Among them, there are 43 Japanese.

This means that a total of 1723 passengers and crew members were inspected on the cruise ship, and a total of 454 infections were confirmed.

According to the Ministry of Health, Labor and Welfare, 19 of the confirmed individuals are seriously ill, some of whom are being treated in intensive care units.

According to the Ministry of Health, Labor and Welfare, the Ministry of Health, Labor and Welfare said that infections were confirmed one after another on cruise ships. Need to be analyzed quickly. "

The Ministry of Health, Labor and Welfare has a policy to conduct a virus test on all passengers and crew members remaining on board, and those who have a negative result will be asked to leave the ship after the 19th.

Story #2

Fourteen people who were evacuated from the Diamond Princess cruise ship and flown back to the United States on charter flights tested positive fornovel coronavirus, according to a joint statement from the US Departments of State and Health and Human Services.

The passengers are among the more than 300 people removed from the ship, which is docked off the Japanese port city of Yokohama, Sunday night and flown to military bases in the United States.

US officials were notified that they had tested positive for coronavirus during the evacuation process, after passengers had disembarked the ship, the agencies said in the joint statement Monday. The passengers had been tested two to three days before the evacuation flights, the statement said.

"After consultation with HHS officials, including experts from the HHS Office of the Assistant Secretary for Preparedness and Response, the State Department made the decision to allow the 14 individuals, who were in isolation, separated from other passengers, and continued to be asymptomatic, to remain on the aircraft to complete the evacuation process," the agencies said.

One charter flight carrying evacuated Americans arrived at Travis Air Force Base near Fairfield, California, around 11:28 p.m. local time Sunday. A second arrived at Joint Base San Antonio-Lackland in San Antonio, Texas at 3:56 a.m. local time Monday.

The passengers who tested positive were isolated from the other passengers during the flights, the statement said. And all passengers are being "closely monitored" throughout the flight.

"Any who become symptomatic will be moved to the specialized containment area, where they will be treated," the statement said.

After the flights land, any passengers that developed symptoms on the flights and those who had already tested positive will be transported to "an appropriate location for continued isolation and care."

The remaining passengers will remain under quarantine for 14 days.

Passengers arriving to Travis Air Force Base will be housed in the same facility as evacuees who arrived from Wuhan earlier this month, a spokesperson for the base told CNN. New evacuees will be kept in a separate area of the Westwind Inn on the base, the spokesperson said.

Before the announcement about the infected flight passengers, some Americans aboard the Diamond Princess said they didn't want to take a chance being evacuated for fear they would be subject to possible infection.

Sacramento resident Matthew Smith told CNN affiliate KOVR that he would rather deal with issues in Japan than be evacuated and quarantined in the United States.

"We decided we would just face whatever consequences here rather than exposing ourselves to that situation," Smith told the affiliate."It kind of didn't make any sense if the us was fearful that these were infected people which is why they're going to quarantine them for another 2 weeks to have thrown them all together"

Smith's wife Katherine Codekas was met with some surprise when she told authorities that she and her husband weren't going to go with the other American evacuees, KOVR reported.

"They came back around again and I said no we're not going and they very sincerely wished us luck but there was a little look of surprise on their face," Codekas explained to the affiliate.

"You know, it's not like we're the last helicopter off the roof top in Ho Chi Mihn City," she told KOVR. "We're on a boat and we're watching people go away and people just make different choices about how they want to confront the virus."

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Monday, February 17, 2020 11:00 AM

To: Tracey McNamara; Dr. Eva K Lee

Cc: Caneva, Duane; Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6);

(b) (6); Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J (b) (6); Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Attached is Bob Glass' original paper—his co-author was his high-school age daughter.

Here is a link to another paper.

Glass RJ, Glass LM, Beyeler WE, Min HJ. Targeted social distancing designs for pandemic influenza. Emerg Infect Dis [serial on the Internet]. 2006 Nov [*date cited*]. http://dx.doi.org/10.3201/eid1211.060255

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Monday, February 17, 2020 9:59 AM

To: Tracey McNamara; Dr. Eva K Lee

Cc: Caneva, Duane; Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6) Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber

(b) (6);
KAUSHIK, SANGEETA;
Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

This is the original graph of Bob Glass' data. He modeled the various interventions alone or in combination. Along one axis are the social distancing measures from doing nothing, to just closing schools but allowing kids to mix in the community, to social distancing of kids in the community but keeping schools open, to only social distancing of adults in the community, to closing schools and adults social distancing, to kids and adults social distancing in the community, to closing schools and social distancing of kids in the community, to a combo of all 3. Along the other axis are other interventions including doing nothing, to quarantine (Q), treatment of the ill with antivirals (T), prophylaxis of contacts (P), and various combinations. We observed what we called a "cliff effect" or phase transition or a discontinuity once you closed schools and implemented social distancing among kids. The effect was non-linear and dramatic. As a consequence we began a deep dive to better understand the school environment (including the transportation system half the school age kids use each day) and school age kids. An unsung hero in all this was Lisa Koonin (who was at CDC at the time). If Richard birthed TLC, Lisa kept the baby alive in the neonatal ICU.

We still have much to learn about this virus. Thus far, it seems to be sparing kids (just like SARS). We have been monitoring the reports from China as well as the detailed data we can see from Hong Kong, Singapore, and Japan—the numbers of kids remain very low and disease appears to be mild. Nonetheless, TLC (and the NPIs) is focused on reducing disease transmission (effectively decreasing Ro)—the interventions are really agnostic to severity. It is why CDC had to scale the implementation of TLC (later called CMG) to severity. Despite the absence of severe disease in kids, we really are still in the dark in terms of the amount of asymptomatic disease or mild sub-clinical disease in kids because we just haven't been able to look.

I never forgot this graph of the data from Bob Glass and the inflection point that was observed when the combo of closing schools and social distancing of kids was implemented in his model. Although closing schools is complicated by its 2nd and 3rd order impacts, it is actually a pretty clean intervention in terms of actually pulling the trigger (much cleaner than the other components of TLC). If this outbreak proves to be as severe as our initial estimates, we should think long and hard before dismissing the early implementation of this strategy (closing schools and social distancing of kids).

Sent from Mail for Windows 10

From: Carter Mecher

Sent: Monday, February 17, 2020 8:57 AM

To: Tracey McNamara; Dr. Eva K Lee

Cc: Caneva, Duane; Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6) [redacted]; Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6))'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6); KAUSHIK, SANGEETA; Nathaniel Hupert

Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

NPIs are going to be central to our response to this outbreak (assuming our estimates of severity prove accurate). This email group has grown since we began (not quite epidemic-level growth, but getting there). Looking ahead, I anticipate we might encounter pushback over the implementation of NPIs and would expect similar concerns/arguments as were raised back in 2006 when this strategy first emerged. It was one of the reasons I shared the updated data on US households from American Community Survey, data on USDA programs for nutritional support (including school meal programs), data on schools and enrollment, and even data on juvenile crime. The data that was gathered back in 2006 on social density in various environments (homes, offices/workplaces, schools, daycare, etc., is unchanged). For additional background and context, we attached are 3 papers on NPIs and TLC for those who are interested. Richard Hatchett deserves full credit for birthing the idea of TLC (it was actually developed in response to the threat of H5N1 and later adopted for pandemic influenza response). Duane, perhaps you can store these documents on MAX for safe keeping and access?

The first paper is an historical review of the 1918 pandemic (the comparison of Philadelphia and St. Louis is emblematic of the lesson from 1918 that timing matters when deploying NPIs—need to be early). The second paper is modeling work that was done to evaluate these strategies. At the time, modelers were focused on how best to contain an outbreak overseas (really focusing on using antivirals primarily for treatment and prophylaxis). They focused their models to evaluate the effectiveness of various strategies and quantities of antiviral medications required to quench an emerging outbreak. There were 3 groups who were doing this work back then. They each present their data in that paper. A few things to note. In all the model runs, they did not model perfection or 100% adherence (actually far from it). You will see scenarios from 30/60 (meaning 30% compliance and 60% ascertainment) on up to 90/80). (See figures 1) Even leaky implementation can reduce overall attack rates. The modelers also looked at timing of implementation (see figure 3). At the time there was a great deal of skepticism—was hard for people to believe this was possible. Or even if TLC could be effective, was implementation practical given the challenges trying to implement and the 2nd and 3rd order consequences (especially of closing schools). But the modeling data combined with the historical data was the tipping point. Marty Cetron from CDC and Howard Markel from U of Michigan, published a more extensive historical review of the 1918 pandemic showing much the same. Since then, a group within CDC continued to work on this (collecting additional data from the 2009 pandemic and elsewhere). They published an update of CMG in MMWR in 2017. https://protect2.fireeye.com/url?k=3985fc87-65d1e5fb-3985cdb8-0cc47adc5fa2-bb4a28993b5aa9e0&u=https://www.cdc.gov/media/dpk/cdc-24-7/preventing-pandemic-influenza/community-mitigation-guidelines-for-preventing-pandemic-flu.html

The third paper, is a more recent paper (from 2017) that Richard shared with me. The paper is a little dense, but

I found this paper useful because it provides a vocabulary for strategies that we have raised (Symptom Monitoring vs

Quarantine of potentially infected but symptom-free contacts during an epidemic). This paper identifies those conditions where SM or Q is preferred. Figure 1 is useful for understanding the challenges given the picture that seems to be emerging with this virus. This outbreak seems closer to pandemic flu than SARS in terms of transmission dynamics (and hence the NPIs we would need to employ).

Lastly, another person, Bob Glass at Los Alamos, also did work on this separately from the MIDAS group. He actually began this work as part of a science fair project for his daughter (using social contacts of his daughter and her classmates at school to model disease transmission). He knew someone at VA who forwarded his work to us (chain of transmission). Early on (even before the MIDAS group modeled TLC), we had a "Eureka" moment when we graphed his data in Excel (I can share that single graph to anyone interested). Bob Glass was also interested in trying to determine when you could let up on the NPIs during a pandemic. Here is a story about Bob Glass and that work published in Fast Company https://protect2.fireeye.com/url?k=3862f880-6436e1fc-3862c9bf-0cc47adc5fa2-9ce5af31e3c2cd64&u=https://www.fastcompany.com/3058542/the-scientists-who-simulate-the-end-of-the-world I will see if I can find his work on when to reopen schools. Decisions in terms of letting up on NPIs could be critical down the line.

Sent from Mail for Windows 10

From: Tracey McNamara

Sent: Sunday, February 16, 2020 7:10 PM

To: Carter Mecher; Dr. Eva K Lee

Cc: Caneva, Duane; Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; [redacted] (b) (6) Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6)'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David;

TARANTINO, DAVID A;
WILKINSON, THOMAS; David Gruber
[redacted] (b) (6)
KAUSHIK, SANGEETA;
Nathaniel Hupert

Subject: Re: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Here is the link to a town hall mtg at the Munich Security Conference. Shared by Dr Christian Haggenmiller , Dorector of the German Defense Institute.

https://protect2.fireeye.com/url?k=ec4e0592-b01a1cee-ec4e34ad-0cc47adc5fa2-c00af41a186719a2&u=https://securityconference.org/en/medialibrary/asset/townhall-on-the-coronavirus-outbreak-20200215-1000/

Tracey

Get Outlook for Android

From: Dr. Eva K Lee [redacted] (b) (6) [redacted] >
Sent: Sunday, February 16, 2020 3:05:43 PM
To: Carter Mecher [redacted] (b) (6) >
Cc: Caneva, Duane [redacted] (b) (6)
Dodgen, Daniel (OS/ASPR/SPPR)

<[redacted] (b) (6)>;
DeBord, Kristin
(OS/ASPR/SPPR)
[redacted] (b) (6)>;
Phillips, Sally (OS/ASPR/SPPR)
[redacted] (b) (6)>; David
Marcozzi
[redacted] (b) (6)
>; Hepburn, Matthew J CIV
USARMY (USA)
[redacted] (b) (6)
>; Lisa Koonin
[redacted] (b) (6) Wargo
Michael
[redacted] (b) (6)
Walters, William
(STATE.GOV)
[redacted] (b) (6)
HARVEY, MELISSA
[redacted] (b) (6)
WOLFE, HERBERT
[redacted] (b) (6)
Eastman, Alexander
(b) (6)>
; EVANS, MARIEFRED
[redacted] (b) (6)
>; Callahan, Michael
V.,M.D.
[redacted] (b) (6)
>;
Johnson, Robert
(OS/ASPR/BARDA)
[redacted] (b) (6)
Yeskey, Kevin
[redacted] (b) (6)>;
Disbrow, Gary
(OS/ASPR/BARDA)
<[redacted] (b) (6) Redd,
John (OS/ASPR/SPPR)
[redacted] (b) (6)>; Hassell,
David (Chris) (OS/ASPR/IO)
<[redacted] (b) (6)
Hamel, Joseph (OS/ASPR/IO)

[redacted] (b) (6)>;
Tracey McNamara
<[redacted] (b) (6)>;
Dean, Charity A@CDPH
[redacted] (b) (6);
Richard Hatchett
[redacted] (b) (6);
Lawler, James V
[redacted] (b) (6)>;
Kadlec, Robert (OS/ASPR/IO)
[redacted] (b) (6)>;
'Martin, Gregory J
[redacted] (b) (6) Borio,
Luciana [redacted] (b) (6)>;
Hanfling, Dan
[redacted] (b) (6)>;
McDonald, Eric
[redacted] (b) (6)
Wade, David
(b) (6)
TARANTINO, DAVID A
[redacted] (b) (6)
WILKINSON, THOMAS
[redacted] (b) (6)
David Gruber
(b) (6),
KAUSHIK, SANGEETA
[redacted] (b) (6)>;
Nathaniel Hupert
[redacted] (b) (6)>
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Hi Carter, great points.

1. Separate current ED/ICU patients from COVID-19 is a must.

2. Migrating current ED/ICU (non-COVID) patients to other care sites is great idea.

3. Caring for COVID-19 patients:leveraging ED/ICU personnel for high compliance and usage of limited resources (PPE everything that goes with it) is very critical. Strategic usage and minimizing non-medical staff is necessary --- either these operators are well-trained and protected, or they cannot be there.

4. Concentrating care within ED/ICU for COVID-19 ensures rapid learning and sharing of knowledge among workers as they take care of these patients. Clearly from the standpoint of data collection and clinical symptoms recording and organization, it is more feasible and allow for immediate analysis and feedback.

5. Strategic prioritization of limited resources is extremely important. We must do it now, because the supply chain is already being affected and it can go worse.

6. Primary care and call centers are good. If you want to do strategic testing, this is also a good place to involve.

7. So few children are reported among the confirmed positive cases. They may be good spreaders (not necessarily have to be super) and the more vulnerable people would be ones show up with symptomatic disease characteristics (or no/mild symptoms).

Best, Eva

[redacted] (b) (6)

mobile: [redacted] (b) (6)

Sent with ProtonMail Secure Email.

------- Original Message -------

On Sunday, February 16, 2020 4:30 PM, Carter Mecher <[redacted] (b) (6)> wrote:

> Wanted to bounce something off this group.
>
> I have been concerned about some of the preparedness efforts of healthcare systems

as they are ramping up their capabilities to care for patients with COVID-19 presenting anywhere in their system. Staff working in ERs and ICUs are pretty familiar with the care of these types of patients and the use of appropriate PPE (standard contact and airborne precautions including eye protection). The staff at the hospitals undergo fit testing for respirators, etc. Staff in outpatient clinics (especially remote community based outpatient clinics) don't typically undergo fit testing for respirators. So ERs and ICUs have muscle memory for isolating patients and providing care to patients with infectious respiratory disease. Community based outpatient clinics do not.

As part of the preparedness efforts, there has been interest in fit testing outpatient clinic staff and supplying these clinics with PPE and establishing procedures for evaluating COVID-19 patients in the community based clinics. Given the projected shortages of PPE, that just doesn't seem like the most prudent approach.

Rather than expand the care of potential COVID-19 patients to community based outpatient clinics, I would focus on hospital care--ERs and inpatient areas (especially ICUs). I would not pursue fit testing for staff working in outlying clinics. As a strategy, I suggested dividing COVID patients into two categories—(1) those with illness that is mild enough to be cared for at home (self care or care by other family members); or (2) those who are sick enough to be seen in the ER for possible hospitalization. I would refocus the efforts of outlying clinics away from COVID and toward keeping non-COVID patients with the usual mix of acute and chronic illnesses we see from hypertension to CHF to diabetes, etc., out of the ER and out of the hospital. That is what they can do to help unburden ERs and hospitals for the surge in COVID patients in ERs and hospitals. I would leverage telephone care as much as possible to handle patients with mild disease seeking care related to COVID (and quickly develop algorithms to determine who has mild disease and can be managed by telephone at home and who needs to evaluated in the ER). Think of it like the program Lisa developed for pandemic influenza (Nurse On Call) on steroids, minus the antiviral piece. Could we repurpose and leverage that program for COVID? Such a strategy would help to conserve our PPE supply (avoid the expansion of fit testing and the redirection of already limited supplies of PPE to outlying clinics) and not ask outlying clinics to do something they don't typically do (that usually doesn't out turn out very well). If the outlying clinics focused on what they normally do (caring for patients with chronic diseases), they could help the ER and hospitals cope with the demands of COVID. I would think about Urgent Care centers in the same way—to help to decompress ERs.

I also think that we need to start thinking about strategies to conserve PPE for hospitals. I'm concerned about the projected burn rates and the supply chains for PPE. Click on Amazon and check out the prices now. Or click on WalMart (can't pick up any masks from WalMart now). I saw one supplier selling 200 surgical masks on WalMart's site for only $459.99. Such a deal.

As a conservation strategy, we might think about limiting the amount of staff interacting with infected patients and cohorting patients (even thinking of strategies to minimize need for housekeeping or food service or lab services from entering areas with COVID patients--think Ebola-like strategies (not out of concern of disease transmission but simply to limit number of staff to conserve PPE). Could do something similar with ERs (akin to what pediatricians do to separate sick call patients from other appointments).   I have recommend prioritizing PPE for EDs and ICUs as well as specific inpatient areas where we would likely initially cohort patients, not pursuing fit testing of outpatient clinic staff, and shifting patients with mild COVID disease to telephone care and away from outpatient clinics.

I know several of you are part of large healthcare systems. Am curious how others are approaching this challenge.

I am also resending the questions I posed for handling sick ER/hospital staff or staff members with a confirmed case of COVID in their household. Carter

Sent from Mail for Windows 10

From: Caneva, Duane

Sent: Sunday, February 16, 2020 3:24 PM

To: Dodgen, Daniel (OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally (OS/ASPR/SPPR); David Marcozzi; Hepburn, Matthew J CIV USARMY (USA); Lisa Koonin; Wargo Michael; Walters, William (STATE.GOV); HARVEY, MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS, MARIEFRED; Callahan, Michael V.,M.D.; (b) (6) ; Johnson, Robert

(OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary (OS/ASPR/BARDA); Redd, John (OS/ASPR/SPPR); Hassell, David (Chris) (OS/ASPR/IO); Hamel, Joseph (OS/ASPR/IO); Tracey McNamara; Dean, Charity A@CDPH; Richard Hatchett; Lawler, James V; Kadlec, Robert (OS/ASPR/IO); 'Martin, Gregory J [redacted] (b) (6))'; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade, David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber [redacted] (b) (6) KAUSHIK, SANGEETA; Dr. Eva K Lee; Nathaniel Hupert; Carter Mecher

Subject: Re: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Sorry for spam.

+ Carrer

Get Outlook for iOS

From: Caneva, Duane
Sent: Sunday, February 16, 2020 10:21:38 AM
To: Dodgen, Daniel (OS/ASPR/SPPR) [redacted] (b) (6) >; DeBord, Kristin (OS/ASPR/SPPR) [redacted] (b) (6) >; Phillips, Sally (OS/ASPR/SPPR) [redacted] (b) (6) David Marcozzi [redacted] (b) (6) >; Hepburn, Matthew J CIV USARMY (USA) [redacted] (b) (6) >; Lisa Koonin [redacted] (b) (6) Wargo Michael [redacted] (b) (6) Walters, William (STATE.GOV) [redacted] (b) (6) >; HARVEY, MELISSA [redacted] (b) (6) WOLFE, HERBERT [redacted] (b) (6) >; Eastman, Alexander [redacted] (b) (6) >;

EVANS,
MARIEFRED
[redacted] (b) (6)
Callahan, Michael
V.,M.D.
[redacted] (b) (6)
;
[redacted]
[redacted] >; Johnson, Robert
(OS/ASPR/BARDA)
[redacted] (b) (6)
>; Yeskey,
Kevin
[redacted] (b) (6)
Disbrow, Gary
(OS/ASPR/BARDA)
[redacted] (b) (6)
>; Redd, John
(OS/ASPR/SPPR)
[redacted] (b) (6)
>; Hassell, David
(Chris)
(OS/ASPR/IO)
[redacted] (b) (6)
Hamel, Joseph
(OS/ASPR/IO)
[redacted] (b) (6)
>; Tracey
McNamara
[redacted] (b) (6)
Dean,
Charity A@CDPH
[redacted] (b) (6)
>; Richard
Hatchett
[redacted] (b) (6)
Lawler,
James V
[redacted] (b) (6)
>; Kadlec, Robert

(OS/ASPR/IO)
[redacted] (b) (6)
; 'Martin,
Gregory J
[redacted] (b) (6)
>; Borio, Luciana
[redacted] (b) (6);
Hanfling, Dan
[redacted] (b) (6)
; McDonald, Eric
[redacted] (b) (6)
>;
Wade, David
[redacted] (b) (6)
TARANTINO,
DAVID A
[redacted] (b) (6)
Baric,
Ralph S
[redacted] (b) (6)
WILKINSON,
THOMAS
[redacted] (b) (6)
>; Hassell,
David (Chris)
(OS/ASPR/IO)
[redacted] (b) (6)
>; David Gruber
[redacted] (b) (6)
KAUSHIK,
SANGEETA
[redacted] (b) (6)
Dr. Eva
K Lee [redacted] (b) (6)
Nathaniel Hupert
[redacted] (b) (6)
>
Subject: RE: Red
Dawn Breaking,
COVID-19

Collaborative, Feb 16
start

Some Mark Lipsitch Tweets copied. Sorry, might not be in the right order…

"So far, we have conducted tests for 1,219 individuals. Of those, 355 people tested positive. Of those, 73 individuals are not showing symptoms," Japan's health minister says

Marc Lipsitch (@mlipsitch)

14/02/2020, 17:42

I did actually say the quote that is going around, but the article contained vital context -- we don't know what proportion are symptomatic. Also we have only a rough estimate of what proportion of symptomatic people will have severe outcomes. pic.twitter.com/cWzvINSZBm

Marc Lipsitch (@mlipsitch)

14/02/2020, 17:43

Why do I think a pandemic is likely? The infection is in many parts of China and many countries in the world, with meaningful numbers of secondary transmissions. The scale is much larger than SARS for example (where the US had many introductions and no known onward transmission)

Marc Lipsitch (@mlipsitch)

14/02/2020, 17:45

Why do I think 40-70% infected? Simple math models with oversimple assumptions would predict far more than that given the R0 estimates in the 2-3 range (80-90%). Making more realistic assumptions about mixing, perhaps a little help from seasonality, brings the numbers down

Marc Lipsitch (@mlipsitch)

14/02/2020, 17:48

pandemic flu in 1968 was estimated to _symptomatically_ infect 40% of the population, and in 1918 30%. Those likely had R0 less than COVID-19. Below is from stacks.cdc.gov/view/cdc/11425 pic.twitter.com/EMwjEpA49s

Marc Lipsitch (@mlipsitch)

14/02/2020, 17:49

What could make this scenario not happen? 1) conditions in Wuhan could be so different in some fundamental way from elsewhere that we are mistaken in expecting further outbreaks to have basic aspects in common. No reason I know of to think that but a formal possibility

Marc Lipsitch
(@mlipsitch)

[14/02/2020, 17:53](14/02/2020, 17:53)

2) There could be a higher degree of superspreading than has been appreciated ("dispersion in R0") which could mean that many locations outside Wuhan could "get lucky" and escape major onward transmission. hopkinsidd.github.io/nCoV-Sandbox/D… .

Marc Lipsitch
(@mlipsitch)

[14/02/2020, 17:53](14/02/2020, 17:53)

2) There could be a higher degree of superspreading than has been appreciated ("dispersion in R0") which could mean that many locations outside Wuhan could "get lucky" and escape major onward transmission. hopkinsidd.github.io/nCoV-Sandbox/D… .

Marc Lipsitch
(@mlipsitch)

[14/02/2020, 17:55](14/02/2020, 17:55)

3) Control measures could be extremely effective in locations that have had time to prepare. Maybe in a few, but seems unlikely that is the case in all, especially countries with stretched health systems.

Marc Lipsitch
(@mlipsitch)

14/02/2020, 17:56

4) Seasonal factors could be much more powerful at reducing transmission than we currently expect. That doesn't help the Southern hemisphere, and is not consistent with behavior in China (preprint in queue from □@MauSantillana□ et al.)

From: Caneva, Duane

Sent: Sunday, February 16, 2020 9:39 AM

To: Dodgen, Daniel (OS/ASPR/SPPR) [redacted] (b) (6) >; DeBord, Kristin (OS/ASPR/SPPR) [redacted] (b) (6) >; Phillips, Sally (OS/ASPR/SPPR) [redacted] (b) (6) David Marcozzi [redacted] (b) (6) Hepburn, Matthew J CIV USARMY (USA) [redacted] (b) (6) >; Lisa Koonin [redacted] (b) (6) Wargo Michael [redacted] (b) (6) >; Walters, William [redacted] (b) (6) HARVEY, MELISSA

[redacted] (b) (6)
>; WOLFE,
HERBERT
[redacted] (b) (6)
>; Eastman,
Alexander
[redacted] (b) (6)
EVANS,
MARIEFRED
[redacted] (b) (6)
>;
Callahan, Michael
V.,M.D.
[redacted] (b) (6)
; Johnson, Robert
(OS/ASPR/BARDA)
[redacted] (b) (6)
>; Yeskey,
Kevin
[redacted] (b) (6)
Disbrow, Gary
(OS/ASPR/BARDA)
[redacted] (b) (6)
Redd, John
(OS/ASPR/SPPR)
[redacted] (b) (6)
>; Hassell, David
(Chris)
(OS/ASPR/IO)
[redacted] (b) (6)
>; Hamel, Joseph
(OS/ASPR/IO)
[redacted] (b) (6)
>; Tracey
McNamara
[redacted] (b) (6)
>; Dean,
Charity A@CDPH
[redacted] (b) (6)
Caneva,
Duane

[redacted] (b) (6)
>; Richard
Hatchett
[redacted] (b) (6)
>; Lawler,
James V
[redacted] (b) (6)
>; Kadlec, Robert
(OS/ASPR/IO)
[redacted] (b) (6)
>; 'Martin,
Gregory J
([redacted] (b) (6)
[redacted]
>; Borio, Luciana
[redacted] (b) (6);
Hanfling, Dan
[redacted] (b) (6)>
; McDonald, Eric
[redacted] (b) (6)
>;
Wade, David
[redacted] (b) (6)
TARANTINO,
DAVID A
[redacted] (b) (6)
>; Baric,
Ralph S
[redacted] (b) (6)
WILKINSON,
THOMAS
[redacted] (b) (6)
>; Hassell,
David (Chris)
(OS/ASPR/IO)
[redacted] (b) (6)
David Gruber
[redacted] (b) (6)
)
[redacted]
>;
KAUSHIK,
SANGEETA
[redacted] (b) (6)

Subject: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start

Purpose: This is a new Red Dawn String to cut down the size from the previous string, opportunity to provide thoughts, concerns, raise issues, share information across various colleagues responding to COVID-19.

Including all from previous string plus a few additional folks.

Duane C. Caneva, MD, MS

Chief Medical Officer

Department of Homeland Security

(b) (6)

[redacted]

Executive Assistant:

(b) (6)

[redacted]

[redacted] (b) (6)

(U) Warning: This document is UNCLASSIFIED//FOR OFFICIAL USE ONLY (U//FOUO). It contains information that may be exempt from public release under the Freedom of Information Act

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 11:08:54 +0000
To: Gilman, James (NIH/CC/OD) [E];Tabak, Lawrence (NIH/OD) [E]
Cc: Davey, Richard (NIH/NIAID) [E]
Subject: RE: 3 COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

We should probably also include Rick Davey on all communication regarding such patients

---

From: Gilman, James (NIH/CC/OD) [E] [redacted] (b) (6)>
Sent: Monday, February 24, 2020 12:40 AM
To: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: 3 COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Larry

Best POC is Dr Palmore.

Jim

From: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)>
Date: Sunday, February 23, 2020 at 10:02:41 PM
To: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6), "Gilman, James (NIH/CC/OD) [E]" [redacted] (b) (6)>
Subject: FW: 3 COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Who is P-O-C, related to transfer? Pius

From: "Kadlec, Robert (OS/ASPR/IO)" [redacted] (b) (6)>
Date: Sunday, February 23, 2020 at 9:56 PM
To: "Harrison, Brian (HHS/IOS)" < [redacted] (b) (6)>, "Stecker, Judy (OS/IOS)" [redacted] (b) (6)>, "Mango, Paul (HHS/IOS)" [redacted] (b) (6)>, "Murphy, Ryan (OS/ASPA)" < [redacted] (b) (6)>, "Arbes, Sarah (HHS/ASL)" [redacted] (b) (6)>, Anthony Fauci [redacted] (b) (6)>, "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)"Redfield, Robert R. (CDC/OD)" [redacted] (b) (6), "McGowan, Robert (Kyle) (CDC/OD/OCS)" [redacted] (b) (6)>
Cc: "Lee, Scott (OS/ASPR/EMMO)" [redacted] (b) (6)>, "Yeskey, Kevin (OS/ASPR/IO)" [redacted] (b) (6), "Waters, Cicely (OS/ASPR/OEA)" [redacted] (b) (6), "Shuy, Bryan (OS/ASPR/IO)" [redacted] (b) (6), "Greene, Jonathan (OS/ASPR/EMMO)" < [redacted] (b) (6)>, "Imbriale, Samuel (OS/ASPR/SIIM)" [redacted] (b) (6), "Austin, Meredith (uscg.mil)" [redacted] (b) (6), "Herrmann, Jack (OS/ASPR/OEA)" [redacted] (b) (6)
Subject: 3 COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Initial CDC testing of the 100 individuals repatriated from the Diamond Princess yielded three individuals COVID-19 POS who are currently asymptomatic at Travis. These individuals are being transferred to local hospital for evaluation and admission. Currently ASPR TEAM at Travis is ascertaining

(b) (5)

[redacted]

My team is working the details of transfer via aeromedical aircraft. Dr Kevin Yeskey and CAPT Scott Lee copied here are leading the operational planning
For 3 courses of action:

(b) (5)

[redacted]

Will advise as these course are pursued in parallel.

WILL NEED A POC at NIH to connect with Dr Yeskey and CAPT Lee ASAP to begin arrangements.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 14:01:20 +0000
To: Grigsby, Garrett (HHS/OS/OGA)
Subject: RE: CDC L2 THN Korea

Thanks, Garrett.

From: Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)
Sent: Saturday, February 22, 2020 8:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: CDC L2 THN Korea

Dr F,

Here it is: [redacted] (b) (6)

Sent from my iPhone

> On Feb 21, 2020, at 9:41 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:
>
> Garrett:
> Please send me the call in number for tomorrow's call at 11:00 AM
> Thanks,
> Tony
>
> ---
>
> **From:** Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)
> **Sent:** Friday, February 21, 2020 9:24 PM
> **To:** Phil Ferro [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> **Cc:** Zebley, Kyle (HHS/OS/OGA) <[redacted] (b) (6)>; Harrison, Brian (HHS/IOS) [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) <[redacted] (b) (6)
> **Subject:** Fwd: CDC L2 THN Korea
>
> Gentlemen,
>
> Can you please circulate this for discussion at the 11am call tomorrow?
>
> Many thanks!!
>
> Sent from my iPhone

Begin forwarded message:

> **From:** "Cetron, Marty (CDC/DDID/NCEZID/DGMQ)" (b) (6)
> **Date:** February 21, 2020 at 9:01:06 PM EST
> **To:** (b) (6) (OS/IOS)' (b) (6)>, "Harrison, Brian (HHS/IOS)" (b) (6), "Grigsby, Garrett (HHS/OS/OGA)" (b) (6)>
> **Cc**: "Redfield, Robert R. (CDC/OD)" (b) (6), "Cetron, Marty (CDC/DDID/NCEZID/DGMQ)" (b) (6)>
> **Subject: CDC L2 THN Korea**
>
> Per WHTF request CDC L2 THN RoK. Please share w Sec Biegun at DOS. We will post when he is ready presumably Sat
> Thks
> MSC

<Coronavirus L2 - South Korea.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 02:40:45 +0000
To: Grigsby, Garrett (HHS/OS/OGA)
Subject: FW: CDC L2 THN Korea
Attachments: Coronavirus L2 - South Korea.docx, ATT00001.htm

Garrett:
Please send me the call in number for tomorrow's call at 11:00 AM
Thanks,
Tony

From: Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)
Sent: Friday, February 21, 2020 9:24 PM
To: Phil Ferro [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6)>; Harrison, Brian (HHS/IOS) [redacted] (b) (6) Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)>
Subject: Fwd: CDC L2 THN Korea

Gentlemen,

Can you please circulate this for discussion at the 11am call tomorrow?

Many thanks!!

Sent from my iPhone

Begin forwarded message:

> **From:** "Cetron, Marty (CDC/DDID/NCEZID/DGMQ)" [redacted] (b) (6)>
> **Date:** February 21, 2020 at 9:01:06 PM EST
> **To:** [redacted] (b) (6) (OS/IOS)" [redacted] (b) (6)>, "Harrison, Brian (HHS/IOS)" [redacted] (b) (6), "Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)>
> **Cc:** "Redfield, Robert R. (CDC/OD)" [redacted] (b) (6), "Cetron, Marty (CDC/DDID/NCEZID/DGMQ)" [redacted] (b) (6)
> **Subject: CDC L2 THN Korea**
>
> Per WHTF request CDC L2 THN RoK. Please share w Sec Biegun at DOS. We will post when he is ready presumably Sat
> Thks
> MSC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 10:55:47 +0000
To: Kadlec, Robert (OS/ASPR/IO)
Subject: RE: Good morning

Bob:
No problem. Got you covered.
Best,
Tony

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>
Sent: Friday, February 21, 2020 5:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Good morning
Importance: High

Tony during today's table top as we walk through the placement I will ask you to walk through the Critical Information Requirements and ask you to highlight what we know, don't know and what we think about the this coronavirus. Let me know if you have any questions . Best Bob

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 21:26:05 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: HHS COVID 19 Response TTX Concept Placemat_Senior Leader_19Feb2020v2.pptx
Attachments: HHS COVID 19 Response TTX Concept Placemat_Senior Leader_19Feb2020v2.pptx, ATT00001.htm

Here it is

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kadlec, Robert (OS/ASPR/IO) <[redacted] (b) (6)>
Sent: Wednesday, February 19, 2020 6:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Fwd: HHS COVID 19 Response TTX Concept Placemat_Senior Leader_19Feb2020v2.pptx

Sent from my iPhone

Begin forwarded message:

> **From:** "Mackay, Thomas (OS/ASPR/EEAA)" [redacted] (b) (6)>
> **Date:** February 19, 2020 at 5:55:17 PM EST
> **To:** "Kadlec, Robert (OS/ASPR/IO)" [redacted] (b) (6), "Yeskey, Kevin (OS/ASPR/IO)" [redacted] (b) (6)>
> **Cc:** "Ford-Barnes, Arwenthia (OS/ASPR/IO)" [redacted] (b) (6)>, "Holland, Tara (OS/ASPR/EMMO)" [redacted] (b) (6)>, "Callahan, Victoria (OS/ASPR/IO) (CTR)" [redacted] (b) (6)>
> **Subject: HHS COVID 19 Response TTX Concept Placemat_Senior Leader_19Feb2020v2.pptx**

Gentlemen – attached is the latest version of the Placemat. The reason there are four slides is to give you the option of how the backside is laid out. Slide one and three are identical, the information on slides two and four are also identical just laid out differently. Standing by for corrections as necessary.

v/r Tom

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 04:02:40 +0000
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID);Giroir, Brett (HHS/OASH);Shuy, Bryan (OS/ASPR/IO);Schuchat, Anne MD (CDC/OD);Cetron, Marty (CDC/DDID/NCEZID/DGMQ);McGowan, Robert (Kyle) (CDC/OD/OCS);Grigsby, Garrett (HHS/OS/OGA);Zebley, Kyle (HHS/OS/OGA);Redfield, Robert R. (CDC/OD)
Subject: RE: Updated Draft in Track Changes
Attachments: Phases of USG nCoV Response _WHTF_13 Feb_PCC_Master.Final ASPR Edits - CDC BG.docx

HHS Team:
I have been following these various iterations closely over the past couple of hours and I agree with Dan. It looks like we have actually finally arrived at a good place and a point of comfortable agreement between ASPR and CDC. Am I correct and do we all agree with the latest tracked document (see attached)?
Thanks,
Tony

From: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b) (6)
Sent: Wednesday, February 19, 2020 10:54 PM
To: Giroir, Brett (HHS/OASH) (b) (6)>; Shuy, Bryan (OS/ASPR/IO) < (b) (6)>; Schuchat, Anne MD (CDC/OD) (b) (6)>; Cetron, Marty (CDC/DDID/NCEZID/DGMQ) < (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)>; Grigsby, Garrett (HHS/OS/OGA) (b) (6)>; Zebley, Kyle (HHS/OS/OGA) (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)>
Subject: RE: Updated Draft in Track Changes

Here with Adm Giroir's input as well. I think we may have arrived?
Dan.

From: Giroir, Brett (HHS/OASH) (b) (6)
Sent: Wednesday, February 19, 2020 10:06 PM
To: Shuy, Bryan (OS/ASPR/IO) (b) (6)>; Schuchat, Anne MD (CDC/OD) < (b) (6); Cetron, Marty (CDC/DDID/NCEZID/DGMQ) < (b) (6)>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)>; Grigsby, Garrett (HHS/OS/OGA) (b) (6)>; Zebley, Kyle (HHS/OS/OGA) < (b) (6)
Subject: RE: Updated Draft in Track Changes

(b) (5)

Please include me on the email exchange.

I am happy to point force the issue, which I can and will, but I assume it was an accidental ommission

BG

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: [redacted] (b) (6)

From: Giroir, Brett (HHS/OASH)
Sent: Wednesday, February 19, 2020 10:02 PM
To: Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)>; Schuchat, Anne MD (CDC/OD) <[redacted] (b) (6)>; Cetron, Marty (CDC/DDID/NCEZID/DGMQ) [redacted] (b) (6)>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [redacted] (b) (6)>; Anthony (NIH/NIAID) Fauci [E] [redacted] (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6); Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)>; Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6)>
Subject: RE: Updated Draft in Track Changes
Importance: High

(b) (5)
[redacted]

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: [redacted] (b) (6)

Begin forwarded message:

From: "Kadlec, Robert (OS/ASPR/IO)" <[redacted] (b) (6)>
Date: February 19, 2020 at 9:03:33 PM EST
To: "Schuchat, Anne MD (CDC/OD)" [redacted] (b) (6)>, "Cetron, Marty (CDC/DDID/NCEZID/DGMQ)" [redacted] (b) (6)>, "Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)" <[redacted] (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Cc: "McGowan, Robert (Kyle) (CDC/OD/OCS)" [redacted] (b) (6), "Shuy, Bryan (OS/ASPR/IO)" [redacted] (b) (6)>, "Grigsby, Garrett (HHS/OS/OGA)" [redacted] (b) (6), "Zebley, Kyle (HHS/OS/OGA)" [redacted] (b) (6)>
Subject: Updated Draft in Track Changes

Please accept my apologies for the delay I had a competing priority action but please find attached.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 01:38:52 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: CDC Media Statement: Update on the Diamond Princess Cruise Ship in Japan

I am very well aware of their official position and [redacted] (b) (5)

From: Billet, Courtney (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Tuesday, February 18, 2020 8:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Fwd: CDC Media Statement: Update on the Diamond Princess Cruise Ship in Japan

Making sure you have seen CDC's official update on the ship and efforts with Japan. [redacted] (b) (5)

From: "Hall, Bill (HHS/ASPA)" [redacted] (b) (6)>
Date: Tuesday, February 18, 2020 at 4:52:06 PM
Subject: FW: CDC Media Statement: Update on the Diamond Princess Cruise Ship in Japan

---

From: MMWR Media List <MMWR-MEDIA@LISTSERV.CDC.GOV> **On Behalf Of** Media@cdc.gov (CDC)
Sent: Tuesday, February 18, 2020 4:46 PM
To: MMWR-MEDIA@LISTSERV.CDC.GOV
Subject: CDC Media Statement: Update on the Diamond Princess Cruise Ship in Japan

Media Statement

For Immediate Release

Tuesday, February 18, 2020

Contact: CDC Media Relations

(404) 639-3286

Update on the Diamond Princess Cruise Ship in Japan

We commend the extraordinary efforts by the Government of Japan to institute quarantine measures onboard the *Diamond Princess*. While the quarantine potentially conferred a significant public health benefit in slowing transmission, CDC's assessment is that it may not have been sufficient to prevent transmission among individuals on the ship. CDC believes the rate of new infections on board, especially among those without symptoms, represents an ongoing risk. Therefore, to protect the health of the American public, all passengers and crew of the ship have been placed under travel restrictions, preventing them from returning to the United States for at least 14 days after they had left the *Diamond Princess*.

Currently, there are more than 100 U.S. citizens still onboard the *Diamond Princess* cruise ship or in hospitals in Japan. These citizens have been placed under the restrictions, as have the ship's other passengers and crew.

After disembarkation from the *Diamond Princess*, these passengers and crew will be required to wait 14 days without having symptoms or a positive coronavirus test result before they are permitted to board flights to the United States.

If an individual from this cruise arrives in the United States before the 14-day period ends, they will still be subject to a mandatory quarantine until they have completed the 14-day period with no symptoms or positive coronavirus test results.

Because of their high-risk exposure, there may be additional confirmed cases of COVID-19 among the remaining passengers on board the *Diamond Princess*.

CDC is committed to protecting the health and safety of all Americans. We continue to believe that the risk of exposure to COVID-19 to the general public in the United States is currently low. The U.S. Government is taking these measures to protect the *Diamond Princess* passengers and crew, their loved ones, the traveling public, and communities within the United States.

###

U.S. Department of Health and Human Services

CDC works 24/7 protecting America's health, safety and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America's most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.

If you would like to unsubscribe from this ListServ LIST, please send an email to LIST@cdc.gov, enter CDC in the email Subject, and include the following "one" line in the Body of the email: signoff MMWR-MEDIA

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 20:16:44 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Bcc: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Larry, does NIH have a single point person through which all Coronavirus intel bubbles up?

Larry:
Thanks for the note. [redacted] (b) (5)
[redacted] (b) (5) The person who usually subs for me when I cannot be on a call or at a meeting is Hilary Marston. She is up to speed on virtually all this stuff and is the name that you should send to Paul. You can tell Paul that he should channel everything through me and I can turf to Hilary when necessary and appropriate. Hilary is right here in my office and is very close to me.
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tabak, Lawrence (NIH/OD) [E] <[redacted] (b) (6)
Sent: Monday, February 17, 2020 2:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: Larry, does NIH have a single point person through which all Coronavirus intel bubbles up?

Tony
Do want this to be one of your folks or me?
Thanks
Larry

Sent from my iPhone

Begin forwarded message:

> **From:** "Mango, Paul (HHS/IOS)" [redacted] (b) (6)>
> **Date:** February 17, 2020 at 2:45:52 PM EST
> **To:** "Tabak, Lawrence (NIH/OD) [E]" <[redacted] (b) (6)
> **Subject: Larry, does NIH have a single point person through which all Coronavirus intel bubbles up?**
>
> Larry- we are trying to integrate some of the department communications channels. Dr Fauci is on just about every call, but do you have someone else as well who is representing NIH and would be aware of any developments?
>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 15 Feb 2020 18:57:22 +0000
To: Harrison, Brian (HHS/IOS)
Subject: FW: WaPo - fact check on coronavirus story

FYI. See below.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Saturday, February 15, 2020 1:50 PM
To: Oakley, Caitlin B. (OS/ASPA) [redacted] (b) (6)>
Cc: Stecker, Judy (OS/IOS) [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: WaPo - fact check on coronavirus story

Caitlin/Judy:

I had a long and good conversation with Yasmeen Abutaleb and went over (and countered) all of the issues that had any negative connotations for the Secretary and/or the President. I spoke on the record and gave her permission to use my quotes as she so wishes. Mission accomplished.

Best regards.,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)

FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Oakley, Caitlin B. (OS/ASPA) [redacted] (b) (6)
Sent: Saturday, February 15, 2020 11:31 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Stecker, Judy (OS/IOS) [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: WaPo - fact check on coronavirus story

Dr. Fauci—Thank you for the chat. Here is the reporter's contact info and she is expecting your call.

Yasmeen Abutaleb
The Washington Post
Health policy reporter
o: 202-334-8387 c: [redacted] (b) (6)
Yasmeen.Abutaleb@washpost.com

Caitlin B. Oakley
Deputy Assistant Secretary, National Spokesperson
Office of the Assistant Secretary for Public Affairs
U.S. Department of Health and Human Services
[redacted] (b) (6)

From: Abutaleb, Yasmeen <Yasmeen.Abutaleb@washpost.com>
Sent: Friday, February 14, 2020 4:40 PM
To: Oakley, Caitlin B. (OS/ASPA) [redacted] (b) (6)>; McKeogh, Katherine (OS/ASPA) [redacted] (b) (6)
Subject: WaPo - fact check on coronavirus story

Hey Caitlin and Katie,

Happy Friday! I'm working on a story about the coronavirus response, aiming to publish tomorrow. The story is about how President Trump has praised China and President Xi, but that has made some of his advisors uncomfortable given the lack of transparency from China and the inability to get CDC scientists in to the country. We also have some details about the response and the task force, and some disagreements that have arisen. I've listed the points we have in the story that pertain to HHS – would you be able to take a look, let me know if there are any issues and potentially provide a comment? I included some quotes from Sec. Azar's interviews on Friday with CNN and CNBC but also happy to include a quote from the agency.

I realize I'm sending this at the end of the day, so would it be possible for you to get back to me by 1 pm tomorrow? Let me know what works on your end. Thanks so much.

- President Trump has lavished praise on China and its ruler, Xi Jinping, for its handling of the growing coronavirus outbreak – a posture some in his administration are growing increasingly uncomfortable with as his advisors remain concerned about China's transparency and handling of the epidemic.
- Trump's praise towards Xi has irked some advisors, who say those comments and others about how the virus will likely behave reflect how the president is being briefed, underscoring tensions within the administration over its handling of the outbreak and the message it should be sending to the American public.
- Worries about the market and tenuous negotiations with China over a trade deal have played a large role in influencing Trump's friendly posture.
- Trump has told advisors he does not want the administration to do or say anything that would further spook the markets, but remains worried that any large-scale outbreak in the U.S. could hurt his reelection bid.
- For weeks, the administration's messaging was that the threat to the American public remained low and the virus was not spreading within communities. But some advisors pushed for a more balanced message because they expect there to eventually be some community spread as the outbreak grows, and the administration has since adjusted its message to reflect that.
- In an effort to keep Trump calm and restrained, Azar has been briefing the president that "everything is under control, totally under control," which has kept Trump from doing or saying anything drastic.
- HHS officials have also told Trump that the number of infections could go down in the spring when it gets warmer, which is mainly an educated guess.
- Some officials have complained that Trump's comments emanate from his briefings with Azar, who they say has sought to control the response. He has told other doctors, including Anthony Fauci, not to get too far into the details of the virus and outbreak with Trump. Instead, Azar has instructed doctors to let him handle it.
- Azar has also wanted to be the one to announce major updates about the administration's response to the virus. On Thursday, he briefed the Senate Finance Committee that the CDC would use public health labs in five cities that normally test for influenza to also test for coronavirus, taking state health officials by surprise.
- Some officials said the response has become smoother and better coordinated in recent weeks.

Yasmeen Abutaleb
The Washington Post
Health policy reporter
o: 202-334-8387 c: (b) (6)
@yabutaleb7

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 21:07:26 +0000
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Cc: Redfield, Robert R. (CDC/OD);Cetron, Marty (CDC/DDID/NCEZID/DGMQ);Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)
Subject: RE: Wpost: New developments suggest coronavirus incubation could be longer than 14 days, as global infections rise

Sounds good to me. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)
Sent: Saturday, February 22, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>; Cetron, Marty (CDC/DDID/NCEZID/DGMQ) [redacted] (b) (6)>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [redacted] (b) (6)>
Subject: Re: Wpost: New developments suggest coronavirus incubation could be longer than 14 days, as global infections rise

[redacted] (b) (5) Sound good?

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, February 22, 2020 3:12:02 PM
To: Redfield, Robert R. (CDC/OD) [redacted] (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>; Cetron, Marty (CDC/DDID/NCEZID/DGMQ) [redacted] (b) (6)>
Subject: FW: Wpost: New developments suggest coronavirus incubation could be longer than 14 days, as global infections rise

Folks:

[redacted] (b) (5)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Saturday, February 22, 2020 10:52 AM
Subject: Wpost: New developments suggest coronavirus incubation could be longer than 14 days, as global infections rise

New developments suggest coronavirus incubation could be longer than 14 days, as global infections rise

Medical workers in protective suits gather Friday at a temporary hospital at Tazihu Gymnasium in Wuhan in central China's Hubei province. (AP)

By
Anna Fifield,
Min Joo Kim and
Simon Denyer

Feb. 22, 2020 at 10:17 a.m. EST

There are new indications that the incubation period for the virus could be longer than the currently believed 14 days, with patients testing positive after much longer quarantine periods. This development came as infections rose in South Korea, Japan, Iran and Italy and the head of the World Health Organization warned that the window for stopping the epidemic was narrowing.

Here's what we know:

- Chinese leader Xi Jinping has been advised that the situation in Wuhan "remains grim and complex."
- South Korea and Japan both reported a sharp spike in cases Saturday, with the number of cases in South Korea doubling in a day. A fifth person died in Iran from the virus, while Italy now has 50 confirmed cases, making it the largest hot spot in Europe.
- China reported only 397 new cases Saturday, as the rate of increase continued to decline, but an additional 109 people have died. There continues to be a great deal of skepticism about China's numbers as the criteria for diagnosing coronavirus keep changing.
- A team of international epidemic experts had Wuhan added to their itinerary in China, following questions about why they wouldn't go to the center of the coronavirus outbreak that has caused more than 2,000 deaths in the country.
- Scientists in China said they had isolated coronavirus strains in urine, raising the possibility that it might be transmissible that way, as well as through fecal matter and respiratory droplets.

BEIJING — Scientists are studying reports that the incubation period for coronavirus could be longer than the currently believed 14 days, potentially casting doubt on current quarantine criteria for containing the virus amid an increasingly urgent effort to stop the epidemic from spreading in northeast Asia and across the world.

South Korea and Japan both reported a sharp spike in cases Saturday, while in China, an additional 109 people died and a fifth person died from the virus in Iran. Italian authorities on Saturday said the country was seeing a sudden rise in coronavirus cases, with roughly 50 confirmed in the past two days — an outbreak that represents the largest yet across Europe.

Meanwhile, scientists in China reported indications that the virus might be transmissible through urine. A team of experts from the World Health Organization was due to arrive Saturday in Wuhan, the epicenter of the coronavirus outbreak.

WHO director-general Tedros Adhanom Ghebreyesus on Friday stressed the urgency of containing the spread of the coronavirus, after cases were reported earlier in Iran and Lebanon.

“Although the window of opportunity is narrowing to contain the outbreak, we still have a chance to contain it,” he told reporters in Geneva. “If we don’t, if we squander the opportunity, then there will be a serious problem on our hands.”

Chinese leader Xi Jinping, who has not visited Wuhan since the outbreak began, was briefed that the situation in the city and in surrounding Hubei province “remains grim and complex,” according to a report by the official Xinhua News Agency published Saturday.

“The nationwide inflection point of the epidemic has not yet arrived,” the report said after a meeting of Communist Party leaders.

China’s National Health Commission reported Saturday that 397 new cases of coronavirus had been diagnosed Friday, taking the total to more than 76,000. The rate of infection outside Hubei appears to have slowed markedly, although there has been a great deal of confusion about the statistics this week as officials have repeatedly changed the criteria for confirming cases.

Among the new cases discovered Friday were a 70-year-old man in Hubei who was confirmed as infected after 27 days in isolation, while a man in Jiangxi province tested positive after 14 days of centralized quarantine and five days of isolation at home. On Thursday, authorities reported that a man in Hubei had tested positive for coronavirus after what appeared to be a 38-day incubation period with no symptoms.

Coronavirus cases in South Korea skyrocket; cases triple in Japan

In Seoul, the Korea Centers for Disease Control and Prevention reported Saturday that 229 additional cases of the coronavirus had been detected, taking the total to 433, more than doubling in the space of a day. This makes it the worst-affected country outside China.

“Apart from the Diamond Princess cruise ship, [South] Korea now has the most cases outside China, and we’re working closely with the government to fully understand the transmission dynamics that led to this increase,” Tedros said.

The majority of the new cases have been traced to existing clusters at a church in southern city of Daegu and a hospital in nearby Cheongdo County, according to the KCDC.

The South Korean government has designated Daegu and surrounding North Gyeongsang province as “special care zones” where containment efforts and support will be concentrated.

More than half of South Korea’s cases are connected to Daegu branch of the Shincheonji Church of Jesus the Temple of the Tabernacle of the Testimony.

Since members of the church attended a funeral at nearby Cheongdo Daenam hospital, 111 coronavirus cases have been reported there, including two patients who died from the virus.

The mass infection at the hospital is centered on its locked psychiatric ward, where a confined environment could have aggravated transmissions, said Jung Eun-Kyeong, director of the KCDC.

A man in his 40s was found dead at his home in city of Gyeongju, east of Daegu, after becoming infected with the virus. He is the third person to die from the virus in South Korea.

Trump was not told coronavirus-infected Americans would be flown home from cruise ship

In Japan, the number of coronavirus cases rose to 121 on Saturday, more than tripling in a week. That number excludes the 634 people on board the Diamond Princess who contracted the virus.

One of the latest cases was a teacher in her 60s at a public junior high school east of Tokyo, who complained of nausea while working. The mayor of Chiba city said the school will be closed until Wednesday, public broadcaster NHK reported.

The teacher had not traveled abroad in the past two weeks and has no record of having been in contact with a known infected person, underlining the fact that the virus is now spreading almost invisibly throughout the country, experts say.

Quarantines in effect in parts of Italy amid sudden spike in cases

As numbers suddenly rose in Italy, the government has scrambled to contain the new outbreak, asking some 50,000 people to stay indoors and suspending all public events — including religious ceremonies and school — in 10 small towns to the south of Milan.

Until a few days ago, Italy had seen only three confirmed infections, including a pair of Chinese tourists.

“There is quite an evident contagion, a very strong one,” said Giulio Gallera, health chief of the northern Lombardy region, which has seen the majority of the cases.

Italian officials on Friday attributed the country’s first death to the coronavirus, and on Saturday said that a 77-year-old woman had also tested positive for the virus after being found dead in her home. But Italian authorities said the woman suffered from other health conditions, and were unsure if it was the virus that had killed her.

As of Saturday afternoon, there were 39 confirmed cases in the prosperous Lombardy region, which includes the country’s financial hub, Milan. There were another 12 cases in the neighboring northern region of Veneto.

The regional president of Veneto, Luca Zaia, said it is becoming harder to figure out how the virus is jumping from one place to the next.

“It goes to show you that having other cases of contagion is absolutely possible,” Zaia said.

According to Italian media reports, one of the first people to come down with the virus was a 38-year-old who’d had dinner with somebody who had just come back from China. But some three weeks passed between that dinner and the time the man came down with a fever. In between, he ran a half-marathon, played soccer and traveled to several towns, according to La Repubblica, a major Italian daily.

Iran, meanwhile, announced its fifth death from the virus, raising the country’s overall total confirmed cases to twenty eight.

Efforts to clear the Diamond Princess cruise ship continue

Meanwhile, tests are continuing on the crew members on board the Diamond Princess. At least 74 crew members have so far been found to have the virus.

All of the passengers have now been tested and almost all have left the ship, either to go home if they tested negative, to local hospitals or government facilities if they have the virus, or back to their home countries.

Some passengers were asked to stay on board to serve an additional quarantine if their cabin mate contracted the virus, but this group is also disembarking Saturday to serve out the rest of their quarantine in a government facility, local media reported.

In China’s ‘war’ on coronavirus, hospitals turn away other patients — with dire results

More than 200 port calls in Japan by international cruise ships have been canceled since the beginning of February due to the coronavirus outbreak, a Kyodo News survey showed Saturday, with the lost revenue from passengers coming ashore dealing another blow to Japan's weak economy.

Controversy continues to simmer about the infection control procedures on board the ship, after a doctor complained on Tuesday about "chaotic" and scary conditions on board.

Six people working on the boat or with the passengers, including four government officials, a medic and an ambulance driver, have contracted the virus.

Media reports questioned why about 90 government officials who worked on the ship have returned to work without being tested for the coronavirus. Asked about this, Health Minister Katsunobu Kato said the government is "trying to confirm what operations staff were involved in specifically."

American woman in Malaysia declared free of coronavirus

The 83-year-old woman who tested positive for the coronavirus when she arrived at Kuala Lumpur airport after disembarking in Cambodia from the MS Westerdam cruise ship has recovered, Malaysia health authorities said Saturday.

The woman "is showing good improvement and signs of recovery, however, she is still being monitored and managed in hospital for a slight cough," Malaysia's director general of health, Noor Hisham Abdullah, said in a statement.

The woman repeatedly tested negative while on board the ship and when she disembarked in Sihanoukville, then twice tested positive while transiting in Kuala Lumpur airport on Feb. 15. That set off a global scramble to track the hundreds of other passengers who had also disembarked then boarded planes bound for home.

The woman was taken to a hospital and given antiviral treatment and supplementary oxygen, and she showed improvement after 72 hours of treatment initiation, Abdullah said. Two more tests, conducted 24 hours apart, both came back negative for coronavirus.

But the U.S. Centers for Disease Control and Prevention cast doubt on whether the woman was ever infected, saying she "never had coronavirus to our knowledge."

"I have confirmed that all the passengers were tested, and they have come back negative for coronavirus, including the person who initially tested positive," USA Today quoted CDC spokesperson Richard Quartarone as saying. The woman "may have had a respiratory illness, but if she did, it was not covid-19," he said, using the official name for the virus.

Cambodia's Ministry of Health had previously cleared the 747 crew members who were still on board the Westerdam and the 781 passengers who were still in the country of coronavirus infection.

Chinese scientists isolate coronavirus strains in urine as WHO prepares visit

Separately, scientists in China are continuing to study how the virus is transmitted.

A research team led by renowned Chinese pulmonologist Zhong Nanshan had isolated live coronavirus strains in urine samples from infected patients, Zhao Jincun, a respiratory expert at the State Key Laboratory, told reporters in Guangdong on Saturday.

The team of scientists had previously said the virus, in addition to being carried in respiratory droplets, appeared to be transmissible through fecal matter, underscoring the need to practice good hand washing as a preventive measure.

Zhao did not directly say that the virus could be transmitted through urine, simply noting that the strains had been isolated and that this had implications for public health control. They are continuing to work on isolating the virus and on a cure, the Guangzhou Daily reported.

But he said people should pay more attention to personal and family hygiene to prevent the spread of the virus and recommended frequently washing hands, closing the toilet lid before flushing and making sure bathroom drains are not blocked.

WHO experts have also been on an investigative mission in China this week, holding meetings in Beijing and traveling to the provinces of Sichuan and Guangdong. But they had not been scheduled to travel to Wuhan, where the outbreak began at a live animal market and which remains under strict lockdown in an effort to contain the virus.

This had led to speculation that the Chinese government, which has come under fire for its slow response to the outbreak and where medical workers are stretched to the limit, did not want the experts to visit.

But the WHO said late Friday that the experts would be traveling to the center of the outbreak on Saturday, although they gave no further information about their itinerary.

Kim reported from Seoul and Denyer from Tokyo. Lyric Li in Beijing, Akiko Kashiwagi in Tokyo and Chico Harlan and Stefano Pitrelli in Rome contributed reporting.

Two Beijing hospitals quarantined amid fears coronavirus infections will spike in the capital

Confusion mounts over China's counting methods as coronavirus numbers swing wildly

Coronavirus claims lives of two passengers from Diamond Princess cruise ship, Japanese media says

Today's coverage from Post correspondents around the world

Like Washington Post World on Facebook and stay updated on foreign news

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 18:35:29 +0000
To: Mermin, Jonathan (CDC/DDID/NCHHSTP/OD)
Subject: RE: COVID-19

Jono:

Many thanks for your kind note. Much appreciated. I hope that all is well with you.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mermin, Jonathan (CDC/DDID/NCHHSTP/OD) [redacted] (b) (6)>
Sent: Saturday, February 22, 2020 1:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: COVID-19

Tony:

I just wanted to send you a quick note of compliment. I have seen and heard you speak on COVID-19 over the past few weeks, eloquently, accurately, and as definitively as the data allow. Outstanding work.

Best,

Jono

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 11:59:09 +0000
To: Cetron, Marty (CDC/DDID/NCEZID/DGMQ);Collins, Francis (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Charles, Julia (CDC/OD/OCS);Eidex, Rachel Barwick (CDC/DDID/NCEZID/DGMQ)
Subject: RE: Infectious disease advice for NSO Asia tour

Thanks, Marty.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cetron, Marty (CDC/DDID/NCEZID/DGMQ) (b) (6)>
Sent: Friday, February 21, 2020 6:31 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Charles, Julia (CDC/OD/OCS) (b) (6); Eidex, Rachel Barwick (CDC/DDID/NCEZID/DGMQ) (b) (6)>
Subject: Re: Infectious disease advice for NSO Asia tour

Tony and Francis
Happy to be a POC for Deborah. She can text me (b) (6) and we can arrange a time to speak. My cell reception in EOC not great. Alternatively EOC can track me down (b) (6)

Email pretty clogged these days...
Best,
MSC

Get [Outlook for iOS]

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Friday, February 21, 2020 5:46:50 AM
To: Collins, Francis (NIH/OD) [E] (b) (6)

Cc: Cetron, Marty (CDC/DDID/NCEZID/DGMQ) [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Infectious disease advice for NSO Asia tour

Francis:
[redacted] (b) (5)
[redacted] (b) (5) The best person in the world for this is Marty Cetron at the CDC. I am copying him on this e-mail. Perhaps he can directly get back to you.
Best,
Tony

-----Original Message-----
From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Friday, February 21, 2020 5:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Infectious disease advice for NSO Asia tour

Hi Tony,

See below from Deborah Rutter, the head of the Kennedy Center. [redacted] (b) (5)

Who would you recommend at NIH or CDC to be a contact?

Francis

-----Original Message-----
From: Rutter, Deborah F. <DFRutter@Kennedy-Center.org>
Sent: Thursday, February 20, 2020 5:59 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Ginstling, Gary <GGinstling@Kennedy-Center.org>
Subject: Infectious disease advice for NSO Asia tour

Dear Francis
As you may know, the National Symphony Orchestra has long had an Asia your on its schedule for March this year, leaving in just two weeks or so. The China portion of the tour was cancelled a few weeks ago but the Japan portion of the trip has been sustained. Now, with increased focus on Japan, some of the members and our management are looking for additional advice on travel concerns and any infectious disease warning/direction. Would you have someone amongst your brilliant colleagues who could be a resource to our team?

I have included Gary Ginstling on this email as he is our Executive Director of the NSO. Thank you so much for any direction you can offer us!

Deborah

This e-mail message is intended only for the recipient(s) named above. This message may contain trade secrets, attorney-client communication, or other privileged and confidential information. Any review, re-transmission, dissemination, reproduction or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the Sender and delete the material from any computer.

From: [redacted] (b) (6)
Sent: Tue, 18 Feb 2020 15:41:35 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Lunch with AMB at Thai Residence on 27 Feb or 4 March

Let us discuss.

Begin forwarded message:

> **From:** "Wolfe, Mitchell (CDC/OD)" [redacted] (b) (6)
> **Date:** February 18, 2020 at 1:08:55 PM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6),
> [redacted] (b) (6)
> **Subject: FW: Lunch with AMB at Thai Residence on 27 Feb or 4 March**
>
> Tony,
>
> The Thai Ambassador has invited you, and CDC, to lunch at his residence either 27 Feb or 4 March. They didn't have your contact and asked (per below) if I could contact you to ask. Dr. Redfield is in Washington, DC on 27 Feb and I will ask if he wants to attend. If you or your staff can let me know, I will get back with them.
>
> Best regards,
>
> Mitchell Wolfe, MD, MPH
> RADM, USPHS
> Chief Medical Officer, Office of the Director
> Centers for Disease Control and Prevention
> Ph: [redacted] (b) (6)
>
> **From:** Panupat Chavananikul <panupatc@thaiembdc.org>
> **Sent:** Tuesday, February 18, 2020 12:42 PM
> **To:** Wolfe, Mitchell (CDC/OD) [redacted] (b) (6)
> **Cc:** Chuliepote Isarankura Na Ayudhaya <chuliepotei@thaiembdc.org>
> **Subject:** Lunch with AMB at Thai Residence on 27 Feb or 4 March
>
> Dear P Mitch krub,
> Ref: invitation for Lunch on 27 Feb OR 4 March
>
> 1. Hope all is well with you. Hopefully you had some rest last weekend. Since you were living in Thailand for a while you must be missing authentic Thai food. Ambassador Thani

wiould like to extend his invitation to you and CDC colleagues to have lunch at Thai residence **either on Thursday 27 Feb or Wednesday 4 March at 12.30 pm**. His residence located at (b) (6) You may invite your colleagues who involve in Coronavirus or Thailand, and please let me know their name and ranking as well as your available date.

For the Embassy 's side, there will be Ambassador + Ms. Chuliepote + me + and some of our colleagues.

2. Also, Ambassador Thani and I attended Dr. Tony Fauci's briefing, organized by NSC, on Feb 6., but unfortunately we didn't have much time to talk to him. Dr. Fauci also received Prince Mahidol award back in 2013. Ambassador would also like to have him join our lunch at his residence as well.

Is it possible that you may reach out to him to see whether he can have lunch with us or not, OR you may provide me his contact details.

Thank you krub &Best wishes,

Panupat (boat)

--
Mr.Panupat Chavananikul
Counsellor (Consul)
Royal Thai Embassy
Cell (b) (6)
Work 202 640-5308

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 14:57:27 +0000
To: Redfield, Robert R. (CDC/OD)
Subject: RE: Severity Assessment for U.S. Response - CDC
Attachments: Severity Assessment for U.S. Response - CDC.docx

Bob:

See my minor tracked edits.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Redfield, Robert R. (CDC/OD) [redacted] (b) (6)
Sent: Tuesday, February 18, 2020 9:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: Severity Assessment for U.S. Response - CDC

Take a look ?edits thoughts
Dr. Robert Redfield

From: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [redacted] (b) (6)
Sent: Monday, February 17, 2020 10:48:48 PM
To: Redfield, Robert R. (CDC/OD) [redacted] (b) (6)
Cc: Schuchat, Anne MD (CDC/OD) [redacted] (b) (6)>; Cetron, Marty (CDC/DDID/NCEZID/DGMQ) [redacted] (b) (6)>; Butler, Jay C. (CDC/DDID/OD) [redacted] (b) (6)>
Subject: Severity Assessment for U.S. Response - CDC

Dr. Redfield:

Here is the severity assessment in response to your request from yesterday. Take a look and see if this addresses your request.

Dan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 12:03:04 +0000
To: Marks, Peter;Schuchat, Anne MD (CDC/OD)
Cc: Cho, David S (CBER) (FDA/CBER);Munster, Vincent (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Covid-19 Survival on Surfaces

Peter:

Vincent Munster at NIAID's RML has done work on this. I am copying him on this e-mail.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marks, Peter [redacted] (b) (6)>
Sent: Wednesday, February 19, 2020 6:41 AM
To: Schuchat, Anne MD (CDC/OD) [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Cho, David S (CBER) (FDA/CBER) [redacted] (b) (6)
Subject: Covid-19 Survival on Surfaces

Dear Anne and Tony,

I am sorry to bother you, but I am hoping that you can direct me to anyone at NIAID or CDC who is working on the survival of Covid-19 on surfaces. This could include shipping boxes, but also on various products and other perishable items. The food safety people here at FDA are quite concerned about the latter, given published reports of differential coronavirus survival on various surfaces.

If it turns out that this has not been evaluated, or is not in the process of being evaluated, we are happy to work on this in our BSL-3 labs, which are now in receipt of the virus.

Thanks so much for any direction that you can provide.

Best Regards,
Peter

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 15 Feb 2020 12:55:47 +0000
To: Gilman, James (NIH/CC/OD) [E];Collins, Francis (NIH/OD) [E];Gottesman, Michael (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E];Schwetz, Tara (NIH/OD) [E]
Cc: Holland, Steven (NIH/NIAID) [E];Johnson, Alfred (NIH/OD) [E];McGowan, Colleen (NIH/OD/ORS) [E];Schmitt, James (NIH/OD/ORS) [E]
Subject: RE: COVID-19 messaging

[redacted] (b) (5)

From: Gilman, James (NIH/CC/OD) [E] [redacted] (b) (6)
Sent: Friday, February 14, 2020 11:32 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Gottesman, Michael (NIH/OD) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); Schwetz, Tara (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6); McGowan, Colleen (NIH/OD/ORS) [E] [redacted] (b) (6); Schmitt, James (NIH/OD/ORS) [E] [redacted] (b) (6)
Subject: Re: COVID-19 messaging

[redacted] (b) (5)

Jim

From: "Collins, Francis (NIH/OD) [E]" [redacted] (b) (6)>
Date: Friday, February 14, 2020 at 8:04:30 PM
To: "Gottesman, Michael (NIH/OD) [E]" [redacted] (b) (6)>, "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)>, "Schwetz, Tara (NIH/OD) [E]" [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
Cc: "Holland, Steven (NIH/NIAID) [E]" [redacted] (b) (6)>, "Johnson, Alfred (NIH/OD) [E]" [redacted] (b) (6)>, "McGowan, Colleen (NIH/OD/ORS) [E]" < [redacted] (b) (6), "Schmitt, James (NIH/OD/ORS) [E]" [redacted] (b) (6), "Gilman, James (NIH/CC/OD) [E]" [redacted] (b) (6)>
Subject: RE: COVID-19 messaging

This seems reasonable. [redacted] (b) (5) [redacted] Looping in Jim Gilman.

FC

From: Gottesman, Michael (NIH/OD) [E] < [redacted] (b) (6)>
Sent: Friday, February 14, 2020 6:03 PM

To: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Schwetz, Tara (NIH/OD) [E] [redacted] (b) (6); Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6); McGowan, Colleen (NIH/OD/ORS) [E] <[redacted] (b) (6)>; Schmitt, James (NIH/OD/ORS) [E] <[redacted] (b) (6)>
Subject: COVID-19 messaging

We have had many requests for additional guidance concerning staff potentially exposed to COVID-19.
OMS has prepared the attached message which has been reviewed by Steve Holland and HR.
The intent is to send this from OMS to all hands.
Michael

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 15 Feb 2020 02:23:37 +0000
To: Holland, Steven (NIH/NIAID) [E]
Subject: RE: COVID-19 messaging
Attachments: COVID-smh - with Fauci edits.docx

Steve:

See my tracked edits. [redacted] (b) (5) (b) (5)

Thanks,
Tony

From: Holland, Steven (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, February 14, 2020 9:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: COVID-19 messaging

Tony,

Could you please look at the attached and make any edits you think would help. [redacted] (b) (5), (b) (5)

Steve

--
Director, Division of Intramural Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960
[redacted] (b) (6) voice
301-480-4507 fax
[redacted] (b) (6) email

Assistant lab: Eva Portillo
[redacted] (b) (6) email
[redacted] (b) (6) voice

Assistant to SD: Beth Schmidt

[redacted] (b) (6)
[redacted] (b) (6) voice

From: "Gottesman, Michael (NIH/OD) [E]" [redacted] (b) (6)>
Date: Friday, February 14, 2020 at 6:12 PM
To: "Schmitt, James (NIH/OD/ORS) [E]" [redacted] (b) (6)
Cc: "Moss, Bradley (NIH/OD/ORS) [E]" [redacted] (b) (6), Steven Holland
[redacted] (b) (6)
Subject: Re: COVID-19 messaging

[redacted] (b) (5)
[redacted]. This can wait until next week.
Michael

From: "Schmitt, James (NIH/OD/ORS) [E]" [redacted] (b) (6)
Date: Friday, February 14, 2020 at 6:07 PM
To: "Gottesman, Michael (NIH/OD) [E]" <[redacted] (b) (6)>
Subject: FW: COVID-19 messaging

I meant to copy you on this Michael. Jim

From: Schmitt, James (NIH/OD/ORS) [E]
Sent: Friday, February 14, 2020 6:07 PM
To: Moss, Bradley (NIH/OD/ORS) [E] [redacted] (b) (6)>; Bailin, Heike
[redacted] (b) (6)
Cc: Newcomer, Derek (NIH/OD/ORS) [E] [redacted] (b) (6)
[redacted] (b) (6)>; Wheeland, Daniel (NIH/OD/ORF) [E] [redacted] (b) (6);
McGowan, Colleen (NIH/OD/ORS) [E] [redacted] (b) (6)>; Tosten, Timothy
(NIH/OD/ORS) [E] <[redacted] (b) (6)
Subject: FW: COVID-19 messaging

Hi Brad,

It sounds like Dr. Gottesman wants this sent from OMS to everyone.

I don't know how to do that. Can you help us with this and how soon can it be sent?

I'm heading out of town and won't return to the clinic until Tuesday. Dr. Bailin will be in charge of OMS in my absence.

Jim

James M. Schmitt, M.D., M.S.
Medical Director
Occupational Medical Service, DOHS

National Institutes of Health
10 Center Drive
Bethesda, MD 20892-1584
[redacted] (b) (6)

From: Gottesman, Michael (NIH/OD) [E] <[redacted] (b) (6)>
Sent: Friday, February 14, 2020 6:03 PM
To: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Schwetz, Tara (NIH/OD) [E] [redacted] (b) (6); Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6); McGowan, Colleen (NIH/OD/ORS) [E] [redacted] (b) (6)>; Schmitt, James (NIH/OD/ORS) [E] [redacted] (b) (6)>
Subject: COVID-19 messaging

We have had many requests for additional guidance concerning staff potentially exposed to COVID-19. OMS has prepared the attached message which has been reviewed by Steve Holland and HR.
The intent is to send this from OMS to all hands.
Michael

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 15 Feb 2020 02:08:57 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C];Marston, Hilary (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Rapid instrument-free NAAT for COVID-19
Attachments: VisbyMedical_TechWatch_Feb2020_nCoV_NIH.pdf

See attachment as per prior e-mail.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Friday, February 14, 2020 9:08 PM
To: Gary K. Schoolnik [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6); Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Rapid instrument-free NAAT for COVID-19

Gary:
Thanks for the note. I would be happy to discuss this with you. Please have your office contact my Special Assistant, Patty Conrad, (copied here) to set up a mutually convenient time when we can chat.
Best regards,
Tony

From: Gary K. Schoolnik [redacted] (b) (6)>
Sent: Friday, February 14, 2020 6:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>
Cc: Adam de la Zerda < [redacted] (b) (6)
Subject: Rapid instrument-free NAAT for COVID-19

Dear Tony,

In addition to my role as a Stanford Medical School professor, I am the Chief Medical Officer of Visby Medical, a relatively new Silicon Valley diagnostics company focused on rapid detection of infectious agents. Visby Medical has developed a rapid (~25 min sample-to-answer) palm-sized, 40 cycle PCR (or RT-PCR) single-use device that does not require an instrument; it is used once, and then discarded or recycled. [redacted] (b) (4) The device is stable at room temperature for up to two years and thus it could be deployed widely.

We are seriously considering using this platform to develop a rapid test to detect COVID-19. Proof of principles that have been achieved toward that end are our demonstration that the device can use two-step RT-PCR to detect influenza A and B in NP swab samples. The main features of the device are described in the brief accompanying PDF.

I write now because we are unsure, if we were to produce a COVID-19 device, how it would be deployed, by whom it would be used and who might be willing to purchase it. I would be very grateful if you might be able to speak briefly with me and my colleagues about these open questions. I am convinced this device can meet a major unmet need in clinical care and disease control for this epidemic and we, as a group, want to make a difference. Your advice would be invaluable as we weigh the risks and benefits of pivoting the company to this application.

With all best wishes; I hope all is well with you and your family.
gary

Gary Schoolnik, M.D.
Professor of Medicine
Stanford Medical School
Attending Physician (Internal Medicine, Infectious Diseases)
Stanford University Hospital
Chief Medical officer
Visby Medical

From: [redacted] (b) (6)
Sent: Fri, 14 Feb 2020 18:45:53 -0500
To: Julia Belluz
Subject: Re: call

My pleasure!

> On Feb 14, 2020, at 6:10 PM, Julia Belluz <julia.belluz@vox.com>wrote:
>
> Thank you so much for making the time to comment at what I know is a crushingly busy time. As usual don't hesitate to ping if you have any further comments or questions! Julia
>
> https://www.vox.com/2020/2/14/21134473/coronavirus-outbreak-singapore-us-symptoms-pandemic
>
> Sent from my iPhone
>
>> On Feb 14, 2020, at 1:21 PM, Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>wrote:
>>
>> Julia:
>> I just called you now (7:20 AM Washington, DC time) and got mvoice mail in German that I could not understand. You can call me at [redacted] (b) (6)
>> Thanks,
>> Tony
>> **Anthony S. Fauci, MD**
>> **Director**
>> **National Institute of Allergy and Infectious Diseases**
>> **Building 31, Room 7A-03**
>> **31 Center Drive, MSC 2520**
>> **National Institutes of Health**
>> **Bethesda, MD 20892-2520**
>> **Phone:** [redacted] (b) (6)
>> **FAX: (301) 496-4409**
>> **E-mail:** [redacted] (b) (6)
>> **The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or**

any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 21:09:40 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Your Expertise requested/COVID-19 Forum

OK. Let us discuss. As long as it is remote...

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, February 14, 2020 3:45 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Your Expertise requested/COVID-19 Forum

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Roache, Christina <[redacted] (b) (6)>
Sent: Friday, February 14, 2020 3:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Your Expertise requested/COVID-19 Forum

Dear Dr. Fauci,

You have been kind enough to be a panelist on our Forums at the Harvard T.H. Chan School of Public Health, and I wanted to see if you were available to participate remotely in a Forum that we are organizing on **March 2** about **COVID-19**.

The Forum will live stream on the websites of The World and The Forum, as well as on Facebook and YouTube.

The World will send a journalist to moderate and co-promote.

The Forum is called **"The Coronavirus Outbreak: Tracking COVID-19", presented jointly with The World from PRX & WGBH.**

Should you agree to participate, we ask that you join us remotely from **11:40am-1pm ET on March 2**; the actual live webcast will be noon-1pm ET.

We have been active is covering this outbreak. We did a highly successful Facebook Live Q&A last week and are doing another Q&A next week.

As a reminder, Forum webcasts are one-hour long and are panel discussions, typically with 3-4 panelists, plus a moderator. As noted, these discussions are live streamed from our Leadership Studio at our school in front of a studio audience (about 40 seats) and an online audience. Anyone with an Internet connection can watch the live webcasts; no registration or fee is required.

Previous speakers in The Forum series have included Gina McCarthy, former EPA Administrator; Anthony Foxx, then U.S. Secretary of Transportation; Eric Holder, then U.S. Attorney General; Kathleen Sebelius, then U.S. Secretary of Health and Human Services; Gordon Brown, former UK Prime Minister; as well as numerous former governors and key public health policymakers and officials from a range of public and private sector entities.

The Forum live webcasts are also streamed on The Forum website, where they are accompanied by a live chat and online commenting, and on Facebook and YouTube. These webcasts are later posted as on-demand videos to our site and to Harvard's YouTube and iTunesU channels. We also make available podcasts, transcripts and other materials. Collectively, the programs and complementary content have resulted in nearly five million viewer engagements so far, and our website has received visits from more than 200 countries and territories and every U.S. state.

Please share your thoughts when you are able.

Cheers,

Christina Roache
Associate Director, Production and Web, The Leadership Studio
Harvard T.H. Chan School of Public Health
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 20:23:04 +0000
To: Clayton, Janine (NIH/OD) [E]
Subject: RE: Sex differences in COVID-19

Not much at this point. [redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Clayton, Janine (NIH/OD) [E] <[redacted] (b) (6)>
Sent: Friday, February 14, 2020 3:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Sex differences in COVID-19

Hi Tony,

[redacted] (b) (5)

Janine

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 20:21:51 +0000
To: Richard Allen Johnson
Subject: RE: 2020.02.14 Friday

Dick:

Thanks for the note. I certainly appreciate your concerns about WHO. Not much sleep for me lately. Just like internship.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Allen Johnson [redacted] (b) (6)
Sent: Friday, February 14, 2020 3:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Richard Allen Johnson [redacted] (b) (6)
Subject: 2020.02.14 Friday

Hi, Tony,

I am very distressed by the Face of the WHO. Their public face, their news updates, are of the quality of those of a third world country. I only hope that they function better than their news updates suggest. They need a world class public relations firm.

I am deeply concerned re Covid-19 in India (with a population of 1500 million) and Africa (population 100 million). News reports do not mention anything of this pandemic waiting to happen.

Hope that you are well and getting a good night's rest.

Best,
Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 18:27:24 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: inhaled buformin for coronavirus
Attachments: [redacted] (b) (4)

[redacted]

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Steven Lehrer [redacted] (b) (6)>
Sent: Friday, February 14, 2020 1:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: [redacted] (b) (4) for coronavirus

Dr. Fauci,

[redacted] (b) (4)

Steven Lehrer, MD

[redacted] (b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 17:39:33 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: RE: for review: proposed responses for Italian media request

Nice Job. I have made one minor edit in the first response. Otherwise, it is ready to go. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, February 14, 2020 12:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6) Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: for review: proposed responses for Italian media request

Dr. Fauci –

This is not urgent for today. A reporter from the Italian health website Pazienti.it reached out to you directly with questions about coronavirus vaccine development. I have drafted proposed responses for your review attached and pasted below. I will send the final responses to the reporter attributed to you.

Coronavirus vaccine: when will it be available? What are the difficulties?

The National Institutes of Health is on track to test an experimental messenger RNA (mRNA) vaccine in a Phase 1 clinical trial this spring. This first phase of clinical testing will involve giving the vaccine to healthy adults in the United States to see if it is safe and if it can induce an immune response in recipients. It is important to realize that the development of investigational vaccines and the clinical testing to establish their safety and effectiveness takes time. A vaccine against the novel coronavirus will likely not be widely available for at least a year.

Could the Coronavirus mutate, if a vaccine cannot be found in time?
We are learning more about the novel coronavirus every day. At this time, we are not aware of any mutations that might affect vaccine development. Based on our experience with other coronaviruses, including SARS-CoV and MERS-CoV, it is unlikely—but not impossible—that the novel coronavirus will mutate in a way that would have an impact on the development of medical countermeasures. We are continuing to monitor this.

Will the vaccine be the solution against Coronavirus?
A safe and effective vaccine would be an extremely valuable tool to help stop the spread of infection and prevent future outbreaks. However, proven public health practices of identifying cases, isolating patients, and tracing contacts must continue alongside a vaccination program.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 17:23:43 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: [redacted] (b) (4)

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hardham, John M [redacted] (b) (6) >
Sent: Friday, February 14, 2020 9:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) >
Subject: [redacted] (b) (4)

Tony:

It was good to see you again at the ASM Biothreats Conference. We had worked together on the Medical Countermeasure Initiative when I was the Medical Officer for the DOD Chem Bio Program (under ASD Andrew Weber) several years ago.

[redacted] (b) (4)

If you or your staff have any interest, please feel free to reach out to me.

Hope you have a wonderful day!

John

John M. Hardham, Ph.D. | Research Director, Global Biologics Research
Director, Zoetis Center for Transboundary and Emerging Diseases
Zoetis | 333 Portage Street, KZO-300-204.3, Kalamazoo, MI 49007
Office: (b) (6) | Mobile: (b) (6) | (b) (6)
Visit Us: zoetis.com

zoetis
FOR ANIMALS. FOR HEALTH. FOR YOU.

Emerging Infectious Diseases
First to know...*Fast to market*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 15:52:49 +0000
To: Strauss, Nicole
Cc: Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [redacted] (b) (4) | [redacted] (b) (4)

Nicole:

Thank you for your note and interest. I will copy on this e-mail Drs. John Mascola and Barney Graham of our Vaccine Research Center who are developing the vaccine with Moderna so that they can respond directly to you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Strauss, Nicole [redacted] (b) (6)
Sent: Friday, February 14, 2020 10:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Weisser, Karen [redacted] (b) (6)
Subject: [redacted] (b) (4) | [redacted] (b) (4)

Dear Dr. Anthony Fauci,

[redacted] (b) (4)

Best regards,
Nicole

Pfizer CentreOne

Nicole Strauss
Pipeline Development & Innovation Lead
T: (b) (6) | M: (b) (6)
500 Arcola Road, Collegeville, PA 19426
Website | LinkedIn

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 14:22:00 +0000
To: Greg Folkers ([redacted] (b) (6)
Subject: NEJM
Attachments: NEJM Editorial - Fauci et al -1st draft - 02-13-2020.docx, nejmoa2001316.pdf

Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 03:20:06 +0000
To: Embry, Alan (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Institutional request for information

Thanks, Alan.

From: Embry, Alan (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 13, 2020 10:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Fried, Linda P. (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Goldman, Lee (b) (6)>; Booth, Jane (b) (6)>; Katznelson, Ira I. (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6)
Subject: RE: Institutional request for information

Dear Dr. Fried,

Answers to your questions are below.

1. **Is the CDC or NIH overseeing the distribution of the live virus in the U.S.?**
   There is an interagency working group convened by the Assistant Secretary for Preparedness and Response overseeing samples, and NIH and CDC are central to this. Virus is being deposited in BEI Resources (a NIAID contract resource) for characterization, growth and distribution. The WA isolate is available now and a Hong Kong isolate may be added soon.

2. **Will you be the sole source of distribution in the U.S., or will institutions be permitted to obtain it directly from other sources?**
   Assuming appropriate permits are in place, there is no limitation on an institution obtaining samples directly from BEI or other sources. In a public health emergency, the U.S. government seeks to make isolates available under a Simple Letter Agreement that does not impose IP restrictions on academics or developers (see attached language).

3. **If it can be obtained from other sources, what sources will be permitted? For example, the China or Hong Kong CDC or University of Hong Kong?**
   Assuming appropriate permits and safety controls, there is no limitation on from where samples can be obtained. However, there may be intellectual property restrictions from some sources and your technology transfer office would need to negotiate if requested directly.

4. **If you are to be the sole source, when would you expect to have a process for considering requests?**
   BEI resources already has a process for sharing in place and is currently sharing the viral isolate obtained from the first Washington case. NIAID anticipates that other viral isolates will be obtained soon, and BEI is committed to making those available to the scientific community as soon as

possible. We (NIAID/ USG) do not expect to be the only source, but will likely be one of the main sources for this research resource based on experience with Zika.

5. If someone wishes to travel to China to work on the live virus, are there any travel restrictions other than the self isolation/quarantine already in place (and of course subject to change over time)?
For that, contacting CDC directly would make sense. If you would like us to inquire, we can. For high consequence viruses, use of proper PPE has been a mitigating factor in quarantine consideration.

Please feel free to contact me if you have additional questions.

Thanks,
Alan

Alan Embry, Ph.D.
Chief, Respiratory Diseases Branch
Division of Microbiology and Infectious Diseases, NIAID, NIH
5601 Fishers Lane, Room 8E31
Rockville, MD 20892
(b) (6)
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 13, 2020 6:35 PM
To: Fried, Linda P. (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6); Goldman, Lee (b) (6)>; Booth, Jane <(b) (6)>; Katznelson, Ira I. (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Embry, Alan (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6)>
Subject: RE: Institutional request for information

Linda:

There is a "sample sharing" working group involving NIH and CDC. I have copied both Hilary Marston and Alan Embry from NIAID who are involved in this group and will ask them by this e-mail to respond to items #1 through 4. Regarding returning travelers from China (item #5) if in Wuhan (Hubei province) within previous 14 days, they submit to institutional quarantine; if in non-Hubei province part of China, then they face self-isolation.

Hope that this is helpful.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fried, Linda P. [redacted] (b) (6)
Sent: Thursday, February 13, 2020 12:45 PM
To: Redfield, Robert R. (CDC/OD) [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Goldman, Lee [redacted] (b) (6)>; Booth, Jane [redacted] (b) (6)>; Katznelson, Ira I. [redacted] (b) (6)
Subject: Institutional request for information

Dear Drs. Redfield and Fauci,

I am writing on behalf of Columbia University, which has received a request from Dr. Ian Lipkin to transfer live novel coronavirus from Hong Kong to his BSL3 facility at the University. As we evaluate his request, we note that he has approval from a CDC official to import the virus (see attached). However, as we consider the risks and benefits of Dr. Lipkin's proposal, we ask the two of you:

1. Is the CDC or NIH overseeing the distribution of the live virus in the U.S.?
2. Will you be the sole source of distribution in the U.S., or will institutions be permitted to obtain it directly from other sources?
3. If it can be obtained from other sources, what sources will be permitted? For example, the China or Hong Kong CDC or University of Hong Kong?
4. If you are to be the sole source, when would you expect to have a process for considering requests?
5. If someone wishes to travel to China to work on the live virus, are there any travel restrictions other than the self isolation/quarantine already in place (and of course subject to change over time)?

Thank you very much for your help with these important questions as we all try to do our best to contribute solutions to this health crisis.

With best regards,
Linda

Linda P. Fried, M.D., M.P.H.
Dean and DeLamar Professor of Public Health
Professor of Epidemiology
Mailman School of Public Health
Professor of Medicine, Vagelos College of Physicians and Surgeons
Senior Vice President, Columbia University Irving Medical Center
Columbia University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 03:00:23 +0000
To: Mansoura, Monique K.
Cc: Conrad, Patricia (NIH/NIAID) [E];Andrew W Lo;Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: A proposed solution to finance COVID-19 vaccines - Introducing MIT's Professor Andrew Lo

Thanks, Monique. Please have Andrew send the proposal to Cristina Cassetti (copied here) and she can then brief me on it.
Best,
Tony

From: Mansoura, Monique K. [redacted] (b) (6)>
Sent: Thursday, February 13, 2020 10:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Andrew W Lo < [redacted] (b) (6)>
Subject: A proposed solution to finance COVID-19 vaccines - Introducing MIT's Professor Andrew Lo

Dr. Fauci,

The nation again is fortunate to have your leadership for this latest public health emergency. Thank you for all you are doing. I know you are extraordinarily busy, so I'll be brief.

I want to introduce you to MIT Sloan Professor Andrew Lo, a world leader in healthcare finance who has focused much of his work recently on accelerating biomedical innovation via novel financing structures. I have worked with him to explore financial engineering approaches to establish more durable public-private partnerships for medical countermeasures. The persistent challenges you articulated at the Aspen Institute event this week resonate loudly with Andrew and me.

He has proposal for COVID-19 that he would like to present to you. I defer to him to provide further information.

Respectfully,
Monique

MONIQUE K. MANSOURA, PH.D., M.B.A.
Executive Director, Global Health Security and Biotechnology
The MITRE Corporation
202 Burlington Road | Bedford, MA | 01730-1420
Office: [redacted] (b) (6)
Mobile: [redacted] (b) (6)
Email: [redacted] (b) (6)

The MITRE Corporation is a not-for-profit organization that operates federally funded research and development centers for the United States government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 02:56:17 +0000
To: Greg Folkers ([redacted] (b) (6))
Subject: FW: FYI -- images of SARS-CoV-2 now up

Let us make some power point slides from these. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, February 13, 2020 1:22 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FYI -- images of SARS-CoV-2 now up

https://www.niaid.nih.gov/news-events/novel-coronavirus-sarscov2-images
https://www.flickr.com/photos/niaid/albums/72157712914621487

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 02:42:53 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6))
Subject: FW: PBS'S FIRING LINE REQUEST // DR. ANTHONY S. FAUCI

Patty: Let us discuss.

Greg: Are they a big deal?

From: Melanie Starling <melanie@thedocumentarygroup.com>
Sent: Thursday, February 13, 2020 6:39 PM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: PBS'S FIRING LINE REQUEST // DR. ANTHONY S. FAUCI
Importance: High

Good Evening,

Please see below for Dr. Anthony S. Fauci for ***PBS'S FIRING LINE WITH MARGARET HOOVER***.

Due to a last minute cancellation, we are crashing on a deadline and need to know if he is able to join us ASAP.

I look forward to hearing your thoughts and all best,
Melanie

Melanie Starling
Firing Line with Margaret Hoover
Cell: +(b) (6)
Email: melanie@thedocumentarygroup.com

FIRING LINE
With MARGARET HOOVER

Good Evening,

This is Melanie Starling writing on behalf of ***PBS'S FIRING LINE WITH MARGARET HOOVER***.

FIRING LINE is the rare program in the political landscape that seeks a rigorous and earnest exchange of ideas, with the luxury to let the conversation breathe. Margaret has brought back the spirit of this venerated show, which aired from 1966 to 1999, that is lacking in today's polarized cable news ecosystem – at a time when we need it more than ever. One guest. 30 minutes. Airing to a thoughtful and engaged ***PBS*** audience.

We would be honored to have Dr. Anthony S. Fauci join *Firing Line* for an interview.

Dr. Fauci has dedicated his career to understanding, preventing, and protecting people across the globe from infectious diseases, which is why we would be so honored to share our stage with him at this time. As the coronavirus continues to spread, we are interested in better understanding the deadly virus the world is racing to contain. Equally, we are interested in highlighting any other public health issues or policies close to Dr. Fauci's heart. Most importantly, with our program, we have the luxury of time – where we can truly delve into these issues in a substantive, nuanced manner that is missing in much of today's 24-hour news cycle.

THE DETAILS FOR TAPING

TAPE DATE: TARGETING FEBRUARY 19TH – EVENING TAPING IS PREFERED
TAPE TIME: 45 MINUTES
LOCATION: NYC (WNET STUDIOS NEAR LINCOLN CENTER)
TRAVEL, HAIR, & MAKE-UP IS PROVIDED ON REQUEST.

FIRING LINE is carried nationwide on PBS with 99% market pick-up, and is suggested programming for PBS's 8:30 PM ET on Friday nights with multiple airings through the week. On Twitter, we have a growing 2.9M+ monthly impressions. Equally, as you know, PBS remains a coveted home for intellectual, elevated programming – and stands out as a **top 5 outlet to reach persuadable voters**.

HIGHLIGHT REEL

FIRING LINE is produced by the **Oscar-nominated Tom Yellin** at The Documentary Group.

Please reach out to me if there is any interest. We will bend over backwards to get it done.

Thank you in advance for your consideration, and please feel free to reach out to me 24/7 with questions or concerns.

All the best,

Melanie

Melanie Starling
Firing Line with Margaret Hoover
Cell: (b) (6)
Email: melanie@thedocumentarygroup.com

ABOUT FIRING LINE WITH MARGARET HOOVER

Firing Line with Margaret Hoover is a refreshing reprisal of William F. Buckley's iconic PBS program, a smart, civil and engaging contest of ideas. The series maintains the character of the original, providing a platform that is diligent in its commitment to civility and the rigorous exchange of opinion. *Firing Line with Margaret Hoover* comes at a time when meaningful discourse is needed more than ever. Interviews and debates will highlight leading lights from the left and right, complemented by archival footage from the original *Firing Line* to remind viewers of longstanding conservative and liberal arguments, where they've been disproved or reinforced over time. It is an opportunity to engage in the debate about the America that we want to create for the 21st century — and summon Americans of every political persuasion to a rigorous examination of the choices we must make together in the challenging years ahead. Showrunner is Emmy, Dupont and Murrow-winning producer Alyssa Litoff.

ABOUT MARGARET HOOVER

Margaret Hoover is an American political commentator. In addition, she is also an author, feminist, and gay rights activist. Currently, she works as a political commentator for CNN.

HIGHLIGHTS ON FIRING LINE WITH MARGARET HOOVER

Speaker Paul Ryan, Sen. Ben Sasse (R-NE), Gov. Chris Christie, Gov. Mitch Daniels, Gov. John Kasich, Gov. Scott Walker, Rep. Alexandria Ocasio-Cortez (D-NY), Rep. Eric Swalwell (D-CA), Stacey Abrams, Donna Brazile, Gretchen Carlson, Caitlyn Jenner, Christine Lagarde, Peter Navarro, Oliver North, Andrew McCabe, Tom Steyer, H.R. McMaster, Rep. Tulsi Gabbard, Ann Coulter, Tony Blair, José Andrés, Rep. Liz Cheney (R-WY), Rep. Jim Clyburn (D-SC), Rep. Pramila Jayapal (D-WA), Sen. Ted Cruz (R-TX), Gen. Jim Mattis, Condoleezza Rice, Andrew Yang, Michael Bloomberg, Michael Moore, Paul Krugman, Amb. Nikki Haley, Adam Schiff (D-CA)

Melanie Starling
PBS's *Firing Line with Margaret Hoover*
Cell: + (b) (6)
Email: melanie@thedocumentarygroup.com

FIRING LINE
WITH MARGARET HOOVER

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 02:36:46 +0000
To: ncalio@airlines.org
Cc: Conrad, Patricia (NIH/NIAID) [E];Redfield, Robert R. (CDC/OD);Cetron, Marty (CDC/DDID/NCEZID/DGMQ)
Subject: FW: Coronavirus Task Force
Attachments: Fauci A4A Letter to Coronavirus Task Force .pdf

Nick:

Many thanks for sending this. The CDC would be very interested in your willingness to move in the direction of having complete contact information on passengers available to them. I am copying CDC Director Bob Redfield and his CDC colleague Marty Cetron on this e-mail. I am sure that one of them will contact you about this issue.

Best regards,
Tony

From: Calio, Nicholas <ncalio@airlines.org>
Sent: Thursday, February 13, 2020 8:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus Task Force

Dear Dr. Fauci,

Please see the attached letter.

Thank you,

Nick Calio

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 02:09:44 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Invitation: 388393 Santos (Coronavirus Preparedness Workshop)

Tell them that I turned down the same invitation and he should turn it down also. It is not a major event

---

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, February 13, 2020 8:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Invitation: 388393 Santos (Coronavirus Preparedness Workshop)

Please see below. You were invited to this – it was discussed in our daily meeting and we decided to decline it for you. we did decline it. would you recommend the same as they are now asking Dr Collins.

Pls advise.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harris, Kara (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Wednesday, February 12, 2020 4:18 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Invitation: 388393 Santos (Coronavirus Preparedness Workshop)

Hi, Patty -

Exec Sec would like Dr. Fauci's opinion on whether Dr. Collins should accept the attached invitation to speak at an upcoming Coronavirus Preparedness Summit & Workshop being held this June in Washington, DC. The conference is being organized by Syllabusx, a group of "international specialists in public health and emergency planning events and disaster recovery conferences."

Given the nature of the conference topics, do you concur with recommending Dr. Collins decline the invitation and refer to CDC?

Thanks for your input.
Kara

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 23:22:27 +0000
To: Alison Galvani
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Lancet special issue proposal

Alison:

Thanks for the note. I really appreciate your kind invitation, but unfortunately, I will have to decline. My plate is already overflowing and I just cannot take on any additional editorial responsibilities. In addition, I am swamped with coronavirus "stuff" that is not going to end soon. I hope that you understand.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alison Galvani [redacted] (b) (6)
Sent: Wednesday, February 12, 2020 2:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Lancet special issue proposal

Hi Tony,

I hope you are well.

[redacted] (b) (4)

Thank you so much for your consideration.

Warmest regards,
Alison

--
Alison Galvani, PhD

Director, Yale Center for Infectious Disease Modeling and Analysis (CIDMA)
Burnett and Stender Families Professor of Epidemiology
Yale School of Public Health
Yale School of Medicine
New Haven, CT 06520

(b) (6)
http://cidma.yale.edu/

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 23:10:07 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Personal connection

Please set this up (5 minutes) for Monday.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 12, 2020 8:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Personal connection

This guy called last night and seemed to know you – let me know if and where you want me to direct him.

Or maybe do a call with you on a quieter day - Monday on Pres day holiday?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Banner, Jon {PEP} <(b) (6)>
Sent: Tuesday, February 11, 2020 9:44 PM
To: (b) (6) Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Personal connection

Dear Dr. Fauci,

Jon Banner here. You may remember me from my days at ABC News, where I was Executive Producer of World News Tonight with Peter Jennings, Charlie Gibson, and Diane Sawyer. I was also Executive Producer of This Week with George Stephanopoulos and early on I was George Strait's producer. Back then, you were the most engaging, eloquent guests on the subject of HIV/AIDS and other life and death issues of our time, and your input was of enormous value to our viewers and the general public.

Today, I am President of the PepsiCo Foundation and EVP of Global Communications for the company. I was hoping you could help us identify an expert to provide similar insight and analysis for our company as we deal with the impact of the Wuhan coronavirus. While we would of course welcome your counsel, I recognize that you have a full plate of critical responsibilities with NIH and don't want to take up too much of your time.

If you have a few minutes for a quick call, I'd love to get your take and catch up. If not, I would deeply appreciate it if you could connect me with another expert over email.

Thanks very much, and hope you are doing well!

Warm regards,

Jon

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 22:47:23 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Institutional request for information
Attachments: CII 2020 CDC import permit.pdf

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fried, Linda P. [redacted] (b) (6)
Sent: Thursday, February 13, 2020 12:45 PM
To: Redfield, Robert R. (CDC/OD) [redacted] (b) (6) Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Goldman, Lee [redacted] (b) (6); Booth, Jane [redacted] (b) (6); Katznelson, Ira I. [redacted] (b) (6)
Subject: Institutional request for information

Dear Drs. Redfield and Fauci,

I am writing on behalf of Columbia University, which has received a request from Dr. Ian Lipkin to transfer live novel coronavirus from Hong Kong to his BSL3 facility at the University. As we evaluate his request, we note that he has approval from a CDC official to import the virus (see attached). However, as we consider the risks and benefits of Dr. Lipkin's proposal, we ask the two of you:

1. Is the CDC or NIH overseeing the distribution of the live virus in the U.S.?
2. Will you be the sole source of distribution in the U.S., or will institutions be permitted to obtain it directly from other sources?
3. If it can be obtained from other sources, what sources will be permitted? For example, the China or Hong Kong CDC or University of Hong Kong?
4. If you are to be the sole source, when would you expect to have a process for considering requests?

5. If someone wishes to travel to China to work on the live virus, are there any travel restrictions other than the self isolation/quarantine already in place (and of course subject to change over time)?

Thank you very much for your help with these important questions as we all try to do our best to contribute solutions to this health crisis.

With best regards,
Linda

Linda P. Fried, M.D., M.P.H.
Dean and DeLamar Professor of Public Health
Professor of Epidemiology
Mailman School of Public Health
Professor of Medicine, Vagelos College of Physicians and Surgeons
Senior Vice President, Columbia University Irving Medical Center
Columbia University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 22:44:12 +0000
To: Stoffels, Paul [JJCUS]
Cc: Riccobene, Kim [JJCUS];Van Hoof, Johan [JRDBE];Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C];Eisinger, Robert (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Erbelding, Emily (NIH/NIAID) [E]
Subject: RE: COVID-19 vaccine development

Paul:

Thanks for the note. I will have Patty Conrad (copied here) try to work something out for Feb. 21st. My schedule is at the mercy of the White House and the Congress and so I cannot guarantee anything right now.

Best Regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stoffels, Paul [JJCUS] [redacted] (b) (6)>
Sent: Thursday, February 13, 2020 9:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Riccobene, Kim [JJCUS] [redacted] (b) (6); Van Hoof, Johan [JRDBE] [redacted] (b) (6)>
Subject: COVID-19 vaccine development

Dear Tony,

Four weeks ago our team kicked of the experimental work on the development of a COVID-19 - vaccine.

(b) (4) [redacted]

[redacted] (b) (4)

If you have time for a meeting on the 21st in the afternoon or a call in the course of the next 10 days, I would much very appreciate.
Feel free to call me or have you assistant connect with my assistant Kim Riccobene to set up a call. I will be in Europe till the 19th.

Best regards,

Paul

Paul Stoffels, MD
Vice Chairman & CSO
Johnson & Johnson

[redacted] (b) (6) (Mobile Europe)
(Office US)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 03:16:08 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Run of show - 2/13, 9-10am White House Roundtable on COVID-19

Make sure that this is in my folder.

From: Selgrade, Sara (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Wednesday, February 12, 2020 3:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6) Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Run of show - 2/13, 9-10am White House Roundtable on COVID-19

Dr. Fauci,

Please see below for information we have received from HHS thus far regarding tomorrow's briefing on coronavirus at the White House. Patty has submitted your information via the WAVES link for the event. We are checking with HHS ASL to make sure your clearance has been processed.

We will share any additional information as we receive it. Please let me know if you have any questions.

Thanks,
Sara

White House Congressional Roundtable on Coronavirus
Date: Thursday, February 13
Time: 9:00 – 10:00 a.m.
Location: Roosevelt Room

Run of show:

- Acting Chief of Staff Mulvaney will open the proceedings and briefly frame all that we are doing and why we have asked the Members to assemble (to gain their insight and to seek their wisdom).

- Anne Schuchat will give a brief overview of current status and material issues.
- Anthony Fauci will give a brief explanation of our understanding of the virus and development of countermeasures.
- Brig Gen. Paul Friedrichs of DoD will provide a brief status report on force protection.
- Acting Chief of Staff Mulvaney will open the floor for questions and moderate the proceedings - possible that White House legislative affairs will stand in here (Eric Ueland or Mike McKenna).

Expected participants:

Members (confirmed RSVPs thus far)
Senator James Risch
Leader McCarthy
Rep. Kay Granger
Rep. Greg Walden
Rep. Nita Lowey

Briefers
DHS – Alex Zemek
CDC—Dr. Anne Schuchat
NIAID—Dr. Tony Fauci
ASPR—Dr. Bob Kadlec
FDA—Dr. Steve Hahn
DHS - Ken Cuccinelli
NSC – Anthony Riggiero
NSC – Matt Pottinger
State – Stephen Biegun (tentative)
DOD – Brig Gen. Paul Friedrichs

From: (b) (6)
Sent: Wed, 12 Feb 2020 11:02:30 -0500
To: John Lauerman
Subject: Re: Interview

I tried calling but the call would not go through

> On Feb 12, 2020, at 6:15 AM, John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>wrote:
>
> Hi Dr. Fauci: I saw that you spoke about the lack of major drugmakers stepping up to make coronavirus vaccine, and my colleague James Paton is working on a story about that issue. James's story has to do with a biosecurity initiative related to these types of threats at GSK that was started in 2016 and quickly put on the back burner. I don't know whether you'd want to comment on the company or its activities itself, but would be helpful if you could talk about the importance of getting big drugmakers involved in helping to fill the need for new vaccines. I'm in Geneva right now at the WHO coronavirus science forum, but hope we can talk for a minute or two. Best way to reach me is via Whatsapp, where my number is (b) (6). Please let me know if/when you're free. Thanks and regards, JL
>
> From: John Lauerman (BLOOMBERG/ NEWSROOM:) At: 02/07/20 15:53:34
> To: (b) (6)
> Subject: RE: Interview
> Understood. Hope you get a chance to rest
>
> From: afauci@niaid.nih.gov At: 02/07/20 15:51:39
> To: John Lauerman (BLOOMBERG/ NEWSROOM:)
> Subject: RE: Interview
>
> Sorry John. I am totally tied up right now and besides, I am completely hoarse and can barely speak. Let us try some other time.
>
> **Anthony S. Fauci, MD**
> **Director**
> **National Institute of Allergy and Infectious Diseases**
> **Building 31, Room 7A-03**
> **31 Center Drive, MSC 2520**
> **National Institutes of Health**
> **Bethesda, MD 20892-2520**
> **Phone:** (b) (6)

FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 3, 2020 8:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Interview

Hi Dr. Fauci: How are you? I'm writing to see whether we can talk again for a few minutes. We're working on a biggish piece about the larger bio-security issue worldwide and what the coronavirus outbreak tells us about it. What can we do about the weakest links in disease control in poorer nations in Africa, Asia and elsewhere? The WHO today brought up the importance of access to health care along with spending on public health, and clearly this is an issue in poor counties. Is it also important in infectious disease in the US and if so, is it adequately recognized? Companies and research centers have made huge strides in quick development of vaccines and drugs; what can take it to the next level? Is there anything that could be done to attract more companies to this field? What kind of new technologies can help us track new viruses in the community? I've been talking with people using handheld nanopore sequencers to track coronavirus and Ebola; what else is out there? Do we need to do a better job of tracking the movement of people and goods? Also glad to get any other observations. Please give me a call today or tomorrow morning at [redacted] (b) (6) or let me know when and at what number to call you. Thanks and regards, look forward to hearing from you, JL

……

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell [redacted] (b) (6)
http://www.bloomberg.com
http://www.bloomberg.com/prognosis

From: [redacted] (b) (6)
Sent: Wed, 12 Feb 2020 10:24:06 -0500
To: Daniel Lucey
Subject: Re: Update IDSA Science Speaks post today # 10: PPE mass production and POlyclonal/mAbs Rx PReP and PEP

Thanks dan

> On Feb 12, 2020, at 9:34 AM, Daniel Lucey <[redacted] (b) (6)>wrote:
>
> Bob K., Tony and Bob (Redfield),
> Given the news of health care personnel in Wuhan and Hubei being infected, and acute shortage of PPE for COVID-19, I posted these Q&A s on the ID Society America "Science Speaks" website as the 10th in a series of my updates since January 6th.
>
> The final Question asks and answers that mass production of COVID-19 PPE should occur now.
>
> Dan
> Hong Kong Feb. 12, 2020
>
> https://sciencespeaksblog.org/2020/02/12/immune-survivors-of-covid-19-protective-antibody-for-treatment-and-prophylaxis/

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 12 Feb 2020 15:23:15 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: Re: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.
Attachments: image003.jpg, image004.jpg, image005.jpg

Okay. Go with it

> On Feb 12, 2020, at 9:38 AM, Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
>
> Will add
> I would vote for: no slides –
> I would send these three papers (all on director's page) – CoV, Ebola, Ending HIV
>
> <image003.jpg>
>
> Foreign Policy
> <image004.jpg>
>
> <image005.jpg>
>
> ---
>
> **From:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
> **Sent:** Wednesday, February 12, 2020 9:11 AM
> **To:** Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
> **Cc:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
> **Subject:** FW: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.
>
> Kim – pls add all to the folder thx

G – this needs to be added to matrix. IT was a "fireside chat" that we thought would not include slides but see below – they are ok with a few slides

Will need to discuss things to send and topics given the "theme"

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marlene Colucci <mcolucci@businesscouncil.com>
Sent: Tuesday, February 11, 2020 6:29 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Adrienne Ball <aball@businesscouncil.com>; Gillian Auger <gauger@businesscouncil.com>
Subject: Re: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.

Patty,

I wanted to check back with you and Dr. Fauci on a few things in advance of his fireside chat with David Rubenstein on Friday, February 21.

- Are there any articles that Dr. Fauci thinks would be useful to send out to our CEOs in advance of the discussion (it may be something related to the Coronavirus or something that looks at the future of health and what CEOs should be thinking about in the next decade?

- The theme for our upcoming meeting is "The Next Decade - Major trends in technology, geopolitics, politics, economy and health". I have attached a copy of our Draft CONFIDENTIAL and list of attendees for Dr. Fauci's reference.

- During his discussion with David Rubenstein, are there any slides he would like to use for reference? We do not use a lot of these but thought there might be slides that would aid in his discussion? Just let us know.

Warmest regards,

Marlene

Marlene Colucci

EXECUTIVE
DIRECTOR

THE
BUSINESS
COUNCIL

T: 202-298-7650
C: (b) (6)
F: 202-785-0296

> On Feb 5, 2020, at 9:19 AM, Marlene Colucci <mcolucci@businesscouncil.com> wrote:
>
> Thank you Patty for checking. As soon as I can find out whether Dr. Collins will also be a part of the discussion I will work on setting up that call. Ive been pressing their office so fingers crossed!
>
> Marlene
>
> Marlene Colucci
>
> EXECUTIVE
> DIRECTOR
>
> THE
> BUSINESS
> COUNCIL
>
> T: 202-298-7650
> C: (b) (6)
> F: 202-785-0296

On Feb 5, 2020, at 9:01 AM, Conrad, Patricia (NIH/NIAID) [E]
<[redacted] (b) (6) wrote:

Good morning:

Dr. Fauci will not be able to attend the dinner the night before but wanted me to thank you for thinking of him.

Best,
-patty

From: Marlene Colucci <mcolucci@businesscouncil.com>
Sent: Friday, January 31, 2020 2:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); David Rubenstein [redacted] (b) (6); MaryPat Decker [redacted] (b) (6)
Subject: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.

Dear Dr. Fauci,

On behalf of our co-chairs for the winter meeting of The Business Council, David Rubenstein of The Carlyle Group and Ginni Rometty of IBM, we would like to formally invite you to participate in our meeting on February 20-21, 2020 in Washington, D.C. The theme of the meeting is "The Next Decade." (See formal invitation attached as well as list of CEO members).

We would like for you to participate in a 50 minute fireside chat with David Rubenstein (and possibly Dr. Francis Collins) to discuss the current coronavirus as well as what we should expect in the next decade. We want to give our CEOs insights into what the next 10 years will bring in terms of detection, diagnosis and treatment of diseases. All conversations are strictly off the record and closed press. We will cover all lodging and transportation.

As you know, The Business Council is comprised of the chief executive officers of the largest global corporations, representing all segments of the economy. We expect at least 150 CEO members, spouses and speakers to be in attendance.

As a participant you and your spouse are also invited to join us for our special reception, dinner and speaker at the REACH (Kennedy Center) on Thursday, February 20 at 6:30pm. It is the best opportunity for you to meet our CEO members and spouses, speakers and other special guests in an informal atmosphere.

If you are interested and available, please let me know. We can also set up a very brief call with you to discuss any additional details and answer any questions you may have. We look forward to hearing from you and would be honored to have you participate with us again.

Warmest regards,

Marlene

Marlene Colucci

EXECUTIVE
DIRECTOR

THE BUSINESS COUNCIL

T: 202-298-7650
C: (b) (6)
F: 202-785-0296



New Online Views 304,257 Citations 0 Altmetric 2109

Viewpoint

ONLINE FIR

January 23, 2020

Coronavirus Infections—More Than Just the Common Cold

Catharine I. Paules, MD[1]; Hilary D. Marston, MD, MPH[2]; Anthony S. Fauci, MD[2]

> Author Affiliations | Article Information

JAMA. Published online January 23, 2020. doi:10.1001/jama.2020.0757



ARGUMENT

On the Front Lines of the Trump Administration's Ebola Response

The United States has mounted a wide-ranging response to the latest deadly outbreak, as only it can.

BY ALEX M. AZAR II, ROBERT R. REDFIELD, ANTHONY S. FAUCI | NOVEMBER 4, 2019, 1:55 PM



Ending the Human Immunodeficiency Virus Pandemic: Optimizing the Prevention and Treatment Toolkits

Robert W Eisinger, Gregory K Folkers, Anthony S Fauci

Clinical Infectious Diseases, Volume 69, Issue 12, 15 December 2019, Pages 2212–2217, https://doi.org/10.1093/cid/ciz998

Published: 24 October 2019 **Article history** ▾



New Online | Views 304,257 | Citations 0 | Altmetric 2109

Viewpoint

ONLINE FIRS

January 23, 2020

Coronavirus Infections—More Than Just the Common Cold

Catharine I. Paules, MD[1]; Hilary D. Marston, MD, M[illegible]uci, MD[2]

> Author Affiliations | Article Information

JAMA. Published online January 23, 2020. doi:10.1001/jama.2020.0757



ARGUMENT

On the Front Lines of the Trump Administration's Ebola Response

The United States has mounted a wide-ranging response to the latest deadly outbreak, as only it can.

BY ALEX M. AZAR II, ROBERT R. REDFIELD, ANTHONY S. FAUCI | NOVEMBER 4, 2019, 1:55 PM



Ending the Human Immunodeficiency Virus Pandemic: Optimizing the Prevention and Treatment Toolkits

Robert W Eisinger, Gregory K Folkers, Anthony S Fauci

Clinical Infectious Diseases, Volun [illegible], 15 December 2019, Pages 2212–2217,
https://doi.org/10.1093/cid/ciz998
Published: 24 October 2019 **Article history ▾**

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 12 Feb 2020 12:04:55 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: epiqar for Coronavirus assistance

Please handle. Thanks.

From: Daniel Goldberg <daniel@eng.us>
Sent: Tuesday, February 11, 2020 11:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Subject: epiqar for Coronavirus assistance

Dr. Fauci,

I wanted to reach out to see if **epiqar** (https://epiqar.com/) can help your efforts with the Coronavirus- we are the only system in the world built for remote surgical help & interactive emergency surgeon support over the web browser.

epiqar has created the most advanced surgical video collaboration technology, allowing surgeons to consult and train remotely on a low-cost and easy-to-use online surgical collaboration platform and Cloud-archiving system built for the operating room. With the outbreak of Coronavirus, this has become more vital as surgeon mobility and access to critical surgical spaces in need of more help are severely limited, and specialists will not risk entering spreading viral hot zones.

Patient care isn't just a concern with the virus itself, but with the host of medical issues facing patients that will no longer be treated by local specialists easily, and facing caregivers: surgeon involvement from around the world is needed urgently.

Although **epiqar** is an American company, our rollout in recent months has been in France, making selected French institutions the most prepared in the world for remote video care. We obviously weren't anticipating the Coronavirus and now we're dedicated to delivering our technology to where the world needs it asap.

epiqar's parent company **ENGAUGE** (https://eng.us/) is a state-of-the-art online healthcare company for surgeon training and has served clients such as **Johnson & Johnson**, **Intuitive Surgical,** and many other of the world largest & smallest medical device companies. **ENGAUGE** has helped surgeons all over the world have access to secure online training that has improved their understanding of the innovations in robotics and many of the latest surgical techniques and medical devices for best patient care.

I've linked a whitepaper below with details of the system's use. Please let me know if you would like to speak further and/or need anything additional.

Thanks,

Danny

www.epiqar.com

epiqar | **whitepaper**

Daniel Goldberg
CEO
ENGAUGE
www.eng.us
www.epiqar.com
The world's first low-cost telementoring, surgeon training and instant Cloud-archiving Platform
US 888.615.7874
EUROPE 44 2031399059

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 12 Feb 2020 00:16:12 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: AMA news interview request: What to tell your patients about COVID-19

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Sara Berg <Sara.Berg@ama-assn.org>
Sent: Tuesday, February 11, 2020 4:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: AMA news interview request: What to tell your patients about COVID-19

Dear Dr. Fauci,

My name is Sara Berg and I am a senior writer for the AMA. I am reaching out to you today because you have shared a lot of great information about COVID-19 with the JAMA network. I know you are very busy, but I was wondering if you would be available tomorrow or Thursday for a quick phone interview about what to tell patients who suspect they have COVID-19? This would be an AMA news article for physicians about what to tell patients. The CDC has a list of preventive steps: https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-prevent-spread.html.

This would be what physicians should tell patients who suspect they have COVID-19. One tip might be "Call before you come in." Do you think this is something you would be available to participate in?

I look forward to hearing from you.

Thank you,

AMA

Sara Berg
Senior Communications Specialist
Sara.Berg@ama-assn.org
Office: (312) 464-4104

AMA membership: Join or renew today!

MEMBERSHIP
MOVES
MEDICINE™

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 12 Feb 2020 00:13:52 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: 2019 nCoV brief fyi (2+ pages)
Attachments: Brief 2019 nCoV host Se status.doc

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michalann Harthill [redacted] (b) (6)
Sent: Tuesday, February 11, 2020 3:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Morens, David (NIH/NIAID) [E] [redacted] (b) (6)
Subject: 2019 nCoV brief fyi (2+ pages)

Dear Dr. Fauci,

Please find attached, FYI , my synopsis **Emergence of a novel coronavirus (2019-nCoV), Wuhan, Hubei Province, China: human host selenium-deficient status as a possible "driving" etiological determinant.** (2 1/4 pages, ~70 refs, no graphics)

Best regards,
Michal Harthill
GHI, Inc., Frederick, MD
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 12 Feb 2020 00:05:00 +0000
To: [redacted] (b) (6)
Subject: FW: take a look at figure 3 of the new nejm paper
Attachments: nejmoa2001316.pdf

See Greg/David comment below.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, February 11, 2020 2:50 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: take a look at figure 3 of the new nejm paper

[redacted] (b) (5)

Thanks david

(b) (5)

[redacted]

From: Folkers, Greg (NIH/NIAID) [E]
Sent: Tuesday, February 11, 2020 10:04 AM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: this is the nejm paper discussed this a.m.

That asf is opining on

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 23:58:00 +0000
To: NIAID OD AM
Subject: FW: Keynote Invitation: 3/20 CSIS Coronavirus Public Event

This could be good since it is local. Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stephen Morrison <SMorriso@csis.org>
Sent: Tuesday, February 11, 2020 1:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Anna Carroll <ACarroll@csis.org>; Samantha Stroman <SStroman@csis.org>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Keynote Invitation: 3/20 CSIS Coronavirus Public Event

Dear Dr. Fauci,

I hope this note finds you well. It is my pleasure to invite you to be the opening keynote speaker at a CSIS public event on coronavirus on **Friday, March 20, 1:30-3:30 pm at CSIS** (1616 Rhode Island Avenue NW). The event will focus on the science, economics, and politics of the coronavirus and will feature experts on Chinese and international politics and economics, as well as public health. We would ask you to speak approximately **1:30-2:00 pm**. Your keynote would be followed by a panel discussion and a closing address, and we invite you to stay for as much of the event as you are able. Please find the full draft agenda and speakers for the event below for your reference.

We would be honored to have you participate in this important and timely event. Thank you for your consideration, and please let us know if you would like to discuss further or if we can answer any questions. We look forward to hearing from you.

Best,
Steve

Draft Agenda:

1:30-2:00 pm – Opening Keynote
Dr. Anthony Fauci, NIAID
Introduced by Steve Morrison, CSIS Global Health Policy Center

2:00-2:50 pm – Panel Discussion
[The economics/business] Joyce Chang, JP Morgan *(confirmed)*
[The politics] Jude Blanchette, CSIS Freeman Chair in China Studies *(confirmed)*
[The foreign politics] Melanie Hart, Center for American Progress *(to be invited),* or Bonnie Glaser, CSIS China Power Project
[The public health] Steve Morrison, CSIS Global Health Policy Center *(confirmed)*
Moderator: Scott Kennedy, CSIS Trustee Chair in Chinese Business and Economics

2:50-3:30 pm – Newsmaker Speech
Matt Pottinger, NSC *(to be invited)*
Moderator and Follow-up Interview: Bonnie Glaser, CSIS China Power Project

J. Stephen Morrison
Senior Vice President & Director, Global Health Policy Center
Center for Strategic and International Studies (CSIS)
1616 Rhode Island Ave NW
Washington D.C. 20036
(202) 775-3276

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 23:45:51 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Pharmacist's/Prescriber's Letter Review Request - Coronavirus

Please take a look at this and respond for me.
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jennifer Nieman <jnieman@pletter.com>
Sent: Tuesday, February 11, 2020 11:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Pharmacist's/Prescriber's Letter Review Request - Coronavirus

Dear Dr. Fauci,

In the March 2020 issues of *Pharmacist's Letter* and *Prescriber's Letter*, we plan to write about coronavirus.

Pharmacist's and *Prescriber's Letter* is an independent advisory service for pharmacists and physicians. We are not affiliated with any other group, organization, or company. We are 100% subscriber supported. Our focus is providing practical, unbiased advice to subscribers on issues related to drug therapy. Each month we turn to experts like you to help us pin down the most relevant and important information to share with our readers. Our newsletter is well known for being concise and accurate. You will notice the excerpt we are sending you is relatively short.

We would be most appreciative if you would take just a few moments to review what we have written for accuracy and content. Please share any comments or suggestions for changes you may have on the article.

In order to incorporate your comments into the final *Letter*, please let me hear from you by **Monday, Feb. 17th**. I can be reached by email jnieman@PLetter.com or phone (402) 660-4715.

I look forward to your reply.

INFECTION CONTROL

The ongoing outbreak of the novel coronavirus will raise questions about how to limit the spread of respiratory infections.

Managing this situation is similar to outbreaks of SARS and MERS...since coronaviruses are spread by respiratory secretions.

Put the risk in perspective to calm worried patients...since it doesn't come close to the risk of influenza.

For example, over 35 MILLION U.S. patients got the flu last season...with about 500,000 hospitalizations and 34,000 deaths.

Emphasize getting a flu vaccine each year.

And use this coronavirus outbreak as an opportunity to stress infection control...since there's no treatment or vaccine yet.

Reinforce proper hand hygiene. Educate that handwashing with soap and water is the best way to get rid of germs. Advise washing for 20 seconds...about the time it takes to sing the ABC song.

Or recommend using a hand sanitizer with at least 60% alcohol if handwashing isn't practical. Many products contain this much.

But tell patients to be wary of efficacy claims. For example, hand sanitizers are shown to kill enveloped viruses. Coronaviruses are enveloped viruses...but they aren't specifically studied.

Tell patients to avoid touching their eyes, nose, and mouth.

Clear up confusion about masks. Emphasize that masks are for SICK patients...to help keep their germs from getting into the air.

But discourage surgical masks for most patients withOUT symptoms...there's no evidence they help. They're too loose to limit inhaling germs...and viruses can also get in through the eyes.

If patients ask about N95 respirators, tell them these require fitting and training before use. Save them for healthcare workers.

Caution that unnecessary mask use may contribute to shortages.

Continue to ask patients WITH respiratory symptoms to put a surgical mask on when they come to clinic.

And suggest that sick patients wear a mask at home if in close contact with infants, elderly, or immunocompromised patients.

Tell patients to discard masks when damp...and to use a fresh one at least daily.

Encourage patients to stay home when they're sick.

1. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
2. https://www.cdc.gov/coronavirus/2019-ncov/index.html
3. https://www.cdc.gov/flu/professionals/infectioncontrol/maskguidance.htm
4. https://www.who.int/publications-detail/advice-on-the-use-of-masks-the-community-during-home-care-and-in-health-care-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak

Sincerely,

Jennifer A. Nieman, PharmD, BCPS

Associate Editor, TRC Healthcare

M: 402-660-4715 **E:** jnieman@pletter.com **W:** TRCHealthcare.com
Pharmacist's Letter | Prescriber's Letter | Natural Medicines | Pharmacy Technician's Letter | Pharmacy Technicians University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 23:06:37 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 【Dear Prof. Anthony Letter of interview from China Science Daily】

Can we please get someone to fashion answers for me to edit and send to her.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: 韩扬眉 <ymhan@stimes.cn>
Sent: Monday, February 10, 2020 2:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: 【Dear Prof. Anthony Letter of interview from China Science Daily】

Dear Prof. Anthony,

I am yangmei Han, a journalist from CHINA SCIENCE DAILY.
China Science Daily is
a newspaper in Chinese, published by The Chinese Academy of Sciences.
Recently, your article "Coronavirus Infections—More Than Just the Common Cold" mention about vaccines research in NIAID. We are interested and there are some questions and I want to get more informations.

1、What is the current research progress about vaccines in NIAID?

2、What are the factors restricting the development of vaccines？and did you break through them?

3、What is the standard of vaccine that can be injected to patients? and according your forecasting, how will it work？

4、Can this vaccines research play a role in the 2019-nCoV? Or as a treatment for a common infectious disease in the future?

5、Does vaccines have side effects？how can we restrain it？

6、If vaccines research success in a certain country, Will it be open to the world？if it will, what conditions will need for open？

if you could, we would like you reply as soon as possible
Thank you very much
I am looking forward to your reply!

Sincerely yours,
Yangmei Han (Miss)

--
韩扬眉
中国科学报社采访中心记者
邮箱：ymhan@stimes.cn;576942717@qq.com
电话：[redacted] (b) (6)
地址：北京市海淀区中关村南一条乙中国科学报社

中国科学报社：由中国科学院、中国工程院、国家自然科学基金委员会和中国科学技术协会主办。普及科学知识、倡导科学方法、传播科学思想、弘扬科学精神。

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 20:54:02 +0000
To: Natalie Rahhal
Subject: RE: Interview re: coronavirus patient characteristics

If this is true, which it might not be, there is no clear explanation for why right now. There will likely be studies coming out that say that the relative proportion of male:female is closer to 50:50. Even one of the ones that you quoted was 54%

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Natalie Rahhal <Natalie.Rahhal@mailonline.com>
Sent: Tuesday, February 11, 2020 1:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Interview re: coronavirus patient characteristics

Hi Dr Fauci,

I'm sure you're extraordinarily busy right now, but I've seen several studies and reports that coronavirus seems to disproportionately strike men (making up 54-68% of cases, depending on which study you reference). I was wondering if you might have any comments to offer on why this might be?

Thank you,

Natalie A Rahhal
Acting US Health Editor

DailyMail.com

Daily Mail Online |**51 Astor Place**, 9th floor, New York NY 10003

Tel: +1 212 402 9086
Mobile: (b) (6)
Twitter: https://twitter.com/natalier78?lang=en
Email: Natalie.rahhal@mailonline.com

Disclaimer

This e-mail and any attached files are intended for the named addressee only. It contains information, which may be confidential and legally privileged and also protected by copyright. Unless you are the named addressee (or authorised to receive for the addressee) you may not copy or use it, or disclose it to anyone else. If you received it in error please notify the sender immediately and then delete it from your system. Associated Newspapers Ltd. Registered Office: Northcliffe House, 2 Derry St, Kensington, London, W8 5TT. Registered No 84121 England.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 20:10:45 +0000
To: Nabel, Gary /US
Subject: RE: WHO meeting

Gary:
Thanks for the note. [redacted] (b) (4)

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Nabel, Gary /US [redacted] (b) (6)
Sent: Tuesday, February 11, 2020 1:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: WHO meeting

Not a problem. I just wanted you to know that I was willing to help.

[redacted] (b) (4)

Best
Gary

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, February 10, 2020 3:07 PM
To: Nabel, Gary /US <[redacted] (b) (6)>

Subject: [EXTERNAL] RE: WHO meeting

EXTERNAL : Real sender is [redacted] (b) (6)

I submitted your name to the group as one of my priority suggestions. I have no idea whom they will select.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: afauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Nabel, Gary /US [redacted] (b) (6)
Sent: Monday, February 10, 2020 2:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: WHO meeting

Hi Tony
Thanks for taking the time to talk and help with the HIV trispecific work last week. I appreciate your efforts.

While I was there, you mentioned a WHO Coronavirus meeting you thought I should join. I'm happy to attend but have not yet received an invite. Sometimes WHO excludes companies from such meetings, which is unfortunate and to their detriment. In any case, please let me know if I can help in any way.
Best regards
Gary

Sent from my iPhone

From: [redacted] (b) (6)
Sent: Tue, 11 Feb 2020 11:22:43 -0500
To: Martin Blaser
Cc: Conrad, Patricia (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: Re: SARS 2003, Influenza 2009 and the present

Marty:

Thanks for the note. Indeed, immune sera is foremost on our mind as are mAbs. Hope that all is well with you.

Best,
Tony

> On Feb 11, 2020, at 9:55 AM, Martin Blaser [redacted] (b) (6)>wrote:
>
> Dear Tony,
>
> I dont mean to bother you, but I have a suggestion, in case you have not considered it.
>
> China will have hundreds of thousands of Coronavirus survivors. Their convalescent (immune) serum is valuable. China should try to collect it and give it as a good-will gesture to people around the world.
>
> For moderately to seriously ill people, Immune serum should save many lives.
>
> If cases start to come here, we also should collect serum from survivors, but hopefully we will be very late in the pandemic, and it is not needed because of all of the others things you are doing.
>
> Thank you for everything you and NIAID are doing!
>
> Best wishes, Marty
>
> (Just as in SARS, the Ro for nCo-2019 is higher in hospitals than in the community, but it still is too high in the community).
>
> .
>
> Martin J. Blaser, M.D.
> Henry Rutgers Chair of the Human Microbiome
> Professor of Medicine and Microbiology – RWJMS
> Director, Center for Advanced Biotechnology and Medicine
> Rutgers University
> 679 Hoes Lane West, Room 106A
> Piscataway, NJ 08854
>
> Office Phone: [redacted] (b) (6)
> Fax: 732-235-5318
> Email: [redacted] (b) (6)

https://cabm.rutgers.edu

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, January 26, 2020 7:16 PM
To: Martin Blaser [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: SARS 2003, Influenza 2009 and the present

Marty:
Many thanks. This is very helpful.
Best regards,
Tony

From: Martin Blaser [redacted] (b) (6)
Sent: Saturday, January 25, 2020 9:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: SARS 2003, Influenza 2009 and the present

Webb G, Blaser MJ, Zhu H, Ardal S, Wu J. Critical role of nosocomial transmission in the Toronto SARS outbreak. Mathematical Biosciences and Engineering 2004; 1: 1-13. [PMID: 20369956] [Paper of the year, 2004]

Webb GF, Hsieh Y-H, Wu J, Blaser MJ. Pre-symptomatic influenza transmission, surveillance, and school closings: implications for novel influenza A (H1N1). Mathematical Modelling of Natural Phenomena 2010; 5:191-205.

Dear Tony,

Thanks for your JAMA piece on 2019-nCoV. Perhaps I can help in a small way:

In 2003, with SARS, the Ro was initially considered to be over 2, but in fact that was the conflation of the nosocomial and community rates. In the 2004 paper, we showed that nosocomial rate was much higher, and that the Ro in the community was between 1 and 2. A lower Ro in the community accounts for why moderate public health actions could move it toward extinction--and why it propagated in Beijing, but not Shanghai, in Toronto but not in Vancouver--the Ro in North America became less than one pretty quickly.

To me, one important aspect is the control of respiratory transmission in the hospital, avoiding extensive nebulization/aerosolization, or doing so in negative pressure rooms, as for TB isolation.

(Treating patients with robots is a good idea!)

In the community, standard public health quarantine, contact tracing should be sufficient for starters.

Although hundreds of cases are reported in China, the actual number of infections is likely much higher. The 41 deaths are the tip of the iceberg of not 800 infections (5% fatality rate), but maybe 8,000 infections (0.5%). Although that rate is much better, if the mutating virus becomes very contagious—then the impact could be similar to 1918 flu. That's why containment is so important.—and although draconian, the Chinese government is doing the right thing (as far as we know).

When a new pathogen arrives, children often have mild disease but they are important vectors for transmission in the community, reaching many households. The second paper is the importance of closing schools to minimize transmission—This was for flu with a short (pre-symptomatic) incubation, but may be even more relevant for 2019-nCoV. It is much too early to even think of this in the USA, but it may come to this--and sooner will be better than later, when that time point comes.

Happy to help, any way that I can. Thank you for all you and NIAID are doing!!!

Best wishes , Marty

Martin J. Blaser, M.D.
Henry Rutgers Chair of the Human Microbiome
Professor of Medicine and Microbiology – RWJMS
Director, Center for Advanced Biotechnology and Medicine
Rutgers University
679 Hoes Lane West, Room 106A
Piscataway, NJ 08854

Office Phone: [redacted] (b) (6)
Fax: 732-235-5318
Email: [redacted] (b) (6)
https://cabm.rutgers.edu

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 13:22:53 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Interview / Coronavirus vaccine - Pazienti.it

Have Jen Routh or someone prepare brief responses that I can check. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alessandra Lucivero <alessandra.lucivero@pazienti.it>
Sent: Tuesday, February 11, 2020 5:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Camilla Mantegazza <camilla.mantegazza@pazienti.it>; Irene Bocca <irene.bocca@pazienti.it>
Subject: Interview / Coronavirus vaccine - Pazienti.it

Good morning prof. Fauci,
my name is **Alessandra Lucivero** and I'm the **Editorial Manager of Pazienti.it**, an Italian health website, followed by over 3 million users every month.

We would like to ask you some **questions related to the Coronavirus vaccine**.
We will publish the interview in Italian on our blog here: https://www.pazienti.it/news-di-salute.

The questions are:

- *Coronavirus vaccine: when will it be available? What are the difficulties?*
- *Could the Coronavirus mutate, if a vaccine cannot be found in time?*
- *Will the vaccine be the solution against Coronavirus?*

I hope you can be kind enough to answer my questions.
I look forward to hearing from you.

Thank you very much for your time.

Alessandra Lucivero

--
Alessandra Lucivero
Responsabile editoriale
alessandra.lucivero@pazienti.it

PAZIENTI.it

Il portale della salute dove farsi vedere da uno bravo.

Questo messaggio e i suoi allegati sono indirizzati esclusivamente alle persone indicate. La diffusione, la modifica, la riproduzione di queste informazioni sono vietate. Qualora abbiate ricevuto questo documento per errore, vi preghiamo di comunicarlo al mittente e di provvedere alla sua eliminazione. Vi informiamo inoltre che questo indirizzo di posta è utilizzato solo a scopo professionale: non si garantisce che la corrispondenza verso questa casella venga letta dal solo destinatario poiché, in determinate circostante, l'accesso può avvenire anche da parte di terzi appartenenti alla Società. Pertanto si consiglia di non inviare messaggi di natura personale. Grazie.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 13:14:45 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus Auto Termination
Attachments: Retrovirus Auto Termination.PDF

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Pali Nazir [redacted] (b) (6)>
Sent: Tuesday, February 11, 2020 4:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Chun, Tae-Wook (NIH/NIAID) [E] [redacted] (b) (6); Connors, Mark (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Lusso, Paolo (NIH/NIAID) [E] [redacted] (b) (6)>; Sereti, Irini (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Coronavirus Auto Termination

Dear Mrs. / Sir,

We have a solution to the new recent global problem Coronavirus (2019-nCoV).

Best Regards,
Dr. Pali Nazir

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 13:12:28 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronaviruses

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: [redacted] (b) (6)
Sent: Tuesday, February 11, 2020 8:01 AM
To: [redacted] (b) (6) Holbrook, Michael (NIH/NIAID) [C] <[redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: coronaviruses

Hello,

Working as an occupational physician in France, I would like to draw your attention to the antiviral activity of proton pump inhibitors, including for the Gibbon Ape Leukemia virus, a virus which does not require acidification of endosomes for entry into cells, as is the case with coronaviruses.

Indeed, in 2015 Long et al. (1) found that « ...The commonly used proton pump inhibitors, Omeprazole and Esomeprazole were also able to inhibit entry of all PVs tested but at higher drug concentrations than may be achieved in vivo... ».
Using omeprazole and esomeprazole magnesium hydrate, prepared in sterile DMSO (Sigma), they concluded that « ... OM and ESOM appeared to decrease fluorescence, and therefore increase endosomal pH, only at a concentration of 200μM, higher than that required to inhibit PV entry. Moreover cellular toxicity was observed at this concentration after 24 hours... ».

In 2016, Dowall et al. (2) found : « ...Whereas omeprazole and esomeprazole demonstrated in vitro activity against EBOV, the results were in line with a previous report using pseudotyped viruses where the values of drug concentration causing 50% inhibition (IC50) were in the region of 50 μM [10]. This suggested that doses required for potent inhibition would be difficult to achieve without concomitant and significant toxicity (the licenced dosing for 40 mg esomeprazole, 20 mg esomeprazole and 20 mg omeprazole generates median maximum plasma concentrations of 1.59–9.61 μM, 0.51–4.78 μM and 0.15–3.51 μM, respectively... ».

However, omeprazole is marketed in a non-ionized form and must be ionized (in acidic environment) to be

transformed into an active molecule(3). It is the ionized form which establishes covalent bonds with the SH group of the cysteine of the a subunit of the proton pump.
The solution used in 2015 by Jason Long et al. was, as in 2016 by Dowall et al., DMSO(Dimethyl Sulfoxide).
DMSO is a polar and aprotic organic solvent with dissociation constant pKa = 35.1 This is probably an explanation for the surprising findings from these studies regarding proton pump inhibitors: Inhibition of viruses at 100 µM (at 50 µM esomeprazole for 4 of the 5 viruses tested) and increase in endosomal pH only at a concentration of 200 µM.

This is a situation which, from my point of view, does not reflect the human tissue situation, because in this situation omeprazole can be ionized in the intracellular space but also already in the extracellular space.
Besides, that's probably its advantage: to be ionized and activated where there is an acidic environment.

Without taking into account the tissue situation and the need that omeprazole must be ionized to be transformed into an active molecule, it would not be possible to explain the following publications, since it would be impossible to obtain tissue concentrations required:

- « Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy » (4)

- « Anti-Rhinovirus activity of lansoprazole, which was probably due to an endosomal anti-acidic mechanism » (5)

- « The use of omeprazole family compounds was associated with a lower probability of influenza-like illness » (6)

- « PPIs exert an antiviral function by effectively inhibiting virus-specific serine proteases » (7)

- « Proton pump inhibitors for chronic obstructive pulmonary disease » (8)

- « The ngH,K-ATPase shares approximately 65% sequence homology with the gH,K-ATPase » (9)

- « Omeprazole blocked another P-type ATPase, ATP7A (Menkes protein) in human epidermal mélanocytes » (10)

- « pH-dependent antitumor activity of proton pump inhibitors » (11)

- « V-ATPase as a candidate target molecule or biomarker for cancer treatment and provide a potential role for omeprazole as a chemosensitizer in clear cell carcinoma of the ovary » (12)

- « Proton pump inhibitors such as omeprazole, used clinically to suppress gastric acidity in gastritis, are activated by acidic conditions and tend to decrease intracellular pH and increase the extracellular pH via inhibition of V-ATPases in a covalent interaction » (13)

- « proton pump inhibitors have been shown to be highly effective at inhibiting V-ATPases in vitro » (14)

Specifically at the pulmonary level, we observe concerning proton pump inhibitors:

- « …Since ATP12A shares approximately 65% identity with the gastric H+/K+-ATPase (ATP4A), we investigated the potential of using clinically approved ATP4A proton pump inhibitors (PPIs) for their ability to restore ASL pH in CF hAECs. We show that, despite not expressing ATP4A transcripts, acute exposure to the PPI esomeprezole, produced changes in intracellular pH that were consistent with the inhibition of H+ secretion, but this response was independent of ATP12A. More importantly, chronic exposure of CF hAECs to esomeprazole alkalinized the ASL without disrupting the epithelial barrier integrity, but this increase in ASL pH was consistent with a decrease in mRNA expression of ATP12A. We conclude that PPIs may offer a new approach to restore ASL pH in CF airways, which is independent of CFTR…. » (15)

- « …On the other hand, even though the gastric H+/K+-ATPase was not expressed in airway epithelial cells, exposure to esomeprazole acidified the cytosol and increased ASL pH of primary CF hAECs. We show that esomeprazole had a dual mechanism of action: acutely, it induced intracellular acidification in an ATP12A-independent manner but, chronic exposure, which importantly did not have any deleterious effect on epithelial integrity, was linked to decreased ATP12A mRNA levels. These results open up the possibility of repurposing PPIs as a new therapeutic approach for treating CF lung disease… » (15)

- « …we found that the mRNA of ATP12A, the non-gastric H+/K+-ATPase, shares 70% identity with the gastric H+/K+-ATPase, ATP4A mRNA, which translates to around 65% identity in the protein products… » (15)

- « Proton pump inhibitor therapy predisposes to increased risk of developing pneumonia » (16)

- « Na+/H+ Exchangers Are Required for the Development and Function of Vertebrate Mucociliary Epithelia » (17)

- « ATP4a is required for development and function of the Xenopus mucociliary epidermis - a potential model to study proton pump inhibitor-associated pneumonia » (18)

Regarding coronaviruses and Golgi complex:

- « …Coronaviruses (CoVs) acquire their envelopes from the endoplasmic reticulum-Golgi intermediate compartment (…), also called the cis-Golgi network (…). The three main envelope proteins (S, M and E) are synthesized in the ER and move to the ERGIC/Golgi region where they orchestrate assembly of virus by interacting with the viral nucleocapsid (…). Once virions have budded into the lumen of the ERGIC, the ~120 nm particles must move through the host secretory pathway to be released from infected cells. Coronaviruses are believed to follow the constitutive secretory pathway for exocytosis, although only a few studies have addressed the release of virions. During infection, a progressive disruption of Golgi structure is observed, with swollen unstacked cisternae late in infection… »
« …Weak bases (which disrupt acidification), v-ATPase inhibitors, and expression of a pH activated proton channel all block a number of membrane trafficking steps (…) One mechanism for how luminal pH can affect vesicular trafficking involves a subunit of the membrane sector of the v-ATPase, which has been shown to act as a pH sensor in endosomes. This subunit undergoes a conformational change as the luminal pH drops, which recruits cytoplasmic machinery leading to subsequent vesicle formation… » (19)

- « …Pharmacological and other manipulations of the pH gradient that result in neutralization of the lumen have all been shown to cause slow trafficking of cargo through the Golgi complex as well as alteration in Golgi morphology… »
« …Similar to M2, the infectious bronchitis virus (IBV) coronavirus E protein elicits multiple secretory pathway disruption phenotypes when overexpressed in mammalian cells… » (20)

- « …The envelope protein (E) of coronaviruses plays an important role in virus assembly (…) Using coronavirus infectious clones, it was shown that the transmissible gastroenteritis virus E protein is essential for virus production, and murine hepatitis virus lacking E protein is viable but extremely debilitated… »
« …The exact mechanism of coronavirus release after budding into the endoplasmic reticulum–Golgi intermediate compartment is not known. Large vacuoles containing budded virions are observed in infected cells, presumably en route to the plasma membrane where fusion of the vacuole results in release of virions… » (21, 22)

- « …It might be worth investigating whether ion-channel inhibitors, such as amantadine, or proton pump inhibitors specifically are able to inhibit this increase in Golgi pH. For now, though, it still remains to be seen whether CoV release is mediated by viroporin ion channel activity or through PPIs with host proteins of the secretory pathway… » (23)

- « V-ATPases are also important for transportation of newly synthesized acid hydrolases from Golgi to lysosomes » (24)

- «...cardiotonic steroids ouabain and bufalin, which are known not to affect the transport function of Na+,K+-ATPase, inhibited infection of cells with MHV, FIPV, Middle East respiratory syndrome (MERS)-CoV, and VSV, but not IAV, when the compounds were present during virus inoculation. Cardiotonic steroids were shown to inhibit entry of MHV at an early stage, resulting in accumulation of virions close to the cell surface and, as a consequence, in reduced fusion. In agreement with an early block in infection, the inhibition of VSV by CTSs could be bypassed by low-pH shock. Viral RNA replication was not affected when these compounds were added after virus entry. The antiviral effect of ouabain could be relieved by the addition of different Src kinase inhibitors, indicating that Src signaling mediated via ATP1A1 plays a crucial role in the inhibition of CoV and VSV infections...» (25)

In conclusion, in order to verify the possible efficacy of omeprazole and esomeprazole in the control of infection by coronaviruses :

- The equivalent of the maximum serum concentration that can be obtained in the human body should be used and tested in active (ionized) form in vitro.
Unlike an in vitro test, the human body is an open system, a dissipative system. However, local concentrations of the ionized form should not exceed serum concentrations of the inactive non-ionized form in the absence of active transport.
But the transformation from the non-ionized form to the ionized form could continue until the saturation of the reactions at the cellular level or until the depletion of the transformation capacity from the inactive form to an active form, linked to a change in acidity or the depletion of the inactive form.

- As omeprazole can modify or even inhibit the action of the M2 protein of the influenza virus at the cellular level (26), based on a computer simulation test, it would be desirable to check the interaction capabilities of omeprazole with protein E of the coronavirus. Protein E is likely to resemble the protein M2 in its mode of action.

- In the absence of a treatment recognized as effective in the context of a coronavirus infection and in the absence of data clearly demonstrating the ineffectiveness of omeprazole, personally, I would be tempted to take omeprazole after being in contact (at a distance of less than 2 to 3 meters) with people at risk of contamination or if I had the first symptoms, hoping for the inhibitory activity of omeprazole on P-type ATPases (27, 28) in the context of coronavirus exocytosis, in analogy to the action "off target on the endosomal vATPase" during endocytosis processes.
This step, if effective, will not prevent infection, but could lessen its importance, slow the process down and give the immune system a complementary option to defend itself...

- Personal experience, using omeprazole in the context of seasonal respiratory viral infections since 2007, reminds me of the indication to divide the daily dose into two daily doses (omeprazole 10mg morning and evening is usually already effective for seasonal respiratory viral infections). According to the evolution and the importance of inflammatory state I associate an antihistamine, eg cetirizine.

In the context of the coronavirus, I would be tempted

- share the maximum permissible daily dose of omeprazole in 3 divided doses after being in contact with people at risk of contamination at a distance of less than 2 to 3 meters

- divide the daily dose of omeprazole into two daily doses in case of minor symptoms

- take the daily dose of omeprazole in a single dose if the symptoms worsen with repercussions on the general condition

- to resume the daily dose of omeprazole in two daily doses when the symptoms of severity diminish.

The effectiveness of esomeprazole may be greater than omeprazole.

Taking into account the aforementioned publications, it should not be forgotten that omeprazole will reduce secretions at the respiratory level. A positive effect on respiratory secretions during acute viral respiratory diseases which can become negative (by modifying the pH, the ciliary mobility and the volume of secretions) during prolonged use, thus promoting the risk of bacterial pneumonia (29).
The advantages and disadvantages may vary depending on the user phenotype of omeprazole with regard to cytochrome P 450 (30).

Best regards

Johannes Hambura

1. Long J, Wright E, Molesti E, Temperton N, Barclay W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Res. 2015;4:30. Published 2015 Jan 29. doi:10.12688/f1000research.6085.2

2. Dowall SD, Bewley K, Watson RJ, et al. Antiviral Screening of Multiple Compounds against Ebola Virus. Viruses. 2016;8(11):277. Published 2016 Oct 27. doi:10.3390/v8110277

3. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25–35. doi:10.5056/jnm.2013.19.1.25

4. Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res. 2010;29(1):44. Published 2010 May 8. doi:10.1186/1756-9966-29-44

5. Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, Nishimura H, Sasaki H. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol. 2005;14:201–210. doi: 10.1016/j.ejphar.2004.12.042.

6. Gasparini R, Lai PL, Casabona F, et al. Do the omeprazole family compounds exert a protective effect against influenza-like illness?. BMC Infect Dis. 2014;14:297. Published 2014 Jun 2. doi:10.1186/1471-2334-14-297

7. Moormann AEBDP, Flynn DL, Hui LI, Villamil CI, Inventor method of using (H+/K+)ATPase inhibitors as antiviral agents. United States1999 Jun. 14, 2005.

8. Kikuchi S, Naoki Y, Tajiri T, Watanabe N. Proton pump inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;2018(8):CD013113. Published 2018 Aug 30. doi:10.1002/14651858.CD013113

9. Modyanov N, Pestov N, Adams G, Crambert G, Tillekeratne M, Zhao H, Korneenko T, Shakhparonov M, Geering K. Nongastric H,K-ATPase: structure and functional properties. Ann N Y Acad Sci. 2003 Apr; 986():183-7.

10. Matsui MS, Petris MJ, Niki Y, Karaman-Jurukovska N, Muizzuddin N, Ichihashi M, Yarosh DB. Omeprazole, a gastric proton pump inhibitor, inhibits melanogenesis by blocking ATP7A trafficking. J Invest Dermatol. 2015 Mar; 135(3):834-841.

11. De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Mina PD, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2009.

12. Lee YY, Jeon HK, Hong JE, et al. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. Oncotarget. 2015;6(33):35040–35050. doi:10.18632/oncotarget.5319

13. Larsson H, Mattson H, Sundell G, Carlsson E. Animal pharmacodynamics of omeprazole. A survey of its

pharmacological properties in vivo. Scand J Gastroenterol Suppl. 1985;108:23–35.

14. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96:1702–1713.

15. Delpiano L, Thomas JJ, Yates AR, Rice SJ, Gray MA, Saint-Criq V. Esomeprazole Increases Airway Surface Liquid pH in Primary Cystic Fibrosis Epithelial Cells. Front Pharmacol. 2018;9:1462. Published 2018 Dec 11. doi:10.3389/fphar.2018.01462

16. de Jager CP, Wever PC, Gemen EF, van Oijen MG, van Gageldonk-Lafeber AB, Siersema PD, Kusters GC, Laheij RJ. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther. 2012 Nov;36(10):941-9. doi: 10.1111/apt.12069. Epub 2012 Oct 3.

17. Sun DI, Tasca A, Haas M, et al. Na+/H+ Exchangers Are Required for the Development and Function of Vertebrate Mucociliary Epithelia. Cells Tissues Organs. 2018;205(5-6):279–292. doi:10.1159/000492973

18. Walentek P, Beyer T, Hagenlocher C, et al. ATP4a is required for development and function of the Xenopus mucociliary epidermis - a potential model to study proton pump inhibitor-associated pneumonia. Dev Biol. 2015;408(2):292–304. doi:10.1016/j.ydbio.2015.03.013

19. Machamer CE. Accommodation of large cargo within Golgi cisternae. Histochem Cell Biol. 2013;140(3):261–269. doi:10.1007/s00418-013-1120-y

20. Jason W. Westerbeck, Carolyn E. Machamer. The Infectious Bronchitis Coronavirus Envelope Protein Alters Golgi pH To Protect the Spike Protein and Promote the Release of Infectious Virus. Journal of Virology May 2019, 93 (11) e00015-19; DOI: 10.1128/JVI.00015-19

21. Machamer CE1, Youn S. The transmembrane domain of the infectious bronchitis virus E protein is required for efficient virus release. Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. PMID: 17037529 DOI: 10.1007/978-0-387-33012-9_33

22. Tooze, J., Tooze, S. A., and Fuller, S. D., 1987, Sorting of progeny coronavirus from condensed secretory proteins at the exit from the trans-Golgi network of AtT20 cells, J. Cell Biol. 105:1215.

23. Schoeman, D., Fielding, B.C. Coronavirus envelope protein: current knowledge. Virol J 16, 69 (2019). https://doi.org/10.1186/s12985-019-1182-0

24. Pamarthy S, Kulshrestha A, Katara GK, Beaman KD. The curious case of vacuolar ATPase: regulation of signaling pathways. Mol Cancer. 2018;17(1):41. Published 2018 Feb 15. doi:10.1186/s12943-018-0811-3

25. Burkard C, Verheije MH, Haagmans BL, van Kuppeveld FJ, Rottier PJM, Bosch B-J, de Haan CAM. 2015. ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells. J Virol 89:4434–4448. doi:10.1128/JVI.03274-14

26. Bozdaganyan M, Orekhov Ph, Bragazzi N, Panatto D, Amicizia D, Pechkova E, Nicolini C, Gasparini R. Docking and Molecular Dynamics (MD) Simulations in Potential Drugs Discovery: An Application to Influenza Virus M2 Protein. American Journal of Biochemistry and Biotechnology 2014/11/08. 10.3844/ajbbsp.2014.180.188

27. Lisa A. Dunbar and Michael J. Caplan. Ion Pumps in Polarized Cells: Sorting and Regulation of the Na+,K+- and H+,K+-ATPases. J. Biol. Chem. 2001 276: 29617-. doi:10.1074/jbc.R100023200

28. Amarelle L, Lecuona E. The Antiviral Effects of Na,K-ATPase Inhibition: A Minireview. Int J Mol Sci. 2018;19(8):2154. Published 2018 Jul 24. doi:10.3390/ijms19082154

29. Yu LY, Sun LN, Zhang XH, et al. A Review of the Novel Application and Potential Adverse Effects of Proton

Pump Inhibitors. Adv Ther. 2017;34(5):1070–1086. doi:10.1007/s12325-017-0532-9

30. El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14(4):447–460. doi:10.1080/17425255.2018.1461835

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 12:52:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: WTOP Request

OK by me. Please set it up.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Tuesday, February 11, 2020 7:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: WTOP Request

1040 before you depart for aspen event?

Sent from my iPhone

Begin forwarded message:

> **From:** "Chesson, Joslyn" <jchesson@wtop.com>
> **Date:** February 11, 2020 at 7:16:26 AM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: WTOP Request**
>
> Good morning,
>
> Hoping Dr. Fauci has some availability this late morning and early afternoon to discuss the coronavirus and the quarantining on cruise ships.
>
> We have 10:40a, 11:10a, and 12:10pm all open.

Let me know if any of those times work for him!

Thanks,

Joslyn Chesson
Editor
WTOP News
(202) 895-5060

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 12:20:02 +0000
To: Lisa Monaco
Subject: RE: The Coronavirus Shows Why the U.S. Must Make Pandemic Disease a National Security Priority - Lawfare

Lisa:
Thanks for the note and for sending this. Very nice piece! I hope that all is well with you. I miss very much our interactions.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Lisa Monaco <(b) (6)>
Sent: Monday, February 10, 2020 8:09 PM
To: Lisa Monaco (b) (6)
Subject: The Coronavirus Shows Why the U.S. Must Make Pandemic Disease a National Security Priority - Lawfare

In case you missed this, my latest on the coronovirus.

https://www.lawfareblog.com/coronavirus-shows-why-us-must-make-pandemic-disease-national-security-priority

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 22:44:53 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: RE: for review: responses for Washington Times
Attachments: responses to Washington Times 2.10.2020 AL - with Fauci tracked changes.docx

See my tracked changes in attached document. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 10, 2020 4:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6) Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: for review: responses for Washington Times

Dr. Fauci –

The reporter Shen Wu Tan from the Washington Times reached out to us this morning with some questions about 2019-nCoV. I drafted proposed responses to these questions with input from Andrea. Please see attached. Please let me know if you have edits. I will send the final responses back to the reporter, and I will note they are attributed to you.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations

National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: ([redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 20:22:28 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Subject: FW: Wpost: Q&A with Anthony Fauci: Are we past the point of containment for coronavirus?

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Sent: Monday, February 10, 2020 2:37 PM
Subject: Wpost: Q&A with Anthony Fauci: Are we past the point of containment for coronavirus?

Opinions

Q&A with Anthony Fauci: Are we past the point of containment for coronavirus?

A man wears a protective mask while walking in Wuhan, China, on Feb. 10. (Stringer/AFP/Getty Images)

By
Robert Gebelhoff
Assistant editor and Opinions contributor
Feb. 10, 2020 at 2:22 p.m. EST

The latest strain of coronavirus continues to rage across China. Its death toll has surpassed 900, eclipsing the body count from China's SARS outbreak in 2002 and 2003.

To get a better sense of the disease and the U.S. government's response to it, we spoke to Anthony S. Fauci, immunologist and director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Below is a transcript of an interview with Fauci, edited for clarity and brevity.

Robert Gebelhoff: Right off the bat, what makes this virus different?

Anthony Fauci: Well, we have to be concerned whenever there's a virus that has — and I'm going to use a big word here — pathogenic potential. ... [The coronavirus] is brand-new, and there's no real underlying experience with it, so the general population is naive with regard to protection. And it has serious potential, because it's already spreading rapidly. It's the unknown aspect of something that already tells you it's a serious problem. We don't know where it's going.

Gebelhoff: Are we past the point of containment for this coronavirus?

Fauci: No, we're not. The short answer is we're not past the point of containment. But it really does have the potential to turn into a global pandemic. What we have now is a very serious epidemic in China. ... [But outside of China,] there is very little — but some — transmission from person to person. Once you get multiple countries that have sustained transmission from person to person, then it's beyond the situation where you can contain it. You can only mitigate it.

In the United States, we are clearly in the containment phase. ... And what we've done is we've identified. We've isolated. And we've done contact-tracing [identifying who might have come in contact with an infected person]. That seems to be successful. But once it it starts spreading all over the world ... then it's almost inevitable that it's going to start spreading here.

Gebelhoff: The Post reported last week that China withheld information from the public, including silencing medical professionals, and that this made the spread of the virus worse. How does the United States work with a government that we can't even trust to tell the truth to its people?

Fauci: That is an issue. And it's the reason why I have been saying that we need some of our people — CDC, NIH people — there on the ground, both helping and seeing with their own eyes exactly the extent of this. We want to be part of a [World Health Organization] convening group that goes there. But thus far, we've not been able to make that a reality.

Gebelhoff: And why's that?

Fauci: I don't know. We have asked. We have colleagues — scientific colleagues — in China that we've dealt with for years if not decades. Many of them have trained in the United States. And we know them as friends and as colleagues. They are the ones that are not holding back. ... But they're not the ones that make the official proclamations of what comes out. The solution to the problem in the question you're posing is that we really do want people there, so that we can not only help them but also provide some expertise that might supplement or complement their own expertise.

Gebelhoff: What does the United States do if [the coronavirus] does become a pandemic in the developing world?

Fauci: Well obviously we will try to help them to contain as best as possible. ... Right now, by definition, it is not truly a global pandemic. It is a very serious outbreak and epidemic in China, but the amount of sustained transmission outside of China is still minimal. ... But there are some countries where it is going to be very difficult to stop the evolution into sustained transmission. Obviously the [World Health Organization] and the global security network that we put up over the years will try to help those countries, but there's no guarantee that we'll be successful.

Gebelhoff: On that point, the head of the WHO has criticized travel bans and restrictions around the world as not helpful to stopping the outbreak. He said it was potentially "increasing fear and stigma." What

Fauci: Everyone agrees that travel bans and restrictions are almost never successful in completely stopping something is that invariably going to turn into a pandemic. ... What we are trying to do is to pause temporarily and give China enough time to put the lid on [this virus] to prevent it from becoming global and to give us a little more time to prepare. There's no indication or imagination that if this becomes a global pandemic that travel restrictions are going to mean anything. But they can mean something, as a temporizing activity.

Gebelhoff: What should the average person be doing right now about coronavirus?

Fauci: It's a good question. 1) They should realize at this point, it is a low risk. And 2) that risk can change, so pay attention to what's going on [and] to the ... announcements coming from the CDC. ... The things that you do for influenza — get vaccinated, wash your hands, avoid crowded places — are exactly the same things that you would do if we did get coronavirus here. So the question is, should we do anything different from what we're already doing? No. Should we all be wearing a mask? Absolutely not.

Read more:

The Post's View: The virus that shook China's system
Chen Guangcheng: Warning: Chinese authoritarianism is hazardous to your health
David Ignatius: The coronavirus outbreak shows the vulnerability of the 'Chinese model'
John M. Barry: Can this virus be contained? Probably not.
John Pomfret: The coronavirus reawakens old racist tropes against Chinese people

Robert Gebelhoff

Robert Gebelhoff is an assistant editor for The Post's Opinions section. He has been with The Post since 2015.Follow

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 20:18:24 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Potential Treament Strategy to Reduce Motality Caused by Coronavirus Infection

NIAID inquiries, Please

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Monday, February 10, 2020 3:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Potential Treament Strategy to Reduce Motality Caused by Coronavirus Infection

Dear Dr. Fauci:

One effective way to get things done is through the individuals like you at the frontline with authorities. I know that you are very busy, and I am sorry to bother you. You probably already knew what I'm going to say and appear to be so relaxed.

With the significant concern for the quick spread of coronavirus infection, I would like to propose a cell-based immunomodulation strategy to reduce the "cytokine storm", the main pathophysiologcal cause for the mortality. The scientific rationale regarding this strategy has been partially discussed in an article entitled " Extending the Horizon of Cell Based Immunotherapy by Understanding the Mechanisms of Action of Photopheresis" and other related articles on this topic.

Several potential treatment modality could be derived from this concept if more laboratory and clinical data support this motion, which include : (1) ozone therapy (withdraw about 50 ml – 100 ml blood from patient in transfusion bag, mixing with small amount of ozone ex vivo and re-infuse back to patient in 30 minutes); (2) Cupping therapy (medically induced subcutaneous hemorrhage by heat and vacuums effects) to expose self antigens to the abundant dendritic cells in the subcutaneous tissue in order to reinforce the self antigen tolerance. The best timing for these interventions in theory would be at the period of fever, viremia stage. These simple approaches can be incorporated with the other medical treatments and supportive care.

I cannot be certain, but want to help as a holistic physician. Thank you very much for reading this email and providing your insight as well as help.

Sincerely,

Ching Y. Voss, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 20:10:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Invitation to Speak at US-Asia Institute Event: February 26, Washington DC

Sorry. Cannot do. Congressional Hearing.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Zev Moses <zev.moses@usasiainstitute.org>
Sent: Monday, February 10, 2020 2:21 PM
To: Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Invitation to Speak at US-Asia Institute Event: February 26, Washington DC

Good afternoon,

The US-Asia Institute would like to formally invite Director Dr. Anthony Fauci to speak at an event on February 26 in Rayburn House Office Building, Room 2253, at 1:00 pm. Our formal invitation is attached.

This event will focus on the public health impacts of the novel coronavirus, the facts on the ground, trajectory of the virus, and work to contain the outbreak. The event aims to educate Congressional staff on these topics and to dispel rumors associated with the virus. We believe that Director Dr. Fauci's current research is vital to supporting productive and informative dialogue.

Please let us know if Director Dr. Fauci, or another NIAID representative, is available to participate in this event. We would be honored to host him or others from NIAID and our audience would be extremely interested to learn from your agency's research.

Sincerely,
Zev Moses

--

Zev Moses | Director, International & Government Affairs
US-Asia Institute
232 East Capitol St. NE
Washington, D.C. 20003
202-544-3181
www.usasiainstitute.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 19:19:42 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Invitation to Speak at the March 13-15 Trilateral Commission Meeting in Washington, D.C.
Attachments: Dr. Anthony Fauci - Trilateral Plenary Meeting Speaking Invitation.pdf

Let us discuss. We do not need to bring before the OD AM group. I would like to do this if possible. It is an invitation from Meghan O'Sullivan who was one of the security crew from Bush 43.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Fontaine <rfontaine@trilateral.org>
Sent: Monday, February 10, 2020 11:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Meghan O'Sullivan [redacted] (b) (6) Torrey Taussig <ttaussig@trilateral.org>
Subject: Invitation to Speak at the March 13-15 Trilateral Commission Meeting in Washington, D.C.

Dear Dr. Fauci,

The Trilateral Commission will hold its invitation-only annual plenary meeting in Washington, D.C., on March 13-15, 2020. I would like to invite you to participate in a conversation at the meeting on responding to the coronavirus and global pandemics.

As you may know, the Trilateral Commission was launched by David Rockefeller in 1973 to think through the shared challenges and leadership responsibilities of the three principal industrialized democratic areas of the world: Europe, North American, and Japan (now Asia). Today, the Commission believes its original mission of bringing democratic countries together to tackle international challenges should once again be a major priority for our country and our partners. This year's plenary meeting is a major, three-day gathering of our global membership during which we will explore the theme "Democracy and Capitalism at a Crossroads."

Your participation would make a great difference if you are available. Attached to this email you will find an invitation from North American chair Meghan O'Sullivan. Please do let us know if you have any questions about the event or your potential role in it, and we hope that you are able to accept our invitation.

Best wishes,

Richard

Richard Fontaine
Executive Director
Trilateral Commission - North America

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 18:52:31 +0000
To: Strauss, Eric M.
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Heat kills novel Coronavirus

Eric:

The following is all on background. Coronaviruses in general tend to circulate and infect predominantly in the winter season (Northern and Southern hemispheres have opposite seasons). We do not know for sure why this is the case; however, many believe that the enclosed spaces in winter (mostly indoor because it is cold) allows better spread of a respiratory borne virus. Also, some viruses tend to thrive in cold, dry weather as opposed to warm, moist weather. Remember, however, that when it is summer here, it is winter in Australia and Argentina. This may be the genesis of the information given to President Xi and President Trump that the virus may "go away" in the warm weather. However, this is a brand new virus with which we have no prior experience and it is entirely conceivable that seasonal changes will not have any impact on the spread.
Hope that this is helpful.
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Monday, February 10, 2020 12:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Heat kills novel Coronavirus

Dr. Fauci:

We've been seeing a lot about people saying the heat will kill the novel coronavirus? Is this medically sound?

Trump discussed Coronavirus briefly: He said he had a long talk with President Xi two nights ago, and the Chinese president told him "the heat generally kills this kind of virus."

The president claimed the virus will go away in April as the seasons change: "The virus that we're talking about having to do a lot of people. We think that goes away in April with the heat," he said.

____
Eric M. Strauss, ABC News
Managing Editor, Medical Unit
www.ericmstrauss.com
Phone: 212-456-2016
Connect on Social: T/I/F = @ericMstrauss

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 18:08:29 +0000
To: Jon LaPook
Subject: FW: "Coronavirus is airborne, Chinese official confirms"
Attachments: Amoy Gardens and SARS.pdf

Jon:
Thanks for the note. See attachment for our future discussion.
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Jon LaPook [redacted] (b) (6)>
Sent: Monday, February 10, 2020 10:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: amb@cbsnews.com; Kevin Finnegan <kpf@cbsnews.com>; Alturo Rhymes <RhymesA@cbsnews.com>; Jay Shaylor <Shaylor@cbsnews.com>; CBS LaPook <lapookj@cbsnews.com>
Subject: "Coronavirus is airborne, Chinese official confirms"

Hi Tony,
I need a Fauci brain dump.
You may have seen this:
https://www.nzherald.co.nz/world/news/article.cfm?c_id=2&objectid=12307276

Is this news? Don't we already know that the virus spread via droplet transmission? This article says aerosol transmission means "it can float a long distance to the air and cause infection later when it is breathed in." That makes it sound like the kind of spread that happens with measles, where the virus can linger in a room and infect somebody 2 hours after somebody with measles leaves the room.

Tomorrow, I will be giving an hour and a half of affiliate debriefings on this virus. So we will be reaching millions of people. I'd love to get the latest and greatest public health message. Incidentally, Howard Zucker and the infectious disease folks at NYU Langone are very concerned about overloading our emergency rooms with patients who have upper respiratory infection symptoms. What is the right message? If somebody calls thinking they have coronavirus, do you tell them to come in – risking infection of others? Do they stay home and wait for symptoms to get worse? Of course, it would be great if you could send them a kit and happen to home testing. But that's nowhere in the near future, right?

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 12:54:14 +0000
To: Sciutto, Jim
Subject: RE: Long time, no see!

Jim:

Thanks for the note. All is well here except that I am not getting much sleep - coronavirus 24/7. I look forward to being on your show.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Sciutto, Jim <Jim.Sciutto@cnn.com>
Sent: Monday, February 10, 2020 7:43 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Long time, no see!

Glad to have you on the show today. Looking forward. Hope all is well. Jim

Jim Sciutto
Newsroom Anchor & Chief National Security Correspondent
CNN
Email: jim.sciutto@cnn.com
Mobile: [redacted] (b) (6)
Twitter: @jimsciutto

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 11:18:00 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Awwad, David (NIH/NIAID) [C]
Subject: FW: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

We did this before, but we cannot do it at 7:30 AM [redacted] (b) (6). If they want to do it later in the day and we can fit them in, then fine. If not, that is OK too. Not the highest priority

---

From: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Sent: Monday, February 10, 2020 6:05 AM
To: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6); Richa Sharma (WION) <Richa.sharma@zeemedia.esselgroup.com>
Subject: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Dear Anthony S. Fauci,

M.D., NIAID Director

Greetings from WION!

I would like to request for **your** time for an interview with us today for **10-15 minutes at 7:30 am Monday, in Maryland, USA via Skype.**

It's regarding the update in the story of Coronavirus - The World Health Organization chief says there have been 'concerning instances' of onward transmission of coronavirus among people who hadn't been to China.

Waiting for your confirmation.

CLICK HERE TO WATCH WION LIVE :

https://www.wionews.com/live-tv

Live TV, News | wionews.com

© 1998-2019 Zee Media Corporation Ltd (An Essel Group Company), All rights reserved.

www.wionews.com

Look forward hearing from you .

Regards

Latika Chugh

WION TV , India

From: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Sent: Thursday, February 6, 2020 6:41 PM
To: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>; KUMAR SUNNY <KUMAR.SUNNY@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Richa Sharma (WION) <Richa.sharma@zeemedia.esselgroup.com>
Subject: RE: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Our pleasure. Thank you again.

David

David Awwad, Contractor
Customer Services Branch, NIH\NIAID\OCICB
NTT DATA Services Federal, LLC
Phone: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Sent: Thursday, February 6, 2020 8:06 AM
To: Awwad, David (NIH/NIAID) [C] <[redacted] (b) (6)>; KUMAR SUNNY <KUMAR.SUNNY@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Richa Sharma (WION) <Richa.sharma@zeemedia.esselgroup.com>
Subject: Re: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

David,
Many thanks for the Interview.

He really added value in our show.

We look forward to have his presence in future on WION.

Regards
Latika Chugh

From: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)
Sent: Thursday, February 6, 2020 5:00 PM
To: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>; KUMAR SUNNY <KUMAR.SUNNY@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] <[redacted] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Richa Sharma (WION) <Richa.sharma@zeemedia.esselgroup.com>
Subject: RE: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Thank you much.

From: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Sent: Thursday, February 6, 2020 6:29 AM
To: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>; KUMAR SUNNY <KUMAR.SUNNY@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6); Richa Sharma (WION) <Richa.sharma@zeemedia.esselgroup.com>
Subject: Re: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Dear David,

It will be **live** Interview on WION with Dr. Fauci at 7 am Maryland Time for 10 -15 minutes only on Skype.

My colleague **Mr. Sunny** (marked in email) will patch the Skype sharp in 30 minutes from now.

Also, We have send you Skype Request from WION Skype Id some hours ago. I request you to please add us.

Regards
Latika Chugh

From: Awwad, David (NIH/NIAID) [C] <[redacted] (b) (6)
Sent: Thursday, February 6, 2020 4:54 PM
To: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Let me know if you would like to connect a couple minutes earlier. I am on standby.

David
[redacted] (b) (6) (cell)

David Awwad, Contractor
Customer Services Branch, NIH\NIAID\OCICB
NTT DATA Services Federal, LLC
Phone: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Sent: Wednesday, February 5, 2020 9:25 AM
To: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Barasch, Kimberly (NIH/NIAID) [C]

[redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Thanks
See you tomorrow

Latika : [redacted] (b) (6)

Get [Outlook for Android]

From: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 7:50:26 PM
To: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Skype Handle: Live:niaidithelp or niaidithelp@outlook.com

David: [redacted] (b) (6)

Sent from my iPhone

> On Feb 5, 2020, at 9:16 AM, Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com> wrote:
>
> Yes,
>
> It completely fine with us.
>
> Our Skype Id - wion record. Please share your Skype id with us.
>
> We will be online at **7 AM ET TIME WHICH WILL BE 5:30 PM OUR TIME IN IST.**
>
> Regards
> Latika Chugh
> Producer , Wion
> India
>
> ---
>
> **From:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
> **Sent:** Wednesday, February 5, 2020 7:35 PM
> **To:** Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
> **Cc:** Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>; Awwad, David

(NIH/NIAID) [C] [redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Dr. Fauci can do a skype interview Thursday morning 7 am – 7:15 am ET by skype. Please let us know asap if that works.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Sent: Tuesday, February 4, 2020 5:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Wion Guest Relations <wion.guestrelations@zeemedia.esselgroup.com>
Subject: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Dear Anthony S. Fauci,
M.D., NIAID Director

Greetings from WION!

World Is One News (WION)is an international English news channel from the Zee Media Group, India's premier television brand. WION is uniquely positioned as the 'Global Voice of India', presenting its own perspective on international issues of critical significance. WION is the preferred channel for most opinion makers across the world as they happily attend our shows bringing in credible viewpoints on many issues. WION is currently available in India, Indonesia, The Republic of Philippines, Australia, Vietnam, Hong Kong, UAE, Malaysia, Singapore and South Africa etc.

WION's shows have featured Indian Political scenario & global leaders speaking on issues facing their country and the world in general.

I would like to request for **your** time for an interview with us anytime soon today for **10-15 minutes**. We usually conduct Interview via **Skype**. Request you to share your Skype Id.

It's regarding CORONAVIRUS.

Please let us know when is the best time for you to join us via Skype. Waiting for your confirmation.

CLICK HERE TO WATCH WION LIVE :
https://www.wionews.com/live-tv

Live TV, News | wionews.com

© 1998-2019 Zee Media Corporation Ltd (An Essel Group Company), All rights reserved.

www.wionews.com

Look forward hearing from you .

Regards

Latika Chugh

WION TV , India

Zee Disclaimer: Confidentiality / Proprietary Note: This communication is confidential /proprietary and is intended for use only by the addressee. Zee Media Corporation Ltd. accepts no responsibility for any mistransmission of, orinterference with, this communication

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 00:49:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNN Interview CONFIRMATION: Dr. Anthony Fauci

Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Sunday, February 9, 2020 7:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: CNN Interview CONFIRMATION: Dr. Anthony Fauci

Sent from my iPhone

Begin forwarded message:

> **From:** "Griffin, Janelle" <Janelle.Griffin@turner.com>
> **Date:** February 9, 2020 at 5:54:23 PM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)
> **Cc:** "Stover, Kathy (NIH/NIAID) [E]" (b) (6), "Routh, Jennifer (NIH/NIAID) [E]" (b) (6), "Akinso, Woleola (NIH/OD) [E]" (b) (6), "Greene, Nyja" <Nyja.Greene@turner.com>
> **Subject: CNN Interview CONFIRMATION: Dr. Anthony Fauci**
>
> Hello,
>
> We're all set for tomorrow! ☺
>
> Dr. Fauci is confirmed for a live segment at 10:15a et on Newsroom w/Poppy Harlow & Jim Sciutto.
> Please ensure he's seated no later than 10:05a et. (the show is aware that Dr. Fauci has a hard at 10:20a et)
>
> Nyja Greene, cc'd on this email, will be your Atlanta based show point of contact tomorrow.
> Any issues or changes please don't hesitate to reach out to her in the morning.
>
> Monday's segment will focus on latest Coronavirus developments: Dr. Fauci covered the SARS outbreak almost 17 years ago- from what he's seeing now with the Coronavirus, how bad do think this could become? How does the Coronavirus compare/contrast with others like Ebola or Zika? How effective are quarantines in situations like this? What, if any, precautions should we be taking right now in America? Any thoughts/talking points you can send over from Dr. Fauci evening would be super helpful.

Patricia- thank you sooo much for all of your help with organizing. We really appreciate it and look forward to Dr. Fauci joining the show.

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Saturday, February 8, 2020 1:04 PM
To: Griffin, Janelle <Janelle.Griffin@turner.com>
Cc: Stover, Kathy (NIH/NIAID) [E] <[redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6) Akinso, Woleola (NIH/OD) [E] [redacted] (b) (6)>
Subject: Re: CNN Interview Request: Dr. Anthony Fauci

Ok thx

Sent from my iPhone

> On Feb 8, 2020, at 12:54 PM, Griffin, Janelle <Janelle.Griffin@turner.com> wrote:
>
> Great- thank you!
>
> Let's keep things for a segment at 10:15a on Monday.
>
> I'll be back in touch after my 6p show planning conference call Sunday evening.
>
> Thank so much Patricia ☺
>
> ---
>
> **From:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
> **Sent:** Saturday, February 8, 2020 12:53 PM
> **To:** Griffin, Janelle <Janelle.Griffin@turner.com>
> **Cc:** Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6); Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Akinso, Woleola (NIH/OD) [E] [redacted] (b) (6)>
> **Subject:** Re: CNN Interview Request: Dr. Anthony Fauci
>
> We can make the 9 am hour work too. Pls let us know ASAP so I can make sure our studio is available. When will you have a final answer?
>
> My cell is [redacted] (b) (6) and am always on email which is better for me.
>
> Sent from my iPhone

On Feb 8, 2020, at 12:48 PM, Griffin, Janelle
<Janelle.Griffin@turner.com> wrote:

That's great- thanks Patricia!
We'll add him to our calendar for 10:15a et.

If we needed to move him his segment to the 9a et hour would that also work?

May I have your cell number for my records?

From: Conrad, Patricia (NIH/NIAID) [E]
[redacted] (b) (6)>
Sent: Saturday, February 8, 2020 12:46 PM
To: Griffin, Janelle <Janelle.Griffin@turner.com>
Subject: Fwd: CNN Interview Request: Dr. Anthony Fauci

Hi Janelle

We can make this work - it would need to be from between 10 am - 1020 am hard stop.

Will that work?

It would need to be from our NIH Readycam studio with Videolink

Let me know if that works

From: Griffin, Janelle
<Janelle.Griffin@turner.com>
Sent: Saturday, February 8, 2020 11:33 AM
To: Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)
Subject: CNN Interview Request: Dr. Anthony

Fauci
Importance: High

Good morning Dr. Fauci,

I hope this email finds you doing well.

I'm reaching out on behalf of Newsroom w/Poppy Harlow & Jim Sciutto hoping you can join for an interview.
Are you available to join CNN this Monday February 10th in the 10a et hour?
This would be live for about 5-7 minutes to discuss developments regarding the coronavirus.

Please feel free to contact me via email or at (404) 452-7769 to let me know.

Thanks for your time- I look forward to hearing from you soon.

Janelle Griffin-Butts
Editorial Producer, **CNN**
Email: janelle.griffin@turner.com | Twitter: @janellegCNN

From: [redacted] (b) (6)
Sent: Sun, 9 Feb 2020 16:36:38 -0500
To: autotell|
Subject: Re: Help Re: Novel Rx for Coronavirus

Thanks, Andy.
Best regards,
Tony

> On Feb 9, 2020, at 4:29 PM, autotell| [redacted] (b) (6)>wrote:
>
> Thank you my friend, hope it leads to something good for patients and the public.
> I was at a meeting of the "Philosophical Society of Texas" this week end and meet with a lot of Bush alums like Don Evans and Margaret Spellings etc and Margaret was commenting on the coronavirus scare and how fortunate we are to have you there at NIH looking after us!! If you ever decide to relocate to Texas you have a fan club here!
> All my best
> Andy
>
> ---
>
> **From:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> **Sent:** Sunday, February 9, 2020 7:24 AM
> **To:** autotell| [redacted] (b) (6)>
> **Subject:** RE: Help Re: Novel Rx for Coronavirus
>
> Andy:
> Thanks for the note. I will take a look at this and more importantly, I will run it by the people here at NIAID who are running the nCoV research initiative. I will get back to you with their and my assessment. I hope that all is well with you. We are doing a lot of late nighters here. Feels like my internship. ☐☐
> Best regards,
> Tony
>
> ---
>
> **From:** autotell| < [redacted] (b) (6)t>
> **Sent:** Friday, February 7, 2020 2:50 PM
> **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> **Cc:** Xiaokui Zhang [redacted] (b) (6)>; Robert Hariri [redacted] (b) (6)>
> **Subject:** Help Re: Novel Rx for Coronavirus
>
> Tony

Greetings. Always proud to see you at the White House (with Alex) leading the fight against this latest infectious disease threat [redacted] (b) (4)

(b) (4)

[redacted]

I trust this email finds my Paisano happy and content as you continue to be a gift to this nation and the world. Please let me know you received this email.
My best to you and your family. Hope our paths cross soon
Andy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 18:23:24 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus

WOW! I did not know that. Good talking point for press conferences.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Sunday, February 9, 2020 1:13 PM
Subject: Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus

Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus

by Savannah Koplon

- February 07, 2020
- Print
- Email



Richard Whitley, M.D., Distinguished Professor at UAB and principal investigator of the U19 grant

The investigational drug remdesivir, developed through research conducted through the Antiviral Drug Discovery and Development Center, or AD3C, and centered at the University of Alabama at Birmingham, is being used to treat select infected patients in the United States and in China who have been affected by the outbreak of novel coronavirus (2019-nCoV).

UAB was awarded a $37.5 million, five-year U19 grant from the National Institute of Allergy and Infectious Diseases Centers of Excellence for Translational Research to study and develop treatment for high-priority emerging infections. Work has been taking place in earnest to develop drugs for emerging influenza, flaviviruses (dengue, West Nile virus and Zika), coronaviruses that cause SARS and MERS, and alphaviruses such as Venezuelan equine encephalitis virus and chikungunya. The grant is a multi-institutional collaboration to accelerate drug discovery for these emerging infections and is a public-private partnership between academic institutions and Gilead Sciences.

Remdesivir, developed to treat the coronavirus causing MERS, was found to have significant activity against the 2019-nCoV strain when the outbreak began in the Chinese city of Wuhan. Importantly, remdesivir had demonstrated efficacy in treating other medically important coronaviruses MERS and SARS in cell culture and animal models. Based on the compassionate plea requests of treating physicians in the United States, Gilead Sciences released remdesivir for use in a few patients, although the drug has not yet been tested for safety or efficacy in these diseases. "The release of remdesivir for safety and efficacy studies is a major accomplishment for the AD3C – namely the U19 grant – as it shows significant and swift advance of antiviral drugs to help treat and respond to emerging infectious disease outbreaks on an international scale and, importantly, to anticipate the introduction of these infections in the United States," said Richard Whitley, M.D., Distinguished Professor at UAB and principal investigator of the U19 grant.

WATCH: UAB infectious disease experts provide information on the 2019 novel coronavirus.

Gilead Sciences and supporting researchers and clinicians are working with health authorities from the World Health Organization and in China to establish a placebo-controlled study to determine whether remdesivir is safe and effective in treating 2019-nCoV.

> "This is a prime example of how the research we are conducting at UAB plays a critical role in treating patients on a global scale and our contribution of substantial scientific advances."
>
> – Richard Whitley, M.D., UAB Distinguished Professor

"The collaboration between UAB, our colleagues at Southern Research, Vanderbilt University and the University of North Carolina, along with our pharmaceutical partner Gilead Sciences, is indicative of our collaborative approach to respond to outbreaks in real time, and in helping communities worldwide fight 2019-nCoV. This is a prime example of how the research we are conducting at UAB plays a critical role in treating patients on a global scale and our contribution of substantial scientific advances," Whitley continued.

Whitley expressed that the potential for mutation of 2019-nCoV means that UAB's AD3C and partners will need to build backup molecules for potential testing and treatment in the near future.

The World Health Organization has declared the 2019-nCoV outbreak a "public health emergency of international concern."

UAB is the lead institution for AD3C and research conducted; but the team unifies scientists experienced in virology, viral immunology, pathogenesis, medicinal chemistry and translation to human disease from UAB, University of North Carolina, Vanderbilt University, Emory University, Washington University, The University of Texas Medical Branch, Southern Research, the Emory Institute of Drug Discovery, the University of Colorado, Denver, and Oregon Health & Science University.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 18:20:45 +0000
To: Liz Szabo
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Plumbing as possible means of spread of coronaviruses
Attachments: Amoy Gardens and SARS.pdf

Liz:

Thanks for the note. I do not know enough about the plumbing system on the cruise ships to make any meaningful comments, certainly not any comments that could be attributable to me. And so, I will pass on this one, The best person to comment or opine on this would be Mart Cetron of CDC. FYI, in case you do not have it in front of you, I am attaching the original NEJM article on the Amoy Gardens Apartment story in Hong Kong with SARS.
Best regards,
Tony

From: Liz Szabo <LSzabo@kff.org>
Sent: Saturday, February 8, 2020 7:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Plumbing as possible means of spread of coronaviruses

HI Dr. Fauci,

I hope you're doing well. I know you must be very busy.

Our editor, Dr. Elizabeth Rosenthal, is wondering whether the new coronavirus might be spreading through plumbing on the cruise ship? She sent me these links, below, about how plumbing played a role in spreading SARS in the Amoy Gardens apartment complex in Hong Kong. Libby lived in China during the SARS outbreaks and remembers that the sinks there don't have the typical U-bend trap that sinks have here, which allows sewer gases and unpleasant odors to come through.

If plumbing is a risk for spreading coronaviruses, what could be done to protect passengers on cruise ships?

I'd love to hear your thoughts on this, even if just by email.

Thanks for your time.

Liz Szabo
Kaiser Health News
571-201-9009

https://www.cbsnews.com/news/leaky-plumbing-linked-to-sars-spread/

https://www.cnn.com/2013/02/21/world/asia/sars-amoy-gardens/index.html

https://plumbingconnection.com.au/new-report-proves-plumbing-link-to-sars/

https://www.infectioncontroltoday.com/personal-protective-equipment/sars-and-plumbing-role-sewage-plays-spreading-disease

https://jamanetwork.com/journals/jama/fullarticle/2761044?guestAccessKey=f61bd430-07d8-4b86-a749-bec05bfffb65&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=020720

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:59:10 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Cc: Schwetz, Tara (NIH/OD) [E];Erbelding, Emily (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [C] [redacted] (b) (6))
Subject: RE: NCATs request re. Coronavirus

Larry:

[redacted] (b) (5)

Best,
Tony

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Sent: Sunday, February 9, 2020 12:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Schwetz, Tara (NIH/OD) [E] [redacted] (b) (6)>
Subject: NCATs request re. Coronavirus

Tony,

[redacted] (b) (5)

Thanks,
Larry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:53:04 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci

OK. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, February 9, 2020 12:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci

I am working on this.

Sent from my iPhone

Begin forwarded message:

> **From:** "Varon, Sophie" <Sophie.Varon@turner.com>
> **Date:** February 9, 2020 at 12:30:31 PM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci**
>
> Hello Dr. Fauci and Patricia,
>
> I hope you're both doing well.
> I'm reaching out to see if Dr. Fauci could be available for an interview with Anderson Cooper on Monday for his CNN digital program, Full Circle. Full Circle is an interesting platform because it allows us to take live viewer questions. This taped interview would air on Tuesday at 5PM and Anderson could tape tomorrow in the 4PM hour or after 5:45PM.
>
> The topic is of course the Coronavirus.
>
> Thank you for considering this request!
>
> Sophie Varon
> Editorial Producer, CNN AC360
> cell- [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:52:22 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci

If we can do this, I would be happy to.

From: Varon, Sophie <Sophie.Varon@turner.com>
Sent: Sunday, February 9, 2020 12:30 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)
Subject: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci

Hello Dr. Fauci and Patricia,

I hope you're both doing well.

I'm reaching out to see if Dr. Fauci could be available for an interview with Anderson Cooper on Monday for his CNN digital program, Full Circle. Full Circle is an interesting platform because it allows us to take live viewer questions. This taped interview would air on Tuesday at 5PM and Anderson could tape tomorrow in the 4PM hour or after 5:45PM.

The topic is of course the Coronavirus.

Thank you for considering this request!

Sophie Varon

Editorial Producer, CNN AC360

cell- [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:51:21 +0000
To: Hall, Bill (HHS/ASPA)
Subject: FW: CNNI Interview with Dr. Anthony Fauci,

Bill:
This link below is for an interview that I gave for CNN International this morning. As we all know, it makes such a big difference when the interviewer knows the subject and asks good questions that this interviewer did. Would that they were all like her.
Best regards,
Tony

From: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Sent: Sunday, February 9, 2020 12:30 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: RE: CNNI Interview Request: Dr. Anthony Fauci,

We are so glad to!

Here is the clip https://we.tl/t-BOkVJSyQVB

All the best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: 09 February 2020 16:15
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

My pleasure- so glad we could make it work. Please do send us the the video segment

Best ,
Patty.

Sent from my iPhone

> On Feb 9, 2020, at 11:06 AM, Hynds, Joanna (NE) <Joanna.Hynds@turner.com> wrote:
>
> Dear Mr Fauci,

I just wanted to thank you for your accommodation at such short notice for the earlier interview. I do apologise for the miscommunication on my part.

We really enjoyed having you on the show!

Thanks too to Patricia, for helping coordinate this all at last minute.

I hope you both have a great evening.

Many thanks again for your patience and understanding.

If you would like a video segment of your hit I will gladly send you it on request.

Best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: 09 February 2020 14:26
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

Do you have the hit time and contact info please send ASAP.

Sent from my iPhone

> On Feb 9, 2020, at 8:38 AM, Hynds, Joanna (NE) <Joanna.Hynds@turner.com> wrote:
>
> Perfect – we really appreciate this.
>
> I will get you these details ASAP.
>
> Does Dr Fauci need a car?
>
> Best,
>
> Joanna

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: 09 February 2020 13:33
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

Adding Dr Fauci here

He can come to the WDC CNN studio. Please send us the exact live hit time as well as the studio address and on-site contact name, number and cell number ASAP. Dr Fauci cell is [redacted] (b) (6) and you have mine.

Thank you.

Sent from my iPhone

> On Feb 9, 2020, at 8:21 AM, Hynds, Joanna (NE) <Joanna.Hynds@turner.com> wrote:
>
> Dear Patricia,
>
> Just following up from our phone conversation, unfortunately I won't be able to facilitate a StudioGo truck for this interview.
>
> We are still really keen to get Dr Fauci on the show – will he be able to come to the bureau?
>
> I will be able to book him a car if he needs.
>
> Let me know what suits,
>
> Best,
>
> Joanna
>
> **From:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
> **Sent:** 09 February 2020 13:00
> **To:** Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
> **Subject:** Re: CNNI Interview Request: Dr. Anthony Fauci,

For the trick- the location is northwest Washington DC. Near American university.

Sent from my iPhone

> On Feb 9, 2020, at 7:51 AM, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
>
> Please call me ASAP at [redacted] (b) (6) for this request.
>
> Sent from my iPhone
>
> Begin forwarded message:
>
>> **From:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
>> **Date:** February 9, 2020 at 7:08:54 AM EST
>> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
>> **Subject: Fwd: CNNI Interview Request: Dr. Anthony Fauci,**
>>
>> Sent from my iPhone
>>
>> Begin forwarded message:
>>
>>> **From:** "Hynds, Joanna (NE)" <Joanna.Hynds@turner.com>
>>> **Date:** February 9, 2020 at 6:06:15 AM EST
>>> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
>>> **Cc**: "Tejera, Isabel (Intern)" <isabel.Tejera@turner.com>, "Lovejoy, Hannah

(NE)"
<Hannah.Lovejoy@turner.com>
Subject: CNNI Interview Request: Dr. Anthony Fauci,

Dear Dr Fauci,

I hope you are well! I am reaching out from CNN International to enquire if you are available today to join us on **Connect the World** at **11aET** to discuss the coronavirus.

Might this be a possibility? It would be great to arrange this.

Background on CNN

- CNN International reaches more than 250 million households worldwide including in the US via DIRECTV.
- CNN International is the number one international TV news channel according to all major media surveys across Europe, the Middle East and Africa, the Asia

Pacific region and Latin America.
- In September 2019 CNN.com had 162 million unique readers globally per month and 114 million mobile readers a month, leading the BBC, Yahoo and New York Times.

Best,

Joanna Hynds

Planning Desk
CNN International
+ 44 207 693 1640 (office)
+ [redacted] (b) (6) (cell)
joanna.hynds@turner.com
<image001.png>

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks.

Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:34:16 +0000
To: Denise Ober
Subject: RE: HEART WRENCHING QUESTION! ❤?

The State Department and CDC travel alerts for China, which advise only absolutely essential travel, do not officially include Hong Kong and so there is no official restriction right now (but this could change), and there is no quarantine requirement upon returning from Hong Kong. However, this all could change quickly. [redacted] (b) (6)

-----Original Message-----
From: Denise Ober [redacted] (b) (6)>
Sent: Saturday, February 8, 2020 3:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: HEART WRENCHING QUESTION! ❤□

Dear Dr. Fauci,
I realize this is a long shot for you to answer this email. Please forgive me since Im sure you are so extremely busy and so very importantly needed at this time. I do apologize for taking even a moment from your high demand schedule. But thought I'd try to reach out anyway in case you did see this.
I saw an interview recently you had with Dr Baucher posted by JAMA. From your expertise and knowledge about the coronavirus thus far, if you had planned to travel to Thailand mid March via stop over at Hong Kong would you?
(b) (6) [redacted]

Thank you from my concerned heart!
Thank you for EVERYTHING you do and have done in the past!
Best to you,
Denise Ober
Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:26:01 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [C] ([redacted] (b) (6));Barasch, Kimberly (NIH/NIAID) [C];Greg Folkers [redacted] (b) (6);Marston, Hilary (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Help Re: Novel Rx for Coronavirus
Attachments: [redacted] (b) (4) in 2019-CoV Proposal 07Feb2020.docx

Cristina:

This is not just your ordinary person writing to us. This is Dr. Andrew von Eschenbach, former Director of NCI and Former Commissioner of FDA. I have no idea if this proposal has any merit; however, please have someone go over it carefully and put together a response. Also, only if appropriate, and feasible, see if there is any way we can be of assistance to him. Thanks.
Best regards,
Tony

From: autotell| [redacted] (b) (6)
Sent: Friday, February 7, 2020 2:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Xiaokui Zhang [redacted] (b) (6)>; Robert Hariri [redacted] (b) (6) [redacted] (b) (6)
Subject: Help Re: Novel Rx for Coronavirus

Tony
Greetings. Always proud to see you at the White House (with Alex) leading the fight against this latest infectious disease threat. [redacted] (b) (4)
[redacted] (b) (4)

I trust this email finds my Paisano happy and content as you continue to be a gift to this nation and the world. Please let me know you received this email.
My best to you and your family. Hope our paths cross soon
Andy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:17:07 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft responses to questions from Italian news agency

See my edits in red.

From: Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, February 7, 2020 2:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FOR ASF REVIEW: Draft responses to questions from Italian news agency

Hi Dr. Fauci,

Below are draft responses to questions from a reporter with the Italian news agency ANSA. Please let me know if you have any suggested edits, and I'll move it along.

Thanks,
Kathy

Enrica Battifoglia
Science and Technology Head Editor
ANSA news agency (Italian news)
Enrica.Battifoglia@ansa.it
Expected place of publication: ANSA Science web page (www.ansa.it/scienza)

Dear Professor Fauci,

I am Enrica Battifoglia of the Italian news agency ANSA, I already have had the pleasure to interview you several times at the AIDS world conferences.

I would like to ask you some questions about Coronavirus 2019-nCoV, to be published on the ANSA Science web page (www.ansa.it/scienza), the main online science news resource in Italy with over 1.5M contacts each month. I am sure that your clarity and competence will be highly valuable to put some much-needed order among so many contrasting news and data, and would be much appreciated by our readers.

1. **Do the current available data allow to understand the threat level of coronavirus 2019-nCoV in terms of both lethality and diffusion speed, and about the possible evolution scenarios of the disease?**

There is much that we do not know about the novel coronavirus. Currently, there have been more than 3**7**,000 confirmed cases in China, and China has reported more than **8**00 deaths. As you know, there have been three confirmed cases in Italy to date. **The reported case fatality rate (lethality) among the 37,000 cases that have come to the attention of the health care system is 2%. However, given that there are likely many more cases that are without symptoms or with minimal symptoms , the actual death rate is probably lower than 2%.**

It is impossible to predict how the virus will evolve. It is our hope that the extraordinary containment measures that China has implemented will help **prevent** the outbreak from becoming a global pandemic. But given that the virus is present in 27 countries to date and can be transmitted from person-to-person, it may take a foothold and **evolve into a global pandemic**.

2) **What exactly do we know about its modes of transmission, especially from people who do not yet have the symptoms?**

Again, there is much that we do not know about the novel coronavirus, including its specific transmission abilities. Based on initial findings that have been reported, we suspect its transmission is similar to influenza and other respiratory viruses, namely that is transmitted through respiratory droplets when an infected person coughs or sneezes, and by touching surfaces, such as door handles, that **recently** have virus on them and then touching your face. There have also been reports that the virus **is present in feces and vomit. However, it is still uncertain that the virus can be transmitted through this route**.

Traditionally, most viruses are transmitted when someone has symptoms. With the novel coronavirus; however, there appears to be asymptomatic transmission occurring. We do not know how many cases are being driven by asymptomatic transmission or by those with symptoms. Typically, viruses are largely transmitted by infected people experiencing symptoms.

3) **Are the genetic sequences provided by China enough to start working on a vaccine?**

The genetic sequences provided by China enabled researchers to quickly develop a diagnostic that is being used to determine whether someone is infected with the novel coronavirus. The genetic information has also been useful in work to develop a preventive vaccine. The National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, is building on its experience with the SARS and MERS coronaviruses to better understand the virus as well as develop and test rapid point-of-care diagnostics, vaccines and treatments, including broad-spectrum antivirals and antibody therapies. In terms of vaccines specifically, we are working with the biotechnology company Moderna and the Coalition for Epidemic Preparedness Innovation (CEPI) to develop a "messenger RNA" vaccine for the novel coronavirus. Other countries and companies are working to develop a vaccine as well.

4) **What are the technical times to develop a working vaccine in terms of scientific research, and what are the approx times for the necessary legal certifications, and for industrial production and distribution?**

In terms of our work with Moderna and CEPI to develop a vaccine, we anticipate having an experimental vaccine ready for Phase 1 clinical trials within 2 to 3 months. This Phase 1 clinical trial will involve administering the vaccine to a small number of healthy adults in the United States to see if it is safe and has some ability to induce an immune response. If that is successful and the outbreak has not ended, we will move to a larger Phase 2 clinical trial with the expectation of **proving the efficacy (or not) of the vaccine within 1 to 1.5 years. If efficacious, it will still take additional months to produce enough vaccine to distribute widely.**.

In addition to this vaccine, NIAID is also supporting scientists and companies to develop other vaccine candidates.

5) **2019-nCov is the third Coronavirus aggressive for humans that has appeared in the East in the last 20 years and in 2009 the virus responsible for the flu pandemic too did come from China: what sort of preventive measures could be practicable to reduce the risk of repetition of these events?**

To clarify, the 2009 H1N1 influenza virus was first reported in Mexico, not China.

Viruses affecting humans have occurred throughout history, from the Bubonic Plague to the 1918 flu. We cannot predict what emerging infectious diseases will occur nor prevent the unknown from occurring in the first place. What we can do is learn as much as we can about emerging viruses, so that we can rapidly develop safe and effective point-of-care diagnostics, treatments and vaccines to protect against infection.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 16:41:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Cowen Health Care Conference in Boston - China Pharma Market Panel - March 2, 2020 in Boston

Please RSVP no.

From: Scala, Steve <Steve.Scala@cowen.com>
Sent: Sunday, February 9, 2020 11:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Nadeau, Phil <Phil.Nadeau@cowen.com>; Miner, Kathy <Kathy.Miner@cowen.com>; Nedelcovych, Michael <Michael.Nedelcovych@cowen.com>
Subject: Cowen Health Care Conference in Boston - China Pharma Market Panel - March 2, 2020 in Boston

Hi Dr. Fauci

I am a pharmaceutical industry analyst at Cowen and Company, a New York City based investment company that specializes in health care. Each year we host a Health Care Conference in Boston in March that attracts 200+ companies and 1000+ investors. During this year's conference, we had planned to host a one-hour panel discussion on the evolution of and reforms within the China Health Care System and China Pharmaceutical market. However, given global concerns around Coronavirus, we have decided to focus the panel instead on the virus and the outlook for emerging treatments. This perspective is critical to health care companies and therefore the institutions that invest in them.

Our panel will take place during Cowen's 40th Annual Health Care Conference, which will be held at the Marriott Copley Place in Boston on March 2-4, 2020. We plan to host this panel on **Monday morning, March 2nd, between 9:05-10:05AM**. Attendees at our conference include institutional investors from insurance companies, mutual funds, pension funds, banks, and other types of funds, mainly in the U.S. and EU.

Cowen would provide you an honorarium for your time during the one-hour panel. **We propose an honorarium of $1,500**, and we reimburse conference-related travel expenses.

The discussion will be Q&A only and no presentation on your part is requested.

We look forward to hearing from you.

Sincerely,

Steve Scala

In line with best practices suggested for brokerage firms, Cowen has a policy regarding our interaction with subject matter experts such as yourself, and by accepting and participating in this engagement, you agree to the conditions of this policy, including that you will not knowingly disclose any material non-public and/or confidential information; that your current employer permits you to participate in our event; that you are not employed by any of the companies anticipated to be discussed; and that your participation will not cause you to knowingly violate any contract (e.g., employment contract or consulting contract), agreement (e.g., confidentiality agreement) or other duty of confidentiality (e.g., serving on a board of directors) that you may have.

COWEN

Steve Scala
Pharmaceutical Industry Analyst
Equity Research

Cowen and Company, LLC
Two International Place, 28th Fl.
Boston, MA 02110
617-946-3923
steve.scala@cowen.com
www.cowen.com

This message and any attachments are confidential. If you are not the intended recipient, please notify the sender immediately and destroy this email. Any unauthorized use or dissemination is prohibited. All email sent to or from our system is subject to review and retention. Nothing contained in this email shall be considered an offer or solicitation with respect to the purchase or sale of any security in any jurisdiction where such an offer or solicitation would be illegal. Neither Cowen Inc. nor any of its affiliates ("Cowen") represent that any of the information contained herein is accurate, complete or up to date, nor shall Cowen have any responsibility to update any opinions or other information contained herein.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 16:41:04 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Podcast: Newt's World Ep 56: China's Coronavirus http://bit.ly/2Sud2am

Definitely for the Director's page

From: Folkers, Greg (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Sunday, February 9, 2020 9:45 AM
Subject: Podcast: Newt's World Ep 56: China's Coronavirus http://bit.ly/2Sud2am

Is the Coronavirus the next global pandemic or will the disease be eradicated in a short period of time? Newt's guests, Dr. Anthony Fauci and Dr. Peter Daszak, provide the information you need to know about the Coronavirus crisis.

NEWT'S WORLD
Westwood One
Newt's World
Episode 56: China's Coronavirus
ART
SHARE
SUBSCRIBE
DOWNLOAD
DESCRIPTION
00:00 / 47:52
PLAYLIST

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: [redacted] (b) (6)
Sent: Sun, 9 Feb 2020 10:53:02 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Subject: Fwd: CNNI Interview Request: Dr. Anthony Fauci,

Done

Begin forwarded message:

> **From:** "Hynds, Joanna (NE)" <Joanna.Hynds@turner.com>
> **Date:** February 9, 2020 at 9:49:21 AM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** "Pfeifer, Hazel" <Hazel.Pfeifer@turner.com>, "Lovejoy, Hannah (NE)" <Hannah.Lovejoy@turner.com>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: RE: CNNI Interview Request: Dr. Anthony Fauci,**
>
> Hi Patricia,
>
> I have let DC know, Angie will be there to greet him at 10.20a and bring him straight up.
>
> DC Number: +1 202 5100172.
>
> Best,
>
> Joanna
>
> ---
>
> **From:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
> **Sent:** 09 February 2020 14:42
> **To:** Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
> **Cc:** Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> **Subject:** Re: CNNI Interview Request: Dr. Anthony Fauci,
>
> We are good. 1030 am ET his is firm. He will arrive the wdc cnn studio at 820 am ET so if you can have someone meet him at the entrance lobby to get him upstairs quickly that would be helpful.
>
> Sent from my iPhone

On Feb 9, 2020, at 9:39 AM, Hynds, Joanna (NE)
<Joanna.Hynds@turner.com>wrote:

Hi Patricia,

That would be perfect. I am so sorry on the miscommunication on my part.

We really appreciate you accommodating us at this short notice.

Best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: 09 February 2020 14:35
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

Dr DrFauci can be there for a 1030 am hit

We need to know ASAP if this is firm and what the exact hit time

Sent from my iPhone

> On Feb 9, 2020, at 9:26 AM, Hynds, Joanna (NE)
> <Joanna.Hynds@turner.com>wrote:
>
> Just wanted to let you know the Flash Studio will be **DC G Studio CAM 23**
>
> Our Bureau Address is
> **820 First ST NE**
> **20002 Washington**
>
> Please contact the bureau at +1-202-898-7911

Please arrive at 10.40, you will be on around 11 – I will update with exact hit time as soon as I have it.

Best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>
Sent: 09 February 2020 13:33
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

Adding Dr Fauci here

He can come to the WDC CNN studio. Please send us the exact live hit time as well as the studio address and on-site contact name, number and cell number ASAP. Dr Fauci cell is (b) (6) and you have mine.

Thank you.

Sent from my iPhone

> On Feb 9, 2020, at 8:21 AM, Hynds, Joanna (NE) <Joanna.Hynds@turner.com>wrote:
>
> Dear Patricia,
>
> Just following up from our phone conversation, unfortunately I won't be able to facilitate a StudioGo truck for this interview.
>
> We are still really keen to get Dr Fauci on the show – will he be able to come to the bureau?
>
> I will be able to book him a car if he needs.
>
> Let me know what suits,

Best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E]
[redacted] (b) (6)>
Sent: 09 February 2020 13:00
To: Hynds, Joanna (NE)
<Joanna.Hynds@turner.com>
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

For the trick- the location is northwest Washington DC. Near American university.

Sent from my iPhone

> On Feb 9, 2020, at 7:51 AM, Conrad, Patricia (NIH/NIAID) [E]
> [redacted] (b) (6)>wrote:
>
> Please call me ASAP at [redacted] (b) (6) for this request.
>
> Sent from my iPhone
>
> Begin forwarded message:
>
> > **From:** "Fauci, Anthony (NIH/NIAID) [E]"
> > [redacted] (b) (6)
> > **Date:** February 9, 2020 at 7:08:54 AM EST
> > **To:** "Conrad, Patricia (NIH/NIAID) [E]"
> > [redacted] (b) (6)
> > [redacted]
> > **Subject: Fwd: CNNI Interview Request: Dr. Anthony Fauci,**

Sent from my iPhone

Begin forwarded message:

> **From:** "Hynds, Joanna (NE)" <Joanna.Hynds@turner.com>
> **Date:** February 9, 2020 at 6:06:15 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) [redacted]
> **Cc:** "Tejera, Isabel (Intern)" <isabel.Tejera@turner.com>, "Lovejoy, Hannah (NE)" <Hannah.Lovejoy@turner.com>
> **Subject: CNNI Interview Request: Dr. Anthony Fauci,**

Dear Dr Fauci,

I hope you are well! I am reaching out from CNN International to enquire if you are available today to join us on **Connect the World** at **11aET** to discuss the coronavirus.

Might this be a possibility? It would be great to arrange this.

Background on CNN

- CNN International reaches

more than 250 million households worldwide including in the US via DIRECTV.

- CNN International is the

number one international TV news channel according to all major media surveys across Europe, the Midd le East and Africa, the Asia Pacific region and Latin America.

- In September 2019 CNN.com had 162 million unique readers globally per month and 114 million mobile readers a month, leading the BBC, Yahoo and

New York Times.

Best,

Joanna Hynds

Planning Desk
CNN International
+ 44 207 693 1640 (office)
(b) (6)
(b) (6) (cell)
joanna.hynds@turner.com
<image001.png>

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee

. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal

and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International

Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner

House, 16 Great Marlborough Street, London W1F
7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail

communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 13:05:06 +0000
To: Kaplan, Edward H
Cc: Redfield, Robert R. (CDC/OD);Cetron, Marty (CDC/DDID/NCEZID/DGMQ);Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: RE: Coronavirus containment modeling
Attachments: hcms_Wuhan_Feb7_2020_In_Press.pdf

Ed:
Many thanks for sending the manuscript. I hope that all is well with you.
Best regards,
Tony

-----Original Message-----
From: Kaplan, Edward H (b) (6)>
Sent: Saturday, February 8, 2020 10:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus containment modeling

Dear Dr. Fauci,

It has been many years since we corresponded regarding smallpox bioterrorism and vaccination control.

The attached paper on containing a community coronavirus outbreak from a few initial cases via isolation and quarantine might interest you. The news is mostly good - isolation and quarantine can get the transmission rate below epidemic threshold - but the key is rapid detection of infected persons. Also discussed are some ideas for alleviating congestion in the hospital. I hope that you find it helpful.

Best, Ed Kaplan

Edward H. Kaplan, Ph.D.
William N. and Marie A. Beach Professor of Operations Research Professor of Public Health Professor of Engineering Yale School of Management Box 208200 New Haven, Connecticut 06520-8200

Phone: (b) (6)
e-mail: (b) (6)

http://faculty.som.yale.edu/EdKaplan/

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 12:40:23 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNNI Interview Request: Dr. Anthony Fauci,

I will do this and if they can bring a truck to the house like they did last time, it was great. Let us discuss.

From: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Sent: Sunday, February 9, 2020 6:06 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: Tejera, Isabel (Intern) <isabel.Tejera@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Subject: CNNI Interview Request: Dr. Anthony Fauci,

Dear Dr Fauci,

I hope you are well! I am reaching out from CNN International to enquire if you are available today to join us on **Connect the World** at **11aET** to discuss the coronavirus.

Might this be a possibility? It would be great to arrange this.

Background on CNN

- CNN International reaches more than 250 million households worldwide including in the US via DIRECTV.
- CNN International is the number one international TV news channel according to all major media surveys across Europe, the Middle East and Africa, the Asia Pacific region and Latin America.
- In September 2019 CNN.com had 162 million unique readers globally per month and 114 million mobile readers a month, leading the BBC, Yahoo and New York Times.

Best,

Joanna Hynds

Planning Desk
CNN International
+ 44 207 693 1640 (office)
+ (b) (6) (cell)
joanna.hynds@turner.com
CNN *go there*

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: [redacted] (b) (6)
Sent: Sun, 9 Feb 2020 07:08:49 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: CNNI Interview Request: Dr. Anthony Fauci,

Sent from my iPhone

Begin forwarded message:

> **From:** "Hynds, Joanna (NE)" <Joanna.Hynds@turner.com>
> **Date:** February 9, 2020 at 6:06:15 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
> **Cc:** "Tejera, Isabel (Intern)" <isabel.Tejera@turner.com>, "Lovejoy, Hannah (NE)" <Hannah.Lovejoy@turner.com>
> **Subject: CNNI Interview Request: Dr. Anthony Fauci,**
>
> Dear Dr Fauci,
>
> I hope you are well! I am reaching out from CNN International to enquire if you are available today to join us on **Connect the World** at **11aET** to discuss the coronavirus.
>
> Might this be a possibility? It would be great to arrange this.
>
> Background on CNN
>
> - CNN International reaches more than 250 million households worldwide including in the US via DIRECTV.
> - CNN International is the number one international TV news channel according to all major media surveys across Europe, the Middle East and Africa, the Asia Pacific region and Latin America.
> - In September 2019 CNN.com had 162 million unique readers globally per month and 114 million mobile readers a month, leading the BBC, Yahoo and New York Times.
>
> Best,
>
> **Joanna Hynds**
>
> **Planning Desk**
> **CNN International**
> + 44 207 693 1640 (office)
> + [redacted] (b) (6) (cell)

joanna.hynds@turner.com

go there

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 03:33:50 +0000
To: Janet Tobias
Subject: RE: Background question

Janet:
Nothing definite on this. To my knowledge, no one has specifically looked at real cross-reactivity although there have been speculation that because there is about 80-90% homology between nCoV and SARS that there may be some use of the mAbs made against SARS for nCoV. I have not seen any data where people took sera from patients with nCoV and checked if it neutralized SARS and vice versa.
Best,
Tony

-----Original Message-----
From: Janet Tobias <janet@ikanamedia.com>
Sent: Saturday, February 8, 2020 6:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Background question

Dear Tony: I have a background question as I am wading through reading as much as possible on the 2019 coronavirus. Do we know if the antibodies that can neutralize SARS are also effective against the 2019 coronavirus? I may be completely off track, but just trying to think through some things I am reading.

Janet

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 03:28:39 +0000
To: Lenardo, Michael (NIH/NIAID) [E]
Subject: RE: Hope you're doing well.

Thanks, Mike. Am hanging in there.

From: Lenardo, Michael (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, February 8, 2020 5:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Hope you're doing well.

Hi Tony,

Was just leaving the lab and saw your car out in front of building 31. Hope you're doing well! I'm sure you're busy with the coronavirus crisis.

You continue to be my inspiration!

Best wishes, Mike

Michael Lenardo M.D.
NIH Distinguished Investigator
Chief, Molecular Development of the Immune System Section
Laboratory of Immune System Biology,
Director, Clinical Genomics Program,
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Building 10, Room 11D14
10 Center Drive, MSC 1892
Bethesda, MD 20892-1892 USA

Tel: [redacted] (b) (6) (O); [redacted] (b) (6)(M)
FAX: 301-402-8530
Email: [redacted] (b) (6)

ASSISTANT: Gloria Rodela
Tel: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 20:54:52 +0000
To: [redacted] (b) (6)
Subject: FW: Invite
Attachments: nejmoa2001316.pdf

Here it is. As discussed, let us re-read and convene sometime tomorrow to outline our approach.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Saturday, February 8, 2020 12:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Invite

Tony,
As I am sure you are aware we recently web released the attached paper providing some initial estimates of key transmission parameters associated with nCoV-2019 virus. It will soon be coming out in a print issue and we would like an editorial to go with it. Might you be willing/interested in authoring such a piece? Our editorials are typically about 800 words with up to 10 references. As soon as you provide it to us we will web release it and then link it with the attached article in an upcoming print issue. Are you interested?
Please confirm no potential COIs.
Thank you for considering,
Lindsey

Lindsey R. Baden, MD
Deputy Editor
New England Journal of Medicine

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 17:44:45 +0000
To: Robinson, Sae;Conrad, Patricia (NIH/NIAID) [E]
Cc: naugenstein@wtop.com
Subject: RE: request for info from WTOP's Neal Augenstein

Sae:
I assume that this is taken care of with the interview that I just gave for WTOP today
Thanks,
Tony

From: Robinson, Sae <srobinson@wtop.com>
Sent: Saturday, February 8, 2020 7:57 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: request for info from WTOP's Neal Augenstein

We will call at 11:20 am. Thank you both!

> On Feb 8, 2020, at 07:52, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
>
> Dr Fauci can be available for an interview between 11 am ET and 1130 am ET. Please call him at [redacted] (b) (6) back up cell at [redacted] (b) (6)
>
> What is the exact hit time?
>
> Sent from my iPhone
>
> > On Feb 8, 2020, at 7:42 AM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
> >
> > Sae:
> > Patty will get back to you today.
> > Best,
> > Tony
> >
> > ---
> >
> > **From:** Robinson, Sae <srobinson@wtop.com>
> > **Sent:** Saturday, February 8, 2020 7:06 AM
> > **To:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Fauci,

Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: request for info from WTOP's Neal Augenstein

Good morning.

I'd like to follow up on yesterday's inquiry from our reporter Neal.

If Dr. Fauci is available to address the concerns of this cruise ship in Japan with Corona virus (re: air circulation system) today, we'd love him to have him on.

Unfortunately, the first available interview time is after 11 a.m.

If it works, please let me know. This time, we'd like to record an interview to be used for air so we have some flexibility.

Thank you!

Sae Robinson
WTOP News
202-895-5060

> On Feb 7, 2020, at 12:59, Augenstein, Neal <naugenstein@wtop.com> wrote
>
> Begin forwarded message:
>
> **From:** "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>
> **Date:** February 7, 2020 at 12:17:40 PM EST
> **To:** "Augenstein, Neal" <naugenstein@wtop.com>
> **Subject: RE: request for info from WTOP's Neal Augenstein**
>
> Dr Fauci asked that I respond – he is in back to back meeting today up until about 7 pm. If you want to speak with him tomorrow – we might be able to make that work
>
> Patricia L. Conrad
> Public Health Analyst and
> Special Assistant to the Director

National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Augenstein, Neal <naugenstein@wtop.com>
Sent: Friday, February 7, 2020 8:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: request for info from WTOP's Neal Augenstein

Hi, Dr. Fauci. Hope you're well

Spoke with some passengers aboard the Diamond Princess cruise ship in Japan, where the number of coronavirus cases onboard are jumping. Can we do a brief interview re: thoughts on quarantining on board ship (with, I would assume a closed circulating air system) versus evacuating them?

I'm available at your earliest convenience. Or, if you'd like to just email some thoughts, that'd be great. Thanks and best.

Neal Augenstein

Reporter

103.5FM and wtop.com

Washington, DC

(b) (6) cell

202-895-5060 newsroom

naugenstein@wtop.com

Twitter: @AugensteinWTOP

Skype: WTOPNealAugenstein

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 17:30:45 +0000
To: Awwad, David (NIH/NIAID) [C];Folkers, Greg (NIH/NIAID) [E]
Cc: NIAID OD AM
Subject: RE: David -- how do we put a link to the Coronavirus public folder on ASF' desktop?

Monday is fine.

From: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Sent: Saturday, February 8, 2020 12:11 PM
To: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Re: David -- how do we put a link to the Coronavirus public folder on ASF' desktop?

I will add Monday, unless you want me to connect now.

Sent from my iPhone

> On Feb 8, 2020, at 11:42 AM, Folkers, Greg (NIH/NIAID) [E] < [redacted] (b) (6) wrote:
>
> <image001.jpg>
>
> **Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.**

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 17:29:51 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Fox and Friends video -- US confirms first American coronavirus death / AS Fauci http://bit.ly/2tLtgne

Fyi. It came out well.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Saturday, February 8, 2020 11:34 AM
Subject: Fox and Friends video -- US confirms first American coronavirus death / AS Fauci http://bit.ly/2tLtgne

FOX NEWS channel
▸ DR. ANTHONY FAUCI | MEMBER OF WH CORONAVIRUS TASK FORCE
400 AMERICANS QUARANTINED ON CRUISE SHIP IN JAPAN
00:23 / 03:44
SHARE

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 17:24:25 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: CNN Interview Request: Dr. Anthony Fauci

I believe that we can do this if they do it early in the 10:00 AM segment on Monday. We may also be able to encroach a bit on Diane Rehm's podcast (10:30) since I believe that this is taped. I leave this up to you and so please get back to them and work it out if you can. Jim Sciutto [redacted] (b) (6)). Thanks.

From: Griffin, Janelle <Janelle.Griffin@turner.com>
Sent: Saturday, February 8, 2020 11:33 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: CNN Interview Request: Dr. Anthony Fauci
Importance: High

Good morning Dr. Fauci,

I hope this email finds you doing well.

I'm reaching out on behalf of Newsroom w/Poppy Harlow & Jim Sciutto hoping you can join for an interview.
Are you available to join CNN this Monday February 10th in the 10a et hour?
This would be live for about 5-7 minutes to discuss developments regarding the coronavirus.

Please feel free to contact me via email or at [redacted] (b) (6) to let me know.

Thanks for your time- I look forward to hearing from you soon.

Janelle Griffin-Butts
Editorial Producer, **CNN**
Email: janelle.griffin@turner.com | Twitter: @janellegCNN

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 03:23:51 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Details for "Fox & Friends" Tomorrow (Saturday) LIVE at 8:30am ET

I am OK with their coming to the house without a truck. I will call you in the AM.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, February 7, 2020 7:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: Details for "Fox & Friends" Tomorrow (Saturday) LIVE at 8:30am ET

Am at dinner. Will call u later

Sent from my iPhone

Begin forwarded message:

> **From:** "Zuccaro, Alexandra" <Alexandra.Zuccaro@FOXNEWS.COM>
> **Date:** February 7, 2020 at 7:16:21 PM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: RE: Details for "Fox & Friends" Tomorrow (Saturday) LIVE at 8:30am ET**
>
> They'll be at his house. Sorry, the truck wasn't available, but this will work just as well too!
>
> ---
>
> **From:** Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
> **Sent:** Friday, February 7, 2020 6:51 PM
> **To:** Zuccaro, Alexandra <Alexandra.Zuccaro@FOXNEWS.COM>
> **Subject:** [EXTERNAL] Re: Details for "Fox & Friends" Tomorrow (Saturday) LIVE at 8:30am ET
>
> Will they set up outside his house or is this the trick that he goes into it for the interview?
>
> Sent from my iPhone
>
> > On Feb 7, 2020, at 6:49 PM, Zuccaro, Alexandra <Alexandra.Zuccaro@foxnews.com> wrote:
> >
> > Hi Everyone,

Babu Aryankalayil is set to arrive at [redacted] (b) (6) around 7:30am/est tomorrow for our interview with Dr. Anthony Fauci. Babu, please give Dr. Fauci a call on his cell about 15 minutes before arrival. The IFB and PL Numbers are below. Please let us know if you have any questions, and please also let us know what REM this will be on.

"Fox & Friends"

DATE: Saturday, February 8th

CREW ARRIVAL TIME: 7:30am ET

ADDRESS: [redacted] (b) (6)

LIVE TALK BACK: 8:35am ET – 8:40am ET with Pete Hegseth, Emily Compagno, & Jason Chaffetz

Satellite Window: 0700-0800

GUEST: Dr. Anthony Fauci

TOPIC: CORONAVIRUS CRUISE SHIP LATEST

GUEST CONTACT: Dr. Anthony Fauci, [redacted] (b) (6) / Media contact Patricia Conrad cell: [redacted] (b) (6) cell: [redacted] (b) (6)

CREW CONTACT: Babu Aryankalayil, [redacted] (b) (6) / [redacted] (b) (6)

F&F NYC CONTACTS:

Technical Director: Todd Boone: Phone - [redacted] (b) (6) email: todd.boone@foxnews.com
F&F Control Room Contact: Tami Radabaugh, [redacted] (b) (6) email: Tami.Radabaugh@FOXNEWS.COM
PL: 800-369-5815, Camera and Tech: [redacted] (b) (4) Producers: [redacted] (b) (4)
IFB: 800-369-6719
ACQ and REM Coordinator: 212-301-3200
NY Transmission: 212-301-3100
NY Sat Desk (Bookings) 212-301-3400

A.M. Emergency Contact: Mary Carol Butterfield: Cell: [redacted] (b) (6) & NYC Greenroom (212) 301-1983 email: Mary.Butterfield@FOXNEWS.COM

Thanks,

Alexandra Zuccaro

"Fox & Friends"
Fox News Channel
1211 Avenue of the Americas, 2nd Floor
New York, NY 10036
Cell: (b) (6)
Alexandra.Zuccaro@FOXNEWS.COM

This message and its attachments may contain legally privileged or confidential information. It is intended solely for the named addressee. If you are not the addressee indicated in this message (or responsible for delivery of the message to the addressee), you may not copy or deliver this message or its attachments to anyone. Rather, you should permanently delete this message and its attachments and kindly notify the sender by reply e-mail. Any content of this message and its attachments that does not relate to the official business of Fox News or Fox Business must not be taken to have been sent or endorsed by either of them. No representation is made that this email or its attachments are without defect.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 20:20:58 +0000
To: Mellors, John W
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: Re: Important Brief Conversation
Attachments: image001.gif

I know. Glad we could work it out

> On Feb 7, 2020, at 11:48 AM, Mellors, John W [redacted] (b) (6)> wrote:
>
> Dear Tony,
> Approval received from DHHS. The shipment of remdesivir to China is on it's way.
> No need to connect.
> Thanks,
> John
>
> **From:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> **Sent:** Thursday, February 6, 2020 7:04:53 PM
> **To:** Mellors, John W [redacted] (b) (6)>
> **Cc:** Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
> **Subject:** RE: Important Brief Conversation
>
> John:
> Please give me office a call tomorrow and they will set up a time to connect us.
> Best,
> Tony
>
> **From:** Mellors, John W [redacted] (b) (6)
> **Sent:** Thursday, February 6, 2020 5:38 PM
> **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
> **Cc:** Mellors, John W [redacted] (b) (6)>
> **Subject:** Important Brief Conversation
>
> Dear Tony, Cliff
>
> Could we speak briefly about an important international coronavirus trial that is in jeopardy?
>
> My mobile phone number is [redacted] (b) (6)
>
> John

John W. Mellors, M.D.
Chief, Division of Infectious Diseases
Distinguished Professor and Endowed Chair for Elimination of HIV and AIDS
University of Pittsburgh School of Medicine
Scaife Hall, Suite 818
3550 Terrace Street
Pittsburgh, PA 15261

Tel: [redacted] (b) (6)
Fax: 412 383-7982

E-mail: [redacted] (b) (6)
Visit our Division website: http://www.dept-med.pitt.edu/ID/
Read the "ID Pitt Stop" blog: https://idpittstop.wordpress.com
Like us
<image001.gif>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 15:37:53 +0000
To: [redacted] (b) (6)
Subject: RE: NIH position on travel to Singapore???

Go to CDC website. There are no travel alerts for Singapore and so for now it is OK to travel there.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Friday, February 7, 2020 9:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: NIH position on travel to Singapore???

jim lynch is asking for sources of info for travel advice re: coronavirus. [redacted] (b) (6) is planning to go to Singapore. any suggestions?

---------- Forwarded message ---------
From: **James L** [redacted] (b) (6)>
Date: Thu, Feb 6, 2020 at 8:16 AM
Subject: NIH position on travel to Singapore???
To: [redacted] (b) (6)

Hi [redacted] (b) (6)
[redacted] (b) (6) is scheduled to travel to Singapore on March 9th for a week.

What is the best source of up-to-date information and travel recommendations related to the coronavirus?

Thanks

Jim

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 10:46:54 +0000
To: NIAID OD AM
Subject: FW: Royal Society of Medicine london

Let us discus.

-----Original Message-----
From: Ian Hosein [redacted] (b) (6)
Sent: Friday, February 7, 2020 5:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Royal Society of Medicine london

Hello Dr Fauci,
By way of introduction, I was Jim MacLowry's last fellow at the NIH and have been working in the UK since then as a medical microbiologist and hospital epidemiologist.
I am the lead medical microbiologist at the Royal Society of Medicine in the UK and was wondering about your availability please to speak at a conference on emergent Coronavirus threats to be held at the RSM on November 24th coming?
The RSM is a unique educational charity here and we have councils covering all aspects of healthcare. The program is still developing but I wanted to check on your availability quickly- we have an academic fund to which I can apply to cover your trip but will need to do so soon.
It was both exciting and inspirational being a senior staff fellow at the NIH - my background is international; [redacted] (b) (6) and the international perspectives at the NIH were so encouraging. All non- American fellows recognised the national strategic remit of the NIH for the US , but I have often wondered if an assessment has ever been made of how fellows like myself have brought the spirit of that institution to other nations.
With kind regards,
Ian

Ian K Hosein MD FCAP FRCPath MBA
Royal Society of Medicine
London
Mobile [redacted] (b) (6)

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:56:15 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Comment on NEJM details of "asymptomatic" contact in Germany
Attachments: nejmc2001468_appendix.pdf

Please set up a call. Happy to do over the weekend or Friday evening.

From: Ian Ingram <iingram@medpagetoday.com>
Sent: Thursday, February 6, 2020 1:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Comment on NEJM details of "asymptomatic" contact in Germany

Hi Dr. Fauci,
I'm filling in for Molly Walker on the coronavirus beat while she's covering a meeting for *MedPage Today,* but I wanted to see if you could were available to offer your quick reaction to the Supplementary Index published today (attached) in the *New England Journal of Medicine* regarding the widely reported asymptomatic contact in Germany.

Looking at the patient's daily take on how she felt it's unclear to me whether this qualifies as symptomatic or not. I imagine this will be disputed.
Best regards,
- Ian

--
Ian Ingram
Deputy Managing Editor
MedPage Today LLC
(b) (6)
iingram@medpagetoday.com
medpagetoday.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:53:47 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: BuzzFeed News: 2019-nCoV vaccine development questions

Please set up a call with this person. Happy to do over the weekend.

From: Dan Vergano <dan.vergano@buzzfeed.com>
Sent: Wednesday, February 5, 2020 3:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: BuzzFeed News: 2019-nCoV vaccine development questions

Dr. Fauci,

As you may recall, I'm a science reporter at BuzzFeed News. We wonder if you might have any perspective (or might recommend someone to comment) for a novel coronavirus story we are writing for this weekend, regarding vaccine efforts.

In short, we wonder how you see an eventual vaccine playing a role in the future of the outbreak? CDC has described the virus as not mutating as much as influenza -- does that suggest a vaccine would provide more than seasonal protection?

In the long term, we had a few other questions. Is this something you could see added to the MMR protocol for the general public, or only in regions where there are local outbreaks (is there an analogy to SARS or MERS vaccines in this contemplated use)? Is there any aspect of a race against time in vaccine development if this coronavirus is seasonal like influenza?

We are basically trying to understand where a vaccine fits into the future response to this new virus. we asked you these sort of questions about the Zika vaccine efforts and your perspective really helped a lot. Apologies for all the questions, if you had any perspective, we'd be grateful

Dan Vergano
BuzzFeed News
(b) (6)

cc: Kathy Stover

Dan Vergano | Science Desk (DC) | (b) (6)
BuzzFeed News
1630 Connecticut Ave. 7th Floor, Washington DC 20009
Send secure tips -- contact.buzzfeed.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:45:34 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: ASF / please see table from 1-29-2019 NEJM paper on Wuhan cases

Very interesting!!

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, February 6, 2020 2:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF / please see table from 1-29-2019 NEJM paper on Wuhan cases

Please see next to last line, which gives % of transmissions with "no exposure to either market or person with respiratory symptoms"

(b) (5)

N Engl J Med. 2020 Jan 29. doi: 10.1056/NEJMoa2001316. [Epub ahead of print]

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Li Q[1], Guan X[1], Wu P[1], Wang X[1], Zhou L[1], Tong Y[1], Ren R[1], Leung KSM[1], Lau EHY[1], Wong JY[1], Xing X[1], Xiang N[1], Wu Y[1], Li C[1], Chen Q[1], Li D[1], Liu T[1], Zhao J[1], Li M[1], Tu W[1], Chen C[1], Jin L[1], Yang R[1], Wang Q[1], Zhou S[1], Wang R[1], Liu H[1], Luo Y[1], Liu Y[1], Shao G[1], Li H[1], Tao Z[1], Yang Y[1], Deng Z[1], Liu B[1], Ma Z[1], Zhang Y[1], Shi G[1], Lam TTY[1], Wu JTK[1], Gao GF[1], Cowling BJ[1], Yang B[1], Leung GM[1], Feng Z[1].
DOI:10.1056/NEJMoa2001316



Table 1. Characteristics of Patients with Novel Coronavirus–Infected Pneumonia in Wuhan as of January 22, 2020.*

Characteristic	Before January 1 (N=47)	January 1 –January 11 (N=248)	January 12 –January 22 (N=130)
Median age (range) — yr	56 (26–82)	60 (21–89)	61 (15–89)
Age group — no./total no. (%)			
<15 yr	0/47	0/248	0/130
15–44 yr	12/47 (26)	39/248 (16)	33/130 (25)
45–64 yr	24/47 (51)	106/248 (43)	49/130 (38)
≥65 yr	11/47 (23)	103/248 (42)	48/130 (37)
Male sex — no./total no. (%)	31/47 (66)	147/248 (59)	62/130 (48)
Exposure history — no./total no. (%)			
Wet market exposure	30/47 (64)	32/196 (16)	5/81 (6)
Huanan Seafood Wholesale Market	26/47 (55)	19/196 (10)	5/81 (6)
Other wet market but not Huanan Seafood Wholesale Market	4/47 (9)	13/196 (7)	0/81
Contact with another person with respiratory symptoms	14/47 (30)	30/196 (15)	21/83 (25)
No exposure to either market or person with respiratory symptoms	12/47 (26)	141/196 (72)	59/81 (73)
Health care worker — no./total no. (%)	0/47	7/248 (3)	8/122 (7)

* Reduced denominators indicate missing data. Percentages may not total 100 because of rounding.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:38:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Latest

Please set up a call with David for the weekend.

From: davidwillman [redacted] (b) (6)
Sent: Thursday, February 6, 2020 2:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Latest

Hi Tony,
I know you must be swamped by matters related to the coronavirus. Nonetheless, I'd really like to confer, even if briefly. Would you have any window by phone today, over the weekend or next week? I'll also call Kim Barasch, per your recent guidance.

I'm researching an article that will chiefly explore the status of the Defense Department's advanced development and manufacturing facility in Alachua, Florida. On a related note, I'm also curious re the three HHS/BARDA facilities.

Best, David

David Willman
Washington Post
202-334-7081 –desk
[redacted] (b) (6) –mobile
301-656-3401 --alternate desk
david.willman@washpost.com
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:11:47 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Reporter working on coronavirus vaccine story

Let us discuss. Maybe over the weekend

From: Morris, Amanda <Amanda.Morris@gannett.com>
Sent: Thursday, February 6, 2020 4:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Reporter working on coronavirus vaccine story

Hi Anthony,

I hope this email finds you well! My name is Amanda Morris and I'm a bioscience reporter at the Arizona Republic, part of the USA Today network. I'm reaching out because I'm currently working on a story about how some ASU researchers (Brenda Hogue, Bert Jacobs and Shawn Chen) are trying to develop strategies to make a vaccine against the new coronavirus as well as a general platform they can use in the case of future new coronavirus strain outbreaks in humans.

I know globally there are many researchers trying to develop a vaccine for this new coronavirus, and that the NIH is working with Moderna to do so – and hopes to start testing with in a few months. I'm wondering if I can talk to you over the phone and ask a few questions about the work that NIH is doing, and what the broader challenges are for developing a vaccine? I'd like to have broader context about vaccines for our readers.

Please let me know as soon as possible. You can call or text me at (b) (6) Thank you!

All my best,
Amanda Morris

Bioscience Reporter for The Arizona Republic
Work phone: 602-444-8739
After hours and weekends, you can call or text my cell: (b) (6)
Email: amorris@gannett.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:04:53 +0000
To: Mellors, John W
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Important Brief Conversation

John:

Please give me office a call tomorrow and they will set up a time to connect us.

Best,
Tony

From: Mellors, John W (b) (6)
Sent: Thursday, February 6, 2020 5:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: Mellors, John W (b) (6)
Subject: Important Brief Conversation

Dear Tony, Cliff

Could we speak briefly about an important international coronavirus trial that is in jeopardy?

My mobile phone number is (b) (6)

John

John W. Mellors, M.D.
Chief, Division of Infectious Diseases
Distinguished Professor and Endowed Chair for Elimination of HIV and AIDS
University of Pittsburgh School of Medicine
Scaife Hall, Suite 818
3550 Terrace Street
Pittsburgh, PA 15261

Tel: (b) (6)
Fax: 412 383-7982

E-mail (b) (6)
Visit our Division website: http://www.dept-med.pitt.edu/ID/
Read the "ID Pitt Stop" blog: https://idpittstop.wordpress.com
Like us

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:01:07 +0000
To: Howard Bauchner
Subject: RE: Subtitled Coronavirus Video

Howard:
Thanks for the feedback.
Best,
Tony

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Thursday, February 6, 2020 6:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Subtitled Coronavirus Video

Tony

First live stream/podcast now with Chinese interpretation. URL below.

Second live stream/podcast will be put up tomorrow. URL below.

Couple big thank yous from prominent science writers – NYT/WSJ – said learned more listening to you for 30 minutes then everything they read in the last few weeks.

My response when you have a very wise scientist, who hears the question and answers the question, and has 40+ years of experience we should listen and learn.

Be well.

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my chats with authors

From: Karen Adams-Taylor <Karen.Adams-Taylor@ama-assn.org>
Date: Thursday, February 6, 2020 at 4:59 PM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>, Annette Flanagin <Annette.Flanagin@jamanetwork.org>, Michael Berkwits <Michael.Berkwits@jamanetwork.org>, Tom Easley <Tom.Easley@ama-assn.org>, Brian Shields <Brian.Shields@ama-assn.org>, Betsy Solaro <Elizabeth.Solaro@ama-assn.org>, Sean O'Donnell

<Sean.O'Donnell@ama-assn.org>, Tiffany Jones <Tiffany.Jones@ama-assn.org>
Subject: Subtitled Coronavirus Video

The 1/27 Fauci subtitled video is now live: https://jamanetwork.com/journals/jama/pages/coronavirus-alert The 2/6 Fauci update video will go to the translator tomorrow.

-Karen

. . . . .

Karen Adams-Taylor
Vice President, Publishing Production Operations

JAMA Network™
330 N Wabash Ave, Ste 39300, Chicago, IL 60611

T (b) (6)
jamanetwork.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:00:35 +0000
To: Greg Folkers [redacted] (b) (6);Billet, Courtney (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Subtitled Coronavirus Video

fyi

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Thursday, February 6, 2020 6:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Subtitled Coronavirus Video

Tony

First live stream/podcast now with Chinese interpretation. URL below.

Second live stream/podcast will be put up tomorrow. URL below.

Couple big thank yous from prominent science writers – NYT/WSJ – said learned more listening to you for 30 minutes then everything they read in the last few weeks.

My response when you have a very wise scientist, who hears the question and answers the question, and has 40+ years of experience we should listen and learn.

Be well.

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my chats with authors

From: Karen Adams-Taylor <Karen.Adams-Taylor@ama-assn.org>
Date: Thursday, February 6, 2020 at 4:59 PM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>, Annette Flanagin <Annette.Flanagin@jamanetwork.org>, Michael Berkwits <Michael.Berkwits@jamanetwork.org>, Tom Easley <Tom.Easley@ama-assn.org>, Brian Shields <Brian.Shields@ama-assn.org>, Betsy Solaro <Elizabeth.Solaro@ama-assn.org>, Sean O'Donnell <Sean.O'Donnell@ama-assn.org>, Tiffany Jones <Tiffany.Jones@ama-assn.org>
Subject: Subtitled Coronavirus Video

The 1/27 Fauci subtitled video is now live: https://jamanetwork.com/journals/jama/pages/coronavirus-alert The 2/6 Fauci update video will go to the translator tomorrow.

-Karen

.....

Karen Adams-Taylor
Vice President, Publishing Production Operations

JAMA Network™
330 N Wabash Ave, Ste 39300, Chicago, IL 60611

T (b) (6)
jamanetwork.com

From: [redacted] (b) (6)
Sent: Thu, 6 Feb 2020 15:09:43 -0500
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: Re: ASF --- Morens + Daszak +Taubeneberger paper

I agree. I will not be a co-author

> On Feb 6, 2020, at 1:59 PM, Folkers, Greg (NIH/NIAID) [E]
> [redacted] (b) (6)>wrote:
>
> [redacted] (b) (4)
>
> So the question to you – do you want to be part of this? ie be a coauthor
>
> I would vote no – it wud look weird to add you as a coauthor now. Plus, plate too full……
>
> **Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.**

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 17:36:11 +0000
To: [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: RE: nCoV: Heads-up

Thanks, Jim.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Thursday, February 6, 2020 10:33 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: nCoV: Heads-up

Tony : As per below, we wanted to give you a heads up that [redacted] (b) (4) . We will keep you updated. Best. John and Jim

French drugmaker Sanofi working on coronavirus initiative

CHINA-HEALTH/SANOFI (PIX):French drugmaker Sanofi working on coronavirus initiative

PARIS, Feb 6 (Reuters) - French drugmaker Sanofi will announce a new coronavirus initiative within the next two weeks, its chief executive said on Thursday, adding that it wants to present something concrete and not add to "fantasies".

At least a dozen drugmakers are working on vaccines or antivirals to help those infected with the fast-spreading virus that has killed more than 500 people in China, but several have warned that development of treatments will take time.

"We have seen a flurry of activities from other companies," CEO Paul Hudson told a news conference after Sanofi published 2019 results on Thursday.

"We are one of the few companies that has the expertise to know when it is just a fantasy, or when it could be real. In the next week or two, you will see something more confirmatory about the approach we will take."

Hudson declined to give further details.

Sanofi had already said it was sharing its expertise and data acquired from other outbreaks with the Coalition for Epidemic Preparedness Innovations (CEPI), which is working with biotech businesses to try to develop a vaccine candidate for the coronavirus.

Britain's GlaxoSmithKline is also collaborating with CEPI.

"The objective here is not a newspaper headline, it is real work that will make a difference," Hudson said.

(Reporting by Matthias Blamont Writing by Sarah White Editing by David Goodman)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 16:28:04 +0000
To: hiattf@washpost.com
Cc: Redfield, Robert R. (CDC/OD);Fauci, Anthony (NIH/NIAID) [E]
Subject: Proposed OpEd
Attachments: Redfield and Fauci - Coronavirus OpEd - 02-06-2020 - FINAL.docx

Fred:

I hope that all is well with you. [redacted] (b) (6) [redacted] (b) (6). Within this context, Bob Redfield and I have written an OpEd on the government response to the novel coronavirus outbreak. Would the *Post* have any interest in this? Many thanks.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 14:34:57 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Requested coronavirus talking points for press conference
Attachments: Talking Points for NIAID Director Dr. Fauci - press conference - 02-06-2020 - Fauci Press remarks with tracked edits.docx

Oooops! Forgot the attachment. Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thursday, February 6, 2020 9:34 AM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Requested coronavirus talking points for press conference

Here is my revised and updated press remarks with my tracked edits showing. Please accept edits, do a spell and grammar check and resubmit. Also, put a copy in my folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)

FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, February 6, 2020 9:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Requested coronavirus talking points for press conference

HHS has asked us for your talking points for the press conference by 11am. We were planning to resubmit these. As was the case last time, this is a placeholder for the WH to know the outlines of what you would say. This is not a script.

Is it OK for us to send this to Bill?

From: Selgrade, Sara (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, February 6, 2020 8:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Requested coronavirus talking points for press conference

Dr. Fauci,

Attached please find the requested talking points from your last coronavirus press conference.

Please let us know if you need anything else.

Thanks,
Sara

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 10:58:13 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Cassetti, Cristina (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Follow up on Addis Meeting

Francis:
Thanks for the note. Best to have Trevor have his program person who will be leading this effort contact Cristina Cassetti in DMID. Cristina and Emily Erbelding could do all of the necessary and appropriate coordination.
Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Thursday, February 6, 2020 4:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Follow up on Addis Meeting

See reference to coronavirus research in the note from Trevor. How would you like to coordinate this?

FC

From: Trevor Mundel [redacted] (b) (6)>
Sent: Wednesday, February 5, 2020 10:55 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Cc: Eiss, Robert (NIH/FIC) [E] [redacted] (b) (6); Glass, Roger (NIH/FIC) [E] < [redacted] (b) (6); Kedest Tesfagiorgis < [redacted] (b) (6)>
Subject: Re: Follow up on Addis Meeting

That would be great Francis. You might have seen our announcement this morning on the Coronavirus reponse funding and $60M of the 100 is for R&D especially therapeutics rather than vaccines so we might want a quick call in the next few days to think about how we coordinate this - I've been in touch with Jeremy as well. Trevor

Trevor Mundel, MD, PhD
President, Global Health Program
V [redacted] (b) (6)
F +1.206.494.7041
E [redacted] (b) (6)

[redacted] (b) (6)
Executive Assistant
Office of the President, Global Health

V [redacted] (b) (6)
M [redacted] (b) (6)
E [redacted] (b) (6)
Bill & Melinda Gates Foundation
www.gatesfoundation.org

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Wednesday, February 5, 2020 3:11 PM
To: Trevor Mundel
Cc: Eiss, Robert (NIH/FIC) [E]; Glass, Roger (NIH/FIC) [E]
Subject: RE: Follow up on Addis Meeting

Hey Trevor,

This is an excellent development. How about I send you a proposal of possible CARI TPs for Elioda – in the next 24 hours?

Francis

From: Trevor Mundel [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 4:43 PM
To: Tumwesigye Elioda [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: [redacted] (b) (6)
Subject: Re: Follow up on Addis Meeting

That's great to hear Elioda and congratulations, many thanks for letting us know. We will certainly get back to you shortly to enlist your help with the CARI initiative at AU level.

Warm regards,
Trevor

From: Tumwesigye Elioda [redacted] (b) (6)>
Sent: Wednesday, February 5, 2020 1:16 PM
To: Trevor Mundel; Francis Collins
Cc: [redacted] (b) (6)
Subject: Follow up on Addis Meeting

Dear Trevor,

Greetings from Uganda and indeed Africa. It was pleasure meeting you at the Grand Challenges Meeting in Ethiopia late last year. While there you, Francis Collins and I among others discussed the CARI Initiative and the need to support research, entrepreneurship and innovation in a big way in Africa. We also explored the mechanism for CARI Funding. We were also looking for a mechanism to reach the Committee of Ten (C10) Heads of State and Government championing Education, Science and Technology in Africa.

Well allow me to inform you that on 13th Dec 2019, I was elected to chair for 2 years the Ministers of Education and of Science and Technology in all the 55 Members States in Africa. We do this under the Specialized Technical Committee on Education, Science and Technology (STC-EST). This Saturday on 8th Feb in Addis, as chair of the ST -EST I will attend and speak at the Meeting of the above-mentioned C10.

The purpose of this message is to let you know of my added responsibilities and related opportunities as well as seek for any update or latest information regarding the CARI initiative. I look forward to intensified communication and collaboration.

Regards

Dr. Elioda Tumwesigye
Minister Science, Technology and Innovation
Republic of Uganda
Tel: (b) (6)

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 04:10:50 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Pandemic Threat Reduction

Similar e-0mail from Dr. Tubb.

From: Richard Tubb (b) (6)>
Sent: Thursday, January 30, 2020 11:35 AM
To: (b) (6) Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Fwd: Pandemic Threat Reduction

Good morning Tony.
Given your most recent appointment, I wanted to show you the courtesy of letting you know what I have already provided to senior leaders at the White House regarding a possible mitigating strategy until the definitive solution to the CoV is available and implemented. The string below includes additional information as to how titanium dioxide can fit into both the White House and the National/International solutions, and the open-source website for the company. Please keep in mind that because this product is already approved and in use in the EU for a variety of commercial uses, the data provided does not specifically address the applications I, and you, are interested in. However, with a deep understanding of the White House mission, I can say that there is not a big leap in that thought migration.

Dr. Jackson has already provided the same material to some of your White House Commission colleagues. I will also be reaching out to another friend of mine from the Bush-now-Trump Administration, Steve Biegun.

I encourage your representatives to meet with the company leadership and scientists while they are in the US next week. Please let me know if you have any questions that I can address. Thank you for once again stepping up to the plate for our Country.

v/r

Dick

ps...I remembered this morning where you and I last spoke--Bush (41) funeral.

---------- Forwarded message ---------
From: **Richard Tubb** [redacted] (b) (6) >
Date: Thu, Jan 30, 2020 at 8:54 AM
Subject: Re: Pandemic Threat Reduction

Good morning Gentlemen,

I just spoke with Ronny and believe I need to offer A relevant update and one point of explanation.

First, the company's joint venture partner in India is meeting with the Indian government as we speak. It appears likely that in light of the news of India's introduction to the corona virus the government will utilize their "National Catastrophe Budget" to expedite the funding necessary to secure and execute a contract with this company.

Secondly, I will attach the open source web site for the company to provide you background information that, out of respect for your time and for the sake of brevity, I left out of yesterday's note. It's important to note a couple of things:

This product is already proved and is in use in the EU with all the approvals appropriate for the same.

Secondly, in our language, this is a "standoff productr"—I.e. you apply it once and it continues to decontaminate and disinfect in the background for up to 1-5 years before retreating. (Depending on the type of use, normal daily cleaning using their cleaning solution—that is cheaper and more effective than what the application normally would use, e.g. in a hotel—continues). The chemical treats anything organic, I.e. bacteria, viruses, VOC, bio threats, etc. because it is a catalyst, it is neither used up, nor does it produce microbial resistance or superbugs. It decontaminates and disinfects surfaces (e,g, airplanes and government critical infrastructures) and the air around the surface (and HVAC filters and air handlers).

The leadership will be in DC next week. I highly encourage any and all potential stakeholders make time to meet with them while they are here. To that end, I had already emailed Dr. Fauci (with whom I worked a great deal on similar chalenges during the Bush Administration) before the announcement of his participation on the new coronavirus commission, I will also reach out to an old friend and colleague Steve BIEGUN now that he is in the commission. Please feel free to forward the information to others as you deem appropriate.

Thanks,

Dick Tubb

https://act.global/

Ps...once again, in my haste to get this to you, via iPad, please forgive typos and other apparent crimes against the dictionary.

Sent from my iPad

> On Jan 29, 2020, at 3:15 PM, Richard Tubb [redacted] (b) (6)> wrote:
>
> Gentlemen, Brothers, and Others...
>
> This is Dick Tubb, writing on behalf of Admiral Jackson and Dr. Hofmann (both copied herein). It feels like "old times"--I'm undecided as to whether they are good old times, or otherwise. Regardless, it does feel like we've been down a very similar road before. Perhaps we can apply some of the lessons-learned to the inevitable problems ahead.

In light of the current and evolving threat presented by the corona virus, I am writing to you as a courtesy to inform you of a project that Admiral Jackson, Dr. Hofmann, and I have been consulting on. We believe so strongly in the technology, people, and potential that we have been consulting pro bono and currently have no financial stake in the project. While not developed specifically designed for such purposes, I increasingly believe that until a vaccination and treatment for the corona virus is available, this technology may be the last best chance in containing, and eradicating the virus, thereby protecting the homeland, our economy, the Continuity of the Presidency, an Enduring Constitutional Government, our people and our Country. Moreover, reverting to my "lessons-learned, problems-ahead" statement, even after this crisis is over, and a vaccine and treatment procured, it will only be a matter of time until "next time." This letter is proof-positive of that reality. My experiences, especially in the early 2000's (e.g. anthrax and other biothreats, SARs, etc.) underpin my beliefs.

The technology that provides the solution, both now and in the future, involves a unique formulation of a photo catalytic nano titanium dioxide solution (the Air Force guys will, of course, understand what that means, so you non-Air Force folks, just buy them a beer and they'll explain it to you) that is safer, more effective, and more cost effective than any other solution. It was developed and approved in the EU, and I have asked the senior leadership of the company to come to Washington DC next week. Dr. Hofmann and I spent the day yesterday with a Chinese “titan" respected by and with access to the most senior government officials, academic and medical giants, and investment and industry captains. I have encouraged, and he has agreed in principal, to follow our recommendations as they relate to their largest airline, and their key facilities.

In short, our strategic priority is to first fortify the weak link in the pandemic chain: the airlines. Doing so will provide the time necessary to isolate, contain, and ultimately destroy the threat at its source (Wuhan),and in its home (China). As President Bush so commonly stated about a very different threat, we need to fight the battle over there, so that we don't have to fight the battle here. Although President Bush was a true believer in the threat of a pandemic, I believe this threat, and the threats that are surely to follow are, in reality, many, many times greater than the threat he envisioned when making that statement. By fighting a possible impending pandemic at its source we will preserve and protect the safety and confidence of our people, and the strength of our economy.

Once we have interrupted the threat supply chain, we can then shore up our critical infrastructure using the same technology and process, then assist the Chinese in addressing their challenges, and protect our international allies elsewhere. In that vein, in addition to the Chinese, I have also discussed this technology and strategy with senior proxies for another of my former patients, His Royal Highness, the Crown Prince of Saudi Arabia, and his father, the King.

As I noted above, I have asked the leadership of the company to come to Washington (from Germany and Denmark) next week for a variety of meetings. While Admiral Jackson will be "tied up in Texas" for the foreseeable future, please let me know if you would like to meet with myself or Dr. Hofmann, or the company leadership while they are here, to learn more.

Thank you and my best to you all as you plan for and continue to protect our Country,

Very Respectfully,

Dick Tubb

ps. For your SA, I have also attached below the latest sit rep on the coronavirus.

--
Richard J. Tubb, MD
Brigadier General (retired)
White House Physician Emeritus

Shoreland's *Travax News Alert* Service—Abbreviated

China: More than 2,800 Cases of 2019-nCoV in 30 Provinces/Municipalities, Mainly in Wuhan; Cases Exported to 16 Countries

WHAT'S NEW

According to regional health authorities, more than 1,800 additional, confirmed cases (including 25 deaths) of pneumonia caused by 2019 novel coronavirus (2019-nCoV) have been reported since January 27, 2020, throughout the country, mainly in the provinces of Hubei (1,291), Guangdong (207), Zhejiang (173), Henan (168), and Hunan (143) and in the cities of Chongqing (132), Beijing (19), and Shanghai (13). Most new cases had a travel history to Wuhan. Almost all the recent deaths occurred in Hubei Province. Twenty more patients have recovered and been discharged. More than 4,600 confirmed cases (including > 100 deaths) have occurred since December 8, 2019.

A total of 13 additional, exported, confirmed cases have been reported (through January 28, 2:00 p.m. EST) since Monday, January 27. More than 25 cases have been exported in the past 7 days. Cases reported since Monday arrived in the following countries on the dates shown: Singapore (January 19 and 23), Taiwan (January 22), Japan (January 20 and 21), France (arrival date unknown), and Thailand (arrival dates unknown). All of these cases had travel history to Wuhan or contact with an ill person from Wuhan while in China.

In addition to these exported cases, 7 locally acquired cases have been reported since Monday in Germany (4), Japan, Taiwan and Vietnam. The cases in Japan, Taiwan, and Vietnam reported contact with an obviously ill person from China. In Germany all 4 cases had close contact in a business seminar with an apparently asymptomatic Chinese woman on January 21 (who previously had contact with relatives from Wuhan); the women states symptom onset was on a flight to Shanghai on January 23, and she was later confirmed to have 2019-nCoV. Incubation periods in these cases have been as short as 3 days. In light of the secondary cases in Germany in a business setting, the most cautious approach of having arrivals stay at home or in a hotel for 14 days after their last possible exposure in China is increasingly justified.

Updated travel advisories include: 1) Australia: reconsider travel to China; 2) Canada: avoid all travel to Hubei Province; 3) Finland: avoid nonessential travel to Hubei Province; 4) France: avoid all travel to Hubei Province; 5) Germany: avoid nonessential travel to China and avoid all travel to Hubei Province; 6) India: avoid all nonessential travel to China; 7) New Zealand: avoid all travel to Hubei Province; 8) Taiwan: avoid all nonessential travel to China.

Singapore now denies entry to residents of Hubei Province and those who have traveled there in the past 14 days.

Mongolia and 3 regions (Amur Oblast, Khabarovsk Kray, Yevreyskaya Oblast) in Far Eastern Federal District, Russia have closed their land borders with China.

Bangladesh, Canada, India, Kazakhstan, Russia, and South Korea are arranging flights to repatriate their respective citizens from Wuhan. These persons will be closely monitored and present little threat of onward transmission.

All tourist attractions in Tibet Autonomous Region have been closed.

Current influenza vaccination is recommended to decrease the risk of simple influenza being mistaken for 2019-nCoV upon return.

Infection control supplies have been depleted in medical facilities in the smaller cities in central China; the situation is critical in many areas and resupply is uncertain.

OVERALL RISK ASSESSMENT

The epidemic in China is months from peaking. A report indicates that just prior to the cordoning off of Wuhan, over 5 million residents (many potentially infectious) left for other parts of China, and many thousands left for Hong Kong, Singapore, Thailand, and Japan. Exported cases have so far been to countries likely to be capable of controlling (but not preventing) ongoing transmission, which will inevitably occur. In light of the secondary cases in Germany in a business setting, the most cautious approach of having arrivals stay at home or in a hotel for 14 days after their last possible exposure in China is increasingly justified.

Based on increasing data on virology, clinical presentation, and transmission, this coronavirus closely resembles SARS-CoV in many behaviors. Fortunately, sequential sequencing of viral isolates over time indicate no significant new viral mutations; mutations often increase transmission or virulence. WHO assesses the risk of this event to be very high in China, high at the regional level, and high at the global level. The closing of Wuhan airport and the major cities of Hubei province have yet to stem the flow of exported cases. The originally implicated animal market, now closed indefinitely, bears little relevance to the ongoing situation. Whether the market was the focus of a species jump from animals to humans or merely one of multiple amplification settings for initial cases is increasingly unclear. The degree of human-to-human spread outside of Hubei province remains unclear. A reproductive number, R_0, is estimated at 1.4–2.5 by Chinese authorities and up to 5.5 by other scientists. An R_0 greater than 1 indicates that each case leads to more than 1 subsequent case, making control much more difficult. The spectrum of disease manifestations in a large cohort study has yet to be disclosed; a severe case rate of 20% has been consistent. The existence of mildly symptomatic and asymptomatic infectious cases could increase the risk of global spread. Case fatality is impossible to ascertain at present, and lesser or greater clinical virulence compared to MERS-CoV or SARS-CoV remains speculative.

See 2019 Novel Coronavirus Outbreak for detailed information.

© 2020 Shoreland, Inc. All rights reserved.

Travax News Alert items are incorporated into Shoreland's subscriptions. Travax content represents decision-relevant, expert synthesis of real-time data reconciled with new and existing available advice from authoritative national and international bodies.

For email service changes, please forward this message to service@shoreland.com with your request. If the change should apply to all email subscriptions (Content Changes, Literature Watch and News Alert), please specify that in your request. [Account: SI53213; Recipient: bg.richard.tubb@gmail.com]

2019 Novel Coronavirus Outbreak Report—comprehensive

Last updated January 28, 2020.

What's New

According to regional health authorities, more than 1,800 additional, confirmed cases (including 25 deaths) of pneumonia caused by 2019 novel coronavirus (2019-nCoV) have been reported since January 27, 2020, throughout the country, mainly in the provinces of Hubei (1,291), Guangdong (207), Zhejiang (173), Henan (168), and Hunan (143) and in the cities of Chongqing (132), Beijing (19), and Shanghai (13). Most new cases had a travel history to Wuhan. Almost all the recent deaths occurred in Hubei Province. Twenty more patients have recovered and been discharged. More than 4,600 confirmed cases (including > 100 deaths) have occurred since December 8, 2019.

A total of 13 additional, exported, confirmed cases have been reported (through January 28, 2:00 p.m. EST) since Monday, January 27. More than 25 cases have been exported in the past 7 days. Cases reported since Monday arrived in the following countries on the dates shown: Singapore (January 19 and 23), Taiwan (January 22), Japan (January 20 and 21), France (arrival date unknown), and Thailand (arrival dates unknown). All of these cases had travel history to Wuhan or contact with an ill person from Wuhan while in China.

In addition to these exported cases, 7 locally acquired cases have been reported since Monday in Germany (4), Japan, Taiwan, and Vietnam. The cases in Japan, Taiwan, and Vietnam reported contact with an obviously ill person from China. In Germany, all 4 cases had close contact in a business seminar with an apparently asymptomatic Chinese woman on January 21 (who previously had contact with relatives from Wuhan); the woman states symptom onset was on a flight to Shanghai on January 23, and she was later confirmed to have 2019-nCoV. Incubation periods in these cases have been as short as 3 days. In light of the secondary cases in Germany in a business setting, the most cautious approach of having arrivals stay at home or in a hotel for 14 days after their last possible exposure in China is increasingly justified.

Updated travel advisories include: 1) Australia: reconsider travel to China; 2) Canada: avoid all travel to Hubei Province; 3) Finland: avoid nonessential travel to Hubei Province; 4) France: avoid all travel to Hubei Province; 5) Germany: avoid nonessential travel to China and avoid all travel to Hubei Province; 6) India: avoid all nonessential travel to China; 7) New Zealand: avoid all travel to Hubei Province; 8) Taiwan: avoid all nonessential travel to China.

Singapore now denies entry to residents of Hubei Province and those who have traveled there in the past 14 days.

Mongolia and 3 regions (Amur Oblast, Khabarovsk Krai, Jewish Autonomous Oblast) in Far Eastern Federal District, Russia have closed their land borders with China.

Bangladesh, Canada, India, Kazakhstan, Russia, and South Korea are arranging flights to repatriate their respective citizens from Wuhan. These persons will be closely monitored and present little threat of onward transmission.

All tourist attractions in Tibet Autonomous Region have been closed.

Current influenza vaccination is recommended to decrease the risk of simple influenza being mistaken for 2019-nCoV upon return.

Infection control supplies have been depleted in medical facilities in the smaller cities in central China; the situation is critical in many areas and resupply is uncertain.

Overall Risk Assessment

The epidemic in China is months from peaking. A report indicates that just prior to the cordoning off of Wuhan, over 5 million residents (many potentially infectious) left for other parts of China, and many thousands left for Hong Kong, Singapore, Thailand, and Japan. Exported cases have so far been to countries likely to be capable of controlling (but not preventing) ongoing transmission, which will inevitably occur. In light of the secondary cases in Germany in a business setting, the most cautious approach of having arrivals stay at home or in a hotel for 14 days after their last possible exposure in China is increasingly justified.

Based on increasing data on virology, clinical presentation, and transmission, this coronavirus closely resembles SARS-CoV in many behaviors. Fortunately, sequential sequencing of viral isolates over time indicates no significant new viral mutations; mutations often increase transmission or virulence. WHO assesses the risk of this event to be very high in China, high at the regional level, and high at the global level. The closing of Wuhan airport and the major cities of Hubei province have yet to stem the flow of exported cases. The originally implicated animal market, now closed indefinitely, bears little relevance to the ongoing situation. Whether the market was the focus of a species jump from animals to humans or merely one of multiple amplification settings for initial cases is increasingly unclear. The degree of human-to-human spread outside of Hubei province remains unclear. A reproductive number, R_0, is estimated at 1.4–2.5 by Chinese authorities and up to 5.5 by other scientists. An R_0 greater than 1 indicates that each case leads to more than 1 subsequent case, making control much more difficult. The spectrum of disease manifestations in a large cohort study has yet to be disclosed; a severe case rate of 20% has been consistent. The existence of mildly symptomatic and asymptomatic infectious cases could increase the risk of global spread. Case fatality is impossible to ascertain at present, and lesser or greater clinical virulence compared to MERS-CoV or SARS-CoV remains speculative.

Current Disease Situation

More than 4,600 confirmed cases (976 severe and critical cases and 106 deaths) have occurred since December 8, 2019, in the provinces of Hubei (> 2,700; mainly in Wuhan), Guangdong (207), Zhejiang (173), Henan (168), Hunan (143), and Anhui (106); in the cities of Chongqing (132), Beijing (91), and Shanghai (66); and in 21 other provinces throughout the country. An additional 6,900 suspected cases have been reported since January 21, 2020. In the setting of a large outbreak and with increased delays in testing, a high proportion of suspected cases will evolve into confirmed cases. Seventy-nine cases have been discharged. Two-thirds of the cases are male. The youngest case is 10 years old and the oldest is 89; more than 70% of cases are over 40 years old, but the co-morbidity profiles of most cases are unknown.

The number of persons becoming infected with the virus has been doubling every six days. The outbreak in China is not approaching peak, and modeling indicates that is months away.

Exported Cases

Seventy-seven imported cases of 2019-nCoV (confirmed after arrival) presented at international ports of entry January 6-25 in 16 countries. Of these cases, more than 25 cases arrived in the past 7 days.

All 77 cases had exposure in Wuhan or exposure to ill persons from Wuhan in China and symptom onset dates after December 31, 2019; none had visited the implicated market.

Australia (5 cases): One case traveled while asymptomatic aboard China Southern Airlines flight CZ231 to Melbourne, Victoria State on January 19 and was hospitalized on January 23. Contact tracing is underway; movement around Melbourne was limited prior to isolation. The remaining 4 cases traveled while asymptomatic aboard flights to Sydney, New South Wales State on January 6, 18, 20, and 23, and were hospitalized on January 15, 20, and 24. One of the patients had limited movement around Sydney prior to isolation; movement history for the other 3 cases is unknown.

Cambodia (1 case): The case traveled while asymptomatic to the city of Sihanoukville on January 23, 2020, and developed symptoms on January 25.

Canada (2 cases): Both cases (a couple) traveled aboard China Southern Airlines flight CZ311 to Toronto, Ontario Province on January 22. The first case was symptomatic while traveling and was hospitalized on January 23. The second case was under self-isolation and was confirmed on January 27. Contact tracing is underway; patient movement around Toronto was limited prior to isolation.

France (4 cases): Two cases traveled while asymptomatic aboard a flight to Paris on January 18, and 1 case traveled aboard a flight to Bordeaux on January 22. Travel history for the fourth case in unknown. All cases were hospitalized.

Hong Kong (8 cases): Three cases traveled while symptomatic on January 19 and 25; the first aboard a train to West Kowloon, the second aboard a flight to Hong Kong International Airport, and the third to Lo Wu Control Point. Four of the cases traveled while asymptomatic aboard trains on January 19 and 22. The last case traveled with diminished symptoms aboard a train on January 23. All cases were hospitalized.

Japan (6 cases): Two cases traveled while symptomatic; the first aboard a flight to Kanagawa Prefecture on January 6 and the second aboard a flight to Tokyo on January 19. The first was hospitalized on January 10 and discharged on January 15 following recovery, and the second was hospitalized on January 22. Another 2 cases traveled while asymptomatic: the first aboard a flight to Tokyo on January 18 and the second aboard a flight to Aichi Prefecture on January 22. The first was hospitalized on January 23, and the second was hospitalized on January 24. The remaining 2 cases arrived on January 20 and 21 in Aichi and Tokyo prefectures.

Macau (7 cases): The first case traveled while asymptomatic aboard a train and a bus on January 19, and the second case traveled while symptomatic (travel method unknown) on January 22. The first case was hospitalized on January 19 and the second case on January 21. The third case traveled aboard a ferry on January 23 and was immediately hospitalized. Three cases traveled (methods unknown) on January 22; all were hospitalized. The last case traveled while asymptomatic on January 23 and was hospitalized January 27.

Malaysia (4 cases): The first case traveled while asymptomatic aboard a bus to Johor Baharu on January 22 and was hospitalized on January 23. The remaining 3 cases traveled (method unknown) to Johor Baharu on January 23; all were hospitalized.

Nepal (1 case): The case traveled to Kathmandu on January 5, was hospitalized on January 13, and was discharged on January 17 following recovery.

Singapore (7 cases): All 7 cases traveled while asymptomatic aboard flights on January 18, 19, 20, 21, 22, and 23.

South Korea (4 cases): Two cases traveled while symptomatic to Incheon International Airport and to Gimpo International Airport on January 19 and 23, and both were immediately hospitalized. The remaining cases traveled while asymptomatic on January 20 and were hospitalized on January 25.

Sri Lanka (1 case): The case traveled while asymptomatic on January 29, 2020, and developed symptoms on January 25.

Taiwan (7 cases): The cases arrived on January 20, 21, 22, and 25; at least 3 cases arrived at Taiwan Taoyuan International Airport.

Thailand (14 cases): Three cases traveled while symptomatic to Suvarnabhumi Airport on January 8, 13, and 19 and were hospitalized; the travel history of the fourth case is unknown. The fifth case traveled to Bangkok on January 21 and was hospitalized on January 23. The travel histories of the remaining 9 cases are unknown.

U.S. (5 cases): Two cases traveled while asymptomatic: the first to O'Hare International Airport on January 13 and the second to Seattle-Tacoma International Airport on January 15. The first was hospitalized several days after arrival, and the second was hospitalized on January 19. The remaining 3 cases were reported in Maricopa County, Arizona and Los Angeles and Orange counties, California; information on the patients' travel histories are unknown. Contact tracing for all cases is underway. The first case reported limited movement around Chicago prior to hospitalization; movement history for the other 2 cases in unknown.

Vietnam (1 case): The case arrived in Hanoi on January 13 and was hospitalized on January 22 in Ho Chi Minh City.

In addition to these exported cases, 7 locally acquired cases have been reported since Monday in Germany (4), Japan, Taiwan, and Vietnam. The cases in Japan, Taiwan, and Vietnam reported contact with an obviously ill person from China. In Germany, all 4 cases had close contact in a business seminar with an apparently asymptomatic Chinese woman on January 21 (who previously had contact with relatives from Wuhan); the woman states symptom onset was on a flight to Shanghai on January 23, and she was later confirmed to have 2019-nCoV. Incubation periods in these cases have been as short as 3 days.

Entry/Exit Screening

In a reversal of long-standing policy, WHO now recommends that all countries implement temperature screening at points of entry for passengers arriving from 2019-nCoV–affected countries. Screening should be accompanied by dissemination of risk-communication messages at points of entry to later capture asymptomatic persons who are in the incubation phase.

In early January, some exit screening was implemented at Wuhan Tianhe International Airport (nonstop flights to Istanbul, London, New York, Osaka, Paris, Rome, San Francisco, Tokyo, and major hubs throughout Southeast Asia), as well as at 3 major rail stations in Wuhan. More restrictive screening was instituted on January 15 in Hubei until cessation of international flights on January 23. Despite exit screening at all international airports in China in the past week, significant numbers of cases continue to be exported.

Entry screening at international ports of entry has been or is being implemented as noted below, and anyone with fever and respiratory symptoms who has been to 2019-nCoV–affected areas in the previous 14 days will be detained and isolated at these locations:

Algeria: Houari Boumediene Airport, Mohamed Boudiaf International Airport, Oran Ahmed Ben Balla Airport

Burma (Myanmar): Yangon International Airport

Egypt: Cairo International Airport (all flights from China)

Hong Kong: All border checkpoints, including Hong Kong International Airport and the railway station in West Kowloon

India: Bengaluru, Chennai, Delhi, Hyderabad, Kochi, Kolkata, and Mumbai international airports (all flights from China and Hong Kong)

Italy: Leonardo da Vinci-Fiumicino Airport

Iran: Tehran Imam Khomeini International Airport (all flights from China)

Macau: Macau International Airport

North Macedonia: Skopje International Airport (connecting flights from Asia)

Qatar: Hamad International Airport (all flights from China)

Russia: Moscow, Irkutsk Oblast, and Yekaterinburg international airports and points of entry in Amur Oblast

Singapore: Changi Airport

South Africa: O.R. Tambo International Airport (all flights from China)

South Korea: Incheon International Airport

Taiwan: All international airports

Thailand: Krabi, Suvarnabhumi, Don Mueang, Phuket, and Chiang Mai airports

Turkey: All international airports (all flights from China)

United Arab Emirates: Abu Dhabi International Airport and Dubai International Airport (all flights from China)

U.K.: Heathrow International Airport

U.S.: Twenty points of entry, including Hartsfield-Jackson Atlanta International Airport, John F. Kennedy International Airport, Los Angeles International Airport, O'Hare International Airport, and San Francisco International Airport. Travelers from Wuhan may have their temperatures taken and/or be required to complete a symptom questionnaire; travelers with symptoms (fever, cough, difficulty breathing) will be detained for additional assessment.

Australia, Bahrain, Bangladesh, Belarus, Canada, Cote d'Ivoire, Ghana, Indonesia, Japan, Kazakhstan, Kenya, Kyrgyzstan, Madagascar, Malaysia, Nepal, Nigeria, North Korea, Philippines, Saudi Arabia, Serbia, Senegal, Sri Lanka, Tajikistan, Tunisia, Vietnam: Airports and other ports of entry

Travel Advisories

The following countries and/or organizations have published travel recommendations:

Avoid All Travel to Hubei Province: Australia, Canada, China (see below), France, Germany, Japan, Mexico, New Zealand, U.K., U.S.

Avoid Nonessential Travel to Hubei Province: Finland, Ukraine

Avoid All Travel to China: None at present

Avoid Nonessential Travel to China: Australia, Germany, India, Taiwan, U.S.

No Advisory: WHO

Travel Restrictions

Different levels of travel restrictions are in effect:

No Flights from China: Finnair Airlines (flights from Beijing and Nanjing), Air Seoul

No Flights from Wuhan: Wuhan Airport is closed to all international and domestic flights.

Land Borders with China Closed: Kyrgyzstan, Mongolia, North Korea, Russia (Amur Oblast, Khabarovsk Krai, Jewish Autonomous Oblast in Far Eastern Federal District); high speed rails and ferry services suspended in Hong Kong

No Residents from Hubei Province: Hong Kong, Macau, and Singapore (including visitors in past 14 days), Malaysia, and Taiwan

Internal Travel Restrictions in China: Major cities in Hubei Province have instituted a travel ban on occupants of their cities, suspending urban buses, subways, ferries, and long-distance passenger transport from the cities, including flights and trains, and closing intercity roads. Interprovince shuttle buses in major areas have stopped. Many bars, restaurants, shops, and museums are closed in Hubei Province, Guangdong, and many other affected areas. Major tourist attractions have closed in Beijing, Shanghai, Sanya (Hainan Province), Hong Kong, and Tibet Autonomous Region. China has stopped all inbound and outbound tour groups but not individual travel. Internal travel for the Lunar New Year Holiday has been severely limited by the government, and public gatherings are forbidden. The reopening of schools and universities has been postponed in many areas. Shanghai has temporarily closed all nonessential workplaces. Visitors from Hubei Province will be actively monitored for 14 days in Haikou, Hainan Province.

No Flights from 2019-nCoV–Affected Countries: Travelers going to Samoa must spend at least 14 days in a country free of 2019-nCoV and undergo medical clearance prior to travel to Samoa.

Australia, Bangladesh, Belgium, Canada, France, Germany, India, Japan, Kazakhstan, Morocco, Netherlands, Russia, South Korea, Spain, Thailand, U.K., and U.S. are arranging flights to repatriate their respective citizens from Wuhan. These persons will be closely monitored and present little threat of onward transmission.

Transmission

The detailed epidemiology of possible causative animal exposures and zoonotic transmission remains unclear. Many (27 of 41) earlier cases were directly linked to South China Seafood City market in Jianghan District, which sold seafood and other wildlife (including birds). More than 580 environmental samples, without indication as to whether animal tissue was included, were collected from the implicated market. Of these, 33 tested positive for 2019-nCoV, indicating that the market was an–or the–origin point of the large-scale outbreak. Thirty-one of the positive samples (94%) were collected from the western part of the market, where wildlife was traded. The first published epi-curve shows that the symptom onset date of the first patient identified in the outbreak was December 1, 2019. The patient reported no exposure to the implicated market; no epidemiological link has been detected between this case and later cases. This finding raises the possibility of an initial jump of 2019-nCoV directly from bat to human, with subsequent initial human-to-human propagation within the seafood market.

Infected intermediate animal hosts, if they exist, may still be present in the supply chain. South China Seafood City market, now closed indefinitely, remained in operation through December 31, 2019. Other points of infection would be likely because many subsequent cases had no contact with the implicated market. Chinese authorities have now stated that human-to-human transmission is in the fourth generation in Wuhan and at least the second generation elsewhere (mostly in clusters). A reproductive number, R_0, is estimated at 1.4–2.5by Chinese authorities and at up to 5.5 by some scientists. An R_0greater than 1 indicates that each case leads to more than 1 subsequent case, making control much more difficult. R_0 is not a constant number and changes with the ongoing circumstances and evolution of an outbreak. One published cluster study indicates asymptomatic shedding (but not transmission) by a single patient. Sequence data from several small clusters indicate identical virus in all subjects within the cluster.

More than 47,800 close contacts remain under surveillance (> 1,200 have been released), and contact tracing is ongoing in affected provinces and municipalities. However, not all contacts are being ascertained or monitored adequately. As many as 16 health care workers (HCWs) have been confirmed as infected by at least 1 case in Wuhan in a potential super-spreading event, but overall infectivity for HCWs has not been established. No case of 2019-nCoV has been attributed to transmission on an aircraft.

The survival rate of the virus on surfaces or in the environment is unknown. Disinfection processes that are effective for other zoonotic coronaviruses should be followed for now. Clean daily all "high-touch" surfaces, such as counters, tabletops, doorknobs, bathroom fixtures, toilets, phones, keyboards, tables, and bedside tables. Also, clean any surfaces that may have blood, bodily fluids, and/or secretions or excretions on them. Use a diluted bleach solution or a household disinfectant with a label that says "EPA-approved." To make a bleach solution, add 15 mL (1 tablespoon) of bleach to 1 L (1 quart) of water; for a larger supply, add 60 mL (2 oz) of bleach to 4 L (1 gallon) of water.

Clinical Manifestations

Most cases have reportedly exhibited symptoms of fever, respiratory compromise, and bilateral pneumonia with diffuse, ground glass-like infiltrates on chest x-ray or CT scan. Unlike SARS-CoV, upper respiratory illness symptoms (rhinorrhea, sneezing, sore throat) and diarrhea are not common. Overall, about 20% of the cases have been severe or critical, including pneumonia, respiratory failure, and in some cases death. The existence of asymptomatic cases has not been ascertained. No known treatment exists for 2019-nCoV, although remdesivir will be available shortly from the U.S. CDC for compassionate use. Usual antiviral drugs, including oseltamivir (Tamiflu), baloxavir, ribavirin, and acyclovir, are ineffective. Steroids should not be used. Based on earlier literature, the combined use of lopinavir and ritonavir is under study in China. Current influenza vaccination is recommended to decrease the risk of simple influenza being mistaken for 2019-nCoV upon return.

In a small cohort of 41 patients (median age was 49 years; interquartile range: 41-58) conducted early in the epidemic (presentation before January 2), the most common symptoms at onset of illness were fever (98%), cough (76%), and myalgia or fatigue (44%). Dyspnea developed in 55% of patients at a median of 8 days. All cases except 1 had bilateral pneumonia. Milder cases had chest CTs that showed bilateral ground-glass opacity with subsegmental areas of consolidation, whereas ICU patients had bilateral lobar and subsegmental areas of consolidation. Only 66% of cases (even in this early cohort) had been exposed to the South China Seafood City market. The case-fatality rate was estimated to be 15%, but more severe cases tend to predominate early in an epidemic. Limited data from another published cluster study indicate a 3- to 6-day incubation period similar to SARS-CoV and clinical and radiologic features similar to SARS-CoV cases in 2003. Another report indicates an incubation period ranging from 1 to 14 days.

Virology

2019-nCoV was initially isolated from 1 case and entirely sequenced; this information was published internationally by Chinese scientists on January 10. Electron microscopy of 1 specimen demonstrated classic coronavirus particles. 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Novel coronaviruses from Wuhan, together with 2 bat-derived SARS-like strains, form a distinct clade in lineage B of the subgenus sarbecovirus. 2019-nCov is a group 2b coronavirus (as are MERS-CoV and SARS-CoV), with a whole genome similarity of up to 80% to SARS-CoV but with a similarity between different gene segments ranging from 60% to 90%. 2019-nCoV exhibits a 96.5% similarity to the known bat coronavirus precursors in the same viral clade.

Sequence data allowed national laboratories to rapidly develop diagnostic kits, which are now available in most developed countries and most Asian countries. HKU1, NL63, 229E, and OC43 are human coronaviruses that are detected by some routine multiplex PCR panels used in routine clinical practice. These coronaviruses are associated with minor upper respiratory infections and viral pneumonia, but unlike SARS-CoV, MERS-CoV, and 2019-nCoV, these agents are not associated with major outbreaks or severe respiratory distress syndrome. 2019-nCoV is not reactive in these tests. The findings so far strongly favor (but do not prove) causation. 2019-nCoV has been shown to use the same cell-entry receptor as SARS-CoV. Viral loads appear to be highest in lower respiratory tract specimens, which should be the primary specimen obtained. Prediction of human-to-human transmissibility from sequence data is difficult because coronaviruses vary widely in their transmissibility; coronaviruses acquired from animals generally have some potential for human-to-human transmission. Evidence from subsequent whole genome sequences acquired over the last several weeks show little genetic variation, indicating that the virus jumped from an animal reservoir to humans within the last few months. Identical recent mutations in epidemiologically unlinked cases support sustained human-to-human transmission.

Criteria for Testing of Suspected Cases

U.S. CDC

Persons meeting the following criteria (clinical features and epidemiologic risk) for suspected cases of 2019-nCoV will be considered persons under investigation (PUI):

- Fever *and* symptoms of lower respiratory illness (e.g., cough, shortness of breath) *plus* a history of travel to Wuhan or close contact with a PUI for 2019-nCoV while that person was ill in the past 14 days before symptom onset
- Fever *or* symptoms of lower respiratory illness (e.g., cough, shortness of breath) *plus* close contact with an ill, laboratory-confirmed 2019-nCoV case in the past 14 days before symptom onset

HCWs entering the room with a PUI should use standard precautions, contact precautions, airborne precautions, and eye protection (e.g., goggles or a face shield).

PUIs for 2019-nCoV should be asked to wear a surgical mask as soon as they are identified and be evaluated in a private room with the door closed, ideally an airborne-infection isolation room if available.

Prevention

Travelers going to Wuhan should avoid animals (alive or dead), animal markets, products that come from animals (such as uncooked meat), and contact with ill-appearing persons. Quality of infection control at medical facilities in Wuhan is uncertain, and those with minor medical problems should avoid busy medical settings.

Infection control supplies have been depleted in medical facilities in the smaller cities in central China; the situation is critical in many areas and resupply is uncertain. Travelers who develop fever and respiratory symptoms within 14 days of travel to Wuhan should immediately be isolated, and public health authorities should be alerted.

Employees, Students, Visitors, All Others Coming from Wuhan

Whether asymptomatic individuals infected with 2019-nCoV are infectious to others is unknown. Influenza viruses can be transmitted 1 to 2 days prior to symptom onset. SARS-CoV did not transmit until 4 days after symptom onset, which led to its eradication because all contacts with fever could be promptly identified and isolated.

If 2019-nCoV is similar to SARS-CoV, asymptomatic arrivals from Wuhan should self-monitor by taking a temperature reading immediately prior to coming into the workplace or school for 14 days after their last exposure in Wuhan. Arrivals with fever at any time should self-report to public health authorities (or telephone ahead before presenting to a hospital) and should wear a mask as soon as possible. A more stringent approach would require that an employee, student, or visitor—upon arrival to a workplace or school—be instructed to perform an additional temperature check in the presence of medical personnel to ensure compliance with local self-monitoring requirements. In addition, prior to any gathering of ≥ 2 persons, attendees could be required to perform additional self-monitoring.

Based on advanced information and employee or visitor medical screening, additional preventive measures may be required (e.g., increased ventilation, larger meeting rooms with more personal space per participant, disinfection of work areas and lavatories, and provision of alcohol wipes).

The most cautious approach would be for arrivals to stay at home or in a hotel for 14 days after their last possible exposure in China. To date, all known cases exported to other countries had either visited Wuhan or had contact with an ill person from Wuhan while in China.

Sent from my magical iPad!

> On Jan 29, 2020, at 2:46 PM, Richard Tubb <bg.richard.tubb@gmail.com> wrote:

--

Richard J. Tubb, MD
Brigadier General (retired)
White House Physician Emeritus

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 04:03:31 +0000
To: Howard Bauchner
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE:
Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

Thanks, Howard. Talk soon.

-----Original Message-----
From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Wednesday, February 5, 2020 6:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: RE: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

The author of our case-series - proof today will send to you - is an ICU doc in Wuhan - trained with Derek Angus - he has been great - but I have asked him about himself, his family - we loss track of the personal - which is so important.

I have had a few "emergencies" like this - at BCH - with Jerry Klein - some infectious disease outbreaks; a couple major car accidents; etc. Also worked at the Berhorst Clinic in Guatemala in 1978 (before there was global health) numerous 5-10-15 people emergencies - always end though - for you this is the pandemic that never stops giving.

Try to take a break; have a good glass of Claret on me.

HCB

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, February 05, 2020 5:31 AM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

[Warning External Email]

Howard:
Your outline looks fine. Am hanging in there. Feels like my internship and first year residency when I was on every other night and every other weekend, but actually never left the hospital because the patients were so sick.
Best,
Tony

-----Original Message-----
From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Wednesday, February 5, 2020 6:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

Likely come up tomorrow in our discussion - not NEJM paper but just the concept.

Outline if OK with you

What's up in China

What's up around the world

What's up in US

And then more specific questions

Is this more like H1N1 than MERS

Can we really know mortality risk (denominator problem).

Incubation period

How "infectious"

News on treatment

Quarantine working

Sound OK?

You surviving - worried a bit about your workload.

HCB

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Wednesday, February 05, 2020 5:20 AM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Subject: RE: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

[Warning External Email]

The paper was flawed, Embarrassment for NEJM. However, the concept is correct. Spoke in detail to the Director of the Chinese CDC (confidential) and they are seeing asymptomatic transmission (low level) in China.

-----Original Message-----
From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Wednesday, February 5, 2020 6:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

Tony

Suspect you saw this. Big problem if true - rushing to publication - leads to big mistakes.

HCB

-----Original Message-----
From: Redberg, Rita <[redacted] (b) (6)>
Sent: Wednesday, February 05, 2020 5:13 AM

To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>; Phil Fontanarosa
<Phil.Fontanarosa@jamanetwork.org>
Subject: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

[Warning External Email]

Assume you saw, but.

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.sciencemag.org_news_2020_02_paper-2Dnon-2Dsymptomatic-2Dpatient-2Dtransmitting-2Dcoronavirus-2Dwrong&d=DwIFAg&c=iqeSLYkBTKTEV8nJYtdW_A&r=CpYvDJwppPNcFUZ7y8a6zr8BltWA4gtfRWytiKfFoVM&m=4xruNHFPsXovMmiMLZW-iD9OzCNhiiGOKmtHhrZcP8c&s=afNfNjVB5xiV3y8BiCPHkwBnAiRXsktAbH1rM9a3jPY&e=

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 03:59:46 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] [redacted] (b) (6)
Subject: FW: touching base about Texas Biomedical Research Institute

Please take care of this .

From: Larry Schlesinger [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 8:42 AM
To: Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: touching base about Texas Biomedical Research Institute

Hi Tony and Hugh.

I know that I am writing to you at a busy time during yet another infectious disease outbreak that is rapidly evolving. However, I wanted to send you a brief note to update you about the transformational change going on in the landscape of our free standing institute with its new, sharply defined goal to be the global leader in eradicating infectious disease threats in the world. I know that you are familiar with us.

I have been leading the institute since June of 2017 and currently finishing year one of a 10 year board-approved plan of growth in our scientists, educational programming and campus modernization. I believe that you are aware that we house the only private BSL4. We also just opened our newest of 5 BSL3 facilities, this newest one being nearly 8000 sq. ft. with capacity for ~100 NHPs, small animals, a complete aerosol suite and a PET CT. We also house the SNPRC, now under the leadership of Deepak Kaushal (who replaced Robert Lanford) and with the largest marmoset colony as a result of restructuring our building facilities (in addition to our other species). [redacted] (b) (4)

Please check out our newly designed website: www.txbiomed.org.

The bottom line is that I left university life to lead an organization that is determined to not only discover critical, new fundamental science but also effectively and efficiently bring it full forward to create portfolios for the FDA through our business model, nimbleness, regulated science culture (GLP level), longstanding public and private partners through contract science (esp. BARDA), culture and community support.

We want to help! Please let us know if and how we can contribute to this outbreak and undoubtedly others going forward.

I truly appreciate your leadership. The country gets the voice of reason on infectious disease outbreaks through your public efforts. I enjoyed learning more about this during my time on council.

Best,

Larry

Larry Schlesinger, MD
Professor
President and CEO
Texas Biomedical Research Institute
8715 W. Military Drive, San Antonio, TX 78227
Email: (b) (6)
Teamwork | Integrity | Diversity | Excellence | Safety

Executive assistant:
(b) (6)
(b) (6) Phone
(b) (6) Mobile
Email: (b) (6)

CONFIDENTIALITY NOTICE: This e-mail and any files and/or attachments transmitted, may contain privileged and confidential information and is intended solely for the exclusive use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are hereby notified that any review, dissemination, distribution or copying of this e-mail and/or attachments is strictly prohibited. If you have received this e-mail in error, please immediately notify the sender stating that this transmission was misdirected; return the e-mail to sender; destroy all paper copies and delete all electronic copies from your system without disclosing its contents.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 03:49:36 +0000
To: Robert Knobler
Cc: Cassetti, Cristina (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Potential Approach to Wuhan Coronavirus

Bob:

Thanks for your note. It was good to hear from you. I am copying Cristina Cassetti on this e-mail. Cristina directs the extramural coronavirus research activities. Perhaps you two can connect to discuss research opportunities.

Best,
Tony

-----Original Message-----
From: Robert Knobler [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 10:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Potential Approach to Wuhan Coronavirus

Dear Dr. Fauci,

You likely do not recall meeting me when I was looking at potential fellowships in 1978, however, I never forgot your enthusiasm. I went out to San Diego and worked with Mike Oldstone, between 1979 and 1984.

I did study a mouse coronavirus while there, mouse hepatitis virus (MHV). I focused on genetic resistance, and eventually described a mouse locus for susceptibility, which coded for the MHV receptor.

Lacking the correct receptor or blocking binding of the virus spike protein to the receptor with monoclonal antibodies blocked infection.

On to the present problem of human coronaviruses. Vaccines will take a long time for the current crisis. The angiotensin converting enzyme 2 receptor has been identified as the relevant human coronavirus receptor in earlier studies of SARS and MERS human coronavirus outbreaks. I am writing to suggest the investigation of ARBs as potential blocking agents to either reduce or completely block infection. Perhaps this can be checked. if correct, there may still be sufficient untainted supplies of ARBs, such as irbesartan, available, or production can be scaled up, if this truly is the eve of a pandemic.

Wishing you success in this endeavor. I am willing to contribute in any way I can. Please feel free to contact me by e-mail or my cell phone.

I also did do clinical trials while with Mike, and then when I joined the neurology faculty of Jefferson in Philadelphia. I have been out on my own since December 1998, but I have never lost my interest in this work. For another time, I also have some novel ideas on how HIV becomes AIDS, as well. Ironically, these ideas were based upon observations I made during my analysis of MHV.

All the Best,
Robert L Knobler, MD, PhD
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 03:28:54 +0000
To: Cohen, Elizabeth
Subject: RE: treatment protocols

The Chinese are putting together protocols to test certain drugs such as remdesivir.

From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
Sent: Wednesday, February 5, 2020 3:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: treatment protocols

Hi Tony,
We were wondering if there are any particular protocols being suggested for treating the Wuhan coronavirus cases in the US. Are there discussions among the teams caring for these patients about the best approach?
Many thanks.
Best,
Elizabeth

Elizabeth Cohen, MPH
CNN Senior Medical Correspondent

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 02:54:42 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona virus/sepsis treatment
Attachments: CBR Baum Satz (5).pdf, Kim Brechbiel Satz.pdf, Kim supplement-01.doc, REFERENCES Corona Virus.docx

Please handle.

From: stanley satz [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 7:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Corona virus/sepsis treatment

Dear Dr. Fauci,

(b) (4)
[redacted]

(b) (4)

[redacted]

Best regards,

Stanley Satz, Ph.D.
Chairman and Chief Scientific Officer

Advanced Innovative Partners, Inc.

Professor, Florida Atlantic University,
University of Miami School of Medicine

www.advancedinnovativepartners.com
www.bionucleonics.com

(b) (6)

[redacted]

--

Confidentiality Notice

This message is being sent by or on behalf of Dr. Satz. It is intended exclusively for the individual or entity to which it is addressed. This communication may contain information that is proprietary, privileged or confidential or otherwise legally exempt from disclosure. If you are not the named addressee, you are not authorized to read, print, retain, copy or disseminate this message or any part of it. If you have received this message in error, please notify the sender immediately by e-mail and delete all copies of the message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 02:54:19 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Dr. Levitt summarizes CDC 2019-nCoV Committee Report released today 5 Feb 2020
Attachments: M and M Wuhan Virus.pdf

See me about getting someone to prepare a response.

From: Robert Levitt (b) (6)>
Sent: Wednesday, February 5, 2020 7:50 PM
To: Azar, Alex (OS/IOS) (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Dr. Levitt summarizes CDC 2019-nCoV Committee Report released today 5 Feb 2020

Dear Secretary Azar and Dr. Fauci,

I have read carefully the CDC's report issued this morning on the Wuhan virus (2019-nCoV) epidemic originating in Wuhan, Hubei Province, PRC. The Report was prepared by CDC's best Ph.D.s, M.D.s, and D.V.M.s See the pdf attached above for the complete report.

Below I have recorded what I think the most important facts in the report for Secretary Azar and other federal officials who must stop the spread of 2019-nCoV in the U.S. by identifying all infected persons and their contacts. I have also added my personal thoughts on how to stop the spread of this novel coronavirus and a personal fear I have communicated to Secretary Azar in the past:

-- President Trump signed an order preventing entry into the U.S. of any person who has traveled to mainland China (PRC). Exceptions include U.S. citizens and permanent residents and their families. Thank you Mr. Trump.

-- CDC maintains an office in the PRC. So information from Wuhan, Hubei, PRC, should be 'real time'.

-- Enhanced screening of persons entering the U.S. is taking place at 18 ports and 5 airports. The number of ports and especially airports needs to be increased. The Report states that 14,000 Chinese enter the U.S. daily. **If the 5 airports receive 85% of these Chinese, then 2,100 Chinese enter the U.S. daily at other airports without enhanced screening.**

-- CDC has developed its own RT-PCR test to detect 2019-nCoV in respiratory specimens. I have read case reports where state laboratories have required too much proof of suspected Wuhan virus from clinicians before performing RT-PCR testing of specimens. **CDC should provide their improved RT-PCR test to all states and HHS should insure that all states have sufficient equipment and trained personnel for rapid turn-around time.**

-- CDC has grown the 2019-nCoV virus. **CDC should expedite distribution of the grown virus to researchers with verified credentials and vetting in a safe and monitored procedure.**

-- CDC recommends that persons suspected by clinicians of having 2019-nCoV be placed in a separate room with a N95 face mask so that they are not in range of other patients. **HCW should wear personal protection: gloves, gown, face shield or N95 mask and goggles.**

-- Clinicians have identified 8 of the current 11 patients infected with 2019-nCoV in the U.S. **CDC is doing a terrific job in getting the message out to clinicians and the public.**

Sent from Outlook

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Thu, 6 Feb 2020 00:56:18 +0000
To:	Mak, Tak
Cc:	Cassetti, Cristina (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject:	RE: An Idea

Tak:

Thanks for the note. It likely will be more efficient if I refer you to the program people in my Institute who could go over these data with you and then get me involved later. The reason that is that I am doing 18 hours pe day (seriously) as part of the White House Task Force and it would very difficult for me to fit in a meeting to go over data. I have copied Dr. Cristina Cassetti who runs our coronavirus extramural research program. I will ask her by this e-mail to contact you to have our people discuss your work with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mak, Tak < [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 7:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: An Idea

Dear Tony,

It has been a while since we discussed science. [redacted] (b) (4)

[redacted] (b) (4)

(b) (4)

[redacted]

Best regards, Tak

This e-mail may contain confidential and/or privileged information for the sole use of the intended recipient.
Any review or distribution by anyone other than the person for whom it was originally intended is strictly prohibited.
If you have received this e-mail in error, please contact the sender and delete all copies.
Opinions, conclusions or other information contained in this e-mail may not be that of the organization.

If you feel you have received an email from UHN of a commercial nature and would like to be removed from the sender's mailing list please do one of the following:
(1) Follow any unsubscribe process the sender has included in their email
(2) Where no unsubscribe process has been included, reply to the sender and type "unsubscribe" in the subject line. If you require additional information please go to our UHN Newsletters and Mailing Lists page.
Please note that we are unable to automatically unsubscribe individuals from all UHN mailing lists.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 00:00:36 +0000
To: Jeremy Farrar;Collins, Francis (NIH/OD) [E]
Cc: Josie Golding;Tabak, Lawrence (NIH/OD) [E]
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

Jeremy:

I left out an important name for the coronavirus evolution working group. Please include her: Pardis Sabeti at the Broad Institute of MIT and Harvard
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, February 5, 2020 5:25 PM
To: Jeremy Farrar <[redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Cc: Josie Golding <[redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E]
[redacted] (b) (6)
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

Jeremy:

Thanks for the note. Looks like things are moving along with WHO. I will list below a number of names for potential members of the working group to examine the evolutionary origin of the 2019-nCoV in addition to the individuals who were on the call with us last Saturday:

Harold Varmus – Weill Cornell Medical Center – New York City
Feng Zhang – MIT (CRISPR expert)
Joseph DeRisi - Chan Zuckerberg (CZ) BioHub (he's paying close attention to the Wuhan strain vs other bat viruses and the SARS virus)

Don Ganem - University of California at San Francisco (UCSF) and the CZ BioHub (knows more about hepadnaviruses but an outstanding clinical and basic virologist)
John Coffin - Tufts and National Cancer Institute, NIH (worked out the confusion over the alleged Chronic Fatigue Syndrome retrovirus that proved to be a xenotropic MLV)
Eugene Koonin - NCBI/National Libreary of Medicine, NIH; https://www.ncbi.nlm.nih.gov/research/groups/koonin/)
Wayne Hendrickson – Columbia University and the New York Structural Biology Center
Gary Nabel – Sanofi (Boston)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 6:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Josie Golding [redacted] (b) (6)
Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Francis and Tony

Couple of things:

- I spoke again with WHO this morning. I believe they have listened and acted. Let me know if you agree
    - At the WHO meeting next week they will set up the Group who will "look at the origins and evolution of 2019n-CoV"
    - They have asked for names to sit on that Group – please do send any names

  - We can have a call this week with a core group of that to frame the work of the Group including – if you could join?
  - I think this puts it under the umbrella of WHO, with action this week and into next
  - With names to be put forward into the Group from us and pressure on this group from your and our teams next week.
- The team will update the draft today and I will forward immediately – they will add further comments on the glycans

Does that sound reasonable to you?

Jeremy

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, 4 February 2020 at 13:18
To: Francis Collins < [redacted] (b) (6)>, Jeremy Farrar [redacted] (b) (6)
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

?? [redacted] (b) (4)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Tuesday, February 4, 2020 6:12 AM
To: Jeremy Farrar [redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

Yes, [redacted] (b) (4)

Francis

From: Jeremy Farrar [redacted] (b) (6)
Sent: Tuesday, February 4, 2020 6:08 AM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

[redacted] (b) (4)

On 4 Feb 2020, at 10:58, Collins, Francis (NIH/OD) [E] [redacted] (b) (6)> wrote:

Very thoughtful analysis. [redacted] (b) (4)
(b) (4)

Francis

From: Jeremy Farrar [redacted] (b) (6)
Sent: Tuesday, February 4, 2020 2:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E]
< [redacted] (b) (6)
Subject: FW: Prevalence of infection and stage of the epidemic in Wuhan

Please treat in confidence – a very rough first draft from Eddie and team – they will send on the edited, cleaner version later.

Pushing WHO again today

From: Edward Holmes [redacted] (b) (6)>
Date: Tuesday, 4 February 2020 at 06:33
To: Jeremy Farrar [redacted] (b) (6)>
Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Here's our summary so far. Will be edited further.

It's fundamental science and completely neutral as written. Did not mention other anomalies as this will make us look like loons. As it stands it is excellent basic science I think, which is a service in itself.

Will finish as soon as we can.

PROFESSOR EDWARD C. HOLMES FAA FRS
ARC Australian Laureate Fellow

THE UNIVERSITY OF SYDNEY
Marie Bashir Institute for Infectious Diseases & Biosecurity,
School of Life & Environmental Sciences and School of Medical Sciences,
The University of Sydney | Sydney | NSW | 2006 | Australia
T [redacted] (b) (6)
E [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 20:52:29 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: note to Patty -- and Tony Fauci

Let us discuss. Steve is a good guy, but I do not want to kill myself trying to do too many thingsdat the same time.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Wednesday, February 5, 2020 3:27 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: note to Patty -- and Tony Fauci

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Steve Clemons <sclemons@thehill.com>
Sent: Wednesday, February 5, 2020 3:20 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: note to Patty -- and Tony Fauci

Greetings Patty and Tony -- I see you on TV constantly guiding us through the terrain on our preparedness for outbreaks such as what we have seen in China. I want to see if I can add one more request to your pile to think about....and I am trying to see if what I am suggesting might work right before your Aspen talk next Tuesday at noon.

In addition to my great role at The Hill, I am host of a new show called "The Bottom Line" on Al Jazeera English that runs four times a week on their global network and is garnering between 100k-200k views a week on YouTube in the US. The show is doing really well and is a 24 minute panel discussion of three experts on a single topic that I facilitate. I would love to have you, Tony, be the anchor commentator on what we should do not only on the coronavirus but in general on the infrastructure of pandemic preparedness in the country -- sort of a shorter form of that great PBS show you did called Invisible Killers.

We would want to tape in our studio at 21st and M Streets NW from 11:00 am - 11:30 am (we don't go over), or I could move it 15 to 30 minutes earlier if you like next Tuesday, 11 February. I know you have to be at Aspen at noon (I was invited too) -- so I could take you if you like.

I realize that this may be too much . -- but in these times, I think it's important to get smart commentary and analysis out there -- and I think I can add a couple hundred thousand eyeballs and ears to the millions you are already reaching. The producers are also able to provide car and driver (b) (4) (b) (4)

Hope this might work my friend. I may send a short form of this to your cell phone.

Call me if you want to chat, either of you, at (b) (6).

all best, STEVE

THE HILL
TheHill.com

Steve Clemons
Editor at Large, The Hill
1625 K Street NW, Suite 900
Washington, DC 20006
Tel: +1.202.628.8500
Cell: (b) (6)
Email: SClemons@TheHill.com
Follow me on Twitter **@SCClemons**

From: [redacted] (b) (6)
Sent: Wed, 5 Feb 2020 10:33:15 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: NTV Broadcasting Interview Request

FYI

Begin forwarded message:

> **From:** Сефербеков Хаджи-Мурат Караханович <HSeferbekov@ntv.ru>
> **Date:** February 5, 2020 at 10:21:15 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Subject: NTV Broadcasting Interview Request**
>
> Mr. Fauci, my name is Murat, I am a producer of "Week Summary" for NTV Broadcasting company.
> We would like to film a brief interview with you about coronavirus, and different hypotheses about its appearance. We want to solve the problem with mass disinformation about this virus, and need a professional opinion.
> Will it be possible to do this at 6th, or 7th of February?
>
> Best regards,
> Seferbekov Murat
> NTV Broadcasting Company

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 14:36:13 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Interview request by BBC Chinese

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tsung-Hsien Lee <zach.lee@bbc.co.uk>
Sent: Wednesday, February 5, 2020 8:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Interview request by BBC Chinese

Dear Dr Anthony S Fauci,

This is Zachary from BBC Chinese.

I am now writing a piece regarding the treatment of people in isolation or quarantine over coronavirus in different countries.

Most of the countries told the public where the people evacuated from Wuhan reside for quarantine and some drew local's protests. They expressed concern over close vicinity and some even went to protest in these places.
Others like Taiwan, the authority decided to keep the quarantine location confidential. The reason is to avoid unnecessary worrisome and let people rest well.

I would like to have an interview with you by e-mail or Skype phone with you to give some insights or comments on this issue.

If you could be quoted, the questions are as below

1. Why does the government tell the public the quarantine location? Is it necessary? Or why not?

2. Many residents protested because they don’t want the quarantine Center for Coronavirus in their neighborhood. Do they need to worry about it?

3. What is your suggestion regarding the location of quarantine those people from Wuhan. And what is essential for Quarantine Center for Coronavirus?

Thank you very much for your time.
Zachary Lee
BBC Chinese

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 01:17:02 +0000
To: Harper, Jill (NIH/NIAID) [E]
Subject: RE: Approps TA: DOE Reimbursement for Coronavirus Super Computing

[redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Saturday, February 29, 2020 9:43 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Approps TA: DOE Reimbursement for Coronavirus Super Computing

Tony,

[redacted] (b) (5)

Thanks,
Jill

From: "Harper, Jill (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Friday, February 28, 2020 at 5:33:38 PM

To: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: Fwd: Approps TA: DOE Reimbursement for Coronavirus Super Computing

Tony, I will call you about this in a minute

From: "Haskins, Melinda (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Friday, February 28, 2020 at 5:24:43 PM
To: "Mitchell, Michelle (NIH/OD) [E]" [redacted] (b) (6)>
Cc: "NIAID OCGR Leg" <NIAIDOCGRLeg@mail.nih.gov>, "LaMontagne, Karen (NIH/OD) [E]" [redacted] (b) (6) "Harper, Jill (NIH/NIAID) [E]" [redacted] (b) (6), "Johnson, Martin S. (NIH/NIAID) [E]" [redacted] (b) (6) "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6), "Shapiro, Neil (NIH/OD) [E]" [redacted] (b) (6)
Subject: Re: Approps TA: [redacted] (b) (5)

[redacted] (b) (5)

Sent from my iPhone

> On Feb 28, 2020, at 5:17 PM, Mitchell, Michelle (NIH/OD) [E] [redacted] (b) (6)> wrote:
>
> Hi Melinda,
>
> Would you let me know what you all think of this language?
>
> Thanks.
>
> MM
>
> ---
>
> **From:** Friedel, Laura (Appropriations) [redacted] (b) (6)>
> **Sent:** Friday, February 28, 2020 5:13 PM
> **To:** Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)>; Mitchell, Michelle (NIH/OD) [E] [redacted] (b) (6)
> **Subject:** RE: DOE Reimbursement for Coronavirus Super Computing
>
> Any progress on this Michelle? Here is language that I'm thinking of.
>
> For an additional amount for "National Institute of Allergy and Infectious Diseases", to prevent, prepare for, and respond to SARS-CoV-2, a virus strain mutating therefrom ("coronavirus"), or other emerging or reemerging infectious disease threats, domestically or internationally, $xxx,000,000, to remain available

until September 30, 2024: [*Provided*. That up to $99,500,000 of such amounts may be transferred to the Department of Energy to provide support and access to scientific user facilities, including equipment, enabling technologies, and personnel associated with the operations of those scientific user facilities:]

Laura Friedel
Majority Clerk
Committee on Appropriations
Subcommittee on Labor, HHS and Education
136 Dirksen Senate Office Building
Washington, DC 20510
[redacted] (b) (6)

From: Friedel, Laura (Appropriations)
Sent: Friday, February 28, 2020 3:13 PM
To: Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)>; Michelle Mitchell [redacted] (b) (6)
Subject: DOE Reimbursement for Coronavirus Super Computing

Hi,

Dept. of Energy is looking for $99.5 million. They are concerned that NIH will use their super computers for coronavirus (which NIH doesn't pay for) and displace paying customers. What is the expectation that NIH will need to use DOE super computers? We would include additional funds (please make sure TF knows I would not take his funds and give to DOE), but this seems extremely high to me and I was trying to understand the need from your perspective for these super computers. Happy to jump on the phone if that is easier, but need this as fast as you can get it to me please – within the next hour or so. Language is below. Thank you!

Sec. ___. (a) Funds appropriated in this title may be made available to restore amounts, either directly or through reimbursement, for obligations incurred by agencies of the Department of Health and Human Services for the purposes provided herein prior to the date of enactment of this Act. This subsection shall not apply to obligations incurred by the Infectious Diseases Rapid Response Reserve Fund.

(b) Funds appropriated in this title [may/shall] be used when [awarding/to award] grants and cooperative agreements in fiscal year 2020 to reimburse State or local costs incurred for the purposes provided herein after January 20, 2020, and prior to the issuance of such awards.

[(c) Funds appropriated in this title shall be transferred to other federal agencies for costs related to medical screening for coronavirus including any costs incurred through a grant, cooperative agreement, other transaction, or contract and, once transferred, may be used to reimburse obligations incurred for such purposes prior to enactment of this Act.]

(d) Up to $99,500,000 of the funds appropriated in this title may be transferred to the Department of Energy to provide support and access to scientific user facilities, including equipment, enabling technologies, and personnel associated with the operations of those scientific user facilities.

(e) If any funds have been reprogrammed or transferred from an appropriation, as described in the notification submitted by the Secretary to the Committees on Appropriations of the House of Representatives and the Senate on February 2, 2020, prior to the date of enactment of this Act, such amounts shall be reprogrammed or transferred back to that appropriation within 45 days of the date of enactment of this Act.

Laura Friedel
Majority Clerk
Committee on Appropriations
Subcommittee on Labor, HHS and Education
136 Dirksen Senate Office Building
Washington, DC 20510
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 22:36:17 +0000
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: RE: NAS

Nancy:

The official USG group will be convened by NAS. Bob Kadlec is the person with direct knowledge of that. In addition, there is an ad hoc group informally led by Jeremy Farrar of Wellcome Trust. This group has about 15 people, all of whom are highly respected scientists, mostly evolutionary biologists who are convening by e-mail and conference calls (I have been on 2 of these calls since Jeremy invited me) to look at all of the bat, pangolin and human coronavirus sequences to try and determine the evolutionary origin. This is not my area of expertise and so I have backed off and am leaving it all to Jeremy.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>
Sent: Thursday, February 13, 2020 5:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: NAS

Thanks. Is someone convening them?

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, February 13, 2020 5:07 PM

To: Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)
Subject: RE: NAS

Nancy:

It is not a report. It is a letter from NAS to OSTP saying that it is important to bring together a group of experts to study the evolutionary origin the COVID19. I am attaching it here. I have no idea if it has been widely distributed and so please keep it internal.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)
Sent: Thursday, February 13, 2020 1:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: NAS

Either you or Bob Kadlec made reference to a NAS report on the origins of SARS – COV2. (b) (5) [redacted]

Thanks.
Nancy

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Thu, 13 Feb 2020 22:06:37 +0000
To:	Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject:	RE: NAS
Attachments:	NASEM Response to OSTP re Coronavirus_February 6 2020.pdf

Nancy:

It is not a report. It is a letter from NAS to OSTP saying that it is important to bring together a group of experts to study the evolutionary origin the COVID19. I am attaching it here. I have no idea if it has been widely distributed and so please keep it internal.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>
Sent: Thursday, February 13, 2020 1:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: NAS

Either you or Bob Kadlec made reference to a NAS report on the origins of SARS – COV2. [redacted] (b) (5)

Thanks.
Nancy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 15:21:22 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Redfield/Fauci nCoV op-ed
Attachments: Coronavirus OpEd - Redfield and Fauci - 02-06-2020.docx

Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 3:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Redfield/Fauci nCoV op-ed

Here is the op-ed as cleared by WH.
Any issues with this?
[redacted] (b) (5)

From: Brennan, Patrick (OS/ASPA) < [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 3:39 PM
To: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Lepore, Loretta (CDC/OD/OCS) [redacted] (b) (6)
Cc: Fine, Amanda (NIH/OD) [E] [redacted] (b) (6) Galatas, Kate (CDC/OD/OADC) [redacted] (b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>; Campbell, Amanda (CDC/OD/OCS) [redacted] (b) (6);

Stecker, Judy (OS/IOS) [redacted] (b) (6); Murphy, Ryan (OS/ASPA) [redacted] (b) (6) Pratt, Michael (OS/ASPA) [redacted] (b) (6)Oakley, Caitlin B. (OS/ASPA) [redacted] (b) (6)>; Hall, Bill (HHS/ASPA) <[redacted] (b) (6)>; Myles, Renate (NIH/OD) [E] [redacted] (b) (6); Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Redfield/Fauci nCoV op-ed

Attached is a tracked changes version and a clean version of what cleared the WH – they had a few sentences they would like to be added (which, in the tracekd changes version, I have added comments to explain who suggested it and in some cases why), but almost all of these edits are non-substantive.

Assuming CDC and NIAID are good with these (feel free to modify the additions as needed), you all are good to pitch this as you wish – [redacted] (b) (5)

From: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, February 2, 2020 6:11 PM
To: Lepore, Loretta (CDC/OD/OCS) <[redacted] (b) (6)>
Cc: Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>; Galatas, Kate (CDC/OD/OADC) [redacted] (b) (6)>; Brennan, Patrick (OS/ASPA) [redacted] (b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] <[redacted] (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>; Campbell, Amanda (CDC/OD/OCS) [redacted] (b) (6)>; Stecker, Judy (OS/IOS) [redacted] (b) (6)>; Murphy, Ryan (OS/ASPA) [redacted] (b) (6)>; Pratt, Michael (OS/ASPA) [redacted] (b) (6)>; Oakley, Caitlin B. (OS/ASPA) [redacted] (b) (6)>; Hall, Bill (HHS/ASPA) [redacted] (b) (6); Myles, Renate (NIH/OD) [E] [redacted] (b) (6); Burklow, John (NIH/OD) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Redfield/Fauci nCoV op-ed

All – attached is a track changes draft and a clean version with input from NIAID and Dr. Fauci.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lepore, Loretta (CDC/OD/OCS) [redacted] (b) (6)
Sent: Sunday, February 2, 2020 2:39 PM

To: Fine, Amanda (NIH/OD) [E]; Galatas, Kate (CDC/OD/OADC); Brennan, Patrick (OS/ASPA); Bonds, Michelle E. (CDC/OD/OADC); Conrad, Patricia (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS); Campbell, Amanda (CDC/OD/OCS); Stecker, Judy (OS/IOS); Murphy, Ryan (OS/ASPA); Pratt, Michael (OS/ASPA); Oakley, Caitlin B. (OS/ASPA); Hall, Bill (HHS/ASPA); Myles, Renate (NIH/OD) [E]
Subject: RE: Redfield/Fauci nCoV op-ed

Good afternoon all,

I am forwarding the op-ed drafted by CDC and reviewed by Dr. Redfield for review by Dr. Fauci and our colleagues at NIH.

Please reach out with any questions.

Best,
Loretta

From: Fine, Amanda (NIH/OD) [E] (b) (6)
Sent: Friday, January 31, 2020 6:36 PM
To: Galatas, Kate (CDC/OD/OADC) (b) (6)>; Brennan, Patrick (OS/ASPA) (b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Lepore, Loretta (CDC/OD/OCS) (b) (6)>
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Campbell, Amanda (CDC/OD/OCS) (b) (6)>; Stecker, Judy (OS/IOS) (b) (6); Murphy, Ryan (OS/ASPA) (b) (6); Pratt, Michael (OS/ASPA) (b) (6); Oakley, Caitlin B. (OS/ASPA) < (b) (6)>; Hall, Bill (HHS/ASPA) < (b) (6)>; Myles, Renate (NIH/OD) [E] (b) (6)
Subject: RE: Redfield/Fauci nCoV op-ed

+ Renate Myles for awareness

From: Galatas, Kate (CDC/OD/OADC) (b) (6)
Sent: Friday, January 31, 2020 6:34 PM
To: Brennan, Patrick (OS/ASPA) < (b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) (b) (6); Fine, Amanda (NIH/OD) [E] < (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Lepore, Loretta (CDC/OD/OCS) (b) (6)
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)>; Campbell, Amanda (CDC/OD/OCS) (b) (6)>; Stecker, Judy (OS/IOS) < (b) (6); Murphy, Ryan (OS/ASPA) (b) (6)>; Pratt, Michael (OS/ASPA) (b) (6) Oakley, Caitlin B. (OS/ASPA) (b) (6); Hall, Bill (HHS/ASPA) (b) (6)
Subject: Re: Redfield/Fauci nCoV op-ed

Hi, Patrick -
We've put this in motion — once it's cleared thru CDC, we will send back to this group so NIH comms can move thru with their editing/revisions.

Let me know if that sounds OK. We will likely not have a cleared version out of CDC until late Saturday at the earliest.
Take care,
Kate

Get [Outlook for iOS]()

From: Brennan, Patrick (OS/ASPA) <[redacted] (b) (6)
Sent: Friday, January 31, 2020 5:31:46 PM
To: Bonds, Michelle E. (CDC/OD/OADC) [redacted] (b) (6)>; Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Lepore, Loretta (CDC/OD/OCS) [redacted] (b) (6)>
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6); Campbell, Amanda (CDC/OD/OCS) [redacted] (b) (6)>; Stecker, Judy (OS/IOS) [redacted] (b) (6); Murphy, Ryan (OS/ASPA) [redacted] (b) (6); Pratt, Michael (OS/ASPA) [redacted] (b) (6); Oakley, Caitlin B. (OS/ASPA) [redacted] (b) (6)>; Hall, Bill (HHS/ASPA) [redacted] (b) (6)>; Galatas, Kate (CDC/OD/OADC) [redacted] (b) (6)>
Subject: Redfield/Fauci nCoV op-ed

CDC and NIH folks,

Per some discussion after the presser, we'd like Dr. Redfield and Dr. Fauci to pen an op-ed regarding the reasons/thinking behind the policy announced today. I assume the right building blocks for it would be the remarks they made today – which I believe you all should have the copy/notes for? I have the Secretary's, which we'll be sending around/posting shortly and I'll make sure to re-up it here so you all have it.

It would be great to have a draft of this cleared to get to the WH over the weekend. (I anticipate faster-than-average clearance from them!)

Please let me know how I can help with this.

Best,
Patrick

Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office: [redacted] (b) (6) | Cell [redacted] (b) (6)

Predecisional/deliberative communication

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 12:54:11 +0000
To: [redacted] (b) (6)
Subject: FW: Following Up If We can Be of Any Assistance

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>
Sent: Tuesday, February 11, 2020 7:28 AM
To: [redacted] (b) (6)
Cc: [redacted] (b) (6) Elvander, Erika (OS/OGA) [redacted] (b) (6); Lamana, Joseph (OS/ASPR/EMMO) <[redacted] (b) (6); Disbrow, Gary (OS/ASPR/BARDA) [redacted] (b) (6); Yeskey, Kevin (OS/ASPR/IO) [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Following Up If We can Be of Any Assistance

Dear Dr. Suzuki we heard from Jun the news that your Prime Minister gave approval for the deployment of our team. We are moving expeditiously to get them there to assist. In light of the situation and the increasing numbers of cases on the ship, [redacted] (b) (5)

[redacted] (b) (5)

Again, we are grateful and excited that we have the opportunity to work together.

Kanpai!

Bob

From: Kadlec, Robert (OS/ASPR/IO)
Sent: Monday, February 10, 2020 8:14 PM
To: [redacted] (b) (6)
Cc: [redacted] (b) (6); Elvander, Erika (OS/OGA) [redacted] (b) (6); Lamana, Joseph (HHS/ASPR/OEM) [redacted] (b) (6)
[redacted] (b) (6)
Subject: Following Up If We can Be of Any Assistance

Dear Dr. Suzuki –

I hope this finds you I good health and expect that you are deeply involved in the events of coronavirus in your region. I understand from various communications with the MHLW that is considering ending the quarantine early and releasing passengers from the Diamond Princess, especially those who are 80 years of age or older. Given the media reports and public perception there is pressure to do this. However, as medical experts, you and I both know that days 3 – 8 are within the normal incubation period and these new positives do not likely represent shipboard transmission. As such, HHS is willing to coordinate U.S. medical experts who can engage with English language media explaining and reassuring the passengers, crew, and public.

Regarding support for the quarantine, ASPR is ready to deploy a team of 3-5 people quickly, and as many 12 people to Japan to support as suggested in the previous call. If we can assist you and your team in managing the Americans currently in quarantine please let me know. If there is other support do let me know and ASPR will work to assist. As we've talked for the past 18 months about such a scenario, this may not be the one we envisioned, but it is a perfect case as we can clearly identify the Americans, they are in a contained area. Our mutual efforts and planning have paid unexpected dividends.

I am available to discuss via teleconference at your convenience. I am grateful for all MHLW has done to support this complicated response on top of your work supporting repatriation and domestic monitoring of your own citizens. We are grateful for Dr. Sugihara's herculean information sharing efforts and the rest of your MHLW team support during this event; it validates of the importance of our ongoing liaison program and the long term benefits of our mutual commitment to each other's public health security

Please remain well and I look forward to see you again soon.

Best wishes and warm regards.

Dr Bob Kadlec
ASPR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 18:43:59 +0000
To: Brennan, Patrick (OS/ASPA)
Cc: Hall, Bill (HHS/ASPA);Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Draft of email
Attachments: 2 10 20 email - with Fauci edits.docx

Here is the document with my tracked changes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Brennan, Patrick (OS/ASPA) (b) (6)
Sent: Monday, February 10, 2020 1:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Hall, Bill (HHS/ASPA) <Bill.Hall@HHS.GOV>
Subject: Draft of email

Dr. Fauci – below and in the attached is our proposed draft response, and then Cuccinelli's email text below for context. We're waiting on a potential detail/point or two from ASPR that may help flesh it out a bit but we'll see if we actually need it. Thank you!

<< File: 2 10 20 email.docx >>
Draft HHS response

Fellow task force members,

Thanks for your message, Ken, and I look forward to our discussion today.

(b) (5)

[redacted]

Looking forward to discussing more later today.

Ken

To my fellow task force members,

(b) (5)

[redacted]

(b) (5)

[redacted]

I look forward to speaking with you all again this afternoon.

Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office: (b) (6) | Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 23:54:27 +0000
To: [redacted] (b) (6)
Subject: FW: WHO advance team on coronavirus on way to China - Tedros tweet

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Grigsby, Garrett (HHS/OS/OGA) <[redacted] (b) (6)>
Sent: Sunday, February 9, 2020 6:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6); Harrison, Brian (HHS/IOS) [redacted] (b) (6)
Cc: Kerr, Lawrence (HHS/OS/OGA) <[redacted] (b) (6); Elvander, Erika (OS/OGA) [redacted] (b) (6)>; Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6) Redfield, Robert R. (CDC/OD) [redacted] (b) (6); Kadlec, Robert (OS/ASPR/IO) <[redacted] (b) (6); Abram, Anna (FDA/OC) <[redacted] (b) (6)>; Bright, Rick (OS/ASPR/BARDA) [redacted] (b) (6)>
Subject: RE: WHO advance team on coronavirus on way to China - Tedros tweet

Dr F,

[redacted] (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, February 9, 2020 6:24 PM
To: Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)>; Harrison, Brian (HHS/IOS) [redacted] (b) (6)>

Cc: Kerr, Lawrence (HHS/OS/OGA) <[redacted] (b) (6)>; Elvander, Erika (OS/OGA)
[redacted] (b) (6); Zebley, Kyle (HHS/OS/OGA) <[redacted] (b) (6)>; Redfield, Robert R.
(CDC/OD) [redacted] (b) (6)>; Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>; Abram, Anna
(FDA/OC) [redacted] (b) (6)>; Bright, Rick (OS/ASPR/BARDA) [redacted] (b) (6)
Subject: RE: WHO advance team on coronavirus on way to China - Tedros tweet

[redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Grigsby, Garrett (HHS/OS/OGA) <[redacted] (b) (6)
Sent: Sunday, February 9, 2020 6:03 PM
To: Harrison, Brian (HHS/IOS) [redacted] (b) (6)
Cc: Kerr, Lawrence (HHS/OS/OGA) [redacted] (b) (6); Elvander, Erika (OS/OGA)
<[redacted] (b) (6); Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6)>; Redfield, Robert R.
(CDC/OD) [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>; Kadlec, Robert
(OS/ASPR/IO) [redacted] (b) (6)>; Abram, Anna (FDA/OC) [redacted] (b) (6)>; Bright,
Rick (OS/ASPR/BARDA) <[redacted] (b) (6)
Subject: FW: WHO advance team on coronavirus on way to China - Tedros tweet

Brian – more clarity from "the horse's mouth" on this advance trip…see below.

From: Grigsby, Garrett (HHS/OS/OGA)
Sent: Sunday, February 9, 2020 6:01 PM
To: SCHWARTLANDER, Bernhard F. [redacted] (b) (6)
Cc: SIMONSON, Stewart [redacted] (b) (6)>
Subject: RE: WHO advance team on coronavirus on way to China - Tedros tweet

Many thanks, Bernard! I know I'll be asked, so I will pass your email up the chain…

Take care and thanks again!

From: SCHWARTLANDER, Bernhard F. [redacted] (b) (6)
Sent: Sunday, February 9, 2020 5:59 PM
To: Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)>
Cc: SIMONSON, Stewart [redacted] (b) (6)
Subject: Re: WHO advance team on coronavirus on way to China - Tedros tweet

Hi Garrett,

We have three people on the way to Beijing who will work with our Chinese counterparts on finalizing the TOR and composition of the joint WHO - China mission. As you are much aware, the US has given us a number of names who will be able and willing to join such a mission. We have received similar proposals from other countries and will now match the "long list" of experts with the required specific expertise.

We are hoping to have more clarity over the coming days and will obviously keep you in the loop. The overall number will be kept at a level to make sure that the team is fully operational.

With my warmest wishes

Bernhard

Dr Bernhard Schwartländer
Chef de Cabinet
World Health Organization

> On 9 Feb 2020, at 23:24, Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)> wrote:
>
> Bernard,
>
> Hope you had a good weekend.
>
> I'm reaching out to get more clarity on the WHO experts team issue – please see article below. I've heard everything from an advance group of one or two individuals to 15 people discussed in the article. I haven't heard any word about US people, and I was just with Dr Redfield late this afternoon and he was in the dark too.

Any additional information will be deeply appreciated.

Thanks!

From: Kerr, Lawrence (HHS/OS/OGA) [redacted] (b) (6)>
Sent: Sunday, February 9, 2020 5:03 PM
To: Grigsby, Garrett (HHS/OS/OGA) < [redacted] (b) (6); Zebley, Kyle (HHS/OS/OGA) < [redacted] (b) (6)>; Elvander, Erika (OS/OGA) [redacted] (b) (6); Tracy Carson [redacted] (b) (6)>
Subject: WHO advance team on coronavirus on way to China - Tedros tweet

February 9, 2020 / 4:01 PM / Updated an hour ago

UPDATE 1-WHO advance team on coronavirus on way to China - Tedros tweet

Stephanie Nebehay

By Stephanie Nebehay

GENEVA, Feb 9 (Reuters) - An advance team of international experts led by the World Health Organization (WHO) has left for Beijing to help investigate China's coronavirus epidemic, the Geneva-based agency said on Sunday.

WHO director-general Tedros Adhanom Ghebreyesus, who made a trip to Beijing for talks with President Xi Jinping and Chinese ministers in late January, returned with an agreement on sending an international mission.

But it has taken nearly two weeks to get the government's green light on its composition, which was not announced, other than to say that WHO veteran Dr. Bruce Aylward, a Canadian epidemiologist and emergencies expert, was heading it.

"I've just been at the airport seeing off members of an advance team for the @WHO-led #2019nCoV international expert mission to #China, led by Dr Bruce Aylward, veteran of past public health emergencies," Tedros said in a tweet from Geneva.

Dr. Sylvie Briand, who accompanied Tedros last month and stayed behind for talks with top Chinese health officials, told Reuters last week that they were discussing a list of experts with China.

"Because it is a joint mission, they need to be on board, it's not just an international group going there. We have about 15 people," said Briand, director of Global Infectious Hazard Preparedness at WHO.

China raised the death toll from the coronavirus outbreak to 811 on Sunday, passing the number killed globally by the SARS epidemic, as authorities made plans for millions of people returning to work after an extended Lunar New Year break.

The virus, which has spread to two dozen countries, has killed some 2% of more than 37,550 cases worldwide, with 99 percent of infections in China, WHO figures show.

The WHO declared the outbreak a global emergency on Jan. 30, days after the Chinese central government imposed a lockdown on 60 million people in Hubei province and its capital Wuhan, epicentre of the virus that emerged in December in a seafood market.

Tedros said on Saturday that he hoped the team would include experts from the U.S. Centers for Disease Control (CDC).

“It has to be meaningful on the ground,” Lawrence Gostin, professor of global health law at Georgetown Law, said in an interview in Geneva this week.

Gostin called for a “genuine partnership with transparent flows of information and accountability for the response”, adding that there should be a strong CDC presence.

“CDC has got no peer in terms of its experience and technical expertise in dealing with international outbreaks,” he said.

“But the other benefit is the smart diplomacy, what it could signal is that despite all of our differences in ideology, trade, politics, that when faced with a common threat to humanity, we come together as a human community to tackle it,” Gostin said.

Reporting by Stephanie Nebehay; Editing by Pravin Char, Kirsten Donovan

Our Standards:The Thomson Reuters Trust Principles.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:55:22 +0000
To: Shapiro, Neil (NIH/OD) [E];Collins, Francis (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E];Johnson, Alfred (NIH/OD) [E];Hallett, Adrienne (NIH/OD) [E]
Cc: Shaya, Cecile (NIH/OD) [E]
Subject: RE: Coronavirus - HHS Supplemental Table - Close Hold

[redacted] (b) (5)

From: Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6)
Sent: Thursday, February 6, 2020 8:08 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Shaya, Cecile (NIH/OD) [E] [redacted] (b) (6)
Subject: RE: Coronavirus - HHS Supplemental Table - Close Hold

I'll ask, unless Tony knows. [redacted] (b) (5)

Neil

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Thursday, February 6, 2020 4:59 PM
To: Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] < [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Shaya, Cecile (NIH/OD) [E] [redacted] (b) (6)>
Subject: RE: Coronavirus - HHS Supplemental Table - Close Hold

[redacted] (b) (5)

FC

From: Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6)>
Sent: Thursday, February 6, 2020 3:22 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6) Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Shaya, Cecile (NIH/OD) [E] [redacted] (b) (6)
Subject: FW: Coronavirus - HHS Supplemental Table - Close Hold
Importance: High

ASFR provided the pdf attachment and the explanation below. They emphasized on the phone too that this is very close hold. [redacted] (b) (5):, (b) (5)

Neil

From: Cabezas, Miriam (HHS/ASFR) [redacted] (b) (6)>
Sent: Thursday, February 6, 2020 2:32 PM
To: Kelly, Alison (CDC/OCOO/OFR/OA) [redacted] (b) (6)>; Berger, Sherri (CDC/OCOO/OD) [redacted] (b) (6); Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6)>; Shaya, Cecile (NIH/OD) [E] [redacted] (b) (6)>; Petillo, Jay (OS/ASPR/MFHC) [redacted] (b) (6)>; Dubay, Johanna (OS/ASPR/MFHC) [redacted] (b) (6)
Cc: Goyle, Suraj (OS/ASFR) < [redacted] (b) (6)>; Falisi, Angela (OS/ASFR) [redacted] (b) (6)>; White, RaeShawn (OS/ASFR) [redacted] (b) (6)>; Cormier, Justin (HHS/ASFR) [redacted] (b) (6)>
Subject: Coronavirus - HHS Supplemental Table - Close Hold

Information in this email is close hold.

Good afternoon –

Attached you will find CDC, ASPR, and NIH specific totals that were provided to OMB last night. We want to make sure you have awareness of the activities that are identified across these three agencies. Let us know if you have any questions. This information should not be shared broadly.

Miriam

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:38:07 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: ** Time-Sensitive Clearance ** DUE BY 3:30 TODAY- Coronavirus - Minister Ma of China Response Letter - 00430215

Please take care of this on my behalf. Thanks.

From: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, February 6, 2020 3:11 PM
To: Harris, Kara (NIH/NIAID) [E] < [redacted] (b) (6); Handley, Gray (NIH/NIAID) [E] <h [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] < [redacted] (b) (6)>; Harper, Jill (NIH/NIAID) [E] [redacted] (b) (6)>; McGowan, John J. (NIH/NIAID) [E] [redacted] (b) (6); Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: NIAID OCGR Correspondence <NIAIDOCGRCorrespondence@mail.nih.gov>; Gilles, Sharon (NIH/NIAID) [E] [redacted] (b) (6) Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: ** Time-Sensitive Clearance ** DUE BY 3:30 TODAY- Coronavirus - Minister Ma of China Response Letter - 00430215

[redacted] (b) (5)

From: Harris, Kara (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Thursday, February 6, 2020 3:00 PM
To: Handley, Gray (NIH/NIAID) [E] [redacted] (b) (6) Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6); Eisinger, Robert (NIH/NIAID) [E] [redacted] (b) (6) Harper, Jill (NIH/NIAID) [E] < [redacted] (b) (6) McGowan, John J. (NIH/NIAID) [E] <j [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] < [redacted] (b) (6)>
Cc: NIAID OCGR Correspondence <NIAIDOCGRCorrespondence@mail.nih.gov>; Gilles, Sharon (NIH/NIAID) [E] [redacted] (b) (6)

Subject: FW: ** Time-Sensitive Clearance ** DUE BY 3:30 TODAY- Coronavirus - Minister Ma of China Response Letter - 00430215
Importance: High

All –

Please see the note below from Exec Sec. Please provide any comments to NIAID OCGR Correspondence by 3:30 p.m. Please note – Exec Sec is looking for **show-stopping comments only**.

Thank you,
Kara

From: Malliou, Ekaterini (OS/IOS) [redacted] (b) (6)>
Sent: Thursday, February 6, 2020 2:25 PM
To: Stannard, Paula (HHS/IOS) <[redacted] (b) (6); Hoffmann, Lauren (CDC/OD/OCS) [redacted] (b) (6)>; Clark, Cynthia K. (CDC/OD/OCS) [redacted] (b) (6); Stimson, Brian (HHS/OGC) [redacted] (b) (6) Chang, William (HHS/OGC) [redacted] (b) (6)>; Barry, Daniel J (HHS/OGC) <[redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6); Bird, Catherine (OS/OGC) [redacted] (b) (6) OS OGC-IO <ControlDesk.OGCIO@hhs.gov>; ASPR Exec Sec (OS/ASPR) <ASPRExecSec@hhs.gov>
Cc: Steele, Danielle (HHS/IOS) [redacted] (b) (6); Agnew, Ann (HHS/IOS) [redacted] (b) (6)>; Hawkins, Jamar (HHS/OS) [redacted] (b) (6); Horska, Katerina (HHS/IOS) [redacted] (b) (6)>; Varnado, Martina (FDA/OC) [redacted] (b) (6); Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] [redacted] (b) (6) [redacted]
Subject: Clearance Due 6pm (2/6): ** Time-Sensitive ** Coronavirus - Minister Ma of China Response Letter - 00430215

Please find attached for your clearance a response to Minister Ma's letter to the Secretary, and a recent conversation with him. [redacted] (b) (5)

Please note that the Secretary has already reviewed and edited the attached response

We appreciate your expedited review and clearance by 6pm today, 2/6.

Thank you,

Kat

****

Ekaterini (Kat) Malliou, DrPH, MPH
Senior Policy Coordinator
Immediate Office of the Secretary, U.S. Department of Health and Human Services
200 Independence Ave SW, Suite 619H, Washington, DC 20201, USA
Tel: [redacted] (b) (6) Cell: [redacted] (b) (6), Email: [redacted] (b) (6)

From: (b) (6)
Sent: Thu, 6 Feb 2020 18:56:07 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: Re: FROM CAITLIN OAKLEY - Atlantic reporter responded

Please schedule call for tomorrow.

> On Feb 6, 2020, at 4:17 PM, Conrad, Patricia (NIH/NIAID) [E] (b) (6)>wrote:
>
> See below – the reporter responded to Caitlyn – not Courtney – he can speak today or tomorrow. Do you want to call tonight or have me schedule for tomorrow?
>
> Tomorrow is quite full but can make it happen...let me know
>
> Yes, happy to talk today or tomorrow.
> I'm at (b) (6)
>
> If Dr. Fauci is available, that would be great.
>
> Best,
>
> Peter Nicholas
>
> Patricia L. Conrad
> Public Health Analyst and
> Special Assistant to the Director
> National Institute of Allergy and Infectious Diseases
> The National Institutes of Health
> 31 Center Drive, MSC 2520 - Room 7A03
> Bethesda, Maryland 20892
> (b) (6)
> 301-496-4409 fax
>
> Disclaimer:
> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It

should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Oakley, Caitlin B. (OS/ASPA) <[redacted] (b) (6)>
Sent: Thursday, February 6, 2020 4:12 PM
To: Billet, Courtney (NIH/NIAID) [E] <[redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: follow up re: Coronavirus story

Caitlin B. Oakley
Deputy Assistant Secretary, National Spokesperson
Office of the Assistant Secretary for Public Affairs
U.S. Department of Health and Human Services
[redacted] (b) (6)

From: Peter Nicholas <pnicholas@theatlantic.com>
Sent: Thursday, February 6, 2020 3:00 PM
To: Oakley, Caitlin B. (OS/ASPA) [redacted] (b) (6)>
Subject: Re: follow up re: Coronavirus story

Hi,

Yes, happy to talk today or tomorrow.
I'm at [redacted] (b) (6). If Dr. Fauci is available, that would be great.

Best,

Peter

On Thu, Feb 6, 2020 at 11:09 AM Oakley, Caitlin B. (OS/ASPA) [redacted] (b) (6)>wrote:

> Following up on this….does today work?
>
> And I know Dr. Fauci's office is trying to get in contact as well. He's a member of the taskforce. Can we make this happen?
>
> **Caitlin B. Oakley**
> Deputy Assistant Secretary, National Spokesperson
> Office of the Assistant Secretary for Public Affairs
> U.S. Department of Health and Human Services
> [redacted] (b) (6)

From: Oakley, Caitlin B. (OS/ASPA)
Sent: Wednesday, February 5, 2020 3:55 PM
To: pnicholas@theatlantic.com
Cc: Hall, Bill (HHS/ASPA) (b) (6)>
Subject: follow up re: Coronavirus story

Peter—Thanks for the chat yesterday. Have a few folks that I'd like to get you on the phone with about your piece. Would you have time to chat with Bill Hall and I later today?

And when is your deadline for the piece?

Talk soon,

Caitlin B. Oakley
Deputy Assistant Secretary, National Spokesperson
Office of the Assistant Secretary for Public Affairs
U.S. Department of Health and Human Services
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 15:21:22 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Redfield/Fauci nCoV op-ed
Attachments: Coronavirus OpEd - Redfield and Fauci - 02-06-2020.docx

Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 3:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Redfield/Fauci nCoV op-ed

Here is the op-ed as cleared by WH.
Any issues with this?
[redacted] (b) (5)

From: Brennan, Patrick (OS/ASPA) < [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 3:39 PM
To: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Lepore, Loretta (CDC/OD/OCS) [redacted] (b) (6)
Cc: Fine, Amanda (NIH/OD) [E] [redacted] (b) (6) Galatas, Kate (CDC/OD/OADC) [redacted] (b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>; Campbell, Amanda (CDC/OD/OCS) [redacted] (b) (6);

Stecker, Judy (OS/IOS) [redacted] (b) (6); Murphy, Ryan (OS/ASPA) [redacted] (b) (6)
Pratt, Michael (OS/ASPA) [redacted] (b) (6) Oakley, Caitlin B. (OS/ASPA)
[redacted] (b) (6)>; Hall, Bill (HHS/ASPA) < [redacted] (b) (6)>; Myles, Renate (NIH/OD) [E]
[redacted] (b) (6); Burklow, John (NIH/OD) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID)
[E] [redacted] (b) (6)
Subject: RE: Redfield/Fauci nCoV op-ed

Attached is a tracked changes version and a clean version of what cleared the WH – they had a few sentences they would like to be added (which, in the tracekd changes version, I have added comments to explain who suggested it and in some cases why), but almost all of these edits are non-substantive.

Assuming CDC and NIAID are good with these (feel free to modify the additions as needed), you all are good to pitch this as you wish – [redacted] (b) (5)

From: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, February 2, 2020 6:11 PM
To: Lepore, Loretta (CDC/OD/OCS) < [redacted] (b) (6)>
Cc: Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>; Galatas, Kate (CDC/OD/OADC) [redacted] (b) (6)>; Brennan, Patrick (OS/ASPA) [redacted] (b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] < [redacted] (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>; Campbell, Amanda (CDC/OD/OCS) [redacted] (b) (6)>; Stecker, Judy (OS/IOS) [redacted] (b) (6)>; Murphy, Ryan (OS/ASPA) [redacted] (b) (6)>; Pratt, Michael (OS/ASPA) [redacted] (b) (6)>; Oakley, Caitlin B. (OS/ASPA) [redacted] (b) (6)>; Hall, Bill (HHS/ASPA) [redacted] (b) (6); Myles, Renate (NIH/OD) [E] [redacted] (b) (6); Burklow, John (NIH/OD) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Redfield/Fauci nCoV op-ed

All – attached is a track changes draft and a clean version with input from NIAID and Dr. Fauci.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lepore, Loretta (CDC/OD/OCS) [redacted] (b) (6)
Sent: Sunday, February 2, 2020 2:39 PM

To: Fine, Amanda (NIH/OD) [E]; Galatas, Kate (CDC/OD/OADC); Brennan, Patrick (OS/ASPA); Bonds, Michelle E. (CDC/OD/OADC); Conrad, Patricia (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS); Campbell, Amanda (CDC/OD/OCS); Stecker, Judy (OS/IOS); Murphy, Ryan (OS/ASPA); Pratt, Michael (OS/ASPA); Oakley, Caitlin B. (OS/ASPA); Hall, Bill (HHS/ASPA); Myles, Renate (NIH/OD) [E]
Subject: RE: Redfield/Fauci nCoV op-ed

Good afternoon all,

I am forwarding the op-ed drafted by CDC and reviewed by Dr. Redfield for review by Dr. Fauci and our colleagues at NIH.

Please reach out with any questions.

Best,
Loretta

From: Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)
Sent: Friday, January 31, 2020 6:36 PM
To: Galatas, Kate (CDC/OD/OADC) [redacted] (b) (6)>; Brennan, Patrick (OS/ASPA) [redacted] (b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Lepore, Loretta (CDC/OD/OCS) [redacted] (b) (6)>
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6); Campbell, Amanda (CDC/OD/OCS) [redacted] (b) (6)>; Stecker, Judy (OS/IOS) [redacted] (b) (6); Murphy, Ryan (OS/ASPA) [redacted] (b) (6); Pratt, Michael (OS/ASPA) [redacted] (b) (6); Oakley, Caitlin B. (OS/ASPA) < [redacted] (b) (6)>; Hall, Bill (HHS/ASPA) < [redacted] (b) (6)>; Myles, Renate (NIH/OD) [E] [redacted] (b) (6)
Subject: RE: Redfield/Fauci nCoV op-ed

+ Renate Myles for awareness

From: Galatas, Kate (CDC/OD/OADC) [redacted] (b) (6)
Sent: Friday, January 31, 2020 6:34 PM
To: Brennan, Patrick (OS/ASPA) < [redacted] (b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) [redacted] (b) (6); Fine, Amanda (NIH/OD) [E] < [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Lepore, Loretta (CDC/OD/OCS) [redacted] (b) (6)
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6)>; Campbell, Amanda (CDC/OD/OCS) [redacted] (b) (6)>; Stecker, Judy (OS/IOS) < [redacted] (b) (6); Murphy, Ryan (OS/ASPA) [redacted] (b) (6)>; Pratt, Michael (OS/ASPA) [redacted] (b) (6) Oakley, Caitlin B. (OS/ASPA) [redacted] (b) (6); Hall, Bill (HHS/ASPA) [redacted] (b) (6)
Subject: Re: Redfield/Fauci nCoV op-ed

Hi, Patrick -
We've put this in motion — once it's cleared thru CDC, we will send back to this group so NIH comms can move thru with their editing/revisions.

Let me know if that sounds OK. We will likely not have a cleared version out of CDC until late Saturday at the earliest.
Take care,
Kate

Get Outlook for iOS

From: Brennan, Patrick (OS/ASPA) <[redacted] (b) (6)
Sent: Friday, January 31, 2020 5:31:46 PM
To: Bonds, Michelle E. (CDC/OD/OADC) [redacted] (b) (6)>; Fine, Amanda (NIH/OD) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Lepore, Loretta (CDC/OD/OCS) [redacted] (b) (6)>
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) [redacted] (b) (6); Campbell, Amanda (CDC/OD/OCS) [redacted] (b) (6)>; Stecker, Judy (OS/IOS) [redacted] (b) (6); Murphy, Ryan (OS/ASPA) [redacted] (b) (6); Pratt, Michael (OS/ASPA) [redacted] (b) (6); Oakley, Caitlin B. (OS/ASPA) [redacted] (b) (6)>; Hall, Bill (HHS/ASPA) [redacted] (b) (6)>; Galatas, Kate (CDC/OD/OADC) [redacted] (b) (6)>
Subject: Redfield/Fauci nCoV op-ed

CDC and NIH folks,

Per some discussion after the presser, we'd like Dr. Redfield and Dr. Fauci to pen an op-ed regarding the reasons/thinking behind the policy announced today. I assume the right building blocks for it would be the remarks they made today – which I believe you all should have the copy/notes for? I have the Secretary's, which we'll be sending around/posting shortly and I'll make sure to re-up it here so you all have it.

It would be great to have a draft of this cleared to get to the WH over the weekend. (I anticipate faster-than-average clearance from them!)

Please let me know how I can help with this.

Best,
Patrick

Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office: [redacted] (b) (6) | Cell [redacted] (b) (6)

Predecisional/deliberative communication

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 14:54:16 +0000
To: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: ASF: rAzar/Pompeo op-ed
Attachments: 2 5 20 pompeo azar op-ed State - with Fauci tracked edits..docx

Here are my tracked edits. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Thursday, February 6, 2020 7:31 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: ASF: rAzar/Pompeo op-ed

Sending to all of you simultaneously, in the interest of time. Our comments are due back at noon.

From: "Brennan, Patrick (OS/ASPA)" <[redacted] (b) (6)>
Date: Thursday, February 6, 2020 at 1:23:26 AM
To: "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)>, "Bonds, Michelle E. (CDC/OD/OADC)" [redacted] (b) (6), "Galatas, Kate (CDC/OD/OADC)" [redacted] (b) (6)>, "Fine, Amanda (NIH/OD) [E]" [redacted] (b) (6)>, "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "Kane, Elleen (OS/ASPR/OEA)" [redacted] (b) (6)>, "Michael, Gretchen (OS/ASPR/OEA)" [redacted] (b) (6), "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)>, "Lepore, Loretta (CDC/OD/OCS)" [redacted] (b) (6), "McGowan, Robert (Kyle) (CDC/OD/OCS)" [redacted] (b) (6), "Campbell, Amanda (CDC/OD/OCS)" [redacted] (b) (6)>, "Zebley, Kyle (HHS/OS/OGA)"

[redacted] (b) (6)>, "Chang, William (HHS/OGC)" [redacted] (b) (6), "Keveney, Sean (HHS/OGC)" [redacted] (b) (6)>, "Grigsby, Garrett (HHS/OS/OGA)" [redacted] (b) (6)
Cc: "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)>, "ASPA-Deputies" <ASPA-Deputies@hhs.gov>
Subject: For review by noon Thurs: revised Azar/Pompeo op-ed

Hi all,

Attached is a largely new draft of the Azar/Pompeo op-ed that [redacted] (b) (5)

[redacted] (b) (5) I've made a couple additions and edits to their new version, which I've tracked/flagged.

NIAID, CDC, and OGC, please let me know if this looks OK by noon tomorrow. Thank you!

Best,

Patrick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 14:24:54 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: ASF: for review, Azar coronavirus presser remarks
Attachments: Secretary's remarks with minor Fauci edits.docx

Here are my edits for Azar's press comments

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Thursday, February 6, 2020 7:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: ASF: for review, Azar coronavirus presser remarks

Pls see Secretary's remarks for press conf and let us know if anything glaring needs to be fixed.

They also would like talking points from us, covering what you would say. These are really just a placeholder. We could resubmit what we sent last time. Is there anything new you would anticipate saying?

From: "Brennan, Patrick (OS/ASPA)" [redacted] (b) (6)>
Date: Wednesday, February 5, 2020 at 11:25:33 PM
To: "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)>, "Bonds, Michelle E. (CDC/OD/OADC)" [redacted] (b) (6)>, "Galatas, Kate (CDC/OD/OADC)" [redacted] (b) (6), "Fine, Amanda (NIH/OD) [E]" [redacted] (b) (6)>, "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "Kane, Elleen

(OS/ASPR/OEA)" [redacted] (b) (6)>, "Michael, Gretchen (OS/ASPR/OEA)" [redacted] (b) (6)>, "Billet, Courtney (NIH/NIAID) [E]" < [redacted] (b) (6), "Steele, Danielle (HHS/IOS)" [redacted] (b) (6)>, "Arbes, Sarah (HHS/ASL)" [redacted] (b) (6)>, "Moughalian, Jen (HHS/ASFR)" < [redacted] (b) (6)>, "Shuy, Caitrin (HHS/ASFR)" [redacted] (b) (6), "Caliguiri, Laura (FDA/OC)" [redacted] (b) (6)>, "Janik, Heather (FDA/OC)" [redacted] (b) (6)>, "Lepore, Loretta (CDC/OD/OCS)" [redacted] (b) (6), "McGowan, Robert (Kyle) (CDC/OD/OCS)" [redacted] (b) (6)>, "Campbell, Amanda (CDC/OD/OCS)" [redacted] (b) (6), "Zebley, Kyle (HHS/OS/OGA)" [redacted] (b) (6), "Chang, William (HHS/OGC)" [redacted] (b) (6)>, "Keveney, Sean (HHS/OGC)" [redacted] (b) (6)>, "Pence, Laura (HHS/ASL)" [redacted] (b) (6)"Grigsby, Garrett (HHS/OS/OGA)" [redacted] (b) (6)>
Cc: "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)>, "Stover, Kathy (NIH/NIAID) [E]" [redacted] (b) (6)>, "ASPA-Deputies" <ASPA-Deputies@hhs.gov>
Subject: For review by 11 AM Thurs: Sec. Azar coronavirus presser remarks

Hi all,

Attached are draft remarks for the Secretary to deliver tomorrow evening at the scheduled press conference on coronavirus – after which the plan is for Dr. Redfield and then Dr. Fauci, and then whoever from State and DHS (I think?) to speak.

Can CDC, NIAID, OGC, FDA, and ASPR let me know if this looks OK by 11 AM tomorrow?

And once CDC and NIAID have their draft TPs, it would be great to see those as well.

Thank you!

- Patrick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 03:59:18 +0000
To: Grigsby, Garrett (HHS/OS/OGA);Lane, Cliff (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E];Zebley, Kyle (HHS/OS/OGA);Kerr, Lawrence (HHS/OS/OGA);Burr, Mara (HHS/OS/OGA);Levine, Maya (OS/OGA);Mciff, Colin (HHS/OS/OGA);Arboleda, Nelson (HHS/OS/OGA);Alexander, Thomas (OS/OGA)
Subject: RE: Coronavirus collaborating center

Yes. Thanks you.

-----Original Message-----
From: Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)>
Sent: Wednesday, February 5, 2020 8:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Zebley, Kyle (HHS/OS/OGA) [redacted] (b) (6)>; Kerr, Lawrence (HHS/OS/OGA) [redacted] (b) (6)>; Burr, Mara (HHS/OS/OGA) [redacted] (b) (6)>; Levine, Maya (OS/OGA) [redacted] (b) (6); Mciff, Colin (HHS/OS/OGA) < [redacted] (b) (6) Arboleda, Nelson (HHS/OS/OGA) [redacted] (b) (6); Alexander, Thomas (OS/OGA) [redacted] (b) (6)>
Subject: FW: Coronavirus collaborating center
Importance: High

Drs F & L,

Confirming that you want me to reply in the affirmative asap...?

-----Original Message-----
From: Lamourelle, Gabrielle (HHS/OS/OGA) [redacted] (b) (6)>
Sent: Wednesday, February 5, 2020 6:50 AM
To: Grigsby, Garrett (HHS/OS/OGA) < [redacted] (b) (6); Mciff, Colin (HHS/OS/OGA) [redacted] (b) (6); Kerr, Lawrence (HHS/OS/OGA) < [redacted] (b) (6)>; Burr, Mara (HHS/OS/OGA) [redacted] (b) (6)>; Elvander, Erika (OS/OGA) [redacted] (b) (6)>
Cc: Tracy Carson [redacted] (b) (6)>; Smith, Steven T (Geneva) [redacted] (b) (6); Stewart, Jessica L. (HHS/OS/OGA) < [redacted] (b) (6); Levine, Maya (OS/OGA) [redacted] (b) (6)>; Wood, Rachel (HHS/OS/OGA) [redacted] (b) (6); Fernandez, Jose (OS/OGA) [redacted] (b) (6)
Subject: FW: Coronavirus collaborating center
Importance: High

Dear Garrett and all,
I have received the hard copy of the attached letter from Matias Tuler (WHO Collaborating Centers team) with the request that we review and provide a reply as quickly as possible. The letter, as usual form, says they will go forward in 8 weeks if they hear no objection from us.

Given the coronavirus situation [redacted] (b) (5) If you have any questions, let me know.

Thank you,
Gabrielle

-----Original Message-----
From: TULER, Matias [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 9:35 AM

To: Lamourelle, Gabrielle (HHS/OS/OGA) <[redacted] (b) (6)
Cc: OGA Multilateral <OGAmultilateral@hhs.gov>
Subject: RE: Coronavirus collaborating center

Dear Gabrielle,
Many thanks for the email.
I sent you an email with the letter just after we talked. I do not know if you received it. I am attaching the letter to this email again, just in case.
Thank you very much in advance.
Best regards,
Matias

Matias Tuler
Programme Manager
WHO Collaborating Centres, and WHO Expert Advisory Panels and Committees World Health Organization
Geneva , Switzerland
Office: [redacted] (b) (6)
Web: http://www.who.int/collaboratingcentres/information/en/
http://www.who.int/about/collaborations/expert_panels/en/
Follow WHO on Facebook, Twitter, YouTube, Instagram

-----Original Message-----
From: Lamourelle, Gabrielle (HHS/OS/OGA) [redacted] (b) (6)>
Sent: Wednesday, February 5, 2020 9:17
To: TULER, Matias [redacted] (b) (6)
Cc: OGA Multilateral <OGAmultilateral@hhs.gov>
Subject: Coronavirus collaborating center

Dear Matias,
Thank you for sharing the hard copy of the Coronavirus collaborating center letter. Please send me an electronic copy as well and I will send back immediately to our office for a rapid reply.

With best wishes,
Gabrielle Lamourelle

Deputy Director, Multilateral Relations
HHS Office of Global Affairs

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 02:55:19 +0000
To: Kerr, Lawrence (HHS/OS/OGA)
Cc: Grigsby, Garrett (HHS/OS/OGA)
Subject: RE: Spoke with Soumya re: evolutionary origin of nCoV

I do not see any problem with your doing this. Go for it.
Best,
Tony

From: Kerr, Lawrence (HHS/OS/OGA) [redacted] (b) (6)>
Sent: Wednesday, February 5, 2020 7:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6)>
Subject: Spoke with Soumya re: evolutionary origin of nCoV

Dr. Fauci,

(b) (5)

[redacted]

I welcome your advice please. Much thanks,

Larry

From: [redacted] (b) (6)
Sent: Wed, 11 Mar 2020 19:30:25 -0400
To: John M Jessup
Subject: Re: You are great - a thought

Kim:
Thanks for the note. That is exactly what the cdc is starting to do.
Best,
Tony

On Mar 11, 2020, at 7:22 PM, John M Jessup [redacted] (b) (6)>wrote:

Tony,

We have seen each other over the decades. I am the [redacted] (b) (6) from NCI who decreid the lack of information about Eboal since it was limited to fruit bats as a reservoir.

An idea about testing. Maryland still has testing limited to subjects with symptoms who have contact with people from affected areas or who really ill with a respiratory infection

Why not forget the contacts and test those with flu-like symptoms without the need for contacts but instead test for flu and if that is negative move on to covid-19.

That would still be a tremendous demand so ... go to a formal two-tier test where PCR is done with approved PCR primers and if that is positive then the confirmation is with a FDA test for covid-19.

There are a lot of manufacturers of PCR primers, most clinical labs have PCR machines so that screening tests ought to be supported without a lengthy FDA clearance if it winnows the number of patients who need a formal test.

You are terrific. Keep it up with common sense as opposed to whatever the top of the administration suggests. I bet that the primer manufacturers would be supportive.

Kim

J. Milburn Jessup, MD, FACS
Research Scientist
Division of Research
Washington DC VAMC
50 Irving Street NW
Washington, DC 20422
[redacted] (b) (6) or [redacted] (b) (6)

Affiliate Professor – Systems Biology

College of Science
George Mason University
(b) (6)

(b) (6) Diagnostics Evaluation Branch, CDP, DCTD, NCI, NIH

From: [redacted] (b) (6)
Sent: Wed, 5 Feb 2020 08:56:13 -0500
To: Baden, Lindsey, M.D.
Cc: Marston, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E];Morens, David (NIH/NIAID) [E]
Subject: Re: favor

[redacted] (b) (6), (b) (4)

On Feb 5, 2020, at 8:29 AM, Baden, Lindsey, M.D. <lbaden@nejm.org>wrote:

Tony,

[redacted] (b) (6), (b) (4)

Lindsey

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, February 4, 2020 at 7:06 PM
To: "Baden, Lindsey, M.D." <lbaden@nejm.org>
Cc: "Marston, Hilary (NIH/NIAID) [E]" [redacted] (b) (6) "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6), "Lerner, Andrea (NIH/NIAID) [E]" [redacted] (b) (6), "Lane, Cliff (NIH/NIAID) [E]" [redacted] (b) (6)>, "Morens, David (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: RE: favor

Lindsey:

[redacted] (b) (6), (b) (4)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03

31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Tuesday, February 4, 2020 3:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: favor

Tony (and Hilary),
Much appreciated. [redacted] (b) (6), (b) (4).
Thank you,
Lindsey

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, February 4, 2020 at 2:16 PM
To: "Baden, Lindsey, M.D." <lbaden@nejm.org>
Cc: "Marston, Hilary (NIH/NIAID) [E]" < [redacted] (b) (6), "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: RE: favor

Lindsay:

[redacted] (b) (6), (b) (4)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health

Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Tuesday, February 4, 2020 12:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: favor

Tony,

[redacted] (b) (6), (b) (4)

Thank you for considering,
Lindsey

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have

received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: [redacted] (b) (6)
Sent: Wed, 5 Feb 2020 08:41:40 -0500
To: Baden, Lindsey, M.D.
Subject: Re: favor

Thanks, Lindsey. I am always happy to help in any way I can

On Feb 5, 2020, at 8:32 AM, Baden, Lindsey, M.D. <lbaden@nejm.org>wrote:

Tony,
On a different note, as the spread of the nCoV-2019 virus is so complex and fast moving, any advice on how we at the *Journal* can help in the response would be great.
Your advice is always appreciated as we all try to get it right and be responsive.
Lindsey

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, February 4, 2020 at 7:06 PM
To: "Baden, Lindsey, M.D." <lbaden@nejm.org>
Cc: "Marston, Hilary (NIH/NIAID) [E]" [redacted] (b) (6), "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6), "Lerner, Andrea (NIH/NIAID) [E]" [redacted] (b) (6)>, "Lane, Cliff (NIH/NIAID) [E]" [redacted] (b) (6) "Morens, David (NIH/NIAID) [E]' [redacted] (b) (6)
Subject: RE: favor

Lindsey:

[redacted] (b) (6), (b) (4)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520

Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Tuesday, February 4, 2020 3:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: favor

Tony (and Hilary),
Much appreciated [redacted] (b) (6), (b) (4).
Thank you,
Lindsey

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, February 4, 2020 at 2:16 PM
To: "Baden, Lindsey, M.D." <lbaden@nejm.org>
Cc: "Marston, Hilary (NIH/NIAID) [E]" [redacted] (b) (6), "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: RE: favor

Lindsay:

[redacted] (b) (6), (b) (4)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)

FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Tuesday, February 4, 2020 12:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: favor

Tony,

(b) (6), (b) (4)

[redacted]

Thank you for considering,

Lindsey

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 11:52:41 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: INTERVIEW- A HABER/ A NEWS

For discussion.

From: GULSEN EDA ULUSOY <EDA.ULUSOY@ahaber.com.tr>
Sent: Wednesday, February 5, 2020 3:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: INTERVIEW- A HABER/ A NEWS

Dear Mr. Fauci,

This is Eda Ulusoy from Turkey's number one ranking news channel A Haber/ A News.

We would like to take few minutes of your time and kindly ask if we could possibly have the opportunity to make a Skype interview with you about China coronavirus outbreak.

We can have the interview this week or next week. I can arrange it according to your programme.

It will only take 15 minutes of your time.

We would really appreciate if we can make this interview.

Thank you for your kind consideration.

I'm looking forward to your reply.

Sincerely,

Eda Ulusoy
Correspondent

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 11:52:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Interview invitation from Dialogue CGTN

:et us discuss.

From: Bai Jacinta [redacted] (b) (6)
Sent: Wednesday, February 5, 2020 2:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Interview invitation from Dialogue CGTN

Dear Mr. Fauci,

This is Jacinta from Dialogue, CGTN of China Central Television. I hope this email finds you well.

I'm reaching out to ask if you have time for a satellite interview at 6:30 am on Feb 6, Thursday, DC time. I read the interview to you on New York Times and sincerely wish that you could share more with our global audience. It would be our honor to have you on.

Topics will cover the evolution of coronavirus and its mortality rate, difficulties in controlling the outbreak, cooperation in international communities, prevention measures and so on.

Please kindly let me know if you are available for the show. I'll send the proposed questions beforehand and book the closest studio for you.

Appreciate it!

Best,
Jacinta Bai
Dialogue, CGTN

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 11:34:46 +0000
To: Ho, David D.
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: 2019-nCoV

David:
Thanks for the note. Please have your office contact my Special Assistant, Patty Conrad (copied here) to set up a call. I down at the Congress and White House most of the day, but we can probably squeeze a call in between meetings.
Best,
Tony

From: Ho, David D. [redacted] (b) (6)>
Sent: Tuesday, February 4, 2020 12:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: 2019-nCoV

Tony,

Greetings. As you can see below, our institute has moved. We are now part of Columbia.

Do you have a brief moment to chat about the new coronavirus?

Best,

David

David D. Ho, M.D.
Director, Aaron Diamond AIDS Research Center
Clyde and Helen Wu Professor of Medicine
Director, Wu Family China Center
Columbia University Vagelos College of Physicians and Surgeons
701 W. 168th Street, HHSC 1102
New York, NY 10032

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 11:17:05 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Harper, Jill (NIH/NIAID) [E];Johnson, Martin S. (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Tabak, Lawrence (NIH/OD) [E];Shapiro, Neil (NIH/OD) [E];McGowan, John J. (NIH/NIAID) ([redacted] (b) (6);Auchincloss, Hugh (NIH/NIAID) [C] [redacted] (b) (6)
Subject: RE: Coronavirus

Francis:

(b) (5)
[redacted]

[redacted] (b) (5) Happy to discuss further.

Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)
Sent: Wednesday, February 5, 2020 5:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6)
Subject: FW: Coronavirus
Importance: High

Hey there Tony,

(b) (5)
[redacted]

Thanks, Francis

From: Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6)>
Sent: Tuesday, February 4, 2020 8:31 PM
To: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6); Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6) Schwetz, Tara (NIH/OD) [E] [redacted] (b) (6)>

Cc: Shaya, Cecile (NIH/OD) [E] [redacted] (b) (6)
Subject: RE: Coronavirus
Importance: High

[redacted] (b) (5)

From: Shapiro, Neil (NIH/OD) [E]
Sent: Tuesday, February 4, 2020 4:46 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6); Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6) Schwetz, Tara (NIH/OD) [E] [redacted] (b) (6)
Cc: Shaya, Cecile (NIH/OD) [E] [redacted] (b) (6)
Subject: RE: Coronavirus

Francis,

[redacted] (b) (5)

Neil

From: Shapiro, Neil (NIH/OD) [E]
Sent: Wednesday, January 29, 2020 2:34 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)>
Subject: RE: Coronavirus

I'm sending them the first part, thanks.

From: Collins, Francis (NIH/OD) [E] < [redacted] (b) (6)
Sent: Wednesday, January 29, 2020 5:23 AM
To: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6) Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6) Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)
Subject: RE: Coronavirus

[redacted] (b) (4)

FC

From: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)
Sent: Tuesday, January 28, 2020 6:25 PM
To: Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6) Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6); Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6); Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)
Subject: Re: Coronavirus

[redacted] (b) (5)

Larry

From: "Shapiro, Neil (NIH/OD) [E]" [redacted] (b) (6)>
Date: Tuesday, January 28, 2020 at 5:31 PM
To: Francis Collins [redacted] (b) (6), "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)>, "Johnson, Alfred (NIH/OD) [E]" < [redacted] (b) (6) "Wolinetz, Carrie (NIH/OD) [E]" < [redacted] (b) (6)>, "Hallett, Adrienne (NIH/OD) [E]" [redacted] (b) (6)
Subject: Coronavirus

[redacted] (b) (5)

(b) (5)

[redacted]

Neil

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 04:18:25 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.

No dinner.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, February 4, 2020 11:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
Subject: FW: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.

See highlight – will you and [redacted] (b) (6) attend the dinner. Pls advise.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marlene Colucci <mcolucci@businesscouncil.com>
Sent: Friday, January 31, 2020 2:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); David Rubenstein <David.Rubenstein@carlyle.com>; MaryPat Decker <marypat.decker@carlyle.com>
Subject: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.

Dear Dr. Fauci,

On behalf of our co-chairs for the winter meeting of The Business Council, David Rubenstein of The Carlyle Group and Ginni Rometty of IBM, we would like to formally invite you to participate in our meeting on February 20-21, 2020 in Washington, D.C. The theme of the meeting is "The Next Decade." (See formal invitation attached as well as list of CEO members).

We would like for you to participate in a 50 minute fireside chat with David Rubenstein (and possibly Dr. Francis Collins) to discuss the current coronavirus as well as what we should expect in the next decade. We want to give our CEOs insights into what the next 10 years will bring in terms of detection, diagnosis and treatment of diseases. All conversations are strictly off the record and closed press. We will cover all lodging and transportation.

As you know, The Business Council is comprised of the chief executive officers of the largest global corporations, representing all segments of the economy. We expect at least 150 CEO members, spouses and speakers to be in attendance.

As a participant you and your spouse are also invited to join us for our special reception, dinner and speaker at the REACH (Kennedy Center) on Thursday, February 20 at 6:30pm. It is the best opportunity for you to meet our CEO members and spouses, speakers and other special guests in an informal atmosphere.

If you are interested and available, please let me know. We can also set up a very brief call with you to discuss any additional details and answer any questions you may have. We look forward to hearing from you and would be honored to have you participate with us again.

Warmest regards,

Marlene

Marlene Colucci

EXECUTIVE
DIRECTOR

THE
BUSINESS
COUNCIL

T: 202-298-7650
C: (b) (6)
F: 202-785-0296

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 04:17:19 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Comment on story about how confident people feel about their govt's response to a health epidemic

Please try to draft a response for me. Thanks.

From: Rajeshni Naidu-Ghelani <Rajeshni.Naidu-Ghelani@ipsos.com>
Sent: Tuesday, February 4, 2020 12:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Comment on story about how confident people feel about their govt's response to a health epidemic

Hi Dr. Fauci,

I hope all is well. I'm working on a news story tied to the coronavirus outbreak and tying it to how people responded to a recent global Ipsos poll about the threat of a major health epidemic in their country in the next 12 months. https://www.ipsos.com/sites/default/files/ct/news/documents/2019-11/a-more-dangerous-world-fear-2019.pdf

I was hoping to get your comments on this, considering your expertise in infectious disease control. Below are some questions. If you could respond via email, that would be great as I am on a tight deadline to get this story up. If it's easier to give you a call, I can do that as well. Please let me know what works best. The story will be published on Ipsos.com, on social media and our various country websites. Thank you and I look forward to your response.

1. In our survey of more than 18,500 people in 28 countries done in late last summer, more than half (51%) of people said there was threat of a major health epidemic in their country in the next 12 months with people in emerging markets at the top of the list. Are you surprised by this result? It's among the highest reading for this question since the Ebola outbreak in 2014 when the percentage climbed to 59%.
2. The U.S. is the only developed country in the top 10 list where most people think a major health epidemic will occur. Why do you think this is?
3. A follow up question to the previous one is how confident people are that their government could protect them or respond effectively if such an outbreak was to occur. Over half globally said they were confident in their gov't's response. Do you think people have a lot of trust in those in power to do the right thing in times of an outbreak?
4. Seven of the top 10 countries where people had the most confidence in govts are in the developed world. How important are developed healthcare systems when it comes to outbreaks like the coronavirus?
5. Likewise, many countries at the bottom of this list are emerging markets. What can govts in these countries do to ease peoples' fears on how they are or will handle an outbreak like the coronavirus?

6. How difficult is it for governments and health officials to prevent the spreading of a virus like this before it becomes a pandemic? What measures can be taken?

Please free to add any additional information that you think may be relevant. I hope to hear from you soon.

Regards,
Rajeshni

Rajeshni Naidu-Ghelani | *Data Journalist*
Public Affairs

160 Bloor Street East, Suite 300
M4W 1B9 Toronto – Canada
Phone : +1 416 572 5143
Mobile : (b) (6)
rajeshni.naidu-ghelani@ipsos.com
www.ipsos.com

IT'S TIME TO
CHANGE THE GAME

GAME CHANGERS Ipsos

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 04:12:18 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: RE: for review: responses for Elemental news site (not urgent)

I made some modifications. You can send it. Thanks.

From: Routh, Jennifer (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Tuesday, February 4, 2020 4:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: for review: responses for Elemental news site (not urgent)

Dr. Fauci –

This request is not urgent for today. The reporter Rob Britt (writes for Elemental, a health and wellness news site) reached out to you directly on Sunday with some questions about 2019-nCoV. I have drafted proposed responses for you in red below. Please let me know if you have edits. I will send responses back to the reporter attributed to you.

Thanks,
Jen

> **From:** Rob Britt [redacted] (b) (6)
> **Sent:** Sunday, February 2, 2020 5:10 PM
> **To:** Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> **Subject:** Coronavirus - reporter's questions
>
> Hi Dr. Fauci: We are updating our coronavirus story periodically, keeping it factual and level-headed, and I have seen your comments on NPR Friday and in the NY Times over the weekend, so I hope you could comment very briefly for our story:
>
> -- What's your expectation for whether this will become a pandemic?
> The novel coronavirus outbreak will likely become a pandemic. We know the virus is very transmissible. The infection continues to accelerate and there is efficient transmission in china. If sustained transmission also occurs in other countries throughout the world, the outbreak would fulfill the definitive of a pandemic
> -- Pandemic does not necessarily equate to a terrible situation, compared to, say bad flu seasons. What's your expectation on the potential severity of this coronavirus?
> It is difficult to predict the severity at this time. Even if the mortality rate of a virus remains low, if it is easily transmissible, the global impact can be significant.
> -- And your suggestion to people in the U.S. who might be very concerned?

We are treating the emergence of a novel coronavirus as a very serious public health threat. However, the risk to the general American public remains low at this time. We understand that people may be worried. We ask that people not let fear or panic guide their actions.

Thanks for any help you can provide.

Cheers,
Rob

Robert Roy Britt
Top Writer on Medium in Science & Health.
Contributor to OneZero (science) & Elemental (health).
Former editor-in-chief of Live Science and Space.com.
(b) (6)
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 04:06:33 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: For Dr. Anthony Fauci (NIAID/NIH) - forward of my email letter to Dr. Gregory Poland (Mayo Clinic) regarding Chinese 15 minute Coronavirus test and other concerns

Please handle.

-----Original Message-----
From: Jon M [redacted] (b) (6)
Sent: Tuesday, February 4, 2020 4:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: For Dr. Anthony Fauci (NIAID/NIH) - forward of my email letter to Dr. Gregory Poland (Mayo Clinic) regarding Chinese 15 minute Coronavirus test and other concerns

From: Jon M < [redacted] (b) (6)
To: ocpostoffice@niaid.nih.gov
Subject: Attention Meylin - Forward of my email lietter to Dr Gregory Poland (Mayo Clinic) for Dr Anthony Fauci (NIAID/NIH}
Date: Feb 4, 2020 1:45 PM

Hello Meylin,
Thank you for taking my call yesterday and forwarding the following email I sent to Dr. Gregory Poland care of his assistant, Joseph Roberts, to Dr. Fauci.
Jon Markowitz

From: Jon M [redacted] (b) (6)
To: [redacted] (b) (6)
Subject: JOE - We spoke on phone today... Please forward my email with reference links to Dr. Gregory Poland
Date: Feb 4, 2020 12:57 PM

Hello Joseph Roberts (Mayo Clinic),
We spoke on phone today...
Please forward my email with reference links to Dr. Gregory Poland Thank you, Jon Markowitz

----

Feb 4, 2020

Dear Dr. Gregory Poland

I saw your appearance Feb 3 on a CNBC news program:
https://www.youtube.com/watch?v=Wq33oZdQ-R4
'We're basically at a pandemic now': Mayo Clinic physician on coronavirus

Fyi, I am not a doctor, nurse or medical student nor do I work in the medical field. I am a musician. I am 65 years old and live in Los Angeles.

A news article published on rt.com Feb 31, 2020 (see link below) announced the Chinese have developed a 15 minute test for the Coronavirus, yet I've not seen or heard about this news anywhere else. I had heard there were efforts here to develp a faster test than what is being employed currently by the CDC, but believe its critical the

White House arrange for the new Chinese test to be available in the US everywhere immediately.

This news should have been mentioned by NIH doctor Anthony Fauchi at the White House Briefing on Jan 31, 2020 but was not, nor was it mentioned by Mayor Di Blasio on Feb 1 at Bellevue Hospital in NY.

At this point, the NIH, CDC and White House should have already obtained the Chinese 15 minute test for the virus and implement at all US medical centers and airports receiving travelers from the infectious regions.

Due to the exponential growth of infection rates from 'seed' individuals who are asymptomatic but don't know they are infectious, whether returning from infection zones or are infected by others already here, I am hoping you and other infectious disease experts waste no time in vigorously pursuading the White House, NIH, CDC and all other agencies as to the necessity to test ALL travelers (not just those who are symptomatic) coming into the country by air and sea with the Chinese 15 minute test as well as pull out all the stops to develop an even quicker test that's portable.

As the numbers of infections increases exponentially in the US and other countries this next 2 to 4 weeks from increasing numbers of asymptomatic 'seed' individuals unknowingly spreading the disease, we are certainly on the precipice of an unstopable runaway epidemic.

What is also desperately needed from the federal government are frank and honest recommendations regarding what is necessary to prevent becoming infected such as:
surgical or construction respirators that seal to the face, eye protection goggles, nitrile exam gloves, sanitizer wipes along with specific protocols on how not to bring the virus particles back to ones car, home and possessions.

It is imperative that manufacturing of EFFECTIVE respirator masks or equivalent non-disposable respirators be ramped up to huge scale. Without adequate numbers of these, exam gloves and eye protection this country will not be capable of containing this epidemic.

Below this article, I've pasted in a number of useful youtube links of relevant and timely information in reference.

Thank you very much for your attention to this issue.

Jon Markowitz
Los Angeles

References:

https://www.rt.com/news/479705-china-develop-coronavirus-rapid-test/
China develops rapid Coronavirus test that works in under 15 MINUTES
31 Jan, 2020 10:48

Scientists in China have reportedly developed an express test which can detect the 2019-nCoV novel coronavirus in under fifteen minutes, in a major breakthrough which will hopefully help stem the tide of infection.

Experts from a tech company based in Wuxi in eastern China's Jiangsu Province, working with the National Institute for Viral Disease Control and Prevention, developed the rapid nucleic test kit in just ten days, according to the Xinhua news agency.
The test takes between eight and 15 minutes to produce a result and is currently being mass-manufactured at a rate of 4,000 kits per day, with the city government in Wuxi exploring efforts to boost production even further.

The first batch of kits has reportedly already been deployed to the frontlines at the epicentre of the outbreak, Wuhan, in Hubei province.

https://www.youtube.com/watch?v=Wq33oZdQ-R4
'We're basically at a pandemic now': Mayo Clinic physician on coronavirus
114,173 views

•Feb 3, 2020
CNBC Television

https://www.youtube.com/watch?v=VdUi_kwuw7I
11 confirmed US coronavirus cases, experts warn of pandemic | ABC News
157,773 views
•Feb 3, 2020
ABC News

https://www.youtube.com/watch?v=8Hjy3UfaTSc
Coronavirus Epidemic Update 9: Fecal-Oral Transmission, Recovery vs Death Rate
129,190 views
•Feb 3, 2020
MedCram

https://www.youtube.com/watch?v=GpbUoLvpdCo
Coronavirus Outbreak Update 8: Travel Ban, Spread Outside of China, Quarantine, & MRSA
329,919 views
•Feb 2, 2020
MedCram

https://www.youtube.com/user/MEDCRAMvideos/videos
MedCram youtube channel
[Dr. Roger Seheult - https://www.medcram.com/]

https://www.youtube.com/watch?v=z05ZrMfKUDc
Coronavirus, Contagion and Complications
228,007 views
•Feb 2, 2020
Dr. John Campbell

https://www.youtube.com/watch?v=u7D3AoNdp84
Wuhan virus compared to MERS and SARS
45,569 views
•Feb 3, 2020
Dr. John Campbell

https://www.youtube.com/user/Campbellteaching/videos
Dr. John Campbell youtube channel

https://www.youtube.com/watch?v=_zczkLZNI94
Mayor de Blasio Holds Media Availability
334 views
Feb 1, 2020
NYC Mayor's Office

https://www.youtube.com/watch?v=oMI-9Kvoj7Q
Coronavirus: U.S. Declares Public Health Emergency, Will Quarantine China Travelers [White House Briefing]
121,648 views
•Streamed live on Jan 31, 2020
QuickTake by Bloomberg

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 04:03:41 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus
Attachments: Wuhan Coronavirus Vaccine.docx

Please handle.

From: John Howard [redacted] (b) (6)>
Sent: Tuesday, February 4, 2020 6:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: coronavirus

Dear Dr, Fauchi,

I understand you are leading an effort on the Wuhan Coronavirus. I am writing to enquire how we may help in this effort. [redacted] (b) (4) (b) (4)

Thanks for your attention regarding this matter.

Sincerely,

John Howard, PhD
President ABI
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 03:49:07 +0000
To: Fleisher, Thomas (NIH/CC/DLM) [V]
Subject: RE: Question

No problem.

From: Fleisher, Thomas (NIH/CC/DLM) [V] [redacted] (b) (6)>
Sent: Tuesday, February 4, 2020 9:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>
Subject: Re: Question

Tony,
Would you be willing to have your statement "we are in the middle of influenza season..." included in the Academy's online Practice Matters email Thursday going out to all members (attributed to you) along with a link to the CDC website devoted to Coronavirus?
Thanks,
Tom

From: "Fauci, Anthony (NIH/NIAID) [E]" < [redacted] (b) (6)>
Date: Tuesday, February 4, 2020 at 3:14:47 PM
To: "Fleisher, Thomas (NIH/CC/DLM) [V]" [redacted] (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: RE: Question

Tom:
Right now nothing specific to communicate except that we are still in the middle of an influenza season and the things that we do to prevent spread of flu (i.e. hand washing, social distancing from crowds) are the same things that we would do if we have transmissions of nCoV here.
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fleisher, Thomas (NIH/CC/DLM) [V] [redacted] (b) (6)>
Sent: Tuesday, February 4, 2020 1:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Question

Tony,
I was asked if there is any message that the A&I community should receive in regards to the current Coronavirus outbreak in China and potential impact on the US. I recognize the CDC and state medical boards are releasing updates and recommendations but the question posed to me was is there anything AAAAI should communicate to our members? Thank you for considering this question.
Regards,
Tom

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 03:48:11 +0000
To: Sylvia Burwell
Subject: RE: A couple of quick questions.

Sylvia:

Masks are really for infected people to prevent them from spreading infection to people who are not infected rather than protecting uninfected people from acquiring infection. The typical mask you buy in the drug store is not really effective in keeping out virus, which is small enough to pass through the material. It might, however, provide some slight benefit in keep out gross droplets if someone coughs or sneezes on you. I do not recommend that you wear a mask, particularly since you are going to a vey low risk location. Your instincts are correct, money is best spent on medical countermeasures such as diagnostics and vaccines.

Safe travels.
Best regards,
Tony

From: Sylvia Burwell [redacted] (b) (6)>
Sent: Tuesday, February 4, 2020 10:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: A couple of quick questions.

Begin forwarded message:

> **From:** Sylvia Burwell [redacted] (b) (6)
> **Date:** February 4, 2020 at 9:35:03 PM EST
> **To:** Sylvia Burwell [redacted] (b) (6)
> **Subject: Fwd: Advice re a donation**
>
> **EXTERNAL EMAIL:** Use caution with links and attachments.
>
> Begin forwarded message:
>
> > **From:** Sylvia Burwell [redacted] (b) (6)
> > **Date:** February 4, 2020 at 9:33:47 PM EST
> > **To:** Tony Fauci [redacted] (b) (6)>
> > **Subject: Fwd: Advice re a donation**

Tony

Two quick questions

1. I am traveling to [redacted] (b) (6) Folks are suggesting I take a mask for the airport. Is this something I should do.

2. Please see below. Do the Chinese have needs for support right now? Would money be better spent on diagnostics or vaccine work?

Thanks!

Sylvia

Begin forwarded message:

> **From:** Richard Falkenrath [redacted] (b) (6)
> **Date:** February 4, 2020 at 5:27:32 PM EST
> **To:** [redacted] (b) (6) Sylvia Mathews Burwell
> [redacted] (b) (6)
> **Subject: Advice re a donation**
>
> Hi Sylvia
>
> I hope this find you well.
>
> Quick question, a little bit from left field, but drawing on your experience at Gates and HHS. Ray Dalio and Bridgewater are interested in making a very sizable donation to help China deal with the global public health challenge arising from the new coronavirus. Any suggestions of where we should look to donate the funds?
>
> Thanks so much. [redacted] (b) (6) Looking forward to seeing you again soon.
>
> Richard
> [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 00:42:06 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Interview with Voice of America

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Rattaphol Onsanit <ronsanit@voanews.com>
Sent: Tuesday, February 4, 2020 2:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Interview with Voice of America

Dear Dr. Fauci,

I'm Chief of Voice of America's Thai Services. We met at the Thai Embassy on a Mahidol Award ceremony years ago.

I'm now working on a news story about how developing countries equip themselves with medical readiness and policy responsiveness in the wake of the coronavirus outbreak. I'm interested in this aspect because when I looked at Global Health Security Index, Thailand was ranked the highest in its ability to tackle epidemics ahead of Japan, Korea and Singapore. It's also by far the highest among developing countries.

I'm curious to find out about contributing factors for developing countries' readiness to effectively handle an outbreak like coronavirus. There may be some essential aspects each country can learn from one another during this outbreak and I hope that this story could shed lights on that.

If you are free in the coming days, I would like to have an interview with you, if possible, on Skype. I would really appreciate the opportunity to speak with you again.

Thank you,
Rattaphol

Rattaphol "Ahn" Onsanit
Chief of VOA Thai

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 00:31:31 +0000
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: FW: WSJ In Japan, a local bus driver in his 60s tested positive after he drove tourists from Wuhan, none of whom had exhibited severe symptoms

Nancy:

See yellow highlight below. Did they misquote the CDC?

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, February 4, 2020 12:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: WSJ In Japan, a local bus driver in his 60s tested positive after he drove tourists from Wuhan, none of whom had exhibited severe symptoms

---

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Sent: Monday, February 3, 2020 1:50 PM
Subject: WSJ: Experts Race to Figure Out How Contagious the Coronavirus Is

Experts Race to Figure Out How Contagious the Coronavirus Is

The outbreak of novel coronavirus appears more contagious than seasonal flu and is on par with SARS in 2002 and 2003, studies say

China says that as of Saturday there were 4,109 infected people in the city of Wuhan. Photo: china daily/Reuters

By

Chao Deng and

Jeremy Page

Updated Feb. 2, 2020 7:34 pm ET

BEIJING—Public-health experts around the world have been crunching numbers about the advance of China's dangerous new coronavirus to estimate how far and fast it could spread.

Studies published in recent days say the new virus appears to be more contagious than seasonal flu and on par with the similar pathogen behind an outbreak of severe acute respiratory syndrome in 2002 and 2003. The new virus' mortality rate, however, is far below that of SARS.

China says that as of Sunday there were 5,142 infected people in Wuhan, the locked-down city where the outbreak began. Some scientists estimate based on statistical models that the number could be in the tens of thousands.

As health authorities race to control the outbreak, they are also scrambling to figure out, based on imperfect data, how the virus is transmitted, the length of the incubation period and the degree to which people without symptoms can spread the disease.

China's health commission says incubation is generally between three and seven days, with the longest period being 14 days, and that people can spread the virus before appearing ill. That makes a two-week quarantine an important prevention measure—and casts doubt on the efficacy of temperature checks, the main screening method at immigration and other checkpoints.

"For a given level of transmissibility, more asymptomatic transmission makes a disease harder to control," said Christl A. Donnelly, a professor at University of Oxford and Imperial College London.

The U.S. Centers for Disease Control and Prevention, which warns against nonessential travel to China, says it isn't clear how easily or sustainably the virus is spreading between people, but notes its ability to spread from infected patients without symptoms to close contacts within about 6 feet.

A study led by a researcher from Boston's Northeastern University—using mathematical probability models based on travel patterns and confirmed international cases—estimated the median number of infections in Wuhan at 31,200 as of Wednesday, compared with that day's official tally of 2,261.

Professors at the University of Hong Kong using similar methods published a study in the Lancet on Friday that estimated there were 75,815 infected in Wuhan as of Jan. 25, when official counts were still in the hundreds.

"We think only 1 in 20 people who are getting infected are actually being diagnosed" in Wuhan, said Jonathan M. Read, lead author of a study from Britain's Lancaster University that also put Wuhan numbers in the tens of thousands as of Jan. 22. "It's quite a bit more transmissible than seasonal flu."

Several recent studies published by scientists estimate that each person infected will, on average, infect two to three others. Epidemiologists call that the reproduction number.

A reproduction number over 2 suggests an epidemic will expand rapidly, while below 1 suggests the problem is dwindling. Estimates of the reproduction number differ widely, with some studies using probability models and others based on regression analysis of cases over different time periods.

Still, "they all point in the same direction," said Christian L. Althaus, an epidemiologist at the University of Bern in Switzerland who co-wrote a study estimating the basic reproduction number of the virus at 2.2. "There is a potential threat of a global pandemic if this reproduction number cannot be reduced."

In Japan, a local bus driver in his 60s tested positive after he drove tourists from Wuhan, none of whom had exhibited severe symptoms. In Germany, four employees at an auto-parts supplier contracted the virus after attending a training session with a colleague from China, according to the company. The Chinese woman didn't exhibit symptoms, but started feeling ill on her flight home, where she tested positive for the new coronavirus.

A study published in the New England Journal of Medicine study by Chinese authors including at the Chinese Center for Disease Control and Prevention says the virus spread between people as early as mid-December. The researchers analyzed 425 patients, with more than half of the cases linked to the Huanan seafood wholesale market where authorities believe the virus first spread to humans from wild animals.

The researchers started identifying and collecting cases around the start of the year, by interviewing patients, relatives and other close contacts. They estimated the reproduction number at 2.2 and said that the majority of patients weren't hospitalized until after five days of being ill.

Researchers of recent studies cautioned that even their estimates of the virus' reproduction number are based on early and incomplete data and only assess its potential to spread before travel restrictions and other control measures begin. Thereafter, the reproduction number can vary depending on those measures' effectiveness and other circumstances of the outbreak.

Chinese officials have said the outbreak could peak or even begin to subside by Feb. 8, though some overseas experts have suggested the outbreak might not peak for several weeks.

They note that the reproduction number doesn't necessarily predict an outbreak's severity, as many other factors come into play. Measles, for example, has a reproduction number of 12 to 18, but doesn't spread that fast because there is a widely used vaccine.

As yet, there are no vaccines for the new coronavirus, so Chinese authorities are relying on physical intervention measures, including locking down entire cities and forced quarantine.

Recent studies indicate that stringent control measures will be needed not just in China, but in several other countries, to curtail the outbreak.
"This is unprecedented both in terms of the virus and the control measures that have been put in place," says Adam Kucharski, associate professor at the London School of Hygiene and Tropical Medicine.
—Raffaele Huang, Miho Inada and Ruth Bender contributed to this article.
Write to Chao Deng at Chao.Deng@wsj.com and Jeremy Page at jeremy.page@wsj.com
Copyright ©2019 Dow Jones & Company, Inc. All Rights Reserved.
87990cbe856818d5eddac44c7b1cdeb8

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 00:05:35 +0000
To: Baden, Lindsey, M.D.
Cc: Marston, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6);Morens, David (NIH/NIAID) [E]
Subject: RE: favor
Attachments: [redacted] (b) (6), (b) (4)

Lindsey:

[redacted] (b) (6), (b) (4)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Tuesday, February 4, 2020 3:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: favor

Tony (and Hilary),
Much appreciated. [redacted] (b) (6), (b) (4).
Thank you,
Lindsey

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, February 4, 2020 at 2:16 PM
To: "Baden, Lindsey, M.D." <lbaden@nejm.org>
Cc: "Marston, Hilary (NIH/NIAID) [E]" [redacted] (b) (6)>, "Conrad, Patricia (NIH/NIAID) [E]" < [redacted] (b) (6)
Subject: RE: favor

Lindsay:

[redacted] (b) (6), (b) (4)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Tuesday, February 4, 2020 12:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: favor

Tony,

[redacted] (b) (6), (b) (4)

Thank you for considering,

Lindsey

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 22:59:29 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Subject: RE: favor

Thanks. Safe travels

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, February 4, 2020 4:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: favor

[redacted] (b) (6), (b) (4).

On Feb 4, 2020, at 9:13 PM, Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6)> wrote:

[redacted] (b) (6), (b) (4)

On Feb 4, 2020, at 8:46 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
wrote:

[redacted] (b) (6), (b) (4)
[redacted]. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Tuesday, February 4, 2020 3:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] <[redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: favor

Tony (and Hilary),
Much appreciated. [redacted] (b) (6), (b) (4)
Thank you,
Lindsey

From: "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)>
Date: Tuesday, February 4, 2020 at 2:16 PM
To: "Baden, Lindsey, M.D." <lbaden@nejm.org>
Cc: "Marston, Hilary (NIH/NIAID) [E]" [redacted] (b) (6), "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: RE: favor

Lindsay:

(b) (6), (b) (4) [redacted]

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Tuesday, February 4, 2020 12:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: favor

Tony,

(b) (6), (b) (4) [redacted]

Thank you for considering,
Lindsey

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

(b) (6), (b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 21:28:48 +0000
To: Seder, Robert (NIH/VRC) [E]
Subject: [redacted] (b) (6)

Bob:

[redacted] (b) (6) I am drowning here in coronavirus. Hope to talk to you soon.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 21:01:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Media Request: CBC News

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Adam Miller <adam.miller@cbc.ca>
Sent: Tuesday, February 4, 2020 3:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Media Request: CBC News

Hi Dr. Fauci,

I'm a senior writer with Canada's public broadcaster, CBC News, and I'm working on a national feature story about the containment efforts of the coronavirus outbreak and what future scenarios could be possible with the coronavirus globally.

You spoke with my colleague Kelly Crowe by phone recently, and I'm hoping you could spare a few minutes by phone to talk about the possibility and implications of the outbreak becoming endemic.

Would it be possible to speak briefly by phone this week? I would only need a few minutes of your time and your expertise would be very beneficial for Canadians in their understanding of this story.

Thanks very much,

Adam

--
Adam Miller

Senior Digital Writer
CBC News
Desk: 416-205-5719
Cell: (b) (6)
Twitter: @adamsmiller

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 20:46:18 +0000
To: [redacted] (b) (6)
Subject: FW: favor
Attachments: [redacted] (b) (6), (b) (4)

[redacted] (b) (6), (b) (4)

[redacted] (b) (6), (b) (4) Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Tuesday, February 4, 2020 3:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: favor

Tony (and Hilary),
Much appreciated. [redacted] (b) (6), (b) (4)
Thank you,
Lindsey

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Tuesday, February 4, 2020 at 2:16 PM
To: "Baden, Lindsey, M.D." <lbaden@nejm.org>
Cc: "Marston, Hilary (NIH/NIAID) [E]" [redacted] (b) (6)>, "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: RE: favor

Lindsay:

[redacted] (b) (6), (b) (4)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Tuesday, February 4, 2020 12:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: favor

Tony,

[redacted] (b) (6), (b) (4)

Thank you for considering,

Lindsey

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 19:36:10 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Delivery Status Notification (Failure)

Please take a look and handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Robert Knobler (b) (6)>
Sent: Tuesday, February 4, 2020 1:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: Delivery Status Notification (Failure)

---------- Forwarded message ---------
From: **Mail Delivery Subsystem** (b) (6)
Date: Tue, Feb 4, 2020 at 1:30 PM
Subject: Delivery Status Notification (Failure)
To: (b) (6)

Address not found

Your message wasn't delivered to [redacted] (b) (6) because the address couldn't be found, or is unable to receive mail.

The response from the remote server was:

```
550 #5.1.0 Address rejected.
```

---------- Forwarded message ----------
From: Robert Knobler [redacted] (b) (6)
To: [redacted] (b) (6)
Cc:
Bcc:
Date: Tue, 4 Feb 2020 13:29:23 -0500
Subject: Potential Coronavirus Prophylaxis

Dear Dr. Fauci,

You likely do not recall meeting me when I was looking at potential fellowships in 1978, however, I never forgot your enthusiasm. I went out to San Diego and worked with Mike Oldstone between 1979 and 11984. I did study a mouse coronavirus while there, mouse hepatitis virus (MHV). I focused on genetic resistance, and eventually described a mouse locus for susceptibility, which coded for the MHV receptor. On to the present problem of human coronaviruses. Vaccines will take a long time for the current crisis. The angiotensin convertin enzyme 2 receptor has been identifed as the relevant human coronavirus receptor. I am writing to suggest the investigation of ARBs as potential blocking agents to either reduce or completely block infection. Perhaps this can be checked. There may still be sufficient untainted supplies of ARBs, such as irbesartan, available, or production can be scaled up, if this truly is the eve of a pandemic. Wishing you success in this endeavor. I am willing to contribute in any way I can. Please feel free to contact me by e-mail or my cell phone.

I did do clinical trial while with Mike, and then when I joined the

neurology faculty of Jefferson in Philadelphia. I have been out on my own since December 1998, but I have never lost my interest in this work. I have some novel ideas on how HIV becomes AIDS, as well.
All the Best,
Robert L Knobler, MD, PhD
(b) (6)
(b) (6) Cell

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 15:54:25 +0000
To: (b) (6)
Subject: FW: STAT: Quick retraction of a faulty coronavirus paper was a good moment for science http://bit.ly/389QguM

Heather:

As per our recent conversation. This is your story (see below).

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

The Watchdogs

Quick retraction of a faulty coronavirus paper was a good moment for science

By Ivan Oransky *and* Adam Marcus
February 3, 2020



Hyacinth Empinado/STAT

As fears of the novel coronavirus 2019-nCoV continued to spread last Friday, an inflammatory new paper appeared on bioRxiv, a preprint server, where scientists post work that hasn't been vetted. Titled "Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag," the paper claimed to find similarities between the new coronavirus and HIV, the virus that causes AIDS. The use of the word "uncanny" in the title, together with "unlikely to be fortuitous" in the abstract, led some to think that the authors were suggesting the virus had somehow been engineered by humans.

The paper, from academic institutions in New Delhi, India, was critical and alarming, if true. Except that it wasn't.

The paper was almost immediately withdrawn, but not before plenty of handwringing from researchers who complained that the appearance of such shoddy work on a preprint server without vetting by peer reviewers is precisely why the hoary old model of science publishing is better at keeping junk science out of the literature.

Except that's not true, either. The old model has its advantages, to be sure, but it, too, is prone to the menace of pseudoscience, bad data, and other flaws — despite traditional academic journals' army of peer reviewers. And when these publications publish bad or erroneous research, it can take months or years for the papers to be corrected or retracted — if they ever are.

In contrast, the reaction from the scientific community to the bioRxiv paper was swift. In a nutshell, commenters on bioRxiv and Twitter said, the author's methods seemed rushed, and the findings were at most a coincidence. By Saturday morning, bioRxiv had placed a special warning on all papers about coronavirus. Later Saturday, the authors commented on their paper, saying they were withdrawing it. And on Sunday, a more formal retraction appeared: "This paper has been withdrawn by its authors. They intend to revise it in response to comments received from the research community on their technical approach and their interpretation of the results."

All of that happened before a single news outlet with any reach covered the paper, as best we can tell. But none of it was quite fast enough for some critics. "This is why preprints can be bad," said one scientist on Twitter. That scientist, Michael Shiloh, said he had even used bioRxiv to post preprints. "What bugs me about this preprint is that had this manuscript undergone legitimate peer review, these flaws would have led to a swift rejection and it wouldn't be contributing to the conspiracy theories and fear surrounding this outbreak," Shiloh continued.

History suggests that Shiloh's confidence in peer review's ability to suss out pseudoscience may be a bit misplaced. The fraudulent 1998 paper that set off the vaccine-autism scare was published in The Lancet, one of the world's leading peer-reviewed medical journals. Other examples — including a paper by an intelligent design advocate questioning the validity of the second law of thermodynamics as it pertained to evolution — abound. Papers claiming a link between autism and vaccines pop up nearly every year.

Preprints can fill a void in times of rapidly changing science

And even when peer-reviewed journals do realize they've been had, retractions can take months or years. The Lancet took 12 years. Another journal took five years to retract a paper claiming that HIV did not cause AIDS. We could go on, and the list includes papers that have never even been corrected.

Those who claim preprint servers are dangerous because they lack peer review — bioRxiv has a perfunctory screening process — sometimes acknowledge that journals have had to speed up their game to meet the pressures of an outbreak like coronavirus, or SARS in the early part of this century.

Angela Cochran, president of the Society for Scholarly Publishing, a trade group for publishers, said on Twitter: "Earlier this week, folks celebrated that coronavirus papers were popping up in preprint servers. Now there is a reminder not to use them to guide clinical practice because they haven't been reviewed. Journals ARE reviewing coronavirus papers and getting [them] pub'd quickly."

Kent Anderson, another publishing industry veteran, put it more bluntly: "Journals Win The Coronavirus Race."

Publishers have been looking for ways to score points against — and shut down — preprints for at least half a century. Journals have speedily published a number of important papers on the new coronavirus already, no doubt. Publishing industry champions are often quick to say that speedy peer review does not mean sloppy peer review — even in cases that require massive corrections.

It now turns out that one of the world's leading peer-reviewed medical journals, the New England Journal of Medicine, published a letter last week about apparent coronavirus transmission from an asymptomatic person that turns out to be wrong. Such letters to the editor are not typically peer-reviewed, or at least not as rigorously as a full study. But it's a glaring example of how a peer-reviewed journal can end up getting things wrong. Now we get to wait and see how long it takes NEJM to correct the record.

We'll see whether peer-review champions, who are often unwilling — with some notable and welcome exceptions — to acknowledge how slow and ineffective correction in science can be, note this apparent failure of one of their gatekeepers. Doing so might, after all, make some people question the expensive subscription deals universities agree to with publishers, as well as the article processing charges that can run into the thousands of dollars for open access publications.

Peer review can add a valuable filter. But those who work in publishing seem to be so wedded to the existing process that they can't admit its flaws — or that it might be a good idea to also embrace preprint servers that could upend their business models. Just like in politics, maybe it's time to agree that the publishing process is a messy one, and stop using single episodes, free of context, to score points against one's rivals.

This article has been updated with information about a flawed report in the New England Journal of Medicine.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 15:03:33 +0000
To: Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E];Erbelding, Emily (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: Universal coronavirus vaccine

[redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 14:32:42 +0000
To: Greg Folkers ([redacted] (b) (6));Marston, Hilary (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus
Attachments: JVP200014(1).pdf, Coronavirus clean version 2-3-2020pbf-DCA.docx, JVP200011(1).pdf

FYI. Confidential for now

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Tuesday, February 4, 2020 9:19 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Coronavirus

Tony

See attachment – accepted case series – likely to be published Friday – after we talk – but likely to mention it on Thursday - thought you should see it.

HCB

From: Howard Bauchner
Sent: Tuesday, February 04, 2020 7:23 AM
To: Annette Flanagin <Annette.Flanagin@jamanetwork.org>; Christiansen, Stacy <stacy.christiansen@jama-archives.org>; Christopher Muth <Christopher.Muth@jamanetwork.org>; Demetrios Kyriacou <Demetrios.Kyriacou@jamanetwork.org>; Edward Livingston [redacted] (b) (6)>; Fontanaros, Phil <phil.fontanarosa@jama-archives.org>; Golub, Robert <robert.golub@jama-archives.org>; Gregory Curfman

<Gregory.Curfman@jamanetwork.org>; howard.bauchner@jama-archives.org; Jody Zylke
<Jody.Zylke@jamanetwork.org>; McDermott, Mary [redacted] (b) (6)>; Mike Berkwits
<michael.berkwits@jamanetwork.org>; [redacted] (b) (6); Anne Cappola
[redacted] (b) (6)>; Basch, Ethan Martin [redacted] (b) (6)>; David Mark
<David.Mark@jamanetwork.org>; Demetrios Kyriacou <Demetrios.Kyriacou@jamanetwork.org>; Derek
Angus [redacted] (b) (6)>; Feero, Greg [redacted] (b) (6)>; George O'Connor
[redacted] (b) (6) Goff, Donald [redacted] (b) (6)>; Jeff Saver [redacted] (b) (6)
[redacted] (b) (6); Joynt Maddox, Karen [redacted] (b) (6) Preeti
Malani [redacted] (b) (6)>; Robert Golub <Robert.Golub@jamanetwork.org>; Saitz, Richard
[redacted] (b) (6) Schrag, Deborah,M.D. [redacted] (b) (6)
Tom Cole [redacted] (b) (6)>; Winkelmayer, Wolfgang C. [redacted] (b) (6);
Armstrong, Katrina,M.D. < [redacted] (b) (6)
[redacted]; Cutler, David [redacted] (b) (6); Eric
Peterson, M.D. [redacted] (b) (6)>; Goldman, Lee [redacted] (b) (6)>;
[redacted] (b) (6) John Wong Eu Li (Div Head, Med Dept) [redacted] (b) (6)>; Josh
Sharfstein [redacted] (b) (6)>; Julie Freischlag, M.D. [redacted] (b) (6); Merchant,
Raina [redacted] (b) (6)>; 'Rodgers, Griffin (NIH/NIDDK) [E]'
[redacted] (b) (6); Steven E. Nissen [redacted] (b) (6)>; Vokes,
Everett [MED] [redacted] (b) (6) Zeke
Emanuel [redacted] (b) (6)>; Andy Josephson [redacted] (b) (6)
[redacted] (b) (6) Bonow, Robert, M.D. [redacted] (b) (6)
Bressler, Neil [redacted] (b) (6); Dimitri A. Christakis, MD, MPH [redacted] (b) (6)
[redacted] >; Disis, Nora < [redacted] (b) (6)>; Fred Rivara, MD
[redacted] (b) (6); Ongur, Dost < [redacted] (b) (6)
[redacted]; Rita Redberg, MD [redacted] (b) (6)>; Shinkai, Kanade
[redacted] (b) (6)
Subject: Coronavirus

So a quick update.

Attached is a VP that will go up tomorrow – information for clinicians by Carlos del Rio and Preeti. They worked on it this weekend – thanks to both.

Attached is a VP from Don and Ken Shine that came in before the epidemic/pandemic – but is definitely related. Going up this week.

Attached is the largest case-series yet – from Wuhan – old colleague of Derek's. [redacted] (b) (6), (b) (4) – it will be published on Friday. A big thank you to Phil and Derek.

A RL has also been accepted – it will go up Thursday.

I cannot thank Stacy and her team (and publishing) – everyone has been working overtime to process manuscripts in record time, put up a microsite; add CME for US clinicians; etc. Mike (and his team) and Ed have been a big help.

As we have done in the past everything will be free to the world.

I am interviewing Tony Fauci again on Thursday – the last podcast, video has close to 150K views – Tony – as I have said many times – is a national treasure.

(b) (4)

[redacted]

All that said we are definitely interested in novel research report (many can be research letters). Just let me know.

HCB

Howard Bauchner, MD
Editor in Chief, JAMA and The JAMA Network

Email: howard.bauchner@jamanetwork.org
Telephone: 312-464-2400

Please respect the confidential nature of this email.

For my chats with authors please see: https://jamanetwork.com/journals/jama/pages/jama-author-interviews

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 14:09:40 +0000
To: Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E];NIAID OD AM
Subject: RE: Thanks and filming

I am leaving it up to you all to determine what is doable, feasible and/or appropriate. We can discuss at our OD AM meeting.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, February 4, 2020 8:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: RE: Thanks and filming

Just to keep in mind: [redacted] (b) (4), (b) (5) (b) (4), (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, February 4, 2020 6:42 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Thanks and filming

OK

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, February 4, 2020 6:35 AM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Haskins, Melinda (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: Thanks and filming

For discussion. [redacted] (b) (4), (b) (5)

Sent from my iPhone

Begin forwarded message:

> **From:** Janet Tobias <janet@ikanamedia.com>
> **Date:** February 4, 2020 at 6:28:24 AM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)
> **Cc:** "Robinson, Whitney (NIH/NIAID) [C]" [redacted] (b) (6) "Barasch, Kimberly (NIH/NIAID) [C]" [redacted] (b) (6)>
> **Subject: Re: Thanks and filming**
>
> [redacted] (b) (4)
>
> Janet
>
> Sent from my iPhone
>
> > On Feb 3, 2020, at 12:27 PM, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
> >
> > Just called you. sorry crazy morning
> >
> > Call me at [redacted] (b) (6)- they can pull me from a meeting
> >
> > Patricia L. Conrad
> > Public Health Analyst and
> > Special Assistant to the Director
> > National Institute of Allergy and Infectious Diseases

The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Janet Tobias <janet@ikanamedia.com>
Sent: Monday, February 3, 2020 8:43 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: Thanks and filming

Patty can I call you quickly about something—will take 3 minutes.

Sent from my iPhone

> On Jan 30, 2020, at 10:02 PM, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)> wrote:
>
> It's been super busy. Will group with others tomorrow and get back to you.
>
> Sent from my iPhone
>
>> On Jan 30, 2020, at 7:51 PM, Janet Tobias <janet@ikanamedia.com> wrote:
>>
>> Hi Patty: Thanks for arranging the phone call. [redacted] (b) (4)
>>
>> (b) (4) [redacted]

(b) (4)

Never a dull moment in your world!

Janet

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 13:58:53 +0000
To: Sylvia Burwell
Subject: RE: Travel restriction policy

Thanks, Sylvia. I miss our late night phone calls during the Ebola and Zika crises. It was tough, but we got it right.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Sylvia Burwell [redacted] (b) (6)
Sent: Tuesday, February 4, 2020 8:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Travel restriction policy

Tony,

Thanks so much for sending this AND for your very valuable time on Sunday.

Our students that returned last week are in self-quarantine...

Let me know if I can be helpful to you in any way.

Best,

Sylvia

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, February 3, 2020 7:04 PM
To: Sylvia Burwell [redacted] (b) (6)
Subject: Travel restriction policy

EXTERNAL EMAIL: Use caution with links and attachments.

Sylvia:

You probably already have this information, but here is the official policy as pe our recent discussion (see link).

https://china.usembassy-china.org.cn/proclamation-on-suspension-of-entry-as-immigrants-and-nonimmigrants-bof-persons-who-pose-a-risk-of-transmitting-2019-novel-coronavirus/

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 13:07:15 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Phone interview request from Seoul, Korea

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: The Scoop tbs eFM [redacted] (b) (6)
Sent: Tuesday, February 4, 2020 6:06 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: Phone interview request from Seoul, Korea

Hello, Dr. Anthony Fauci.

This is Seyoung, a writer of an English radio show, The Scoop, in Seoul, South Korea.

We deliver local and international trending news to English speaking listeners around the world.

We'd like to invite you to talk with us on the phone for a special interview regarding the novel coronavirus outbreak.

If you are interested and available to talk to us through a phone call **at 10:30 am Friday or Saturday this week, OR**
sometime between 9:30 and 10:30 am next Monday, please let us know.

And if you're not available for the given time, please also **let us know other times feasible for you.**

The interview will run for about 10 minutes and you'll get your questions in advance.

If you could provide your knowledge that is essential especially at this time, it'll be highly appreciated.

I look forward to hearing from you soon.

Thank you very much.

Seyoung Lee

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 13:05:59 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: 2019-nCoV: potential infection on CD4 cells.
Attachments: Insert positions in HIV gp120.pdf

Please have someone respond to this person.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)
Sent: Tuesday, February 4, 2020 2:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: 2019-nCoV: potential infection on CD4 cells.

Dear Dr. Fauci,

As you realized the Indian researcher published a paper few days ago entitled "Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag", which was latterly withdrawn due to the controversial indication. I did a quick SWISS-MODEL online calculation. Page 1-3 of the attachment show the flexible loops of insertion "1", "2", and "3" originally from V4, V5 and V1 of HIV-1 gp120, respectively. But they are in presence on the spike protein of both bat and 2019 coronavirus (page 4 and 6). These insertions are potential CD4 binding domains (no proof yet but highly likely) and spatially won't interfere with ACE-2 binding domain (both SARS and 2019 coronavirus target ACE-2, page 5 and 6). In another word, the 2019 virus could be potentially dual-targeting, infecting the lung and potentially CD4 T cells too (like HIV, see page 6)!

It is **VERY URGENT** to have clinicians follow up the confirmed cases such as by isolating their CD4 cells and doing RT-PCR. Please reach out to them. Research labs including mine after obtaining Spike protein of 2019-nCoV shall examine its interaction with CD4.

Thank you for your immediate attention. Please keep me anonymous.

God bless us,

(b) (6)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 12:36:50 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: names for WHO working group

Francis:

Derek Kan, Acting Deputy Director of OMB and a member of the President's Coronavirus Task Force called me last night and in a very nice way said he would like to send me a list of names for consideration to be on the working groups to examine the evolution of the nCoV. He worked as an executive in biotech prior to joining the USG and knows these individuals well. They are all people that we know and so I am just passing them on to you for our consideration.

[redacted] (b) (5)

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 11:43:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Let us discuss.

From: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Sent: Tuesday, February 4, 2020 5:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Wion Guest Relations <wion.guestrelations@zeemedia.esselgroup.com>
Subject: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Dear Anthony S. Fauci,
M.D., NIAID Director

Greetings from WION!

World Is One News (WION)is an international English news channel from the Zee Media Group, India's premier television brand. WION is uniquely positioned as the 'Global Voice of India', presenting its own perspective on international issues of critical significance. WION is the preferred channel for most opinion makers across the world as they happily attend our shows bringing in credible viewpoints on many issues. WION is currently available in India, Indonesia, The Republic of Philippines, Australia, Vietnam, Hong Kong, UAE, Malaysia, Singapore and South Africa etc.

WION's shows have featured Indian Political scenario & global leaders speaking on issues facing their country and the world in general.

I would like to request for **your** time for an interview with us anytime soon today for **10-15 minutes**. We usually conduct Interview via **Skype**. Request you to share your Skype Id.

It's regarding CORONAVIRUS.

Please let us know when is the best time for you to join us via Skype. Waiting for your confirmation.

CLICK HERE TO WATCH WION LIVE :
https://www.wionews.com/live-tv

Live TV, News | wionews.com

© 1998-2019 Zee Media Corporation Ltd (An Essel Group Company), All rights reserved.

www.wionews.com

Look forward hearing from you .

Regards

Latika Chugh

WION TV , India

Zee Disclaimer: Confidentiality / Proprietary Note: This communication is confidential /proprietary and is intended for use only by the addressee. Zee Media Corporation Ltd. accepts no responsibility for any mistransmission of, orinterference with, this communication

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 03:02:57 +0000
To: Shalimar Adorno
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Message from Dr. Jim Yong Kim

Shalimar:
Thank you for your note. I certainly will speak with Dr. Kim. My schedule is packed due to the coronavirus situation, and so please contact my Special Assistant, Patty Conrad (copied here and at [redacted] (b) (6) to squeeze in a time that works for Jim and me. Thank you.
Best regards,
Tony

From: Shalimar Adorno < [redacted] (b) (6)
Sent: Monday, February 3, 2020 6:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Message from Dr. Jim Yong Kim

Good evening Dr. Fauci,

I am writing on behalf of Dr. Jim Yong Kim who would like to have a call with you tomorrow.

Can you please advise if you have any availability?

Kindly,

Shalimar Adorno
Assistant Vice President
Global Infrastructure Partners
1345 Avenue of the Americas, 30th Floor
New York, NY 10105
T [redacted] (b) (6)
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 01:14:05 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: Coronavirus

Thanks, Francis. [redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Monday, February 3, 2020 7:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Coronavirus

From: Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6)
Sent: Monday, February 3, 2020 6:02 PM
To: Collins, Francis (NIH/OD) [E] < [redacted] (b) (6) Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6) Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)
Cc: Shaya, Cecile (NIH/OD) [E] [redacted] (b) (6)
Subject: RE: Coronavirus

[redacted] (b) (5)

From: Shapiro, Neil (NIH/OD) [E]
Sent: Monday, February 3, 2020 4:05 PM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)
Cc: Shaya, Cecile (NIH/OD) [E] [redacted] (b) (6)
Subject: RE: Coronavirus

[redacted] (b) (5)

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Sent: Monday, February 3, 2020 1:48 PM
To: Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6) Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)
Cc: Shaya, Cecile (NIH/OD) [E] [redacted] (b) (6)
Subject: RE: Coronavirus

[redacted] (b) (5)

FC

From: Shapiro, Neil (NIH/OD) [E] [redacted] (b) (6)>
Sent: Monday, February 3, 2020 11:33 AM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [redacted] (b) (6); Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] [redacted] (b) (6)
Cc: Shaya, Cecile (NIH/OD) [E] < [redacted] (b) (6)>
Subject: Coronavirus
Importance: High

[redacted] (b) (5)

Neil

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 01:08:37 +0000
To: Kai Kupferschmidt
Cc: Greg Folkers ([redacted] (b) (6));Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: coronavirus quick question

Kai:
Error in my statement to you. I meant to say that "……most transmissions occur from someone who is symptomatic" – not asymptomatic. I am really tired. Not much sleep these days.
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kai Kupferschmidt [redacted] (b) (6)
Sent: Monday, February 3, 2020 7:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>
Subject: Re: coronavirus quick question

Thanks Tony,

this is interesting and I'm sorry I didn't have more time to get a comment from you. I can only imagine your workload at the moment. I will include comment from you now.

Best
Kai

On 4. Feb 2020, at 01:29, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> wrote:

Sorry that I got to this so late. I have been swamped. I just read your story in Science. It is unfortunate that they did not interview the patient. Obviously, this changes the conclusion of the paper. My comment: "There's no doubt after reading [the *NEJM*] paper that asymptomatic transmission is occurring" was made because there has been a lot of discussion among Chinese investigators that asymptomatic infection is occurring in Wuhan City and Hubei Province, yet no publication came out and said this. Since this was the first publication supposedly documenting this phenomenon, that is why I referred to the paper and made my comment. It is unfortunate that this error was published, but it still does not really change anything. Rather than rely on rumors, this evening I telephoned one of my colleagues in China who is a highly respected infectious diseases scientist and health official. He said that he is convinced that there is asymptomatic infection and that some asymptomatic people are transmitting infection. The NEJM paper may be incorrect, but according to reputable Chinese scientists, my statement is correct. Having said that, I have been saying for some time that even if asymptomatic infection occurs, it is very unlikely to be a major driver of the outbreak since most transmissions occur from someone who is asymptomatic.

Best regards,
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 00:37:32 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Tony and Conronavirus

Set up a call for me with Ed Henry

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 3, 2020 12:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)
Subject: FW: Tony and Conronavirus

Firm for Feb 11

ASF will you cancel DDCF or do I need to? Please advise

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Katz, Ruth <Ruth.Katz@aspeninstitute.org>
Sent: Monday, February 3, 2020 12:20 PM

To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Katz, Ruth <Ruth.Katz@aspeninstitute.org>
Subject: RE: Tony and Conronavirus

We have a room on the 11th. Ron is available and holding the date. Think time would work for you guys. Time would be over lunch. Attendees arrive around 11:30 to grab lunch. Program starts at noon and runs to about 1-1:15. Of course, Tony is more than welcome to come in time for lunch. But he need not actually arrive until shortly before noon so we can mike him up.

I might also try to get someone from CDC to round out the discussion. But if only Tony and Ron, we will run with it. Also need to line up the moderator. But that shouldn't be a problem. Would run options by you first.

Our comms team is really interested in pushing this --

Ruth

RUTH J. KATZ
Vice President, Aspen Institute
Executive Director, Health, Medicine and Society Program The Aspen Institute

ruth.katz@aspeninstitute.org
202-736-5827

-----Original Message-----
From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, February 3, 2020 11:57 AM
To: Katz, Ruth <Ruth.Katz@aspeninstitute.org>
Subject: RE: Tony and Conronavirus

If you have a room and Mr. Klain is available on Feb 11 - please let me know. Best between 11 am - 3 or 4 pm

Let me know

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Katz, Ruth <Ruth.Katz@aspeninstitute.org>
Sent: Monday, February 3, 2020 11:43 AM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Katz, Ruth <Ruth.Katz@aspeninstitute.org>

Subject: RE: Tony and Conronavirus

Hi Patty,

Thanks so much and understand completely. Can only imagine how crazed you all must be.

Definitely don't want to do this without Tony. If next week doesn't work, please send some potential options. Getting a room can be the real challenge here. So I'd like to at least reserve space and cancel if need be. Also trying to coordinate with Ron Klain who is very eager to participate.

Let me know if I should definitely cancel our space for February 11 or continue to hold for now.

Thanks again for everything!

Ruth

RUTH J. KATZ
Vice President, Aspen Institute
Executive Director, Health, Medicine and Society Program The Aspen Institute

ruth.katz@aspeninstitute.org
202-736-5827

-----Original Message-----
From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 3, 2020 11:36 AM
To: Katz, Ruth <Ruth.Katz@aspeninstitute.org>
Subject: RE: Tony and Conronavirus

Hi Ruth - circling back - hope we can make this work - will get back to you in a day or two....

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Conrad, Patricia (NIH/NIAID) [E]
Sent: Monday, February 3, 2020 8:40 AM
To: Katz, Ruth <Ruth.Katz@aspeninstitute.org>
Subject: RE: Tony and Conronavirus

Hi - sorry for the delay - its been insanely busy.

He would love to do this but our schedule has been changing literally by the minute - so much so that we have had to cancel meetings, events and 2 trips he had scheduled for out of town last week. So - while he would love to do this and would make himself available...it might be better to do later when things hopefully quiet down a bit.

Defer to you tho as to when you want to do your event. Happy to chat more ....

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Katz, Ruth <Ruth.Katz@aspeninstitute.org>
Sent: Friday, January 31, 2020 5:33 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Cc: Katz, Ruth <Ruth.Katz@aspeninstitute.org>
Subject: Re: Tony and Conronavirus

Hi Patty,

Sorry to bother you. Just checking in to see if you have any update. We continue to hold the date and room.

Thanks so much. Hope all is well —

Ruth

Sent from my iPhone

On Jan 27, 2020, at 2:45 PM, Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>> wrote:

Hi ruth – will get back to you as soon as we can

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Katz, Ruth <Ruth.Katz@aspeninstitute.org<mailto:Ruth.Katz@aspeninstitute.org>>
Sent: Monday, January 27, 2020 4:25 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Katz, Ruth <Ruth.Katz@aspeninstitute.org<mailto:Ruth.Katz@aspeninstitute.org>>
Subject: Tony and Conronavirus

Hi Patty,

Hope all is well and that your 2020 is off to a good, if no doubt, busy start.

Contacting you directly because you have always been my best "go to" person when it comes to Tony and activities at the Institute. Hope you can be of help again.

I would like to do a Public Health Grand Rounds session on the coronavirus here at our Aspen DC offices – hopefully on February 11 (from 12 until about 1:15pm; lunch is made available to attendees). Ron Klain, former Obama Ebola czar -- is available -- and hope Tony might be as well. Tony and Ron are my first two choices. Perhaps we might add someone from CDC. I suspect we could get some good press, especially if Tony is in the lineup.

Know how terribly busy Tony is, but hope this might be a possibility. Any chance?

As always, many thanks –

All best,
Ruth

RUTH J. KATZ
Vice President, Aspen Institute
Executive Director, Health, Medicine and Society Program The Aspen Institute

ruth.katz@aspeninstitute.org<mailto:ruth.katz@aspeninstitute.org>
202-736-5827

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 4 Feb 2020 00:29:06 +0000
To: Kai Kupferschmidt
Cc: Greg Folkers [redacted] (b) (6);Billet, Courtney (NIH/NIAID) [E]
Subject: RE: coronavirus quick question

Kai:

Sorry that I got to this so late. I have been swamped. I just read your story in Science. It is unfortunate that they did not interview the patient. Obviously, this changes the conclusion of the paper. My comment: "There's no doubt after reading [the *NEJM*] paper that asymptomatic transmission is occurring" was made because there has been a lot of discussion among Chinese investigators that asymptomatic infection is occurring in Wuhan City and Hubei Province, yet no publication came out and said this. Since this was the first publication supposedly documenting this phenomenon, that is why I referred to the paper and made my comment. It is unfortunate that this error was published, but it still does not really change anything. Rather than rely on rumors, this evening I telephoned one of my colleagues in China who is a highly respected infectious diseases scientist and health official. He said that he is convinced that there is asymptomatic infection and that some asymptomatic people are transmitting infection. The NEJM paper may be incorrect, but according to reputable Chinese scientists, my statement is correct. Having said that, I have been saying for some time that even if asymptomatic infection occurs, it is very unlikely to be a major driver of the outbreak since most transmissions occur from someone who is asymptomatic.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not

accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kai Kupferschmidt [redacted] (b) (6)
Sent: Monday, February 3, 2020 11:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: coronavirus quick question

Tony,

do you have 5 minutes for a quick phone call? Writing a story about the German paper claiming an asymptomatic case. Turns out the woman did have symptoms. You gave the paper a lot importance, so really wanted to get your reaction on this.

Cheers
Kai

Kai Kupferschmidt
contributing correspondent "Science"
[redacted] (b) (6)
[redacted] (b) (6)

twitter: @kakape

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 3 Feb 2020 22:28:34 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Coronavirus - reporter's questions

NIAID inquiries, please.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Rob Britt [redacted] (b) (6)
Sent: Sunday, February 2, 2020 5:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Coronavirus - reporter's questions

Hi Dr. Fauci: We are updating our coronavirus story periodically, keeping it factual and level-headed, and I have seen your comments on NPR Friday and in the NY Times over the weekend, so I hope you could comment very briefly for our story:

-- What's your expectation for whether this will become a pandemic?

-- Pandemic does not necessarily equate to a terrible situation, compared to, say bad flu seasons. What's your expectation on the potential severity of this coronavirus?

-- And your suggestion to people in the U.S. who might be very concerned?

Thanks for any help you can provide.
Cheers,
Rob

Robert Roy Britt
Top Writer on Medium in Science & Health.
Contributor to OneZero (science) & Elemental (health).
Former editor-in-chief of Live Science and Space.com.

(b) (6)

(b) (6)

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Mon, 3 Feb 2020 22:27:31 +0000
To:	Seth Lederman
Cc:	Erbelding, Emily (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E]
Subject:	RE: New NHP data on our vaccine for smallpox & monkeypox

Seth:

I am swamped with coronavirus stuff, and so I am forwarding this to Emily Erbelding to take a look and respond. Thanks.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Seth Lederman (b) (6)>
Sent: Friday, January 31, 2020 11:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: New NHP data on our vaccine for smallpox & monkeypox

Dear Tony,

I enjoyed your corona virus presentation at ASM Biothreats, and understand why you couldn't linger.

I'm writing with an update on our horsepox-based vaccine program. On Wednesday, we presented a poster on our further work with TNX-801 (horsepox) as a potential vaccine for smallpox and monkeypox. We found that vaccination of cynos with TNX-801 resulted in sterilizing immunity (no lesions) in 8/8 animals compared to a synthesized ACAM-like vaccinia which resulted in protection, but lesions on 2/3 animals. More complete information is on the poster attached, which is available on our website at (https://content.equisolve.net/tonixpharma/media/10929ac27f4fb5f5204f5cf41d59a121.pdf). The press release is also attached and available on our website at (https://ir.tonixpharma.com/press-releases/detail/1186).

[redacted] (b) (4)

[redacted] (b) (4)

We'd welcome the opportunity to discuss the data with you and your team.

Best, Seth

Seth Lederman, MD | Chief Executive Officer
Tonix Pharmaceuticals Holding Corp. | NASDAQ: TNXP
509 Madison Avenue - Suite 1608, New York, NY 10022
Tel [redacted] (b) (6) | Fax 212 923 5700
[redacted] (b) (6) | www.TonixPharma.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 3 Feb 2020 22:21:41 +0000
To: Steinberg, Danielle
Cc: Conrad, Patricia (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E]
Subject: RE: PBS Nature inquiry about Coronavirus

Danielle:

Many coronaviruses exist in animal reservoirs, particularly in bats. Remember that for the SARS outbreak in 2002, bats infected palm civet cats who were sold in live/wet markets and the civet cats spread the virus to human. Same for MERS – bats to camels to humans. You ask that there have been animal markets for a long time, and so why now. The fact is that this is likely pure chance +/- more interactions in the human-animal interface. Animal viruses mutate and most of the time the mutations have no significant impact on virus transmission to humans. Sometimes they mutate and allow single “dead end” transmissions to individual humans with no efficiency in going human to human and so we get individual infections and no outbreak as we have seen with H5N1 and H7N9 influenzas that jump from chickens to humans but do not go from human to human. And then rarely, animal viruses mutate and the mutation allows them not only to jump species to humans, but to also efficiently spread from human to human. That is what we saw in SARS and now we see this with 2019-nCoV, which seems to have adapted itself very well to human to human transmission, as per what is happening in China.

I hope that this is helpful.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Steinberg, Danielle <SteinbergD@thirteen.org>
Sent: Friday, January 31, 2020 2:20 PM
To: Fauci, Anthony (NIH/NIAID) [E[redacted] (b) (6)>
Subject: PBS Nature inquiry about Coronavirus

Hi Dr. Fauci,

Hari Sreenivasan of PBS NewsHour suggested I reach out to you with a specific nature question that we're writing about. I hope you'll be able to give us some insights – I'm sure you're extremely busy!

We're wondering about the impact of animals on the virus and specifically, why now? Presumably, China has been using animal markets/wildlife trade in these exact ways for a while, so what changed or is different now to cause this illness and outbreak? Any other information you can provide on how animals are involved would be greatly appreciated.

Thank you!

Best,
Danielle Steinberg

Danielle Steinberg | Digital Lead, NATURE | +1 (212) 560-3049 (office)
WNET | 825 Eighth Avenue 14th Fl. | New York, NY 10019-7435
pbs.org/nature | Facebook | Twitter | Instagram | YouTube

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 3 Feb 2020 16:43:08 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Bloomberg Radio 2/4

This is Bloomberg and so if we can do this, let us try. If it is too much of a hassle then say sorry no. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jameelah D Robinson (BLOOMBERG/ NEWSROOM:) <jrobinson158@bloomberg.net>
Sent: Monday, February 3, 2020 11:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Bloomberg Radio 2/4

Hi Dr. Fauci!

I Hope this email finds you well. I'm emailing to see if you can join Tom Keene, Bloomberg Suveillance Anchor/Editor-at-Large on his radio show tomorrow morning as a PHONER at 8:00am or 8:15am Et to discuss the Coronavirus. Please let me know if we can make this happen. Many thanks!

-Jameelah

Jameelah Robinson, M.S.
Bloomberg Surveillance
Television & Radio

Bloomberg TV is the world's most-watched business news network, available in more than 360 million homes worldwide. Watch us live on our website, smartphones, iPad

app and the Bloomberg Professional Service.
http://Bloomberg.com/tv/

Bloomberg Radio can be heard live in NY (Bloomberg 1130AM), Boston (1200AM), San Francisco (960AM) and now Washington D.C. (99.1FM) via our local stations. You can hear us nationally on Sirus/XM Channel 119, and globally via the Radio+, I Heart, and Tune-In Radio Apps, or 24/7 at http://www.bloomberg.com/audio

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 3 Feb 2020 15:17:23 +0000
To: Walensky, Loren D.,M.D.,Ph.D.;Glimcher, Laurie,M.D.;Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: Wuhan nCoV Inhibitors

Loren:

Thanks for the note. [redacted] (b) (6)

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Walensky, Loren D.,M.D.,Ph.D. [redacted] (b) (6)
Sent: Sunday, February 2, 2020 11:28 PM
To: Glimcher, Laurie,M.D. [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Wuhan nCoV Inhibitors

(b) (4) [redacted]

[redacted] (b) (4)

PS: Dr. Fauci, [redacted] (b) (6)

Thank you again for any guidance you can provide so that we can try to be of help.

Best,
Loren

Loren D. Walensky, M.D., Ph.D.
Professor of Pediatrics
Principal Investigator, Linde Program in Cancer Chemical Biology
Attending Physician in Pediatric Oncology
Director, Harvard/MIT MD-PhD Program
Dana-Farber Cancer Institute / Harvard Medical School
450 Brookline Avenue, LC3216
Boston, MA 02215
Office: [redacted] (b) (6)
Fax: 617-582-8240
Email: [redacted] (b) (6)
Twitter: [redacted] (b) (6)

From: Glimcher, Laurie,M.D. [redacted] (b) (6)
Sent: Sunday, February 2, 2020 9:33 PM
To: Anthony (NIH/NIAID) Fauci [redacted] (b) (6) Hugh Jr Auchincloss [redacted] (b) (6)
Cc: Walensky, Loren D.,M.D.,Ph.D. [redacted] (b) (6)
Subject: Fwd: Wuhan nCoV Inhibitors

Tony and Hugh,
Loren Walensky is a superb physician-scientist at Dana-Farber [redacted] (b) (4)
If this is of interest to you, please let me know or contact him directly.
Many thanks,
Laurie
Laurie H. Glimcher, M.D.
President and CEO

Dana-Farber Cancer Institute
Richard and Susan Smith
Professor of Medicine
Harvard Medical School

450 Brookline Avenue, Dana 1628
Boston, MA 02215
[redacted] (b) (6) tel.
617.632.2161 fax
[redacted] (b) (6)

Begin forwarded message:

From: "Walensky, Loren D.,M.D.,Ph.D." <[redacted] (b) (6)>
Subject: Wuhan nCoV Inhibitors
Date: January 30, 2020 at 7:23:54 PM EST
To: "Glimcher, Laurie,M.D." [redacted] (b) (6)>

Hi Laurie. I hope all is well on your end. [redacted] (b) (4)

(b) (4)
[redacted]

[redacted] (b) (4)

Thanks so much,
Loren

Loren D. Walensky, M.D., Ph.D.
Professor of Pediatrics
Principal Investigator, Linde Program in Cancer Chemical Biology
Attending Physician in Pediatric Oncology
Director, Harvard/MIT MD-PhD Program
Dana-Farber Cancer Institute / Harvard Medical School
450 Brookline Avenue, LC3216
Boston, MA 02215
Office: [redacted] (b) (6)
Fax: 617-582-8240
Email: [redacted] (b) (6)

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at http://www.partners.org/complianceline . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 3 Feb 2020 15:12:39 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: ANSA news agency

Please get someone to provide answers for me to send to this person. I do not have time to do it myself,

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Battifoglia Enrica <Enrica.Battifoglia@ansa.it>
Sent: Monday, February 3, 2020 5:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: ANSA news agency

Dear Professor Fauci,

I am Enrica Battifoglia of the Italian news agency ANSA, I already have had the pleasure to interview you several times at the AIDS world conferences.

I would like to ask you some questions about Coronoravirus 2019-nCoV, to be published on the ANSA Science web page (www.ansa.it/scienza), the main online science news resource in Italy with over 1.5M contacts each month. I am sure that your clarity and competence will be highly valuable to put some much-needed order among so many contrasting news and data, and would be much appreciated by our readers.

1) Do the current available data allow to understand the threat level of coronarivus 2019-nCoV in terms of both lethality and diffusion speed, and about the possible evolution scenarios of the disease?

2) What exactly we know about its modes of transmission, especially from people who do not yet have the symptoms?

3) Are the genetic sequences provided by China enough to start working on a vaccine?

What are the technical times to develop a working vaccine in terms of scientific research, and what are the approx times for the necessary legal certifications, and for industrial production and distribution?

4) 2019-nCov is the third Coronavirus aggressive for humans that has appeared in the East in the last 20 years and in 2009 the virus responsible for the flu pandemic too did come from China: what sort of preventive measures could be practicable to reduce the risk of repetition of these events?

Thank you so much for your time your attention!

Kindest Regards

Enrica Battifoglia
Science and Technology Head Editor

ANSA News Agency

Il contenuto di questa e-mail è rivolto unicamente alle persone alle quali è indirizzato; le relative informazioni sono da considerarsi strettamente riservate e tutelate ai sensi del Regolamento UE 2016/679 (GDPR) per la Protezione dei Dati Personali, nonché del D. Lgs. n. 196/2003 e successive modifiche. Sono vietati la riproduzione, la diffusione e l'uso di questa e-mail in mancanza di autorizzazione del destinatario. In caso di ricezione della presente e-mail per errore, si prega di non *diffonderla, di informare immediatamente il mittente e di eliminarne ogni copia. Le opinioni espresse in questa e-mail appartengono esclusivamente al mittente e potrebbero non riflettere necessariamente quelle dell'Agenzia ANSA.*

The content of this e-mail is only addressed to the people to whom it is addressed; the relevant information has to be considered as confidential and protected under the Regulation EU 2016/679 (GDPR), General Data Protection Regulation, as well as the Legislative Decree 196/2003 and subsequent amendments. The reproduction, distribution and use of this e-mail in the absence of the recipient's authorization is forbidden. If you receive this e-mail by mistake, please do not disseminate it, inform the sender immediately and delete any copies. The opinions expressed in this message belong to sender alone and may not necessarily reflect those of ANSA AGENCY.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 3 Feb 2020 15:10:32 +0000
To: Joe Palca
Subject: RE: Coronavirus vaccine

Joe:

Thanks for the note. The has nothing to do with the validity of the test. We see this with other viruses when you look at shedding. When there is a low titer of virus, any specific site (in this case a nose or throat swab) may vary between positive and negative even though the person is clearly still infected. It could be that the virus is there in the throat at one point and cleared at another and comes back again. Alternatively, it may be that the virus is always there, but at different titers and at some points it is present below the sensitivity of the test, even though the test is in general quite sensitive.

Hope that this is helpful.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Joe Palca <JPalca@npr.org>
Sent: Monday, February 3, 2020 9:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: Coronavirus vaccine

From: Joe Palca
Sent: Monday, February 3, 2020 9:13 AM

To: 'anthony.facui@nih.gov' (b) (6)>
Cc: 'Deatrick, Elizabeth (NIH/NIAID) [C]' (b) (6)>; Scott Hensley
(b) (6)
Subject: RE: Coronavirus vaccine

Hi Tony,

It's been nice hearing you on the various press conferences...can't believe we're still both doing this.

Have a question about something Redfield said in Friday in the White House briefing about nCoV. He said using their PCR assay, the virus can be detectable one day, then not the next, then detectable.

I'm curious about this. I see a few possibilities:

1. The test isn't as sensitive as CDC hopes
2. The sample was taken from different places
3. With low viral titer, it may seem like the virus "disappears" from one day to the next.
4. The virus may be hanging out in the terminal bronchioles, and only pop up to the upper respiratory system from time to time.

Am I on the right track? Would you have a few minutes today to record an interview with me?

Joe

From: [redacted] (b) (6)
Sent: Mon, 3 Feb 2020 05:45:35 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview request (Seoul, Korea)

Sent from my iPhone

Begin forwarded message:

> **From:** 차현나 [redacted] (b) (6)>
> **Date:** February 3, 2020 at 2:29:21 AM EST
> **To:** "Fauci, Anthony (NIH/NIAID) [E]' [redacted] (b) (6)>
> **Subject: Interview request (Seoul, Korea)**
>
> Dear Dr. Fauci,
>
> I am Mrs. Hyun-Na Cha of TBS, metropolitan radio station of Seoul, South Korea.
> I am the director of currunt-issue radio show of TBS and I'd like to have a telephone interview with you on my radio program about coronavirus issue all over the world.
> As Korea is a very close country to China and many people are very concerned about this issue.
> I would like to hear your opinion as a world authority on this issue.
> The time for phone interview would be about 6 a.m. at Maryland time and I want to proceed it through an English-Korean interpreter.
> I would appreciate it if you could reply to me if you are possible.
> The host of my program is a political expert who is a Ph.D. from MIT, Dr.Kim.
>
> Respectfully,
> Mrs. Hyun-na Cha
> [redacted] (b) (6)
> TBS, Seoul, Korea

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 3 Feb 2020 03:47:33 +0000
To: Howard Schatz
Subject: RE: If too busy then pass---I'd understand

Too soon to predict. It probably will evolve into a widespread infection (pandemic) with lower mortality than we are now seeing (2%). More similar to 2009 H1N1 flu than SARS even though the virus (coronavirus) is in the same family of viruses as SARS.

-----Original Message-----
From: Howard Schatz <[redacted] (b) (6)
Sent: Friday, January 31, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: If too busy then pass---I'd understand

Tony,

New Coronavirus: saw you on national news with a dozen others at DT's table yesterday.

Seems like this new one though serious and very contagious is not as lethal (40:1 ?) as SARS, others.

What is your current thinking on it?

Hope all is well, otherwise.

Thanks,

howard

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 3 Feb 2020 03:45:59 +0000
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: FW: Wuhan nCoV Inhibitors
Attachments: [redacted] (b) (4)
[redacted]

Please handle this. Thanks.

From: Glimcher, Laurie,M.D. [redacted] (b) (6)>
Sent: Sunday, February 2, 2020 9:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Walensky, Loren D.,M.D.,Ph.D. [redacted] (b) (6)
Subject: Fwd: Wuhan nCoV Inhibitors

Tony and Hugh,
Loren Walensky is a superb physician-scientist at Dana-Farber [redacted] (b) (4)
If this is of interest to you, please let me know or contact him directly.
Many thanks,
Laurie
Laurie H. Glimcher, M.D.
President and CEO
Dana-Farber Cancer Institute
Richard and Susan Smith
Professor of Medicine
Harvard Medical School

450 Brookline Avenue, Dana 1628
Boston, MA 02215
[redacted] (b) (6) tel.
617.632.2161 fax
[redacted] (b) (6)

Begin forwarded message:

From: "Walensky, Loren D.,M.D.,Ph.D." [redacted] (b) (6)>
Subject: Wuhan nCoV Inhibitors
Date: January 30, 2020 at 7:23:54 PM EST
To: "Glimcher, Laurie,M.D." [redacted] (b) (6)

Hi Laurie. I hope all is well on your end. [redacted] (b) (4)

(b) (4) [redacted]

Thanks so much,
Loren

Loren D. Walensky, M.D., Ph.D.
Professor of Pediatrics
Principal Investigator, Linde Program in Cancer Chemical Biology
Attending Physician in Pediatric Oncology
Director, Harvard/MIT MD-PhD Program
Dana-Farber Cancer Institute / Harvard Medical School
450 Brookline Avenue, LC3216
Boston, MA 02215
Office: [redacted] (b) (6)
Fax: 617-582-8240
Email [redacted] (b) (6)

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at http://www.partners.org/complianceline . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Mon, 3 Feb 2020 02:10:49 +0000
To:	Cassetti, Cristina (NIH/NIAID) [E]
Subject:	FW: Homozygous for Alpha-1 antitrypsin and coronavirus?

Please handle.

From: Ulrica Mölstad [redacted] (b) (6) >
Sent: Sunday, February 2, 2020 9:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) >
Cc: Ulrica Mölstad [redacted] (b) (6) >
Subject: Homozygous for Alpha-1 antitrypsin and coronavirus?

Hi!

I read that you are an expert working for NIAID and that you got interviewed about treatments for the coronavirus.

I am a Swedish physician specialized in clinical chemistry. [redacted] (b) (6) and wanted to share a hypothesis I have. I believe that some patients who are seriously ill in corona virus (or flue/SARS) with lung symptoms have a lack of normal/well functioning Alpha-1-antitrypsin for example PiZZ. Alpha-1 antitrypsin is an acute phase reactant and increases in sick people. I have seen that the Alpha-1-antitrypsin level can be elevated in a severely ill person (H1N1) if measured in a laboratory, even thought the patient was homozygous for mutations in the Alpha-1-antitrypsin gene. An elevated level of Alpha-1 antitrypsin is misleading and can result in the physician believing that there is nothing wrong with the patients function of Alpha-1-antitrypsin.

[redacted] (b) (4)

I also guess that critically ill ECMO-treated patients with lung symptoms might benefit from receiving Alpha-1 antiprotease inhibitor in addition to other medications given to them. What do you think?

I believe that this information can contribute in understanding why some supposedly healthy individuals gets really sick and even die in corona virus, flue/H1N1 or SARS. [redacted] (b) (4)

I would appreciate if you replied shortly to me so that I know that my e-mail has been read.

Best regards, Ulrica Molstad, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 3 Feb 2020 00:50:43 +0000
To: James Krellenstein
Subject: RE: 2019-nCoV Testing for Public Health Labs

James:
Thanks for the heads-up. I will see what I can do.
Best,
Tony

From: James Krellenstein [redacted] (b) (6)
Sent: Sunday, February 2, 2020 7:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: David Barr [redacted] (b) (6)>; Lord, Aaron [redacted] (b) (6)Peter Staley [redacted] (b) (6)
Subject: 2019-nCoV Testing for Public Health Labs

Tony:

I hope this email finds you well. Over the past 48 hours, PrEP4All has received multiple requests from leaders of public health departments and public health practitioners to begin publicly pressuring CDC/HHS to ensure that properly equipped public health labs (besides CDC's lab in Atlanta) can perform real time reverse transcription PCR (qRT-PCR) testing for 2019 Novel-Coronavirus (2019-nCoV).

Our understanding is that given the public health emergency declared by HHS, an emergency use authorization (EUA) from the FDA is required for public health labs to perform their own lab developed test for 2019-nCoV, even if it is using the CDC's published qRT-PCR protocol and primer/probe sequences (https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-for-detection-instructions.pdf) , and the lab is capable of handling BSL3+ samples.

We understand the extreme delicateness of this situation, and also that it is outside of our normal wheelhouse. But given the concerns of our colleagues in the public health sector, we thought it was important to give you a heads up regarding this request.

Let us know if there is anyway we can help.

Sincerely,

James Krellenstein
Data, Science and Policy Committee
The PrEP4All Collaboration
109 S 5th St, Brooklyn, NY 11249
[redacted] (b) (6)

--

James B. Krellenstein
he - him - his
(b) (6)
(Sent from a mobile device)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 23:54:27 +0000
To: NIAID OD AM
Subject: FW: Invitation for an expert panel webinar on the role of micronutrients and coronavirus
Attachments: 2020.02.02 Expert panel objectives.docx

Let us discuss. Probably no.

From: [redacted] (b) (6)>
Sent: Sunday, February 2, 2020 9:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Cc: Peter van-Dael [redacted] (b) (6)
Subject: Invitation for an expert panel webinar on the role of micronutrients and coronavirus

Dear Dr. Fanci,

I would like to address you for an expert panel webinar on the role of micronutrients and coronavirus

Due to the new coronavirus outbreak and the rapidly escalating global spread, lots of questions are raised regarding the role of micronutrients in supporting the immune system. DSM has reached out to me with a request to organize rapidly a focused expert panel in order to establish expert guidance summarizing key points with respect to the role of micronutrients in supporting our body's immune response, in light of the current general consciousness that among other factors nutrition is important in combatting infectious diseases. Peter Van Dael, head of Nutrition Science & Advocacy, is responsible for the coordination of this activity at DSM.

I agreed to take on this challenge and therefore intend to organize this expert panel through webinar in order to manage the challenges related to busy agendas and travel within the next week, if possible. The webinar is expected to last for about 3 hours maximum and would be facilitate through the distribution of a short background document I will share in order to facilitate the discussion.

I will try to reach out to you tomorrow by phone in order to review whether you would be available for this engagement and whether you would you have potential questions prior to agreeing to participate.

With our best regards,

Manfred Peter

Dr. Manfred Eggersdorfer

Professor for Healthy Ageing

(b) (6)

(b) (6)

Dr. Peter Van Dael

DSM Nutrition Science & Advocacy

From: [redacted] (b) (6)
Sent: Sun, 2 Feb 2020 18:20:17 -0500
To: Carlos del Rio
Subject: Re: [External] RE: Mexican researchers have defined the structure of the Corona virus

Very interesting.

> On Feb 2, 2020, at 9:07 AM, Del Rio, Carlos [redacted] (b) (6)>wrote:
>
> [redacted] (b) (6) sent me this update. Thought you would enjoy.
> Interesting to see how they view outbreaks.....
> Coronavirus news over the weekend was a small net positive (although there were plenty of negatives). Encouragingly, doctors appear to be having some success treating patients with existing antiviral drugs – GILD's remdesivir improved the clinical conditions of a coronavirus patient in Washington state (WSJ) while Thailand said it had achieved good results using antiviral drugs originally designed for the flu and HIV (Bloomberg). It's way too early to tell whether these drugs will perform well in other patients (and a vaccine is still some time away), but the progress noted in the US and Thailand is positive. The PBOC said it would inject CNY1.2T worth of liquidity on Monday 2/3 to ensure markets operate smoothly when they reopen from the New Year holiday (this works out to about CNY150B of net incremental liquidity given CNY1.05T of reverse reports are set to mature on Monday). The gov't also announced other steps (including waiving equity ownership limits for some insurers) aimed to bolstering market confidence. The global coronavirus case count continues to rise (it now stands at ~15K as of Sunday morning w/the death toll north of 300) while more travel restrictions are being imposed by governments and companies around the world (Apple said it would shutter all its stores and offices in China until Feb 9). According to a CNBC update, areas of China responsible for ~80% of GDP and ~90% of exports are set to stay closed until at least Feb 10.
>
> Carlos del Rio, MD.
> Sent from my iPhone
>
>> On Feb 1, 2020, at 11:13 PM, Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>wrote:
>>
>> I love it! □□

-----Original Message-----
From: Del Rio, Carlos <[redacted] (b) (6)>
Sent: Friday, January 31, 2020 10:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Mexican researchers have defined the structure of the Corona virus

---

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 22:56:05 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus

From: Dr.h.c. Richard Hajdu [redacted] (b) (6)>
Sent: Sunday, February 2, 2020 2:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: coronavirus

Dear Anthony Fauci.
I speak hard English so I write to you using google translator.
I have a cured corona virus cure. I am willing to provide you. In laboratory conditions you can try. This medicine can destroy the virus within 12 hours.
If you are interested, it is necessary to provide a way to deliver the medicine to you. I live in the Czech Republic. In the city of Brno.
Dr. Richard Hajdu

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 22:43:15 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus - easy, safe, and likely highly effective treatment.
Attachments: Corona Virus Solution b.docx, MedGasRes_2019_9_4_232_273962.pdf, published article on ozone and ebola 3578-10714-4-PB.pdf

Please handle.

From: Robert Jay Rowen (b) (6)>
Sent: Sunday, February 2, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: coronavirus - easy, safe, and likely highly effective treatment.

Dear Dr. Fauci,

I am a mere clinician. But I have published repeatedly on a therapy which, I believe, will remedy patients with coronavirus and spare a possible catastrophe, if the virus is as lethal as it appears.

The therapy is ozone. It can be performed, depending on the method, for mere pennies in materials. It is not patentable, so, it lacks profitability needed for some payback for the basic research to get it "approved".

It attacks a key vulnerability on this virus and even Ebola. We got to 5 Ebola cases in Sierra Leone. All 5 recovered almost immediately. No sequela. No one has reported anything like that.

I have used ozone therapy for 33 years, ;longer than anyone in North America. It absolutely changed my practice. I write essentially no prescriptions for antibiotics, including for Lyme disease. This therapy, I recently published, might be the solution the world desperately needs for the emerging crisis in resistant infections.

I am attaching 2 papers I recently published on ozone therapy, And a manuscript we just got done to address corona virus, which I am trying to get published. It is not easy. The medical world is vested in Pharmaceuticals.

I urge you to please look at this. Not patentable, it will never be a darling of industry. But just for that reason (dirt cheap), it could be a savior for thousands or more who might die from a pandemic. I am coming to you about this as one physicist came to President Roosevelt about harnessing the power of the atom at the dawn of world war 2. I do hope you will take note of what I am forwarding to you.

> The first file is a word document I am seeking to get published. Usually, an author will hold up on making material like this public until he get published. However, with lives immediately on the line, we want to alert people that the does exist an available very inexpensive and extremely safe medical treatment for this and other infections.
>
> If you have questions, please contact me here.
> Sincerely,

Robert Jay Rowen, MD
[redacted] (b) (6)

www.DrRowenDrSu.com
http://www.youtube.com/user/RobertRowenMD
https://www.facebook.com/DrRobertJRowen

" The doctor of the future will no longer treat the human frame with drugs, but rather will cure and prevent disease with nutrition" , Thomas Edison

HIPAA Notification: This electronic message (including any attachments) is intended only for the exclusive use of the individual to whom it is addressed. This email, including any attachments, is confidential and is legally privileged. If you have received it in error please advise the sender immediately by return email and then delete it from your system. The unauthorized use, distribution, copying or alterations of this email is strictly forbidden. If you need assistance please contact [redacted] (b) (6) Note to Patients: There are inherent confidentiality risks in communicating by email. While safeguards are in place to ensure your privacy, you should not use email communication if you are concerned about any breaches of privacy that might inadvertently occur.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 22:40:07 +0000
To: Greg Folkers ((b) (6))
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Getty images from coronavirus presser etc http://bit.ly/2GJ3u5F

See below the link that (b) (6) sent me. It is a picture of me briefing President Reagan at the NIH in 1988. Please insert it into our flickr file with the legend that I just gave. Thanks.

From: (b) (6) (NIH/CC/BEP) [E] (b) (6)
Sent: Sunday, February 2, 2020 5:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: RE: Getty images from coronavirus presser etc http://bit.ly/2GJ3u5F

The oldest one in the batch:

https://www.gettyimages.com/detail/news-photo/dr-anthony-fauci-lecturing-to-pres-ronald-w-reagan-and-news-photo/50454084?adppopup=true

---

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, February 1, 2020 10:09 PM
To: (b) (6) (NIH/CC/BEP) [E] (b) (6)
Subject: FW: Getty images from coronavirus presser etc http://bit.ly/2GJ3u5F

fyi

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Saturday, February 1, 2020 9:02 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Getty images from coronavirus presser etc http://bit.ly/2GJ3u5F

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 22:36:41 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Fauci/Redfield op-ed for review
Attachments: Redfield-Fauci Joint Op-Ed V2 020120_EOC Cleared Revised wR3 2.2.20 JR HM GF - with additional Fauci tracked changes still showing.docx, Redfield-Fauci Joint Op-Ed V2 020120_EOC Cleared Revised wR3 2.2.20 JR HM GF - with Fauci changes added - clean copy.docx

I have gone over the document and have made a number of tracked changes. In addition, for ease of reading I have accepted all the tracked changes and am sending a clean copy. Hence there are 2 attachments: 1) one with all tracked changes; 2) a clean copy accepting all changes. Please note that the CDC has not announced the 3 additional cases and so depending on when this goes out we need to make sure that the official number is 11 and not still 8Thanks!

From: Routh, Jennifer (NIH/NIAID) [E] <(b) (6)
Sent: Sunday, February 2, 2020 4:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Subject: Fauci/Redfield op-ed for review

Dr. Fauci –

Attached is the draft op-ed for your review. Greg, Hilary and I have added proposed edits in track changes. We will send back to CDC/HHS one document with all NIAID edits in track changes. HHS would like to get a draft to the White House at some point this evening.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 19:24:26 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Specific Questions About CoronaVirus

Please handle.

From: Rafael C. R. [redacted] (b) (6)>
Sent: Sunday, February 2, 2020 12:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Specific Questions About CoronaVirus

Hi Dr. Fauci, you might not remember me from my previous email. I'm a Brazilian who asked you some months ago about the influenza virus differences across regions. I recently traveled to DC and NY and had a great time there (before the Corona Virus outbreak)

I have some specific questions about the new Corona Virus, and would be very grateful if you can answer them:

1- Using available data, I've made a simple spreadsheet attempting to predict the virus behavior: https://docs.google.com/spreadsheets/d/1DAHQtFzXO-FKU405k8p864JBVHAlfzsHQghuywaTNbE/edit#gid=0
I've used **exponential trend,** although it seems to be spreading slower than the expected, I'd like to know if there's an accurate model for predicting this virus. Also, I assume virus don't always spread exponentially?

2- I listened to your interview podcast https://edhub.ama-assn.org/jn-learning/audio-player/18197306. Really amazing content. Let's assume this is going to be a worldwide outbreak. How can I get prepared for the worst? Buy water, dry food, stay indoors, withdraw money, etc?

Once again, I'd like to thank you very much for reading this email. I bet this is a very busy time for you, so it means a lot to me
Thank you,
Rafael

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 18:33:43 +0000
To: Liang, Jake (NIH/NIDDK) [E]
Cc: Mark Dybul;Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Favor

Thanks, Jake. Mark will contact you directly.

From: Liang, Jake (NIH/NIDDK) [E] [redacted] (b) (6)>
Sent: Sunday, February 2, 2020 1:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Mark Dybul [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
Subject: Re: Favor

Hi, Tony, I just returned from an overseas trip but should be around tomorrow and can certainly clear some time to meet with Mark. I met Mark at the NAM meeting last year and would love to hear what they have to say. Let me know what works. Good luck in dealing with the new coronavirus pandemic (not sure whether it is qualified as one yet; if not, pretty close)!! Jake

---

From: Anthony Fauci < [redacted] (b) (6)
Date: Sunday, February 2, 2020 at 12:20 PM
To: Jake Liang [redacted] (b) (6)>
Cc: Mark Dybul [redacted] (b) (6)>, "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6), "Barasch, Kimberly (NIH/NIAID) [C]" [redacted] (b) (6)>
Subject: Favor

Jake:

Sorry for this last minute ask, but [redacted] (b) (6), Ambassador Mark Dybul, who is the former Head of PEPFAR and the former Director of the Global Fund to Fight AIDS, TB, and Malaria will be at the NIH tomorrow with a scientist who has some very interesting data on hepatitis B. I was supposed to meet with them, but I am swamped with the coronavirus. Is there any chance that you can meet with them briefly tomorrow. I believe that you might be interested in seeing them. I have copied Mark on this e-mail and so I will ask him to e-mail you to see if you can make this happen. Many thanks.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 18:02:22 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Seeking comment on Indian paper about new Coronavirus

Geeeez

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, February 2, 2020 12:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: Seeking comment on Indian paper about new Coronavirus

FYI re the paper from the Indian researchers.
Talk about trying to put the genie back in the bottle! Yeesh.

From: "Mascola, John (NIH/VRC) [E]" < [redacted] (b) (6)
Date: Sunday, February 2, 2020 at 10:39:42 AM
To: "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)>, "Graham, Barney (NIH/VRC) [E]" [redacted] (b) (6) "Hiatt, Nissa (NIH/VRC) [C]" [redacted] (b) (6)>
Cc: "Marston, Hilary (NIH/NIAID) [E]" < [redacted] (b) (6)>, "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)>, "Stover, Kathy (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: RE: Seeking comment on Indian paper about new Coronavirus

Also note the following from the author on the BioRxiv comment section:



Prashant Pradhan • 8 hours ago

This is a preliminary study. Considering the grave situation, it was shared in BioRxiv as soon as possible to have creative discussion on the fast evolution of SARS-like corona viruses. It was not our intention to feed into the conspiracy theories and no such claims are made here. While we appreciate the criticisms and comments provided by scientific colleagues at BioRxiv forum and elsewhere, the story has been differently interpreted and shared by social media and news platforms. We have positively received all criticisms and comments. To avoid further misinterpretation and confusions world-over, we have decided to withdraw the current version of the preprint and will get back with a revised version after reanalysis, addressing the comments and concerns. Thank you to all who contributed in this open-review process.
: Authors of the Manuscript

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Sunday, February 2, 2020 10:35 AM
To: Graham, Barney (NIH/VRC) [E] (b) (6); Hiatt, Nissa (NIH/VRC) [C] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Mascola, John (NIH/VRC) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] < (b) (6)
Subject: RE: Seeking comment on Indian paper about new Coronavirus

Hi Barney –

We consulted with HHS and ASF. OCGR is going to send a note to the reporter to decline, noting that the paper is not peer-reviewed. Please let us know if you receive similar requests.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Graham, Barney (NIH/VRC) [E] (b) (6)
Sent: Saturday, February 1, 2020 2:11 PM
To: Hiatt, Nissa (NIH/VRC) [C] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6)
Subject: FW: Seeking comment on Indian paper about new Coronavirus

Hi Nissa and Jen,

This is one we don't want to answer without high-level input, but wanted you to know about the rising controversy.

BG

From: Issam AHMED <Issam.AHMED@afp.com>
Sent: Friday, January 31, 2020 5:27 PM
To: Graham, Barney (NIH/VRC) [E] [redacted] (b) (6)
Subject: Seeking comment on Indian paper about new Coronavirus

Dear Dr Graham,

I'm a science journalist with news agency Agence France-Presse writing with a request -- apologies for reaching out on a Friday evening! I was told by a contact you may be willing to give an opinion on this paper that has just gone live https://www.biorxiv.org/content/10.1101/2020.01.30.927871v1.full.pdf it suggests the new Coronavirus has four inserts similar to HIV-1 and this is not a coincidence.

Thanks you very much, if you are able.

Issam Ahmed

Issam AHMED
Health, Science and Environment Correspondent
1500 K St. NW - 20005 Washington
Tel: (202) 414-0521

AFP

June 24, 2020
Virus death toll nears half a million as cases surge in US, Latin America

Join us on:

afp.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 17:13:03 +0000
To: Mark Dybul
Subject: RE: A connection to jake

Mark:
Thanks for the note. Sorry that I had to cancel. This is White House in full overdrive and I am in the middle of it. Reminiscent of post-anthrax days. I will send an email to Jake today to introduce you. Again, sorry about the cancellation. Hope to see you soon. Regards to Jason.
Best,
Tony

-----Original Message-----
From: Mark Dybul [redacted] (b) (6)>
Sent: Sunday, February 2, 2020 11:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: A connection to jake

Hey tony

Know you are buried in coronavirus. Totally understand need to cancel meeting tomorrow. We will set up a zoom in hen things calm down.

We have made additional progress on hbv including data from 2 new mouse models. We were going to share Monday

Realize this is last minute but might it be possible for you to connect me to jake liang in case we can squeeze in a meeting with him (serhat is already on east coast - we took a risk knowing you might have to cancel)?

If you are not comfortable with that I could send him a cold call email mentioning we have shared the data with you. You were kind enough to introduce us at the nam dinner when [redacted] (b) (6).

Hope you at least have time to enjoy Super Bowl. Hang in there - am sure everyone is leaning heavily on you as usual.

Thanks much
Mark
Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 16:49:35 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]
Subject: FW: Teleconference

Francis:
Do you have a minute for a quick call?
Tony

From: Jeremy Farrar [redacted] (b) (6)
Sent: Sunday, February 2, 2020 11:28 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>
Subject: Re: Teleconference

Tedros and Bernhard have apparently gone into conclave....they need to decide today in my view. If they do prevaricate, I would appreciate a call with you later tonight or tomorrow to think how we might take forward.

Meanwhile....

https://www.zerohedge.com/geopolitical/coronavirus-contains-hiv-insertions-stoking-fears-over-artificially-created-bioweapon

---

From: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
Date: Sunday, 2 February 2020 at 15:30
To: Jeremy Farrar [redacted] (b) (6)>, Francis Collins [redacted] (b) (6)>
Cc: "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)
Subject: RE: Teleconference

Jeremy:
Sorry that I took so long to weigh in on your e-mails with Francis and me. I was on conference calls. [redacted] (b) (5)
(b) (5)

Best regards,
Tony

From: Jeremy Farrar [redacted] (b) (6)>
Sent: Sunday, February 2, 2020 7:13 AM

To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E]
< [redacted] (b) (6)
Subject: Re: Teleconference

....Really appreciate us thinking through the options... [redacted] (b) (5)

From: Francis Collins < [redacted] (b) (6)>
Date: Sunday, 2 February 2020 at 12:03
To: Jeremy Farrar < [redacted] (b) (6)>
Cc: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6), "Tabak, Lawrence (NIH/OD) [E]"
[redacted] (b) (6)
Subject: RE: Teleconference

Hi Jeremy,

Thanks for forwarding these additional reflections from Mike and Bob. [redacted] (b) (5)
(b) (5) [redacted]

Francis

From: Jeremy Farrar [redacted] (b) (6)
Sent: Sunday, February 2, 2020 6:53 AM
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E]
[redacted] (b) (6)
Subject: Re: Teleconference

Thank you

See thoughts overnight from others.

(b) (5) [redacted]

Jeremy

(b) (5)

[redacted]

From: Francis Collins [redacted] (b) (6)>
Date: Sunday, 2 February 2020 at 10:27
To: Jeremy Farrar [redacted] (b) (6)
Cc: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6), "Tabak, Lawrence (NIH/OD) [E]" [redacted] (b) (6)
Subject: RE: Teleconference

Jeremy,

[redacted] (b) (5)

I'm available any time today except 3:15 – 5:45 pm EST (on a plane) for a call to Tedros. Let me know if I can help get through his thicket of protectors.

Francis

From: Jeremy Farrar [redacted] (b) (6)
Sent: Sunday, February 2, 2020 4:48 AM
To: Andrew Rambaut < [redacted] (b) (6)>
Cc: R.A.M. Fouchier [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Patrick Vallance [redacted] (b) (6); Drosten, Christian [redacted] (b) (6)>; M.P.G. Koopmans [redacted] (b) (6); Eddie Holmes [redacted] (b) (6); Kristian G. Andersen [redacted] (b) (6); Paul Schreier [redacted] (b) (6); Ferguson, Mike [redacted] (b) (6); Collins, Francis (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Josie Golding [redacted] (b) (6)
Subject: Re: Teleconference

This is a very complex issue.

I will:

[redacted] (b) (5)

[redacted] (b) (5)

I suggest we don't get into a further scientific discussion here, but wait for that group to be established.

Jeremy

From: '[redacted] (b) (6)
Date: Sunday, 2 February 2020 at 09:38
To: Jeremy Farrar <[redacted] (b) (6)>
Cc: [redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6), Patrick Vallance [redacted] (b) (6)>, "Drosten, Christian" [redacted] (b) (6), Marion Koopmans <[redacted] (b) (6), Edward Holmes [redacted] (b) (6) [redacted] (b) (6), "Kristian G. Andersen" [redacted] (b) (6), Paul Schreier [redacted] (b) (6) Michael FMedSci [redacted] (b) (6)>, Francis Collins [redacted] (b) (6) [redacted] (b) (6) Josie Golding [redacted] (b) (6)
Subject: Re: Teleconference

Dear Jeremey, Ron and all,

Thanks for inviting me on the call yesterday. [redacted] (b) (5)

[redacted] (b) (5)

[redacted] (b) (5)

Best,
Andrew

On 2 Feb 2020, at 08:40, Jeremy Farrar [redacted] (b) (6)> wrote:

Thanks Ron

[redacted] (b) (5)

Thoughts on that very welcome.

On 2 Feb 2020, at 08:30, R.A.M. Fouchier [redacted] (b) (6)> wrote:

Dear Jeremy and others,

This was a very useful teleconference. [redacted] (b) (5)
[redacted] (b) (5)

Thanks for organizing this on such short notice,
Kind regards

Ron

Ron's notes:

(b) (5)

[redacted]

(b) (5)

[redacted]

[redacted] (b) (5)

Van: Jeremy Farrar [redacted] (b) (6)
Datum: zaterdag 1 februari 2020 om 21:59
Aan: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>, Patrick Vallance [redacted] (b) (6)
CC: Christian Drosten [redacted] (b) (6) "M. Koopmans" [redacted] (b) (6), "R.A.M. Fouchier" [redacted] (b) (6), Edward Holmes [redacted] (b) (6), Andrew Rambaut [redacted] (b) (6) "Kristian G. Andersen" [redacted] (b) (6), Paul Schreier [redacted] (b) (6), "Ferguson, Mike" [redacted] (b) (6) Francis Collins [redacted] (b) (6), ' [redacted] (b) (6)>, Josie Golding [redacted] (b) (6)
Onderwerp: Re: Teleconference

Thank you to everyone for joining.

There is clearly much to understand understand in this. This call was very helpful to hear some of our current understanding and the many gaps in our knowledge. [redacted] (b) (5)

[redacted] (b) (5)

[redacted] (b) (5)

I hope that is a reasonable approach, please send any thoughts or suggestions.

Once again, thank you for making time over a weekend and for such an informed discussion on a complex issue.

Thank you and best wishes Jeremy

From: Jeremy Farrar [redacted] (b) (6)
Date: Saturday, 1 February 2020 at 15:34
To: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>, Patrick Vallance < [redacted] (b) (6)
Cc: "Drosten, Christian" [redacted] (b) (6)>, Marion Koopmans [redacted] (b) (6) " [redacted] (b) (6) Edward Holmes [redacted] (b) (6) [redacted] (b) (6) [redacted] (b) (6) "Kristian G. Andersen" [redacted] (b) (6), Paul Schreier [redacted] (b) (6) [redacted] (b) (6)>, Michael FMedSci [redacted] (b) (6)
Subject: Teleconference

1st February (2nd Feb for Eddie)
Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.
Please mute phones.
I will be on email throughout – email Paul or I Paul if any problems
If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney
8pm CET
7pm GMT
2pm EST
11am PST
(Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- Introduction, focus and desired outcomes - JF
- Summary – KA
- Comments – EH
- Q&A – All
- Summary and next steps - JF

Kristian Anderson
Bob Garry - I have not been able to contact Bob. Please forward if you can.
Christian Drosten
Tony Fauci
Mike Ferguson
Ron Fouchier
Eddie Holmes
Marion Koopmans
Stefan Pohlmann
Andrew Rambaut
Paul Schreier
Patrick Vallance

Andrew Rambaut
Institute for Evolutionary Biology
Ashworth Laboratories, University of Edinburgh, Edinburgh, EH9 3FL, UK

contact – [redacted] (b) (6) | http://tree.bio.ed.ac.uk | tel [redacted] (b) (6)

The University of Edinburgh is a charitable body, registered in Scotland, with registration number SC005336.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 15:45:28 +0000
To: Goldner, Shannah (NBCUniversal);Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Thank you so much

My pleasure!

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Sunday, February 2, 2020 10:33 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6) Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)
Subject: Thank you so much

Dr. Fauci, thank you so much for making time for our show this morning. We are very grateful to have you on, sharing your knowledge on this issue. I know you are extremely busy, but again, so many thanks.

Sincerely – and have a good day, though I know a busy one. Shannah

And Patricia, thank you so much for your help and patience with me, I appreciate it.

Shannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, February 01, 2020 8:42 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Fauci, Anthony (NIH/NIAID) [E]
[redacted] (b) (6)
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: [EXTERNAL] Re: details re tomorrow's MSNBC morning interview

Adding dr Fauci here - he will arrive at the Nebraska ave studio no later than 710 am for your 730 am ET live hit as per below.

If there are any changes or cancellations in the morning please call his cell at [redacted] (b) (6). My cell is [redacted] (b) (6)

Thank you.

Sent from my iPhone

> On Feb 1, 2020, at 8:32 PM, Goldner, Shannah (NBCUniversal)
> <shannah.goldner@nbcuni.com> wrote:

Patricia, hi...the contact at the NBC bureau (4001 Nebraska Ave) is Parita Desai. The number at the studio is 202-885-4800. The bureau is aware that Dr. Fauci is driving himself and he can park at the bureau.

The interview time is scheduled for approx 7:30am, so if he can be at the studio by 7am for powder and to be seated, that would be appreciated.

The producer in NY who will email you the information details for the segment tomorrow is Cyndi Antoniak. If you need to reach her before she reaches you in the morning, her email is Cynthia.antoniak@nbcuni.com and her phone number is [redacted] (b) (6)

The interview is one on one with our anchors Kendis Gibson and Cori Coffin.

If you need more information, please let me know. Thank you for your help and your patience today, I appreciate it.

All the best,
Shannah

Shannah Goldner
MSNBC
W: 212-664-1289
C: [redacted] (b) (6)

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Saturday, February 01, 2020 7:54 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Subject: [EXTERNAL] RE: Thank you so much

Hi – are we firm for tomorrow? need onsite contact info..thx

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Saturday, February 1, 2020 1:28 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6) Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Thank you so much

I will forward all that soon. Thank you!

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, February 01, 2020 1:26 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [EXTERNAL] RE: Thank you so much

Yes – he can do that hit time – just let us know when it is firm. He will drive his car to the studio.

I will need an onsite name and cell number for him at the studio herein dc

---

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Saturday, February 1, 2020 1:20 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Thank you so much
Importance: High

Patricia, hi, thank you so much for getting back to me and again, apologies to Dr. Fauci, I do understand how swamped he.

With that said, I'll confirm the exact time at around 2pm our time, but I think the interview will be at approx 7:30am.

Would you like me to arrange transportation to and from the studio? We'd like Dr. Fauci to be at the studio by 7:10am-ish?

Thank you so much. Shannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Saturday, February 01, 2020 12:41 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)
Subject: [EXTERNAL] FW: request for a live interview tomorrow morning, on MSNBC
Importance: High

Good afternoon –

I believe we can make this work – if we can – it would need to be done in your NBC Studio in WDC at 4001 Nebraska Ave NW

Will that work and what would the exact hit time be?

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Saturday, February 1, 2020 11:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: request for a live interview tomorrow morning, on MSNBC
Importance: High

Dr. Fauci, good morning.
Are you available to do an interview tomorrow sometime in the 7:30 to 8am ET hour, to discuss the latest news about the Coronavirus? The interview would be one on one and approx 5mins. I saw you on the Today show yesterday and I would love to get you on MSNBC to discuss this, I know our viewers will have a better understanding of the situation if you can take us through it.
I can arrange a satellite location/transportation/whatever is needed to make this work out.

Thank you for your consideration and I hope to hear from you soon.
All the best,
Shannah

Shannah Goldner
MSNBC
W: 212-664-1289
C: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 15:44:24 +0000
To: Daley, George Q.
Cc: Collins, Francis (NIH/OD) [E] [redacted](b) (6));Marston, Hilary (NIH/NIAID) [E];Graham, Barney (NIH/VRC) [E]
Subject: RE: Inquiry and possible pone call

George:

Thanks for the note. There is a lot of communications between scientists in China and their colleagues in the USA , many with whom they have been collaborating prior to the outbreak. There is no real "coordination" of this response since we do not know who is doing what until we are told – just like you have done here. Dr. Soumya Swaminathan, Chief Scientist at WHO is organizing a meeting on Feb. 11-12 in Geneva to try and develop a research agenda for nCoV. I am sure that Chinese scientists will be there. It might be helpful to contact her. Her e-mail address is [redacted](b) (6).

I hope that this is helpful. I will follow-up with a call.

Best,
Tony

From: Daley, George Q. <[redacted](b) (6)>
Sent: Sunday, February 2, 2020 10:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted](b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted](b) (6)>
Subject: Inquiry and possible pone call

Dear Tony,

Alan Garber, Harvard's Provost, and I met yesterday with a team led by Jack Xia, the CEO of China's Evergrande Company, and Dr Jack Liu, Evergrande's chief health officer, who stated thy were acting on behalf of Dr Zhong Nanshan, China's key point person on the coronavirus outbreak (see below). [redacted](b) (4), and they arranged a conference call for tomorrow morning EST with Dr. Zhong.

While I have been mobilizing efforts of our community to react to the virus and to this request, I am not naïve to the challenging politics of such a relationship. I do not want to complicate or duplicate efforts already underway, and am writing to request whatever information you are willing to share on your current efforts to coordinate a response.

If a phone call is more facile, please do not hesitate to try my cell: [redacted] (b) (6) anytime today.

Sincerely,

George

George Q. Daley, MD, PhD
Dean, Harvard Medical School
Caroline Shields Walker Professor of Medicine
Professor of Biological Chemistry and Molecular Pharmacology

Office of the Dean, Gordon Hall
25 Shattuck Street, Boston MA 02115
Contact: [redacted] (b) (6)
[redacted] (b) (6)

From: Jack Liu [redacted] (b) (6)
Date: Saturday, February 1, 2020 at 11:26 PM
To: Public HMS Email [redacted] (b) (6)
Cc: 谈朝晖 [redacted] (b) (6), 陈敏 Min Chen
[redacted] (b) (6)
Subject: Follow up on today's meeting

Dear Dr. Daley:
Per our discussion this afternoon in the conference room at your school, [redacted] (b) (4)

[redacted]

(b) (4)

[redacted]

Jack Liu, MD

该邮件从移动设备发送

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 15:33:34 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E];Wolinetz, Carrie (NIH/OD) [E];Conrad, Patricia (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: RE: 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap Feb 11-12, 2020 Geneva WHO HQ

Francis:

This is a meeting aimed at setting research priorities and I do not believe that it impacts or overlaps with the Tedros proposal. I will have my staff submit some names (mostly high level program people) to represent us at this meeting.
Tony

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Sunday, February 2, 2020 10:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6); Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)
Subject: FW: 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap Feb 11-12, 2020 Geneva WHO HQ

Hi Tony,

Just encountered this message from Soumya of WHO, inviting attendance at a meeting in Geneva on Feb. 11 – 12. I'm not sure how that will fit with the Tedros proposal.

Who would be the right persons from NIH to propose for Soumya's meeting?

Francis

From: SWAMINATHAN, Soumya [redacted] (b) (6)>
Sent: Friday, January 31, 2020 4:41 AM
[redacted] (b) (6)
[redacted] (b) (6) Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Cc: SATHIYAMOORTHY, Vaseeharan < [redacted] (b) (6)>; RIVEROS BALTA, Alina Ximena [redacted] (b) (6); BORGES, Andrea [redacted] (b) (6); MCLELLAN, Faith [redacted] (b) (6)>; HILL, Suzanne Rose [redacted] (b) (6); GARAPO, Charity Helen [redacted] (b) (6)>

Subject: 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap Feb 11-12, 2020 Geneva WHO HQ

Dear All,

I am delighted to inform you that WHO is organizing a global research partners forum on February 11th and 12th in Geneva, to discuss research priorities related to the novel Corona virus. The expected outcome is a research roadmap with clearly defined priorities and a governance framework to take each thematic area forward. Several thematic areas will be considered at the meeting, namely: virus, diagnostics; natural history and transmission; clinical; therapeutics; vaccines; ethics; regulatory science; animal health; data/samples analysis and sharing and; social sciences. We believe that this meeting will be critical in consensus building on the most important research questions, as well as in building global partnerships and collaborations to take this work forward.

This meeting is being organized in partnership with GLOPID R and is being supported by the Bill and Melinda Gates foundation, DFID, Wellcome Trust and several other partners. The secretariat within WHO is the R&D blueprint, co-chaired by Dr Mike Ryan and myself.

As the head of an agency that would play an important role in addressing this new viral outbreak, either by undertaking or funding research, or both, I take great pleasure in inviting you to this meeting. I apologize for the short notice, but you will understand that we have had to plan this in the past few days, keeping in mind the evolving situation.

Kindly let me know if you (or your nominee) will be able to attend and if you need any support from us. Please copy [redacted] (b) (6) and [redacted] (b) (6) in your response.

With best wishes,
Soumya
Chief Scientist

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 12:35:48 +0000
To: Lorsch, Jon (NIH/NIGMS) [E]
Subject: RE: Update from Ming

Exhausted, but OK. Thanks.

-----Original Message-----
From: Lorsch, Jon (NIH/NIGMS) [E] <[redacted] (b) (6)>
Sent: Sunday, February 2, 2020 7:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Update from Ming

Thanks, Tony. [redacted] (b) (6)

I hope you are hanging in there!

Jon

On 2/1/20, 11:20 PM, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)> wrote:

> Jon:
> [redacted] (b) (6)
>
> Best,
> Tony
>
> -----Original Message-----
> From: Lorsch, Jon (NIH/NIGMS) [E] [redacted] (b) (6)
> Sent: Friday, January 31, 2020 6:57 AM
> To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
> Subject: FW: Update from Ming
>
> Tony,
>
> [redacted] (b) (6)
>
> Jon
>
> On 1/31/20, 5:32 AM, "Lei, Ming (NIH/NIGMS) [E]" [redacted] (b) (6)> wrote:
>
> > Thanks, Jon.
> > [redacted] (b) (6)
> >
> > Ming
> >
> > Sent from my iPad

> On Jan 31, 2020, at 6:08 PM, Lorsch, Jon (NIH/NIGMS) [E] [redacted] (b) (6)> wrote:
>
> Thanks, Ming. [redacted] (b) (6)
>
> On 1/30/20, 9:10 PM, "Lei, Ming (NIH/NIGMS) [E]" [redacted] (b) (6)> wrote:
>
> Jon,
>
> Here is an update of my situation:

[redacted] (b) (6)

>
> Best.
> Ming
>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 11:26:13 +0000
To: Collins, Francis (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E];Wolinetz, Carrie (NIH/OD) [E]
Subject: RE: More on evolution of coronavirus

The Indian paper is really outlandish. Agree about Jon Cohen's nice summary.

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Sunday, February 2, 2020 5:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] [redacted] (b) (6)>
Subject: More on evolution of coronavirus

In case you haven't seen, attached is the Indian paper claiming HIV sequences have been inserted into 2019-nCoV, which has been roundly debunked.

I found Jon Cohen's piece in Science to be a pretty useful summary:

https://www.sciencemag.org/news/2020/01/mining-coronavirus-genomes-clues-outbreak-s-origins

FC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 04:24:27 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: [redacted] (b) (4)
Attachments:

Please handle.

From: Ryan Muldoon [redacted] (b) (6)
Sent: Thursday, January 30, 2020 3:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: [redacted] (b) (4)

Dear Tony,

[redacted] (b) (4)

Kind regards,
Ryan

PrEPBiopharm
Ryan Muldoon
CEO

Tel: [redacted] (b) (6)
Email: [redacted] (b) (6)
www.prepbiopharm.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 04:21:44 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Dear Prof. Anthony Fauci, here is a request from MIT Technology Review（Chinese）

NIAID inquiries, please.

From: Tao Sun (b) (6)
Sent: Friday, January 31, 2020 2:06 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: Dear Prof. Anthony Fauci, here is a request from MIT Technology Review（Chinese）

Dear Prof. Anthony Fauci,

Thank you. Dr. Catharine provided me useful information. As the epidemic develops, here are a few new questions to ask. Chinese readers want to know the opinions of foreign independent experts

1 Some media said Wuhan virus' fatality rate approaches that of the flu, saying that people need not panic. What do you think of this view? In reality, Chinese residents are already scared and are already rushing to buy masks.

2 R0 is a developing number, and it is not easy to calculate. Does it make sense to talk about R0 at this stage?

3 You had talked about asymptomatic patients, and how public health workers should treat asymptomatic people? AND why are some viral infections asymptomatic? Can they wear masks to help prevent epidemics?

4 To what extent will the closure of Wuhan prevent the epidemic?

Looking forward to your reply.

Best

Tao Sun (b) (6)> 于2020年1月24日周五 下午3:45写道：

> Dear Prof. Anthony Fauci,
>
> I am Tao Sun, a reporter from Beijing. I am currently writing reports for the MIT Technology Review（Chinese）.
>
> JAMA published your article Coronavirus Infections—More Than Just the Common Cold, and Xinhua News Agency reported this article. Here are some questions I would like to ask you.
>
> 1 Some people think that it is not necessary to develop a new vaccine against SARS or coronavirus in

Wuhan. The reason is that, firstly, there is no commercial interest to pharmaceutical manufacturers, and secondly, such outbreaks may not return after the extinction.
What do you think of these views?

2 For the Wuhan virus vaccine being developed, the epidemic is likely to be eliminated after three months, so is it still necessary to develop a vaccine?

3 You can talk about SARS. How much does a vaccine against SARS actually play?

Looking forward to your reply.

--
TAO SUN

DEEPTECH MIT Technology Review

(b) (6)

suntao@mittrchina.com

7th FL, Tower AB Office Park, 10 Jintong West Road, Chaoyang District, Beijing

http://www.mittrchina.com

--
TAO SUN

DEEPTECH MIT Technology Review

(b) (6)

suntao@mittrchina.com

7th FL, Tower AB Office Park, 10 Jintong West Road, Chaoyang District, Beijing

http://www.mittrchina.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 04:08:48 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Strategy to attack 2019-nCoV coronavirus

Please handle.

From: Jingyue Ju [redacted] (b) (6)
Sent: Friday, January 31, 2020 12:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Redfield, Robert R. (CDC/OD) [redacted] (b) (6)
Cc: Mary C Boyce [redacted] (b) (6); Lee Goldman [redacted] (b) (6)>; Shelanski, Michael L. [redacted] (b) (6)
Subject: Strategy to attack 2019-nCoV coronavirus

Dear Drs. Fauci and Redfield,

[redacted] (b) (4)

Please let me know if you would like to receive the full manuscript.

Thank you very much for your consideration.

Sincerely,

Jingyue

Jingyue Ju, Ph.D.
Samuel Ruben-Peter G. Viele Professor of Engineering
Professor of Chemical Engineering and Pharmacology
Director, Center for Genome Technology & Biomolecular Engineering
Columbia University
Northwest Corner Building, Room 1000M1

Phone: (b) (6) (Office) (b) (6) (Cell)
Fax: 212-851-9330
Email: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 04:08:13 +0000
To: Arnold Monto
Subject: RE: Coronavirus issues

Arnold:
Thanks for the note. I actually have recommended to several press people that they contact you when they ask for non-government experts. I will continue to do that.
Best,
Tony

From: Arnold Monto [redacted] (b) (6)>
Sent: Friday, January 31, 2020 1:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Coronavirus issues

Hi, Tony:

As this progresses, and as other news items quiet, I am concerned that this is not being handled like the 2009 pandemic when you and Rich Besser functioned as something like a tag team. This gets really tricky when public health interventions are the way SARS was handled and remain the focus. I am being contacted by the media currently, not because I was in Beijing at the end of SARS but because of general epidemiology credentials I am trying to put things into context based on past history, even though I know other sensational information may come to light which will further muddy the waters. And we know who will be the main muddiers

Keiji put me on the 2009 WHO Emergency Committee as a non-governmental person who was not bound by clearances etc I am trying to figure out if I can play that role here I have not yet been contacted by Elizabeth Cohen, our mutual friend, but I am sure I will.The one thing I can do is to try to [redacted] (b) (4)

I am attaching a paper which I wrote post 2009 which shows how the way it was handled adversely affected programs in much of Europe It might be of interest to those who were not around at that time.

Regards

Arnold

--

Arnold S. Monto, M.D.
Thomas Francis Collegiate Professor
Department of Epidemiology
School of Public Health
University of Michigan
1415 Washington Heights
Ann Arbor, MI 48109-2029
Tel: [redacted] (b) (6)
Fax: (734) 764-3192
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 04:01:50 +0000
To: toygar civelek
Subject: RE: Coronavirus

Many thanks!

From: toygar civelek [redacted] (b) (6)>
Sent: Friday, January 31, 2020 2:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Coronavirus

Dear Mr. Fauci,

I am hoping that this email reaches you as I saw this email address on line on the NIH website.

As we as the public get to hear, read and see with the current coronavirus scare, here in the US and worldwide, it is comforting to have professionals and experts like you, who really know what they are talking about, what is going on, what can be done, timelines, action plans, and inform the public in a reliable and comforting way, yet being very transparent, informing the public on social media.

Kudos to you sir and please keep up the excellent work.

Sincerely,

Mur. Civelek

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 04:01:28 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6);Barasch, Kimberly (NIH/NIAID) [C];Greg Folkers (b) (6)
Subject: FW: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.
Attachments: Fauci, Anthony Feb. 2020 Invitation.docx, BC Active Members Jan. 2020.pdf

I definitely want o do this. Please respond. Thanks.

From: Marlene Colucci <mcolucci@businesscouncil.com>
Sent: Friday, January 31, 2020 2:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) David Rubenstein <David.Rubenstein@carlyle.com>; MaryPat Decker <marypat.decker@carlyle.com>
Subject: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.

Dear Dr. Fauci,

On behalf of our co-chairs for the winter meeting of The Business Council, David Rubenstein of The Carlyle Group and Ginni Rometty of IBM, we would like to formally invite you to participate in our meeting on February 20-21, 2020 in Washington, D.C. The theme of the meeting is "The Next Decade." (See formal invitation attached as well as list of CEO members).

We would like for you to participate in a 50 minute fireside chat with David Rubenstein (and possibly Dr. Francis Collins) to discuss the current coronavirus as well as what we should expect in the next decade. We want to give our CEOs insights into what the next 10 years will bring in terms of detection, diagnosis and treatment of diseases. All conversations are strictly off the record and closed press. We will cover all lodging and transportation.

As you know, The Business Council is comprised of the chief executive officers of the largest global corporations, representing all segments of the economy. We expect at least 150 CEO members, spouses and speakers to be in attendance.

As a participant you and your spouse are also invited to join us for our special reception, dinner and speaker at the REACH (Kennedy Center) on Thursday, February 20 at 6:30pm. It is the best opportunity for you to meet our CEO members and spouses, speakers and other special guests in an informal atmosphere.

If you are interested and available, please let me know. We can also set up a very brief call with you to discuss any additional details and answer any questions you may have. We look forward to hearing from you and would be honored to have you participate with us again.

Warmest regards,

Marlene

Marlene Colucci

EXECUTIVE
DIRECTOR

THE BUSINESS COUNCIL

T: 202-298-7650
C: (b) (6)
F: 202-785-0296

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 03:48:52 +0000
To: Morens, David (NIH/NIAID) [E]
Subject: RE: Potential PHS Officer Deployment

Got it.

From: Morens, David (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, January 31, 2020 4:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Potential PHS Officer Deployment

Tony & Hugh, in follow up, the PHS has informed all PHS officers that as of 2/3 they are subject to deployment for coronavirus work "without supervisory approval", meaning that if needed, officers can be deployed and assigned anywhere, for indefinite periods, by the Assistant Secretary of Health.

We are hearing that many officers, especially physicians and nurses, may be deployed for quarantine efforts and to assist State agencies.

I haven't heard anything personally, but just want to let you know. These deployment orders can come with almost no advance warning, although I don't expect that.

David

David M. Morens, M.D.
CAPT, United States Public Health Service
Senior Advisor to the Director
Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Building 31, Room 7A-03
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520
☎ [redacted] (b) (6) (assistants: Kimberly Barasch; Whitney Robinson)
📠 301 496 4409
💻 [redacted] (b) (6)

Disclaimer: This message is intended for the exclusive use of the recipient(s) named above. It may contain information that is PROTECTED, PRIVILEGED, and/or CONFIDENTIAL, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. All sensitive documents must be properly labeled before dissemination via email. If you are not the intended recipient, any dissemination, distribution, or copying is strictly prohibited. If you have received this communication in error, please erase all copies of the message and its attachments and notify us immediately.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 03:28:01 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Control 2019-nCoV Wuhan

Please handle.

From: [redacted] (b) (6)
Sent: Saturday, February 1, 2020 8:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Control 2019-nCoV Wuhan

Tri-Prime Gene Pharmaceutical Co
Beijing China
Cheng YongQing
CEO Tri-Prime Gene.
regards

My name is Robert Vera. I am [redacted] (b) (6) years old. I live in [redacted] (b) (6) Ecuador South America. Here in Ecuador in 1999 in shrimp farms in Ecuador there was a lethal disease among shrimp called the white spot virus syndrome. He appeared in 1999 in Ecuador and made shrimp sick and eliminated them. In China it appeared in 1993. White spot virus syndrome is caused by a virus from the nimaviridae family that infects a vibran parahaemolitycus. I applied more than 10 billion liters of natural and organic biological molecules of my invention for 10 years from 2002 to 2011 in more than 10 thousand hectares of shrimp farms. These molecules have antiviral characteristics and inhibit the glycoproteins of viruses. These glycoproteins are what open cell receptors to infect and replicate. Also these natural molecules invented in [redacted] (b) (6) Ecuador in 2001 inhibit the cytokinins that inflame hepatopancreas. Cytokinins cause the desquamation of epithelial cells from tubules that end up collapsing to the liver and shrimp pancreas. These viruses infect the parahaemolitycus vibrating bacteria and create an incurable syndrome in the shrimp. In 2002 we defeated this disease and controlled it ... with this Ecuador to produce little shrimp, now in 2019 it is the number one in the world to export shrimp. In the same way, the coronavirus 2019-nCoV Wuhan infects the pneumococci of the lung and the respiratory syndrome develops. Wuhan coronavirus is the seventh among the coronaviruses after sars and mers. Another 4 are simpler in animals that cause the flu. 2019-nCoV causes 2% of deaths. There are 250 dead as of January 31, 2020 and more than 10 thousand infected in China. 20 countries have infections. It is transmitted even without symptoms and its incubation is 2 to 14 days.

We can spray with more than 1000 million liters of these virus inhibitory molecules throughout Wuhan. 1 million hectares (10,000 m2) can be fumigated by fumigation planes as they are made in banana plantations in Ecuador. We can inhibit all viruses with bacteria and biological molecules to inhibit viruses. And we can give them more than 100 million liters to take for more than 100 million liters for humans to more than 100 million inhabitants of the entire province of Hubei in China, so that they do not transmit coronaviruses ... and the seriously ill can also heal They are natural antibacterial, anviral and antifungal biological molecules ... they are immune regenerating cell bioimmunmodulators and immune boosting immune response in immunocompromised people who have diabetes and high blood pressure. Others may have cytokinin and immunoglobulin problems. We can finish with the 2019-nCoV Wuhan in the environment and in humans so be found in the lungs whose epithelial cells are already collapsing with an increase in inflammation and difficulty breathing. We can beat the coronaviruses

throughout China.
Atte
Robert Vera
Graduated from the [redacted] (b) (6)
Whataspp [redacted] (b) (6)


4% 19:56
abc.es
ES NOTICIA
Real Madrid-Atlético
Antonio Resines
Coronavirus Ch
ABC SOCIEDAD

VIRUS CHINA

Los fármacos que pueden combatir el coronavirus chino

- Científicos del Instituto de Salud de Estados Unidos proponen reutilizar antivirales diseñados contra el SARS para acelerar la llegada de tratamientos. Una nueva vacuna podría estar lista en solo tres meses, dicen

N. R. C.

MADRID - Actualizado: 27/01/2020 10:02h

Enviado desde mi smartphone Samsung Galaxy.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 23:56:07 +0000
To: Jason Gale
Subject: RE: (BN) Coronavirus Lurking in Feces May Reveal Hidden Risk of Spread

Thanks, Jason.
Best regards,
Tony

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Saturday, February 1, 2020 6:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: (BN) Coronavirus Lurking in Feces May Reveal Hidden Risk of Spread

Hello Dr Fauci,
Just been watching the press conference on YouTube with you and your federal colleagues.
Thought you might find this interesting, if you have time to breathe let alone read media reports!
All the best and hope to see you at the end of next month.
Jason

Coronavirus Lurking in Feces May Reveal Hidden Risk of Spread
2020-02-01 06:55:00.469 GMT

By Jason Gale

(Bloomberg) -- While doctors have focused on respiratory samples from pneumonia cases to identify coronavirus patients, they might have ignored a less apparent and hidden source of the spread: diarrhea.

The novel coronavirus was detected in the loose stool of the first U.S. case -- a finding that hasn't featured among case reports from Wuhan, China, the epicenter of the outbreak. However, that doesn't surprise scientists who have studied coronaviruses, nor doctors familiar with the bug that caused SARS.

Diarrhea occurred in about 10-20% of patients afflicted with severe acute respiratory syndrome about 17 years ago and was the source of an explosive SARS outbreak in the Amoy Gardens residential complex in Hong Kong.

SARS and Wuhan viruses bind to the same distinctly shaped protein receptors in the body that are expressed in the lungs and intestines, making these organs the primary targets for both viruses, said Fang Li, an associate professor of veterinary and biomedical sciences at the University of Minnesota.

The discovery of the Wuhan virus, dubbed 2019-nCoV, in the fecal material of the 35-year-old man treated at the Providence

Regional Medical Center Everett in Washington is "interesting," said Scott Lindquist, the state epidemiologist for infectious disease at Washington's Department of Health.

"That adds to the knowledge about this," he told reporters on a conference call Friday. "It's not only excreted in your respiratory secretions, it's also secreted in your stool."

Read More: What You Need to Know About the Spreading Coronavirus

Researchers don't yet know how exactly 2019-nCoV spreads from person to person, but suspect it's most likely from coming into contact with virus-containing droplets that could be emitted by an infected person's cough and transferred to their hands or surfaces and objects.

Face Masks

That's led to a run on face masks. But those may be of limited benefit in the event the virus is being transmitted via the fecal-oral route, said John Nicholls, a clinical professor of pathology at the University of Hong Kong.

Squat latrines, common in China, lacking covers and hands that aren't washed thoroughly with soap and water after visiting the bathroom could be a source of virus transmission, said Nicholls, who was part of the research team that isolated and characterized the SARS virus.

A virus-laden aerosol plume emanating from a SARS patient with diarrhea was implicated in possibly hundreds of cases at Hong Kong's Amoy Gardens housing complex in 2003. That led the city's researchers to understand the importance of the virus's spread through the gastrointestinal tract, and to recognize both the limitation of face masks and importance of cleanliness and hygiene, Nicholls said in an interview.

"I think in Wuhan, that would be a very likely place where you might get the transmission" from fecal material, he said. "If it's using the same receptor as for SARS, I can't see why it shouldn't be replicating in the gut."

Nicholls and colleagues at the University of Hong Kong are testing laboratory models of human tissues and specimens to understand where and how the Wuhan virus replicates, he said.

Emerging Evidence

Doctors have reported diarrhea infrequently in 2019-nCoV patientsadmitted to Wuhan hospitals, though it's been more prominent among reported cases outside the city, including members of a Shenzhen family infected in Wuhan, and more recently in the first U.S. case in Washington state. That patient experienced a two-day bout of diarrhea from which a sample tested positive.

The lab in Washington didn't attempt to grow the virus from that specimen, said Lindquist, the state epidemiologist, "because it wasn't going to add anything to his care."

Many of the emerging coronaviruses are so-called pneumoenteric viruses, meaning they can replicate both in the respiratory tract and the gastrointestinal system, said Ralph Baric, professor of microbiology and immunology at the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill, who has studied coronaviruses for decades.

Overwhelmed by hundreds of severely sick pneumonia patients, doctors in Wuhan might not have focused on any gastric signs, Baric said in a phone interview.

'So Overwhelmed'

"The Chinese are so overwhelmed at the moment and trying to do a combination of treating patients and dealing with the scope of the outbreak, and then trying to get out papers that describe what's happening," he said.

Any virus in stool is more likely to be present during the acute phase of an infection, occuring before hospitalized patients develop a life-threatening complication known as acute respiratory distress syndrome, Baric said.

"I have also spent most of my time focusing on the respiratory tract symptomology rather than the gut because of the relationship between these different emerging viruses and acute respiratory distress syndrome," he said.

Zijian Feng, deputy director general of Chinese Center for Disease Control and Prevention, and colleagues released a report Wednesday on the first 425 Wuhan cases, and noted that early infections that didn't appear to display typical signs -- such as fever and viral pneumonia -- or had mild symptoms might have been missed.

"The initial focus of case detection was on patients with pneumonia, but we now understand that some patients can present with gastrointestinal symptoms," Feng and co-authors said in their report, which was published in the New England Journal of Medicine.

Emerging evidence of virus-containing diarrhea warrants further investigation, said Peter Collignon, a professor of clinical medicine at the Australian National University Medical School in Canberra, who advises the Australian government on infection control.

"This is something new," Collignon said in an interview.

"We presume it's respiratory droplets, but with SARS there was evidence of other routes. We have to keep an open mind."

To contact the reporter on this story:
Jason Gale in Melbourne at j.gale@bloomberg.net
To contact the editors responsible for this story:
Brian Bremner at bbremner@bloomberg.net;
Shamim Adam at sadam2@bloomberg.net

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 23:19:46 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: article from IIT/India on Coronovirus
Attachments: [redacted] (b) (4)

Please handle.

From: Hong Cai [redacted] (b) (6)
Sent: Saturday, February 1, 2020 5:33 PM
To: WRB Gmail <wrbrody@gmail.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: article from IIT/India on Coronovirus

Dear Fauci,

I knew you must be super busy with the recent Coronavirus outbreak. [redacted] (b) (4)

[redacted] (b) (4)

Thank you for your assistance in advance!

mesabiotech™

Hong Cai, Ph.D
Co-Founder and CEO
Mesa Biotech, Inc.
6190 Cornerstone Court East, Suite 220
San Diego, CA 92121
www.mesabiotech.com
[redacted] (b) (6)
[redacted] (b) (6)

From: WRB [redacted] (b) (6)
Date: Saturday, February 1, 2020 at 7:27 AM

To: "Anthony (NIH/NIAID) Fauci [E]" [redacted] (b) (6)
Cc: Hong Cai [redacted] (b) (6)
Subject: article from IIT/India on Coronovirus

Hi Tony,
I hope you are coping with the chaos around coronavirus.

I am [redacted] (b) (6) but still active, currently chair of Mesa Biotech, a [redacted] (b) (4)

[redacted] (b) (4)

No doubt you have seen, but in case not, I am sending a copy.

Hopefully someone at NIH is trying to replicate this study or to find problems with their methodology.

With best wishes,
Bill

William R. Brody
[redacted] (b) (6) Johns Hopkins University
Salk Institute for Biological Studies

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 22:06:26 +0000
To: Jeremy Farrar;Collins, Francis (NIH/OD) [E]
Subject: RE: Teleconference

Thanks, Jeremy. We really appreciate what you are doing here. Pleasure to work with you.
Best,
Tony

From: Jeremy Farrar [redacted] (b) (6)>
Sent: Saturday, February 1, 2020 4:00 PM
To: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Teleconference

We are altogether as you know! Conversations with you and Tony, and Patrick and others – always great working with you both

---

From: Francis Collins [redacted] (b) (6)>
Date: Saturday, 1 February 2020 at 20:50
To: Jeremy Farrar [redacted] (b) (6)
Cc: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: Re: Teleconference

Hi Jeremy,
I can make myself available at any time 24/7 for the call with Tedros. Just let me know.
Thanks for your leadership on this critical and sensitive issue.
Francis

Sent from my iPhone

> On Feb 1, 2020, at 3:07 PM, Jeremy Farrar [redacted] (b) (6)> wrote:
>
> I have rejoined so a line is open if any help to rejoin.
>
> ---
>
> **From:** Jeremy Farrar [redacted] (b) (6)>
> **Date:** Saturday, 1 February 2020 at 19:56
> **To:** "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6), Francis Collins [redacted] (b) (6)>, Michael FMedSci [redacted] (b) (6), Patrick Vallance [redacted] (b) (6)
> **Subject:** Re: Teleconference

Can I suggest we shut down the call and then redial in?

Just for 5-10mins?

From: Marion Koopmans [redacted] (b) (6)
Date: Saturday, 1 February 2020 at 19:43
To: Jeremy Farrar [redacted] (b) (6)>
Cc: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>, Patrick Vallance [redacted] (b) (6) "Drosten, Christian" [redacted] (b) (6) [redacted] (b) (6)>, Edward Holmes [redacted] (b) (6), [redacted] (b) (6) [redacted] (b) (6)>, "Kristian G. Andersen" [redacted] (b) (6), Paul Schreier [redacted] (b) (6) < [redacted] (b) (6) Michael FMedSci [redacted] (b) (6) Francis Collins [redacted] (b) (6)>
Subject: Re: Teleconference

[redacted] (b) (5)

On 1 Feb 2020, at 19:12, Jeremy Farrar [redacted] (b) (6)> wrote:

Kristen and Eddie have shared this and will talk through it on the call. Thank you.

Hope it will help frame the discussions.

From: Jeremy Farrar [redacted] (b) (6)>
Date: Saturday, 1 February 2020 at 15:34

1st February (2nd Feb for Eddie)
Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.
Please mute phones.
I will be on email throughout – email Paul or I Paul if any problems
If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney
8pm CET
7pm GMT
2pm EST
11am PST
(Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- Introduction, focus and desired outcomes - JF
- Summary – KA
- Comments – EH
- Q&A – All
- Summary and next steps - JF

Kristian Anderson
Bob Garry - I have not been able to contact Bob. Please forward if you can.
Christian Drosten
Tony Fauci
Mike Ferguson
Ron Fouchier
Eddie Holmes
Marion Koopmans
Stefan Pohlmann
Andrew Rambaut

Paul Schreier
Patrick Vallance

<Coronavirus sequence comparison[1].pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 22:00:47 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: FOR YOUR REVIEW: Staff Communication on Novel Coronavirus
Attachments: Draft_AllStaff_Novel_Coronavirus_2.1.2020.docx, Draft_OHR_Flexibilities_Novel_Coronavirus_2.1.2020.docx

Please handle this. Thanks

From: Myles, Renate (NIH/OD) [E] (b) (6)>
Sent: Saturday, February 1, 2020 4:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] < (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Gottesman, Michael (NIH/OD) [E] (b) (6); Johnson, Alfred (NIH/OD) [E] (b) (6)>; Berko, Julie (NIH/OD) [E] (b) (6); McGowan, Colleen (NIH/OD/ORS) [E] (b) (6); Burklow, John (NIH/OD) [E] (b) (6)>; Chandler, Beth (NIH/OD) [E] (b) (6)
Subject: FOR YOUR REVIEW: Staff Communication on Novel Coronavirus

Good afternoon, Dr. Fauci and team:

Working in coordination with OHR, ORS, OIR, and others, we have developed two communication products to address questions/concerns that are being raised by NIH staff related to the novel coronavirus. The two products are:

1. All staff email from Dr. Collins to provide general information and guidance to NIH staff
2. QA for use by Executive Officers (not for broad distribution) on human resources flexibilities in response to coronavirus

These products are provided for your review and guidance. We also plan to share with HHS for review/awareness. The current plan to disseminate these products on Monday. We look forward to your input.

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Office of Communications and Public Liaison
National Institutes of Health
Tel: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 20:03:12 +0000
To: Jeremy Farrar
Subject: RE: Teleconference

Yes

From: Jeremy Farrar [redacted] (b) (6)
Sent: Saturday, February 1, 2020 2:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Collins, Francis (NIH/OD) [E] [redacted] (b) (6); Ferguson, Mike [redacted] (b) (6); Patrick Vallance [redacted] (b) (6)
Subject: Re: Teleconference

Can I suggest we shut down the call and then redial in?

Just for 5-10mins?

From: Marion Koopmans [redacted] (b) (6)
Date: Saturday, 1 February 2020 at 19:43
To: Jeremy Farrar [redacted] (b) (6)
Cc: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6), Patrick Vallance [redacted] (b) (6)>, "Drosten, Christian" [redacted] (b) (6)>, [redacted] (b) (6) Edward Holmes [redacted] (b) (6)>, [redacted] (b) (6) "Kristian G. Andersen" [redacted] (b) (6), Paul Schreier [redacted] (b) (6) Michael FMedSci [redacted] (b) (6)>, Francis Collins [redacted] (b) (6)>
Subject: Re: Teleconference

[redacted] (b) (5)

On 1 Feb 2020, at 19:12, Jeremy Farrar <[redacted] (b) (6)> wrote:

Kristen and Eddie have shared this and will talk through it on the call. Thank you.

Hope it will help frame the discussions.

From: Jeremy Farrar [redacted] (b) (6)>
Date: Saturday, 1 February 2020 at 15:34

1st February (2nd Feb for Eddie)
Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.
Please mute phones.
I will be on email throughout – email Paul or I Paul if any problems
If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney
8pm CET
7pm GMT
2pm EST
11am PST
(Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- Introduction, focus and desired outcomes - JF
- Summary – KA
- Comments – EH
- Q&A – All
- Summary and next steps - JF

Kristian Anderson
Bob Garry - I have not been able to contact Bob. Please forward if you can.
Christian Drosten

Tony Fauci
Mike Ferguson
Ron Fouchier
Eddie Holmes
Marion Koopmans
Stefan Pohlmann
Andrew Rambaut
Paul Schreier
Patrick Vallance

<Coronavirus sequence comparison[1].pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 19:02:40 +0000
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: FW: Offering assistance during this public health emergency

Please handle.

From: Albert Rizzo [redacted] (b) (6)
Sent: Friday, January 31, 2020 5:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Harold Wimmer [redacted] (b) (6)
Subject: Offering assistance during this public health emergency

Hello Dr. Fauci:

As the coronavirus continues to be a public health emergency, the American Lung Association is closely following guidance and reports being issued by NIAID, WHO, and CDC. Our Association is working to help relay important public health information provided by the various agencies.

As Chief Medical Officer for the American Lung Association, and with the full support of our CEO, Harold Wimmer, and our Board of Directors, I would like to offer the American Lung Association support on strategies that would be appropriate for our organization to participate in or communicate.

I am happy to discuss any potential opportunities in which you feel we may be of assistance.

Sincerely,

Albert A. Rizzo MD FACP FCCP
Chief Medical Officer
American Lung Association
Cell [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 18:55:58 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Consultancy request - Coronavirus

Please handle.

From: Tatsch, Fernando Franciosi (b) (6)>
Sent: Friday, January 31, 2020 6:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Bacher, Hans P < (b) (6)>; Vallabh, Bhadrish < (b) (6)>
Subject: RE: Consultancy request - Coronavirus

Dear Dr. Fauci,

The below invitation is for a meeting identical to an advisory board.

We wonder if a short phone call could be beneficial to offer further context.

With best regards, Fernando Tatsch

FERNANDO TATSCH, MD, MBA
Therapeutic Area Head – HCV / RSV
Global Medical Affairs

2SW 102 08 | 1 N Waukegan Rd | North Chicago, IL 60064
OFFICE (b) (6) | **CELL** (b) (6) | **EMAIL** (b) (6)

abbvie.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

From: Tatsch, Fernando Franciosi
Sent: Thursday, January 30, 2020 4:53 PM
To: (b) (6)
Subject: Consultancy request - Coronavirus

Dear Dr. Fauci,

On behalf of AbbVie, I would like to explore your interest and availability for a scientific consultation.

AbbVie is interested in your scientific view of the 2019-nCoV epidemic.

Your assessment will be very informative for us in the context of (b) (4)
.

If you are interested, we will need a brief CV in order to elaborate a consultation contract.

Once the contract is executed, we would like to invite you for a phone conference which will include few medical AbbVie colleagues.

Looking forward to hearing from you.

With best regards, Fernando Tatsch

FERNANDO TATSCH, MD, MBA
Therapeutic Area Head – HCV / RSV
Global Medical Affairs

2SW 102 08 | 1 N Waukegan Rd | North Chicago, IL 60064
OFFICE + (b) (6) | **CELL** - (b) (6) | **EMAIL** (b) (6)

abbvie.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 18:50:25 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: 60 Minutes / Coronavirus

If we can fit this in next week depending on what is hitting the fan, I will do it.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, January 31, 2020 7:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Fwd: 60 Minutes / Coronavirus

Pls advise

Sent from my iPhone

Begin forwarded message:

> **From:** "Stover, Kathy (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Date:** January 31, 2020 at 7:52:16 PM EST
> **To:** "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>
> **Cc:** "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)>, "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)
> **Subject: Fwd: 60 Minutes / Coronavirus**
>
> Hi Patty,
> See below. Would Dr. Fauci want to meet with this 60 Mins producer, or shall I suggest an alternative? Note, this isn't for on-camera—-it's background for a potential story.
>
> Sent from my iPhone
>
> Begin forwarded message:
>
>> **From:** "Lieberman, Marc E." <MLP@cbsnews.com>
>> **Date:** January 31, 2020 at 5:57:24 PM EST
>> **To:** [redacted] (b) (6)
>> [redacted]
>> **Subject: 60 Minutes / Coronavirus**
>>
>> Hi, I am a producer at 60 Minutes researching a possible story about the coronavirus outbreak. The effort to find a vaccine strikes me as interesting and I wonder if we might be to chat about it. I am going to be in the DC area next week. Would you have time for a brief meeting either Wednesday morning or Tuesday? Thanks in advance for your help.
>>
>> Best,

Marc Lieberman

Marc Lieberman | Producer | 60 Minutes | w: 212-975-6385 c: (b)(6) |
mlp@cbsnews.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 18:45:22 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: ASF: Dan Chertow invitation

No problem with Dan doing this.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, January 31, 2020 10:05 PM
To: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6) Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6) Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: ASF: Dan Chertow invitation

Agree with Courtney

Dan is a good speaker and would represent nih well

From: Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, January 31, 2020 9:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6) Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: ASF: Dan Chertow invitation

Dan Chertow has been asked to speak at this event, which has some rather high profile participants and media attendance. He would like to do it.

NIH is asking if NIAID is ok with him doing this. [redacted] (b) (5) Do you agree?

From: "Cohen, Justin (NIH/CC/OD) [E]" [redacted] (b) (6)>
Date: Friday, January 31, 2020 at 4:43:08 PM
To: "Myles, Renate (NIH/OD) [E]" [redacted] (b) (6), "Fine, Amanda (NIH/OD) [E]" [redacted] (b) (6)>, "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)>, "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6)
Cc: "Burklow, John (NIH/OD) [E]" [redacted] (b) (6), "Wojtowicz, Emma (NIH/OD) [E]"

[redacted] (b) (6), "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>
Subject: FW: coronavirus speaking opportunity

Obviously given the current environment (not to mention some of the names involved in the event), I want to make sure I'm in lockstep with you all from square one. How would you like me to proceed with the request below? The event is open to the public / press.

From: Chertow, Daniel (NIH/CC/CCMD) [E] [redacted] (b) (6)>
Sent: Thursday, January 30, 2020 6:16 PM
To: Cohen, Justin (NIH/CC/OD) [E] [redacted] (b) (6)>; Freimuth, Molly (NIH/CC/OC) [E] [redacted] (b) (6)>
Cc: Suffredini, Anthony (NIH/CC/CCMD) [E] [redacted] (b) (6)>; Masur, Henry (NIH/CC/CCMD) [E] [redacted] (b) (6)
Subject: FW: Hudson Institute speaking request

Dear Justin,

I am checking back in with you regarding the below invitation to speak.

I would like to participate in this if possible.

Please confirm that you have received my email.

Thank you.

Sincerely,

Dan

From: "Asha M. George" <asha.george@biodefensecommission.org>
Date: Thursday, January 30, 2020 at 6:09 PM
To: "Chertow, Daniel (NIH/CC/CCMD) [E]" [redacted] (b) (6)>
Subject: Re: Hudson Institute speaking request

Dear Dan,
Sorry, we have changed something slightly. Instead of taking questions directly from the audience, we will obtain questions from the audience via email while the first part of the event occurs, curate them, and then have them available for Senator Lieberman to ask them of the speakers.
Asha

Asha M. George, DrPH
Executive Director

BIPARTISAN COMMISSION ON BIODEFENSE

202.974.2416

biodefensecommission.org

LinkedIn | Twitter | Facebook | Instagram

BIPARTISAN COMMISSION ON BIODEFENSE

Beyond the blueprint

From: Asha M. George <asha.george@biodefensecommission.org>
Sent: Thursday, January 30, 2020 6:02 PM
To: Chertow, Daniel (NIH/CC/CCMD) [E] [redacted] (b) (6)
Subject: Re: Hudson Institute speaking request

Dear Dan,
Here are some more specifics regarding the event we will holding at Hudson Institute on novel coronavirus. The meeting will be on February 10th, from 2:00 - 3:30 pm in the Stern Conference Center at Hudson Institute, which is located at 1201 Pennsylvania Avenue, NW, 4th floor, Washington, DC 20004.

We also have the executive conference room reserved from 1:30 pm on. Please plan to arrive around then, so that you can talk with Senator Lieberman and the other speakers before the event starts at 2:00 pm. Just ask the receptionist to direct you where to go.

Here are the speakers:

- Former Senator Joe Lieberman, co-chair, Bipartisan Commission on Biodefense
- Dr. Julie Gerberding, Executive Vice President & Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health, Merck; former Director, Centers for Disease Control and Prevention
- Dr. Billy Karesh, ex officio, Bipartisan Commission on Biodefense; Executive VP, EcoHealth Alliance
- The Honorable Tim Morrison, Senior Fellow, Hudson Institute; former Deputy Assistant to President Trump for National Security; former Special Assistant to the President and Senior Director for Weapons of Mass Destruction and Biodefense
- Mr. Eric Brown, Senior Fellow, Hudson Institute

- Dr. Daniel S. Chertow (CAPT - US Public Health Service), Head, Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center & Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health *(invited)*

The setting will be relatively informal. Scooter Libby will first introduce Senator Lieberman. Then Senator Lieberman will make a short opening statement, and look to Billy to set the stage and talk about the zoonotic nature of the disease, associated disease management considerations, etc., in about 5 minutes. The Senator will then ask each of the other speakers to say a few words from their perspectives. After that, Senator Lieberman will ask some questions of the group, allowing you all to answer and converse. All of this should take about 45 minutes. Then we will allow the audience to ask questions.

We are planning for Senator Lieberman to moderate the discussion and take questions from the audience, but if for some reason he cannot do so, then Billy Karesh will.

I hope you will be able to make it, Dan. Let me know if you have any questions (and if you will be able to make it, of course) and I look forward to seeing you on February 10th.

Asha

Asha M. George, DrPH
Executive Director

BIPARTISAN COMMISSION ON BIODEFENSE

202.974.2416

biodefensecommission.org

LinkedIn | Twitter | Facebook | Instagram

BIPARTISAN COMMISSION ON BIODEFENSE

Beyond the blueprint

From: Chertow, Daniel (NIH/CC/CCMD) [E] (b) (6)>
Sent: Tuesday, January 28, 2020 7:18 PM
To: Asha M. George <asha.george@biodefensecommission.org>
Subject: Re: Hudson Institute speaking request

Dear Asha,

Given that this is a public/press event, I will require additional clearance from my organization in order to participate.

I will reach out to them now and get back to you.

Thank you.

Dan

From: "Asha M. George" <asha.george@biodefensecommission.org>
Date: Tuesday, January 28, 2020 at 7:15 PM
To: "Chertow, Daniel (NIH/CC/CCMD) [E]" (b) (6)>
Subject: Re: Hudson Institute speaking request

Dear Dan,
Thank you! The meeting will be held on February 10th. We are still trying to nail down a time with Senator Lieberman and Governor Ridge, so I will get back to you about that as soon as possible, hopefully tomorrow.

The meeting will be open to the public and to the press, but Hudson Institute is a think tank, so it's never a negative or rowdy crowd.

Asha

Asha M. George, DrPH
Executive Director

BIPARTISAN COMMISSION ON BIODEFENSE

202.974.2416

biodefensecommission.org

LinkedIn | Twitter | Facebook | Instagram

BIPARTISAN
COMMISSION
ON BIODEFENSE
Beyond the blueprint

From: Chertow, Daniel (NIH/CC/CCMD) [E] [redacted] (b) (6)
Sent: Tuesday, January 28, 2020 5:53 PM
To: Asha M. George <asha.george@biodefensecommission.org>
Subject: Re: Hudson Institute speaking request

Dear Asha,

I am available Feb 10th or 13th and would be happy to present to the group.

Please clarify who will be in attendance and if the event is open or closed to press/public as this would require additional clearance on my end.

Thank you.

Sincerely,

Dan

Daniel S. Chertow, MD, MPH, FCCM, FIDSA
CAPT, United States Public Health Service
Head, Emerging Pathogens Section
Critical Care Medicine Department, NIH Clinical Center &
Laboratory of Immunoregulation, NIAID

From: "Asha M. George" <asha.george@biodefensecommission.org>
Date: Monday, January 27, 2020 at 6:09 PM

To: "Chertow, Daniel (NIH/CC/CCMD) [E]" <[redacted] (b) (6)
Subject: Hudson Institute speaking request

Dear Dr. Chertow,
I am the Executive Director of the Bipartisan Commission on Biodefense, co-chaired by former Senator Joe Lieberman and Governor Tom Ridge. Our fiscal sponsor is Hudson Institute, one of the think tanks here in DC. Hudson Institute's chair of the board of trustees (Sarah May Stern) has asked Hudson Institute to run a 90 minute meeting on the novel coronavirus situation. Hudson has asked us to help them pull a brief meeting together in short order.

Considering your experience on the ground dealing with other outbreaks, Hudson Institute invites you to speak at this event. In addition to one of Hudson Institute's China experts, we are also seeing whether Senator Lieberman and Governor Ridge are available to speak.

Here are the dates they are a looking at: February 6, February 10, and February 13. Could you let me know if you are available and if so, when on those dates?

Thank you for your consideration, Dan. I look forward to hearing from you soon.

Asha

Asha M. George, DrPH
Executive Director

BIPARTISAN COMMISSION ON BIODEFENSE

202.974.2416

biodefensecommission.org

LinkedIn | Twitter | Facebook | Instagram

BIPARTISAN
COMMISSION
ON BIODEFENSE

Beyond the blueprint

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 18:43:31 +0000
To: Kristian G. Andersen
Subject: RE: FW: Science: Mining coronavirus genomes for clues to the outbreak's origins

Thanks, Kristian. Talk soon on the call.

From: Kristian G. Andersen [redacted] (b) (6)>
Sent: Friday, January 31, 2020 10:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Jeremy Farrar [redacted] (b) (6)>
Subject: Re: FW: Science: Mining coronavirus genomes for clues to the outbreak's origins

Hi Tony,

Thanks for sharing. Yes, I saw this earlier today and both Eddie and myself are actually quoted in it. It's a great article, but the problem is that our phylogenetic analyses aren't able to answer whether the sequences are unusual at individual residues, except if they are completely off. On a phylogenetic tree the virus looks totally normal and the close clustering with bats suggest that bats serve as the reservoir. The unusual features of the virus make up a really small part of the genome (<0.1%) so one has to look really closely at all the sequences to see that some of the features (potentially) look engineered.

We have a good team lined up to look very critically at this, so we should know much more at the end of the weekend. I should mention that after discussions earlier today, Eddie, Bob, Mike, and myself all find the genome inconsistent with expectations from evolutionary theory. But we have to look at this much more closely and there are still further analyses to be done, so those opinions could still change.

Best,
Kristian

On Fri, Jan 31, 2020 at 18:47 Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:

> Jeremy/Kristian:
> This just came out today. You may have seen it. If not, it is of interest to the current discussion.
> Best,
> Tony
>
> ---
>
> **From:** Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
> **Sent:** Friday, January 31, 2020 8:43 PM
> **Subject:** Science: Mining coronavirus genomes for clues to the outbreak's origins

As part of a long-running effort to see what viruses bats harbor, researchers in China collect one from a cave in Guandong.
EcoHealth Alliance

Mining coronavirus genomes for clues to the outbreak's origins

By Jon CohenJan. 31, 2020 , 6:20 PM

attaaaggtt tataccttcc caggtaacaa accaaccaac tttcgatctc ttgtagatct ...

That string of apparent gibberish is anything but: It's a snippet of a DNA sequence from the viral pathogen, dubbed 2019 novel coronavirus (2019-nCoV), that is overwhelming China and frightening the entire world. Scientists are publicly sharing an ever-growing number of full sequences of the virus from patients—53 at last count in the Global Initiative on Sharing All Influenza Data database. These viral genomes are being intensely studied to try to understand the origin of 2019-nCoV and how it fits on the family tree of related viruses found in bats and other species. They have also given glimpses into what this newly discovered virus physically looks like, how it's changing, and how it might be stopped.

"One of the biggest takeaway messages [from the viral sequences] is that there was a single introduction into humans and then human-to-human spread," says Trevor Bedford, a bioinformatics specialist at the University of Washington, Seattle. The role of Huanan Seafood Wholesale Market in Wuhan, China, in spreading 2019-nCoV remains murky, though such sequencing, combined with sampling the market's environment for the presence of the virus, is clarifying that it indeed had an important early role in amplifying the outbreak. The viral sequences, most researchers say, also knock down the idea the pathogen came from a virology institute in Wuhan.

In all, 2019-nCoV has nearly 29,000 nucleotides bases that hold the genetic instruction book to produce the virus. Although it's one of the many viruses whose genes are in the form of RNA, scientists convert the viral genome into DNA, with bases known in shorthand as A, T, C, and G, to make it easier to study. Many analyses of 2019-nCoV's sequences have already appeared on virological.org, nextstrain.org, preprint servers like bioRxiv, and even in peer-reviewed journals. The sharing of the sequences by Chinese researchers allowed public health labs around the world to develop their own diagnostics for the virus, which now has been found in 18 other countries. (*Science*'s news stories on the outbreak can be found here.)

When the first 2019-nCoV sequence became available, researchers placed it on a family tree of known coronaviruses—which are abundant and infect many species—and found that it was most closely related to relatives found in bats. A team led by Shi Zheng-Li, a coronavirus specialist at the Wuhan Institute of Virology, reported on 23 January on bioRxiv that 2019-nCoV's sequence was 96.2% similar to a bat virus and had 79.5% similarity to the coronavirus that causes severe acute respiratory syndrome (SARS), a disease whose initial outbreak was also in China more than 15 years ago. But the SARS coronavirus has a similarly close relationship to bat viruses, and sequence data make a powerful case that it jumped into people from a coronavirus in civets that differed from human SARS viruses by as few as 10 nucleotides. That's one reason why many scientists suspect there's an "intermediary" host species—or several—between bats and 2019-nCoV.

According to Bedford's analysis, the bat coronavirus sequence that Shi Zheng-Li's team highlighted, dubbed RaTG13, differs from 2019-nCoV by nearly 1100 nucleotides. On nextstrain.org, a site he co-founded, Bedford has created coronavirus family trees (example below) that include bat, civet, SARS, and 2019-nCoV sequences. (The trees are interactive—by dragging a computer mouse over them, it's easy to see the differences and similarities between the sequences.)


Phylogeny
virus type
SARS-related coronavirus
novel coronavirus
RESET LAYOUT
TW5
TW10
TW9
TW3
Sino3_11
ZJ0301
HKU_39849
TW4
Sin850
BJ02
GZ0402
GZ0401
HC/GZ/32/03
civet020
PC4_227
PC4_13
civet007
SZ3
SARS
Rs4874
Rs4231
Rs4084
RsSHC014
WIV1
Rs3367
Rs9401
Rs7327
Rs4255
Rs4081
Rs672
Rs4247
Rs4237
As6526
Rf4092
YNLF_31C
YNLF_34C
LYRa11
HKU3_9
HKU3_6
HKU3_2
HKU3_3
HKU3_7
BetaCoV/Wuhan/WIV
BetaCoV/Wuhan/IVDC
BetaCoV/Wuhan/IVDC
BetaCoV/Wuhan/IPBC
WH-Human_1
BetaCoV/bat/Yunnan/
nCoV
bat_SL_CoVZXC21
bat_SL_CoVZC45
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16

Bedford's analyses of RaTG13 and 2019-nCoV suggest that the two viruses shared a common ancestor 25 to 65 years ago, an estimate he arrived at by combining the difference in nucleotides between the viruses with the presumed rates of mutation in other coronaviruses. So it likely took decades for RaTG13-like viruses to mutate into 2019-nCoV.

Middle East respiratory syndrome (MERS), another human disease caused by a coronavirus, similarly has a link to bat viruses. But studies have built a compelling case it jumped to humans from camels. And the phylogenetic tree from Shi's bioRxiv paper (below) makes the camel-MERS link easy to see.


TGEV
Mink CoV
Ferret CoV
Bat CoV CDPHE15
Scotophilus bat CoV 512
PEDV
Bat CoV HKU10
Miniopterus bat CoV 1
Miniopterus bat CoV HKU8
Human CoV NL63
Bat NL63-related CoV
Human CoV 229E
SADS-CoV
Rhinolophus bat CoV HKU2
Human CoV OC43
Murine hepatitis virus
Rat CoV HKU24
Human CoV HKU1
Human MERS-CoV
Camel MERS-CoV
Pipistrellus bat CoV HKU5
Tylonycteris Bat CoV HKU4
Hedgehog CoV
SARS-CoV BJ01
Civet SARS-CoV SZ3
Bat SARSr-CoV WIV1
Bat SARSr-CoV SHC014
Bat SARSr-CoV LYRa11
Bat SARSr-CoV Rf1
Bat SARSr-CoV ZC45
Bat SARSr-CoV HKU3-1
Bat SARSr-CoV BM48-31
BetaCoV/Wuhan/WIV05/2019
BetaCoV/Wuhan/WIV02/2019
BetaCoV/Wuhan/WIV04/2019
BetaCoV/Wuhan/WIV06/2019
BetaCoV/Wuhan/WIV07/2019
Bat CoV RaTG13
Bat Hp BetaCoV Zhejiang 2013
Rousettus bat CoV HKU9
Bat CoV GCCDC1
IBV
0.1
100
100
100
98
84
99
86
100
100
100
100
100
55
100
100
100
96
96
100
100
100
100
100
100
90
83
100
97
100
100
100
100
97
100

The longer a virus circulates in a human populations, the more time it has to develop mutations that differentiate strains in infected people, and given that the 2019-nCoV sequences analyzed to date differ from each other by seven nucleotides at most, this suggests it jumped into humans very recently. But it remains a mystery which animal spread the virus to humans. "There's a very large gray area between viruses detected in bats and the virus now isolated in humans," says Vincent Munster, a virologist at the U.S. National Institute of Allergy and Infectious Diseases who studies coronaviruses in bats, camels, and others species.

Strong evidence suggests the marketplace played an early role in spreading 2019-nCoV, but whether it was the origin of the outbreak remains uncertain. Many of the initially confirmed 2019-nCoV cases—27 of the first 41 in one report, 26 of 47 in another—were connected to the Wuhan market, but up to 45%, including the earliest handful, were not. This raises the possibility that the initial jump into people happened elsewhere.

According to Xinhua, the state-run news agency, "environmental sampling" of the Wuhan seafood market has found evidence of 2019-nCoV. Of the 585 samples tested, 33 were positive for 2019-nCoV and all were in the huge market's western portion, which is where wildlife were sold. "The positive tests from the wet market are hugely important," says Edward Holmes, an evolutionary biologist at the University of Sydney who collaborated with the first group to publicly release a 2019-nCoV sequence. "Such a high rate of positive tests would strongly imply that animals in the market played a key role in the emergence of the virus."

Yet there have been no preprints or official scientific reports on the sampling, so it's not clear which, if any, animals tested positive. "Until you consistently isolate the virus out of a single species, it's really, really difficult to try and determine what the natural host is," says Kristian Andersen, an evolutionary biologist at Scripps Research.

One possible explanation for the confusion about where the virus first entered humans is if there was a batch of recently infected animals sold at different marketplaces. Or an infected animal trader could have transmitted the virus to different people at different markets. Or, Bedford suggests, those early cases could have been infected by viruses that didn't easily transmit and sputtered out. "It would be hugely helpful to have just a sequence or two from the marketplace [environmental sampling] that could illuminate how many zoonoses occurred and when they occurred," Bedford says.

A research group sent fecal and other bodily samples from bats they trapped in caves to the Wuhan Institute of Virology to search for coronaviruses.

EcoHealth Alliance

In the absence of clear conclusions about the outbreak's origin, theories thrive, and some have been scientifically shaky. A sequence analysis led by Wei Ji of Peking University and published online by the *Journal of Medical Virology* received substantial press coverage when it suggested that "snake is the most probable wildlife animal reservoir for the 2019-nCoV." Sequence specialists, however, pilloried it.

Conspiracy theories also abound. A CBC News report about the Canadian government deporting Chinese scientists who worked in a Winnipeg lab that studies dangerous pathogens was distorted on social media to suggest that they were spies who had smuggled out coronaviruses. The Wuhan Institute of Virology, which is the premier lab in China that studies bat and human coronaviruses, has also come under fire. "Experts debunk fringe theory linking China's coronavirus to weapons research," read a headline on a story in *The Washington Post* that focused on the facility.

Concerns about the institute predate this outbreak. *Nature* ran a story in 2017 about it building a new biosafety level 4 lab and included molecular biologist Richard Ebright of Rutgers University, Piscataway, expressing concerns about accidental infections, which he noted repeatedly happened with lab workers handling SARS in Beijing. Ebright, who has a long history of raising red flags about studies with dangerous pathogens, also in 2015 criticized an experiment in which modifications were made to a SARS-like virus circulating in Chinese bats to see whether it had the potential to cause disease in humans. Earlier this week, Ebright questioned the accuracy of Bedford's calculation that there are at least 25 years of evolutionary distance between RaTG13—the virus held in the Wuhan virology institute—and 2019-nCoV, arguing that the mutation rate may have been different as it passed through different hosts before humans. Ebright tells *Science*Insider that the 2019-nCoV data are "consistent with entry into the human population as a natural accident."

Shi did not reply to emails from *Science*, but her longtime collaborator, disease ecologist Peter Daszak of the EcoHealth Alliance, dismissed Ebright's conjecture. "Every time there's an emerging disease, a new virus, the same story comes out: This is a spillover or the release of an agent or a bioengineered virus," Daszak says. "It's just a shame. It seems humans can't resist controversy and these myths, yet it's staring us right in the face. There's this incredible diversity of viruses in wildlife and we've just scratched the surface. Within that diversity, there will be some that can infect people and within that group will be some that cause illness."

A team of researchers from the Wuhan Institute of Virology and the EcoHealth Alliance have trapped bats in caves all over China, like this one in Guangdong, to sample them for coronaviruses.
EcoHealth Alliance

Daszak and Shi's group have for 8 years been trapping bats in caves around China to sample their feces and blood for viruses. He says they have sampled more than 10,000 bats and 2000 other species. They have found some 500 novel coronaviruses, about 50 of which fall relatively close to the SARS virus on the family tree, including RaTG13—it was fished out of a bat fecal sample they collected in 2013 from a cave in Moglang in Yunnan province. "We cannot assume that just because this virus from Yunnan has high sequence identity with the new one that that's the origin," Daszak says, noting that only a tiny fraction of coronaviruses that infect bats have been discovered. "I expect that once we've sampled and sampled and sampled across southern China and central China that we're going to find many other viruses and some of them will be closer [to 2019-nCoV]."

It's not just a "curious interest" to figure out what sparked the current outbreak, Daszak says. "If we don't find the origin, it could still be a raging infection at a farm somewhere, and once this outbreak dies, there could be a continued spillover that's really hard to stop. But the jury is still out on what the real origins of this are."

Posted in:

- Asia/Pacific

- Health
- Coronavirus

doi:10.1126/science.abb1256

Jon Cohen

Jon is a staff writer for *Science*.

- Email Jon
- Twitter

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 18:39:50 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Possible cure medically to the new coronavirus,corona virus,from wuhan china.
Attachments: medicalcure.docx

NIAID inquiries, please

From: andrew igla [redacted] (b) (6)>
Sent: Saturday, February 1, 2020 2:22 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fw: Possible cure medically to the new coronavirus,corona virus,from wuhan china.

read this email.

From: andrew igla [redacted] (b) (6)
Sent: Tuesday, 28 January 2020 6:36 PM
To: secretary@hhs.gov <secretary@hhs.gov>
Subject: Fw: Possible cure medically to the new coronavirus,corona virus,from wuhan china.

From: andrew igla [redacted] (b) (6)>
Sent: Sunday, 26 January 2020 9:10 PM
To: secretary@hhs.gov <secretary@hhs.gov>
Subject: Possible cure medically to the new coronavirus,corona virus,from wuhan china.

For secretary Azar this email.

From: andrew igla [redacted] (b) (6)>
Sent: Sunday, 26 January 2020 8:59 PM
To: secretary@HHS.gov <secretary@HHS.gov>
Subject: Possible cure medically to the new coronavirus,corona virus,from wuhan china.

From: andrew igla (b) (6)
Sent: Sunday, 26 January 2020 1:25

This email is to be sent to the doctors treating medically patients in hospitals involving the new coronavirus,corona virus, from wuhan china.This email contains the possible medical cure to the new coronavirus,corona virus,from wuhan china.URGENT.Discovered from an australian friend of the american people,andrew igla.

This email is about orally taking zovirax and ciproxin together for one day.

Orally taking ciproxin,inhibiting gyrase,orally taking zovirax,inhibiting viral DNA polymerase, together at the same time, stops viral dna moving medically curing viruses in host cells stoping duplicating viral infected cells and stoping a virus invading new uninfected cells.

Attached document contains possible medical cure to new corona virus from wuhan in china to help you win over this virus.

Dear professor and politican,

My name is andrew igla and work as a research science person in dengue virus and anaconda sea snake virus.
Attached is a business document for you.
Thanks ,
Andrew igla. melbourne australia.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 18:35:10 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: 2019-nCoV
Attachments: Aminopeptidase N inhibitors and Coronaviruses-LANCET 2003.pdf

Please handle.

From: Kontoyiannis,Dimitrios P [redacted] (b) (6)>
Sent: Saturday, February 1, 2020 1:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: 2019-nCoV

Dear Dr Fauci, I enjoyed your recent editorial in JAMA re Coronaviruses
Although the viral disease is not an area of my expertise, you might want to take a look at a hypothesis we had proposed, long ago (back in the era of SARS), re the potential of immune-modulating Coronavirus infection natural history with blockage of aminopeptidase N.
I am not aware of any studies whether aminopeptidase is a receptor of China 2019-nCoV, though.
Sincerely
DPK

Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM, FAAAS
Texas 4000 Distinguished Endowed Professor For Cancer Research
Deputy Head, Division of Internal Medicine
The University of Texas MD Anderson Cancer Center

ECMM Diamond Excellence in Mycology Center/www.ecmm.info

Adj Professor Baylor College of Medicine
Adj Professor UT School of Public Health
Adj Professor University of Houston

The information contained in this e-mail message may be privileged, confidential, and/or protected from disclosure. This e-mail message may contain protected health information (PHI); dissemination of PHI should comply with applicable federal and state laws. If you are not the intended recipient, or an authorized representative of the intended recipient, any further review, disclosure, use, dissemination, distribution, or copying of this message or any attachment (or the information contained therein) is strictly prohibited. If you think that you have received this e-mail message in error, please notify the sender by return e-mail and delete all references to it and its contents from your systems.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 18:34:43 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: FW: Teleconference
Attachments: Coronavirus sequence comparison[1].pdf

FYI

From: Jeremy Farrar (b) (6)>
Sent: Saturday, February 1, 2020 1:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Patrick Vallance (b) (6)
Cc: Drosten, Christian (b) (6); Marion Koopmans (b) (6)>; R.A.M. Fouchier (b) (6); Edward Holmes (b) (6) Andrew Rambaut (b) (6) Kristian G. Andersen (b) (6); Paul Schreier (b) (6); (b) (6); Ferguson, Mike (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Re: Teleconference

Kristen and Eddie have shared this and will talk through it on the call. Thank you.

Hope it will help frame the discussions.

From: Jeremy Farrar (b) (6)
Date: Saturday, 1 February 2020 at 15:34

1st February (2nd Feb for Eddie)
Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.
Please mute phones.
I will be on email throughout – email Paul or I Paul if any problems
If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney
8pm CET

7pm GMT
2pm EST
11am PST
(Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- Introduction, focus and desired outcomes - JF
- Summary – KA
- Comments – EH
- Q&A – All
- Summary and next steps - JF

Kristian Anderson
Bob Garry - I have not been able to contact Bob. Please forward if you can.
Christian Drosten
Tony Fauci
Mike Ferguson
Ron Fouchier
Eddie Holmes
Marion Koopmans
Stefan Pohlmann
Andrew Rambaut
Paul Schreier
Patrick Vallance

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 18:23:07 +0000
To: Kay Johnson
Subject: RE: thank you for continuing leadership

Kay:
Thank you for your kind note. Much appreciated.
Best regards,
Tony

From: Kay Johnson [redacted] (b) (6)
Sent: Saturday, February 1, 2020 9:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: thank you for continuing leadership

Dear Dr. Fauci - We met long ago when I was a young health policy staff person at the Children's Defense Fund and you gave a talk on HIV/AIDS at the annual CDF conference around 1984-86.

When I served on the National Vaccine Advisory Committee (NVAC) during the 1990-91 measles epidemic and helped to write the measles whitepaper, I had other occasions to hear your insights.

Since that time, I have frequently heard you on the PBS NewsHour and NPR, I see your perspectives in JAMA and other journals. (For example, this week I heard NPR piece and read JAMA opinion piece on coronavirus.) In every instance, I am struck again by how clearly you articulate the science, the issues for public concern, and options for our nation's response.

While I've worked with many public health leaders and watched others in the media over the past 35 years of my Maternal and Child Health public policy career, I believe no one is better at communications than you. It is in some ways a thankless job. I am writing to say that your continuing leadership and dedication to our nation's health is deeply appreciated by me and millions of others.

Best regards, Kay

Kay Johnson
President, Johnson Group Consulting, Inc.

voice: [redacted] (b) (6)
fax: 802-482-3008
Email: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 17:56:42 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: article from IIT/India on Coronovirus
Attachments: 20200130.2019-nCOV sequence paper.927871v1.full.pdf

Please handle.

From: WRB Gmail <[redacted] (b) (6)>
Sent: Saturday, February 1, 2020 10:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Hong Cai [redacted] (b) (6)
Subject: article from IIT/India on Coronovirus

Hi Tony,
I hope you are coping with the chaos around coronavirus.

I am [redacted] (b) (6) but still active, currently chair of Mesa Biotech, [redacted] (b) (4)
[redacted] (b) (4)

No doubt you have seen, but in case not, I am sending a copy.

Hopefully someone at NIH is trying to replicate this study or to find problems with their methodology.

With best wishes,
Bill

William R. Brody
[redacted] (b) (6) Johns Hopkins University
Salk Institute for Biological Studies

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 17:54:38 +0000
To: Greg Folkers (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: POLITICO: New FDA chief plans for 'the most serious scenarios' of coronavirus outbreak

We should make a similar slide for upcoming talks.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Saturday, February 1, 2020 10:44 AM
Subject: POLITICO: New FDA chief plans for 'the most serious scenarios' of coronavirus outbreak

EXCLUSIVE

New FDA chief plans for 'the most serious scenarios' of coronavirus outbreak

CBD, drug prices, safety — plus Wuhan coronavirus — make for a crowded agenda for Stephen Hahn.

The FDA for years has mostly stayed out of the debate around drug prices | Jacquelyn Martin, File/AP Photo

By SARAH OWERMOHLE and SARAH KARLIN-SMITH

01/31/2020 04:54 PM EST

Updated: 01/31/2020 05:28 PM EST

New FDA commissioner Stephen Hahn faced a jam-packed agenda: opioids, CBD, vaping, and how to let states safely import drugs. Then the Wuhan coronavirus broke out.

The virus was declared a public health emergency by HHS just a few hours after Hahn's exclusive interview with POLITICO Friday. That kicks the agency into overdrive in multiple roles — helping speed vaccine, drug and diagnostic test development while also trying to avoid shortages of drugs and devices the United States needs that are made in China.

Advertisement

Hahn said there have not been any reports yet of disruption of the supply chain or shortages, but the agency is looking ahead and planning for "what could potentially be the most serious of scenarios." As of now FDA inspections in China are being conducted on a case-by-case basis.

"We are taking on an individual-by-individual basis what's the regulatory need for anything in China ... versus what are the personnel risks associated," he said.

Monitoring the the situation in China could soon get trickier as the State Department expands mandatory evacuation from affected areas of the country.

The coronavirus also broke out in an election year when President Donald Trump wants to deliver on his promise to bring down drug prices — not traditionally the province of the FDA, a regulatory agency designed to focus on safety and efficacy.

"If my patients couldn't get access to something because of cost — that was a real problem for me as a doctor. Now I'm on the other end of that, but what can we do to make sure that that pipeline flows in the best way possible?" said Hahn, 60, an oncologist, researcher and Washington newcomer.

Hahn was confirmed as commissioner on Dec. 18, the night before the administration announced its plan to let states import cheaper medicines from Canada — an approach that prior FDA commissioners opposed over fears it would jeopardize the safety of the drug supply. Trump has endorsed letting states such as Florida do this.



WHO declares global health emergency

The novel coronavirus that first infected people in Wuhan, China, has spread to more than 20 other countries, with Russia and the U.K. reporting their first cases of the viral pneumonia on Jan. 31.

2019-nCoV *is a coronavirus, a type of virus similar to the common cold, SARS and MERS. It is spread by close contact with people who are infected. One study suggests men might be more susceptible to the virus than women.*

Cases confirmed by WHO

AS OF JAN. 31

Jan. 20
21
23
24
25
26
27
28
29
30
31
282
314
581
846
1,320
2,014
2,798
4,593
6,065
7,818
9,826
Confirmed deaths
6
6
17
25
41
56
80
106
132
170
213

Sources: WHO, South China Morning Post, news reports

By Patterson Clark, POLITICO Pro DataPoint

Patterson Clark/POLITICO Pro DataPoint

"There is a compelling reason that the American people want us to consider this and so we're going to have to figure this one out and balance both of those issues," Hahn said, referring to safety and affordability.

The FDA for years has mostly stayed out of the debate around drug prices; the agency doesn't regulate the cost of medicines or health insurance coverage. But Hahn talked up FDA's role in getting prices down by approving more generics, acknowledging that "the American people are expecting us to do more." Trump has touted the FDA's record on boosting competition via generic approvals.

As FDA works on finalizing the importation rule, Hahn said the agency will be open to addressing criticism that states can't save money bringing in drugs from Canada if the pathway is too burdensome. But he stressed safety is tantamount. "Our primary concern is the protection of the drug supply," he said.

Hahn said he has also talked with CMS Administrator Seema Verma about addressing costs of new brand-name products that are approved with limited data sets, similar to the way CMS decides to cover some medical devices. That approach — known as coverage with evidence development — lets CMS cover a new product on the condition that manufacturers keep providing data.

FDA has not done that, but new medicines are increasingly being approved on smaller clinical trials without hard data on clinical benefits — and can come with six-figure price tags.

As an academic, Hahn had co-written an editorial suggesting that payments for newly approved radiation oncology devices could be linked to older products until enough evidence builds up to show that the new products are superior. Only then would manufacturers have more pricing leeway.

"It's a CMS call about coverage with evidence development, but I do think in this world where we are concerned, and rightfully so, about the cost of medicine and health et cetera, that we should be looking at all avenues to approach that," he told POLITICO.

Over the last few years, some critics have said the FDA is overcorrecting and moving too quickly to approve drugs without adequate evidence. But Hahn did not indicate he would put the brakes on.

"At the end of the day there is this balance between the gold standard and being efficient and getting things in people's hands I'm totally confident in the agency's ability to do that."

Hahn must balance all that while leading the FDA's response to the Wuhan crisis, which has heightened some lawmakers' concern about U.S. reliance on Chinese drug manufacturing after incidents of contamination with carcinogens.

"We have to be concerned about the supply chain to make sure that we have enough of what we need if there are any potential outbreaks here," Rep. Susan Brooks (R-Ind.) said after a closed-door briefing Thursday for Energy and Commerce committee members with top health officials. The fact that China manufactures much of the protective medical gear used in U.S. hospitals and clinics "should cause us to be reexamining what we're doing in China versus what should be brought back to this country." she said.

Outside of the coronavirus, a host of thorny regulatory issues await Hahn. Industry and lawmakers have pressed for a clear FDA framework on selling cannabidiol, the popular hemp and marijuana byproduct decriminalized by the 2018 farm bill — and since sold as medicine, dietary supplements and infused in food, cosmetics and skincare products.

"You cannot walk down the street without seeing the products" but there is a dearth of solid data on how safe and effective CBD actually is, said Hahn.

Those CBD challenges have fueled larger discussions about how to better regulate the vast dietary supplement market, where manufacturers often push legal boundaries by making unverified claims about how herbal or homeopathic products can help people.

"It will be something else next," said Hahn. We don't want to overstep our bounds but we want to make sure that safe and effective products are in the hands of people."

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 17:51:31 +0000
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: Continued

OK. Stay tuned.

-----Original Message-----
From: Auchincloss, Hugh (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, February 1, 2020 11:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Continued

The paper you sent me says the experiments were performed before the gain of function pause but have since been reviewed and approved by NIH. Not sure what that means since Emily is sure that no Coronavirus work has gone through the P3 framework. She will try to determine if we have any distant ties to this work abroad.

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 17:32:40 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: 2019 Novel Coronavirus:NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus

Pease handle.

-----Original Message-----
From: Amit Gupta [redacted] (b) (6)>
Sent: Saturday, February 1, 2020 12:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: 2019 Novel Coronavirus:NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus

Dear Dr. Fauci.

Wondering if you have see the coronavirus treatment news. I know you were involved in Ebola previously. You are a great Scientist and Doctor.

Coronavirus update: WHO says prepare for local coronavirus outbreaks in other countries;

What do you think about this treatment.
Regards,
Amit

SHELTON, CONNECTICUT -- Thursday, January 30, 2020 -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is confirming public disclosures in articles by various industry journals and other articles, that it is working on developing a treatment for the novel coronavirus 2019-nCoV, or the Wuhan coronavirus.

"We have already initiated a program for developing a treatment for the 2019-nCOV," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "Our platform technology enables possibly the most rapid pathway for new drug development against viral diseases. Of course, we will need support from governmental and international agencies such as the US CDC, WHO, and Chinese CDC to successfully develop these treatments, and, if developed, to get them to the patients in the fastest possible time. At this time, the Company does not have a collaboration with any of these agencies, and we have not been contacted by any of these entities or asked to develop a treatment for this virus. We had collaborations with the CDC and USAMRIID in the past. The Company intends to pursue a relevant collaboration for testing of our drug candidates soon."

The new 2019-nCoV is known to be closely related to the SARS-CoV of 2002-2003 epidemic. In fact it has been shown to use the same cell surface receptor as SARS-CoV, namely ACE2.

"We have already found some lead candidate ligands in our chemical library that can bind to the SARS-CoV spike protein in the same fashion as it binds to the cognate receptor, ACE2, using molecular modeling tools," explained Dr. Diwan, adding, "We believe this means we may already be significantly ahead in developing a potential treatment for the new Wuhan virus."

While the Company commissions synthesis of the anti-nCoV nanoviricide drug candidates for testing, some of which are already in our hands, in parallel, the Company has also started preparing for testing of the candidates in cell cultures against certain known BSL2 coronaviruses, including ones that use the ACE2 receptor. Less threatful viruses in the same family that use the same receptor can serve as valid test viruses for screening our broad-spectrum antiviral drug candidates. The Company has its own BSL2-certified virology laboratory at its Shelton campus where it intends to perform this testing.

The Company has its own cGMP-capable drug manufacturing facility. This highly customizable facility can be employed to produce several thousand doses of drugs per batch for treating coronavirus patients, if the Company's drug successfully transitions to obtaining an exploratory treatment approval for use in patients.

The Company's platform technology has already proven that it can result in safe drugs. The Company's first IND-ready clinical drug candidate, namely NV-HHV-101, has successfully undergone a standard battery of Safety and Toxicological testing, as previously disclosed by the Company in press releases and SEC filings.

The Company is building on its previous work against coronaviruses. The Company's technology relies on copying the human cell-surface receptor to which the virus binds, and making small chemicals that are called "ligands" that will bind to the virus in the same fashion as the cognate receptor. These ligands are chemically attached to a nanomicelle, to create a nanoviricide®. It is anticipated that when a virus comes in contact with the nanoviricide, not only would it land on the nanoviricide surface, binding to the copious number of ligands presented there, but it would also get entrapped because the nanomicelle polymer would turn around and fuse with the virus lipid envelop, harnessing a well known biophysical phenomenon.

"It is like a 'Venus-Fly-Trap' for the virus," explained Dr. Diwan.

The Company focuses on developing broad-spectrum ligands and, thereby, broad-spectrum nanoviricides, copying the specific human cellular receptor. No matter how much a virus mutates, it lands on the same cell surface receptor, and binds in the same fashion. Thus, it is highly unlikely that a virus might escape a nanoviricide against it, in spite of mutations.

In 2014, the Company had worked on developing antiviral treatments against MERS-CoV, and coronaviruses in general. It had developed potential candidates for testing in animal models. The MERS-CoV threat was eclipsed by the Ebola epidemic of 2015. The Company developed viable drug candidates against Ebola in a rapid response time of a few weeks and sent them for testing to USAMRIID. These initial candidates showed significant activity. The Company believes that another cycle of optimization would have resulted in a candidate ready for animal testing under the criteria established by USAMRIID then.

During these previous crises, the Company did not have the modern labs, the cGMP drug manufacturing facility or the BSL2 virology testing facility, all of which were commissioned after 2015 at its modern campus in Shelton, CT.

The Company is preparing an IND application for its first clinical drug candidate to go into human clinical trials. This drug candidate, NV-HHV-101, is a skin cream with the treatment of shingles rash as its first indication. It has shown broad-spectrum activity against HSV-1 (cause of "cold sores"), HSV-2 (cause of "genital ulcers"), and VZV (the varicella-zoster virus, that causes chickenpox in children and immune-compromised humans, and shingles in adults).

NV-HHV-101 has already gone through standard battery of safety-toxicological testing, which provides confidence that our platform is capable of creating safe drugs.

The Company has its own cGMP-capable drug manufacturing facility where it intends to produce the drugs for clinical supply.

The Company's top priority remains working on its first IND application for NV-HHV-101. The Company intends to solicit interest and financing from government agencies in order to accelerate its work on the coronaviruses.

The market size for the treatment of shingles is estimated at approximately one billion dollars by various estimates. These estimates take into account the Shingrix® vaccine as well as existing vaccines. About 500,000 to 1million cases of shingles occur in the USA alone every year.

The market size for our immediate target drugs in the HerpeCide™ program is variously estimated at billions to tens of billions of dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide™ program, namely, HSV-1 "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials. These additional candidates are based on NV-HHV-101, thereby maximizing return on investments and shareholder value.

The Company develops its class of drugs, that we call nanoviricides®, using a platform technology. This approach enables rapid development of new drugs against a number of different viruses. A nanoviricide is a "biomimetic" - it is designed to "look like" the cell surface to the virus. The nanoviricide® technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody. In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is the only technology in the world, to the best of our knowledge, that is capable of both (a) attacking extracellular virus, thereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.

About NanoViricides

NanoViricides, Inc.(www.nanoviricides.com)is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls".

Contact:
NanoViricides, Inc.
info@nanoviricides.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 13:19:06 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: FW: IMPORTANT
Attachments: Baric, Shi et al - Nature medicine - SARS Gain of function.pdf

Here it is

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 12:43:22 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap Feb 11-12, 2020 Geneva WHO HQ
Attachments: Global Research Forum dv2AMHR AM.PDF

We need to talk about this later in the day.. I am on Conference calls now. I will call you later. Apparently Soumya is reaching out separately to other people in NIAID.

From: SWAMINATHAN, Soumya [redacted] (b) (6)
Sent: Saturday, February 1, 2020 7:19 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap Feb 11-12, 2020 Geneva WHO HQ

Dear Tony

I am delighted to inform you that WHO is organizing a global research partners forum on February 11th and 12th in Geneva, to discuss research priorities related to the novel Corona virus. The expected outcome is a research roadmap with clearly defined priorities and a governance framework to take each thematic area forward. Several thematic areas will be considered at the meeting, namely: virus, diagnostics; natural history and transmission; clinical; therapeutics; vaccines; ethics; regulatory science; animal health; data/samples analysis and sharing and; social sciences. We believe that this meeting will be critical in consensus building on the most important research questions, as well as in building global partnerships and collaborations to take this work forward.

This meeting is being organized in partnership with GLOPID R and is being supported by the Bill and Melinda Gates foundation, DFID, Wellcome Trust and several other partners. The secretariat within WHO is the R&D blueprint, co-chaired by Dr Mike Ryan and myself.

As the head of an agency that would play an important role in addressing this new viral outbreak, either by undertaking or funding research, or both, I take great pleasure in inviting you to this meeting. I apologize for the short notice, but you will understand that we have had to plan this in the past few days, keeping in mind the evolving situation.

Kindly let me know if you (or your nominee) will be able to attend and if you need any support from us. Please copy [redacted] (b) (6) and [redacted] (b) (6) in your response.

With best wishes,
Soumya

Dr Soumya Swaminathan

Chief Scientist

PS: Sorry if this is a duplication – just want to make sure the key people receive the invite. Sorry about the short notice!

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 12:32:57 +0000
To: (b) (6)
Subject: FW: 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap Feb 11-12, 2020 Geneva WHO HQ
Attachments: Global Research Forum dv2AMHR AM.PDF

Cliff:
Whom should I nominate? See yellow highlight
Tony

From: SWAMINATHAN, Soumya <(b) (6)
Sent: Saturday, February 1, 2020 7:19 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap Feb 11-12, 2020 Geneva WHO HQ

Dear Tony

I am delighted to inform you that WHO is organizing a global research partners forum on February 11th and 12th in Geneva, to discuss research priorities related to the novel Corona virus. The expected outcome is a research roadmap with clearly defined priorities and a governance framework to take each thematic area forward. Several thematic areas will be considered at the meeting, namely: virus, diagnostics; natural history and transmission; clinical; therapeutics; vaccines; ethics; regulatory science; animal health; data/samples analysis and sharing and; social sciences. We believe that this meeting will be critical in consensus building on the most important research questions, as well as in building global partnerships and collaborations to take this work forward.

This meeting is being organized in partnership with GLOPID R and is being supported by the Bill and Melinda Gates foundation, DFID, Wellcome Trust and several other partners. The secretariat within WHO is the R&D blueprint, co-chaired by Dr Mike Ryan and myself.

As the head of an agency that would play an important role in addressing this new viral outbreak, either by undertaking or funding research, or both, I take great pleasure in inviting you to this meeting. I apologize for the short notice, but you will understand that we have had to plan this in the past few days, keeping in mind the evolving situation.

Kindly let me know if you (or your nominee) will be able to attend and if you need any support from us. Please copy (b) (6) and (b) (6) in your response.

With best wishes,
Soumya

Dr Soumya Swaminathan

Chief Scientist

PS: Sorry if this is a duplication – just want to make sure the key people receive the invite. Sorry about the short notice!

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 12:29:36 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: FW: Science: Mining coronavirus genomes for clues to the outbreak's origins

As per my prior e-mail.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, January 31, 2020 8:43 PM
Subject: Science: Mining coronavirus genomes for clues to the outbreak's origins

As part of a long-running effort to see what viruses bats harbor, researchers in China collect one from a cave in Guandong.
EcoHealth Alliance

Mining coronavirus genomes for clues to the outbreak's origins

By Jon CohenJan. 31, 2020 , 6:20 PM

attaaaggtt tataccttcc caggtaacaa accaaccaac tttcgatctc ttgtagatct ...

That string of apparent gibberish is anything but: It's a snippet of a DNA sequence from the viral pathogen, dubbed 2019 novel coronavirus (2019-nCoV), that is overwhelming China and frightening the entire world. Scientists are publicly sharing an ever-growing number of full sequences of the virus from patients—53 at last count in the Global Initiative on Sharing All Influenza Data database. These viral genomes are being intensely studied to try to understand the origin of 2019-nCoV and how it fits on the family tree of related viruses found in bats and other species. They have also given glimpses into what this newly discovered virus physically looks like, how it's changing, and how it might be stopped.

"One of the biggest takeaway messages [from the viral sequences] is that there was a single introduction into humans and then human-to-human spread," says Trevor Bedford, a bioinformatics specialist at the University of Washington, Seattle. The role of Huanan Seafood Wholesale Market in

Wuhan, China, in spreading 2019-nCoV remains murky, though such sequencing, combined with sampling the market's environment for the presence of the virus, is clarifying that it indeed had an important early role in amplifying the outbreak. The viral sequences, most researchers say, also knock down the idea the pathogen came from a virology institute in Wuhan.

In all, 2019-nCoV has nearly 29,000 nucleotides bases that hold the genetic instruction book to produce the virus. Although it's one of the many viruses whose genes are in the form of RNA, scientists convert the viral genome into DNA, with bases known in shorthand as A, T, C, and G, to make it easier to study. Many analyses of 2019-nCoV's sequences have already appeared on virological.org, nextstrain.org, preprint servers like bioRxiv, and even in peer-reviewed journals. The sharing of the sequences by Chinese researchers allowed public health labs around the world to develop their own diagnostics for the virus, which now has been found in 18 other countries. (*Science*'s news stories on the outbreak can be found here.)

When the first 2019-nCoV sequence became available, researchers placed it on a family tree of known coronaviruses—which are abundant and infect many species—and found that it was most closely related to relatives found in bats. A team led by Shi Zheng-Li, a coronavirus specialist at the Wuhan Institute of Virology, reported on 23 January on bioRxiv that 2019-nCoV's sequence was 96.2% similar to a bat virus and had 79.5% similarity to the coronavirus that causes severe acute respiratory syndrome (SARS), a disease whose initial outbreak was also in China more than 15 years ago. But the SARS coronavirus has a similarly close relationship to bat viruses, and sequence data make a powerful case that it jumped into people from a coronavirus in civets that differed from human SARS viruses by as few as 10 nucleotides. That's one reason why many scientists suspect there's an "intermediary" host species—or several—between bats and 2019-nCoV.

According to Bedford's analysis, the bat coronavirus sequence that Shi Zheng-Li's team highlighted, dubbed RaTG13, differs from 2019-nCoV by nearly 1100 nucleotides. On nextstrain.org, a site he co-founded, Bedford has created coronavirus family trees (example below) that include bat, civet, SARS, and 2019-nCoV sequences. (The trees are interactive—by dragging a computer mouse over them, it's easy to see the differences and similarities between the sequences.)


Phylogeny
virus type ^
SARS related coronavirus
novel coronavirus
RESET LAYOUT
TW5
TW10
TW9
TW2
Sino3_11
ZJ0301
HKU_39849
TW4
Sin850
BJ02
GZ0402
GZ0401
HC/GZ/32/03
civet020
PC4_227
PC4_13
civet007
SZ3
SARS
Rs4874
Rs4231
Rs4084
RsSHC014
WIV1
Rs3367
Rs9401
Rs7327
Rs4255
Rs4081
Rs672
Rs4247
Rs4237
As6526
Rf4092
YNLF_31C
YNLF_34C
LYRa11
HKU3_9
HKU3_6
HKU3_2
HKU3_3
HKU3_7
BetaCoV/Wuhan/WIV4
BetaCoV/Wuhan/IVDC
nCoV
BetaCoV/Wuhan/IVDC
BetaCoV/Wuhan/IPBC
WH-Human_1
BetaCoV/bat/Yunnan/
bat_SL_CoVZXC21
bat_SL_CoVZC45
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16

Bedford's analyses of RaTG13 and 2019-nCoV suggest that the two viruses shared a common ancestor 25 to 65 years ago, an estimate he arrived at by combining the difference in nucleotides between the viruses with the presumed rates of mutation in other coronaviruses. So it likely took decades for RaTG13-like viruses to mutate into 2019-nCoV.

Middle East respiratory syndrome (MERS), another human disease caused by a coronavirus, similarly has a link to bat viruses. But studies have built a compelling case it jumped to humans from camels. And the phylogenetic tree from Shi's bioRxiv paper (below) makes the camel-MERS link easy to see.


TGEV
Mink CoV
Ferret CoV
Bat CoV CDPHE15
Scotophilus bat CoV 512
PEDV
Bat CoV HKU10
Miniopterus bat CoV 1
Miniopterus bat CoV HKU8
Human CoV NL63
Bat NL63-related CoV
Human CoV 229E
SADS-CoV
Rhinolophus bat CoV HKU2
Human CoV OC43
Murine hepatitis virus
Rat CoV HKU24
Human CoV HKU1
Human MERS-CoV
Camel MERS-CoV
Pipistrellus bat CoV HKU5
Tylonycteris Bat CoV HKU4
Hedgehog CoV
SARS-CoV BJ01
Civet SARS-CoV SZ3
Bat SARSr-CoV WIV1
Bat SARSr-CoV SHC014
Bat SARSr-CoV LYRa11
Bat SARSr-CoV Rf1
Bat SARSr-CoV ZC45
Bat SARSr-CoV HKU3-1
Bat SARSr-CoV BM48-31
BetaCoV/Wuhan/WIV05/2019
BetaCoV/Wuhan/WIV02/2019
BetaCoV/Wuhan/WIV04/2019
BetaCoV/Wuhan/WIV06/2019
BetaCoV/Wuhan/WIV07/2019
Bat CoV RaTG13
Bat Hp BetaCoV Zhejiang 2013
Rousettus bat CoV HKU9
Bat CoV GCCDC1
IBV
0.1

The longer a virus circulates in a human populations, the more time it has to develop mutations that differentiate strains in infected people, and given that the 2019-nCoV sequences analyzed to date differ from each other by seven nucleotides at most, this suggests it jumped into humans very recently. But it remains a mystery which animal spread the virus to humans. "There's a very large gray area between viruses detected in bats and the virus now isolated in humans," says Vincent Munster, a virologist at the

U.S. National Institute of Allergy and Infectious Diseases who studies coronaviruses in bats, camels, and others species.

Strong evidence suggests the marketplace played an early role in spreading 2019-nCoV, but whether it was the origin of the outbreak remains uncertain. Many of the initially confirmed 2019-nCoV cases—27 of the first 41 in one report, 26 of 47 in another—were connected to the Wuhan market, but up to 45%, including the earliest handful, were not. This raises the possibility that the initial jump into people happened elsewhere.

According to Xinhua, the state-run news agency, "environmental sampling" of the Wuhan seafood market has found evidence of 2019-nCoV. Of the 585 samples tested, 33 were positive for 2019-nCoV and all were in the huge market's western portion, which is where wildlife were sold. "The positive tests from the wet market are hugely important," says Edward Holmes, an evolutionary biologist at the University of Sydney who collaborated with the first group to publicly release a 2019-nCoV sequence. "Such a high rate of positive tests would strongly imply that animals in the market played a key role in the emergence of the virus."

Yet there have been no preprints or official scientific reports on the sampling, so it's not clear which, if any, animals tested positive. "Until you consistently isolate the virus out of a single species, it's really, really difficult to try and determine what the natural host is," says Kristian Andersen, an evolutionary biologist at Scripps Research.

One possible explanation for the confusion about where the virus first entered humans is if there was a batch of recently infected animals sold at different marketplaces. Or an infected animal trader could have transmitted the virus to different people at different markets. Or, Bedford suggests, those early cases could have been infected by viruses that didn't easily transmit and sputtered out. "It would be hugely helpful to have just a sequence or two from the marketplace [environmental sampling] that could illuminate how many zoonoses occurred and when they occurred," Bedford says.

A research group sent fecal and other bodily samples from bats they trapped in caves to the Wuhan Institute of Virology to search for coronaviruses.

EcoHealth Alliance

In the absence of clear conclusions about the outbreak's origin, theories thrive, and some have been scientifically shaky. A sequence analysis led by Wei Ji of Peking University and published online by the *Journal of Medical Virology* received substantial press coverage when it suggested that "snake is the most probable wildlife animal reservoir for the 2019-nCoV." Sequence specialists, however, pilloried it. Conspiracy theories also abound. A CBC News report about the Canadian government deporting Chinese scientists who worked in a Winnipeg lab that studies dangerous pathogens was distorted on social media to suggest that they were spies who had smuggled out coronaviruses. The Wuhan Institute of

Virology, which is the premier lab in China that studies bat and human coronaviruses, has also come under fire. "Experts debunk fringe theory linking China's coronavirus to weapons research," read a headline on a story in *The Washington Post* that focused on the facility.

Concerns about the institute predate this outbreak. *Nature* ran a story in 2017 about it building a new biosafety level 4 lab and included molecular biologist Richard Ebright of Rutgers University, Piscataway, expressing concerns about accidental infections, which he noted repeatedly happened with lab workers handling SARS in Beijing. Ebright, who has a long history of raising red flags about studies with dangerous pathogens, also in 2015 criticized an experiment in which modifications were made to a SARS-like virus circulating in Chinese bats to see whether it had the potential to cause disease in humans. Earlier this week, Ebright questioned the accuracy of Bedford's calculation that there are at least 25 years of evolutionary distance between RaTG13—the virus held in the Wuhan virology institute—and 2019-nCoV, arguing that the mutation rate may have been different as it passed through different hosts before humans. Ebright tells *Science*Insider that the 2019-nCoV data are "consistent with entry into the human population as a natural accident."

Shi did not reply to emails from *Science*, but her longtime collaborator, disease ecologist Peter Daszak of the EcoHealth Alliance, dismissed Ebright's conjecture. "Every time there's an emerging disease, a new virus, the same story comes out: This is a spillover or the release of an agent or a bioengineered virus," Daszak says. "It's just a shame. It seems humans can't resist controversy and these myths, yet it's staring us right in the face. There's this incredible diversity of viruses in wildlife and we've just scratched the surface. Within that diversity, there will be some that can infect people and within that group will be some that cause illness."

A team of researchers from the Wuhan Institute of Virology and the EcoHealth Alliance have trapped bats in caves all over China, like this one in Guangdong, to sample them for coronaviruses.

EcoHealth Alliance

Daszak and Shi's group have for 8 years been trapping bats in caves around China to sample their feces and blood for viruses. He says they have sampled more than 10,000 bats and 2000 other species. They have found some 500 novel coronaviruses, about 50 of which fall relatively close to the SARS virus on the family tree, including RaTG13—it was fished out of a bat fecal sample they collected in 2013 from a cave in Moglang in Yunnan province. "We cannot assume that just because this virus from Yunnan has high sequence identity with the new one that that's the origin," Daszak says, noting that only a tiny fraction of coronaviruses that infect bats have been discovered. "I expect that once we've sampled and sampled and sampled across southern China and central China that we're going to find many other viruses and some of them will be closer [to 2019-nCoV]."

It's not just a "curious interest" to figure out what sparked the current outbreak, Daszak says. "If we don't find the origin, it could still be a raging infection at a farm somewhere, and once this outbreak dies, there could be a continued spillover that's really hard to stop. But the jury is still out on what the real origins of this are."
Posted in:

- Asia/Pacific
- Health
- Coronavirus

doi:10.1126/science.abb1256

Jon Cohen
Jon is a staff writer for *Science*.

- Email Jon
- Twitter

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 12:29:01 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] (b) (6)
Cc: (b) (6)
Subject: IMPORTANT
Attachments: Baric, Shi et al - Nature medicine - SARS Gain of function.pdf

Hugh:

It is essential that we speak this AM. Keep your cell phone on. I have a conference call at 7:45 AM with Azar. It likely will be over at 8:45 AM. Read this paper as well as the e-mail that I will forward to you now. You will have tasks today that must be done.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 02:48:59 +0000
To: Kadlec, Robert (OS/ASPR/IO)
Cc: (b) (6)
Subject: FW: Science: Mining coronavirus genomes for clues to the outbreak's origins

Bob:
This just came out today. Gives a balanced view.
Best,
Tony

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Sent: Friday, January 31, 2020 8:43 PM
Subject: Science: Mining coronavirus genomes for clues to the outbreak's origins

As part of a long-running effort to see what viruses bats harbor, researchers in China collect one from a cave in Guandong.
EcoHealth Alliance

Mining coronavirus genomes for clues to the outbreak's origins

By Jon CohenJan. 31, 2020 , 6:20 PM

attaaaggtt tataccttcc caggtaacaa accaaccaac tttcgatctc ttgtagatct ...

That string of apparent gibberish is anything but: It's a snippet of a DNA sequence from the viral pathogen, dubbed 2019 novel coronavirus (2019-nCoV), that is overwhelming China and frightening the entire world. Scientists are publicly sharing an ever-growing number of full sequences of the virus from patients—53 at last count in the Global Initiative on Sharing All Influenza Data database. These viral genomes are being intensely studied to try to understand the origin of 2019-nCoV and how it fits on the family tree of related viruses found in bats and other species. They have also given glimpses into what this newly discovered virus physically looks like, how it's changing, and how it might be stopped.

“One of the biggest takeaway messages [from the viral sequences] is that there was a single introduction into humans and then human-to-human spread,” says Trevor Bedford, a bioinformatics specialist at the University of Washington, Seattle. The role of Huanan Seafood Wholesale Market in Wuhan, China, in spreading 2019-nCoV remains murky, though such sequencing, combined with sampling the market’s environment for the presence of the virus, is clarifying that it indeed had an important early role in amplifying the outbreak. The viral sequences, most researchers say, also knock down the idea the pathogen came from a virology institute in Wuhan.

In all, 2019-nCoV has nearly 29,000 nucleotides bases that hold the genetic instruction book to produce the virus. Although it’s one of the many viruses whose genes are in the form of RNA, scientists convert the viral genome into DNA, with bases known in shorthand as A, T, C, and G, to make it easier to study. Many analyses of 2019-nCoV’s sequences have already appeared on virological.org, nextstrain.org, preprint servers like bioRxiv, and even in peer-reviewed journals. The sharing of the sequences by Chinese researchers allowed public health labs around the world to develop their own diagnostics for the virus, which now has been found in 18 other countries. (*Science*'s news stories on the outbreak can be found here.)

When the first 2019-nCoV sequence became available, researchers placed it on a family tree of known coronaviruses—which are abundant and infect many species—and found that it was most closely related to relatives found in bats. A team led by Shi Zheng-Li, a coronavirus specialist at the Wuhan Institute of Virology, reported on 23 January on bioRxiv that 2019-nCoV’s sequence was 96.2% similar to a bat virus and had 79.5% similarity to the coronavirus that causes severe acute respiratory syndrome (SARS), a disease whose initial outbreak was also in China more than 15 years ago. But the SARS coronavirus has a similarly close relationship to bat viruses, and sequence data make a powerful case that it jumped into people from a coronavirus in civets that differed from human SARS viruses by as few as 10 nucleotides. That’s one reason why many scientists suspect there’s an “intermediary” host species—or several—between bats and 2019-nCoV.

According to Bedford’s analysis, the bat coronavirus sequence that Shi Zheng-Li’s team highlighted, dubbed RaTG13, differs from 2019-nCoV by nearly 1100 nucleotides. On nextstrain.org, a site he co-founded, Bedford has created coronavirus family trees (example below) that include bat, civet, SARS, and 2019-nCoV sequences. (The trees are interactive—by dragging a computer mouse over them, it’s easy to see the differences and similarities between the sequences.)



Bedford's analyses of RaTG13 and 2019-nCoV suggest that the two viruses shared a common ancestor 25 to 65 years ago, an estimate he arrived at by combining the difference in nucleotides between the viruses with the presumed rates of mutation in other coronaviruses. So it likely took decades for RaTG13-like viruses to mutate into 2019-nCoV.

Middle East respiratory syndrome (MERS), another human disease caused by a coronavirus, similarly has a link to bat viruses. But studies have built a compelling case it jumped to humans from camels. And the phylogenetic tree from Shi's bioRxiv paper (below) makes the camel-MERS link easy to see.


100
TGEV
Mink CoV
100
Ferret CoV
98
Bat CoV CDPHE15
100
Scotophilus bat CoV 512
84
99
PEDV
Bat CoV HKU10
86
Miniopterus bat CoV 1
100
Miniopterus bat CoV HKU8
100
100
Human CoV NL63
100
Bat NL63-related CoV
Human CoV 229E
SADS-CoV
100
Rhinolophus bat CoV HKU2
55
Human CoV OC43
100
Murine hepatitis virus
100
Rat CoV HKU24
Human CoV HKU1
100
Human MERS-CoV
96
Camel MERS-CoV
96
Pipistrellus bat CoV HKU5
100
Tylonycteris Bat CoV HKU4
Hedgehog CoV
100
100
SARS-CoV BJ01
100
Civet SARS-CoV SZ3
100
Bat SARSr-CoV WIV1
Bat SARSr-CoV SHC014
100
Bat SARSr-CoV LYRa11
Bat SARSr-CoV Rf1
90
83
Bat SARSr-CoV ZC45
100
Bat SARSr-CoV HKU3-1
Bat SARSr-CoV BM48-31
100
BetaCoV/Wuhan/WIV05/2019
100
BetaCoV/Wuhan/WIV02/2019
BetaCoV/Wuhan/WIV04/2019
100
BetaCoV/Wuhan/WIV06/2019
100
BetaCoV/Wuhan/WIV07/2019
Bat CoV RaTG13
97
Bat Hp BetaCoV Zhejiang 2013
Rousettus bat CoV HKU9
97
100
Bat CoV GCCDC1
IBV
0.1

The longer a virus circulates in a human populations, the more time it has to develop mutations that differentiate strains in infected people, and given that the 2019-nCoV sequences analyzed to date differ from each other by seven nucleotides at most, this suggests it jumped into humans very recently. But it remains a mystery which animal spread the virus to humans. "There's a very large gray area between viruses detected in bats and the virus now isolated in humans," says Vincent Munster, a virologist at the U.S. National Institute of Allergy and Infectious Diseases who studies coronaviruses in bats, camels, and others species.

Strong evidence suggests the marketplace played an early role in spreading 2019-nCoV, but whether it was the origin of the outbreak remains uncertain. Many of the initially confirmed 2019-nCoV cases—27 of the first 41 in one report, 26 of 47 in another—were connected to the Wuhan market, but up to 45%, including the earliest handful, were not. This raises the possibility that the initial jump into people happened elsewhere.

According to Xinhua, the state-run news agency, "environmental sampling" of the Wuhan seafood market has found evidence of 2019-nCoV. Of the 585 samples tested, 33 were positive for 2019-nCoV and all were in the huge market's western portion, which is where wildlife were sold. "The positive tests from the wet market are hugely important," says Edward Holmes, an evolutionary biologist at the University of Sydney who collaborated with the first group to publicly release a 2019-nCoV sequence. "Such a high rate of positive tests would strongly imply that animals in the market played a key role in the emergence of the virus."

Yet there have been no preprints or official scientific reports on the sampling, so it's not clear which, if any, animals tested positive. "Until you consistently isolate the virus out of a single species, it's really, really difficult to try and determine what the natural host is," says Kristian Andersen, an evolutionary biologist at Scripps Research.

One possible explanation for the confusion about where the virus first entered humans is if there was a batch of recently infected animals sold at different marketplaces. Or an infected animal trader could have transmitted the virus to different people at different markets. Or, Bedford suggests, those early cases could have been infected by viruses that didn't easily transmit and sputtered out. "It would be hugely helpful to have just a sequence or two from the marketplace [environmental sampling] that could illuminate how many zoonoses occurred and when they occurred," Bedford says.

A research group sent fecal and other bodily samples from bats they trapped in caves to the Wuhan Institute of Virology to search for coronaviruses.

EcoHealth Alliance

In the absence of clear conclusions about the outbreak's origin, theories thrive, and some have been scientifically shaky. A sequence analysis led by Wei Ji of Peking University and published online by the *Journal of Medical Virology* received substantial press coverage when it suggested that "snake is the most probable wildlife animal reservoir for the 2019-nCoV." Sequence specialists, however, pilloried it.

Conspiracy theories also abound. A CBC News report about the Canadian government deporting Chinese scientists who worked in a Winnipeg lab that studies dangerous pathogens was distorted on social media to suggest that they were spies who had smuggled out coronaviruses. The Wuhan Institute of Virology, which is the premier lab in China that studies bat and human coronaviruses, has also come under fire. "Experts debunk fringe theory linking China's coronavirus to weapons research," read a headline on a story in *The Washington Post* that focused on the facility.

Concerns about the institute predate this outbreak. *Nature* ran a story in 2017 about it building a new biosafety level 4 lab and included molecular biologist Richard Ebright of Rutgers University, Piscataway, expressing concerns about accidental infections, which he noted repeatedly happened with lab workers handling SARS in Beijing. Ebright, who has a long history of raising red flags about studies with dangerous pathogens, also in 2015 criticized an experiment in which modifications were made to a SARS-like virus circulating in Chinese bats to see whether it had the potential to cause disease in humans. Earlier this week, Ebright questioned the accuracy of Bedford's calculation that there are at least 25 years of evolutionary distance between RaTG13—the virus held in the Wuhan virology institute—and 2019-nCoV, arguing that the mutation rate may have been different as it passed through different hosts before humans. Ebright tells *Science*Insider that the 2019-nCoV data are "consistent with entry into the human population as a natural accident."

Shi did not reply to emails from *Science*, but her longtime collaborator, disease ecologist Peter Daszak of the EcoHealth Alliance, dismissed Ebright's conjecture. "Every time there's an emerging disease, a new virus, the same story comes out: This is a spillover or the release of an agent or a bioengineered virus," Daszak says. "It's just a shame. It seems humans can't resist controversy and these myths, yet it's staring us right in the face. There's this incredible diversity of viruses in wildlife and we've just scratched the surface. Within that diversity, there will be some that can infect people and within that group will be some that cause illness."

A team of researchers from the Wuhan Institute of Virology and the EcoHealth Alliance have trapped bats in caves all over China, like this one in Guangdong, to sample them for coronaviruses.
EcoHealth Alliance

Daszak and Shi's group have for 8 years been trapping bats in caves around China to sample their feces and blood for viruses. He says they have sampled more than 10,000 bats and 2000 other species. They have found some 500 novel coronaviruses, about 50 of which fall relatively close to the SARS virus on the family tree, including RaTG13—it was fished out of a bat fecal sample they collected in 2013 from a cave in Moglang in Yunnan province. "We cannot assume that just because this virus from Yunnan has high sequence identity with the new one that that's the origin," Daszak says, noting that only a tiny fraction of coronaviruses that infect bats have been discovered. "I expect that once we've sampled and sampled and sampled across southern China and central China that we're going to find many other viruses and some of them will be closer [to 2019-nCoV]."

It's not just a "curious interest" to figure out what sparked the current outbreak, Daszak says. "If we don't find the origin, it could still be a raging infection at a farm somewhere, and once this outbreak dies, there could be a continued spillover that's really hard to stop. But the jury is still out on what the real origins of this are."

Posted in:

- Asia/Pacific
- Health

- Coronavirus

doi:10.1126/science.abb1256

Jon Cohen
Jon is a staff writer for *Science*.

- Email Jon
- Twitter

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 02:46:21 +0000
To: Mascola, John (NIH/VRC) [E]
Subject: FW: Science: Mining coronavirus genomes for clues to the outbreak's origins

Here is the Jon Cohen article.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, January 31, 2020 8:43 PM
Subject: Science: Mining coronavirus genomes for clues to the outbreak's origins

As part of a long-running effort to see what viruses bats harbor, researchers in China collect one from a cave in Guandong.
EcoHealth Alliance

Mining coronavirus genomes for clues to the outbreak's origins

By Jon CohenJan. 31, 2020 , 6:20 PM

attaaaggtt tataccttcc caggtaacaa accaaccaac tttcgatctc ttgtagatct ...

That string of apparent gibberish is anything but: It's a snippet of a DNA sequence from the viral pathogen, dubbed 2019 novel coronavirus (2019-nCoV), that is overwhelming China and frightening the entire world. Scientists are publicly sharing an ever-growing number of full sequences of the virus from patients—53 at last count in the Global Initiative on Sharing All Influenza Data database. These viral genomes are being intensely studied to try to understand the origin of 2019-nCoV and how it fits on the family tree of related viruses found in bats and other species. They have also given glimpses into what this newly discovered virus physically looks like, how it's changing, and how it might be stopped.

"One of the biggest takeaway messages [from the viral sequences] is that there was a single introduction into humans and then human-to-human spread," says Trevor Bedford, a bioinformatics specialist at the University of Washington, Seattle. The role of Huanan Seafood Wholesale Market in Wuhan, China, in spreading 2019-nCoV remains murky, though such sequencing, combined with sampling the market's environment for the presence of the virus, is clarifying that it indeed had an important early role in amplifying the outbreak. The viral sequences, most researchers say, also knock down the idea the pathogen came from a virology institute in Wuhan.

In all, 2019-nCoV has nearly 29,000 nucleotides bases that hold the genetic instruction book to produce the virus. Although it's one of the many viruses whose genes are in the form of RNA, scientists convert the viral genome into DNA, with bases known in shorthand as A, T, C, and G, to make it easier to study. Many analyses of 2019-nCoV's sequences have already appeared on virological.org, nextstrain.org, preprint servers like bioRxiv, and even in peer-reviewed journals. The sharing of the sequences by Chinese researchers allowed public health labs around the world to develop their own diagnostics for the virus, which now has been found in 18 other countries. (*Science*'s news stories on the outbreak can be found here.)

When the first 2019-nCoV sequence became available, researchers placed it on a family tree of known coronaviruses—which are abundant and infect many species—and found that it was most closely related to relatives found in bats. A team led by Shi Zheng-Li, a coronavirus specialist at the Wuhan Institute of Virology, reported on 23 January on bioRxiv that 2019-nCoV's sequence was 96.2% similar to a bat virus and had 79.5% similarity to the coronavirus that causes severe acute respiratory syndrome (SARS), a disease whose initial outbreak was also in China more than 15 years ago. But the SARS coronavirus has a similarly close relationship to bat viruses, and sequence data make a powerful case that it jumped into people from a coronavirus in civets that differed from human SARS viruses by as few as 10 nucleotides. That's one reason why many scientists suspect there's an "intermediary" host species—or several—between bats and 2019-nCoV.

According to Bedford's analysis, the bat coronavirus sequence that Shi Zheng-Li's team highlighted, dubbed RaTG13, differs from 2019-nCoV by nearly 1100 nucleotides. On nextstrain.org, a site he co-founded, Bedford has created coronavirus family trees (example below) that include bat, civet, SARS, and 2019-nCoV sequences. (The trees are interactive—by dragging a computer mouse over them, it's easy to see the differences and similarities between the sequences.)



Bedford's analyses of RaTG13 and 2019-nCoV suggest that the two viruses shared a common ancestor 25 to 65 years ago, an estimate he arrived at by combining the difference in nucleotides between the viruses with the presumed rates of mutation in other coronaviruses. So it likely took decades for RaTG13-like viruses to mutate into 2019-nCoV.

Middle East respiratory syndrome (MERS), another human disease caused by a coronavirus, similarly has a link to bat viruses. But studies have built a compelling case it jumped to humans from camels. And the phylogenetic tree from Shi's bioRxiv paper (below) makes the camel-MERS link easy to see.


TGEV
Mink CoV
Ferret CoV
Bat CoV CDPHE15
Scotophilus bat CoV 512
PEDV
Bat CoV HKU10
Miniopterus bat CoV 1
Miniopterus bat CoV HKU8
Human CoV NL63
Bat NL63-related CoV
Human CoV 229E
SADS-CoV
Rhinolophus bat CoV HKU2
Human CoV OC43
Murine hepatitis virus
Rat CoV HKU24
Human CoV HKU1
Human MERS-CoV
Camel MERS-CoV
Pipistrellus bat CoV HKU5
Tylonycteris Bat CoV HKU4
Hedgehog CoV
SARS-CoV BJ01
Civet SARS-CoV SZ3
Bat SARSr-CoV WIV1
Bat SARSr-CoV SHC014
Bat SARSr-CoV LYRa11
Bat SARSr-CoV Rf1
Bat SARSr-CoV ZC45
Bat SARSr-CoV HKU3-1
Bat SARSr-CoV BM48-31
BetaCoV/Wuhan/WIV05/2019
BetaCoV/Wuhan/WIV02/2019
BetaCoV/Wuhan/WIV04/2019
BetaCoV/Wuhan/WIV06/2019
BetaCoV/Wuhan/WIV07/2019
Bat CoV RaTG13
Bat Hp BetaCoV Zhejiang 2013
Rousettus bat CoV HKU9
Bat CoV GCCDC1
IBV
100
100
98
100
84
99
86
100
100
100
100
100
100
55
100
100
100
96
96
100
100
100
100
100
100
90
83
100
100
100
100
100
97
97
0.1

The longer a virus circulates in a human populations, the more time it has to develop mutations that differentiate strains in infected people, and given that the 2019-nCoV sequences analyzed to date differ from each other by seven nucleotides at most, this suggests it jumped into humans very recently. But it remains a mystery which animal spread the virus to humans. "There's a very large gray area between viruses detected in bats and the virus now isolated in humans," says Vincent Munster, a virologist at the U.S. National Institute of Allergy and Infectious Diseases who studies coronaviruses in bats, camels, and others species.

Strong evidence suggests the marketplace played an early role in spreading 2019-nCoV, but whether it was the origin of the outbreak remains uncertain. Many of the initially confirmed 2019-nCoV cases—27 of the first 41 in one report, 26 of 47 in another—were connected to the Wuhan market, but up to 45%, including the earliest handful, were not. This raises the possibility that the initial jump into people happened elsewhere.

According to Xinhua, the state-run news agency, "environmental sampling" of the Wuhan seafood market has found evidence of 2019-nCoV. Of the 585 samples tested, 33 were positive for 2019-nCoV and all were in the huge market's western portion, which is where wildlife were sold. "The positive tests from the wet market are hugely important," says Edward Holmes, an evolutionary biologist at the University of Sydney who collaborated with the first group to publicly release a 2019-nCoV sequence. "Such a high rate of positive tests would strongly imply that animals in the market played a key role in the emergence of the virus."

Yet there have been no preprints or official scientific reports on the sampling, so it's not clear which, if any, animals tested positive. "Until you consistently isolate the virus out of a single species, it's really, really difficult to try and determine what the natural host is," says Kristian Andersen, an evolutionary biologist at Scripps Research.

One possible explanation for the confusion about where the virus first entered humans is if there was a batch of recently infected animals sold at different marketplaces. Or an infected animal trader could have transmitted the virus to different people at different markets. Or, Bedford suggests, those early cases could have been infected by viruses that didn't easily transmit and sputtered out. "It would be hugely helpful to have just a sequence or two from the marketplace [environmental sampling] that could illuminate how many zoonoses occurred and when they occurred," Bedford says.

A research group sent fecal and other bodily samples from bats they trapped in caves to the Wuhan Institute of Virology to search for coronaviruses.

EcoHealth Alliance

In the absence of clear conclusions about the outbreak's origin, theories thrive, and some have been scientifically shaky. A sequence analysis led by Wei Ji of Peking University and published online by the *Journal of Medical Virology* received substantial press coverage when it suggested that "snake is the most probable wildlife animal reservoir for the 2019-nCoV." Sequence specialists, however, pilloried it. Conspiracy theories also abound. A CBC News report about the Canadian government deporting Chinese scientists who worked in a Winnipeg lab that studies dangerous pathogens was distorted on social media to suggest that they were spies who had smuggled out coronaviruses. The Wuhan Institute of Virology, which is the premier lab in China that studies bat and human coronaviruses, has also come under fire. "Experts debunk fringe theory linking China's coronavirus to weapons research," read a headline on a story in *The Washington Post* that focused on the facility.

Concerns about the institute predate this outbreak. *Nature* ran a story in 2017 about it building a new biosafety level 4 lab and included molecular biologist Richard Ebright of Rutgers University, Piscataway, expressing concerns about accidental infections, which he noted repeatedly happened with lab workers handling SARS in Beijing. Ebright, who has a long history of raising red flags about studies with dangerous pathogens, also in 2015 criticized an experiment in which modifications were made to a SARS-like virus circulating in Chinese bats to see whether it had the potential to cause disease in humans. Earlier this week, Ebright questioned the accuracy of Bedford's calculation that there are at least 25 years of evolutionary distance between RaTG13—the virus held in the Wuhan virology institute—and 2019-nCoV, arguing that the mutation rate may have been different as it passed through different hosts before humans. Ebright tells *Science*Insider that the 2019-nCoV data are "consistent with entry into the human population as a natural accident."

Shi did not reply to emails from *Science*, but her longtime collaborator, disease ecologist Peter Daszak of the EcoHealth Alliance, dismissed Ebright's conjecture. "Every time there's an emerging disease, a new virus, the same story comes out: This is a spillover or the release of an agent or a bioengineered virus," Daszak says. "It's just a shame. It seems humans can't resist controversy and these myths, yet it's staring us right in the face. There's this incredible diversity of viruses in wildlife and we've just scratched the surface. Within that diversity, there will be some that can infect people and within that group will be some that cause illness."

A team of researchers from the Wuhan Institute of Virology and the EcoHealth Alliance have trapped bats in caves all over China, like this one in Guangdong, to sample them for coronaviruses.
EcoHealth Alliance

Daszak and Shi's group have for 8 years been trapping bats in caves around China to sample their feces and blood for viruses. He says they have sampled more than 10,000 bats and 2000 other species. They have found some 500 novel coronaviruses, about 50 of which fall relatively close to the SARS virus on the family tree, including RaTG13—it was fished out of a bat fecal sample they collected in 2013 from a cave in Moglang in Yunnan province. "We cannot assume that just because this virus from Yunnan has high sequence identity with the new one that that's the origin," Daszak says, noting that only a tiny fraction of coronaviruses that infect bats have been discovered. "I expect that once we've sampled and sampled and sampled across southern China and central China that we're going to find many other viruses and some of them will be closer [to 2019-nCoV]."

It's not just a "curious interest" to figure out what sparked the current outbreak, Daszak says. "If we don't find the origin, it could still be a raging infection at a farm somewhere, and once this outbreak

dies, there could be a continued spillover that's really hard to stop. But the jury is still out on what the real origins of this are."
Posted in:

- Asia/Pacific
- Health
- Coronavirus

doi:10.1126/science.abb1256

Jon Cohen
Jon is a staff writer for *Science*.

- Email Jon
- Twitter

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.